{"metadata":{"source":"ClinicalTrials.gov API v2","sourceUrl":"https://clinicaltrials.gov/data-api/api","apiVersion":"2.0.5","dataTimestamp":"2026-08-07T09:00:05","retrievedAt":"2026-08-07T20:03:08.052Z","query":"Cancer; industry lead sponsor; interventional Phase 1-3; recruiting, not-yet-recruiting, active-not-recruiting, or enrolling-by-invitation","registryTotal":5395,"exportedTotal":5395,"limitation":"ClinicalTrials.gov is a global registry but is not exhaustive of every trial, preclinical asset, non-public program, CTIS/CDE-only record, or commercial procurement status."},"studies":[{"nctId":"NCT00463814","title":"AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":58,"enrollmentType":"ACTUAL","startDate":"2007-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2008-06-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-26","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Tumor","Cancer"],"interventions":["AZD6244"],"countries":["United States","Netherlands","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT00463814"},{"nctId":"NCT00777582","title":"Phase I Comparative Bioavailability Study","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":197,"enrollmentType":"ACTUAL","startDate":"2008-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2009-02-06","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Solid Tumors"],"interventions":["AZD2281"],"countries":["Australia","Belgium","Switzerland","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["HRD / HRR"],"summary":"The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients","sourceUrl":"https://clinicaltrials.gov/study/NCT00777582"},{"nctId":"NCT00099437","title":"Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":736,"enrollmentType":"ACTUAL","startDate":"2005-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2009-02-27","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Breast Cancer"],"interventions":["Fulvestrant"],"countries":["United States","Belgium","Brazil","Chile","Colombia","Czechia","Hungary","India","Italy","Malta","Mexico","Poland","Russia","Slovakia","Spain","Ukraine","Venezuela"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT00099437"},{"nctId":"NCT00750841","title":"Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":64,"enrollmentType":"ACTUAL","startDate":"2008-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2009-07-30","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Solid Tumors"],"interventions":["cediranib"],"countries":["Canada","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT00750841"},{"nctId":"NCT01081951","title":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":162,"enrollmentType":"ACTUAL","startDate":"2010-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2011-10-10","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Ovarian Cancer"],"interventions":["olaparib","paclitaxel","carboplatin","Drug: carboplatin"],"countries":["United States","Australia","Belgium","Canada","Czechia","Germany","Italy","Japan","Netherlands","Panama","Peru","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT01081951"},{"nctId":"NCT01594723","title":"A Study of LY2784544 in Participants With Myeloproliferative Neoplasms","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2012-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2015-03-20","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Neoplasms, Hematologic"],"interventions":["120 mg LY2784544"],"countries":["United States","Australia","Austria","Canada","France","Germany","Italy","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study is to measure the response rate in participants with the myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an intolerance to, failure of primary response to, or have demonstrated disease progression while on ruxolitinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT01594723"},{"nctId":"NCT01843374","title":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","sponsor":"MedImmune LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":571,"enrollmentType":"ACTUAL","startDate":"2013-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2016-01-24","primaryCompletionType":"ACTUAL","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Unresectable Pleural or Peritoneal Malignant Mesothelioma"],"interventions":["Tremelimumab","Placebo"],"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","Romania","Russia","South Africa","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":104,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.","sourceUrl":"https://clinicaltrials.gov/study/NCT01843374"},{"nctId":"NCT01933932","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":510,"enrollmentType":"ACTUAL","startDate":"2013-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2016-06-07","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV"],"interventions":["Selumetinib","Docetaxel","Placebo","Pegylated G-CSF"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","France","Germany","Hungary","Israel","Italy","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","Spain","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":197,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel","sourceUrl":"https://clinicaltrials.gov/study/NCT01933932"},{"nctId":"NCT02123758","title":"A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Aragon Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":57,"enrollmentType":"ACTUAL","startDate":"2014-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2016-06-27","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms","Metastatic Castration-Resistant Prostate Cancer"],"interventions":["Abiraterone Acetate","Prednisone","JNJ-56021927"],"countries":["United States","Canada","Netherlands","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.","sourceUrl":"https://clinicaltrials.gov/study/NCT02123758"},{"nctId":"NCT01874353","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":327,"enrollmentType":"ACTUAL","startDate":"2013-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2016-09-19","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Platinum Sensitive","BRCA Mutated","Relapsed Ovarian Cancer","Following Complete or Partial Response to Platinum Based Chemotherapy"],"interventions":["Olaparib 300mg tablets","Placebo to match olaparib 300mg"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":126,"serviceSignals":["HRD / HRR"],"summary":"A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT01874353"},{"nctId":"NCT02592317","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","sponsor":"Aragon Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":23,"enrollmentType":"ACTUAL","startDate":"2016-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2016-11-07","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms, Castration-Resistant"],"interventions":["JNJ 56021927","Drug Cocktail","Pioglitazone","Rosuvastatin"],"countries":["Moldova","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the effects of repeat dosing of JNJ-56021927 on the pharmacokinetics for single-dose multiple cytochrome P450 (CYP450) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2C8) and transporter (P-gp and BRCP) substrates in participants with castration-resistant prostate cancer (CRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT02592317"},{"nctId":"NCT02381886","title":"A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":166,"enrollmentType":"ACTUAL","startDate":"2015-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2016-12-07","primaryCompletionType":"ACTUAL","completionDate":"2030-10-31","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Malignancies That Harbor IDHR132 Mutations"],"interventions":["IDH305"],"countries":["United States","Australia","Belgium","Canada","Germany","Netherlands","Singapore","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT02381886"},{"nctId":"NCT02246621","title":"A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":493,"enrollmentType":"ACTUAL","startDate":"2014-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2017-01-31","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Breast Cancer"],"interventions":["Abemaciclib","Anastrozole","Letrozole","Placebo"],"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":155,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.","sourceUrl":"https://clinicaltrials.gov/study/NCT02246621"},{"nctId":"NCT02293980","title":"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ACTUAL","startDate":"2014-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2017-01-31","primaryCompletionType":"ACTUAL","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2024-06-17","conditions":["ccRCC","RCC","Kidney Cancer","Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma"],"interventions":["MK-3795","Nivolumab","Cabozantinib","Bezlutifan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended Phase 2 dose (RP2D) of MK-3795 in patients with advanced clear cell renal cell carcinoma (ccRCC). PART 2: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with nivolumab, in patients with advanced ccRCC.As of Amendment 09 (29 Mar 2024), participants with advanced ccRCC will transition from MK-3795 to belzutifan (MK-6482) in combination with nivolumab or belzutifan alone. PART 3: The primary objective of this study is to identify the MTD of MK-3795 up to the RP2D, in combination with cabozantin","sourceUrl":"https://clinicaltrials.gov/study/NCT02293980"},{"nctId":"NCT02107703","title":"A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":669,"enrollmentType":"ACTUAL","startDate":"2014-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2017-02-14","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Breast Neoplasms"],"interventions":["Abemaciclib","Fulvestrant","Placebo"],"countries":["United States","Australia","Belgium","Canada","Denmark","Finland","France","Germany","Greece","Italy","Japan","Mexico","Poland","Puerto Rico","Romania","Russia","South Korea","Spain","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":146,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.","sourceUrl":"https://clinicaltrials.gov/study/NCT02107703"},{"nctId":"NCT01946204","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","sponsor":"Aragon Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1207,"enrollmentType":"ACTUAL","startDate":"2013-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2017-05-19","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Prostatic Neoplasms"],"interventions":["Apalutamide","Placebo"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Japan","Netherlands","New Zealand","Norway","Poland","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":379,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT01946204"},{"nctId":"NCT02152631","title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":453,"enrollmentType":"ACTUAL","startDate":"2014-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2017-09-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Non Small Cell Lung Cancer"],"interventions":["Abemaciclib","Erlotinib"],"countries":["United States","Argentina","Austria","Brazil","Canada","China","France","Germany","Greece","Israel","Italy","Japan","Poland","Puerto Rico","Romania","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":231,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT02152631"},{"nctId":"NCT02362594","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1019,"enrollmentType":"ACTUAL","startDate":"2015-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2018-01-08","primaryCompletionType":"ACTUAL","completionDate":"2026-11-01","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Melanoma"],"interventions":["pembrolizumab","placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will assess whether post-surgery therapy with pembrolizumab improves recurrence-free survival (RFS) as compared to placebo for high-risk participants with melanoma (Stage IIIA \\[\\> 1 mm metastasis\\], IIIB and IIIC). The study will also assess whether pembrolizumab improves RFS versus placebo in the subgroup of participants with programmed cell death-ligand 1 (PD-L1)-positive tumor expression. Participants will be stratified for stage of disease and region and then will be randomly assigned to receive either pembrolizumab or placebo as post-surgery therapy in Part 1. In Part 2, participants who experience a disease recurrence are eligible for pembrolizumab treatment (if treated wit","sourceUrl":"https://clinicaltrials.gov/study/NCT02362594"},{"nctId":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ACTUAL","startDate":"2016-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2018-01-12","primaryCompletionType":"ACTUAL","completionDate":"2026-09-08","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Solid Tumors","Solid Tumor","Solid Carcinoma","Solid Tumor, Adult","ccRCC","RCC, Clear Cell Adenocarcinoma","RCC","Kidney Cancer","Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma, Metastatic","Renal Cell Carcinoma Recurrent","Renal Cell Carcinoma, Clear Cell Adenocarcinoma","Glioblastoma","Glioblastoma, Adult","GBM","Glioblastoma Multiforme"],"interventions":["Belzutifan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT02974738"},{"nctId":"NCT02711553","title":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":309,"enrollmentType":"ACTUAL","startDate":"2016-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2018-02-16","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Biliary Tract Cancer","Metastatic Cancer","Advanced Cancer"],"interventions":["Ramucirumab","Merestinib","Cisplatin","Gemcitabine","Placebo Oral","Placebo IV"],"countries":["United States","Argentina","Australia","Austria","Belgium","Czechia","Denmark","France","Germany","Hungary","Mexico","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":82,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT02711553"},{"nctId":"NCT02257736","title":"An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)","sponsor":"Aragon Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":982,"enrollmentType":"ACTUAL","startDate":"2014-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2018-03-19","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["Apalutamide","Abiraterone acetate","Prednisone","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","France","Germany","Japan","Mexico","Netherlands","Russia","South Africa","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":173,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy \\[treatment of cancer using drugs\\]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland \\[gland that makes fluid that aids movement of sperm\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT02257736"},{"nctId":"NCT01844986","title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":450,"enrollmentType":"ACTUAL","startDate":"2013-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2018-05-17","primaryCompletionType":"ACTUAL","completionDate":"2028-08-29","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["Newly Diagnosed","Advanced Ovarian Cancer","FIGO Stage III-IV","BRCA Mutation","Complete Response","Partial Response","First Line Platinum Chemotherapy"],"interventions":["Olaparib 300mg tablets"],"countries":["United States","Australia","Brazil","Canada","China","France","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":177,"serviceSignals":["Broad CGP"],"summary":"Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT01844986"},{"nctId":"NCT02747004","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":234,"enrollmentType":"ACTUAL","startDate":"2016-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2018-06-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Metastatic Breast Cancer"],"interventions":["Abemaciclib","Tamoxifen","Prophylactic Loperamide"],"countries":["United States","Argentina","Austria","Belgium","Brazil","Czechia","France","Germany","Italy","Mexico","Russia","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT02747004"},{"nctId":"NCT03207672","title":"Study of E7389 Liposomal Formulation in Participants With Solid Tumor","sponsor":"Eisai Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2017-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2018-07-19","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Solid Tumor"],"interventions":["E7389-LF"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer (up to 3 prior regimens of chemotherapy) in the expansion part 1 and in participants with adenoid cystic carcinoma (ACC), gastric cancer (GC), esophageal cancer (EGC), small cell lung cancer (SCLC) and breast cancer (with no prior regimens of chemotherapy) in the expansion part 2, 3, 4, 5 and 6 respectively.","sourceUrl":"https://clinicaltrials.gov/study/NCT03207672"},{"nctId":"NCT02677922","title":"A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy","sponsor":"Celgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ACTUAL","startDate":"2016-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2018-08-02","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Leukemia, Myeloid, Acute"],"interventions":["AG-120","Azacitidine","AG-221"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Netherlands","Portugal","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.","sourceUrl":"https://clinicaltrials.gov/study/NCT02677922"},{"nctId":"NCT02453282","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1118,"enrollmentType":"ACTUAL","startDate":"2015-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2018-10-04","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-Small-Cell Lung Carcinoma NSCLC"],"interventions":["MEDI4736 (Durvalumab)","MEDI4736 (Durvalumab)+Tremelimumab","Paclitaxel + Carboplatin","Gemcitabine + Cisplatin","Gemcitabine + Carboplatin","Pemetrexed + Cisplatin","Pemetrexed + Carboplatin","Tremelimumab"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Hungary","Italy","Japan","Netherlands","Russia","South Korea","Spain","Switzerland","Taiwan","Thailand","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":196,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT02453282"},{"nctId":"NCT02411448","title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":545,"enrollmentType":"ACTUAL","startDate":"2015-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2019-01-23","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Metastatic Non-Small Cell Lung Cancer"],"interventions":["Ramucirumab","Placebo","Erlotinib","Gefitinib","Osimertinib"],"countries":["United States","Canada","France","Germany","Greece","Hong Kong","Italy","Japan","Romania","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B. The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramuciru","sourceUrl":"https://clinicaltrials.gov/study/NCT02411448"},{"nctId":"NCT02475681","title":"Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL","sponsor":"Acerta Pharma BV","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":535,"enrollmentType":"ACTUAL","startDate":"2015-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2019-02-08","primaryCompletionType":"ACTUAL","completionDate":"2025-09-30","completionType":"ESTIMATED","lastUpdated":"2025-08-27","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Acalabrutinib","Obinutuzumab","Chlorambucil"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","Colombia","France","Germany","Hungary","Israel","Italy","Lithuania","New Zealand","Poland","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":155,"serviceSignals":["Hematology NGS"],"summary":"This Primary objective is evaluating the efficacy of obinutuzumab in combination with chlorambucil (Arm A) compared with acalabrutinib in combination with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectives: 1) To evaluate the efficacy of obinutuzumab in combination with chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) based on IRC assessment of PFS per IWCLL 2008 criteria. 2)To compare obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib plus obinutuzumab (Arm B) and obinutuzumab plus chlorambucil (Arm A) versus acalabrutinib monotherapy (Arm C) in terms of: IRC-assessed objective response rate (ORR); Ti","sourceUrl":"https://clinicaltrials.gov/study/NCT02475681"},{"nctId":"NCT02763566","title":"A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":463,"enrollmentType":"ACTUAL","startDate":"2016-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2019-03-29","primaryCompletionType":"ACTUAL","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Breast Cancer"],"interventions":["Abemaciclib","Anastrozole","Letrozole","Placebo","Fulvestrant"],"countries":["Brazil","China","India","South Africa"],"northAmerica":false,"chinaSites":true,"siteCount":45,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to evaluate the efficacy of the study drug abemaciclib in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT02763566"},{"nctId":"NCT02655016","title":"A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy","sponsor":"Tesaro, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":733,"enrollmentType":"ACTUAL","startDate":"2016-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2019-05-17","primaryCompletionType":"ACTUAL","completionDate":"2026-05-29","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Ovarian Neoplasms"],"interventions":["Niraparib","Placebo"],"countries":["United States","Belgium","Denmark","Finland","France","Germany","Ireland","Israel","Italy","Norway","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":116,"serviceSignals":["HRD / HRR"],"summary":"This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer. Participants must have completed front-line platinum based regimen with complete response (CR) or partial response (PR). Data collection for Secondary Outcome measures is ongoing and the approximate duration of the study will be 7 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT02655016"},{"nctId":"NCT03523442","title":"A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":19,"enrollmentType":"ACTUAL","startDate":"2018-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2019-07-09","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["Apalutamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate pharmacokinetics (PK) following a single dose and multiple dose treatment and the safety of apalutamide in Chinese participants with metastatic castration resistant prostate cancer (mCRPC) at dose of 240 milligram (mg).","sourceUrl":"https://clinicaltrials.gov/study/NCT03523442"},{"nctId":"NCT03091192","title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2017-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2019-08-18","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Carcinoma","Carcinoma, Renal Cell","Kidney Neoplasms","Urologic Neoplasms","Kidney Diseases","Neoplasms by Site","Enzyme Inhibitors","Protein Kinase Inhibitors"],"interventions":["Savolitinib","Sunitinib"],"countries":["United States","Brazil","France","Italy","Russia","South Korea","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.","sourceUrl":"https://clinicaltrials.gov/study/NCT03091192"},{"nctId":"NCT02180724","title":"An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia","sponsor":"Acerta Pharma BV","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":107,"enrollmentType":"ACTUAL","startDate":"2014-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2019-10-01","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Waldenström Macroglobulinemia (WM)"],"interventions":["Acalabrutinib (ACP-196)"],"countries":["United States","France","Greece","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.","sourceUrl":"https://clinicaltrials.gov/study/NCT02180724"},{"nctId":"NCT01744223","title":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","sponsor":"Bellicum Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2013-03","startDateType":"ACTUAL","primaryCompletionDate":"2019-10-09","primaryCompletionType":"ACTUAL","completionDate":"2032-10","completionType":"ESTIMATED","lastUpdated":"2022-07-12","conditions":["Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Lymphoma","Myelodysplastic Syndromes"],"interventions":["BPX-501 dose 1","Rimiducid","BPX-501 dose 2","BPX-501 dose 3","BPX-501 dose 4","SCT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate patients with blood cell cancers who are going to have an allogeneic (donor) blood stem cell transplant from a partially matched relative. The research study will test whether immune cells, called T cells, which come from the donor relative and are specially grown in the laboratory and then given back to the patient along with the stem cell transplant (T cell addback), can help the immune system recover faster after the transplant. As a safety measure, these T cells have been \"programmed\" with a \"self-destruct switch\" so that if, after they have been given to the patient, the T cells start to react against the tissues (called \"graft versus host\" disease, GVHD), the T","sourceUrl":"https://clinicaltrials.gov/study/NCT01744223"},{"nctId":"NCT02477878","title":"Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant","sponsor":"Bellicum Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ACTUAL","startDate":"2016-07","startDateType":"ACTUAL","primaryCompletionDate":"2020-01-14","primaryCompletionType":"ACTUAL","completionDate":"2033-01","completionType":"ESTIMATED","lastUpdated":"2022-07-12","conditions":["Leukemia","Myelodysplastic Syndromes","Lymphoma","Multiple Myeloma","Hematologic Neoplasms"],"interventions":["BPX-501","Rimiducid"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will be investigated for the treatment of aGvHD after BPX-501 T cell infusion to determine a dose that can mitigate GvHD and preserve the graft versus leukemia effect.","sourceUrl":"https://clinicaltrials.gov/study/NCT02477878"},{"nctId":"NCT03043872","title":"Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":987,"enrollmentType":"ACTUAL","startDate":"2017-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2020-01-27","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Small Cell Lung Carcinoma Extensive Disease"],"interventions":["Durvalumab","Tremelimumab","Carboplatin","Cisplatin","Etoposide"],"countries":["United States","Argentina","Austria","Brazil","Bulgaria","China","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Poland","Romania","Russia","Slovakia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":207,"serviceSignals":["Broad CGP"],"summary":"This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03043872"},{"nctId":"NCT02516241","title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1126,"enrollmentType":"ACTUAL","startDate":"2015-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2020-01-27","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Urothelial Cancer"],"interventions":["MEDI4736 (Durvalumab)","Tremelimumab","Cisplatin","Carboplatin","Gemcitabine"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Denmark","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":222,"serviceSignals":["Broad CGP"],"summary":"A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT02516241"},{"nctId":"NCT02779751","title":"A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2016-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2020-02-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Non Small Cell Lung Cancer","Breast Cancer"],"interventions":["Abemaciclib","Pembrolizumab","Anastrozole"],"countries":["United States","Belgium","France","Italy","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT02779751"},{"nctId":"NCT03141177","title":"A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":701,"enrollmentType":"ACTUAL","startDate":"2017-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2020-02-12","primaryCompletionType":"ACTUAL","completionDate":"2026-01-16","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Renal Cell Carcinoma"],"interventions":["Nivolumab","Cabozantinib","Sunitinib","Ipilimumab"],"countries":["United States","Argentina","Australia","Brazil","Chile","Czechia","Germany","Greece","Israel","Italy","Japan","Mexico","Poland","Romania","Russia","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":135,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT03141177"},{"nctId":"NCT03252808","title":"Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.","sponsor":"Takara Bio Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2017-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2020-02-19","primaryCompletionType":"ACTUAL","completionDate":"2035-03-31","completionType":"ESTIMATED","lastUpdated":"2024-12-09","conditions":["Pancreatic Cancer Stage III","Pancreatic Cancer Stage IV"],"interventions":["TBI-1401(HF10)","Gemcitabine","Nab-paclitaxel","TS-1"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03252808"},{"nctId":"NCT02937272","title":"A Study of LY3200882 in Participants With Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":223,"enrollmentType":"ESTIMATED","startDate":"2016-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2020-02-27","primaryCompletionType":"ACTUAL","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Solid Tumor"],"interventions":["LY3200882","LY3300054","Gemcitabine","nab-Paclitaxel","Cisplatin","Intensity Modulated Radiotherapy"],"countries":["United States","Australia","Canada","France","Germany","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT02937272"},{"nctId":"NCT02143466","title":"AZD9291 in Combination With Ascending Doses of Novel Therapeutics","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":344,"enrollmentType":"ACTUAL","startDate":"2014-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2020-03-04","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Advanced Non Small Cell Lung Cancer"],"interventions":["Part A - AZD9291 in combination with AZD6094","Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)","Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)","Part A - AZD9291 in combination with intermittent selumetinib","Part A - AZD9291 in combination with MEDI4736","Part B - AZD9291 in combination with AZD6094","Part B - AZD9291 in combination with selumetinib","Part B - AZD9291 in combination with MEDI4736","Part C - AZD6094 monotherapy (Japan only)","Part C - AZD9291 in combination with AZD6094 (Japan only)","Part D - AZD9291 in combination with AZD6094"],"countries":["United States","Canada","Japan","Poland","Russia","South Korea","Taiwan","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety, tolerability and preliminary anti-tumour activity of AZD9291 when given together with AZD6094 or selumetinib in patients with EGFR mutation positive advanced lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT02143466"},{"nctId":"NCT03155997","title":"Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":5637,"enrollmentType":"ACTUAL","startDate":"2017-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2020-03-16","primaryCompletionType":"ACTUAL","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Breast Cancer"],"interventions":["Abemaciclib","Standard Adjuvant Endocrine Therapy"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Romania","Russia","Saudi Arabia","Singapore","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":619,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03155997"},{"nctId":"NCT02546661","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":117,"enrollmentType":"ACTUAL","startDate":"2016-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2020-03-18","primaryCompletionType":"ACTUAL","completionDate":"2026-01-30","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Muscle Invasive Bladder Cancer"],"interventions":["AZD4547","MEDI4736","Olaparib","AZD1775","Vistusertib","AZD9150","Selumetinib"],"countries":["United States","Canada","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, Phase 1b study in patients with muscle invasive bladder cancer (MIBC) (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetics and anti-tumour activity of multiple agents as monotherapy and as combinations of different novel anti-cancer agents. The study will consist of a number of study modules (sub-studies), each evaluating the safety and tolerability of a specific agent or combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT02546661"},{"nctId":"NCT03052608","title":"A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":296,"enrollmentType":"ACTUAL","startDate":"2017-04-27","startDateType":"ACTUAL","primaryCompletionDate":"2020-03-20","primaryCompletionType":"ACTUAL","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Lorlatinib","Crizotinib"],"countries":["United States","Argentina","Australia","Belgium","Canada","China","Czechia","France","Germany","Hong Kong","India","Italy","Japan","Mexico","Netherlands","Poland","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":166,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population","sourceUrl":"https://clinicaltrials.gov/study/NCT03052608"},{"nctId":"NCT02032823","title":"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1837,"enrollmentType":"ACTUAL","startDate":"2014-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2020-03-27","primaryCompletionType":"ACTUAL","completionDate":"2029-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Breast Cancer"],"interventions":["Olaparib","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","China","France","Germany","Hungary","Iceland","Israel","Italy","Japan","Netherlands","Poland","Portugal","Puerto Rico","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":698,"serviceSignals":["HRD / HRR","HER2 profiling"],"summary":"Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT02032823"},{"nctId":"NCT02979522","title":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","sponsor":"Takeda","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":59,"enrollmentType":"ACTUAL","startDate":"2017-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2020-05-05","primaryCompletionType":"ACTUAL","completionDate":"2029-09-24","completionType":"ESTIMATED","lastUpdated":"2025-11-10","conditions":["Hodgkin Disease"],"interventions":["Brentuximab vedotin","Doxorubicin","Vinblastine","Dacarbazine"],"countries":["United States","Brazil","Italy","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen, doxorubicin (Adriamycin), vinblastine, and dacarbazine, in pediatric participants with advanced stage newly diagnosed classical CD30+ Hodgkin Lymphoma (HL).","sourceUrl":"https://clinicaltrials.gov/study/NCT02979522"},{"nctId":"NCT02586857","title":"A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)","sponsor":"Acerta Pharma BV","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2016-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2020-06-26","primaryCompletionType":"ACTUAL","completionDate":"2026-04-01","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Glioblastoma Multiforme"],"interventions":["ACP-196"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)","sourceUrl":"https://clinicaltrials.gov/study/NCT02586857"},{"nctId":"NCT04188548","title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":379,"enrollmentType":"ACTUAL","startDate":"2019-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2020-06-29","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Breast Cancer","Advanced Breast Cancer","Metastatic Breast Cancer","Endometrial Cancer"],"interventions":["LY3484356","Abemaciclib","Everolimus","Alpelisib","Trastuzumab","Aromatase Inhibitor (AI)","Pertuzumab"],"countries":["United States","Australia","Belgium","France","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":74,"serviceSignals":["Broad CGP"],"summary":"The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04188548"},{"nctId":"NCT02157324","title":"Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia","sponsor":"Acerta Pharma BV","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2014-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2020-07-20","primaryCompletionType":"ACTUAL","completionDate":"2026-04-01","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["acalabrutinib","ACP-319"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)","sourceUrl":"https://clinicaltrials.gov/study/NCT02157324"},{"nctId":"NCT03690388","title":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":187,"enrollmentType":"ACTUAL","startDate":"2018-10-05","startDateType":"ACTUAL","primaryCompletionDate":"2020-08-19","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Differentiated Thyroid Cancer"],"interventions":["Cabozantinib","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Croatia","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Mexico","Netherlands","Poland","Romania","Russia","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":164,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior vascular endothelial growth factor receptor (VEGFR)-Targeted therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03690388"},{"nctId":"NCT02811861","title":"Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma","sponsor":"Eisai Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1069,"enrollmentType":"ACTUAL","startDate":"2016-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2020-08-28","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Renal Cell Carcinoma"],"interventions":["Lenvatinib","Everolimus","Pembrolizumab","Sunitinib"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Greece","Ireland","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":183,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \\[IIR\\] using Response Evaluation Criteria in Solid Tumors \\[RECIST 1.1\\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT02811861"},{"nctId":"NCT02489318","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","sponsor":"Aragon Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1052,"enrollmentType":"ACTUAL","startDate":"2015-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2020-09-07","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostate Cancer"],"interventions":["Apalutamide","Placebo","Androgen Deprivation Therapy (ADT)"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Czechia","France","Germany","Hungary","Israel","Japan","Mexico","Poland","Romania","Russia","South Korea","Spain","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":220,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT02489318"},{"nctId":"NCT02477696","title":"Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)","sponsor":"Acerta Pharma BV","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":533,"enrollmentType":"ACTUAL","startDate":"2015-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2020-09-15","primaryCompletionType":"ACTUAL","completionDate":"2028-01-03","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Acalabrutinib","Ibrutinib"],"countries":["United States","Australia","Belgium","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","New Zealand","Poland","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":130,"serviceSignals":["Hematology NGS"],"summary":"This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT02477696"},{"nctId":"NCT02542293","title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":953,"enrollmentType":"ACTUAL","startDate":"2015-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2020-09-21","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non Small Cell Lung Carcinoma NSCLC"],"interventions":["Durvalumab +Tremelimumab","Paclitaxel + carboplatin","Gemcitabine + cisplatin","Gemcitabine + carboplatin","Pemetrexed + cisplatin","Pemetrexed + carboplatin"],"countries":["United States","Argentina","Brazil","Bulgaria","Chile","China","Denmark","Finland","Greece","Hong Kong","India","Israel","Japan","Malaysia","Mexico","Peru","Philippines","Poland","Portugal","Qatar","Romania","Russia","Saudi Arabia","Singapore","South Korea","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":210,"serviceSignals":["MSI / TMB","Hematology NGS"],"summary":"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT02542293"},{"nctId":"NCT03459846","title":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2018-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2020-10-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Urinary Bladder Neoplasms"],"interventions":["Durvalumab","Olaparib","Placebo"],"countries":["United States","Canada","Russia","South Korea","Spain","Taiwan","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03459846"},{"nctId":"NCT02717611","title":"A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","sponsor":"Acerta Pharma BV","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2016-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2020-10-16","primaryCompletionType":"ACTUAL","completionDate":"2026-06-06","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["ACP-196 (acalabrutinib)"],"countries":["United States","Belgium","France","Israel","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT02717611"},{"nctId":"NCT03444844","title":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","sponsor":"Five Eleven Pharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2018-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2020-10-27","primaryCompletionType":"ACTUAL","completionDate":"2022-07","completionType":"ESTIMATED","lastUpdated":"2022-05-02","conditions":["Prostate Cancer Recurrent","Prostate Cancer"],"interventions":["Ga-68 P16-093 PET/CT scan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT03444844"},{"nctId":"NCT02519348","title":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","sponsor":"MedImmune LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":433,"enrollmentType":"ACTUAL","startDate":"2015-10-19","startDateType":"ACTUAL","primaryCompletionDate":"2020-11-06","primaryCompletionType":"ACTUAL","completionDate":"2026-12-18","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Hepatocellular Carcinoma"],"interventions":["Tremelimumab","Durvalumab","Bevacizumab"],"countries":["United States","China","Hong Kong","Italy","Japan","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT02519348"},{"nctId":"NCT03330847","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":273,"enrollmentType":"ACTUAL","startDate":"2018-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2020-11-13","primaryCompletionType":"ACTUAL","completionDate":"2026-10-09","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Metastatic Triple Negative Breast Cancer"],"interventions":["Olaparib Continuous (28-Day cycle) 300 mg BD.","Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).","Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle)."],"countries":["United States","Belgium","Canada","Czechia","France","Germany","Ireland","Italy","Netherlands","Poland","Portugal","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":141,"serviceSignals":["HRD / HRR"],"summary":"This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \\[AZD6738\\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \\[AZD1775\\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+ Ceralasertib and olaparib+adavosertib. The study subject population will be divided ","sourceUrl":"https://clinicaltrials.gov/study/NCT03330847"},{"nctId":"NCT02213926","title":"An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma","sponsor":"Acerta Pharma BV","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":124,"enrollmentType":"ACTUAL","startDate":"2015-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2020-12-04","primaryCompletionType":"ACTUAL","completionDate":"2026-09-06","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Mantle Cell Lymphoma (MCL)"],"interventions":["ACP-196 (acalabrutinib)"],"countries":["United States","Australia","Belgium","Czechia","France","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT02213926"},{"nctId":"NCT03246529","title":"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)","sponsor":"BioLineRx, Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":180,"enrollmentType":"ACTUAL","startDate":"2018-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2020-12-22","primaryCompletionType":"ACTUAL","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Multiple Myeloma"],"interventions":["BL-8040 1.25 mg/kg + G-CSF","Placebo +G-CSF"],"countries":["United States","Germany","Hungary","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT03246529"},{"nctId":"NCT03775486","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":401,"enrollmentType":"ACTUAL","startDate":"2018-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2021-01-11","primaryCompletionType":"ACTUAL","completionDate":"2026-09-27","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Non-small Cell Lung Cancer NSCLC"],"interventions":["Durvalumab","Placebo for Olaparib","Olaparib","Nab-paclitaxel+carboplatin","Gemcitabine+carboplatin","Pemetrexed+carboplatin","Gemcitabine+cisplatin","Pemetrexed+cisplatin"],"countries":["United States","Belgium","Hungary","India","Japan","Mexico","Netherlands","Poland","Russia","South Korea","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["HRD / HRR","Hematology NGS"],"summary":"This is a randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care (SoC) platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.","sourceUrl":"https://clinicaltrials.gov/study/NCT03775486"},{"nctId":"NCT03470922","title":"A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":714,"enrollmentType":"ACTUAL","startDate":"2018-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2021-01-25","primaryCompletionType":"ACTUAL","completionDate":"2030-12-15","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Melanoma"],"interventions":["Relatlimab","Nivolumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Mexico","New Zealand","Norway","Poland","Romania","Russia","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":127,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab monotherapy in treating unresectable melanoma or melanoma that has spread.","sourceUrl":"https://clinicaltrials.gov/study/NCT03470922"},{"nctId":"NCT03462719","title":"A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":211,"enrollmentType":"ACTUAL","startDate":"2018-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2021-02-26","primaryCompletionType":"ACTUAL","completionDate":"2029-04-05","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Leukemia, Lymphocytic, Chronic, B-Cell"],"interventions":["Ibrutinib","Venetoclax","Chlorambucil","Obinutuzumab","Ibrutinib (as Subsequent Therapy)"],"countries":["United States","Belgium","Canada","Czechia","Denmark","France","Israel","Netherlands","Poland","Russia","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":88,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03462719"},{"nctId":"NCT03164616","title":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1186,"enrollmentType":"ACTUAL","startDate":"2017-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2021-03-12","primaryCompletionType":"ACTUAL","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Non Small Cell Lung Cancer NSCLC"],"interventions":["Durvalumab","Tremelimumab","Abraxane + carboplatin","Gemcitabine + cisplatin","Gemcitabine + carboplatin","Pemetrexed + carboplatin","Pemetrexed + cisplatin"],"countries":["United States","Brazil","Bulgaria","China","Germany","Hong Kong","Hungary","Japan","Mexico","Peru","Poland","Russia","South Africa","South Korea","Taiwan","Thailand","Ukraine","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":175,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.","sourceUrl":"https://clinicaltrials.gov/study/NCT03164616"},{"nctId":"NCT02057133","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2014-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2021-03-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Breast Neoplasms"],"interventions":["LY2835219","Letrozole","Anastrozole","Tamoxifen","Exemestane","Everolimus","Trastuzumab","LY3023414","Fulvestrant","Pertuzumab","Loperamide","Endocrine therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.","sourceUrl":"https://clinicaltrials.gov/study/NCT02057133"},{"nctId":"NCT04280081","title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":77,"enrollmentType":"ACTUAL","startDate":"2020-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2021-03-25","primaryCompletionType":"ACTUAL","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Solid Tumor","Medullary Thyroid Cancer"],"interventions":["Selpercatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["RNA fusion"],"summary":"The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04280081"},{"nctId":"NCT03336333","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","sponsor":"BeiGene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":590,"enrollmentType":"ACTUAL","startDate":"2017-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2021-05-07","primaryCompletionType":"ACTUAL","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Zanubrutinib","Bendamustine","Rituximab","Venetoclax"],"countries":["United States","Australia","Austria","Belgium","China","Czechia","France","Italy","New Zealand","Poland","Russia","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":158,"serviceSignals":["Hematology NGS"],"summary":"To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression free survival assess by Independent Central Review.","sourceUrl":"https://clinicaltrials.gov/study/NCT03336333"},{"nctId":"NCT03301168","title":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","sponsor":"Bellicum Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2014-04","startDateType":"ACTUAL","primaryCompletionDate":"2021-05-11","primaryCompletionType":"ACTUAL","completionDate":"2034-05","completionType":"ESTIMATED","lastUpdated":"2022-07-12","conditions":["Acute Lymphoblastic Leukemia","Leukemia, Acute Myeloid (AML), Child","Lymphoma, Non-Hodgkin","Myelodysplastic Syndromes","Primary Immune Deficiency Disorder","Osteopetrosis","Cytopenia","Hemoglobinopathy in Children","Anemia, Aplastic"],"interventions":["BPX-501 T cells","Rimiducid"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (graft versus host disease).","sourceUrl":"https://clinicaltrials.gov/study/NCT03301168"},{"nctId":"NCT03529110","title":"DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":524,"enrollmentType":"ACTUAL","startDate":"2018-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2021-05-21","primaryCompletionType":"ACTUAL","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Breast Cancer"],"interventions":["Trastuzumab deruxtecan (T-DXd)","Ado-trastuzumab emtansine (T-DM1)"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Hong Kong","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":164,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study is designed to compare the anti-tumor activity as well as the safety and efficacy of DS-8201a versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.","sourceUrl":"https://clinicaltrials.gov/study/NCT03529110"},{"nctId":"NCT03381274","title":"Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study","sponsor":"MedImmune LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":43,"enrollmentType":"ACTUAL","startDate":"2018-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2021-05-24","primaryCompletionType":"ACTUAL","completionDate":"2026-11-06","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Oleclumab","Osimertinib","AZD4635"],"countries":["United States","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to investigate the safety, tolerability, and antitumor activity of novel combination therapies administered in participants with advanced EGFRm NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT03381274"},{"nctId":"NCT04325828","title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","sponsor":"Janssen Pharmaceutical K.K.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2020-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2021-06-09","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Salivary Gland Neoplasms"],"interventions":["Apalutamide","GnRH Agonist"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04325828"},{"nctId":"NCT03553836","title":"Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":976,"enrollmentType":"ACTUAL","startDate":"2018-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2021-06-21","primaryCompletionType":"ACTUAL","completionDate":"2033-10-12","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["Melanoma"],"interventions":["Pembrolizumab","Placebo"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","France","Germany","Israel","Italy","Japan","Poland","South Africa","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":159,"serviceSignals":["Broad CGP"],"summary":"This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/\\~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up to 35 cycles (up to \\~2 years) in Part 2 in an open label design. Participants who complete the initial treatment of pla","sourceUrl":"https://clinicaltrials.gov/study/NCT03553836"},{"nctId":"NCT03897543","title":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","sponsor":"Abivax S.A.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2019-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2021-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2023-06-30","completionType":"ESTIMATED","lastUpdated":"2021-03-26","conditions":["Carcinoma, Hepatocellular"],"interventions":["ABX196"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT03897543"},{"nctId":"NCT02029443","title":"ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia","sponsor":"Acerta Pharma BV","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":306,"enrollmentType":"ACTUAL","startDate":"2014-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2021-07-15","primaryCompletionType":"ACTUAL","completionDate":"2027-06-09","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Richter's Syndrome","Prolymphocytic Leukemia"],"interventions":["Acalabrutinib"],"countries":["United States","Italy","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).","sourceUrl":"https://clinicaltrials.gov/study/NCT02029443"},{"nctId":"NCT03732820","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":895,"enrollmentType":"ACTUAL","startDate":"2018-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2021-07-30","primaryCompletionType":"ACTUAL","completionDate":"2027-02-05","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["olaparib","abiraterone acetate"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Italy","Japan","Netherlands","Slovakia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":132,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT03732820"},{"nctId":"NCT04454437","title":"Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ACTUAL","startDate":"2020-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2021-08-06","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Metastatic Triple-negative Breast Cancer"],"interventions":["Sacituzumab Govitecan-hziy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to learn more about the effectiveness of the study drug, sacituzumab govitecan-hziy, in Chinese participants with metastatic triple-negative breast cancer (mTNBC) who received at least 2 systemic chemotherapy regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT04454437"},{"nctId":"NCT03875235","title":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":810,"enrollmentType":"ACTUAL","startDate":"2019-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2021-08-11","primaryCompletionType":"ACTUAL","completionDate":"2027-05-16","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Biliary Tract Neoplasms"],"interventions":["Durvalumab","Placebo"],"countries":["United States","Argentina","Bulgaria","Chile","China","France","Hong Kong","India","Italy","Japan","Poland","Russia","South Korea","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":126,"serviceSignals":["Broad CGP"],"summary":"Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).","sourceUrl":"https://clinicaltrials.gov/study/NCT03875235"},{"nctId":"NCT03298451","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1324,"enrollmentType":"ACTUAL","startDate":"2017-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2021-08-27","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Hepatocellular Carcinoma"],"interventions":["Durvalumab","Tremelimumab (Regimen 1)","Tremelimumab (Regimen 2)","Sorafenib","Durvalumab (Regimen 1)","Durvalumab (Regimen 2)"],"countries":["United States","Brazil","Canada","China","France","Germany","Hong Kong","India","Italy","Japan","Russia","South Korea","Spain","Taiwan","Thailand","Ukraine","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":160,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03298451"},{"nctId":"NCT04044768","title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","sponsor":"USWM CT, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":52,"enrollmentType":"ACTUAL","startDate":"2019-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2021-08-29","primaryCompletionType":"ACTUAL","completionDate":"2038-04-01","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Synovial Sarcoma","Myxoid Liposarcoma"],"interventions":["afamitresgene autoleucel (previously ADP-A2M4)"],"countries":["United States","Canada","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["HLA / TCR"],"summary":"This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .","sourceUrl":"https://clinicaltrials.gov/study/NCT04044768"},{"nctId":"NCT03431350","title":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":136,"enrollmentType":"ACTUAL","startDate":"2018-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2021-08-31","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Prostatic Neoplasms, Castration-Resistant"],"interventions":["Niraparib 200 mg","Cetrelimab 240 mg","Cetrelimab 480 mg","Abiraterone acetate 1000 mg","Prednisone 5 mg"],"countries":["United States","Belgium","Canada","Israel","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":50,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants with metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03431350"},{"nctId":"NCT03673501","title":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":453,"enrollmentType":"ACTUAL","startDate":"2019-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2021-09-01","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Gastrointestinal Stromal Tumors"],"interventions":["Ripretinib","Sunitinib"],"countries":["United States","Argentina","Australia","Belgium","Canada","Chile","Czechia","France","Germany","Hungary","Israel","Italy","Netherlands","Norway","Poland","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":121,"serviceSignals":["Broad CGP"],"summary":"This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).","sourceUrl":"https://clinicaltrials.gov/study/NCT03673501"},{"nctId":"NCT02970318","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","sponsor":"Acerta Pharma BV","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":310,"enrollmentType":"ACTUAL","startDate":"2017-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2021-09-03","primaryCompletionType":"ACTUAL","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Acalabrutinib (ACP-196)","Rituximab","Idelalisib","Bendamustine"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","New Zealand","Poland","Russia","Singapore","Slovakia","South Korea","Spain","Sweden","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":157,"serviceSignals":["Hematology NGS"],"summary":"This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).","sourceUrl":"https://clinicaltrials.gov/study/NCT02970318"},{"nctId":"NCT03328273","title":"A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","sponsor":"Acerta Pharma BV","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2018-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2021-09-07","primaryCompletionType":"ACTUAL","completionDate":"2026-08-26","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Ceralasertib","Acalabrutinib"],"countries":["Poland","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This study evaluates the safety, pharmacokinetics, pharmacodynamics and efficacy of acalabrutinib and ceralasertib (known as AZD6738) when taken in combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT03328273"},{"nctId":"NCT03787992","title":"Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":358,"enrollmentType":"ACTUAL","startDate":"2019-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2021-09-15","primaryCompletionType":"ACTUAL","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-04-11","conditions":["Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer"],"interventions":["Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo","Placebo Gefitinib 250 mg","Gefitinib 250 mg","Placebo AST2818 80mg//40 mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of Alflutinib Mesylate versus Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03787992"},{"nctId":"NCT02734004","title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":264,"enrollmentType":"ACTUAL","startDate":"2016-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2021-09-17","primaryCompletionType":"ACTUAL","completionDate":"2026-09-17","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Ovarian","Breast","SCLC","Gastric Cancers"],"interventions":["Olaparib","MEDI4736","Bevacizumab"],"countries":["United States","France","Israel","Netherlands","South Korea","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.","sourceUrl":"https://clinicaltrials.gov/study/NCT02734004"},{"nctId":"NCT03748641","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":765,"enrollmentType":"ACTUAL","startDate":"2019-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2021-10-08","primaryCompletionType":"ACTUAL","completionDate":"2027-02-27","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Castration-Resistant Prostatic Cancer"],"interventions":["Niraparib","Abiraterone Acetate","Prednisone","Placebo","New Formulation of Niraparib and Abiraterone Acetate (AA)"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Hungary","Israel","Italy","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Russia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":318,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT03748641"},{"nctId":"NCT04577833","title":"A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":136,"enrollmentType":"ACTUAL","startDate":"2020-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2021-10-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["Niraparib","Abiraterone Acetate (AA)","Prednisone"],"countries":["United States","Belgium","France","Georgia","Moldova","Netherlands","Poland","Spain","Sweden","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under modified fasted conditions in participants with metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04577833"},{"nctId":"NCT02671435","title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","sponsor":"MedImmune LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":383,"enrollmentType":"ACTUAL","startDate":"2016-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2021-10-26","primaryCompletionType":"ACTUAL","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced Solid Tumors"],"interventions":["Monalizumab","Durvalumab","Cetuximab","mFOLFOX6","Bevacizumab"],"countries":["United States","Australia","Belgium","Canada","France","Hungary","Italy","New Zealand","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT02671435"},{"nctId":"NCT04488822","title":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT","sponsor":"Daiichi Sankyo Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2020-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2021-10-27","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Tenosynovial Giant Cell Tumor"],"interventions":["Pexidartinib"],"countries":["China","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT04488822"},{"nctId":"NCT03807778","title":"A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer","sponsor":"Takeda","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":53,"enrollmentType":"ACTUAL","startDate":"2019-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2021-11-08","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Mobocertinib"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":25,"serviceSignals":["HER2 profiling"],"summary":"This study is in 2 parts. Different participants will take part in the 1st and 2nd parts of the study. The main aim of the 1st part of the study is to check how much Mobocertinib adults with non-small cell lung cancer (NSCLC) can receive without getting side effects from it. The main aim of the 2nd part of the study is to learn if the condition of adults with non-small cell lung cancer improves after treatment with Mobocertinib. Another aim is to continue checking for side effects from Mobocertinib. In the 1st part of the study, at the first visit, the study doctor will check who can take part. For those that can take part, participants will take a capsule of Mobocertinib once a day for 28 d","sourceUrl":"https://clinicaltrials.gov/study/NCT03807778"},{"nctId":"NCT04557098","title":"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":194,"enrollmentType":"ACTUAL","startDate":"2020-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2021-11-09","primaryCompletionType":"ACTUAL","completionDate":"2027-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Hematological Malignancies"],"interventions":["Teclistamab"],"countries":["United States","Belgium","Canada","China","France","Germany","Italy","Netherlands","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":51,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT04557098"},{"nctId":"NCT03212404","title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","sponsor":"Checkpoint Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":272,"enrollmentType":"ACTUAL","startDate":"2017-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2021-11-18","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-02-03","conditions":["Lung Neoplasms","Carcinoma, Non-Small-Cell Lung","Carcinoma, Small Cell","Malignant Mesothelioma, Advanced","Head and Neck Cancer","Melanoma","Merkel Cell Carcinoma","Renal Cell Carcinoma","Urothelial Carcinoma","Classical Hodgkin Lymphoma","Cutaneous Squamous Cell Carcinoma","Non Hodgkin Lymphoma","Endometrial Cancer"],"interventions":["CK-301 (cosibelimab)"],"countries":["Australia","France","New Zealand","Poland","Russia","South Africa","Spain","Thailand","Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":48,"serviceSignals":["Hematology NGS"],"summary":"CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT03212404"},{"nctId":"NCT03692429","title":"alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells","sponsor":"Celyad Oncology SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2018-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2021-11-28","primaryCompletionType":"ESTIMATED","completionDate":"2036-02-17","completionType":"ESTIMATED","lastUpdated":"2020-11-20","conditions":["Unresectable Metastatic Colorectal Cancer"],"interventions":["CYAD-101","FOLFOX","FOLFIRI"],"countries":["United States","Belgium"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03692429"},{"nctId":"NCT03755791","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":837,"enrollmentType":"ACTUAL","startDate":"2018-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2021-11-30","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Hepatocellular Carcinoma"],"interventions":["Cabozantinib","Sorafenib","Atezolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Colombia","Czechia","France","Georgia","Germany","Hong Kong","Hungary","Ireland","Israel","Italy","Mexico","Netherlands","New Zealand","Philippines","Poland","Romania","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":245,"serviceSignals":["Broad CGP"],"summary":"This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which participants receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT03755791"},{"nctId":"NCT04167696","title":"Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02","sponsor":"Celyad Oncology SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2019-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2021-12","primaryCompletionType":"ESTIMATED","completionDate":"2035-02","completionType":"ESTIMATED","lastUpdated":"2020-06-09","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"interventions":["CYAD-02","ENDOXAN","Fludara"],"countries":["United States","Belgium"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT04167696"},{"nctId":"NCT02993523","title":"A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":443,"enrollmentType":"ACTUAL","startDate":"2017-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2021-12-01","primaryCompletionType":"ACTUAL","completionDate":"2026-06-15","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["Azacitidine","Venetoclax","Placebo"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Croatia","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Japan","Norway","Poland","Portugal","Puerto Rico","Russia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":172,"serviceSignals":["Hematology NGS"],"summary":"Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful treatment of AML is dependent on what subtype of AML the participant has, and the age of the participant when diagnosed. Venetoclax is an experimental drug that kills cancer cells by blocking a protein (part of a cell) that allows cancer cells to stay alive. This study is designed to see if adding venetoclax to azacitidine works better than azacitidine on its own. This is a Phase 3, randomized, double-blind (treatment is unknown to participants and doctors), placebo controlled study in patients with AML who are \\>= 18 or more years old and have ","sourceUrl":"https://clinicaltrials.gov/study/NCT02993523"},{"nctId":"NCT03734029","title":"Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":557,"enrollmentType":"ACTUAL","startDate":"2018-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2022-01-11","primaryCompletionType":"ACTUAL","completionDate":"2026-08-01","completionType":"ESTIMATED","lastUpdated":"2025-10-06","conditions":["Breast Cancer"],"interventions":["Trastuzumab deruxtecan (DS-8201a)","Capecitabine","Eribulin","Gemcitabine","Paclitaxel","Nab-paclitaxel"],"countries":["United States","Austria","Belgium","Canada","China","France","Germany","Greece","Hungary","Israel","Italy","Japan","Portugal","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":208,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: * Cannot be removed by an operation * Has spread to other parts of the body","sourceUrl":"https://clinicaltrials.gov/study/NCT03734029"},{"nctId":"NCT03937219","title":"Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":855,"enrollmentType":"ACTUAL","startDate":"2019-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2022-01-31","primaryCompletionType":"ACTUAL","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Renal Cell Carcinoma"],"interventions":["Cabozantinib","Nivolumab","Ipilimumab","Cabozantinib-matched placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Finland","France","Germany","Hong Kong","Hungary","Israel","Italy","Mexico","Netherlands","New Zealand","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":159,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.","sourceUrl":"https://clinicaltrials.gov/study/NCT03937219"},{"nctId":"NCT04576455","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":303,"enrollmentType":"ACTUAL","startDate":"2020-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2022-02-18","primaryCompletionType":"ACTUAL","completionDate":"2027-08-25","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer"],"interventions":["Giredestrant","Fulvestrant or an Aromatase Inhibitor (Physician Choice)","LHRH Agonist"],"countries":["United States","Argentina","Australia","Brazil","China","Germany","Israel","Poland","Russia","Singapore","South Africa","South Korea","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":81,"serviceSignals":["HER2 profiling"],"summary":"This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of endocrine monotherapy in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT04576455"},{"nctId":"NCT02193503","title":"MVX-ONCO-1 in Patients With Solid Tumor","sponsor":"Maxivax SA","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2014-03","startDateType":"ACTUAL","primaryCompletionDate":"2022-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-09-28","conditions":["Solid Tumor","Cancer"],"interventions":["Treatment"],"countries":["Switzerland"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT02193503"},{"nctId":"NCT03865082","title":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","sponsor":"Idera Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2019-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2022-03","primaryCompletionType":"ESTIMATED","completionDate":"2022-04","completionType":"ESTIMATED","lastUpdated":"2022-02-17","conditions":["Solid Tumor"],"interventions":["Tilsotolimod","Nivolumab","Ipilimumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotherapy drugs ipilimumab and nivolumab in different solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03865082"},{"nctId":"NCT04806464","title":"Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer","sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2021-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2022-03-21","primaryCompletionType":"ACTUAL","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Primary Liver Cancer"],"interventions":["Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of VG161 and find recommended dose of VG161. Part 2: This part is extended dose design to determine the effectiveness of VG161.","sourceUrl":"https://clinicaltrials.gov/study/NCT04806464"},{"nctId":"NCT03669965","title":"KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera","sponsor":"Kartos Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ACTUAL","startDate":"2019-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2022-04","primaryCompletionType":"ESTIMATED","completionDate":"2022-10","completionType":"ESTIMATED","lastUpdated":"2020-07-31","conditions":["Polycythemia Vera"],"interventions":["KRT-232","Ruxolitinib"],"countries":["United States","France","Germany","Hungary","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to hydroxyurea or have undergone treatment with interferon. In Part B, patients must be resistant or intolerant to hydroxyurea. This study is a global, open-label Phase 2a/2b study to determine the efficacy and safety of KRT-232. In Part A of the study, patients will be randomly assigned to 5 arms with 2 different doses and 3 different dosing schedules of KRT 232. In Part B of the study, patients will be randomized either to t","sourceUrl":"https://clinicaltrials.gov/study/NCT03669965"},{"nctId":"NCT04114825","title":"Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer","sponsor":"RhoVac APS","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2019-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2022-04","primaryCompletionType":"ESTIMATED","completionDate":"2022-11","completionType":"ESTIMATED","lastUpdated":"2021-09-28","conditions":["Prostate Cancer Recurrent"],"interventions":["RV001V","Placebo"],"countries":["United States","Belgium","Denmark","Finland","Germany","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"This Phase II trial will enroll approximately 180 adult male patients with an earlier histologic diagnosis of prostatic adenocarcinoma and a biochemical recurrence (BCR) within 3 years of radical prostatectomy (RP) or definitive RT and no distant metastasis or locoregional recurrence. The trial is a randomized placebo-controlled double-blind study of a peptide cancer vaccine (RV001V).","sourceUrl":"https://clinicaltrials.gov/study/NCT04114825"},{"nctId":"NCT05101148","title":"Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2021-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2022-04-06","primaryCompletionType":"ACTUAL","completionDate":"2028-04-28","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Neurofibromatosis Type 1"],"interventions":["Selumetinib"],"countries":["United States","Poland","Russia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study in adolescent participants with NF1 who have inoperable PN is designed to evaluate the effect of a low fat meal on steady state selumetinib exposure; to assess the effect on GI tolerability when selumetinib is dosed under fed and fasted conditions; and potentially, to confirm an appropriate dosing recommendation of selumetinib with a low fat meal that maintains efficacy with acceptable safety. These results may support labelling statements with regard to posology and food.","sourceUrl":"https://clinicaltrials.gov/study/NCT05101148"},{"nctId":"NCT02511106","title":"AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":682,"enrollmentType":"ACTUAL","startDate":"2015-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2022-04-11","primaryCompletionType":"ACTUAL","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Stage IB-IIIA Non-small Cell Lung Carcinoma"],"interventions":["AZD9291 80 mg/40 mg","Placebo AZD9291 80 mg/40 mg","Open-label AZD9291 80 mg/40 mg"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Netherlands","Poland","Romania","Russia","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":238,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT02511106"},{"nctId":"NCT04106219","title":"A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2020-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2022-04-13","primaryCompletionType":"ACTUAL","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Neuroblastoma"],"interventions":["LY3295668 Erbumine","Topotecan","Cyclophosphamide"],"countries":["United States","Australia","Belgium","France","Germany","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04106219"},{"nctId":"NCT04590963","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":370,"enrollmentType":"ACTUAL","startDate":"2020-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2022-05-11","primaryCompletionType":"ACTUAL","completionDate":"2026-09-24","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Squamous Cell Carcinoma of the Head and Neck"],"interventions":["Monalizumab","Cetuximab","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","France","Germany","Greece","Italy","Japan","Netherlands","Philippines","Poland","Portugal","Russia","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":127,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in Participants with recurrent or metastatic head and neck cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04590963"},{"nctId":"NCT02864992","title":"Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":337,"enrollmentType":"ACTUAL","startDate":"2016-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2022-05-16","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification","Lung Adenocarcinoma Stage IIIB/IV"],"interventions":["Tepotinib"],"countries":["United States","Austria","Belgium","China","France","Germany","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":176,"serviceSignals":["MET profiling"],"summary":"This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT02864992"},{"nctId":"NCT02665065","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Actinium Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":153,"enrollmentType":"ACTUAL","startDate":"2016-06","startDateType":"","primaryCompletionDate":"2022-06","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-07-19","conditions":["Acute Myeloid Leukemia","Leukemia, Acute Myeloid","Myeloid Leukemia, Acute","Leukemia, Myeloid, Acute","Acute Myelogenous Leukemia","Leukemia, Acute Myelogenous","Myelogenous Leukemia, Acute","AML","Bone Marrow Transplant"],"interventions":["Iomab-B","Conventional Care","HCT"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).","sourceUrl":"https://clinicaltrials.gov/study/NCT02665065"},{"nctId":"NCT02717624","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","sponsor":"Acerta Pharma BV","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2016-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2022-06-15","primaryCompletionType":"ACTUAL","completionDate":"2027-08-20","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Mantle Cell Lymphoma (MCL)"],"interventions":["Acalabrutinib in combination with BR","Acalabrutinib in combination with VR"],"countries":["United States","Italy","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT02717624"},{"nctId":"NCT04649359","title":"MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":187,"enrollmentType":"ACTUAL","startDate":"2021-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2022-06-17","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Multiple Myeloma"],"interventions":["Elranatamab (PF-06863135)"],"countries":["United States","Australia","Canada","France","Germany","Japan","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.","sourceUrl":"https://clinicaltrials.gov/study/NCT04649359"},{"nctId":"NCT04745689","title":"Study of AZD2811 + Durvalumab in ES-SCLC","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2022-06-18","primaryCompletionType":"ACTUAL","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Small-Cell Lung Cancer"],"interventions":["Durvalumab","AZD2811","Carboplatin","Cisplatin","Etoposide"],"countries":["United States","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04745689"},{"nctId":"NCT04099251","title":"Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":790,"enrollmentType":"ACTUAL","startDate":"2019-10-28","startDateType":"ACTUAL","primaryCompletionDate":"2022-06-28","primaryCompletionType":"ACTUAL","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Melanoma"],"interventions":["Nivolumab","Placebo"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Italy","Netherlands","Norway","Poland","Romania","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":130,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.","sourceUrl":"https://clinicaltrials.gov/study/NCT04099251"},{"nctId":"NCT03399799","title":"Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":279,"enrollmentType":"ACTUAL","startDate":"2017-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2022-07-07","primaryCompletionType":"ACTUAL","completionDate":"2027-10-20","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Hematological Malignancies"],"interventions":["Talquetamab"],"countries":["United States","Belgium","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \\[Dose Escalation\\]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 \\[Dose Expansion\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT03399799"},{"nctId":"NCT04233346","title":"The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation","sponsor":"Otsuka Beijing Research Institute","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":93,"enrollmentType":"ACTUAL","startDate":"2020-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2022-07-22","primaryCompletionType":"ACTUAL","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Chronic Myeloid Leukemia","Acute Lymphoblastic Leukemia"],"interventions":["Ponatinib 30mg OD","Ponatinib 45mg OD"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia","sourceUrl":"https://clinicaltrials.gov/study/NCT04233346"},{"nctId":"NCT04215146","title":"A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study","sponsor":"Oncolytics Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ACTUAL","startDate":"2020-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2022-08-01","primaryCompletionType":"ACTUAL","completionDate":"2025-06","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Breast Cancer Metastatic"],"interventions":["Paclitaxel","Pelareorep","Avelumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to find out the possible anti-cancer effect of pelareorep in combination with chemotherapy \\[paclitaxel\\] and avelumab in treating a type of breast cancer called Hormone Receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 negative(HER2-) breast cancer, which is either locally advanced or has metastasized (cancer that has spread in your body). The study will investigate if pelareorep in combination with paclitaxel and avelumab is more effective than paclitaxel alone, or pelareorep and paclitaxel. The safety of the combination treatments will also be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT04215146"},{"nctId":"NCT04590235","title":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":32,"enrollmentType":"ACTUAL","startDate":"2020-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2022-08-16","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Neurofibromatosis 1","Neurofibroma Plexiform"],"interventions":["Selumetinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN).","sourceUrl":"https://clinicaltrials.gov/study/NCT04590235"},{"nctId":"NCT04214288","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":240,"enrollmentType":"ACTUAL","startDate":"2020-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2022-08-30","primaryCompletionType":"ACTUAL","completionDate":"2027-06-16","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced ER-Positive HER2-Negative Breast Cancer"],"interventions":["AZD9833","Fulvestrant"],"countries":["United States","Belgium","Canada","France","Georgia","Germany","Hungary","Israel","Italy","Poland","Portugal","Russia","South Korea","Spain","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":85,"serviceSignals":["HER2 profiling"],"summary":"This study is randomized, open-label, parallel-group, multicentre Phase 2 study aimed to compare the efficacy and safety of oral AZD9833 versus intramuscular (IM) fulvestrant in women with advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04214288"},{"nctId":"NCT03459170","title":"Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant","sponsor":"Bellicum Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2018-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2022-09","primaryCompletionType":"ESTIMATED","completionDate":"2035-09","completionType":"ESTIMATED","lastUpdated":"2022-07-12","conditions":["Hematologic Malignancy"],"interventions":["BPX-501 T cells","rimiducid"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant. The study will consist of the Main Study and an optional Pharmacokinetics (PK) Sub-Study.","sourceUrl":"https://clinicaltrials.gov/study/NCT03459170"},{"nctId":"NCT04301739","title":"to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":522,"enrollmentType":"ESTIMATED","startDate":"2020-04-17","startDateType":"ESTIMATED","primaryCompletionDate":"2022-09-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-09","completionType":"ESTIMATED","lastUpdated":"2020-03-12","conditions":["Triple Negative Breast Cancer"],"interventions":["HLX10","nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide","Placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as neoadjuvant therapy and HLX10 versus placebo as adjuvant therapy in previously untreated and potentially resectable patients with TNBC and without distant metastasis. Eligible subjects in this study will be randomized to Arm A or Arm B at 2:1 ratio as follows: Arm A (HLX10 arm): HLX10 + chemotherapy (nab-paclitaxel carboplatin) (4 cycles) → HLX10 + chemotherapy (doxorubicin or epirubicin cyclophosphamide) (4 cycles) → surgery → HLX10 (9 cycles) Arm B (placebo arm): Placebo + c","sourceUrl":"https://clinicaltrials.gov/study/NCT04301739"},{"nctId":"NCT05485948","title":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","sponsor":"PharmaEssentia","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":49,"enrollmentType":"ACTUAL","startDate":"2021-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-07","primaryCompletionType":"ACTUAL","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Polycythemia Vera"],"interventions":["Ropeginterferon alfa-2b"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study is a phase II single-arm study designed to evaluate the efficacy and safety of P1101 in Chinese PV patients who are intolerance or resistance to HU.","sourceUrl":"https://clinicaltrials.gov/study/NCT05485948"},{"nctId":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":565,"enrollmentType":"ACTUAL","startDate":"2018-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-09","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"interventions":["zolbetuximab","placebo","oxaliplatin","folinic acid","fluorouracil"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","France","Germany","Israel","Italy","Japan","Mexico","Peru","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":220,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advance","sourceUrl":"https://clinicaltrials.gov/study/NCT03504397"},{"nctId":"NCT04162210","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":325,"enrollmentType":"ACTUAL","startDate":"2020-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-12","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Pom/dex (Pomalidomide plus low dose Dexamethasone)"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","China","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":136,"serviceSignals":["Hematology NGS"],"summary":"This open-label, randomized study for evaluating the efficacy and safety of single agent belantamab mafodotin when compared to pom/dex in participants with RRMM. Participants will be randomized in a 2:1 ratio to receive either single agent belantamab mafodotin or pom/dex. Belantamab mafodotin will be administered on Day 1 (D1) at every 3 weeks (Q3W) schedule. Pomalidomide will be administered daily on Days 1 to 21 of each 28-day cycle, with dexamethasone administered once weekly (Days 1, 8, 15, and 22). Participants in both arms will be treated until disease progression, death, unacceptable toxicity, withdrawal of consent, and lost to follow-up or end of study, whichever comes first.","sourceUrl":"https://clinicaltrials.gov/study/NCT04162210"},{"nctId":"NCT02365597","title":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":239,"enrollmentType":"ACTUAL","startDate":"2015-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-15","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Urothelial Cancer"],"interventions":["Erdafitinib","Midazolam","Metformin"],"countries":["United States","Austria","Belgium","France","Germany","India","Israel","Moldova","Romania","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":105,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the objective response rate (complete response \\[CR\\]+ partial response \\[PR\\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT02365597"},{"nctId":"NCT04288089","title":"A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer","sponsor":"Eisai Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2020-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-16","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Receptors, Estrogen","Genes, Erbb-2","Breast Neoplasms"],"interventions":["Palbociclib (75, 100, 125 milligram [mg])","H3B-6545 (150, 300, 450 mg)"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04288089"},{"nctId":"NCT04684147","title":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","sponsor":"Juventas Cell Therapy Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2020-12-24","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-22","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-08","conditions":["Relapsed or Refractory Acute Lymphoblastic Leukemia"],"interventions":["single dose of CNCT19"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT04684147"},{"nctId":"NCT03473743","title":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2018-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2022-09-30","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Urothelial Carcinoma"],"interventions":["Erdafitinib","Cetrelimab","Cisplatin","Carboplatin"],"countries":["United States","Belarus","Belgium","Brazil","France","Italy","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":127,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab, and for erdafitinib in combination with cetrelimab and platinum (cisplatin and carboplatin) chemotherapy and; (b) to evaluate the safety and clinical activity of erdafitinib alone and in combination with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior systemic therapy for metastatic disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT03473743"},{"nctId":"NCT02503423","title":"Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas","sponsor":"Taiho Oncology, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":253,"enrollmentType":"ACTUAL","startDate":"2015-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2022-10","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Solid Tumors","Lymphoma"],"interventions":["ASTX660"],"countries":["United States","Belgium","Canada","France","Hungary","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660, determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target engagement data, in subjects with advanced solid tumors or lymphoma for whom standard life-prolonging measures are not available.","sourceUrl":"https://clinicaltrials.gov/study/NCT02503423"},{"nctId":"NCT04502394","title":"Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL","sponsor":"Kartos Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2022-10","primaryCompletionType":"ESTIMATED","completionDate":"2024-03","completionType":"ESTIMATED","lastUpdated":"2022-08-04","conditions":["Diffuse Large B Cell Lymphoma","Chronic Lymphocytic Leukemia","Non Hodgkin Lymphoma"],"interventions":["KRT-232","acalabrutinib"],"countries":["United States","Australia","Belgium","Czechia","France","Italy","Poland","Portugal","South Korea","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Hematology NGS"],"summary":"This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)","sourceUrl":"https://clinicaltrials.gov/study/NCT04502394"},{"nctId":"NCT04689828","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":469,"enrollmentType":"ACTUAL","startDate":"2021-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-02","primaryCompletionType":"ACTUAL","completionDate":"2026-09-10","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Prostatic Neoplasms"],"interventions":["177Lu-PSMA-617","68Ga-PSMA-11","ARDT"],"countries":["United States","Austria","Belgium","Canada","Czechia","France","Germany","Netherlands","Poland","Slovakia","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":72,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine whether 177Lu-PSMA-617 improves the Radiographic progression-free survival (rPFS) or Overall Survival (OS) compared to a change in Androgen receptor-directed therapy (ARDT) in metastatic castrate resistant prostate cancer (mCRPC) participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. 469 participants were randomized (235 in the 177Lu-PSMA-617 group and 234 in the ARDT group.","sourceUrl":"https://clinicaltrials.gov/study/NCT04689828"},{"nctId":"NCT03395197","title":"Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1054,"enrollmentType":"ACTUAL","startDate":"2017-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-03","primaryCompletionType":"ACTUAL","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["mCRPC"],"interventions":["Talazoparib with enzalutamide","Placebo with enzalutamide"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Czechia","Finland","France","Germany","Hungary","Israel","Italy","Japan","New Zealand","Norway","Peru","Poland","Portugal","South Africa","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":368,"serviceSignals":["Broad CGP"],"summary":"This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.","sourceUrl":"https://clinicaltrials.gov/study/NCT03395197"},{"nctId":"NCT04068610","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","sponsor":"MedImmune LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2019-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-10","primaryCompletionType":"ACTUAL","completionDate":"2026-11-24","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Metastatic Microsatellite-stable Colorectal Cancer"],"interventions":["Durvalumab","Oleclumab","FOLFOX","Bevacizumab"],"countries":["United States","Australia","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["MSI / TMB"],"summary":"COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04068610"},{"nctId":"NCT05993299","title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","sponsor":"USWM, LLC (dba US WorldMeds)","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":7,"enrollmentType":"ACTUAL","startDate":"2019-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-12","primaryCompletionType":"ACTUAL","completionDate":"2026-07-01","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Neoplasms"],"interventions":["Letetresgene autoleucel","Cyclophosphamide","Fludarabine"],"countries":["United States","Canada","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.","sourceUrl":"https://clinicaltrials.gov/study/NCT05993299"},{"nctId":"NCT05712902","title":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":104,"enrollmentType":"ACTUAL","startDate":"2021-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-17","primaryCompletionType":"ACTUAL","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-30","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Sunvozertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, single-arm, multi-center clinical study to evaluate the anti-tumor efficacy, safety, tolerability and pharmacokinetics of Sunvozertinib in participants with locally advanced or metastatic NSCLC carrying EGFR exon 20 insertion mutations whose disease has progressed on prior platinum-based chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT05712902"},{"nctId":"NCT04492488","title":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","sponsor":"Shanghai Miracogen Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":129,"enrollmentType":"ESTIMATED","startDate":"2021-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-18","primaryCompletionType":"ACTUAL","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-10-22","conditions":["Advanced Solid Tumors","Advanced or Metastatic Gastric Cancer","Advanced or Metastatic Gastroesophageal Junction Cancer"],"interventions":["MRG002"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04492488"},{"nctId":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":507,"enrollmentType":"ACTUAL","startDate":"2018-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-25","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"interventions":["zolbetuximab","oxaliplatin","capecitabine","placebo"],"countries":["United States","Argentina","Canada","China","Croatia","Greece","Ireland","Japan","Malaysia","Netherlands","Portugal","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":165,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called GEJ cancer. Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced stomach cancer or GEJ cancer. This study will give more information about how well zolbetuximab works when given with chemotherapy in adults with advanced stomach cancer or GEJ cancer. In this study, adults with advanced stomach cancer or GEJ canc","sourceUrl":"https://clinicaltrials.gov/study/NCT03653507"},{"nctId":"NCT03003962","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":669,"enrollmentType":"ACTUAL","startDate":"2017-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2022-10-27","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Non Small Cell Lung Carcinoma NSCLC"],"interventions":["Durvalumab (MEDI4736)","Paclitaxel + carboplatin","Gemcitabine + cisplatin","Gemcitabine + carboplatin","Pemetrexed + cisplatin","Pemetrexed + carboplatin"],"countries":["United States","Australia","China","Hungary","Netherlands","Poland","Russia","South Korea","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":92,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, open-label, multi-center Phase III study to determine the efficacy and safety of durvalumab versus platinum-based SoC chemotherapy in the first-line treatment of advanced NSCLC in patients who are epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type and with PD-L1 high expression (PEARL)","sourceUrl":"https://clinicaltrials.gov/study/NCT03003962"},{"nctId":"NCT05662020","title":"A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China","sponsor":"Beijing Health Guard Biotechnology, Inc","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":2750,"enrollmentType":"ACTUAL","startDate":"2022-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2022-11-07","primaryCompletionType":"ACTUAL","completionDate":"2028-03-23","completionType":"ESTIMATED","lastUpdated":"2022-12-27","conditions":["Human Papillomavirus Infection"],"interventions":["Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)","GARDASIL® 9"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune response induced with same conditions in 9-19 age group is non-inferior to 20-26 age group, and if the immune response induced by 9-valent HPV study vaccine administrated with 2-dose schedule in females aged 9-14 years is non-inferior to 3-dose schedule in females aged 20-26 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT05662020"},{"nctId":"NCT03800134","title":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":825,"enrollmentType":"ACTUAL","startDate":"2018-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2022-11-10","primaryCompletionType":"ACTUAL","completionDate":"2028-09-11","completionType":"ESTIMATED","lastUpdated":"2025-06-11","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Durvalumab","Placebo","Carboplatin","Cisplatin","Pemetrexed","Paclitaxel","Gemcitabine","Surgery"],"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Costa Rica","France","Germany","Hungary","India","Italy","Japan","Mexico","Netherlands","Peru","Philippines","Poland","Romania","Russia","South Korea","Spain","Taiwan","Thailand","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":231,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.","sourceUrl":"https://clinicaltrials.gov/study/NCT03800134"},{"nctId":"NCT04076059","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","sponsor":"Astellas (Beijing) Pharmaceutical R&D Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":180,"enrollmentType":"ACTUAL","startDate":"2019-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2022-11-18","primaryCompletionType":"ACTUAL","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Metastatic Hormone Sensitive Prostate Cancer"],"interventions":["Enzalutamide","Placebo","Androgen deprivation therapy (ADT)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC). The study was conducted in two phases: Double-Blind treatment phase and open-label phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT04076059"},{"nctId":"NCT04619004","title":"HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":277,"enrollmentType":"ACTUAL","startDate":"2021-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2022-11-21","primaryCompletionType":"ACTUAL","completionDate":"2027-01-04","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Non-Small Cell Lung Cancer Metastatic","Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor"],"interventions":["Patritumab Deruxtecan (Fixed dose)","Patritumab Deruxtecan (Up-Titration)"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","China","France","Germany","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":123,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT04619004"},{"nctId":"NCT04526834","title":"Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma","sponsor":"Tessa Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2021-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2022-11-22","primaryCompletionType":"ACTUAL","completionDate":"2036-03","completionType":"ESTIMATED","lastUpdated":"2023-04-20","conditions":["Anaplastic Large Cell Lymphoma","Peripheral T Cell Lymphoma","Extranodal NK/T-cell Lymphoma","Diffuse Large B Cell Lymphoma","Primary Mediastinal Large B-Cell Lymphoma (PMBCL)"],"interventions":["CD30.CAR-T"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT04526834"},{"nctId":"NCT04606771","title":"A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2020-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2022-12-21","primaryCompletionType":"ACTUAL","completionDate":"2027-03-15","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Osimertinib + Savolitinib","Savolitinib + Placebo"],"countries":["United States","Argentina","India","Taiwan","Thailand","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with osimertinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04606771"},{"nctId":"NCT04613557","title":"Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Celyad Oncology SA","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":18,"enrollmentType":"ACTUAL","startDate":"2020-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2022-12-21","primaryCompletionType":"ACTUAL","completionDate":"2037-02","completionType":"ESTIMATED","lastUpdated":"2023-08-31","conditions":["Relapse/Refractory Multiple Myeloma"],"interventions":["CYAD-211","Endoxan","Fludara"],"countries":["United States","Belgium"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide","sourceUrl":"https://clinicaltrials.gov/study/NCT04613557"},{"nctId":"NCT03932331","title":"Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":105,"enrollmentType":"ACTUAL","startDate":"2020-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2022-12-22","primaryCompletionType":"ACTUAL","completionDate":"2026-06-24","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Phase I: Relapsed or Refractory B-cell Malignancies","Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma","Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia"],"interventions":["Acalabrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, two-part study to assess the safety, tolerability, pharmacokinetics and clinical efficacy of acalabrutinib in Chinese adult subjects with R/R MCL, CLL and other B-cell malignancies. The study is divided into 2 parts: Phase 1 portion and Phase 2 portion.","sourceUrl":"https://clinicaltrials.gov/study/NCT03932331"},{"nctId":"NCT03132922","title":"MAGE-A4ᶜ¹º³²T for Multi-Tumor","sponsor":"USWM CT, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":71,"enrollmentType":"ACTUAL","startDate":"2017-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2022-12-27","primaryCompletionType":"ACTUAL","completionDate":"2032-09","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Urinary Bladder Cancer","Melanoma","Head and Neck Cancer","Ovarian Cancer","Non-Small Cell Lung Cancer","Esophageal Cancer","Gastric Cancer","Synovial Sarcoma","Myxoid Round Cell Liposarcoma","Gastroesophageal Junction"],"interventions":["Autologous genetically modified MAGE-A4ᶜ¹º³²T cells","Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["HLA / TCR"],"summary":"This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT03132922"},{"nctId":"NCT02732275","title":"DS-3201b in Participants With Lymphomas","sponsor":"Daiichi Sankyo Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2016-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2022-12-31","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Lymphoma, Malignant","Non-hodgkin Lymphoma"],"interventions":["DS-3201b"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"DS-3201b is an experimental drug that is being investigated in clinical research. Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL","sourceUrl":"https://clinicaltrials.gov/study/NCT02732275"},{"nctId":"NCT04639219","title":"A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":102,"enrollmentType":"ACTUAL","startDate":"2020-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2023-01-25","primaryCompletionType":"ACTUAL","completionDate":"2026-07-14","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast"],"interventions":["Trastuzumab deruxtecan"],"countries":["United States","Belgium","Canada","Denmark","France","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology. The target population are patients who have progressed following prior treatment or who have no satisfactory alternative treatment options, including approved second line therapies in the specific tumor type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative methods. Prior HER2 targeting therapy is permitted.","sourceUrl":"https://clinicaltrials.gov/study/NCT04639219"},{"nctId":"NCT02319837","title":"Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1068,"enrollmentType":"ACTUAL","startDate":"2014-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2023-01-31","primaryCompletionType":"ACTUAL","completionDate":"2026-09-19","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Hormone Sensitive Prostate Cancer","Prostate Cancer","Cancer of the Prostate"],"interventions":["Enzalutamide","Placebo (No longer applicable in Open Label study period)","Leuprolide Open Label"],"countries":["United States","Australia","Austria","Brazil","Canada","Denmark","Finland","France","Italy","Netherlands","Poland","Slovakia","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":255,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both. The randomized / blinded portion of the study is now completed following primary endpoint analyses. The study remains ongoing in open label format.","sourceUrl":"https://clinicaltrials.gov/study/NCT02319837"},{"nctId":"NCT05190445","title":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","sponsor":"Pieris Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2021-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2023-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2023-02-01","completionType":"ESTIMATED","lastUpdated":"2022-09-08","conditions":["HER2-positive Gastric Cancer"],"interventions":["Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel","Cinrebafusp alfa (PRS-343) in combination with tucatinib"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["HER2 profiling"],"summary":"A Phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-high and in combination with tucatanib in patients with HER2-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05190445"},{"nctId":"NCT04489771","title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2020-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2023-02-10","primaryCompletionType":"ACTUAL","completionDate":"2026-10-04","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Carcinoma, Renal Cell"],"interventions":["Belzutifan"],"countries":["United States","Australia","Belgium","Greece","Ireland","Israel","Netherlands","Russia","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).","sourceUrl":"https://clinicaltrials.gov/study/NCT04489771"},{"nctId":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":914,"enrollmentType":"ACTUAL","startDate":"2017-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2023-02-21","primaryCompletionType":"ACTUAL","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Urothelial Carcinoma","Renal Cell Carcinoma","Non-Small Cell Lung Cancer","Castration-resistant Prostate Cancer","Triple Negative Breast Cancer","Ovarian Cancer","Endometrial Cancer","Hepatocellular Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Colorectal Cancer","Head and Neck Cancer","Differentiated Thyroid Cancer","Lower Esophageal Cancer"],"interventions":["cabozantinib","atezolizumab"],"countries":["United States","Australia","Belgium","France","Germany","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":124,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\\&N) cancer, and differentiate","sourceUrl":"https://clinicaltrials.gov/study/NCT03170960"},{"nctId":"NCT03837899","title":"Durvalumab and Tremelimumab for Pediatric Malignancies","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ACTUAL","startDate":"2019-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2023-02-28","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Pediatric Cancer","Solid Tumor Pediatric","Hematological Malignancies"],"interventions":["Durvalumab / Tremelimumab Combination Therapy"],"countries":["United States","France","Germany","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to determine the recommended dose of durvalumab and tremelimumab (immunotherapy drugs) in pediatric patients with advanced solid and hematological cancers and expand in a second phase to test the efficacy of these drugs once this dose is determined.","sourceUrl":"https://clinicaltrials.gov/study/NCT03837899"},{"nctId":"NCT03722420","title":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","sponsor":"Il-Yang Pharm. Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":238,"enrollmentType":"ESTIMATED","startDate":"2018-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2023-03-03","primaryCompletionType":"ACTUAL","completionDate":"2025-06-30","completionType":"ESTIMATED","lastUpdated":"2024-10-28","conditions":["Chronic Myeloid Leukemia, Chronic Phase"],"interventions":["Radotinib","Imatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD). This study will be conducted in Chinese patients with newly diagnosed Ph+ Chronic Myelogenous Leukemia(CML)-Chronic Phase(CP) who are previously untreated for Chronic Myelogenous Leukemia(CML).","sourceUrl":"https://clinicaltrials.gov/study/NCT03722420"},{"nctId":"NCT04458272","title":"A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma","sponsor":"Daiichi Sankyo Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2020-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2023-03-10","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["WHO Grade II Glioma"],"interventions":["DS-1001b"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04458272"},{"nctId":"NCT05184712","title":"Phase 3 Clinical Study of AK112 for NSCLC Patients","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":322,"enrollmentType":"ACTUAL","startDate":"2022-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2023-03-10","primaryCompletionType":"ACTUAL","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Non-Squamous Non-small Cell Lung Cancer"],"interventions":["Ivonescimab (SMT112 or AK112) Injection","Placebo Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT05184712"},{"nctId":"NCT04169997","title":"A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer","sponsor":"Impact Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":404,"enrollmentType":"ACTUAL","startDate":"2019-12-24","startDateType":"ACTUAL","primaryCompletionDate":"2023-03-16","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Ovarian Cancer"],"interventions":["IMP4927","Placebos"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT04169997"},{"nctId":"NCT06105619","title":"A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":84,"enrollmentType":"ACTUAL","startDate":"2018-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2023-04-01","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Glioblastoma"],"interventions":["PLB1001","Temozolomide","Cisplatin combined with Etoposide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are: 1. To evaluate overall survival (OS) in the treatment of secondary glioblasts with positive recurrence of PTPRZ1-MET (ZM) fusion gene by PLB1001 Enteric Capsules. 2. To evaluate if it is safety and tolerant in the treatment of secondary glioblasts with positive recurrence of PTPRZ1-MET (ZM) fusion gene by PLB1001 Enteric Capsules. Participants will 1. Be given PLB1001 300mg BID,oral who were randomly assigned in test group. 2. Be given Temozolomide capsules ,oral, who ","sourceUrl":"https://clinicaltrials.gov/study/NCT06105619"},{"nctId":"NCT04035486","title":"A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":587,"enrollmentType":"ACTUAL","startDate":"2019-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2023-04-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12-22","completionType":"ESTIMATED","lastUpdated":"2025-10-10","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Osimertinib","Pemetrexed/Carboplatin","Pemetrexed/Cisplatin"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Czechia","France","India","Japan","Peru","Philippines","Russia","Slovakia","South Africa","South Korea","Taiwan","Thailand","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":153,"serviceSignals":["Broad CGP"],"summary":"The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR). Osimertinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Ep","sourceUrl":"https://clinicaltrials.gov/study/NCT04035486"},{"nctId":"NCT04956692","title":"Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":531,"enrollmentType":"ACTUAL","startDate":"2021-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2023-04-04","primaryCompletionType":"ACTUAL","completionDate":"2026-10-14","completionType":"ESTIMATED","lastUpdated":"2024-12-03","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Pembrolizumab SC","Pembrolizumab IV","Paclitaxel","Nab-Paclitaxel","Carboplatin","Cisplatin","Pemetrexed"],"countries":["United States","Brazil","France","Guatemala","Hungary","Japan","Peru","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":126,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state. Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than d","sourceUrl":"https://clinicaltrials.gov/study/NCT04956692"},{"nctId":"NCT04316364","title":"A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":537,"enrollmentType":"ESTIMATED","startDate":"2020-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2023-04-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-15","completionType":"ESTIMATED","lastUpdated":"2021-11-04","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin","SHR-1316、Chemotherapeutic","Placebo、Chemotherapeutic"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This trial is designed to evaluate the efficacy, safety and immunogenicity of neoadjuvant treatment with monoclonal antibody SHR-1316 or placebo in combination with platinum doublet chemotherapy in participants with resectable Stage II, IIIA, or selected IIIB non-small cell lung cancer (NSCLC) followed by adjuvant SHR-1316 or placebo and monitoring.","sourceUrl":"https://clinicaltrials.gov/study/NCT04316364"},{"nctId":"NCT05243550","title":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","sponsor":"UroGen Pharma Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":240,"enrollmentType":"ACTUAL","startDate":"2022-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2023-04-26","primaryCompletionType":"ACTUAL","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Bladder Cancer","Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"interventions":["UGN-102"],"countries":["United States","Austria","Bulgaria","Estonia","Georgia","Latvia","Lithuania","Poland","Serbia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["Broad CGP"],"summary":"This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05243550"},{"nctId":"NCT04194944","title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":261,"enrollmentType":"ACTUAL","startDate":"2020-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-01","primaryCompletionType":"ACTUAL","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Selpercatinib","Carboplatin","Cisplatin","Pemetrexed","Pembrolizumab"],"countries":["Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Poland","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":196,"serviceSignals":["RNA fusion"],"summary":"The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion-positive non-squamous non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04194944"},{"nctId":"NCT04538664","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":308,"enrollmentType":"ACTUAL","startDate":"2020-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-03","primaryCompletionType":"ACTUAL","completionDate":"2027-08-02","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Amivantamab","Pemetrexed","Carboplatin"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":232,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT04538664"},{"nctId":"NCT05463952","title":"A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6,"enrollmentType":"ACTUAL","startDate":"2022-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-04","primaryCompletionType":"ACTUAL","completionDate":"2025-03-31","completionType":"ESTIMATED","lastUpdated":"2024-11-13","conditions":["Breast Neoplasms"],"interventions":["vepdegestrant"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this clinical trial is to learn about the safety, tolerability, Pharmacokinetics (PK), and preliminary efficacy of ARV-471 as monotherapy in Japanese participants with ER+/HER2- locally advanced or metastatic breast cancer (mBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05463952"},{"nctId":"NCT05423977","title":"Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors","sponsor":"Hangzhou Adcoris Biopharmacy Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2021-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-05","primaryCompletionType":"ACTUAL","completionDate":"2026-07-07","completionType":"ESTIMATED","lastUpdated":"2025-09-30","conditions":["HER2-positive Advanced Solid Tumor"],"interventions":["ZV0203"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"An open-label, multicenter, phase I dose-escalation study to assess the safety, Pharmacokinetic (PK), immunogenicity and preliminary anti-tumor activity of ZV0203 in patients with HER2-Positive advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05423977"},{"nctId":"NCT04661150","title":"A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2021-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-08","primaryCompletionType":"ACTUAL","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["Atezolizumab","Trastuzumab","Capecitabine","Oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"This is a phase II, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of perioperative trastuzumab+XELOX with / without atezolizumab in participants eligible for surgery with locally advanced HER2-positive gastric cancer or adenocarcinoma of GEJ.","sourceUrl":"https://clinicaltrials.gov/study/NCT04661150"},{"nctId":"NCT04305496","title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":818,"enrollmentType":"ACTUAL","startDate":"2020-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-09","primaryCompletionType":"ACTUAL","completionDate":"2026-06-22","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"interventions":["Fulvestrant","Capivasertib","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Canada","China","France","Germany","Hungary","Israel","Italy","Japan","Peru","Poland","Russia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":215,"serviceSignals":["HER2 profiling"],"summary":"Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04305496"},{"nctId":"NCT04703192","title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","sponsor":"Daiichi Sankyo","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":155,"enrollmentType":"ACTUAL","startDate":"2021-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-10","primaryCompletionType":"ACTUAL","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Relapsed/Refractory Peripheral T-Cell Lymphoma","Adult T Cell Leukemia/Lymphoma"],"interventions":["Valemetostat Tosylate"],"countries":["United States","Australia","Canada","France","Germany","Italy","Japan","Netherlands","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":60,"serviceSignals":["Hematology NGS"],"summary":"This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04703192"},{"nctId":"NCT03940703","title":"A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ACTUAL","startDate":"2019-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-11","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Non-small Cell Lung Cancer"],"interventions":["Tepotinib","Osimertinib"],"countries":["United States","Belgium","China","France","Germany","Hong Kong","Italy","Japan","Malaysia","Netherlands","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":179,"serviceSignals":["Broad CGP"],"summary":"This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03940703"},{"nctId":"NCT03789604","title":"A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer","sponsor":"CStone Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":479,"enrollmentType":"ACTUAL","startDate":"2018-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-15","primaryCompletionType":"ACTUAL","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Non Small Cell Lung Cancer"],"interventions":["CS1001 monoclonal antibody","CS1001 placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03789604"},{"nctId":"NCT06391944","title":"JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":161,"enrollmentType":"ACTUAL","startDate":"2021-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-17","primaryCompletionType":"ACTUAL","completionDate":"2026-11-21","completionType":"ESTIMATED","lastUpdated":"2024-04-30","conditions":["Local Advanced or Metastatic NSCLC","Harboring EGFR Common Mutation"],"interventions":["JMT101 Injection","Osimertinib tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This was a multicenter, open-label phase 2 study. This study aimed to evaluate the efficacy and safety of JMT101 combined with Osimertinib in participants with local advanced or metastatic non-small-cell lung cancer harbouring EGFR common mutation with or without prior systemic therapy. Efficacy indexes included investigator-assessed Overall Response Rate(ORR), Disease Control Rate(DCR), Duration of Response( DoR), Progression Free Survival (PFS) per RECIST 1.1 and Overall Survival (OS). Safety indexes included Adverse Events incidence and severity. This study included 4 cohorts, cohort 1 included EGFR-mutated advanced NSCLC patients without prior systemic therapy and accepted JMT101 6mg/Kg ","sourceUrl":"https://clinicaltrials.gov/study/NCT06391944"},{"nctId":"NCT04211337","title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","sponsor":"Loxo Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":291,"enrollmentType":"ACTUAL","startDate":"2020-02-11","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-22","primaryCompletionType":"ACTUAL","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["Medullary Thyroid Cancer"],"interventions":["Selpercatinib","Cabozantinib","Vandetanib"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","India","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":143,"serviceSignals":["Broad CGP"],"summary":"The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04211337"},{"nctId":"NCT03819465","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":175,"enrollmentType":"ACTUAL","startDate":"2018-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-23","primaryCompletionType":"ACTUAL","completionDate":"2026-07-01","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["Durvalumab","Danvatirsen","Oleclumab","MEDI5752","Pemetrexed","Carboplatin","Gemcitabine","Cisplatin","Nab-paclitaxel","AZD2936"],"countries":["United States","Austria","Belgium","Poland","Russia","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["Broad CGP"],"summary":"This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT03819465"},{"nctId":"NCT03319628","title":"First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b","sponsor":"Mersana Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":523,"enrollmentType":"ACTUAL","startDate":"2017-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2023-05-31","primaryCompletionType":"ACTUAL","completionDate":"2024-10-31","completionType":"ESTIMATED","lastUpdated":"2023-11-13","conditions":["Platinum Resistant Ovarian Cancer","Non Small Cell Lung Cancer Metastatic"],"interventions":["upifitamab rilsodotin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) were enrolled in the expansion segment of this study. Patients with platinum-resistant, high-grade serous ovarian cancer were enrolled in the UPLIFT segment of this study. In addition to safety assessments, the pharmacokinetics of the drug were assessed along with ADC activity. A QTc sub-study was added for the UPLIFT cohort for a sub-s","sourceUrl":"https://clinicaltrials.gov/study/NCT03319628"},{"nctId":"NCT03456076","title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":257,"enrollmentType":"ACTUAL","startDate":"2018-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2023-06-26","primaryCompletionType":"ACTUAL","completionDate":"2031-11-19","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Alectnib","Cisplatin","Vinorelbine","Gemcitabine","Pemetrexed","Carboplatin"],"countries":["United States","Australia","Austria","Belarus","Bosnia and Herzegovina","China","Denmark","Egypt","France","Germany","Greece","Hungary","Israel","Italy","Japan","Kazakhstan","North Macedonia","Poland","Romania","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":114,"serviceSignals":["Hematology NGS"],"summary":"This randomized, active-controlled, multicenter, open-label, Phase III study is designed to investigate the efficacy and safety of alectinib compared with platinum-based in the adjuvant setting. Participants in the experimental arm will receive alectinib at 600 mg orally twice daily (BID) taken with food for 24 months. Participants in the control arm will receive one of the protocol specified platinum based chemotherapy regimens for 4 cycles. Following treatment completion, participants will be followed up for their disease until disease recurrence. At the time of disease recurrence, participants will enter a survival follow-up until death, withdrawal of consent or study closure, whichever o","sourceUrl":"https://clinicaltrials.gov/study/NCT03456076"},{"nctId":"NCT03975647","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":466,"enrollmentType":"ACTUAL","startDate":"2019-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2023-06-29","primaryCompletionType":"ACTUAL","completionDate":"2029-03-10","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["HER2-positive Breast Cancer"],"interventions":["tucatinib","placebo","T-DM1"],"countries":["United States","Australia","Austria","Belgium","Canada","China","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":490,"serviceSignals":["HER2 profiling"],"summary":"This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer. Each treatment cycle lasts 21 da","sourceUrl":"https://clinicaltrials.gov/study/NCT03975647"},{"nctId":"NCT04603001","title":"Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2020-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-03","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)","Chronic Myelomonocytic Leukemia (CMML)","Myeloproliferative Neoplasms (MPNs)"],"interventions":["LY3410738","Venetoclax","Azacitidine"],"countries":["United States","Australia","Belgium","Canada","Finland","France","Germany","Israel","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT04603001"},{"nctId":"NCT03425643","title":"Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":797,"enrollmentType":"ACTUAL","startDate":"2018-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-10","primaryCompletionType":"ACTUAL","completionDate":"2026-10-15","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non-small Cell Lung Cancer"],"interventions":["Pembrolizumab","Placebo","Cisplatin","Gemcitabine","Pemetrexed"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Estonia","France","Germany","Ireland","Italy","Japan","Latvia","Lithuania","Malaysia","Poland","Romania","Russia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":227,"serviceSignals":["Broad CGP"],"summary":"This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery \\[neoadjuvant phase\\], followed by pembrolizumab alone after surgery \\[adjuvant phase\\] in participants with resectable stage II, IIIA, and resectable IIIB (T3-4N2) non-small cell lung cancer (NSCLC). The primary hypotheses of this study are that neoadjuvant pembrolizumab (vs. placebo) in combination with NAC, followed by surgery and adjuvant pembrolizumab (vs. placebo) will improve: 1) event free survival (EFS) by biopsy assessed by local pathologist or by investigator-assessed imaging using Response Evaluation Criteria in Solid Tumor","sourceUrl":"https://clinicaltrials.gov/study/NCT03425643"},{"nctId":"NCT04988295","title":"A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":776,"enrollmentType":"ACTUAL","startDate":"2021-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-10","primaryCompletionType":"ACTUAL","completionDate":"2028-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Lazertinib","Amivantamab","Pemetrexed","Carboplatin"],"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","France","Germany","Hong Kong","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":249,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or l","sourceUrl":"https://clinicaltrials.gov/study/NCT04988295"},{"nctId":"NCT04721977","title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":66,"enrollmentType":"ACTUAL","startDate":"2021-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-17","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Breast Cancer"],"interventions":["Tucatinib","Trastuzumab","Capecitabine"],"countries":["Japan","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":28,"serviceSignals":["HER2 profiling"],"summary":"The goal of this study is to evaluate the efficacy and safety of tucatinib in combination with trastuzumab and capecitabine in participants with unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with taxane anti-cancer agent, trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1). The primary hypothesis is that the confirmed objective response rate (cORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as determined by independent central review (ICR) for the combination of tucatinib, trastuzumab and capecitabine, is greater than 20%.","sourceUrl":"https://clinicaltrials.gov/study/NCT04721977"},{"nctId":"NCT04521686","title":"Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2020-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-17","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Cholangiocarcinoma","Chondrosarcoma","Glioma","Any Solid Tumor"],"interventions":["LY3410738","Gemcitabine","Cisplatin","Durvalumab"],"countries":["United States","Australia","France","Hong Kong","Japan","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04521686"},{"nctId":"NCT03972488","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","sponsor":"Advanced Accelerator Applications","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":226,"enrollmentType":"ACTUAL","startDate":"2020-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-20","primaryCompletionType":"ACTUAL","completionDate":"2027-10-29","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"interventions":["Lutathera","30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)","2.5% Lys-Arg sterile amino acid solution","High dose 60 mg octreotide long-acting repeatable"],"countries":["United States","Canada","France","Germany","Italy","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The aim of NETTER-2 was to determine if Lutathera in combination with long-acting octreotide prolongs progression free survival (PFS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients were eligible, as well as patients previously treated with SSAs in the absence of progression.","sourceUrl":"https://clinicaltrials.gov/study/NCT03972488"},{"nctId":"NCT04025879","title":"A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":461,"enrollmentType":"ACTUAL","startDate":"2019-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-26","primaryCompletionType":"ACTUAL","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2025-10-16","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Nivolumab","Carboplatin","Cisplatin","Paclitaxel","Pemetrexed","Placebo","Docetaxel"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Ireland","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":108,"serviceSignals":["Broad CGP"],"summary":"The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04025879"},{"nctId":"NCT04539496","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":402,"enrollmentType":"ACTUAL","startDate":"2018-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2023-07-31","primaryCompletionType":"ACTUAL","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Metastasis Solid Tumors","Advanced Breast Cancer"],"interventions":["XZP-3287","XZP-3287;Letrozole;Anastrozole;Fulvestrant"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study includes single agent/combination dose exploration study and the phase II study. The primary purpose of the dose exploration study is to determine the maximum tolerated dose(MTD)/recommended phase II dose(RP2D) of XZP-3287 and assess its safety and preliminary efficacy in solid tumor patients. The phase II study aims to explore the efficacy and safety profiles of XZP-3287 as a single- agent in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04539496"},{"nctId":"NCT04223856","title":"Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":886,"enrollmentType":"ACTUAL","startDate":"2020-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-08","primaryCompletionType":"ACTUAL","completionDate":"2028-03-01","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Urothelial Cancer"],"interventions":["Enfortumab vedotin","Pembrolizumab","Cisplatin","Carboplatin","Gemcitabine"],"countries":["United States","Argentina","Australia","Belgium","Canada","China","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Poland","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":260,"serviceSignals":["Broad CGP"],"summary":"This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.","sourceUrl":"https://clinicaltrials.gov/study/NCT04223856"},{"nctId":"NCT05059262","title":"Study of Vimseltinib for Tenosynovial Giant Cell Tumor","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":123,"enrollmentType":"ACTUAL","startDate":"2021-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-10","primaryCompletionType":"ACTUAL","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Tenosynovial Giant Cell Tumor","Pigmented Villonodular Synovitis","Giant Cell Tumor of Tendon Sheath","Tenosynovial Giant Cell Tumor, Diffuse","Tenosynovial Giant Cell Tumor, Localized"],"interventions":["Vimseltinib","Placebo"],"countries":["United States","Australia","Canada","France","Germany","Hong Kong","Italy","Netherlands","Norway","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo i","sourceUrl":"https://clinicaltrials.gov/study/NCT05059262"},{"nctId":"NCT04487080","title":"A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1074,"enrollmentType":"ACTUAL","startDate":"2020-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-11","primaryCompletionType":"ACTUAL","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Amivantamab","Osimertinib","Lazertinib","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":269,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \\[Exon 19del\\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04487080"},{"nctId":"NCT04023526","title":"A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy","sponsor":"OncoVerity, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":103,"enrollmentType":"ACTUAL","startDate":"2019-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-15","primaryCompletionType":"ACTUAL","completionDate":"2026-05-15","completionType":"ESTIMATED","lastUpdated":"2025-08-20","conditions":["Leukemia, Myeloid, Acute"],"interventions":["Azacitidine","Cusatuzumab"],"countries":["Australia","Brazil","France","Israel","Italy","Russia","Spain","Switzerland","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":56,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the efficacy of cusatuzumab in combination with azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04023526"},{"nctId":"NCT04556773","title":"A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":138,"enrollmentType":"ACTUAL","startDate":"2020-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-16","primaryCompletionType":"ACTUAL","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Metastatic Breast Cancer"],"interventions":["Trastuzumab deruxtecan","Durvalumab","Paclitaxel","Capivasertib","Anastrozole","Fulvestrant","Capecitabine"],"countries":["United States","Australia","Belgium","Brazil","Canada","France","Mexico","Russia","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04556773"},{"nctId":"NCT04991948","title":"Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer","sponsor":"Celyad Oncology SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":34,"enrollmentType":"ESTIMATED","startDate":"2021-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-21","primaryCompletionType":"ESTIMATED","completionDate":"2038-05-25","completionType":"ESTIMATED","lastUpdated":"2022-03-09","conditions":["Unresectable Metastatic Colorectal Cancer"],"interventions":["CYAD-101","FOLFOX","Pembrolizumab"],"countries":["United States","Belgium"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The purpose of the CYAD-101-002 study is to assess the safety and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered concurrently with FOLFOX chemotherapy, followed by pembrolizumab treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04991948"},{"nctId":"NCT04379635","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","sponsor":"BeiGene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":453,"enrollmentType":"ACTUAL","startDate":"2020-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-21","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Non Small Cell Lung Cancer"],"interventions":["Tislelizumab","Cisplatin injection","Paclitaxel injection","Pemetrexed Disodium","Placebos","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant treatment versus participants receiving placebo plus platinum-based doublet chemotherapy as neoadjuvant treatment followed by placebo as adjuvant treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04379635"},{"nctId":"NCT02180711","title":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","sponsor":"Acerta Pharma BV","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":113,"enrollmentType":"ACTUAL","startDate":"2014-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-25","primaryCompletionType":"ACTUAL","completionDate":"2028-12-11","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Non Hodgkin Lymphoma"],"interventions":["acalabrutinib","rituximab (IV)","Lenalidomide"],"countries":["United States","Canada","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL","sourceUrl":"https://clinicaltrials.gov/study/NCT02180711"},{"nctId":"NCT04666038","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","sponsor":"Loxo Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":238,"enrollmentType":"ACTUAL","startDate":"2021-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-29","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Pirtobrutinib","Idelalisib","Bendamustine","Rituximab"],"countries":["United States","Australia","Austria","Belgium","Canada","China","Croatia","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Poland","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":232,"serviceSignals":["Hematology NGS"],"summary":"This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.","sourceUrl":"https://clinicaltrials.gov/study/NCT04666038"},{"nctId":"NCT04665856","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":123,"enrollmentType":"ACTUAL","startDate":"2020-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2023-08-31","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Small Cell Lung Carcinoma"],"interventions":["Tiragolumab","Atezolizumab","Carboplatin","Etoposide","Tiragolumab Matching Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04665856"},{"nctId":"NCT03386513","title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","sponsor":"AbbVie","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":179,"enrollmentType":"ACTUAL","startDate":"2018-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2023-09-06","primaryCompletionType":"ACTUAL","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Blastic Plasmacytoid Dendritic Cell Neoplasm","Myeloproliferative Neoplasm"],"interventions":["IMGN632"],"countries":["United States","France","Germany","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT03386513"},{"nctId":"NCT03778957","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":724,"enrollmentType":"ACTUAL","startDate":"2018-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2023-09-11","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Hepatocellular Carcinoma"],"interventions":["Durvalumab","Bevacizumab","Placebo","Transarterial Chemoembolization (TACE)"],"countries":["United States","Australia","Brazil","Canada","China","France","Hong Kong","India","Italy","Japan","Mexico","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":166,"serviceSignals":["Broad CGP"],"summary":"A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT03778957"},{"nctId":"NCT03962543","title":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","sponsor":"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":114,"enrollmentType":"ACTUAL","startDate":"2019-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2023-09-20","primaryCompletionType":"ACTUAL","completionDate":"2028-12-22","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Plexiform Neurofibroma","Neurofibromatosis Type 1 (NF1)"],"interventions":["Mirdametinib (PD-0325901) oral capsule or dispersible tablet"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Broad CGP"],"summary":"This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT03962543"},{"nctId":"NCT04974008","title":"Osteosarcoma Maintenance Therapy With OST31-164","sponsor":"Emerald Clinical Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":39,"enrollmentType":"ACTUAL","startDate":"2021-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2023-09-21","primaryCompletionType":"ACTUAL","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Bone Cancer"],"interventions":["OST31-164"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the lungs and has recently been surgically removed will be enrolled. Patients will receive OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT04974008"},{"nctId":"NCT04191499","title":"A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":325,"enrollmentType":"ACTUAL","startDate":"2020-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2023-09-29","primaryCompletionType":"ACTUAL","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Breast Cancer"],"interventions":["Inavolisib","Placebo","Palbociclib","Fulvestrant"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Denmark","France","Georgia","Germany","Greece","Hong Kong","Hungary","Italy","Malaysia","New Zealand","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":135,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT04191499"},{"nctId":"NCT04246047","title":"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":494,"enrollmentType":"ACTUAL","startDate":"2020-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2023-10-02","primaryCompletionType":"ACTUAL","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Daratumumab","Bortezomib","Dexamethasone"],"countries":["United States","Australia","Belgium","China","Greece","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":69,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04246047"},{"nctId":"NCT05514132","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2022-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2023-10-20","primaryCompletionType":"ACTUAL","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Advanced Solid Tumours"],"interventions":["Ceralasertib","Durvalumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label study of ceralasertib given in combination with durvalumab in Chinese participants with advanced solid tumours. In each cohort, a monotherapy lead-in period (Cycle 0, duration of 7 or 14 days), prior to dosing with durvalumab, is added to investigate the PK profile and safety/tolerability of ceralasertib in Chinese participants. This study is designed to investigate and characterise preliminary safety, tolerability, and PK of ceralasertib in DLT-evaluable Chinese participants","sourceUrl":"https://clinicaltrials.gov/study/NCT05514132"},{"nctId":"NCT04270591","title":"Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer","sponsor":"Haihe Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":183,"enrollmentType":"ESTIMATED","startDate":"2019-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2023-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2023-12-30","completionType":"ESTIMATED","lastUpdated":"2022-08-01","conditions":["C-Met Exon 14 Mutation"],"interventions":["Glumetinib"],"countries":["United States","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["MET profiling"],"summary":"Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)","sourceUrl":"https://clinicaltrials.gov/study/NCT04270591"},{"nctId":"NCT04718883","title":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":59,"enrollmentType":"ACTUAL","startDate":"2021-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2023-10-25","primaryCompletionType":"ACTUAL","completionDate":"2028-08-07","completionType":"ESTIMATED","lastUpdated":"2023-11-24","conditions":["Mantle Cell Lymphoma"],"interventions":["CD19-targeted Chimeric Antigen Receptor (CAR) T Cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.","sourceUrl":"https://clinicaltrials.gov/study/NCT04718883"},{"nctId":"NCT04647526","title":"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment","sponsor":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":455,"enrollmentType":"ACTUAL","startDate":"2021-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-01","primaryCompletionType":"ACTUAL","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["[Lu-177]-PNT2002","Abiraterone","Enzalutamide"],"countries":["United States","Canada","France","Netherlands","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of \\[Lu-177\\]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).","sourceUrl":"https://clinicaltrials.gov/study/NCT04647526"},{"nctId":"NCT04579380","title":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":217,"enrollmentType":"ACTUAL","startDate":"2021-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-01","primaryCompletionType":"ACTUAL","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Uterine Neoplasms","Uterine Cervical Neoplasms","Biliary Tract Neoplasms","Urologic Neoplasms","Carcinoma, Non-Small-Cell Lung","HER2 Mutations Breast Neoplasms"],"interventions":["tucatinib","trastuzumab","fulvestrant"],"countries":["United States","Belgium","Germany","Italy","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["HER2 profiling"],"summary":"This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04579380"},{"nctId":"NCT05460273","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":119,"enrollmentType":"ACTUAL","startDate":"2022-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-07","primaryCompletionType":"ACTUAL","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Cancer"],"interventions":["Datopotamab Deruxtecan (Dato-DXd)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). \"Advanced\" usually means that the cancer keeps growing even with treatment. The cancer may also be \"metastatic\", which means that it has spread to other parts of the body or the surrounding tissue. The study drug, Datopotamab deruxtecan, is designed to work by attaching to the tumor cells and stopping the tumor growth. Datopotamab deruxtecan is also known as Dato-DXd. In this study, the researchers want to find out how well Dato-DXd works to stop tumors from growing in Chinese participants with NCSLC or TNBC. This is the first time Dato-DXd is being studied ","sourceUrl":"https://clinicaltrials.gov/study/NCT05460273"},{"nctId":"NCT02908906","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":234,"enrollmentType":"ACTUAL","startDate":"2016-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-17","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Neoplasms"],"interventions":["JNJ-63723283"],"countries":["United States","Moldova","Poland","Russia","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["MSI / TMB"],"summary":"The Primary purpose of this study is to identify the recommended Phase 2 dose \\[RP2D(s)\\] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers including non-small-cell lung cancer (NSCLC), melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer (CRC) in Part 2, to determine one or more additional RP2Ds in Parts 3 and 4.","sourceUrl":"https://clinicaltrials.gov/study/NCT02908906"},{"nctId":"NCT04951622","title":"A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":199,"enrollmentType":"ESTIMATED","startDate":"2021-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-17","primaryCompletionType":"ACTUAL","completionDate":"2029-03-29","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Myasthenia Gravis"],"interventions":["Nipocalimab","Placebo","Nipocalimab SC-LIV"],"countries":["United States","Australia","Belgium","Canada","China","Czechia","Denmark","France","Germany","Italy","Japan","Mexico","Poland","South Korea","Spain","Sweden","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":112,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \\[PD\\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.","sourceUrl":"https://clinicaltrials.gov/study/NCT04951622"},{"nctId":"NCT05009069","title":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":58,"enrollmentType":"ACTUAL","startDate":"2022-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-21","primaryCompletionType":"ACTUAL","completionDate":"2026-11-10","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Rectal Neoplasms","Rectal Cancer"],"interventions":["Radiotherapy","Capecitabine","Fluorouracil","Atezolizumab","Tiragolumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with locally advanced rectal cancer (LARC). The study consists of a safety run-in phase and a randomization phase. Participants enrolled in the safety run-in phase will receive atezolizumab + tiragolumab following nCRT. Upon determination of the safety of the treatment regimen, the study will be proceed to the randomization phase. Participants will be randomized in a 1:1 ratio to the atezolizumab + tiragolumab arm or atezolizumab arm.","sourceUrl":"https://clinicaltrials.gov/study/NCT05009069"},{"nctId":"NCT05027776","title":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1348,"enrollmentType":"ESTIMATED","startDate":"2021-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-22","primaryCompletionType":"ACTUAL","completionDate":"2026-09-29","completionType":"ESTIMATED","lastUpdated":"2024-04-17","conditions":["HPV Infections","Cervical Cancer Stage IIa","Vaginal Cancer","Genital Wart","CIN1","CIN2","CIN3"],"interventions":["2-doses Group among 9-14 years","3-doses Group among 9-19 years","3-doses Group among 20-26 years"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase 3 study will evaluate the immunogenicity and safety of Quadrivalent HPV recombinant vaccine in Chinese females aged 9 to 26 years","sourceUrl":"https://clinicaltrials.gov/study/NCT05027776"},{"nctId":"NCT04971226","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":405,"enrollmentType":"ACTUAL","startDate":"2021-10-06","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-28","primaryCompletionType":"ACTUAL","completionDate":"2031-01-18","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive"],"interventions":["Imatinib","Nilotinib","Bosutinib","Dasatinib","Asciminib"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Netherlands","Norway","Portugal","Singapore","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":110,"serviceSignals":["Hematology NGS"],"summary":"The study is designed to compare the efficacy of asciminib 80 mg QD versus Investigator selected Tyrosine Kinase Inhibitor (TKI) for the treatment of newly diagnosed, previously untreated patients with Ph+ CML-CP. The Investigator selected TKI will be one of the following treatment options for first-line treatment of CML-CP - imatinib 400 mg QD or nilotinib 300 mg BID or dasatinib 100 mg QD or bosutinib 400 mg QD. This study has three periods: 1. Treatment period for all randomized participants, 2. Optional Treatment-Free Remission (TFR) period only for participants meeting TFR eligibility criteria and 3. Treatment Re-Initiation (TRI) period only for participants who relapsed after TFR attem","sourceUrl":"https://clinicaltrials.gov/study/NCT04971226"},{"nctId":"NCT05089734","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":603,"enrollmentType":"ACTUAL","startDate":"2021-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-29","primaryCompletionType":"ACTUAL","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Sacituzumab Govitecan-hziy (SG)","Docetaxel"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":227,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05089734"},{"nctId":"NCT03866499","title":"A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients","sponsor":"Beta Pharma Shanghai","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":369,"enrollmentType":"ACTUAL","startDate":"2021-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-30","primaryCompletionType":"ACTUAL","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2024-08-07","conditions":["NSCLC"],"interventions":["BPI-7711","Gefitinib","Placebo Tablet","Placebo capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT03866499"},{"nctId":"NCT05347134","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2022-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2023-11-30","primaryCompletionType":"ACTUAL","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Triple Negative Breast Cancer"],"interventions":["SKB264"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy of SKB264 in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer who have failed second-line or above prior standard of care","sourceUrl":"https://clinicaltrials.gov/study/NCT05347134"},{"nctId":"NCT04328844","title":"A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers","sponsor":"iOnctura","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2020-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2023-12-13","primaryCompletionType":"ACTUAL","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Solid Tumor, Adult","Non-Hodgkin Lymphoma, Adult","NSCLC","Myelofibrosis","Uveal Melanoma"],"interventions":["IOA-244","Avelumab Injection","Pemetrexed","Cisplatin","Ruxolitinib"],"countries":["Italy","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"The objective of study IOA-244-101 is to determine whether IOA-244 is safe and tolerable in cancer patients (Part A). In addition, the study will assess whether IOA-244 can increase the anti-tumour immune response in patients both as monotherapy and in combination pemetrexed/cisplatin/avelumab (Part B Mesothelioma and NSCLC 1st line), in combination with avelumab (Part B Cutaneous Melanoma and NSCLC 2nd/3rd line) and ruxolitinib (Part B Primary Myelofibrosis)","sourceUrl":"https://clinicaltrials.gov/study/NCT04328844"},{"nctId":"NCT03182244","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation","sponsor":"Astellas Pharma Inc","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":276,"enrollmentType":"ACTUAL","startDate":"2017-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2023-12-25","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["AML With FLT3 Mutation"],"interventions":["Gilteritinib","Cytarabine","Mitoxantrone","Etoposide","G-CSF","Fludarabine"],"countries":["China","Malaysia","Russia","Singapore","Thailand"],"northAmerica":false,"chinaSites":true,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who were refractory to or had relapse after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study evaluated safety as well as determined the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03182244"},{"nctId":"NCT05297890","title":"A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer","sponsor":"CStone Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ACTUAL","startDate":"2022-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2023-12-26","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer"],"interventions":["Lorlatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["RNA fusion"],"summary":"A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)Subjects in China","sourceUrl":"https://clinicaltrials.gov/study/NCT05297890"},{"nctId":"NCT04928222","title":"Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)","sponsor":"SkinJect, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2021-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2023-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2024-06-30","completionType":"ESTIMATED","lastUpdated":"2023-04-14","conditions":["Basal Cell Carcinoma"],"interventions":["Doxorubicin-containing MNA","Placebo-containing MNA"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic location; age; duration of array exposure to the skin; and the criticality of proper array application to the skin. Part II will be a randomized study in which doxorubicin-containing arrays will be applied to subjects demonstrated by biopsy to have basal cell cancer. A subject will be randomized to one of four dose groups: placebo microneedle array and 50 µg, 100 µg, and 200 µg doses of doxorubicin in a tip-loaded, dissolvable microneedle arrays (D-MNA).","sourceUrl":"https://clinicaltrials.gov/study/NCT04928222"},{"nctId":"NCT04685135","title":"Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":453,"enrollmentType":"ACTUAL","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2023-12-30","primaryCompletionType":"ACTUAL","completionDate":"2026-07-02","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Metastatic Non Small Cell Lung Cancer","Advanced Non Small Cell Lung Cancer"],"interventions":["MRTX849","Docetaxel"],"countries":["United States","Australia","Austria","Belgium","Czechia","France","Germany","Greece","Hong Kong","Hungary","Ireland","Italy","Netherlands","Poland","Portugal","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":343,"serviceSignals":["RAS genotyping"],"summary":"This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04685135"},{"nctId":"NCT03836352","title":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors","sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":184,"enrollmentType":"ESTIMATED","startDate":"2018-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2023-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2023-12-31","completionType":"ESTIMATED","lastUpdated":"2022-03-31","conditions":["Ovarian Cancer","Hepatocellular Carcinoma","Non-small Cell Lung Cancer","Bladder Cancer","Microsatellite Instability-High"],"interventions":["DPX-Survivac","Cyclophosphamide","Pembrolizumab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["MSI / TMB"],"summary":"This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT03836352"},{"nctId":"NCT03706365","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":393,"enrollmentType":"ACTUAL","startDate":"2018-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-02","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Prostate Cancer"],"interventions":["Abemaciclib","Placebo","Abiraterone acetate","Prednisone"],"countries":["United States","Australia","China","Denmark","France","Germany","Japan","Netherlands","Romania","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":112,"serviceSignals":["Broad CGP"],"summary":"This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.","sourceUrl":"https://clinicaltrials.gov/study/NCT03706365"},{"nctId":"NCT04075292","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":155,"enrollmentType":"ACTUAL","startDate":"2020-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-03","primaryCompletionType":"ACTUAL","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Untreated Chronic Lymphocytic Leukemia"],"interventions":["Acalabrutinib","Rituximab","Chlorambucil"],"countries":["China","Philippines","Taiwan","Thailand","Vietnam"],"northAmerica":false,"chinaSites":true,"siteCount":46,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT04075292"},{"nctId":"NCT05388669","title":"A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":418,"enrollmentType":"ACTUAL","startDate":"2022-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-03","primaryCompletionType":"ACTUAL","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["Lazertinib","Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)","Amivantamab Intravenous"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","France","Germany","Israel","Italy","Japan","Malaysia","Poland","Portugal","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":187,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.","sourceUrl":"https://clinicaltrials.gov/study/NCT05388669"},{"nctId":"NCT03521154","title":"A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ACTUAL","startDate":"2018-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-05","primaryCompletionType":"ACTUAL","completionDate":"2027-10-29","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Non Small Cell Lung Cancer (Stage III)"],"interventions":["Osimertinib 80mg/40mg","Placebo Osimertinib 80mg/40mg"],"countries":["United States","Argentina","Brazil","China","Hungary","India","Japan","Malaysia","Mexico","Peru","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":118,"serviceSignals":["Broad CGP"],"summary":"A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03521154"},{"nctId":"NCT03993873","title":"Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET","sponsor":"Turning Point Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":95,"enrollmentType":"ACTUAL","startDate":"2019-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-08","primaryCompletionType":"ACTUAL","completionDate":"2027-03-03","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Advanced Solid Tumor","Metastatic Solid Tumors","MET Gene Alterations"],"interventions":["elzovantinib (TPX-0022)"],"countries":["United States","France","North Korea","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["RNA fusion","MET profiling"],"summary":"A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)","sourceUrl":"https://clinicaltrials.gov/study/NCT03993873"},{"nctId":"NCT04110301","title":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","sponsor":"Beijing Mabworks Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":53,"enrollmentType":"ESTIMATED","startDate":"2019-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-09","primaryCompletionType":"ACTUAL","completionDate":"2025-05","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["Follicular Lymphoma and Marginal Zone Lymphoma"],"interventions":["Recombinant Humanized Monoclonal Antibody MIL62 Injection","Lenalidomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT04110301"},{"nctId":"NCT03703297","title":"Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":730,"enrollmentType":"ACTUAL","startDate":"2018-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-15","primaryCompletionType":"ACTUAL","completionDate":"2026-10-23","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Small Cell Lung Cancer"],"interventions":["Durvalumab","Tremelimumab","Placebo"],"countries":["United States","Argentina","Belgium","Canada","China","Czechia","Germany","India","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":183,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03703297"},{"nctId":"NCT06093841","title":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2023-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-21","primaryCompletionType":"ACTUAL","completionDate":"2029-11-04","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Lymphoma, Large B-Cell, Diffuse","Follicular Lymphoma Grade 3B","High-grade B-cell Lymphoma","Mediastinal B-Cell Diffuse Large Cell Lymphoma"],"interventions":["Relmacabtagene Autoleucel","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06093841"},{"nctId":"NCT05171816","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ACTUAL","startDate":"2021-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-22","primaryCompletionType":"ACTUAL","completionDate":"2027-02-05","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["olaparib","abiraterone acetate"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate cancer (mCRPC) stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT05171816"},{"nctId":"NCT02486718","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1280,"enrollmentType":"ACTUAL","startDate":"2015-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-26","primaryCompletionType":"ACTUAL","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Atezolizumab","Cisplatin","Vinorelbine","Docetaxel","Gemcitabine","Pemetrexed"],"countries":["United States","Australia","Belgium","China","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Netherlands","Poland","Portugal","Romania","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":155,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.","sourceUrl":"https://clinicaltrials.gov/study/NCT02486718"},{"nctId":"NCT04484623","title":"Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":302,"enrollmentType":"ACTUAL","startDate":"2020-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-29","primaryCompletionType":"ACTUAL","completionDate":"2029-06-25","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Pomalidomide","Dexamethasone","Bortezomib"],"countries":["United States","Australia","Brazil","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","New Zealand","Poland","Russia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":122,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT04484623"},{"nctId":"NCT05499390","title":"AK112 in Advanced Non-Small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":398,"enrollmentType":"ACTUAL","startDate":"2022-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-29","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Advanced Non-small-cell Lung Cancer"],"interventions":["AK112","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.","sourceUrl":"https://clinicaltrials.gov/study/NCT05499390"},{"nctId":"NCT05587296","title":"A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","sponsor":"Bayer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":474,"enrollmentType":"ACTUAL","startDate":"2022-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-29","primaryCompletionType":"ACTUAL","completionDate":"2028-06-05","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer","Hot Flashes"],"interventions":["Elinzanetant (BAY3427080)","Placebo"],"countries":["Austria","Belgium","Canada","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Kazakhstan","Poland","Portugal","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":102,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy. VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these","sourceUrl":"https://clinicaltrials.gov/study/NCT05587296"},{"nctId":"NCT03671018","title":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":422,"enrollmentType":"ESTIMATED","startDate":"2018-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2024-01-30","primaryCompletionType":"ACTUAL","completionDate":"2025-07-20","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["B-cell Non-Hodgkin Lymphoma"],"interventions":["Mosunetuzumab (IV)","Mosunetuzumab (SC)","Polatuzumab vedotin","Tocilizumab","Rituximab"],"countries":["United States","Belgium","Canada","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy (3L+) for the treatment of R/R mantle cell lymphoma ","sourceUrl":"https://clinicaltrials.gov/study/NCT03671018"},{"nctId":"NCT05308654","title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2022-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-07","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["ABBV-453","Dexamethasone","Daratumumab","Lenalidomide"],"countries":["United States","Australia","Israel","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. ABBV-453 is an investigational drug being developed for the treatment of R/R MM. Part 1 will be a monotherapy dose escalation phase to determine the best dose of ABBV-453. In Part 2, participants are placed in 1 of 3 groups called treatment arms. Each group receives a different treatment. Approximately 28 to 48 adult participants in Part 1 and 150 to 312 adult participants in Part 2 ","sourceUrl":"https://clinicaltrials.gov/study/NCT05308654"},{"nctId":"NCT05169567","title":"Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":368,"enrollmentType":"ACTUAL","startDate":"2022-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-08","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Breast Neoplasm","Neoplasm Metastasis"],"interventions":["Abemaciclib","Fulvestrant","Placebo"],"countries":["United States","Argentina","Belgium","Czechia","Denmark","France","Greece","Hungary","Israel","Italy","Mexico","Poland","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":138,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.","sourceUrl":"https://clinicaltrials.gov/study/NCT05169567"},{"nctId":"NCT04739761","title":"A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":506,"enrollmentType":"ACTUAL","startDate":"2021-06-22","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-08","primaryCompletionType":"ACTUAL","completionDate":"2027-05-26","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Breast Cancer"],"interventions":["Trastuzumab Deruxtecan"],"countries":["United States","Australia","Belgium","Canada","Denmark","Finland","Germany","Ireland","Italy","Japan","Netherlands","Norway","Poland","Portugal","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":81,"serviceSignals":["HER2 profiling"],"summary":"This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).","sourceUrl":"https://clinicaltrials.gov/study/NCT04739761"},{"nctId":"NCT05288166","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":925,"enrollmentType":"ACTUAL","startDate":"2022-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-15","primaryCompletionType":"ACTUAL","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Prostatic Neoplasms","Neoplasm Metastasis","Urogenital Neoplasms","Physiological Effects of Drugs","Antineoplastic Agents","Antineoplastic Agents, Hormonal","Androgens","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Abiraterone Acetate","Steroid Synthesis Inhibitors","Cytochrome P-450","Enzyme Inhibitors","Prednisone","Prednisolone","Cyclin-Dependent Kinase 4","Cyclin-Dependent Kinase 6"],"interventions":["Abemaciclib","Abiraterone","Prednisone or Prednisolone","Placebo for Abemaciclib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Romania","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":266,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT05288166"},{"nctId":"NCT05509790","title":"A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2022-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-18","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Breast Neoplasms"],"interventions":["LY3484356"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["HER2 profiling"],"summary":"This is a study of LY3484356 in Chinese participants with advanced breast cancer. Participants must have breast cancer that is estrogen receptor positive (ER+), HER2 negative (HER2-). The purpose of this study is to measure how much LY3484356 gets into the bloodstream and how long it takes the body to remove it. The safety and effectiveness of LY3484356 will also be studied. Participation could last up to 28 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT05509790"},{"nctId":"NCT03315364","title":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","sponsor":"Daehwa Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":549,"enrollmentType":"ACTUAL","startDate":"2017-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-19","primaryCompletionType":"ACTUAL","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Recurrent or Metastatic Breast Cancer"],"interventions":["Oral paclitaxel","Paclitaxel injection"],"countries":["Bulgaria","China","Hungary","Serbia","South Korea"],"northAmerica":false,"chinaSites":true,"siteCount":51,"serviceSignals":["HER2 profiling"],"summary":"To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03315364"},{"nctId":"NCT05077449","title":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2021-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-22","primaryCompletionType":"ACTUAL","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2024-05-24","conditions":["Advanced Breast Cancer"],"interventions":["XZP-3287+Fulvestrant","Placebo + Fulvestrant"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a phase III clinical trial to evaluate the efficacy and safety of XZP-3287 in combination with Fulvestrant versus placebo combined with Fulvestrant in Patients who have HR positive and Her2 negative recurrent/metastatic breast cancer and have received prior endocrine therapy are eligible for study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05077449"},{"nctId":"NCT04680052","title":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.","sponsor":"Incyte Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":654,"enrollmentType":"ACTUAL","startDate":"2021-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-02-23","primaryCompletionType":"ACTUAL","completionDate":"2028-08-09","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Follicular Lymphoma","Marginal Zone Lymphoma"],"interventions":["tafasitamab","rituximab","lenalidomide","placebo"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Netherlands","Norway","Poland","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":261,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rituximab provides improved clinical benefit compared with lenalidomide as an add-on to rituximab in patients with R/R FL Grade 1 to 3a or R/R MZL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04680052"},{"nctId":"NCT06041061","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years","sponsor":"Sinocelltech Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":18000,"enrollmentType":"ACTUAL","startDate":"2023-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2023-09-18","conditions":["HPV InfectioN","HPV-Related Carcinoma"],"interventions":["Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）","placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.","sourceUrl":"https://clinicaltrials.gov/study/NCT06041061"},{"nctId":"NCT05022901","title":"An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma","sponsor":"Delcath Systems Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2022-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2024-03-01","completionType":"ESTIMATED","lastUpdated":"2023-12-21","conditions":["Metastatic Ocular Melanoma","Metastatic Uveal Melanoma"],"interventions":["Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05022901"},{"nctId":"NCT03967223","title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","sponsor":"USWM CT, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":103,"enrollmentType":"ACTUAL","startDate":"2019-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-01","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Neoplasms"],"interventions":["Letetresgene autoleucel (lete-cel, GSK3377794)","Fludarabine","Cyclophosphamide"],"countries":["United States","Canada","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03967223"},{"nctId":"NCT06703346","title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","sponsor":"USWM CT, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2019-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-01","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Neoplasms"],"interventions":["Letetresgene autoleucel (Lete-Cel (GSK3377794))","Cyclophosphamide","Fludarabine"],"countries":["United States","Canada","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.","sourceUrl":"https://clinicaltrials.gov/study/NCT06703346"},{"nctId":"NCT04711135","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","sponsor":"Advanced Accelerator Applications","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":11,"enrollmentType":"ACTUAL","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-12","primaryCompletionType":"ACTUAL","completionDate":"2034-02-06","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Gastroenteropancreatic Neuroendocrine Tumors","Pheochromocytoma","Paraganglioma"],"interventions":["Lutetium [177Lu] oxodotreotide/dotatate"],"countries":["United States","France","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \\<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT04711135"},{"nctId":"NCT04494425","title":"Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":866,"enrollmentType":"ACTUAL","startDate":"2020-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-18","primaryCompletionType":"ACTUAL","completionDate":"2026-06-19","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Advanced or Metastatic Breast Cancer"],"interventions":["Trastuzumab deruxtecan","Capecitabine","Paclitaxel","Nab-Paclitaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Denmark","France","Germany","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Russia","Saudi Arabia","Singapore","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":293,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT04494425"},{"nctId":"NCT05663866","title":"Premedication to Reduce Amivantamab Associated Infusion Related Reactions","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":68,"enrollmentType":"ACTUAL","startDate":"2023-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-29","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Dexamethasone","Montelukast","Methotrexate","Amivantamab","Lazertinib"],"countries":["United States","France","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.","sourceUrl":"https://clinicaltrials.gov/study/NCT05663866"},{"nctId":"NCT04586478","title":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","sponsor":"Juventas Cell Therapy Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2020-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-30","primaryCompletionType":"ACTUAL","completionDate":"2025-09-30","completionType":"ESTIMATED","lastUpdated":"2025-02-07","conditions":["Non-Hodgkin's Lymphoma"],"interventions":["single dose of CNCT19"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of relapsed or refractory NHL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04586478"},{"nctId":"NCT04143607","title":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":337,"enrollmentType":"ACTUAL","startDate":"2019-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2024-03-31","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2024-06-14","conditions":["Locally Advanced or Metastatic NSCLC"],"interventions":["ASK120067","Placebo Gefitinib 250 mg","Gefitinib","Placebo ASK120067"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of ASK120067 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04143607"},{"nctId":"NCT05181501","title":"A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2022-04","startDateType":"ESTIMATED","primaryCompletionDate":"2024-04","primaryCompletionType":"ESTIMATED","completionDate":"2039-04","completionType":"ESTIMATED","lastUpdated":"2022-01-06","conditions":["Multiple Myeloma"],"interventions":["Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This study is a multi-center, single-arm clinical study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic characteristics of CT103A as the first-line treatment in newly diagnosed high-risk multiple myeloma subjects with induction chemotherapy as bridging therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05181501"},{"nctId":"NCT05320588","title":"A Study in Patients With Advanced Cancers","sponsor":"BiOneCure Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":332,"enrollmentType":"ESTIMATED","startDate":"2022-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2024-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2022-07-19","conditions":["Advanced Cancer","Advanced Solid Tumor","Cancer","Oncology"],"interventions":["BIO-106","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05320588"},{"nctId":"NCT06868654","title":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2021-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-03","primaryCompletionType":"ACTUAL","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Daratumumab","Bortezomib","Dexamethasone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with relapsed/refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06868654"},{"nctId":"NCT06868667","title":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2021-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-03","primaryCompletionType":"ACTUAL","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Daratumumab","Bortezomib","Dexamethasone"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Japanese participants with relapsed refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06868667"},{"nctId":"NCT05061134","title":"A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":194,"enrollmentType":"ACTUAL","startDate":"2022-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-12","primaryCompletionType":"ACTUAL","completionDate":"2026-11-02","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["Melanoma"],"interventions":["Ceralasertib","Durvalumab"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["Broad CGP"],"summary":"Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.","sourceUrl":"https://clinicaltrials.gov/study/NCT05061134"},{"nctId":"NCT04526691","title":"Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":145,"enrollmentType":"ACTUAL","startDate":"2020-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-14","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced or Metastatic NSCLC"],"interventions":["Datopotamab deruxtecan","KEYTRUDA®","Carboplatin","Cisplatin"],"countries":["United States","Italy","Japan","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This study will assess safety and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04526691"},{"nctId":"NCT03390504","title":"A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":629,"enrollmentType":"ACTUAL","startDate":"2018-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Urothelial Cancer"],"interventions":["Erdafitinib","Vinflunine","Docetaxel","Pembrolizumab","Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","France","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":345,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\\[L\\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT03390504"},{"nctId":"NCT04195750","title":"A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":755,"enrollmentType":"ACTUAL","startDate":"2020-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-15","primaryCompletionType":"ACTUAL","completionDate":"2026-09-17","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Carcinoma, Renal Cell"],"interventions":["Belzutifan","Everolimus"],"countries":["United States","Brazil","Canada","Chile","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","Hungary","Italy","Japan","Norway","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":172,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.","sourceUrl":"https://clinicaltrials.gov/study/NCT04195750"},{"nctId":"NCT04446117","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":575,"enrollmentType":"ACTUAL","startDate":"2020-10-19","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-19","primaryCompletionType":"ACTUAL","completionDate":"2026-10-16","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Metastatic Prostate Cancer","Prostate Adenocarcinoma"],"interventions":["Cabozantinib","Atezolizumab","Abiraterone Acetate","Enzalutamide","Prednisone"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Georgia","Germany","Greece","Hungary","Israel","Italy","Japan","Mexico","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":280,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT04446117"},{"nctId":"NCT04682808","title":"A Study of FCN-338 in Patients With Chronic CLL/SLL","sponsor":"Fochon Pharmaceuticals, Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2021-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-28","primaryCompletionType":"ACTUAL","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-13","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["FCN-338"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is being done to evaluate the Tolerability、Pharmacokinetics and Preliminary antitumor activity of oral FCN-338 for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have failed or are intolerant to one or more lines of established therapy or for whom no other treatment options are available.","sourceUrl":"https://clinicaltrials.gov/study/NCT04682808"},{"nctId":"NCT03732677","title":"Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1063,"enrollmentType":"ACTUAL","startDate":"2018-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-29","primaryCompletionType":"ACTUAL","completionDate":"2027-11-08","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Muscle Invasive Bladder Cancer"],"interventions":["Durvalumab","Cisplatin","Gemcitabine"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Israel","Italy","Japan","Netherlands","Philippines","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":188,"serviceSignals":["Broad CGP"],"summary":"A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03732677"},{"nctId":"NCT04165590","title":"Plasmodium Immunotherapy for Advanced Malignant Solid Tumors","sponsor":"CAS Lamvac Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2019-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2024-02-20","conditions":["Advanced Malignant Solid Tumor"],"interventions":["Plasmodium immunotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors. 2) To explore the safe and effective course of the Plasmodium immunotherapy for the advanced malignant solid tumors. 3) To explore the possible indications of Plasmodium immunotherapy for advanced malignant solid tumors. The treatment will last 5-10 weeks from the day of successful infection and will be terminated by antimalarial drugs.","sourceUrl":"https://clinicaltrials.gov/study/NCT04165590"},{"nctId":"NCT04585035","title":"Study to Evaluate D-1553 in Subjects With Solid Tumors","sponsor":"InventisBio Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":180,"enrollmentType":"ACTUAL","startDate":"2020-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2024-04-30","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-18","conditions":["Solid Tumor, Adult","NSCLC","CRC"],"interventions":["D-1553","D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other"],"countries":["United States","Australia","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04585035"},{"nctId":"NCT04181827","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":419,"enrollmentType":"ACTUAL","startDate":"2020-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-01","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Cilta-cel","Pomalidomide","Bortezomib","Dexamethasone","Daratumumab"],"countries":["United States","Australia","Belgium","Denmark","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":88,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy of ciltacabtagene autoleucel (cilta-cel) with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).","sourceUrl":"https://clinicaltrials.gov/study/NCT04181827"},{"nctId":"NCT02773030","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","sponsor":"Celgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":466,"enrollmentType":"ACTUAL","startDate":"2016-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-09","primaryCompletionType":"ACTUAL","completionDate":"2028-07-28","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Multiple Myeloma"],"interventions":["CC-220","Dexamethasone","Daratumumab","Bortezomib","Carfilzomib","Daratumumab - 16mg/kg","Bortezomib (BTZ)","Daratumumab- 1800mg"],"countries":["United States","Australia","Canada","France","Germany","Israel","Italy","Japan","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":162,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT02773030"},{"nctId":"NCT05844150","title":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","sponsor":"Biotheus Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ACTUAL","startDate":"2023-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-10","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["SCLC"],"interventions":["PM8002","Platinum","Etoposide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05844150"},{"nctId":"NCT04656652","title":"Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":605,"enrollmentType":"ACTUAL","startDate":"2020-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-10","primaryCompletionType":"ACTUAL","completionDate":"2027-02-15","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non-small Cell Lung Cancer"],"interventions":["DS-1062a","Docetaxel"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Hong Kong","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":209,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT04656652"},{"nctId":"NCT05346224","title":"A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2022-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-15","primaryCompletionType":"ACTUAL","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-06-10","conditions":["Breast Cancer","Breast Neoplasms","HER2-positive Breast Cancer"],"interventions":["HLX11","EU-Perjeta®"],"countries":["China","Hungary","Poland","Spain"],"northAmerica":false,"chinaSites":true,"siteCount":79,"serviceSignals":["HER2 profiling"],"summary":"This is a phase III, double-blind, randomized, parallel-controlled, multicenter equivalence study to compare the efficacy and safety of pertuzumab biosimilar HLX11 vs. EU-Perjeta® on HER2-positive and HR-negative early-stage or locally advanced breast cancer with a primary tumor \\> 2 cm. Patients are random assignment to 2 arms and treatment with either HLX11 or EU-Perjeta® , and received neoadjuvant THP regimen every 3- weeks 4 cycles，adjuvant AC every 3- weeks 4 cycles and pertuzumab+trastuzumab(HP) every 3- weeks 13cycles.","sourceUrl":"https://clinicaltrials.gov/study/NCT05346224"},{"nctId":"NCT03522246","title":"A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy","sponsor":"pharmaand GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1097,"enrollmentType":"ACTUAL","startDate":"2018-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-20","primaryCompletionType":"ACTUAL","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2025-06-24","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal","Fallopian Tube Cancer","Newly Diagnosed","FIGO Stage III-IV","Partial Response","Complete Response"],"interventions":["Rucaparib","Nivolumab","Placebo Oral Tablet","Placebo IV Infusion"],"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","Finland","Germany","Greece","Ireland","Israel","Italy","Japan","New Zealand","Poland","Romania","Russia","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":238,"serviceSignals":["HRD / HRR","MSI / TMB"],"summary":"This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.","sourceUrl":"https://clinicaltrials.gov/study/NCT03522246"},{"nctId":"NCT04950322","title":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":737,"enrollmentType":"ACTUAL","startDate":"2021-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-20","primaryCompletionType":"ACTUAL","completionDate":"2025-10-01","completionType":"ESTIMATED","lastUpdated":"2025-03-30","conditions":["Gastric or Gastroesophageal Junction Cancer"],"interventions":["SHR-1701、CAPOX","Placebo、CAPOX"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, Double-Blind, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of SHR1701 combined with chemotherapy in the treatment of Previously Untreated, Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. For Part 1 study，the tolerability of SHR-1701 will be evaluated and determine the recommended dose for Part 2.For Part 2 study, all enrolled patients will be randomized to 2 groups and continuously treated until the end criteria of treatment was met.","sourceUrl":"https://clinicaltrials.gov/study/NCT04950322"},{"nctId":"NCT05002127","title":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","sponsor":"ALX Oncology Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":127,"enrollmentType":"ACTUAL","startDate":"2022-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-24","primaryCompletionType":"ACTUAL","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Gastric Adenocarcinoma"],"interventions":["Evorpacept (ALX148)","Trastuzumab","Ramucirumab","Paclitaxel"],"countries":["United States","Australia","Belgium","Czechia","France","Italy","Japan","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":83,"serviceSignals":["HER2 profiling"],"summary":"A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05002127"},{"nctId":"NCT06956170","title":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ACTUAL","startDate":"2022-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-27","primaryCompletionType":"ACTUAL","completionDate":"2029-06-25","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Pomalidomide","Dexamethasone","Bortezomib"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants with relapsed/refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06956170"},{"nctId":"NCT05195632","title":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer","sponsor":"Pierre Fabre Medicament","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":63,"enrollmentType":"ACTUAL","startDate":"2022-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-27","primaryCompletionType":"ACTUAL","completionDate":"2026-12-14","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Encorafenib","Binimetinib"],"countries":["China","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"This is a phase 2, multicenter, single-arm study with a safety lead-in to investigate the efficacy, safety and pharmacokinetics of encorafenib 450 mg once daily (QD) in combination with binimetinib 45 mg twice daily (BID) (Combo450) in adult Chinese participants with metastatic unresectable stage IV BRAF V600E mutant NSCLC, who are BRAF- and MEK-inhibitor treatment-naïve and are either previously untreated or have had one line of prior therapy in metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT05195632"},{"nctId":"NCT04524273","title":"Myasthenia Gravis Inebilizumab Trial","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":238,"enrollmentType":"ACTUAL","startDate":"2020-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-28","primaryCompletionType":"ACTUAL","completionDate":"2029-06-07","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Myasthenia Gravis"],"interventions":["inebilizumab","IV Placebo"],"countries":["United States","Argentina","Belarus","Brazil","Canada","China","Denmark","France","Germany","India","Italy","Japan","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":104,"serviceSignals":["Broad CGP"],"summary":"Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.","sourceUrl":"https://clinicaltrials.gov/study/NCT04524273"},{"nctId":"NCT05366478","title":"A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2022-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2022-08-02","conditions":["Melanoma","Non Small Cell Lung Cancer","Cervical Carcinoma"],"interventions":["Autologous tumor infiltrating lymphocytes (TILs)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.","sourceUrl":"https://clinicaltrials.gov/study/NCT05366478"},{"nctId":"NCT05338970","title":"HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":586,"enrollmentType":"ACTUAL","startDate":"2022-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2024-05-31","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-01-31","conditions":["Nonsquamous Non-small Cell Lung Cancer","EGFR L858R","EGFR Exon 19 Deletion"],"interventions":["Patritumab Deruxtecan","Platinum-based chemotherapy"],"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","Hong Kong","Italy","Japan","Netherlands","Norway","Poland","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":182,"serviceSignals":["Broad CGP"],"summary":"Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05338970"},{"nctId":"NCT05320874","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2022-04","startDateType":"ESTIMATED","primaryCompletionDate":"2024-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2022-04-11","conditions":["Advanced Solid Tumor"],"interventions":["KM257 Bispecific antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a first-in-human, 2-part study to investigate the safety, tolerability, pharmacokinetics and efficacy of KM257 by itself and combined with selected chemotherapy agents in patients with advanced HER2-positive or expressing cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05320874"},{"nctId":"NCT05224141","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":460,"enrollmentType":"ACTUAL","startDate":"2022-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-04","primaryCompletionType":"ACTUAL","completionDate":"2027-06-07","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Small Cell Lung Carcinoma"],"interventions":["Pembrolizumab/Vibostolimab Co-Formulation","Saline placebo","Etoposide","Cisplatin","Atezolizumab","Carboplatin"],"countries":["United States","Argentina","Australia","Austria","Canada","China","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Lithuania","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":140,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05224141"},{"nctId":"NCT04724980","title":"Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis","sponsor":"Precigen, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":38,"enrollmentType":"ACTUAL","startDate":"2021-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-05","primaryCompletionType":"ACTUAL","completionDate":"2026-06-05","completionType":"ESTIMATED","lastUpdated":"2025-06-11","conditions":["Recurrent Respiratory Papillomatosis","Papillomavirus Infections","Papillomaviridae"],"interventions":["PRGN-2012 - Phase I; Dose Level 1","PRGN-2012 - Phase I; Dose Level 2","PRGN-2012 - Phase II; Dose Level 2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2 study in patients with a Recurrent Respiratory Papillomatosis (RRP) disease burden that requires repeated surgical procedures for management. RRP is a rare disease caused by the human papillomavirus (HPV). Participants with a pathologically confirmed diagnosis of papilloma and a clinical diagnosis of RRP will be screened for this protocol.","sourceUrl":"https://clinicaltrials.gov/study/NCT04724980"},{"nctId":"NCT04395677","title":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","sponsor":"Nuvation Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":173,"enrollmentType":"ACTUAL","startDate":"2020-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-07","primaryCompletionType":"ACTUAL","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Non Small Cell Lung Cancer"],"interventions":["AB-106"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04395677"},{"nctId":"NCT05020015","title":"A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","sponsor":"Takeda","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":27,"enrollmentType":"ACTUAL","startDate":"2021-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-16","primaryCompletionType":"ACTUAL","completionDate":"2038-12-20","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)"],"interventions":["TAK-007","Chemotherapy Agents"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL), The main aim of Part 2 is to learn whether lymphoma disease responds to treatment with TAK-007 in adults with r/r B-cell NHL or iNHL. Participants will receive 3 days of chemotherapy to reduce a type of white blood cells called lymphocytes, in the blood. This is called lymphodepleting chemotherapy (LDC) or lymphodepletion. After LDC, patients will receive a single injection of TAK-007 or three weekly injections of TAK-007 (multi-dose injection). After this, participants will regularly visit the clinic for check-ups.","sourceUrl":"https://clinicaltrials.gov/study/NCT05020015"},{"nctId":"NCT04923906","title":"Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":624,"enrollmentType":"ESTIMATED","startDate":"2021-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-18","primaryCompletionType":"ACTUAL","completionDate":"2026-01-31","completionType":"ESTIMATED","lastUpdated":"2024-11-25","conditions":["Non-small Cell Lung Cancer"],"interventions":["Aumolertinib","Placebo Aumolertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor mutations (EGFRm+).","sourceUrl":"https://clinicaltrials.gov/study/NCT04923906"},{"nctId":"NCT05732805","title":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","sponsor":"Biocad","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2022-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-20","primaryCompletionType":"ACTUAL","completionDate":"2025-07","completionType":"ESTIMATED","lastUpdated":"2025-02-27","conditions":["Melanoma","Melanoma (Skin)","Melanoma Stage III","Melanoma Stage IV","Melanoma Unresectable","Melanoma Metastatic","Melanoma Advanced"],"interventions":["BCD-217","BCD-100","Placebo"],"countries":["Belarus","India","Russia"],"northAmerica":false,"chinaSites":false,"siteCount":63,"serviceSignals":["Broad CGP"],"summary":"The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05732805"},{"nctId":"NCT03706690","title":"A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":407,"enrollmentType":"ACTUAL","startDate":"2018-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-23","primaryCompletionType":"ACTUAL","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Durvalumab","Placebo"],"countries":["China","Hong Kong","India","Mexico","Philippines","Poland","Russia","South Korea","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":87,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03706690"},{"nctId":"NCT04975308","title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":874,"enrollmentType":"ACTUAL","startDate":"2021-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-24","primaryCompletionType":"ACTUAL","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Breast Neoplasms","Neoplasm Metastasis"],"interventions":["Imlunestrant","Exemestane","Fulvestrant","Abemaciclib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","China","Czechia","France","Germany","Greece","India","Italy","Japan","Mexico","Netherlands","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":243,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT04975308"},{"nctId":"NCT05533463","title":"Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":102,"enrollmentType":"ACTUAL","startDate":"2022-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-25","primaryCompletionType":"ACTUAL","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Advanced KRAS G12D Mutant Solid Tumors"],"interventions":["HRS-4642"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"The study is being conducted to evaluate the safety and tolerability of HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation.To estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose \\[RP2D\\]) within investigated subject population groups","sourceUrl":"https://clinicaltrials.gov/study/NCT05533463"},{"nctId":"NCT05459844","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","sponsor":"Sinotau Pharmaceutical Group","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":196,"enrollmentType":"ACTUAL","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-26","primaryCompletionType":"ACTUAL","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-09-05","conditions":["Neuroendocrine Tumors"],"interventions":["Lutetium[177Lu] Oxodotreotide Injection","Octreotide LAR"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with Lutetium\\[177Lu\\] Oxodotreotide Injection to high dose (60 mg) Octreotide LAR in patients with unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT05459844"},{"nctId":"NCT04915755","title":"Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2021-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-28","primaryCompletionType":"ACTUAL","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-16","conditions":["Neoplasms, Breast"],"interventions":["Niraparib","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Romania","Russia","South Africa","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":198,"serviceSignals":["ctDNA / MRD","HER2 profiling"],"summary":"This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor \\[HR\\] status, including HR positive \\[+\\] and TNBC) or tumor BRCA wild type (tBRCAwt) TNBC with molecular disease based on the presence of circulating tumor Deoxyribonucleic acid (ctDNA) following surgery or completion of adjuvant therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04915755"},{"nctId":"NCT03949283","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","sponsor":"Cordgenics, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2019-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-30","primaryCompletionType":"ACTUAL","completionDate":"2024-12-30","completionType":"ESTIMATED","lastUpdated":"2024-08-22","conditions":["Recurrent Ovarian Carcinoma","Platinum-resistant Ovarian Cancer"],"interventions":["ChemoID Assay","Standard Chemotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC), fallopian tube, or primary peritoneal cancer. Population studied will be female participants experiencing a recurrent platinum-resistant ovarian cancer (no mucinous, low grade serous, or pure sarcoma types), with ≤ 5 prior treatments, and a performance status 0-1.","sourceUrl":"https://clinicaltrials.gov/study/NCT03949283"},{"nctId":"NCT04684108","title":"SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2021-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2024-06-30","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Relapsed or Refractory Multiple Myeloma","Hematological Malignancy"],"interventions":["SG301"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT04684108"},{"nctId":"NCT04592653","title":"Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)","sponsor":"Mural Oncology, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2020-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2024-07","primaryCompletionType":"ESTIMATED","completionDate":"2024-12","completionType":"ESTIMATED","lastUpdated":"2024-06-07","conditions":["Advanced Solid Tumor"],"interventions":["Nemvaleukin alfa","Pembrolizumab"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The study will be conducted in 2 cohorts. A single-center design for the tumor microenvironment (TME) cohort (Cohort 1), and a multicenter design for the less frequent intravenous (IV) dosing cohort (Cohort 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT04592653"},{"nctId":"NCT05521802","title":"A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Shanghai AbelZeta Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2022-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-07","primaryCompletionType":"ESTIMATED","completionDate":"2037-07","completionType":"ESTIMATED","lastUpdated":"2023-03-24","conditions":["Multiple Myeloma"],"interventions":["B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR)-T cell"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, open-label study to evaluate the safety and efficacy of C-CAR088 in patients with relapsed or refractory multiple myeloma. The phase Ib part of this study is to determine the recommended phase 2 dose (RP2D) of C-CAR088 in the targeted patient population.","sourceUrl":"https://clinicaltrials.gov/study/NCT05521802"},{"nctId":"NCT03390686","title":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients","sponsor":"Prestige Biopharma Limited","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":650,"enrollmentType":"ACTUAL","startDate":"2019-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-01","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["Lung Cancer","Non-small Cell Lung Cancer"],"interventions":["Bevacizumab","HD204","Carboplatin","Paclitaxel"],"countries":["Belarus","Bulgaria","Croatia","Georgia","Greece","Hungary","India","Latvia","Malaysia","Philippines","Poland","Russia","Serbia","Slovakia","Thailand","Turkey (Türkiye)","Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demonstrate equivalence of HD204 and EU-licensed Avastin® in terms of efficacy, safety, pharmacokinetics and immunogenicity.","sourceUrl":"https://clinicaltrials.gov/study/NCT03390686"},{"nctId":"NCT04269200","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":805,"enrollmentType":"ACTUAL","startDate":"2020-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-08","primaryCompletionType":"ACTUAL","completionDate":"2027-04-01","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Endometrial Neoplasms"],"interventions":["olaparib","durvalumab","durvalumab placebo","olaparib placebo","Carboplatin","Paclitaxel"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Colombia","Estonia","Germany","Greece","Hong Kong","Hungary","India","Israel","Japan","Lithuania","Mexico","Poland","Russia","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":201,"serviceSignals":["Broad CGP"],"summary":"A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04269200"},{"nctId":"NCT04687241","title":"Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2021-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-08","primaryCompletionType":"ACTUAL","completionDate":"2029-01-01","completionType":"ESTIMATED","lastUpdated":"2024-11-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["Almonertinib","Placebo Almonertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of Almonertinib versus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm+) stage II-IIIB non-small cell lung cancer (NSCLC), following complete tumor resection with or without adjuvant chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04687241"},{"nctId":"NCT05870319","title":"A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":376,"enrollmentType":"ACTUAL","startDate":"2023-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-11","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Non-small Cell Lung Cancer"],"interventions":["SKB264","Pemetrexed","Carboplatin","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multicenter Phase 3 clinical study to evaluate SKB264 monotherapy versus pemetrexed in combination with platinum in subjects with locally advanced or metastatic non-squamous NSCLC with EGFR mutation who have failed to EGFR-TKI therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05870319"},{"nctId":"NCT05182866","title":"ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer","sponsor":"Rakuten Medical, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":9,"enrollmentType":"ACTUAL","startDate":"2022-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-11","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-08-16","conditions":["Head and Neck Cancer","Squamous Cell Carcinoma of Head and Neck"],"interventions":["ASP-1929 Photoimmunotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase 2, Open-label, Single-arm, Window of opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05182866"},{"nctId":"NCT04606381","title":"A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":158,"enrollmentType":"ACTUAL","startDate":"2020-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-11","primaryCompletionType":"ACTUAL","completionDate":"2027-04-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Neoplasms"],"interventions":["Ami-LC-MD","Ami-LC","Ami-HC","Ami-HC-CF"],"countries":["United States","Canada","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.","sourceUrl":"https://clinicaltrials.gov/study/NCT04606381"},{"nctId":"NCT05722015","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":377,"enrollmentType":"ACTUAL","startDate":"2023-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-12","primaryCompletionType":"ACTUAL","completionDate":"2028-05-22","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Metastatic Non-small Cell Lung Cancer"],"interventions":["Pembrolizumab Formulated with Berahyaluronidase Alfa","Pemetrexed","Cisplatin","Carboplatin","Paclitaxel","Nab-paclitaxel","Pembrolizumab","Filgrastim","Pegylated filgrastim"],"countries":["United States","Argentina","Brazil","Chile","China","France","Guatemala","Hungary","Japan","Poland","Romania","South Africa","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":110,"serviceSignals":["Broad CGP"],"summary":"This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab formulated with berahyaluronidase alfa (MK-3475A) versus (vs) intravenous (IV) pembrolizumab (MK-3475), administered with chemotherapy in first line treatment of adult participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are pembrolizumab formulated with berahyaluronidase alfa subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.","sourceUrl":"https://clinicaltrials.gov/study/NCT05722015"},{"nctId":"NCT05316701","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","sponsor":"Orca Biosystems, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":187,"enrollmentType":"ACTUAL","startDate":"2022-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-15","primaryCompletionType":"ACTUAL","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Acute Myeloid Leukemia","Acute Lymphoid Leukemia","Mixed Phenotype Acute Leukemia","Undifferentiated Leukemia","Myelodysplastic Syndrome","Acute Leukemia","Therapy-Related Myelodysplastic Syndrome"],"interventions":["Orca-T","Standard-of-Care"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies. This posting represents the Phase III component of Precision-T. The Precision-T Ph1b component is described under NCT04013685.","sourceUrl":"https://clinicaltrials.gov/study/NCT05316701"},{"nctId":"NCT04951635","title":"A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2021-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-15","completionType":"ESTIMATED","lastUpdated":"2022-06-16","conditions":["Non-small Cell Lung Cancer"],"interventions":["Almonertinib","Placebo Almonertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04951635"},{"nctId":"NCT05327946","title":"A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2022-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-16","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Solid Tumors"],"interventions":["BI 770371","ezabenlimab"],"countries":["United States","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced cancer (solid tumours). People for whom previous treatment was not successful and for whom no other treatment options exist can join the study. The purpose of this study is to find the highest dose of BI 770371 that people with advanced cancer can tolerate when taken alone or together with a medicine called ezabenlimab. BI 770371 and ezabenlimab are antibodies that may help the immune system fight cancer (checkpoint inhibitors). In this study, BI 770371 is given to people for the first time. Participants get BI 770371 alone or together with ezabenlimab as an infusion every 3 weeks. It is planned that participants can stay in the study for up to 2 ye","sourceUrl":"https://clinicaltrials.gov/study/NCT05327946"},{"nctId":"NCT05222555","title":"Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients","sponsor":"Incyte Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":53,"enrollmentType":"ACTUAL","startDate":"2022-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-17","primaryCompletionType":"ACTUAL","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Diffuse Large B Cell Lymphoma"],"interventions":["Tafasitamab","Lenalidomide"],"countries":["United States","Austria","Czechia","France","Israel","Italy","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":62,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicentre study too Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) who have had at least one, but no more than three prior systemic regimens and who are not eligible for high dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) at the time of study entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05222555"},{"nctId":"NCT05159700","title":"A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors","sponsor":"Zhuhai Yufan Biotechnologies Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":39,"enrollmentType":"ACTUAL","startDate":"2022-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-17","primaryCompletionType":"ACTUAL","completionDate":"2026-06-29","completionType":"ESTIMATED","lastUpdated":"2025-12-15","conditions":["Advanced Solid Tumor","Advanced Solid Malignancies"],"interventions":["PRJ1-3024"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicenter, open-label, 3+3 dose escalation study to determine the safety and preliminary efficacy of PRJ1-3024 in subjects with relapsed/refractory solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05159700"},{"nctId":"NCT03970746","title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","sponsor":"PDC*line Pharma SAS","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":73,"enrollmentType":"ACTUAL","startDate":"2019-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-18","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-05-29","conditions":["Non Small Cell Lung Cancer"],"interventions":["PDC*lung01","Keytruda Injectable Product","Alimta Injectable Product"],"countries":["Belgium","France","Germany","Netherlands","Poland"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC\\*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03970746"},{"nctId":"NCT02637687","title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","sponsor":"Bayer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2015-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-20","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2025-06-22","conditions":["Solid Tumors Harboring NTRK Fusion"],"interventions":["Larotrectinib (Vitrakvi, BAY2757556)"],"countries":["United States","Australia","Canada","China","Czechia","Denmark","France","Germany","Ireland","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":45,"serviceSignals":["RNA fusion"],"summary":"The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.","sourceUrl":"https://clinicaltrials.gov/study/NCT02637687"},{"nctId":"NCT04414163","title":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","sponsor":"ImmuneOncia Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":23,"enrollmentType":"ACTUAL","startDate":"2020-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-23","primaryCompletionType":"ACTUAL","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Extranodal NK/T-cell Lymphoma, Nasal Type","Extranodal NK/T-cell Lymphoma"],"interventions":["IMC-001"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type","sourceUrl":"https://clinicaltrials.gov/study/NCT04414163"},{"nctId":"NCT05104866","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":732,"enrollmentType":"ACTUAL","startDate":"2021-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-24","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Breast Cancer"],"interventions":["Dato-DXd","Capecitabine","Gemcitabine","Eribulin","Vinorelbine"],"countries":["United States","Argentina","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Italy","Japan","Netherlands","Poland","Russia","South Africa","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":167,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05104866"},{"nctId":"NCT03765918","title":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":714,"enrollmentType":"ACTUAL","startDate":"2018-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-25","primaryCompletionType":"ACTUAL","completionDate":"2026-11-17","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Head and Neck Neoplasms"],"interventions":["Pembrolizumab 200 mg","Radiotherapy 60 Gray","Radiotherapy 66 Gray","Radiotherapy 70 Gray","Cisplatin 100 mg/m^2"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","France","Germany","Hungary","Ireland","Israel","Japan","Poland","Portugal","Russia","South Korea","Spain","Switzerland","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":192,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves event-free survival compared to radiotherapy (with or ","sourceUrl":"https://clinicaltrials.gov/study/NCT03765918"},{"nctId":"NCT03393884","title":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","sponsor":"Imunon","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2018-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-25","primaryCompletionType":"ACTUAL","completionDate":"2026-05-30","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["IMNN-001","Carboplatin","Paclitaxel"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT03393884"},{"nctId":"NCT03974022","title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":315,"enrollmentType":"ACTUAL","startDate":"2019-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-29","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Sunvozertinib"],"countries":["United States","Argentina","Australia","Canada","Chile","China","France","Italy","Japan","Malaysia","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":124,"serviceSignals":["HER2 profiling"],"summary":"This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time this drug is tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03974022"},{"nctId":"NCT05091567","title":"A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":660,"enrollmentType":"ACTUAL","startDate":"2021-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-29","primaryCompletionType":"ACTUAL","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Small-Cell Lung Cancer"],"interventions":["Atezolizumab","Lurbinectedin","Carboplatin","Etoposide"],"countries":["United States","Belgium","Germany","Greece","Hungary","Italy","Mexico","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":95,"serviceSignals":["Broad CGP"],"summary":"Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screeni","sourceUrl":"https://clinicaltrials.gov/study/NCT05091567"},{"nctId":"NCT05941897","title":"A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":39,"enrollmentType":"ACTUAL","startDate":"2023-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-29","primaryCompletionType":"ACTUAL","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Advanced or Metastatic NSCLC"],"interventions":["Ceralasertib","Durvalumab"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05941897"},{"nctId":"NCT05043922","title":"A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma","sponsor":"Haihe Biopharma Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":93,"enrollmentType":"ACTUAL","startDate":"2021-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-31","primaryCompletionType":"ACTUAL","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Ovarian Cancer","Recurrent Cancer"],"interventions":["CYH33"],"countries":["China","Japan"],"northAmerica":false,"chinaSites":true,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation, who received prior systemic anti-tumor treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05043922"},{"nctId":"NCT05300269","title":"SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":73,"enrollmentType":"ESTIMATED","startDate":"2022-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2022-07-29","conditions":["Locally Advanced Rectal Cancer"],"interventions":["SHR-1701；Capecitabine；Oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of SHR-1701 combined with radiotherapy and chemotherapy as perioperative treatment for locally advanced rectal cancer. Eligible patients will receive standard chemoradiation with SHR-1701 followed by XELOX combined with SHR-1701. In all subjects, restaging pelvic MRI with chest and abdominal CT will be performed after completion of neoadjuvant treatment to determine resectability and to rule out any evidence of metastases. Subjects who have resectable disease will undergo surgery. Adjuvant XELOX combined with SHR-1701 will be given after surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT05300269"},{"nctId":"NCT04430738","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2020-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-07-31","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-24","conditions":["Colorectal Carcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Esophageal Adenocarcinoma","Cholangiocarcinoma","Gallbladder Carcinoma"],"interventions":["tucatinib","trastuzumab","oxaliplatin","leucovorin","fluorouracil","capecitabine","pembrolizumab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["HER2 profiling"],"summary":"This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs. A side effect is anything the drug does other than treating cancer. It will also look at whether tucatinib works with these drugs to treat certain types of cancer. The participants in this trial have HER2-positive (HER2+) cancer in their gut, stomach, intestines, or gallbladder (gastrointestinal cancer).","sourceUrl":"https://clinicaltrials.gov/study/NCT04430738"},{"nctId":"NCT05862337","title":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2023-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-05-17","conditions":["Hepatocellular Carcinoma"],"interventions":["Anlotinib hydrochloride capsules, Penpulimab injection","Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or ablation in HCC patients with high risk of recurrence by assessing recurrence-free survival (RFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT05862337"},{"nctId":"NCT01436968","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","sponsor":"Candel Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":711,"enrollmentType":"ESTIMATED","startDate":"2011-09","startDateType":"","primaryCompletionDate":"2024-08","primaryCompletionType":"ACTUAL","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-07-30","conditions":["Prostate Cancer"],"interventions":["Aglatimagene besadenovec + valacyclovir","Placebo + valacyclovir"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":73,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity and lower than expected recurrence rates in previous clinical trials. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak or control a","sourceUrl":"https://clinicaltrials.gov/study/NCT01436968"},{"nctId":"NCT03927261","title":"PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS","sponsor":"Precigen, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2019-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-01","primaryCompletionType":"ACTUAL","completionDate":"2025-08-01","completionType":"ESTIMATED","lastUpdated":"2024-11-08","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"interventions":["PRGN-3006 T Cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This is a first-in-human dose escalation/dose expansion study to evaluate the safety and identify the best dose of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with relapsed or refractory acute myeloid leukemia (AML), Minimal Residual Disease (MRD) positive acute myeloid leukemia or higher risk myelodysplastic syndrome (MDS). Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.","sourceUrl":"https://clinicaltrials.gov/study/NCT03927261"},{"nctId":"NCT05204927","title":"177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer","sponsor":"Curium US LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":439,"enrollmentType":"ACTUAL","startDate":"2022-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-02","primaryCompletionType":"ACTUAL","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["Metastasis From Malignant Tumor of Prostate"],"interventions":["177Lu-PSMA-I&T","Abiraterone with Prednisone or Enzalutamide"],"countries":["United States","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05204927"},{"nctId":"NCT04924608","title":"Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":145,"enrollmentType":"ACTUAL","startDate":"2021-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-05","primaryCompletionType":"ACTUAL","completionDate":"2029-02-15","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Neurofibromatosis 1","Plexiform Neurofibroma (PN)"],"interventions":["Selumetinib","Placebo"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Italy","Japan","Poland","Russia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.","sourceUrl":"https://clinicaltrials.gov/study/NCT04924608"},{"nctId":"NCT05436223","title":"Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma","sponsor":"Hrain Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2021-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-09","completionType":"ESTIMATED","lastUpdated":"2022-07-05","conditions":["B-cell Non-Hodgkin's Lymphoma"],"interventions":["Human CD19Targeted T Cells Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.","sourceUrl":"https://clinicaltrials.gov/study/NCT05436223"},{"nctId":"NCT06136364","title":"CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2023-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2038-08-14","completionType":"ESTIMATED","lastUpdated":"2023-11-18","conditions":["T-lymphoblastic Lymphoma","T-ALL"],"interventions":["CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.","sourceUrl":"https://clinicaltrials.gov/study/NCT06136364"},{"nctId":"NCT03778229","title":"Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":367,"enrollmentType":"ACTUAL","startDate":"2019-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-23","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Carcinoma"],"interventions":["osimertinib","savolitinib","placebo"],"countries":["United States","Brazil","Canada","Chile","Denmark","France","India","Italy","Japan","South Korea","Spain","Taiwan","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":90,"serviceSignals":["Broad CGP"],"summary":"This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib","sourceUrl":"https://clinicaltrials.gov/study/NCT03778229"},{"nctId":"NCT03709680","title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":128,"enrollmentType":"ACTUAL","startDate":"2019-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-26","primaryCompletionType":"ACTUAL","completionDate":"2025-10-18","completionType":"ESTIMATED","lastUpdated":"2025-01-14","conditions":["Ewing Sarcoma","Solid Tumors","Rhabdoid Tumor","Rhabdomyosarcoma","Neuroblastoma","Medulloblastoma","Diffuse Intrinsic Pontine Glioma"],"interventions":["Palbociclib","Temozolomide","Irinotecan","Topotecan","Cyclophosphamide"],"countries":["United States","Brazil","Canada","Czechia","France","Germany","India","Poland","Slovakia","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":101,"serviceSignals":["Broad CGP"],"summary":"A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescen","sourceUrl":"https://clinicaltrials.gov/study/NCT03709680"},{"nctId":"NCT04008030","title":"A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":839,"enrollmentType":"ACTUAL","startDate":"2019-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-28","primaryCompletionType":"ACTUAL","completionDate":"2026-06-10","completionType":"ESTIMATED","lastUpdated":"2025-10-03","conditions":["Metastatic Colorectal Cancer"],"interventions":["Ipilimumab","Oxaliplatin","Leucovorin","Fluorouracil","Irinotecan","Bevacizumab","Cetuximab","Nivolumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","France","Germany","Greece","Ireland","Italy","Japan","Netherlands","Norway","Puerto Rico","Romania","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":157,"serviceSignals":["MSI / TMB"],"summary":"The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT04008030"},{"nctId":"NCT03036098","title":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1314,"enrollmentType":"ACTUAL","startDate":"2017-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2024-08-30","primaryCompletionType":"ACTUAL","completionDate":"2026-05-15","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Urothelial Cancer"],"interventions":["Nivolumab","Ipilimumab","Gemcitabine","Cisplatin","Carboplatin"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","Norway","Peru","Poland","Romania","Russia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":174,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine whether an investigational immunotherapy nivolumab in combination with ipilimumab or in combination with standard of care chemotherapy is more effective than standard of care chemotherapy alone in treating participants with previously untreated inoperable or metastatic urothelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03036098"},{"nctId":"NCT04740398","title":"A Study of CBP-1008 in Patients With Advanced Solid Tumor","sponsor":"Coherent Biopharma (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":143,"enrollmentType":"ESTIMATED","startDate":"2019-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2024-09","primaryCompletionType":"ESTIMATED","completionDate":"2024-09","completionType":"ESTIMATED","lastUpdated":"2024-08-28","conditions":["Advanced Solid Tumor"],"interventions":["CBP-1008"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1008, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04740398"},{"nctId":"NCT03110822","title":"A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients","sponsor":"Oncotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2017-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2024-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2023-11-01","conditions":["Multiple Myeloma"],"interventions":["Ruxolitinib Oral Tablet [Jakafi]","Lenalidomide","Methylprednisolone"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT03110822"},{"nctId":"NCT05593614","title":"Efficacy and Safety of ATX01 in Adult Patients With CIPN (Chemotherapy-induced Peripheral Neuropathy)","sponsor":"AlgoTherapeutix","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":276,"enrollmentType":"ACTUAL","startDate":"2023-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-09","primaryCompletionType":"ESTIMATED","completionDate":"2024-09","completionType":"ESTIMATED","lastUpdated":"2024-07-16","conditions":["Chemotherapy-induced Peripheral Neuropathy"],"interventions":["ATX01 10%","ATX01 15%","Placebo"],"countries":["United States","Belgium","Czechia","France","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to compare the efficacy of twice daily applications of ATX01 (10% \\& 15%) versus placebo during a 12-week treatment period in treating chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05593614"},{"nctId":"NCT03478488","title":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2018-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-10","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-29","conditions":["Biliary Tract Neoplasms"],"interventions":["KN035 plus Gemcitabine & oxaliplatin","Gemcitabine & oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, parallel-group multi-center study of Phase 3 study to assess the efficacy and safety of KN035 compared to standard of care (SOC) Gemcitabine-based chemotherapies in the treatment of participants with previously untreated locally advanced or metastatic biliary tract cancer. The primary hypothesis of this study is that participants will have a longer overall Survival (OS) when treated with combined therapy than SOC.","sourceUrl":"https://clinicaltrials.gov/study/NCT03478488"},{"nctId":"NCT04514419","title":"Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel","sponsor":"BioRay Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":408,"enrollmentType":"ESTIMATED","startDate":"2020-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-11","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Breast Cancer"],"interventions":["HS627","Pertuzumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).","sourceUrl":"https://clinicaltrials.gov/study/NCT04514419"},{"nctId":"NCT03334617","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":528,"enrollmentType":"ACTUAL","startDate":"2017-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-13","primaryCompletionType":"ACTUAL","completionDate":"2026-09-11","completionType":"ESTIMATED","lastUpdated":"2025-10-27","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Durvalumab","Danvatirsen","Ceralasertib","Vistusertib","Olaparib","Oleclumab","Trastuzumab deruxtecan","Cediranib"],"countries":["United States","Austria","Canada","France","Germany","Israel","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.","sourceUrl":"https://clinicaltrials.gov/study/NCT03334617"},{"nctId":"NCT03616587","title":"Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":396,"enrollmentType":"ACTUAL","startDate":"2018-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-16","primaryCompletionType":"ACTUAL","completionDate":"2027-06-24","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["ER+ HER2- Advanced Breast Cancer"],"interventions":["AZD9833","AZD9833 with palbociclib","AZD9833 with everolimus","AZD9833 with abemaciclib","AZD9833 with capivasertib","AZD9833 with ribociclib","AZD9833 with anastrozole"],"countries":["United States","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)","sourceUrl":"https://clinicaltrials.gov/study/NCT03616587"},{"nctId":"NCT05241834","title":"A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ACTUAL","startDate":"2022-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-17","primaryCompletionType":"ACTUAL","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-09-04","conditions":["Carcinoma, Non-Small-Cell Lung","Thyroid Neoplasms"],"interventions":["LOXO-260"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["RNA fusion"],"summary":"The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.","sourceUrl":"https://clinicaltrials.gov/study/NCT05241834"},{"nctId":"NCT03260023","title":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","sponsor":"Transgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":143,"enrollmentType":"ACTUAL","startDate":"2017-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-18","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["HPV-Related Carcinoma","HPV-Related Cervical Carcinoma","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Penile Squamous Cell Carcinoma","HPV-Related Vulvar Squamous Cell Carcinoma"],"interventions":["TG4001","Avelumab"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 participants at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-participant dose escalation. In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of participants with recurrent or metastatic HPV-16 positive advanced malignancies. In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab","sourceUrl":"https://clinicaltrials.gov/study/NCT03260023"},{"nctId":"NCT05804045","title":"Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":94,"enrollmentType":"ACTUAL","startDate":"2023-04-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-23","primaryCompletionType":"ACTUAL","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Tenosynovial Giant Cell Tumor","Pigmented Villonodular Synovitis","Giant Cell Tumor of Tendon Sheath"],"interventions":["Pimicotinib(ABSK021)","Placebo"],"countries":["United States","Canada","China","Italy","Netherlands","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in patients with Tenosynovial Giant Cell Tumor (TGCT). The main questions it aims to answer are: * Whether the Pimicotinib(ABSK021) works well in patients with TGCT. * Whether the Pimicotinib(ABSK021) is safe in patients with TGCT. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib(ABSK021) or placebo (a placebo is a look-alike substance that contains no active drug) about 24 weeks in study part 1. * Receive the administration of Pimicotinib(ABSK021) about 24 weeks in study part 2. * Receive the administration of Pimicotinib(ABSK021) till study e","sourceUrl":"https://clinicaltrials.gov/study/NCT05804045"},{"nctId":"NCT05867303","title":"A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-16","conditions":["Melanoma","Urothelial Carcinoma","Renal Cell Carcinoma","Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Carcinoma"],"interventions":["RC198 Injection"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"Safety study of RC198 in Subjects with Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05867303"},{"nctId":"NCT04657081","title":"Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)","sponsor":"Taiho Oncology, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":101,"enrollmentType":"ACTUAL","startDate":"2021-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-30","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-08","conditions":["Acute Myeloid Leukemia"],"interventions":["Decitabine and Cedazuridine (ASTX727)","Venetoclax"],"countries":["United States","Canada","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"The Phase 1 portion of this study is a single-arm, open-label, multicenter, non-randomized interventional study to evaluate the pharmacokinetic (PK) interaction, safety, and efficacy of ASTX727 when given in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy by evaluating area under the curve (AUC) and maximum plasma concentration (Cmax) exposure. The Phase 2 portion of the study is to assess the efficacy of A","sourceUrl":"https://clinicaltrials.gov/study/NCT04657081"},{"nctId":"NCT03600233","title":"Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors","sponsor":"TaiRx, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2018-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-30","primaryCompletionType":"ACTUAL","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Neuroendocrine Tumors","Pancreatic Neuroendocrine Tumor","Gastro-enteropancreatic Neuroendocrine Tumor","Lung Neuroendocrine Neoplasm","Neuroendocrine Carcinoma"],"interventions":["CVM-1118"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03600233"},{"nctId":"NCT05617755","title":"AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer","sponsor":"Arsenal Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":19,"enrollmentType":"ACTUAL","startDate":"2022-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2024-09-30","primaryCompletionType":"ACTUAL","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-07-30","conditions":["Carcinoma, Ovarian Epithelial","Ovarian Neoplasms","Fallopian Tube Neoplasms","Peritoneal Neoplasms","Neoplasms, Glandular and Epithelial","Ovarian Diseases","Genital Neoplasm, Female","Abdominal Neoplasm","Recurrence"],"interventions":["AB-1015"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label phase 1 dose escalation trial that uses a modified 3+3 design to identify a recommended phase 2 dose (RP2D) of AB-1015 cell product. Backfill cohorts will enroll additional subjects at doses deemed to be safe for a total enrollment of up to 12 subjects per each backfill cohort on the protocol.","sourceUrl":"https://clinicaltrials.gov/study/NCT05617755"},{"nctId":"NCT04920617","title":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2021-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-10","primaryCompletionType":"ESTIMATED","completionDate":"2025-04","completionType":"ESTIMATED","lastUpdated":"2023-04-07","conditions":["Relapsed Diffuse Large B-cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma"],"interventions":["DPX-Survivac","Pembrolizumab","CPA"],"countries":["United States","Australia","Canada","France","Hungary","New Zealand","Poland","Romania","Serbia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":50,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04920617"},{"nctId":"NCT02938299","title":"Neoadjuvant L19IL2/L19TNF- Pivotal Study","sponsor":"Philogen S.p.A.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":214,"enrollmentType":"ESTIMATED","startDate":"2016-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2024-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Malignant Melanoma"],"interventions":["L19IL2 + L19TNF","Surgery"],"countries":["France","Germany","Italy","Poland"],"northAmerica":false,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT02938299"},{"nctId":"NCT04928612","title":"A Study of CBP-1018 in Patients With Advanced Solid Tumors","sponsor":"Coherent Biopharma (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2021-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2024-10","primaryCompletionType":"ESTIMATED","completionDate":"2024-12","completionType":"ESTIMATED","lastUpdated":"2024-08-28","conditions":["Solid Tumor"],"interventions":["CBP-1018"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, non-randomized, multi-center, phase I study of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors. This study will be conducted in 2 parts: Part A (Dose Escalation) and Part B (Dose Expansion). Both parts include screening period, treatment period, end of treatment (EOT)/withdrawal, safety follow-up (SFU) and long-term-follow-up (LTFU). CBP-1018 will be administrated on eligible subjects until disease progression, unacceptable toxicity, withdrawal of consent or Sponsor's decision to stop the study, etc.","sourceUrl":"https://clinicaltrials.gov/study/NCT04928612"},{"nctId":"NCT03022825","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","sponsor":"ImmunityBio, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":190,"enrollmentType":"ACTUAL","startDate":"2017-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-01","primaryCompletionType":"ACTUAL","completionDate":"2029-03-01","completionType":"ESTIMATED","lastUpdated":"2025-10-16","conditions":["Bladder Cancer"],"interventions":["N-803 and BCG","N-803"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high grade non-muscle invasive bladder cancer (NMIBC). All patients treated in the study will receive via a urinary catheter in the bladder, BCG plus N-803 or N-803 only weekly for 6 consecutive weeks (initial induction treatment period). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18. Eligible patients hav","sourceUrl":"https://clinicaltrials.gov/study/NCT03022825"},{"nctId":"NCT04623944","title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","sponsor":"Nkarta, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2020-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-02","primaryCompletionType":"ACTUAL","completionDate":"2039-07","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Relapsed/Refractory AML","AML, Adult","MDS","Refractory Myelodysplastic Syndromes"],"interventions":["NKX101 - CAR NK cell therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.","sourceUrl":"https://clinicaltrials.gov/study/NCT04623944"},{"nctId":"NCT04155749","title":"Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma","sponsor":"Kite, A Gilead Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2019-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-03","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Relapsed and Refractory Multiple Myeloma"],"interventions":["anitocabtagene-autoleucel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.","sourceUrl":"https://clinicaltrials.gov/study/NCT04155749"},{"nctId":"NCT04999969","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":126,"enrollmentType":"ACTUAL","startDate":"2021-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-07","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Locally Advanced or Metastatic Solid Tumours"],"interventions":["AZD0171","Durvalumab","Gemcitabine","Nab-paclitaxel"],"countries":["United States","Canada","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04999969"},{"nctId":"NCT06255964","title":"A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":236,"enrollmentType":"ESTIMATED","startDate":"2024-02-15","startDateType":"ESTIMATED","primaryCompletionDate":"2024-10-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-07","completionType":"ESTIMATED","lastUpdated":"2024-02-13","conditions":["Bladder Cancer"],"interventions":["IAP0971","IAP0971＋BCG"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The efficacy and safety of IAP0971 single drug or combined with BCG intravesical instillation in the treatment of high-risk non muscle invasive bladder cancer with BCG treatment failure.","sourceUrl":"https://clinicaltrials.gov/study/NCT06255964"},{"nctId":"NCT04493853","title":"Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1012,"enrollmentType":"ACTUAL","startDate":"2020-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-07","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Hormone-Sensitive Prostate Cancer"],"interventions":["Capivasertib","Placebo","Abiraterone Acetate"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Czechia","France","Germany","Hong Kong","India","Israel","Japan","Mexico","Netherlands","Peru","Philippines","Poland","Russia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":323,"serviceSignals":["Broad CGP"],"summary":"This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid ","sourceUrl":"https://clinicaltrials.gov/study/NCT04493853"},{"nctId":"NCT04351555","title":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":358,"enrollmentType":"ACTUAL","startDate":"2020-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-15","primaryCompletionType":"ACTUAL","completionDate":"2029-06-13","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Osimertinib","Cisplatin","Carboplatin","Placebo","Pemetrexed"],"countries":["United States","Austria","Brazil","Bulgaria","Canada","Chile","China","France","Germany","India","Israel","Italy","Japan","Mexico","Peru","Poland","Russia","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":158,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04351555"},{"nctId":"NCT04581473","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection","sponsor":"CARsgen Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2020-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-18","primaryCompletionType":"ACTUAL","completionDate":"2038-06-30","completionType":"ESTIMATED","lastUpdated":"2025-06-05","conditions":["Gastric Adenocarcinoma","Pancreatic Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["CT041 autologous CAR T-cell injection","Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"An open, multicenter, phase Ib/II study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection in patients with advanced gastric/ gastroesophageal junction adenocarcinoma and pancreatic cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04581473"},{"nctId":"NCT05091541","title":"A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2021-10-20","startDateType":"ESTIMATED","primaryCompletionDate":"2024-10-20","primaryCompletionType":"ESTIMATED","completionDate":"2039-10-20","completionType":"ESTIMATED","lastUpdated":"2021-10-25","conditions":["B-cell Non-Hodgkin's Lymphoma"],"interventions":["Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study is a single-armed, open-label,multicenter Phase 1/2 study to evaluate the safety and efficacy of CT120 in subjects with relapsed/refractory B-cell non-Hodgkin's lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05091541"},{"nctId":"NCT03913949","title":"A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":74,"enrollmentType":"ESTIMATED","startDate":"2019-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-20","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Chronic Lymphocytic Leukemia","Non Hodgkin Lymphoma"],"interventions":["APG-2575"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT03913949"},{"nctId":"NCT04494503","title":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2020-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-20","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-04-16","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["APG-2575","Rituximab","Ibrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04494503"},{"nctId":"NCT04511871","title":"A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors","sponsor":"Shanghai PerHum Therapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2020-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-24","primaryCompletionType":"ACTUAL","completionDate":"2025-03-29","completionType":"ESTIMATED","lastUpdated":"2024-10-28","conditions":["Solid Tumor","Gastric Cancer","Breast Cancer","Ovarian Cancer","Sarcoma"],"interventions":["CCT303-406"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04511871"},{"nctId":"NCT05053880","title":"A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme","sponsor":"Accendatech USA Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2021-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-25","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Recurrent Glioblastoma Multiforme(GBM)"],"interventions":["ACT001","ACT001 + Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.","sourceUrl":"https://clinicaltrials.gov/study/NCT05053880"},{"nctId":"NCT04936308","title":"Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":453,"enrollmentType":"ACTUAL","startDate":"2021-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-28","primaryCompletionType":"ACTUAL","completionDate":"2026-07-16","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Arthritis, Psoriatic"],"interventions":["Guselkumab","Placebo"],"countries":["United States","Argentina","Australia","Bulgaria","Czechia","Hungary","Israel","Malaysia","Poland","Puerto Rico","Russia","Spain","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":169,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.","sourceUrl":"https://clinicaltrials.gov/study/NCT04936308"},{"nctId":"NCT04765059","title":"A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":98,"enrollmentType":"ACTUAL","startDate":"2021-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-28","primaryCompletionType":"ACTUAL","completionDate":"2027-06-02","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin","Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin"],"countries":["United States","China","Germany","Israel","Italy","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The study will evaluate the efficacy and safety of treatment with chemotherapy in combination with osimertinib compared to chemotherapy in combination with placebo in patients whose disease has progressed extracranially following first-line osimertinib treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04765059"},{"nctId":"NCT06354114","title":"A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-04","startDateType":"ESTIMATED","primaryCompletionDate":"2024-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-04-09","conditions":["Advanced Breast Cancer"],"interventions":["SYHX2011"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011","sourceUrl":"https://clinicaltrials.gov/study/NCT06354114"},{"nctId":"NCT03602859","title":"A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer","sponsor":"Tesaro, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1400,"enrollmentType":"ACTUAL","startDate":"2018-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-31","primaryCompletionType":"ACTUAL","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Ovarian Neoplasms","Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma"],"interventions":["Niraparib","Dostarlimab (TSR-042)","Standard of care","Dostarlimab-Placebo","Niraparib-Placebo"],"countries":["United States","Belarus","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Netherlands","Norway","Poland","Romania","Spain","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":182,"serviceSignals":["Broad CGP"],"summary":"Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular endothelial growth factor (VEGF) receptor, programmed death receptor ligands 1 (PD-L1) expression, and deoxyribonucleic acid (DNA) damage in ovarian tumors provide several targets for treatment and maintenance of disease response. Given the unmet medical need of participants with advanced or metastatic ovarian cancer, this study design will enable investigators to provide participants with current SOC for ovarian cancer for the duration of the study. This is a global, multicenter, randomized, double-blind, controlled Phase 3 study that will primarily compare the ","sourceUrl":"https://clinicaltrials.gov/study/NCT03602859"},{"nctId":"NCT06723964","title":"A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors","sponsor":"AP Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":35,"enrollmentType":"ACTUAL","startDate":"2023-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2024-10-31","primaryCompletionType":"ACTUAL","completionDate":"2025-11-30","completionType":"ESTIMATED","lastUpdated":"2024-12-09","conditions":["Advanced Solid Tumors"],"interventions":["AP505"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors. The study will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for AP505.","sourceUrl":"https://clinicaltrials.gov/study/NCT06723964"},{"nctId":"NCT06175338","title":"Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis","sponsor":"Mabscale, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":208,"enrollmentType":"ACTUAL","startDate":"2023-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-11","primaryCompletionType":"ESTIMATED","completionDate":"2025-04","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Rheumatoid Arthritis"],"interventions":["Rituximab","MabThera®"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"A randomised, double blind, parallel group, multicentre study to compare the pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) versus MabThera® in patients with rheumatoid arthritis.","sourceUrl":"https://clinicaltrials.gov/study/NCT06175338"},{"nctId":"NCT02768363","title":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","sponsor":"Candel Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":187,"enrollmentType":"ACTUAL","startDate":"2016-05","startDateType":"","primaryCompletionDate":"2024-11","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-07-30","conditions":["Prostate Cancer"],"interventions":["aglatimagene besadenovec","placebo","valacyclovir"],"countries":["United States","Mexico"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the effectiveness of CAN-2409 immunotherapy in patients undergoing active surveillance for localized prostate cancer. CAN-2409 involves the use of aglatimagene besadenovec to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. CAN-2409 has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that CAN-2409 can lead to improvement in the clinical outc","sourceUrl":"https://clinicaltrials.gov/study/NCT02768363"},{"nctId":"NCT03659448","title":"Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer","sponsor":"Surgimab","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2019-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2024-11","primaryCompletionType":"ESTIMATED","completionDate":"2024-12","completionType":"ESTIMATED","lastUpdated":"2024-04-24","conditions":["Colorectal Neoplasms"],"interventions":["SGM-101"],"countries":["United States","Germany","Italy","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard \"white light\" visualization during surgical resections of colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03659448"},{"nctId":"NCT05475184","title":"A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor","sponsor":"Onconic Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2024-11","primaryCompletionType":"ESTIMATED","completionDate":"2025-06","completionType":"ESTIMATED","lastUpdated":"2024-08-27","conditions":["Ovarian Cancer"],"interventions":["JPI-547"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor","sourceUrl":"https://clinicaltrials.gov/study/NCT05475184"},{"nctId":"NCT05246514","title":"A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2022-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-04","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["HER2-mutant Non-Small Cell Lung Cancer"],"interventions":["Trastuzumab deruxtecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05246514"},{"nctId":"NCT05445843","title":"Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":95,"enrollmentType":"ACTUAL","startDate":"2022-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-04","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation"],"interventions":["JDQ443"],"countries":["United States","Argentina","Austria","Belgium","Brazil","China","France","Germany","Greece","Hungary","India","Italy","Malaysia","Netherlands","Portugal","Spain","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":45,"serviceSignals":["RAS genotyping"],"summary":"This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and have a PD-L1 expression \\< 1% (cohort A) or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).","sourceUrl":"https://clinicaltrials.gov/study/NCT05445843"},{"nctId":"NCT05495295","title":"First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours","sponsor":"Phost'In Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":149,"enrollmentType":"ESTIMATED","startDate":"2022-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-04","primaryCompletionType":"ACTUAL","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-04-08","conditions":["Malignant Tumor","Advanced Solid Tumor","Glioblastoma Multiforme","Metastatic Cancer"],"interventions":["PhOx430"],"countries":["France","Italy"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit academic research institution aimed at promoting therapeutic innovation in oncology.. The trial includes two parts, a dose escalation phase which will enroll patients with non-selected tumour types, followed by a cohort expansion phase in selected tumour types.","sourceUrl":"https://clinicaltrials.gov/study/NCT05495295"},{"nctId":"NCT06212752","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":39,"enrollmentType":"ACTUAL","startDate":"2023-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-06","primaryCompletionType":"ACTUAL","completionDate":"2028-05-22","completionType":"ESTIMATED","lastUpdated":"2025-11-12","conditions":["Metastatic Non-small Cell Lung Cancer"],"interventions":["Pembrolizumab (+) Berahyaluronidase alfa","Pemetrexed","Cisplatin","Carboplatin","Paclitaxel","Nab-paclitaxel","Pembrolizumab","Filgrastim","Pegylated filgrastim"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab (+) berahyaluronidase alfa vs intravenous (IV) pembrolizumab, administered with chemotherapy in first line treatment of adult Japanese participants with metastatic non-small cell lung cancer. The primary hypotheses of this study are pembrolizumab (+) berahyaluronidase alfa subcutaneous (SC) is noninferior to pembrolizumab IV with respect to PK parameters.","sourceUrl":"https://clinicaltrials.gov/study/NCT06212752"},{"nctId":"NCT03899792","title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ACTUAL","startDate":"2019-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-08","primaryCompletionType":"ACTUAL","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-01-06","conditions":["Medullary Thyroid Cancer","Infantile Myofibromatosis","Infantile Fibrosarcoma","Papillary Thyroid Cancer","Soft Tissue Sarcoma"],"interventions":["Selpercatinib"],"countries":["United States","Australia","Canada","Denmark","France","Germany","Italy","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["RNA fusion"],"summary":"This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT03899792"},{"nctId":"NCT04285086","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","sponsor":"PharmaEssentia","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":174,"enrollmentType":"ACTUAL","startDate":"2020-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-12","primaryCompletionType":"ACTUAL","completionDate":"2029-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Essential Thrombocythemia"],"interventions":["Ropeginterferon alfa-2b","Anagrelide"],"countries":["United States","Canada","China","Hong Kong","Japan","Singapore","South Korea","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of P1101 compared with ANA after 12 months of treatment as second-line therapy for subjects with ET who have had a suboptimal or failed response to HU.","sourceUrl":"https://clinicaltrials.gov/study/NCT04285086"},{"nctId":"NCT04625270","title":"A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation","sponsor":"Verastem, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2020-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-01-29","conditions":["Low Grade Ovarian Serous Adenocarcinoma","Ovarian Cancer"],"interventions":["avutometinib (VS-6766)","avutometinib (VS-6766) and defactinib"],"countries":["United States","Belgium","Canada","France","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)","sourceUrl":"https://clinicaltrials.gov/study/NCT04625270"},{"nctId":"NCT05940896","title":"RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2023-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2023-11-27","conditions":["Solid Tumor"],"interventions":["Disitamab vedotin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"To evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of Disitamab Vedotin(DV, RC48-ADC) intravenously combined with radiotherapy in the treatment of locally advanced solid tumors with HER2 expression","sourceUrl":"https://clinicaltrials.gov/study/NCT05940896"},{"nctId":"NCT03907852","title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","sponsor":"TCR2 Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":57,"enrollmentType":"ACTUAL","startDate":"2019-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-19","primaryCompletionType":"ACTUAL","completionDate":"2028-11-02","completionType":"ESTIMATED","lastUpdated":"2025-08-27","conditions":["Mesothelioma","Mesothelioma, Malignant","Mesothelioma; Pleura","Mesotheliomas Pleural","Mesothelioma Peritoneum","Cholangiocarcinoma","Cholangiocarcinoma Recurrent","Ovarian Cancer","Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","High Grade Ovarian Serous Adenocarcinoma"],"interventions":["gavo-cel","fludarabine","cyclophosphamide","Nivolumab","Ipilimumab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["HLA / TCR"],"summary":"Gavocabtagene autoleucel (gavo-cel; TC-210) is a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.","sourceUrl":"https://clinicaltrials.gov/study/NCT03907852"},{"nctId":"NCT04843098","title":"Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Suzhou Junde Biotechnology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2021-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-20","primaryCompletionType":"ACTUAL","completionDate":"2025-06","completionType":"ESTIMATED","lastUpdated":"2024-12-09","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["TL117","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, pharmacokinetic and efficacy of TL117 plus paclitaxel in patients with recurrent or metastatic head and neck cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04843098"},{"nctId":"NCT05498155","title":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ACTUAL","startDate":"2022-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-20","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Breast Cancer"],"interventions":["Neoadjuvant Olaparib monotherapy group","Neoadjuvant combination therapy with olaparib plus durvalumab"],"countries":["United States","Australia","Austria","Belgium","Germany","Israel","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["HER2 profiling"],"summary":"This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems. Olaparib is a type of drug called a PARP (poly \\[adenosine diphosphate-ribose\\] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Durvalumab is a type of anticancer drug called immunotherapy that targets cancer c","sourceUrl":"https://clinicaltrials.gov/study/NCT05498155"},{"nctId":"NCT03049189","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","sponsor":"ITM Solucin GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":324,"enrollmentType":"ACTUAL","startDate":"2017-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-27","primaryCompletionType":"ACTUAL","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Neuroendocrine Tumors"],"interventions":["177Lu-edotreotide PRRT","Everolimus","Amino-Acid Solution"],"countries":["United States","Australia","Austria","Belgium","Czechia","France","Germany","Italy","Netherlands","Poland","South Africa","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).","sourceUrl":"https://clinicaltrials.gov/study/NCT03049189"},{"nctId":"NCT03742102","title":"A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":243,"enrollmentType":"ACTUAL","startDate":"2018-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-29","primaryCompletionType":"ACTUAL","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Triple Negative Breast Neoplasms"],"interventions":["Durvalumab","Capivasertib","Oleclumab","Paclitaxel","Trastuzumab deruxtecan","Datopotamab deruxtecan"],"countries":["United States","Canada","Poland","South Korea","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03742102"},{"nctId":"NCT05923008","title":"A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2024-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2023-11-29","conditions":["Solid Tumor"],"interventions":["IBI130"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2 multicenter, open-label, first-in-human study of IBI130. It includes a phase 1 dose escalation and expansion section to identify MTD/RP2D of IBI130, plan to enroll 20\\~182 subjects,and a phase 2 to explore efficacy, safety and tolerability of IBI130 at RP2D in specified types of solid tumor.Approximately 150 evaluable subjects will be enrolled for phase 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT05923008"},{"nctId":"NCT05278546","title":"A Study of ILB2109 in Patients With Advanced Solid Malignancies","sponsor":"Innolake Biopharm","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2022-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-02","completionType":"ESTIMATED","lastUpdated":"2024-11-12","conditions":["Advanced Solid Tumor"],"interventions":["ILB2109"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase Ia study to evaluate the safety, tolerability and preliminary efficacy of ILB2109, a A2a receptor antagonist, in patients with locally advanced or metastatic solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05278546"},{"nctId":"NCT03842085","title":"Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor","sponsor":"Beijing Mabworks Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":34,"enrollmentType":"ESTIMATED","startDate":"2019-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2024-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["HER2-positive Recurrent or Metastatic Malignant Solid Tumor"],"interventions":["Recombinant Humanized Bispecific Monoclonal Antibody MBS301"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a phase I study evaluating the safety and pharmacokinetics of MBS301 after intravenous administration in patients with HER-2 positive recurrent or metastatic malignant solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT03842085"},{"nctId":"NCT05868174","title":"Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2023-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2024-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-05-01","conditions":["Solid Tumor, Adult","Advanced Solid Tumor","Advanced Renal Cell Carcinoma"],"interventions":["89Zr-TLX250","177Lu-TLX250 and Peposertib"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05868174"},{"nctId":"NCT05658003","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":63,"enrollmentType":"ACTUAL","startDate":"2023-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-02","primaryCompletionType":"ACTUAL","completionDate":"2027-01-13","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"interventions":["[177Lu]Lu-PSMA-617","ARDT","[68Ga]Ga-PSMA-11","Best supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy of \\[177Lu\\]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic castration-resistant prostate cancer patients, who were previously treated with another ARDT as last treatment and who have not been exposed to a taxane-containing regimen in castrate resistant prostate cancer (CRPC) or hormone-sensitive prostate cancer (HSPC) settings and who are considered appropriate for delaying taxane-based chemotherapy. The primary endpoint of rPFS will be assessed via blinded independent centralized review of radiographic images provided by th","sourceUrl":"https://clinicaltrials.gov/study/NCT05658003"},{"nctId":"NCT04165317","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1068,"enrollmentType":"ACTUAL","startDate":"2019-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-02","primaryCompletionType":"ACTUAL","completionDate":"2026-12-02","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Non-muscle Invasive Bladder Cancer"],"interventions":["PF-06801591","Bacillus Calmette-Guerin"],"countries":["United States","Australia","Belgium","Canada","China","France","Germany","Italy","Japan","Poland","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":194,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn about the safety and effects of the study medicine (sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk (Part A) or was previously treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer (Part B). In Part A (enrollment closed), each participant was assigned to one of three study treatment groups. * One group is given sasanlimab and BCG at the study clinic. * The second group is given sasanlimab and BCG at the study clinic. This group will receive BC","sourceUrl":"https://clinicaltrials.gov/study/NCT04165317"},{"nctId":"NCT05117242","title":"Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer","sponsor":"Genmab","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2021-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-02","primaryCompletionType":"ACTUAL","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Non Small Cell Lung Cancer Metastatic"],"interventions":["Acasunlimab","Pembrolizumab"],"countries":["United States","France","Germany","Italy","Netherlands","Poland","Portugal","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to compare the safety and efficacy (how well the drug works) of acasunlimab (also known as GEN1046) when it is used alone (monotherapy) versus when it is combined with a cancer drug (pembrolizumab) for participants with relapsed/refractory (disease has returned after treatment or did not respond to treatment) non-small cell lung cancer (NSCLC; the most common type of lung cancer). This trial has 2 parts. The purpose of the first part is to find out if the combination of acasunlimab and pembrolizumab is safe and to find out the best doses to use. The purpose of the second part is to give acasunlimab and pembrolizumab to more participants to evaluate efficacy","sourceUrl":"https://clinicaltrials.gov/study/NCT05117242"},{"nctId":"NCT04931654","title":"A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":136,"enrollmentType":"ACTUAL","startDate":"2021-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-04","primaryCompletionType":"ACTUAL","completionDate":"2026-08-12","completionType":"ESTIMATED","lastUpdated":"2025-10-09","conditions":["Carcinoma, Non-Small-Cell Lung","Gastric Cancer","Gastroesophageal Junction Cancer"],"interventions":["AZD7789"],"countries":["United States","Canada","China","France","Georgia","Japan","Moldova","Netherlands","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04931654"},{"nctId":"NCT04858958","title":"Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2020-08-10","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-05","primaryCompletionType":"ACTUAL","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["NSCLC"],"interventions":["Furmonertinib 160mg","Furmonertinib 240mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ctDNA / MRD"],"summary":"This is a phase Ⅰb multi-center clinical study. To explore the preliminary efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation. The study plans to enroll 30 subjects, including 20 treated patients and 10 treatment-naïve patients. The subjects with disease progression after previous systematic anti-tumor therapy will be randomized to receive Furmonertinib Mesilate 160 mg/day (N=10) or 240 mg/day (N=10), respectively. The treatment-naïve patients do not need to be randomized and all will receive Furmonertinib Mesilate 240 mg/day (N=10) until disease progression, death or intolerability. The prima","sourceUrl":"https://clinicaltrials.gov/study/NCT04858958"},{"nctId":"NCT05716087","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2023-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-05","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Mantle Cell Lymphoma (MCL)"],"interventions":["Rocbrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":43,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05716087"},{"nctId":"NCT05883956","title":"A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia","sponsor":"Otsuka Australia Pharmaceutical Pty Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":13,"enrollmentType":"ACTUAL","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-06","primaryCompletionType":"ACTUAL","completionDate":"2025-05","completionType":"ESTIMATED","lastUpdated":"2025-03-20","conditions":["Myelodysplastic Syndromes","Leukemia, Myeloid, Acute","Leukemia, Myelomonocytic, Chronic","Patient Preference"],"interventions":["Subcutaneous azacitidine","Oral decitabine/cedazuridine"],"countries":["Australia","New Zealand"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"It is hypothesized that significantly more patients would prefer oral decitabine/cedazuridine to subcutaneous (SC) azacitidine (AZA) due to several factors, including improved treatment convenience, the reduced risk of nosocomial infections, and reduced treatment discomfort. However, this hypothesis has not been formally studied in a controlled setting. This study aims to address this evidence gap and evaluate patient, primary caregiver (carer), and clinician treatment preference between oral decitabine/cedazuridine and SC AZA in the treatment of adult patients with International Prognostic Scoring System-Revised (IPSS-R) intermediate, IPSS intermediate-2, or high-risk myelodysplastic syndro","sourceUrl":"https://clinicaltrials.gov/study/NCT05883956"},{"nctId":"NCT05159440","title":"First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-15","completionType":"ESTIMATED","lastUpdated":"2024-10-22","conditions":["Advanced Solid Tumor","Gastric Cancer","Pancreas Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["TORL-2-307-MAB"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05159440"},{"nctId":"NCT03907527","title":"Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer","sponsor":"Precigen, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2019-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-15","completionType":"ESTIMATED","lastUpdated":"2024-11-08","conditions":["Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Refractory Fallopian Tube Carcinoma","Refractory Ovarian Carcinoma","Refractory Primary Peritoneal Carcinoma","Stage III Fallopian Tube Cancer AJCC V8","Stage III Ovarian Cancer AJCC V8","Stage III Primary Peritoneal Cancer AJCC V8","Stage IIIA Fallopian Tube Cancer AJCC V8","Stage IIIA Ovarian Cancer AJCC V8","Stage IIIA Primary Peritoneal Cancer AJCC V8","Stage IIIA1 Fallopian Tube Cancer AJCC V8","Stage IIIA1 Ovarian Cancer AJCC V8","Stage IIIA2 Fallopian Tube Cancer AJCC V8","Stage IIIA2 Ovarian Cancer AJCC V8","Stage IIIB Fallopian Tube Cancer AJCC V8","Stage IIIB Ovarian Cancer AJCC V8","Stage IIIB Primary Peritoneal Cancer AJCC V8","Stage IIIC Fallopian Tube Cancer AJCC V8","Stage IIIC Ovarian Cancer AJCC V8","Stage IIIC Primary Peritoneal Cancer AJCC V8","Stage IV Fallopian Tube Cancer AJCC V8","Stage IV Ovarian Cancer AJCC V8","Stage IV Primary Peritoneal Cancer AJCC V8","Stage IVA Fallopian Tube Cancer AJCC V8","Stage IVA Ovarian Cancer AJCC V8","Stage IVA Primary Peritoneal Cancer AJCC V8","Stage IVB Fallopian Tube Cancer AJCC V8","Stage IVB Ovarian Cancer AJCC V8","Stage IVB Primary Peritoneal Cancer AJCC V8"],"interventions":["PRGN-3005 UltraCAR-T cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen, Inc.) in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body, that has come back and is resistant to platinum chemotherapy. Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.","sourceUrl":"https://clinicaltrials.gov/study/NCT03907527"},{"nctId":"NCT04592913","title":"Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":957,"enrollmentType":"ACTUAL","startDate":"2020-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-20","primaryCompletionType":"ACTUAL","completionDate":"2027-09-27","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Gastrointestinal Neoplasms","Esophagogastric Junction"],"interventions":["Durvalumab","FLOT chemotherapy"],"countries":["United States","Argentina","Belgium","Brazil","Canada","Chile","Denmark","France","Germany","Hungary","Japan","Netherlands","Peru","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":156,"serviceSignals":["Broad CGP"],"summary":"This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).","sourceUrl":"https://clinicaltrials.gov/study/NCT04592913"},{"nctId":"NCT03190278","title":"Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"Cellectis S.A.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":29,"enrollmentType":"ACTUAL","startDate":"2017-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-24","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Relapsed/Refractory Acute Myeloid Leukemia"],"interventions":["UCART123v1.2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"Phase I, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of Universal Chimeric Antigen Receptor T-cell (UCART) targeting the Cluster of Differentiation 123 (CD123) in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of Universal Chimeric Antigen Receptor T-cells targeting CD123 (UCART123v1.2) and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT03190278"},{"nctId":"NCT05955391","title":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":164,"enrollmentType":"ACTUAL","startDate":"2023-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-29","primaryCompletionType":"ACTUAL","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Non-small Cell Lung Cancer"],"interventions":["TGRX-326"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"This is a multi-center, single-arm, open-label, Phase II clinical trial which explores the safety and efficacy of TGRX-326 in patients with ALK-positive advanced NSCLC who have failed prior 2nd-generation ALK treatments due to progressive disease or intolerance.","sourceUrl":"https://clinicaltrials.gov/study/NCT05955391"},{"nctId":"NCT05126719","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma","sponsor":"Shanghai Miracogen Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":238,"enrollmentType":"ESTIMATED","startDate":"2023-04-06","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-30","primaryCompletionType":"ACTUAL","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Recurrent or Metastatic Nasopharyngeal Carcinoma"],"interventions":["MRG003","Capecitabine tablets","Docetaxel injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["ADC biomarker"],"summary":"The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05126719"},{"nctId":"NCT04024696","title":"A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients","sponsor":"Xynomic Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2020-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-30","primaryCompletionType":"ACTUAL","completionDate":"2025-11-30","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Non Hodgkin Lymphoma"],"interventions":["Abexinostat"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, non-randomized clinical study to evaluate the pharmacokinetic (PK) profiles, safety, tolerability and preliminary efficacy of oral abexinostat monotherapy in patients with non-Hodgkin's lymphoma who have failed standard of care, and thereby to determine the pharmacokinetic (PK) parameters, the maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of the oral monotherapy of abexinostat.","sourceUrl":"https://clinicaltrials.gov/study/NCT04024696"},{"nctId":"NCT05367700","title":"A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2022-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2023-01-13","conditions":["CML, Chronic Phase","CML, Accelerated Phase"],"interventions":["HS-10382(Part 1: Dose escalation)","HS-10382(Part 2: Dose expansion)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05367700"},{"nctId":"NCT03915184","title":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","sponsor":"CARsgen Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2019-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-12-31","completionType":"ESTIMATED","lastUpdated":"2023-12-19","conditions":["Multiple Myeloma"],"interventions":["zevor-cel"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT03915184"},{"nctId":"NCT05768529","title":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2023-09-21","conditions":["Relapsed or Refractory Non-Hodgkin's Lymphoma"],"interventions":["U16"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.","sourceUrl":"https://clinicaltrials.gov/study/NCT05768529"},{"nctId":"NCT05263479","title":"A Study of HS-20089 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hansoh Biomedical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":177,"enrollmentType":"ESTIMATED","startDate":"2022-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-04-03","conditions":["Advanced Solid Tumor"],"interventions":["HS-20089 (Phase Ia：Dose escalation )","HS-20089 (Phase Ib: Dose expansion)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"HS-20089 is a novel DAR-6 antibody-drug conjugate （ADC） targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20089 in Patients With Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05263479"},{"nctId":"NCT05007938","title":"Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2021-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-23","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Icotinib","Befotertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05007938"},{"nctId":"NCT06548347","title":"A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":606,"enrollmentType":"ESTIMATED","startDate":"2024-09-10","startDateType":"ESTIMATED","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2024-08-12","conditions":["Peripheral T Cell Lymphoma"],"interventions":["Linperlisib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase II/III, international multiple center study to evaluate the efficacy, safety, and PK of Linperlisib plus CHOP and CHOP in adult patients with Newly Diagnosed Peripheral T Cell Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06548347"},{"nctId":"NCT05103358","title":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","sponsor":"Aadi Bioscience, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2022-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-06-03","conditions":["Tumor","Tumor, Solid","Metastasis","Metastatic Cancer","Cancer","Cancer Metastatic","Tumors","Neoplasms","Neoplasm Metastasis","Solid Tumor","Advanced Solid Tumor","Advanced Cancer","Malignant Solid Tumor","Malignant Solid Neoplasm","Malignant Neoplasm","Malignant Tumor","TSC","TSC1","TSC2","Metastatic Solid Tumor","Metastatic Neoplasm"],"interventions":["nab-sirolimus"],"countries":["United States","Puerto Rico","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":166,"serviceSignals":["Broad CGP"],"summary":"A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes","sourceUrl":"https://clinicaltrials.gov/study/NCT05103358"},{"nctId":"NCT04495153","title":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","sponsor":"Candel Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ACTUAL","startDate":"2020-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Non Small Cell Lung Cancer"],"interventions":["Aglatimagene besadenovec"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04495153"},{"nctId":"NCT04921527","title":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":454,"enrollmentType":"ESTIMATED","startDate":"2021-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-31","completionType":"ESTIMATED","lastUpdated":"2024-10-18","conditions":["Ovarian Cancer","Relapsed or Refractory","Chiauranib","Paclitaxel"],"interventions":["chiauranib","Placebo","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04921527"},{"nctId":"NCT04854668","title":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":748,"enrollmentType":"ACTUAL","startDate":"2021-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Metastatic Colorectal Cancer"],"interventions":["Anlotinib hydrochloride capsule","Bevacizumab","Oxaliplatin","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":92,"serviceSignals":["Broad CGP"],"summary":"This is an open label, randomized, phase Ⅲ study to treat subjects with RAS/BRAF wild-type, unresectable metastatic colorectal cancer. The patients will be randomized into two arms consist of Anlotinib (3 weeks/cycle) + CapeOx and Bevacizumab (3 week/cycle) + CapeOx at a ratio of 1:1. This study is conducted to assess the efficacy and safety of Anlotinib and Chemotherapy as first-line treatment in subjects with RAS/BRAF wild-type Metastatic Colorectal Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04854668"},{"nctId":"NCT06616727","title":"The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM","sponsor":"Shanghai Simnova Biotechnology Co.,Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-27","conditions":["Recurrent Glioblastoma Multiforme (GBM)"],"interventions":["SNC109"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM","sourceUrl":"https://clinicaltrials.gov/study/NCT06616727"},{"nctId":"NCT05773937","title":"A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2022-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced Malignant Solid Tumors"],"interventions":["9MW2821"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase 1, first-in-human, open-label, dose-escalation and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetics, preliminary antitumor activity and immunogenicity of 9MW2821 administered by intravenous (IV) infusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT05773937"},{"nctId":"NCT05293964","title":"Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":214,"enrollmentType":"ACTUAL","startDate":"2022-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-09-08","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["Breast Cancer"],"interventions":["SIM0270","Palbociclib","everolimus"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a multi-center, open-label, Phase 1 clinical study to evaluate the safety, pharmacokinetic (PK) and anti-tumor efficacy of SIM0270 and SIM0270 in combination with palbociclib or everolimus in subjects with estrogen receptor (ER) -positive, human epidermal growth factor receptor (HER-2) -negative locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05293964"},{"nctId":"NCT05547061","title":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","sponsor":"Cellbion Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":91,"enrollmentType":"ACTUAL","startDate":"2021-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2024-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-11","conditions":["Prostate Cancer","mCRPC"],"interventions":["Lu-177-DGUL","Ga-68-NGUL"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is an open-label, single-arm, multi-center, escalation (Phase 1 Part B only), rater-blind (Phase 2 only), phase 1/2 trial to evaluate the diagnostic validity/safety of Ga-68-NGUL and efficacy/safety of Lu-177-DGUL on the anti-tumor activity that aims to simultaneously evaluate diagnostic and therapeutic validity.","sourceUrl":"https://clinicaltrials.gov/study/NCT05547061"},{"nctId":"NCT05558007","title":"Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients","sponsor":"Biozeus Biopharmaceutical S.A.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2023-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-01-31","completionType":"ESTIMATED","lastUpdated":"2024-10-22","conditions":["Erectile Dysfunction Following Radical Prostatectomy","Erectile Dysfunction","Prostate Cancer","Radical Prostatectomy"],"interventions":["Tadalafil 5mg","BZ371A","Oral Placebo","Topical Placebo"],"countries":["Brazil"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT05558007"},{"nctId":"NCT04282031","title":"A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer","sponsor":"Beta Pharma (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2020-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-06-30","completionType":"ESTIMATED","lastUpdated":"2024-08-07","conditions":["Advanced Solid Tumor","HR+/HER2- Breast Cancer"],"interventions":["BPI-1178","Fulvestrant","Letrozole"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"BPI-1178 is a novel, orally administered inhibitor of both cyclin-dependent kinase 4（CDK4）and CDK6 kinase activity. This Phase I study is a first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of oral BPI-1178 in patients with advanced solid tumors. The Phase IIa trial is designed to investigate the anti-tumor activity and safety of BPI-1178 in combination with endocrine therapy in patients with HR+/HER2-advanced breast cancer and to determine the dosing regimen for combination with endocrine therapy in a later confirmatory study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04282031"},{"nctId":"NCT05266612","title":"Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors","sponsor":"Virogin Biotech Canada Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2022-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2024-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-09","conditions":["Solid Tumor"],"interventions":["VG2025","Nivolumab Injection [Opdivo]"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, dose-escalation trial using standard 3+3 dose-escalation design in patients with advanced malignant solid tumors. All patients within a given dose level cohort will be treated with the same dose schedule of VG2025, administered as intratumoral injections at Day 1 and Day 15 biweekly at each treatment cycle (monotherapy cohorts 1-4 and combination cohort 1) and on day 1 and either day 2 or day 3 at the first 2 cycles followed by day 1 only at subsequent cycles (combination cohort 2). Dose limiting toxicity (DLT) evaluation period is for 4 weeks, from the start of treatment, Day 1, through Day 28. There are two parts to this study a monotherapy arm and a combinat","sourceUrl":"https://clinicaltrials.gov/study/NCT05266612"},{"nctId":"NCT03379428","title":"Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer","sponsor":"US Oncology Research","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2017-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-01","completionType":"ESTIMATED","lastUpdated":"2024-12-06","conditions":["Breast Neoplasms","Malignant Neoplasm of Breast"],"interventions":["Trastuzumab","Ibrutinib 560 mg","Ibrutinib 840 mg","Ibrutinib 420 mg"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with trastuzumab administered through the vein, in patients with HER2-amplified Metastatic Breast Cancer that has gotten worse after prior therapy with ado-trastuzumab emtansine (T-DM1).","sourceUrl":"https://clinicaltrials.gov/study/NCT03379428"},{"nctId":"NCT04020575","title":"Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)","sponsor":"Minerva Biotechnologies Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":69,"enrollmentType":"ESTIMATED","startDate":"2020-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-01","primaryCompletionType":"ESTIMATED","completionDate":"2035-01-15","completionType":"ESTIMATED","lastUpdated":"2023-06-18","conditions":["Metastatic Breast Cancer"],"interventions":["huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells","huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase I/II study of adoptive immunotherapy for advanced MUC1\\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1\\*).","sourceUrl":"https://clinicaltrials.gov/study/NCT04020575"},{"nctId":"NCT04497844","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":696,"enrollmentType":"ACTUAL","startDate":"2020-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-07","primaryCompletionType":"ACTUAL","completionDate":"2027-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Metastatic Castration-sensitive Prostate Cancer"],"interventions":["Niraparib","Abiraterone acetate (AA)","Prednisone","Placebo for Niraparib"],"countries":["United States","Argentina","Australia","Belarus","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Malaysia","Mexico","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Russia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":387,"serviceSignals":["HRD / HRR"],"summary":"The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT04497844"},{"nctId":"NCT05403541","title":"Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis","sponsor":"Immunovant Sciences GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2022-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-10","primaryCompletionType":"ACTUAL","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Generalized Myasthenia Gravis"],"interventions":["Batoclimab 680 mg SC weekly","Batoclimab 340 mg SC weekly","Matching Placebo SC","Batoclimab 340 mg SC bi-weekly"],"countries":["United States","Argentina","Brazil","Canada","Georgia","Germany","Hungary","Italy","Japan","Mexico","Poland","Romania","Serbia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":93,"serviceSignals":["Broad CGP"],"summary":"The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previously treated with batoclimab will be re-randomized to stay on batoclimab (340 mg SC QW or 340 mg SC every two weeks) or receive placebo treatment. The secondary endpoint of maintenance of efficacy wil","sourceUrl":"https://clinicaltrials.gov/study/NCT05403541"},{"nctId":"NCT03860272","title":"Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer","sponsor":"Agenus Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":499,"enrollmentType":"ACTUAL","startDate":"2019-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-13","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Advanced Cancer","Angiosarcoma","Colorectal Cancer Without Liver Metastases","Endometrial Cancer","Fibrolamellar Carcinoma","Non-small-cell Lung Cancer","Ovarian Cancer","Prostate Cancer"],"interventions":["Botensilimab","Balstilimab"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1) antibody (balstilimab), and to assess the maximum tolerated dose (MTD) in participants with advanced solid tumors. This study will also determine the recommended phase 2 dose (RP2D) of botensilimab monotherapy and in combination with balstilimab.","sourceUrl":"https://clinicaltrials.gov/study/NCT03860272"},{"nctId":"NCT04720157","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1140,"enrollmentType":"ACTUAL","startDate":"2021-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-13","primaryCompletionType":"ACTUAL","completionDate":"2027-02-11","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Prostatic Neoplasms"],"interventions":["177Lu-PSMA-617","68Ga-PSMA-11","ARDT","ADT"],"countries":["United States","Austria","Belgium","Canada","China","Czechia","Denmark","France","Germany","Japan","Netherlands","Poland","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":167,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 20 countries.","sourceUrl":"https://clinicaltrials.gov/study/NCT04720157"},{"nctId":"NCT04844866","title":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":213,"enrollmentType":"ESTIMATED","startDate":"2021-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-15","primaryCompletionType":"ACTUAL","completionDate":"2031-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["MB-CART2019.1","Standard of Care"],"countries":["Austria","Belgium","Croatia","Czechia","Finland","France","Germany","Hungary","Italy","Netherlands","Poland","Portugal","Spain","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":51,"serviceSignals":["Hematology NGS"],"summary":"In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation. Part II is a Phase II single-arm, open-label, multi-centre study evaluating the efficacy and safety of MB-CART2019.1 in younger, fit participants with R-R DLBCL. Part II will start after completion of enrolment in Part I.","sourceUrl":"https://clinicaltrials.gov/study/NCT04844866"},{"nctId":"NCT05440786","title":"CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2022-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Sarcoma, Ewing","Neoplasm Metastasis"],"interventions":["Abemaciclib","Irinotecan","Temozolomide"],"countries":["United States","Australia","France","Germany","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.","sourceUrl":"https://clinicaltrials.gov/study/NCT05440786"},{"nctId":"NCT03964727","title":"Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":227,"enrollmentType":"ACTUAL","startDate":"2019-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-15","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Metastatic Solid Tumor"],"interventions":["Sacituzumab Govitecan-hziy"],"countries":["United States","Australia","Belgium","Canada","France","Hong Kong","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03964727"},{"nctId":"NCT04940052","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":153,"enrollmentType":"ACTUAL","startDate":"2021-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-22","primaryCompletionType":"ACTUAL","completionDate":"2027-05-25","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Differentiated Thyroid Cancer (DTC)"],"interventions":["Dabrafenib","Trametinib","Trametinib Placebo","Dabrafenib placebo"],"countries":["United States","Argentina","Brazil","Canada","China","India","Malaysia","South Korea","Taiwan","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":41,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT04940052"},{"nctId":"NCT05479994","title":"Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","sponsor":"BeiGene","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ACTUAL","startDate":"2022-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-24","primaryCompletionType":"ACTUAL","completionDate":"2027-08-25","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Leukemia","Lymphoma","Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","Small Lymphocytic Lymphoma","Relapsed Chronic Lymphocytic Leukemia"],"interventions":["BGB-11417"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":50,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy of BGB-11417 in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)","sourceUrl":"https://clinicaltrials.gov/study/NCT05479994"},{"nctId":"NCT05197426","title":"A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":19,"enrollmentType":"ACTUAL","startDate":"2022-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-27","primaryCompletionType":"ACTUAL","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Acute Myeloid Leukemia"],"interventions":["Oral Azacitidine","Placebo"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute Myeloid Leukemia (AML) and in complete remission/complete remission with incomplete blood count recovery after conventional induction chemotherapy with or without consolidation chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05197426"},{"nctId":"NCT04468984","title":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2020-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-29","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Myelofibrosis (MF)"],"interventions":["Navitoclax","Ruxolitinib","Best Available Therapy (BAT)"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Japan","New Zealand","Poland","Puerto Rico","Russia","Serbia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":229,"serviceSignals":["Broad CGP"],"summary":"Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF. Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters. In Arm A, participants will","sourceUrl":"https://clinicaltrials.gov/study/NCT04468984"},{"nctId":"NCT05740566","title":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":509,"enrollmentType":"ACTUAL","startDate":"2023-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-29","primaryCompletionType":"ACTUAL","completionDate":"2028-03-26","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Small Cell Lung Cancer (SCLC)"],"interventions":["Tarlatamab","Lurbinectedin","Topotecan","Amrubicin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Romania","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":223,"serviceSignals":["Broad CGP"],"summary":"The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT05740566"},{"nctId":"NCT03934567","title":"A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma","sponsor":"Xynomic Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ACTUAL","startDate":"2020-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-29","primaryCompletionType":"ACTUAL","completionDate":"2025-10-30","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Lymphoma, Follicular"],"interventions":["Abexinostat"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with relapsed or refractory follicular lymphoma (FL)","sourceUrl":"https://clinicaltrials.gov/study/NCT03934567"},{"nctId":"NCT05654623","title":"A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":624,"enrollmentType":"ACTUAL","startDate":"2023-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-31","primaryCompletionType":"ACTUAL","completionDate":"2028-05-15","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Advanced Breast Cancer"],"interventions":["ARV-471","Fulvestrant"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Finland","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Mexico","Poland","Puerto Rico","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":312,"serviceSignals":["HER2 profiling"],"summary":"A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05654623"},{"nctId":"NCT04676477","title":"HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":246,"enrollmentType":"ACTUAL","startDate":"2021-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-31","primaryCompletionType":"ACTUAL","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2025-06-22","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["HER3-DXd","Osimertinib"],"countries":["United States","Japan","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"This study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety. The primary objectives: Dose Escalation: To assess the safety and tolerability of HER3-DXd (patritumab deruxtecan; U3-1402) and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 19 deletion or L858R mutation with tumor progression after treatment with osimertinib, and to determine the recommended combination dose (RCD). Second-Line Dose Expansion Arm 1 and Arm 1b: To assess the preliminary antitumor activity of HER3-DXd and osimertinib in subjects with locally advanced or","sourceUrl":"https://clinicaltrials.gov/study/NCT04676477"},{"nctId":"NCT06155383","title":"Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2023-12-14","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["Capecitabine","oxaliplatin","Disitamab Vedotin","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06155383"},{"nctId":"NCT04538742","title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":245,"enrollmentType":"ACTUAL","startDate":"2020-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-01-31","primaryCompletionType":"ACTUAL","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2025-12-08","conditions":["Metastatic Breast Cancer"],"interventions":["Trastuzumab deruxtecan","Durvalumab","Paclitaxel","Pertuzumab","Tucatinib"],"countries":["United States","Australia","Brazil","Canada","France","Germany","India","Italy","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":72,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04538742"},{"nctId":"NCT05683886","title":"A Study of KC1036 in Patients with Advanced Thymic Tumors","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2024-10-17","conditions":["Thymic Tumors"],"interventions":["KC1036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a single arm，open-label, multicentric, phase II study to evaluate the efficacy and safety of KC1036 in patients with advanced recurrent or metastatic thymoma or thymic carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05683886"},{"nctId":"NCT05909241","title":"A Study of BA1202 in Patients With Advanced Solid Tumors","sponsor":"Shandong Boan Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2023-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-04-25","conditions":["Advanced Solid Tumor"],"interventions":["BA1202"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, single-arm phase I study in patients with advanced solid tumors which consists of a dose escalation part (Part A) and a dose extension part (Part B). Part A aims to evaluate the safety and tolerability of BA1202, and determine the MTD. Part B will also evaluate the preliminary efficacy of BA1202.","sourceUrl":"https://clinicaltrials.gov/study/NCT05909241"},{"nctId":"NCT05128487","title":"A Study of NDI 1150-101 in Patients With Solid Tumors","sponsor":"Nimbus Saturn, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":106,"enrollmentType":"ESTIMATED","startDate":"2021-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-02","primaryCompletionType":"ESTIMATED","completionDate":"2025-05","completionType":"ESTIMATED","lastUpdated":"2024-11-25","conditions":["Solid Tumor","Renal Cell Carcinoma (Kidney Cancer)","Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","Non-Small Cell Lung Cancer"],"interventions":["NDI-101150","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adult patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05128487"},{"nctId":"NCT05688280","title":"Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS","sponsor":"Immunophotonics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2022-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-02","primaryCompletionType":"ESTIMATED","completionDate":"2025-02","completionType":"ESTIMATED","lastUpdated":"2025-01-08","conditions":["Metastatic Solid Tumor","Colon Cancer","Nonsmall Cell Lung Cancer","Soft Tissue Sarcoma"],"interventions":["1.0% IP-001 for Injection"],"countries":["United States","France","Germany","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05688280"},{"nctId":"NCT06226363","title":"Phase I Study of LNF1901 in Advanced Malignant Tumors","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2024-02-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2024-01-26","conditions":["Advanced Malignant Tumors"],"interventions":["LNF1901 Monoclonal Antibody Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open, phase I dose-escalation and dose-expansion study to evaluate the safety, tolerability, initial antitumor efficacy, PK and immunogenic characteristics of LNF1901 in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06226363"},{"nctId":"NCT06206915","title":"Phase I Study of XZ120 in Malignant Tumors","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2024-02-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2024-01-16","conditions":["Advanced Malignancies"],"interventions":["XZ120 injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This research includes two parts: the first part of the patients with late malignant tumor monotherapy study, at the beginning of the second part in treat DLBCL and research on combination therapy in patients with advanced breast cancer. Research purpose: to evaluate XZ120 safety, tolerability, for the treatment of malignant tumor patients pharmacokinetic characteristics and preliminary effectiveness.","sourceUrl":"https://clinicaltrials.gov/study/NCT06206915"},{"nctId":"NCT04914598","title":"A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2021-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-10","primaryCompletionType":"ACTUAL","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Malignant Pleural Effusion"],"interventions":["ENDOSTAR，cisplatin","Placebo , cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Malignant Pleural Effusion or Ascites is a common complication of malignant tumor, The objective of this study is to compare the efficacy of Endostar/cisplatin with placebo/cisplatin in patients with malignant pleural effusion or ascites.","sourceUrl":"https://clinicaltrials.gov/study/NCT04914598"},{"nctId":"NCT03157128","title":"A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)","sponsor":"Eli Lilly and Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":857,"enrollmentType":"ACTUAL","startDate":"2017-05-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-14","primaryCompletionType":"ACTUAL","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Non-Small Cell Lung Cancer","Medullary Thyroid Cancer","Colon Cancer","Any Solid Tumor"],"interventions":["LOXO-292"],"countries":["United States","Australia","Canada","Denmark","France","Germany","Hong Kong","Israel","Italy","Japan","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":85,"serviceSignals":["RNA fusion"],"summary":"This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.","sourceUrl":"https://clinicaltrials.gov/study/NCT03157128"},{"nctId":"NCT05171647","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":208,"enrollmentType":"ACTUAL","startDate":"2022-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-17","primaryCompletionType":"ACTUAL","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Non-Hodgkin Lymphoma"],"interventions":["Mosunetuzumab","Polatuzumab vedotin","Tocilizumab","Rituximab","Gemcitabine","Oxaliplatin"],"countries":["United States","Argentina","Brazil","Canada","China","Israel","Japan","Mexico","New Zealand","Peru","South Korea","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":51,"serviceSignals":["Hematology NGS"],"summary":"This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).","sourceUrl":"https://clinicaltrials.gov/study/NCT05171647"},{"nctId":"NCT06257680","title":"A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors","sponsor":"Aeonvital Biomedicine","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2024-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-18","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-18","completionType":"ESTIMATED","lastUpdated":"2024-07-31","conditions":["Advanced Solid Tumor"],"interventions":["ReT01 ACT"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.","sourceUrl":"https://clinicaltrials.gov/study/NCT06257680"},{"nctId":"NCT05210790","title":"A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera","sponsor":"Protagonist Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":293,"enrollmentType":"ACTUAL","startDate":"2022-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-21","primaryCompletionType":"ACTUAL","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Polycythemia Vera"],"interventions":["Placebo","Rusfertide"],"countries":["United States","Australia","Austria","Belgium","Canada","Chile","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Mexico","Netherlands","Poland","Portugal","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":184,"serviceSignals":["Broad CGP"],"summary":"The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.","sourceUrl":"https://clinicaltrials.gov/study/NCT05210790"},{"nctId":"NCT04225117","title":"A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":329,"enrollmentType":"ACTUAL","startDate":"2020-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-25","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Locally Advanced or Metastatic Malignant Solid Tumors"],"interventions":["enfortumab vedotin","pembrolizumab"],"countries":["United States","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["HER2 profiling"],"summary":"The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.","sourceUrl":"https://clinicaltrials.gov/study/NCT04225117"},{"nctId":"NCT06206174","title":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2024-04-10","conditions":["Hematologic Malignancy","Non Hodgkin Lymphoma","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia, Adult","Myelodysplastic Syndromes"],"interventions":["TGRX-814"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this single- arm, open-label, dose escalation and dose expansion phase I/II study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-814 in patients with hematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, aute lymphoblastic leukemia and myelodysplastic syndromes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06206174"},{"nctId":"NCT04954001","title":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2021-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2025-03-30","completionType":"ESTIMATED","lastUpdated":"2024-11-12","conditions":["Neurofibromatosis 1","Plexiform Neurofibroma","NF1"],"interventions":["FCN-159"],"countries":["United States","China","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"FCN-159 is a highly active MEK1/2 inhibitor that was designed, synthesized and screened on the basis of the structure of trametinib. FCN-159 is an orally available and highly potent selective inhibitor of MEK1/2, which is expected to be a targeted therapy for the treatment of advanced solid tumors and neurofibromatosis type 1.","sourceUrl":"https://clinicaltrials.gov/study/NCT04954001"},{"nctId":"NCT05840016","title":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":532,"enrollmentType":"ACTUAL","startDate":"2023-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-02-28","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-02","conditions":["Advanced Squamous Non Small Cell Lung Cancer"],"interventions":["AK112, Carboplatin, Paxlitaxel","Tislelizumab, Carboplatin, Paxlitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or stage IV squamous non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with chemotherapy versus Tislelizumab combined with chemotherapy in patients with advanced squamous NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05840016"},{"nctId":"NCT04834024","title":"MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma","sponsor":"Beijing Mabworks Biotech Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2021-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-03","primaryCompletionType":"ESTIMATED","completionDate":"2025-03","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["Follicular Lymphoma and Marginal Zone Lymphoma"],"interventions":["Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide","lenalinomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT04834024"},{"nctId":"NCT05199272","title":"A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies","sponsor":"23andMe, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":141,"enrollmentType":"ESTIMATED","startDate":"2021-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-03","primaryCompletionType":"ESTIMATED","completionDate":"2025-03","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["Solid Tumor","Clear Cell Renal Cell Carcinoma","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma","Neuroendocrine Tumors","MSI-H Cancer","Cancer With A High Tumor Mutational Burden","Extensive-stage Small-cell Lung Cancer"],"interventions":["23ME-00610"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["MSI / TMB"],"summary":"This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies","sourceUrl":"https://clinicaltrials.gov/study/NCT05199272"},{"nctId":"NCT04230499","title":"Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance","sponsor":"Rapamycin Holdings Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2021-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-03","primaryCompletionType":"ESTIMATED","completionDate":"2025-03","completionType":"ESTIMATED","lastUpdated":"2025-01-09","conditions":["Familial Adenomatous Polyposis"],"interventions":["Encapsulated Rapamycin (eRapa)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.","sourceUrl":"https://clinicaltrials.gov/study/NCT04230499"},{"nctId":"NCT05263583","title":"Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma","sponsor":"Cothera Bioscience, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2022-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-06-30","completionType":"ESTIMATED","lastUpdated":"2025-01-14","conditions":["High-grade B-cell Lymphoma","Burkitt Lymphoma","Lymphoma, B-Cell","Lymphoma, Large B-Cell, Diffuse","Lymphatic Diseases","Lymphoma, High-Grade","C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma","C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma","C-Myc Gene Rearrangement"],"interventions":["Sepantronium Bromide"],"countries":["China","South Korea"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"This is a multi-center Phase 2 study to determine the safety and efficacy of sepantronium bromide (SepB) in adult patients with relapsed or refractory high-grade B-cell lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05263583"},{"nctId":"NCT04607421","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":841,"enrollmentType":"ACTUAL","startDate":"2020-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-01","primaryCompletionType":"ACTUAL","completionDate":"2027-12-28","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Neoplasms"],"interventions":["Encorafenib","Cetuximab","Oxaliplatin","Irinotecan","Leucovorin","5-FU","Capecitabine","Bevacizumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Finland","Germany","India","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Poland","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":272,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: * has spread to other parts of the body (metastatic); * has a certain type of abnormal gene called \"BRAF\"; and * has not received prior treatment. Participants in this study will receive one of the following study treatments: * Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic. * Encorafenib plus cetuximab with chemotherapy: These participa","sourceUrl":"https://clinicaltrials.gov/study/NCT04607421"},{"nctId":"NCT04675294","title":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","sponsor":"ALX Oncology Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":189,"enrollmentType":"ACTUAL","startDate":"2021-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-03","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma"],"interventions":["evorpacept","pembrolizumab"],"countries":["United States","Australia","Belgium","Canada","Netherlands","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04675294"},{"nctId":"NCT05280470","title":"Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","sponsor":"Daiichi Sankyo","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":187,"enrollmentType":"ACTUAL","startDate":"2022-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12-15","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":["Ifinatamab Deruxtecan (I-DXd)"],"countries":["United States","China","France","Germany","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":58,"serviceSignals":["ADC biomarker"],"summary":"This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung Cancer (ES-SCLC) who received at least 1 prior line of platinum-based chemotherapy and a maximum of 3 prior lines of therapy (Part 1) and a minimum of two previous lines of systemic therapy (Part 2). This study will also investigate I-DXd anti-tumor activity in this population.","sourceUrl":"https://clinicaltrials.gov/study/NCT05280470"},{"nctId":"NCT04675333","title":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","sponsor":"ALX Oncology Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":172,"enrollmentType":"ACTUAL","startDate":"2021-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-03","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma"],"interventions":["evorpacept","pembrolizumab","Cisplatin/Carboplatin; 5FU"],"countries":["United States","Australia","Belgium","Netherlands","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04675333"},{"nctId":"NCT05864014","title":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":213,"enrollmentType":"ACTUAL","startDate":"2023-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-03","primaryCompletionType":"ACTUAL","completionDate":"2025-09","completionType":"ESTIMATED","lastUpdated":"2025-04-16","conditions":["Chemotherapy-Induced Thrombocytopenia"],"interventions":["Hetrombopag","Hetrombopag plus Placebo","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05864014"},{"nctId":"NCT02264678","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":358,"enrollmentType":"ACTUAL","startDate":"2014-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-04","primaryCompletionType":"ACTUAL","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer"],"interventions":["Administration of ceralasertib","Administration of ceralasertib in combination with olaparib","Administation of ceralasertib in combination with durvalumab","Administration of ceralasertib monotherapy","Administration of ceralasertib and olaparib","Administration of ceralasertib and durvalumab","Administration of ceralasertib in combination with AZD5305","Administration of ceralasertib in combination with carboplatin"],"countries":["United States","France","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["HER2 profiling"],"summary":"This is a modular, phase I/ phase 1 b, open-label, multicentre study of ceralasertib administered orally in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced malignancies. The study design allows an investigation of optimal combination dose of ceralasertib with other anti-cancer treatments, with intensive safety monitoring to ensure the safety of the patients. The initial combination to be investigated is ceralasertib with carboplatin. The second combination to be investigated is ceralasertib with Olaparib. The third combination to be investigated is ceralasertib with durvalumab. The fourth module will investigate the effect of food o","sourceUrl":"https://clinicaltrials.gov/study/NCT02264678"},{"nctId":"NCT06759857","title":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2021-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-04","primaryCompletionType":"ESTIMATED","completionDate":"2025-05-01","completionType":"ESTIMATED","lastUpdated":"2025-01-06","conditions":["Non Small Cell Lung Cancer"],"interventions":["FHND9041","Afatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the effectiveness and safety of FHND9041 compared to afatinib as first-line treatments for epidermal growth factor receptor mutation-positive (EGFRm+) locally advanced or metastatic non-small cell lung cancer (NSCLC). The main questions it aims to answer are: * Does FHND9041 improve progression-free survival (PFS) compared to afatinib? * Are there differences in safety profiles between FHND9041 and afatinib? Researchers will compare FHND9041 (80 mg, orally, once daily) with afatinib (40 mg, orally, once daily) in a randomized, open-label, parallel-controlled, multicenter Phase III trial. Participants who meet the inclusion criteria, including ha","sourceUrl":"https://clinicaltrials.gov/study/NCT06759857"},{"nctId":"NCT05116189","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":643,"enrollmentType":"ACTUAL","startDate":"2021-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-05","primaryCompletionType":"ACTUAL","completionDate":"2027-07-16","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Ovarian Cancer","Carcinoma, Ovarian Epithelial","Fallopian Tube Neoplasms"],"interventions":["Pembrolizumab","Paclitaxel","Bevacizumab","Placebo for pembrolizumab","Docetaxel"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Denmark","Finland","France","Germany","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Poland","Russia","South Korea","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":187,"serviceSignals":["Broad CGP"],"summary":"The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the investigator for participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \\[CPS\\] ≥1) and that pembrolizumab plus paclitaxel with or without bevacizumab is superi","sourceUrl":"https://clinicaltrials.gov/study/NCT05116189"},{"nctId":"NCT06015503","title":"A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":139,"enrollmentType":"ESTIMATED","startDate":"2023-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-06","primaryCompletionType":"ACTUAL","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["NSCLC (Non-small Cell Lung Cancer)"],"interventions":["PLB1004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06015503"},{"nctId":"NCT05567185","title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","sponsor":"Janssen Pharmaceutical K.K.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":5,"enrollmentType":"ACTUAL","startDate":"2023-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-11","primaryCompletionType":"ACTUAL","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Urinary Bladder Neoplasms","Receptors, Fibroblast Growth Factor"],"interventions":["Erdafitinib Intravesical Delivery System"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT05567185"},{"nctId":"NCT05113251","title":"Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":927,"enrollmentType":"ACTUAL","startDate":"2021-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-12","primaryCompletionType":"ACTUAL","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Breast Neoplasms","Breast Cancer","HER2-positive Early Breast Cancer"],"interventions":["Trastuzumab Deruxtecan","Paclitaxel","Trastuzumab","Pertuzumab","Doxorubicin","cyclophosphamide"],"countries":["United States","Brazil","Bulgaria","Canada","China","Germany","India","Italy","Japan","Peru","Philippines","Poland","Russia","Saudi Arabia","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":145,"serviceSignals":["HER2 profiling"],"summary":"This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05113251"},{"nctId":"NCT05287113","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","sponsor":"Incyte Biosciences International Sàrl","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":176,"enrollmentType":"ACTUAL","startDate":"2022-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-14","primaryCompletionType":"ACTUAL","completionDate":"2026-07-10","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Head and Neck Cancer"],"interventions":["Retifanlimab","INCAGN02385","INCAGN02390","Placebo"],"countries":["United States","Belgium","Canada","France","Georgia","Germany","Greece","Italy","Netherlands","Poland","Portugal","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":91,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).","sourceUrl":"https://clinicaltrials.gov/study/NCT05287113"},{"nctId":"NCT06672653","title":"Tolerance and Effectiveness of C14 on HPV Infection","sponsor":"MGB Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2024-11-15","startDateType":"ESTIMATED","primaryCompletionDate":"2025-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-15","completionType":"ESTIMATED","lastUpdated":"2024-11-04","conditions":["HPV-induced Cancers","HPV Infections","HIV","Cervical Cancers","Trial","C14","Monoterpenoid Zinc Tetra-ascorbo-camphorate"],"interventions":["The monoterpenoid zinc tetra-ascorbo-camphorate (\"C14\")","Distilled water group"],"countries":["Democratic Republic of the Congo"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug. The aim of this clinical trial is to determine whether C14 is effective in reducing the genital viral load of HR-HPV and in treating low-grade dysplastic lesions of the cervix. It will also determine the tolerability of C14. The main questions to be answered by the clinical trial are as follows: Does C14 reduce the genital HR-HPV viral load in participants with persistent HR-HPV infections? What medical problems do partic","sourceUrl":"https://clinicaltrials.gov/study/NCT06672653"},{"nctId":"NCT03737643","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1407,"enrollmentType":"ACTUAL","startDate":"2019-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-17","primaryCompletionType":"ACTUAL","completionDate":"2026-12-23","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Ovarian Cancer"],"interventions":["Bevacizumab","Durvalumab","Olaparib","Placebo olaparib","Durvalumab placebo","Carboplatin+Paclitaxel"],"countries":["United States","Austria","Belgium","Brazil","Bulgaria","Canada","China","Denmark","Finland","France","Germany","Hungary","Italy","Japan","Peru","Poland","Romania","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":214,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03737643"},{"nctId":"NCT04586426","title":"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":228,"enrollmentType":"ACTUAL","startDate":"2020-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-18","primaryCompletionType":"ACTUAL","completionDate":"2026-10-27","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Multiple Myeloma"],"interventions":["Talquetamab","Teclistamab"],"countries":["United States","Australia","Canada","Israel","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R\\[s\\]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).","sourceUrl":"https://clinicaltrials.gov/study/NCT04586426"},{"nctId":"NCT05180799","title":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","sponsor":"BioAtla, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-19","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-06-15","conditions":["NSCLC","Melanoma"],"interventions":["BA3071","Nivolumab","Pembrolizumab","Pemetrexed (Alimta)"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["RAS genotyping"],"summary":"The objective of this study is to assess safety and efficacy of BA3071 in solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05180799"},{"nctId":"NCT05257408","title":"Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer","sponsor":"Corcept Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":381,"enrollmentType":"ACTUAL","startDate":"2022-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-24","primaryCompletionType":"ACTUAL","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-04-16","conditions":["Ovarian Neoplasm","Fallopian Tube Neoplasms","Peritoneal Neoplasms"],"interventions":["Nab-paclitaxel 80 mg/m^2","Relacorilant 150 mg once daily (QD)","Nab-paclitaxel 100 mg/m^2"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","France","Hungary","Israel","Italy","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":117,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of Relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05257408"},{"nctId":"NCT05583552","title":"Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy","sponsor":"GCP-Service International West GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-27","primaryCompletionType":"ACTUAL","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Myelodysplastic Syndromes","Acute Myeloid Leukemia"],"interventions":["Imetelstat sodium"],"countries":["Australia","France","Germany"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy, in terms of hematologic improvement, and safety of imetelstat in participants with high-risk (HR) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that is relapsed/refractory to hypomethylating agents (HMAs) treatment. Responding patients are eligible to continue treatment until loss of response/disease progression.","sourceUrl":"https://clinicaltrials.gov/study/NCT05583552"},{"nctId":"NCT06502977","title":"Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment","sponsor":"Amgen","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":32,"enrollmentType":"ACTUAL","startDate":"2024-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-28","primaryCompletionType":"ACTUAL","completionDate":"2027-09-10","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["Tarlatamab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).","sourceUrl":"https://clinicaltrials.gov/study/NCT06502977"},{"nctId":"NCT06612281","title":"Evaluation of Gixam's Performance in a FIT Negative Population","sponsor":"Jubaan Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2024-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-04-30","completionType":"ESTIMATED","lastUpdated":"2024-11-14","conditions":["Colorectal Adenoma","Colorectal Cancer (CRC)","Colorectal Cancer (CRC) Screening"],"interventions":["colorectal cancer (CRC) screening","colorectal cancer screening","Colonoscopy after bowel cleansing"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"In the United States, colorectal cancer ranks second to lung cancer as a cause of cancer death and is the third most commonly occurring cancer in both men and women. Colorectal cancer in most cases develops slowly over a period of years, starting with the growth of precancerous polyps on the colon or rectum wall. The slow development of colorectal cancer makes it possible to detect and prevent it entirely by the removal of the precancerous polyps with colonoscopy. To date, there is no screening test, other than colonoscopy, able to detect the precancerous polyps. Gixam is a camera that takes multiple pictures of your tongue and uses artificial intelligence software to predict the presence of","sourceUrl":"https://clinicaltrials.gov/study/NCT06612281"},{"nctId":"NCT05435248","title":"Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":354,"enrollmentType":"ESTIMATED","startDate":"2022-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2024-11-04","conditions":["Advanced or Metastatic NSCLC"],"interventions":["HS-10375"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05435248"},{"nctId":"NCT05050097","title":"A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":166,"enrollmentType":"ACTUAL","startDate":"2021-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-31","primaryCompletionType":"ACTUAL","completionDate":"2027-04-07","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Talquetamab","Carfilzomib","Daratumumab SC","Lenalidomide","Pomalidomide"],"countries":["United States","Australia","Belgium","France","Netherlands","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT05050097"},{"nctId":"NCT05020678","title":"NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers","sponsor":"Nkarta, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2021-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-31","primaryCompletionType":"ACTUAL","completionDate":"2038-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Lymphoma, Non-Hodgkin","B-cell Acute Lymphoblastic Leukemia","Large B-cell Lymphoma","Mantle Cell Lymphoma","Indolent Lymphoma","Waldenstrom Macroglobulinemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Aggressive Lymphoma","Large-cell Lymphoma"],"interventions":["NKX019"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)","sourceUrl":"https://clinicaltrials.gov/study/NCT05020678"},{"nctId":"NCT03916627","title":"Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2019-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-31","primaryCompletionType":"ACTUAL","completionDate":"2030-05-14","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Non-small Cell Lung Cancer","Hepatocellular Carcinoma","Head and Neck Squamous Cell Carcinoma"],"interventions":["cemiplimab","Platinum Doublet","fianlimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is being done to better understand whether or not cemiplimab by itself and in combination with other treatments given prior to surgery will cause your tumor to respond in a beneficial way; whether the drug(s) are safe and what side effects they cause; and other details about how they function in the body. One of the treatments that will be combined cemiplimab is another experimental drug called fianlimab. In this form, cemiplimab and fianlimab will each individually be called \"study drug\" or \"study drugs\" when combined. Cemiplimab (also known as REGN2810) and fianlimab (also known as REGN3767) are both a type of drug called a monoclonal antibody. Antibodies are proteins naturally ","sourceUrl":"https://clinicaltrials.gov/study/NCT03916627"},{"nctId":"NCT04643418","title":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","sponsor":"MegaPro Biomedical Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2022-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-03-31","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-11-03","conditions":["Solid Tumor, Unspecified, Adult"],"interventions":["MPB-1734"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, open-label, uncontrolled, Phase 1/2a study with dose escalation in patients with advanced solid tumors (Part 1) and cohorts of up to 15 patients per selected indication (Part 2). The solid tumor types in Part 2 will be decided by the sponsor prior to the start of Part 2, but not be solely based on the efficacy results in Part 1.","sourceUrl":"https://clinicaltrials.gov/study/NCT04643418"},{"nctId":"NCT04072458","title":"A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies","sponsor":"Bio-Path Holdings, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2020-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-04","primaryCompletionType":"ESTIMATED","completionDate":"2025-04","completionType":"ESTIMATED","lastUpdated":"2025-02-24","conditions":["Mantle Cell Lymphoma","Peripheral T-cell Lymphoma (PTCL)","Cutaneous T-cell Lymphoma (CTCL)","Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)","Follicular Lymphoma","Marginal Zone Lymphoma","Hodgkin Lymphoma","Waldenstrom Macroglobulinemia","DLBCL"],"interventions":["L-Bcl-2 antisense oligonucleotide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.","sourceUrl":"https://clinicaltrials.gov/study/NCT04072458"},{"nctId":"NCT03899636","title":"A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer","sponsor":"Angiodynamics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":528,"enrollmentType":"ESTIMATED","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-04","primaryCompletionType":"ESTIMATED","completionDate":"2025-04","completionType":"ESTIMATED","lastUpdated":"2025-02-12","conditions":["Stage III Pancreatic Cancer"],"interventions":["Modified FOLFIRINOX Regimen","NanoKnife System"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT). There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX regimen alone; and the irreversible electroporation (IRE) arm, receiving chemotherapy with the modified FOLFIRINOX regimen followed by IRE with the NanoKnife System using either an open or a percutaneous approach. All subjects will be treated with the modified FOLFIRINOX regimen for at least 3 months; randomization to either control or IRE arm will take place at the time of completion of the 3 month modified FOLFIRINOX chemotherapy regimen. Randomization will be conducted ","sourceUrl":"https://clinicaltrials.gov/study/NCT03899636"},{"nctId":"NCT04827953","title":"Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer","sponsor":"Nelum Corp","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":28,"enrollmentType":"ACTUAL","startDate":"2021-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-04","primaryCompletionType":"ESTIMATED","completionDate":"2025-04","completionType":"ESTIMATED","lastUpdated":"2024-12-30","conditions":["Pancreatic Ductal Adenocarcinoma"],"interventions":["Gemcitabine","Nab paclitaxel","NLM-001","Zalifrelimab"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.","sourceUrl":"https://clinicaltrials.gov/study/NCT04827953"},{"nctId":"NCT05201248","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":49,"enrollmentType":"ACTUAL","startDate":"2022-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-04","primaryCompletionType":"ESTIMATED","completionDate":"2025-04","completionType":"ESTIMATED","lastUpdated":"2025-01-07","conditions":["B-Cell Non-Hodgkin Lymphoma"],"interventions":["Epcoritamab","Cyclophosphamide","Rituximab","Doxorubicin","Vincristine","Prednisone","Lenalidomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and toxicity of epcoritamab as a monotherapy and when combined with standard of care therapy \\[Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or Rituximab and lenalidomide (R2)\\] in adult participants in China with B-Cell Non-Hodgkin Lymphoma. Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of B-Cell Non-Hodgkin Lymphoma. Study doctors put the participants in groups called treatment arms. A mo","sourceUrl":"https://clinicaltrials.gov/study/NCT05201248"},{"nctId":"NCT03917381","title":"GEN1046 Safety Trial in Patients With Malignant Solid Tumors","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":429,"enrollmentType":"ACTUAL","startDate":"2019-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-01","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumors"],"interventions":["Acasunlimab","Acasunlimab in combination with docetaxel (in a single expansion cohort)","Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)","Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)"],"countries":["United States","Czechia","Georgia","Hungary","Israel","Italy","Poland","Spain","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":57,"serviceSignals":["Broad CGP"],"summary":"The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo. This trial has 2 parts. The purpose of the first part is to find out if acasunlimab at various doses is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first par","sourceUrl":"https://clinicaltrials.gov/study/NCT03917381"},{"nctId":"NCT03528694","title":"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1018,"enrollmentType":"ACTUAL","startDate":"2018-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-03","primaryCompletionType":"ACTUAL","completionDate":"2028-10-03","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Non-muscle-invasive Bladder Cancer"],"interventions":["Durvalumab (MEDI4736)","Bacillus Calmette-Guerin (BCG)"],"countries":["Australia","Austria","Belgium","Canada","France","Germany","Japan","Netherlands","Poland","Russia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":120,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multi-center, global, phase III study to determine the efficacy and safety of Durvalumab + BCG combination therapy in the treatment of patients with non-muscle-invasive bladder cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03528694"},{"nctId":"NCT04512235","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":281,"enrollmentType":"ACTUAL","startDate":"2020-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-08","primaryCompletionType":"ACTUAL","completionDate":"2027-04-08","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["AL Amyloidosis"],"interventions":["CAEL-101","Placebo","cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","Poland","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":110,"serviceSignals":["Broad CGP"],"summary":"AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT04512235"},{"nctId":"NCT04649073","title":"Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma","sponsor":"Otsuka Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":11,"enrollmentType":"ACTUAL","startDate":"2021-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-09","primaryCompletionType":"ACTUAL","completionDate":"2041-01","completionType":"ESTIMATED","lastUpdated":"2025-05-25","conditions":["Multiple Myeloma (MM)"],"interventions":["OPC-415"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the tolerability,safety and efficacy of OPC-415 in patients with relapsed and/or refractory Multiple Myeloma (MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT04649073"},{"nctId":"NCT06099782","title":"A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":147,"enrollmentType":"ACTUAL","startDate":"2023-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-09","primaryCompletionType":"ACTUAL","completionDate":"2027-02-15","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Non-Small Cell Lung Cancer","Renal Cell Carcinoma","Melanoma"],"interventions":["Pembrolizumab (+) Berahyaluronidase alfa","Pembrolizumab"],"countries":["United States","Argentina","Australia","Chile","France","Japan","New Zealand","Poland","South Africa","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa \\[MK-3475A\\] administered subcutaneously (SC) over pembrolizumab \\[MK-3475\\] administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06099782"},{"nctId":"NCT06101134","title":"A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ACTUAL","startDate":"2023-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-10","primaryCompletionType":"ACTUAL","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Melanoma"],"interventions":["relatlimab+nivolumab","relatlimab+nivolumab+rHuPH20","nivolumab","nivolumab+rHuPH20"],"countries":["United States","Chile","Greece","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration. This study will also generate safety data which will further characterize the safety profile of patients switching the route of administration from intravenous (IV) to SC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06101134"},{"nctId":"NCT06396065","title":"Phase III Study of AK112 for NSCLC Patients","sponsor":"Summit Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":420,"enrollmentType":"ACTUAL","startDate":"2023-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-12","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Non-Squamous Non-small Cell Lung Cancer"],"interventions":["AK112 Injection","Placebo Injection"],"countries":["United States","Canada","France","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":74,"serviceSignals":["Broad CGP"],"summary":"A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)","sourceUrl":"https://clinicaltrials.gov/study/NCT06396065"},{"nctId":"NCT05153772","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","sponsor":"Orano Med LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2021-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-14","primaryCompletionType":"ACTUAL","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Neuroendocrine Tumors"],"interventions":["AlphaMedix"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with either no prior history of peptide receptor radionuclide therapy (PRRT naive) or prior history of peptide receptor radionuclide therapy (Previous PRRT)","sourceUrl":"https://clinicaltrials.gov/study/NCT05153772"},{"nctId":"NCT06390995","title":"A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors","sponsor":"Takeda","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":28,"enrollmentType":"ACTUAL","startDate":"2024-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-16","primaryCompletionType":"ACTUAL","completionDate":"2027-03-19","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Ovarian Cancer","Solid Tumors"],"interventions":["TAK-853"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853 stays in their blood over time. The study will be conducted in two phases including Phase 1 Part and Phase 2 Part. In Phase 1 Part, the participants will stay in the hospital for 3 days at least after their 1st injection for some tests and to check for any side effects from their treatment. In Phase 2 Part, participants will visit their study hospital for multiple times. In both phases, the participants will receive TAK-853 on the first days of each 3-week cycle. The","sourceUrl":"https://clinicaltrials.gov/study/NCT06390995"},{"nctId":"NCT04126200","title":"Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":208,"enrollmentType":"ACTUAL","startDate":"2019-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","GSK3174998","Feladilimab","Nirogacestat","Dostarlimab","Isatuximab","Lenalidomide","Dexamethasone","Pomalidomide"],"countries":["United States","Brazil","Canada","France","Germany","Greece","Mexico","Netherlands","Norway","Poland","South Korea","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.","sourceUrl":"https://clinicaltrials.gov/study/NCT04126200"},{"nctId":"NCT07084896","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":106,"enrollmentType":"ACTUAL","startDate":"2020-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Nirogacestat"],"countries":["United States","Australia","Canada","France","Germany","Greece","Netherlands","Norway","Poland","Russia","South Korea","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).","sourceUrl":"https://clinicaltrials.gov/study/NCT07084896"},{"nctId":"NCT05789602","title":"A Study of BPI-460372 in Advanced Solid Tumor Patients","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2023-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-17","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Advanced Solid Tumor"],"interventions":["BPI-460372"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05789602"},{"nctId":"NCT07217184","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2021-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Isatuximab"],"countries":["United States","Australia","Brazil","Canada","France","Greece","Mexico","Norway","South Korea","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with isatuximab, and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).","sourceUrl":"https://clinicaltrials.gov/study/NCT07217184"},{"nctId":"NCT07217119","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ACTUAL","startDate":"2019-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Feladilimab"],"countries":["United States","Australia","Canada","France","Germany","Netherlands","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).","sourceUrl":"https://clinicaltrials.gov/study/NCT07217119"},{"nctId":"NCT07150091","title":"Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ACTUAL","startDate":"2022-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Nirogacestat","Lenalidomide","Dexamethasone"],"countries":["United States","Brazil","Canada","France","Germany","Greece","Mexico","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, lenalidomide, and dexamethasone, and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).","sourceUrl":"https://clinicaltrials.gov/study/NCT07150091"},{"nctId":"NCT07150104","title":"Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-17","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Nirogacestat","Pomalidomide","Dexamethasone"],"countries":["Brazil","Canada","France","Mexico","Norway","Poland","South Korea","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, pomalidomide, and dexamethasone and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).","sourceUrl":"https://clinicaltrials.gov/study/NCT07150104"},{"nctId":"NCT04398745","title":"A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ACTUAL","startDate":"2020-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-21","primaryCompletionType":"ACTUAL","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin"],"countries":["Greece","South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at risk or already has renal dysfunction at initial diagnosis. The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with RRMM, who have had at least 3 lines of prior treatment (or at least 2 lines of prior treatment if ineligible for autologous stem cell transplantation ) and have either normal or impaired renal functions. The study will consist of two","sourceUrl":"https://clinicaltrials.gov/study/NCT04398745"},{"nctId":"NCT05673785","title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","sponsor":"Takeda","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":52,"enrollmentType":"ACTUAL","startDate":"2023-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-27","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Lymphoma"],"interventions":["Brentuximab Vedotin","Cyclophosphamide","Doxorubicin","Prednisone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This study will use a combination of Brentuximab vedotin with CHP to treat adult Chinese participants with CD30+ PTCL. The main aims of the study are to evaluate: * Side effect from the A+CHP * Check how much A+CHP stays in their blood over time. This will help Takeda to work out the best dose to give people in the future. * If A+CHP improves outcome of newly diagnosed CD30+ PTCL Brentuximab vedotin will be given through vein on Day 1 of each 21-day cycle. Cyclophosphamide and doxorubicin will be given through vein. Prednisone will be given orally daily on Days 1 through 5.","sourceUrl":"https://clinicaltrials.gov/study/NCT05673785"},{"nctId":"NCT05194995","title":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ACTUAL","startDate":"2022-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Advanced Colorectal Cancer","Small Intestinal Cancer","Appendiceal Cancer"],"interventions":["JAB-21822","Cetuximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["RAS genotyping"],"summary":"This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer，advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05194995"},{"nctId":"NCT04013685","title":"Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","sponsor":"Orca Biosystems, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":155,"enrollmentType":"ACTUAL","startDate":"2019-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ACTUAL","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Acute Myeloid Leukemia","Acute Lymphoid Leukemia","Myelodysplastic Syndromes","Acute Leukemia","Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","Chronic Myeloid Leukemia"],"interventions":["Orca-T"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04013685"},{"nctId":"NCT06471673","title":"A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer","sponsor":"BriaCell Therapeutics Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-30","completionType":"ESTIMATED","lastUpdated":"2024-08-26","conditions":["Breast Cancer","Breast Tumor","Cancer of Breast","Cancer of the Breast","Malignant Tumor of Breast","Tumors, Breast"],"interventions":["BC1 cell line","Bria-OTS regimen and CPI (tislelizumab)","Bria-OTS regimen and CPI (tislelizumab) expansion cohort"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the","sourceUrl":"https://clinicaltrials.gov/study/NCT06471673"},{"nctId":"NCT05244551","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2022-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-04-30","completionType":"ESTIMATED","lastUpdated":"2024-08-12","conditions":["Solid Tumor"],"interventions":["ABSK061"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT05244551"},{"nctId":"NCT05879068","title":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","sponsor":"Biotheus Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2022-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2024-12-18","conditions":["SCLC"],"interventions":["PM8002","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05879068"},{"nctId":"NCT05280314","title":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","sponsor":"IO Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2024-03-18","conditions":["Melanoma","Squamous Cell Carcinoma of Head and Neck"],"interventions":["IO102-IO103","Pembrolizumab KEYTRUDA®"],"countries":["United States","Australia","Denmark","France","Germany","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.","sourceUrl":"https://clinicaltrials.gov/study/NCT05280314"},{"nctId":"NCT06479356","title":"CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma","sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-21","conditions":["Non-Hodgkin Lymphoma","Large B-cell Lymphoma"],"interventions":["Relma-cel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.","sourceUrl":"https://clinicaltrials.gov/study/NCT06479356"},{"nctId":"NCT05367778","title":"Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":176,"enrollmentType":"ESTIMATED","startDate":"2022-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced Solid Tumor"],"interventions":["HS-10370"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05367778"},{"nctId":"NCT06727630","title":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma","sponsor":"Zhuhai Yufan Biotechnologies Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-30","completionType":"ESTIMATED","lastUpdated":"2024-12-11","conditions":["Melanoma"],"interventions":["PRJ1-3024"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06727630"},{"nctId":"NCT05765032","title":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":220,"enrollmentType":"ACTUAL","startDate":"2022-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2024-09-26","conditions":["Advanced Solid Tumor"],"interventions":["SHR-A1921；"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05765032"},{"nctId":"NCT05636215","title":"A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":368,"enrollmentType":"ESTIMATED","startDate":"2023-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2025-03-20","conditions":["Locally Advanced Unresectable or Metastatic Solid Tumors"],"interventions":["IBI354"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI354 (study drug), and to explore and confirm the efficacy, safety and tolerability of IBI354 in subjects with locally advanced unresectable or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05636215"},{"nctId":"NCT05382728","title":"Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)","sponsor":"TYK Medicines, Inc","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":680,"enrollmentType":"ESTIMATED","startDate":"2022-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-01-30","conditions":["NSCLC","EGFR Activating Mutation"],"interventions":["TY-9591","placebo Osimertinib","Osimertinib","placebo TY-9591"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05382728"},{"nctId":"NCT05788107","title":"Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-06","startDateType":"ESTIMATED","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2023-08-09","conditions":["Solid Tumor, Adult Lymphoma"],"interventions":["HLX51"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX51 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05788107"},{"nctId":"NCT04268706","title":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","sponsor":"Tessa Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":97,"enrollmentType":"ESTIMATED","startDate":"2021-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2037-03","completionType":"ESTIMATED","lastUpdated":"2023-04-05","conditions":["Hodgkin Lymphoma, Adult","Hodgkin Disease Recurrent","Hodgkin Disease Refractory","Hodgkin Disease, Pediatric"],"interventions":["CD30.CAR-T","Fludarabine","Bendamustine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04268706"},{"nctId":"NCT05749549","title":"Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers","sponsor":"Shanghai Blueray Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":191,"enrollmentType":"ESTIMATED","startDate":"2023-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2024-08-07","conditions":["Advanced Cancer","Follicular Lymphoma","Peripheral T Cell Lymphoma","Diffuse Large B Cell Lymphoma"],"interventions":["BR1733"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a Phase I/IIa, multi-center, open-label study of BR1733 with a dose escalation part followed by a dose expansion part in adult subjects with advanced cancers. This treatment to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment will be administered until the subject experiences unacceptable toxicity, progressive disease, and/or has treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.","sourceUrl":"https://clinicaltrials.gov/study/NCT05749549"},{"nctId":"NCT05488548","title":"Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies","sponsor":"Epigenetix, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2022-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2025-05","completionType":"ESTIMATED","lastUpdated":"2025-01-14","conditions":["Castrate Resistant Prostate Cancer","NUT Carcinoma","Chronic Myelomonocytic Leukemia","Myelofibrosis"],"interventions":["EP31670"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT05488548"},{"nctId":"NCT05052255","title":"RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors","sponsor":"Ryvu Therapeutics SA","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2021-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2025-05","completionType":"ESTIMATED","lastUpdated":"2024-12-17","conditions":["Advanced Solid Tumor"],"interventions":["RVU120"],"countries":["Poland","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, dose-escalation and expansion study investigating the safety, pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced solid tumors progressing from previous lines of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05052255"},{"nctId":"NCT05410730","title":"A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2022-11-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-01-28","conditions":["High-risk NMIBC"],"interventions":["SHR-1501"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is to evaluate the safety and tolerability of SHR-1501 alone or in combination with BCG or SHR-1316 in the patients with NMIBC, and to determine the RP2D of SHR-1501 in combination with BCG or SHR-1316. To evaluate the preliminary efficacy of SHR-1501 alone or in combination with BCG or SHR-1316 in the treatment of NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05410730"},{"nctId":"NCT05798819","title":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":424,"enrollmentType":"ESTIMATED","startDate":"2023-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2023-04-05","conditions":["Persistent, Recurrent, or Metastatic Cervical Cancer"],"interventions":["GLS-010","Placebo","paclitaxel","cisplatin","carboplatin","bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05798819"},{"nctId":"NCT05312801","title":"Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma","sponsor":"Luminary Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-09-02","completionType":"ESTIMATED","lastUpdated":"2024-10-21","conditions":["Lymphoma, Non-Hodgkin Lymphoma, B-Cell"],"interventions":["BAFF CAR-T"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory lymphoma, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory lymphoma, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against relapsed non-Hodgkin lymphoma using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.","sourceUrl":"https://clinicaltrials.gov/study/NCT05312801"},{"nctId":"NCT03944772","title":"Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":247,"enrollmentType":"ACTUAL","startDate":"2019-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-05-06","completionType":"ESTIMATED","lastUpdated":"2025-01-30","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Osimertinib","Savolitinib","Gefitinib","Necitumumab","Durvalumab","Carboplatin","Pemetrexed","Alectinib","Selpercatinib","Selumetinib","Etoposide","Cisplatin","Datopotamab deruxtecan"],"countries":["United States","Denmark","Italy","Japan","Netherlands","Norway","South Korea","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["RNA fusion","RAS genotyping","MET profiling"],"summary":"Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT03944772"},{"nctId":"NCT05904886","title":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":687,"enrollmentType":"ACTUAL","startDate":"2023-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-08","primaryCompletionType":"ACTUAL","completionDate":"2026-09-01","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Hepatocellular Carcinoma"],"interventions":["Atezolizumab","Bevacizumab","Tiragolumab","Placebo"],"countries":["United States","Belgium","Brazil","Canada","China","Côte d’Ivoire","France","Germany","Ghana","Hong Kong","Italy","Japan","Kenya","Mexico","New Zealand","Nigeria","Poland","Puerto Rico","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Uganda","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":171,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue recei","sourceUrl":"https://clinicaltrials.gov/study/NCT05904886"},{"nctId":"NCT06198751","title":"A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2024-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-08","primaryCompletionType":"ACTUAL","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Breast Cancer"],"interventions":["6.0 mg/kg of TQB2102 for injection","7.5 mg/kg of TQB2102 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["HER2 profiling"],"summary":"To evaluate the efficacy and safety of neoadjuvant treatment with TQB2102 for injection in patients with Her2 positive breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06198751"},{"nctId":"NCT05482971","title":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","sponsor":"PharmaEssentia","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":91,"enrollmentType":"ACTUAL","startDate":"2022-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-09","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Essential Thrombocythemia"],"interventions":["Ropeginterferon alfa-2b-njft (P1101)"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia","sourceUrl":"https://clinicaltrials.gov/study/NCT05482971"},{"nctId":"NCT05997056","title":"Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors","sponsor":"Aadi Bioscience, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-08","completionType":"ESTIMATED","lastUpdated":"2024-07-16","conditions":["Neuroendocrine Tumors","NET","Pancreatic Neuroendocrine Tumor","Gastrointestinal Neuroendocrine Tumor","Pulmonary Neuroendocrine Tumor"],"interventions":["nab-sirolimus"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors","sourceUrl":"https://clinicaltrials.gov/study/NCT05997056"},{"nctId":"NCT04504825","title":"A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2020-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-10","primaryCompletionType":"ACTUAL","completionDate":"2027-10-22","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["AL Amyloidosis"],"interventions":["CAEL-101","Placebo","cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":90,"serviceSignals":["Broad CGP"],"summary":"AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIb AL amyloidosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT04504825"},{"nctId":"NCT05200650","title":"A Single Arm, Prospective, Open Label, Multi Center, Phase Ib Study to Evaluate the Safety, Tolerability and Initial Efficacy of a Single Intra-tumoral Injection of IntraGel's Polymer-based Cisplatin-loaded Gel (TumoCure) in Subjects With Progressive or Radio-resistant Primary Head and Neck Tumor","sponsor":"IntraGel Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-01","completionType":"ESTIMATED","lastUpdated":"2024-10-08","conditions":["Head and Neck Cancer"],"interventions":["TumoCure"],"countries":["Israel"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"IntraGel's polymer-based Cisplatin loaded Gel (TumoCure) is a single injectable compound, aimed at localized chemotherapy treatment. The treatment is offered to patients who currently have no other available treatment options, either due to inefficacy, intolerability or inapplicability of standard treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT05200650"},{"nctId":"NCT05456191","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":568,"enrollmentType":"ACTUAL","startDate":"2022-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-15","primaryCompletionType":"ACTUAL","completionDate":"2031-07-07","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Philadelphia Chromosome-Positive Chronic Myeloid Leukemia"],"interventions":["Asciminib","Nilotinib"],"countries":["United States","Argentina","Bulgaria","Canada","Czechia","France","Germany","Greece","Hungary","India","Italy","Jordan","Malaysia","Netherlands","Oman","Romania","Singapore","Slovakia","South Africa","South Korea","Switzerland","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":120,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study was to assess the tolerability of oral asciminib (80 mg QD) in comparison with that of the second generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).","sourceUrl":"https://clinicaltrials.gov/study/NCT05456191"},{"nctId":"NCT03440450","title":"A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ACTUAL","startDate":"2018-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-15","primaryCompletionType":"ACTUAL","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Advanced Solid Tumors","Biliary Tract Cancer"],"interventions":["FF-10832 Gemcitabine Liposome Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT) and recommended Phase 2 dose (RP2D) in patients who receive FF-10832 (Gemcitabine Liposome Injection) for treatment of advanced solid tumors including biliary tract cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03440450"},{"nctId":"NCT06314828","title":"A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL","sponsor":"Guangdong Ruishun Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-05-20","startDateType":"ESTIMATED","primaryCompletionDate":"2025-05-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-20","completionType":"ESTIMATED","lastUpdated":"2024-03-18","conditions":["B-cell Non-Hodgkin's Lymphoma"],"interventions":["RJMty19 (CD19-CAR-DNT cells)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.","sourceUrl":"https://clinicaltrials.gov/study/NCT06314828"},{"nctId":"NCT04895722","title":"Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":302,"enrollmentType":"ACTUAL","startDate":"2021-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-21","primaryCompletionType":"ACTUAL","completionDate":"2026-08-06","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Colorectal Cancer"],"interventions":["Pembrolizumab","Pembrolizumab/Quavonlimab","Pembrolizumab/Favezelimab","Pembrolizumab/Vibostolimab","MK-4830"],"countries":["United States","Belgium","Canada","Colombia","Costa Rica","Denmark","Estonia","France","Germany","Greece","Guatemala","Hungary","Italy","Lithuania","Netherlands","Poland","Romania","Russia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":109,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04895722"},{"nctId":"NCT06143007","title":"A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors","sponsor":"Broadenbio Ltd., Co.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-22","primaryCompletionType":"ACTUAL","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Solid Tumor"],"interventions":["BB3008 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB3008 as monotherapy in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06143007"},{"nctId":"NCT05186753","title":"(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis","sponsor":"Cogent Biosciences, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":237,"enrollmentType":"ESTIMATED","startDate":"2022-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-22","primaryCompletionType":"ACTUAL","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["SSM","Mastocytosis, Indolent","Mastocytosis, Systemic","Mastocytosis","ISM","BMM","Smoldering Systemic Mastocytosis","Bone Marrow Mastocytosis"],"interventions":["Bezuclastinib Tablets (Formulation A)","Bezuclastinib Tablets (Formulation B)","Placebo Tablets"],"countries":["United States","Australia","Belgium","Canada","Czechia","France","Germany","Ireland","Italy","Netherlands","Norway","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":57,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with nonadvanced systemic mastocytosis (NonAdvSM), including indolent systemic mastocytosis and smoldering systemic mastocytosis, whose symptoms are not adequately controlled by BSC. This study will be conducted in three parts. Patients in Parts 1a, 1b and 2 will receive bezuclastinib or placebo, and may roll over onto Part 3 to receive treatment with bezuclastinib. Additionally, a substudy of subjects will investigate the efficacy, safety, and tolerability of bezuclastinib in p","sourceUrl":"https://clinicaltrials.gov/study/NCT05186753"},{"nctId":"NCT05609370","title":"A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer","sponsor":"BeiGene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":113,"enrollmentType":"ACTUAL","startDate":"2023-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-23","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer"],"interventions":["Alcestobart","Tislelizumab","Bevacizumab or Bevacizumab biosimilar","Fluoropyrimidine (FP)"],"countries":["United States","Australia","China","Puerto Rico"],"northAmerica":true,"chinaSites":true,"siteCount":64,"serviceSignals":["MSI / TMB"],"summary":"This is a Phase 1b/2 study to investigate the efficacy and safety of alcestobart (LBL-007) plus tislelizumab when administered in combination with bevacizumab plus fluoropyrimidine, and alcestobart in combination with bevacizumab plus fluoropyrimidine versus bevacizumab plus fluoropyrimidine to participants with colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05609370"},{"nctId":"NCT04717414","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":313,"enrollmentType":"ACTUAL","startDate":"2021-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-26","primaryCompletionType":"ACTUAL","completionDate":"2032-08-18","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Myeloproliferative Disorders","Myelofibrosis","Primary Myelofibrosis","Post-Polycythemia Vera Myelofibrosis","Anemia"],"interventions":["ACE-536","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","China","Colombia","Czechia","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Lebanon","Poland","Romania","Russia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":185,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period. Following the Day 169 Response Assessment, subjects who did not show clinical benefit will have the option to unblind. Su","sourceUrl":"https://clinicaltrials.gov/study/NCT04717414"},{"nctId":"NCT05556096","title":"Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":260,"enrollmentType":"ACTUAL","startDate":"2022-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-27","primaryCompletionType":"ACTUAL","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Generalized Myasthenia Gravis"],"interventions":["ALXN1720","Placebo"],"countries":["United States","Argentina","Austria","Brazil","Canada","China","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Poland","Portugal","Serbia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":132,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).","sourceUrl":"https://clinicaltrials.gov/study/NCT05556096"},{"nctId":"NCT05661955","title":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","sponsor":"BeiGene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":113,"enrollmentType":"ACTUAL","startDate":"2023-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-27","primaryCompletionType":"ACTUAL","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Urothelial Carcinoma","Renal Cell Carcinoma","Melanoma","Non-mucosal Melanoma"],"interventions":["BGB-A445","Tislelizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to assess the overall response rate, evaluate the antitumor activity, and characterize the safety and tolerability of BGB-A445 alone or in combination with tislelizumab in participants With Advanced or Metastatic Urothelial Carcinoma (UC), Renal Cell Carcinoma (RCC), or Melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05661955"},{"nctId":"NCT05059236","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","sponsor":"Bayer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":223,"enrollmentType":"ACTUAL","startDate":"2021-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ACTUAL","completionDate":"2026-06-05","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"interventions":["Darolutamide (BAY1841788, Nubeqa)","ADT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in participants with metastatic hormone-sensitive prostate cancer (mHSPC) by progression-free survival. The researchers want to learn how long it takes for the cancer to get worse (also known as \"progression-free survival\") by either increasing symptoms, new metastases, PSA rise or death. All participants will be on treatment and take darolutamide with ADT until their cancer spreads, they have a medical problem, or they leave the study. The results will then be compared with patients' results from another study who received ADT alone (CHAARTED). This","sourceUrl":"https://clinicaltrials.gov/study/NCT05059236"},{"nctId":"NCT06332430","title":"Intratumoral CAN2109 in Subjects With Solid Tumors","sponsor":"Canwell Biotech Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2024-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-30","completionType":"ESTIMATED","lastUpdated":"2024-12-19","conditions":["Solid Tumor","Lymphoma"],"interventions":["CAN2109"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT06332430"},{"nctId":"NCT05155254","title":"IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)","sponsor":"IO Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":407,"enrollmentType":"ACTUAL","startDate":"2022-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ACTUAL","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-08-28","conditions":["Metastatic Melanoma","Unresectable Melanoma"],"interventions":["IO102-IO103","Pembrolizumab"],"countries":["United States","Australia","Belgium","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","South Africa","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":112,"serviceSignals":["Broad CGP"],"summary":"Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma. Patients will be stratified on the basis of the following factors; Disease stage: Stage III (unresectable) and IV M1a-b versus stage IV M1c-d and BRAFV600 mutation status: mutated vs wild type. All patients will receive pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles (up to 2 years treatment). Patients randomized to IO102-IO103 dual-antigen, immunotherapeutic arm will also be given IO102-IO103 Q3W ","sourceUrl":"https://clinicaltrials.gov/study/NCT05155254"},{"nctId":"NCT05667506","title":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","sponsor":"Juventas Cell Therapy Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":47,"enrollmentType":"ESTIMATED","startDate":"2023-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ACTUAL","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["B-cell Acute Lymphoblastic Leukemia"],"interventions":["single dose of CNCT19"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05667506"},{"nctId":"NCT06265025","title":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","sponsor":"GeneMedicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2024-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2024-03-21","conditions":["Head and Neck Cancer","Malignant Melanoma","Colorectal Cancer","Renal Cell Carcinoma","Cervical Cancer","Breast Cancer"],"interventions":["GM103 (Part A)","GM103 (Part B)","GM103 and Pembrolizumab (Part C)"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:","sourceUrl":"https://clinicaltrials.gov/study/NCT06265025"},{"nctId":"NCT06034275","title":"Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","sponsor":"Vincerx Pharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2023-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["Acute Myeloid Leukemia","B-cell Acute Lymphoblastic Leukemia","High-risk Myelodysplastic Syndrome"],"interventions":["VIP943 (QW)","VIP943 (BIW)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06034275"},{"nctId":"NCT05219500","title":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","sponsor":"Fusion Pharmaceuticals Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2021-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-30","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Metastatic Castration Resistant Prostate Cancer"],"interventions":["FPI-2265"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The treatment regimen will consist of 4 doses of FPI-2265","sourceUrl":"https://clinicaltrials.gov/study/NCT05219500"},{"nctId":"NCT04046445","title":"Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer","sponsor":"Amal Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2019-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-31","completionType":"ESTIMATED","lastUpdated":"2025-01-29","conditions":["Colorectal Cancer","MSS","Stage IV Colon Cancer","Stage IV Rectal Cancer","Metastatic Colorectal Cancer","Liver Metastasis Colon Cancer"],"interventions":["ATP128","BI 754091","VSV-GP128"],"countries":["United States","Belgium","Germany","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["MSI / TMB"],"summary":"This is a multi-center, non-randomised Phase 1b study to evaluate the safety and tolerability of ATP128 alone or in combination with BI 754091 and of heterologous prime-boost ATP128 + VSV-GP128 in combination with BI 754091. ATP128 is a self-adjuvanted chimeric recombinant protein vaccine being developed in combination with programmed cell death 1 (PD-1) blockade for the treatment of microsatellite stable (MSS) patients not responding to PD-1 blockade. The PD-1 inhibitor being tested with ATP128 is the BI 754091 (Ezabenlimab) compound which belongs to the human immunoglobulin G4 (IgG4) subclass of antibodies. VSV-GP is a recombinant chimeric vesicular stomatitis virus (VSV, Indiana strain Rh","sourceUrl":"https://clinicaltrials.gov/study/NCT04046445"},{"nctId":"NCT05561374","title":"Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma","sponsor":"Oblato, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2023-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-06-30","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["High-grade Glioma","Oligodendroglioma","Astrocytoma","Glioblastoma Multiforme"],"interventions":["Low-dose OKN-007, BID","Low-dose OKN-007, TID","Mid-dose OKN-007, TID","High-dose OKN-007, TID"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05561374"},{"nctId":"NCT05504278","title":"Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2022-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Advanced Non-Small Cell Lung Cancer"],"interventions":["IBI351","Cetuximab","pemetrexed","Carboplatin","Sintilimab","cis-platinum"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05504278"},{"nctId":"NCT03671044","title":"A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients","sponsor":"Jina Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":657,"enrollmentType":"ESTIMATED","startDate":"2018-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-21","conditions":["Triple Negative Breast Cancer"],"interventions":["Nanosomal Docetaxel Lipid Suspension (75 mg/m2)","Nanosomal Docetaxel Lipid Suspension (100 mg/m2)","Taxotere® (100 mg/m2)"],"countries":["United States","India"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety profile by eliminating excipients, polysorbate 80 and ethanol which are present in conventional Docetaxel formulations (Taxotere®). This randomized, open-label study is designed to assess the efficacy and safety of Nanosomal Docetaxel Lipid Suspension at the dose of 75 mg/m2 and at the dose of 100 mg/m2 compared to Taxotere® at the dose of 100 mg/m2 in triple-negative breast cancer patients with Locally Advanced or Metastatic Breast Cancer. Patients will con","sourceUrl":"https://clinicaltrials.gov/study/NCT03671044"},{"nctId":"NCT05232136","title":"OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2022-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-10","completionType":"ESTIMATED","lastUpdated":"2024-08-12","conditions":["Non-muscle-invasive Bladder Cancer"],"interventions":["OH2 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase Ⅰb/Ⅱ study evaluates the safety and efficacy of OH2 for adjuvant therapy in non-muscle-invasive bladder cancer after first-line prophylactic intravesical instillation therapy. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.","sourceUrl":"https://clinicaltrials.gov/study/NCT05232136"},{"nctId":"NCT05118776","title":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":136,"enrollmentType":"ACTUAL","startDate":"2022-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-06","completionType":"ESTIMATED","lastUpdated":"2024-10-31","conditions":["Recurrent Glioblastoma"],"interventions":["ASC40 tablets","Placebo tablets","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.","sourceUrl":"https://clinicaltrials.gov/study/NCT05118776"},{"nctId":"NCT06022861","title":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","sponsor":"Shandong Boan Biotechnology Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2023-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["LY01015","Fluorouracil","Cisplatin","Opdivo®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable advanced, recurrent or metastatic previously untreated esophageal squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06022861"},{"nctId":"NCT06493760","title":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Metastatic Colorectal Cancer"],"interventions":["SSGJ-707","Bevacizumab","Oxaliplatin","Capecitabine","Calcium Folinate","5-fluorouracil"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06493760"},{"nctId":"NCT05628870","title":"A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2023-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-06-30","completionType":"ESTIMATED","lastUpdated":"2025-03-17","conditions":["Breast Cancer"],"interventions":["HRS-1358"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT05628870"},{"nctId":"NCT06593145","title":"CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms","sponsor":"FamiCordTx","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2023-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-06","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Acute Lymphoblastic Leukemia (ALL)","Mantle Cell Lymphoma (MCL)","Large B-cell Lymphoma"],"interventions":["FCTX-CL19-1 (Tarcidomgen Kimleucel)"],"countries":["Poland"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT06593145"},{"nctId":"NCT06415903","title":"A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":59,"enrollmentType":"ESTIMATED","startDate":"2024-06","startDateType":"ESTIMATED","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2024-05-16","conditions":["Advanced Malignant Cancer"],"interventions":["TQB3117 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is divided into two phases: dose escalation and dose extension. The dosing regimens include a single-dose study and a multiple-dose study. It adopts a single-center, open-label, non-randomized, single-arm clinical trial design, where patients with advanced malignant cancer are selected to orally take TQB3117 tablets. The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TQB3117 tablets in patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06415903"},{"nctId":"NCT05936658","title":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","sponsor":"FutureChem","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":138,"enrollmentType":"ACTUAL","startDate":"2023-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-06","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["High Risk Prostate Carcinoma"],"interventions":["[F-18]Florastamin"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by \\[18F\\]Florastamin PET/CT imaging examination to determine the presence of recurrent or metastatic prostate cancer in patients whose recurrent or metastatic lesions have been confirmed through the conventional imaging.","sourceUrl":"https://clinicaltrials.gov/study/NCT05936658"},{"nctId":"NCT05772455","title":"A Study of XZB-0004 in Patients With Solid Tumors","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2023-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2024-10-28","conditions":["Advanced Solid Tumor","NSCLC"],"interventions":["XZB-0004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL. This is an open-label, multicentre phase I study of XZB-0004 in patients with solid tumors. Part 1 is a dose-escalation study to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic profile of XZB-0004, and then to identify a safe and pharmacologically active dose for evaluation in subsequent cohorts or clinical studies. Part 2 is a study to evaluate the efficacy and safety of XZB-0004 combined with Penpulimab in patients with NSCLC or advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05772455"},{"nctId":"NCT04523272","title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":528,"enrollmentType":"ACTUAL","startDate":"2020-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Advanced Renal Cancer"],"interventions":["TQB2450","Anlotinib","Sunitinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04523272"},{"nctId":"NCT05967416","title":"Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma","sponsor":"SIRPant Immunotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-12-20","conditions":["Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma"],"interventions":["SIRPant-M","External-beam radiotherapy (XRT)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05967416"},{"nctId":"NCT05859750","title":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2023-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Pancreatic Cancer"],"interventions":["AK104","Gemcitabine","Nab-Paclitaxel","Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate","Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line therapy in subjects with advanced unresectable or metastatic pancreatic ductal adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05859750"},{"nctId":"NCT06957379","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ACTUAL","startDate":"2024-02-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-06","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-05-04","conditions":["HR+/HER2- Advanced/Metastatic Breast Cancer"],"interventions":["Letrozole","Anastrozole","Exemestane","Fulvestrant","Sirolimus for Injection (Albumin-bound)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a multicenter, open, non-randomized phase II clinical trial consisting of a safety introduction phase followed by a single-arm phase 2 phase. This phase II trial enrolled patients with HR+/HER2- advanced breast cancer who had failed aromatase inhibitor (AI)/fulvestrant ± CDK4/6i. Pts failing prior AI ± CDK4/6i received nab-Sirolimus + fulvestrant, while those failing fulvestrant ± CDK4/6i received nab-Sirolimus + AI.","sourceUrl":"https://clinicaltrials.gov/study/NCT06957379"},{"nctId":"NCT05487170","title":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2022-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-09-01","completionType":"ESTIMATED","lastUpdated":"2025-03-04","conditions":["Advanced Solid Tumor","DLBCL"],"interventions":["RNK05047"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05487170"},{"nctId":"NCT06389006","title":"To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":79,"enrollmentType":"ESTIMATED","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-05-23","conditions":["Breast Cancer"],"interventions":["Disitamab Vedotin for Injection","Toripalimab","Epirubicin","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Toripalimab sequential chemotherapy as in patients with HR-positive, HER2-low breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06389006"},{"nctId":"NCT05217693","title":"A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors","sponsor":"Bliss Biopharmaceutical (Hangzhou) Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":288,"enrollmentType":"ESTIMATED","startDate":"2022-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ACTUAL","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Solid Tumor"],"interventions":["BB-1705"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"The study consists of two phases: dose-escalation (Phase I) and cohort expansion (Phase II).","sourceUrl":"https://clinicaltrials.gov/study/NCT05217693"},{"nctId":"NCT05341583","title":"Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":202,"enrollmentType":"ESTIMATED","startDate":"2022-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-23","completionType":"ESTIMATED","lastUpdated":"2024-08-23","conditions":["Non-small Cell Lung Cancer"],"interventions":["Ensartinib","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This double-blind, randomized, placebo-controlled, multicenter, Phase III study is designed to evaluate the efficacy and safety of ensatinib compared with placebo as adjuvant treatment in ALK positive stage II-IIIB non-small cell lung cancer after surgical resection with or without chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05341583"},{"nctId":"NCT04404595","title":"Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers","sponsor":"CARsgen Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2020-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2035-09-01","completionType":"ESTIMATED","lastUpdated":"2025-01-08","conditions":["Gastric Cancer","Pancreatic Cancer"],"interventions":["CT041"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT04404595"},{"nctId":"NCT05004285","title":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","sponsor":"FutureChem","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":398,"enrollmentType":"ESTIMATED","startDate":"2021-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-06-01","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["High Risk Prostate Carcinoma"],"interventions":["[F-18]Florastamin"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"Only in subjects who satisfy the inclusion/exclusion criteria, a single dose of \\[F-18\\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \\[F-18\\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.","sourceUrl":"https://clinicaltrials.gov/study/NCT05004285"},{"nctId":"NCT05514496","title":"A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer","sponsor":"Nalo Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2022-10-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-01","completionType":"ESTIMATED","lastUpdated":"2025-03-11","conditions":["EGFR Mutation-Related Tumors"],"interventions":["NX-019"],"countries":["United States","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of NX-019 and preliminary efficacy in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutant cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05514496"},{"nctId":"NCT04091126","title":"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":118,"enrollmentType":"ACTUAL","startDate":"2019-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-02","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Bortezomib","Lenalidomide","Dexamethasone"],"countries":["United States","Australia","Canada","France","Germany","Italy","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination of bortezomib, lenalidomide and dexamethasone (VRd) on a 3-week cycle until cycle 8, followed by the combination of lenalidomide and dexamethasone (Rd) on a 4-week cycle thereafter as per dosing schedule. Participants will receive belantamab mafodotin on a schedule that is dependent on the cohort to which they are assigned. Belantam","sourceUrl":"https://clinicaltrials.gov/study/NCT04091126"},{"nctId":"NCT05364073","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","sponsor":"ArriVent BioPharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ACTUAL","startDate":"2022-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Non-Small Cell Lung Cancer (NSCLC)","Metastatic Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","HER2 Exon 20 Mutations","EGFR Exon 20 Mutations","EGFR Uncommon Mutations, Including G719X and S768I"],"interventions":["Furmonertinib"],"countries":["United States","Australia","Canada","China","France","Italy","Japan","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":42,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1b, open-label, multi-center, dose-escalation and dose expansion study designed to evaluate the safety, pharmacokinetics (PK), and preliminary antitumor activity of furmonertinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating, including uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) mutations. Patients will be enrolled into one of 2 stages: Stage 1 (Dose Escalation and Backfill Cohorts) and Stage 2 (Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05364073"},{"nctId":"NCT06425991","title":"A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":108,"enrollmentType":"ACTUAL","startDate":"2024-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-03","primaryCompletionType":"ACTUAL","completionDate":"2028-01-13","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["Teclistamab"],"countries":["United States","Australia","Canada","France","Germany","Israel","Italy","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).","sourceUrl":"https://clinicaltrials.gov/study/NCT06425991"},{"nctId":"NCT04655976","title":"Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy","sponsor":"GlaxoSmithKline","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":758,"enrollmentType":"ACTUAL","startDate":"2020-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-05","primaryCompletionType":"ACTUAL","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Lung Cancer, Non-Small Cell"],"interventions":["Cobolimab","Dostarlimab","Docetaxel"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Finland","France","Germany","Greece","Italy","Japan","Mexico","Netherlands","Poland","Romania","Russia","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":163,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04655976"},{"nctId":"NCT03924895","title":"Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":595,"enrollmentType":"ACTUAL","startDate":"2019-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-06","primaryCompletionType":"ACTUAL","completionDate":"2027-12-15","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Urinary Bladder Cancer, Muscle-invasive"],"interventions":["Pembrolizumab","Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])","Enfortumab Vedotin"],"countries":["United States","Argentina","Australia","Belgium","Canada","Colombia","Denmark","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Philippines","Poland","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":242,"serviceSignals":["Broad CGP"],"summary":"This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plus pelvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination with pembrolizumab plus RC+PLND will achieve superior event-free survival (EFS) compared with RC+PLND alone. With Amendment 5, outcome measures for programmed cell death ligand 1 (PD-L1) combined positive score (CPS) were removed. With Amendment 8, the primary outcome measure of pathologic complete respon","sourceUrl":"https://clinicaltrials.gov/study/NCT03924895"},{"nctId":"NCT05802225","title":"Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer","sponsor":"Biocad","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":398,"enrollmentType":"ACTUAL","startDate":"2023-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-06","primaryCompletionType":"ACTUAL","completionDate":"2026-02-20","completionType":"ESTIMATED","lastUpdated":"2025-07-20","conditions":["Breast Cancer"],"interventions":["BCD-178","Perjeta"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"The goal of this study is to compare the efficacy and safety of BCD-178 and Perjeta as neoadjuvant therapy for HER2-positive breast cancer. Subjects with histologically confirmed diagnosis of HER2-positive invasive breast cancer (stage II-III, tumor size \\> 2 cm), with no estrogen (ER) and progesterone (PR) receptors will be randomized to one of two treatment groups (BCD-178 group or Perjeta group) in a 1:1 ratio.","sourceUrl":"https://clinicaltrials.gov/study/NCT05802225"},{"nctId":"NCT04906993","title":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":443,"enrollmentType":"ACTUAL","startDate":"2021-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-10","primaryCompletionType":"ACTUAL","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Cervical Cancer"],"interventions":["camrelizumab； famitinib malate","platinum-based chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT04906993"},{"nctId":"NCT05879978","title":"A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ACTUAL","startDate":"2023-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-11","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Small Cell Lung Carcinoma (SCLC)","Neuroendocrine Neoplasms"],"interventions":["Obrixtamig","Ezabenlimab"],"countries":["Belgium","France","Germany","Japan"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"This study is open to adults with small cell lung cancer and other neuroendocrine tumours that are positive for the tumour marker Delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig that people can tolerate when taken together with another medicine called ezabenlimab. Obrixtamig and ezabenlimab may help the immune system fight cancer. Participants get obrixtamig and ezabenlimab as infusions into a vein. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During th","sourceUrl":"https://clinicaltrials.gov/study/NCT05879978"},{"nctId":"NCT04919811","title":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","sponsor":"Nuvation Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":217,"enrollmentType":"ACTUAL","startDate":"2021-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-11","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Non Small Cell Lung Cancer"],"interventions":["Taletrectinib"],"countries":["United States","Canada","China","France","Italy","Japan","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":77,"serviceSignals":["RNA fusion"],"summary":"The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04919811"},{"nctId":"NCT06117540","title":"A Study of WX390 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2021-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-12","completionType":"ESTIMATED","lastUpdated":"2024-11-19","conditions":["Solid Tumor"],"interventions":["WX390"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.","sourceUrl":"https://clinicaltrials.gov/study/NCT06117540"},{"nctId":"NCT05403385","title":"Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer","sponsor":"iTeos Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ACTUAL","startDate":"2022-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-13","primaryCompletionType":"ACTUAL","completionDate":"2025-10","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Metastatic NSCLC - Non-Small Cell Lung Cancer","Locally Advanced NSCLC - Non-Small Cell Lung Cancer"],"interventions":["inupadenant","Placebo","Carboplatin","Pemetrexed"],"countries":["United States","Belgium","Canada","Czechia","France","Italy","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or metastatic non-small cell lung cancer. The efficacy and safety of the combination is then compared to standard of care carboplatin and pemetrexed in the same populations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05403385"},{"nctId":"NCT06394713","title":"A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-06-15","startDateType":"ESTIMATED","primaryCompletionDate":"2025-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-15","completionType":"ESTIMATED","lastUpdated":"2024-05-01","conditions":["Advanced Malignant Neoplasm"],"interventions":["QLF31907","Irinotecan","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate the safety and efficacy of QLF31907 combination therapy in advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06394713"},{"nctId":"NCT04660344","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":761,"enrollmentType":"ACTUAL","startDate":"2021-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-15","primaryCompletionType":"ACTUAL","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Muscle-invasive Bladder Cancer"],"interventions":["Atezolizumab","Placebo","Signatera"],"countries":["United States","Argentina","Belgium","Brazil","China","Colombia","Czechia","France","Germany","Greece","Hong Kong","Ireland","Israel","Italy","Japan","Mexico","Poland","Russia","Singapore","South Korea","Spain","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":148,"serviceSignals":["ctDNA / MRD"],"summary":"This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with MIBC who are circulating tumour deoxyribonucleic acid (ctDNA) positive and are at high risk for recurrence following cystectomy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04660344"},{"nctId":"NCT05823285","title":"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2023-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-15","completionType":"ESTIMATED","lastUpdated":"2023-04-21","conditions":["Advanced Solid Tumors"],"interventions":["QLS31903"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate safety, pharmacokinetics,immunogenicity and efficacy of QLS31903 alone in the treatment of advanced cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05823285"},{"nctId":"NCT05943106","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ACTUAL","startDate":"2023-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-16","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Non-Muscle- Invasive Bladder Cancer"],"interventions":["Durvalumab","BCG"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.","sourceUrl":"https://clinicaltrials.gov/study/NCT05943106"},{"nctId":"NCT05909904","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma","sponsor":"BeiGene","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ACTUAL","startDate":"2023-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-17","primaryCompletionType":"ACTUAL","completionDate":"2026-07-09","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Head and Neck Squamous Cell Carcinoma","Head and Neck Cancer"],"interventions":["Tislelizumab","BGB-A425","LBL-007"],"countries":["United States","Australia","Canada","China","France","Georgia","Italy","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":73,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05909904"},{"nctId":"NCT04194775","title":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","sponsor":"CStone Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":534,"enrollmentType":"ACTUAL","startDate":"2019-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-18","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Hepatocellular Carcinoma"],"interventions":["Nofazinlimab (CS1003)+Lenvatinib","Nofazinlimab (CS1003) Placebo+Lenvatinib"],"countries":["United States","China","Italy","Poland","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":74,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of subjects with no prior systemic treatment and with unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for locoregional therapy. In this study, Nofazinlimab (CS1003) (or placebo) and lenvatinib are both considered as the study treatment while Nofazinlimab (CS1003) (or placebo) is the investigational product and lenvatinib is selected as the basic treatment for HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04194775"},{"nctId":"NCT04629729","title":"FT819 in Subjects With B-cell Malignancies","sponsor":"Fate Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ACTUAL","startDate":"2021-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-18","primaryCompletionType":"ACTUAL","completionDate":"2039-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["Lymphoma, B-Cell","Chronic Lymphocytic Leukemia","Precursor B-Cell Acute Lymphoblastic Leukemia"],"interventions":["FT819","Cyclophosphamide","Fludarabine","IL-2","Bendamustine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT04629729"},{"nctId":"NCT05327530","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":256,"enrollmentType":"ACTUAL","startDate":"2022-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-20","primaryCompletionType":"ACTUAL","completionDate":"2026-06-25","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Locally Advanced or Metastatic Urothelial Carcinoma"],"interventions":["Avelumab","Sacituzumab Govitecan","M6223","NKTR-255"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Greece","Italy","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":97,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05327530"},{"nctId":"NCT05614258","title":"Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors","sponsor":"Adagene Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2023-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-25","primaryCompletionType":"ACTUAL","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["ADG206"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"ADG206 is an activatable prodrug form of a fully human monoclonal antibody (mAb) of the immunoglobulin G1 (IgG1) subclass that specifically targets cluster of differentiation 137 (CD137) (also known as 4-1BB) as a co-stimulatory receptor agonist for the treatment of advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05614258"},{"nctId":"NCT05466149","title":"Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-27","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["NSCLC"],"interventions":["Furmonertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Furmonertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations. The study plans to enroll approximately 100 patients from approximately 70 sites. Patients are locally advanced or metastatic NSCLC with EGFR exon 20 insertions who have progressed during or after platinum-based chemotherapy. Furmonertinib Mesilate will be treated 240 mg QD until disease progression or unacceptable toxicity. Primary endpoint is ORR. Secondary endpoints include DOR, DCR, DepOR, PFS, OS, CNS ORR, CNS DOR, CNS PFS, safety and","sourceUrl":"https://clinicaltrials.gov/study/NCT05466149"},{"nctId":"NCT05580991","title":"Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors","sponsor":"Canwell Biotech Limited","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":27,"enrollmentType":"ACTUAL","startDate":"2022-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-06-30","completionType":"ESTIMATED","lastUpdated":"2025-02-13","conditions":["Solid Tumor"],"interventions":["CAN1012"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05580991"},{"nctId":"NCT06183736","title":"CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency","sponsor":"Convalife (Shanghai) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ESTIMATED","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2023-12-27","conditions":["Advanced Solid Tumors"],"interventions":["CVL237 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor types.","sourceUrl":"https://clinicaltrials.gov/study/NCT06183736"},{"nctId":"NCT06468098","title":"A Study of IBI363 in Subjects With Advanced Malignancies","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":556,"enrollmentType":"ESTIMATED","startDate":"2024-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-07-18","conditions":["Advanced Malignancies"],"interventions":["IBI363 + chemotherapy","IBI363 + Investigator's Choice SOC"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients","sourceUrl":"https://clinicaltrials.gov/study/NCT06468098"},{"nctId":"NCT05481151","title":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","sponsor":"PharmaEssentia","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":111,"enrollmentType":"ACTUAL","startDate":"2022-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ACTUAL","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Polycythemia Vera"],"interventions":["P1101 (Ropeginterferon alfa-2b-njft)","Ropeginterferon alfa-2b-njft (P1101)"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV","sourceUrl":"https://clinicaltrials.gov/study/NCT05481151"},{"nctId":"NCT06298552","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis","sponsor":"argenx","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":119,"enrollmentType":"ACTUAL","startDate":"2024-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ACTUAL","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-11-05","conditions":["Generalized Myasthenia Gravis","gMG","Myasthenia Gravis, Generalized","Myasthenia Gravis"],"interventions":["Efgartigimod IV","Placebo IV"],"countries":["United States","Belgium","Canada","China","Cyprus","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hungary","Netherlands","Norway","Poland","Portugal","Romania","Saudi Arabia","Serbia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":91,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to measure the efficacy and safety of efgartigimod IV compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). The study consists of a Part A where participants will be randomized to receive either efgartigimod IV or placebo IV and a Part B where participants completing part A will receive open-label efgartigimod IV. Participants will be in the study for up to (approximately) 2.5 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06298552"},{"nctId":"NCT06383052","title":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","sponsor":"Norroy Bioscience Co., LTD","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2024-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-21","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["177Lu-NYM032 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong affinity for PSMA.","sourceUrl":"https://clinicaltrials.gov/study/NCT06383052"},{"nctId":"NCT04964934","title":"Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":315,"enrollmentType":"ACTUAL","startDate":"2021-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ACTUAL","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["ER-Positive HER2-Negative Breast Cancer"],"interventions":["AZD9833","AZD9833 Placebo","Anastrozole","Anastrozole placebo","Letrozole","Letrozole placebo","Palbociclib","Abemaciclib","Luteinizing hormone-releasing hormone (LHRH) agonist","Ribociclib"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","France","Germany","Hungary","Israel","Italy","Japan","Norway","Poland","Portugal","Russia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":264,"serviceSignals":["ctDNA / MRD","HER2 profiling"],"summary":"The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04964934"},{"nctId":"NCT05948813","title":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","sponsor":"TYK Medicines, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2023-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2024-11-21","conditions":["NSCLC","EGFR Activating Mutation","Brain Metastases"],"interventions":["TY-9591","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05948813"},{"nctId":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2023-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-07","conditions":["Pancreatic Adenocarcinoma Metastatic","Lung Cancer (NSCLC)","Ovarian Cancer","Colorectal Cancer Metastatic","Biliary Tract Cancer","Gastric Carcinoma","Gastroesophageal Junction Adenocarcinoma"],"interventions":["XNW27011"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are intolerant to standard therapies. XNW27011 is an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a transmembrane protein important to tight junctions. The study consists of 2 parts: Part 1 is the dose-escalation phase (Phase I), and Part 2 is the does-expansion phase (Phase II). In phase I part of the study, approximately 42 patients with locally advanced and/or metastatic solid tumors will be enrolled, irrespective of CLDN18.2 expression. However, the mos","sourceUrl":"https://clinicaltrials.gov/study/NCT06792435"},{"nctId":"NCT06179524","title":"CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL","sponsor":"Beijing Yongtai Ruike Biotechnology Company Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-01-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2025-01-13","conditions":["Relapsed B-cell Acute Lymphoblastic Leukemia","Refractory B-cell Acute Lymphoblastic Leukemia"],"interventions":["CAR-T-19 cell injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06179524"},{"nctId":"NCT04787042","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","sponsor":"Simcha IL-18, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":316,"enrollmentType":"ESTIMATED","startDate":"2021-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["Cancer","Solid Tumor","Melanoma","Renal Cell Carcinoma","Triple-negative Breast Cancer","Non Small Cell Lung Cancer","Squamous Cell Carcinoma of the Head and Neck","Carcinoma","MSI-High"],"interventions":["ST-067","Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]","pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["MSI / TMB"],"summary":"This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \\[Gazyva®\\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT04787042"},{"nctId":"NCT05215574","title":"Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors","sponsor":"NGM Biopharmaceuticals, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2022-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2024-10-10","conditions":["Pancreatic Cancer","Breast Cancer","Gastric Cancer","Non-small Cell Lung Cancer","Cervical Cancer","Endocervical Cancer","Squamous Cell Carcinoma of Head and Neck","Bladder Urothelial Cancer","Colorectal Carcinoma","Esophageal Cancer","Ovarian Cancer","Renal Cell Carcinoma","Prostate Cancer","Melanoma","Mesothelioma","Cholangiocarcinoma"],"interventions":["NGM831","NGM831 plus pembrolizumab (KEYTRUDA®)","NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05215574"},{"nctId":"NCT05572684","title":"A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors","sponsor":"NextCure, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":97,"enrollmentType":"ACTUAL","startDate":"2022-10-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-07","primaryCompletionType":"ESTIMATED","completionDate":"2025-11","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Advanced or Metastatic Solid Tumors","Microsatellite Instability Low","Microsatellite Instability High","Microsatellite Stable","Ovarian Cancer","Gastric Cancer","Colo-rectal Cancer","Esophageal Cancer","Endometrial Cancer","Head Neck Cancer","Cervical Cancer","Lung Cancer"],"interventions":["NC410","pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["MSI / TMB"],"summary":"This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05572684"},{"nctId":"NCT03480971","title":"Treatment of Radiation and Cisplatin Induced Toxicities with Tempol","sponsor":"Matrix Biomed, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2019-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-07","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["Mucositis","Nephrotoxicity","Ototoxicity"],"interventions":["Tempol","Placebo Solution"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT03480971"},{"nctId":"NCT05704985","title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","sponsor":"DEKA Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":39,"enrollmentType":"ACTUAL","startDate":"2023-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-07","primaryCompletionType":"ESTIMATED","completionDate":"2025-10","completionType":"ESTIMATED","lastUpdated":"2025-05-29","conditions":["Cancer","Solid Tumor","Colorectal Cancer","Pancreas Cancer","Non Small Cell Lung Cancer","Head and Neck Cancer","Gynecologic Cancer","Skin Cancer","Kidney Cancer"],"interventions":["DK210 (EGFR)","Radiation therapy","Immune checkpoint blockers","Chemotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05704985"},{"nctId":"NCT04661007","title":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)","sponsor":"Incyte Biosciences Japan GK","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2020-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-01","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Non Hodgkins Lymphoma","Diffuse Large B-cell Lymphoma"],"interventions":["tafasitamab","lenalidomide","parsaclisib","R-CHOP"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicenter study to evaluate safety and tolerability, determine the RP2Ds of tafasitamab alone in Japanese participants with R/R NHL, or to evaluate efficacy and safety of tafasitamab in combination with lenalidomide in Japanese participants with R/R DLBCL, or tafasitimab in combination with lenalidomide plus R-CHOP in Japanese participants with previously untreated DLBC, or tafasitimab in combination with lenalidomide in Japanese participants with previously R/R DLBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04661007"},{"nctId":"NCT05907304","title":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations","sponsor":"Erasca, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":86,"enrollmentType":"ACTUAL","startDate":"2023-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-01","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["Naporafenib","Trametinib"],"countries":["United States","Australia","Canada","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05907304"},{"nctId":"NCT04622319","title":"A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1600,"enrollmentType":"ESTIMATED","startDate":"2020-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-02","primaryCompletionType":"ACTUAL","completionDate":"2028-06-20","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["HER2-Positive Primary Breast Cancer","Residual Invasive Breast Cancer"],"interventions":["DS-8201a","T-DM1"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","France","Germany","Greece","Hong Kong","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":482,"serviceSignals":["HER2 profiling"],"summary":"Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04622319"},{"nctId":"NCT05914376","title":"Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors","sponsor":"Hangzhou Converd Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2023-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-02","primaryCompletionType":"ACTUAL","completionDate":"2027-06-10","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced Solid Tumors"],"interventions":["Recombinant human IL-21-expressing oncolytic vaccinia virus injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerance, pharmacokinetics, and biological properties of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05914376"},{"nctId":"NCT05365178","title":"To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":432,"enrollmentType":"ACTUAL","startDate":"2022-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-02","primaryCompletionType":"ACTUAL","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["HR-positive, HER2-negative Breast Neoplasms"],"interventions":["TQB3616 capsule","Placebo","Fulvestrant injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":88,"serviceSignals":["HER2 profiling"],"summary":"A randomized, double-blind, parallel-controlled, multicenter trial design was used in this study. Subjects who meet the criteria will be randomly divided into 2:1 groups to receive TBQ3616 capsule combined with Fulvestrant injection (experimental group) or placebo capsule combined with fulvestrant (control group). A total of 428 subjects were required.","sourceUrl":"https://clinicaltrials.gov/study/NCT05365178"},{"nctId":"NCT04640623","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":220,"enrollmentType":"ACTUAL","startDate":"2020-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-03","primaryCompletionType":"ACTUAL","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Urinary Bladder Neoplasms"],"interventions":["TAR-200","Cetrelimab"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Greece","Italy","Japan","Netherlands","Portugal","Russia","South Korea","Spain","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":144,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).","sourceUrl":"https://clinicaltrials.gov/study/NCT04640623"},{"nctId":"NCT05675449","title":"A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":59,"enrollmentType":"ESTIMATED","startDate":"2022-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-07","primaryCompletionType":"ACTUAL","completionDate":"2028-02-29","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Carfilzomib","Maplirpacept"],"countries":["United States","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part","sourceUrl":"https://clinicaltrials.gov/study/NCT05675449"},{"nctId":"NCT05070858","title":"A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":288,"enrollmentType":"ACTUAL","startDate":"2021-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-08","primaryCompletionType":"ACTUAL","completionDate":"2028-11-11","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Generalized Myasthenia Gravis"],"interventions":["Pozelimab + Cemdisiran","Cemdisiran","Placebo","Pozelimab"],"countries":["United States","Belgium","Brazil","Canada","China","Denmark","France","Georgia","Germany","India","Italy","Japan","Poland","Serbia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":116,"serviceSignals":["Broad CGP"],"summary":"This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with gMG. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How the study drugs work inside the body * How much of the study","sourceUrl":"https://clinicaltrials.gov/study/NCT05070858"},{"nctId":"NCT05980481","title":"A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":201,"enrollmentType":"ESTIMATED","startDate":"2023-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-10","primaryCompletionType":"ACTUAL","completionDate":"2026-10-10","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Gastric Cancer"],"interventions":["RC48-ADC（2.5mg/kg）","Trastuzumab","Toripalimab","Oxaliplatin（130mg/m2 ）","Capecitabine（1000mg/m2）","RC48-ADC（2.0mg/kg）","Capecitabine（750mg/m2）","Oxaliplatin（100mg/m2 ）"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a Phase II/III, randomized, multicenter, open-label clinical trial designed to evaluate safety and efficacy of RC48-ADC combine with Toripalimab and chemotherapy or RC48-ADC combine with Toripalimab and Trastuzumab as first-line treatment in human epidermal growth factor receptor 2 (HER2)-expression or non-expression participants with locally advanced or metastatic gastric cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05980481"},{"nctId":"NCT05023980","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","sponsor":"Loxo Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":309,"enrollmentType":"ACTUAL","startDate":"2021-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-11","primaryCompletionType":"ACTUAL","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Pirtobrutinib","Bendamustine","Rituximab"],"countries":["United States","Australia","Austria","Brazil","Bulgaria","China","Czechia","France","Hungary","Italy","Japan","New Zealand","Poland","Portugal","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":108,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL who have not been treated. Participation could last up to five years.","sourceUrl":"https://clinicaltrials.gov/study/NCT05023980"},{"nctId":"NCT03530397","title":"A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors","sponsor":"MedImmune LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":400,"enrollmentType":"ACTUAL","startDate":"2018-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-14","primaryCompletionType":"ACTUAL","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Selected Advanced Solid Tumors"],"interventions":["MEDI5752","Pemetrexed","Carboplatin","Pembrolizumab","Paclitaxel or Nab-Paclitaxel"],"countries":["United States","Australia","France","Italy","Netherlands","Portugal","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03530397"},{"nctId":"NCT05306340","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","sponsor":"Genentech, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":373,"enrollmentType":"ACTUAL","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-16","primaryCompletionType":"ACTUAL","completionDate":"2026-10-15","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer"],"interventions":["Giredestrant","Exemestane","Fulvestrant","Tamoxifen","Everolimus","LHRH Agonist","Dexamethasone Mouth Rinse"],"countries":["United States","Argentina","Germany","Greece","Italy","Japan","Singapore","South Africa","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":136,"serviceSignals":["HER2 profiling"],"summary":"This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT05306340"},{"nctId":"NCT06126510","title":"Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma","sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-17","primaryCompletionType":"ESTIMATED","completionDate":"2026-01-17","completionType":"ESTIMATED","lastUpdated":"2024-12-24","conditions":["Sarcoma"],"interventions":["Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle. Tumor imaging evaluation was performed every 8±1 weeks from the first dose of C1D1 until an event that met the criteria for treatment discontinuation occurred.","sourceUrl":"https://clinicaltrials.gov/study/NCT06126510"},{"nctId":"NCT05471843","title":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","sponsor":"BeiGene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2022-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-18","primaryCompletionType":"ACTUAL","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Mantle Cell Lymphoma","Refractory Mantle Cell Lymphoma (MCL)","Relapsed Mantle Cell Lymphoma"],"interventions":["BGB-11417"],"countries":["United States","Argentina","Belgium","Brazil","Canada","China","France","Germany","Israel","Italy","Poland","Puerto Rico","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":104,"serviceSignals":["Hematology NGS"],"summary":"The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417 (sonrotoclax) monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from Part 1.","sourceUrl":"https://clinicaltrials.gov/study/NCT05471843"},{"nctId":"NCT04042701","title":"DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2020-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-21","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Breast Cancer","Non-small Cell Lung Carcinoma"],"interventions":["Trastuzumab deruxtecan (DS-8201a)","Pembrolizumab"],"countries":["United States","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT04042701"},{"nctId":"NCT05735496","title":"Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":219,"enrollmentType":"ACTUAL","startDate":"2023-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-21","primaryCompletionType":"ACTUAL","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Advanced Cancer"],"interventions":["TQB2102 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB102 injection in subjects with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05735496"},{"nctId":"NCT06445400","title":"A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":83,"enrollmentType":"ACTUAL","startDate":"2024-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-21","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["HER2-positive Breast Cancer"],"interventions":["BL-M07D1","Pertuzumab","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a phase II clinical trial to evaluate the safety and efficacy of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel as first-line treatment in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06445400"},{"nctId":"NCT06282159","title":"A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)","sponsor":"Dianthus Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2024-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-28","primaryCompletionType":"ACTUAL","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Myasthenia Gravis, Generalized"],"interventions":["Claseprubart","Placebo"],"countries":["United States","Argentina","Canada","Czechia","Denmark","France","Israel","Italy","Netherlands","North Macedonia","Norway","Poland","Serbia","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT06282159"},{"nctId":"NCT04810078","title":"A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":681,"enrollmentType":"ACTUAL","startDate":"2021-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-29","primaryCompletionType":"ACTUAL","completionDate":"2027-05-10","completionType":"ESTIMATED","lastUpdated":"2025-10-09","conditions":["Clear Cell Renal Cell Carcinoma"],"interventions":["Nivolumab and rHuPH20","Nivolumab"],"countries":["United States","Argentina","Brazil","Chile","Czechia","Finland","France","Ireland","Italy","Mexico","New Zealand","Poland","Portugal","Romania","Russia","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":89,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.","sourceUrl":"https://clinicaltrials.gov/study/NCT04810078"},{"nctId":"NCT05940116","title":"A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":322,"enrollmentType":"ESTIMATED","startDate":"2023-07-20","startDateType":"ESTIMATED","primaryCompletionDate":"2025-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2023-07-12","conditions":["Non-Small Cell Lung Cancer","Solid Tumor"],"interventions":["HS-20117"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05940116"},{"nctId":"NCT05767892","title":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","sponsor":"Suzhou Puhe Pharmaceutical Technology Co., LTD","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2023-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2023-04-05","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["YK-209A tablet","Pemetrexed+carboplatin/Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the effectiveness of YK-029A as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups YK-029A group or Platinum-based chemotherapy group. Participants will receive YK-029A orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinua","sourceUrl":"https://clinicaltrials.gov/study/NCT05767892"},{"nctId":"NCT05970016","title":"A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2023-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-03-21","conditions":["Patients with Advanced Solid Tumors"],"interventions":["TCC1727 tablet（1）","TCC1727 tablet（2）"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a 2-part, phase I/II, open-label, multicenter study designed to evaluate the safety, PK, PD and preliminary efficacy of TCC1727 tablets administered orally QD.","sourceUrl":"https://clinicaltrials.gov/study/NCT05970016"},{"nctId":"NCT06299124","title":"A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors","sponsor":"Regor Pharmaceuticals Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-30","completionType":"ESTIMATED","lastUpdated":"2025-01-20","conditions":["Breast Cancer","Advanced Solid Tumor"],"interventions":["RGT-419B"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2- advanced/metastatic breast cancer and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06299124"},{"nctId":"NCT05838066","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":880,"enrollmentType":"ESTIMATED","startDate":"2023-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-30","conditions":["First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer"],"interventions":["Recombinant Humanized Bispecific antibody against HER2，KN026","HB1801","Pertuzumab","Trastuzumab","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05838066"},{"nctId":"NCT06569420","title":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":275,"enrollmentType":"ACTUAL","startDate":"2021-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-26","conditions":["Non-Small Cell Lung Cancer","ALK-positive","SAF-189s"],"interventions":["Drug: Foritinib Succinate","Drug: Crizotinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of SAF-189s versus crizotinib treatment in participants with treatment-naive ALK-positive advanced NSCLC. Participants will be randomized 1:1 into one of the two treatment groups to receive either SAF-189s (160 milligrams \\[mg\\] once daily \\[QD\\]) or crizotinib (250 mg BID) orally, respectively.","sourceUrl":"https://clinicaltrials.gov/study/NCT06569420"},{"nctId":"NCT03647163","title":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","sponsor":"Vyriad, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":33,"enrollmentType":"ACTUAL","startDate":"2019-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ACTUAL","completionDate":"2025-09-30","completionType":"ESTIMATED","lastUpdated":"2025-09-16","conditions":["Solid Tumor","Non Small Cell Lung Cancer","Neuroendocrine Carcinoma","Renal Cell Carcinoma (RCC)"],"interventions":["VSV-IFNβ-NIS","Pembrolizumab","ipilimumab + nivolumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious.","sourceUrl":"https://clinicaltrials.gov/study/NCT03647163"},{"nctId":"NCT05546723","title":"LMY-920 for Treatment of Relapsed or Refractory Myeloma","sponsor":"Luminary Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2024-10-18","conditions":["Multiple Myeloma, Refractory","Multiple Myeloma in Relapse"],"interventions":["Autologous CAR-T cell therapy expressing the BAFF-ligand."],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05546723"},{"nctId":"NCT06224387","title":"CTS2190 Phase I /II Clinical Study in Patients","sponsor":"CytosinLab Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2023-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2024-08-23","conditions":["Solid Tumors","Pancreatic Cancer","Non-small Cell Lung Cancer","Triple-negative Breast Cancer"],"interventions":["CTS2190 capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06224387"},{"nctId":"NCT05608876","title":"A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer","sponsor":"QBiotics Group Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ACTUAL","startDate":"2022-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ACTUAL","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Head and Neck Cancer"],"interventions":["Tigilanol Tiglate"],"countries":["Australia","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05608876"},{"nctId":"NCT06823245","title":"Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-31","completionType":"ESTIMATED","lastUpdated":"2025-02-12","conditions":["Advanced Non-small Cell Lung Cancer"],"interventions":["HS-10241"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages. Based on the research results of moderate hepatic Impairment and matched control subjects with normal hepatic function, the sponsor will make a comprehensive analysis to decide whether it is necessary to conduct a study on the mild hepatic Impairment and matched control subjects with normal hepatic function.","sourceUrl":"https://clinicaltrials.gov/study/NCT06823245"},{"nctId":"NCT04146051","title":"Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)","sponsor":"Cartesian Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2019-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2025-05-28","conditions":["Myasthenia Gravis, Generalized"],"interventions":["Descartes-08"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis","sourceUrl":"https://clinicaltrials.gov/study/NCT04146051"},{"nctId":"NCT06091943","title":"Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"BeiGene","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":62,"enrollmentType":"ACTUAL","startDate":"2023-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Non-small Cell Lung Cancer"],"interventions":["Tislelizumab IV","Tislelizumab SC","Histology-Based Chemotherapy Doublet"],"countries":["China","Georgia","Moldova"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung cancer (NSCLC). This clinical study will be divided into 2 parts: dose/injection site exploration (Part 1) and dose expansion (Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT06091943"},{"nctId":"NCT05594797","title":"Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM","sponsor":"Hrain Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2022-12-09","conditions":["Multiple Myeloma"],"interventions":["Human BCMA Targeted T Cells Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.","sourceUrl":"https://clinicaltrials.gov/study/NCT05594797"},{"nctId":"NCT06823258","title":"Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2025-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-07-31","completionType":"ESTIMATED","lastUpdated":"2025-02-12","conditions":["NSCLC (advanced Non-small Cell Lung Cancer)"],"interventions":["HS-10365"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted in subjects with moderate Hepatic Impairment, mild hepatic Impairment and normal hepatic function. The study will be conducted in two stages. Based on the research results of moderate hepatic Impairment and matched control subjects with normal hepatic function, the sponsor will make a comprehensive analysis to decide whether it is necessary to conduct a study on the mild hepatic Impairment and matched control subjects with normal hepatic function","sourceUrl":"https://clinicaltrials.gov/study/NCT06823258"},{"nctId":"NCT04282044","title":"Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies","sponsor":"BioEclipse Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2021-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2024-02-08","conditions":["Solid Tumor, Adult","Triple Negative Breast Cancer","Colorectal Cancer","Hepatocellular Carcinoma","Osteosarcoma","Epithelial Ovarian Cancer","Gastric Cancer","Non-small Cell Lung Cancer","Malignant Melanoma"],"interventions":["CRX100 suspension for infusion","Fludarabine","Cyclophosphamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovarian cancer, colorectal cancer, hepatocellular carcinoma (HCC), malignant melanoma (excluding uveal melanoma), gastric cancer, triple negative breast cancer, and osteosarcoma. The study will start with m","sourceUrl":"https://clinicaltrials.gov/study/NCT04282044"},{"nctId":"NCT04959903","title":"Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT","sponsor":"Smart Immune SAS","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2022-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2023-03-06","conditions":["Hematological Malignancies"],"interventions":["Allogeneic T cell progenitors, cultured ex-vivo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04959903"},{"nctId":"NCT05797831","title":"Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer","sponsor":"Kartos Therapeutics, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":268,"enrollmentType":"ESTIMATED","startDate":"2023-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2024-05-02","conditions":["Endometrial Cancer"],"interventions":["Navtemadlin","Navtemadlin Placebo"],"countries":["United States","Austria","Canada","Denmark","Estonia","Finland","Georgia","Hungary","Israel","Italy","Lithuania","Norway","Poland","Romania","Slovenia","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":83,"serviceSignals":["Broad CGP"],"summary":"This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT05797831"},{"nctId":"NCT06963840","title":"Effect of Theronomic Ova-All Care on Biomarkers of Ovarian Health in Adult Female With Polycystic Ovarian Syndrome","sponsor":"Wellizen Australia","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2025-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2025-08","completionType":"ESTIMATED","lastUpdated":"2025-08-29","conditions":["Polycystic Ovarian Syndrome (PCOS)"],"interventions":["Theronomic Ova-All Care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Theronomic Ova-All Care is a tribiotic health product aimed at improving ovarian health in people with polycystic ovarian syndrome (PCOS). In this study, a total of 16 participants with PCOS diagnosed by a gynaecologist will be invited to take Ova-All Care, two capsule once a day, for 12 weeks. Biomarkers of ovarian health will be measured at baseline, four weeks after the start of the intervention, and at the end of the intervention.","sourceUrl":"https://clinicaltrials.gov/study/NCT06963840"},{"nctId":"NCT05877924","title":"A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.","sponsor":"NovaRock Biotherapeutics, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-03-26","conditions":["Advanced Malignant Tumors"],"interventions":["NBL-020 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.","sourceUrl":"https://clinicaltrials.gov/study/NCT05877924"},{"nctId":"NCT06522828","title":"A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2024-10-21","conditions":["Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer"],"interventions":["SSGJ-707","carboplatin","paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06522828"},{"nctId":"NCT05698459","title":"OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2023-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-01","completionType":"ESTIMATED","lastUpdated":"2024-12-20","conditions":["Advanced Liver Cancer"],"interventions":["OH2 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05698459"},{"nctId":"NCT06663137","title":"Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC","sponsor":"Relmada Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2024-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-06-13","conditions":["Non Muscle Invasive Bladder Cancer"],"interventions":["NDV01 intravesical controlled release formulation of gemcitabine and docetaxel"],"countries":["Israel"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, single-arm study evaluating the safety and efficacy of NDV01 KIT, a fixed-dose combination of gemcitabine HCl and docetaxel, administered via intravesical instillation in patients with high-grade Non-Muscle Invasive Bladder Cancer (NMIBC). NDV01 KIT includes 60 mL Carbopol Gel followed by 15 g NDV01 solution (gemcitabine HCl 1000 mg and docetaxel 40 mg), administered biweekly for six treatments, followed by monthly maintenance therapy for up to 12 months. The study includes a pharmacokinetic (PK) sub-study assessing systemic exposure to NDV01's active ingredients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06663137"},{"nctId":"NCT05417321","title":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2022-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-01","completionType":"ESTIMATED","lastUpdated":"2025-01-03","conditions":["Advanced Solid Tumor","NSCLC"],"interventions":["HB0036"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05417321"},{"nctId":"NCT05625399","title":"A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":579,"enrollmentType":"ACTUAL","startDate":"2023-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-04","primaryCompletionType":"ACTUAL","completionDate":"2027-11-18","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Melanoma"],"interventions":["Nivolumab + Relatlimab","rHuPH20"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Finland","France","Germany","Israel","Italy","Norway","Poland","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":149,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05625399"},{"nctId":"NCT05990127","title":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":642,"enrollmentType":"ESTIMATED","startDate":"2023-11-14","startDateType":"ESTIMATED","primaryCompletionDate":"2025-08-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-28","completionType":"ESTIMATED","lastUpdated":"2023-08-14","conditions":["Locally Advanced or Metastatic NSCLC"],"interventions":["AK104","Tislelizumab","carboplatin","Pemetrexed","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":62,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK104 combined chemotherapy versus Tislelizumab combined chemotherapy in first-line treatment of Locally advanced or metastatic NSCLC with PD-L1 TPS \\< 1%.","sourceUrl":"https://clinicaltrials.gov/study/NCT05990127"},{"nctId":"NCT04961996","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":4170,"enrollmentType":"ACTUAL","startDate":"2021-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-08","primaryCompletionType":"ACTUAL","completionDate":"2033-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Early Breast Cancer"],"interventions":["Giredestrant","Physician's Choice of Endocrine Therapy","LHRH Agonist"],"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Costa Rica","Croatia","Czechia","Egypt","Finland","France","Georgia","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Kenya","Latvia","Malaysia","Mexico","Netherlands","North Macedonia","Peru","Philippines","Poland","Portugal","Romania","Serbia","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Uganda","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":622,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04961996"},{"nctId":"NCT06754761","title":"Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2025-01-17","startDateType":"ESTIMATED","primaryCompletionDate":"2025-08-08","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-08","completionType":"ESTIMATED","lastUpdated":"2025-01-01","conditions":["Neoplasm"],"interventions":["[14C] AZD6738","AZD6738 / ceralasertib"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, two-part study in participants with NSCLC, ovarian cancer, or endometrial cancer and will be conducted at multiple study sites. Participants will be assessed for study eligibility prior to admission to the study site. Part A will assess the absolute bioavailability, determine the excretory routes of \\[14C\\]-Ceralasertib, and evaluate the PK parameters of a Ceralasertib oral dose and a radiolabelled IV microdose of \\[14C\\]-Ceralasertib. Participants will be admitted to the study site pre-dose Part A and will remain at the study site for excreta (urine and faeces) collections, PK sampling and safety assessments. A washout period days will be observed between dosing in Pa","sourceUrl":"https://clinicaltrials.gov/study/NCT06754761"},{"nctId":"NCT07130916","title":"A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-09","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Aumolertinib"],"countries":["Bosnia and Herzegovina","Bulgaria","Moldova"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, multiple-dose study to evaluate aumolertinib in European participants with a confirmed diagnosis of activating EGFR mutation positive (EGFRm+) locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07130916"},{"nctId":"NCT06045806","title":"A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":79,"enrollmentType":"ACTUAL","startDate":"2023-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-11","primaryCompletionType":"ACTUAL","completionDate":"2029-11-20","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Multiple Myeloma"],"interventions":["idecabtagene vicleucel","Lenalidomide","Fludarabine","Cyclophosphamide"],"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Greece","Israel","Italy","Japan","Norway","Poland","Romania","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":101,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).","sourceUrl":"https://clinicaltrials.gov/study/NCT06045806"},{"nctId":"NCT03742895","title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":329,"enrollmentType":"ACTUAL","startDate":"2018-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-12","primaryCompletionType":"ACTUAL","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced Solid Neoplasms"],"interventions":["Olaparib"],"countries":["United States","Argentina","Australia","Canada","Colombia","Denmark","France","Guatemala","Ireland","Israel","Italy","Japan","Mexico","Peru","Romania","Russia","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":130,"serviceSignals":["HRD / HRR"],"summary":"This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).","sourceUrl":"https://clinicaltrials.gov/study/NCT03742895"},{"nctId":"NCT05384587","title":"Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2022-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-13","primaryCompletionType":"ACTUAL","completionDate":"2027-10-17","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["Chronic Myelogenous Leukemia - Chronic Phase"],"interventions":["asciminib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":80,"serviceSignals":["Hematology NGS"],"summary":"This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT05384587"},{"nctId":"NCT05607550","title":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","sponsor":"ArriVent BioPharma, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":398,"enrollmentType":"ACTUAL","startDate":"2023-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-15","completionType":"ESTIMATED","lastUpdated":"2025-06-22","conditions":["Metastatic Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer","EGFR Exon 20 Mutations"],"interventions":["furmonertinib 240 mg oral, daily","furmonertinib 160 mg oral, daily","platinum-based chemotherapy"],"countries":["United States","Australia","Brazil","Canada","China","France","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Philippines","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":208,"serviceSignals":["Broad CGP"],"summary":"Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of furmonertinib (firmonertinib) at 2 dose levels (160 mg once daily \\[QD\\] and 240 mg QD) compared to platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations. A target of approximately 375 patients will be randomized in a 1:1:1 ratio to treatment with furmonertinib 240 mg QD, furmonertinib 160 mg QD, or platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05607550"},{"nctId":"NCT06718738","title":"Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer","sponsor":"Beijing Immunochina Medical Science & Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2024-12-15","startDateType":"ESTIMATED","primaryCompletionDate":"2025-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-15","completionType":"ESTIMATED","lastUpdated":"2024-12-05","conditions":["Colorectal Cancer (CRC)"],"interventions":["IM96 CAR-T Cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced colorectal cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06718738"},{"nctId":"NCT05247684","title":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ACTUAL","startDate":"2022-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-18","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Resectable Non-small Cell Lung Cancer"],"interventions":["AK112","Carboplatin","Cisplatin","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT05247684"},{"nctId":"NCT05913037","title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":167,"enrollmentType":"ACTUAL","startDate":"2023-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-19","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-03-06","conditions":["Neurofibromatosis 1","Plexiform Neurofibroma","NF1"],"interventions":["Test group (Group A): FCN-159 8 mg, orally, once daily;","Control group (Group B): Placebo, orally, once daily;"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate the efficacy of FCN-159 in adult patients with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05913037"},{"nctId":"NCT05374512","title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":644,"enrollmentType":"ACTUAL","startDate":"2022-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-25","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Breast Cancer"],"interventions":["Dato-DXd","Paclitaxel","Nab-paclitaxel","Carboplatin","Capecitabine","Eribulin mesylate"],"countries":["United States","Argentina","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Italy","Japan","Mexico","Philippines","Poland","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":228,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC in participants with locally recurrent inoperable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05374512"},{"nctId":"NCT06252298","title":"A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies","sponsor":"Sinocelltech Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":74,"enrollmentType":"ESTIMATED","startDate":"2024-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2024-04-22","conditions":["Relapsed or Refractory Hematologic Malignancies"],"interventions":["SCTC21C"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and efficacy of SCTC21C in patients with CD38+ hematologic malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06252298"},{"nctId":"NCT05728658","title":"The Study of ICP-248 in Patients With Mature B-cell Malignancies","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":191,"enrollmentType":"ESTIMATED","startDate":"2023-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Hematological Malignancies"],"interventions":["ICP-248","ICP-248+Orelabrutinib","ICP-248 +Rituximab","ICP-248+Orelabrutinib+Rituximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.","sourceUrl":"https://clinicaltrials.gov/study/NCT05728658"},{"nctId":"NCT05594927","title":"Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)","sponsor":"Beijing Shenogen Biomedical Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":261,"enrollmentType":"ESTIMATED","startDate":"2022-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-30","completionType":"ESTIMATED","lastUpdated":"2024-08-07","conditions":["Hepatocellular Carcinoma"],"interventions":["Icaritin","Huachansu"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate the efficacy and safety of icaritin versus huachansu in the first-line treatment of unresectable hepatocellular carcinoma with poor conditions and biomarker enrichment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05594927"},{"nctId":"NCT06181266","title":"A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer","sponsor":"Prokarium Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":22,"enrollmentType":"ACTUAL","startDate":"2024-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["NMIBC","High Risk NMIBC","Non Muscle Invasive Bladder Cancer"],"interventions":["ZH9"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, Phase 1/1b, 3-part, double-blind study of ZH9 in patients with recurrent NMIBC who are eligible for intravesical therapy. In Part 1, the safety, tolerability, and pharmacology of ZH9 IVI will be evaluated in a single ascending dose (SAD) patient cohort. In Part 2, the safety, tolerability, and pharmacology of ZH9 oral prime followed by ZH9 IVI will be evaluated in 2 patient cohorts at the doses and schedule established in Part 1. In Part 3, the safety, pharmacology, and clinical efficacy of ZH9 will be further evaluated in 2 expansion cohorts of patients with recurrent intermediate- and high-risk NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06181266"},{"nctId":"NCT03866525","title":"OH2 Oncolytic Viral Therapy in Solid Tumors","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2019-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-30","completionType":"ESTIMATED","lastUpdated":"2024-12-20","conditions":["Solid Tumor","Gastrointestinal Cancer"],"interventions":["OH2 injection, with or without irinotecan or HX008"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft tissue sarcomas). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.","sourceUrl":"https://clinicaltrials.gov/study/NCT03866525"},{"nctId":"NCT06752746","title":"A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2024-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-11","conditions":["Polycythemia Vera"],"interventions":["9MW3011"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of 9MW3011 in Chinese patients with Polycythemia Vera（PV）.","sourceUrl":"https://clinicaltrials.gov/study/NCT06752746"},{"nctId":"NCT05701709","title":"Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":395,"enrollmentType":"ESTIMATED","startDate":"2023-04-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-31","completionType":"ESTIMATED","lastUpdated":"2025-07-22","conditions":["Advanced Solid Tumors"],"interventions":["SHR-A2102"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in patients with advanced solid tumors. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05701709"},{"nctId":"NCT05222802","title":"A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)","sponsor":"Katmai Pharmaceuticals Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":52,"enrollmentType":"ACTUAL","startDate":"2022-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-09-30","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Glioblastoma Multiforme"],"interventions":["ERAS-801"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"* To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. * To evaluate the antitumor activity of ERAS-801. * To evaluate the PK profile of ERAS-801.","sourceUrl":"https://clinicaltrials.gov/study/NCT05222802"},{"nctId":"NCT05441956","title":"TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":198,"enrollmentType":"ACTUAL","startDate":"2021-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Non-small Cell Lung Cancer"],"interventions":["TGRX-326"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"This trial is a multi-center, single-arm, open-label, Phase I clinical trial in 3 phases: dose escalation phase, dose expansion phase and indication expansion phase, which will explore the safety, tolerability, PK and preliminary efficacy of TGRX-326 in patients with ALK-positive or ROS1-positive advanced NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05441956"},{"nctId":"NCT06654440","title":"A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2024-12-10","conditions":["Advanced Gynecological Malignancy"],"interventions":["SHR-A2102 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main objective of this study is to evaluate the effectiveness and safety of SHR-A2102 for participants with advanced gynaecological cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06654440"},{"nctId":"NCT05942001","title":"Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-08-31","completionType":"ESTIMATED","lastUpdated":"2025-02-19","conditions":["Advanced Prostate Cancer"],"interventions":["HRS-5041"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer. The objective of this study was to determine the dose-limiting toxicity, maximum tolerance and recommended dose of HRS-5041 in phase II study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05942001"},{"nctId":"NCT04980885","title":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":68,"enrollmentType":"ACTUAL","startDate":"2021-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-03","conditions":["Acute Myeloid Leukemia"],"interventions":["AK117","Azacitidine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a open label, phase Ib/II study. All patients are diagnosed with AML, Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine in subjects with AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT04980885"},{"nctId":"NCT04440735","title":"A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors","sponsor":"Kahr Medical","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2020-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-09","completionType":"ESTIMATED","lastUpdated":"2025-01-09","conditions":["Advanced Solid Tumor","Non Small Cell Lung Cancer","Colorectal Cancer"],"interventions":["DSP107","Atezolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Part 1: A first-in-human, open-label, Phase I dose escalation study of DSP107 monotherapy and combination therapy with atezolizumab in patients with advanced solid tumors. Part 2: Preliminary efficacy assessment of DSP107 in combination with atezolizumab in second or third line treatment of non small cell lung cancer. Preliminary efficacy assessment of DSP107 as a single agent or in combination with atezolizumab in third line treatment of colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04440735"},{"nctId":"NCT04891757","title":"FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies","sponsor":"Foghorn Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2021-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-07-10","conditions":["Advanced Hematologic Malignancy","Relapsed Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia","Relapsed Myelodysplastic Syndromes","Refractory Myelodysplastic Syndromes","Relapsed Chronic Myelomonocytic Leukemia","Refractory Chronic Myelomonocytic Leukemia"],"interventions":["FHD-286","Low Dose Cytarabine","Decitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This Phase 1, multicenter, open-label, dose escalation study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 administered orally as monotherapy or combination therapy, in subjects with advanced hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04891757"},{"nctId":"NCT03851640","title":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","sponsor":"Hinova Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":417,"enrollmentType":"ESTIMATED","startDate":"2019-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-09","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["MCRPC"],"interventions":["HC-1119","placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical study evaluating the efficacy and safety of HC-1119 soft capsules versus placebo in mCRPC patients who have failed or become intolerant to the treatments with both abiraterone acetate and docetaxel, or who are not suitable for docetaxel treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT03851640"},{"nctId":"NCT05829629","title":"Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women","sponsor":"BlueSky Immunotherapies GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-11","completionType":"ESTIMATED","lastUpdated":"2025-02-14","conditions":["HPV Infection","HPV-Related Cervical Carcinoma"],"interventions":["FluBHPVE6E7","Placebo"],"countries":["Slovakia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).","sourceUrl":"https://clinicaltrials.gov/study/NCT05829629"},{"nctId":"NCT06036121","title":"A Study of ADRX-0706 in Select Advanced Solid Tumors","sponsor":"Adcentrx Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2023-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Solid Tumors","Triple Negative Breast Cancer (TNBC)","Urothelial Cancer","Cervical Cancer"],"interventions":["ADRX-0706"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["ADC biomarker"],"summary":"The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06036121"},{"nctId":"NCT05588648","title":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","sponsor":"MedPacto, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Osteosarcoma"],"interventions":["Vactosertib"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05588648"},{"nctId":"NCT04996121","title":"A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2021-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2022-08-30","conditions":["Locally Advanced or Metastatic Solid Tumors","Locally Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["XZP-5955 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion","sourceUrl":"https://clinicaltrials.gov/study/NCT04996121"},{"nctId":"NCT04050436","title":"Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","sponsor":"Replimune, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":231,"enrollmentType":"ACTUAL","startDate":"2019-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-09","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Cutaneous Squamous Cell Carcinoma","Advanced Cutaneous Squamous Cell Carcinoma","Metastatic Cutaneous Squamous Cell Carcinoma"],"interventions":["Cemiplimab","RP1"],"countries":["United States","Australia","Bulgaria","Canada","France","Germany","Greece","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.","sourceUrl":"https://clinicaltrials.gov/study/NCT04050436"},{"nctId":"NCT06026254","title":"A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial","sponsor":"ImmuneSensor Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":2,"enrollmentType":"ESTIMATED","startDate":"2023-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-09","completionType":"ESTIMATED","lastUpdated":"2024-11-18","conditions":["Solid Tumor, Adult"],"interventions":["IMSA101","Immune Checkpoint Inhibitor"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).","sourceUrl":"https://clinicaltrials.gov/study/NCT06026254"},{"nctId":"NCT06241755","title":"Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","sponsor":"Chengdu CoenBiotech Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":412,"enrollmentType":"ESTIMATED","startDate":"2023-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-03","completionType":"ESTIMATED","lastUpdated":"2024-02-05","conditions":["Non-Muscle Invasive Bladder Cancer"],"interventions":["BCG for Therapeutic Use"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A phase III multi-center randomized, double-blind and positive-controlled clinical trial for evaluating the efficacy and safety of BCG for Therapeutic Use（BCG） in the prevention of postoperative recurrence of medium/high-risk non-muscle invasive bladder cancer (NMIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06241755"},{"nctId":"NCT05759793","title":"A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2023-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2025-05-20","conditions":["Relapsed/Refractory Multiple Myeloma","Plasma Cell Leukemia"],"interventions":["CAR-GPRC5D"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a single-center, open-label, dose-escalation study to observe the safety and efficacy of different doses of CAR-GPRC5D in patients with R/R MM or Plasma Cell Leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT05759793"},{"nctId":"NCT06968221","title":"Bovine Reinforcement in Stomach, Colorectal and Lung Operation","sponsor":"Shanghai Cingularbio Co. Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":172,"enrollmentType":"ESTIMATED","startDate":"2025-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2025-05-15","conditions":["Rectal Cancer Stage III","Lung Cancer Stage III"],"interventions":["Bioabsorbable Staple Line Reinforcemen"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this prospective, randomized multicenter center study is to evaluate and compare the outcomes of stomach,colorectal and lung anastomoses reinforced with a bioabsorbable staple line reinforcement material compared with standard non-reinforced techniques with respect to the incidence of postoperative hemorrage rate, anastomotic leakage, if applicable.","sourceUrl":"https://clinicaltrials.gov/study/NCT06968221"},{"nctId":"NCT05132582","title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":654,"enrollmentType":"ACTUAL","startDate":"2022-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-05","primaryCompletionType":"ACTUAL","completionDate":"2027-09-28","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["HER2 Positive Breast Cancer"],"interventions":["Tucatinib","Trastuzumab","Pertuzumab","Combination product: Trastuzumab + Pertuzumab","Placebo"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Finland","France","Germany","Greece","Italy","Japan","Netherlands","Poland","Portugal","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":307,"serviceSignals":["HER2 profiling"],"summary":"This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned ra","sourceUrl":"https://clinicaltrials.gov/study/NCT05132582"},{"nctId":"NCT06206837","title":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":71,"enrollmentType":"ACTUAL","startDate":"2024-02-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-05","primaryCompletionType":"ACTUAL","completionDate":"2026-09-07","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Breast Cancer"],"interventions":["vepdegestrant","PF-07220060"],"countries":["United States","Belgium","Canada","China","France","Japan","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":58,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). * is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken before starting this study. All the participants will receive vepdegestrant and PF-0","sourceUrl":"https://clinicaltrials.gov/study/NCT06206837"},{"nctId":"NCT06331299","title":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","sponsor":"UroGen Pharma Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":99,"enrollmentType":"ACTUAL","startDate":"2024-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-11","primaryCompletionType":"ACTUAL","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Bladder Cancer","Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"interventions":["UGN-103"],"countries":["United States","Bulgaria","Estonia","Georgia","Latvia","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06331299"},{"nctId":"NCT06305910","title":"CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults","sponsor":"OX2 Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-03-15","startDateType":"ESTIMATED","primaryCompletionDate":"2025-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-15","completionType":"ESTIMATED","lastUpdated":"2024-03-12","conditions":["Diffuse Midline Glioma, H3 K27M-Mutant","Recurrent High Grade Glioma"],"interventions":["Treatment with CD200AR-L"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single center Phase I study of a new adjuvant CD200 activation receptor ligand, CD200AR-L, in combination with imiquimod and GBM6-AD vaccine to treat malignant glioma in children and young adults. The primary objective of this study is to determine the maximum tolerated dose (MTD) of CD200AR-L when given with a fixed dose of GBM6-AD vaccine, imiquimod, and a single dose of radiation for patients with recurrent High Grade Glioma (HGG) or following standard of care therapy radiation therapy for newly diagnosed Newly Diagnosed Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma (DIPG/DMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT06305910"},{"nctId":"NCT05083169","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":587,"enrollmentType":"ACTUAL","startDate":"2021-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-15","primaryCompletionType":"ACTUAL","completionDate":"2028-09-15","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Multiple Myeloma"],"interventions":["Daratumumab","Pomalidomide","Dexamethasone","Bortezomib","Teclistamab"],"countries":["United States","Argentina","Belgium","Brazil","Canada","China","Denmark","France","Germany","Greece","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":176,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).","sourceUrl":"https://clinicaltrials.gov/study/NCT05083169"},{"nctId":"NCT04996875","title":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","sponsor":"Cogent Biosciences, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2021-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-19","primaryCompletionType":"ACTUAL","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced Systemic Mastocytosis (AdvSM)","SM With an Associated Hematologic Neoplasm (SM-AHN)","Mast Cell Leukemia (MCL)","Aggressive Systemic Mastocytosis (ASM)"],"interventions":["bezuclastinib"],"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Italy","Netherlands","Norway","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT04996875"},{"nctId":"NCT04547166","title":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":568,"enrollmentType":"ESTIMATED","startDate":"2021-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-10-17","conditions":["Metastatic Colorectal Cancer"],"interventions":["HLX10","HLX04、"],"countries":["China","Japan"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a two-arm, randomized, double-blinded, multicenter phase III clinical study to evaluate the clinical efficacy of Serplulimab (HLX10) in Combination With Bevacizumab and Chemotherapy (XELOX) Versus Placebo in Combination With Bevacizumab and Chemotherapy (XELOX) in First-line Treatment of Patients With Metastatic Colorectal Cancer (mCRC)","sourceUrl":"https://clinicaltrials.gov/study/NCT04547166"},{"nctId":"NCT05430373","title":"GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors","sponsor":"Grit Biotechnology","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2022-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-25","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Solid Tumors, Adult"],"interventions":["GT101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an \"autologous tumor-infiltrating lymphocyte therapy\" regimen that includes： 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).","sourceUrl":"https://clinicaltrials.gov/study/NCT05430373"},{"nctId":"NCT03145181","title":"Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":302,"enrollmentType":"ACTUAL","startDate":"2017-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-25","primaryCompletionType":"ACTUAL","completionDate":"2027-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Hematological Malignancies"],"interventions":["Teclistamab (IV)","Teclistamab(SC)"],"countries":["United States","France","Netherlands","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.","sourceUrl":"https://clinicaltrials.gov/study/NCT03145181"},{"nctId":"NCT04522323","title":"A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma","sponsor":"MedImmune LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":67,"enrollmentType":"ACTUAL","startDate":"2020-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-26","primaryCompletionType":"ESTIMATED","completionDate":"2025-09-26","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["Advanced Renal Cell Carcinoma"],"interventions":["MEDI5752","Axitinib","Lenvatinib"],"countries":["United States","Australia","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate MEDI5752 in combination with Lenvatinib (or Axitinib), in subjects with advanced renal cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04522323"},{"nctId":"NCT06359002","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.","sponsor":"Byondis B.V.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2024-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ACTUAL","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Relapsed / Refractory AML","Relapsed / Refractory MDS"],"interventions":["BYON4413"],"countries":["Belgium","Netherlands","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is the first-in-human trial with BYON4413 to evaluate safety, PK, immunogenicity, and anti-leukemia activity of BYON4413 in patients with AML or MDS.","sourceUrl":"https://clinicaltrials.gov/study/NCT06359002"},{"nctId":"NCT05674526","title":"A Phase 1b Study of WU-NK-101 in Combination With Cetuximab","sponsor":"Allotera Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-01","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Colorectal Cancer Metastatic","Squamous Cell Carcinoma of Head and Neck"],"interventions":["WU-NK-101 - Dose Escalation","Cetuximab - Dose Escalation","WU-NK-101 - Cohort Expansion","Cetuximab - Cohort Expansion"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase 1b open-label study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or metastatic SCCHN (Cohort 2). The overall study will be comprised of two phases, a Dose Escalation Phase, and a Cohort Expansion Phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT05674526"},{"nctId":"NCT05208047","title":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","sponsor":"Cogent Biosciences, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":482,"enrollmentType":"ESTIMATED","startDate":"2022-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ACTUAL","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Advanced Gastrointestinal Stromal Tumors","Metastatic Cancer"],"interventions":["CGT9486","Sunitinib","Midazolam"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Czechia","Denmark","France","Germany","Hong Kong","Hungary","Italy","Mexico","Netherlands","Norway","Poland","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":126,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for Gastrointestinal Stromal Tumors (GIST) and 2) evaluating the potential for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients who have received at least two prior tyrosine kinase inhibitors (TKIs) for GISTs. The second part of the study will enroll approximately 388 patients wh","sourceUrl":"https://clinicaltrials.gov/study/NCT05208047"},{"nctId":"NCT06260774","title":"Study of TTX-MC138 in Subjects With Advanced Solid Tumors","sponsor":"TransCode Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2024-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ACTUAL","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Advanced Solid Tumor"],"interventions":["TTX-MC138"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06260774"},{"nctId":"NCT06992687","title":"A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-11-30","completionType":"ESTIMATED","lastUpdated":"2025-05-28","conditions":["Solid Tumors"],"interventions":["HB0052 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and tolerability of HB0052 in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06992687"},{"nctId":"NCT05167071","title":"HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study","sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":53,"enrollmentType":"ACTUAL","startDate":"2021-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-04-27","conditions":["Solid Tumors","Neuroendocrine Tumors","CRC"],"interventions":["HBM4003","Toripalimab","Tislelizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients with advanced NEN and other solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05167071"},{"nctId":"NCT05309421","title":"A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma","sponsor":"Evaxion Biotech A/S","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2022-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-30","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Melanoma Stage IV","Unresectable Melanoma"],"interventions":["EVX-01","Pembrolizumab 25 MG/ML"],"countries":["Australia","Italy"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT05309421"},{"nctId":"NCT05205850","title":"A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2022-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-01","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Advanced Solid Tumor"],"interventions":["RC118-ADC"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。","sourceUrl":"https://clinicaltrials.gov/study/NCT05205850"},{"nctId":"NCT04093466","title":"A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2020-04-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-10-17","conditions":["Advanced Solid Tumor"],"interventions":["CX1003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET). This study aimed to evaluate the safety, pharmacokinetics, and antitumor activity of CX1003 in patients with refractory advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04093466"},{"nctId":"NCT06663839","title":"A Study of NILK-2301 in Patients with Locally Advanced or Metastatic Low Tumor Volume (LTV) Colorectal Cancer","sponsor":"Light Chain Bioscience - Novimmune SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2024-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-01","completionType":"ESTIMATED","lastUpdated":"2024-10-29","conditions":["Colorectal Cancer Metastatic"],"interventions":["Biological NILK-2301"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Study LCB-2301-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NILK-2301 in patients with locally advanced or metastatic low tumor volume (LTV) colorectal cancer. The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of NILK-2301 to determine the maximum tolerated dose (MTD) and non-tolerated toxic dose (NTD) of NILK-2301 monotherapy. The expansion part (Part B) will further evaluate the safety and efficacy of NILK-2301 monotherapy administered at or below the MTD in up to 10 additional subjects in order to determine the recommended Phase 2 dose (RP2D). Treatments will be a","sourceUrl":"https://clinicaltrials.gov/study/NCT06663839"},{"nctId":"NCT06069570","title":"Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases","sponsor":"Kiromic BioPharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-03-05","conditions":["Carcinoma, Non-Small-Cell Lung Cancer","Bone Metastases From Solid Tumors"],"interventions":["KB-GDT-01"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06069570"},{"nctId":"NCT06315491","title":"A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer","sponsor":"Cybrexa Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2025-10","completionType":"ESTIMATED","lastUpdated":"2025-10-06","conditions":["Platinum-resistant Ovarian Cancer","Refractory Ovarian Carcinoma"],"interventions":["CBX-12"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.","sourceUrl":"https://clinicaltrials.gov/study/NCT06315491"},{"nctId":"NCT06096974","title":"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2025-04-09","conditions":["Advanced Solid Tumors"],"interventions":["YL-17231"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["RAS genotyping"],"summary":"This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or NRAS.","sourceUrl":"https://clinicaltrials.gov/study/NCT06096974"},{"nctId":"NCT05866692","title":"A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"TYK Medicines, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2023-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2023-11-07","conditions":["Solid Tumor, Adult"],"interventions":["TY-2699a"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, multicenter, open-label study. The study will investigate the safety, tolerability, PK, and preliminary efficacy of TY-2699a on locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05866692"},{"nctId":"NCT05754853","title":"A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer","sponsor":"Shanghai Miracogen Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2023-04-06","startDateType":"ESTIMATED","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2023-04-13","conditions":["Advanced or Metastatic Urothelium Cancer"],"interventions":["MRG002","Docetaxel Injection","Paclitaxel Injection","Gemcitabine Hydrochloride for Injection","Pemetrexed Disodium Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05754853"},{"nctId":"NCT06589401","title":"Oral Paclitaxel for Patients with Advanced Solid Tumors","sponsor":"InnoUp Farma S.L.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Solid Tumor"],"interventions":["INP12"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase I trial evaluating the safety, tolerability, and pharmacokinetic profile of INP12, a nanoparticles-based oral paclitaxel, in patients with advanced solid tumors The aim in Part A (Escalation phase) is to determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (in the absence of exceeding the MTD)and the recommended phase II dose (RP2D) of INP12 administered orally once a week during three consecutive weeks under a 28-day cycle in patients with advanced solid tumors. The aim in Part B (Expansion phase) is to assess the safety and tolerability of INP12 as monotherapy at the RP2D or highest protocol-defined dose in patients with selected advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06589401"},{"nctId":"NCT07011186","title":"A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2024-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-06-08","conditions":["Myeloid Malignancy"],"interventions":["TQB3909 Tablets + Azacitidine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07011186"},{"nctId":"NCT06854445","title":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2025-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2025-03-24","conditions":["Diffuse Large Cell B-lymphoma"],"interventions":["TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06854445"},{"nctId":"NCT03891706","title":"Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2019-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Solid Tumor"],"interventions":["tumor-specific TCR-T cells","Interleukin-2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor . The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .","sourceUrl":"https://clinicaltrials.gov/study/NCT03891706"},{"nctId":"NCT05223816","title":"An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma","sponsor":"Virogin Biotech Canada Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":97,"enrollmentType":"ESTIMATED","startDate":"2024-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-09","conditions":["Hepatocellular Carcinoma","Intrahepatic Cholangiocarcinoma"],"interventions":["VG161","Nivolumab Injection [Opdivo]"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Safety Run-in Cohort (cohort 1): 10 patients will be treated with IT injection of VG161 in the cohort 1 at dose level of 1.0x10E8 PFU x 3 days. Monotherapy Cohorts (Cohort 2 and 3) Cohort 2 (HCC) This part is a single-agent, single one-dose level and single-arm design. Approximately 39 subjects will be enrolled in the study to receive VG161. In the first stage, 21 subjects will be enrolled. If there is only 1 or fewer subjects has been observed with objective response and no more than 12 (\\<13) subjects have PFS longer than 3 months, the trial will be stopped. Otherwise, this study will continue to enter the second stage, and 18 additional subjects will be added, and the total number of tria","sourceUrl":"https://clinicaltrials.gov/study/NCT05223816"},{"nctId":"NCT06075810","title":"A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer","sponsor":"MBQ Pharma","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2024-12-12","conditions":["Breast Cancer","Breast Neoplasm","Breast Cancer Stage IV"],"interventions":["MBQ-167"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.","sourceUrl":"https://clinicaltrials.gov/study/NCT06075810"},{"nctId":"NCT05771480","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":142,"enrollmentType":"ACTUAL","startDate":"2023-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-02","primaryCompletionType":"ACTUAL","completionDate":"2026-09-17","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Biliary Tract Cancer"],"interventions":["Durvalumab","Gemcitabine monotherapy","Gemcitabine + cisplatin","Gemcitabine + oxaliplatin","Gemcitabine + carboplatin","Gemcitabine + cisplatin + S-1","Gemcitabine + S-1","Gemcitabine + cisplatin + albumin-bound paclitaxel"],"countries":["United States","France","Germany","Italy","Japan","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05771480"},{"nctId":"NCT04722146","title":"A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ACTUAL","startDate":"2021-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-03","primaryCompletionType":"ACTUAL","completionDate":"2027-10-13","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["Teclistamab","Daratumumab","Pomalidomide","Lenalidomide","Bortezomib","Nirogacestat"],"countries":["United States","Australia","Belgium","France","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT04722146"},{"nctId":"NCT05450692","title":"A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":594,"enrollmentType":"ACTUAL","startDate":"2022-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-06","primaryCompletionType":"ACTUAL","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Advanced or Metastatic Non-Small Cell Lung Cancer"],"interventions":["Ceralasertib","Durvalumab","Docetaxel"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Hong Kong","Hungary","India","Ireland","Italy","Japan","Netherlands","Poland","Romania","Serbia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":191,"serviceSignals":["Broad CGP"],"summary":"This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05450692"},{"nctId":"NCT05700084","title":"Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2023-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-08","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor"],"interventions":["Utidelone Capsule (Part 1)","Drug A Utidelone Capsule (Part 2: Group A-B)","Drug A Utidelone Capsule (Part 2: Group B-A)","Drug B Utidelone Injection (Part 2: Group A-B)","Drug B Utidelone Injection (Part 2: Group B-A)","Capecitabine","Utidelone Capsule (Part 3)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This study has three parts. Part 1 is a dose-escalation trial, Part 2 is a pharmacokinetic comparison and food effect study, and Part 3 is extended trial of combination of utidelone capsule and capecitabine. The primary objectives are 1. To evaluate the safety and tolerability of utidelone capsules in patients with advanced solid tumors and to determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT). 2. To evaluate the objective response rate in patients with advanced metastatic breast cancer treated with the combination of utidelone capsule and capecitabine. The secondary objectives are: 1. to evaluate the absolute bioavailability of utidelone capsules relative to utidelo","sourceUrl":"https://clinicaltrials.gov/study/NCT05700084"},{"nctId":"NCT06256328","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":226,"enrollmentType":"ACTUAL","startDate":"2024-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-09","primaryCompletionType":"ACTUAL","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Gastric Cancer"],"interventions":["ONO-4578","Oxaliplatin","Capecitabine","S-1","Nivolumab","Placebo"],"countries":["Japan","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":63,"serviceSignals":["HER2 profiling"],"summary":"This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naïve participants with HER2- negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).","sourceUrl":"https://clinicaltrials.gov/study/NCT06256328"},{"nctId":"NCT04628494","title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":483,"enrollmentType":"ACTUAL","startDate":"2021-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-13","primaryCompletionType":"ACTUAL","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["Epcoritamab","Investigator's Choice Chemotherapy"],"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Norway","Poland","Russia","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":186,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \\[R-GemOx\\], or bendamustine + rituximab \\[BR\\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT). Epcoritamab will be injected under the skin","sourceUrl":"https://clinicaltrials.gov/study/NCT04628494"},{"nctId":"NCT07226752","title":"A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2022-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-13","primaryCompletionType":"ACTUAL","completionDate":"2028-06-14","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["Epcoritamab","Investigator's Choice Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this Chinese sub-study trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come back following treatment with at least 1 prior systemic cancer therapy. All participants in this trial will be randomly assigned to receive either epcoritamab or a pre-specified investigator's choice (standard of care) chemotherapy (either rituximab + gemcitabine + oxaliplatin \\[R-GemOx\\], or bendamustine + rituximab \\[BR\\]). Participants must have failed or be ineligible to receive an autologous stem cell transplant (ASCT). Epcoritamab will be injec","sourceUrl":"https://clinicaltrials.gov/study/NCT07226752"},{"nctId":"NCT04036682","title":"A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer","sponsor":"Cullinan Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":284,"enrollmentType":"ESTIMATED","startDate":"2019-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-13","primaryCompletionType":"ACTUAL","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Non Small Cell Lung Cancer","EGFR Exon 20 Mutation"],"interventions":["CLN-081"],"countries":["United States","Hong Kong","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["Broad CGP"],"summary":"CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04036682"},{"nctId":"NCT05572515","title":"A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":614,"enrollmentType":"ACTUAL","startDate":"2023-03-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-13","primaryCompletionType":"ACTUAL","completionDate":"2031-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["Teclistamab","Pomalidomide","Bortezomib","Dexamethasone","Carfilzomib"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","India","Israel","Italy","Japan","Malaysia","Netherlands","Poland","Portugal","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":211,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05572515"},{"nctId":"NCT04390399","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":328,"enrollmentType":"ESTIMATED","startDate":"2020-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-13","primaryCompletionType":"ACTUAL","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-12-15","conditions":["Pancreatic Cancer"],"interventions":["N-803","Aldoxorubicin HCl","PD-L1 t-haNK","Nab-paclitaxel","Gemcitabine","Cyclophosphamide","5-Fluorouracil","Leucovorin","SBRT","Irinotecan liposome"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a phase 2, three-cohort (2 randomized and 1 single-arm), open-label study to evaluate the comparative efficacy and overall safety of standard-of-care chemotherapy versus standard-of-care chemotherapy in combination with aldoxorubicin HCl, N-803, and PD-L1 t-haNK in subjects with locally advanced or metastatic pancreatic cancer. Each treatment setting (ie, first line maintenance, second line, or third line or greater) will be evaluated independently as a separate cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT04390399"},{"nctId":"NCT05239650","title":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2022-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2025-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-15","completionType":"ESTIMATED","lastUpdated":"2022-05-03","conditions":["CRC"],"interventions":["HLX07","HLX10","mFOLFOX6"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) + HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) + mFOLFOX6 or HLX07 Monotherapy in Patients with Metastatic Colorectal Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05239650"},{"nctId":"NCT05032040","title":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","sponsor":"Xencor, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2022-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-02-07","conditions":["Ovarian Cancer","Clear Cell Carcinoma","Endometrial Cancer","Cervical Carcinoma","Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"interventions":["vudalimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05032040"},{"nctId":"NCT07386938","title":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","sponsor":"R-Pharm","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":246,"enrollmentType":"ESTIMATED","startDate":"2024-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-15","primaryCompletionType":"ACTUAL","completionDate":"2027-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Locally Advanced Breast Cancer","Metastatic Breast Cancer"],"interventions":["RPH-051","Docetaxel","Perjeta®","Trastuzumab"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":45,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta® in combination with trastuzumab and docetaxel as the 1st line therapy for patients with HER2-positive breast cancer (BC). Secondary Purposes are to evaluate the pharmacokinetics of RPH-051 in comparison with Perjeta® after a single-dose and repeated intravenous administration","sourceUrl":"https://clinicaltrials.gov/study/NCT07386938"},{"nctId":"NCT06059547","title":"Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer","sponsor":"CatalYm GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2023-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-16","primaryCompletionType":"ACTUAL","completionDate":"2026-10-16","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Bladder Cancer","Adult Solid Tumor"],"interventions":["Nivolumab","Visugromab (CTL-002)","Placebo"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, stratified and single-blinded Phase 2 trial of neoadjuvant immunotherapy in combination with the anti-GDF15 antibody visugromab (CTL-002) for the treatment of participants with MIBC set to undergo radical Cystectomy (RC)/Re-TURBT who cannot receive or refuse to receive cisplatin-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06059547"},{"nctId":"NCT06491446","title":"Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts","sponsor":"Antiva Biosciences","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":141,"enrollmentType":"ACTUAL","startDate":"2024-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-16","primaryCompletionType":"ACTUAL","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Human Papillomavirus Infection"],"interventions":["ABI-2280"],"countries":["Australia","Kenya","Mexico","New Zealand"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a blinded study to assess safety, tolerability, and efficacy of ABI-2280 vaginal inserts in participants diagnosed with persistent cervical hrHPV infection. This study will have up to 11 cohorts with various dose strengths and regimens. Each cohort will start with a sentinel cohort of 8 participants. Sentinel cohorts may be expanded to include an additional up to 32 participants to provide additional proof of concept data to further understanding of benefit/risk of a given dose/dose regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT06491446"},{"nctId":"NCT06304974","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":497,"enrollmentType":"ACTUAL","startDate":"2024-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-17","primaryCompletionType":"ACTUAL","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["BL-B01D1","Irinotecan","paclitaxel","docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a registered phase Ill, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic esophageal squamous cell carcinoma after failure of PD-1/PD-L1 monoclonal antibody in combination with platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06304974"},{"nctId":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","sponsor":"Salubris Biotherapeutics Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":263,"enrollmentType":"ESTIMATED","startDate":"2022-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-17","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-20","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Cancer","Tumor, Solid","Advanced Solid Tumor","Metastatic Cancer","Melanoma","Colorectal Cancer","Non-small Cell Lung Cancer","Small-cell Lung Cancer","Urothelial Carcinoma","Squamous Cell Carcinoma of Head and Neck","Luminal Breast Cancer","Triple Negative Breast Cancer","Clear Cell Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Gastric Adenocarcinoma","GastroEsophageal Cancer","Squamous Cell Carcinoma Skin","Pancreatic Adenocarcinoma","Hepatocellular Carcinoma","Colorectal Adenocarcinoma","Epithelial Ovarian Cancer","Thyroid Cancer"],"interventions":["JK08","Pembrolizumab","Lenvatinib Pill"],"countries":["Belgium","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["RNA fusion"],"summary":"This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced or metastatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05620134"},{"nctId":"NCT05144854","title":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":626,"enrollmentType":"ACTUAL","startDate":"2021-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-20","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Gastric Cancer"],"interventions":["ONO-4538","Ipilimumab","Oxaliplatin","Capecitabine","S-1"],"countries":["Japan","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":57,"serviceSignals":["HER2 profiling"],"summary":"This study is to compare and evaluate the efficacy and safety of ONO-4538 in combination with ipilimumab and chemotherapy versus chemotherapy in chemotherapy-naïve participants with HER2-negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).","sourceUrl":"https://clinicaltrials.gov/study/NCT05144854"},{"nctId":"NCT05120271","title":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","sponsor":"Sotio Biotech Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":7,"enrollmentType":"ACTUAL","startDate":"2022-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-24","primaryCompletionType":"ACTUAL","completionDate":"2042-12","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Hepatocellular Carcinoma","Squamous Cell Carcinoma of the Lung","Merkel Cell Carcinoma","Myxoid/Round Cell Liposarcoma"],"interventions":["CAR-GPC3 T Cells"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), Phase 1/2, open-label, multicenter study to assess safety and determine the recommended Phase 2 dose (RP2D) of BOXR1030 administration after lymphodepleting chemotherapy (LD chemotherapy) in subjects with glypican-3 positive (GPC3+) advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05120271"},{"nctId":"NCT06371157","title":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":469,"enrollmentType":"ESTIMATED","startDate":"2024-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-23","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Hepatocellular Carcinoma"],"interventions":["AK104","Lenvatinib","TACE","Placebo for AK104","Placebo for Lenvatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06371157"},{"nctId":"NCT04700124","title":"Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":808,"enrollmentType":"ACTUAL","startDate":"2021-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-27","primaryCompletionType":"ACTUAL","completionDate":"2028-05-18","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Bladder Cancer"],"interventions":["Pembrolizumab","Enfortumab vedotin (EV)","RC + PLND","Gemcitabine","Cisplatin"],"countries":["United States","Argentina","Australia","Bulgaria","Canada","China","Colombia","Croatia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Malaysia","Philippines","Poland","Portugal","Romania","Russia","Singapore","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":188,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy \\[gemcitabine plus cisplatin\\] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The primary hypothesis is perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and RC + PLND (Arm B).","sourceUrl":"https://clinicaltrials.gov/study/NCT04700124"},{"nctId":"NCT04938583","title":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","sponsor":"CanariaBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2021-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-30","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Ovarian Cancer by FIGO Stage","Ovarian Cancer Stage III","Ovarian Cancer Stage IV"],"interventions":["Oregovomab","Bevacizumab","Paclitaxel","Carboplatin"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, previously treated with 1 prior lines of therapy, and with platinum free intervals of \\>6 months since last platinum-based treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04938583"},{"nctId":"NCT05331105","title":"HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","sponsor":"Shanghai Kechow Pharma, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2021-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2023-05-31","conditions":["Neurofibromatosis 1","Plexiform Neurofibromas"],"interventions":["HL-085"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)","sourceUrl":"https://clinicaltrials.gov/study/NCT05331105"},{"nctId":"NCT05260385","title":"To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":133,"enrollmentType":"ESTIMATED","startDate":"2022-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2024-10-17","conditions":["Digestive System Tumors"],"interventions":["KC1036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05260385"},{"nctId":"NCT04652076","title":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","sponsor":"NETRIS Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2020-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2024-10-08","conditions":["Endometrial Carcinoma","Cervix Carcinoma"],"interventions":["NP137","Pembrolizumab","Paclitaxel","Carboplatin"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial carcinoma and cervix carcinoma).","sourceUrl":"https://clinicaltrials.gov/study/NCT04652076"},{"nctId":"NCT05690581","title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2023-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Advanced Solid Tumors and Hematologic Malignancies"],"interventions":["CM369"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05690581"},{"nctId":"NCT06756269","title":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2025-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-30","primaryCompletionType":"ACTUAL","completionDate":"2026-01-13","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["HPV Infection","HPV-Related Carcinoma","HPV-Related Intraepithelial Neoplasia","Genital Wart"],"interventions":["Medium dose for 15-HPV vaccine","High dose for 15-HPV vaccine","Placebo","9-HPV vaccine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06756269"},{"nctId":"NCT05413018","title":"An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2022-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ACTUAL","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Leukemia, Myeloid, Acute"],"interventions":["CC-486","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Oral Azacitidine (CC-486) in Chinese participants with acute myeloid leukemia in complete remission.","sourceUrl":"https://clinicaltrials.gov/study/NCT05413018"},{"nctId":"NCT06005740","title":"A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2025-03-04","conditions":["Advanced Solid Tumor","Hepatocellular Carcinoma"],"interventions":["TORL-4-500"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["ADC biomarker"],"summary":"This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06005740"},{"nctId":"NCT05911464","title":"A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":248,"enrollmentType":"ESTIMATED","startDate":"2023-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2023-06-22","conditions":["Advanced Solid Tumor"],"interventions":["HS-10386"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT05911464"},{"nctId":"NCT06632574","title":"A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2014-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2024-10-09","conditions":["Advanced Solid Tumor"],"interventions":["paclitaxel cationic liposomes"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose-escalation and expansion, cohort expansion, multicenter Phase I clinical study in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06632574"},{"nctId":"NCT06758557","title":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","sponsor":"Huabo Biopharm Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":282,"enrollmentType":"ESTIMATED","startDate":"2024-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2025-01-23","conditions":["Advanced NSCLC","Advanced Endometrial Cancer"],"interventions":["HB0025","Pemetrexed","Paclitaxel","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, two-tumor, multi-cohort, dose-escalation and dose-expansion Phase Ib/II clinical trial of HB0025 combined with chemotherapy, consists of two phases: the dose escalation phase (Ib) and the dose expansion phase (II). 1. The dose escalation phase (Phase Ⅰb) The primary purpose is to determine the Maximum Tolerated Dose(MTD) and/or dose limiting toxicity (DLT) of HB0025 combined with chemotherapy. The dose escalation is carried out using the \"3+3 dose escalation\" principle. In the initial stage of the dose escalation process, the chemotherapy dose remains unchanged to explore the safety and tolerability of the currently confirmed safe doses of HB0025 as monotherapy a","sourceUrl":"https://clinicaltrials.gov/study/NCT06758557"},{"nctId":"NCT06649708","title":"HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies","sponsor":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2025-01-14","conditions":["Advanced Solid Tumor Malignancies"],"interventions":["HX044"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The study will consist of a dose-escalation and dose-expansion component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and to evaluate the preliminary antitumor activity of HX044. HX044 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes. This is the first study in which HX044 will be given to humans. The study drug has been tested in animals and was found to be well-tolerated with minimal side effects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06649708"},{"nctId":"NCT06926413","title":"A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Non Small Cell Lung Cancer"],"interventions":["Aumolertinib；midazolam"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, fixed-sequence Phase I clinical study that evaluates the effect of multiple doses of aumolertinib on the pharmacokinetics of midazolam (CYP 3A4 probe substrate) in sensitive EGFR (Epidermal Growth Factor Receptor) mutation-harboring patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06926413"},{"nctId":"NCT05632939","title":"ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.","sponsor":"AskGene Pharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":62,"enrollmentType":"ACTUAL","startDate":"2023-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-10","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Gastric Cancer","Gastroesophageal Cancer (GC)"],"interventions":["ASKB589 +CAPOX+Sintilimab/Tislelizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05632939"},{"nctId":"NCT05424822","title":"A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":167,"enrollmentType":"ACTUAL","startDate":"2022-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ACTUAL","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Lymphoma, Non-Hodgkin","Leukemia, Lymphocytic, Chronic, B-Cell"],"interventions":["JNJ-80948543"],"countries":["United States","Australia","China","Denmark","France","Israel","Japan","Poland"],"northAmerica":true,"chinaSites":true,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\\[s\\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05424822"},{"nctId":"NCT06909877","title":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","sponsor":"Haihe Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ACTUAL","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)"],"interventions":["HH2853 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a an open-label, multinational, multicenter, single-arm Phase Ⅰb/Ⅱ Study to Evaluate Efficacy and Safety of Oral HH2853 in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06909877"},{"nctId":"NCT05477849","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors","sponsor":"Shanghai Virogin Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2022-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-01","conditions":["Advanced Malignant Solid Tumor"],"interventions":["Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT05477849"},{"nctId":"NCT04387916","title":"A Study of KC1036 in Patients with Advanced Solid Tumors","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":207,"enrollmentType":"ESTIMATED","startDate":"2020-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-10-17","conditions":["Advanced Solid Tumors"],"interventions":["KC1036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into three parts: dose-escalation phase, dose-expansion phase, RP2D-extension phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT04387916"},{"nctId":"NCT05607498","title":"First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma","sponsor":"EpimAb Biotherapeutics (Suzhou)Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2023-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2025-03-03","conditions":["Advanced/Metastatic Solid Tumors","Relapse/Refractory Lymphoma"],"interventions":["EMB07"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"For solid tumors and lymphoma, respectively: This study is to evaluate the safety and tolerability of EMB-07 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-07 will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT05607498"},{"nctId":"NCT06084806","title":"Test-retest Evaluation of [18F]F-AraG PET","sponsor":"CellSight Technologies, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2023-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-10-31","completionType":"ESTIMATED","lastUpdated":"2024-10-24","conditions":["Non-small Cell Lung Cancer"],"interventions":["[18F]F-ARAG PET"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This pilot study aims to evaluate the test-retest variability of \\[18F\\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \\[18F\\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \\[18F\\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06084806"},{"nctId":"NCT04632108","title":"A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":199,"enrollmentType":"ACTUAL","startDate":"2021-01-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Malignant Solid Tumor"],"interventions":["ASKB589 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.","sourceUrl":"https://clinicaltrials.gov/study/NCT04632108"},{"nctId":"NCT06662760","title":"Clinical Trial of TQB3002 in Patients With Advanced Cancers","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Advanced Cancer"],"interventions":["TQB3002 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB3002 in subjects with advanced cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT06662760"},{"nctId":"NCT05868876","title":"A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":205,"enrollmentType":"ESTIMATED","startDate":"2023-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2025-03-03","conditions":["Advanced Malignant Tumors"],"interventions":["AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase Ia/Ib open label，clinical study evaluating the safety, tolerability and preliminary efficacy of AK127 in combination with AK104 in patients with advanced malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05868876"},{"nctId":"NCT05427383","title":"KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":286,"enrollmentType":"ESTIMATED","startDate":"2022-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2023-12-19","conditions":["Stomach Cancer"],"interventions":["KN026/Placbo Injection","Paclitaxel Injection","Docetaxel Injection","Irinotecan Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05427383"},{"nctId":"NCT06449027","title":"Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":211,"enrollmentType":"ACTUAL","startDate":"2024-08-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Breast Cancer Subjects"],"interventions":["T Leuprolide Injectable Emulsion","Leuprorelin Acetate Microspheres for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is to assess the safety, efficacy and pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06449027"},{"nctId":"NCT05302037","title":"Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)","sponsor":"CytoMed Therapeutics Pte Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-11-22","conditions":["Cancer","Malignancy","Refractory Cancer","Relapsed Cancer"],"interventions":["Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)"],"countries":["Singapore"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"CAR-T is a pioneering cancer treatment which has found success in some cancers. This treatment is made first by taking blood cells from the patient. Then in the lab, an artificial protein - a Chimeric Antigen Receptor (CAR), is grafted on the surface of immune cells. The modified cells, which are readministered to the patient, have enhanced abilities to target and destroy cancers than unmodified immune cells. Currently approved CAR-T can only be used autologously. i.e. the patient will receive CAR-T treatment made from their own cells. This is because current CAR-T treatment uses αβ T cells - a type of immune cell which are largely non-transferable between individual human beings due to the ","sourceUrl":"https://clinicaltrials.gov/study/NCT05302037"},{"nctId":"NCT05806099","title":"A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL","sponsor":"Beijing Mabworks Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2023-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["Non-Hodgkin's Lymphoma"],"interventions":["MBS303"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel T-Cell bispecific (TCB), MBS303, administered by intravenous (IV) infusion in participants with relapsed or refractory B-cell NHL. This entry-to-human study consists of 2 parts: a dose escalation part (Phase I) and an expansion part (Phase Ⅱ)","sourceUrl":"https://clinicaltrials.gov/study/NCT05806099"},{"nctId":"NCT04521413","title":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","sponsor":"Treadwell Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2020-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-05-21","conditions":["Advanced Solid Malignancies"],"interventions":["CFI-402411","Pembrolizumab"],"countries":["United States","Canada","Hong Kong"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04521413"},{"nctId":"NCT06298916","title":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","sponsor":"Lantheus Medical Imaging","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":26,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2025-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Metastatic Sarcoma","Esophageal Cancer","Gastric Cancer","Pancreatic Cancer","Colorectal Cancer","Sarcoma"],"interventions":["64Cu-LNTH-1363S"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT06298916"},{"nctId":"NCT05256290","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","sponsor":"Black Diamond Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2022-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-03","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Non-Small Cell Lung Cancer","Advanced Non-Small Cell Squamous Lung Cancer","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Cancer","NSCLC","Advanced Lung Carcinoma","Epidermal Growth Factor Receptor C797S","Epidermal Growth Factor Receptor G719X","EGF-R Positive Non-Small Cell Lung Cancer","EGFR-TKI Resistant Mutation"],"interventions":["silevertinib (BDTX-1535) monotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment ","sourceUrl":"https://clinicaltrials.gov/study/NCT05256290"},{"nctId":"NCT05878184","title":"Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)","sponsor":"Sana Biotechnology","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2023-05-02","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-04","primaryCompletionType":"ESTIMATED","completionDate":"2038-11-04","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Non Hodgkin Lymphoma","Chronic Lymphocytic Leukemia"],"interventions":["SC291"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05878184"},{"nctId":"NCT06117566","title":"A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-09","primaryCompletionType":"ESTIMATED","completionDate":"2025-11-09","completionType":"ESTIMATED","lastUpdated":"2024-11-25","conditions":["Solid Tumor"],"interventions":["WX390","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.","sourceUrl":"https://clinicaltrials.gov/study/NCT06117566"},{"nctId":"NCT06167486","title":"SG2918 For Advanced Malignant Tumors","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2023-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-11","primaryCompletionType":"ACTUAL","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Advanced Malignant Tumors"],"interventions":["SG2918"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG2918 in subjects with Advanced Malignant Tumors who are refractory or resistant to standard therapy, or without available standard or curative therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06167486"},{"nctId":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","sponsor":"GI Innovation, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":358,"enrollmentType":"ESTIMATED","startDate":"2023-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-24","completionType":"ESTIMATED","lastUpdated":"2024-11-25","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Soft Tissue Sarcoma (STS)","Platinum-resistant Ovarian Cancer (PROC)","Hepatocellular Carcinoma (HCC)","Colorectal Cancer (CRC)","HER2 Negative Breast Cancer","Cutaneous Melanoma","Renal Cell Carcinoma (RCC)"],"interventions":["GI-102 subcutaneous (SC)","GI-102","doxorubicin","paclitaxel","bevacizumab","eribulin","trastuzumab deruxtecan (T-DXd)","pembrolizumab"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RNA fusion","HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05824975"},{"nctId":"NCT05794659","title":"Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer","sponsor":"Aston Sci. Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2023-11-15","startDateType":"ESTIMATED","primaryCompletionDate":"2025-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2023-07-20","conditions":["Advanced Ovarian Cancer"],"interventions":["AST-201","Paclitaxel","Carboplatin","Placebo","rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).","sourceUrl":"https://clinicaltrials.gov/study/NCT05794659"},{"nctId":"NCT06687681","title":"Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas","sponsor":"Marzieh Ebrahimi","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-25","completionType":"ESTIMATED","lastUpdated":"2025-04-09","conditions":["Glioma Glioblastoma Multiforme","High Grade Glioma (III or IV)"],"interventions":["NK cell therapy"],"countries":["Iran"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults. Surgical removal and tumor resection are the primary treatment approaches for gliomas. In such cases, whole-brain radiation therapy is also employed as a therapeutic option, which itself has significant side effects, and studies have shown limited impact on improving patient survival. Targeted therapy and recently investigated approaches such as targeted therapy have shown some tumor regression, but in most cases, tumor recurrence has been observed after initial regression. Therefore, they have","sourceUrl":"https://clinicaltrials.gov/study/NCT06687681"},{"nctId":"NCT06271837","title":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":127,"enrollmentType":"ACTUAL","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-28","primaryCompletionType":"ACTUAL","completionDate":"2027-02-10","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)"],"interventions":["Trastuzumab deruxtecan","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":29,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06271837"},{"nctId":"NCT05104515","title":"First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine","sponsor":"Oxford Vacmedix UK Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2021-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-01-31","completionType":"ESTIMATED","lastUpdated":"2025-02-14","conditions":["Prostate Cancer","Non Small Cell Lung Cancer","Ovarian Cancer"],"interventions":["OVM-200"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find out if OVM-200 is safe to continue studying it in patients with cancer. The Study consists of 2 parts: a dose escalation part and a dose expansion part. In the dose escalation part, up to 4 increasing doses of OVM-200 will be evaluated in small groups of cancer patients to find the recommended dose for the expansion part. The recommended dose of OVM-200 will then be given to cancer patients in the dose expansion part to confirm safety and understand how effective it is against their disease and if there are any side","sourceUrl":"https://clinicaltrials.gov/study/NCT05104515"},{"nctId":"NCT06689163","title":"A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2024-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Prostate Cancer"],"interventions":["HRS-1167 tablets","Abiraterone Acetate tablets（II）","Prednisone Acetate tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.","sourceUrl":"https://clinicaltrials.gov/study/NCT06689163"},{"nctId":"NCT05991583","title":"A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2023-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-01-17","conditions":["Advanced Malignant Tumors"],"interventions":["IBB0979"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05991583"},{"nctId":"NCT06239155","title":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors","sponsor":"Ascentawits Pharmaceuticals, Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2019-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-11-30","completionType":"ESTIMATED","lastUpdated":"2025-02-25","conditions":["Advanced Solid Tumors","Hepatocellular Carcinoma"],"interventions":["AST-3424"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent","sourceUrl":"https://clinicaltrials.gov/study/NCT06239155"},{"nctId":"NCT05918445","title":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","sponsor":"Biotheus Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2021-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-11-30","completionType":"ESTIMATED","lastUpdated":"2024-12-05","conditions":["Malignant Neoplasm"],"interventions":["PM8002"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05918445"},{"nctId":"NCT04762641","title":"This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors","sponsor":"ABL Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2021-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-15","completionType":"ESTIMATED","lastUpdated":"2025-02-06","conditions":["Advanced Solid Tumor"],"interventions":["ABL503"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progressive locally advanced (unresectable) or metastatic solid tumors who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 3 parts: a dose-escalation part, a dose-expansion part and tumor-expansion part","sourceUrl":"https://clinicaltrials.gov/study/NCT04762641"},{"nctId":"NCT04616443","title":"OH2 Injection in Combination With HX008 for Melanoma.","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2020-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-11-30","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Melanoma"],"interventions":["OH2 injection","HX008 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase Ib study evaluates the safety and efficacy of OH2 in combination with HX008, an anti-PD-1 antibody, in patients with Melanoma. OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.","sourceUrl":"https://clinicaltrials.gov/study/NCT04616443"},{"nctId":"NCT06867562","title":"Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer","sponsor":"Jina Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":166,"enrollmentType":"ESTIMATED","startDate":"2025-04","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Platinum-Resistant Primary Peritoneal Carcinoma","Platinum Resistant High Grade Epithelial Ovarian Cancer","Platinum Resistant High Grade Serous Ovarian Cancer"],"interventions":["Paclitaxel Lipid Suspension","Conventional paclitaxel or Taxol"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a phase-3, open-label, multicenter, two-arm treatment study to evaluate the efficacy and safety of weekly Paclitaxel Lipid Suspension compared with weekly conventional paclitaxel in participants with platinum-resistant/refractory recurrent high-grade serous epithelial ovarian cancer. Paclitaxel Lipid Suspension or conventional paclitaxel will be administered intravenously at a dose level of 80 mg/m2 on Day 1, Day 8 and Day 15 of each 28 days cycle. The primary objective is to establish the non-inferiority of Paclitaxel Lipid Suspension in comparison with conventional paclitaxel for Injection in participants with platinum-resistant/refractory recurrent advanced high-grade serous epith","sourceUrl":"https://clinicaltrials.gov/study/NCT06867562"},{"nctId":"NCT06169579","title":"An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers","sponsor":"Shenzhen NewDEL Biotech, Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2024-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["Advanced Solid Tumor"],"interventions":["ND-003 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["RNA fusion"],"summary":"This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.","sourceUrl":"https://clinicaltrials.gov/study/NCT06169579"},{"nctId":"NCT06313086","title":"DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":442,"enrollmentType":"ESTIMATED","startDate":"2024-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2024-05-10","conditions":["HER2-positive Breast Cancer"],"interventions":["DP303c","trastuzumab emtansine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06313086"},{"nctId":"NCT07028268","title":"A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2025-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors"],"interventions":["SHR-2017、Denosumab placebo","Denosumab；SHR-2017 placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07028268"},{"nctId":"NCT05044897","title":"A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":11,"enrollmentType":"ACTUAL","startDate":"2021-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["SI-B001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This multi-center, open label phase II clinical study is performed in patients with recurrent metastatic squamous cell carcinoma of the head and neck progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 as a single agent in patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05044897"},{"nctId":"NCT04047251","title":"A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2019-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-04","conditions":["Advanced Solid Tumors","Merkel Cell Carcinoma"],"interventions":["FF-10850 Topotecan Liposome Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors including Merkel Cell Carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT04047251"},{"nctId":"NCT05020769","title":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2022-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Non-small Cell Lung Cancer"],"interventions":["SI-B001","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This multi-center, open label Phase II/III clinical study is performed in patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment or with non TKI-sensitizing mutation or patients with EGFR exon20ins mutation. This study is investigating the safety and efficacy of SI-B001 at monotherapy RP2D or lower combined with Osimertinib in patients with locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05020769"},{"nctId":"NCT01906385","title":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","sponsor":"Plus Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2015-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-26","conditions":["Glioma"],"interventions":["Rhenium Liposome Treatment"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.","sourceUrl":"https://clinicaltrials.gov/study/NCT01906385"},{"nctId":"NCT06143553","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2023-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["Metastatic Breast Cancer (MBC)"],"interventions":["Paclitaxel Polymeric Micelles for Injection","Eribulin Mesilate injection","Capecitabine Tablets","Gemcitabine Hydrochloride for Injection","Vinorelbine Tartrate Injection","Paclitaxel (albumin-bound)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"This multicenter, randomized, open, parallel positive control study compares the clinical efficacy and safety of paclitaxel polymeric micelles for injection with TPC in HER2- MBC subjects who have failed ≥2 to≤4 previous chemotherapy regimens. Treatment Protocol: Subjects are randomized into paclitaxel polymeric micelles for injection group and the Physician's Choice (TPC) group by the proportion of 1:1. Randomization is stratified according to three factors: number of lines of previous treatment for metastatic disease (2 or 3/4 lines), receptor status (triple-negative, non-triple-negative), and visceral metastasis (yes/no). Progression-free survival (PFS) is the main efficacy indicator in t","sourceUrl":"https://clinicaltrials.gov/study/NCT06143553"},{"nctId":"NCT05949619","title":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2023-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-M02D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ib: To explore the safety and preliminary efficacy of BL-M02D1 to further define RP2D in a variety of solid tumors such as locally advanced or metastatic non-small cell lung cancer. Phase II: To explore the efficacy of BL-M02D1 using single-agent RP2D obtained from phase I clinical studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05949619"},{"nctId":"NCT06585059","title":"Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-09","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-09-05","conditions":["Advanced Non-small Cell Lung Cancer"],"interventions":["TQB2928 injection + Almonertinib Mesilate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II dose (RP2CD).","sourceUrl":"https://clinicaltrials.gov/study/NCT06585059"},{"nctId":"NCT06732531","title":"Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer","sponsor":"Zhuhai Beihai Biotech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-01-09","conditions":["Bladder Cancer","Non Muscle Invasive"],"interventions":["BH011"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer（NMIBC） after Bacillus Calmette-Guerin（BCG） failure and to assess the preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06732531"},{"nctId":"NCT06873763","title":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","sponsor":"STCube, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2025-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Metastatic Colorectal Cancer (CRC)","Recurrent Colorectal Cancer"],"interventions":["Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The objective of this multi-center, single-group, open-label Phase Ib/II study is to evaluate the safety, pharmacokinetics, and efficacy of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in metastatic or recurrent colorectal cancer patients with resistance or intolerance to oxaliplatin- and irinotecan-based chemotherapy, and to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and the efficacy and safety of the combination therapy in BTN1A1-positive patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06873763"},{"nctId":"NCT03769506","title":"ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy","sponsor":"Rakuten Medical, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":135,"enrollmentType":"ACTUAL","startDate":"2019-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Head and Neck Cancer"],"interventions":["ASP-1929 Photoimmunotherapy","Physician's Choice SOC"],"countries":["United States","India","Japan","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03769506"},{"nctId":"NCT00248287","title":"PhII ICb With/Without Erbitux in MBC Pts","sponsor":"US Oncology Research","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2005-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-01-29","conditions":["Metastatic Breast Cancer"],"interventions":["Irinotecan + Carboplatin","irinotecan + Carboplatin + erbitux"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT00248287"},{"nctId":"NCT06426680","title":"A Study of the ILB-3101 in Patients with Advanced Solid Tumors","sponsor":"Innolake Biopharm","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2024-12-09","conditions":["Advanced Solid Tumor"],"interventions":["ILB-3101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"ILB-3101 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of ILB-3101 in Chinese advanced solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06426680"},{"nctId":"NCT05104775","title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":33,"enrollmentType":"ACTUAL","startDate":"2022-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Hematologic Malignancies"],"interventions":["GNC-035"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.","sourceUrl":"https://clinicaltrials.gov/study/NCT05104775"},{"nctId":"NCT05393427","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":4,"enrollmentType":"ACTUAL","startDate":"2022-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Locally Advanced or Metastatic Urinary Tumors","Other Solid Tumors"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05393427"},{"nctId":"NCT04606472","title":"A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2020-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Solid Tumor"],"interventions":["SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of SI-B003. In the phase Ib study, the safety and tolerability of SI-B003 in specific tumors will be further investigated by selecting multiple doses based on the results of phase Ia study or/and the fixed-dose administration method with the closest exposure level, and recommended phase II dose (RP2D) for phase II clinical studies will be determined.","sourceUrl":"https://clinicaltrials.gov/study/NCT04606472"},{"nctId":"NCT04706962","title":"TH1902 in Patients With Advanced Solid Tumors","sponsor":"Theratechnologies","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2021-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-01","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Solid Tumor","TNBC - Triple-Negative Breast Cancer","Hormone Receptor-positive Breast Cancer","Epithelial Ovarian Cancer","Endometrial Cancer","Cutaneous Melanoma","Thyroid Cancer","Small-cell Lung Cancer","Prostate Cancer","SORT1+ Cancers"],"interventions":["TH1902"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. Part 2 (expansion): selected patient populations with recurrent advanced TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, prostate cancer and other cancers known to express SORT1 that are refractory to standard therapy. Part 3 (optimization): patients diagnosed with histologically or cytologically confirmed high grade serou","sourceUrl":"https://clinicaltrials.gov/study/NCT04706962"},{"nctId":"NCT05440227","title":"PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients","sponsor":"PhytoHealth Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2023-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-06-05","conditions":["Cancer-related Fatigue"],"interventions":["PG2 Lyo. Injection 500mg","Placebo 0.9% normal saline"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to assess the efficacy of weekly PG2 regimen as a complementary treatment for patients with recurrent unresectable (local or regional) or metastatic breast cancer who experienced moderate to severe fatigue while receiving chemotherapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05440227"},{"nctId":"NCT04965077","title":"Treatment of Advanced and Metastatic Solid Tumors With MIL97","sponsor":"Beijing Mabworks Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2022-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-03-13","conditions":["Advanced or Metastatic Solid Tumor"],"interventions":["Recombinant Humanized Monoclonal Antibody MIL97 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, global, multi-center, open-label, multiple-dose, first-in-human study of MIL97 to evaluate the safety, tolerability, pharmacokinetics, biomarkers and efficacy in subjects with advanced or metastatic solid tumor. The study consists of a dose escalation phase and a dose expansion phase. An accelerated titration design (cohorts 1-2 only) followed by 3+3 dose-escalation design will be used in dose escalation phase. The starting dose for dose escalation phase is 0.01 mg/kg Q3W, followed by 5 dose cohorts (0.03mg/kg Q3W, 0.1mg/kg Q3W, 0.2mg/kg Q3W, 0.3mg/kg Q3W and 0.45mg/kg Q3W). Duration of dose limiting toxicity (DLT) observation is 21 days. Based on data of 3-week treatment ","sourceUrl":"https://clinicaltrials.gov/study/NCT04965077"},{"nctId":"NCT04998422","title":"A Study of HG381 Administered to Patients With Advanced Solid Tumors","sponsor":"HitGen Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":57,"enrollmentType":"ESTIMATED","startDate":"2021-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-13","conditions":["Advanced Solid Tumor"],"interventions":["HG381"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, first in human, open-label, non-randomized, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy and establish a recommended dose of HG381 administered intravenously (IV) alone in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04998422"},{"nctId":"NCT05627856","title":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":4,"enrollmentType":"ACTUAL","startDate":"2023-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["NK/T Cell Lymphoma","Vascular Immunomother T Cell Lymphoma","Non-Hodgkin Lymphoma"],"interventions":["GNC-038"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"To explore the safety and efficacy of GNC-038 in relapsed or refractory NK/T cell lymphoma, vascular immunomother T cell lymphoma, and other relapsed or refractory NHL, and to determine MTD, MAD, DLT, and RP2D of GNC-038, as well as its pharmacokinetic characteristics and immunogenicity.","sourceUrl":"https://clinicaltrials.gov/study/NCT05627856"},{"nctId":"NCT05947344","title":"A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2023-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-17","conditions":["AML, Adult"],"interventions":["STI-8591"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human, dose-escalation and dose-expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of STI-8591 in subjects with advanced AML who have signed an informed consent form (ICF) and have been screened for enrollment in this study. * Dose escalation phase: rapid titration and conventional 3+3 test design were used to evaluate the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and PK characteristics of STI-8591. * Dose Expansion Phase: Evaluate the safety, preliminary efficacy and determine the recommended phase II dose (RP2D) of STI-8591 for the treatment of subjects with advanced AML under the conditions of reachi","sourceUrl":"https://clinicaltrials.gov/study/NCT05947344"},{"nctId":"NCT06540391","title":"A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients","sponsor":"Microbiotica Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":41,"enrollmentType":"ACTUAL","startDate":"2024-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Melanoma"],"interventions":["MB097","Pembrolizumab","Vancomycin"],"countries":["France","Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06540391"},{"nctId":"NCT06086522","title":"Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors","sponsor":"Qualigen Theraputics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-05-01","conditions":["Solid Tumor"],"interventions":["QN-302"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \\[='PD'\\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \\[='PK'\\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patient.","sourceUrl":"https://clinicaltrials.gov/study/NCT06086522"},{"nctId":"NCT04606433","title":"Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":47,"enrollmentType":"ACTUAL","startDate":"2020-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Non Hodgkin Lymphoma","Acute Lymphoblastic Leukemia"],"interventions":["GNC-038"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's lymphoma, relapsed or refractory acute lymphoblastic leukemia, and refractory or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04606433"},{"nctId":"NCT04794972","title":"A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2021-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Recurrent Glioma","Solid Tumor"],"interventions":["GNC-039"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.","sourceUrl":"https://clinicaltrials.gov/study/NCT04794972"},{"nctId":"NCT03791112","title":"A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2019-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Advanced Solid Cancer"],"interventions":["BPI-16350"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This was an open-label Phase I study. The primary objective of the study was to assess safety, tolerability, efficacy, and pharmacokinetic characteristics of BPI-16350 in different dose groups.","sourceUrl":"https://clinicaltrials.gov/study/NCT03791112"},{"nctId":"NCT06313983","title":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":339,"enrollmentType":"ESTIMATED","startDate":"2022-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-04-22","conditions":["Breast Cancer"],"interventions":["Hemay022+AI","Lapatinib+Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the effectiveness of Hemay022 combined with AI (exemestane or letrozole) in the treatment of ER+/HER2+ advanced breast cancer patients based on the progression-free survival (PFS) assessed by the independent review committee (IRC). The second purpose of this study is to evaluate the pharmacokinetics and efficacy of Hemay022 in combination with AI, and the safety of Hemay022 in combination with AI. The trial plans to recruit 339 subjects, who will be randomly divided into two cohorts (the experimental group is hemay022 combined with AI, and the control group is lapatinib combined with capecitabine). During the treatment period, imaging examinations and","sourceUrl":"https://clinicaltrials.gov/study/NCT06313983"},{"nctId":"NCT05385692","title":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":22,"enrollmentType":"ACTUAL","startDate":"2022-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Locally Advanced or Metastatic Digestive Tract Tumors","Solid Tumor"],"interventions":["BL-M02D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic gastroenteric tumor or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M02D1. In phase Ib study, the safety and tolerability of BL-M02D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M02D1 in patients with locally advanced or metastatic gastroenteric tumor or other solid tumors will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05385692"},{"nctId":"NCT06682572","title":"A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients","sponsor":"Verastem, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Low Grade Serous Ovarian Cancer","Ovarian Cancer"],"interventions":["Avutometinib (VS-6766) + Defactinib (VS-6063)"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["RAS genotyping"],"summary":"This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06682572"},{"nctId":"NCT06285422","title":"Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)","sponsor":"Sana Biotechnology","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2024-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Non Hodgkin's Lymphoma","Large B-cell Lymphoma"],"interventions":["SC262"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.","sourceUrl":"https://clinicaltrials.gov/study/NCT06285422"},{"nctId":"NCT07108309","title":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","sponsor":"Biocad","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2024-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Triple Negative Breast Cancer"],"interventions":["BCD-236","Chemotherapy"],"countries":["Belarus","Russia"],"northAmerica":false,"chinaSites":false,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07108309"},{"nctId":"NCT06127238","title":"Study of ST-1898 in Advanced Renal Cell Carcinoma","sponsor":"Beijing Scitech-Mq Pharmaceuticals Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-08-24","conditions":["Advanced Renal Cell Carcinoma"],"interventions":["ST-1898 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL，PDGFRA，RET，KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in patients with advanced renal cell carcinoma (RCC). In phase Ib, the primary objectives are to assess the safety and tolerability, and to determine the maximum tolerated dose (MTD) of ST-1898 tablets in patients with advanced RCC. Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy in patients with advanced RCC. In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in patients with advanced RCC. The","sourceUrl":"https://clinicaltrials.gov/study/NCT06127238"},{"nctId":"NCT06063681","title":"A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors","sponsor":"Stingray Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2023-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-06-08","conditions":["Advanced / Metastatic Solid Tumor"],"interventions":["SR-8541A","Immune checkpoint inhibitor (ICI)"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06063681"},{"nctId":"NCT04001777","title":"A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2019-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["EGFR Positive Non-small Cell Lung Cancer"],"interventions":["APG-1252","Osimertinib Mesylate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT04001777"},{"nctId":"NCT06227117","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-03-19","conditions":["Breast Cancer"],"interventions":["Disitamab Vedotin Injection （18 weeks）","Toripalimab （18weeks）","Carboplatin","Disitamab Vedotin Injection （12 weeks）","Sequential Epirubicin","Sequential CTX","Toripalimab （12weeks）"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06227117"},{"nctId":"NCT05054439","title":"A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2021-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["SI-B001","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This multi-center, open label phase II clinical study is performed in patients with relapsed metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) progressed on prior 1st or 2nd line with anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with paclitaxel in patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05054439"},{"nctId":"NCT06550713","title":"A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2019-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-08-13","conditions":["Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)"],"interventions":["TQB3455 tablet+Azacitidine for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"This study is a clinical trial to evaluate the tolerability and pharmacokinetics of TQB3455 tablets in patients with hematological malignancies. TQB3455 is an isocitrate dehydrogenase 2(IDH2) inhibitor . This project is divided into two stages. The first stage aims to evaluate the safety and tolerability of single or multiple oral administration of TQB3455 tablets in subjects with malignant hematological tumors. The second phase aims to evaluate the efficacy and safety of TQB3455 tablets alone or in combination with azacitidine in subjects with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06550713"},{"nctId":"NCT05766527","title":"A Study of KM602 in Patients With Advanced Solid Tumors","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2023-04","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-03-13","conditions":["Advanced Solid Tumor"],"interventions":["KM602"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase 1 open-label, first-in-human, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and activity of KM602 as monotherapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05766527"},{"nctId":"NCT06652529","title":"Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors","sponsor":"Aromics Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2025-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-11-07","conditions":["Solid Tumors (Phase 1)","Mesothelioma","Colorectal Carcinoma","Ovarian Cancer","NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["AROG4-01"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one. Once it is identiffied, up to 20 patients will be treated with that dose, to check if thye get clinical benefit. Participants will: receive intravenous administrations of ARG4-01 twice weekly, and visit the clinic twice every week for checkups and tests.","sourceUrl":"https://clinicaltrials.gov/study/NCT06652529"},{"nctId":"NCT05020457","title":"SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2021-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Non Small Cell Lung Cancer"],"interventions":["SI-B001","AP or TP","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based chemotherapy. This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with chemotherapy in patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05020457"},{"nctId":"NCT06640530","title":"Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin","sponsor":"Biocad","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2024-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Advanced Melanoma","Melanoma (Skin)"],"interventions":["BCD-263","Opdivo"],"countries":["Belarus","Pakistan","Russia"],"northAmerica":false,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"The aim of the study BCD-263-2/UNIVERSE is to demonstrate comparable efficacy and similar safety and immunogenicity profile of BCD-263 and Opdivo after repeated intravenous doses in subjects with advanced unresectable or metastatic melanoma of the skin.","sourceUrl":"https://clinicaltrials.gov/study/NCT06640530"},{"nctId":"NCT04603287","title":"A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2020-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Locally Advanced or Metastatic Epithelial Tumor"],"interventions":["SI-B001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of SI-B001. In the phase Ib study, the safety and tolerability of SI-B001 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of SI-B001 in patients with locally advanced or metastatic epithelial tumors will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT04603287"},{"nctId":"NCT06373406","title":"A Study of MHB036C for Advanced Solid Tumor","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Advanced Solid Tumor"],"interventions":["MHB036C"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06373406"},{"nctId":"NCT05339685","title":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":82,"enrollmentType":"ACTUAL","startDate":"2022-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Breast Cancer"],"interventions":["BL-M02D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M02D1. In phase Ib study, the safety and tolerability of BL-M02D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05339685"},{"nctId":"NCT05160545","title":"A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ACTUAL","startDate":"2021-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Breast Cancer"],"interventions":["GNC-035"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.","sourceUrl":"https://clinicaltrials.gov/study/NCT05160545"},{"nctId":"NCT05192486","title":"A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2022-08-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["GNC-038"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.","sourceUrl":"https://clinicaltrials.gov/study/NCT05192486"},{"nctId":"NCT07008703","title":"Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2024-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Cancer Pain"],"interventions":["Injection of humanized nerve growth factor (NGF) antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/IIa, multicenter, sequential clinical trial evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SSS40 injection in patients with moderate-to-severe bone metastatic cancer pain. The study includes two stages: a single-arm, open-label, dose-escalation and dose-expansion Phase Ib followed by a randomized, double-blind, placebo-controlled Phase IIa.","sourceUrl":"https://clinicaltrials.gov/study/NCT07008703"},{"nctId":"NCT06462183","title":"Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)","sponsor":"Rgenta Therapeutics Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2024-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-11-14","conditions":["Adenoid Cystic Carcinoma","Colorectal Cancer"],"interventions":["RGT-61159"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC","sourceUrl":"https://clinicaltrials.gov/study/NCT06462183"},{"nctId":"NCT04229979","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","sponsor":"Sellas Life Sciences Group","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":127,"enrollmentType":"ACTUAL","startDate":"2021-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Acute Myeloid Leukemia"],"interventions":["Galinpepimut-S","Azacitidine","Venetoclax","Decitabine","Cytarabine","Observation","GM-CSF","Montanide"],"countries":["United States","France","Germany","Greece","Hungary","India","Poland","Serbia","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":73,"serviceSignals":["Hematology NGS"],"summary":"To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second or later complete remission (CR2) or second or later complete remission with incomplete platelet recovery (CRp2).","sourceUrl":"https://clinicaltrials.gov/study/NCT04229979"},{"nctId":"NCT06385678","title":"A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":47,"enrollmentType":"ACTUAL","startDate":"2024-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-09-19","conditions":["Advanced KRAS G12D Mutant Solid Tumors"],"interventions":["HRS-4642","Adebrelimab","SHR-9839","Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection","Cetuximab Solution for Infusion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06385678"},{"nctId":"NCT05944978","title":"A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":3,"enrollmentType":"ACTUAL","startDate":"2023-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Relapsed/Refractory Chronic Lymphocytic Leukemia"],"interventions":["GNC-035"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with relapsed or refractory chronic lymphocytic leukemia and other hematological malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT05944978"},{"nctId":"NCT07113925","title":"A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-08-11","conditions":["Advanced Hematologic Malignancies"],"interventions":["TQB2101 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"TQB2101 for Injection is an Antibody-Drug Conjugate (ADC) targeting Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1).It consists of three main components: a ROR1 monoclonal antibody responsible for selectively recognizing the surface antigen of cancer cells, a small molecule toxin responsible for killing cancer cells, and a linker connecting the antibody and the small molecule toxin. It is intended for clinical use in the treatment of advanced malignant tumors, including advanced malignant hematological tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07113925"},{"nctId":"NCT04733183","title":"Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma","sponsor":"Philogen S.p.A.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2020-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Soft Tissue Sarcoma"],"interventions":["Dacarbazine","onfekafusp alfa"],"countries":["France","Germany","Italy","Poland","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":23,"serviceSignals":["RNA fusion"],"summary":"Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04733183"},{"nctId":"NCT05881525","title":"NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors","sponsor":"TCRCure Biopharma Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2023-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-07-16","conditions":["Advanced Solid Tumors"],"interventions":["TC-N201 cells","IL-2","Fludarabine","Cyclophosphamide","Nab-paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"New York Esophageal Squamous Cell Carcinoma 1 (NY-ESO-1) is a cancer-testis antigen (CTA) which is expressed in various tumors. In TCR-T therapy, researchers take the blood of a certain patient, select T cells and insert genes into the cell that expressing a kind of protein that targeting NY-ESO-1. The genetically engineered cells are called NY-ESO-1 TCR-T cells. Then the engineered cells are re-infused to the cancer patients to cure the disease or prolong life.","sourceUrl":"https://clinicaltrials.gov/study/NCT05881525"},{"nctId":"NCT06423911","title":"Study of Olverembatinib (HQP1351) in Patients With CP-CML","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":285,"enrollmentType":"ESTIMATED","startDate":"2024-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2025-06-03","conditions":["Chronic Myeloid Leukemia","CML","CML, Chronic Phase"],"interventions":["olverembatinib","Bosutinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)","sourceUrl":"https://clinicaltrials.gov/study/NCT06423911"},{"nctId":"NCT06547957","title":"A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors","sponsor":"iTeos Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":55,"enrollmentType":"ACTUAL","startDate":"2023-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Advanced Solid Tumors"],"interventions":["EOS301984","Anti-PD-1 monoclonal antibody"],"countries":["Belgium"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"APT-008 is an open-label, Phase I/Ib, dose escalation and expansion cohort study to evaluate the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and preliminary efficacy of EOS301984 as monotherapy and in combination with other anticancer therapies in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06547957"},{"nctId":"NCT01394679","title":"A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer","sponsor":"Cell>Point LLC","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2025-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-03","conditions":["Lung Cancer"],"interventions":["(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)","18 F FDG followed by PET/CT imaging"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine if the images of the primary lesions of lung cancer and any metastatic lesions seen from the investigational SPECT/CT 99mTC-EC-DG scans are the same as the PET/CT 18F-FDG scans.","sourceUrl":"https://clinicaltrials.gov/study/NCT01394679"},{"nctId":"NCT06866795","title":"Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"Geode Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-07","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Metastatic Castration Resistant Prostate Cancer"],"interventions":["GT-220F capsule"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to test GT-220F in patients with metastatic castration resistant prostate cancer and learn about the best dose required for further study. Participants will be adults with metastatic castration resistant prostate cancer. The main questions the study aims to answer are: 1) What medical problems do participants have when taking GT-220F? 2) What dose strength is best to use in further clinical trials? Participants will be asked to * take GT-220F every day * take medical tests every week","sourceUrl":"https://clinicaltrials.gov/study/NCT06866795"},{"nctId":"NCT06105021","title":"Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor","sponsor":"Affini-T Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2025-07-30","conditions":["Pancreatic Ductal Adenocarcinoma","Non-Small Cell Lung Cancer","Colorectal Cancer","Solid Tumor","KRAS G12V"],"interventions":["AFNT-211"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["RAS genotyping","HLA / TCR"],"summary":"This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\\*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell produ","sourceUrl":"https://clinicaltrials.gov/study/NCT06105021"},{"nctId":"NCT05664243","title":"A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma","sponsor":"In8bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":4,"enrollmentType":"ESTIMATED","startDate":"2023-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12","primaryCompletionType":"ESTIMATED","completionDate":"2025-12","completionType":"ESTIMATED","lastUpdated":"2025-05-01","conditions":["Glioblastoma"],"interventions":["Autologous genetically modified gamma-delta T cells","Allogeneic genetically modified gamma-delta T cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.","sourceUrl":"https://clinicaltrials.gov/study/NCT05664243"},{"nctId":"NCT04877717","title":"A Study of SHR-A1904 in Patients With Advanced Solid Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":107,"enrollmentType":"ACTUAL","startDate":"2021-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-01","completionType":"ESTIMATED","lastUpdated":"2025-03-25","conditions":["Advanced Solid Cancer"],"interventions":["SHR-A1904"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to assess the safety and tolerability of SHR-A1904 in patients with advanced solid cancer and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1904","sourceUrl":"https://clinicaltrials.gov/study/NCT04877717"},{"nctId":"NCT04412616","title":"ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies","sponsor":"Changchun Intellicrown Pharmaceutical Co. LTD","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2020-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-06","completionType":"ESTIMATED","lastUpdated":"2025-06-10","conditions":["Advanced EGFR Positive Solid Tumor"],"interventions":["ZZ06"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to have current standard anti-tumor therapies. The purpose of this study is to determine the maximum tolerated dose (MTD) , to characterise the safety, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of ZZ06 as a single agent in adult participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04412616"},{"nctId":"NCT06524063","title":"Targeted Survivin DC Cell Injection for the Treatment of GBM","sponsor":"Beijing Tricision Biotherapeutics Inc","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2024-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2024-07-29","conditions":["Glioblastoma"],"interventions":["Survivin-loaded dendritic cell injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Primary Objective: To evaluate the safety and tolerability of targeted Survivin DC cell injection for postoperative treatment of newly diagnosed primary glioblastoma multiforme. Secondary Objectives: Utilize progression-free survival (PFS) and overall survival (OS) to preliminarily assess the effectiveness of targeted Survivin DC cell injection for postoperative treatment of newly diagnosed primary glioblastoma multiforme in China. Evaluate the immunological effects of targeted Survivin DC cell injection. Explore the impact of targeted Survivin DC cell injection on human DC cell activity and in vivo processes. Patients will undergo a combined treatment of radiotherapy and temozolomide (TMZ) ","sourceUrl":"https://clinicaltrials.gov/study/NCT06524063"},{"nctId":"NCT03519230","title":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","sponsor":"BeiGene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":224,"enrollmentType":"ACTUAL","startDate":"2018-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ACTUAL","completionDate":"2027-01-30","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Ovarian Cancer"],"interventions":["Pamiparib capsule","Placebo capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03519230"},{"nctId":"NCT05943379","title":"RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2023-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2023-07-13","conditions":["NMIBC"],"interventions":["RC48-ADC in Combination with gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) who are BCG Naïve or BCG Unresponsive and are considered ineligible for or have refused to undergo radical cystectomy, will receive RC48-ADC in combination with gemcitabine.","sourceUrl":"https://clinicaltrials.gov/study/NCT05943379"},{"nctId":"NCT04381130","title":"A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer","sponsor":"Everfront Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2025-02-26","conditions":["Pancreatic Cancer"],"interventions":["EF-009"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderline resectable and unresectable pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04381130"},{"nctId":"NCT05656573","title":"CART-PSMA Cells for Advanced Prostate Cancer","sponsor":"Nova Therapeutics LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-01","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["Prostate Cancer"],"interventions":["CART-PSMA cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05656573"},{"nctId":"NCT05945901","title":"A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":669,"enrollmentType":"ACTUAL","startDate":"2023-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Colorectal Cancer"],"interventions":["HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab","HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a double-blind, randomized, multi-center, II/III study in at least 606 patients with advanced colorectal cancer. The study is being conducted to evaluate the safety of HR070803 combined with oxaliplatin, 5-FU/LV and bevacizumab in phase II and to evaluate the efficacy of HR070803 in combination with oxaliplatin, 5-FU/LV, and bevacizumab versus HR070803 simulator in combination with FOLFOX and bevacizumab for first-line treatment of patients with unresectable metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05945901"},{"nctId":"NCT04871282","title":"A Study of AL102 in Patients With Progressing Desmoid Tumors","sponsor":"Immunome, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":198,"enrollmentType":"ACTUAL","startDate":"2021-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Desmoid","Desmoid Tumor"],"interventions":["AL102","Placebo"],"countries":["United States","Australia","Belgium","Germany","Israel","Italy","Netherlands","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04871282"},{"nctId":"NCT05109728","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2022-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-03","primaryCompletionType":"ACTUAL","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Glioblastoma"],"interventions":["[177Lu]Lu-DOTA-TATE","[68Ga]Ga-DOTA-TATE","Temozolomide","Radiotherapy"],"countries":["United States","France","Portugal","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"A Dose Finding Study of \\[177Lu\\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent","sourceUrl":"https://clinicaltrials.gov/study/NCT05109728"},{"nctId":"NCT04274426","title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","sponsor":"AGO Research GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2021-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-03","primaryCompletionType":"ACTUAL","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma"],"interventions":["Carboplatin","Pegylated liposomal doxorubicin (PLD)","Gemcitabine","Paclitaxel","Mirvetuximab Soravtansine"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, randomized, two-arm, open-label, comparative phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04274426"},{"nctId":"NCT05257395","title":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":397,"enrollmentType":"ACTUAL","startDate":"2022-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-05","completionType":"ESTIMATED","lastUpdated":"2025-07-17","conditions":["Advanced Breast Cancer"],"interventions":["XZP-3287+ Letrozole/Anastrozole","Placebo + Letrozole/Anastrozole"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III clinical trial designed to evaluate the efficacy and safety of XZP-3287 in combination with Letrozole/Anastrozole versus placebo in combination with Letrozole/Anastrozole in patients with HR-positive and HER2-negative recurrent/metastatic breast cancer who have not received systemic anticancer therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05257395"},{"nctId":"NCT06641609","title":"A Phase I Study of CFT8919 in Patients With Advanced NSCLC","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":166,"enrollmentType":"ESTIMATED","startDate":"2024-12-13","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-03","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Non-Small Cell Lung Cancer With EGFR Mutation"],"interventions":["Dose-Escalation (Phase Ia) CFT8919 capsule","Dose-Expansion (Phase Ib) CFT8919 capsule","Cohort-Expansion (Phase Ic) CFT8919 capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of CFT8919 capsules in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR mutations. The main questions it aims to answer are: * What is the maximum tolerated dose (MTD) of CFT8919? * Does CFT8919 demonstrate antitumor activity in these patients? Participants will: * Take CFT8919 capsules at different doses. * Undergo regular assessments for safety, pharmacokinetics, and tumor response. Researchers will compare different dose levels to determine the best balance between safety and efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06641609"},{"nctId":"NCT06007729","title":"ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2023-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-12","completionType":"ESTIMATED","lastUpdated":"2024-08-20","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["HS-20093"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with head and neck squamous cell carcinoma and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06007729"},{"nctId":"NCT05932212","title":"AK104 for Recurrent or Metastatic Vulvar Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-15","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Vulvar Cancer"],"interventions":["AK104","AK104+ Paclitaxel+Cisplatin or Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05932212"},{"nctId":"NCT05034497","title":"Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases","sponsor":"Plus Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2021-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-21","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-03-26","conditions":["Leptomeningeal Metastasis"],"interventions":["186RNL"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is an open-label Phase I clinical study that will administer a single dose of 186RNL via intraventricular catheter for treatment of Leptomeningeal Metastases (LM).","sourceUrl":"https://clinicaltrials.gov/study/NCT05034497"},{"nctId":"NCT05908409","title":"A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies","sponsor":"IDP Discovery Pharma S.L.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-22","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-22","completionType":"ESTIMATED","lastUpdated":"2025-05-01","conditions":["Multiple Myeloma (MM)","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Double Hit Lymphoma","High Grade B-Cell Lymphoma, Not Otherwise Specified","Chronic Lymphocytic Leukemia (CLL)","Triple Hit Lymphoma"],"interventions":["IDP-121"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose ","sourceUrl":"https://clinicaltrials.gov/study/NCT05908409"},{"nctId":"NCT05704049","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","sponsor":"Sanofi","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":118,"enrollmentType":"ACTUAL","startDate":"2023-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-22","primaryCompletionType":"ACTUAL","completionDate":"2028-05-12","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["Isatuximab","Carfilzomib","Dexamethasone","Dexamethasone IV","Montelukast","Acetaminophen","Diphenhydramine","Methylprednisolone"],"countries":["Australia","Brazil","China","Czechia","Greece","Japan","Portugal"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy, and to characterize the PK of isatuximab in combination with carfilzomib and dexamethasone after manual and On Body Delivery System (OBDS) administration. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery methods of SC isatuximab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05704049"},{"nctId":"NCT05417789","title":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","sponsor":"SynOx Therapeutics Limited","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2024-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-23","primaryCompletionType":"ACTUAL","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["TGCT"],"interventions":["Emactuzumab","Placebo"],"countries":["United States","Belgium","Canada","France","Italy","Netherlands","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option. The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1. A number of assessments wi","sourceUrl":"https://clinicaltrials.gov/study/NCT05417789"},{"nctId":"NCT06030258","title":"IN10018 Combination Therapy in Treatment-naïve ES-SCLC","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-24","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-24","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Small Cell Lung Cancer Extensive Stage"],"interventions":["IN10018","Tislelizumab","Carboplatin","Etoposide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed as the combination drug) and chemotherapy (platinum and etoposide) as the first-line treatment in Extensive-stage small cell lung cancer (ES-SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06030258"},{"nctId":"NCT06014086","title":"Intratumoral PH-762 for Cutaneous Carcinoma","sponsor":"Phio Pharmaceuticals Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-29","primaryCompletionType":"ACTUAL","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Squamous Cell Carcinoma of the Skin","Malignant Melanoma of Skin","Merkel Cell Carcinoma of Skin"],"interventions":["PH-762"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.","sourceUrl":"https://clinicaltrials.gov/study/NCT06014086"},{"nctId":"NCT06111274","title":"A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2023-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-29","completionType":"ESTIMATED","lastUpdated":"2024-04-11","conditions":["Advanced Pancreatic Cancer"],"interventions":["Pimicotinib (ABSK021)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer. The main questions it aims to answer are: * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is safe in patients with advanced pancreatic cancer. * Whether the Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab is effective in patients with advanced pancreatic cancer. Participants will be asked to complete the study procedures: * Receive the administration of Pimicotinib (ABSK021) in combination with chemotherapy with ","sourceUrl":"https://clinicaltrials.gov/study/NCT06111274"},{"nctId":"NCT06247956","title":"Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":153,"enrollmentType":"ACTUAL","startDate":"2024-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma"],"interventions":["SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection","Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Objective response rate (ORR) was evaluated to evaluate the efficacy of SHR-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06247956"},{"nctId":"NCT06742593","title":"Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors","sponsor":"Suzhou Maximum Bio-tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-12-19","conditions":["Brain (Nervous System) Cancers","Brain and Central Nervous System Tumors","Brain Tumors"],"interventions":["MT027 cells suspension"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"MT027 is an off-the-shelf, allogeneic chimeric antigen receptor T cell (UCAR-T) injection prepared from healthy donor T cells targeting B7-H3. It is a next-generation, ready-to-use CAR-T product that can be used immediately and promptly for patients to solve the problem of unmet medical needs for a large number of patients who have a demand for CAR-T therapy but cannot receive it due to the common reasons of long production cycle, insufficient production capacity, and incompatibility of patients' T cells with the production conditions. In addition, the expected medical cost of allogeneic CAR-T cells is significantly lower, which can greatly alleviate the economic burden on patients. MT027 is","sourceUrl":"https://clinicaltrials.gov/study/NCT06742593"},{"nctId":"NCT02767804","title":"eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients","sponsor":"Xcovery Holdings, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":290,"enrollmentType":"ACTUAL","startDate":"2016-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["Non-small Cell Lung Cancer"],"interventions":["X-396 (ensartinib)","crizotinib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Hong Kong","Israel","Italy","Netherlands","Poland","Russia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":72,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The primary purpose of this study is to evaluate the efficacy and safety of X-396 (ensartinib) vs. crizotinib in patients with ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT02767804"},{"nctId":"NCT03562637","title":"Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC","sponsor":"OBI Pharma, Inc","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":575,"enrollmentType":"ACTUAL","startDate":"2018-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-05-09","conditions":["Triple Negative Breast Cancer"],"interventions":["adagloxad simolenin combined with OBI-821","Globo H IHC Assay","Standard of care treatment"],"countries":["United States","Australia","Brazil","China","Hong Kong","Mexico","Peru","Poland","Russia","South Africa","South Korea","Taiwan","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":128,"serviceSignals":["Broad CGP"],"summary":"The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT03562637"},{"nctId":"NCT06126666","title":"A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors","sponsor":"ABL Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Advanced Solid Tumor"],"interventions":["ABL103"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation study of ABL103 to evaluate the safety, tolerability, MTD (maximum tolerated dose) and/or RP2D (recommended phase 2 dose), pharmacokinetics, immunogenicity, preliminary antitumor activity of ABL103 in subjects with any progressive locally advanced(unresectable) or metastatic solid tumor who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 2 parts: a dose-escalation part and tumor-expansion part","sourceUrl":"https://clinicaltrials.gov/study/NCT06126666"},{"nctId":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2018-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Unresectable or Metastatic Melanoma or Advanced Solid Tumors","Melanoma","Uveal Melanoma","P53 Mutation","MDM2 Gene Mutation","Cutaneous Melanoma","Mucosal Melanoma","Malignant Peripheral Nerve Sheath Tumors (MPNST)"],"interventions":["Phase 1b: APG-115+pembrolizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03611868"},{"nctId":"NCT06302062","title":"Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":23,"enrollmentType":"ESTIMATED","startDate":"2023-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-12-03","conditions":["Advanced Solid Tumor","Tumor Associated Lymph Node T Cell","Immunotherapy"],"interventions":["Tumor Associated Lymph node T cell","cyclophosphamide","IL-2","Serplulimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A total of 17 to 23 participants are anticipated to be enrolled in the Phase I clinical trial, which is further divided into two distinct parts: one part involves single-agent cell therapy, while the other entails a combination of cell therapy and Serplulimab Injection. To be more precise, the study aims to include patients who have been diagnosed with metastatic or locally advanced refractory/recurrent malignant solid tumors and have shown resistance to standard therapeutic interventions. These tumor types may encompass head and neck cancer, ovarian cancer, lung cancer, melanoma, and others.","sourceUrl":"https://clinicaltrials.gov/study/NCT06302062"},{"nctId":"NCT06784648","title":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","sponsor":"BioInvent International AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2024-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Melanoma Metastatic","Melanoma of Skin","Melanoma BRAF V600E/K Mutated","Melanoma Recurrent","Melanoma Stage III or IV","Melanoma","Melanoma Negative for bRAF","Melanoma Negative for nRAS","Melanomas","Uveal Melanoma, Metastatic"],"interventions":["pembrolizumab (KEYTRUDA®)","BI-1607","Ipilimumab (YervoyTM, 50 mg/10 mL solution)"],"countries":["Germany","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically. Melanoma is a type of skin cancer that starts in melanocytes, the cells that make the pigment that gives skin its color. In people with cancer, the body cannot control the growth of cells, which can come together to form tumors. This trial's new treatment is called BI-1607. BI-1607 is designed to work by improving the effectiveness of other targeted therapies already used for melanoma treatment; ipilimumab and pembrolizumab. BI-1607 will improve the ability of these two treatments to help the body's defense system to destroy cancer cells.","sourceUrl":"https://clinicaltrials.gov/study/NCT06784648"},{"nctId":"NCT04982237","title":"A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":445,"enrollmentType":"ACTUAL","startDate":"2021-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-30","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Cervical Cancer"],"interventions":["AK104","paclitaxel","carboplatin","cisplatin","bevacizumab","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04982237"},{"nctId":"NCT05394103","title":"Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","sponsor":"Qurient Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2022-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Advanced Cancer","Metastatic Cancer"],"interventions":["Q901","KEYTRUDA® (pembrolizumab)"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab","sourceUrl":"https://clinicaltrials.gov/study/NCT05394103"},{"nctId":"NCT06819215","title":"Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors","sponsor":"Zhejiang Yangli Pharmaceutical Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":188,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-30","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Cancer","Neoplasms","Neoplasms, Breast","Tumor","PARP","Ovarian Neoplasms","Prostatic Cancer","Pancreatic Cancer","Breast Cancer","Biliary Cancer","Colorectal Cancer"],"interventions":["VB15010"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This research is designed to determine if experimental treatment with PARP1 inhibitor, VB15010 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06819215"},{"nctId":"NCT05718219","title":"Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":408,"enrollmentType":"ESTIMATED","startDate":"2023-03-29","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Advanced Solid Tumors"],"interventions":["SIM0348","SIM0348 + Sintilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open label, phase I trial to evaluate the safety and tolerability, pharmacokinetic/ pharmacodynamic characteristics and to assess the preliminary efficacy of SIM0348 as monotherapy or with sintilimab in adult subjects with advanced and metastatic solid tumors. The trial starts with a dose escalation and dose expansion part (Part 1) followed by a cohort expansion part (Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT05718219"},{"nctId":"NCT04083599","title":"GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":350,"enrollmentType":"ACTUAL","startDate":"2019-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ACTUAL","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Malignant Solid Tumor","Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Melanoma","Head and Neck Squamous Cell Carcinoma (HNSCC)","Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["GEN1042","Pembrolizumab","Cisplatin","Carboplatin","5-FU","Gemcitabine","Nab paclitaxel","Pemetrexed","Paclitaxel"],"countries":["United States","Denmark","France","Georgia","Germany","Israel","Italy","Moldova","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":76,"serviceSignals":["Broad CGP"],"summary":"The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with certain types of cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04083599"},{"nctId":"NCT06826313","title":"A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2025-07-18","conditions":["Solid Tumors"],"interventions":["VRT106"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06826313"},{"nctId":"NCT06119685","title":"IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers","sponsor":"Indapta Therapeutics, INC.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2023-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-06-03","conditions":["NHL","Multiple Myeloma","Blood Cancer","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Multiple Myeloma","Relapsed Multiple Myeloma"],"interventions":["IDP-023","Rituximab","Daratumumab","Interleukin-2","Cyclophosphamide","Fludarabine","Mesna","Isatuximab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT06119685"},{"nctId":"NCT05374915","title":"Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)","sponsor":"Kintara Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2024-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-28","conditions":["Cutaneous Breast Cancer"],"interventions":["REM-001 photodynamic therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography","sourceUrl":"https://clinicaltrials.gov/study/NCT05374915"},{"nctId":"NCT05548634","title":"A Study of TAVO412 in Patients with Cancer","sponsor":"Tavotek Biotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-01","completionType":"ESTIMATED","lastUpdated":"2024-10-23","conditions":["Cancer"],"interventions":["TAVO412"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412. Part 1 will utilize a standard 3 + 3 design to determine the MTD/RP2D of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Part 2 will further evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacologic activity of TAVO412 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR \\> PR ","sourceUrl":"https://clinicaltrials.gov/study/NCT05548634"},{"nctId":"NCT05047250","title":"A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2022-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ACTUAL","completionDate":"2027-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Atezolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with stage IV non-squamous or squamous NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05047250"},{"nctId":"NCT05934513","title":"A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2023-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-12-13","conditions":["Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)"],"interventions":["GFH009"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05934513"},{"nctId":"NCT06892431","title":"JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2025-03-25","conditions":["Recurrent or Metastatic Nasopharyngeal Cancer","Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy"],"interventions":["Mitoxantrone Hydrochloride Liposome","JMT101 injection","Capecitabine","Docetaxel injection","Gemcitabine hydrochloride for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06892431"},{"nctId":"NCT05827796","title":"IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Pancreatic Cancer"],"interventions":["IN10018","Albumin-Bound Paclitaxel","Gemcitabine","KN046"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, single-arm, phase Ib/II clinical study comprising two phases: dose confirmation phase and dose expansion phase. The objective of the dose confirmation phase is to determine the recommended Phase II dose (RP2D) of IN10018+ standard chemotherapy (albumin-bound paclitaxel + gemcitabine) and IN10018 + KN046 + standard chemotherapy in subjects with advanced pancreatic cancer. The dose expansion phase will further explore the antitumor activities and safety of combination therapy in subjects with advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05827796"},{"nctId":"NCT06332092","title":"FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma","sponsor":"Fulgent Pharma LLC.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2024-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["FID007"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this FID-007 Clinical Trial is to compare the efficacy of different dosing regimens of FID-007 in combination with Cetuximab in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). The main questions it aims to answer are: to evaluate the efficacy, and to characterize the safety and tolerability. Eligible participants will be enrolled and randomized to 1 of 2 arms of FID-007 with fixed-dose Cetuximab in each 28-day cycle.","sourceUrl":"https://clinicaltrials.gov/study/NCT06332092"},{"nctId":"NCT06617000","title":"A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related","sponsor":"SCG Cell Therapy Pte. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2022-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-27","conditions":["HCC","Hepatitis B Virus Related Hepatocellular Carcinoma","Hepatocellular Carcinoma"],"interventions":["SCG101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["HLA / TCR"],"summary":"This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06617000"},{"nctId":"NCT06276283","title":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Non-small Cell Lung Cancer"],"interventions":["DZD9008 plus Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study tests a combination therapy (i.e., DZD9008 plus bevacizumab) in patients with advanced NSCLC harboring EGFR mutations who have progressed on or after standard of care, which aims to understand whether the combination therapy is safe, how well the combination therapy works, and how the body will process DZD9008 when used in combination with bevacizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06276283"},{"nctId":"NCT07016997","title":"A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.","sponsor":"Chiome Bioscience Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-06-12","conditions":["Solid Tumors","Refractory Cancer"],"interventions":["CBA-1535","CBA-1535+Pembrolizumab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a First in Human muticenter, non-randomized, open-label Phase I dose-escalation study of CBA-1535. The study will have 2 parts (Part 1 and Part 2). Part 1 is the dose-escalation cohorts of CBA-1535 single agent theapy. Part 2 is the dose-escalation cohorts of CBA-1535 in combination with Pembrlizumab. This study will evaluate the safety, tolerability, PK, biomarker profiles and preliminary efficacy of CBA-1535.","sourceUrl":"https://clinicaltrials.gov/study/NCT07016997"},{"nctId":"NCT04807257","title":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","sponsor":"NanoRay Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-08-05","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-07-24","conditions":["Malignant Fungating Wound"],"interventions":["Auger Molecular Therapy (AMT)"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, single-arm, open-label, dose escalating study to determine the safety and the recommended maximum tolerated dose of the AMT in subjects with malignant cutaneous lesions. AMT is a combination therapy of a drug (IUdR) and a device (AUTRON Therapy System). IUdR is an iodinated thymidine analogue that is preferentially incorporated into DNA in rapid growing cells. The AUTRON Therapy System generates characteristic X-Ray photons around 33.4 keV, matching the K-edge energy of Iodine (33.17 keV), which can efficiently induce Auger electron emissions from IUdR in cancer DNA, resulting in extensive DNA damage and cancer cell death.","sourceUrl":"https://clinicaltrials.gov/study/NCT04807257"},{"nctId":"NCT06016062","title":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":221,"enrollmentType":"ESTIMATED","startDate":"2023-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-23","conditions":["Solid Tumor"],"interventions":["RC148 Monotherapy","RC148+docetaxel Combination Therapy","RC148+RC48 Combination Therapy","RC148+RC88 Combination Therapy","RC148/Bevacizumab+RC88 Combination Therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The primary objective of Phase I of this trial is to evaluate the safety, tolerability, maximum tolerated dose (MTD)/maximum administered dose (MAD) of RC148 in patients with locally advanced unresectable or metastatic solid tumors to determine the recommended Phase II dose (RP2D), and the secondary objective is to evaluate the PK and PD characteristics, immunogenicity and preliminary clinical efficacy of RC148. Phase II will primarily evaluate the efficacy of the RC148 combination regimen, and secondarily will assess safety and tolerability, PK characteristics, and immunogenicity. During the trial, investigators will also evaluate the potential correlation of biomarkers with efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06016062"},{"nctId":"NCT07149831","title":"A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults","sponsor":"Sinotau Pharmaceutical Group","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2025-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-02","conditions":["Prostate Cancer"],"interventions":["Flotufolastat F-18 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Flotufolastat F-18 Injection is a positron emission tomography (PET) imaging tracer that targets the extracellular domain of prostate-specific membrane antigen (PSMA). This phase I study investigated the safety, biodistribution, radiation dosimetry and Pharmacokinetics of Flotufolastat F-18 Injection in 6 healthy elderly Chinese volunteers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07149831"},{"nctId":"NCT06740019","title":"A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion","sponsor":"Jemincare","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Malignant Pleural Effusions (Mpe)"],"interventions":["JMKX000197","Tube thoracostomy drainage"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase Ib Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion","sourceUrl":"https://clinicaltrials.gov/study/NCT06740019"},{"nctId":"NCT05635708","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","sponsor":"BeiGene","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2023-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ACTUAL","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Non-small Cell Lung Cancer","Metastatic Non-small Cell Lung Cancer"],"interventions":["Tislelizumab","BGB-A445","LBL-007","Carboplatin","Cisplatin","pemetrexed","Paclitaxel","Nab paclitaxel","BGB-15025"],"countries":["United States","Australia","Brazil","Canada","China","France","Georgia","Italy","Malaysia","Moldova","Romania","Singapore","South Korea","Spain","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":61,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\\< 50%).","sourceUrl":"https://clinicaltrials.gov/study/NCT05635708"},{"nctId":"NCT04651634","title":"MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients","sponsor":"MitoImmune Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2021-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-06","conditions":["Head and Neck Squamous Cell Carcinoma","Oral Mucositis"],"interventions":["MIT-001 plus CCRT"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).","sourceUrl":"https://clinicaltrials.gov/study/NCT04651634"},{"nctId":"NCT05176665","title":"EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2021-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-26","conditions":["Neoplasms","Neoplasm Metastasis","Metastatic Gastrointestinal Carcinoid Tumor"],"interventions":["EMB-01"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05176665"},{"nctId":"NCT06014190","title":"HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2023-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-29","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","Endometrial Cancer"],"interventions":["HS-20089"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["ADC biomarker"],"summary":"HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20089 as monotherapy in patients with recurrent or metastatic ovarian cancer and endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06014190"},{"nctId":"NCT06010862","title":"Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2023-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2023-11-08","conditions":["Gastric Cancer","Colon Cancer","Pancreas Cancer","Esophagus Cancer","Cholangiocarcinoma","Lung Cancer","Breast Cancer"],"interventions":["CEA CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT06010862"},{"nctId":"NCT04939142","title":"A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)","sponsor":"Antengene Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2021-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["SVd (Selinexor+Bortezomib+dexamethasone)","Vd (Bortezomib+dexamethasone)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":33,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase III Randomized, Controlled, Multicenter, Open-label Study of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT04939142"},{"nctId":"NCT05043090","title":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":148,"enrollmentType":"ACTUAL","startDate":"2021-10-28","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ACTUAL","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Papillary Renal Cell Carcinoma"],"interventions":["savolitinib","durvalumab","sunitinib"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Czechia","France","Germany","Hong Kong","India","Israel","Italy","Mexico","Netherlands","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":137,"serviceSignals":["Broad CGP"],"summary":"A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).","sourceUrl":"https://clinicaltrials.gov/study/NCT05043090"},{"nctId":"NCT06107374","title":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","sponsor":"CellSight Technologies, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2024-10-24","conditions":["Advanced Non Small Cell Lung Cancer"],"interventions":["[18F]F-AraG"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This pilot study uses \\[18F\\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to quantify the change in \\[18F\\]F AraG PET signal before and while on CkIT therapy and to correlate this change in \\[18F\\]F AraG PET signal with radiographic response. To explore these objectives, eligible subjects will undergo pre- and on - CkIT treatment \\[18F\\]F AraG PET/CT scans, and will be followed up for 12 months for assessment of radiographic and clinical outcomes. This study is a single-site, open label, non randomized, single arm pilot trial. Patients and care providers will not be bli","sourceUrl":"https://clinicaltrials.gov/study/NCT06107374"},{"nctId":"NCT05022927","title":"A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma","sponsor":"Chugai Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":179,"enrollmentType":"ESTIMATED","startDate":"2021-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-05","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["ERY974","Tocilicumab","Atezolizumab","Bevacizumab"],"countries":["Japan","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05022927"},{"nctId":"NCT06010875","title":"A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-11-30","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2023-11-08","conditions":["Renal Cell Carcinoma","Ovarian Cancer","Cervix Cancer","Metastatic Cancer","Advanced Cancer"],"interventions":["CD70 CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.","sourceUrl":"https://clinicaltrials.gov/study/NCT06010875"},{"nctId":"NCT05830123","title":"ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2023-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-23","conditions":["Osteosarcoma","Sarcoma"],"interventions":["HS-20093"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. This is a phase 2, open-label, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of HS-20093 as a monotherapy in patients with relapsed or refractory osteosarcoma and other sarcomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05830123"},{"nctId":"NCT06725524","title":"A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2021-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-10","conditions":["B-cell Non Hodgkin Lymphoma"],"interventions":["JMT601"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1, open-label, multi-center study to evaluate the safety of JMT601 in the treatment of relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma and to determine the recommended dose for Phase 2 studies (RP2D). Study consists of 2 parts. The first part is a dose-escalation part using a 3+3 design with up to 6 dose(0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 12 mg/kg and 20 mg/kg) escalation cohorts at increasing levels. The second part is a dose-expansion part at R2PD dose to assess preliminary efficacy of JMT601.","sourceUrl":"https://clinicaltrials.gov/study/NCT06725524"},{"nctId":"NCT06307925","title":"A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors","sponsor":"HC Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2024-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-13","conditions":["Advanced Solid Tumor"],"interventions":["HC010"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06307925"},{"nctId":"NCT06737081","title":"SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-12-17","conditions":["Anemia"],"interventions":["SAL-0951 tablets 4mg","SAL-0951 tablets 5mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of SAL-0951 in the treatment of chemotherapy-induced anemia (CIA) in patients with non-myeloid malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06737081"},{"nctId":"NCT06980454","title":"Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":322,"enrollmentType":"ESTIMATED","startDate":"2025-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Cancer","mCRC"],"interventions":["HLX05","EU-Erbitux®","US-Erbitux®","CN-Erbitux®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, single intravenous dose, parallel study to compare the PK characteristics, safety, tolerability, and immunogenicity of HLX05 vs. Erbitux® (US-, EU-, and CN-sourced) in healthy adult male Chinese subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06980454"},{"nctId":"NCT05978492","title":"A Study of TXN10128 in Subjects With Solid Tumors","sponsor":"Txinno Bioscience Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2023-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-04-24","conditions":["Locally Advanced (Unresectable) or Metastatic Solid Tumors"],"interventions":["TXN10128","Irinotecan","Paclitaxel"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors. This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.","sourceUrl":"https://clinicaltrials.gov/study/NCT05978492"},{"nctId":"NCT06180174","title":"Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2023-12-31","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2023-12-28","conditions":["B Cell Lymphoma","Non Hodgkin Lymphoma"],"interventions":["MC-1-50"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06180174"},{"nctId":"NCT06244992","title":"PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Pyrotech Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2024-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["PTT-936","Combination of PTT-936 and anti-PD-1/L1 therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 when administered as a monotherapy. Phase 2a (Part B) will assess the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy in patients suitable for anti- PD-1/L1 monotherapy. The study aims to understand how PTT-936, alone or in combination, impacts tumor progression and patients' overall response.","sourceUrl":"https://clinicaltrials.gov/study/NCT06244992"},{"nctId":"NCT06706713","title":"Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer","sponsor":"BeBetter Med Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2022-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-11-26","conditions":["Non-Small Cell Lung Cancer","EGFR Exon 20 Insertion Mutation"],"interventions":["BEBT-109 Capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in locally advanced or metastatic Non-Small Cell Lung Cancer （NSCLC）.","sourceUrl":"https://clinicaltrials.gov/study/NCT06706713"},{"nctId":"NCT05354323","title":"NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors","sponsor":"NEC OncoImmunity AS","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6,"enrollmentType":"ACTUAL","startDate":"2022-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2025-06-26","conditions":["Solid Tumors, Adult"],"interventions":["NECVAX-NEO1"],"countries":["Lithuania"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in n=6 patients with solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05354323"},{"nctId":"NCT06596915","title":"Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors","sponsor":"Shandong Boan Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":167,"enrollmentType":"ESTIMATED","startDate":"2024-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Non-Small Cell Lung Cancer","Pancreatic Adenocarcinoma","Breast Cancer","Melanoma"],"interventions":["BA1302"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).","sourceUrl":"https://clinicaltrials.gov/study/NCT06596915"},{"nctId":"NCT06126406","title":"Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2023-11-13","conditions":["Gastric Cancer","Colon Cancer","Rectal Cancer","Breast Cancer","Lung Cancer","Esophagus Cancer","Cholangiocarcinoma","Pancreas Cancer"],"interventions":["CEA-targeted CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CART cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.","sourceUrl":"https://clinicaltrials.gov/study/NCT06126406"},{"nctId":"NCT06251180","title":"Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2024-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-25","conditions":["B-cell Non-Hodgkin Lymphoma"],"interventions":["Rocbrutinib","Rituximab","Cyclophosphamide","doxorubicin","Vincristin","Prednisone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicentre Phase Ib study to evaluate the safety and preliminary efficacy of new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib in combination to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristin, Prednison) in adult patients with newly diagnosed, previously untreated B-cell Non-Hodgkin Lymphoma \\[Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma (MZL) or Mantle Cell Lymphoma (MCL)\\].","sourceUrl":"https://clinicaltrials.gov/study/NCT06251180"},{"nctId":"NCT06006390","title":"CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-09-07","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2024-08-09","conditions":["Gastric Cancer","Colon Cancer","Rectal Cancer","Esophageal Cancer","Pancreas Cancer","Lung Cancer","Breast Cancer"],"interventions":["CEA-targeted CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.","sourceUrl":"https://clinicaltrials.gov/study/NCT06006390"},{"nctId":"NCT05662397","title":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","sponsor":"HotSpot Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":77,"enrollmentType":"ACTUAL","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-04","conditions":["Solid Tumor, Adult","Relapsed Cancer","Refractory Cancer"],"interventions":["HST-1011","Cemiplimab"],"countries":["United States","Canada","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT05662397"},{"nctId":"NCT07096869","title":"Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2025-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-25","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["Bioequivalence"],"interventions":["Paclitaxel protein-bound particles for injectable suspension (albumin-bound)","Abraxane®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the bioequivalence of paclitaxel protein-bound particles for injectable suspension (albumin-bound) (100 mg, test product) and Abraxane® (100 mg, reference product) in breast cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07096869"},{"nctId":"NCT05566041","title":"A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer","sponsor":"EpicentRx, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":292,"enrollmentType":"ESTIMATED","startDate":"2022-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-10-31","conditions":["Carcinoma, Small Cell Lung"],"interventions":["RRx-001 + eLOOP Device","Cisplatin/carboplatin plus etoposide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This Global Phase 3 study aims to find out whether RRx-001 + platinum chemotherapy is more effective than platinum chemotherapy alone in 3rd line or beyond small cell cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05566041"},{"nctId":"NCT04275518","title":"A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2020-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2025-12-31","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Acute Myeloid Leukemia (AML)","Myelodysplastic Syndromes (MDS)"],"interventions":["APG-115","Azacitidine","Cytarabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"Acute myeloid leukemia is a malignant disorder characterized by the rapid, uncontrolled proliferation of malignant clonal hematopoietic stem cells that accumulate as immature, undifferentiated cells (blasts) in the bone marrow and circulation. APG-115 is a potent and orally active small-molecule MDM2 inhibitor, it binds to MDM2 protein and shows potent cell growth inhibitory activity in vitro with low nanomolar potencies in a subset of human cancer cell lines. APG-115 has demonstrated its strong antitumor activities with either daily or less frequent dosing-schedules in the acute leukemia xenograft models. This is a phase 1b, open-label, three-stages study that will initially evaluate the sa","sourceUrl":"https://clinicaltrials.gov/study/NCT04275518"},{"nctId":"NCT05442060","title":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"OBI Pharma, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2022-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Non-small Cell Lung Cancer"],"interventions":["30 μg OBI-833/100 μg OBI-821","Erlotinib (150 mg daily)"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, active control, open-label, phase 2 trial. Erlotinib-treated NSCLC patients will be screened for Globo H, and only Globo H+ (H score ≥ 100) subjects are eligible for the study. Eligible subjects who have been treated with 3±1 months of first-line erlotinib and have achieved stable disease (SD) or partial response (PR) status will be randomized in the ratio of 1:1 to receive erlotinib alone or erlotinib plus OBI-833/OBI-821 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05442060"},{"nctId":"NCT05280626","title":"First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-03-25","startDateType":"ESTIMATED","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2022-03-15","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["Sintilimab","Rituximab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma。The majority of refractory patients have PD-L1 expression due to P53 mutations, some of which account for about 10% of DLBCL.Our department has found that in refractory DLBCL with high PD-L1 expression, cedilizumab monotherapy is also more effective and has reversed chemotherapy resistance.The aim of this study was to determine whether the addition of sindilizumab to the R-CHOP regimen could improve the objective efficiency of DLBCL patients with P53 mutation with PD-L1 expression and to see if it could prolong patient survival.","sourceUrl":"https://clinicaltrials.gov/study/NCT05280626"},{"nctId":"NCT06998108","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","sponsor":"BeBetter Med Inc","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2022-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2025-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["HR+/HER2- Locally Advanced, Metastatic Breast Cancer"],"interventions":["BEBT-209 capsules","BEBT-209 Placebo capluses","Fulvestrant Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of BEBT-209 in combination with fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06998108"},{"nctId":"NCT04853342","title":"To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":318,"enrollmentType":"ESTIMATED","startDate":"2021-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Non-small Cell Lung Carcinoma"],"interventions":["Drug: Furmonertinib 80 mg","Furmonertinib 80 mg placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04853342"},{"nctId":"NCT06410092","title":"Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001","sponsor":"Sound Biopharmaceuticals Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2024-05-10","conditions":["Solid Tumor"],"interventions":["FTL001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open, multi-center, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics and initial efficacy of FTL001 in patients with advanced and metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06410092"},{"nctId":"NCT05979155","title":"A Study of NWY001 in Subjects With Advanced Solid Tumors","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":196,"enrollmentType":"ESTIMATED","startDate":"2024-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2024-07-16","conditions":["Advanced Solid Tumor"],"interventions":["NWY001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts: Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part","sourceUrl":"https://clinicaltrials.gov/study/NCT05979155"},{"nctId":"NCT06293651","title":"Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Dong-A ST Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2024-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2025-02-12","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["DA-4505","DA-4505 + Pembrolizumab"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06293651"},{"nctId":"NCT05565417","title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","sponsor":"Immunitas Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":67,"enrollmentType":"ACTUAL","startDate":"2022-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-01","completionType":"ESTIMATED","lastUpdated":"2025-10-16","conditions":["Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Triple Negative Breast Cancer","Cutaneous Squamous Cell Carcinoma","Hormone Receptor Positive Breast Carcinoma","Small Bowel Cancer","Esophageal Cancer","Colorectal Cancer","Diffuse Large B Cell Lymphoma","Hodgkin Lymphoma","Burkitt Lymphoma","Follicular Lymphoma"],"interventions":["IMT-009","Fruquintinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009","sourceUrl":"https://clinicaltrials.gov/study/NCT05565417"},{"nctId":"NCT05698238","title":"Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours","sponsor":"Mabpro, a.s.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2023-03-15","conditions":["Clear Cell Renal Cell Carcinoma Metastatic","TNBC - Triple-Negative Breast Cancer","Head and Neck Cancer","Non-small-cell Lung Carcinoma","Mesothelioma, Malignant"],"interventions":["CA9hu-1"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Carbonic anhydrase IX (CA IX) has been implicated in the progression of most solid tumours and expression has been demonstrated in clinical samples from a variety of solid cancers. High expression is often associated with high grade or metastatic disease and poor prognosis. CA IX is not expressed in normal tissue, potentially providing a cancer-associated target that would not likely result in significant interruption of normal biologic function in organs not affected by cancer. A humanized monoclonal antibody CA9hu-1 has shown robust activity in a variety of tumour models including models of ovarian, prostate, breast, pancreatic, colon and lung where tumour growth and metastasis are inhibit","sourceUrl":"https://clinicaltrials.gov/study/NCT05698238"},{"nctId":"NCT05901935","title":"DP303c in Patients With HER2-positive Advanced Breast Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2023-07","startDateType":"ESTIMATED","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2023-06-13","conditions":["HER2-positive Advanced Breast Cancer"],"interventions":["DP303c","Trastuzumab","Vinorelbine Tartrate","Capecitabine tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This is a study of DP303c in patients with HER2-positive advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05901935"},{"nctId":"NCT07070349","title":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Patients With Solid Tumors"],"interventions":["HRS-6213"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.","sourceUrl":"https://clinicaltrials.gov/study/NCT07070349"},{"nctId":"NCT04730258","title":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML","sponsor":"Treadwell Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2021-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-01","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia","AML","MDS","CMML"],"interventions":["CFI-400945","Azacitidine"],"countries":["United States","Canada","Hong Kong"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.","sourceUrl":"https://clinicaltrials.gov/study/NCT04730258"},{"nctId":"NCT06754085","title":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","sponsor":"HTA Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":131,"enrollmentType":"ESTIMATED","startDate":"2024-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-01","completionType":"ESTIMATED","lastUpdated":"2024-12-31","conditions":["Prostate Cancer"],"interventions":["Florastamin[18F] Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"In this study, 18F-Florastamin PET/CT will be performed in patients with suspected recurrence of prostate cancer, to assess the diagnostic performance and safety of 18F-Florastamin PET/CT imaging.","sourceUrl":"https://clinicaltrials.gov/study/NCT06754085"},{"nctId":"NCT04205227","title":"ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors","sponsor":"ENB Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":137,"enrollmentType":"ESTIMATED","startDate":"2020-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Cancer","Melanoma","Ovary Cancer","Pancreatic Cancer","Solid Tumor"],"interventions":["ENB003","Pembrolizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in combination with Pembrolizumab in solid tumors. The study is separated into two parts. Part A is a 3+3 dose escalation to define the recommended RP2D; this part will include metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer patients subjects, but other solid tumors will be allowed. Once the RP2D is selected, the study will be expanded into metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer subjects. A small number of sarcoma subjects will be included, as exploratory.","sourceUrl":"https://clinicaltrials.gov/study/NCT04205227"},{"nctId":"NCT06761651","title":"A Study of TAVO412 in Patients with Cancer (TAVO412)","sponsor":"Tavotek Biotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-15","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Cancer"],"interventions":["TAVO412"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412. Part 1 will utilize a standard 3 + 3 design to determine the MTD/RP2D of TAVO412 in subjects with advanced or metastatic solid tumors who progressed on prior approved standard of care therapy. Part 2 will further evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and pharmacologic activity of TAVO412 in a new set of subjects with advanced or metastatic gastric cancer, non-small cell lung cancer (NSCLC), or subjects of other solid tumor types with best clinical responses (e.g., CR \\> PR ","sourceUrl":"https://clinicaltrials.gov/study/NCT06761651"},{"nctId":"NCT06618651","title":"A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Solid Tumors"],"interventions":["SHR-3821 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3821 injection in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06618651"},{"nctId":"NCT05144698","title":"RAPA-201 Therapy of Solid Tumors","sponsor":"Rapa Therapeutics LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2021-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-14","conditions":["Solid Tumor","Small Cell and Non-small Cell Lung Cancer","Head and Neck Cancer","Squamous Cell Carcinoma of Oral Cavity","Squamous Cell Carcinoma of Larynx","Squamous Cell Carcinoma of Nasopharynx","Squamous Cell Carcinoma of Other Specified Sites of Skin","Malignant Melanoma","Esophageal Squamous Cell Carcinoma"],"interventions":["RAPA-201 Rapamycin Resistant T Cells","Chemotherapy Prior to RAPA-201 Therapy","Pembrolizumab (PD-1 Blocking Antibody)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evaluate the adoptive transfer of RAPA-201 cells, which are checkpoint-deficient polyclonal T cells that represent an analogous yet distinct immune therapy treatment platform for solid tumors. The administration of polyclonal, metabolically-fit RAPA-201 cells is a novel adoptive T cell therapy approach that is suitable for regenerative medicine efforts. RAPA-201 is a novel immunotherapy product consisting of repr","sourceUrl":"https://clinicaltrials.gov/study/NCT05144698"},{"nctId":"NCT06703177","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":876,"enrollmentType":"ESTIMATED","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2025-12-03","conditions":["Advanced Solid Tumors"],"interventions":["SHR-1826","SHR-4642","SHR-9839","SHR-8068","Bevacizumab Injection","Fluorouracil Injection","Calcium Folinate Injection","Adebrelimab Injection","Capecitabine tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06703177"},{"nctId":"NCT06105632","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":333,"enrollmentType":"ACTUAL","startDate":"2024-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-12","primaryCompletionType":"ACTUAL","completionDate":"2028-01-21","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Advanced or Metastatic Breast Cancer"],"interventions":["PF-07220060 CDK4 inhibitor","Fulvestrant","Everolimus","Exemestane"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","India","Israel","Japan","Mexico","South Korea","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":128,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: * are 18 years of age or older; * are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; * have advanced or metastatic breast cancer after taking other treatments before this study; * have not taken or need to ","sourceUrl":"https://clinicaltrials.gov/study/NCT06105632"},{"nctId":"NCT04819100","title":"A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2021-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-12","primaryCompletionType":"ACTUAL","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Selpercatinib","Placebo"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hong Kong","India","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":211,"serviceSignals":["RNA fusion"],"summary":"The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.","sourceUrl":"https://clinicaltrials.gov/study/NCT04819100"},{"nctId":"NCT05925530","title":"Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":142,"enrollmentType":"ACTUAL","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-12","primaryCompletionType":"ACTUAL","completionDate":"2027-08-27","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Non-small Cell Lung Cancer"],"interventions":["Durvalumab"],"countries":["United States","Austria","Canada","Czechia","France","Germany","Hungary","Italy","Portugal","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05925530"},{"nctId":"NCT06558279","title":"A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis","sponsor":"argenx","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":141,"enrollmentType":"ACTUAL","startDate":"2024-09-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-12","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Myasthenia Gravis, Ocular"],"interventions":["Efgartigimod PH20 SC","Placebo PH20 SC"],"countries":["United States","Australia","Austria","Belgium","Canada","China","Cyprus","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Italy","Japan","Netherlands","Poland","Portugal","Serbia","South Korea","Spain","Sweden","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":102,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of efgartigimod PH20 SC given by a pre-filled syringe in adult patients with ocular myasthenia gravis. The study consists of a part A (approximately 7 weeks) and a part B (up to 2 years). In part A, half of the participants will receive efgartigimod PH20 SC and the other half will receive placebo. In part B, all participants will receive efgartigimod PH20 SC. The participants will be in the study for about up to 2 years and 12 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT06558279"},{"nctId":"NCT04657991","title":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":257,"enrollmentType":"ACTUAL","startDate":"2021-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-12","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Melanoma"],"interventions":["Encorafenib","Binimetinib","Pembrolizumab"],"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Finland","France","Germany","Greece","Hungary","Israel","Italy","Mexico","New Zealand","Norway","Poland","Russia","Slovakia","South Africa","Spain","Switzerland","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":143,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the treatment of melanoma that: * is advanced or metastatic (spread to other parts of the body); * has a certain type of abnormal gene called \"BRAF\"; and * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic once every 3 weeks as an intravenous (IV) infusion (given directly into a vein). In addition, half of the participants will take encorafenib and binimetinib orally (by mouth) at home every day. Participants may receive pembrolizumab for up to two years. Those participants taking encora","sourceUrl":"https://clinicaltrials.gov/study/NCT04657991"},{"nctId":"NCT06382142","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":418,"enrollmentType":"ACTUAL","startDate":"2024-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-13","primaryCompletionType":"ACTUAL","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Triple-Negative Breast Cancer"],"interventions":["BL-B01D1","Eribulin","Vinorelbine","Gemcitabine","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure.","sourceUrl":"https://clinicaltrials.gov/study/NCT06382142"},{"nctId":"NCT06239480","title":"SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations","sponsor":"Palvella Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":51,"enrollmentType":"ACTUAL","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-14","primaryCompletionType":"ACTUAL","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Microcystic Lymphatic Malformation"],"interventions":["QTORIN 3.9% Rapamycin Anhydrous Gel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess the change in microcystic lymphatic malformations IGA after 24 weeks of treatment with QTORIN 3.9% Rapamycin Anhydrous Gel in approximately 40 participants with microcystic lymphatic malformations. Efficacy will be evaluated at 24 weeks and patients have the option of continuing on treatment for \\>24 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT06239480"},{"nctId":"NCT04250922","title":"LAM561 With RT and TMZ for Adults With Glioblastoma","sponsor":"Laminar Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":144,"enrollmentType":"ACTUAL","startDate":"2019-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Primary Glioblastoma","Glioblastoma Multiforme"],"interventions":["LAM561","TMZ","RT"],"countries":["France","Israel","Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04250922"},{"nctId":"NCT05668988","title":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":324,"enrollmentType":"ACTUAL","startDate":"2022-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-16","primaryCompletionType":"ACTUAL","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Non-small Cell Lung Cancer"],"interventions":["sunvozertinib","Pemetrexed+carboplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Italy","Poland","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":158,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by ","sourceUrl":"https://clinicaltrials.gov/study/NCT05668988"},{"nctId":"NCT04793958","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":461,"enrollmentType":"ACTUAL","startDate":"2021-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-16","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Colorectal Cancer","Metastatic Colorectal Cancer"],"interventions":["MRTX849","Cetuximab","mFOLFOX6 Regimen","FOLFIRI Regimen"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Ireland","Italy","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","Singapore","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":419,"serviceSignals":["RAS genotyping"],"summary":"Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04793958"},{"nctId":"NCT06660563","title":"A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":19,"enrollmentType":"ACTUAL","startDate":"2024-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-19","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["JNJ-80948543","JNJ-75348780"],"countries":["Australia","Spain","Taiwan","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT06660563"},{"nctId":"NCT05068102","title":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2022-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-22","primaryCompletionType":"ACTUAL","completionDate":"2027-07-14","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Carcinoma, Squamous Cell of Head and Neck (HNSCC)","Melanoma","Non-small Cell Lung Cancer (NSCLC)"],"interventions":["BI 765063","Ezabenlimab","[89Zr]Zr- BI 765063","BI 770371","[89Zr]Zr- BI 770371"],"countries":["Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced head and neck cancer, skin cancer, or non-small cell lung cancer. People can take part if previous treatments were not successful. The purpose of this study is to find out how 2 medicines called BI 765063 and BI 770371 are taken up in the tumours and how they get distributed in the body. In addition to BI 765063 or BI 770371, participants also receive ezabenlimab. BI 765063, BI 770371 and ezabenlimab are antibodies that may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. Participants get either BI 765063 or BI 770371 in combination with ezabenlimab as an infusion into a vein every 3 weeks. In the fir","sourceUrl":"https://clinicaltrials.gov/study/NCT05068102"},{"nctId":"NCT04404283","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":239,"enrollmentType":"ACTUAL","startDate":"2020-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-23","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["Brentuximab vedotin","Rituximab","Lenalidomide","Placebo"],"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","France","Italy","Poland","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":143,"serviceSignals":["Hematology NGS"],"summary":"Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is \"blinded,\" participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04404283"},{"nctId":"NCT06731699","title":"A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS","sponsor":"Chengdu FenDi Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2024-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-01","completionType":"ESTIMATED","lastUpdated":"2024-12-17","conditions":["AML","NHL"],"interventions":["FD-001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, dose-escalation and dose-expansion phase I clinical trial aimed at assessing the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary efficacy of FD-001 capsules in the treatment of recurrent/refractory hematologic malignancies(AML/MDS/NHL/MM). The trial consists of two phases: the initial phase (dose escalation) and the subsequent phase (dose expansion). The primary objectives are to evaluate the safety and tolerability of FD-001 in subjects with recurrent/refractory hematologic tumors and determine the maximum tolerated dose (MTD) as well as the recommended Phase II dose (RP2D) for FD-001 in this patient population.","sourceUrl":"https://clinicaltrials.gov/study/NCT06731699"},{"nctId":"NCT05466799","title":"FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma","sponsor":"OncoSil Medical Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":88,"enrollmentType":"ACTUAL","startDate":"2023-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-26","primaryCompletionType":"ACTUAL","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Locally Advanced Pancreatic Cancer"],"interventions":["FOLFIRINOX chemotherapy","OncoSil™"],"countries":["Australia","Belgium","Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the safety and efficacy of OncoSil™ when given in addition to standard FOLFIRINOX chemotherapy for treatment of Locally Advanced Pancreatic Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05466799"},{"nctId":"NCT07179081","title":"A Study of AL58805 in Patients With Advanced Tumors","sponsor":"Advenchen Laboratories Nanjing Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2020-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-26","primaryCompletionType":"ESTIMATED","completionDate":"2026-01-26","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Advanced Tumors"],"interventions":["AL58805"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT07179081"},{"nctId":"NCT05399654","title":"A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors","sponsor":"Tallac Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2022-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-27","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-19","completionType":"ESTIMATED","lastUpdated":"2024-08-16","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["TAC-001"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.","sourceUrl":"https://clinicaltrials.gov/study/NCT05399654"},{"nctId":"NCT05945823","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","sponsor":"Taiho Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":53,"enrollmentType":"ACTUAL","startDate":"2023-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-28","primaryCompletionType":"ACTUAL","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer","Esophageal Adenocarcinoma","Esophageal Squamous Cell Cancer","Siewert Type 1 GEJ Cancer","Pancreatic Cancer"],"interventions":["Futibatinib","Pembrolizumab","Cisplatin","5-FU","Oxaliplatin","Leucovorin","Levoleucovorin","Irinotecan"],"countries":["United States","France","Germany","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is a nonrandomized, uncontrolled, open-label, multicenter Phase 2 study to evaluate the efficacy, safety, and tolerability of futibatinib in combination with PD-1 antibody-based SoC therapy in adult patients with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05945823"},{"nctId":"NCT05290597","title":"A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2022-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-28","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Solid Malignancies or Lymphomas"],"interventions":["IBI363"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI363 (study drug) in subjects with advanced, refractory solid malignancies or lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05290597"},{"nctId":"NCT05489289","title":"A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2023-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Hepatocellular Carcinoma"],"interventions":["AK104","placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The efficacy and safety of AK104 as adjuvant therapy in hepatocellular carcinoma of high recurrence risk after curative resection.","sourceUrl":"https://clinicaltrials.gov/study/NCT05489289"},{"nctId":"NCT06139406","title":"A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ACTUAL","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-30","primaryCompletionType":"ACTUAL","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["JNJ-87801493","JNJ-80948543","JNJ-75348780"],"countries":["Australia","Denmark","Israel","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) \\[Part A: Dose Escalation\\] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs \\[Part B: Dose Expansion\\].","sourceUrl":"https://clinicaltrials.gov/study/NCT06139406"},{"nctId":"NCT04546009","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":992,"enrollmentType":"ACTUAL","startDate":"2020-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-30","primaryCompletionType":"ACTUAL","completionDate":"2028-03-25","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer"],"interventions":["Giredestrant","Giredestrant-matched Placebo","Letrozole","Letrozole-matched Placebo","Palbociclib","LHRH Agonist"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Denmark","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","New Zealand","Peru","Poland","Portugal","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":256,"serviceSignals":["HER2 profiling"],"summary":"This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04546009"},{"nctId":"NCT06125197","title":"Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer","sponsor":"TILT Biotherapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2024-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-30","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Lung Cancer"],"interventions":["TILT-123","KEYTRUDA®"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open label, Phase 1, dose escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with immune checkpoint inhibitor refractory non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06125197"},{"nctId":"NCT06616389","title":"Study of ODX (OsteoDex) in Multiple Myeloma","sponsor":"DexTech Medical AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2023-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-01-30","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Multiple Myeloma"],"interventions":["ODX (Osteodex)"],"countries":["Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The current phase I/IIa trial is a multi-center, prospective, open-label, ascending dose study to evaluate safety and biological efficacy of up to 3 dose levels of ODX. Each dose cohort will consist of 4 subjects. Each subject will receive up to 7 doses of ODX, given at 2-week intervals, until unacceptable toxicity or disease progression. A follow-up visit will be conducted 2 weeks after the last dose. Primary objectives: • To determine the safety and tolerability of ODX in subjects with relapsed/refractory multiple myeloma. Secondary objectives: * To evaluate the preliminary efficacy of ODX, as determined by the IMWG response criteria, in subjects with relapsed/refractory multiple myeloma. ","sourceUrl":"https://clinicaltrials.gov/study/NCT06616389"},{"nctId":"NCT05851014","title":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","sponsor":"Genor Biopharma Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2022-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-30","completionType":"ESTIMATED","lastUpdated":"2023-05-09","conditions":["Breast Cancer"],"interventions":["GB491 combined with Letrozole","Placebo combined with Letrozole"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":52,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT05851014"},{"nctId":"NCT05749432","title":"A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2023-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-04-18","conditions":["Solid Tumor"],"interventions":["Hemay181"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study will be conducted in about 51 participants in total. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor efficacy of Hemay181 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05749432"},{"nctId":"NCT06927466","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.","sponsor":"Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2024-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-22","conditions":["Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia"],"interventions":["B019"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06927466"},{"nctId":"NCT06757335","title":"A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer","sponsor":"Hinova Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":204,"enrollmentType":"ESTIMATED","startDate":"2025-01-07","startDateType":"ESTIMATED","primaryCompletionDate":"2026-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-27","completionType":"ESTIMATED","lastUpdated":"2025-01-03","conditions":["Breast Cancer"],"interventions":["HP568","HP568 in combination with palbociclib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06757335"},{"nctId":"NCT06219356","title":"A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas","sponsor":"Hangzhou GluBio Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Non-Hodgkin Lymphoma"],"interventions":["GLB-002"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06219356"},{"nctId":"NCT05276726","title":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2022-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Non-small Cell Lung Cancer"],"interventions":["JAB 21822"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["RAS genotyping"],"summary":"Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05276726"},{"nctId":"NCT06277154","title":"MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma","sponsor":"HRYZ Biotech Co.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":148,"enrollmentType":"ESTIMATED","startDate":"2024-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Leiomyosarcoma","Liposarcoma","Synovial Sarcoma","Angiosarcoma","Undifferentiated Pleomorphic Sarcoma","Epithelioid Sarcoma","Malignant Peripheral Nerve Sheath Tumors","Fibrosarcoma","Pleomorphic Rhabdomyosarcoma","Endometrial Stromal Sarcoma","Desmoplastic Small Round Cell Tumor"],"interventions":["MASCT-I","Doxorubicin","Ifosfamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06277154"},{"nctId":"NCT06268574","title":"Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML","sponsor":"Ryvu Therapeutics SA","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2024-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-05-08","conditions":["Acute Myeloid Leukemia (AML)","High-risk Myelodysplastic Syndrome"],"interventions":["RVU120"],"countries":["France","Italy","Poland","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":41,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to assess the safety, tolerability, anti-tumor activity (efficacy), pharmacokinetics (PK), and pharmacodynamics (PD) of the agent RVU120 when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progressing high-risk myelodysplastic syndrome (HR-MDS) and who have no alternative therapies available. The study consists of two parts. Part 1 will assess the safety and tolerability of the dosages given and the level of anti-tumor activity or clinical response. Based on the results from part 1 the study will continue to enrol patient into Part 2 which will continue to evaluate safety and tolerability and anti-tumor activit","sourceUrl":"https://clinicaltrials.gov/study/NCT06268574"},{"nctId":"NCT05787613","title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2023-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["NSCLC Stage IV"],"interventions":["HLX26","Serplulimab","Chemotherapy drug","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) Patients","sourceUrl":"https://clinicaltrials.gov/study/NCT05787613"},{"nctId":"NCT06299839","title":"PAS-004 in Patients With Advanced Solid Tumors","sponsor":"Pasithea Therapeutics Corp.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2024-02-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-12-03","conditions":["RAS Mutation","NF1 Mutation","RAF Mutation","Advanced Solid Tumors"],"interventions":["PAS-004 Capsules","PAS-004 Tablets"],"countries":["United States","Bulgaria","Romania"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of this clinical trial is to test PAS-004 in people with advanced solid tumors with rat sarcoma virus (RAS), neurofibromatosis type I (NF1), or rapidly accelerated fibrosarcoma (RAF) mutations. The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. Study participants will have regular visits to the study doctor and be asked to have tests and exams done to check on their health and safety. Everyone participating in the study will take PAS-004 by mouth as a single dose, followed by one week observation, then once a day during the study, in 28-day cycles. Participants will conti","sourceUrl":"https://clinicaltrials.gov/study/NCT06299839"},{"nctId":"NCT05737628","title":"First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228","sponsor":"Byondis B.V.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2024-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Lymphoma"],"interventions":["BYON4228 + Rituximab"],"countries":["Italy","Netherlands","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.","sourceUrl":"https://clinicaltrials.gov/study/NCT05737628"},{"nctId":"NCT06668792","title":"An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Biocad","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-02-04","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["BCD-248"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"The aim of the study is to assess the efficacy and safety of BCD-248 as a therapy for relapsing and/or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06668792"},{"nctId":"NCT07051486","title":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Recurrent or Metastatic Cervical Cancer"],"interventions":["SHR-A1811 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study is a single-arm, multicenter Phase II clinical trial of SHR-A1811 for injection in patients with HER2-expressing recurrent or metastatic cervical cancer who have failed prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07051486"},{"nctId":"NCT06191263","title":"Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML","sponsor":"Ryvu Therapeutics SA","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2024-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Acute Myeloid Leukemia"],"interventions":["RVU120","Venetoclax"],"countries":["France","Italy","Poland","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia (AML) who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent. The study consists of three parts. Part 1 aims to identify the doses of RVU120 and venetoclax that are considered to be safe and tolerated. Part 2 will assess the safety and efficacy of the doses selected. And Part 3 is a confirmatory cohort where patients will be treated at the same doses assessed in Part 2","sourceUrl":"https://clinicaltrials.gov/study/NCT06191263"},{"nctId":"NCT06240546","title":"First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.","sponsor":"Luye Pharma Group Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2024-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2024-03-15","conditions":["Advanced Solid Tumor"],"interventions":["LPM6690176"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06240546"},{"nctId":"NCT06182592","title":"A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2023-12-28","conditions":["High-risk (Secondary) Acute Myeloid Leukemia"],"interventions":["Liposomal cytarabine-daunorubicin for injection","7+3 (cytarabine and daunorubicin)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this bridging study is to determine the efficacy of liposomal cytarabine-daunorubicin for injection compared with cytarabine and daunorubicin in older patients with high-risk (secondary) acute myeloid leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06182592"},{"nctId":"NCT04721015","title":"Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":81,"enrollmentType":"ACTUAL","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2025-07-03","conditions":["Advanced Solid Tumors Cancer","Non Small Cell Lung Cancer (NSCLC)"],"interventions":["ABBV-637","Docetaxel","Osimertinib"],"countries":["United States","Australia","France","Israel","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to evaluate the safety and efficacy (how well the study drug works against the disease) of ABBV-637 alone or in combination with docetaxel/osimertinib in participants with solid tumors (NSCLC). Adverse events and change in disease activity will be assessed. ABBV-637 is an investigational drug being developed for the treatment of solid tumors. Study consists of 3 parts - monotherapy dose escalation (Part 1), combination dose escalation and expansion (Par","sourceUrl":"https://clinicaltrials.gov/study/NCT04721015"},{"nctId":"NCT06946927","title":"A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation","sponsor":"Jemincare","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["JMKX001899","IN10018","Chemotherapy: Pemetrexed","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06946927"},{"nctId":"NCT05201404","title":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","sponsor":"Can-Fite BioPharma","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":471,"enrollmentType":"ESTIMATED","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-04-29","conditions":["Hepatocellular Carcinoma","Cirrhosis"],"interventions":["Namodenoson","Placebo"],"countries":["United States","Bosnia and Herzegovina","Bulgaria","Israel","Moldova","Poland","Romania","Serbia","Slovakia"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT05201404"},{"nctId":"NCT05768919","title":"Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas","sponsor":"SignPath Pharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["Glioblastoma"],"interventions":["Treatment Period 1","Treatment Period 2","Treatment Period 3","Treatment Period 4a"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).","sourceUrl":"https://clinicaltrials.gov/study/NCT05768919"},{"nctId":"NCT06430437","title":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2024-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Non-Small Cell Lung Cancer With HER2- Mutations"],"interventions":["SHR-A1811","PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 versus Standard of Care as first-line treatment of advanced or metastatic Non-Small Cell Lung Cancer with HER2- Mutations","sourceUrl":"https://clinicaltrials.gov/study/NCT06430437"},{"nctId":"NCT06325748","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","sponsor":"Senti Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2024-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2040-08","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["AML/MDS","CD33 Expressing Hematological Malignancies","FLT3 Expressing Hematological Malignancies"],"interventions":["SENTI-202"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label study of the safety, biodynamics, and anti-cancer activity of SENTI-202 (an off-the-shelf logic gated CAR NK cell therapy) in patients with CD33 and/or FLT3 expressing blood cancers, including AML and MDS.","sourceUrl":"https://clinicaltrials.gov/study/NCT06325748"},{"nctId":"NCT06232096","title":"A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.","sponsor":"Beijing Mabworks Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2024-03-15","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["MBS314 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I/Ⅱ, multicenter, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics(PD) and efficacy of a novel asymmetric trivalent tri-specific humanized antibody, MBS314, administered by intravenous (IV) infusion in participants with relapsed or refractory multiple myeloma. This entry-to-human study is divided in 2 parts: a dose escalation part (Phase Ⅰa) and an expansion part (Phase Ⅰb/Ⅱ).","sourceUrl":"https://clinicaltrials.gov/study/NCT06232096"},{"nctId":"NCT06265428","title":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","sponsor":"DualityBio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":228,"enrollmentType":"ACTUAL","startDate":"2024-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-02","completionType":"ESTIMATED","lastUpdated":"2025-10-20","conditions":["HER2-positive Breast Cancer"],"interventions":["DB-1303/BNT323","T-DM1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":48,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.","sourceUrl":"https://clinicaltrials.gov/study/NCT06265428"},{"nctId":"NCT05645276","title":"A Study of AK129 in Patients With Advanced Malignant Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2023-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-03-03","conditions":["Advanced Malignant Tumors(Stage IA-IB)"],"interventions":["AK129 IV infusion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase Ia/Ib, open label, dose escalation and dose extension trial of Anti-PD-1 and LAG-3 bispecific antibody, AK129, to evaluate the safety, tolerability and antitumor efficacy in patients with advanced malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05645276"},{"nctId":"NCT04670679","title":"A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Erasca, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ACTUAL","startDate":"2020-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-01","primaryCompletionType":"ACTUAL","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["ERAS-601","Cetuximab","Pembrolizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04670679"},{"nctId":"NCT06484829","title":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-01","completionType":"ESTIMATED","lastUpdated":"2025-04-02","conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"interventions":["Purinostat Mesylate 4 mg/m2","Purinostat Mesylate 6 mg/m2","Purinostat Mesylate 8.4 mg/m2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Primary Purpose Phase Ib. To determine the Maximum Tolerated Dose (MTD) and establish the Recommended Phase IIa Dose (RP2D) of Purinostat Mesylate for Injection combined with fixed-dose Pomalidomide Capsules and Dexamethasone in patients with relapsed or refractory multiple myeloma. Phase IIa. To further evaluate the safety and tolerability of Purinostat Mesylate for Injection at the RP2D combined with fixed-dose Pomalidomide Capsules and Dexamethasone in patients with relapsed and refractory multiple myeloma (RRMM). Secondary Objectives Phase Ib 1. To evaluate the safety and tolerability of Purinostat Mesylate for Injection combined with fixed-dose Pomalidomide Capsules and Dexamethasone in","sourceUrl":"https://clinicaltrials.gov/study/NCT06484829"},{"nctId":"NCT04586231","title":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":747,"enrollmentType":"ACTUAL","startDate":"2021-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-02","primaryCompletionType":"ACTUAL","completionDate":"2027-02-11","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Carcinoma, Renal Cell"],"interventions":["Belzutifan","Lenvatinib","Cabozantinib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Finland","France","Germany","Greece","Ireland","Italy","Japan","Netherlands","Poland","Romania","Russia","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":184,"serviceSignals":["Broad CGP"],"summary":"This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.","sourceUrl":"https://clinicaltrials.gov/study/NCT04586231"},{"nctId":"NCT06899061","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":41,"enrollmentType":"ACTUAL","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-03","primaryCompletionType":"ACTUAL","completionDate":"2028-05-19","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Solid Malignancies"],"interventions":["Saruparib","Digoxin","Furosemide","Metformin Hydrochloride","Rosuvastatin","Rabeprazole"],"countries":["Bulgaria","Moldova","Romania"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A Phase I modular study to assess the effect of oral saruparib on other treatments in patients with advanced solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06899061"},{"nctId":"NCT05807035","title":"Autologous Tumour Vaccine Trial","sponsor":"Vaxine Pty Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-10","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Solid Tumor"],"interventions":["Radvax"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid cancers either as monotherapy or in combination with other standard of care agents","sourceUrl":"https://clinicaltrials.gov/study/NCT05807035"},{"nctId":"NCT03603951","title":"A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":272,"enrollmentType":"ACTUAL","startDate":"2018-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-14","completionType":"ESTIMATED","lastUpdated":"2024-10-01","conditions":["Relapsed or Refractory Mature Lymphoid Neoplasms"],"interventions":["SHR2554"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554. This study will assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in participants with relapsed or refractory mature lymphoid neoplasms in part I, and the the efficacy in PTCL patients will be studied in Part II.","sourceUrl":"https://clinicaltrials.gov/study/NCT03603951"},{"nctId":"NCT03661320","title":"A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":855,"enrollmentType":"ACTUAL","startDate":"2018-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-16","primaryCompletionType":"ACTUAL","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Urinary Bladder Neoplasms","Muscle-Invasive Bladder Cancer"],"interventions":["Nivolumab","Gemcitabine","Cisplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Finland","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Portugal","Romania","Russia","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":172,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03661320"},{"nctId":"NCT04821622","title":"Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":599,"enrollmentType":"ACTUAL","startDate":"2021-05-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-18","primaryCompletionType":"ACTUAL","completionDate":"2027-08-28","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Prostate Cancer"],"interventions":["talazoparib plus enzalutamide","Placebo plus enzalutamide"],"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","China","Czechia","Finland","France","Germany","Hungary","India","Italy","Japan","Mexico","Netherlands","Norway","Russia","Slovakia","South Africa","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":313,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04821622"},{"nctId":"NCT06268613","title":"A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy","sponsor":"Samsung Bioepis Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":163,"enrollmentType":"ACTUAL","startDate":"2024-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-19","primaryCompletionType":"ACTUAL","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Non-small Cell Lung Cancer Stage II","Non-small Cell Lung Cancer Stage IIIA"],"interventions":["SB27","EU sourced Keytruda","US sourced Keytruda"],"countries":["Poland","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC) patients who underwent surgery and adjuvant chemotherapy. The main question it aims to answer is: • What the body does to the study drug, which is called \"pharmacokinetic\" Participants will receive investigational product (IP) administration every 3 weeks, maximum 18 cycles over about 51 weeks and blood sample will be collected. Researchers will compare 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) to see if SB27 works in the same way as EU and US so","sourceUrl":"https://clinicaltrials.gov/study/NCT06268613"},{"nctId":"NCT06738966","title":"A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer","sponsor":"Shanghai Best-Link Bioscience, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2025-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-26","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Breast Cancer","Ovarian Cancer","Endometrial Cancer"],"interventions":["BL0175"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to learn if the investigational drug BL0175 works to treat adult postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative locally advanced or metastatic breast cancer, ovarian cancer and endometrial cancer. It will also learn about the safety of BL0175. The main questions it aims to answer are: * Does the investigational drug BL0175 is safe for participants after dosed -multiple times? * Which is the highest safety dose of BL0175 after multiple dose? * What medical problems do participants have when using BL0175? * Does the investigational drug BL0175 works for participants after dosed -multiple times?","sourceUrl":"https://clinicaltrials.gov/study/NCT06738966"},{"nctId":"NCT04562389","title":"Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis","sponsor":"Karyopharm Therapeutics Inc","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":353,"enrollmentType":"ACTUAL","startDate":"2021-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-20","primaryCompletionType":"ACTUAL","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Myelofibrosis"],"interventions":["Selinexor","Placebo","Ruxolitinib"],"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","Poland","Romania","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":166,"serviceSignals":["Hematology NGS"],"summary":"This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). Phase 3 (ongoing), double-blind, placebo-controlled part of the study comparing the efficacy and safety of combination therapy of selinexor + ruxolitinib with com","sourceUrl":"https://clinicaltrials.gov/study/NCT04562389"},{"nctId":"NCT05301842","title":"Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":760,"enrollmentType":"ACTUAL","startDate":"2022-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-23","primaryCompletionType":"ACTUAL","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Hepatocellular Carcinoma"],"interventions":["Tremelimumab","Durvalumab","Transarterial Chemoembolization (TACE)","Lenvatinib"],"countries":["United States","Belgium","Brazil","Canada","China","Egypt","France","Germany","India","Italy","Japan","Malaysia","Mexico","Philippines","Portugal","Puerto Rico","Saudi Arabia","South Korea","Spain","Taiwan","Thailand","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":171,"serviceSignals":["Broad CGP"],"summary":"A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05301842"},{"nctId":"NCT04974398","title":"A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":296,"enrollmentType":"ACTUAL","startDate":"2021-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-23","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-23","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Nasopharyngeal Carcinoma"],"interventions":["Penpulimab","placebo"],"countries":["United States","Australia","Brazil","Canada","China"],"northAmerica":true,"chinaSites":true,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04974398"},{"nctId":"NCT06592625","title":"Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-09-20","startDateType":"ESTIMATED","primaryCompletionDate":"2026-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Untreated Early-stage or Locally Advanced Breast Cancer"],"interventions":["SHR-A1811","Adebrelimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The study is being conducted to evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of the combination of SHR-A1811 with Adebrelimab Injection in treatment-naive patients with early-stage or locally advanced HR-negative or low expression, HER2 low expression breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06592625"},{"nctId":"NCT07364422","title":"To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","sponsor":"Onconic Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2026-02-27","startDateType":"ESTIMATED","primaryCompletionDate":"2026-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Gastric Cancer (GC)"],"interventions":["JPI-547","Irinotecan (drug)"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07364422"},{"nctId":"NCT06038396","title":"A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2025-01-29","conditions":["Advanced Solid Tumor"],"interventions":["RC118","Toripalimab","RC148"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":18,"serviceSignals":["ADC biomarker"],"summary":"This is an open, multi-center, dose escalation and expansion phase I/II study. The Phase I study will explore the tolerability and safety of RC118 in combination with Toripalimab for the treatment of patients with Claudin 18.2-positive, locally advanced unresectable or metastatic malignant solid tumors, and to establish the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); The Phase II study will evaluate the efficacy and safety of RC118 in combination with Toripalimab or RC148 in patients with locally advanced or metastatic Gastric cancer/Gastro-esophageal junction cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06038396"},{"nctId":"NCT05261750","title":"Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer","sponsor":"PT. Prodia Stem Cell Indonesia","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2022-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-02-28","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Nasopharyngeal Cancer"],"interventions":["Placebo (Aqua Pro-Injection)","Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy)","Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)"],"countries":["Indonesia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05261750"},{"nctId":"NCT05468489","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2022-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["Serplulimab + chemotherapy (carboplatin-etoposide)","Atezolizumab + chemotherapy (carboplatin-etoposide)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)","sourceUrl":"https://clinicaltrials.gov/study/NCT05468489"},{"nctId":"NCT06037018","title":"Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies","sponsor":"CytoCares Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2023-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Non-hodgkin Lymphoma","Acute Lymphoblastic Leukaemia","Chronic Lymphocytic Leukemia"],"interventions":["CC312"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1, open-label, dose-escalation study to evaluate the safety, PK, PD and immunogenicity of CC312 following intravenous doses of CC312 in patients with relapsed and refractory (r/r) CD19 expressing B-cell non-Hodgkin lymphoma and B-cell lymphocytic leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06037018"},{"nctId":"NCT07137819","title":"Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic Keratosis","sponsor":"Aresus Pharma GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2024-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Actinic Keratosis of Face and Scalp"],"interventions":["Topical treatment"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to show superiority of Veregen® 10% ointment to Placebo measured by complete (100%) clearance of a pre-defined treatment area (TA) following a treatment period of 12 weeks and a 4-weeks post-treatment (PT) period (i.e., after 16 weeks at most in patients without complete clearance at the end of the treatment (EoT) period).","sourceUrl":"https://clinicaltrials.gov/study/NCT07137819"},{"nctId":"NCT06825494","title":"Clinical Studies for the Treatment of Advanced Solid Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":194,"enrollmentType":"ESTIMATED","startDate":"2025-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Advanced Solid Tumor"],"interventions":["LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine","Tislelizumab+Oxaliplatin+Capecitabine","LM-108 injection 10mg/kg +penpulimab","LM-108 injection 600mg + penpulimab","enpulimab+ Oxaliplatin+Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"This trial is part of a multicenter, open-label Phase Ib/II clinical study evaluating the efficacy, safety, and tolerability of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors. Phase Ib of Cohort A1 determines the dose of LM-108 in combination with penpulimab + oxaliplatin + capecitabine. Phase II explores the efficacy and safety of LM-108 in combination with anti-tumor therapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06825494"},{"nctId":"NCT07318675","title":"A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-12-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2026-01-06","conditions":["Actinic Keratosis (AK)"],"interventions":["HW211026","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07318675"},{"nctId":"NCT06144723","title":"Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":402,"enrollmentType":"ESTIMATED","startDate":"2024-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2023-11-22","conditions":["Advanced Solid Tumor"],"interventions":["HS-20105"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"HS-20105 is a novel antibody-drug conjugate (ADC) targeting Trop-2. This first-in-human trial is aimed to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics (PK), safety and preliminary anti-tumor activity of HS-20105 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06144723"},{"nctId":"NCT04243785","title":"A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","sponsor":"Edgewood Oncology Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2020-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2024-03-20","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"interventions":["BTX-A51","Azacitidine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done in three parts. Part 1a (Monotherapy Dose Escalation) of this study is designed to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of orally administered BTX-A51 in up to 35 participants who are evaluable for toxicity. Once the MTD is determined, it is planned that an additional 15 participants will be enrolled in Part 1b (Monotherapy Cohort Expansion) of this study fo","sourceUrl":"https://clinicaltrials.gov/study/NCT04243785"},{"nctId":"NCT03893955","title":"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2019-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Cancer","Advanced Solid Tumors","Triple-Negative Breast Cancer (TNBC)","Non-small-cell-lung-cancer (NSCLC)","Metastatic Solid Tumors"],"interventions":["ABBV-927","ABBV-368","ABBV-181","Carboplatin","Nab-paclitaxel"],"countries":["United States","Australia","France","Israel","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT03893955"},{"nctId":"NCT05266105","title":"A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients","sponsor":"Olema Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2021-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Breast Cancer"],"interventions":["Palazestrant","Palbociclib"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, Phase 1b dose escalation and expansion study to determine the maximum tolerated dose (MTD) of OP-1250 in combination with palbociclib (Ibrance®️, Pfizer Inc.). Purpose of study is to evaluate the safety and pharmacokinetic (PK) profile, and estimate the preliminary anti-tumor activity of the combination in adult subjects with hormone receptor-positive (ER+ / HER2-) advanced or metastatic breast cancer (MBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05266105"},{"nctId":"NCT06084416","title":"A Study of Sovilnesib in Subjects With Ovarian Cancer","sponsor":"Volastra Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2025-10-20","conditions":["High Grade Serous Adenocarcinoma of Ovary","Fallopian Tube Cancer","Primary Peritoneal Carcinoma","Chromosomal Instability"],"interventions":["Sovilnesib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of sovilnesib at different dose levels to establish the Recommended Phase 2 Dose (RP2D) of sovilnesib in subjects with high grade serous ovarian cancer (HGSOC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06084416"},{"nctId":"NCT05868707","title":"OH2 Injection in Melanoma","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2023-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["Melanoma"],"interventions":["OH2","Salvage chemotherapy or best supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy of OH2 injection in patients with unresectable or metastatic melanoma who have failed at least second-line standard therapy, using investigator-selected salvage chemotherapy or best supportive care (BSC) as controls.","sourceUrl":"https://clinicaltrials.gov/study/NCT05868707"},{"nctId":"NCT06155084","title":"A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients","sponsor":"Hinova Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2023-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["HP518 - Dose Escalation","HP518 -Dose Expansion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase","sourceUrl":"https://clinicaltrials.gov/study/NCT06155084"},{"nctId":"NCT06220838","title":"Study SC-101 in Subjects With Advanced Malignancies","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-07-29","conditions":["Advanced Solid Tumor"],"interventions":["SC-101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06220838"},{"nctId":"NCT05286229","title":"A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":8,"enrollmentType":"ACTUAL","startDate":"2022-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-08-08","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["Etentamig"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease state of etentamig in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Two doses of ABBV-383 will be explored. Each treatment arm receives a different dose of ABBV-383 to determine a tolerable dose. Approximately 12 adult participants with R/R MM will b","sourceUrl":"https://clinicaltrials.gov/study/NCT05286229"},{"nctId":"NCT04868877","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","sponsor":"Merus B.V.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":194,"enrollmentType":"ACTUAL","startDate":"2021-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Non-Small Cell Lung Cancer Metastatic","Gastric Cancer","Esophageal Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Colorectal Cancer"],"interventions":["MCLA-129","Osimertinib","Chemotherapy"],"countries":["United States","Belgium","France","Germany","Italy","Netherlands","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["MET profiling"],"summary":"A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT04868877"},{"nctId":"NCT07110194","title":"Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["CD20-positive Hematological Malignancies"],"interventions":["TQB2825 Injection (Subcutaneous Injection)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to evaluate the pharmacokinetic characteristics, safety and efficacy of the TQB2825 injection (subcutaneous administration) in patients with CD20-positive hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07110194"},{"nctId":"NCT06700395","title":"A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2024-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2024-12-06","conditions":["Multiple Myeloma"],"interventions":["TQB2029 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a study to evaluate the maximum tolerated dose (MTD), dose limiting toxicity (DLT), occurrence of all adverse events (AEs) and serious adverse events (SAEs), pharmacokinetic parameters, pharmacodynamic parameters, immunogenicity, and anti-tumor effects of TQB2029 for injection in Chinese adult subjects with multiple myeloma. The study is divided into Phase Ia and Ib, Phase Ia: dose escalation phase, to evaluate the safety and tolerability of TQB2029 for injection, and determining DLT and MTD; Phase Ib: Dose extension phase, to evaluate the effectiveness of TQB2029 for injection in subjects with multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06700395"},{"nctId":"NCT05117476","title":"A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","sponsor":"Cullinan Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2021-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Advanced Solid Tumor","NSCLC"],"interventions":["CLN-619","Pembrolizumab","Paclitaxel","Carboplatin AUC 6","pemetrexed","Datopotamab deruxtecan-dlnk (Dato-DXd)"],"countries":["United States","Australia","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05117476"},{"nctId":"NCT06064812","title":"A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.","sponsor":"Forward Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2023-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Metastatic Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer Stage IV","ER+/HER2- Breast Cancer"],"interventions":["FWD1802"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":22,"serviceSignals":["HER2 profiling"],"summary":"A Phase I/II, Open-label study to assess the safety, tolerability, pharmacokinetic, and antitumor efficacy of FWD1802 monotherapy in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. This clinical trial aims to explore the role of FWD1802 in the ER+/HER2- advanced breast cancer patient population. The primary objectives are to address the following questions: Phase I Study: Determine the Recommended Phase II Dose (RP2D) and/or Maximum Tolerated Dose (MTD) of FWD1802 in patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer. Phase II Study: To evaluate the efficacy of FWD1802 at the RP2D in patients with ESR1-mutated ER-positive/","sourceUrl":"https://clinicaltrials.gov/study/NCT06064812"},{"nctId":"NCT06225843","title":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","sponsor":"Alethia Biotherapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":17,"enrollmentType":"ESTIMATED","startDate":"2024-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-02-19","conditions":["Metastatic Colorectal Cancer"],"interventions":["Sotevtamab","FOLFOX"],"countries":["Canada"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).","sourceUrl":"https://clinicaltrials.gov/study/NCT06225843"},{"nctId":"NCT04561362","title":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","sponsor":"BicycleTx Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":329,"enrollmentType":"ESTIMATED","startDate":"2020-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-14","conditions":["Urinary Bladder Neoplasm","Triple Negative Breast Neoplasms","Hormone Receptor Positive, HER2-negative Neoplasms","Hormone Receptor Positive, HER2-low Neoplasms","Breast Neoplasms","Non-Small-Cell Lung Neoplasms","Ovarian Neoplasm","Advanced Solid Tumor"],"interventions":["BT8009","Pembrolizumab"],"countries":["United States","Canada","France","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study is a Phase I/II, multicenter, first-in-human, open-label dose-escalation study of BT8009 given as a single agent and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency. The primary endpoints are: Dose limiting toxicities (Parts A-1 and A-2), Overall response rate per RECIST v1.1 (Parts B1-B7), Safety and tolerability (Parts B-8, B-9 and C), and characterization of the pharmacokinetics (Part D).","sourceUrl":"https://clinicaltrials.gov/study/NCT04561362"},{"nctId":"NCT06566586","title":"A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["B-cell Lymphoma"],"interventions":["TQB3702 tablets+Chemotherapy regimen"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06566586"},{"nctId":"NCT06578624","title":"Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Lamassu Bio Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-06-05","conditions":["Solid Tumor"],"interventions":["SA53-OS (phase 1)","SA53-OS (phase 2)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to assess the safety, efficacy, and pharmacokinetics of SA53-OS in adult participants with refractory solid tumors. The study is comprised of 2 parts: Part 1 called dose escalation, and Part 2a called dose expansion. This study starts with Part 1 where participants who are diagnosed with advanced or metastatic solid tumor cancers receive different doses of SA53-OS (starting with the lowest dose) to find the maximum tolerated dose (MTD) of SA53-OS. Once the MTD of SA53-OS is known, the study continues to Part 2a where participants who are diagnosed with dedifferentiated liposarcoma (DD LPS) or other solid tumor cancers will receive SA53-OS at the MTD. The study ","sourceUrl":"https://clinicaltrials.gov/study/NCT06578624"},{"nctId":"NCT06537596","title":"89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2024-12-19","conditions":["Soft Tissue Sarcoma"],"interventions":["89Zr-DFOsq-olaratumab (89Zr-TLX300-CDx)"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Soft Tissue Sarcoma (STS) is a type of cancer that develops in soft tissues such as muscles, tendons, fat, blood vessels, and nerves. STSs generally express a protein called Platelet-Derived Growth Factor Receptor (PDGFR)α, which makes them a target for the development of STS therapies, such as olaratumab. Olaratumab has been identified as a promising candidate to which radioactive substances can be attached for imaging or therapeutic purposes. Thus, this first in human imaging trial aims to study olaratumab combined with a radioactive metal called zirconium-89 (89Zr-TLX300-CDx) as a potential new product that may be used for STS imaging and identification of patients that may benefit from f","sourceUrl":"https://clinicaltrials.gov/study/NCT06537596"},{"nctId":"NCT05288205","title":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2022-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-03","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["KRAS P.G12C","Non-small Cell Lung Cancer","Colorectal Cancer","Pancreatic Ductal Carcinoma"],"interventions":["JAB-21822","JAB-3312"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":27,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label phase 1/2a study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of JAB-21822 in combination with JAB-3312 in patients with advanced solid tumors harboring KRAS p.G12C mutation and to determine the RP2D for the combination therapy. In the dose expansion phase, preliminary efficacy and safety of the combination therapy at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05288205"},{"nctId":"NCT05434312","title":"TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2021-03-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-02-24","conditions":["Chronic Myelogenous Leukemia"],"interventions":["TGRX-678"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT05434312"},{"nctId":"NCT06281678","title":"A Study of IBI363 in Subjects with Advanced Solid Malignancies","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2024-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-19","conditions":["Melanoma","Non-small Cell Lung Cancer","Colorectal Cancer","Renal Cell Cancer"],"interventions":["IBI363"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06281678"},{"nctId":"NCT03943004","title":"Trial of DFP-14927 in Advanced Solid Tumors","sponsor":"Delta-Fly Pharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2019-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-01","completionType":"ESTIMATED","lastUpdated":"2025-03-03","conditions":["Solid Tumor","Cancer"],"interventions":["DFP-14927"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03943004"},{"nctId":"NCT06993870","title":"Phase I Study of HBT-708 for Patients With Advanced Solid Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-28","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Advanced Solid Tumors"],"interventions":["HBT-708"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study will be to evaluate the safety, tolerability, and inital efficacy of HBT-708 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06993870"},{"nctId":"NCT06328673","title":"A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors","sponsor":"D2M Biotherapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2024-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-01","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Advanced Solid Tumor"],"interventions":["DM919","Pembrolizumab"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab?? Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to measure whether DM-919 will have the effect on tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06328673"},{"nctId":"NCT04648202","title":"FS120 Phase 1/1b Study in Patients With Advanced Malignancies","sponsor":"invoX Pharma Limited","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":82,"enrollmentType":"ACTUAL","startDate":"2020-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-01","completionType":"ESTIMATED","lastUpdated":"2025-06-27","conditions":["Advanced Cancer","Metastatic Cancer"],"interventions":["FS120"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT04648202"},{"nctId":"NCT06613217","title":"Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia","sponsor":"Pacylex Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2025-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-01","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Relapsed Adult AML"],"interventions":["zelenirstat"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a dose-finding study of oral zelenirstat (PCLX-001) in patients with R/R AML. There are two parts to the study: Dose Escalation and Dose Expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06613217"},{"nctId":"NCT06223841","title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2024-02-20","conditions":["Advanced Malignant Tumors"],"interventions":["IAP0971"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06223841"},{"nctId":"NCT06235229","title":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2023-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-02","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Multiple Myeloma"],"interventions":["GC012F"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06235229"},{"nctId":"NCT04960709","title":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":712,"enrollmentType":"ACTUAL","startDate":"2021-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-02","primaryCompletionType":"ACTUAL","completionDate":"2028-09-08","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Muscle Invasive Bladder Cancer"],"interventions":["Durvalumab","Tremelimumab","Enfortumab Vedotin","Radical Cystectomy"],"countries":["United States","Argentina","Austria","Brazil","Canada","Chile","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":196,"serviceSignals":["Broad CGP"],"summary":"A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or who refuse Cisplatin based chemotherapy Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. The goal of the study is to explore the triplet combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or the duplet combination of Durvalumab and Enfortumab vedotin in terms of efficacy and safety compared to the current Standard Of Care (SOC). VOLGA trial consists of two parts: Safety Run-In and Main Stud","sourceUrl":"https://clinicaltrials.gov/study/NCT04960709"},{"nctId":"NCT05348577","title":"Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1035,"enrollmentType":"ACTUAL","startDate":"2022-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-04","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Prostate Cancer"],"interventions":["capivasertib","docetaxel","placebo"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Czechia","France","Greece","Hungary","India","Israel","Japan","Mexico","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":217,"serviceSignals":["Broad CGP"],"summary":"This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT05348577"},{"nctId":"NCT05736406","title":"A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma","sponsor":"Hemerion Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-06","primaryCompletionType":"ACTUAL","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Primary Glioblastoma"],"interventions":["5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 200 J/cm^2","5-ALA HCl intraoperative Photodynamic Therapy (PDT) at 400 J/cm^2"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 75 with newly diagnosed glioblastoma. This treatment will be carried out in addition to the maximal surgical resection. Data collected during this trial will be used to design the upcoming pivotal study . The study will utilize an independent Data and Safety Monitoring Board (iDSMB) that will review safety data to allow dose escalation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05736406"},{"nctId":"NCT06830031","title":"Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma","sponsor":"Shanghai Exuma Biotechnology Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-11","completionType":"ESTIMATED","lastUpdated":"2025-06-13","conditions":["Diffuse Large B-cell-lymphoma","DLBCL, Nos Genetic Subtypes","Follicular Lymphoma Grade 3B","PMBL","HGBL With MYC and BCL2 and/or BCL6 Rearrangements","HGBL, Nos"],"interventions":["C402-CD19-CAR"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is to investigate the safety and tolerability of C402-CD19-CAR treatment in subjects with relapsed or refractory large B-cell lymphoma and further determine the recommended Phase 2 dose of C402-CD19-CAR.","sourceUrl":"https://clinicaltrials.gov/study/NCT06830031"},{"nctId":"NCT03937154","title":"Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":145,"enrollmentType":"ACTUAL","startDate":"2020-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-10","primaryCompletionType":"ACTUAL","completionDate":"2027-02-23","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Chemotherapy-induced Thrombocytopenia"],"interventions":["Romiplostim","Placebo"],"countries":["United States","Argentina","Austria","Brazil","Bulgaria","Chile","Colombia","Greece","Hungary","Mexico","Peru","Poland","Portugal","Romania","Russia","Spain","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":139,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03937154"},{"nctId":"NCT06348199","title":"A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer","sponsor":"Samsung Bioepis Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":555,"enrollmentType":"ACTUAL","startDate":"2024-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-10","primaryCompletionType":"ACTUAL","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Non-small Cell Lung Cancer Stage IV"],"interventions":["SB27","Keytruda"],"countries":["Bosnia and Herzegovina","Brazil","Georgia","Germany","India","Japan","Malaysia","Mexico","Philippines","Romania","Serbia","Spain","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":93,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is: • How effective the study drug is Participants will receive either investigational product (SB27 or Keytruda) and chemotherapy every 3 weeks. Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda.","sourceUrl":"https://clinicaltrials.gov/study/NCT06348199"},{"nctId":"NCT05352672","title":"Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1546,"enrollmentType":"ACTUAL","startDate":"2022-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-12","primaryCompletionType":"ACTUAL","completionDate":"2031-09-16","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Melanoma"],"interventions":["Fianlimab","Cemiplimab","Pembrolizumab","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Georgia","Germany","Hungary","Ireland","Italy","Mexico","Netherlands","Peru","Poland","Romania","South Africa","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":210,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a \"study drug\" or called \"study drugs\" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medication, pembrolizumab, approved for the treatment of melanoma skin cancer in adults, and to observe any similarities, or differences, in how the study drugs work in adolescent participants compared with ad","sourceUrl":"https://clinicaltrials.gov/study/NCT05352672"},{"nctId":"NCT06698042","title":"A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":67,"enrollmentType":"ACTUAL","startDate":"2024-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-12","primaryCompletionType":"ACTUAL","completionDate":"2027-04-17","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Lung Cancer","Non-Small Cell Lung Cancer"],"interventions":["Pembrolizumab (+) Berahyaluronidase alfa","Pembrolizumab"],"countries":["United States","China","Germany","Guatemala","Japan","Peru","Poland","Romania","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to learn what happens to pembrolizumab in a person's body over time when it is given as an IV infusion or SC injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06698042"},{"nctId":"NCT06140836","title":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2023-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-15","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Repotrectinib","Crizotinib"],"countries":["United States","Argentina","Austria","Brazil","Canada","Chile","China","France","Germany","Greece","Hungary","India","Italy","Japan","Netherlands","Poland","Romania","South Korea","Spain","Switzerland","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":122,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06140836"},{"nctId":"NCT06297941","title":"Study of REM-422 in Patients With AML or Higher Risk MDS","sponsor":"Remix Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-15","completionType":"ESTIMATED","lastUpdated":"2025-04-23","conditions":["Myelodysplastic Syndromes","Higher Risk Myelodysplastic Syndromes","Acute Myeloid Leukemia","Acute Myeloid Leukemia Refractory"],"interventions":["REM-422"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML","sourceUrl":"https://clinicaltrials.gov/study/NCT06297941"},{"nctId":"NCT05627063","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":169,"enrollmentType":"ESTIMATED","startDate":"2023-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-10-20","conditions":["Solid Tumor"],"interventions":["ABSK121-NX"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK121-NX administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK121-NX at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT05627063"},{"nctId":"NCT06304571","title":"A Study of HC006 in Subjects With Advanced Solid Tumors","sponsor":"HC Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2024-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-16","completionType":"ESTIMATED","lastUpdated":"2025-05-06","conditions":["Advanced Solid Tumor"],"interventions":["HC006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06304571"},{"nctId":"NCT03997123","title":"Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":923,"enrollmentType":"ACTUAL","startDate":"2019-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-16","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-16","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Triple Negative Breast Neoplasms"],"interventions":["Capivasertib","Paclitaxel","Placebo"],"countries":["United States","Argentina","Brazil","Canada","China","Colombia","Czechia","France","Greece","Hungary","India","Japan","Malaysia","Mexico","Peru","Philippines","Poland","Portugal","Russia","Saudi Arabia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":260,"serviceSignals":["Broad CGP"],"summary":"Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)","sourceUrl":"https://clinicaltrials.gov/study/NCT03997123"},{"nctId":"NCT05099172","title":"First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)","sponsor":"Bayer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2021-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-16","primaryCompletionType":"ACTUAL","completionDate":"2029-06-29","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Advanced Non-small Cell Lung Cancer","EGFR Mutation","HER2 Mutation"],"interventions":["BAY2927088_formulation A","BAY2927088_formulation B_1","BAY2927088_formulation B_2","BAY2927088_formulation B_3"],"countries":["United States","Belgium","Brazil","China","France","Hong Kong","Israel","Italy","Japan","Netherlands","Poland","Portugal","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":94,"serviceSignals":["HER2 profiling"],"summary":"Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are proteins that help cells to grow and divide. A damage (also called mutation) to the building plans (genes) for these proteins in cancer cells leads to a production of abnormal EGFR and/or HER2. These abnormal proteins drive the growth and the spread of the cancer. Several EGFR and/or HER2 mutations exist in the cancer cells. The study treatment, sevabertinib (BAY2927088), is expected to block the mut","sourceUrl":"https://clinicaltrials.gov/study/NCT05099172"},{"nctId":"NCT06076291","title":"An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2023-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-18","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Advanced Solid Tumors"],"interventions":["SG1827"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, dose escalation and dose expansion study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in subjects with Advanced Solid Tumors, refractory or resistant to standard therapy, or without available standard or curative therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06076291"},{"nctId":"NCT05359445","title":"IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor","sponsor":"Immatics Biotechnologies GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2022-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-18","primaryCompletionType":"ACTUAL","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","Cancer"],"interventions":["IMA401 (Phase Ia)","Pembrolizumab (Phase Ia)","IMA 401 (Phase Ib)"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":21,"serviceSignals":["HLA / TCR"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability and initial anti-tumor activity of IMA401 as monotherapy or in combination with checkpoint inhibitor in patients with recurrent and/or refractory solid tumors. Patients' HLA status and expression of the MAGE-A4 and/or MAGE-A8 target in the tumor must be confirmed. Primary objective: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA401 as monotherapy and in combination with pembrolizumab Secondary objectives: * To characterize the safety and tolerability of IMA401 as monotherapy and in combination with pembrolizumab * To evaluate initial anti-tumor activity of IMA401 as monotherapy an","sourceUrl":"https://clinicaltrials.gov/study/NCT05359445"},{"nctId":"NCT03485209","title":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":350,"enrollmentType":"ACTUAL","startDate":"2018-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-20","primaryCompletionType":"ACTUAL","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung","Exocrine Pancreatic Cancer","Carcinoma, Squamous Cell of Head and Neck"],"interventions":["tisotumab vedotin","pembrolizumab","carboplatin","cisplatin"],"countries":["United States","Canada","France","Germany","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":175,"serviceSignals":["Broad CGP"],"summary":"This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, participants will receive tisotumab vedotin every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. * Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembroli","sourceUrl":"https://clinicaltrials.gov/study/NCT03485209"},{"nctId":"NCT05814354","title":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":551,"enrollmentType":"ACTUAL","startDate":"2023-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-20","primaryCompletionType":"ACTUAL","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Cancer"],"interventions":["SHR-A1811","Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05814354"},{"nctId":"NCT03557619","title":"A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2019-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-21","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-21","completionType":"ESTIMATED","lastUpdated":"2024-08-29","conditions":["Hematologic Malignancies"],"interventions":["Venetoclax","ethinyl estradiol/levonorgestrel"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.","sourceUrl":"https://clinicaltrials.gov/study/NCT03557619"},{"nctId":"NCT06968572","title":"Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":245,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-08","completionType":"ESTIMATED","lastUpdated":"2025-05-13","conditions":["Advanced Solid Tumors"],"interventions":["HSK41959"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK41959 when given orally in patients with MTAP Deletion locally advanced or metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06968572"},{"nctId":"NCT06003231","title":"A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ACTUAL","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-27","primaryCompletionType":"ACTUAL","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Carcinoma, Non-Small-Cell Lung","Ovarian Neoplasms","Endometrial Neoplasms","Head and Neck Neoplasms"],"interventions":["disitamab vedotin"],"countries":["United States","Australia","Canada","Italy","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":96,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. In the first part of the study, participants must have tumors that have a marker called HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks. This study is being done ","sourceUrl":"https://clinicaltrials.gov/study/NCT06003231"},{"nctId":"NCT06895031","title":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","sponsor":"Guangzhou JOYO Pharma Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Solid Tumor","Pancreatic Ductal Adenocarcinoma (PDAC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)"],"interventions":["JYP0015"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06895031"},{"nctId":"NCT03175224","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","sponsor":"Apollomics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":497,"enrollmentType":"ESTIMATED","startDate":"2017-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2025-06-27","conditions":["Solid Tumors","Advanced Cancer","Renal Cancer","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","NSCLC","Lung Cancer","Brain Tumor","Glioblastoma Multiforme","EGFR Gene Mutation","MET Amplification","HGF","Thyroid Cancer","Pancreatic Cancer","Colon Cancer","MET Alteration","MET Fusion","Exon 14 Skipping"],"interventions":["APL-101 Oral Capsules"],"countries":["United States","Australia","Canada","France","Hungary","Italy","Russia","Singapore","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["RNA fusion","MET profiling"],"summary":"To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)","sourceUrl":"https://clinicaltrials.gov/study/NCT03175224"},{"nctId":"NCT05230810","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","sponsor":"Criterium, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2022-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["HER2-positive Metastatic Breast Cancer"],"interventions":["Alpelisib","Tucatinib","Fulvestrant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["HER2 profiling"],"summary":"Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05230810"},{"nctId":"NCT05429268","title":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","sponsor":"Incyte Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":82,"enrollmentType":"ACTUAL","startDate":"2022-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-30","primaryCompletionType":"ACTUAL","completionDate":"2027-04-01","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma"],"interventions":["Tafasitamab","Lenalidomide"],"countries":["Bulgaria","Croatia","Czechia","Denmark","Finland","Hungary","Ireland","Israel","Norway","Poland","Romania","Serbia","Turkey (Türkiye)","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":61,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous systemic DLBCL treatment regimens and who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT).","sourceUrl":"https://clinicaltrials.gov/study/NCT05429268"},{"nctId":"NCT06621563","title":"Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":780,"enrollmentType":"ESTIMATED","startDate":"2024-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2025-04-09","conditions":["Solid Tumors","Non-Small Cell Lung Cancer","Colorectal Cancer"],"interventions":["HS-20117 combined HS-20093","HS-20117 combined Platinum-containing chemotherapy","HS-20117 combined HS-20093 and 5-FU","HS-20117+CAPEOX","HS-20117+FOLFIRI","HS-20117+mFOLFOX6"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling","ADC biomarker"],"summary":"HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other drugs in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06621563"},{"nctId":"NCT05883644","title":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":111,"enrollmentType":"ACTUAL","startDate":"2023-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-30","primaryCompletionType":"ACTUAL","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Advanced Hepatocellular Carcinoma"],"interventions":["Durvalumab","Tremelimumab"],"countries":["United States","France","Germany","Hong Kong","Italy","Japan","Singapore","South Korea","Spain","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05883644"},{"nctId":"NCT06797297","title":"A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Melanoma"],"interventions":["IBI363","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, open-label, randomized, multi-center study to assess the efficacy and safety of IBI363 monotherapy compared to Pembrolizumab in the treatment of patients with unresectable locally advanced or metastatic mucosal or acral melanoma who had not previously received systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06797297"},{"nctId":"NCT05654532","title":"Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer","sponsor":"Accutar Biotechnology Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-09-30","conditions":["Breast Cancer"],"interventions":["AC699"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["HER2 profiling"],"summary":"This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699","sourceUrl":"https://clinicaltrials.gov/study/NCT05654532"},{"nctId":"NCT03260491","title":"U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":312,"enrollmentType":"ACTUAL","startDate":"2017-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["HER3-DXd (FL-DP)","HER3-DXd (CTM-1 Lyo-DP)","HER3-DXd (CTM-3 Lyo-DP)"],"countries":["United States","Japan","Netherlands","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["RAS genotyping"],"summary":"This study was designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion. In Dose Escalation, HER3-DXd was evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy. In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without EGFR-activating mutations) with disease progression during/after systemic treatment for locally advanced or metastatic disease. In addition, HER3-DX","sourceUrl":"https://clinicaltrials.gov/study/NCT03260491"},{"nctId":"NCT06382168","title":"DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Delta-Fly Pharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2024-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Leukemia, Myeloid, Acute"],"interventions":["DFP-10917","Venetoclax"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal, more patients are added to confirm safety. If the lower dose level shows tolerability, it proceeds to the Phase II expansion to assess the treatment's effectiveness against leukemia using a Simon's t","sourceUrl":"https://clinicaltrials.gov/study/NCT06382168"},{"nctId":"NCT06860789","title":"AK135 in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-06","conditions":["Chemotherapy-induced Peripheral Neuropathy (CIPN)"],"interventions":["AK135"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AK135 for the treatment of chemotherapy-induced peripheral neuropathy in patients with malignant tumor","sourceUrl":"https://clinicaltrials.gov/study/NCT06860789"},{"nctId":"NCT05518045","title":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2022-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Advanced Solid Tumor"],"interventions":["LM-108","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05518045"},{"nctId":"NCT04384484","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","sponsor":"ADC Therapeutics S.A.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":440,"enrollmentType":"ACTUAL","startDate":"2020-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ACTUAL","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Relapsed Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"interventions":["Loncastuximab Tesirine","Rituximab","Gemcitabine","Oxaliplatin"],"countries":["United States","Argentina","Belgium","Brazil","Canada","Chile","China","Czechia","France","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":144,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04384484"},{"nctId":"NCT06245915","title":"AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)","sponsor":"Arsenal Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":37,"enrollmentType":"ACTUAL","startDate":"2024-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Advanced/Metastatic Clear Cell Renal Cell Carcinoma","Recurrence"],"interventions":["AB-2100"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT06245915"},{"nctId":"NCT06500507","title":"A Study of QLS4131 in Patients With Recurrent or Refractory Multiple Myeloma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2024-07-15","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["QLS4131 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety of QLS4131 injection and to determine the recommended Phase 2 dose (RP2D) and to further evaluate the efficacy and safety of QLS4131 injection in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT06500507"},{"nctId":"NCT06342336","title":"HS-IT101 Injection in the Treatment of Advanced Solid Tumors","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2024-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2024-04-02","conditions":["Solid Tumor"],"interventions":["HS-IT101 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06342336"},{"nctId":"NCT05780034","title":"A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies","sponsor":"Accutar Biotechnology Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Relapsed/Refractory B-cell Malignancies"],"interventions":["AC676"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This clinical trial is evaluating a drug called AC676 in participants with Relapsed/Refractory B-cell Malignancies. The main goals of the study are to: * Identify the recommended dose of AC676 that can be given safely to participants * Evaluate the safety profile of AC676 * Evaluate the pharmacokinetics of AC676 * Evaluate the effectiveness of AC676","sourceUrl":"https://clinicaltrials.gov/study/NCT05780034"},{"nctId":"NCT05322590","title":"BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma","sponsor":"Bexion Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":195,"enrollmentType":"ESTIMATED","startDate":"2023-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2024-12-20","conditions":["Metastatic Colorectal Carcinoma","Neuropathy"],"interventions":["BXQ-350","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The study will assess the safety and efficacy of BXQ-350 plus modified FOLFOX7 (mFOLFOX7) and bevacizumab in participants who have newly diagnosed metastatic adenocarcinoma of the colon/rectum. The study will also evaluate if the administration of BXQ-350 with mFOLFOX7 and bevacizumab may diminish oxaliplatin induced sensory neurotoxicity, enabling participants to receive the total and planned doses of mFOLFOX7. All participants will receive BXQ-350 by intravenous (IV) infusion along with standard of care doses of mFOLFOX and bevacizumab. The study is divided into two stages: Stage 1 will be open label and will enroll participants at increasing dose levels of BXQ-350 in order to determine th","sourceUrl":"https://clinicaltrials.gov/study/NCT05322590"},{"nctId":"NCT05150691","title":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":796,"enrollmentType":"ESTIMATED","startDate":"2022-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["HER2-positive Advanced Solid Tumor"],"interventions":["DB-1303/BNT323","Pertuzumab Injection","Ritonavir","Itraconazole"],"countries":["United States","Australia","China","Puerto Rico","South Korea","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":102,"serviceSignals":["HER2 profiling"],"summary":"This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.","sourceUrl":"https://clinicaltrials.gov/study/NCT05150691"},{"nctId":"NCT04785196","title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2021-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2025-02-26","conditions":["Liposarcoma","Advanced Solid Tumor"],"interventions":["APG-115","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Part 1 is a phase Ib standard \"3 + 3\" design, will be employed to determine the MTD of APG-115 by assessing the DLT of APG-115 in combination with PD-1 inhibitor(toripalimab) in advanced solid tumors. Part 2 is a Simon two-stage phase II study design. At RP2D of APG-115 in combination with toripalimab in advanced liposarcoma, approximately 34 patients will be treated with the combination until disease progression, unacceptable toxicity, or another discontinuation criterion is met.","sourceUrl":"https://clinicaltrials.gov/study/NCT04785196"},{"nctId":"NCT06337084","title":"Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors","sponsor":"Monopar Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2025-05-22","conditions":["Solid Tumor, Adult","Bladder Cancer","Urothelial Carcinoma","Triple-negative Breast Cancer","Lung Cancer","Colorectal Cancer","Gastric Cancer","Ovarian Cancer","Pancreatic Cancer"],"interventions":["MNPR-101-DFO*-89Zr","PET/CT Diagnostic Imaging"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO\\*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian, and pancreatic cancers. MNPR-101-DFO\\*-89Zr is made of MNPR-101, a humanized IgG1 monoclonal antibody and a radioisotope Zirconium-89. This imaging agent may show where tumors are present in the body using a PET-scan. Participants will be injected with the radioactive tracer once. After injection, participants will have 3 PET-scans. Each PET-scan will take about 30 minutes. The PET-scans are on separate days within 10 days after injection (e.g., 2 hours after injectio","sourceUrl":"https://clinicaltrials.gov/study/NCT06337084"},{"nctId":"NCT05239143","title":"P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors","sponsor":"Poseida Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2022-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2039-04","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Breast Cancer","Ovarian Cancer","Non Small Cell Lung Cancer","Colorectal Cancer","Pancreatic Cancer","Renal Cell Carcinoma","Nasopharyngeal Cancer","Head and Neck Squamous Cell Carcinoma","Gastric Cancer"],"interventions":["P-MUC1C-ALLO1 CAR-T cells","Rimiducid"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.","sourceUrl":"https://clinicaltrials.gov/study/NCT05239143"},{"nctId":"NCT06283719","title":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":265,"enrollmentType":"ESTIMATED","startDate":"2024-09-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Small Cell Lung Cancer","Neuroendocrine Cancer"],"interventions":["ZG006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase I/II study consisting of two parts: Part 1 is a Phase I dose-escalation study of ZG006, aimed at evaluating the safety and tolerability of ZG006 in Participants with advanced small-cell lung cancer or neuroendocrine carcinoma. Upon completion of Part 1, the investigators and sponsor will jointly determine two preliminary recommended Phase II doses for Part 2, based on the available safety, preliminary efficacy, and pharmacokinetic data. Part 2 is a Phase II dose-expansion study of ZG006, designed to explore and confirm the efficacy and safety of ZG006 monotherapy in advanced small-cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06283719"},{"nctId":"NCT06932952","title":"A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Byondis B.V.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":7,"enrollmentType":"ACTUAL","startDate":"2025-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Solid Tumor"],"interventions":["BYON4228 + Pembrolizumab"],"countries":["Belgium","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a phase I trial with BYON4228, a humanized monoclonal antibody (mAb) directed against signal regulatory protein (SIRP)α in solid tumors, alone and in combination with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06932952"},{"nctId":"NCT06199973","title":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ACTUAL","startDate":"2024-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-07-17","conditions":["Advanced Colorectal Cancer"],"interventions":["SHR-A1811","TAS-102, Regorafenib , Fruquintinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, and safety of SHR-A1811 in advanced colorectal cancer subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06199973"},{"nctId":"NCT06925581","title":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-12-03","conditions":["Advanced Solid Tumors"],"interventions":["HRS-6768"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06925581"},{"nctId":"NCT06947226","title":"A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":188,"enrollmentType":"ESTIMATED","startDate":"2025-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-04-27","conditions":["Solid Tumors"],"interventions":["9MW2821","Other anti-cancer therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase Ib/ll, open-label, multicenter study designed to evaluate the safety and efficacy of 9MW2821 monotherapy or combined with other anticancer therapy in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06947226"},{"nctId":"NCT07340697","title":"Evaluate RLS-1496 Topical Cream for Actinic Keratosis","sponsor":"Rubedo Life Sciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Actinic Keratosis (AK)"],"interventions":["RLS-1496 1.0% cream"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatment with RLS-1496 cream is to clear or decrease the number of AK in the treated area, per lesion counts performed by the Investigator. The main questions it aims to answer are: * Is it safe to apply topical RLS-1496 cream to treat AK once daily for 28 days? * Does topical RLS-1496 lower the number of AKs or eliminate AKs in a treated area when applied once daily for 28 days? Researchers will compare","sourceUrl":"https://clinicaltrials.gov/study/NCT07340697"},{"nctId":"NCT06387420","title":"A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-04-29","startDateType":"ESTIMATED","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2024-04-29","conditions":["ACUTE MYELOID LEUKEMIA; AML"],"interventions":["AK117","Azacitidine","Venetoclax","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT06387420"},{"nctId":"NCT06258304","title":"A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","sponsor":"GigaGen, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Advanced or Metastatic Solid Tumor Malignancies"],"interventions":["GIGA-564"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06258304"},{"nctId":"NCT05918692","title":"A Phase 1 Study of BMF-500 in Adults With Acute Leukemia","sponsor":"Biomea Fusion Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":35,"enrollmentType":"ACTUAL","startDate":"2023-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-04","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Acute Myeloid Leukemia"],"interventions":["BMF-500"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT05918692"},{"nctId":"NCT07032298","title":"A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["Advanced Malignant Tumors"],"interventions":["SSGJ-612"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.","sourceUrl":"https://clinicaltrials.gov/study/NCT07032298"},{"nctId":"NCT06938867","title":"Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant","sponsor":"SNIPR Biome Aps.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-01","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["E Coli Infections","Allogenic Transplant Patients"],"interventions":["SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli","Placebo 10 mL"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin.","sourceUrl":"https://clinicaltrials.gov/study/NCT06938867"},{"nctId":"NCT06033586","title":"Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera","sponsor":"Protagonist Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2024-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-01","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["Polycythemia Vera"],"interventions":["Open-label rusfertide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.","sourceUrl":"https://clinicaltrials.gov/study/NCT06033586"},{"nctId":"NCT05740956","title":"A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":318,"enrollmentType":"ESTIMATED","startDate":"2023-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2025-06-05","conditions":["Ovarian Cancer","Breast Cancer","Pancreatic Cancer","Prostatic Cancer","Colorectal Cancer"],"interventions":["HS-10502"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HRD / HRR"],"summary":"HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05740956"},{"nctId":"NCT06894693","title":"A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies","sponsor":"Guangdong Ruishun Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":13,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-01","completionType":"ESTIMATED","lastUpdated":"2025-03-25","conditions":["B-cell Non-Hodgkin's Lymphoma","Acute Lymphoblastic Leukemia"],"interventions":["RS001 injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed/refractory B-cell malignancies (BCM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06894693"},{"nctId":"NCT06079983","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2023-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-01","completionType":"ESTIMATED","lastUpdated":"2025-09-12","conditions":["Breast Cancer"],"interventions":["JSKN003","Capecitabine tablets","Gemcitabine hydrochloride for injection","Vinorelbine tartrate injection","Paclitaxel for injection (albumin-bound type)","Docetaxel injection","Eribulin mesylate injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":87,"serviceSignals":["HER2 profiling"],"summary":"This study is a randomized controlled, open-label, multicenter phase III clinical study evaluating the efficacy and safety of chemotherapy selected by investigator JSKN003 s in subjects with recurrent or metastatic breast cancer who have previously failed first- or second-line chemotherapy in subjects with recurrent or metastatic breast cancer who have failed prior first- or second-line chemotherapy. The study planned to enroll 408 subjects in a 1:1 ratio and stratified block randomization method assigned to: * Experimental group: JSKN003 monotherapy * Control group: investigator's chosen chemotherapy drug (capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribu","sourceUrl":"https://clinicaltrials.gov/study/NCT06079983"},{"nctId":"NCT06208150","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":838,"enrollmentType":"ACTUAL","startDate":"2024-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ACTUAL","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Multiple Myeloma"],"interventions":["Talquetamab","Pomalidomide","Teclistamab","Elotuzumab","Dexamethasone","Bortezomib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Saudi Arabia","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":242,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).","sourceUrl":"https://clinicaltrials.gov/study/NCT06208150"},{"nctId":"NCT04342910","title":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2020-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-01","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Gastric Cancer"],"interventions":["camrelizumab","Apatinib Mesylate","Paclitaxel","Irinotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT04342910"},{"nctId":"NCT07236112","title":"Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer","sponsor":"C Ray Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2026-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-01","primaryCompletionType":"ACTUAL","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Prostate Cancer"],"interventions":["Intravenous (IV) single dose"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"TRDC002 uses a radioactive form (64Cu) to trace the PSMA positive prostate cancer. The purpose of this study is to investigate TRDC002 as a PSMA PET tracer to localize PSMA positive lesions in adult patients with recurrent or metastatic prostate cancer. We plan to assess the PSMA PET/CT image quality following administration of two dose levels of TRDC002 to determine an acceptable dose and optimal acquisition time for obtaining diagnostic quality PET/CT images. The safety and tolerability, PK, biodistribution, dosimetry of TRDC002 will also be evaluated in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07236112"},{"nctId":"NCT06341114","title":"A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors","sponsor":"Bio-Thera Solutions","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2024-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-28","completionType":"ESTIMATED","lastUpdated":"2025-12-08","conditions":["Advanced Solid Tumors"],"interventions":["BAT8008 injection","BAT1308 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study, led by Zhejiang Cancer Hospital and sponsored by Bio-Thera Solutions, Ltd., is an exploratory multicenter, open-label phase Ib-II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the combination of BAT8008 with BAT1308 in patients with advanced solid tumors. This study aims to explore the safety, tolerability, and pharmacokinetic characteristics of BAT8008 combined with BAT1308 in patients with advanced solid tumors, determine the maximum tolerated dose (MTD), provide recommended doses and reasonable dosing regimens for subsequent clinical studies, and preliminarily evaluate the antitumor efficacy. The study is divide","sourceUrl":"https://clinicaltrials.gov/study/NCT06341114"},{"nctId":"NCT06336707","title":"HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":1048,"enrollmentType":"ESTIMATED","startDate":"2024-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-08","completionType":"ESTIMATED","lastUpdated":"2024-07-18","conditions":["Advanced Solid Tumors"],"interventions":["HS-20089","Adebrelimab","Bevacizumab","Cisplatin / carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6. This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06336707"},{"nctId":"NCT06492941","title":"A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":142,"enrollmentType":"ESTIMATED","startDate":"2024-08-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-21","completionType":"ESTIMATED","lastUpdated":"2024-07-09","conditions":["Advanced Pancreatic Cancer"],"interventions":["Docetaxel for Injection (Albumin bound)","Placebo","Best supportive care"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-blind, multicenter, phase Ⅲ clinical study to compare the clinical efficacy and safety of Docetaxel for Injection (Albumin Bound) in combination with best supportive care versus placebo in combination with best supportive care in participants with pancreatic cancer who have received gemcitabine-containing and fluorouracil-containing regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT06492941"},{"nctId":"NCT06462365","title":"Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)","sponsor":"Tr1X, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2024-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-15","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Hematologic Malignancy","GvHD","GVHD,Acute","GVHD, Chronic","Hematopoietic Stem Cell Transplant","Acute Lymphoblastic Leukemia, Adult B-Cell","Acute Lymphoblastic Leukemia, Adult T-Cell","Acute Myeloid Leukemia in Remission","Myelodysplastic Syndromes","Chronic Myelomonocytic Leukemia, in Remission","Cancer Remission"],"interventions":["TRX103"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.","sourceUrl":"https://clinicaltrials.gov/study/NCT06462365"},{"nctId":"NCT05726864","title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","sponsor":"Elicio Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":158,"enrollmentType":"ACTUAL","startDate":"2023-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-20","primaryCompletionType":"ACTUAL","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","KRAS G12D","KRAS G12R","KRAS G12V","KRAS G12A","KRAS G12C","KRAS G12S","KRAS G13D","NRAS G12D","NRAS G12R","NRAS G12V","NRAS G12C","NRAS G12S"],"interventions":["ELI-002 7P"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["ctDNA / MRD","RAS genotyping"],"summary":"This is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \\[Amph-CpG-7909\\] plus a mixture of lipid-conjugated peptide-based antigens \\[Amph-Peptides 7P\\]) as adjuvant treatment in subjects with solid tumors with mutated KRAS/NRAS. This study builds on the experience obtained with related product ELI-002 2P, which was studied in protocol ELI-002-001 under IND 26909.","sourceUrl":"https://clinicaltrials.gov/study/NCT05726864"},{"nctId":"NCT06161441","title":"A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":195,"enrollmentType":"ACTUAL","startDate":"2024-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-20","primaryCompletionType":"ACTUAL","completionDate":"2029-11-04","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Resectable Non-small Cell Lung Cancer"],"interventions":["Fianlimab","Cemiplimab","Pemetrexed","Paclitaxel","Carboplatin","Cisplatin","Placebo"],"countries":["United States","Australia","Chile","France","Georgia","Germany","Italy","Malaysia","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":123,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a \"study drug\" or collectively called \"study drugs\", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC. The study is looking at several other research questions, including: * ","sourceUrl":"https://clinicaltrials.gov/study/NCT06161441"},{"nctId":"NCT06600789","title":"A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies","sponsor":"Carrick Therapeutics Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-22","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-22","completionType":"ESTIMATED","lastUpdated":"2025-11-03","conditions":["Solid Malignancies"],"interventions":["CT7439 Capsules (0.5 mg, 1mg, 3mg)"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06600789"},{"nctId":"NCT06777433","title":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","sponsor":"Radiopharm Theranostics, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-23","primaryCompletionType":"ACTUAL","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Brain Metastases From Solid Tumors"],"interventions":["RAD101 (18F-FPIA)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, single dose, single arm, multicenter Phase 2b study to establish the imaging performance of RAD101 PET in participants who are ≥ 18 years of age and with suspected recurrent brain metastases from solid tumors. The study consists of a 4-week Screening Period, a 3-day Imaging and Safety Follow-Up Period, and a Data Collection Period of up to 6 months. Participant eligibility will be determined during the Screening Period and eligible participants will be enrolled in the study. On Day 1, the enrolled participants will receive a single dose of the investigational medicinal product (IMP), RAD101. Participants will then proceed with a whole brain PET scan. A high-resolution ","sourceUrl":"https://clinicaltrials.gov/study/NCT06777433"},{"nctId":"NCT04895358","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":342,"enrollmentType":"ACTUAL","startDate":"2021-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-24","primaryCompletionType":"ACTUAL","completionDate":"2027-12-18","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Breast Neoplasms"],"interventions":["pembrolizumab","paclitaxel","nab-paclitaxel","liposomal doxorubicin","capecitabine","normal saline","dextrose"],"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","China","Colombia","France","Germany","Greece","Guatemala","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Philippines","Poland","Portugal","Romania","Russia","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":256,"serviceSignals":["HER2 profiling"],"summary":"The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1. Prior to protocol amendment 7, participants who discontinued pembrolizumab/p","sourceUrl":"https://clinicaltrials.gov/study/NCT04895358"},{"nctId":"NCT05020236","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":944,"enrollmentType":"ESTIMATED","startDate":"2021-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Daratumumab","Pomalidomide","Dexamethasone"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Czechia","Finland","France","Germany","Greece","Italy","Japan","Mexico","New Zealand","Norway","Poland","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":90,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this clinical trial is to (1) learn whether the BCMA-CD3 bispecific antibody elranatamab can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone, and (2) learn about the safety and activity of elranatamab in combination with the anti-CD38 monoclonal antibody daratumumab. People with multiple myeloma who have received previous treatment including lenalidomide will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive","sourceUrl":"https://clinicaltrials.gov/study/NCT05020236"},{"nctId":"NCT04762069","title":"A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme","sponsor":"CNS Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":252,"enrollmentType":"ACTUAL","startDate":"2021-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-15","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Glioblastoma Multiforme, Adult"],"interventions":["Berubicin","Lomustine"],"countries":["United States","France","Italy","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused duri","sourceUrl":"https://clinicaltrials.gov/study/NCT04762069"},{"nctId":"NCT04958239","title":"A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":151,"enrollmentType":"ACTUAL","startDate":"2021-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-27","primaryCompletionType":"ACTUAL","completionDate":"2028-02-17","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Neoplasms"],"interventions":["BI 765179","Ezabenlimab","Pembrolizumab"],"countries":["United States","Australia","Belgium","Brazil","China","Czechia","France","Germany","Israel","Italy","Japan","Mexico","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer. In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2","sourceUrl":"https://clinicaltrials.gov/study/NCT04958239"},{"nctId":"NCT07063407","title":"Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer","sponsor":"Shanghai Hansoh Biomedical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-07-14","conditions":["Extensive Stage Small Cell Lung Cancer (ES-SCLC)"],"interventions":["HS-20093 in combination with Adebrelimab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07063407"},{"nctId":"NCT06589778","title":"A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2024-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2024-11-12","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SHR-A2102","Adebelimab (SHR-1316)","SHR-8068"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06589778"},{"nctId":"NCT06082635","title":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":321,"enrollmentType":"ACTUAL","startDate":"2023-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Non Small Cell Lung Cancer"],"interventions":["TGRX-326","Crizotinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"This is a multi-center, randomized, open-label, Phase III clinical trial which compares the safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or metastatic NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT06082635"},{"nctId":"NCT04906395","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","sponsor":"Tolmar Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2021-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Breast Cancer"],"interventions":["TOL2506","Tamoxifen","Letrozole Tablets","Anastrozole Tablets","Exemestane Tablets"],"countries":["United States","Argentina","Brazil","Canada","India","Mexico","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["HER2 profiling"],"summary":"This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+, HER2-negative breast cancer. The study will also aim to assess the safety of TOL2506 in men with HR+, HER2-negative breast cancer. The Screening Period will be conducted in two parts: 1) an abbreviated, initial screening where premenopausal status will be determined prior to neoadjuvant or adjuvant chemotherapy (if planned) and 2) the full screening assessment conducted after neoadjuvant or adjuvant chemotherapy (or for subjects who enter the study without having received chemotherapy). Following the Screening Period, eligible subjects will ent","sourceUrl":"https://clinicaltrials.gov/study/NCT04906395"},{"nctId":"NCT06209580","title":"AMT-253 in Patients With Advanced Solid Tumours","sponsor":"Multitude Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2024-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-05","conditions":["Malignant Melanoma","Advanced Solid Tumors"],"interventions":["AMT-253 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06209580"},{"nctId":"NCT03952078","title":"A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma","sponsor":"Corvus Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":151,"enrollmentType":"ESTIMATED","startDate":"2019-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-04-30","completionType":"ESTIMATED","lastUpdated":"2025-04-16","conditions":["T-cell Lymphoma"],"interventions":["CPI-818"],"countries":["United States","Australia","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/1b, open-label, first in human study of CPI-818, an oral interleukin-2-inducible tyrosine kinase (ITK) inhibitor for the treatment of relapsed/refractory (R/R) T-cell lymphoma.. This trial will study the safety, tolerability, and anti-tumor activity of CPI-818 as a single drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT03952078"},{"nctId":"NCT04707248","title":"A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":179,"enrollmentType":"ACTUAL","startDate":"2020-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-07-28","conditions":["Renal Cell Carcinoma","Ovarian Tumor"],"interventions":["DS-6000a"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.","sourceUrl":"https://clinicaltrials.gov/study/NCT04707248"},{"nctId":"NCT05423691","title":"Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs","sponsor":"Cellenkos, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2022-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Myelofibrosis"],"interventions":["CK0804"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib","sourceUrl":"https://clinicaltrials.gov/study/NCT05423691"},{"nctId":"NCT05895825","title":"A Study of EOC237 in Patients With Advanced Solid Tumor","sponsor":"Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2023-11-02","conditions":["Advanced Solid Tumor"],"interventions":["EOC237"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05895825"},{"nctId":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","sponsor":"OncoNano Medicine, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2023-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-29","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Triple Negative Breast Cancer","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Lymphoma, Non-Hodgkin","Mantle Cell Lymphoma","Bladder Cancer","Uveal Melanoma, Recurrent","Cervix Cancer","Carcinoma in Situ","Head and Neck Squamous Cell Carcinoma","Skin Cancer","Metastatic Cancer","Tumor, Solid","Tumor Recurrence"],"interventions":["ONM-501","Cemiplimab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["HRD / HRR","Hematology NGS"],"summary":"A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT06022029"},{"nctId":"NCT06298058","title":"A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.","sponsor":"Shanghai Institute Of Biological Products","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Advanced Solid Tumor"],"interventions":["SIBP-A13 formulation for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06298058"},{"nctId":"NCT06115135","title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","sponsor":"Oncotherapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2024-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Multiple Myeloma in Relapse","Multiple Myeloma, Refractory"],"interventions":["Venetoclax"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"A phase 2 study of venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma patients with t(11;14)","sourceUrl":"https://clinicaltrials.gov/study/NCT06115135"},{"nctId":"NCT06783569","title":"A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors","sponsor":"JiaRay Group","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2024-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Solid Tumors","Gastric Cancer","Esophagogastric Juction Cancer","Colorectal Cancer"],"interventions":["JR8603"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.","sourceUrl":"https://clinicaltrials.gov/study/NCT06783569"},{"nctId":"NCT05710848","title":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","sponsor":"SURGE Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2023-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Non-muscle-invasive Bladder Cancer"],"interventions":["STM-416"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05710848"},{"nctId":"NCT05732831","title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","sponsor":"Tango Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2023-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Locally Advanced Solid Tumor"],"interventions":["TNG462","Pembrolizumab"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT05732831"},{"nctId":"NCT06349811","title":"A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2025-06-15","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["BL-M05D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06349811"},{"nctId":"NCT04872166","title":"A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer","sponsor":"Edgewood Oncology Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2021-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-01-30","conditions":["Advanced Solid Tumor","Metastatic Breast Cancer"],"interventions":["BTX-A51"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"This is a multicenter, open label, nonrandomized, sequential dose escalation/dose ranging, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 alone and in combination with fulvestrant in subjects with advanced solid tumors. The study will be done in three phases, described below. Phase 1a (Dose Escalation Phase): The Phase 1a portion is designed to determine the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of orally administered BTX-A51. BTX-A51 will be administered once daily on a weekly schedule of 5 days on/2 days off. Dose escalation will proceed according to a modified 3+3","sourceUrl":"https://clinicaltrials.gov/study/NCT04872166"},{"nctId":"NCT05718557","title":"Study of PYX-106 in Solid Tumors","sponsor":"Pyxis Oncology, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":47,"enrollmentType":"ACTUAL","startDate":"2023-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Solid Tumor"],"interventions":["PYX-106"],"countries":["United States","Belgium","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05718557"},{"nctId":"NCT06829771","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Diffuse Large B Cell Lymphoma"],"interventions":["TQB2825 injection +R-CHOP regimen","TQB2825 injection + GemOx"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["Hematology NGS"],"summary":"To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR rate),progression free survival (PFS), duration of response (DOR) and overall survival(OS). The safety evaluation indicators are dose-limiting toxicity (DLT) , maximum tolerated dose (MTD)and recommended phase II dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06829771"},{"nctId":"NCT06055439","title":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","sponsor":"Chimeric Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2024-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Neuroendocrine Tumors","Colorectal Cancer","Gastric Cancer"],"interventions":["CHM-2101 CAR-T cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06055439"},{"nctId":"NCT06798207","title":"A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-07-18","conditions":["Gynecological Tumors"],"interventions":["TQB2102 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in recurrent/metastatic advanced gynecological tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06798207"},{"nctId":"NCT06139575","title":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","sponsor":"Bivision Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-05-13","conditions":["Prostate Cancer"],"interventions":["Lutetium Lu 177 JH020002 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06139575"},{"nctId":"NCT06440057","title":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2024-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Neuroendocrine Carcinoma"],"interventions":["ZG006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label phase I/II study, divided into 2 parts: Part 1 involves a dose-escalation study of ZG006 in which the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. Upon completion of Part 1, investigators and the sponsor will discuss and determine two recommended phase II doses (RP2D) based on safety, preliminary efficacy, and pharmacokinetic results for use in Part 2. Part 2 is a phase II dose-expansion study of ZG006, aiming to investigate the efficacy and safety of ZG006 in patients with Neuroendocrine Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06440057"},{"nctId":"NCT05277168","title":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":83,"enrollmentType":"ESTIMATED","startDate":"2022-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Advanced Solid Tumors"],"interventions":["SHR-A1904"],"countries":["United States","Australia","Moldova","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05277168"},{"nctId":"NCT06243458","title":"RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms","sponsor":"GCP-Service International West GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":41,"enrollmentType":"ACTUAL","startDate":"2024-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-05-22","conditions":["Low Risk Myelodysplastic Syndromes"],"interventions":["RVU120 (SEL120)"],"countries":["France","Germany","Italy","Poland","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":25,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate orally administered RVU120, a novel small molecule Cyclin-dependent Kinase (CDK) 8/19 inhibitor, in terms of erythroid hematologic improvement (HI-E) and safety in participants with lower-risk myelodysplastic syndrome (MDS). Responding patients are eligible to continue treatment until loss of response/disease progression.","sourceUrl":"https://clinicaltrials.gov/study/NCT06243458"},{"nctId":"NCT05546268","title":"Study of Oral MRT-2359 in Selected Cancer Patients","sponsor":"Monte Rosa Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2022-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["NSCLC","SCLC","High Grade Neuroendocrine Cancer","DLBCL","L-MYC and N-MYC Amplified Solid Tumors","NSCLC With High or Low L-MYC or N-MYC Expression","HR-positive, HER2-negative Breast Cancer","Prostate Cancer"],"interventions":["Oral MRT-2359"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling","Hematology NGS"],"summary":"This Phase 1/2, open-label, multicenter study is conducted in patients with previously treated selected solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), high-grade neuroendocrine cancer of any primary site, diffuse large B-cell lymphoma (DLBCL), and tumors with L-MYC or N-MYC amplification. Patients receive escalating doses of a GSPT1 molecular glue degrader MRT-2359 to determine safety, tolerability, maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of MRT-2359. Once the MTD and/or RP2D is identified, additional patients enroll to Phase 2 study, which includes molecular biomarkers stratification or selection, namely expression or a","sourceUrl":"https://clinicaltrials.gov/study/NCT05546268"},{"nctId":"NCT06639256","title":"Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2024-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Safety","Tolerability","Efficacy"],"interventions":["Test Product HY07121"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06639256"},{"nctId":"NCT06693375","title":"To Evaluate Dose and Safety of NanoEcho Particle-1 Using NanoEcho Imaging Device Examinations of Rectal Lymph Nodes in Healthy Volunteers and Rectal Cancer Patients.","sponsor":"NanoEcho AB","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2024-11-18","conditions":["Healthy Volunteers","Rectal Cancer Patients"],"interventions":["Iron oxide nanoparticles","Rectal Magnetomotoric ultrasound (MMUS)"],"countries":["Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Clinical nodal staging for rectal cancer tumours in early stages, is today shown to be unreliable and no precise or accurate methods exist. Thus, there is an unmet need for better clinical staging of rectal cancer in early stages. If new imaging techniques for clinical staging of early rectal cancer are developed an opportunity for increased treatment by local excision and decreased unnecessary radical surgery would be possible. NanoEcho Particle-1 (NEP-1, Ferumoxtran Lyophilisate 20 mg Fe/mL) will be used, in combination with NanoEcho Imaging Device, to enhance the signal in the detection and identification of possible spread of rectal cancer to nearby rectal regional lymph nodes by magneto","sourceUrl":"https://clinicaltrials.gov/study/NCT06693375"},{"nctId":"NCT05001828","title":"Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia","sponsor":"Polaris Group","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":38,"enrollmentType":"ACTUAL","startDate":"2022-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Acute Myeloid Leukemia, Adult"],"interventions":["ADI-PEG 20"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"Pegylated arginine deiminase (ADI-PEG 20) will be combined with venetoclax and azacitidine for treatment of subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05001828"},{"nctId":"NCT06726564","title":"A Study of MT027 in Patients with Pleural Malignant Tumors","sponsor":"Suzhou Maximum Bio-tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2024-12-10","conditions":["Advanced Malignant Solid Tumor","Malignant Pleural Effusion","Pleura Carcinoma","Pleural Mesothelioma","Pleural Malignant Mesothelioma","Pleural Metastases"],"interventions":["MT027 cells suspension"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06726564"},{"nctId":"NCT05678270","title":"A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-02-07","conditions":["Intrahepatic Cholangiocarcinoma (ICC)"],"interventions":["ICP-192"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT05678270"},{"nctId":"NCT05009329","title":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":315,"enrollmentType":"ACTUAL","startDate":"2021-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["NSCLC","Solid Tumor"],"interventions":["JAB-21822"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05009329"},{"nctId":"NCT04830137","title":"A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies","sponsor":"Nurix Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":248,"enrollmentType":"ESTIMATED","startDate":"2021-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)","Waldenstrom Macroglobulinemia (WM)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Follicular Lymphoma (FL)","Diffuse Large B-cell Lymphoma (DLBCL)","Primary Central Nervous System Lymphoma (PCNSL)"],"interventions":["NX-2127"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04830137"},{"nctId":"NCT03933735","title":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":220,"enrollmentType":"ACTUAL","startDate":"2019-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-05","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Multiple Myeloma"],"interventions":["TNB-383B"],"countries":["United States","Germany"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in participants with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 4 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B), Monotherapy once every 4 weeks (Q4W) dosing (Arm E), Monotherapy once every 3 weeks (Q3W) dosing (Arm F). Arm A will evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of escalating doses of single-agent TNB-383B, administered Q3W, in approximately 73 participants. Once the maximu","sourceUrl":"https://clinicaltrials.gov/study/NCT03933735"},{"nctId":"NCT05235516","title":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":636,"enrollmentType":"ESTIMATED","startDate":"2022-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2024-08-13","conditions":["Locally Advanced Cervical Carcinoma"],"interventions":["AK104","EBRT","BT","cisplatin","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05235516"},{"nctId":"NCT05610891","title":"Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG","sponsor":"Cellectar Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["High-Grade Glioma"],"interventions":["CLR 131"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this dose finding study is to evaluate the safety and efficacy of 2 different dose levels of CLR 131 in children, adolescents and young adults with relapsed or refractory high-grade glioma (HGG).","sourceUrl":"https://clinicaltrials.gov/study/NCT05610891"},{"nctId":"NCT06840002","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-30","conditions":["Ovarian Cancer"],"interventions":["SHR-A1811","Carboplatin","Bevacizumab","Oxaliplatin for Injection","Paclitaxel injection","Doxorubicin hydrochloride liposome injection","Adebrelimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06840002"},{"nctId":"NCT07363057","title":"A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer Survivors","sponsor":"GI Innovation, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Cancer Survivors","Healthy Participant","Elderly"],"interventions":["GI-102 in combination with GIB-7","Placebo"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This Phase 2a clinical study (GIANTS-1) aims to evaluate a novel dual-combination strategy using GI-102 and GIB-7 to address key pathological features of aging, including immunosenescence (the aging of the immune system), metabolic dysfunction, and gut-brain-muscle axis dysregulation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07363057"},{"nctId":"NCT05836948","title":"The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2023-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-01","completionType":"ESTIMATED","lastUpdated":"2025-08-11","conditions":["Advanced Solid Tumor"],"interventions":["SHR-9839"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT05836948"},{"nctId":"NCT06644573","title":"Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia","sponsor":"Nyree Penn","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-11-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-01","completionType":"ESTIMATED","lastUpdated":"2025-05-28","conditions":["Chronic Insomnia","Sleep Deprivation","REM Behavior Disorder","REM Sleep Behavior Disorder","REM Sleep Measurement","Insomnia","Insomnia Related to Specified Disorder","Insomnia Due to Other Mental Disorder","Insomnia Comorbid to Psychiatric Disorder","Insomnia Due to Anxiety and Fear","Insomnia Related to Another Mental Condition","Insomnia Disorders","Idiopathic Hypersomnia","Sleep Disorders, Circadian Rhythm","Post Trauma Nightmares","PTSD - Post Traumatic Stress Disorder","Sleep Quality","Anesthesia","Anxiety","Depression","Mental Health","Alzheimer Disease or Associated Disorder","Parkinsons","Circadian Rhythm","Circadian Dysregulation","PTSD","Post-Traumatic","Post-Traumatic Stress Disorder Complex","Military Combat Stress Reaction","Sleep","Military Activity","Veterans","Shift Work Sleep Disorder","Menopause Related Conditions","Pain","Cancer Pain","Athletes"],"interventions":["PROSOMNIA Sleep Therapy™ (PSTx)","Anesthesia-Induced Sleep Therapy","Diprivan (propofol), Astra-Zeneca","Continuous EEG Monitoring"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture. Objectives: The primary goals of the trial are to determine: 1. Whether PROSOMNIA Sleep Therapy increases the qu","sourceUrl":"https://clinicaltrials.gov/study/NCT06644573"},{"nctId":"NCT06364501","title":"Phase 1 Trial of KH801","sponsor":"Beijing Kanghong Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":17,"enrollmentType":"ESTIMATED","startDate":"2024-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-01","completionType":"ESTIMATED","lastUpdated":"2024-08-07","conditions":["Advanced Solid Tumors"],"interventions":["KH801"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"KH801 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Or 0.9% sodium chloride Injection. This study is expected to include a total of approximately 17-42 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06364501"},{"nctId":"NCT06560112","title":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":172,"enrollmentType":"ESTIMATED","startDate":"2024-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Recurrent Ovarian Cancer"],"interventions":["AK104","AK112","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06560112"},{"nctId":"NCT06806982","title":"A Study of VRN101099 in Patients With HER2-Positive Solid Tumors","sponsor":"Voronoi, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-08-28","conditions":["HER2-positive Solid Tumors"],"interventions":["VRN101099"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This FIH open-label study aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor effect of VRN101099 in patients with HER2-positive solid tumors for whom no standard therapies are available.","sourceUrl":"https://clinicaltrials.gov/study/NCT06806982"},{"nctId":"NCT06431243","title":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2024-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-01","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Advanced Solid Tumor"],"interventions":["A0/B0 group Purinostat Mesylate 11.2mg/m2","A0/B0 group Purinostat Mesylate 15mg/m2","A group Purinostat Mesylate 6mg/m2","A group Purinostat Mesylate 8.4mg/m2","A group Purinostat Mesylate 11.2mg/m2","A group Purinostat Mesylate 15 mg/m2","B group Purinostat Mesylate 6 mg/m2","B group Purinostat Mesylate 8.4 mg/m2","B group Purinostat Mesylate 11.2mg/m2","B group Purinostat Mesylate 15mg/m2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Primary Objectives Phase Ib To evaluate the safety and tolerability of Purinostat Mesylate in combination therapy for advanced solid tumors; and to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of Purinostat Mesylate in combination therapy in patients with advanced solid tumors. To determine the recommended Phase II dose (RP2D) of Purinostat Mesylate in combination therapy for advanced solid tumors. Phase IIa To further evaluate the preliminary efficacy of Purinostat Mesylate in combination therapy in patients with advanced solid tumors. Secondary Objectives Phase Ib To evaluate the safety and tolerability of Purinostat Mesylate Monotherapy for the treatment of ad","sourceUrl":"https://clinicaltrials.gov/study/NCT06431243"},{"nctId":"NCT05951608","title":"A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2023-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-15","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Advanced Solid Tumors"],"interventions":["AK127 in combination with AK112"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05951608"},{"nctId":"NCT06606847","title":"A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2024-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-04","primaryCompletionType":"ACTUAL","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Oleclumab","Durvalumab"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), who have not progressed following platinum-based concurrent or sequential chemoradiotherapy (cCRT or sCRT).","sourceUrl":"https://clinicaltrials.gov/study/NCT06606847"},{"nctId":"NCT04612751","title":"Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":155,"enrollmentType":"ACTUAL","startDate":"2021-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-04","primaryCompletionType":"ACTUAL","completionDate":"2027-05-04","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Advanced or Metastatic NSCLC"],"interventions":["Datopotamab deruxtecan","Durvalumab","Carboplatin","AZD2936","MEDI5752","AZD7789"],"countries":["United States","Belgium","Italy","Japan","Poland","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Broad CGP"],"summary":"This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04612751"},{"nctId":"NCT06769425","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":157,"enrollmentType":"ESTIMATED","startDate":"2025-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2025-06-24","conditions":["Recurrent Ovarian Cancer","HER2-negative","Advanced Breast Cancer","TNBC","Advanced Prostate Cancer","Advanced Gastric Cancer"],"interventions":["HS-10502 + NHA","HS-10502 + HS-20093","HS-10502+ Apatinib","HS-10502 + HS-20089","HS-10502 + Platinum + Bevacizumab","HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan","HS-10502 + Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06769425"},{"nctId":"NCT05846867","title":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2023-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-11","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Colorectal Cancer"],"interventions":["AK119","AK112","Oxaliplatin","Irinotecan","Calcium folinate","Fluorouracil"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multicenter Phase Ib/II clinical study on the efficacy and safety of AK119 and AK112 in combination with or without chemotherapy, and AK112 monotherapy in pMMR/MSS CRC","sourceUrl":"https://clinicaltrials.gov/study/NCT05846867"},{"nctId":"NCT06530810","title":"Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-08","completionType":"ESTIMATED","lastUpdated":"2024-07-31","conditions":["Chronic Myelogenous Leukemia","CML Chronic Phase","CML Accelerated Phase"],"interventions":["HS-10382+Flumatinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. Flumatinib is the first approved second generation TKI in China and a derivative of imatinib. The primary objective of this study is to evaluation the safety and tolerability and of HS-10382 combination therapy in patients with chronic myeloid leukemia (CML). The secondary objectives is to evaluate the PK profile, major metabolites and efficacy of HS-10382 in CML-CP/AP subjects after combination therapy, and to explore the kinase domain mutations associated with TKI resistance","sourceUrl":"https://clinicaltrials.gov/study/NCT06530810"},{"nctId":"NCT06703398","title":"A Study of GC101 TIL in Advanced Melanoma","sponsor":"Shanghai Juncell Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2024-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-12","primaryCompletionType":"ACTUAL","completionDate":"2027-12-20","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Melanoma"],"interventions":["GC101 TIL","dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months","sourceUrl":"https://clinicaltrials.gov/study/NCT06703398"},{"nctId":"NCT06601504","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","sponsor":"Hutchmed","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2024-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-12","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Relapsed/Refractory Diffuse Large B-Cell Lymphoma"],"interventions":["HMPL-760 planned dose 1","R-GemOx","HMPL-760 placebo planned dose 1","HMPL-760 planned dose 2","HMPL-760 placebo planned dose 2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to evaluate the efficacy of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06601504"},{"nctId":"NCT06702995","title":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":307,"enrollmentType":"ESTIMATED","startDate":"2023-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-13","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-19","completionType":"ESTIMATED","lastUpdated":"2025-04-20","conditions":["Metastatic Castrate-Resistant Prostate Cancer","mCRPC (Metastatic Castration-resistant Prostate Cancer)"],"interventions":["XNW5004","enzalutamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in combination with enzalutamide.","sourceUrl":"https://clinicaltrials.gov/study/NCT06702995"},{"nctId":"NCT06190886","title":"A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors","sponsor":"Proviva Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":26,"enrollmentType":"ESTIMATED","startDate":"2024-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-14","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-24","completionType":"ESTIMATED","lastUpdated":"2024-11-07","conditions":["Advanced Cancer","Solid Tumor","Metastatic Cancer"],"interventions":["PTX-912"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants will be treated with PTX-912 via iv infusion, every 2 weeks until progression of disease, unacceptable toxicity, or 12 months of total study therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06190886"},{"nctId":"NCT07553988","title":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","sponsor":"R-Pharm International, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-14","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-09","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["RS-113, 160 mg","RS-113, 240 mg","RS-113, 320 mg","Abiraterone","Prednisolone","Androgen deprivation therapy (ADT)"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of different doses of RS-113 versus abiraterone, as well as to investigate pharmacokinetics profile and to perform a pilot evaluation of pharmacokinetics parameters of RS-113 in patients with metastatic castration-resistant prostate cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07553988"},{"nctId":"NCT07069335","title":"A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer","sponsor":"Boryung Pharmaceutical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-15","completionType":"ESTIMATED","lastUpdated":"2025-07-16","conditions":["Ovarian Cancer"],"interventions":["Olaparib 150 MG"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07069335"},{"nctId":"NCT07543744","title":"A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI","sponsor":"R-Pharm","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Metastatic Colorectal Cancer"],"interventions":["RPH-030","Vectibix®","Irinotecan","Calcium Folinate","Fluorouracil"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to demonstrate equivalence of pharmacokinetic properties, and comparability of safety and immunogenicity parameters of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI. The additional objective is to perform a pilot evaluation of the efficacy of RPH-030 and Vectibix® following a single (first) intravenous administration to patients with mCRC with wild-type RAS genes as 1-line therapy in combination with FOLFIRI.","sourceUrl":"https://clinicaltrials.gov/study/NCT07543744"},{"nctId":"NCT05382442","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2022-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-12","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["Metastatic Colorectal Cancer"],"interventions":["AK112","AK117","Oxaliplatin","Capecitabine","Irinotecan","Leucovorin","5-fluorouracil"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK112 with or without AK117 in participants with metastatic colorectal cancer who are not suitable for surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT05382442"},{"nctId":"NCT06592417","title":"To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-17","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced Malignant Solid Tumor"],"interventions":["JSKN016 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.","sourceUrl":"https://clinicaltrials.gov/study/NCT06592417"},{"nctId":"NCT02715284","title":"Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors","sponsor":"Tesaro, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":730,"enrollmentType":"ACTUAL","startDate":"2016-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-18","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-25","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Neoplasms"],"interventions":["Dostarlimab"],"countries":["United States","Brazil","Canada","Czechia","Denmark","France","Italy","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":105,"serviceSignals":["MSI / TMB"],"summary":"This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging","sourceUrl":"https://clinicaltrials.gov/study/NCT02715284"},{"nctId":"NCT06012435","title":"A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":762,"enrollmentType":"ACTUAL","startDate":"2024-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-18","primaryCompletionType":"ACTUAL","completionDate":"2028-05-17","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["sigvotatug vedotin","docetaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Norway","Poland","Romania","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":331,"serviceSignals":["ADC biomarker"],"summary":"This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy. This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also ","sourceUrl":"https://clinicaltrials.gov/study/NCT06012435"},{"nctId":"NCT06497556","title":"A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":338,"enrollmentType":"ACTUAL","startDate":"2024-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-19","primaryCompletionType":"ACTUAL","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Non-Small Cell Lung Cancer","KRAS G12C Lung Cancer"],"interventions":["Divarasib","Sotorasib","Adagrasib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Denmark","Finland","France","Germany","Greece","Hong Kong","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":151,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06497556"},{"nctId":"NCT06586866","title":"JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases","sponsor":"JenKem Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2024-09-26","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05-26","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-26","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Triple Negative Breast Cancer (TNBC)","Brain Metastasases"],"interventions":["JK-1201I"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study was designed to evaluate the safety, efficacy and pharmacokinetics of JK-1201I in triple negative breast cancer patients with brain metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT06586866"},{"nctId":"NCT03383458","title":"A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":545,"enrollmentType":"ACTUAL","startDate":"2018-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-27","primaryCompletionType":"ACTUAL","completionDate":"2031-05-27","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Hepatocellular Carcinoma","Liver Cancer"],"interventions":["Nivolumab","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","France","Germany","Hong Kong","Italy","Japan","Mexico","Netherlands","New Zealand","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":184,"serviceSignals":["Broad CGP"],"summary":"This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence","sourceUrl":"https://clinicaltrials.gov/study/NCT03383458"},{"nctId":"NCT06607939","title":"ORB-021 In Patients With Advanced Solid Tumors","sponsor":"Orionis Biosciences Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2024-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Advanced Solid Tumors Cancer"],"interventions":["ORB-021"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical research study is to determine if an investigational new drug, named ORB-021, developed by Orionis Biosciences is safe and can be tolerated in people diagnosed with an advanced solid tumor. The study also aims to find the biologically optimal dose of the study medicine by assessing the safety and potential activity in the treatment of solid tumors. There are three phases to this study: screening, treatment and end of treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06607939"},{"nctId":"NCT05673057","title":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"Molecular Partners AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":249,"enrollmentType":"ESTIMATED","startDate":"2022-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-29","primaryCompletionType":"ACTUAL","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Leukemia","Myeloid","Acute","Newly Diagnosed"],"interventions":["MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1","MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A","MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) + azacitidine + venetoclax","MP0533 with Obinutuzumab pretreatment","MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B relapsed/refractory AML","MP0533 + azacitidine + venetoclax with optional Obinutuzumab pretreatment, Arm B in treatment naïve patients"],"countries":["France","Lithuania","Netherlands","Switzerland"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","sourceUrl":"https://clinicaltrials.gov/study/NCT05673057"},{"nctId":"NCT03847428","title":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":908,"enrollmentType":"ACTUAL","startDate":"2019-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Hepatocellular Carcinoma"],"interventions":["Durvalumab","Bevacizumab","Placebo"],"countries":["United States","Australia","Austria","Brazil","Canada","China","Egypt","France","Germany","Hong Kong","India","Italy","Japan","Peru","Philippines","Poland","Puerto Rico","Russia","Singapore","South Korea","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":217,"serviceSignals":["Broad CGP"],"summary":"A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.","sourceUrl":"https://clinicaltrials.gov/study/NCT03847428"},{"nctId":"NCT07254845","title":"A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS","sponsor":"VPIX Medical","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Frozen Sections","Indocyanine Green (ICG)","Brain Tumor"],"interventions":["cCeLL In vivo","Indocyanine Green"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this single-center study is to demonstrate the performance of cCeLL, used in real time, compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, and the images will be immediately transmitted to a single pathologist for real-time evaluation, without influencing the surgical decision-making process. The comparison will be made between the device and the conventional intraoperati","sourceUrl":"https://clinicaltrials.gov/study/NCT07254845"},{"nctId":"NCT06074497","title":"This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.","sponsor":"Kangabio AUSTRALIA LTD PTY","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["KGX101- Cohort -1","KGX101- Cohort 1","KGX101- Cohort 2","KGX101- Cohort 3","KGX101- Cohort 4","KGX101- Cohort 5","KGX101 and Envafolimab"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open label, two-part, multicenter, multi-regional phase I trial to investigate the safety, tolerability, and PK of KGX101 monotherapy and combination therapy with Envafolimab in patients with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06074497"},{"nctId":"NCT06215846","title":"A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-28","completionType":"ESTIMATED","lastUpdated":"2025-11-26","conditions":["Solid Tumor"],"interventions":["BioTTT001 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.","sourceUrl":"https://clinicaltrials.gov/study/NCT06215846"},{"nctId":"NCT06332170","title":"ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":610,"enrollmentType":"ESTIMATED","startDate":"2024-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2024-07-18","conditions":["Advanced Solid Tumor"],"interventions":["HS-20093","Adebrelimab","Cisplatin/ Carboplatin","Cetuximab","Enzalutamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06332170"},{"nctId":"NCT06238401","title":"An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors","sponsor":"Hangzhou Adcoris Biopharmacy Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":77,"enrollmentType":"ESTIMATED","startDate":"2024-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Advanced Solid Tumors"],"interventions":["ACR246 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.","sourceUrl":"https://clinicaltrials.gov/study/NCT06238401"},{"nctId":"NCT06963814","title":"Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors","sponsor":"HC Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2025-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2025-07-17","conditions":["Advanced Cancer"],"interventions":["HC006","KEYTRUDA ®( Pembrolizumab)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced solid tumors. The trial is divided into two stages: dose-escalation and dose expansion. First, the dose-escalation study is completed to determine the recommended dose for subsequent extension studies, and then the dose expansion study is conducted in the proposed tumors with potential treatment benefits.","sourceUrl":"https://clinicaltrials.gov/study/NCT06963814"},{"nctId":"NCT04396821","title":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2020-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Advanced Cancer","Gastric Cancer","Gastroesophageal-junction Cancer","Pancreatic Cancer"],"interventions":["TST001","Nivolumab Injection [Opdivo]","mFOLFOX6","Gemcitabine","Albumin-Bound Paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["ADC biomarker"],"summary":"This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT04396821"},{"nctId":"NCT05403554","title":"A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers","sponsor":"Light Chain Bioscience - Novimmune SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2024-10-29","conditions":["Epithelial Ovarian Cancer","Triple Negative Breast Cancer","Non-squamous Non-small-cell Lung Cancer","Pancreatic Adenocarcinoma (ductal Adenocarcinoma)","Endometrioid Ovarian Cancer"],"interventions":["Biological NI-1801","NI-1801 in combination with anti-PD1 (Pembrolizumab)","NI-1801 in combination with paclitaxel","Paclitaxel"],"countries":["France","Italy"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Study LCB-1801-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of NI-1801 in patients with advanced, metastatic, or recurrent solid malignancies expressing mesothelin (MSLN). The dose escalation part (Part A) of the main study will evaluate the safety and tolerability of escalating doses of NI-1801 to determine the maximum tolerated dose (MTD) and non-tolerated toxic dose (NTD) of NI-1801. The expansion part (Part B) of the main study will further evaluate the safety and efficacy of NI-1801 administered at or below the MTD in up to 10 additional subjects in order to determine the recommended Phase 2 dose (RP2D). Treatments will be","sourceUrl":"https://clinicaltrials.gov/study/NCT05403554"},{"nctId":"NCT05744687","title":"Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":374,"enrollmentType":"ESTIMATED","startDate":"2023-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["SPH4336 Tablets 400mg","SPH4336 Tablets Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to evaluate the safety and efficacy of SPH4336 combined with letrozole in first-line treatment of locally advanced or metastatic breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05744687"},{"nctId":"NCT05551507","title":"IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2020-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Platinum-resistant Ovarian Cancer"],"interventions":["IN10018 in combination with PLD"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).","sourceUrl":"https://clinicaltrials.gov/study/NCT05551507"},{"nctId":"NCT06346392","title":"AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":594,"enrollmentType":"ACTUAL","startDate":"2024-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ACTUAL","completionDate":"2026-10-14","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"interventions":["AZD0901","Ramucirumab+ paclitaxel","Paclitaxel","Docetaxel","Irinotecan","TAS-102","Apatinib"],"countries":["United States","Brazil","Canada","China","France","Germany","Hong Kong","India","Italy","Japan","Poland","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":158,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.","sourceUrl":"https://clinicaltrials.gov/study/NCT06346392"},{"nctId":"NCT06962865","title":"A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-16","conditions":["Non-Small Cell Lung Cancer"],"interventions":["RC108","Furmonertinib Mesilate Tablets Monotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":34,"serviceSignals":["MET profiling"],"summary":"Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT06962865"},{"nctId":"NCT04496349","title":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2021-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-11-04","conditions":["T-Prolymphocytic Leukemia","Non-Hodgkins Lymphoma"],"interventions":["APG-115","APG-2575"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04496349"},{"nctId":"NCT04898543","title":"QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"ImmunityBio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2021-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Metastatic Solid Tumor"],"interventions":["M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)","N-803 (Cohort 2 part B)","Apheresis collection of MNCs (part A)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a two-part, open-label phase 1 study to evaluate safety and preliminary efficacy of M-CENK Suspension for Infusion, Cryopreserved, and N-803 for subcutaneous administration in subjects with locally advanced or metastatic solid tumors. The study consists of two cohorts: cohort 1 includes subjects with either newly diagnosed solid tumors who have not received prior therapy or subjects who have received prior first line treatment; and cohort 2 that includes subjects with relapsed/refractory (r/r) solid tumors who have progressive disease after receiving ≥ 2 prior therapies. The two cohorts will be conducted simultaneously.","sourceUrl":"https://clinicaltrials.gov/study/NCT04898543"},{"nctId":"NCT06059001","title":"Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC","sponsor":"Peptomyc S.L.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":26,"enrollmentType":"ACTUAL","startDate":"2023-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Metastatic Pancreatic Cancer"],"interventions":["OMO-103","Nab-Paclitaxel","Gemcitabine"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicentre, Phase 1b trial designed to determine the safety, tolerability, efficacy, PK, pharmacodynamics (PD) and proof-of-concept of OMO-103 in combination with the standard regimen gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer who are treatment-naïve in the advanced disease setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06059001"},{"nctId":"NCT04782687","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","sponsor":"US Oncology Research","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":73,"enrollmentType":"ACTUAL","startDate":"2021-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Multiple Myeloma","Myeloma Multiple","Kahler Disease","Myeloma, Plasma Cell","Myeloma-Multiple","Myelomatosis","Plasma Cell Myeloma"],"interventions":["Selinexor","Dexamethasone Oral","Daratumumab","Lenalidomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus dexamethasone in multiple myeloma after four prior therapies, and DRd is also already approved by the FDA for multiple myeloma. This study will use all four (S-DRd) together to treat MM as an initial treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04782687"},{"nctId":"NCT06394492","title":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2024-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-09","conditions":["Ovarian Cancer"],"interventions":["SHR-A1921","Doxorubicin","Paclitaxel","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06394492"},{"nctId":"NCT06403735","title":"A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2024-05-08","conditions":["Non-small Cell Lung Cancer","Colorectal Cancer","Pancreatic Cancer","Solid Tumor"],"interventions":["QLC1101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["RAS genotyping"],"summary":"QLC1101 is a selective reversible inhibitor of KRAS G12D, with the dosage form of capsules and administration route of oral administration. In the first-in-humans (FIH) study, the sponsor will explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of QLC1101 in subjects with advanced solid tumors harboring a KRAS G12D mutation. The FIH study includes dose escalation, PK expansion, and efficacy expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06403735"},{"nctId":"NCT06087653","title":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","sponsor":"Starton Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2023-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Multiple Myeloma"],"interventions":["Lenalidomide","Lenalidomide 25 MG Oral Capsule"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"Primary Objective • Assess the safety and tolerability of low-dose lenalidomide administered by continuous subcutaneous (SC) infusion (STAR-LLD) in combination with dexamethasone and a proteasome inhibitor (PI). Secondary Objectives * • To establish the pharmacokinetic (PK) profile of STAR-LLD at a defined infusion rate targeting steady-state blood concentrations. * • Evaluate changes in efficacy indicators including objective response rate (ORR), progression-free survival (PFS), and duration of response (DOR). Exploratory Objective * To assess the impact of STAR-LLD on patient reported symptoms and outcomes. Primary Endpoints * The grade, frequency, and relationship of treatment-emergent ad","sourceUrl":"https://clinicaltrials.gov/study/NCT06087653"},{"nctId":"NCT06933069","title":"Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2025-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-05-31","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Solid Malignancies"],"interventions":["CMAB017"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06933069"},{"nctId":"NCT06940440","title":"IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)","sponsor":"TuHURA Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2025-10","startDateType":"ESTIMATED","primaryCompletionDate":"2026-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2025-10-15","conditions":["Advanced Or Metastatic Merkel Cell Carcinoma"],"interventions":["IFx-Hu2.0","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 years) with non-cutaneous Merkel Cell Carcinoma. Nine subjects will receive IFx-Hu2.0 as a visceral lesion injection in a single lesion followed by pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06940440"},{"nctId":"NCT07369505","title":"Sapu003 in Advanced mTOR-sensitive Solid Tumors","sponsor":"SAPU NANO (US) LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Breast Cancer Metastatic","Renal Cell Carcinoma (RCC)","Neuroendocrine Tumors","Tuberous Sclerosis Complex (TSC)","Hepatocellular Carcinoma (HCC)"],"interventions":["Sapu003","Exemestane 25 MG"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative breast cancer, renal cell carcinoma \\[RCC\\], neuroendocrine tumors \\[NETs\\], tuberous sclerosis complex \\[TSC\\]-associated tumors, and hepatocellular carcinoma \\[HCC\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT07369505"},{"nctId":"NCT06336291","title":"A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence","sponsor":"Philogen S.p.A.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Glioblastoma"],"interventions":["L19TNF","Lomustine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence","sourceUrl":"https://clinicaltrials.gov/study/NCT06336291"},{"nctId":"NCT06540443","title":"Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas","sponsor":"MegaPro Biomedical Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-05-08","conditions":["Head and Neck Squamous Cell Carcinoma","Lymph Node Metastasis"],"interventions":["MPB-2043 of 0.5 mg/kg","MPB-2043 of 1.0 mg/kg","MPB-2043 of 2.0 mg/kg","MPB-2043 of 3.0 mg/kg"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study evaluates the safety and effectiveness of MPB-2043, a superparamagnetic iron oxide (SPIO) contrast agent, for enhancing MRI in detecting metastatic lymph nodes in head and neck cancer. The study compares four doses of MPB-2043 (0.5 mg/kg, 1 mg/kg, 2 mg/kg, and 3 mg/kg) and assesses the optimal timing for post-dose imaging using T1/T2/T2\\*-weighted sequences to improve the accuracy of nodal staging.","sourceUrl":"https://clinicaltrials.gov/study/NCT06540443"},{"nctId":"NCT06823427","title":"9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-03-21","conditions":["Urothelial Carcinoma","Urothelial Carcinoma Bladder","Urothelial Carcinoma Recurrent","Urothelial Carcinoma of the Renal Pelvis and Ureter"],"interventions":["9MW2821","Toripalimab (JS001 )"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06823427"},{"nctId":"NCT04305795","title":"An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors","sponsor":"Rakuten Medical, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":23,"enrollmentType":"ACTUAL","startDate":"2020-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Recurrent Head and Neck Squamous Cell Carcinoma","Metastatic Head-and-neck Squamous-cell Carcinoma","Locally Advanced Cutaneous Squamous Cell Carcinoma","Metastatic Cutaneous Squamous Cell Carcinoma"],"interventions":["200 mg Pembrolizumab","350 mg Cemiplimab","ASP-1929 PIT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04305795"},{"nctId":"NCT06463327","title":"ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML","sponsor":"TC Biopharm","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":69,"enrollmentType":"ESTIMATED","startDate":"2025-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2024-06-17","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"interventions":["TCB008"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"TCB008-003 (ACHIEVE2) is an open-label, multi-center study conducted in 2 parts (dose escalation followed by dose expansion) to evaluate safety, persistence/expansion, and preliminary efficacy of single and multiple intravenous doses of TCB008 in patients with Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML, who have failed or are intolerant to the current standard of care. The dose escalation will follow a 3+3 design with 3 cohorts planned. Once the recommended dose for further investigation has been confirmed, based on dose-limiting toxicities (DLTs), overall safety data, and preliminary efficacy data, up to 20 patients will be enrolled to into one ","sourceUrl":"https://clinicaltrials.gov/study/NCT06463327"},{"nctId":"NCT06773507","title":"Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors","sponsor":"Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-05-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["Advanced Esophageal Cancers","Advanced Non-small Cell Lung Cancer (NSCLC)"],"interventions":["BC008-1A 900mg","BC008-1A 1200mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to learn if BC008-1A given 900mg or 1200mg intravenously once every 3 weeks is safe and effective to treat patients with advanced esophageal cancer or advanced non-small cell lung cancer. It will also learn about the safety and pharmacokinetics of BC008-1A.","sourceUrl":"https://clinicaltrials.gov/study/NCT06773507"},{"nctId":"NCT01954992","title":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","sponsor":"Eleison Pharmaceuticals LLC.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2014-04","startDateType":"","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-12-31","conditions":["Metastatic Pancreatic Adenocarcinoma"],"interventions":["Glufosfamide","Fluorouracil"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT01954992"},{"nctId":"NCT06452706","title":"The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2024-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2024-11-19","conditions":["Breast Cancer"],"interventions":["TQB2102 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["HER2 profiling"],"summary":"This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06452706"},{"nctId":"NCT05703971","title":"Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients","sponsor":"Genprex, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2024-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Small Cell Lung Cancer Extensive Stage"],"interventions":["quaratusugene ozeplasmid","atezolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC). The study is comprised of 2 phases, a dose selection phase (Phase 1) and a safety and efficacy evaluation phase (Phase 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT05703971"},{"nctId":"NCT05627960","title":"First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies","sponsor":"A&G Pharmaceutical Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":77,"enrollmentType":"ESTIMATED","startDate":"2022-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2022-11-28","conditions":["Triple Negative Breast Cancer","Hormone-Resistant Breast Cancer","Non Small Cell Lung Cancer","Mesothelioma"],"interventions":["AG-01 Compound"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells. This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01 antibody to be evaluated in the cohor","sourceUrl":"https://clinicaltrials.gov/study/NCT05627960"},{"nctId":"NCT07014449","title":"Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"Hangzhou Weben Pharma Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2025-06-11","conditions":["AML (Acute Myelogenous Leukemia","Relapsed Acute Myelogenous Leukemia","Refractory Acute Myeloid Leukemia","Hematologic Malignancy","C-Myc","Adult Acute Myeloid Leukemia"],"interventions":["WBC100 QD"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The main questions it aims to answer are: * What is the safety and tolerability profile of WBC100 in R/R AML patients? * Can WBC100 effectively induce remission in R/R AML patients? Participants will: * Take WBC100 capsules orally once daily in 28-day treatment cycles; * Undergo regular safety assessments, including adverse event monitoring and laboratory tests; * Provide blood samples for pharmacokinetic (PK) analysis; * Have their remission status and efficacy evaluated according","sourceUrl":"https://clinicaltrials.gov/study/NCT07014449"},{"nctId":"NCT04157127","title":"Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma","sponsor":"Diakonos Oncology Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2020-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-05-25","conditions":["Pancreatic Adenocarcinoma","Pancreatic Cancer","Pancreatic Adenosquamous Carcinoma"],"interventions":["Autologous DC Therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04157127"},{"nctId":"NCT06687369","title":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)","sponsor":"mAbxience Research S.L.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":726,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Non Squamous Non Small Cell Lung Cancer"],"interventions":["MB12 (Proposed Pembrolizumab Biosimilar)","EU-sourced Keytruda®","US-sourced Keytruda®","Pemetrexed","Carboplatin","Cisplatin"],"countries":["Armenia","Bosnia and Herzegovina","Georgia","Greece","Italy","Japan","Jordan","Malaysia","Moldova","Panama","Philippines","Poland","Portugal","Romania","Serbia","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Tunisia","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":151,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, multicenter, multinational, double-blind, integrated pharmacokinetics (PK) and efficacy similarity study to compare the PK, efficacy, safety, and immunogenicity of MB12 versus Keytruda® in combination with pemetrexed-platinum chemotherapy as first-line treatment in patients with metastatic non-squamous NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06687369"},{"nctId":"NCT04868162","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","sponsor":"Shanghai Miracogen Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2021-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck"],"interventions":["MRG003","MRG003+HX008"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.","sourceUrl":"https://clinicaltrials.gov/study/NCT04868162"},{"nctId":"NCT03872947","title":"A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors","sponsor":"Toray Industries, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":138,"enrollmentType":"ACTUAL","startDate":"2019-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Solid Tumor","Colorectal Cancer","Cholangiocarcinoma","Bladder Cancer","Ovarian Cancer","Gastric Cancer","Palpable Subcutaneous Malignant Lesions","Renal Cell Carcinoma","Melanoma","Epithelial Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer"],"interventions":["TRK-950","Irinotecan","Leucovorin","5-FU","Gemcitabine","Cisplatin","Carboplatin","Ramucirumab","Paclitaxel","Nivolumab","Pembrolizumab","Imiquimod Cream","Bevacizumab","PLD"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03872947"},{"nctId":"NCT06568094","title":"A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Prostate Cancer"],"interventions":["HRS-5041 tablets","Abiraterone Acetate tablets（II）","Prednisone Acetate tablets","Docetaxel Injection","HRS-1167 tablets","SHR2554 tablets","HRS-6208 capsules","Darolutamide Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06568094"},{"nctId":"NCT05687682","title":"Safety of AM-928 Infusion in Advanced Solid Tumors","sponsor":"AcadeMab Biomedical Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2023-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Advanced Solid Tumor"],"interventions":["AM-928"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, dose-escalation study for a novel cancer treatment, AM-928, intravenous infusion antibody for advanced solid tumor. The study is aimed to learn the safety, tolerability, pharmacokinetics, and preliminary efficacy profile of AM-928. The dose escalation strategy will adopt accelerated titration combined with a Bayesian optimal interval (BOIN) design. Seven dose levels are designed and each participant will be assigned to a specific dose regimen depending on the time of enrollment. In the study, each participant will receive AM-928 treatment cycles till meeting any treatment discontinuation criterion and be followed for safety and long-term survival. The whole stu","sourceUrl":"https://clinicaltrials.gov/study/NCT05687682"},{"nctId":"NCT06365853","title":"A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Recurrent Ovarian Cancer","Folate Receptor-Alpha Positive"],"interventions":["Mirvetuximab Soravtansine","Lubricating Eye Drops","Prednisolone acetate ophthalmic suspension 1% eye drops","Brimonidine tartrate ophthalmic solution eye drops"],"countries":["United States","Australia","Belgium","Canada","France","Ireland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the incidence rate and severity of prespecified mirvetuximab soravtansine (MIRV)-related ocular treatment-emergent adverse events (TEAEs) and assess prophylaxis strategies in all participants (symptomatic and asymptomatic) undergoing prospective ophthalmic evaluation with recurrent ovarian cancer (participants with either platinum-sensitive ovarian cancer \\[PSOC\\] or platinum-resistant ovarian cancer \\[PROC\\]) with high folate receptor alpha (FRα) expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT06365853"},{"nctId":"NCT06530251","title":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2024-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Hepatocellular Carcinoma"],"interventions":["AK112","Cadonilimab","AK127","AK130","Sintilimab Injection","Bevacizumab biosimilar"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK112 in combination therapies for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced hepatocellular carcinoma (HCC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination therapy or monotherapy in the treatment of HCC compared to the combination of Sintilimab and Bevacizumab biosimilar.","sourceUrl":"https://clinicaltrials.gov/study/NCT06530251"},{"nctId":"NCT06422936","title":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","sponsor":"Highlight Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Basal Cell Carcinoma"],"interventions":["BO-112"],"countries":["Israel","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability, pharmacodynamics and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma. * primary endpoint is visual and pathological response \\[at surgery\\] on patient level assessed by central review * secondary endpoints are 1. Occurrence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation or death on patient level. 2. Pathological response \\[at surgery\\] on patient level assessed by the investigator and central review, respectively, and visual response \\[during the study and at surgery\\]","sourceUrl":"https://clinicaltrials.gov/study/NCT06422936"},{"nctId":"NCT06773481","title":"BC008-1A Injection for Recurrent CNS WHO G4 Glioma","sponsor":"Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["Glioma","Glioma Tumor Recurrence","Glioma, Recurrent High Grade","Glioblastomas (GBM)","Glioblastoma WHO Grade IV"],"interventions":["BC008-1A"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase I clinical study is to evaluate the safety, preliminary efficacy and pharmacokinetic characteristics of BC008-1A injection in subjects with recurrent CNS WHO grade 4 glioma. This is a randomized and open-label study, with two dose groups set up, and 10 to 20 subjects will be enrolled in each group.","sourceUrl":"https://clinicaltrials.gov/study/NCT06773481"},{"nctId":"NCT06496490","title":"A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Non-Small Cell Lung Cancer"],"interventions":["TQB2102 for injection","TQB2102 for injection combined with Benmelstobart injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in locally advanced or metastatic non-small cell lung cancer with HER2 gene abnormality.","sourceUrl":"https://clinicaltrials.gov/study/NCT06496490"},{"nctId":"NCT05731271","title":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":111,"enrollmentType":"ACTUAL","startDate":"2023-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Locally Advanced Solid Tumor","Metastatic Tumor","Colorectal Adenocarcinoma"],"interventions":["TST003"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question\\[s\\] it aims to answer are: * What is the recommended dose patients can safely receive? * How long does this drug remain in the body after administration? * What are the side effects of this drug? * Does your cancer respond to TST003? * Participants on this study will get TST003 intravenously (through a needle into your vein), once every 3 weeks. * You may need to come to the study site 2-4 times to have tests to see if you are eligible to be in the study before you begin to receive the study drug. * After you start the study drug, you will need to return to the site several times after","sourceUrl":"https://clinicaltrials.gov/study/NCT05731271"},{"nctId":"NCT05630209","title":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)","sponsor":"InSightec","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2023-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Brain Tumor"],"interventions":["Exablate","Doxorubicin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients","sourceUrl":"https://clinicaltrials.gov/study/NCT05630209"},{"nctId":"NCT06392009","title":"Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II","sponsor":"GRIN Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Tuberous Sclerosis Complex","Focal Cortical Dysplasia"],"interventions":["Radiprodil"],"countries":["Australia","Belgium","Canada","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Study RAD-GRIN-201 is a phase 1B/2A trial to assess safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in participants with Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) type II. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A and one year in Part B/long-term treatment period. The treatment period in Part B may be extended based on a favorable benefit/risk profile.","sourceUrl":"https://clinicaltrials.gov/study/NCT06392009"},{"nctId":"NCT06383871","title":"A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":233,"enrollmentType":"ESTIMATED","startDate":"2024-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Advanced Malignant Tumour"],"interventions":["HRS-7058 capsule/ HRS-7058 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.","sourceUrl":"https://clinicaltrials.gov/study/NCT06383871"},{"nctId":"NCT06319963","title":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","sponsor":"Theravectys S.A.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2024-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["HPV-Related Cervical Carcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma"],"interventions":["Two IM injections Lenti-HPV-07","One IM injection Lenti-HPV-07"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly fo","sourceUrl":"https://clinicaltrials.gov/study/NCT06319963"},{"nctId":"NCT05074810","title":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","sponsor":"Verastem, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2022-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Non Small Cell Lung Cancer","KRAS Activating Mutation"],"interventions":["avutometinib and sotorasib","avutometinib and sotorasib and defactinib"],"countries":["United States","Belgium","France","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05074810"},{"nctId":"NCT03678883","title":"9-ING-41 in Patients With Advanced Cancers","sponsor":"Actuate Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2019-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Cancer","Pancreatic Cancer","Sarcoma","Renal Cancer","Refractory Cancer","Refractory Neoplasm","Refractory Non-Hodgkin Lymphoma","Pancreatic Adenocarcinoma","Resistant Cancer","Neoplasm Metastasis","Neoplasm of Bone","Neoplasm, Breast","Neoplasm of Lung","Neoplasms,Colorectal","Neoplasms Pancreatic","Malignant Glioma","Malignancies","Malignancies Multiple","Bone Metastases","Bone Neoplasm","Bone Cancer","Pancreas Cancer","Pancreatic Neoplasms","Breast Neoplasms","Acute T Cell Leukemia Lymphoma"],"interventions":["9-ING-41","Gemcitabine - 21 day cycle","Doxorubicin.","Lomustine","Carboplatin.","Nab paclitaxel.","Paclitaxel.","Gemcitabine - 28 day cycle","Irinotecan"],"countries":["United States","Belgium","Canada","France","Netherlands","Portugal","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["Hematology NGS"],"summary":"GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT03678883"},{"nctId":"NCT06625320","title":"Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"Revolution Medicines, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":500,"enrollmentType":"ACTUAL","startDate":"2024-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Pancreatic Cancer","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma"],"interventions":["RMC-6236","Gemcitabine","nab-paclitaxel","Irinotecan","Liposomal irinotecan","5-fluorouracil","leucovorin","Oxaliplatin"],"countries":["United States","France","Germany","Italy","Japan","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":60,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06625320"},{"nctId":"NCT06480565","title":"A Phase 1/2 Trial of ADI-270 in ccRCC","sponsor":"Adicet Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Clear Cell Renal Cell Carcinoma"],"interventions":["ADI-270","Fludarabine","Cyclophosphamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \\[CAR\\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06480565"},{"nctId":"NCT05450744","title":"131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2023-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Neoplastic Disease","Glioblastoma","Glioblastoma Multiforme"],"interventions":["131I-IPA"],"countries":["Australia","Austria","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05450744"},{"nctId":"NCT05615623","title":"Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG","sponsor":"InSightec","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2023-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Brain Tumor"],"interventions":["Exablate","Doxorubicin"],"countries":["Canada"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients","sourceUrl":"https://clinicaltrials.gov/study/NCT05615623"},{"nctId":"NCT06106672","title":"Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis","sponsor":"COUR Pharmaceutical Development Company, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Myasthenia Gravis","Generalized Myasthenia","AChR Myasthenia Gravis","MuSK MG"],"interventions":["CNP-106","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.","sourceUrl":"https://clinicaltrials.gov/study/NCT06106672"},{"nctId":"NCT06416358","title":"A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed","sponsor":"AlaMab Therapeutics (Shanghai) Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-05-16","conditions":["Advanced Solid Tumors With Bone Only Metastasis"],"interventions":["ALMB-0168"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Bone metastasis is a common disease of advanced tumors. It refers to the metastasis of malignant tumors originating in a certain organ to the bones through the blood circulation or lymphatic system. The incidence of bone metastasis in breast and prostate cancer is as high as 65%-75%. Bone metastasis of malignant tumors often leads to severe bone lesions, including bone pain, pathological fractures, spinal cord compression, hypercalcemia and other bone-related events (SRE). SRE caused by bone metastasis of tumors can greatly reduce the quality of life of tumor patients. In severe cases, it can lead to rapid deterioration of the condition or even death, which greatly affects the extension of t","sourceUrl":"https://clinicaltrials.gov/study/NCT06416358"},{"nctId":"NCT06397313","title":"RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis","sponsor":"Ryvu Therapeutics SA","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2024-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["Myelofibrosis"],"interventions":["RVU120","Ruxolitinib"],"countries":["Italy","Poland"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT06397313"},{"nctId":"NCT05761223","title":"A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849","sponsor":"1ST Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":151,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Advanced Solid Tumor"],"interventions":["Phase Ia dose-escalation part of FB849 Monotherapy","Phase Ib dose-expansion of FB849 monotherapy","Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab","Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)","Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)","Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is the first-in-human, multicenter, open-label Phase I/II study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of FB849 alone and in combination with pembrolizumab in subjects with advanced solid tumors for whom no standard therapy is available.","sourceUrl":"https://clinicaltrials.gov/study/NCT05761223"},{"nctId":"NCT05585320","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","sponsor":"Immuneering Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":209,"enrollmentType":"ACTUAL","startDate":"2022-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-09-02","conditions":["Advanced Solid Tumor","Pancreatic Adenocarcinoma","Malignant Melanoma (Cutaneous)","Non-small Cell Lung Cancer (NSCLC)"],"interventions":["IMM-1-104 Monotherapy (Treatment Group A)","IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)","IMM-1-104 + modified FOLFIRINOX (Treatment Group C)","IMM-1-104 + dabrafenib (Treatment Group D)","IMM-1-104 + pembrolizumab (Treatment Group E)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["RAS genotyping"],"summary":"This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest.","sourceUrl":"https://clinicaltrials.gov/study/NCT05585320"},{"nctId":"NCT06702618","title":"Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Breast Cancer"],"interventions":["TQB3616 capsule+Fulvestrant Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"Evaluation of the Efficacy and Safety of TQB3616 Capsules Combined with Hormonal Therapy in a Phase II Clinical Trial for Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor-Resistant, HR-Positive, HER2-Negative Recurrent/Metastatic Breast Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06702618"},{"nctId":"NCT06500091","title":"TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2024-07","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-07-15","conditions":["Soft Tissue Sarcoma","Melanoma"],"interventions":["TQB2916 injection + doxorubicin hydrochloride for injection","TQB2916 injection+penpulimab injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This project is a clinical trial on the efficacy and safety of TQB2916 injection combined with chemotherapy or penpulimab injection in solid tumors. This project is divided into two cohorts. Cohort 1 aims to explore the safety and efficacy of specific subtypes of soft tissue sarcoma in subjects; Cohort 2 aims to explore safety and efficacy in subjects with undifferentiated pleomorphic sarcoma and melanoma. A total of 54 subjects are planned to be enrolled in this project.","sourceUrl":"https://clinicaltrials.gov/study/NCT06500091"},{"nctId":"NCT05601726","title":"First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients","sponsor":"Advanced BioDesign","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2022-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-01-20","conditions":["Acute Myeloid Leukemia, Adult","Myelodysplastic Syndromes"],"interventions":["ABD-3001"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This First In Human (FIH) study is a prospective, open-label, multicenter, Phase 1 study, with a dose escalation design, followed by an optimized design. It will consist in a Single Ascending Dose (SAD) part and a Multiple Ascending Dose (MAD) part.","sourceUrl":"https://clinicaltrials.gov/study/NCT05601726"},{"nctId":"NCT06178159","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Breast Cancer"],"interventions":["Disitamab Vedotin Injection","Pertuzumab Injection","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin in combination with Pertuzumab with or without Toripalimab neoadjuvant therapy in patients with HER2-positive breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06178159"},{"nctId":"NCT05320809","title":"Study of 3D189 in Patients With Hematologic Malignancies","sponsor":"3D Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ACTUAL","startDate":"2022-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-05-29","conditions":["Acute Leukemia","Multiple Myeloma","Non-Hodgkin Lymphoma","Higher-risk Myelodysplastic Syndrome"],"interventions":["3D189"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"To assess the safety, immunogenicity and preliminary efficacy of 3D189 in patients with hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05320809"},{"nctId":"NCT06634875","title":"Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)","sponsor":"Buzzard Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Colorectal Cancer Metastatic"],"interventions":["isunakinra"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["RAS genotyping","MSI / TMB"],"summary":"This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06634875"},{"nctId":"NCT03257033","title":"Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC","sponsor":"RenovoRx","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2018-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2025-11-14","conditions":["Locally Advanced Pancreatic Cancer"],"interventions":["Gemcitabine","nab-paclitaxel","RenovoCath"],"countries":["United States","Belgium"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Broad CGP"],"summary":"The study is a multi-center, open-label, randomized active controlled study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.","sourceUrl":"https://clinicaltrials.gov/study/NCT03257033"},{"nctId":"NCT06385522","title":"A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System","sponsor":"Boston Immune Technologies and Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["NHL","Cutaneous T Cell Lymphoma","Peripheral T-cell Lymphoma"],"interventions":["BITR2101"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this trial is to learn if a new drug, BITR2101, works to treat non-Hodgkin lymphoma (NHL) in adults, with CTCL patients being sought in particular. The trial also seeks to learn about the safety of this drug. This drug is a protein called an antibody. The drug prevents a molecule called a receptor, named TNFR2, from being made. TNFR2 regulates the immune system and provides important signals to lymphoma cells to grow, make more of themselves and survive. When the drug prevents TNFR2 from being produced in lymphoma cells from CTCL patients, those cells died in the laboratory. Therefore, the trial seeks to enroll CTCL patients in particular, in addition to other subtypes of NHL. Wh","sourceUrl":"https://clinicaltrials.gov/study/NCT06385522"},{"nctId":"NCT06167694","title":"Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Unresectable or Metastatic Breast Cancer"],"interventions":["HRS-8080; Dalpiciclib Isethionate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This is a multicenter, open phase Ib/II clinical study, which is divided into two phases: dose exploration and efficacy expansion. Participants entering the study will receive HRS-8080 combined with Dalpiciclib Isethionate Tablets therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06167694"},{"nctId":"NCT05902988","title":"A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer","sponsor":"Volastra Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-04","conditions":["Advanced Solid Tumor","High Grade Serous Adenocarcinoma of Ovary","Squamous Non-small-cell Lung Cancer","Triple Negative Breast Cancer","Head and Neck Squamous Cell Carcinoma","Ovarian Carcinosarcoma","Uterine Carcinosarcoma","Uterine Serous Carcinoma","Endometrium Cancer","Chromosomal Instability"],"interventions":["VLS-1488"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05902988"},{"nctId":"NCT07610148","title":"A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-06","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Breast Cancer"],"interventions":["HRS-6209 Capsule (old formulation)","HRS-6209 Capsule (new formulation)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the pharmacokinetics of HRS-6209 capsules (old and new formulation) in healthy participants. The effect of high-fat food on the pharmacokinetics of HRS-6209 in new formulation will also be evaluated. A total of 21 healthy participants will be randomised to receive a single oral dose of HRS-6209 in three treatment periods: old formulation (fasted); new formulation (fasted); new formulation (fasted).","sourceUrl":"https://clinicaltrials.gov/study/NCT07610148"},{"nctId":"NCT05913089","title":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2023-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-06-29","conditions":["Non Small Cell Lung Cancer"],"interventions":["TQB2450 injection + Chemotherapy","TQB2450 injection + Anlotinib Hydrochloride Capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer. The part I study was planned to enroll 58 subjects, 1:1 randomized into two cohorts. The treatment regimen was as follows: Cohort 1: 3-4 cycles of TQB2450 combined with chemotherapy, surgery should be performed 4-6 weeks after the last administration, and TQB2450 therapy should be continued for 1 year after surgery. Cohort 2: 4 cycles of TQB2450 combined with 3 cycles of anlotinib hydrochloride capsule. Surgery was performed 4-6 weeks after the last dose and continued for 1 year starting","sourceUrl":"https://clinicaltrials.gov/study/NCT05913089"},{"nctId":"NCT06925659","title":"A Study of QLM2011 in Subjects With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":172,"enrollmentType":"ESTIMATED","startDate":"2025-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-04-17","conditions":["Advanced Solid Tumors"],"interventions":["QLM2011","Taxotere®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This trial is an open-label, single-center, dose-escalation and cohort-expansion Phase I clinical study in patients with advanced solid tumors. The purposeaim of this study is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of QLM2011 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06925659"},{"nctId":"NCT06501196","title":"A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome","sponsor":"BlossomHill Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2024-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Leukemia","Leukemia, Myeloid","Leukemia, Myeloid, Acute","Preleukemia","Myelodysplastic Syndromes","Refractory Acute Myeloid Leukemia"],"interventions":["BH-30236","Venetoclax"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1, Part 1 Dose Escalation - Monotherapy. Phase 1, Part 2 Dose Escalation - Combination with Venetoclax will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30","sourceUrl":"https://clinicaltrials.gov/study/NCT06501196"},{"nctId":"NCT06018337","title":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)","sponsor":"DualityBio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":541,"enrollmentType":"ACTUAL","startDate":"2024-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Metastatic Breast Cancer"],"interventions":["DB-1303/BNT323","Capecitabine","Paclitaxel","Nab-paclitaxel"],"countries":["United States","Argentina","Australia","Belgium","Canada","China","France","Germany","Hong Kong","Hungary","Israel","Italy","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":258,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \\[IHC\\]2+/in situ hybridization \\[ISH\\]- and IHC 1+) population.","sourceUrl":"https://clinicaltrials.gov/study/NCT06018337"},{"nctId":"NCT04969315","title":"TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors","sponsor":"Portage Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-02","conditions":["Renal Cell Cancer","Castrate Resistant Prostate Cancer","Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Cancer (CRC)","Endometrial Cancer","Ovarian Cancer"],"interventions":["TT-10","TT-4"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) 2. To determine the maximum tolerated dose or the recommended phase 2 dose of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) 3. To obtain a preliminary estimate of efficacy of TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04969315"},{"nctId":"NCT06079346","title":"A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer","sponsor":"Oncotelic Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":455,"enrollmentType":"ESTIMATED","startDate":"2024-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2024-08-13","conditions":["Pancreatic Ductal Adenocarcinoma"],"interventions":["OT-101","mFOLFIRINOX"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06079346"},{"nctId":"NCT07131189","title":"A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-10","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Locally Advanced/Metastatic Solid Tumors"],"interventions":["FL115"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of FL115 administered as monotherapy in subjects with unresectable locally advanced or metastatic solid tumors. The study consists of a dose escalation phase followed by a dose expansion phase to further characterize the safety profile and clinical activity at the recommended dose level.","sourceUrl":"https://clinicaltrials.gov/study/NCT07131189"},{"nctId":"NCT06504368","title":"Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors","sponsor":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-06","conditions":["Solid Tumors, Adult"],"interventions":["DCR-PDL1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.","sourceUrl":"https://clinicaltrials.gov/study/NCT06504368"},{"nctId":"NCT07541001","title":"PRL3-Zumab in Patients With Advanced Solid Tumors","sponsor":"Intra-IMMUSG Pte Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2021-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Advanced Malignant Solid Tumor"],"interventions":["PRL3-ZUMAB"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, Phase II, open-label, single-dose-level (6 mg/kg) study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumors. PRL3-zumab will be administered via intravenous (IV) infusion until discontinuation criteria are met (e.g., disease progression per RECIST v1.1/iRECIST, intolerable toxicity, or withdrawal of consent). Study Periods and Duration The study is divided into the following phases: * Screening Period: Day -21 to Day -1; all assessments must be completed prior to the first dose. * Treatment Period: One cycle is defined as 4 weeks, consisting of two infusions administered 2 weeks apart. * End-of-Treatment (EOT) Visit: To be conducted withi","sourceUrl":"https://clinicaltrials.gov/study/NCT07541001"},{"nctId":"NCT06296706","title":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2024-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2024-11-14","conditions":["Gastric Cancer"],"interventions":["Docetaxel for injection (Albumin-bound)","Taxotere (docetaxel)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a multicenter, randomized, controlled phase Ш clinical study of comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma with previous first-line treatment failure.","sourceUrl":"https://clinicaltrials.gov/study/NCT06296706"},{"nctId":"NCT05701306","title":"APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-25","conditions":["Neuroblastoma","Solid Tumor"],"interventions":["APG-115","APG-2575"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05701306"},{"nctId":"NCT06417008","title":"A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":1080,"enrollmentType":"ESTIMATED","startDate":"2024-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-01","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"interventions":["HS-20117","Aumolertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of this study is to assess the safety, efficacy, pharmacokinetics and immunogenicity of HS-20117 combined with Aumolertinib in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \\[Exon 19del\\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06417008"},{"nctId":"NCT05661461","title":"Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment","sponsor":"Aadi Bioscience, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2022-11-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-01","completionType":"ESTIMATED","lastUpdated":"2025-11-13","conditions":["Tumor, Solid","Tumor","Advanced Solid Tumor"],"interventions":["nab-sirolimus"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.","sourceUrl":"https://clinicaltrials.gov/study/NCT05661461"},{"nctId":"NCT07403266","title":"Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)","sponsor":"Oils4Cure","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2024-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Tuberous Sclerosis Complex (TSC)"],"interventions":["YCJ-01 Full Spectrum cannbis Extract","Placebo"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"1\\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.","sourceUrl":"https://clinicaltrials.gov/study/NCT07403266"},{"nctId":"NCT04888312","title":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","sponsor":"Alligator Bioscience AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":94,"enrollmentType":"ACTUAL","startDate":"2021-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-10-08","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"interventions":["CD40 agonist mitazalimab in combination with chemotherapy"],"countries":["Belgium","France","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04888312"},{"nctId":"NCT03682068","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1246,"enrollmentType":"ACTUAL","startDate":"2018-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Unresectable Locally Advanced Urothelial Cancer","Metastatic Urothelial Cancer"],"interventions":["Durvalumab","Tremelimumab","Cisplatin + Gemcitabine","Carboplatin + Gemcitabine"],"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Canada","China","Czechia","Hungary","India","Israel","Italy","Japan","Philippines","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":222,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra).","sourceUrl":"https://clinicaltrials.gov/study/NCT03682068"},{"nctId":"NCT04421820","title":"BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","sponsor":"Bold Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2020-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-01","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Colorectal Cancer","Pancreatic Cancer","Gastric Cancers","Cholangiocarcinoma"],"interventions":["BOLD-100 +/- FOLFOX Chemotherapy (Arm VII)","BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)"],"countries":["United States","Canada","Germany","Ireland","Italy","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT04421820"},{"nctId":"NCT04712097","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":478,"enrollmentType":"ACTUAL","startDate":"2021-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-03","primaryCompletionType":"ACTUAL","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Relapsed or Refractory Follicular Lymphoma"],"interventions":["Mosunetuzumab","Lenalidomide","Rituximab","Tociluzumab"],"countries":["United States","Australia","Brazil","China","France","Germany","Italy","Japan","Poland","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":112,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04712097"},{"nctId":"NCT06898255","title":"A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-06","completionType":"ESTIMATED","lastUpdated":"2025-06-05","conditions":["Cancer Cachexia"],"interventions":["GFS202A injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An open-label, multi-center, phase I study to evaluate the safety/tolerability and pharmacokinetics of GFS202A in advanced solid tumor patients with pre-cachexia or cachexia. The primary objective is to assess the safety/tolerability of GFS202A, determine its maximum tolerated dose (MTD), and recommend a dose range for future studies. Enroll participants with cancer cachexia or precachexia to receive GFS202A monotherapy. During the study period, participants will undergo assessments for safety and preliminary efficacy according to the visit schedule. Pharmacokinetic, anti-drug antibody (ADA), and pharmacodynamic (PD) /biomarker samples will be collected.","sourceUrl":"https://clinicaltrials.gov/study/NCT06898255"},{"nctId":"NCT05048797","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":454,"enrollmentType":"ACTUAL","startDate":"2021-10-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-09","primaryCompletionType":"ACTUAL","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"interventions":["Trastuzumab Deruxtecan","Cisplatin","Carboplatin","Pembrolizumab","Pemetrexed"],"countries":["United States","Austria","Belgium","Brazil","Canada","China","Denmark","France","Germany","Hong Kong","India","Italy","Japan","Mexico","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":130,"serviceSignals":["HER2 profiling"],"summary":"DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations","sourceUrl":"https://clinicaltrials.gov/study/NCT05048797"},{"nctId":"NCT06432296","title":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","sponsor":"Wuhan YZY Biopharma Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":312,"enrollmentType":"ACTUAL","startDate":"2024-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-12","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Malignant Ascites"],"interventions":["M701","paracentesis"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Randomized, Controlled, Multi-Center Phase III Clinical Study to Compare the Efficacy and Safety of Recombinant Anti-EpCAM and Anti-CD3 Human-Mouse Chimeric Bispecific Antibody (M701) for Intraperitoneal Injection to Paracentesis alone in Patients with Malignant Ascites Caused by Advanced Epithelial Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06432296"},{"nctId":"NCT06433219","title":"Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":63,"enrollmentType":"ACTUAL","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-14","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Ovarian Cancer"],"interventions":["Tuvusertib (M1774)","Niraparib","Lartesertib (M4076)"],"countries":["United States","Australia","Belgium","Denmark","France","Germany","Israel","Italy","Netherlands","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":84,"serviceSignals":["HRD / HRR"],"summary":"The purpose of this study is to measure the effect and safety of treatment with tuvusertib combined with either niraparib or lartesertib in participants with epithelial ovarian cancer and to assess any differences between tuvusertib monotherapy and combination therapy. The participants will previously have progressed while treated with a poly ADP ribose polymerase (PARP) inhibitor. The primary objectives of this study are to assess the effect of the treatment in terms of overall response, i.e. whether the tumor disappears, shrinks, remains unchanged, or gets worse and safety in terms of adverse events.","sourceUrl":"https://clinicaltrials.gov/study/NCT06433219"},{"nctId":"NCT05298423","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":611,"enrollmentType":"ACTUAL","startDate":"2022-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-19","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["pembrolizumab/vibostolimab","durvalumab","cisplatin","pemetrexed","etoposide","carboplatin","paclitaxel","thoracic radiotherapy"],"countries":["United States","Argentina","Australia","Brazil","Chile","China","Costa Rica","Czechia","Dominican Republic","Germany","Greece","Guatemala","Israel","Italy","Japan","Malaysia","Mexico","Philippines","Portugal","Romania","South Africa","South Korea","Spain","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":160,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat people with locally advanced non-small cell lung cancer (NSCLC). The goal of this study is to learn if people who receive the combination of vibostolimab and pembrolizumab (MK-7684A) live longer without the cancer getting worse and live longer overall than people who receive durvalumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05298423"},{"nctId":"NCT05156866","title":"First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":163,"enrollmentType":"ACTUAL","startDate":"2022-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-15","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Advanced Solid Tumor","Gastric Cancer","Pancreas Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["TORL-2-307-ADC"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05156866"},{"nctId":"NCT04969835","title":"A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours","sponsor":"Avacta Life Sciences Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":158,"enrollmentType":"ESTIMATED","startDate":"2021-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-15","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Salivary Gland Tumor","Urothelial Carcinoma","Ovarian Carcinoma","Breast Cancer","Soft Tissue Sarcoma"],"interventions":["AVA6000"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.","sourceUrl":"https://clinicaltrials.gov/study/NCT04969835"},{"nctId":"NCT05425940","title":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":901,"enrollmentType":"ACTUAL","startDate":"2022-09-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-16","primaryCompletionType":"ACTUAL","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Colorectal Cancer"],"interventions":["XL092","Atezolizumab","Regorafenib"],"countries":["United States","Australia","Belgium","France","Germany","Hong Kong","Hungary","New Zealand","Poland","Portugal","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":133,"serviceSignals":["MSI / TMB"],"summary":"The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05425940"},{"nctId":"NCT03476681","title":"Study of NEO-201 in Solid Tumors Expansion Cohorts","sponsor":"Precision Biologics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2019-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-17","primaryCompletionType":"ACTUAL","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Cervical Cancer","Uterine Cancer"],"interventions":["NEO-201 in combination with pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), cervical and uterine cancers who progressed on front line therapy. Subjects will be treated with NEO-201 at the RP2D (1.5 mg/kg) every 2 weeks in combination with pembrolizumab, given 1 day after the NEO-201, at 400 mg IV every 6 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT03476681"},{"nctId":"NCT03888105","title":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":515,"enrollmentType":"ACTUAL","startDate":"2019-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-17","primaryCompletionType":"ACTUAL","completionDate":"2028-12-15","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["B-cell Non-Hodgkin Lymphoma (B-NHL)"],"interventions":["Odronextamab"],"countries":["United States","Australia","Canada","China","France","Germany","Italy","Japan","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":119,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works in the body * How much odronextamab is present in the blood","sourceUrl":"https://clinicaltrials.gov/study/NCT03888105"},{"nctId":"NCT06425302","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","sponsor":"Celgene","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":95,"enrollmentType":"ACTUAL","startDate":"2024-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-19","primaryCompletionType":"ACTUAL","completionDate":"2028-11-27","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Lymphoma, Follicular"],"interventions":["Golcadomide","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone","Bendamustine"],"countries":["United States","Australia","Brazil","Canada","Chile","France","Germany","Italy","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06425302"},{"nctId":"NCT05217446","title":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":108,"enrollmentType":"ACTUAL","startDate":"2022-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-19","primaryCompletionType":"ACTUAL","completionDate":"2027-01-26","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Metastatic Colorectal Cancer"],"interventions":["Encorafenib","Cetuximab","Pembrolizumab"],"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","France","Germany","Italy","Netherlands","Norway","Poland","Slovakia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that: * is metastatic (spread to other parts of the body); * has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR) * has a certain type of abnormal gene called \"BRAF\" and; * has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic as an intravenous (IV) infusion (given directly into a vein) at the study clinic. In addition, half of the participants will take encorafenib by mouth at home every day and cetuximab ","sourceUrl":"https://clinicaltrials.gov/study/NCT05217446"},{"nctId":"NCT05055791","title":"A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":312,"enrollmentType":"ESTIMATED","startDate":"2021-12-29","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-20","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-20","completionType":"ESTIMATED","lastUpdated":"2021-09-24","conditions":["Acute Myeloid Leukemia","Lymphoma","Multiple Myeloma"],"interventions":["SYHX1903"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This trial is an open-label, multi-center, dose escalation, dose expansion, and cohort expansion phase I/II clinical study of SYHX1903 in patients with relapsed/refractory hematologic malignancies. This trial aims to evaluate the safety, tolerance, pharmacokinetics, and preliminary antitumor activity of SYHX1903 in patients with relapsed/refractory hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05055791"},{"nctId":"NCT06710847","title":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2024-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-22","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-22","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Neoplasms, Colorectal","Solid Tumor","Colon Cancer","Rectal Cancer","Endometrial Cancer"],"interventions":["GSK4418959","PD-1 inhibitor"],"countries":["United States","Australia","Belgium","Japan","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["MSI / TMB"],"summary":"Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.","sourceUrl":"https://clinicaltrials.gov/study/NCT06710847"},{"nctId":"NCT02952508","title":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","sponsor":"Cellectar Biosciences, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2017-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-22","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Waldenstrom Macroglobulinemia","Multiple Myeloma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Lymphoplasmacytic Lymphoma","Marginal Zone Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","Central Nervous System Lymphoma"],"interventions":["Iopofosine I 131 single dose","Iopofosine I 131 multiple dose","Iopofosine I 131 fractionated dose"],"countries":["United States","Australia","Brazil","Czechia","Finland","France","Greece","Israel","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Hematology NGS"],"summary":"Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT02952508"},{"nctId":"NCT03785249","title":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":731,"enrollmentType":"ACTUAL","startDate":"2019-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-23","primaryCompletionType":"ACTUAL","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced Cancer","Metastatic Cancer","Malignant Neoplastic Disease"],"interventions":["MRTX849","Pembrolizumab","Cetuximab","Afatinib"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":222,"serviceSignals":["RAS genotyping"],"summary":"This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT03785249"},{"nctId":"NCT06615193","title":"A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":111,"enrollmentType":"ESTIMATED","startDate":"2024-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-24","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-01","completionType":"ESTIMATED","lastUpdated":"2024-09-26","conditions":["Advanced Solid Tumors","Refractory Lymphoma","Relapsed Hematologic Malignancy"],"interventions":["HDM2005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2005 in patients with relapsed/refractory B-cell lymphoma and advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06615193"},{"nctId":"NCT05948826","title":"First in Human Study of TORL-3-600 in Participants With Advanced Cancer","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-25","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-15","completionType":"ESTIMATED","lastUpdated":"2025-10-10","conditions":["Advanced Solid Tumor","Colorectal Cancer"],"interventions":["TORL-3-600"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05948826"},{"nctId":"NCT04495296","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2020-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-25","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Advanced Cancer"],"interventions":["TST001","Oxaliplatin","Capecitabine","Paclitaxel","Gemcitabine","Cisplatin","Nivolumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center, Phase I trial of TST001. Subjects with locally advanced or metastatic solid tumors will be enrolled. The study will consist of two parts: Part A is dose escalation and dose expansion phase for mono-therapy, and Part B is dose escalation and dose expansion phase for combination therapy in gastric, gastroesophageal junction(G/GEJ) and biliary tract cancer, etc.","sourceUrl":"https://clinicaltrials.gov/study/NCT04495296"},{"nctId":"NCT06446388","title":"Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2024-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2024-06-06","conditions":["Advanced Solid Tumor"],"interventions":["QLS31905","Oxaliplatin","Capecitabine","Gemcitabine","Cisplatin","QL1706","Chemotherapy drug"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06446388"},{"nctId":"NCT05311397","title":"A Study of A166 in Patients With Advanced Solid Malignant Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2018-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Breast Cancer"],"interventions":["A166"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05311397"},{"nctId":"NCT06685796","title":"A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer","sponsor":"BeBetter Med Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-11-13","conditions":["Advanced Triple-Negative Breast Cancer"],"interventions":["BEBT-209 capsules","Carboplatin injection","Gemcitabine hydrochloride for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06685796"},{"nctId":"NCT05879367","title":"Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma","sponsor":"Orbus Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2023-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-06-25","conditions":["Glioblastoma, IDH-wildtype","Glioblastoma","Glioblastoma Multiforme","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","GBM","Astrocytoma","Astrocytoma, IDH-Mutant"],"interventions":["Eflornithine (Dose Level 1)","Eflornithine (Dose Level 2)","Eflornithine (Dose Level -1)","Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT05879367"},{"nctId":"NCT06241898","title":"A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors","sponsor":"Bliss Biopharmaceutical (Hangzhou) Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Solid Tumor"],"interventions":["BB-1709"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: * to assess the safety and tolerability of BB-1709. * to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709","sourceUrl":"https://clinicaltrials.gov/study/NCT06241898"},{"nctId":"NCT02650401","title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2016-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Solid Tumors","CNS Tumors"],"interventions":["Entrectinib"],"countries":["United States","Canada","China","France","Germany","Hong Kong","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["RNA fusion"],"summary":"This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.","sourceUrl":"https://clinicaltrials.gov/study/NCT02650401"},{"nctId":"NCT05204862","title":"Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors","sponsor":"TiumBio Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2021-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2023-04-03","conditions":["Advanced Solid Tumor"],"interventions":["TU2218","Anti-PD-1 antibody"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 and the main purpose of Phase 2 is to evaluate the antitumor activity of TU2218 at RP2D.","sourceUrl":"https://clinicaltrials.gov/study/NCT05204862"},{"nctId":"NCT06514651","title":"MAQ-001 in Patients With Advanced Solid Tumors","sponsor":"MabQuest SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2024-07-23","conditions":["Advanced Solid Tumor"],"interventions":["MAQ-001","Ipilimumab"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this interventional study is to test a new monoclonal antibody, called MAQ-001, as a potential treatment for certain types of advanced cancers in different organs or compartments, such as skin, lung, kidney, liver, stomach, bowel, the female reproductive system, and hematology lymph node cancers. The main question\\[s\\] it aims to answer are: * the best dose of MAQ-001 that is safe to use alone or in combination with another anti-cancer medicine ipilimumab; * how MAQ-001 works in the body and how it affects the whole cancer and its cells. Participants will: * receive a defined dose of MAQ-001 or MAQ-001 in combination with ipilimumab (depending on rank of enrolment) on day 1 of a ","sourceUrl":"https://clinicaltrials.gov/study/NCT06514651"},{"nctId":"NCT06666270","title":"Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors","sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-07-20","conditions":["Advanced Solid Cancer","Metastatic Solid Tumor","Ovarian Cancer","Breast Cancer","Prostate Cancer","BRCA Mutation","HRR Deficiency"],"interventions":["SYN818"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 as monotherapy in adult patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06666270"},{"nctId":"NCT07254585","title":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["SYS6010 injection","Enlonstobart injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a n open-label, multi-center, phase II study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart in the recurrent or metastatic head and neck squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07254585"},{"nctId":"NCT05904379","title":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":233,"enrollmentType":"ESTIMATED","startDate":"2023-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Advanced Non-small-cell Lung Cancer"],"interventions":["AK112","AK104","Carboplatin","paclitaxel","pemetrexed","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase Ib/II study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and AK104 with or without chemotherapy in subjects with advanced NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05904379"},{"nctId":"NCT07229898","title":"A Phase Ⅰ Clinical Study of GEN-725 Tablets in Patients With Advanced Solid Tumors","sponsor":"Henan Genuine Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Solid Tumors"],"interventions":["GEN-725 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A phase Ⅰ clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of GEN-725 tablets in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229898"},{"nctId":"NCT06782334","title":"AMT-116 in Patients with Solid Tumors","sponsor":"Multitude Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-01-17","conditions":["Advanced Solid Tumors"],"interventions":["AMT-116"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06782334"},{"nctId":"NCT04866641","title":"Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors","sponsor":"Taivex Therapeutics Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2021-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-05-30","conditions":["Advanced Solid Tumor"],"interventions":["T-1201 Injection 100 mg Kit"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of T-1201 injection in subjects with advanced solid tumors refractory to standard therapy, or for whom no standard therapy is available. The main questions it aims to answer are: * The Maximum tolerated dose (MTD) of T-1201 on different dosing schedules. * The Recommended Phase 2 dose (RP2D) of T-1201 on different dosing schedules. Researchers will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of T-1201. Participants will: Received T-1201 either once every 4 (Part A)/2 (Part B)/3 (Part C) weeks, depend on they participate in which parts","sourceUrl":"https://clinicaltrials.gov/study/NCT04866641"},{"nctId":"NCT05367635","title":"A Study of SKB315 in Patients With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":246,"enrollmentType":"ESTIMATED","startDate":"2022-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumors"],"interventions":["SKB315 for injection","Drug: Tagitanlimab Drug: Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05367635"},{"nctId":"NCT06016738","title":"OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","sponsor":"Olema Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2023-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Breast Cancer","Advanced Breast Cancer","Metastatic Breast Cancer","ER Positive Breast Cancer","HER2 Negative Breast Carcinoma"],"interventions":["Palazestrant","Fulvestrant","Anastrozole","Letrozole","Exemestane"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","France","Germany","Hong Kong","Hungary","Italy","Malaysia","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":233,"serviceSignals":["HER2 profiling"],"summary":"This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06016738"},{"nctId":"NCT05023486","title":"NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies","sponsor":"Novita Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":121,"enrollmentType":"ACTUAL","startDate":"2021-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Advanced or Metastatic Solid Tumor Malignancies"],"interventions":["NP-G2-044 Monotherapy","Anti-PD-1 Therapy","NP-G2-044 Combination therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05023486"},{"nctId":"NCT06187402","title":"A Study of LM-24C5 For Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Advanced Solid Tumor"],"interventions":["LM-24C5"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06187402"},{"nctId":"NCT05501886","title":"Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)","sponsor":"Celcuity Inc","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":701,"enrollmentType":"ESTIMATED","startDate":"2022-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Breast Cancer"],"interventions":["Gedatolisib","Palbociclib","Fulvestrant","Alpelisib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","France","Germany","Greece","Hungary","India","Italy","Mexico","Poland","Romania","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":235,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05501886"},{"nctId":"NCT06440967","title":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":982,"enrollmentType":"ACTUAL","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Hot Flashes"],"interventions":["Fezolinetant","Placebo","Tamoxifen","Aromatase inhibitor"],"countries":["Canada","Czechia","Denmark","France","Germany","Hungary","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":110,"serviceSignals":["Broad CGP"],"summary":"One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this study, women on hormone therapy for breast cancer who have moderate to severe hot flashes will take part. They will either take fezolinetant or a placebo to treat their hot flashes. The placebo looks","sourceUrl":"https://clinicaltrials.gov/study/NCT06440967"},{"nctId":"NCT05352750","title":"Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors","sponsor":"Sonnet BioTherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2022-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Advanced Solid Tumor","Soft Tissue Sarcoma Adult"],"interventions":["SON-1010"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05352750"},{"nctId":"NCT06128148","title":"Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors","sponsor":"Guangzhou JOYO Pharma Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":101,"enrollmentType":"ESTIMATED","startDate":"2022-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-07-14","conditions":["Protein Kinase Inhibitors","Other Protocol Specified Criteria","Lung Neoplasms","Brain Neoplasms"],"interventions":["JYP0322 50 mg qd","JYP0322 100 mg qd","JYP0322 200 mg qd","JYP0322 100 mg bid","JYP0322 150 mg bid","JYP0322 200 mg bid","JYP0322 150mg tid"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"An open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of JYP0322 in patients with ROS1+ locally advanced/metastatic solid tumors .","sourceUrl":"https://clinicaltrials.gov/study/NCT06128148"},{"nctId":"NCT06375044","title":"Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["SIM0500"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT06375044"},{"nctId":"NCT06092580","title":"Phase 1 Study of AWT020 in Advanced Cancer","sponsor":"Anwita Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2025-09-02","conditions":["Advanced Cancer"],"interventions":["AWT020"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The aims of this clinical trial are (1) to assess the safety of AWT020 at different dose levels; (2) to determine the pharmacokinetics and pharmacodynamics of AWT020 in subjects with locally advanced or metastatic cancer who have failed standard therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06092580"},{"nctId":"NCT07045428","title":"68Ga-GP-01 Injection in Solid Tumors Participants","sponsor":"GrandPharma (China) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-10-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2025-07-03","conditions":["Solid Tumor Malignancies"],"interventions":["68Ga-GP-01 Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A company named Chengdu Shetai Medical Technology Co., Ltd. is conducting a research study to test a new type of scan for detecting solid tumors in patients who are scheduled for surgery. During the scan, the investigators will use a special experimental drug called 68Ga-GP-01 Injection, which is given through a vein (IV). This drug isn't yet approved by the TGA for this use. The scan works by targeting a protein called FAP that's often found in high amounts in tumor tissues. FAP is mainly present in cells surrounding tumors, but sometimes in cancer cells themselves too - especially in certain cancers like ovarian, breast, pancreatic, and some sarcomas. Researchers think this could be useful","sourceUrl":"https://clinicaltrials.gov/study/NCT07045428"},{"nctId":"NCT06867978","title":"Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis.","sponsor":"VPIX Medical","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Frozen Sections","Indocyanine Green","Brain Tumor"],"interventions":["cCeLL In vivo","Indocyanine Green"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to demonstrate the non-inferiority of cCeLL compared to frozen section analysis. The investigational device is intended for use with indocyanine green (ICG) for fluorescence imaging as an aid in the visualization of vessels (micro- and macro-vasculature) blood flow in the cerebrovascular before, during or after cranial diagnostic and therapeutic procedures, such as tumor biopsy and resection, which is then read and analyzed by trained-professional for intraoperative diagnosis. The comparison will be held by the device with the conventional intraoperative histological frozen section analysis of identical brain tissue samples in the same patient. Both met","sourceUrl":"https://clinicaltrials.gov/study/NCT06867978"},{"nctId":"NCT06453902","title":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2025-02-21","conditions":["Chronic Myeloid Leukemia","Accelerated Phase CML"],"interventions":["TGRX-678"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06453902"},{"nctId":"NCT06711523","title":"Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy","sponsor":"Kexing Biopharm Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Neutropenia, Chemotherapy-Induced Febrile","Breast Neoplasm Female"],"interventions":["PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.)","PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.) as a positive control.","sourceUrl":"https://clinicaltrials.gov/study/NCT06711523"},{"nctId":"NCT04655092","title":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","sponsor":"PharmaEssentia Japan K.K.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2021-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-11-08","conditions":["Polycythemia Vera (PV)"],"interventions":["P1101 (Ropeginterferon alfa-2b)"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.","sourceUrl":"https://clinicaltrials.gov/study/NCT04655092"},{"nctId":"NCT06974812","title":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Unresectable Locally Advanced or Metastatic Solid Tumors"],"interventions":["IBI3014"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06974812"},{"nctId":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","sponsor":"Medicenna Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2021-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["Advanced Solid Tumor","Unresectable Solid Tumor","Clear Cell Renal Cell Carcinoma","Triple Negative Breast Cancer","Non-Small Cell Lung Cancer Squamous","Non-Small Cell Lung Cancer Non-squamous","Colorectal Cancer (MSI-H)","Gastric Cancer","Cervical Cancer","Basal Cell Carcinoma","Bladder Cancer","Merkel Cell Carcinoma","Squamous Cell Carcinoma of Head and Neck","Cutaneous Squamous Cell Carcinoma","Pleural Mesothelioma","Esophageal Cancer","Endometrial Carcinoma","Solid Tumor","Solid Tumor, Adult","MSI-H Solid Malignant Tumor","Cancer With A High Tumor Mutational Burden","Epithelial Ovarian Carcinoma","Primary Peritoneal Cancer","Gastroesophageal Junction (GEJ) Cancer","Acral Melanoma","Mucosal Melanoma","Cutaneous Melanoma","DMMR Solid Malignant Tumor","Fallopian Tube Cancer","Ovarian Cancer","MSI-H Cancer","DMMR Cancer","Pancreas Adenocarcinoma (MSI-H)","Skin Cancer","Viral Cancer","Cervical Cancers","Endometrial Cancer"],"interventions":["MDNA11","Pembrolizumab (KEYTRUDA®)"],"countries":["United States","Australia","Canada","Ireland","Portugal","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["MSI / TMB"],"summary":"This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05086692"},{"nctId":"NCT06551064","title":"Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients","sponsor":"Formycon AG","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":96,"enrollmentType":"ACTUAL","startDate":"2024-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-04","conditions":["Melanoma, Stage II","Melanoma Stage III"],"interventions":["FYB206","Keytruda"],"countries":["Bosnia and Herzegovina","Bulgaria","Estonia","Georgia","Lithuania","Moldova","North Macedonia","Poland","Romania","Serbia","Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"Melanoma is a kind of skin cancer that starts in the melanocytes. Melanocytes are cells that make the pigment that gives skin its colour. 'Resected' means the melanoma has been completely removed with surgery. Pembrolizumab is an anti-cancer therapy that works with the immune system to fight cancer cells. Some cancer cells develop a way to hide from the body's immune system and, thus, allow the cancer cells to spread and grow. Pembrolizumab helps the immune system recognize and kill these cancer cells that want to hide. Pembrolizumab is a biologic drug (produced by living organisms) available in the market under the brand name Keytruda. Keytruda is approved globally for the treatment of a va","sourceUrl":"https://clinicaltrials.gov/study/NCT06551064"},{"nctId":"NCT06115642","title":"A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":367,"enrollmentType":"ESTIMATED","startDate":"2023-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Advanced/Metastatic Malignant Solid Tumors"],"interventions":["HLX43","HLX10"],"countries":["United States","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":10,"serviceSignals":["ADC biomarker"],"summary":"This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 in patients with advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06115642"},{"nctId":"NCT03459534","title":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","sponsor":"Il-Yang Pharm. Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":173,"enrollmentType":"ESTIMATED","startDate":"2018-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-10-28","conditions":["Chronic Myeloid Leukemia, Chronic Phase","CML, Chronic Phase","CML, Refractory","CML - Philadelphia Chromosome"],"interventions":["Radotinib HCl"],"countries":["Russia","South Korea","Turkey (Türkiye)","Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.","sourceUrl":"https://clinicaltrials.gov/study/NCT03459534"},{"nctId":"NCT05353257","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":511,"enrollmentType":"ACTUAL","startDate":"2022-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Limited-Stage Small Cell Lung Cancer"],"interventions":["HLX10","carboplatin/cisplatin-etoposide","Thoracic radiotherapy","Placebo","Prophylactic Cranial Irradiation (PCI)"],"countries":["United States","Austria","China","Czechia","Germany","Greece","Hungary","Latvia","Netherlands","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":129,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of Serplulimab + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05353257"},{"nctId":"NCT06093698","title":"An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases","sponsor":"ITabMed Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2023-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2023-10-23","conditions":["Recurrent or Metastatic Solid Tumors"],"interventions":["Recombinant Anti-EpCAM-CD3 Antibody Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Title: An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases","sourceUrl":"https://clinicaltrials.gov/study/NCT06093698"},{"nctId":"NCT06447597","title":"A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2024-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Generalized Myasthenia Gravis"],"interventions":["B007","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT06447597"},{"nctId":"NCT06077877","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2023-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Neoplasms"],"interventions":["GSK4524101","Niraparib"],"countries":["United States","Canada","Panama"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT06077877"},{"nctId":"NCT06046742","title":"A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-20","completionType":"ESTIMATED","lastUpdated":"2025-03-13","conditions":["Solid Tumor"],"interventions":["M1-c6v1"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A Phase I Study of the Safety and Tolerability of M1-c6v1 Administered Via Intravenously for Treatment of Patients With Locally Advanced or Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06046742"},{"nctId":"NCT05816252","title":"A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)","sponsor":"Klus Pharma Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":356,"enrollmentType":"ACTUAL","startDate":"2023-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Non-small Cell Lung Cancer"],"interventions":["SKB264","Pembrolizumab","Carboplatin","Osimertinib"],"countries":["China","Georgia","Romania","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":true,"siteCount":50,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05816252"},{"nctId":"NCT04150497","title":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","sponsor":"Cellectis S.A.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2019-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["B-cell Acute Lymphoblastic Leukemia"],"interventions":["UCART22","CLLS52"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)","sourceUrl":"https://clinicaltrials.gov/study/NCT04150497"},{"nctId":"NCT06038578","title":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","sponsor":"Toray Industries, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2023-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Gastric Adenocarcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["TRK-950","Ramucirumab","Paclitaxel"],"countries":["United States","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06038578"},{"nctId":"NCT03363373","title":"Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow","sponsor":"Y-mAbs Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2018-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ACTUAL","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Neuroblastoma"],"interventions":["GM-CSF + Naxitamab"],"countries":["United States","Canada","Denmark","Germany","Hong Kong","India","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2","sourceUrl":"https://clinicaltrials.gov/study/NCT03363373"},{"nctId":"NCT06737146","title":"Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma","sponsor":"Suzhou Maximum Bio-tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-12-17","conditions":["High-grade Glioma"],"interventions":["MT027 cells suspension"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The clinical protocol plans to preset three dose groups, namely 1×10⁷ cells per dose, 3×10⁷ cells per dose, and 6×10⁷ cells per dose. The injection will be administered once every three weeks, adopting a \"3 + 3\" dose escalation design. The dosing interval is based on the pharmacokinetic (PK), safety and preliminary efficacy data of MT027 investigator-initiated trial (IIT) previously conducted at Dushu Lake Hospital of Soochow University. Accordingly, it is recommended to maintain the dosing interval of once every three weeks, with a window period of ±7 days. According to past experience, the dosing cycle should be at least 6 cycles, with each cycle lasting 21 days. If patients still benefit ","sourceUrl":"https://clinicaltrials.gov/study/NCT06737146"},{"nctId":"NCT04130516","title":"Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab","sponsor":"Linnaeus Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2019-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ACTUAL","completionDate":"2026-08-15","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Solid Tumor, Adult"],"interventions":["LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER","Pembrolizumab - anti-PD-1 antibody"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combination with pembrolizumab. The study will include a dose escalation phase, a dose expansion phase, and phase 2A cohorts. Up to 200 patients will be accrued for this study. Up to 15 study sites in the United States will participate in the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04130516"},{"nctId":"NCT06428331","title":"A Study of SKB518 in Patients With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumors"],"interventions":["SKB518 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), phase 1, multicenter, open-label, dose-escalation study of SKB518 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor relapsed/refractory to standard therapies or for which no effective standard therapy is available.","sourceUrl":"https://clinicaltrials.gov/study/NCT06428331"},{"nctId":"NCT07529782","title":"Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Multiple Myeloma and Other Plasma Cell Neoplasms"],"interventions":["HDP-101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This study is a 2-part study with a dose-escalation part and a dose-expansion part. The aim of the dose-escalation part is to determine the maximum tolerated dose (MTD) and/or establish the recommended Phase 2 dose (RP2D) in the Chinese population, in order to select the treatment dose for the dose-expansion part. The dose-escalation part will be followed by the dose-expansion part once the MTD(s) and/or RP2D of HDP-101 monotherapy in the Chinese population have been determined. The dose-expansion part of the study is intended to collect preliminary evidence of antitumor activity and to confirm the safety of the HDP-101 as monotherapy in Chinese patients with r/r MM.","sourceUrl":"https://clinicaltrials.gov/study/NCT07529782"},{"nctId":"NCT06472076","title":"A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":88,"enrollmentType":"ACTUAL","startDate":"2024-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ACTUAL","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Lung Cancer, Non-Small Cell"],"interventions":["Dostarlimab","Belrestotug","Pembrolizumab","Placebo"],"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","China","Finland","France","Germany","Hong Kong","India","Japan","Mexico","Netherlands","Panama","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":108,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06472076"},{"nctId":"NCT05652894","title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","sponsor":"Taizhou Hanzhong biomedical co. LTD","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2023-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-20","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Metastatic Colorectal Cancer"],"interventions":["HX008(Pucotenlimab)","Investigator's Choice Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":63,"serviceSignals":["MSI / TMB"],"summary":"The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05652894"},{"nctId":"NCT06590194","title":"PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","sponsor":"Suzhou Puhe Pharmaceutical Technology Co., LTD","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2024-09-10","startDateType":"ESTIMATED","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["PH009-1 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study will contain three stages: Phase I includes dose escalation phase (i.e., phase Ia) and dose expansion phase (i.e., phase Ib). Once the dosage regimen is confirmed, the sponsor can decide to start the cohort expansion phase (i.e., phase IIa)","sourceUrl":"https://clinicaltrials.gov/study/NCT06590194"},{"nctId":"NCT06485219","title":"A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","Cutaneous T-cell Lymphoma (CTCL)"],"interventions":["11.2 mg/m2 Purinostat Mesylate","15 mg/m2 Purinostat Mesylate"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"Primary Objective To evaluate the preliminary efficacy of Purinostat Mesylate for Injection in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Secondary Objectives 1. To evaluate the safety and tolerability of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. 2. To evaluate the population pharmacokinetic characteristics of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. Exploratory Objective To investigate the relationship between tumor biomarkers and the therapeutic efficacy/safety profile of Purinostat Mesylate for Injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06485219"},{"nctId":"NCT06750419","title":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2024-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Clear Cell Renal Cell Carcinoma"],"interventions":["89Zr-TLX250 PET/CT"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"89Zr-TLX250 is under clinical development as a diagnostic agent targeting clear cell renal cell carcinoma, and this Phase 3 bridging study in mainland Chinese patients is intended to support the successful ZIRCON data (ZIRCON Clinicaltrial.gov ID: NCT03849118)","sourceUrl":"https://clinicaltrials.gov/study/NCT06750419"},{"nctId":"NCT02531516","title":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","sponsor":"Aragon Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1503,"enrollmentType":"ACTUAL","startDate":"2015-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-29","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["Apalutamide","Bicalutamide","Bicalutamide Placebo","Apalutamide Placebo","GnRH (agonist)","74-80 Grays (units of radiation)"],"countries":["United States","Argentina","Belgium","Brazil","Canada","China","Czechia","France","Germany","Israel","Malaysia","Mexico","Netherlands","Poland","Romania","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":263,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) results in an improvement of metastasis-free survival (MFS) based on conventional imaging assessed by blinded independent central review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT02531516"},{"nctId":"NCT06927349","title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.","sponsor":"Shandong Boan Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Advanced Solid Tumours"],"interventions":["BA1301"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1301 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06927349"},{"nctId":"NCT06402201","title":"First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors","sponsor":"CDR-Life AG","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2024-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Select Advanced Solid Tumors"],"interventions":["CDR404"],"countries":["United States","Belgium","Denmark","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A\\*02:01 tissue marker and whose cancer is positive for MAGE-A4.","sourceUrl":"https://clinicaltrials.gov/study/NCT06402201"},{"nctId":"NCT04014205","title":"A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2019-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Part 1：r/r B-cell Malignancies","Part 2：B-cell Malignancies"],"interventions":["Orelabrutinib (ICP-022)"],"countries":["United States","Israel","Poland","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies. The study contains two parts, Part 1 (dose escalation) and Part 2 (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT04014205"},{"nctId":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","sponsor":"OncoC4, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":733,"enrollmentType":"ESTIMATED","startDate":"2020-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-23","conditions":["Non Small Cell Lung Cancer","Advanced Solid Tumor","Metastatic Melanoma","Metastatic Head and Neck Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Colorectal Cancer","Sarcomas","Metastatic Prostate Cancer","Ovarian Cancer","Small Cell Lung Cancer","Metastatic Breast Cancer","Pancreas Cancer","Gastric Cancer","Esophageal Cancer","Gastroesophageal Junction Adenocarcinoma","Cervical Cancer","Adenoid Cystic Carcinoma","Salivary Gland Cancer","Urothelial Carcinoma"],"interventions":["ONC-392","Pembrolizumab","Docetaxel"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT04140526"},{"nctId":"NCT06682988","title":"A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Advanced High-Grade Epithelial Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancers"],"interventions":["Mirvetuximab Soravtansine"],"countries":["United States","Australia","Belgium","France","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["ADC biomarker"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FR","sourceUrl":"https://clinicaltrials.gov/study/NCT06682988"},{"nctId":"NCT06539338","title":"A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment","sponsor":"Kite, A Gilead Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ACTUAL","startDate":"2024-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Lymphomas Non-Hodgkin's B-Cell","Precursor Cell Lymphoblastic Leukemia-Lymphoma"],"interventions":["INT2104"],"countries":["Australia","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained. INT2104 is a gene therapy delivering a transgene for a chimeric antigen receptor (CAR) specific for CD20 (CAR20). The lentiviral vector is designed to generate CAR T and CAR Natural Killer (NK) cells inside the body following intravenous (IV) administration. Study details include the following: * The study duration will be 5 years * The treatment duration will be a one-time intravenous (IV) infusion of INT2104","sourceUrl":"https://clinicaltrials.gov/study/NCT06539338"},{"nctId":"NCT06469008","title":"A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2024-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Head and Neck Squamous Cell Carcinomas","Solid Tumor"],"interventions":["BL-B16D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerance, pharmacokinetic characteristics and preliminary effectiveness of BL-B16D1 in recurrent or metastatic head and neck squamous cell carcinomas and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06469008"},{"nctId":"NCT04872478","title":"Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL","sponsor":"Meryx, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2022-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia"],"interventions":["MRX-2843"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT04872478"},{"nctId":"NCT06710379","title":"A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors","sponsor":"Adcentrx Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-09","conditions":["Solid Tumors"],"interventions":["ADRX-0405"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06710379"},{"nctId":"NCT06372626","title":"Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":93,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2024-06-14","conditions":["Neuroendocrine Carcinoma"],"interventions":["ZG005","Etoposide","Cisplatin","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The trial is divided into two parts. PART 1 is a dose escalation study of the ZG005 combined with Etoposide and Cisplatin, primarily assessing the tolerability and safety of this combined treatment. PART 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06372626"},{"nctId":"NCT04162353","title":"BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma","sponsor":"iCell Gene Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2019-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-16","conditions":["Multiple Myeloma in Relapse","Refractory Multiple Myeloma","Plasmacytoid; Lymphoma"],"interventions":["BCMA-CD19 cCAR T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04162353"},{"nctId":"NCT06093672","title":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","sponsor":"Italfarmaco","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Polycythemia Vera"],"interventions":["Givinostat","Hydroxyurea"],"countries":["United States","Austria","Bulgaria","Croatia","France","Germany","Hungary","Ireland","Israel","Italy","Netherlands","Poland","Serbia","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":90,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06093672"},{"nctId":"NCT05650879","title":"ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer","sponsor":"Enliven Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2023-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-07-15","conditions":["HER2 Mutant Non-small Cell Lung Cancer","HER2-positive Metastatic Breast Cancer","HER2 Gene Mutation","HER2 Amplification"],"interventions":["ELVN-002","Fam-Trastuzumab Deruxtecan-Nxki","Trastuzumab emtansine"],"countries":["United States","Australia","France","Italy","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05650879"},{"nctId":"NCT05141149","title":"First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer","sponsor":"Prestige Biopharma Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Pancreatic Cancer"],"interventions":["PBP1510 (400mg/16mL)","Gemcitabine (1000 mg/m^2)"],"countries":["United States","Australia","Singapore","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The first in human clinical study is planned as an open-label, dose-escalation, and dose-expansion, multicentre, two-part, Phase 1/2a study of PBP1510 administered to patients with advanced/metastatic pancreatic cancer. The study will be conducted in two parts, Part 1 as a PBP1510 single agent dose-escalation, and PBP1510 dose-escalation in combination with gemcitabine, and Part 2 as PBP1510 dose-expansion at the RP2D in combination with gemcitabine.","sourceUrl":"https://clinicaltrials.gov/study/NCT05141149"},{"nctId":"NCT06475131","title":"A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2024-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Solid Tumor"],"interventions":["BL-B16D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, dose-escalation and expansion-enrollment and nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-B16D1 in locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06475131"},{"nctId":"NCT07102004","title":"Study of MHB088C for Patients With Advanced Solid Malignant Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":515,"enrollmentType":"ESTIMATED","startDate":"2023-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["MHB088C for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of MHB088C in participants with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07102004"},{"nctId":"NCT04541082","title":"Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms","sponsor":"Jazz Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2020-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Central Nervous System Neoplasms","Glioblastoma","Gliosarcoma, Adult","Anaplastic Oligodendroglioma","Anaplastic Astrocytoma","Pilocytic Astrocytoma","Oligodendroglioma","Gliomatosis Cerebri","Pleomorphic Xanthoastrocytoma","Anaplastic Pleomorphic Xanthoastrocytoma","Diffuse Midline Glioma, H3 K27M-Mutant","Ependymoma","Ependymoma, Anaplastic","Medulloblastoma","Teratoid Rhabdoid Tumor","Neuroectodermal Tumors, Primitive","Neuroectodermal Tumors","Anaplastic Meningioma","Atypical Meningioma","Choroid Plexus Neoplasms","Pineal Tumor","Diffuse Astrocytoma","Glial Tumor"],"interventions":["ONC206"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT04541082"},{"nctId":"NCT06279364","title":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":524,"enrollmentType":"ESTIMATED","startDate":"2024-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Triple Negative Breast Cancer"],"interventions":["SKB264","Paclitaxel","Nab-paclitaxel","Capecitabine","Eribulin","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 positive tumors who received prior anti-programmed cell death 1 (PD-1)/PD-L1 inhibitor in early setting","sourceUrl":"https://clinicaltrials.gov/study/NCT06279364"},{"nctId":"NCT05877430","title":"Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer","sponsor":"CJ Bioscience, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2023-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2024-12-20","conditions":["NSCLC","HNSCC","Melanoma","Metastatic Cancer","Advanced Solid Tumor","Advanced Cancer"],"interventions":["CJRB-101","Pembrolizumab injection"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05877430"},{"nctId":"NCT06433947","title":"Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma","sponsor":"Opna Bio LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Relapsed Multiple Myeloma","Refractory Multiple Myeloma"],"interventions":["OPN-6602","Dexamethasone"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.","sourceUrl":"https://clinicaltrials.gov/study/NCT06433947"},{"nctId":"NCT06848348","title":"Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain","sponsor":"Dogwood Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Chemotherapy Induced Neuropathic Pain","Chemotherapy Induced Pain Neuropathy","Chemotherapy Induced Pain"],"interventions":["Halneuron","Placebo","Halneuron (Open Label Extension)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.","sourceUrl":"https://clinicaltrials.gov/study/NCT06848348"},{"nctId":"NCT03539536","title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":270,"enrollmentType":"ACTUAL","startDate":"2018-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-11-05","conditions":["Non-small Cell Lung Cancer"],"interventions":["Telisotuzumab vedotin"],"countries":["United States","Australia","Belgium","Bulgaria","Canada","China","Czechia","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Netherlands","Poland","Puerto Rico","Romania","Russia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":252,"serviceSignals":["MET profiling"],"summary":"This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).","sourceUrl":"https://clinicaltrials.gov/study/NCT03539536"},{"nctId":"NCT02446249","title":"Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction","sponsor":"MeiraGTx, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2015-05-04","startDateType":"","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Squamous Cell Head and Neck Cancer","Radiation Induced Xerostomia","Salivary Hypofunction"],"interventions":["AAV2hAQP1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Background: \\- Radiation can cause the parotid salivary glands to make less saliva (dry mouth). This can cause problems like infections and tooth decay. Researchers hope a new drug can help people with dry mouth caused by radiation. Objectives: \\- To examine the safety of AAV2hAQP1 gene therapy. To see if the drug increases saliva in people whose parotid glands have had radiation. Eligibility: \\- People at least 18 years of age with a history of radiation therapy for head and neck cancer. Design: Participants will be screened in 2 visits with: * medical history * physical exam * scans of the head, neck, and chest * intravenous administration of glycopyrrolate to stop saliva * saliva collecti","sourceUrl":"https://clinicaltrials.gov/study/NCT02446249"},{"nctId":"NCT05065957","title":"Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer","sponsor":"InnoPharmax Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2022-03-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Biliary Tract Cancer"],"interventions":["D07001-softgel capsules + Xeloda (or TS-1)","mFOLFOX"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The primary objective are: To assess the safety and tolerability of the combination of D07001-softgel capsules and Xeloda/TS-1. To evaluate the efficacy of the combination of D07001-softgel capsules and Xeloda/TS-1, as assessed by disease control rate (DCR).","sourceUrl":"https://clinicaltrials.gov/study/NCT05065957"},{"nctId":"NCT06014658","title":"Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors","sponsor":"MBrace Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Cancer"],"interventions":["Antibody-Drug Conjugate"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human (FIH), open label Phase 1/1b / Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment. Phase 1 will identify potential optimal biologically relevant doses (OBRD) and the maximum tolerated dose (MTD) of MBRC-101 at one 1 or more dosing regimens. Phase 1b will evaluate the safety and preliminary clinical activity of MBRC-101 at potential OBRDs. Phase 1 and Phase 1b will both characterize single and multiple-dose PK profiles and evaluate incidence and persistence of anti-MBRC-101 Ab. Phase 2 will evaluate the efficacy of MBRC-101 at the RP2D from Phase1b.","sourceUrl":"https://clinicaltrials.gov/study/NCT06014658"},{"nctId":"NCT06566092","title":"Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Soft Tissue Sarcoma","Primary Central Nervous System Carcinoma","Melanoma","Rhabdomyosarcoma","Ewing Sarcoma"],"interventions":["LN-145/LN-144"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist. Study details include: * The study will last up to 2 years after the TIL infusion (Day 0) for each person. * The treatment will last up to 10 days for each person. * Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT06566092"},{"nctId":"NCT06547840","title":"A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha","sponsor":"Epsilogen Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2024-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Advanced Ovarian Cancer","Platinum-resistant Ovarian Cancer","Triple Negative Breast Cancer (TNBC)","Triple -Negative Breast Cancer","Endometrial Cancer","Advanced Endometrial Cancer"],"interventions":["MOv18 IgE"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD). Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18 IgE.","sourceUrl":"https://clinicaltrials.gov/study/NCT06547840"},{"nctId":"NCT06493864","title":"A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2024-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Breast Cancer","Solid Tumor"],"interventions":["BL-B16D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, increasing dose and dose extension nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-B16D1 in patients with unresectable locally advanced or metastatic breast cancer and other solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06493864"},{"nctId":"NCT06492005","title":"A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2024-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-01-10","conditions":["Triple-Negative Breast Cancer"],"interventions":["9MW2821","PD-1 inhibitior"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase 2, open-label,multicenter study designed to evaluate the efficacy and safety of 9MW2821monotherapy or combined with PD-1 inhibitor in locally advanced or metastatic Triple-Negative Breast Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06492005"},{"nctId":"NCT04674683","title":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","sponsor":"HUYABIO International, LLC.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":450,"enrollmentType":"ACTUAL","startDate":"2021-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Unresectable or Metastatic Melanoma","Progressive Brain Metastasis"],"interventions":["HBI-8000 in combination with nivolumab","Placebo in combination with nivolumab"],"countries":["United States","Australia","Austria","Belgium","Brazil","Czechia","France","Germany","Italy","Japan","New Zealand","Puerto Rico","Singapore","South Africa","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":139,"serviceSignals":["Broad CGP"],"summary":"This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive brain metastasis or adolescents with or without new progressive brain metastasis receive HBI-8000 combined with nivolumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT04674683"},{"nctId":"NCT07639905","title":"A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-07","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Malignant Solid Tumor"],"interventions":["HRS-2189 Tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-center, single-dose, randomized, open-label, two-period, crossover phase I clinical trial, comparing the bioavailability and safety of the new and old processes of HRS-2189 tablets in healthy subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT07639905"},{"nctId":"NCT07044908","title":"TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["RAS/BRAF Wild Type Colorectal Cancer"],"interventions":["TQB2922 injection ± TAS-102 tablets","TQB2922 injection+TAS-102 tablets ± Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open Phase Ib/II clinical study evaluating the safety and efficacy of TQB2922 in combination with TAS-102±bevacizumab in subjects with RAS/BRAF wild-type unresectable locally advanced or metastatic colorectal cancer that has failed treatment with oxaliplatin, fluorouracil-based and irinotecan.","sourceUrl":"https://clinicaltrials.gov/study/NCT07044908"},{"nctId":"NCT06456528","title":"QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":235,"enrollmentType":"ESTIMATED","startDate":"2024-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Cancer Treatment-Induced Thrombocytopenia"],"interventions":["QL0911","QL0911 plus Placebo","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of QL0911 in cancer treatment-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia is a side effect of cancer treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06456528"},{"nctId":"NCT06040099","title":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":58,"enrollmentType":"ACTUAL","startDate":"2024-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-01","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["Durvalumab","Bevacizumab","Transarterial Radioembolization (TARE)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with unresectable hepatocellular carcinoma (HCC) amenable to embolization.","sourceUrl":"https://clinicaltrials.gov/study/NCT06040099"},{"nctId":"NCT04745403","title":"Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)","sponsor":"Lion TCR Pte. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2022-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2023-11-18","conditions":["Hepatocellular Carcinoma"],"interventions":["mRNA HBV/TCR T-cells"],"countries":["Singapore"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in subjects with HBV-related HCC who are not amenable to/failed conventional treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04745403"},{"nctId":"NCT05934331","title":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","sponsor":"LaNova Medicines Zhejiang Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":276,"enrollmentType":"ESTIMATED","startDate":"2023-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2025-09-12","conditions":["Malignant Neoplasms of Digestive Organs"],"interventions":["LM-302","Toripalimab","Capecitabine","Tegafur, Gimeracil and Oteracil Potassium Capsules","Nivolumab","Apatinib","Gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05934331"},{"nctId":"NCT06460298","title":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","sponsor":"ProDa BioTech, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2024-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Triple Negative Breast Cancer"],"interventions":["ProAgio Dose Levels (DL) 1,2,3,4","ProAgio Dose Expansion"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06460298"},{"nctId":"NCT06499350","title":"A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors","sponsor":"FindCure Biosciences (ZhongShan) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Advanced Malignant Solid Tumors"],"interventions":["FC084CSA+Tislelizumab combination (dose escalation)","RP2D of FC084CSA+Tislelizumab combination (dose expansion)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06499350"},{"nctId":"NCT05582590","title":"Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers","sponsor":"NexImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-25","completionType":"ESTIMATED","lastUpdated":"2024-01-16","conditions":["Oropharyngeal Cancer","Human Papilloma Virus","Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Cancer, Metastatic","Head and Neck Cancer Metastatic","HPV-Related Squamous Cell Carcinoma","HPV-Related Mucosal Head and Neck Squamous Cell Carcinoma","Relapsed Oropharyngeal SCC","Refractory Oropharyngeal Squamous Cell Carcinoma"],"interventions":["Fludarabine","Cyclophosphamide","NEXI-003 T cells"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This is a multicenter, open-label, Phase I, first-in-human trial to characterize the safety and clinical activity of an antigen-specific CD8+ T-cell product in patients with relapsed or refractory locally advanced or metastatic HPV-related oropharyngeal cancers. Patients must have received at least one prior standard treatment regimen consisting of systemic immunotherapy and/or chemotherapy. The investigative agent is an autologous adoptive T-cell product derived from the patient's endogenous cytolytic T cells that are directed toward HPV-16 E6/E7, HPV-18 E6/E7 antigens, and a tumor-associated antigen (Survivin) by ex vivo exposure to an artificial antigen presenting cell to which HLA-A2 ant","sourceUrl":"https://clinicaltrials.gov/study/NCT05582590"},{"nctId":"NCT05329532","title":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","sponsor":"Scancell Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2022-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Triple Negative Breast Cancer","Renal Cell Cancer","High Grade Ovarian Serous Adenocarcinoma","Squamous Cell Carcinoma of the Head and Neck"],"interventions":["Modi-1 Moditope","Pembrolizumab","MicronJet600™ microneedle device (NanoPass)"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The main objectives of this study are to assess the safety, tolerability, immunological activity, and preliminary efficacy of the Modi-1 Moditope vaccine, both as monotherapy and in combination with a checkpoint inhibitor (CPI) such as pembrolizumab or nivolumab with or without Ipilimumab (where these are standard of care in a non-neoadjuvant setting), in patients with advanced triple negative breast cancer (TNBC), advanced/unresectable human papillomavirus-negative squamous cell carcinoma of the head and neck (SCCHN), high grade serous ovarian carcinoma (HGSOC), or renal cell carcinoma (RCC). Modi-1 Moditope will also be investigated in the neoadjuvant setting for patients with SCCHN underg","sourceUrl":"https://clinicaltrials.gov/study/NCT05329532"},{"nctId":"NCT06319313","title":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":534,"enrollmentType":"ESTIMATED","startDate":"2024-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2024-03-20","conditions":["Squamous Cell Non-small Cell Lung Cancer"],"interventions":["JMT101","docetaxel","HB1801"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a phase II/III, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with docetaxel/ HB1801 in Patients with Squamous cell non-small cell lung cancer （sqNSCLC）.","sourceUrl":"https://clinicaltrials.gov/study/NCT06319313"},{"nctId":"NCT05479812","title":"Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors","sponsor":"Werewolf Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2022-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor"],"interventions":["WTX-124","pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05479812"},{"nctId":"NCT06146257","title":"A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes","sponsor":"GluBio Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-08","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"interventions":["GLB-001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The dose escalation part (Phase 1a) of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 administered orally. Approximately 24 participants (up to 42 participants) may be enrolled in Phase 1a of the study. The dose expansion part (Phase 1b) will be followed to understand the relationships among dose, exposure, toxicity, ","sourceUrl":"https://clinicaltrials.gov/study/NCT06146257"},{"nctId":"NCT05261399","title":"Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":341,"enrollmentType":"ACTUAL","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-06","primaryCompletionType":"ACTUAL","completionDate":"2026-11-23","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Carcinoma","Non-Small-Cell Lung"],"interventions":["Savolitinib","Osimertinib","Pemetrexed","Cisplatin","Carboplatin"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Malaysia","Philippines","Poland","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":214,"serviceSignals":["Broad CGP"],"summary":"Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05261399"},{"nctId":"NCT06194448","title":"To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":76,"enrollmentType":"ACTUAL","startDate":"2024-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-07","primaryCompletionType":"ACTUAL","completionDate":"2027-07-07","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Lung Cancer"],"interventions":["Osimertinib","Cisplatin or Carboplatin; Pemetrexed or Paclitaxel","Radiation"],"countries":["United States","China","Israel","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent CRT and maintenance osimertinib in adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).","sourceUrl":"https://clinicaltrials.gov/study/NCT06194448"},{"nctId":"NCT07550634","title":"Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment","sponsor":"MindRank AI Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-07-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B)","Hepatic Insufficiency (MeSH ID: D048550)"],"interventions":["MDR-001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment and to matched healthy controls. The study aims to evaluate the pharmacokinetics and safety of MDR-001 in these populations. Primary pharmacokinetic endpoints include AUC and Cmax; safety endpoints include adverse events, vital signs, ECG, and laboratory assessments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07550634"},{"nctId":"NCT04039607","title":"A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":732,"enrollmentType":"ACTUAL","startDate":"2019-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-09","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Hepatocellular Carcinoma"],"interventions":["Nivolumab","Ipilimumab","Sorafenib","lenvatinib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Hong Kong","Italy","Japan","New Zealand","Poland","Puerto Rico","Romania","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":210,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to compare the overall survival (OS) of nivolumab plus ipilimumab versus standard of care (SOC) (sorafenib or lenvatinib) in all randomized participants with advanced hepatocellular carcinoma (HCC) who have not received prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04039607"},{"nctId":"NCT07269782","title":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Non Small Cell Lung Cancer"],"interventions":["HLX43 DOSE 1","HLX43 DOSE 2","Serplulimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to to explore the reasonable dosage and evaluate the efficacy and safety of HLX43 (Anti-PD-L1 ADC) in Combination with Serplulimab (Anti-PD-1 Recombinant Humanized Monoclonal Antibody) as Neoadjuvant Therapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07269782"},{"nctId":"NCT06551324","title":"A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2024-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-13","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-29","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Metastatic Castrate Resistant Prostate Cancer (mCRPC)"],"interventions":["PF-06821497","Docetaxel","Enzalutamide"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","Poland","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":230,"serviceSignals":["Broad CGP"],"summary":"Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment. The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.","sourceUrl":"https://clinicaltrials.gov/study/NCT06551324"},{"nctId":"NCT07277270","title":"A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-13","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-29","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Neoplasms"],"interventions":["GSK5764227","Bevacizumab","Fluorouracil","leucovorin","Enzalutamide"],"countries":["United States","Australia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07277270"},{"nctId":"NCT05589896","title":"A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies","sponsor":"Ossium Health, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Acute Leukemia","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Acute Biphenotypic Leukemia","Acute Undifferentiated Leukemia","CLL (Chronic Lymphocytic Leukemia)","Chronic Myeloid Leukemia (CML)","MDS (Myelodysplastic Syndrome)","Non-Hodgkin Lymphomas","Hodgkins Lymphoma","Cutaneous T Cell Lymphomas (CTCL)"],"interventions":["Ossium HPC Marrow, Bone Marrow Transplant","Pre-transplant conditioning - Myeloablative (MAC)","Pre-transplant conditioning - Reduced Intensity (RIC)","Post-transplant treatment"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.","sourceUrl":"https://clinicaltrials.gov/study/NCT05589896"},{"nctId":"NCT05644561","title":"Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2023-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Generalized Myasthenia Gravis","gMG"],"interventions":["Ravulizumab"],"countries":["United States","Italy","Japan","Serbia","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.","sourceUrl":"https://clinicaltrials.gov/study/NCT05644561"},{"nctId":"NCT06317311","title":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":41,"enrollmentType":"ACTUAL","startDate":"2024-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["Carcinoma"],"interventions":["Dostarlimab","Carboplatin","Paclitaxel"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06317311"},{"nctId":"NCT06387342","title":"Namodenoson Treatment of Advanced Pancreatic Cancer","sponsor":"Can-Fite BioPharma","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-15","completionType":"ESTIMATED","lastUpdated":"2025-01-31","conditions":["Pancreatic Adenocarcinoma","Pancreatic Cancer"],"interventions":["Namodenoson 25mg"],"countries":["Israel"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06387342"},{"nctId":"NCT07116824","title":"HB1801 Combined Treatment of HER2-positive Breast Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-09-15","startDateType":"ESTIMATED","primaryCompletionDate":"2026-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-07","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["HER2-positive Breast Cancer"],"interventions":["HB1801","Trastuzumab","Pertuzumab","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07116824"},{"nctId":"NCT05614102","title":"A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":284,"enrollmentType":"ESTIMATED","startDate":"2022-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-17","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-14","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Solid Tumors"],"interventions":["BAY2965501","Pembrolizumab","Platinum-based Chemotherapy"],"countries":["United States","Belgium","China","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. This study focuses on certain types of skin cancer, kidney cancer, stomach cancer, and lung cancer. The study treatment BAY2965501 is currently under development as monotherapy or in combination for the treatment of people with advanced solid tumors. BAY2965501 blocks an enzyme in T-cells to activate them. T-cells are a type of immune cell that are known to have an anti-cancer effect and BAY29","sourceUrl":"https://clinicaltrials.gov/study/NCT05614102"},{"nctId":"NCT05552976","title":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":606,"enrollmentType":"ACTUAL","startDate":"2023-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-25","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["Mezigdomide","Carfilzomib","Dexamethasone"],"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","China","Colombia","Denmark","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Netherlands","Norway","Puerto Rico","Romania","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":207,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.","sourceUrl":"https://clinicaltrials.gov/study/NCT05552976"},{"nctId":"NCT06953453","title":"A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors","sponsor":"Lee's Pharmaceutical Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-20","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-20","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Cancer"],"interventions":["Inhaled Fentanyl Aerosol","Fentanyl Citrate Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a single-dose, open-label, 2-cycle crossover design, comparing the pharmacokinetic parameters and safety of Inhaled Fentanyl Aerosol and intravenous fentanyl injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06953453"},{"nctId":"NCT06131398","title":"A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":77,"enrollmentType":"ACTUAL","startDate":"2024-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-21","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-21","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advanced Solid Tumors"],"interventions":["AMG 355","Pembrolizumab"],"countries":["United States","Australia","Canada","France","Japan","Netherlands","Poland","South Korea","Spain","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06131398"},{"nctId":"NCT05879822","title":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","sponsor":"Incyte Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":73,"enrollmentType":"ACTUAL","startDate":"2023-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-22","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-22","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Advanced Solid Tumor"],"interventions":["INCB099280"],"countries":["Brazil","China","Georgia","Greece","Hungary","New Zealand","Romania","South Africa","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":true,"siteCount":54,"serviceSignals":["MSI / TMB"],"summary":"This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05879822"},{"nctId":"NCT04884360","title":"D9319C00001- 1L OC Mono Global RCT","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":366,"enrollmentType":"ACTUAL","startDate":"2021-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-27","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Ovarian Cancer"],"interventions":["Olaparib","Matching placebo"],"countries":["Chile","China","Colombia","India","Peru","Russia","South Africa","Turkey (Türkiye)","Ukraine","Vietnam"],"northAmerica":false,"chinaSites":true,"siteCount":89,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial response following treatment with standard first-line platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04884360"},{"nctId":"NCT04225871","title":"Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ACTUAL","startDate":"2019-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-27","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Generalized Myasthenia Gravis"],"interventions":["zilucoplan (RA101495)"],"countries":["United States","Canada","France","Germany","Italy","Japan","Norway","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04225871"},{"nctId":"NCT05608291","title":"A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1564,"enrollmentType":"ACTUAL","startDate":"2023-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-03","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Melanoma"],"interventions":["Fianlimab","Cemiplimab","Pembrolizumab","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Czechia","France","Georgia","Germany","Greece","Ireland","Israel","Italy","Mexico","Poland","Romania","South Africa","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":211,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a \"study drug\" or called \"study drugs\" when combined) compared with an approved medication called pembrolizumab. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab in patients that have had melanoma removal surgery but are still at high risk for the recurrence of the disease. Pembrolizumab is an approved treatment in some countries in this clinical setting. The study is looking at several other research questions, including: * What","sourceUrl":"https://clinicaltrials.gov/study/NCT05608291"},{"nctId":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","sponsor":"Lantern Pharma Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":64,"enrollmentType":"ACTUAL","startDate":"2023-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-28","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","GBM","TNBC - Triple-Negative Breast Cancer","NSCLC","Pancreatic Adenocarcinoma","DDR Gene Mutation"],"interventions":["LP-184","Olaparib","Nivolumab & Ipilimumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity","sourceUrl":"https://clinicaltrials.gov/study/NCT05933265"},{"nctId":"NCT06194656","title":"Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma","sponsor":"Shanghai Institute Of Biological Products","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2024-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["HER3 Monoclonal antibodies-Dose A","HER3 Monoclonal antibodies-Dose B","HER3 Monoclonal antibodies-Dose C","HER3 Monoclonal antibodies-Dose D","Placebo","Cetuximab injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.","sourceUrl":"https://clinicaltrials.gov/study/NCT06194656"},{"nctId":"NCT06927986","title":"Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2025-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["EGFR-mutated Locally Advanced or Metastatic NSCLC"],"interventions":["SYS6010","Pemetrexed","Cisplatin","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06927986"},{"nctId":"NCT02704858","title":"Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma","sponsor":"Neonc Technologies, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2017-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Glioblastoma Multiforme"],"interventions":["Perillyl alcohol"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with radiographically-confirmed progression of Grade IV glioma or recurrent primary or secondary Grade IV glioma. The study will have two phases, Phase 1 and Phase 2a. Phase 1 is a standard cohort dose escalation 3+3 design used to determine the maximum tolerated dose for Phase 2a. There will be up to 24 patients enrolled in Phase 1. There will be 25 patients enrolled in Phase 2a. For both phases of the study, NEO100 will be self-administered four times daily for a 28-day treatment cycles","sourceUrl":"https://clinicaltrials.gov/study/NCT02704858"},{"nctId":"NCT06512116","title":"A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.","sponsor":"Shanghai Institute Of Biological Products","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":196,"enrollmentType":"ESTIMATED","startDate":"2024-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Advanced Solid Tumor"],"interventions":["SIBP-A17"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A17 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06512116"},{"nctId":"NCT06439771","title":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-29","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["YL202 should be intravenously infused"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression","sourceUrl":"https://clinicaltrials.gov/study/NCT06439771"},{"nctId":"NCT06873789","title":"A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors","sponsor":"Incyte Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":9,"enrollmentType":"ACTUAL","startDate":"2025-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Solid Tumors","Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["INCB177054","Retifanlimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06873789"},{"nctId":"NCT04170153","title":"Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":161,"enrollmentType":"ACTUAL","startDate":"2019-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Metastatic or Locally Advanced Unresectable Solid Tumors"],"interventions":["M1774","Niraparib"],"countries":["United States","China","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, Phase I, first-in-human (FIH) multicenter, clinical study conducted in multiple parts to establish the safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) profile (with and without food) and early signs of efficacy of Tuvuseritib (M1774) as monotherapy and in combination with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04170153"},{"nctId":"NCT05744427","title":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":725,"enrollmentType":"ESTIMATED","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Advanced Solid Tumor"],"interventions":["JSKN003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"This is an open, multicenter study of phase I/II in Chinese subjects with unresectable locally advanced/metastatic solid tumors. It is divided into the dose escalation period and the cohort expansion period. A total of 8 dose groups (Q3W on the first day of intravenous administration) were designed in the dose escalation period. The initial dose was 1.0mg/kg administered Q3W, with a DLT observation period of 21 days. In the dose expansion phase, 7 cohorts were established.","sourceUrl":"https://clinicaltrials.gov/study/NCT05744427"},{"nctId":"NCT05320692","title":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":423,"enrollmentType":"ACTUAL","startDate":"2022-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-30","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Hepatocellular Carcinoma"],"interventions":["TACE+Camrelizumab+Apatinib mesylate","TACE"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate efficacy and safety of transarterial chemoembolization (TACE) in combination with Camrelizumab and Rivoceranib (Apatinib) therapy in patients with incurable hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05320692"},{"nctId":"NCT04724369","title":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","sponsor":"Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":43,"enrollmentType":"ACTUAL","startDate":"2021-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Neuroblastoma"],"interventions":["18F-MFBG"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma","sourceUrl":"https://clinicaltrials.gov/study/NCT04724369"},{"nctId":"NCT06980272","title":"SSGJ-707 in Advanced Non-Small Cell Lung Cancer","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2025-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-06-24","conditions":["Advanced Non-Small Cell Lung Cancer"],"interventions":["SSGJ-707","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase III study. All patients are stage IIIB/C (unsuitable for radical therapy) or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of SSGJ-707 comparing Pembrolizumab in subjects with advanced NSCLC whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%.","sourceUrl":"https://clinicaltrials.gov/study/NCT06980272"},{"nctId":"NCT04725994","title":"Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer","sponsor":"Idience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ACTUAL","startDate":"2021-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Gastric Cancer"],"interventions":["IDX-1197+XELOX","IDX-1197+Irinotecan"],"countries":["United States","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04725994"},{"nctId":"NCT07186452","title":"Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Advanced Solid Tumors"],"interventions":["HS-20093","Itraconazole"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07186452"},{"nctId":"NCT07709637","title":"Evaluation of Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 in Severe Coronavirus Disease 2019 Patients","sponsor":"LucasBio","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1,"enrollmentType":"ACTUAL","startDate":"2025-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["COVID-19","COVID-19 (SARS-CoV-2 Infection)"],"interventions":["LB-DTK-COV19"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of allogeneic SARS-CoV-2-Specific T cells (LB-DTK-COV19) in patients with persistent clinical symptoms following a positive SARS-CoV-2 PCR test for 14 days or longer. The main questions it aims to answer are: * What is the maximum tolerated dose of LB-DTK-COV19 based on dose-limiting toxicity? * What treatment emergent adverse events occur following LB-DTK-COV19 infusion? * Does LB-DTK-COV19 result in clinically significant improvement or worsening of clinical symptoms following infusion? Participants will: * Receive a single intravenous infusion of LB-DTK-COV19 (low dose: 5x10\\^6/m\\^2; mid dose:1x10\\^7/m\\^","sourceUrl":"https://clinicaltrials.gov/study/NCT07709637"},{"nctId":"NCT06112704","title":"HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-02","conditions":["Advanced Solid Tumor"],"interventions":["HS-20093"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06112704"},{"nctId":"NCT03436485","title":"Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","sponsor":"Orion Corporation, Orion Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":204,"enrollmentType":"ACTUAL","startDate":"2018-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-07-22","conditions":["Prostate Cancer Metastatic"],"interventions":["ODM-208","Midazolam"],"countries":["United States","Finland","France","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03436485"},{"nctId":"NCT03711032","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1397,"enrollmentType":"ESTIMATED","startDate":"2018-12-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-11-20","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["High-risk Non-muscle Invasive Bladder Cancer"],"interventions":["Pembrolizumab","BCG"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Colombia","Costa Rica","Finland","France","Germany","Greece","Guatemala","Hungary","Italy","Japan","Malaysia","Netherlands","Norway","Peru","Poland","Portugal","Puerto Rico","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":209,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. The goals of this study are to learn: 1. If more people who receive pembrolizumab with Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer without the cancer growing, spreading, or coming back compared to people who receive BCG alone. 2. About the safety and how well people tolerate BCG alone or in combination with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT03711032"},{"nctId":"NCT05382325","title":"A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2024-11-14","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["MK-1484","Pembrolizumab"],"countries":["United States","Canada","Israel","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05382325"},{"nctId":"NCT06542237","title":"Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males","sponsor":"YourChoice Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2024-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Male Contraception"],"interventions":["YCT-529"],"countries":["New Zealand"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b/2a open-label, dose escalation 3 part-study, 28-day, 90-day or 180 day repeat dose study of YCT-529 in healthy males who have decided to have a vasectomy and are waiting for the procedure and for men who have decided not to father children in the future. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and to assess sexual function and mood.","sourceUrl":"https://clinicaltrials.gov/study/NCT06542237"},{"nctId":"NCT05858736","title":"Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors","sponsor":"OncoC4, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2023-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Melanoma","Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","High Grade Serous Adenocarcinoma of Ovary","Primary Peritoneal Carcinoma","Fallopian Tube Cancer","Endometrial Cancer","Cervical Cancer","Renal Cell Carcinoma","Bladder Cancer","Esophageal Cancer","Gastric Cancer","Gastroesophageal-junction Cancer","Colorectal Cancer","Anal Cancer","Hepatocellular Carcinoma","Bile Duct Cancer"],"interventions":["AI-061"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT05858736"},{"nctId":"NCT04180371","title":"Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression","sponsor":"BicycleTx Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":288,"enrollmentType":"ESTIMATED","startDate":"2019-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Solid Tumor Historically Known for High EphA2 Expression","Urothelial Cancer","Ovarian Cancer","Non-small Cell Lung Cancer","Head and Neck Cancer","Triple Negative Breast Cancer","Gastric/Upper Gastrointestinal Cancer"],"interventions":["BT5528","Nivolumab"],"countries":["United States","Belgium","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to: * Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab * Learn more about the side effects of BT5528 * Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cancer (NSCLC), triple-negative breast cancer, head and neck cancer (HNSCC), and gastric/upper gastrointestinal cancer. * Learn more about BT5528 therapy alone and in combination with nivolumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT04180371"},{"nctId":"NCT05152147","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","sponsor":"Jazz Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":920,"enrollmentType":"ACTUAL","startDate":"2021-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Gastric Neoplasms","Gastroesophageal Adenocarcinoma","Esophageal Adenocarcinoma"],"interventions":["Zanidatamab","Tislelizumab","Trastuzumab","Capecitabine","Oxaliplatin","Cisplatin","5-Fluorouracil"],"countries":["Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Estonia","France","Georgia","Germany","Greece","Guatemala","India","Ireland","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Romania","Serbia","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":227,"serviceSignals":["HER2 profiling"],"summary":"This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).","sourceUrl":"https://clinicaltrials.gov/study/NCT05152147"},{"nctId":"NCT04098744","title":"Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)","sponsor":"Frantz Viral Therapeutics, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2020-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["CIN 2/3","HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease"],"interventions":["Artesunate vaginal insert","Placebo vaginal insert"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).","sourceUrl":"https://clinicaltrials.gov/study/NCT04098744"},{"nctId":"NCT05783622","title":"Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies","sponsor":"Janux Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Non-Small Cell Lung Cancer","Renal Cell Carcinoma","Squamous Cell Carcinoma of the Head and Neck","Colorectal Carcinoma","Small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Triple-negative Breast Cancer"],"interventions":["JANX008"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.","sourceUrl":"https://clinicaltrials.gov/study/NCT05783622"},{"nctId":"NCT05994131","title":"IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2023-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["NSCLC"],"interventions":["IN10018","Furmonertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05994131"},{"nctId":"NCT04639180","title":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":687,"enrollmentType":"ACTUAL","startDate":"2021-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["Camrelizumab","Rivoceranib (Apatinib)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04639180"},{"nctId":"NCT06507306","title":"A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":92,"enrollmentType":"ACTUAL","startDate":"2024-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Solid Tumor, Adult"],"interventions":["KQB198","Osimertinib","Amivantamab"],"countries":["United States","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that","sourceUrl":"https://clinicaltrials.gov/study/NCT06507306"},{"nctId":"NCT06553339","title":"A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2024-08-14","conditions":["Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma"],"interventions":["Oral HS-10516"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06553339"},{"nctId":"NCT07090954","title":"A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2025-07-29","conditions":["Multiple Myeloma"],"interventions":["GR1803 injection","Anti-CD38 Monoclonal Antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT07090954"},{"nctId":"NCT06605222","title":"A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":201,"enrollmentType":"ESTIMATED","startDate":"2024-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2024-10-18","conditions":["Advanced Solid Tumors"],"interventions":["SHR-7787 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-7787 injection monotherapy for patients with advanced solid tumors. To explore the reasonable dosage of SHR-7787 injection monotherapy for patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06605222"},{"nctId":"NCT06631079","title":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors","sponsor":"NEC Bio B.V","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Solid Tumor"],"interventions":["NECVAX-NEO1"],"countries":["Germany","Lithuania","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["HLA / TCR"],"summary":"Phase I/II multicenter, open-label, single-arm trial in patients to evaluate the safety and effect of NECVAX-NEO1 administered in combination with PD-1/PD-L1 mABs in patients with solid tumors. Patients with solid tumors who will be treated with approved standard of care (SoC) PD-1 or PD-L1 monoclonal antibody inhibitor therapy, and who after starting treatment with PD-1/PD-L1 inhibitor reached either Stable Disease (SD) or Partial Response (PR) (Cohort 1) or PD (Cohort 2) according to RECIST 1.1 and iRECIST assessed at the Baseline visit may be enrolled in the study","sourceUrl":"https://clinicaltrials.gov/study/NCT06631079"},{"nctId":"NCT03936153","title":"Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","sponsor":"Xynomic Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2020-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Diffuse Large B-cell Lymphoma (DLBCL)"],"interventions":["abexinostat"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","sourceUrl":"https://clinicaltrials.gov/study/NCT03936153"},{"nctId":"NCT06396091","title":"A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-07-31","completionType":"ESTIMATED","lastUpdated":"2025-11-13","conditions":["Metastatic Pancreatic Adenocarcinoma"],"interventions":["zolbetuximab","mFOLFIRINOX"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. In this study, zolbetuximab will be given together with chemotherapy to people with pancreatic cancer. Zolbetuximab attaches to a protein called CLDN18.2 found at high levels on the surface of the cancer tumor. This switches on the immune system to attack the tumor. Adults 18 years or older with metastatic pancreatic cancer who have not previously had chemotherapy can take part in the study. There are 2 main a","sourceUrl":"https://clinicaltrials.gov/study/NCT06396091"},{"nctId":"NCT05163041","title":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","sponsor":"BicycleTx Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2021-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Advanced Solid Tumor"],"interventions":["BT7480","Nivolumab"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: * Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab * Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab * Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body * Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function","sourceUrl":"https://clinicaltrials.gov/study/NCT05163041"},{"nctId":"NCT06498986","title":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-05-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","Osimertinib Mesylate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06498986"},{"nctId":"NCT05653882","title":"A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors","sponsor":"Asher Biotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":552,"enrollmentType":"ESTIMATED","startDate":"2023-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Solid Tumor","Non Small Cell Lung Cancer","Melanoma","Squamous Cell Carcinoma of Head and Neck","Renal Cell Carcinoma"],"interventions":["etakafusp alfa (AB248)","pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult participants with locally advanced or metastatic solid tumors. The study will consist of a dose escalation and a dose expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT05653882"},{"nctId":"NCT06987058","title":"RVU120 Rollover Study","sponsor":"Ryvu Therapeutics SA","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":14,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Solid Tumors","Acute Myeloid Leukaemia (AML)","High-risk Myelodysplastic Syndrome"],"interventions":["RVU120"],"countries":["Poland","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter rollover study to provide continued treatment to eligible participants previously enrolled in a RVU120 clinical study and to evaluate the safety of the treatment and record the time on treatment when continued under the same regimen as in the parent study. To be eligible for this rollover study, participants must be continuing to benefit from their treatment, show an acceptable safety profile, and not have access to commercially available comparator anticancer therapy. Once transitioned to this study, participants will continue with their next planned dose per the regimen of their parent study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06987058"},{"nctId":"NCT06727565","title":"Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["Domvanalimab","Zimberelimab","Paclitaxel","Carboplatin"],"countries":["United States","Australia","China","France","Italy","Malaysia","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"Master protocol: The main goal of this master clinical study is to evaluate the efficacy and safety of multiple novel combination therapies in participants with head and neck squamous cell carcinoma (HNSCC) in various substudies. Substudy-01 will evaluate the efficacy and safety of novel combination of treatment regimens, domvanalimab (DOM) and zimberelimab (ZIM) combined with chemotherapy vs ZIM combined with chemotherapy. The primary objective is to assess the efficacy of DOM and ZIM in combination with chemotherapy versus ZIM in combination with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06727565"},{"nctId":"NCT05568095","title":"A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1040,"enrollmentType":"ACTUAL","startDate":"2022-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced Upper Gastrointestinal Tract Adenocarcinoma"],"interventions":["Domvanalimab","Zimberelimab","Capecitabine","Fluorouracil","Leucovorin","Oxaliplatin","Nivolumab"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","France","Georgia","Guatemala","Hong Kong","Hungary","Israel","Italy","Japan","Lithuania","Malaysia","Mexico","Peru","Philippines","Poland","Portugal","Romania","Serbia","South Korea","Spain","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":168,"serviceSignals":["Hematology NGS"],"summary":"This randomized Phase 3 open-label study will compare the efficacy of the T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) monoclonal antibody domvanalimab, the anti programmed cell death protein 1 (PD-1) monoclonal antibody zimberelimab, and multiagent chemotherapy versus the anti PD-1 monoclonal antibody nivolumab and multiagent chemotherapy in the first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05568095"},{"nctId":"NCT05799274","title":"Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors","sponsor":"Radiopharm Theranostics, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2023-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Healthy Volunteers","Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer (NSCLC)","Esophageal Squamous Cell Carcinoma","Cervical Cancer","Endometrial Cancer","Ovarian Cancer"],"interventions":["RAD301 ([68Ga]-RAD301)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05799274"},{"nctId":"NCT07620951","title":"Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2026-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["EGFR Mutant Advanced Non-small Cell Lung Cancer","Central Nervous System (CNS) Metastases"],"interventions":["[14C]Zorifertinib Oral Formulation"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of \\[14C\\]Zorifertinib in healthy Chinese adult male participants. The study includes a screening period (Day -14 to Day -1) and a dosing and observation period (Day 1 to Day 14). Blood, urine, and feces samples will be collected to measure radioactivity, drug concentrations, and metabolites. Safety will be assessed by adverse events, vital signs, laboratory tests, 12-lead ECG, and ophthalmic examinations. The target total radioactivity recovery is ≥90% of the administered dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT07620951"},{"nctId":"NCT06873555","title":"A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","sponsor":"Heronova Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-03-19","conditions":["Solid Tumors","Ovarian Cancer","Small Cell Lung Cancer"],"interventions":["DC05F01"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, cohort expansion Phase Ib/IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of DC05F01 in patients with recurrent/refractory ovarian cancer and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06873555"},{"nctId":"NCT06382116","title":"A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":432,"enrollmentType":"ACTUAL","startDate":"2024-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","Pemetrexed+Cisplatin or Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure.","sourceUrl":"https://clinicaltrials.gov/study/NCT06382116"},{"nctId":"NCT06050122","title":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","sponsor":"Sol-Gel Technologies, Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["Gorlin Syndrome"],"interventions":["Patidegib Topical Gel","Patidegib Topical Gel with no active patidegib"],"countries":["United States","France","Germany","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. People who take part will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between those who used Patidegib Gel 2% or Vehicle Gel after 12 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT06050122"},{"nctId":"NCT06343948","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":383,"enrollmentType":"ACTUAL","startDate":"2024-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["HR+HER2- Breast Cancer"],"interventions":["BL-B01D1","Eribulin","Vinorelbine","Gemcitabine","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+HER2- breast cancer after failure of at least one prior line of chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06343948"},{"nctId":"NCT04503265","title":"A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies","sponsor":"AtlasMedx, Incorporated","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2020-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-05-01","conditions":["Advanced Malignant Neoplasm","Breast Cancer","Ovarian Cancer","Homologous Recombination Deficiency","Prostate Cancer","Pancreatic Cancer"],"interventions":["AMXI-5001:Dose Escalation Phase I","AMXI-5001:Dose Expansion Phase II"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["HRD / HRR"],"summary":"ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.","sourceUrl":"https://clinicaltrials.gov/study/NCT04503265"},{"nctId":"NCT07276789","title":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","sponsor":"Integro Theranostics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2025-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Non Small Cell Lung Cancer (NSCLC)"],"interventions":["LS301-IT 0.1 mg/kg"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The aim of this Phase 2 study is to investigate the efficacy and safety of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by intravenous (IV) infusion in patients undergoing VATS (Video-Assisted Thoracoscopic Surgery) or RATS (Robotic-Assisted Thoracoscopic Surgery) resection of Stage I-II non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07276789"},{"nctId":"NCT07056439","title":"Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-07","startDateType":"ESTIMATED","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["PET Imaging in Patients With Prostate Cancer"],"interventions":["HRS-1738 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and pharmacokinetics of HRS-1738 injection in adult patients with prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07056439"},{"nctId":"NCT03539744","title":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":265,"enrollmentType":"ACTUAL","startDate":"2018-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Multiple Myeloma"],"interventions":["Pomalidomide","Dexamethasone","Venetoclax"],"countries":["United States","Australia","Canada","China","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Japan","Russia","Singapore","South Korea","Spain","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":180,"serviceSignals":["Hematology NGS"],"summary":"A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexamethasone versus pomalidomide in combination with dexamethasone.","sourceUrl":"https://clinicaltrials.gov/study/NCT03539744"},{"nctId":"NCT05211570","title":"AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"AB Science","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2022-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Acute Myeloid Leukemia Refractory","Acute Myeloid Leukemia, in Relapse","Myelodysplastic Syndrome Acute Myeloid Leukemia"],"interventions":["AB8939","Venetoclax"],"countries":["United States","France","Greece","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05211570"},{"nctId":"NCT03161431","title":"SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab","sponsor":"Syntrix Biosystems, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":77,"enrollmentType":"ESTIMATED","startDate":"2019-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Melanoma Stage III","Melanoma Stage IV"],"interventions":["SX-682","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer, and thus will allow a patient's own immune system to attack the cancer. The first participants enrolled in the study will receive for 21 days SX-682 as monotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03161431"},{"nctId":"NCT07332000","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","sponsor":"Candel Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2025-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Prostate Cancer Patients Treated by Radiotherapy","Prostate Cancer (Adenocarcinoma)"],"interventions":["aglatimagene besadenovec + valacyclovir","External Beam Radiation Therapy (EBRT)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).","sourceUrl":"https://clinicaltrials.gov/study/NCT07332000"},{"nctId":"NCT04415853","title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","sponsor":"Sunshine Lake Pharma Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2021-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Esophageal Cancer"],"interventions":["Lerotinib","Irinotecan/Tegafur"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively. Subjects are administered until disease progression assessed by the RECIST V1.1 standard (unless the investigator evaluates that the subject continues to have clinical benefit from continuing treatment, the sub","sourceUrl":"https://clinicaltrials.gov/study/NCT04415853"},{"nctId":"NCT07110571","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Gastric Cancer","Gastroesophageal-junction Cancer"],"interventions":["Adebrelimab Injection","SHR-A1811 for Injection","SHR-A1904 for Injection","SHR-8068 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT07110571"},{"nctId":"NCT07444268","title":"How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers","sponsor":"Sumitomo Pharma America, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2026-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Advanced Hematologic Malignancies"],"interventions":["DSP-5336","[14C]-DSP-5336"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07444268"},{"nctId":"NCT06416852","title":"Clinical Study of 18F-Alfatide Injection PET/CT","sponsor":"Yantai LNC Biotechnology Singapore PTE. LTD.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":428,"enrollmentType":"ESTIMATED","startDate":"2024-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-05-16","conditions":["Non-Small Cell Lung Cancer NSCLC"],"interventions":["18F-Alfatide Injection","18F-FDG Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open, non-inferiority Phase III clinical study to evaluate the efficacy of 18F-Alfatide Injection PET/CT compared with 18F-FDG PET/CT in the diagnosis of lymph node metastasis in non-small cell lung cancer. This trial will include 428 patients with non-small cell lung cancer confirmed by imaging, histopathology and/or cytology or highly suspected by investigators, suspected lymph node metastasis and proposed radical surgery and lymph node dissection. Eligible subjects will receive 18F-Alfatide Injection PET/CT and 18F-FDG PET/CT scans within 1 week. Subjects will undergo relevant security checks before and after each scan. The subjects underwent radical surgery and lym","sourceUrl":"https://clinicaltrials.gov/study/NCT06416852"},{"nctId":"NCT05308264","title":"Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)","sponsor":"Rigel Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":86,"enrollmentType":"ESTIMATED","startDate":"2022-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Low Risk Myelodysplastic Syndromes"],"interventions":["R906289 Monosodium (R289 Na)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)","sourceUrl":"https://clinicaltrials.gov/study/NCT05308264"},{"nctId":"NCT02099058","title":"A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":237,"enrollmentType":"ACTUAL","startDate":"2014-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Advanced Solid Tumors Cancer"],"interventions":["Osimertinib","Nivolumab","Telisotuzumab vedotin","Erlotinib"],"countries":["United States","Belgium","Finland","France","Italy","Japan","Netherlands","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["MET profiling","ADC biomarker"],"summary":"This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.","sourceUrl":"https://clinicaltrials.gov/study/NCT02099058"},{"nctId":"NCT07735377","title":"A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Prostate Cancer"],"interventions":["SHR-6914"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1 study to assess the safety and tolerability of SHR-6914 as monotherapy therapy in adult subjects with prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07735377"},{"nctId":"NCT05611931","title":"Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma","sponsor":"Karyopharm Therapeutics Inc","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":257,"enrollmentType":"ACTUAL","startDate":"2023-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Endometrial Cancer"],"interventions":["Selinexor","Matching Placebo for selinexor"],"countries":["United States","Australia","Belgium","Canada","Czechia","Georgia","Germany","Greece","Hungary","Ireland","Israel","Italy","Slovakia","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":204,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST v 1.1\\]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT05611931"},{"nctId":"NCT07446816","title":"A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Advanced Solid Tumors"],"interventions":["Hemay181"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07446816"},{"nctId":"NCT03328078","title":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","sponsor":"Curis, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2017-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Relapsed Hematologic Malignancy","Refractory Hematologic Malignancy","Relapsed Primary Central Nervous System Lymphoma","Refractory Primary Central Nervous System Lymphoma"],"interventions":["Emavusertib","Ibrutinib"],"countries":["United States","Czechia","France","Israel","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated in combination with ibrutinib at 560 milligrams (mg) once daily (QD) or 420 mg QD as indicated by disease (Part A2 complete). Part B will comprise 2 cohorts to assess safety and efficacy of emavuserti","sourceUrl":"https://clinicaltrials.gov/study/NCT03328078"},{"nctId":"NCT06500052","title":"A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Esophageal Cancer","Gastric Cancer","Pancreatic Cancer","Colorectal Cancer","Solid Tumor"],"interventions":["BL-M17D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06500052"},{"nctId":"NCT05351788","title":"SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2022-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Non-small Cell Lung Cancer"],"interventions":["SKB264","KL-A167","Carboplatin","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT05351788"},{"nctId":"NCT06503783","title":"A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-08-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Breast Cancer","Solid Tumor"],"interventions":["BL-M17D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in patients with locally advanced or metastatic HER2 positive/negative breast cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06503783"},{"nctId":"NCT06724263","title":"A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2024-12-09","conditions":["Recurrent Platinum-resistant Epithelial Ovarian Cancer","Triple Negative Breast Cancer (TNBC)","Cervical Cancers","Small Cell Lung Cancer","Hepatocellular Carcinoma (HCC)","Colorectal Cancer","Non-Squamous Non-Small Cell Lung Cancer"],"interventions":["B1962"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors. The study consists of a Screening Period, a Treatment Period, and a Follow-up Period (EOT Visit, Safety Follow-up, and Survival Follow-up). Subjects who meet the inclusion criteria and do not meet the exclusion criteria at screening will enter the appropriate study co-hort according to tumor type and receive B1962 until unacceptable toxicity, radiographic disease progression, or withdrawal of the sub-ject for other reasons, whichever comes first, for a maximum of 24 months of treatment. Enrollment will be conducted according to three stages: Stag","sourceUrl":"https://clinicaltrials.gov/study/NCT06724263"},{"nctId":"NCT05251714","title":"CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer","sponsor":"Treadwell Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2022-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Advanced Solid Tumor","Breast Cancer"],"interventions":["CFI-402257","Fulvestrant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to test the safety of an investigational drug called CFI-402257 alone in advanced solid tumors and in combination with Fulvestrant in advanced breast cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05251714"},{"nctId":"NCT06166888","title":"A Study of AK131 in Patients With Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2024-01-17","conditions":["Solid Tumor"],"interventions":["AK131"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ia/Ib study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK131 in advanced solid tumor patients","sourceUrl":"https://clinicaltrials.gov/study/NCT06166888"},{"nctId":"NCT05490472","title":"JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2022-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Solid Tumors","ER+ Breast Cancer","Triple Negative Breast Cancer, TNBC","ARID1A Gene Mutation","Small Cell Lung Cancer, SCLC"],"interventions":["JAB-2485 (Aurora A inhibitor)"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05490472"},{"nctId":"NCT06736418","title":"Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy","sponsor":"Abdera Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2025-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Small-Cell Lung Cancer (SCLC)","Large Cell Neuroendocrine Carcinoma of the Lung"],"interventions":["225Ac-ABD147"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"The study has 2 parts, Phase 1a and Phase 1b. The goal of Phase 1a is to gather safety, PK and initial efficacy data for 225Ac-ABD147 to better understand best doses for patients with small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) of the lung following platinum-based chemotherapy. An initial group of patients will also be given an experimental imaging agent called 111In-ABD147 to help understand where ABD147 goes in the body. The goal of Phase 1b is to gather additional safety and efficacy data on 225Ac-ABD147 to determine the best dose and to understand how those doses affect the same types of patients' cancers explored enrolled in Phase 1a.","sourceUrl":"https://clinicaltrials.gov/study/NCT06736418"},{"nctId":"NCT06505824","title":"A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2024-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Small Cell Lung Cancer","Neuroendocrine Tumors"],"interventions":["BL-M14D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M14D1 in locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06505824"},{"nctId":"NCT06906341","title":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","sponsor":"Corcept Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Neoplasms","Endometrial Cancer"],"interventions":["Relacorilant 150 mg once daily (QD)","Nab-paclitaxel 80 mg/m^2","Bevacizumab 10 mg/kg"],"countries":["United States","Belgium","France","Germany","Italy","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT06906341"},{"nctId":"NCT06049667","title":"A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2023-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-08","completionType":"ESTIMATED","lastUpdated":"2023-09-22","conditions":["Relapsed/Refractory Acute Myeloid Leukemia (AML)"],"interventions":["NTQ2494 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06049667"},{"nctId":"NCT05841472","title":"Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","sponsor":"CrystalGenomics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-08-30","conditions":["Non Squamous Non Small Cell Lung Cancer"],"interventions":["Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed advanced or metastatic (Stage IIIB-IV), EGFR/ALK wild-type, non-squamous, non-small cell lung cancer. In this study, subjects with advanced or metastatic, EGFR/ALK wild-type, non-squamous, non-small lung cancer will receive anti-PD-1 antibody therapy of camrelizumab in combination with pemetrexed + carboplatin as first-line treatment for at least 8 cycles (24 weeks). Then, the best overall RECIST responses (BOR) from subjects who have had at least 1 post-baseline tumor","sourceUrl":"https://clinicaltrials.gov/study/NCT05841472"},{"nctId":"NCT06001788","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"Kura Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":171,"enrollmentType":"ESTIMATED","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["AML","AML With Mutated NPM1","Hematologic Malignancy","KMT2Ar","NPM1 Mutation","MLL Rearrangement","Leukemia","Acute Myeloid Leukemia","Leukemia, Myeloid","Leukemia, Myeloid, Acute","Acute Leukemia","Neoplasms by Histologic Type"],"interventions":["Ziftomenib","Fludarabine","Idarubicin","Cytarabine","Gilteritinib","Granulocyte colony-stimulating factor"],"countries":["United States","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT06001788"},{"nctId":"NCT06090266","title":"A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents","sponsor":"OncoResponse, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2023-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2025-01-07","conditions":["Cancer","Tumor, Solid","Malignant Neoplasm","Metastatic Cancer","Advanced Solid Tumor","Cutaneous Melanoma","Non-small Cell Lung Cancer"],"interventions":["OR502","Cemiplimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with cemiplimab in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06090266"},{"nctId":"NCT05920135","title":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","sponsor":"Bridge Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2023-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2025-04-27","conditions":["EGFR Mutant Advanced Non-Small Cell Lung Cancer"],"interventions":["BBT-207"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, Phase 1/2 study evaluating the safety, tolerability, PK, PD, and preliminary efficacy (antitumor activity) of BBT-207. It will consist of 3 parts; dose escalation, recommended phase 2 dose selection, and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT05920135"},{"nctId":"NCT06424665","title":"A Study of FZ-AD005 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2024-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)"],"interventions":["FZ-AD005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06424665"},{"nctId":"NCT06174987","title":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-17","completionType":"ESTIMATED","lastUpdated":"2025-10-15","conditions":["Advanced Cancer","Metastatic Cancer"],"interventions":["T-DXd"],"countries":["United States","Australia","Belgium","Brazil","France","Israel","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).","sourceUrl":"https://clinicaltrials.gov/study/NCT06174987"},{"nctId":"NCT04420754","title":"Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer","sponsor":"AffyImmune Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2020-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-04","completionType":"ESTIMATED","lastUpdated":"2025-03-30","conditions":["Anaplastic Thyroid Cancer","Relapsed/Refractory Poorly Differentiated Thyroid Cancer"],"interventions":["AIC100 CAR T Cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.","sourceUrl":"https://clinicaltrials.gov/study/NCT04420754"},{"nctId":"NCT05773820","title":"A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2023-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-23","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Advanced Solid Tumors"],"interventions":["WJB001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II study to evaluate the safety and tolerability, DLT(Dose limited toxicity), MTD(Maximum tolerated dose), and RP2D(Recommended phase II dose) of WJB001 capsules in patients with advanced solid tumors, including dose escalation phase, dose expansion phase and cohort expansion phase.The study includes screening, treatment and follow-up periods. In the Dose Escalation phase:Accelerated titration (the first two dose groups) and \"BOIN\" combination (the subsequent dose group) were used for dose escalation. In the Dose Expansion phase:Based on the previous data, 1 to 2 doses were selected to further evaluate the initial efficacy, safety, tolerability and pharmacokinetic character","sourceUrl":"https://clinicaltrials.gov/study/NCT05773820"},{"nctId":"NCT06515314","title":"HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors","sponsor":"Shanghai Ruiliyuan Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-10","completionType":"ESTIMATED","lastUpdated":"2025-12-02","conditions":["Hepatic Cell Carcinoma"],"interventions":["AFP Specific T Cell Receptor T Cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT06515314"},{"nctId":"NCT06149559","title":"A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":14,"enrollmentType":"ACTUAL","startDate":"2024-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-19","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Generalized Myasthenia Gravis"],"interventions":["rozanolixizumab"],"countries":["Italy","Japan","Poland","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \\<18 years with generalized Myasthenia Gravis (gMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT06149559"},{"nctId":"NCT05963867","title":"A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-25","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Small Cell Lung Carcinoma (SCLC)","Neuroendocrine Neoplasms"],"interventions":["BI 764532","[89Zr]Zr-BI 764532"],"countries":["Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with small cell lung cancer and other neuroendocrine cancers. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out how a medicine called BI 764532 gets distributed in the body and in tumours. Participants get BI 764532 when starting treatment. In the first weeks, doctors check how BI 764532 is taken up in tumours by means of an imaging method. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number","sourceUrl":"https://clinicaltrials.gov/study/NCT05963867"},{"nctId":"NCT05601752","title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","sponsor":"USWM CT, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2023-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-12","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Ovarian Cancer"],"interventions":["Autologous genetically modified ADP-A2M4CD8 cells","Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab"],"countries":["United States","Canada","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["HLA / TCR"],"summary":"This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.","sourceUrl":"https://clinicaltrials.gov/study/NCT05601752"},{"nctId":"NCT06667141","title":"Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors","sponsor":"Acrivon Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-12","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Specific Advanced Solid Tumors"],"interventions":["ACR-2316"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06667141"},{"nctId":"NCT06475937","title":"A Study of DM001 in Patients With Advanced Solid Tumors","sponsor":"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2024-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-13","completionType":"ESTIMATED","lastUpdated":"2025-04-17","conditions":["Breast Neoplasms","Carcinoma, Non-Small-Cell Lung","Solid Carcinoma"],"interventions":["DM001"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM001 for patients with the advanced solid tumors. DM001 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. Participants will have up to 17 visits during the study.There will be up to a 4-week Screening Period followed by a treatment period that will be divided into 3-week cycles/ Participants will have 5 study visits during Cycle 1, 3 visits during Cycles 2 and 3, and 1 visit during subsequent cycles. Participants will have an End of Treatment visit 21 days (+ 7 days) after last dose of study drug and then a follow-up visit 30 days (± 7 ","sourceUrl":"https://clinicaltrials.gov/study/NCT06475937"},{"nctId":"NCT04585750","title":"The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)","sponsor":"PMV Pharmaceuticals, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2020-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Advanced Solid Tumor","Advanced Malignant Neoplasm","Metastatic Cancer","Metastatic Solid Tumor","Lung Cancer","Ovarian Cancer","Endometrial Cancer","Prostate Cancer","Colorectal Cancer","Breast Cancer","Other Cancer","Locally Advanced","Head and Neck Cancer","Gall Bladder Cancer","Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Small Cell Lung Carcinoma","NSCLC","NSCLC (Non-small Cell Lung Cancer)","SCLC","Non-Small Cell Lung Carcinoma","Triple Negative Breast Cancer","TNBC","HER2+ Breast Cancer","Non-Small Cell Lung Cancer","ER/PR Positive Breast Cancer","HER2- Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","ER/PR(+), Her2(-) Breast Cancer"],"interventions":["rezatapopt","pembrolizumab"],"countries":["United States","Australia","France","Germany","Italy","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":77,"serviceSignals":["HER2 profiling"],"summary":"The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT04585750"},{"nctId":"NCT06595186","title":"JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)","sponsor":"JenKem Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2022-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-16","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-16","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Glioblastoma Multiforme (GBM)"],"interventions":["JK-1201I","Temozolomide (TMZ)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was designed to evaluate the safety, tolerability, efficacy and pharmacokinetics of JK-1201I combined with adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme after surgery and concomitant radio-chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06595186"},{"nctId":"NCT06864169","title":"A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-04","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Gastrointestinal Cancer"],"interventions":["Raludotatug Deruxtecan (R-DXd)"],"countries":["United States","Argentina","Canada","Chile","France","Hong Kong","Spain","Switzerland","Taiwan","Thailand"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat certain types of advanced gastrointestinal (GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goal of this study is to learn if the cancer responds to treatment (gets smaller or goes away).","sourceUrl":"https://clinicaltrials.gov/study/NCT06864169"},{"nctId":"NCT06519370","title":"FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2024-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-18","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-20","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Triple Negative Breast Cancer"],"interventions":["FDA018-ADC","Eribulin","Capecitabine","Gemcitabine","Vinorelbine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase III, randomized, open-label, 2-arm, multicentre, international study assessing the efficacy and safety of FDA018-ADC compared with Investigator's Choice Chemotherapy(ICC) in participants with locally recurrent inoperable or metastatic Triple-negative Breast Cancer(TNBC) who are resistant to, or recurring during or after taxane therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06519370"},{"nctId":"NCT04626479","title":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2020-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-21","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-21","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Carcinoma, Renal Cell"],"interventions":["Pembrolizumab","Favezelimab/Pembrolizumab","Belzutifan","Lenvatinib","Pembrolizumab/Quavonlimab","Vibostolimab/Pembrolizumab"],"countries":["United States","Australia","Canada","Chile","Colombia","France","Hungary","Israel","Netherlands","New Zealand","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":55,"serviceSignals":["Broad CGP"],"summary":"Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04626479"},{"nctId":"NCT04626518","title":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":370,"enrollmentType":"ESTIMATED","startDate":"2020-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-21","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-21","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Carcinoma, Renal Cell"],"interventions":["Pembrolizumab","MK-4830","Belzutifan","Lenvatinib","Pembrolizumab/Quavonlimab","Favezelimab/Pembrolizumab"],"countries":["United States","Australia","Canada","Chile","France","Hungary","Israel","Netherlands","New Zealand","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["Broad CGP"],"summary":"Substudy 03B is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03B is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced second line plus (2L+) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04626518"},{"nctId":"NCT03815643","title":"Avelumab Program Rollover Study","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":205,"enrollmentType":"ACTUAL","startDate":"2019-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-21","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-21","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Solid Tumors"],"interventions":["Avelumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Czechia","France","Germany","Hungary","Italy","Japan","Mexico","Poland","Romania","Russia","South Korea","Spain","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":104,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.","sourceUrl":"https://clinicaltrials.gov/study/NCT03815643"},{"nctId":"NCT05262400","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":192,"enrollmentType":"ACTUAL","startDate":"2022-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-23","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-23","completionType":"ESTIMATED","lastUpdated":"2024-11-18","conditions":["Breast Cancer","Solid Tumors"],"interventions":["PF-07220060 + PF-07104091 combination dose escalation","PF-07104091 + PF-07220060 + fulvestrant dose expansion","PF-07104091 + PF-07220060 + letrozole dose expansion"],"countries":["United States","Argentina","Brazil","Bulgaria","China","Czechia","Mexico","South Africa","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":51,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: * Have been diagnosed with Breast Cancer (BC) of either types: * Have HR+, HER2- BC * Refractory HR-positive/HER2-positive BC * Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-negative BC Part 1 will include increasing doses of PF-07220060 with PF-07104091. In part 2, participants will take 1 of 2 study medicine combinations. This will help us decide the highest amount o","sourceUrl":"https://clinicaltrials.gov/study/NCT05262400"},{"nctId":"NCT04429087","title":"A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2020-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-24","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-01","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3"],"interventions":["Obrixtamig - parenteral 1","Obrixtamig - parenteral 2"],"countries":["United States","Germany","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of obrixtamig and the best treatment schedule that people can tolerate. Obrixtamig is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, obrixtamig is given to people for the first time. Interim clinical data are available for obrixtamig. Participants get obrixtamig either weekly or once every 3 weeks. If th","sourceUrl":"https://clinicaltrials.gov/study/NCT04429087"},{"nctId":"NCT04711252","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1370,"enrollmentType":"ACTUAL","startDate":"2021-01-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-24","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-01","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["ER-Positive HER2-Negative Breast Cancer"],"interventions":["AZD9833","Anastrozole","Anastrozole placebo","AZD9833 placebo","Palbociclib","Luteinizing hormone-releasing hormone (LHRH) agonist"],"countries":["United States","Austria","Belgium","Bulgaria","Canada","Chile","China","Czechia","France","Germany","Hungary","India","Italy","Japan","Malaysia","Mexico","Norway","Poland","Portugal","Russia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":263,"serviceSignals":["HER2 profiling"],"summary":"The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer. INFORMATION FOR TRIAL PARTICIPANTS In this trial, the researchers will look at how well camizestrant with palbociclib works, compared with anastrozole with palbociclib, in participants with breast cancer that has either spread into other parts of the body at the time of diagnosis, or has come back after at least 2 years of standard endocrine treatment. Part","sourceUrl":"https://clinicaltrials.gov/study/NCT04711252"},{"nctId":"NCT05132075","title":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":95,"enrollmentType":"ACTUAL","startDate":"2022-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-25","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-23","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Non-Small Cell Lung Cancer"],"interventions":["JDQ443","docetaxel"],"countries":["United States","Argentina","Australia","Canada","China","Finland","Greece","Hong Kong","Hungary","Iceland","India","Italy","Jordan","Lebanon","Malaysia","Mexico","Portugal","Romania","Slovenia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":51,"serviceSignals":["RAS genotyping"],"summary":"This is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT05132075"},{"nctId":"NCT04752813","title":"A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)","sponsor":"BPGbio","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2022-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-25","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-26","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Glioblastoma","Glioblastoma Multiforme"],"interventions":["BPM31510","Vitamin K1","Temozolomide (TMZ)","Radiation"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04752813"},{"nctId":"NCT03478462","title":"Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas","sponsor":"Cellectar Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2019-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-25","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Pediatric Solid Tumor","Pediatric Lymphoma","Pediatric Brain Tumor","DIPG","Neuroblastoma","Ewing Sarcoma","Rhabdomyosarcoma","Osteosarcoma"],"interventions":["CLR 131"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.","sourceUrl":"https://clinicaltrials.gov/study/NCT03478462"},{"nctId":"NCT05413850","title":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","sponsor":"Blue Earth Therapeutics Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2022-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-27","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","mCRPC","Urogenital Neoplasms","Prostatic Neoplasms","Prostatic Diseases"],"interventions":["Lutetium (177Lu) rhPSMA-10.1 Injection","18F-rhPSMA-7.3 injection (in phase 1 only)"],"countries":["United States","Belgium","Germany","Netherlands","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05413850"},{"nctId":"NCT04995523","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":212,"enrollmentType":"ACTUAL","startDate":"2021-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Non-Small-Cell Lung Carcinoma"],"interventions":["AZD2936"],"countries":["United States","Australia","Belgium","Brazil","China","Denmark","France","Georgia","Japan","Malaysia","Moldova","Netherlands","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04995523"},{"nctId":"NCT06624059","title":"A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":11,"enrollmentType":"ACTUAL","startDate":"2024-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-28","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Alectinib","Cisplatin","Carboplatin","Pemetrexed"],"countries":["Australia","Brazil","Chile","China","Italy","South Korea"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to explore the safety of alectinib in combination with chemotherapy in participants with resectable NSCLC. Cohort B1 is a phase II cohort that will assess the safety of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06624059"},{"nctId":"NCT05634499","title":"A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-28","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Endometrial Cancer"],"interventions":["Giredestrant"],"countries":["United States","Canada","Italy","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This Phase II, global, single-arm study is designed to evaluate the efficacy, safety, and pharmacokinetics of giredestrant monotherapy in participants with Grade 1 endometrioid endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05634499"},{"nctId":"NCT05254171","title":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","sponsor":"Panbela Therapeutics, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2022-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2024-11-06","conditions":["Pancreatic Cancer Metastatic","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer Stage IV"],"interventions":["SBP-101","Nab-paclitaxel","Gemcitabine","Placebo"],"countries":["United States","Australia","Austria","Belgium","France","Germany","Italy","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":93,"serviceSignals":["Broad CGP"],"summary":"The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05254171"},{"nctId":"NCT06220318","title":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","sponsor":"Fujian Haixi Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2023-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Solid Tumor"],"interventions":["C019199","Sintilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II non-randomized, open-label, single-arm, multicenter study to evaluate the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06220318"},{"nctId":"NCT03812874","title":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","sponsor":"TCM Biotech International Corp.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2020-10-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-11-21","conditions":["Carcinoma, Hepatocellular"],"interventions":["PTX-9908 Injection","Placebo"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, Phase I/II study in patients with non-resectable hepatocellular carcinoma following TACE treatment. Phase I (Open-label dose escalation) This study will be an open-label study with an Accelerated Phase and a Standard Phase. For the Accelerated Phase of the study, one patient per dose level (1 mg/kg, and 2 mg/kg) is planned. For the dose levels in the standard phase (4 mg/kg, 8 mg/kg and 16 mg/kg), it will follow the Fibonacci's rule of 3 + 3 design. All eligible patients who have received TACE treatment and recovered well, will be administrated PTX-9908 Injection intravenously one dose per day for 5 days on Week 1 (excludes weekends and public holidays), and one dose p","sourceUrl":"https://clinicaltrials.gov/study/NCT03812874"},{"nctId":"NCT06536400","title":"Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":316,"enrollmentType":"ESTIMATED","startDate":"2024-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-07","completionType":"ESTIMATED","lastUpdated":"2024-08-05","conditions":["Solid Tumors"],"interventions":["HSK42360"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360 when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06536400"},{"nctId":"NCT06152575","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":492,"enrollmentType":"ESTIMATED","startDate":"2024-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Elotuzumab","Pomalidomide","Dexamethasone","Bortezomib","Carfilzomib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Croatia","Czechia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Norway","Portugal","Slovakia","Slovenia","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":270,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study cl","sourceUrl":"https://clinicaltrials.gov/study/NCT06152575"},{"nctId":"NCT05446298","title":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","sponsor":"OncoC4, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":58,"enrollmentType":"ACTUAL","startDate":"2022-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-30","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Ovarian Cancer","High Grade Serous Adenocarcinoma of Ovary","Primary Peritoneal Carcinoma","Fallopian Tube Cancer"],"interventions":["ONC-392","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05446298"},{"nctId":"NCT05649345","title":"TR64 in Patients With Advanced Solid Tumors","sponsor":"Tarapeutics Science Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":19,"enrollmentType":"ESTIMATED","startDate":"2023-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-05-14","conditions":["Advanced Solid Tumor"],"interventions":["TR64"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when administered qd in patients with advanced solid tumors. Up to 6 cohorts of 1-6 or 3-6 patients each will be treated in the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05649345"},{"nctId":"NCT07105176","title":"HS-IT101 Injection for Advanced NSCLC","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Advanced Non-Small Cell Lung Cancer"],"interventions":["Cyclophosphamide","Fludarabine","IL-2 (interleukin 2)","HS-IT101 monotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Open-Label, Single-Arm Phase Ib Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HS-IT101 Injection in Subjects with Advanced NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07105176"},{"nctId":"NCT07005336","title":"A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer","sponsor":"TJ Biopharma Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-09","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Non Small Cell Lung Cancer"],"interventions":["Uliledlimab","Sintilimab","Pemetrexed","Gemcitabine","Cisplatin Or Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with sintilimab and chemotherapy versus sintilimab combined with chemotherapy in patients with previously untreated locally advanced unresectable or metastatic NSCLC who are not suitable for targeted therapies such as EGFR or ALK. Eligible subjects will be randomly assigned in a 1:1 ratio to receive either uliledlimab combined with sintilimab and chemotherapy or sintilimab combined with chemotherapy. Enrolled subjects will first enter a safety run-in period. When at least 12 subjects have been randomly assigned to Group A and have received ≥ 1 dose of study drug (with ","sourceUrl":"https://clinicaltrials.gov/study/NCT07005336"},{"nctId":"NCT06810804","title":"A Phase IIa Study to Evaluate NBQ72S","sponsor":"Nantong Bencao Quadriga Medical Technology Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2025-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Breast Cancer"],"interventions":["NBQ72S"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06810804"},{"nctId":"NCT05669482","title":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","sponsor":"Verastem, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2025-09-02","conditions":["KRAS Activating Mutation","Metastatic Cancer","Pancreas Cancer","Neoplasms Pancreatic","Malignant Neoplasm of Pancreas"],"interventions":["avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05669482"},{"nctId":"NCT05103683","title":"First in Human Study of TORL-1-23 in Participants With Advanced Cancer","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2021-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-15","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Advanced Solid Tumor","Ovarian Cancer","Endometrial Cancer","NSCLC"],"interventions":["TORL-1-23"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05103683"},{"nctId":"NCT04704934","title":"Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":490,"enrollmentType":"ESTIMATED","startDate":"2021-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Gastric Cancer, Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"interventions":["Trastuzumab deruxtecan","Ramucirumab","Paclitaxel"],"countries":["Argentina","Belgium","Brazil","Chile","China","France","Germany","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":false,"chinaSites":true,"siteCount":156,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04704934"},{"nctId":"NCT03845166","title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":325,"enrollmentType":"ACTUAL","startDate":"2019-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2024-11-19","conditions":["Neoplasm Malignant","Renal Cell Carcinoma","Hormone Receptor Positive Breast Carcinoma","Metastatic Castration-resistant Prostate Cancer","Colorectal Cancer"],"interventions":["XL092","Atezolizumab","Avelumab"],"countries":["United States","Australia","Belgium","Czechia","France","Germany","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":86,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03845166"},{"nctId":"NCT07171606","title":"A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["First-line Advanced NSCLC Patients"],"interventions":["SSGJ-706","pemetrexed /carboplatin","Carboplatin/Paclitaxel","PD-1 Inhibitor + Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT07171606"},{"nctId":"NCT07202364","title":"A Study of YL202 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Non Small Cell Lung Cancer","Colorectal Cancer","Cervical Cancer","Locally Advanced or Metastatic Solid Tumors"],"interventions":["YL202"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07202364"},{"nctId":"NCT06883630","title":"A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":121,"enrollmentType":"ACTUAL","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Non-Small Cell Lung Cancer"],"interventions":["RC148 plus Carboplatin and Paclitaxel/pemetrexed","RC148"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy, safety, pharmacokinetics and immunogenicity of RC148 injection as a single agent or in combination for the treatment of locally advanced or metastatic non-small cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06883630"},{"nctId":"NCT03816163","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":393,"enrollmentType":"ACTUAL","startDate":"2019-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"interventions":["zolbetuximab","nab-paclitaxel","gemcitabine"],"countries":["United States","Australia","Brazil","China","France","Ireland","Italy","Japan","Mexico","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":136,"serviceSignals":["ADC biomarker"],"summary":"Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's immune system to attack the tumor. Zolbetuximab is a potential treatment for people with pancreatic cancer. There is an unmet medical need to treat people with pancreatic cancer. This study will help find the dose of zolbetuximab to be used with chemotherapy and provide more information on this treatment in adults with metastatic pancreatic cancer. The study is currently ongoing globally. People in this study will be ","sourceUrl":"https://clinicaltrials.gov/study/NCT03816163"},{"nctId":"NCT06257264","title":"A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors","sponsor":"BeiGene","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":103,"enrollmentType":"ACTUAL","startDate":"2024-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Breast Cancer","Small Cell Lung Cancer","Ovarian Cancer","Gastric Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Advanced Solid Tumor","Endometrial Cancer","Prostate Cancer","TNBC - Triple-Negative Breast Cancer","GastroEsophageal Cancer","Bladder Cancer"],"interventions":["BG-68501","Fulvestrant","BGB-43395"],"countries":["United States","Australia","China","Israel","Moldova","New Zealand"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["HER2 profiling"],"summary":"This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC). The study will also identify a recommended dose for expansion (RDFE) for BG-68501 as monotherapy and in combination for subsequent disease directed studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06257264"},{"nctId":"NCT06935409","title":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":117,"enrollmentType":"ESTIMATED","startDate":"2025-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Osteosarcoma"],"interventions":["HS-20093","Gemcitabine combined with docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at least second-line treatment failure.","sourceUrl":"https://clinicaltrials.gov/study/NCT06935409"},{"nctId":"NCT06379217","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2024-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Metastatic Neuroendocrine Prostate Cancer"],"interventions":["[68Ga]Ga-PSMA-11","[68Ga]GA-DOTA-TATE","[68Ga]Ga-NeoB","[177Lu]Lu-PSMA-617","[177Lu]Lu-DOTA-TATE","[177Lu]Lu-NeoB","L-Lysine HCl-L-Arginine HCl, 2.5 %,","Gonadotropin-releasing hormone (GnRH) analogues","GnRH antagonists","Antiemetics & antinauseants","Metoclopramide"],"countries":["United States","France","Germany","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the change in the expression of treatment targets on the surface of tumor cells (Prostate Specific Membrane Antigen (PSMA), Somatostatin Receptor 2 (SSTR2), and Gastrin Releasing Peptide Receptor (GRPR) between the baseline and following targeted radioligand therapy (RLT). Study will use radioligand imaging (RLI) to determine predominantly expressed target on the surface of tumor cells. Based on predominant expression of target, corresponding RLT targeting PSMA, SSTR2, or GRPR RLT will be given for up to 6 cycles every 6 weeks as intravenous (i.v.) injection in participants with metastatic neuroendocrine prostate cancer (mNEPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06379217"},{"nctId":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","sponsor":"Nurix Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":345,"enrollmentType":"ESTIMATED","startDate":"2021-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Ovarian Cancer, Epithelial","Gastric Cancer","GastroEsophageal Junction (GEJ) Cancer","Head and Neck Squamous Cell Carcinoma","Metastatic or Unresectable Melanoma","Non-small Cell Lung Cancer (NSCLC)","Metastatic Castration-resistant Prostate Cancer (mCRPC)","Malignant Pleural Mesothelioma (MPM)","Triple Negative Breast Cancer (TNBC)","Metastatic Urothelial Carcinoma","Cervical Cancer","Diffuse Large B Cell Lymphoma (DLBCL)","Richter Transformation","Microsatellite Stable Colorectal Carcinoma"],"interventions":["NX-1607","Paclitaxel"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["MSI / TMB","Hematology NGS"],"summary":"This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05107674"},{"nctId":"NCT04883957","title":"Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies","sponsor":"BeiGene","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":64,"enrollmentType":"ACTUAL","startDate":"2021-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Mature B-cell Malignancies"],"interventions":["BGB-11417"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and tolerability of BGB-11417 monotherapy, define the maximum tolerated dose (MTD) or maximum administered dose and the recommended Phase 2 dose (RP2D) of BGB-11417 monotherapy for the selected B-cell malignancy dose finding cohorts, and evaluate the safety and tolerability of the ramp-up dosing schedule in the evaluated disease types.","sourceUrl":"https://clinicaltrials.gov/study/NCT04883957"},{"nctId":"NCT05717764","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2023-02","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2023-02-08","conditions":["Recurrent Metastatic Nasopharyngeal Carcinoma"],"interventions":["Mitoxantrone hydrochloride liposome injection","Capecitabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, positive-controlled, multicenter Phase Ш study to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome injection combined with capecitabine versus capecitabine monotherapy in patients with recurrent metastatic nasopharyngeal carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05717764"},{"nctId":"NCT06368921","title":"A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Solid Tumor"],"interventions":["VRT106"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06368921"},{"nctId":"NCT07367516","title":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2026-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Esophageal Cancer"],"interventions":["TQB6411 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in participants with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of TQB6411 Injection in this same participants population.","sourceUrl":"https://clinicaltrials.gov/study/NCT07367516"},{"nctId":"NCT06369831","title":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","sponsor":"Abscint NV/SA","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Metastatic Breast Cancer","Metastatic Solid Cancer"],"interventions":["68Ga-NOTA-ABSCINT-HER2 PET/CT"],"countries":["Austria","Belgium"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["HER2 profiling"],"summary":"This phase II study aims to confirm the diagnostic performance and accuracy of 68Ga-ABS011 PET/CT in determining the HER2 expression status, and to evaluate 68Ga-ABS011's ability to drive changes in therapeutic treatment. 68Ga-ABS011 will be compared to the current standard of care (SOCa) diagnostic methods including immunohistochemistry (IHC), in situ hybridization (ISH) and imaging tools used for treatment response follow-up including Fluorodeoxyglucose F-18 (18F-FDG) positron emitted tomography (PET) and contrast enhanced computed tomography (ceCT).","sourceUrl":"https://clinicaltrials.gov/study/NCT06369831"},{"nctId":"NCT05315700","title":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","sponsor":"ORIC Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2022-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-08-05","conditions":["Solid Tumors"],"interventions":["ORIC-114","Chemotherapy drug"],"countries":["United States","Australia","Canada","Hong Kong","Malaysia","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.","sourceUrl":"https://clinicaltrials.gov/study/NCT05315700"},{"nctId":"NCT03853616","title":"MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2018-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Acute Lymphoblastic Leukemia Recurrent","B-cell Lymphoma Recurrent","B-cell Lymphoma Refractory","Chronic Lymphocytic Leukemia Recurrent","Chronic Lymphocytic Leukemia Refractory"],"interventions":["MB-CART19.1"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included in the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).","sourceUrl":"https://clinicaltrials.gov/study/NCT03853616"},{"nctId":"NCT05887492","title":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","sponsor":"Tango Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2023-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Non Small Cell Lung Cancer","Solid Tumors, Adult","Lung Cancer","Lung Adenocarcinoma"],"interventions":["TNG260","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["RAS genotyping"],"summary":"The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\\[s\\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.","sourceUrl":"https://clinicaltrials.gov/study/NCT05887492"},{"nctId":"NCT06450106","title":"Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy","sponsor":"SURGE Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Prostate Cancer"],"interventions":["STM-416p"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy","sourceUrl":"https://clinicaltrials.gov/study/NCT06450106"},{"nctId":"NCT06235151","title":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","sponsor":"Curium US LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":439,"enrollmentType":"ESTIMATED","startDate":"2024-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Prostate Cancer","Prostate Adenocarcinoma"],"interventions":["Copper Cu 64 PSMA I&T"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06235151"},{"nctId":"NCT05186974","title":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":193,"enrollmentType":"ACTUAL","startDate":"2022-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Non-small Cell Lung Cancer"],"interventions":["Sacituzumab Govitecan-hziy (SG)","Pembrolizumab","Carboplatin","Cisplatin"],"countries":["United States","Australia","Canada","France","Germany","Hong Kong","Italy","Malaysia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":101,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy (SG), and its dosing in combination with pembrolizumab or pembrolizumab and a platinum agent (carboplatin or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05186974"},{"nctId":"NCT07377591","title":"A Study of HDM2006 in Patients With Advanced Solid Tumor","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2024-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Advanced Solid Tumors"],"interventions":["HDM2006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2006 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07377591"},{"nctId":"NCT06469879","title":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":358,"enrollmentType":"ESTIMATED","startDate":"2024-09","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2024-07-01","conditions":["Small Cell Lung Cancer Limited Stage"],"interventions":["TQB2450+Anlotinib","TQB2450 placebo + Anlotinib placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of TQB2450 in combination with anlotinib as maintenance therapy in patients with limited-stage small cell lung cancer who have not progressed after chemoradiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06469879"},{"nctId":"NCT06056830","title":"Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy","sponsor":"Clarity Pharmaceuticals Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":383,"enrollmentType":"ESTIMATED","startDate":"2023-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Prostate Cancer","Prostatic Neoplasms"],"interventions":["64Cu-SAR-bisPSMA"],"countries":["United States","Australia","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT06056830"},{"nctId":"NCT02988960","title":"A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":163,"enrollmentType":"ACTUAL","startDate":"2017-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Advanced Solid Tumors Cancer"],"interventions":["ABBV-927","ABBV-181"],"countries":["United States","Australia","Canada","France","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT02988960"},{"nctId":"NCT06950086","title":"Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors","sponsor":"TYK Medicines, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-04-29","conditions":["HR-positive, HER2-negative Advanced Breast Cancer"],"interventions":["TYK-00540"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study is to evaluate the safety, pharmacokinetics, and preliminary antitumor activity of TYK-00540 as monotherapy or combined with fulvestrant in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06950086"},{"nctId":"NCT05499013","title":"Study to Assess SLN124 in Patients With Polycythemia Vera","sponsor":"Silence Therapeutics plc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2023-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Polycythemia Vera"],"interventions":["SLN124","Placebo"],"countries":["United States","Australia","Bulgaria","Canada","Germany","Italy","Malaysia","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.","sourceUrl":"https://clinicaltrials.gov/study/NCT05499013"},{"nctId":"NCT06672263","title":"A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-11","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-11-04","conditions":["Chronic Myelogenous Leukemia"],"interventions":["TQB3911 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06672263"},{"nctId":"NCT06568692","title":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","sponsor":"Processa Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Breast Cancer","TNBC - Triple-Negative Breast Cancer","HER2-negative Breast Cancer"],"interventions":["PCS6422 and capecitabine","Capecitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the study is to assess the efficacy and safety of PCS6422 + Cap as a treatment option for patients with advanced or metastatic breast cancer who are not eligible for anthracycline- or taxane-containing therapies, or other available therapies, including PD-1 or PARP inhibitors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06568692"},{"nctId":"NCT06028074","title":"Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies","sponsor":"Georgiamune Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":111,"enrollmentType":"ESTIMATED","startDate":"2023-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Advanced Solid Malignancies"],"interventions":["GIM122"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06028074"},{"nctId":"NCT06196736","title":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":432,"enrollmentType":"ESTIMATED","startDate":"2023-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Advanced Urothelial Carcinoma"],"interventions":["9MW2821","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06196736"},{"nctId":"NCT06558227","title":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Hepatocellular Carcinoma"],"interventions":["ZG005 for Injection","Bevacizumab","Sintilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06558227"},{"nctId":"NCT06123884","title":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","sponsor":"Bio-Thera Solutions","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":526,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2025-02-10","conditions":["Cervical Cancer"],"interventions":["Recombinant humanized anti-PD-1 monoclonal antibody injection","Cisplatin","Bevacizumab Injection","carboplatin","Paclitaxel for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06123884"},{"nctId":"NCT07207707","title":"A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2025-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Solid Tumor Malignancies"],"interventions":["KQB548"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["RAS genotyping"],"summary":"The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?","sourceUrl":"https://clinicaltrials.gov/study/NCT07207707"},{"nctId":"NCT07303660","title":"A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients","sponsor":"Lomond Therapeutics Holdings, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-01-10","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-12-26","conditions":["Acute Myeloid Leukemia"],"interventions":["ZE50-0134","Azacitidine Days 1-7","ZE 50-0134"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07303660"},{"nctId":"NCT07276373","title":"Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies","sponsor":"Corcept Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Neoplasms"],"interventions":["Nenocorilant 200 mg","Nenocorilant 300 mg","Nenocorilant 400 mg","Nivolumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07276373"},{"nctId":"NCT06959706","title":"Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors","sponsor":"Tagworks Pharmaceuticals BV","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Advanced Solid Tumors"],"interventions":["TGW101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT06959706"},{"nctId":"NCT06934590","title":"Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC","sponsor":"GeneCraft Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-23","conditions":["Non-Small Cell Lung Cancer"],"interventions":["RX001"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is an open-label, dose-escalation Phase I study to evaluate the safety and tolerability of RX001 monotherapy in patients with advanced KRAS mutant NSCLC. Subjects aged ≥19 years with advanced NSCLC with KRAS mutations will be enrolled. Based on the investigator's judgment of the lung tumor location, RX001 will be administered as a single intratumoral treatment via bronchoscopy or CT-guided percutaneous injection. Additionally, after conducting safety, tolerability, and preliminary anti-tumor efficacy assessments for all subjects up to Week 12 (D84) following IP administration, the collected data will be reviewed by the SRC for a comprehensive evaluation. If the IP is designated for long","sourceUrl":"https://clinicaltrials.gov/study/NCT06934590"},{"nctId":"NCT04868604","title":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","sponsor":"Clarity Pharmaceuticals Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2021-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-09","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Prostatic Neoplasms, Castration-Resistant"],"interventions":["64Cu-SAR-bisPSMA","67Cu-SAR-bisPSMA"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04868604"},{"nctId":"NCT06482905","title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","sponsor":"Tcelltech Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2024-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["High-grade Glioma","WHO Grade Ⅳ Glioma"],"interventions":["Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06482905"},{"nctId":"NCT06994507","title":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":352,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["Chemotherapy-induced Peripheral Neuropathy (CIPN)"],"interventions":["GM1","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-blind, multicenter, placebo-controlled phase III clinical trial, aiming to evaluate the efficacy and safety of GM1 in preventing chemotherapy-induced peripheral neuropathy in breast cancer patients treated with Albumin-paclitaxel chemotherapy regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT06994507"},{"nctId":"NCT05838729","title":"Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer","sponsor":"Coordination Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2023-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Head Neck Cancer","Intratumoral Injection"],"interventions":["RiMO-301"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05838729"},{"nctId":"NCT06949761","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-06","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-04-29","conditions":["Solid Tumor"],"interventions":["QLC1101+QL1203","QLC1101+QL2107","QLC1101+QL1706","QLC1101+docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination with Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation. The study includes Phase Ib (combination therapy with dose escalation stage) and Phase II (expansion stage). The study will includes a total of 4 cohorts: Phase Ib will enroll subjects in 4 cohorts (cohorts 1-4). Subjects will be allocated to appropriate cohorts by the investigator according to specific indications and treated with the corresponding combination regimen for safety and tolerability assessment. The Bayesian optimal interval (BOIN) design will be used for dose escalat","sourceUrl":"https://clinicaltrials.gov/study/NCT06949761"},{"nctId":"NCT06160752","title":"Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations","sponsor":"Tyra Biosciences, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Locally Advanced Cholangiocarcinoma","Intrahepatic Cholangiocarcinoma","Solid Tumor","Metastatic Cholangiocarcinoma"],"interventions":["Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles","Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06160752"},{"nctId":"NCT05801237","title":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","sponsor":"Shanghai HyaMab Biotech Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-12-15","conditions":["Locally Advanced/Metastatic Solid Tumors"],"interventions":["PE0116&PE0105"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05801237"},{"nctId":"NCT06381141","title":"A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma","sponsor":"Cullinan Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Multiple Myeloma"],"interventions":["CLN-619"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma","sourceUrl":"https://clinicaltrials.gov/study/NCT06381141"},{"nctId":"NCT05978284","title":"Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2023-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Small Cell Lung Cancer","Neuroendocrine Carcinoma"],"interventions":["ZG006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, Phase Ⅰ/Ⅱ clinical study of ZG006 for the treatment of participants with small cell lung cancer or neuroendocrine carcinoma who had no standard treatment available, or were intolerant to standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05978284"},{"nctId":"NCT06673017","title":"PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"PanTher Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":26,"enrollmentType":"ESTIMATED","startDate":"2025-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Pancreatic Ductal Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","Pancreatic Cancer"],"interventions":["PTM-101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06673017"},{"nctId":"NCT07400744","title":"A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Multiple Myeloma"],"interventions":["QL2109","Darzalex"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT07400744"},{"nctId":"NCT06779045","title":"A Study of AK-1286 in Patients With Advanced Solid Tumors","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-02-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Advanced Solid Tumor"],"interventions":["AK-1286"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1 open label multicenter study to evaluate the maximum tolerance, safety, tolerance and PK of AK-1286 in patients with advanced solid tumors, so as to confirm the recommended phase 2 dose of AK-1286 and obtain the preliminary efficacy information of patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06779045"},{"nctId":"NCT07035379","title":"A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL","sponsor":"Zhejiang Teruisi Pharmaceutical Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"interventions":["TRS005","Cyclophosphamide","Doxorubicin","Prednisolone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the \"3 + 3\" rule. Patients with previously untreated patients with CD20-positive DLBCL were selected to evaluate the safety, tolerance (DLT, MTD), pharmacokinetics, and anti-tumor activity of TRS005 in combination with standard doses of cyclophosphamide, doxorubicin, and prednisone（T-CHP） by intravenous drip every 3 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07035379"},{"nctId":"NCT04824092","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","sponsor":"Incyte Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":899,"enrollmentType":"ACTUAL","startDate":"2021-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-01","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["Tafasitamab","Lenalidomide","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone","Tafasitamab placebo","Lenalidomide placebo"],"countries":["United States","Argentina","Australia","Austria","Canada","Colombia","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Malaysia","New Zealand","Philippines","Poland","Romania","Russia","Serbia","Slovakia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":307,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL","sourceUrl":"https://clinicaltrials.gov/study/NCT04824092"},{"nctId":"NCT05548127","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":37,"enrollmentType":"ACTUAL","startDate":"2023-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-01","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Breast Cancer"],"interventions":["ARV-471","Abemaciclib"],"countries":["United States","Canada","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: * is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy * is sensitive to hormonal therapy (it is called estrogen receptor positive); and * is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study A: All participants will receive ARV-471 and a medicine called abemaciclib. ARV-471 will be given","sourceUrl":"https://clinicaltrials.gov/study/NCT05548127"},{"nctId":"NCT05990452","title":"Phase I/II FIH Study of 9MW2921 in Patients With Advanced Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":261,"enrollmentType":"ESTIMATED","startDate":"2023-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-11-21","conditions":["Advanced Solid Tumor"],"interventions":["9MW2921"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, Phase I-II, first-in-human (FIH) study of 9MW2921 in patients with locally advanced or metastatic solid tumors refractory to all standard therapies. The objective of this study is to evaluate the safety, tolerability, PK, immunogenicity and Preliminary Antitumor Activity of 9MW2921.","sourceUrl":"https://clinicaltrials.gov/study/NCT05990452"},{"nctId":"NCT06062420","title":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":316,"enrollmentType":"ACTUAL","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Neoplasms, Head and Neck"],"interventions":["Dostarlimab","Belrestotug","Nelistotug","Remzistotug"],"countries":["United States","Argentina","Brazil","Canada","Denmark","Finland","France","Germany","Greece","Hungary","Italy","Japan","Norway","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":108,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06062420"},{"nctId":"NCT07169994","title":"A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":414,"enrollmentType":"ESTIMATED","startDate":"2025-09-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2025-09-12","conditions":["Advanced Solid Tumors","Breast Cancer","Non Small Cell Lung Cancer"],"interventions":["YL202 for injection; Toripalimab injection","YL202 for injection; Furmonertinib Mesilate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07169994"},{"nctId":"NCT06077500","title":"DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2024-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-01","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Small Cell Lung Carcinoma (SCLC)"],"interventions":["BI 764532","Carboplatin","Etoposide","Atezolizumab"],"countries":["United States","Belgium","France","Germany","Japan","Poland","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1) immunotherapy. The purpose of this study is to find out the highest dose of BI 764532 (also called obrixtamig) that people can tolerate when taken together with standard of care. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants get BI 764532 and different standard treatments as infusions into a vein. If there is benefit for the participants and if they can tolerate it, the treatment is given for the entire duration of t","sourceUrl":"https://clinicaltrials.gov/study/NCT06077500"},{"nctId":"NCT06210815","title":"A Study of HLX42 in Advanced/Metastatic Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2024-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-14","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Solid Tumor and NSCLC"],"interventions":["HLX42"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study is an open-label first-in-human phase I clinical study to evaluate the safety and tolerability of HLX42.","sourceUrl":"https://clinicaltrials.gov/study/NCT06210815"},{"nctId":"NCT06151574","title":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","sponsor":"Boehringer Ingelheim","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":428,"enrollmentType":"ACTUAL","startDate":"2024-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-28","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Lung Cancer, Non-squamous, Non-small Cell"],"interventions":["zongertinib","pembrolizumab","cisplatin","carboplatin","pemetrexed"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Chile","China","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Puerto Rico","Singapore","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":163,"serviceSignals":["HER2 profiling"],"summary":"This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy. Particip","sourceUrl":"https://clinicaltrials.gov/study/NCT06151574"},{"nctId":"NCT03423628","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":159,"enrollmentType":"ACTUAL","startDate":"2018-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-03","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-03","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Recurrent Glioblastoma Multiforme","Primary Glioblastoma Multiforme","Brain Neoplasms, Malignant","Leptomeningeal Disease (LMD)"],"interventions":["Radiation Therapy","AZD1390"],"countries":["United States","Japan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT03423628"},{"nctId":"NCT06992713","title":"A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors","sponsor":"Shenzhen Hepalink Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-04","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Advanced Solid Tumor"],"interventions":["H1710 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06992713"},{"nctId":"NCT06047197","title":"Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma","sponsor":"Beijing Yongtai Ruike Biotechnology Company Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2023-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-05","completionType":"ESTIMATED","lastUpdated":"2024-08-27","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma"],"interventions":["RC19D2 cell injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This trial is a phase I clinical trial aimed at the safety and tolerability of RC19D2 cell injection in the treatment of CD19 positive patients with recurrent or refractory diffuse large B-cell lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06047197"},{"nctId":"NCT06730750","title":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2025-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-09","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced Solid Tumors"],"interventions":["BMS-986490","Bevacizumab"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a study of BMS-986490 as a monotherapy and in combination with bevacizumab in participants with select advanced solid tumors known to express CEACAM5.","sourceUrl":"https://clinicaltrials.gov/study/NCT06730750"},{"nctId":"NCT06440005","title":"A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors","sponsor":"Angiex, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-06","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Cancer","Advanced Cancer","Locally Advanced Carcinoma","Metastatic Solid Tumor","Breast Cancer","Prostate Cancer","Colorectal Cancer","Pancreatic Cancer","Liver Cancer","Angiosarcoma","Solid Tumor"],"interventions":["AGX101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT06440005"},{"nctId":"NCT06542731","title":"An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2021-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-08-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["ONO-4578","ONO-4538","Docetaxel","Ramucirumab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who were refractory to a combination therapy containing an anti-PD-(L)1 antibody and a platinum-based drug","sourceUrl":"https://clinicaltrials.gov/study/NCT06542731"},{"nctId":"NCT06144671","title":"GT201 Injection For The Treatment Of Advanced Solid Tumors","sponsor":"Grit Biotechnology","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2023-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-13","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-13","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Solid Tumor, Adult"],"interventions":["GT201"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified \"3+3\" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional \"3+3\" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional \"3+3\" dose-escalation principle,The second and third dose groups are based on the traditional \"3+3\" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.","sourceUrl":"https://clinicaltrials.gov/study/NCT06144671"},{"nctId":"NCT05543330","title":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","sponsor":"Wuhan YZY Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2022-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-15","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Malignant Pleural Effusions","NSCLC Stage IV"],"interventions":["M701 pleural infusion","Pleural drainage","Cisplatin pleural infusion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/phase 2, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of M701 in patients with treatment of malignant pleural effusions caused by NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05543330"},{"nctId":"NCT04634877","title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":990,"enrollmentType":"ESTIMATED","startDate":"2021-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-15","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Endometrial Neoplasms"],"interventions":["Pembrolizumab","Carboplatin","Paclitaxel","Placebo for pembrolizumab","Docetaxel","Cisplatin","External Beam Radiotherapy (EBRT)","Cisplatin (as radiosensitizer)","Brachytherapy"],"countries":["United States","Argentina","Austria","Belgium","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Israel","Italy","Japan","Mexico","Norway","Poland","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":231,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.","sourceUrl":"https://clinicaltrials.gov/study/NCT04634877"},{"nctId":"NCT07145333","title":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-28","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["SCLC"],"interventions":["Topotecan - usual","Topotecan - study"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Explore the relationship between drug target topoisomerase I gene single nucleotide polymorphisms and Topotecan therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Topotecan side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.","sourceUrl":"https://clinicaltrials.gov/study/NCT07145333"},{"nctId":"NCT07081984","title":"Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors","sponsor":"Therorna","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["HPV 16+ Recurrent or Metastatic Cancer","HNSCC","Cervical Cancer"],"interventions":["therapeutic tumor vaccine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors. The primary objectives of the study are to assess safety and tolerability of TI-0093 injection in patients with recurrent or metastatic solid tumors, and to determine the maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of TI-0093 injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT07081984"},{"nctId":"NCT05468697","title":"A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2022-08-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-22","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Renal Cell Carcinoma"],"interventions":["Belzutifan","Palbociclib"],"countries":["United States","Australia","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. The study will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05468697"},{"nctId":"NCT04370587","title":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors","sponsor":"ImmVira Pharma Co. Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2020-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-10","completionType":"ESTIMATED","lastUpdated":"2025-10-08","conditions":["Solid Tumor","Melanoma","HNSCC","Sarcoma","Squamous Cell Carcinoma","NSCLC"],"interventions":["T3011","T3011 + pembrolizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04370587"},{"nctId":"NCT05952037","title":"A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia","sponsor":"BeOne Medicines","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":114,"enrollmentType":"ACTUAL","startDate":"2023-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Waldenstrom Macroglobulinemia","Waldenstrom's Macroglobulinemia Recurrent","Waldenstrom's Macroglobulinemia Refractory"],"interventions":["Sonrotoclax","Zanubrutinib"],"countries":["United States","Australia","Canada","China","France","Greece","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":72,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.","sourceUrl":"https://clinicaltrials.gov/study/NCT05952037"},{"nctId":"NCT07038005","title":"A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-08","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Advanced Malignant Tumors"],"interventions":["SPGL008"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.","sourceUrl":"https://clinicaltrials.gov/study/NCT07038005"},{"nctId":"NCT04557449","title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":362,"enrollmentType":"ACTUAL","startDate":"2020-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-23","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Liposarcoma","Prostate Cancer","Breast Neoplasms","Adenocarcinoma of Lung"],"interventions":["PF-07220060","Letrozole","Fulvestrant","Midazolam","Enzalutamide"],"countries":["United States","Argentina","China","Czechia","Japan","Mexico","Slovakia","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and then in combination with endocrine therapy. The study consists of two parts and a China and Japan monotherapy cohort. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort Part 2 includes dose expansion cohorts evaluating PF-07220060 in combination with endocrine therapy or enzalutamide. In Part 1A, single escalating doses of PF-07220060 alone will be administered to determi","sourceUrl":"https://clinicaltrials.gov/study/NCT04557449"},{"nctId":"NCT05951049","title":"A Study of AT-02 in Subjects With Systemic Amyloidosis.","sponsor":"Attralus, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-28","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Amyloidosis; Systemic"],"interventions":["AT02"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT05951049"},{"nctId":"NCT07143604","title":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":33,"enrollmentType":"ACTUAL","startDate":"2025-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-28","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"interventions":["AZD0901"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to measure the efficacy and safety of AZD0901 monotherapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.","sourceUrl":"https://clinicaltrials.gov/study/NCT07143604"},{"nctId":"NCT07295951","title":"A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2025-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-29","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-29","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Acute Lymphoblastic Leukemia","Acute Leukemias","Acute Myeloid Leukemia"],"interventions":["14C-bleximenib","bleximenib"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).","sourceUrl":"https://clinicaltrials.gov/study/NCT07295951"},{"nctId":"NCT07192588","title":"A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer","sponsor":"Graegis Pharmaceuticals Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":273,"enrollmentType":"ESTIMATED","startDate":"2024-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Radiodermatitis; Acute"],"interventions":["GR1014-CG 2.4%","Vehicle Gel","Radiation Therapy","GR1014-CG 4.7%"],"countries":["France","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is testing a new skin gel called GR1014-CG to evaluate its safety and see if it can help prevent or reduce skin irritation (such as redness, soreness, etc.) caused by radiation therapy (RT) after breast-conserving surgery for early-stage breast cancer. The study is for women aged 18 and older who have had surgery to remove a breast tumor and need radiation therapy. The main goals of the study are to find out: * If GR1014-CG is safe to use * If the gel can prevent or lower the severity of skin irritation caused by RT. During the study participants will, * Be randomly assigned to use one of two strengths of GR1014-CG (4.7% or 2.4%) or a placebo gel (a gel with no active dru","sourceUrl":"https://clinicaltrials.gov/study/NCT07192588"},{"nctId":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":74,"enrollmentType":"ACTUAL","startDate":"2022-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["KRAS G12C Mutant Solid Tumors","Carcinoma, Non-Small Cell Lung","Carcinoma, Non-Small-Cell Lung","Non-Small Cell Lung Cancer","Non-Small Cell Lung Carcinoma","Nonsmall Cell Lung Cancer","Colorectal Cancer","Colorectal Carcinoma","Colorectal Neoplasms","Colorectal Tumors","Neoplasms, Colorectal"],"interventions":["JDQ443","trametinib","Ribociclib","cetuximab"],"countries":["United States","Belgium","France","Germany","Italy","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["RAS genotyping"],"summary":"This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05358249"},{"nctId":"NCT02138734","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","sponsor":"ImmunityBio, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":369,"enrollmentType":"ACTUAL","startDate":"2014-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2039-03-04","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Non-muscle Invasive Bladder Cancer"],"interventions":["BCG (50mg/instillation) + N-803 (400 μg/instillation)","BCG (50mg/instillation)"],"countries":["United States","India","South Africa"],"northAmerica":true,"chinaSites":false,"siteCount":108,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients with high-grade NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT02138734"},{"nctId":"NCT05989542","title":"A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2023-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2025-06-29","conditions":["Non-small Cell Lung Cancer"],"interventions":["PLB1001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are: * If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation * If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation Participants will 1. be given PLB1001 200mg BID,oral. 2. be received hematology and urine and ECG examinations every 14 days (First 3 months) or every 28 days (After 3 months) 3. be received Image examination every 8 weeks(First year) or every 12 weeks(After one year)","sourceUrl":"https://clinicaltrials.gov/study/NCT05989542"},{"nctId":"NCT05888831","title":"A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2025-06-11","conditions":["Advanced Solid Tumors"],"interventions":["BMS-986449","Nivolumab"],"countries":["United States","Belgium","France","Italy","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05888831"},{"nctId":"NCT04094610","title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","sponsor":"Turning Point Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2020-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Locally Advanced Solid Tumors","Metastatic Solid Tumors","Lymphoma","Primary CNS Tumors"],"interventions":["Oral repotrectinib (TPX-0005)"],"countries":["United States","Australia","Canada","Denmark","France","Italy","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT04094610"},{"nctId":"NCT07244380","title":"Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2025-11-28","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["T Lymphoblastic Leukemia/Lymphoma"],"interventions":["Autologous CD7-targeting CAR T cells"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07244380"},{"nctId":"NCT05635643","title":"Study of CHS-114 in Participants With Advanced Solid Tumors","sponsor":"Coherus Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2022-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Advanced Solid Tumor","Head and Neck Squamous Cell Carcinoma"],"interventions":["CHS-114","toripalimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05635643"},{"nctId":"NCT05882734","title":"Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2023-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Non-Small Cell Lung Cancer"],"interventions":["M1774","Cemiplimab"],"countries":["United States","Belgium","France","Germany","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"This is an Open-label, multicenter clinical study conducted in two Phases to establish the efficacy, safety, tolerability, and pharmacokinetics of the ataxia telangiectasia mutated and Rad3-related protein kinase (ATR) inhibitor Tuvusertib in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer (nsqNSCLC) that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies..","sourceUrl":"https://clinicaltrials.gov/study/NCT05882734"},{"nctId":"NCT06344052","title":"To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma","sponsor":"Stamford Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2024-09-20","conditions":["Basal Cell Carcinoma"],"interventions":["SP-002","Vismodegib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the efficacy of using SP-002 in participants with locally advanced Basal cell carcinoma. The main question it aims to answer is what the objective response rate for a basal cell carcinoma tumor is following 1 or 3 cycles of SP-002 treatment given as an add-on to hedgehog pathway inhibitor therapy. Researchers will compare the objective response rate for treated Basal cell carcinoma tumors between 3 treatment Arms. * Arm 1 participants will receive daily hedgehog pathway inhibitor, and 3 cycles of SP-002 treatment. * Arm 2 participants will receive daily hedgehog pathway inhibitor, and 1 cycle of SP-002 treatment. * Arm 3 participants will receiv","sourceUrl":"https://clinicaltrials.gov/study/NCT06344052"},{"nctId":"NCT05221840","title":"A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1051,"enrollmentType":"ACTUAL","startDate":"2022-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-02","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Durvalumab","Oleclumab","Monalizumab","Placebo"],"countries":["United States","Australia","Brazil","Canada","China","Colombia","France","Germany","Italy","Japan","Peru","Poland","Portugal","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":202,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unresectable NSCLC, who have not progressed following platinum-based cCRT.","sourceUrl":"https://clinicaltrials.gov/study/NCT05221840"},{"nctId":"NCT05116462","title":"Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":506,"enrollmentType":"ACTUAL","startDate":"2024-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-14","completionType":"ESTIMATED","lastUpdated":"2025-06-26","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Pemetrexed","Carboplatin","Paclitaxel","Sintilimab","Cisplatin","Nab paclitaxel","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, double-blind Phase 3 study to compare the efficacy and safety of Sindilizumab combined with chemotherapy or placebo combined with chemotherapy for neoadjuvant and adjuvant therapy for Resectable Stage II to IIIB (resectable N2 only) non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05116462"},{"nctId":"NCT05986851","title":"Azeliragon in MGMT Unmethylated Glioblastoma","sponsor":"Cantex Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2023-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Glioblastoma"],"interventions":["Azeliragon"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There's no cure for glioblastoma, which is also known as glioblastoma multiforme. Treatments, including surgery, radiation, and chemotherapy might slow cancer growth and reduce symptoms. New treatments of glioblastoma are needed.","sourceUrl":"https://clinicaltrials.gov/study/NCT05986851"},{"nctId":"NCT06392386","title":"A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis","sponsor":"argenx","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Generalized Myasthenia Gravis"],"interventions":["Efgartigimod PH20 SC"],"countries":["United States","Belgium","Canada","Czechia","France","Germany","Israel","Italy","Netherlands","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the pharmacokinetics (PK), pharmacodynamics (PD), safety, tolerability, and immunogenicity of efgartigimod PH20 SC in pediatric participants with gMG aged 2 to \\<18 years. The primary goal is to confirm an appropriate dose of efgartigimod PH20 SC for pediatric patients using PK and PD results from this study. Participants will receive injections of efgartigimod PH20 SC and will be monitored for safety until the end of the study. At the end of the follow-up period, eligible participants may roll over to an open-label extension (OLE) study. The participants will be in the study for up to 14 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT06392386"},{"nctId":"NCT06735391","title":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":516,"enrollmentType":"ESTIMATED","startDate":"2024-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Locally Advanced or Metastatic Non-squamous NSCLC","Harboring EGFR Sensitive Mutations NSCLC","Previously Untreated Systematically NSCLC"],"interventions":["JMT101","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, randomized, positive-controlled, open-label clinical study. The primary objective is to evaluate the efficacy of JMT101 in combination with osimertinib versus osimertinib alone in patients with newly diagnosed locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitive mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06735391"},{"nctId":"NCT06417814","title":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":744,"enrollmentType":"ESTIMATED","startDate":"2024-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-27","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Metastatic Non-small Cell Lung Cancer"],"interventions":["Dato-DXd","Osimertinib","Pemetrexed","Carboplatin","Cisplatin"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Greece","Hong Kong","India","Israel","Italy","Japan","Malaysia","Netherlands","Philippines","Poland","Portugal","Romania","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":303,"serviceSignals":["Broad CGP"],"summary":"This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06417814"},{"nctId":"NCT07098052","title":"A Study of HDM2020 in Patients With Advanced Solid Tumors","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08-11","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Solid Tumor"],"interventions":["HDM2020"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07098052"},{"nctId":"NCT05557838","title":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":214,"enrollmentType":"ACTUAL","startDate":"2023-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Hepatocellular Carcinoma"],"interventions":["Durvalumab","Tremelimumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05557838"},{"nctId":"NCT05609578","title":"Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2022-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced NSCLC","Metastatic Lung Cancer"],"interventions":["Adagrasib oral dose of 400 mg twice daily tablets","Pembrolizumab","Chemotherapy: Pemetrexed","Cisplatin/Carboplatin"],"countries":["United States","France","Greece","Hungary","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":94,"serviceSignals":["RAS genotyping"],"summary":"Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \\<50% and KRAS G12C mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT05609578"},{"nctId":"NCT04756726","title":"Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma","sponsor":"C4 Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2021-04-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Multiple Myeloma","Lymphoma, Non-Hodgkin's"],"interventions":["cemsidomide","Dexamethasone Oral"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.","sourceUrl":"https://clinicaltrials.gov/study/NCT04756726"},{"nctId":"NCT05906862","title":"AMT-253 in Patients With Selected Advanced Solid Tumours","sponsor":"Multitude Therapeutics (Australia) Pty Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2023-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Advanced Solid Tumor"],"interventions":["AMT-253"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-253, in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05906862"},{"nctId":"NCT05304962","title":"FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer","sponsor":"Regor Pharmaceuticals Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":64,"enrollmentType":"ESTIMATED","startDate":"2022-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Breast Cancer"],"interventions":["RGT-419B","RGT-419B in combination with hormonal therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable (Stage III) or metastatic (Stage IV) breast cancer whose disease has progressed during prior therapy with an approved CDK4/6i plus hormonal therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05304962"},{"nctId":"NCT04980222","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2022-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Lymphoma"],"interventions":["Glofitamab","Tocilizumab","Doxorubicin","Vincristine","Prednisone","Rituximab","Cyclophosphamide"],"countries":["United States","Denmark","France","Netherlands","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in individuals with circulating tumor DNA (ctDNA) high-risk diffuse large B-cell lymphoma (DLBCL), as the first line of treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04980222"},{"nctId":"NCT06882135","title":"HW071021 Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Wuhan Humanwell Innovative Drug Research and Development Center Limited Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Advanced Solid Tumors"],"interventions":["HW071021 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HW071021 monotherapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06882135"},{"nctId":"NCT06416410","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Advanced Non-squamous Non-small-cell Lung Cancer","Metastatic Non-squamous Non Small Cell Lung Cancer"],"interventions":["JAB-21822","Tislelizumab","JAB-3312","Pemetrexed","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":37,"serviceSignals":["RAS genotyping"],"summary":"This Phase 3 study will evaluate the efficacy of JAB-21822+JAB-3312 versus tislelizumab (PD-1 Ab) combined with pemetrexed+carboplatin as the first line treatment in subjects with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06416410"},{"nctId":"NCT07124793","title":"A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["EGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer"],"interventions":["IBI363+IBI305"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"CIBI363A203, a Phase 2 study to evaluate the safety, tolerability and preliminary efficacy of IBI363 combined with IBI305 (a bevacizumab biosimilar) in participants with advanced malignancies conducted in China. Primary endpoint is objective response rate (ORR) per RECIST v1.1. Secondary endpoints include DoR, DCR, TTR, PFS, per RECIST v1.1, and OS; the incidence and severity of AEs, irAEs, SAEs, AESIs and their relationship to the investigational drug, and changes in vital signs, physical examination, and laboratory values before and after study treatment; PK, and immunogenicity of IBI363. The cohorts include: IBI363 and IBI305 combination therapy in participants with advanced EGFRmut NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT07124793"},{"nctId":"NCT04716452","title":"Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"Keystone Nano, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia, Refractory","Refractory/Relapse Acute Myeloid Leukemia"],"interventions":["Ceramide NanoLiposome (Ceraxa)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .","sourceUrl":"https://clinicaltrials.gov/study/NCT04716452"},{"nctId":"NCT06498479","title":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2024-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2024-10-16","conditions":["Small Cell Lung Cancer"],"interventions":["HS-20093","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06498479"},{"nctId":"NCT06374888","title":"Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases","sponsor":"Convalife (Shanghai) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2024-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2024-04-19","conditions":["Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis"],"interventions":["Neratinib maleate in combination with capecitabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"To evaluate the efficacy of nilatinib maleate tablets combined with capecitabine in the treatment of HER2-positive advanced esophageal/esophagogastric junction/gastric adenocarcinoma with brain metastasis.","sourceUrl":"https://clinicaltrials.gov/study/NCT06374888"},{"nctId":"NCT06362252","title":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2024-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Extensive Stage-small Cell Lung Cancer"],"interventions":["Ifinatamab deruxtecan","Atezolizumab","Carboplatin"],"countries":["United States","France","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["ADC biomarker"],"summary":"This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06362252"},{"nctId":"NCT05394831","title":"A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC","sponsor":"J Ints Bio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2023-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2025-05-16","conditions":["EGFR Mutant Advanced Non-small Cell Lung Cancer"],"interventions":["JIN-A02"],"countries":["United States","South Korea","Thailand"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["ctDNA / MRD"],"summary":"This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced NSCLC subjects who showed disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapy and/or no more than a single platinum-based anticancer chemotherapy. In Part A of the study, dose escalation is carried out where MTD is evaluated using Bayesian Optimal Interval (BOIN) design in subjects with advanced NSCLC harboring EGFR-mutation of C797S or T790M. In Part B, dose exploration is carried out to further evaluate the safety o","sourceUrl":"https://clinicaltrials.gov/study/NCT05394831"},{"nctId":"NCT06806046","title":"Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ACTUAL","startDate":"2024-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Solid Tumors","Colorectal Cancer"],"interventions":["M9140"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06806046"},{"nctId":"NCT07235293","title":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","sponsor":"Kahr Bio Australia Pty Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Colorectal Cancer"],"interventions":["DSP107 + Atezolizumab","Fruquintinib"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["MSI / TMB"],"summary":"This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07235293"},{"nctId":"NCT05329103","title":"A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors","sponsor":"Peel Therapeutics Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2022-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced Solid Tumor"],"interventions":["PEEL-224","FOLF+B"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05329103"},{"nctId":"NCT05787587","title":"A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors","sponsor":"IDEAYA Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2023-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Advanced or Metastatic Solid Tumors","Breast Cancer","Ovarian Cancer","Prostate Cancer","Endometrial Cancer","Colorectal Cancer","Head and Neck Cancers","Extensive Stage Small Cell Lung Cancer (ES-SCLC)","NSCLC"],"interventions":["IDE-161","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["HRD / HRR","MSI / TMB"],"summary":"The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05787587"},{"nctId":"NCT04299191","title":"Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors","sponsor":"Laminar Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2020-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["High-grade Glioma","Solid Tumor, Unspecified, Child"],"interventions":["LAM561"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard \"3+3\" design to establish dose-limiting toxicity (DLT) and a \"safe\" dose of LAM561 followed by an expanded safety cohort of up to 10 patients treated at the Maximum Tolerated Dose (MTD). If the MTD is well tolerated in the expanded safety cohort, that dose becomes the Recommended Phase 2 Dose (RP2D). Glioma patients and other solid tumor patients (including non-glial brain tumors) will be treated as a single cohort. Patients with either tumor type will be allowed to enrol","sourceUrl":"https://clinicaltrials.gov/study/NCT04299191"},{"nctId":"NCT06316531","title":"A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":274,"enrollmentType":"ACTUAL","startDate":"2024-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["HER2-positive Breast Cancer"],"interventions":["BL-M07D1","T-DM1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally advanced or metastatic HER2-positive breast cancer who had failed previous treatment with taxanes and trastuzumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06316531"},{"nctId":"NCT05226494","title":"Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma","sponsor":"NanoPharmaceuticals LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":34,"enrollmentType":"ESTIMATED","startDate":"2022-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-06-04","conditions":["Glioma, Malignant"],"interventions":["fb-PMT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05226494"},{"nctId":"NCT04777994","title":"Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors","sponsor":"Calico Life Sciences LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":248,"enrollmentType":"ESTIMATED","startDate":"2021-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Advanced Solid Tumor Cancer"],"interventions":["ABBV-CLS-484","Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)","Programmed Cell Death-1 (PD-1) Inhibitor"],"countries":["United States","France","Israel","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["MSI / TMB"],"summary":"The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation and Part 3 Dose Expansion (Monotherapy and Combination therapy). Part 1, ABBV-CLS-484 will be administered alone in escalating dose levels to eligible subjects who have advanced solid tumors. Part 2, ABBV-CLS-484 will be ","sourceUrl":"https://clinicaltrials.gov/study/NCT04777994"},{"nctId":"NCT05119907","title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":53,"enrollmentType":"ACTUAL","startDate":"2021-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Solid Tumor"],"interventions":["Sacituzumab Govitecan-hziy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to see how effective the study drug, sacituzumab govitecan-hziy, is in participants with solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05119907"},{"nctId":"NCT06609187","title":"A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Breast Cancer","Solid Tumor"],"interventions":["GNC-077"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic breast cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06609187"},{"nctId":"NCT06584071","title":"A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC","sponsor":"Biotheus Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["HCC","Liver Cancer"],"interventions":["PM8002","PM1009","atezolizumab","bevacizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study to evaluate the preliminary efficacy, safety and pharmacokinetics of PM8002 combined with PM1009 in Patients with first-line Hepatocellular Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06584071"},{"nctId":"NCT06859775","title":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Recurrent or Metastatic Cervical Cancer"],"interventions":["SHR-A1811","Adebelimab injection","Bevacizumab injection","SHR-8068","Cisplatin injection","Carboplatin injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicentre, open-label, dose-finding/efficacy-expanding phase Ib/II clinical trial to evaluate the tolerability, safety, pharmacokinetic profile and immunogenicity of SHR-A1811 combination regimen in the treatment of recurrent or metastatic cervical cancer and to preliminarily evaluate the efficacy of SHR-A1811 combination regimen for recurrent or metastatic cervical cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06859775"},{"nctId":"NCT06589830","title":"TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer","sponsor":"Suzhou Teligene Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Colorectal Cancer Metastatic","Advanced Colorectal Cancer"],"interventions":["TL938 Capsules","Trastuzumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase II trial designed to determine the optimal dose and evaluate the effectiveness of TL938 and trastuzumab in treating patients with HER2+ colorectal cancer that has metastasized or recurred and is inoperable.","sourceUrl":"https://clinicaltrials.gov/study/NCT06589830"},{"nctId":"NCT06773312","title":"BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.","sponsor":"Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Advanced or Metastatic Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["BC001+Sintilimab+XELOX"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn the efficaty and safety of BC001 in combination with Sintilimab and XELOX in treating patients with advanced or metastatic GC/GEJ. Participants will: Be administered with BC001, Sintilimab and Oxaliplatin once every three weeks for up to 24 months or until disease progression as per RECIST 1.1 or withdrawal from this study. Take Capecitabine once daily in the first two weeks of each three-week treatment cycle for up to 24 months or until disease progression as per RECIST 1.1 or withdrawal from this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06773312"},{"nctId":"NCT04291105","title":"Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients","sponsor":"Vyriad, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2020-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Melanoma","Head and Neck Squamous Cell Carcinoma","Colo-rectal Cancer"],"interventions":["VV1","Cemiplimab"],"countries":["United States","Brazil"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. (CRC and melenoma cohorts are now closed to new patients)","sourceUrl":"https://clinicaltrials.gov/study/NCT04291105"},{"nctId":"NCT06929325","title":"Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":312,"enrollmentType":"ESTIMATED","startDate":"2025-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-04-16","conditions":["HR+/HER2- Advanced/Metastatic Breast Cancer"],"interventions":["Sirolimus for Injection (Albumin-bound)","Fulvestrant Injection","Placebo for Sirolimus for Injection (Albumin-bound)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"A randomized, double-blind, multicenter phase III clinical study to evaluate the efficacy and safety of sirolimus for injection (albumin-bound) combined with fulvestrant in patients with HR+ and HER2- advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06929325"},{"nctId":"NCT07104617","title":"Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）","sponsor":"TYK Medicines, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-08-05","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["TY-302","Abiraptor"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07104617"},{"nctId":"NCT07229729","title":"A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2025-12-01","conditions":["Non-small Cell Lung Cancer"],"interventions":["SHR-A2102","Adebrelimab","Paclitaxel","Carboplatin","Alomnertinib Mesilate","Furmonertini Mesilate","Osimertinib Mesylate"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229729"},{"nctId":"NCT06492122","title":"Study With [225Ac]Ac-FL-020 in mCRPC Participants","sponsor":"Full-Life Technologies UK Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["[225Ac]Ac-FL-020","Blood samples for PK","[111In]In-FL-020","Blood and urine samples collection","SPECT/CT images"],"countries":["United States","Australia","China","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, therapeutic effect, and pharmacokinetics of \\[225Ac\\]Ac-FL-020 in participants with metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06492122"},{"nctId":"NCT04443010","title":"Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma","sponsor":"Philogen S.p.A.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":226,"enrollmentType":"ESTIMATED","startDate":"2021-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-10-10","conditions":["Glioblastoma"],"interventions":["Onfekafusp alfa","Temozolomide"],"countries":["Switzerland"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to explore the safety profile and establish a recommended dose (RD) for phase II of the antibody-cytokine fusion protein L19TNF plus standard TMZ chemoradiotherapy in patients with newly diagnosed glioblastoma. The study will be conducted in three consecutive parts: a dose finding part to determine the RD of L19TNF in combination with chemoradiotherapy, followed by a signal seeking part that investigates first signs of activity and then an activity evaluation part that studies the efficacy of L19TNF in combination with chemoradiotherapy against chemoradiotherapy alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT04443010"},{"nctId":"NCT04243499","title":"First-in-Human Study of ICT01 in Patients With Advanced Cancer","sponsor":"ImCheck Therapeutics, an Ipsen company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":293,"enrollmentType":"ACTUAL","startDate":"2020-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Solid Tumor, Adult","Hematopoietic/Lymphoid Cancer"],"interventions":["IV ICT01"],"countries":["United States","Belgium","France","Germany","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT04243499"},{"nctId":"NCT05893888","title":"A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers","sponsor":"Privo Technologies","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Oral Squamous Cell Carcinoma"],"interventions":["PRV211 (Intraoperative Cisplatin System)","PRV111 (Cisplatin Transmucosal System)","PRV131 (Cisplatin Intratumoral Injectable)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Situ (CIS) (WHO 2017) Arm 2 (Phase 1) PRV211: Intraoperative Locoregional Delivery Placed into the Resected Tumor Bed Primary Endpoint: Safety Primary Objective: Determine Safety of PRV211 in intraoperative setting Arm 3 (Phase 1/2) PRV131: Intratumoral Injectable delivery into the Tumor Primary Endpoint: Safety and Objective Response Rate (ORR) Primary objective: Determine a safe and effective dose for PRV131 intratumoral injectable Subject Assignment: Subjec","sourceUrl":"https://clinicaltrials.gov/study/NCT05893888"},{"nctId":"NCT05592626","title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","sponsor":"Marengo Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":365,"enrollmentType":"ESTIMATED","startDate":"2023-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["Advanced Solid Tumors","Genital Neoplasm, Female","Urogenital Neoplasms","Lung Neoplasm","Neoplasms by Site","Papillomavirus Infection","Epstein-Barr Virus Infections","Carcinoma","Neoplasms","Vulvar Neoplasms","Vulvar Diseases","Abdominal Neoplasm"],"interventions":["STAR0602"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["RNA fusion","MSI / TMB","HLA / TCR"],"summary":"This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.","sourceUrl":"https://clinicaltrials.gov/study/NCT05592626"},{"nctId":"NCT04965493","title":"A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","sponsor":"Loxo Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2021-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Pirtobrutinib","Venetoclax","Rituximab"],"countries":["United States","Australia","Belgium","Canada","China","Czechia","Denmark","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Norway","Poland","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":176,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.","sourceUrl":"https://clinicaltrials.gov/study/NCT04965493"},{"nctId":"NCT06948539","title":"To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-29","conditions":["Breast Cancer","Lung Cancer","Colorectal Cancer"],"interventions":["TQB2101 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06948539"},{"nctId":"NCT06273553","title":"A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3","sponsor":"RinuaGene Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2024-03","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-02-22","conditions":["Human Papillomavirus Associated Intraepithelial Neoplasia","Cervical Intraepithelial Neoplasia Grade 2/3","Human Papillomavirus Type 16 Infection","Human Papillomavirus Type 18 Infection"],"interventions":["RG002 injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).","sourceUrl":"https://clinicaltrials.gov/study/NCT06273553"},{"nctId":"NCT05361954","title":"Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors","sponsor":"Sorrento Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2023-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2023-04-12","conditions":["Cancer","Cancer of Pancreas","Sarcoma","Hepatic Metastasis","Solid Tumor"],"interventions":["STI-1386"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b study to assess the safety and tolerability of STI-1386, an oncolytic virus, in subjects with relapsed and refractory solid tumors (RRSTs).","sourceUrl":"https://clinicaltrials.gov/study/NCT05361954"},{"nctId":"NCT06318884","title":"A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma","sponsor":"Sinocelltech Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2024-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-03-22","conditions":["Non-Hodgkin Lymphoma, B-cell"],"interventions":["SCTB35 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06318884"},{"nctId":"NCT06512051","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":248,"enrollmentType":"ESTIMATED","startDate":"2024-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["SHR-A2102 for Injection","Adebrelimab Injection","Cisplatin injection","Carboplatin injection","Bevacizumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06512051"},{"nctId":"NCT05653869","title":"A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions","sponsor":"Applied Pharmaceutical Science, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":108,"enrollmentType":"ACTUAL","startDate":"2023-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["RET-altered Solid Tumors"],"interventions":["APS03118"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/1b, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antineoplastic activity of APS03118 administered orally in participants with RET-altered solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05653869"},{"nctId":"NCT07256782","title":"A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":444,"enrollmentType":"ESTIMATED","startDate":"2025-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2025-12-01","conditions":["Advanced Solid Tumor"],"interventions":["QLC5508","QL1706","Cisplatin/ Carboplatin","QL2107","Paclitaxel","5-fluorouracil (5-FU)","Oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of QLC5508 in combination with other anti-cancer agents in patients with advanced solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07256782"},{"nctId":"NCT06163391","title":"A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer","sponsor":"SOTIO Biotech AG","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-06-29","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["SOT201"],"countries":["United States","Belgium","Czechia","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["RNA fusion"],"summary":"This is a Phase 1, open-label, dose escalation study to assess the safety, tolerability, and preliminary efficacy of SOT201 as monotherapy for participants aged 18 years or above with advanced unresectable or metastatic solid tumors During dose escalation, the recommended dose(s) of SOT201 given every 3 weeks (Q3W) will be determined","sourceUrl":"https://clinicaltrials.gov/study/NCT06163391"},{"nctId":"NCT06300177","title":"D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":522,"enrollmentType":"ESTIMATED","startDate":"2024-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-04-26","conditions":["Non Small Cell Lung Cancer"],"interventions":["D-1553 Tablet","Docetaxel injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":86,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat sarcoma viral oncogene (KRAS) G12C mutation positive locally advanced or metastatic non small cell lung cancer (NSCLC), progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) based on RECIST 1.1 was used as the primary endpoint.","sourceUrl":"https://clinicaltrials.gov/study/NCT06300177"},{"nctId":"NCT07151872","title":"Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["CLDN18.2-positive Advanced Biliary Tract Cancer"],"interventions":["QLS31905 for Injection","Gemcitabine Hydrochloride for Injection","Cisplatin for Injection","QL2107 Injection","Oxaliplatin Injection","Capecitabine Tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, multicenter Phase II clinical study aimed at evaluating the efficacy, safety, PK profile, and immunogenicity of QLS31905 for Injection combined with Chemotherapy ± QL2107 in Patients with CLDN18.2-positive Advanced Biliary Tract Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07151872"},{"nctId":"NCT06413953","title":"A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced Cancers"],"interventions":["TQB3107 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells. This is a clinical study to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06413953"},{"nctId":"NCT06125951","title":"Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease","sponsor":"Actinogen Medical","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":247,"enrollmentType":"ACTUAL","startDate":"2024-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Dementia Moderate","Dementia, Mild","Alzheimer Disease"],"interventions":["Xanamem","Placebo"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion. Participants who have completed the main trial will be eligible to participate in an open-label phase, which involves treatment with 10mg Xanamem once daily for a treatment period of up to a maximum of 108 weeks. The OLE is intended to finish when all partic","sourceUrl":"https://clinicaltrials.gov/study/NCT06125951"},{"nctId":"NCT06591520","title":"AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":682,"enrollmentType":"ACTUAL","startDate":"2024-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Biliary Tract Cancer"],"interventions":["AK112, Gemcitabine, Cisplatin","Durvalumab, Gemcitabine, Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3 study. All subjects are patients with unresectable locally advanced or metastatic biliary tract cancer (BTC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy versus durvalumab in combination with chemotherapy in patients with unresectable locally advanced or metastatic BTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06591520"},{"nctId":"NCT07231211","title":"A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2025-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Solid Tumors"],"interventions":["SHR-4610 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter Phase I/II clinical trial, divided into two stages: dose exploration (including dose escalation and dose extension) and efficacy extension.","sourceUrl":"https://clinicaltrials.gov/study/NCT07231211"},{"nctId":"NCT06739291","title":"A Study of SIGX1094R in Patients With Advanced Solid Tumors","sponsor":"Signet Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Advanced Solid Tumors"],"interventions":["SIGX1094R"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I clinical, first-in-human study of SIGX1094R monotherapy. The goal of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), anti-tumor activity and food effect of SIGX1094R in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06739291"},{"nctId":"NCT06612840","title":"A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Non-small Cell Lung Cancer","Solid Tumor"],"interventions":["GNC-077"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with Locally advanced or metastatic non-small cell lung cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06612840"},{"nctId":"NCT06474468","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":148,"enrollmentType":"ESTIMATED","startDate":"2024-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-01-03","conditions":["Advanced or Metastatic Esophageal Cancer"],"interventions":["SHR-A2102；Adebrelimab；Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Esophageal Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06474468"},{"nctId":"NCT04262466","title":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","sponsor":"Immunocore Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":410,"enrollmentType":"ACTUAL","startDate":"2020-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Select Advanced Solid Tumors"],"interventions":["Brenetafusp","Brenetafusp and pembrolizumab","Brenetafusp and chemotherapy","Brenetafusp and monoclonal antibodies and chemotherapy","Brenetafusp and tebentafusp","Brenetafusp and bevacizumab","Brenetafusp and kinase inhibitors"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","France","Germany","Ireland","Italy","Netherlands","New Zealand","Poland","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":76,"serviceSignals":["HLA / TCR"],"summary":"Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.","sourceUrl":"https://clinicaltrials.gov/study/NCT04262466"},{"nctId":"NCT05804669","title":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","sponsor":"Crinetics Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2023-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Cushing Syndrome","Cushing Disease","Ectopic ACTH Syndrome"],"interventions":["atumelnant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \\[ACTH\\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \\[EAS\\])","sourceUrl":"https://clinicaltrials.gov/study/NCT05804669"},{"nctId":"NCT05840224","title":"Study of GS-4528 in Adults With Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2023-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Solid Tumor"],"interventions":["GS-4528","Zimberelimab"],"countries":["United States","Canada","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody. The primary objectives of this study are: * To assess the safety and tolerability of GS-4528 as monotherapy and in combination with Anti-PD-1 Monoclonal Antibody in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended Phase 2 dose (","sourceUrl":"https://clinicaltrials.gov/study/NCT05840224"},{"nctId":"NCT05835609","title":"PM534 Administered Intravenously to Patients With Advanced Solid Tumors","sponsor":"PharmaMar","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2022-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Patients With Advanced Solid Tumors"],"interventions":["PM534"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goals of this trial are to identify the dose limiting toxicities, to determine the maximum tolerated dose and the recommended dose of PM534 in patients with advanced solid tumors. All Patients will receive PM534 via intravenous.","sourceUrl":"https://clinicaltrials.gov/study/NCT05835609"},{"nctId":"NCT06357377","title":"A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors","sponsor":"Neonc Technologies, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Pediatric Tumor of CNS","Pediatric Tumor of Brain","Diffuse Midline Glioma, H3 K27M-Mutant","Pediatric Tumor of Brain Stem","Pineocytoma","Choroid Plexus Carcinoma, Childhood","Spinal Cord Tumor","High Grade Glioma"],"interventions":["NEO100"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas. Patients will receive IN NEO100 that will follow a dose titration design, followed by a standard dose escalation design to establish safety. Brain tumor delivery of NEO100 will be confirmed in each disease sub-type by surgical resection/needle biopsy only if clinically indicated and scheduled for clinical purposes and testing with residual tissue for NEO100 and the major metabolite of NEO100 (Perillic Acid).","sourceUrl":"https://clinicaltrials.gov/study/NCT06357377"},{"nctId":"NCT06057922","title":"A Study YL201 in Patients With Selected Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":990,"enrollmentType":"ESTIMATED","startDate":"2023-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Advanced Solid Tumor"],"interventions":["YL201 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":52,"serviceSignals":["ADC biomarker"],"summary":"This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors. The study will include 2 parts: Phase 1 dose expansion stage (Part 1) followed by a Phase 2 stage with expanded sample size (Part 2). Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), esophageal squamous cell carcinoma (ESCC), metastatic castration-resistant prostate cancer (mCRPC), head and neck squamous cell carcinoma (HNSCC), sarcoma, ductal adenocarcinoma of pancreas (PDAC), hepatocellular ca","sourceUrl":"https://clinicaltrials.gov/study/NCT06057922"},{"nctId":"NCT06598787","title":"A Study of BL-B01D1 in Patients With Recurrent Glioblastoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-10","primaryCompletionType":"ESTIMATED","completionDate":"2026-10","completionType":"ESTIMATED","lastUpdated":"2025-05-07","conditions":["Recurrent Glioblastoma"],"interventions":["BL-B01D1 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, phase II study to evaluate the safety, efficacy, and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with recurrent glioblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06598787"},{"nctId":"NCT05642455","title":"SPEARHEAD-3 Pediatric Study","sponsor":"USWM CT, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2038-07-30","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Synovial Sarcoma","Malignant Peripheral Nerve Sheath Tumor (MPNST)","Neuroblastoma (NBL)","Osteosarcoma"],"interventions":["Afamitresgene autoleucel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["HLA / TCR"],"summary":"This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05642455"},{"nctId":"NCT06896890","title":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","sponsor":"Inhatarget Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2023-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-01","completionType":"ESTIMATED","lastUpdated":"2025-03-26","conditions":["NSCLC (advanced Non-small Cell Lung Cancer)","Stage IV Lung Cancer"],"interventions":["CIS-DPI"],"countries":["Belgium","France","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The combination of chemotherapy and immunotherapy shows promising results in terms of overall survival (OS) and progression-free survival (PFS) for the treatment of first-line stage IV non-small cell lung cancer (NSCLC) patients, leading to such combinations becoming a real backbone of the Standard of Care (SoC) for NSCLC patients. However, conventional chemotherapy's severe systemic toxicities represent a limiting factor in terms of administered dose and frequency. Administration of cisplatin by inhalation (pulmonary route) is a promising additional approach that may overcome the limitations of conventional chemotherapy. Use of a dry powder inhaler enables a high therapeutic response by del","sourceUrl":"https://clinicaltrials.gov/study/NCT06896890"},{"nctId":"NCT06642545","title":"Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2025-02-17","conditions":["Breast Cancer"],"interventions":["Disitamab Vedotin","RC148","Albumin-bound Paclitaxone","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"Evaluating the Efficacy of Disitamab Vedotin in Combination with RC148 Compared to Albumin-bound Paclitaxone Monotherapy or in Combination with Toripalimab for Subjects with HR-negative, HER2-low Expressing Unresectable Locally Advanced or Metastatic Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06642545"},{"nctId":"NCT07098806","title":"Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases","sponsor":"Plus Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-02","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Leptomeningeal Metastasis"],"interventions":["186RNL"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase 1 study to determine the safety and efficacy of multiple doses at defined intervals of rhenium (186Re) obisbemeda (rhenium-186 nanoliposome, 186RNL) administered via intraventricular catheter for any primary solid tumor cancer with leptomeningeal metastases to identify an MTD/MFD for a given dose, interval duration, and number of doses.","sourceUrl":"https://clinicaltrials.gov/study/NCT07098806"},{"nctId":"NCT06713369","title":"AZD5305 hADME in Patients With Advanced Solid Malignancies","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2025-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-02","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-02","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Locally Advanced or Metastatic Solid Tumor"],"interventions":["Saruparib (AZD5305)","[14C]-AZD5305 microtracer","[14C]-AZD5305 (therapeutic dose)"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of \\[14C\\]-Saruparib in patients with advanced solid malignancies. This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable).","sourceUrl":"https://clinicaltrials.gov/study/NCT06713369"},{"nctId":"NCT03333343","title":"Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":105,"enrollmentType":"ACTUAL","startDate":"2018-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-05","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["EGFR-mutant Non-small Cell Lung Cancer"],"interventions":["EGF816","trametinib","ribociclib","LXH254","INC280","gefitinib"],"countries":["Canada","Germany","Hong Kong","Italy","Singapore","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RNA fusion","MET profiling"],"summary":"The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03333343"},{"nctId":"NCT05164094","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults","sponsor":"ModernaTX, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":867,"enrollmentType":"ACTUAL","startDate":"2021-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-18","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Epstein-Barr Virus Infection"],"interventions":["mRNA-1189","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["Broad CGP"],"summary":"The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \\<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part C is to evaluate the safety and reactogenicity of mRNA-1189 in 10- to 21-year-old healthy adolescents and adults.","sourceUrl":"https://clinicaltrials.gov/study/NCT05164094"},{"nctId":"NCT05831111","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants","sponsor":"ModernaTX, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":482,"enrollmentType":"ACTUAL","startDate":"2023-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-07","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-07","completionType":"ESTIMATED","lastUpdated":"2025-09-30","conditions":["Epstein-Barr Virus Infection"],"interventions":["mRNA-1195.1","mRNA-1195.2","mRNA-1189","Placebo","mRNA-1195"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT05831111"},{"nctId":"NCT06555796","title":"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ACTUAL","startDate":"2024-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-02","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Prostate Cancer","High-risk Biochemical Recurrence","High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer","Non-metastatic Castration-sensitive Prostate Cancer"],"interventions":["Xaluritamig"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06555796"},{"nctId":"NCT06447662","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":64,"enrollmentType":"ACTUAL","startDate":"2024-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-09","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Carcinoma, Pancreatic Ductal","Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung"],"interventions":["PF-07934040","Gemcitabine","Nab-paclitaxel","Cetuximab","Fluorouracil","Oxaliplatin","Leucovorin","Bevacizumab","Pembrolizumab","pemetrexed","Cisplatin","Paclitaxel","Carboplatin","Sasanlimab"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other p","sourceUrl":"https://clinicaltrials.gov/study/NCT06447662"},{"nctId":"NCT07083505","title":"A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Advanced Breast Cancer"],"interventions":["HB1801","Taxotere®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multicenter Phase II clinical trial evaluating the efficacy and safety of HB1801 compared with Taxotere® in patients with advanced breast cancer. A total of 60 subjects with advanced breast cancer are planned to be enrolled.The trial consists of three phases: screening period, open-label treatment period, and follow-up period. HB1801 is Docetaxel for injection (Albumin-bound).","sourceUrl":"https://clinicaltrials.gov/study/NCT07083505"},{"nctId":"NCT05372354","title":"A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2022-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-12","completionType":"ESTIMATED","lastUpdated":"2025-09-05","conditions":["Multiple Myeloma"],"interventions":["CC-92480","Tazemetostat","BMS-986158","Trametinib","Dexamethasone"],"countries":["United States","Canada","Norway","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT05372354"},{"nctId":"NCT05884398","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":420,"enrollmentType":"ACTUAL","startDate":"2023-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Metastatic Castrate-sensitive Prostate Cancer"],"interventions":["Apalutamide","Androgen-deprivation Therapy (ADT)"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Mexico","Poland"],"northAmerica":true,"chinaSites":true,"siteCount":93,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level \\< 0.2 nanograms/millilitres (ng/mL) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes measured as 18-month percent change in severity adjusted hot flash score.","sourceUrl":"https://clinicaltrials.gov/study/NCT05884398"},{"nctId":"NCT06521567","title":"A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":83,"enrollmentType":"ESTIMATED","startDate":"2025-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-13","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-13","completionType":"ESTIMATED","lastUpdated":"2025-11-12","conditions":["Melanoma","Hodgkin Lymphoma","High and Low Grade Glioma","Glioblastoma Multiforme (GBM)","Diffuse Intrinsic Pontine Glioma (DIPG)","Ependymoma","Osteosarcoma","Hepatic Tumors","Hepatoblastoma","Hepatocellular Carcinoma (HCC)","Fibrolamellar Carcinoma","Rhabdomyosarcoma"],"interventions":["Cobolimab","Dostarlimab"],"countries":["United States","Czechia","Denmark","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants","sourceUrl":"https://clinicaltrials.gov/study/NCT06521567"},{"nctId":"NCT06846437","title":"JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-13","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-24","conditions":["Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants"],"interventions":["JSKN003","Trastuzumab emtansine (T-DM1)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.","sourceUrl":"https://clinicaltrials.gov/study/NCT06846437"},{"nctId":"NCT06894511","title":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":7,"enrollmentType":"ACTUAL","startDate":"2025-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-15","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"interventions":["AAA617","ARPI: Abiraterone","ARPI: Enzalutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess safety of combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI and AAA617 alone in PSMA-positive mCRPC patients who were previously treated and progressed on ARPI in the biochemical recurrence (BCR)-non metastatic hormone sensitive prostate cancer (mHSPC), mHSPC, or non-metastatic Castration Resistant Prostate Cancer (nmCRPC) setting and have not previously received a taxane-containing regimen in the metastic castrate resistant prostate cancer (mCRPC) setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06894511"},{"nctId":"NCT05605535","title":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","sponsor":"CanariaBio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2023-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-15","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Ovarian Neoplasm Epithelial","Ovarian Cancer","Fallopian Tube Neoplasms","Peritoneal Carcinoma","Ovarian Serous Adenocarcinoma"],"interventions":["Oregovomab","Paclitaxel","Carboplatin","Placebo"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"A clinical study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05605535"},{"nctId":"NCT03533283","title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":211,"enrollmentType":"ACTUAL","startDate":"2018-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-16","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-16","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Non-Hodgkins Lymphoma"],"interventions":["Glofitamab","Atezolizumab","Obinutuzumab","Tocilizumab","Polatuzumab Vedotin","89Zr-Df-IAB22M2C"],"countries":["Belgium","Denmark","Israel","Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, single arm, multicenter, dose finding, Phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients. This study includes an additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin's lymphoma to image CD8+T-cells at baseline and after treatment with glofitamab, including pre-treatment with obinutuzumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT03533283"},{"nctId":"NCT07033585","title":"Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-28","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Type 2 Diabetes"],"interventions":["Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes","China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Use Dapagliflozin 10 mg, Saxagliptin 5 mg, Metformin 500 mg treat type 2 diabetes patients with controlled cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT07033585"},{"nctId":"NCT06399419","title":"CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer","sponsor":"Osel, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2024-06-19","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10-19","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-19","completionType":"ESTIMATED","lastUpdated":"2024-05-30","conditions":["Advanced Clear Cell Renal Cell Carcinoma","Advanced Renal Cell Carcinoma","Advanced Sarcomatoid Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"interventions":["Biospecimen Collection","Bone Scan","CBM588 Capsules","Computed Tomography","Ipilimumab","Magnetic Resonance Imaging","Nivolumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase I trial tests the safety, side effects, best dose, and effectiveness of CBM588 in combination with nivolumab and ipilimumab in treating patients with kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CBM588 is a live biotherapeutic that may help improve the effects of immunotherapy. Nivolumab and ipilimumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread by enhancing the ability of the body's immune cells to attack tumor cells. CBM588 in combination with nivolumab and ipilimumab may be safe, tolerable, and/or effective in treating patients with advan","sourceUrl":"https://clinicaltrials.gov/study/NCT06399419"},{"nctId":"NCT05875168","title":"First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":590,"enrollmentType":"ESTIMATED","startDate":"2023-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-15","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["DS-3939a"],"countries":["United States","Belgium","Canada","China","France","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05875168"},{"nctId":"NCT06049290","title":"A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":342,"enrollmentType":"ESTIMATED","startDate":"2023-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-20","completionType":"ESTIMATED","lastUpdated":"2025-12-04","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["LBL-034 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of LBL-034 in patients with Relapsed/Refractory Multiple Myeloma (R/R MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06049290"},{"nctId":"NCT06812260","title":"A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":26,"enrollmentType":"ESTIMATED","startDate":"2025-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["SCLC, Extensive Stage"],"interventions":["HLX10+chemo"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06812260"},{"nctId":"NCT07281326","title":"A Study of AK138D1 in Advanced Malignant Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2025-12-15","conditions":["Solid Cancer"],"interventions":["AK138D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I clinical trial testing the safety and effectiveness of AK138D1in patients with advanced cancer. The study will enroll up to 200 patients with various types of advanced solid tumors who haven't responded to standard treatments. Patients will receive AK138D1 to determine the safest dose and evaluate if the drug can help treat their cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07281326"},{"nctId":"NCT05464030","title":"Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":220,"enrollmentType":"ACTUAL","startDate":"2022-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-23","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-23","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Colorectal Cancer"],"interventions":["M9140","Bevacizumab","Capecitabine","5-fluorouracil (5-FU)","Folinic acid"],"countries":["United States","Canada","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this first in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. This study contains 2 parts: Dose escalation (Part 1) and dose expansion (Part 2) Study details include: * Study Duration per participant: Approximately 4 months for Part 1 and 8 months for Part 2 * M9140 is not available through an expanded access program","sourceUrl":"https://clinicaltrials.gov/study/NCT05464030"},{"nctId":"NCT06008093","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":103,"enrollmentType":"ACTUAL","startDate":"2024-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-23","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Durvalumab","Tremelimumab","Pemetrexed","Pembrolizumab","Carboplatin","Cisplatin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["RAS genotyping"],"summary":"The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.","sourceUrl":"https://clinicaltrials.gov/study/NCT06008093"},{"nctId":"NCT05775159","title":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":294,"enrollmentType":"ESTIMATED","startDate":"2023-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-28","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Hepatocellular Carcinoma","Biliary Tract Cancer"],"interventions":["Volrustomig","Bevacizumab","Lenvatinib","Rilvegostomig","Gemcitabine","Cisplatin"],"countries":["United States","China","Hong Kong","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":46,"serviceSignals":["Broad CGP"],"summary":"GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05775159"},{"nctId":"NCT05239728","title":"A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1800,"enrollmentType":"ESTIMATED","startDate":"2022-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-28","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Carcinoma, Renal Cell"],"interventions":["Belzutifan","Pembrolizumab","Placebo"],"countries":["United States","Australia","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Poland","Romania","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":285,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT05239728"},{"nctId":"NCT06617416","title":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2024-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["NSCLC (Non-small Cell Lung Cancer)"],"interventions":["Cadonilimab (AK104)","Sugemalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06617416"},{"nctId":"NCT04736706","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1653,"enrollmentType":"ESTIMATED","startDate":"2021-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-29","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-29","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Carcinoma, Renal Cell"],"interventions":["Pembrolizumab","Belzutifan","Pembrolizumab/Quavonlimab","Lenvatinib"],"countries":["United States","Australia","Brazil","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Finland","France","Germany","Guatemala","Hungary","Ireland","Italy","Japan","Malaysia","Mexico","Norway","Philippines","Poland","Romania","Russia","Serbia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":262,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT04736706"},{"nctId":"NCT06679036","title":"A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Advanced Unresectable or Metastatic Breast Cancer"],"interventions":["HRS-2189","Fluvustat","HRS-8080","HRS-6209","HRS-1358"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06679036"},{"nctId":"NCT03891953","title":"Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":98,"enrollmentType":"ACTUAL","startDate":"2019-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Carcinoma, Non-Small-Cell Lung","Melanoma","Nasopharyngeal Carcinoma","Microsatellite Stable Colorectal Cancer","Triple Negative Breast Cancer"],"interventions":["DKY709","PDR001"],"countries":["United States","Germany","Hong Kong","Japan","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["MSI / TMB"],"summary":"This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.","sourceUrl":"https://clinicaltrials.gov/study/NCT03891953"},{"nctId":"NCT07231458","title":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies","sponsor":"Abalos Therapeutics GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Advanced Solid Tumors"],"interventions":["ABX-001","Pembrolizumab"],"countries":["Germany","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/Ib first-in-human, open-label, non-randomized, multicenter, multi-country study to evaluate the safety and tolerability and to establish a recommended Phase 2 dose (RP2D) as well as assess preliminary clinical activity of ABX-001 administered intravenously (IV) alone (Part A) or co-administered with pembrolizumab (Part B) in participants with refractory/relapsed advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07231458"},{"nctId":"NCT07669467","title":"Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer","sponsor":"Natureceuticals Sdn Bhd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Fatigue Related to Cancer Treatment","Breast Cancer"],"interventions":["Nuvastatic 300","Placebo"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: * Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo? * Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: * Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each ","sourceUrl":"https://clinicaltrials.gov/study/NCT07669467"},{"nctId":"NCT05918133","title":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","sponsor":"Biotheus Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2022-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2025-03-11","conditions":["TNBC"],"interventions":["PM8002","nab-paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"Here, the investigators present the results from a Phase Ib/II study of PM8002 in combination with nab-paclitaxel in subjects with locally advanced or metastatic triple negative breast cancer without previous systematic treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05918133"},{"nctId":"NCT06302426","title":"Trial of INI-4001 in Patients With Advanced Solid Tumours","sponsor":"Inimmune Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Advanced Solid Tumor"],"interventions":["INI-4001","Nivolumab","Pembrolizumab","Cemiplimab","Avelumab","Atezolizumab","Durvalumab"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Phase 1 open-label, dose-escalation and dose-expansion study of INI-4001 as a single agent and in combination with approved checkpoint inhibitors in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06302426"},{"nctId":"NCT04851613","title":"Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer","sponsor":"Laekna Limited","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":256,"enrollmentType":"ESTIMATED","startDate":"2022-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Breast Cancer"],"interventions":["Afuresertib","Afuresertib/placebo"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":55,"serviceSignals":["HER2 profiling"],"summary":"Study LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrine therapy, and/or CDK4/6 inhibitor (up to 1 therapy), and/or chemotherapy (up to 1 chemotherapy) as described in the inclusion criteria.","sourceUrl":"https://clinicaltrials.gov/study/NCT04851613"},{"nctId":"NCT06906471","title":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","sponsor":"Antelope Surgical Solutions, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Prostate Cancer","Prostate Cancer (Adenocarcinoma)","Fluorescence Imaging"],"interventions":["AS1986NS"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS","sourceUrl":"https://clinicaltrials.gov/study/NCT06906471"},{"nctId":"NCT07101601","title":"Study of DM5167 in Patients With Advanced Solid Tumors","sponsor":"DIGMBIO","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2024-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Advanced Breast Cancer"],"interventions":["DM5167"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07101601"},{"nctId":"NCT05453903","title":"A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":196,"enrollmentType":"ACTUAL","startDate":"2022-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-03","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Leukemia, Myeloid, Acute"],"interventions":["Bleximenib","Venetoclax (VEN)","Azacitidine (AZA)","Cytarabine","Daunorubicin or Idarubicin"],"countries":["United States","Australia","Canada","France","Germany","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05453903"},{"nctId":"NCT06931626","title":"Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer","sponsor":"Nerviano Medical Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2025-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Small Cell Lung Cancer"],"interventions":["NMS-03305293","Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.","sourceUrl":"https://clinicaltrials.gov/study/NCT06931626"},{"nctId":"NCT06848699","title":"A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2025-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Solid Tumor Cancer","Non Small Cell Lung Cancer"],"interventions":["HLX43 dose 1","HLX43 dose 2","HLX43 dose 3","HLX43 dose 4","HLX43 dose 5","Serplulimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced/metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06848699"},{"nctId":"NCT06385925","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Malignant Neoplasm"],"interventions":["TSN1611"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":19,"serviceSignals":["RAS genotyping"],"summary":"The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06385925"},{"nctId":"NCT04041310","title":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","sponsor":"Nouscom SRL","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2019-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-30","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Solid Tumor, Adult"],"interventions":["GAd-209-FSP low dose","MVA-209-FSP low dose","GAd-209-FSP high dose","MVA-209-FSP high dose","GAd20-209-FSP, RP2D","MVA-209-FSP, RP2D","KEYTRUDA®"],"countries":["United States","Belgium","Canada","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":46,"serviceSignals":["MSI / TMB"],"summary":"Ref: Protocol Version 9.1 05 December 2024. NOUS-209-01 is a multicenter, open-label, multiple cohorts, clinical study, designed to evaluate safety, tolerability, and immunogenicity, and to detect any preliminary evidence of anti-tumor activity of Nous-209 genetic polyvalent vaccine plus pembrolizumab combination therapy in adult subjects with unresectable or metastatic deficient mismatch repair (dMMR) or MSI-H CRC, gastric, or gastro-esophageal junction (G-E junction) tumors. Nous-209 is based on a heterologous prime/boost regimen composed of the Great Ape Adenovirus GAd20-209-FSP used for priming and Modified Vaccinia virus Ankara MVA-209-FSP used for boosting. The Phase I portion of the s","sourceUrl":"https://clinicaltrials.gov/study/NCT04041310"},{"nctId":"NCT06222879","title":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2024-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2024-11-25","conditions":["Breast Cancer"],"interventions":["HRS-8080; SHR-A1811","HRS-8080; SHR-A2009","SHR-A2009; SHR-1316"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06222879"},{"nctId":"NCT05688475","title":"A Rollover Study of CC-122","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2023-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Non-Hodgkin Lymphoma"],"interventions":["CC-122","Dexamethasone"],"countries":["United States","France","Japan","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to provide CC-122 treatment to participants who have been receiving treatment in other CC-122 clinical trials investigating CC-122 for more than 5 years (CC-122-ST-001 \\[NCT01421524\\], CC-122-ST-002 \\[NCT02509039\\], CC-122-DBCL-001 \\[NCT02031419\\], and CC-122-NHL-001 \\[NCT02417285\\]), receiving clinical benefit from the treatment and to monitor the safety and tolerability of CC-122.","sourceUrl":"https://clinicaltrials.gov/study/NCT05688475"},{"nctId":"NCT06825624","title":"ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2024-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-13","conditions":["Metastatic Colorectal Cancer (CRC)"],"interventions":["HS-20093","Bevacizumab","5-FU","Leucovorin","Capecitabine","Oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and efficacy of HS-20093 in combination with other anti-cancer agents in patients with advanced metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06825624"},{"nctId":"NCT06463340","title":"Study of SGR-3515 In Participants With Advanced Solid Tumors.","sponsor":"Schrödinger, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2024-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Advanced Solid Tumor"],"interventions":["SGR-3515"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06463340"},{"nctId":"NCT04129502","title":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","sponsor":"Takeda","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":354,"enrollmentType":"ACTUAL","startDate":"2020-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["TAK-788","Pemetrexed","Cisplatin","Carboplatin"],"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Netherlands","Portugal","Russia","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":134,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group. Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuatio","sourceUrl":"https://clinicaltrials.gov/study/NCT04129502"},{"nctId":"NCT06769113","title":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2025-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-05","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Esophageal Cancer"],"interventions":["HLX43"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or Intolerance to Standard First-Line Therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06769113"},{"nctId":"NCT05303467","title":"A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM","sponsor":"Boston Scientific Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2022-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Glioblastoma Multiforme","Recurrent Glioblastoma"],"interventions":["TheraSphere GBM"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.","sourceUrl":"https://clinicaltrials.gov/study/NCT05303467"},{"nctId":"NCT05852691","title":"A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":83,"enrollmentType":"ACTUAL","startDate":"2023-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Breast Cancer"],"interventions":["Tobemstomig","Pembrolizumab","Nab-Paclitaxel"],"countries":["United States","Argentina","Australia","Brazil","Czechia","Germany","Hungary","Israel","Italy","Mexico","Peru","Poland","South Africa","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05852691"},{"nctId":"NCT06593522","title":"A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)","sponsor":"Amgen","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2024-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["MTAP-deleted NSCLC"],"interventions":["anvumetostat"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","Hong Kong","Japan","Latvia","Netherlands","Portugal","Singapore","South Korea","Switzerland","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":91,"serviceSignals":["Broad CGP"],"summary":"The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT06593522"},{"nctId":"NCT07669454","title":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","sponsor":"Natureceuticals Sdn Bhd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Fatigue Related to Cancer Treatment","Colon Cancer"],"interventions":["Nuvastatic 300","Placebo"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic 300 capsule significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic 300 capsule safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 capsule vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic 300 capsule or placebo capsules (3 times per day) for 6 cycles of 20 days each (total \\~120 treatment day","sourceUrl":"https://clinicaltrials.gov/study/NCT07669454"},{"nctId":"NCT04842617","title":"Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":5274,"enrollmentType":"ACTUAL","startDate":"2021-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-31","completionType":"ESTIMATED","lastUpdated":"2024-08-01","conditions":["Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer"],"interventions":["SHR6390","placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is to evaluate the efficacy and safety of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative. To observe the PK characteristics of SHR6390 combined with endocrine therapy for the adjuvant treatment of hormone receptor positive,Human Epidermal Receptor 2 negative.","sourceUrl":"https://clinicaltrials.gov/study/NCT04842617"},{"nctId":"NCT06635447","title":"Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":258,"enrollmentType":"ACTUAL","startDate":"2024-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-10","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Breast Cancer"],"interventions":["Capivasertib","Fulvestrant"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":75,"serviceSignals":["HER2 profiling"],"summary":"This is a multi-center, two-cohorts, phase IIIb study of Capivasertib+Fulvestrant in HR+/HER2-ABC who had disease recurrence/progression following 1-2L endocrine therapy. The Primary objective is to assess the efficacy of capi+ful by assessment of TFST (Time to first subsequent treatment) of PIK3CA/AKT1/PTEN-altered subgroup in cohort1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06635447"},{"nctId":"NCT06360354","title":"A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ACTUAL","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers"],"interventions":["Anvumetostat","Gemcitabine","Nab-paclitaxel","Modified FOLFIRINOX","RMC-6236"],"countries":["United States","Australia","Belgium","Canada","China","Denmark","France","Germany","Greece","Hong Kong","Italy","Japan","Netherlands","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":77,"serviceSignals":["Broad CGP"],"summary":"The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT06360354"},{"nctId":"NCT06742892","title":"A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-05","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Carcinoma, Hepatocellular"],"interventions":["HLX43 DOSE 1","HLX43 DOSE 2","HLX43 DOSE 3"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT06742892"},{"nctId":"NCT05683717","title":"A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies","sponsor":"TransThera Sciences (Nanjing), Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2023-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2023-11-21","conditions":["B-Cell Malignancies"],"interventions":["TT-01488 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05683717"},{"nctId":"NCT06083207","title":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2024-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2024-12-13","conditions":["Multiple Myeloma"],"interventions":["IBI3003"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23\\~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06083207"},{"nctId":"NCT06524375","title":"A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period","sponsor":"Genentech, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":118,"enrollmentType":"ACTUAL","startDate":"2024-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Venetoclax","cBTKi Monotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \\[uMRD \\< or 10\\^-4 in peripheral blood (PB)\\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.","sourceUrl":"https://clinicaltrials.gov/study/NCT06524375"},{"nctId":"NCT06333951","title":"Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":49,"enrollmentType":"ACTUAL","startDate":"2024-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Thoracic Tumors","Non-small Cell Lung Cancer"],"interventions":["Anvumetostat","Carboplatin","Paclitaxel","Pembrolizumab","Pemetrexed","Sotorasib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Greece","Hong Kong","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":83,"serviceSignals":["Broad CGP"],"summary":"The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06333951"},{"nctId":"NCT06614686","title":"U87 CAR-T in Patients With Advanced Head and Neck Tumors","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-09-20","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-26","conditions":["Nasopharynx Cancer","Head and Neck Cancer"],"interventions":["U87 autologous CAR T-cell"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U87 injection solution in patients with advanced malignant head and neck tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06614686"},{"nctId":"NCT04336241","title":"Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors","sponsor":"Replimune, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2019-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Cancer"],"interventions":["RP2","nivolumab"],"countries":["Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04336241"},{"nctId":"NCT05405595","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Adagene Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2022-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["ADG126","Pembrolizumab (KEYTRUDA®)","Standard of Care (Trifluridine/Tipiracil-Bevacizumab)","Standard of care (Fruquintinib)"],"countries":["United States","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b/2, open-label, dose escalation, dose expansion and dose optimization study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors. The study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).","sourceUrl":"https://clinicaltrials.gov/study/NCT05405595"},{"nctId":"NCT03178552","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Hoffmann-La Roche","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2017-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Alectinib","Atezolizumab","Pemetrexed","Cisplatin","Carboplatin","Gemcitabine","Entrectinib","Cobimetinib","Vemurafenib","Bevacizumab","Divarasib","Docetaxel"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","New Zealand","Panama","Peru","Poland","Russia","Serbia","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":164,"serviceSignals":["ctDNA / MRD","MSI / TMB"],"summary":"This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by a blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assay.","sourceUrl":"https://clinicaltrials.gov/study/NCT03178552"},{"nctId":"NCT07185880","title":"A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients","sponsor":"Myosin Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-02","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Glioblastoma (GBM)"],"interventions":["MT-125"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with your standard of care treatment. Initially, participants with newly diagnosed glioblastoma will be given different doses of MT-125 in combination with radiotherapy (RT) with the goal of identifying the highest tolerated dose. Up to 36 people with glioblastoma who are at least18 years old are being invited to join this study. MT-125 is a type of study treatment which acts on cancer cells in the brain to destroy them. It will be administered on the same day as your standa","sourceUrl":"https://clinicaltrials.gov/study/NCT07185880"},{"nctId":"NCT07110883","title":"A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2024-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2025-08-08","conditions":["Advanced Solid Tumor"],"interventions":["SYS6023"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07110883"},{"nctId":"NCT06574347","title":"Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-05-21","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["Vebreltinib","Osimertinib","PLB1004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06574347"},{"nctId":"NCT02716116","title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","sponsor":"Takeda","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":334,"enrollmentType":"ESTIMATED","startDate":"2016-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["TAK-788"],"countries":["United States","China","Germany","Italy","Japan","Puerto Rico","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":62,"serviceSignals":["HER2 profiling"],"summary":"This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determi","sourceUrl":"https://clinicaltrials.gov/study/NCT02716116"},{"nctId":"NCT07209813","title":"GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma","sponsor":"Beijing Gene Key Life Technology Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-10-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2025-10-07","conditions":["Hepatocellular Carcinoma"],"interventions":["GKL-006"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, open-label, randomized, multicenter study to evaluate the efficacy and safety of GKL-006 combine with TACE in adult patients with unresectable Hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07209813"},{"nctId":"NCT06594874","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2024-10-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Non-Small Cell Lung Cancer","Advanced Solid Tumors"],"interventions":["HS-10370","Adebrelimab","Cisplatin","Carboplatin","Pemetrexed"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) .","sourceUrl":"https://clinicaltrials.gov/study/NCT06594874"},{"nctId":"NCT05805501","title":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":199,"enrollmentType":"ACTUAL","startDate":"2023-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Renal Cell Carcinoma"],"interventions":["Tobemstomig","Tiragolumab","Pembrolizumab","Axitinib"],"countries":["United States","Australia","China","France","Germany","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05805501"},{"nctId":"NCT06961786","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma","sponsor":"TILT Biotherapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2025-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Metastatic Melanoma"],"interventions":["TILT-123","TIL","Cyclophosphamide","Fludarabine"],"countries":["Denmark"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06961786"},{"nctId":"NCT06015048","title":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":364,"enrollmentType":"ESTIMATED","startDate":"2023-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-29","completionType":"ESTIMATED","lastUpdated":"2024-08-05","conditions":["HER2-expressing Advanced Solid Tumors"],"interventions":["SHR-A1811 combined with Pyrotinib.","SHR-A1811 combined with other antitumor therapies"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06015048"},{"nctId":"NCT07292038","title":"Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors","sponsor":"NucMito Pharmaceuticals Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Cancers"],"interventions":["NM6603"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07292038"},{"nctId":"NCT05596409","title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2023-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Metastatic Breast Cancer"],"interventions":["Elacestrant"],"countries":["United States","Brazil","Bulgaria","Georgia","Mexico","Romania"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT05596409"},{"nctId":"NCT06410131","title":"Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16","sponsor":"Sound Biopharmaceuticals Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2025-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["Solid Tumors"],"interventions":["FTL008.16"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open, multi-center, multi-cohort phase I clinical study designed to evaluate safety, tolerability, pharmacokinetics and initial efficacy of FTL008.16 in patients with advanced and metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06410131"},{"nctId":"NCT06823609","title":"Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Advanced Malignant Tumor"],"interventions":["QLS1304 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06823609"},{"nctId":"NCT06120075","title":"A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":91,"enrollmentType":"ESTIMATED","startDate":"2024-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Advanced Cancer"],"interventions":["AB801","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a recommended AB801 dose for expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06120075"},{"nctId":"NCT07002034","title":"RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses","sponsor":"Reunion Neuroscience Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Adjustment Disorder"],"interventions":["RE104 for Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT07002034"},{"nctId":"NCT05362773","title":"A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies","sponsor":"MacroGenics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2022-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Leukemia, Acute Myeloid","Myelodysplastic Syndromes","Classical Hodgkin Lymphoma","Leukemia, B-cell","Leukemia, Hairy Cell","Mastocytosis, Aggressive Systemic","Blastic Plasmacytoid Dendritic Cell Neoplasm","Chronic Myeloid Leukemia"],"interventions":["MGD024"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have relapsed after treatment. The study is designed to determine the safety, tolerability, pharmacokinetics (affect of the body on the drug), pharmacodynamic (affect of the drug on the body), immunogenicity (development of antibodies against the drug), and preliminary anti-cancer effect of MGD024. Participants will receive treatment with MGD024 in consecutive 28-day cycles for a study treatment period of up to 12 cycles (approximately 1 year) or until treatment or study discontinuation criteria are","sourceUrl":"https://clinicaltrials.gov/study/NCT05362773"},{"nctId":"NCT05006716","title":"A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies","sponsor":"BeOne Medicines","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":645,"enrollmentType":"ESTIMATED","startDate":"2021-09-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["B-cell Malignancy","Marginal Zone Lymphoma","Follicular Lymphoma","Non-Hodgkin Lymphoma","Waldenström Macroglobulinemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma"],"interventions":["BGB-16673"],"countries":["United States","Australia","Brazil","Canada","China","France","Georgia","Germany","Italy","Japan","Moldova","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":114,"serviceSignals":["Hematology NGS"],"summary":"Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)","sourceUrl":"https://clinicaltrials.gov/study/NCT05006716"},{"nctId":"NCT04895436","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2022-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Chronic Lymphocytic Leukemia (CLL)"],"interventions":["Venetoclax","Obinutuzumab"],"countries":["United States","Australia","Austria","Brazil","Bulgaria","Germany","Israel","Italy","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["Hematology NGS"],"summary":"Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous treatment in first-line. Approximately 75 adult participants with CLL who have been treated with venetocl","sourceUrl":"https://clinicaltrials.gov/study/NCT04895436"},{"nctId":"NCT07104643","title":"Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）","sponsor":"TYK Medicines, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-08-05","conditions":["mCRPC"],"interventions":["TYK-00540","Enzalutamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07104643"},{"nctId":"NCT06637501","title":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","sponsor":"BeOne Medicines","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2024-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Sonrotoclax","Zanubrutinib"],"countries":["United States","Brazil","China","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.","sourceUrl":"https://clinicaltrials.gov/study/NCT06637501"},{"nctId":"NCT06649656","title":"A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-11","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-10-21","conditions":["Advanced Cancers"],"interventions":["TQB2252 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06649656"},{"nctId":"NCT06111235","title":"A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT","sponsor":"CG Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":367,"enrollmentType":"ACTUAL","startDate":"2023-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Non Muscle Invasive Bladder Cancer","Urologic Cancer","Bladder Cancer","Urothelial Carcinoma"],"interventions":["Cretostimogene Grenadenorepvec","n-dodecyl-B-D-maltoside"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":95,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06111235"},{"nctId":"NCT06234605","title":"A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma","sponsor":"HiberCell, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Renal Cell Carcinoma"],"interventions":["HC-7366","Belzutifan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastat","sourceUrl":"https://clinicaltrials.gov/study/NCT06234605"},{"nctId":"NCT05822752","title":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ACTUAL","startDate":"2023-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Hepatocellular Carcinoma"],"interventions":["Budigalimab","Livmoniplimab","Lenvatinib","Sorafenib"],"countries":["United States","France","Italy","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), lenvatinib, or sorafenib. Approximately ","sourceUrl":"https://clinicaltrials.gov/study/NCT05822752"},{"nctId":"NCT05532696","title":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","sponsor":"Anbogen Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":61,"enrollmentType":"ESTIMATED","startDate":"2022-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2024-06-24","conditions":["Advanced Solid Tumor","Non Small Cell Lung Cancer","HER2 Mutations"],"interventions":["ABT-101"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["HER2 profiling"],"summary":"A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT05532696"},{"nctId":"NCT07527221","title":"Safety and Tolerability of ZE74-0282 in Healthy Volunteers","sponsor":"Eilean Therapeutics AU Pty Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":64,"enrollmentType":"ESTIMATED","startDate":"2026-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Healthy Volunteers"],"interventions":["ZE74-0282-0001 or placebo"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This first-in-human, randomized, double-blind, placebo-controlled Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of single, split, and multiple oral doses of ZE74-0282 under fasted or fed conditions in healthy adult volunteers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07527221"},{"nctId":"NCT03850574","title":"Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Aptose Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2019-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-08-26","conditions":["Leukemia, Myeloid, Acute","Refractory AML","Relapsed Adult AML","Myelodysplastic Syndrome With Excess Blasts-2","Chronic Myelomonocytic Leukemia"],"interventions":["Tuspetinib","Venetoclax Oral Tablet","Azacitidine for Intravenous Infusion"],"countries":["United States","Australia","Germany","New Zealand","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML) that is relapsed or refractory after at least one line of prior therapy, or in study participants with newly diagnosed AML. Tuspetinib will be administered as a single agent or in combination with other drugs (venetoclax or venetoclax plus azacitidine), as specified for each part of the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT03850574"},{"nctId":"NCT05456685","title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2022-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-10-28","conditions":["High Grade Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer"],"interventions":["Mirvetuximab soravtansine","Carboplatin"],"countries":["United States","Belgium","Canada","Georgia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":69,"serviceSignals":["ADC biomarker"],"summary":"IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 prior line of platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05456685"},{"nctId":"NCT06107686","title":"A Study of YL202 in Selected Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2025-11-26","conditions":["NSCLC","Breast Cancer","HNSCC","Locally Advanced or Metastatic Solid Tumors"],"interventions":["YL202 should be intravenously infused"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":82,"serviceSignals":["ADC biomarker"],"summary":"This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06107686"},{"nctId":"NCT06448312","title":"A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":406,"enrollmentType":"ESTIMATED","startDate":"2024-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SKB264","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":64,"serviceSignals":["Broad CGP"],"summary":"The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06448312"},{"nctId":"NCT06674265","title":"Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma","sponsor":"Marzieh Ebrahimi","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2024-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-04-09","conditions":["Neuroblastoma, Recurrent, Refractory","Neuroblastoma (NB)","Neuroblastoma in Children"],"interventions":["Allogenic NK cells infusion"],"countries":["Iran"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma. Is the injection of allogenic nk cells safe in patients with R/R high-risk neuroblastoma? Is the injection of allogenic nk cells effective in patients with R/R high-risk neuroblastoma? We will compare the NK cell administration group with a control group that receives conventional treatment to determine whether the intervention is safe and effective","sourceUrl":"https://clinicaltrials.gov/study/NCT06674265"},{"nctId":"NCT07336732","title":"Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["PLB1004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, randomized, multicenter phase II/III clinical trial designed to evaluate the efficacy, safety, and tolerability of Andamertinib with or without platinum-based chemothsrapy versus platinum-based chemotherapy in previously untreated participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR atypical mutations. The study comprises two stages: phase II (dose-exploration stage) and phase III (pivotal study stage)","sourceUrl":"https://clinicaltrials.gov/study/NCT07336732"},{"nctId":"NCT05050942","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","sponsor":"Camurus AB","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":332,"enrollmentType":"ACTUAL","startDate":"2021-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"interventions":["CAM2029","Octreotide LAR","Lanreotide ATG"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Hungary","Israel","Italy","Netherlands","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":86,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.","sourceUrl":"https://clinicaltrials.gov/study/NCT05050942"},{"nctId":"NCT05607004","title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","sponsor":"Atossa Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2023-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Breast Neoplasms","Invasive Breast Cancer","Estrogen-receptor-positive Breast Cancer","HER2-negative Breast Cancer"],"interventions":["(Z)-endoxifen","goserelin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["HER2 profiling"],"summary":"This open-label research study is studying (Z)-endoxifen as a possible treatment for pre-menopausal women with ER+/HER2- breast cancer. (Z)-endoxifen belongs to a group of drugs called selective estrogen receptor modulators or \"SERM\", which help block estrogen from attaching to cancer cells. This study has two parts: a pharmacokinetic part and a treatment part. The PK part (how the body processes the drug) will enroll about 18 participants. All participants will take (Z)-endoxifen capsules daily. Twelve participants will be randomly assigned (50/50 chance) to take (Z)-endoxifen alone or (Z)-endoxifen with a monthly injection of goserelin a drug that temporarily stops the ovaries from making ","sourceUrl":"https://clinicaltrials.gov/study/NCT05607004"},{"nctId":"NCT04973605","title":"A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma","sponsor":"BeOne Medicines","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":246,"enrollmentType":"ESTIMATED","startDate":"2021-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["Sonrotoclax","Dexamethasone","Carfilzomib","Daratumumab","Pomalidomide"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Greece","Italy","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":83,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT04973605"},{"nctId":"NCT06829823","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-11","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2025-10-16","conditions":["Non-muscle Invasive Bladder Cancer (NMIBC)"],"interventions":["N-803 and BCG","N-803 and Gemcitabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, phase 2, randomized study of intravesical N-803 plus BCG (experimental arm A) and intravesical N-803 plus gemcitabine (experimental arm B) in participants who have intermediate-risk Ta/T1 papillary disease. The primary objective of this study is to evaluate the efficacy of these experimental therapies without the need for surgical intervention by CR rate at month 3 or month 6 (for re-inducted participants).","sourceUrl":"https://clinicaltrials.gov/study/NCT06829823"},{"nctId":"NCT03736889","title":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","sponsor":"BeiGene","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2018-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["MSI-H/dMMR Solid Tumors"],"interventions":["Tislelizumab (BGB-A317)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":30,"serviceSignals":["MSI / TMB"],"summary":"In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).","sourceUrl":"https://clinicaltrials.gov/study/NCT03736889"},{"nctId":"NCT05879744","title":"A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)","sponsor":"Cullinan Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2024-05-02","conditions":["NHL","NHL, Relapsed, Adult"],"interventions":["CLN-978"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05879744"},{"nctId":"NCT04999384","title":"First in Human, Dose Escalation Study of AN4005","sponsor":"Adlai Nortye Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2021-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Advanced Solid Tumor","Advanced Lymphoma"],"interventions":["AN4005-dose level 0","AN4005-dose level 1","AN4005-dose level 2","AN4005-dose level 3","AN4005-dose level 4","AN4005-food effect"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional \"3 + 3 design\" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.","sourceUrl":"https://clinicaltrials.gov/study/NCT04999384"},{"nctId":"NCT06106308","title":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation","sponsor":"Cardiff Oncology","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ACTUAL","startDate":"2024-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Metastatic Colorectal Cancer","CRC","KRAS/NRAS Mutation"],"interventions":["Onvansertib","FOLFIRI","Bevacizumab","FOLFOX"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06106308"},{"nctId":"NCT06837896","title":"Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-02","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-02-20","conditions":["Prostate Cancer"],"interventions":["QLG1080"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06837896"},{"nctId":"NCT06366490","title":"Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer","sponsor":"PhotonPharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2026-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Ovarian Cancer","Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer"],"interventions":["Innocell Autologous Cellular Immunotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06366490"},{"nctId":"NCT05544552","title":"Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations","sponsor":"Tyra Biosciences, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2022-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Solid Tumor","Urothelial Carcinoma","Solid Tumor, Adult","Bladder Cancer","Non-muscle-invasive Bladder Cancer","FGFR3 Gene Mutation","FGFR3 Gene Alteration","Advanced Solid Tumor","Advanced Urothelial Carcinoma","Urinary Tract Cancer","Urinary Tract Tumor","Urinary Tract Carcinoma"],"interventions":["TYRA-300"],"countries":["United States","Australia","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05544552"},{"nctId":"NCT06767813","title":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2025-09-19","conditions":["Pancreatic Neoplasms"],"interventions":["TQB2868 injection","Gemcitabine injection","Albumin paclitaxel injection","Anlotinib capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of TQB2868 injection combined with anlotinib capsule and chemotherapy in treated patients with Pancreatic Neoplasms","sourceUrl":"https://clinicaltrials.gov/study/NCT06767813"},{"nctId":"NCT04486378","title":"A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer","sponsor":"BioNTech SE","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":327,"enrollmentType":"ESTIMATED","startDate":"2021-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Colorectal Cancer Stage II","Colorectal Cancer Stage III"],"interventions":["RO7198457 intravenous (IV)","Observational group (no intervention)"],"countries":["United States","Belgium","Canada","Germany","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":86,"serviceSignals":["ctDNA / MRD"],"summary":"This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04486378"},{"nctId":"NCT06737731","title":"A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Malignant Solid Tumors"],"interventions":["SHR-1681"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06737731"},{"nctId":"NCT06668961","title":"A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["SI-B001","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a open, multi-center phase II clinical study to explore the efficacy, safety and pharmacokinetic/pharmacodynamic characteristics of SI-B001+SI-B003 combined with platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06668961"},{"nctId":"NCT06118333","title":"A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":386,"enrollmentType":"ACTUAL","startDate":"2023-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Nasopharyngeal Carcinoma"],"interventions":["BL-B01D1","capecitabine","gemcitabine","docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based chemotherapy after receiving PD-1/PD-L1 monoclonal antibody as the last line of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06118333"},{"nctId":"NCT06723236","title":"A Study of MGC028 in Participants With Advanced Solid Tumors","sponsor":"MacroGenics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2025-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Advanced Solid Tumors","NSCLC Adenocarcinoma","Cholangiocarcinoma","Pancreatic Carcinoma","Colorectal Carcinoma"],"interventions":["MGC028"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors? Participants will * Undergo screening procedures to determine eligibility * Rece","sourceUrl":"https://clinicaltrials.gov/study/NCT06723236"},{"nctId":"NCT05187832","title":"A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer","sponsor":"Kind Pharmaceuticals LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":61,"enrollmentType":"ESTIMATED","startDate":"2022-10-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced or Metastatic Breast Cancer"],"interventions":["AND019 PO QD"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a first in human dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of AND019 in postmenopausal women with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \\[HER2\\]-negative) breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05187832"},{"nctId":"NCT05584800","title":"Study of ZGGS18 in Patients With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":222,"enrollmentType":"ESTIMATED","startDate":"2022-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-01","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Advanced Solid Tumor"],"interventions":["ZGGS18 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05584800"},{"nctId":"NCT06614751","title":"A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway","sponsor":"Danatlas Pharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2024-11-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2024-09-27","conditions":["Solid Cancers","BRCA Mutation","HRD Cancer","Breast Cancer","Prostate Cancer","Colorectal Cancer","Pancreatic Cancer","Endometrial Cancer","Gastric Cancer","Advanced Cancer","Metastatic Solid Tumors"],"interventions":["DAT-2645 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HRD / HRR"],"summary":"The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function alterations and/or other defects in the DNA damage repair (DDR) pathway.","sourceUrl":"https://clinicaltrials.gov/study/NCT06614751"},{"nctId":"NCT04866134","title":"A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Erasca, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2021-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["ERAS-007","ERAS-601"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"* To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. * To determine the optimal dose and schedule of ERAS-007 monotherapy. * To evaluate antitumor activity of ERAS-007 in various solid tumors. * To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. * To determine the Maximum Tolerated Dose (MTD) and/or Recom","sourceUrl":"https://clinicaltrials.gov/study/NCT04866134"},{"nctId":"NCT06375187","title":"A Study of GC203 TIL in Advanced Malignant Solid Tumors","sponsor":"Shanghai Juncell Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Solid Tumor","Gynecologic Cancer","Breast Cancer","Gastrointestinal Cancer","Lung Cancer"],"interventions":["Engineering Tumor Infiltrating Lymphocytes"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06375187"},{"nctId":"NCT06603844","title":"First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.","sponsor":"Corbus Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2024-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2025-06-03","conditions":["Solid Tumor"],"interventions":["CRB-601 monoclonal antibody","Anti-PD-1 monoclonal antibody"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expressed by some cancers and not others. This study will focus on tumor types which are know to highly or moderately express this protein. Researchers will evaluate the side effects caused by treatment, levels of CRB-601 in the blood, and the effect on the participant cancer. This will help researchers understand the right dose of CRB-601 to use for treatment and whether it is an effective treatment to","sourceUrl":"https://clinicaltrials.gov/study/NCT06603844"},{"nctId":"NCT05723562","title":"A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2023-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-11","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Neoplasms, Rectal"],"interventions":["Dostarlimab"],"countries":["United States","Canada","France","Germany","Italy","Japan","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical response (cCR) following dostarlimab treatment will undergo non-operative management (NOM), including close surveillance for recurrent disease. The goal of the study is to determine if Dostarlimab therapy alone is an effective treatment that can allow participants to avoid chemotherapy, radiation, and surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT05723562"},{"nctId":"NCT06190951","title":"A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":151,"enrollmentType":"ACTUAL","startDate":"2024-09-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-09","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Melanoma"],"interventions":["cemiplimab","Fixed Dose Combination (FDC) cemiplimab+fianlimab","Placebo"],"countries":["United States","Australia","Austria","Canada","France","Germany","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":104,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a \"study drug\" or called \"study drugs\" when combined) compared with cemiplimab alone. These types of immunotherapy study drugs are collectively known as immune checkpoint inhibitors. Immunotherapies are treatments that use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to cemiplimab in participants with high-r","sourceUrl":"https://clinicaltrials.gov/study/NCT06190951"},{"nctId":"NCT04509700","title":"Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)","sponsor":"Incyte Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":112,"enrollmentType":"ACTUAL","startDate":"2020-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-05","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["B-Cell Malignancies"],"interventions":["Parsaclisib","parsaclisib + itacitinib","parsaclisib + ruxolitinib","parsaclisib + ibrutinib"],"countries":["United States","Austria","Belgium","Czechia","Denmark","France","Hungary","Israel","Italy","Japan","Norway","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":105,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of parsaclisib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04509700"},{"nctId":"NCT06929663","title":"A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-05","completionType":"ESTIMATED","lastUpdated":"2025-07-17","conditions":["Advanced Solid Tumors"],"interventions":["AK146D1 for injection"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06929663"},{"nctId":"NCT07275073","title":"JMT106 Injection in the Treatment of Advanced Solid Tumors","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-15","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Advanced Solid Tumor","Lung Squamous Cell Carcinoma","Hepatocellular Carcinoma"],"interventions":["JMT106 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07275073"},{"nctId":"NCT07067567","title":"A Study of AK146D1 for Injection in Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-05","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Advanced Solid Tumors"],"interventions":["AK146D1 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07067567"},{"nctId":"NCT03407144","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2018-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-06","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-06","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Hodgkin Lymphoma"],"interventions":["pembrolizumab","doxorubicin","vinblastine","dacarbazine","cyclophosphamide","vincristine","prednisone/prednisolone","bleomycin","etoposide","Radiotherapy (RT)"],"countries":["United States","Brazil","Colombia","Czechia","France","Germany","Greece","Guatemala","Italy","Mexico","Netherlands","Slovakia","South Africa","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":93,"serviceSignals":["Hematology NGS"],"summary":"This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03407144"},{"nctId":"NCT05565378","title":"A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":351,"enrollmentType":"ACTUAL","startDate":"2022-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-06","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Lung Cancer, Non-Small Cell"],"interventions":["Pembrolizumab","Dostarlimab","Belrestotug","Nelistotug"],"countries":["United States","Argentina","Belgium","Brazil","Finland","France","Germany","Greece","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","South Africa","South Korea","Spain","Thailand","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":99,"serviceSignals":["Broad CGP"],"summary":"This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \\[TC\\]/ Tumor proportion score \\[TPS\\] \\>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.","sourceUrl":"https://clinicaltrials.gov/study/NCT05565378"},{"nctId":"NCT07231120","title":"A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia","sponsor":"Jiangsu Nutai Biologics Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2025-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-12-08","conditions":["Cachexia-Anorexia Syndrome","Solid Tumor Malignancies"],"interventions":["SXRN Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of SXRN Injection in cancer patients with anorexia-cachexia. Phase Ia employs a single-arm, open-label, dose-escalation design. Phase Ib, an extension of the study, utilizes a design of combination therapy with standard anti-tumor therapy for cancers including but not limited to pancreatic cancer, non-small cell lung cancer (NSCLC), and colon cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07231120"},{"nctId":"NCT06376136","title":"A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors","sponsor":"Bio-Thera Solutions","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2024-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-09","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-09","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Advanced Solid Tumors"],"interventions":["BAT8010 for Injection","BAT1006 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open, exploratory Phase Ib/IIa clinical trial in humans The combination of BAT8010 and BAT1006 was administered in patients with locally advanced or metastatic solid tumors(HER-2 expression, including IHC3+, IHC2+/FISH+, and IHC2+/FISH- patients)Tolerance and PK characteristics, to explore the maximum tolerated dose (MTD) and provide recommendations for subsequent clinical studies Recommended dose (RP2D) and rational administration regimen, and preliminary evaluation of antitumor efficacy. There are two main studies In the first stage, the \"3+3\" dose escalation rule is proposed to explore the safety and tolerance of the drug Sex; The second stage selects the appr","sourceUrl":"https://clinicaltrials.gov/study/NCT06376136"},{"nctId":"NCT04784715","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1157,"enrollmentType":"ACTUAL","startDate":"2021-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Breast Cancer; HER2-positive; Metastatic"],"interventions":["Trastuzumab deruxtecan","Placebo","Taxane","Pertuzumab","Trastuzumab"],"countries":["United States","Argentina","Belgium","Brazil","Canada","China","Denmark","France","Germany","Hungary","India","Israel","Italy","Japan","Mexico","Peru","Philippines","Romania","Russia","Saudi Arabia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":283,"serviceSignals":["HER2 profiling"],"summary":"The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment in the metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT04784715"},{"nctId":"NCT06157151","title":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","sponsor":"Precigen, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-11","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-30","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Cervical Cancer","HPV-Related Carcinoma","HPV-Related Malignancy","Recurrent Cervical Carcinoma","Metastatic Cervical Cancer"],"interventions":["PRGN-2009 plus Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06157151"},{"nctId":"NCT07343960","title":"A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-11","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Moderate Hepatic Impairment"],"interventions":["Capivasertib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).","sourceUrl":"https://clinicaltrials.gov/study/NCT07343960"},{"nctId":"NCT06671548","title":"Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-07","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Heavy Menstrual Bleeding","Uterine Fibroids"],"interventions":["Relugolix","Relugolix placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\\[s\\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids","sourceUrl":"https://clinicaltrials.gov/study/NCT06671548"},{"nctId":"NCT07713290","title":"A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"Beijing Gene Key Life Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6,"enrollmentType":"ACTUAL","startDate":"2025-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Hepatocellular Carcinoma (HCC)","Unresectable Hepatocellular Cancer"],"interventions":["GKL-006 Injection","Transarterial chemoembolization (TACE)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b study of GKL-006 Injection in patients with unresectable hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07713290"},{"nctId":"NCT05646862","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2023-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Breast Cancer"],"interventions":["Inavolisib","Fulvestrant","Alpelisib","Bupropion","Omeprazole","Midazolam"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Italy","Mexico","New Zealand","Poland","South Africa","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":145,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy. Enrollment for the main study is now complete.","sourceUrl":"https://clinicaltrials.gov/study/NCT05646862"},{"nctId":"NCT06137118","title":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":236,"enrollmentType":"ESTIMATED","startDate":"2023-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-29","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["B-cell Acute Lymphoblastic Leukemia (B-ALL)"],"interventions":["AZD0486"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":80,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)","sourceUrl":"https://clinicaltrials.gov/study/NCT06137118"},{"nctId":"NCT06682611","title":"Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-13","completionType":"ESTIMATED","lastUpdated":"2024-11-12","conditions":["Unresectable Locally Advanced or Metastatic Solid Tumors"],"interventions":["SYHA1813","SG001","HB1801","Carboplatin","Cisplatin","Paclitaxel","Etoposide","Everolimus","Regorafenib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center, multi-cohort, phase Ib/II clinical trial, divided into 8 cohorts according to tumor types. Cohorts 1-4 are SYHA1813 combined with different regimens, including safety run-in stage and cohort expansion stage. Cohorts 5-8 are SYHA1813 monotherapy and only include the expansion cohorts. The primary objective was to evaluate the safety and efficacy of SYHA1813 single agent or in combination with different regimens in unresectable locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06682611"},{"nctId":"NCT04626635","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":548,"enrollmentType":"ACTUAL","startDate":"2020-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-05","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced Solid Tumors"],"interventions":["REGN7075","Cemiplimab","Platinum-based doublet chemotherapy","Bevacizumab","Trifluridine-tipiracil"],"countries":["United States","France","Israel","Netherlands","Poland","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at tre","sourceUrl":"https://clinicaltrials.gov/study/NCT04626635"},{"nctId":"NCT06733441","title":"A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma","sponsor":"Treeline Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-15","completionType":"ESTIMATED","lastUpdated":"2025-10-10","conditions":["Lymphoma"],"interventions":["TLN-254"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06733441"},{"nctId":"NCT06055959","title":"A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2024-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-16","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-25","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Generalized Myasthenia Gravis"],"interventions":["Zilucoplan"],"countries":["United States","Italy","Poland","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT06055959"},{"nctId":"NCT06219941","title":"AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":226,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-17","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-28","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer","Biliary Tract Cancer","Pancreatic Ductal Adenocarcinoma"],"interventions":["AZD0901","5-Fluorouracil","Leucovorin","l-leucovorin","Irinotecan","Nanoliposomal Irinotecan","Gemcitabine"],"countries":["United States","Australia","Canada","China","Georgia","Japan","Malaysia","Moldova","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.","sourceUrl":"https://clinicaltrials.gov/study/NCT06219941"},{"nctId":"NCT05987956","title":"Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["ALK-Positive Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["Alectinib - Usual","Alectinib - Study"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["RNA fusion"],"summary":"Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.","sourceUrl":"https://clinicaltrials.gov/study/NCT05987956"},{"nctId":"NCT04690595","title":"BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL","sponsor":"PeproMene Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2021-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-18","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia"],"interventions":["BAFFR-CAR T cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","sourceUrl":"https://clinicaltrials.gov/study/NCT04690595"},{"nctId":"NCT03348670","title":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2023-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Prostate Cancer"],"interventions":["Abiraterone - Usual","Abiraterone - Study"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The usual approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, it will try to look for the relationship between the Abiraterone therapeutic efficacy and the CYP17 SNP Genotyping, and the relationship between the Abiraterone therapeutic safety and the SULT2A1 SNP Genotyping, based on Oxford precisely sequencing drug targets' genes. The study approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on China Import - abiraterone acetate tablet plus prednisone tablet plus BICALUTAMIDE table","sourceUrl":"https://clinicaltrials.gov/study/NCT03348670"},{"nctId":"NCT06693336","title":"An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer","sponsor":"ToLymph Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2024-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)"],"interventions":["SMS001"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06693336"},{"nctId":"NCT01064466","title":"Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Small Cell Lung Cancer"],"interventions":["ETOPOSIDE - Usual","ETOPOSIDE - Study"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Explore the relationship between drug target topoisomerase II gene single nucleotide polymorphisms and Etoposide (VP-16) therapeutic-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and Etoposide (VP-16) side-effects in patients with small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.","sourceUrl":"https://clinicaltrials.gov/study/NCT01064466"},{"nctId":"NCT05646836","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-18","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Multiple Myeloma"],"interventions":["Cevostamab","XmAb24306","Tocilizumab"],"countries":["Australia","Denmark","Greece","Israel","Norway","South Korea","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.","sourceUrl":"https://clinicaltrials.gov/study/NCT05646836"},{"nctId":"NCT07685041","title":"An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-06-27","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-19","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-20","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["NSCLC"],"interventions":["HS-10504； midazolam"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, fixed-sequence Phase I clinical trial to evaluate the effect of HS-10504 on the pharmacokinetics of midazolam (CYP3A4 substrate) in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after treatment with EGFR-TKIs.","sourceUrl":"https://clinicaltrials.gov/study/NCT07685041"},{"nctId":"NCT06839066","title":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-22","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Nasopharyngeal Carcinoma (NPC)"],"interventions":["HLX43 DOSE 1","HLX43 DOSE 2","HLX43 DOSE 3"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06839066"},{"nctId":"NCT06545331","title":"Study of XB010 in Subjects With Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":396,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-20","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Locally Advanced or Metastatic Solid Tumors","Esophageal Squamous Cell Cancer","Head and Neck Squamous Cell Cancer","NSCLC (Non-small Cell Lung Cancer)","Hormone-receptor-positive Breast Cancer","Triple Negative Breast Cancer (TNBC)"],"interventions":["XB010","Pembrolizumab"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.","sourceUrl":"https://clinicaltrials.gov/study/NCT06545331"},{"nctId":"NCT06567782","title":"A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-23","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-26","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Neoplasms, Colon"],"interventions":["Dostarlimab","CAPEOX"],"countries":["Belgium","Italy","Japan","Spain","Switzerland","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":33,"serviceSignals":["MSI / TMB"],"summary":"The main goal of this study is to test a new treatment approach for colon cancer. The treatment involves dostarlimab along with a specific type of chemotherapy called CAPEOX (short for \"capecitabine + oxaliplatin\") to check if using these two together works better than using just CAPEOX by itself. This treatment is given before any surgery takes place; a method referred to as \"neoadjuvant therapy.\" . The aim is to see if this new approach can show early signs of effectiveness in treating participants with a specific type of colon cancer known as mismatch repair proficient/ microsatellite stable (MMRp/MSS), where the cells have normal repair systems and stable DNA sequences. This study will a","sourceUrl":"https://clinicaltrials.gov/study/NCT06567782"},{"nctId":"NCT06267729","title":"Study of AZD0754 in Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-24","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Metastatic Prostate Cancer"],"interventions":["AZD0754","AZD2287"],"countries":["United States","Australia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06267729"},{"nctId":"NCT03981796","title":"A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer","sponsor":"Tesaro, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":785,"enrollmentType":"ACTUAL","startDate":"2019-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-26","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-26","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Neoplasms"],"interventions":["Dostarlimab","Placebo matching dostarlimab","Carboplatin","Paclitaxel","Niraparib","Placebo matching Niraparib"],"countries":["United States","Belarus","Belgium","Canada","Czechia","Denmark","Finland","Germany","Greece","Hungary","Israel","Italy","Netherlands","Norway","Poland","Spain","Sweden","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":169,"serviceSignals":["Broad CGP"],"summary":"This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03981796"},{"nctId":"NCT02403505","title":"Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2021-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Rectal Cancer"],"interventions":["CEA protein antigen plus BCG Vaccine Mix for percutaneous use"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.","sourceUrl":"https://clinicaltrials.gov/study/NCT02403505"},{"nctId":"NCT04973163","title":"A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2021-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-29","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-27","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Solid Tumors, KRAS Mutation"],"interventions":["BI 1823911","BI 1701963","Midazolam"],"countries":["United States","Belgium","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"This study is open to adults with different types of advanced or metastatic cancer (including lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer). This study is for people for whom previous treatment was not successful or no treatment exists. People who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes tumours grow faster. BI 1823911 and BI 1701963 are medicines that may turn off KRAS, each in a different way. In this study, BI 1823911 is given to people for the first time. The purpose of this study is to find the highest dose of BI 1823911 that people can tolerate when taken alone and together with BI 1701963. The most suitable dose ","sourceUrl":"https://clinicaltrials.gov/study/NCT04973163"},{"nctId":"NCT05853575","title":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2024-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Cancer","Metastatic Cancer","Malignant Neoplasm of Lung"],"interventions":["Adagrasib"],"countries":["United States","Brazil","Croatia","France","Greece","Israel","Italy","Japan","Mexico","Netherlands","Poland","Romania","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":98,"serviceSignals":["RAS genotyping"],"summary":"This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05853575"},{"nctId":"NCT04735978","title":"Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours","sponsor":"Replimune, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2020-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced Solid Tumor"],"interventions":["RP3","Nivolumab"],"countries":["United States","France","Greece","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.","sourceUrl":"https://clinicaltrials.gov/study/NCT04735978"},{"nctId":"NCT06799247","title":"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","sponsor":"Cartesian Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Myasthaenia Gravis"],"interventions":["Decartes-08","Placebo Drug"],"countries":["United States","Canada","Italy","Poland","Serbia","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT06799247"},{"nctId":"NCT06840119","title":"Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers","sponsor":"Immunocore Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2024-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Cancer","HLA-A*02:01-positive"],"interventions":["IMC-R117C","Chemotherapy drug","Kinase inhibitor","Antiangiogenic Agent","Monoclonal antibody"],"countries":["Australia","Belgium","Germany","Italy","Netherlands","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["HLA / TCR"],"summary":"This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT06840119"},{"nctId":"NCT07310134","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors","sponsor":"Nanjing Zenshine Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Advanced Solid Tumors"],"interventions":["ZX-8177"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, phase I clinical trial involving dose escalation and dose expansion of ZX-8177 in patients with advanced unresectable, recurrent, or metastatic solid tumors. The study consists of two stages: dose escalation and dose expansion. It primarily aims to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), biomarkers, and preliminary efficacy of ZX-8177 as a monotherapy with continuous administration in Chinese patients with advanced solid tumors who have failed standard treatment or lack standard treatment options. The study also seeks to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD)/optimal biologica","sourceUrl":"https://clinicaltrials.gov/study/NCT07310134"},{"nctId":"NCT06984718","title":"A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-06-25","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-22","conditions":["HCC","Hepatocellular Carcinoma"],"interventions":["AK104+lenvatinib","lenvatinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06984718"},{"nctId":"NCT05924776","title":"Plasmodium Immunotherapy for Advanced Ovarian Cancer","sponsor":"CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-07-20","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2024-07-22","conditions":["Advanced Ovarian Cancer"],"interventions":["Plasmodium immunotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer. Each patient is inoculated with Plasmodium vivax 1-5 × 10\\^6, observe the time when the parasite is detected in the peripheral blood of the subjects after the inoculation of Plasmodium, the change of the parasite density in the peripheral blood of the whole treatment cycle and the control effect of the drug on the parasite density, the main clinical symptoms and signs, laboratory test indicators, immunological test indicators and changes in the quality of life. To evaluate the s","sourceUrl":"https://clinicaltrials.gov/study/NCT05924776"},{"nctId":"NCT05094336","title":"A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)","sponsor":"Amgen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":329,"enrollmentType":"ACTUAL","startDate":"2022-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advanced MTAP-null Solid Tumors"],"interventions":["Anvumetostat","Docetaxel","Comparator Anvumetostat Test Tablet"],"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","Hong Kong","Japan","South Korea","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":75,"serviceSignals":["Broad CGP"],"summary":"The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of Anvumetostat alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of Anvumetostat in adult participants with metastatic or locally advanced MTAP-null solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05094336"},{"nctId":"NCT03579836","title":"Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer","sponsor":"BeyondBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2018-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Locally Advanced or Metastatic Pancreatic Cancer"],"interventions":["BEY1107","Gemcitabine"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03579836"},{"nctId":"NCT07081633","title":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":114,"enrollmentType":"ACTUAL","startDate":"2025-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Hepatocellular Carcinoma"],"interventions":["Durvalumab","Tremelimumab","Lenvatinib"],"countries":["China","Hong Kong"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07081633"},{"nctId":"NCT05093907","title":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer","sponsor":"BeyondBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2021-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Metastatic Colorectal Cancer"],"interventions":["BEY1107","Capecitabine"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05093907"},{"nctId":"NCT06954961","title":"A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer","sponsor":"InventisBio Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":640,"enrollmentType":"ESTIMATED","startDate":"2022-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Breast Cancer"],"interventions":["D-0502","Fulvestrant"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT06954961"},{"nctId":"NCT07256756","title":"A Study of GC203 TIL in Advanced Solid Tumors (NF)","sponsor":"Shanghai Juncell Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumors, Adult"],"interventions":["GC203 TIL"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a prospective, open-label, single-arm clinical trial aimed at evaluating the safety and efficacy of GC203 TIL therapy in treating malignant solid tumors that have failed standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07256756"},{"nctId":"NCT07256509","title":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-11-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-30","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SYS6010","Osimertinib","Pemetrexed","Cisplatin","Carboplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and efficacy of SYS6010 combined with osimertinib as neoadjuvant therapy for patients with resectable EGFR mutation non-squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07256509"},{"nctId":"NCT07122687","title":"IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2025-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer"],"interventions":["Pemetrexed","Cisplatin","IBI363","Carboplatin","Keytruda"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label Phase 2 study to compare the efficacy and safety of IBI363 Combined with Chemotherapy or Pembrolizumab Combined with Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07122687"},{"nctId":"NCT05682443","title":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","sponsor":"OncoC4, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":148,"enrollmentType":"ACTUAL","startDate":"2023-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["ONC-392 low","ONC-392 high","lutetium Lu 177 vipivotide tetraxetan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The study is open-label, randomized with active control, multi-center study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05682443"},{"nctId":"NCT06445517","title":"Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma","sponsor":"InSilico Medicine Hong Kong Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Advanced Solid Tumors","Relapsed/Refractory B-cell Lymphoma"],"interventions":["ISM8207"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06445517"},{"nctId":"NCT03989414","title":"A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)","sponsor":"Celgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":424,"enrollmentType":"ESTIMATED","startDate":"2019-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-11-30","completionType":"ESTIMATED","lastUpdated":"2024-11-29","conditions":["Multiple Myeloma"],"interventions":["CC-92480","Bortezomib","Dexamethasone","Daratumumab","Carfilzomib","Elotuzumab","Isatuximab"],"countries":["United States","Canada","Czechia","Denmark","France","Germany","Greece","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT03989414"},{"nctId":"NCT05769660","title":"A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)","sponsor":"BeyondBio Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2022-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Glioblastoma Multiforme"],"interventions":["BEY1107","Temozolomide"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)","sourceUrl":"https://clinicaltrials.gov/study/NCT05769660"},{"nctId":"NCT07280832","title":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":188,"enrollmentType":"ESTIMATED","startDate":"2025-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Unresectable Locally Advanced or Metastatic Melanoma"],"interventions":["JMT108"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07280832"},{"nctId":"NCT06968585","title":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":365,"enrollmentType":"ACTUAL","startDate":"2023-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["HER2-positive Breast Cancer"],"interventions":["A166","T-DM1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT06968585"},{"nctId":"NCT04302025","title":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","sponsor":"Genentech, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2020-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Non-small Cell Lung Cancer"],"interventions":["Alectinib","Entrectinib","Vemurafenib","Cobimetinib","Pralsetinib","Atezolizumab","SBRT","Resection","Chemotherapy","Divarasib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.","sourceUrl":"https://clinicaltrials.gov/study/NCT04302025"},{"nctId":"NCT07310420","title":"A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer","sponsor":"TerSera Therapeutics LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2026-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Breast Cancer"],"interventions":["ZOLADEX"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["HER2 profiling"],"summary":"The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).","sourceUrl":"https://clinicaltrials.gov/study/NCT07310420"},{"nctId":"NCT06643884","title":"Suprachoroidal Administration in Subjects With Metastases to the Choroid","sponsor":"Aura Biosciences","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Eye Cancer","Primary Cancer"],"interventions":["AU-011","SCS Microinjector","Laser"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06643884"},{"nctId":"NCT05997017","title":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","sponsor":"Aadi Bioscience, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":29,"enrollmentType":"ESTIMATED","startDate":"2023-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-11-13","conditions":["Endometrial Cancer","Endometrioid Tumor","Cancer","Tumor","Recurrent Endometrial Carcinoma","Endometrioid Endometrial Cancer"],"interventions":["nab-sirolimus"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05997017"},{"nctId":"NCT05194982","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2021-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Locally Advanced or Metastatic Solid Tumor"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05194982"},{"nctId":"NCT05470348","title":"A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2022-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Breast Cancer","Solid Tumor"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"In this study, the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase II dose (RP2D), the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 will be investigated in patients with unresectable locally advanced or metastatic breast cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05470348"},{"nctId":"NCT04986423","title":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","sponsor":"Zenith Epigenetics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2021-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["ZEN003694","Enzalutamide"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry. The patient population will be separated into two cohorts: Cohort A: Patients with poor response to prior abiraterone defined as: * Abiraterone started in hormone-sensitive prostate cancer (HSPC) disease setting: \\< 12 months duration on abiraterone or failure to achieve PSA nadir of 0.2 ng/mL while taking abiraterone, or; * Abiraterone started in castrate-resistant prostate cancer (CRPC) disease set","sourceUrl":"https://clinicaltrials.gov/study/NCT04986423"},{"nctId":"NCT06710158","title":"Study of SC-102 in Patients With Advanced Solid Tumors","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-07-29","conditions":["Advanced Solid Cancers"],"interventions":["SC-102"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06710158"},{"nctId":"NCT06725381","title":"A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Solid Malignancies"],"interventions":["SKB571"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), phase 1, multicenter, open-label study of SKB571 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity in adult subjects with advanced or metastatic solid tumor .","sourceUrl":"https://clinicaltrials.gov/study/NCT06725381"},{"nctId":"NCT06414954","title":"Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis","sponsor":"NMD Pharma A/S","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2024-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Myasthenia Gravis","Myasthenia Gravis, MuSK"],"interventions":["NMD670","Placebo"],"countries":["United States","Belgium","Denmark","France","Georgia","Italy","Netherlands","Poland","Serbia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.","sourceUrl":"https://clinicaltrials.gov/study/NCT06414954"},{"nctId":"NCT06555744","title":"A Study of ZW191 in Participants With Solid Tumors","sponsor":"Zymeworks BC Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":145,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Advanced Solid Tumors"],"interventions":["ZW191"],"countries":["United States","Australia","Japan","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT06555744"},{"nctId":"NCT06505551","title":"Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma","sponsor":"SCG Cell Therapy Pte. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2024-10","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2024-07-17","conditions":["HPV-Related Squamous Cell Carcinoma","HPV-Related Cervical Squamous Cell Carcinoma","HPV-Related Vulvar Squamous Cell Carcinoma","HPV-Related Penile Squamous Cell Carcinoma","HPV-Related Vaginal Squamous Cell Carcinoma","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Head and Neck Cancer"],"interventions":["SCG142","Cyclophosphamide","Fludarabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HLA / TCR"],"summary":"This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited to combination chemotherapy and/or combination chemo-immunotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT06505551"},{"nctId":"NCT06243354","title":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":257,"enrollmentType":"ESTIMATED","startDate":"2024-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Safety","Tolerability","Efficacy"],"interventions":["Test product: HYP-2090PTSA"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label phase 1/2 study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of HYP-2090PTSA in patients with advanced solid tumors harboring KRAS mutation and to determine the RP2D. In the dose expansion phase, preliminary efficacy and safety at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06243354"},{"nctId":"NCT05872295","title":"IKS014 in Advanced Solid Tumors That Express HER2","sponsor":"Iksuda Therapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2023-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Breast Cancer","Gastric Cancer","Gastroesophageal-junction Cancer"],"interventions":["IKS014"],"countries":["United States","Australia","New Zealand","Singapore"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05872295"},{"nctId":"NCT07513454","title":"A Phase 2 Study of HW211026","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Actinic Keratosis"],"interventions":["HW211026"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07513454"},{"nctId":"NCT06756035","title":"CT-95 in Advanced Cancers Associated With Mesothelin Expression","sponsor":"Context Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Mesothelin-Expressing Tumors","Epithelial Ovarian Cancer","Malignant Pleural Mesothelioma, Advanced","Malignant Peritoneal Mesothelioma, Advanced","Pancreatic Adenocarcinoma Advanced or Metastatic","Lung Adenocarcinoma Metastatic","Cholangiocarcinoma Advanced","Cholangiocarcinoma Non-resectable","Mesothelin-expressing Advanced Cancers","Mesothelin-positive Advanced Malignant Solid Tumors","Colorectal Cancer"],"interventions":["CT-95"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT06756035"},{"nctId":"NCT06188624","title":"Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-04-25","conditions":["Advanced Cancer"],"interventions":["TQB2922 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT06188624"},{"nctId":"NCT05654454","title":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","sponsor":"Mabscale, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":620,"enrollmentType":"ESTIMATED","startDate":"2023-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2024-08-16","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Bevacizumab","Paclitaxel","Carboplatin"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"BEV-III/2022 is a double-blind randomized multicenter clinical trial comparing efficacy of bevacizumab (manufactured by Mabscale, LLC) and paclitaxel plus carboplatin to Avastin® and paclitaxel plus carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC. The purpose of the study is to demonstrate equivalence of efficacy and safety of bevacizumab (manufactured by Mabscale, LLC) to Avastin®. Study includes pharmacokinetics assessment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05654454"},{"nctId":"NCT06150664","title":"A Phase 1 of CTX-8371 in Patients With Advanced Malignancies","sponsor":"Compass Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2024-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Non Small Cell Lung Cancer","Triple Negative Breast Cancer","Hodgkin Lymphoma","Head and Neck Squamous Cell Carcinoma","Malignant Melanoma"],"interventions":["CTX-8371"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06150664"},{"nctId":"NCT05461768","title":"A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":348,"enrollmentType":"ESTIMATED","startDate":"2022-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Breast Cancer","Locally Advanced or Metastatic Solid Tumor"],"interventions":["BL-M07D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["HER2 profiling"],"summary":"In phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D1. In phase Ib study, the safety and tolerability of BL-M07D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M07D1 in patients","sourceUrl":"https://clinicaltrials.gov/study/NCT05461768"},{"nctId":"NCT05924841","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Small Cell Lung Cancer"],"interventions":["BL-B01D1","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with extensive-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05924841"},{"nctId":"NCT04969731","title":"Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer","sponsor":"GC Cell Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":408,"enrollmentType":"ESTIMATED","startDate":"2021-09-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2021-11-22","conditions":["Pancreatic Ductal Adenocarcinoma"],"interventions":["Immuncell-LC","Gemcitabine"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"PURPOSE: This phase III clinical trial evaluates the efficacy and safety of adjuvant Immuncell-LC therapy combined with gemcitabine versus adjuvant gemcitabine single therapy after R0 or R1 resection in patients with pancreatic ductal adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04969731"},{"nctId":"NCT05378425","title":"A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab","sponsor":"Nectin Therapeutics Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2022-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Cancer","Tumor, Solid","Advanced Solid Tumor","Metastatic Cancer","Locally Advanced Solid Tumor"],"interventions":["NTX-1088","Pembrolizumab"],"countries":["United States","Israel","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1,open-label, multi-center, first-in-human, 2-part (Part 1: dose escalation and Part 2: expansion) study, evaluating multiple doses and schedules of intravenously (IV) administered NTX-1088, with or without pembrolizumab, in patients with advanced solid malignancies (i.e., locally advanced or metastatic).","sourceUrl":"https://clinicaltrials.gov/study/NCT05378425"},{"nctId":"NCT05396885","title":"Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)","sponsor":"Kite, A Gilead Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":136,"enrollmentType":"ACTUAL","startDate":"2022-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Multiple Myeloma"],"interventions":["anitocabtagene-autoleucel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05396885"},{"nctId":"NCT04115306","title":"Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer","sponsor":"Phoenix Molecular Designs","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ESTIMATED","startDate":"2019-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Metastatic Breast Cancer"],"interventions":["PMD-026","fulvestrant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04115306"},{"nctId":"NCT06943820","title":"AK129 Combination Therapy for Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2025-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2025-06-03","conditions":["Non-small Cell Lung Cancer Stage IIIB/IV","Head and Neck Squamous Cell Carcinoma (HNSCC)","Colorectal Adenocarcinoma","Advanced Solid Tumors"],"interventions":["AK129(dose 1)","Pemetrexed","Paclitaxel","Carboplatin","AK129(dose 2)","Docetaxel","Cis-platinum","5-FU (5-fluorouracil)","Cetuximab","Chemotherapy","AK129(RP2D)","Penpulimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open, multicenter phase Ib/II clinical study. The goal of this study is to confirm the Phase II recommended dose (RP2D) of AK129 combinations for advanced solid tumors and evaluate the safety and efficacy of AK129 combinations for non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), colorectal adenocarcinoma (CRC), and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06943820"},{"nctId":"NCT07499674","title":"Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung","sponsor":"Vergent Bioscience, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Lung Cancer","Lung Metastases"],"interventions":["Abenacianine","Near Infrared (NIR) Imaging"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. Approximately 132 partiipants will be enrolled to ensure a minimum of 115 evaluable participants receiving abenacianine and undergoing NIR imaging and a control group of 12 participants who will receive abenacianine but no NIR imaging.","sourceUrl":"https://clinicaltrials.gov/study/NCT07499674"},{"nctId":"NCT05455619","title":"Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer","sponsor":"SynDevRx, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2022-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["HR+/HER2-negative Breast Cancer","Metastatic Breast Cancer"],"interventions":["Evexomostat"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic breast cancer with an alteration in the PI3K pathway, including a mutation of the PIK3CA gene, PTEN loss, or AKT1 mutation, designed to determine the safety of evexomostat (SDX-7320) plus standard of care treatment alpelisib (BYL-719) or capivasertib and fulvestrant (each combined, the 'triplet therapy'), to measure the severity and number of hyperglycemic events, and to assess clinical, anti-tumor benefit of the triplet therapy. The purpose of this study is: * to characterize the safety of the triplet drug combination consisting of e","sourceUrl":"https://clinicaltrials.gov/study/NCT05455619"},{"nctId":"NCT05477576","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","sponsor":"RayzeBio, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":338,"enrollmentType":"ESTIMATED","startDate":"2022-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET"],"interventions":["RYZ101","Everolimus","Sunitinib","Octreotide","Lanreotide"],"countries":["United States","Belgium","Brazil","Canada","France","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperable, advanced, well-differentiated, somatostatin receptor expressing (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following treatment with Lutetium 177-labelled somatostatin analogue (177Lu-SSA) therapy, such as 177Lu-DOTATATE or 177Lu-DOTATOC (177Lu-DOTATATE/TOC), or 177Lu-high affinity \\[HA\\]-DOTATATE.","sourceUrl":"https://clinicaltrials.gov/study/NCT05477576"},{"nctId":"NCT03096093","title":"Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer","sponsor":"Cancer Vaccines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ESTIMATED","startDate":"2017-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Cancer","Neoplasms"],"interventions":["ACIT-1"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study evaluates four different doses of ACIT-1 for safety and for the ability to raise effective anti-cancer immune responses in patients with pancreatic and other cancers. Approximately half of the patients will have pancreatic cancer and the other half will have other cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT03096093"},{"nctId":"NCT05386108","title":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":73,"enrollmentType":"ESTIMATED","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Neoplasms","Brain Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Central Nervous System Neoplasms","Brain Diseases","Central Nervous System Diseases"],"interventions":["Elacestrant","Abemaciclib"],"countries":["United States","Belgium","France","Germany","Greece","Italy","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":86,"serviceSignals":["Broad CGP"],"summary":"This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05386108"},{"nctId":"NCT06451497","title":"This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors","sponsor":"Zumutor Biologics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Pancreas Adenocarcinoma","Biliary Tract Cancer","Prostate Cancer","Urothelial Carcinoma","Colorectal Cancer","Triple Negative Breast Cancer","High Grade Ovarian Serous Adenocarcinoma","Diffuse Large B Cell Lymphoma","Renal Cell Cancer Metastatic"],"interventions":["ZM008"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.","sourceUrl":"https://clinicaltrials.gov/study/NCT06451497"},{"nctId":"NCT06752447","title":"A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2025-01-20","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-12-30","conditions":["Advanced Solid Tumors (Phase 1)"],"interventions":["LNF2007"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A non-randomized, open-ended, phase I dose-escalation and dose-expansion study was designed to evaluate the safety, tolerability, antitumor efficacy, PK and immunogenic characteristics of LNF2007 in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06752447"},{"nctId":"NCT05785754","title":"DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors","sponsor":"DynamiCure Biotechnology","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2023-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-06-26","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["DCSZ11","Pembrolizumab","Doxorubicin","Tebentafusp"],"countries":["United States","Australia","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).","sourceUrl":"https://clinicaltrials.gov/study/NCT05785754"},{"nctId":"NCT07482319","title":"A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors","sponsor":"Beijing Geekgene Technology Co., LTD","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Advanced Solid Tumors"],"interventions":["GK01 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Open-label, Single-arm, Phase I Clinical Study of GK01 Cell Injection in the Treatment of Patients with Advanced Malignant Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07482319"},{"nctId":"NCT06711900","title":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":432,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SKB264","Pembrolizumab","pemetrexed","carboplatin or cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":81,"serviceSignals":["Broad CGP"],"summary":"The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC with PD-L1 negative.","sourceUrl":"https://clinicaltrials.gov/study/NCT06711900"},{"nctId":"NCT06592638","title":"A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["Small Cell Lung Cancer"],"interventions":["ZG006"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard \"3+3\" design will be used to assess the MTD/ recommended dose for the subsequent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06592638"},{"nctId":"NCT06359860","title":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","sponsor":"Beijing Scitech-Mq Pharmaceuticals Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":64,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-08-24","conditions":["Unresectable or Metastatic Melanoma"],"interventions":["ST-1898 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in subjects with unresectable or metastatic melanoma. In phase Ib, the primary objectives are to assess the safety and tolerability, and to determine Recommended Phase 2 dose (RP2D) of ST-1898 tablets in subjects with unresectable or metastatic melanoma. Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy. In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metast","sourceUrl":"https://clinicaltrials.gov/study/NCT06359860"},{"nctId":"NCT07315113","title":"Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer","sponsor":"Nuvectis Pharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["EGFR Mutation Positive Non-small Cell Lung Cancer","EGFR Mutated Non-small Cell Lung Cancer Patients"],"interventions":["NXP900","Osimertinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07315113"},{"nctId":"NCT07291050","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Advanced Cancer"],"interventions":["TQB3217Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07291050"},{"nctId":"NCT06650566","title":"Study of LM-299 in Subjects Advanced Malignant Tumors","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2024-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-05-02","conditions":["Malignant Tumors"],"interventions":["LM-299"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-299 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explorethe recommended dose for expansion (RDE) in patients with advanced solid tumours.. For Phase II Dose Expansion Stage, to assess the antitumor activity of LM-299 in patients with various advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06650566"},{"nctId":"NCT06942767","title":"Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-06","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2025-04-27","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma"],"interventions":["QLS31905 for Injection","QL2107 Injection","Oxaliplatin Injection","Capecitabine Tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, multicenter Phase II clinical study aimed at evaluating the tolerability, safety, efficacy, PK profile, and immunogenicity of QLS31905 for Injection combined with QL2107 Injection and XELOX regimen in the first-line treatment of CLDN18.2-positive unresectable locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06942767"},{"nctId":"NCT05885464","title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","sponsor":"Beam Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":5,"enrollmentType":"ACTUAL","startDate":"2023-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-01-13","conditions":["Lymphoblastic Lymphoma","T-Cell Lymphoblastic Leukemia/Lymphoma","Lymphoblastic Leukemia"],"interventions":["BEAM-201"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \\< 12 years), and a Phase 2 cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT05885464"},{"nctId":"NCT05473156","title":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","sponsor":"AP Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2023-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-03-26","conditions":["Locally Advanced or Metastatic Solid Tumors","Non Small Cell Lung Cancer (NSCLC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":["AP203"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and antitumor activities of AP203 in adult patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05473156"},{"nctId":"NCT06767527","title":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2025-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Triple-Negative Breast Cancer (TNBC)"],"interventions":["AK112","Nab-paclitaxel","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This multicenter, randomized, double-blind study aims to assess the safety and efficacy of AK112 in combination with Nab-Paclitaxel, compared to a placebo plus Nab-Paclitaxel, as a first-line treatment for inoperable locally advanced or metastatic triple-negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06767527"},{"nctId":"NCT05789069","title":"A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","sponsor":"HiFiBiO Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":83,"enrollmentType":"ESTIMATED","startDate":"2023-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Renal Cell Carcinoma","Melanoma","Non Small Cell Lung Cancer","Gastric Cancer","Colorectal Cancer"],"interventions":["HFB200603","Tislelizumab"],"countries":["United States","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to test the safety and tolerability of HFB200603 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200603 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200603 as a single agent or combination therapy is determined. During the expansion part, participants will take the doses of HFB200603 as a monotherapy (optional arm) or in combination with tislelizumab that were determined from the escalation part of the study and will be assigned to a group based on the type","sourceUrl":"https://clinicaltrials.gov/study/NCT05789069"},{"nctId":"NCT07290088","title":"Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients","sponsor":"Intra-IMMUSG Pte Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2023-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Advanced Solid Cancers"],"interventions":["PRL3-ZUMAB"],"countries":["Malaysia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a Multi-Center, Phase II/III, open-label, single dose level (6 mg/kg) basket trial of PRL3-zumab monotherapy in solid cancer patients. The study will consist of a Screening Period (Day - 14 to Day -1) for completion of all screening assessments before the first administration of study treatment, a Treatment Period during which visits will occur every 2-week (PK T1/2 = 12 days ±2 days), once the decision to discontinue treatment for any reason, an End of Treatment (EOT) visit will be performed within 14 days ±4 days after last dose of study treatment. Safety Follow-up/EOS visit will be performed 28 days ±2 days after last dose of study treatment and survival follow-up call will be per","sourceUrl":"https://clinicaltrials.gov/study/NCT07290088"},{"nctId":"NCT06746688","title":"A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.","sponsor":"ExpreS2ion Biotechnologies","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Breast Cancer","Breast Cancer Metastatic"],"interventions":["ES2B-C001","ISA 51 VD"],"countries":["Austria"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"The trial is a first-in-human, phase I, open-label, dose-escalating trial to assess the safety and tolerability of ES2B-C001 combined with or without \\[adjuvant\\], in patients with human epidermal growth factor receptor 2 (HER2) expressing metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06746688"},{"nctId":"NCT04953897","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment","sponsor":"Taiho Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2021-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"interventions":["ASTX727"],"countries":["United States","Armenia","Bulgaria","Lithuania","Poland","Romania","Slovakia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with severe renal impairment and cancer participants with normal renal function as matched control participants. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration per participant is approximately up to 8 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT04953897"},{"nctId":"NCT05652920","title":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","sponsor":"OriCell Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2022-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-04-03","conditions":["Hepatocellular Carcinoma"],"interventions":["Ori-C101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05652920"},{"nctId":"NCT06082960","title":"Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2023-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Solid Tumors"],"interventions":["GS-9911","Zimberelimab"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid t","sourceUrl":"https://clinicaltrials.gov/study/NCT06082960"},{"nctId":"NCT05245968","title":"A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)","sponsor":"Taiho Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2021-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Gastrointestinal Stromal Tumors"],"interventions":["Pimitespib","Imatinib","Sunitinib"],"countries":["Australia","China","Japan","Singapore","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged to be refractory to imatinib, estimate the recommended dose, evaluate safety and pharmacokinetics, and observe the antitumor effect. Expansion part consists of 3 arms. In Arm A, the efficacy and safety will be evaluated, which of the combination of pimitespib and imatinib in patients with GIST who have failed imatinib at doses below the MTD determined in Dose Escalation Part. In Arm B, the efficacy and safety of pimitespib monotherapy will be evaluated and the therap","sourceUrl":"https://clinicaltrials.gov/study/NCT05245968"},{"nctId":"NCT06114511","title":"A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2024-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-M07D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06114511"},{"nctId":"NCT06097832","title":"Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis","sponsor":"Nexcella Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2024-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2039-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Light Chain (AL) Amyloidosis"],"interventions":["NXC-201 CAR-T"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06097832"},{"nctId":"NCT05306132","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2022-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Advanced Solid Tumor"],"interventions":["ASKC202","ASK120067"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is the first-in-human of ASKC202, which is an open-label, non-randomized, multicenter study with a dose escalation phase and a dose expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT05306132"},{"nctId":"NCT06425926","title":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","sponsor":"Georgiamune Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":117,"enrollmentType":"ESTIMATED","startDate":"2024-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Melanoma Stage IV","Solid Tumor"],"interventions":["GIM-531","Anti-PD-1 monoclonal antibody"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).","sourceUrl":"https://clinicaltrials.gov/study/NCT06425926"},{"nctId":"NCT06671379","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":498,"enrollmentType":"ACTUAL","startDate":"2024-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["Non-small Cell Lung Cancer"],"interventions":["SHR-A2009 monotherapy","platinum-based dual-agent chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06671379"},{"nctId":"NCT05147467","title":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2021-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["APG2575"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.","sourceUrl":"https://clinicaltrials.gov/study/NCT05147467"},{"nctId":"NCT05785039","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2023-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Urinary System Tumor","Solid Tumor"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase IIa/IIb clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05785039"},{"nctId":"NCT06131450","title":"A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2024-02-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Gynecological Malignancies"],"interventions":["BL-M07D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06131450"},{"nctId":"NCT06816992","title":"ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC","sponsor":"ORIC Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Solid Tumors","EGFR Exon 20 Insertion Mutations","NSCLC","EGFR-mutated NSCLC"],"interventions":["ORIC-114 Dose 1 + amivantamab","ORIC-114 Dose 2 + amivantamab","ORIC-114 Dose 3 + amivantamab"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06816992"},{"nctId":"NCT05299424","title":"A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Keymed Biosciences Co.Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2022-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Multiple Myeloma"],"interventions":["CM336_group 1","CM336_group 2a","CM336_group 2b","CM336_group 3a","CM336_group 3b","CM336_group 4a","CM336_group 4b","CM336_group 5","CM336_group 6a","CM336_group 6b","CM336_group 7","CM336_group 8a","CM336_group 8b","CM336_group 9","CM336_RP2D"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, open-label, Phase 1/2 study in China to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics and immunogenicity of CM336 in patients with relapsed or refractory multiple myeloma. This study consists of a dose escalation part (Phase 1) and a dose extension part (Phase 2 ). The safety and tolerability of CM336 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of CM336 will be evaluated in Phase 2 study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05299424"},{"nctId":"NCT04900818","title":"Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors","sponsor":"I-Mab Biopharma US Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2021-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Solid Tumor","Advanced Cancer","Metastatic Cancer","Gastric Cancer","Gastroesophageal Junction Carcinoma","Esophageal Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer (BTC)"],"interventions":["TJ033721 (givastomig)","TJ033721 (givastomig) , nivolumab, chemotherapy","TJ033721 (givastomig), chemotherapy","TJ033721 (givastomig), durvalumab, chemotherapy"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04900818"},{"nctId":"NCT06262139","title":"Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients","sponsor":"Songqi Gao","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["MRI Scan"],"interventions":["MT218 injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06262139"},{"nctId":"NCT06745583","title":"A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients","sponsor":"Elixiron Immunotherapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Mild, Moderate, or Severe Alzheimer's Disease"],"interventions":["EI-1071 tablet, oral"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"An open-label, exploratory, phase II, proof-of concept, clinical study to assess the safety and tolerability of EI-1071 and the effects of EI-1071 on neuroinflammation in patients with mild, moderate, or severe Alzheimer's disease","sourceUrl":"https://clinicaltrials.gov/study/NCT06745583"},{"nctId":"NCT05965856","title":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2023-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Urothelial Carcinoma","Solid Tumor"],"interventions":["BL-B01D1","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II study is designed to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with locally advanced or metastatic urothelial carcinoma and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05965856"},{"nctId":"NCT05689853","title":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2023-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Solid Tumor, Adult"],"interventions":["AK119","AK112"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05689853"},{"nctId":"NCT04471987","title":"Safety and Early Signs of Efficacy of IL12-L19L19.","sponsor":"Philogen S.p.A.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2020-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["IL12-L19L19"],"countries":["Germany","Italy","Switzerland"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy. The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD). The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.","sourceUrl":"https://clinicaltrials.gov/study/NCT04471987"},{"nctId":"NCT07580833","title":"A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors","sponsor":"Health Hope Pharma","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Metastatic Breast Cancer"],"interventions":["Oral Paclitaxel in combination with Encequidar tablet"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn about the effect of food on absorption of oral Paclitaxel when co- administered with Encequidar tablets in adult patients with tumours. The main questions it aims to answer are: * The effect of food and fasting on absorption of oral paclitaxel when combined with Encequidar tablets * Assessment of safety and tolerability of oral paclitaxel when combined with Encequidar tablets Participants will take Encequidar and oral paclitaxcel with a 1-hour space in between, either after an overnight fast of 10hours or after a meal three days in a row. After 10 days participants that received paclitaxel after fasting will receive the same medicine in the same wa","sourceUrl":"https://clinicaltrials.gov/study/NCT07580833"},{"nctId":"NCT06667544","title":"A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation","sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2024-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-10-30","conditions":["KRAS G12D Mutation"],"interventions":["RNK08954-01"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["RAS genotyping"],"summary":"This is a first in human (FIH), Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability and pharmacokinetics of RNK08954 to determine the optimal dose and recommended dose for expansion and evaluate clinical activity in patients with advanced solid tumors with KRAS G12D mutation. This is a 2-part study: dose exploration/indication expansion and dose optimization ( to identify a dose that preserves clinical benefit with optimal tolerability).","sourceUrl":"https://clinicaltrials.gov/study/NCT06667544"},{"nctId":"NCT06534437","title":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","sponsor":"Ryvu Therapeutics SA","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2024-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Non-Hodgkin Lymphoma, B-cell"],"interventions":["MEN1703","Glofitamab"],"countries":["France","Poland","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maxi","sourceUrl":"https://clinicaltrials.gov/study/NCT06534437"},{"nctId":"NCT05909436","title":"Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":107,"enrollmentType":"ESTIMATED","startDate":"2022-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-06-18","conditions":["Solid Tumor"],"interventions":["GLS-012","GLS-010"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05909436"},{"nctId":"NCT06006169","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2023-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["BL-B01D1","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06006169"},{"nctId":"NCT07456371","title":"PIC1 Injection Therapy for Relapsed/Refractory B-NHL","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Non-Hodgkin Lymphoma"],"interventions":["PIC1 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is an investigator-initiated trial aimed at assessing the safety and efficacy of PIC1 injection in the treatment of relapsed/refractory B-cell Non-Hodgkin Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07456371"},{"nctId":"NCT05784688","title":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","sponsor":"TiumBio Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2023-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-03-30","conditions":["Solid Tumor","Biliary Tract Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Cancer"],"interventions":["TU2218 + KEYTRUDA® (Pembrolizumab)"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05784688"},{"nctId":"NCT06202261","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2023-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2024-03-12","conditions":["Metastatic Breast Cancer","Recurrent Breast Cancer","Advanced Malignancies"],"interventions":["TQB2930 for injection","Paclitaxel for injection (albumin-bound)","TQB3616 capsule","Fulvestrant injection","Capecitabine tablets","Vinorelbine tartrate injection","Eribulin mesylate injection","gemcitabine hydrochloride for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).","sourceUrl":"https://clinicaltrials.gov/study/NCT06202261"},{"nctId":"NCT06075264","title":"Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)","sponsor":"Frantz Viral Therapeutics, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia"],"interventions":["Artesunate ointment","Placebo ointment"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).","sourceUrl":"https://clinicaltrials.gov/study/NCT06075264"},{"nctId":"NCT06718621","title":"A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2025-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Solid Tumor"],"interventions":["BL-M08D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, dose-escalation and expansion-enrollment, nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for injection in locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06718621"},{"nctId":"NCT02340117","title":"Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer","sponsor":"SynerGene Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2015-01","startDateType":"","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-05-30","conditions":["Metastatic Pancreatic Cancer"],"interventions":["SGT-53","nab-paclitaxel","Gemcitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer. The objective of the study is to evaluate the safety, tolerability, toxicity and efficacy (specifically Progression Free Survival at 5.5 month (PFS5.5mos)) of this combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT02340117"},{"nctId":"NCT06107413","title":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2023-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-12","conditions":["Unresectable Metastatic Colorectal Cancer"],"interventions":["ABBV-400","Bevacizumab","Folinic Acid","Fluorouracil","Irinotecan"],"countries":["United States","Belgium","Germany","Israel","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["Broad CGP"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer. ABBV-400 is an investigational drug being developed for the treatment of unresectable metastatic colorectal cancer. Fluorouracil, folinic acid, and bevacizumab (FFB) is an approved drug for the treatment of unresectable metastatic colorectal cancer. Study doctors put the participants in groups called treatment arms. Each treatment arm receives a different d","sourceUrl":"https://clinicaltrials.gov/study/NCT06107413"},{"nctId":"NCT05623982","title":"A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2022-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Non-hodgkin's Lymphoma"],"interventions":["GNC-038"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"To explore the safety and preliminary efficacy of GNC-038 in patients with relapsed or refractory NHL, and to determine the MTD and RP2D of GNC-038, or the MAD and DLT","sourceUrl":"https://clinicaltrials.gov/study/NCT05623982"},{"nctId":"NCT04953910","title":"Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment","sponsor":"Taiho Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2022-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"interventions":["ASTX727"],"countries":["United States","Armenia","Bulgaria","Lithuania","Poland","Romania","Slovakia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and severe hepatic impairment and cancer participants with normal hepatic function as control participants. Participants with severe hepatic impairment will be enrolled only after the safety evaluation of at least 6 participants with moderate hepatic impairment has been determined and supports the enrollment of participants with severe hepatic impairment. Adult participants with acute myeloid lymphoma (A","sourceUrl":"https://clinicaltrials.gov/study/NCT04953910"},{"nctId":"NCT04617522","title":"Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2021-04-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Advanced or Metastatic Solid Tumor","Liver Failure"],"interventions":["Sacituzumab Govitecan-hziy"],"countries":["United States","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.","sourceUrl":"https://clinicaltrials.gov/study/NCT04617522"},{"nctId":"NCT06773091","title":"A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors","sponsor":"Shanghai NK Cell Technology Co., LTD","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Advanced Solid Tumors"],"interventions":["NK042","Fludarabine (FLU)","Cyclophosphamide (CTX)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, multi-center phase 1 clinical study designed to evaluate the safety and preliminary efficacy of NK042 cell injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06773091"},{"nctId":"NCT05727176","title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","sponsor":"Taiho Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Cholangiocarcinoma","FGFR2 Fusions","Gene Rearrangement"],"interventions":["TAS-120"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Hong Kong","Italy","Japan","Poland","Portugal","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":65,"serviceSignals":["RNA fusion"],"summary":"This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.","sourceUrl":"https://clinicaltrials.gov/study/NCT05727176"},{"nctId":"NCT06443489","title":"A Trial of SHR-4849 in Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-03-05","conditions":["Advanced Solid Tumors"],"interventions":["SHR-4849"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection in Advanced Solid Tumors. To explore the reasonable dosage of SHR-4849 for Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06443489"},{"nctId":"NCT06471205","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2024-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Triple-negative Breast Cancer"],"interventions":["BL-B01D1","PD-1 Monoclonal Antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06471205"},{"nctId":"NCT07691775","title":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","sponsor":"Heron Neutron Medical Corp.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Solid Tumor"],"interventions":["F18 FBPA Injection"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase I/II clinical study, titled \"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors\", aims to evaluate the safety and diagnostic performance of F18 FBPA PET/CT imaging in subjects with solid tumors. The primary objective is to evaluate the safety and establish the optimal screening conditions (including dose, timing and image quality) of F18 FBPA PET/CT in patients with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07691775"},{"nctId":"NCT05804864","title":"A Study of KM501 in Patients With Solid Tumors","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2023-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2023-04-07","conditions":["Advanced Solid Tumors"],"interventions":["KM501"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2","sourceUrl":"https://clinicaltrials.gov/study/NCT05804864"},{"nctId":"NCT05341557","title":"A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2022-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Advanced Solid Tumor","Lymphoma","NSCLC","HCC"],"interventions":["BPI-371153"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05341557"},{"nctId":"NCT05987358","title":"A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2023-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Biliary Carcinoma"],"interventions":["TQB3454 tablets","TQB3454 tablets matching placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study used a randomized, controlled, double-blind, multicenter Phase III clinical design with overall survival (OS) as the primary endpoint. About 165 patients with advanced biliary carcinoma were enrolled and randomly assigned to the experimental group and the control group in a 2:1 ratio to receive TQB3454 tablets or the placebo, respectively, to evaluate the efficacy and safety of TQB3454 tablets in the treatment of advanced biliary carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05987358"},{"nctId":"NCT06131216","title":"Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2023-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2023-11-14","conditions":["Advanced Malignant Cancer"],"interventions":["SHR-2022 Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D","sourceUrl":"https://clinicaltrials.gov/study/NCT06131216"},{"nctId":"NCT04442022","title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","sponsor":"Karyopharm Therapeutics Inc","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":501,"enrollmentType":"ESTIMATED","startDate":"2020-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Relapsed/Refractory Diffuse Large B-cell Lymphoma"],"interventions":["Selinexor (combination therapy)","Placebo matching for Selinexor (combination therapy)","Rituximab (combination therapy)","Gemcitabine (combination therapy)","Dexamethasone (combination therapy)","Cisplatin (combination therapy)","Selinexor (continuous therapy)","Placebo matching for Selinexor (continuous therapy)"],"countries":["United States","China","Israel","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \\[mg\\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified i","sourceUrl":"https://clinicaltrials.gov/study/NCT04442022"},{"nctId":"NCT05948475","title":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","sponsor":"TransThera Sciences (Nanjing), Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Cholangiocarcinoma"],"interventions":["Tinengotinib 8 mg","Tinengotinib 10 mg","Physician's Choice"],"countries":["United States","Austria","Belgium","France","Germany","Italy","Netherlands","Poland","Portugal","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":87,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05948475"},{"nctId":"NCT06277219","title":"A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)","sponsor":"Latticon Antibody Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Advanced Solid Tumor"],"interventions":["LAT010","LAT010 + ICI"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase 1/2, first-in-human (FIH), dose-escalation and cohort-expansion study of LAT010 to evaluate the safety, tolerability, immunogenicity, PK, PD, and antitumor activity in patients with advanced solid tumors. The study consists of 2 parts: Phase 1 dose-escalation and Phase 2 cohort expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06277219"},{"nctId":"NCT06754644","title":"A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":808,"enrollmentType":"ESTIMATED","startDate":"2025-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-06-10","conditions":["NSCLC"],"interventions":["QL2107","Pemetrexed","Carboplatin","Keytruda®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to compare the efficacy similarities between QL2107 and Keytruda in metastatic non-squamous NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06754644"},{"nctId":"NCT06295432","title":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Non-small Cell Lung Cancer"],"interventions":["DZD9008+AZD4205"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"DZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06295432"},{"nctId":"NCT06221748","title":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-04-03","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["Disitamab Vedotin Injection","Cadonilimab Injection","Paclitaxel Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06221748"},{"nctId":"NCT05780567","title":"Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1946,"enrollmentType":"ESTIMATED","startDate":"2023-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Breast Cancer"],"interventions":["TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen","Placebo capsules, Letrozole, Anastrozole, Tamoxifen"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and HER2-negative breast cancer adjuvant therapy. Approximately 1946 female subjects will be randomized to either TQB3616 combined with endocrine group or TQB3616-matching placebo combined endocrine group. Randomization will follow a 2:1 ratio, 1297 subjects in experimental group and 649 in the the Placebo Comparator group.","sourceUrl":"https://clinicaltrials.gov/study/NCT05780567"},{"nctId":"NCT05112991","title":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2022-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Advanced Endometrial Cancer"],"interventions":["Envafolimab+Lenvatinib","Envafolimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center, multi-corhort Phase II study of Envafolimab alone or with Lenvatinib in patients with advanced endometrial cancer.The primary objective is to evaluate objective response rate of envafolimab alone or with lenvatinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05112991"},{"nctId":"NCT07123129","title":"A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Advanced Malignancy"],"interventions":["SHR-7782 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07123129"},{"nctId":"NCT06042894","title":"A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2023-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Breast Cancer"],"interventions":["BL-B01D1","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This phase II study is a clinical study to explore the efficacy and safety of SI-B003 monotherapy and BL-B01D1+SI-B003 combination therapy in patients with unresectable locally advanced or recurrent metastatic HER-2 negative breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06042894"},{"nctId":"NCT07729579","title":"An Open-Label, Two-Cohort, Pharmacokinetic Study in a Maximal Use Setting for Patients With Actinic Keratosis on the Upper Extremities or the Face","sponsor":"Sun Pharmaceutical Industries Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-08-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Actinic Keratosis (AK)"],"interventions":["Investigational drug","Photodynamic therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a treatment that uses application of blue light.","sourceUrl":"https://clinicaltrials.gov/study/NCT07729579"},{"nctId":"NCT06066203","title":"A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Non-hodgkin's Lymphoma"],"interventions":["GNC-035"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Phase I main objectives: To observe the safety and preliminary efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies, to determine the DLT and MTD, or MAD, and to determine RP2D. Phase II Main objective: To explore the efficacy of GNC-035 in patients with relapsed/refractory non-Hodgkin lymphoma and other hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06066203"},{"nctId":"NCT07025018","title":"Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations","sponsor":"Hutchmed","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2025-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-08-01","conditions":["Gliomas Harboring IDH1 and/or IDH2 Mutations"],"interventions":["HMPL-306"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations","sourceUrl":"https://clinicaltrials.gov/study/NCT07025018"},{"nctId":"NCT05265052","title":"3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain","sponsor":"3D Medicines","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":177,"enrollmentType":"ESTIMATED","startDate":"2026-12","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Cancer Pain"],"interventions":["3D1002 (50 mg)(Phase IIa)","3D1002 (100 mg)(Phase IIa)","3D1002 (150 mg)(Phase IIa)","3D1002 monotherapy (Phase IIb)","OxyContin monotherapy (Phase IIb)","3D1002 + OxyContin (Phase IIb)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.","sourceUrl":"https://clinicaltrials.gov/study/NCT05265052"},{"nctId":"NCT05238883","title":"A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors","sponsor":"HiFiBiO Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2022-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Gastric Cancer","Renal Cell Carcinoma","Melanoma","Sarcoma","Testicular Germ Cell Tumor","Cervical Cancer","Mesothelioma","Non Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma"],"interventions":["HFB200301","Tislelizumab"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take the dose of HFB200301 as a monotherapy or in combination with tislelizumab that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the pa","sourceUrl":"https://clinicaltrials.gov/study/NCT05238883"},{"nctId":"NCT07348653","title":"A Study of MG2512 Injection in Participants With Advanced Solid Tumors","sponsor":"Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Advanced Solid Tumor"],"interventions":["MG2512 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and efficacy of MG2512 injection in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07348653"},{"nctId":"NCT02227251","title":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","sponsor":"Karyopharm Therapeutics Inc","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":244,"enrollmentType":"ESTIMATED","startDate":"2014-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["Selinexor"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","France","Germany","Greece","Hungary","India","Israel","Italy","Netherlands","New Zealand","Poland","Serbia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":175,"serviceSignals":["Hematology NGS"],"summary":"A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic options of demonstrated clinical benefit.","sourceUrl":"https://clinicaltrials.gov/study/NCT02227251"},{"nctId":"NCT07269145","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":86,"enrollmentType":"ESTIMATED","startDate":"2026-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Advanced Cancer"],"interventions":["TQB3122 Capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07269145"},{"nctId":"NCT06607458","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","sponsor":"Delcath Systems Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Refractory Metastatic Colorectal Cancer"],"interventions":["Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab","Trifluridine-tipiracil plus Bevacizumab Alone"],"countries":["United States","Czechia","Germany","Italy","Netherlands","Serbia","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone. Participants will: * Undergo up to two liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer treat","sourceUrl":"https://clinicaltrials.gov/study/NCT06607458"},{"nctId":"NCT05195294","title":"Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC","sponsor":"Lion TCR Pte. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2025-03","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Hepatocellular Carcinoma","Liver Cancer, Adult","Liver Cell Carcinoma"],"interventions":["LioCyx-M","Lenvatinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HLA / TCR"],"summary":"This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05195294"},{"nctId":"NCT05281471","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","sponsor":"Genelux Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","High-grade Serous Ovarian Cancer","Endometrioid Ovarian Cancer","Ovarian Clear Cell Carcinoma"],"interventions":["olvimulogene nanivacirepvec","Platinum chemotherapy: carboplatin (preferred) or cisplatin","Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin","Bevacizumab (or biosimilar)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also ","sourceUrl":"https://clinicaltrials.gov/study/NCT05281471"},{"nctId":"NCT07233850","title":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-11","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Gastric/Gastroesophageal Junction Adenocarcinoma","Metastatic Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Oesophageal Cancer"],"interventions":["SSGJ-706+XELOX","SSGJ-706+Bevacizumab+XELOX","SSGJ-706+AG","SSGJ-706+TP"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors. Its objective is to assess the safety, tolerability, and antitumor activity of SSGJ-706 in combination with standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07233850"},{"nctId":"NCT05463263","title":"A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas","sponsor":"Step Pharma, SAS","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Lymphoma, B-Cell","Lymphoma, T-Cell"],"interventions":["STP938"],"countries":["United States","France","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05463263"},{"nctId":"NCT06774963","title":"A Phase 1 Study of LNCB74 in Advanced Solid Tumors","sponsor":"NextCure, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":145,"enrollmentType":"ESTIMATED","startDate":"2025-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Ovarian Cancer","Breast Cancer","Endometrial Cancer","Biliary Tract Cancer","Non-Small Cell Lung Cancer","Advanced or Metastatic Solid Tumors"],"interventions":["LNCB74"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06774963"},{"nctId":"NCT06395519","title":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","sponsor":"858 Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Advanced or Metastatic Solid Tumors","Breast Cancer","Ovarian Cancer","Prostate Cancer","Epithelial Ovarian Cancer","BRCA2 Mutation","ER+ Breast Cancer","Castrate Resistant Prostate Cancer","BRCA1 Mutation","BRCA Mutation","Endometrial Cancer","Colorectal Cancer","Gastric Cancer"],"interventions":["ETX-19477"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["HRD / HRR"],"summary":"This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.","sourceUrl":"https://clinicaltrials.gov/study/NCT06395519"},{"nctId":"NCT05949606","title":"A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2023-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Non-small Cell Lung Cancer"],"interventions":["SI-B001","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small cell lung cancer. Phase II: To evaluate the efficacy of SI-B001+SI-B003 combination with or without chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05949606"},{"nctId":"NCT05205330","title":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","sponsor":"Rottapharm Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":107,"enrollmentType":"ESTIMATED","startDate":"2021-11-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-10-29","conditions":["Refractory Metastatic Colorectal Cancer","Solid Tumor","Metastatic Microsatellite-stable Colorectal Cancer","Mismatch Repair Protein Proficient","Metastatic GI Cancers","Gastric Cancer"],"interventions":["CR6086","AGEN2034"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["MSI / TMB"],"summary":"This Phase Ib/IIa study comprises a Main Study and a Study Extension. The Main Study has been designed according to a 3+3 Dose Escalation/dose Expansion design in refractory pMMR-MSS mCRC patients. The fixed-dose Expansion phase will be conducted at the recommended dose for expansion (RDE), with the purpose of generating additional and more robust safety and efficacy data. 27 patients are predicted in the Dose Escalation phase and 52 in the Expansion phase, respectively. The Study Extension explores in other metastatic GI cancers the Vorbipiprant (CR6086) RDE obtained in the Main Study. 27 patients are predicted. No control arm was included, as the target patient population of this study con","sourceUrl":"https://clinicaltrials.gov/study/NCT05205330"},{"nctId":"NCT06235437","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141","sponsor":"Ascendo Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2024-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Metastatic Solid Tumor"],"interventions":["ASD141"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06235437"},{"nctId":"NCT05990803","title":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Cervical Cancer"],"interventions":["BL-B01D1","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Objective: To explore the efficacy, safety and tolerability of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in patients with recurrent or metastatic cervical cancer and other gynecological malignancies, and to further explore the optimal dose and mode of combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT05990803"},{"nctId":"NCT07169851","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":204,"enrollmentType":"ESTIMATED","startDate":"2025-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Nausea","Vomiting","Drug-Related Side Effects and Adverse Reactions","Neoplasms"],"interventions":["LY3537021","Placebo","Standard of Care Antiemetic Therapies","Background Chemotherapy"],"countries":["United States","Australia","China","France","Italy","Japan","Romania","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT07169851"},{"nctId":"NCT06052813","title":"A Study of BN104 in the Treatment of Acute Leukemia","sponsor":"Institut de Recherches Internationales Servier (I.R.I.S.)","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":66,"enrollmentType":"ACTUAL","startDate":"2023-10-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["ALL, Adult","AML, Adult","Acute Leukaemia","KMT2A Rearrangement","NPM1 Mutation","NUP98 Gene Rearrangement","Menin Inhibitors"],"interventions":["BN104 monotherapy","BN104 monotherapy - rp2d"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06052813"},{"nctId":"NCT01761968","title":"Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms","sponsor":"Italfarmaco","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2013-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Chronic Myeloproliferative Neoplasms"],"interventions":["givinostat"],"countries":["Germany","Italy","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis following core protocols in chronic myeloproliferative neoplasms and/or patient-named compassionate use program (if regulated/allowed by the local regulations, e.g. for Italy D.M. 8/5/2003 \"Uso terapeutico di medicinale sottoposto a sperimentazione clinica\" published on G.U. n. 173 of 28 July 2003, and the following amendments). Patients will continue at their last tolerable dose and treatment schedule of g","sourceUrl":"https://clinicaltrials.gov/study/NCT01761968"},{"nctId":"NCT02584244","title":"Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers","sponsor":"Lumicell, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2016-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Colorectal Cancer","Pancreatic Cancer","Esophageal Cancer","Gastric Cancer"],"interventions":["LUM015","LUM 2.6 Imaging Device"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.","sourceUrl":"https://clinicaltrials.gov/study/NCT02584244"},{"nctId":"NCT03604198","title":"Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome","sponsor":"Corcept Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2018-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Cushing Syndrome"],"interventions":["relacorilant"],"countries":["United States","Austria","Canada","Germany","Israel","Italy","Netherlands","Poland","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT03604198"},{"nctId":"NCT05222932","title":"Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1","sponsor":"TILT Biotherapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2023-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Melanoma","Head and Neck Squamous Cell Carcinoma"],"interventions":["TILT-123","Avelumab"],"countries":["United States","Finland"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, dose-escalation trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with avelumab in patients with advanced solid tumors refractory to or progressing after anti-PD(L)1.","sourceUrl":"https://clinicaltrials.gov/study/NCT05222932"},{"nctId":"NCT06955988","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Locally Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["AST2303 Tablets(ABK3376 Tablets) ，25mg","AST2303 Tablets(ABK3376 Tablets) ，50mg","AST2303 Tablets(ABK3376 Tablets) ，75mg","AST2303 Tablets(ABK3376 Tablets) ，100mg","AST2303 Tablets(ABK3376 Tablets) ，125mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, single arm, open label, phase I clinical trial, including dose escalation (phase IA) and dose expansion (phase IB). This study aimed to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of ast2303 tablets (abk3376 tablets) in subjects with locally advanced or metastatic non-small cell lung cancer. A safety review committee (SRC) was established in this study, which will review the safety, efficacy, pharmacokinetics and other data obtained from the study, and make decisions on key issues such as dose escalation and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06955988"},{"nctId":"NCT06500026","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":722,"enrollmentType":"ACTUAL","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Small Cell Lung Cancer"],"interventions":["BL-B01D1","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent small cell lung cancer after failure of anti-PD-1/PD-L1 Monoclonal Antibodies and platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06500026"},{"nctId":"NCT06154291","title":"FIH XON7 in Advanced/Metastatic Solid Tumors","sponsor":"Xenothera SAS","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":255,"enrollmentType":"ESTIMATED","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-06-22","conditions":["Advanced Solid Tumor","Metastatic Cancer"],"interventions":["XON7"],"countries":["Belgium","France"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to investigate anti-tumors efficacy in selected solid tumor types and to further evaluate safety and tolerability of XON7 at RP2D.","sourceUrl":"https://clinicaltrials.gov/study/NCT06154291"},{"nctId":"NCT03290534","title":"Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®","sponsor":"CivaTech Oncology","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2019-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Lung Cancer","Lung Cancer Stage I","Lung Cancer Stage II"],"interventions":["CivaSheet"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a feasibility study to determine the usefulness of a brachytherapy device that utilizes active components (palladium-103) of standard devices in a novel configuration, which may benefit lung cancer patients by reducing the radiation dose to critical structures, such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a surgical margin.","sourceUrl":"https://clinicaltrials.gov/study/NCT03290534"},{"nctId":"NCT04337177","title":"Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors","sponsor":"Valent Technologies, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2021-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Solid Tumors","Neuroblastoma","Rhabdomyosarcoma","Ewing Sarcoma","Hepatoblastoma","Medulloblastoma"],"interventions":["VAL-413","Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma","sourceUrl":"https://clinicaltrials.gov/study/NCT04337177"},{"nctId":"NCT05262491","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2022-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Gastrointestinal Tumor"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05262491"},{"nctId":"NCT06390774","title":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2024-10-18","conditions":["Locally Advanced, Recurrent or Metastatic Malignancies"],"interventions":["SSGJ-705"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was an open-label phase I study to evaluate the safety, tolerability, PK profile and potential efficacy of SSGJ-705 as a single agent in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06390774"},{"nctId":"NCT07287202","title":"Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)","sponsor":"Sovargen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Focal Cortical Dysplasia","Tuberous Sclerosis Complex (TSC)","Hemimegalencephaly"],"interventions":["SVG103"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME.","sourceUrl":"https://clinicaltrials.gov/study/NCT07287202"},{"nctId":"NCT06008054","title":"A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":376,"enrollmentType":"ESTIMATED","startDate":"2023-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Esophageal Cancer","Gastric Cancer","Colorectal Cancer"],"interventions":["SI-B003","BL-B01D1","PD-1 Monoclonal Antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II study is a clinical study to explore the efficacy and safety of SI-B003 Monotherapy, BL-B01D1+SI-B003 Combination Therapy and BL-B01D1+PD-1 Monoclonal Antibody in patients with locally advanced or metastatic esophageal cancer, gastric cancer, colorectal cancer and other gastrointestinal tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06008054"},{"nctId":"NCT06617169","title":"Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors","sponsor":"Monopar Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2025-05-21","conditions":["Solid Tumor, Adult","Bladder Cancer","Urothelial Carcinoma","Triple-negative Breast Cancer","Lung Cancer","Colorectal Cancer","Gastric Cancer","Ovarian Cancer","Pancreatic Cancer"],"interventions":["MNPR-101-PCTA-177Lu"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the imaging study MNPR-101-D001 (actively recruiting, diagnostic study of MNPR-101-DFO\\*-89Zr). * TITE-BOIN will be used to objectively determine dose increase, no dose change, or dose decrease for each group of two patients. * The treatment period consists of two 12-week cycles. Patients will receive three equal fractions of MNPR-101-PCTA-177Lu with radioactivity ranging from 480-2240 MBq on each of Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (12 weeks after Cycle 1 Day 1). * Patients will be followed for 12 weeks","sourceUrl":"https://clinicaltrials.gov/study/NCT06617169"},{"nctId":"NCT03945162","title":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","sponsor":"Theralase® Technologies Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2019-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG"],"interventions":["Ruvidar® (TLD-1433) bladder infusion and PDT"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Carcinoma In-Situ (\"CIS\") (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin (\"BCG\")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial induction course plus at least two of six doses of a second induction course. Patients experiencing disease relapse within 12 months after f","sourceUrl":"https://clinicaltrials.gov/study/NCT03945162"},{"nctId":"NCT07198633","title":"A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":212,"enrollmentType":"ESTIMATED","startDate":"2025-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Advanced Prostate Cancer"],"interventions":["QLC5508","abiraterone acetate","enzalutamide","QLH12016"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of QLC5508 in combination with NHA (abiraterone or enzalutamide), QLC5508 in combination with QLH12016, QLC5508 in combination with QLH12016 and NHA (abiraterone or enzalutamide), and QLH12016 in combination with NHA (abiraterone or enzalutamide) in subjects with advanced prostate cancer. The study consists of two stages: Phase Ib: is the combination dose-escalation stage, during which the recommended Phase II dose (RP2D) will be determined. Phase II is the efficacy exploration stage, in which, based on the RP2D established i","sourceUrl":"https://clinicaltrials.gov/study/NCT07198633"},{"nctId":"NCT05884255","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2023-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Advanced Gastroenteropancreatic Neuroendocrine Tumor"],"interventions":["Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide","long-acting Octreotide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05884255"},{"nctId":"NCT06915142","title":"A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Advanced Malignant Tumour"],"interventions":["HRS-7058 + SHR-1316","HRS-7058 + SHR-1316 + Platinum-containing doublet chemotherapy","HRS-7058 + Cetuximab","HRS-7058 + SHR-1826","HRS-7058 + SHR-1826 + SHR-1316","HRS-7058 + SHR-A1202","HRS-7058 + BP102","HRS-7058 + SHR-9839","HRS-7058 +SHR-A2102 +SHR-1316","HRS-7058 +SHR-9839(sc)+SHR-1316","HRS-7058 +SHR-1316 +BP102","HRS-7058 +SHR-A2102 +BP102","HRS-7058 +SHR-A2102 +SHR-1316 +BP102"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a multicentre, open phase II clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in combination with antitumor drugs in subjects with advanced malignant tumour. To evaluate the safety, tolerability and efficacy of HRS-7058 in combination with antitumor drugs.","sourceUrl":"https://clinicaltrials.gov/study/NCT06915142"},{"nctId":"NCT05914545","title":"A Study of FZ-AD004 in Patients With Advanced Solid Tumors","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2023-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Advanced and Metastatic Solid Tumor"],"interventions":["FZ-AD004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.","sourceUrl":"https://clinicaltrials.gov/study/NCT05914545"},{"nctId":"NCT06974929","title":"A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Breast Cancer"],"interventions":["HRS-6209 Capsules","Letrozole Tablets","HRS-2189 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06974929"},{"nctId":"NCT06437509","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2024-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":["BL-B01D1","PD-1 monoclonal antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06437509"},{"nctId":"NCT06890832","title":"A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer","sponsor":"Jina Pharmaceuticals Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2025-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-03-24","conditions":["Metastatic Castration-resistant Prostate Cancer, MCRPC"],"interventions":["50 mg cabazitaxel","100 mg cabazitaxel","200 mg cabazitaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone daily till the end of cycle 6. In Group 2, participant will take 100 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone daily till the end of cycle 6. In Group 3, participant will take 200 mg cabazitaxel every 3 weeks for 6 cycles (1 doses per cycle), 10 mg prednisone daily till the end of cycle 6. The study comprises three phases: a 21-day screening phase, an 18-week intervention phase starting on Day 1 (baseline), and a post-intervention fol","sourceUrl":"https://clinicaltrials.gov/study/NCT06890832"},{"nctId":"NCT05956587","title":"A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2024-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Non-small Cell Lung Cancer","Nasopharyngeal Carcinoma"],"interventions":["BL-B01D1","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"Phase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and mode of combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT05956587"},{"nctId":"NCT06031584","title":"A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2024-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Her2-positive/Low-expression Urinary and Digestive Tract Tumors"],"interventions":["BL-M07D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"Phase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors. Phase II: To explore the efficacy of BL-M07D1 in patients with a variety of solid tumors including locally advanced or metastatic HER2-positive/low-expressing urinary and gastrointestinal tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06031584"},{"nctId":"NCT07007910","title":"Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["m CRPC"],"interventions":["HSK46575"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK（pharmacokinetics） and PD（pharmacodynamics） of HSK46575 when given orally in patients with metastatic castration-resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07007910"},{"nctId":"NCT07151040","title":"Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors","sponsor":"One-carbon Therapeutics AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":43,"enrollmentType":"ESTIMATED","startDate":"2025-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Solid Tumor","Colorectal Cancer (CRC)","Squamous Cell Carcinoma of Head and Neck","Non-Small Cell Lung Cancer (NSCLC)","Gastrooesophageal Junction Cancer","Gastric Cancer"],"interventions":["TH9619"],"countries":["France","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07151040"},{"nctId":"NCT04478279","title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","sponsor":"Sapience Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2020-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Glioblastoma","Melanoma Stage IV","Breast Cancer","Prostate Cancer","Glioblastoma Multiforme","GBM","Brain Cancer","Metastatic Breast Cancer","Metastatic Melanoma","Metastatic Prostate Cancer","Melanoma Recurrent","Prostate Cancer Metastatic","Recurrent Glioblastoma","Newly Diagnosed Glioblastoma"],"interventions":["ST101","Temozolomide","Radiation"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT04478279"},{"nctId":"NCT07176650","title":"Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":246,"enrollmentType":"ESTIMATED","startDate":"2025-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["HLX13","Yervoy","OPDIVO"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":51,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07176650"},{"nctId":"NCT05312710","title":"Safety and Efficacy of APG-157 in Head and Neck Cancer","sponsor":"Aveta Biomics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2022-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Head and Neck Cancer","Squamous Cell Carcinoma of Oral Cavity","Squamous Cell Carcinoma of the Oropharynx"],"interventions":["APG-157"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \\& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT05312710"},{"nctId":"NCT04829604","title":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","sponsor":"Ambrx, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ACTUAL","startDate":"2021-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["HER2 Positive Metastatic Breast Cancer"],"interventions":["ARX788"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["HER2 profiling"],"summary":"A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd","sourceUrl":"https://clinicaltrials.gov/study/NCT04829604"},{"nctId":"NCT05456256","title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","sponsor":"Lantern Pharma Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Adenocarcinoma of Lung","Carcinoma, Non-Small-Cell Lung"],"interventions":["LP-300","Pemetrexed","Carboplatin"],"countries":["United States","Japan","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.","sourceUrl":"https://clinicaltrials.gov/study/NCT05456256"},{"nctId":"NCT05653752","title":"A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2022-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Non Small Cell Lung Cancer","Breast Cancer"],"interventions":["YL202"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05653752"},{"nctId":"NCT06258408","title":"A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors","sponsor":"Broadenbio Ltd., Co.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2022-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Solid Tumor"],"interventions":["BB102 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT06258408"},{"nctId":"NCT04639986","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":331,"enrollmentType":"ACTUAL","startDate":"2020-11-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Metastatic Breast Cancer"],"interventions":["Sacituzumab Govitecan-hziy","Eribulin Mesylate Injection","Capecitabine Oral Product","Gemcitabine Injection","Vinorelbine injection"],"countries":["China","South Korea","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":43,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The goal of this study is to compare the study drug, sacituzumab govitecan-hziy, versus doctors' treatment of choice in participants with HR+/HER2- metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT04639986"},{"nctId":"NCT05170958","title":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":396,"enrollmentType":"ESTIMATED","startDate":"2022-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Advanced Solid Tumor"],"interventions":["LBL-024 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05170958"},{"nctId":"NCT06297525","title":"Study of STP938 (Dencatistat) in Advanced Solid Tumours","sponsor":"Step Pharma, SAS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2024-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Solid Tumor"],"interventions":["STP938"],"countries":["United States","France","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The Phase 1a part of the study is a dose escalation of STP938 as a monotherapy. The Phase 1b part of the study is a safety expansion cohort of STP938 as a monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06297525"},{"nctId":"NCT06405425","title":"A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Urothelial Carcinoma"],"interventions":["BL-B01D1","PD-1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 combination therapy in patients with locally advanced or metastatic urothelial carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06405425"},{"nctId":"NCT05803018","title":"A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2023-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Gynecological Malignant Tumor","Solid Tumor"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05803018"},{"nctId":"NCT05924750","title":"A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)"],"interventions":["BL-M11D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT05924750"},{"nctId":"NCT05482568","title":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":324,"enrollmentType":"ESTIMATED","startDate":"2022-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Advanced Non-small Cell Lung Cancer"],"interventions":["SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.","sourceUrl":"https://clinicaltrials.gov/study/NCT05482568"},{"nctId":"NCT06382129","title":"A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":698,"enrollmentType":"ACTUAL","startDate":"2024-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06382129"},{"nctId":"NCT06246110","title":"A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC","sponsor":"Eikon Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2024-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["NSCLC"],"interventions":["EIK1001","Pembrolizumab","Paclitaxel","Pemetrexed","Carboplatin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT06246110"},{"nctId":"NCT05631964","title":"Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":26,"enrollmentType":"ESTIMATED","startDate":"2023-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Locally Advanced or Metastatic Digestive Tract Tumors","Other Solid Tumors"],"interventions":["BL-M07D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Evaluation of BL-M07D1 for injection in Phase I clinical study of safety, tolerability, pharmacokinetic Characteristics, and initial efficacy in patients with locally advanced or metastatic digestive tract tumors and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05631964"},{"nctId":"NCT05024214","title":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2021-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Solid Tumors","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Hepatocellular Carcinoma"],"interventions":["Lenvatinib + Envafolimab","Sunitinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors. The primary hypothesis of this study is that subjects will have a better objective response rate (ORR) when treated with Envafolimab plus Lenvatinib than SOC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05024214"},{"nctId":"NCT05307705","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2022-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Breast Cancer"],"interventions":["LOXO-783","Fulvestrant","Imlunestrant","Abemaciclib","Anastrozole, Exemestane, or Letrozole","Paclitaxel"],"countries":["United States","Australia","Belgium","Canada","China","France","Germany","Japan","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":50,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.","sourceUrl":"https://clinicaltrials.gov/study/NCT05307705"},{"nctId":"NCT07024173","title":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Locally Advanced Breast Cancer","Metastatic Breast Cancer"],"interventions":["HRS-8080 Tablet","Fulvestrant injection","Exemestane tablets","Everolimus Tablets","Anastrozole Tablets","Letrozole Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07024173"},{"nctId":"NCT05668858","title":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Squamous Cell Carcinoma of Head and Neck"],"interventions":["SI-B001","SI-B003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ib: To observe the safety and tolerability of SI-B001+SI-B003 in combination and to identify RP2D in locally advanced or metastatic head and neck squamous cell carcinoma indications. Initial efficacy, pharmacokinetic characteristics and immunogenicity were evaluated. Phase II: To evaluate the efficacy of SI-B001+SI-B003 two-drug combination chemotherapy. Safety and tolerance, PK/PD, immunogenicity were evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05668858"},{"nctId":"NCT05475925","title":"A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas","sponsor":"Dren Bio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2022-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["LGLL - Large Granular Lymphocytic Leukemia","Primary Cutaneous Gamma-Delta T-Cell Lymphoma","Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma","Hepatosplenic T-cell Lymphoma","Subcutaneous Panniculitis-Like T-Cell Lymphoma","Aggressive NK Cell Leukemia","Systemic EBV1 T-cell Lymphoma, if CD8 Positive","Hydroa Vacciniforme-Like Lymphoproliferative Disorder","Extranodal NK/T Cell Lymphoma, Nasal Type","Enteropathy-Associated T-Cell Lymphoma","Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma","Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)","Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)"],"interventions":["DR-01"],"countries":["United States","Australia","France","Germany","Hong Kong","Italy","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas","sourceUrl":"https://clinicaltrials.gov/study/NCT05475925"},{"nctId":"NCT05736731","title":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","sponsor":"A2 Biotherapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2023-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2026-12","completionType":"ESTIMATED","lastUpdated":"2025-04-25","conditions":["Solid Tumor, Adult","Solid Tumor","Pancreatic Cancer","Pancreatic Neoplasms","Pancreas Cancer","Non Small Cell Lung Cancer","Non Small Cell Lung Cancer Recurrent","Non-Small Cell Squamous Lung Cancer","NSCLC","NSCLC, Recurrent","Colorectal Cancer","Colorectal Neoplasms","Colorectal Adenocarcinoma","CRC","Colorectal Cancer Metastatic","Cancer"],"interventions":["A2B530","xT-Onco with HLA-LOH Assay"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other solid tumors that express CEA and have lost HLA-A\\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the maximum or recommended dose of A2B530 that is safe for patients * Phase 2: Does the recommended dose of A2B530 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment and Apheresi","sourceUrl":"https://clinicaltrials.gov/study/NCT05736731"},{"nctId":"NCT06234098","title":"Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors","sponsor":"Alyssum Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Solid Tumor"],"interventions":["AT-1965 Liposome Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06234098"},{"nctId":"NCT05506943","title":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","sponsor":"Compass Therapeutics","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":168,"enrollmentType":"ACTUAL","startDate":"2023-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Biliary Tract Cancer","Cholangiocarcinoma","Gall Bladder Cancer","Ampullary Cancer"],"interventions":["CTX-009","Paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05506943"},{"nctId":"NCT04452955","title":"A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors","sponsor":"Intra-IMMUSG Pte Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":51,"enrollmentType":"ACTUAL","startDate":"2020-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-01","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Solid Tumor"],"interventions":["PRL3-zumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT04452955"},{"nctId":"NCT03767244","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":2517,"enrollmentType":"ACTUAL","startDate":"2019-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-13","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Prostatic Neoplasms"],"interventions":["Apalutamide","Androgen Deprivation Therapy (ADT)","Placebo"],"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","France","Germany","Israel","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":203,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.","sourceUrl":"https://clinicaltrials.gov/study/NCT03767244"},{"nctId":"NCT04673942","title":"A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors","sponsor":"EpicentRx, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2021-03-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Solid Tumor, Adult","Cancer","Neoplasms","Sarcoma","Sarcoma,Soft Tissue","Chondrosarcoma"],"interventions":["AdAPT-001","Checkpoint Inhibitor, Immune"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT04673942"},{"nctId":"NCT05128825","title":"A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2022-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer"],"interventions":["azenosertib"],"countries":["United States","Australia","Belgium","France","Italy","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":92,"serviceSignals":["Broad CGP"],"summary":"This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.","sourceUrl":"https://clinicaltrials.gov/study/NCT05128825"},{"nctId":"NCT06158477","title":"A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Chengdu JOYO pharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2024-01-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2024-11-18","conditions":["Advanced Solid Tumors"],"interventions":["JYP0035 Experimental Drug Treatment"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are: * What is the safety profile of JYP0035 when administered to these patients? * How does JYP0035 capsule behave in the body pharmacokinetically? Participants will: * Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1). * Continue with the identified dose in the dose-expansion phase (PART-2). As this is a single-arm study, there is no comparison group.","sourceUrl":"https://clinicaltrials.gov/study/NCT06158477"},{"nctId":"NCT06669975","title":"A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors","sponsor":"AP Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2025-04-25","conditions":["Advanced Solid Tumor"],"interventions":["AP402 (Part 1 Dose esclation)","AP402 (Part 2 Dose Expansion)"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1/2, multi-regional, multi-center, open-label, first-in-human (FIH), dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of AP402 in HER2-positive patients with locally or advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06669975"},{"nctId":"NCT06218940","title":"HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC","sponsor":"Newsoara Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2024-01-23","conditions":["NSCLC Stage IV"],"interventions":["HY1272"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, dose escalation study of HY1272 (administered via IV) evaluating both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in patients diagnosed with locally advanced or metastatic solid tumors (monotherapy) or locally advanced or metastatic EGFRm+ NSCLC (combination therapy). The study is designed to evaluate safety, tolerability, PK, and anti-tumor activity of HY1272 administered once weekly. Patients in the monotherapy portion of this study will receive only HY1272. Patients in the combination therapy portion of this study will receive osimertinib administered once daily (QD) with HY1272.","sourceUrl":"https://clinicaltrials.gov/study/NCT06218940"},{"nctId":"NCT05860465","title":"Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2023-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["SPH4336 Tablets","SPH4336 Tablets Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":22,"serviceSignals":["HER2 profiling"],"summary":"This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05860465"},{"nctId":"NCT06858618","title":"FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":47,"enrollmentType":"ACTUAL","startDate":"2023-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-03-05","conditions":["Safety","Antitumor Activity","PK Profile"],"interventions":["FCN-338 + Azacitidine","FCN-338 + erythromycin+ Ara-C"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 2, open-label, multicenter study to safety \\& tolerability, antitumor activity, and pharmacokinetics of FCN-338 in Combination with szacitidine (AZA) or chemotherapy(erythromycin, cytarabine(Ara-C)) in Patients with myeloid neoplasms","sourceUrl":"https://clinicaltrials.gov/study/NCT06858618"},{"nctId":"NCT05865535","title":"A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia","sponsor":"AVEO Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Cachexia"],"interventions":["AV-380"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.","sourceUrl":"https://clinicaltrials.gov/study/NCT05865535"},{"nctId":"NCT04234048","title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma","sponsor":"SciTech Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2023-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["T-cell Lymphoma","Cutaneous/Peripheral T-Cell Lymphoma","Peripheral T-cell Lymphoma","Peripheral T-Cell Lymphoma, Not Classified","Primary Cutaneous T-cell Lymphoma","Cutaneous T-Cell Lymphoma, Unspecified","Cutaneous T-cell Lymphoma","Follicular T-Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Sézary's Disease","Mycosis Fungoides"],"interventions":["Fenretinide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT04234048"},{"nctId":"NCT06683703","title":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2024-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2024-11-12","conditions":["Non-small Cell Lung Cancer Patients with Brain Metastases"],"interventions":["Utidelone combined with Bevacizumab","Utidelone"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a prospective, multicenter, two-stage phase II clinical trial evaluating the efficacy and safety of Utidelone combined with Bevacizumab in patients with non-small cell lung cancer with brain metastases. The main objective of the first stage was to determine the combined dose of the first stage and the second stage, and to compare the intracranial efficacy of the two treatment groups. Secondary objectives were to compare other intracranial efficacy, systemic efficacy, safety and tolerability between the two treatment groups.In the second stage, the main purpose was to evaluate the intracranial efficacy of Utidelone combined with Bevacizumab in patients, and the secondary purpose","sourceUrl":"https://clinicaltrials.gov/study/NCT06683703"},{"nctId":"NCT06629779","title":"A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2024-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["PF-06821497","Placebo","Enzalutamide"],"countries":["United States","Argentina","Brazil","Bulgaria","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","New Zealand","Poland","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":237,"serviceSignals":["Broad CGP"],"summary":"This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.","sourceUrl":"https://clinicaltrials.gov/study/NCT06629779"},{"nctId":"NCT07284927","title":"Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-03","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Non-Hodgkin Lymphoma","Acute Lymphoblastic Leukemia"],"interventions":["LV009 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07284927"},{"nctId":"NCT06150157","title":"A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":241,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-14","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Neoplasms"],"interventions":["JNJ-88549968","Ruxolitinib","Momelotinib"],"countries":["United States","Canada","China","France","Germany","Israel","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\\[s\\]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF only.","sourceUrl":"https://clinicaltrials.gov/study/NCT06150157"},{"nctId":"NCT06246071","title":"A Study of TYK-00540 in Adult Patients With Solid Tumors","sponsor":"TYK Medicines, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2024-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-05","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-05","completionType":"ESTIMATED","lastUpdated":"2024-02-07","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["TYK-00540"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT06246071"},{"nctId":"NCT07131202","title":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2026-01-08","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-05","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Advanced Solid Tumors"],"interventions":["FL115+PD-1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase Ib/II clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of FL115 in combination with the anti-PD-1 monoclonal antibody, in participants with advanced solid tumors. All enrolled participants will receive FL115 and Sintilimab via intravenous (IV) infusion. Treatment will continue until disease progression (excluding pseudoprogression), unacceptable toxicity, or other protocol-specified criteria for study or treatment discontinuation, whichever occurs first. The study consists of two parts: a dose-escalation phase (Phase Ib) and a cohort-expansion phase (Phase II). The Phase 2 part w","sourceUrl":"https://clinicaltrials.gov/study/NCT07131202"},{"nctId":"NCT07620041","title":"QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-06-05","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-05","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Refractory or Relapsed Solid Tumors"],"interventions":["QLC5508 (Investigational Product / Formulation T)","QLC5508 (Reference Product / Formulation R)","Itraconazole","Darolutamide","Rifampicin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A clinical trial of QLC5508 for advanced solid tumors The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors. It will also learn how two different formulations of QLC5508 compare in the body, and whether other drugs affect QLC5508. The main questions it aims to answer are: Does a single injection of QLC5508 change the heart's electrical activity (QTc interval)? How do the test formulation and the reference formulation of QLC5508 compare in the body (pharmacokinetics)? Do other drugs (itraconazole, darolutamide, or rifampicin) change how the body processes QLC5508? Investigators will compare the test formulation to the reference formula","sourceUrl":"https://clinicaltrials.gov/study/NCT07620041"},{"nctId":"NCT06756490","title":"A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Moderate or Severe Submental Fullness"],"interventions":["HY-2003 (10 mg/ml), BELKYRA and placebo","HY-2003 (5 mg/ml) and placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo. The secondary objectives include: Evaluating the pharmacokinetic characteristics of HY-2003 after a single administration in humans and obtaining preliminary pharmacokinetic parameters; Evaluating the efficacy of HY-2003 under different doses and dosing frequencies, compared with the positive control and placebo, in the treatment of subjects with moderate to severe submental fat accumulation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06756490"},{"nctId":"NCT04644770","title":"A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":144,"enrollmentType":"ACTUAL","startDate":"2020-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-08","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-08","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms","Adenocarcinoma"],"interventions":["JNJ-69086420","JNJ-78278343","Stereotactic body radiation therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\\[s\\]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.","sourceUrl":"https://clinicaltrials.gov/study/NCT04644770"},{"nctId":"NCT06882746","title":"A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2025-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-12","completionType":"ESTIMATED","lastUpdated":"2026-03-17","conditions":["Colorectal Carcinoma","Gastric Carcinoma","Pancreatic Ductal Adenocarcinoma"],"interventions":["BI 765049"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the highest dose for the study medicine called BI 765049 that people with advanced cancer can tolerate. Another purpose is to find the most suitable dose and best way of administration of BI 765049 for further clinical development. BI 765049 may help the immune system fight cancer. Participants receive BI 765049 at least once every 3 weeks. Participants may continue to get BI 765049 treatment as long as ","sourceUrl":"https://clinicaltrials.gov/study/NCT06882746"},{"nctId":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":237,"enrollmentType":"ACTUAL","startDate":"2018-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-11","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-11","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Neoplasms","Post-polycythemia Vera Myelofibrosis (Post-PV MF)","Primary Myelofibrosis (PMF)","Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)","Primary Myelofibrosis"],"interventions":["MMB"],"countries":["United States","Australia","Austria","Belgium","Bulgaria","Canada","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","Romania","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":112,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/ET MF) enrolled in studies GS-US-352-0101 (NCT01969838), GS-US-352-1214 (NCT02101268), GS-US-352-1154 (NCT02124746), SRA-MMB-301 who are currently receiving treatment with MMB (available as 50mg,100 mg, 150 mg and 200 mg tablets) and have not experienced progression of disease. The secondary objective is to assess overall survival (OS) and leukemia free survival (LFS) in all subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT03441113"},{"nctId":"NCT04879329","title":"A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":372,"enrollmentType":"ESTIMATED","startDate":"2022-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-14","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Urothelial Carcinoma"],"interventions":["disitamab vedotin","pembrolizumab"],"countries":["United States","Argentina","Australia","Belgium","Canada","Chile","Israel","Italy","Japan","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":221,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT04879329"},{"nctId":"NCT06271252","title":"A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study","sponsor":"OriCell Therapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2024-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-12","completionType":"ESTIMATED","lastUpdated":"2024-08-02","conditions":["Neoplasms, Plasma Cell","Neoplasms by Histologic Type","Neoplasms","Hemostatic Disorders","Vascular Diseases","Cardiovascular Diseases","Paraproteinemias","Blood Protein Disorders","Hematologic Diseases","Hemorrhagic Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Diseases","Multiple Myeloma"],"interventions":["OriCAR-017"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma. RIGEL Study","sourceUrl":"https://clinicaltrials.gov/study/NCT06271252"},{"nctId":"NCT07376382","title":"A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":680,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-06","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["NSCLC"],"interventions":["SYS6010","Osimertinib","platinum-pemetrexed"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, multicenter Phase III clinical trial evaluating patients with EGFR-mutant locally advanced or metastatic NSCLC. The Phase III study is planned to enroll approximately 680 participants, who will be randomized in a 1:1 ratio into the following groups: Test group: SYS6010 + osimertinib Control group: Investigator's choice of one treatment（Osimertinib or Osimertinib+ Chemotherapy）","sourceUrl":"https://clinicaltrials.gov/study/NCT07376382"},{"nctId":"NCT06430866","title":"Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":163,"enrollmentType":"ACTUAL","startDate":"2024-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-14","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-14","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)"],"interventions":["ABP 234","Pembrolizumab"],"countries":["Argentina","Bulgaria","Chile","France","Georgia","Germany","Italy","Malaysia","Mexico","Philippines","Poland","Romania","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":128,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to demonstrate pharmacokinetic (PK) similarity ABP 234 with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06430866"},{"nctId":"NCT06004661","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":23,"enrollmentType":"ACTUAL","startDate":"2024-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-14","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-14","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"interventions":["AAA617","68Ga-PSMA-11"],"countries":["United States","France","Germany","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study will address health authorities' requests to determine whether moderate and severe renal impairment have an impact on the biodistribution, dosimetry and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) administered to participants with progressive PSMA-positive metastatic castration-resistant prostate cancer. The study will also characterize the risk of QT prolongation of AAA617 in this participant population.","sourceUrl":"https://clinicaltrials.gov/study/NCT06004661"},{"nctId":"NCT06797336","title":"A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors","sponsor":"PAQ Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2024-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-16","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Solid Tumor"],"interventions":["PT0253"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["RAS genotyping"],"summary":"The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06797336"},{"nctId":"NCT05669430","title":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","sponsor":"GV20 Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":365,"enrollmentType":"ESTIMATED","startDate":"2023-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-05","completionType":"ESTIMATED","lastUpdated":"2025-02-13","conditions":["Solid Tumor, Adult","Refractory Cancer","Endometrial Carcinoma (EC)","Squamous Head and Neck Carcinoma","pMMR/MSS Adenocarcinoma of the Colon or Rectum","Cutaneous Melanoma","Non-Small Cell Lung Cancer"],"interventions":["GV20-0251","GV20-0251 and Pembrolizumab [KEYTRUDA®]"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT05669430"},{"nctId":"NCT07223125","title":"A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2025-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-15","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced-stage Solid Tumors"],"interventions":["JNJ-89862175"],"countries":["United States","France","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \\[RP2Ds\\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07223125"},{"nctId":"NCT06607627","title":"PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-23","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Generalized Myasthenia Gravis","gMG"],"interventions":["Gefurulimab"],"countries":["United States","Brazil","Japan","Poland","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06607627"},{"nctId":"NCT06850623","title":"Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer","sponsor":"EXACT Therapeutics AS","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2025-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-15","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Locally Advanced Pancreatic Adenocarcinoma"],"interventions":["Acoustic Cluster Therapy","Modified FOLFIRINOX"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy (ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06850623"},{"nctId":"NCT04678648","title":"A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","sponsor":"RasCal Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2021-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-30","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Malignant Solid Neoplasm","RAS Mutation","Lung Cancer","Colon Cancer","Glioblastoma","Pancreatic Cancer"],"interventions":["RSC-1255 Dose Escalation","RSC-1255 Dose Expansion"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["RAS genotyping"],"summary":"RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.","sourceUrl":"https://clinicaltrials.gov/study/NCT04678648"},{"nctId":"NCT06747338","title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-16","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Early or Locally Advanced HER2-positive Breast Cancer"],"interventions":["KN026","HB1801","Pertuzumab","Trastuzumab","Docetaxel","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This randomized, controlled, open-label, multicenter study will evaluate the safety and efficacy of KN026 in combination with HB1801 ± Carboplatin as neoadjuvant therapy in patients with early or locally advanced HER2-positive breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06747338"},{"nctId":"NCT04185883","title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":610,"enrollmentType":"ACTUAL","startDate":"2019-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-17","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-05","completionType":"ESTIMATED","lastUpdated":"2025-10-22","conditions":["Advanced Solid Tumors","Kirsten Rat Sarcoma (KRAS) pG12C Mutation"],"interventions":["Sotorasib","Trametinib","RMC-4630","Afatinib","Pembrolizumab","Panitumumab","Carboplatin, pemetrexed, docetaxel, paclitaxel","Atezolizumab","Palbociclib","MVASI® (bevacizumab-awwb)","TNO155","IV Chemotherapy (Regimen 1)","IV Chemotherapy (Regimen 2)","BI 1701963","AMG 404","Everolimus"],"countries":["United States","Australia","Austria","Belgium","Canada","Germany","Italy","Japan","Netherlands","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":90,"serviceSignals":["RAS genotyping"],"summary":"To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04185883"},{"nctId":"NCT06062810","title":"Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-18","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Breast Cancer"],"interventions":["Raloxifene - Usual","Raloxifene - Study"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06062810"},{"nctId":"NCT06716619","title":"A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-19","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-19","completionType":"ESTIMATED","lastUpdated":"2025-03-26","conditions":["Tumor Associated Lymph Node T Cell","Advanced Solid Tumor","Immunotherapy","Serplulimab Injection"],"interventions":["Tumor Associated Lymph node T cell","Serplulimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Phase I clinical trial of the safety and tolerability of tumor-associated lymph node T cell injection in patients with advanced malignant solid tumors, including but not limited to melanoma, head and neck tumors, cervical cancer, and non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06716619"},{"nctId":"NCT07672236","title":"A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.","sponsor":"OncoZenge AB","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Head & Neck Cancer","Oral Mucositis"],"interventions":["BupiZenge 25 mg","Lidocaine viscous 2%"],"countries":["Denmark","Germany","Norway","Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"Most patients who receive radiation therapy for head and neck cancer develop painful sores in the mouth called oral mucositis. For many of them, these sores are severe and result in debilitating pain. The sores usually start in the third week of radiation and last aboutfive weeks, often continuing for two weeks after treatment ends. Current pain treatments, for instance lidocaine solution, only give short-lasting pain relief. BupiZenge is a lozenge that dissolves slowly in the mouth and contains bupivacaine. Bupivacaine is a long-acting pain-relieving medicine and has been safely used for many years for both children and adults, and its safety profile is well understood. The BupiZenge lozeng","sourceUrl":"https://clinicaltrials.gov/study/NCT07672236"},{"nctId":"NCT06402331","title":"FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Fusion Pharmaceuticals Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ACTUAL","startDate":"2024-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-23","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-23","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["FPI-2265"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.","sourceUrl":"https://clinicaltrials.gov/study/NCT06402331"},{"nctId":"NCT05950165","title":"A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma","sponsor":"Cho Pharma Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2020-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-23","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-23","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Non-Hodgkin Lymphoma"],"interventions":["CHO-H01","CHO-H01 at RP2D","Lenalidomide"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This is a 2-part study. Part 1/Phase 1 of the study will be conducted to determine the safety and tolerability of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D). Part 2/Phase 2a will assess the anticancer activity and safety of CHO-H01 plus lenalidomide in subjects with low-grade relapsed/refractory CD20+ non-Hodgkin's lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05950165"},{"nctId":"NCT05849298","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":49,"enrollmentType":"ACTUAL","startDate":"2024-01-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-23","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-23","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Prostatic Neoplasm"],"interventions":["AAA617","AAA517","Piflufolastat F 18","ARPI","ADT","Best supportive care"],"countries":["United States","Brazil","Canada","Czechia","France","Germany","Italy","Poland","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \\[177Lu\\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans).","sourceUrl":"https://clinicaltrials.gov/study/NCT05849298"},{"nctId":"NCT04044859","title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","sponsor":"USWM CT, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2019-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-23","primaryCompletionType":"ESTIMATED","completionDate":"2037-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Endometrial Cancer","Esophageal Cancer","Esophagogastric Junction (EGJ)","Gastric (Stomach) Cancer","Head and Neck Cancer","Melanoma","Ovarian Cancer","Non-small Cell Lung (NSCLC)","Urothelial Cancer"],"interventions":["Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks"],"countries":["United States","Canada","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04044859"},{"nctId":"NCT06783647","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2025-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-24","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Advanced Solid Tumour"],"interventions":["LBL-024 for Injection","Docetaxel Injection","Bevacizumab Injection","Pemetrexed Disodium for Injection","Paclitaxel Injection","Carboplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.","sourceUrl":"https://clinicaltrials.gov/study/NCT06783647"},{"nctId":"NCT06008119","title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","sponsor":"Shanghai Kechow Pharma, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2023-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-24","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Colorectal Cancer Metastatic"],"interventions":["Tunlametinib plus Vemurafenib","Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, Phase 3 study","sourceUrl":"https://clinicaltrials.gov/study/NCT06008119"},{"nctId":"NCT06014528","title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2022-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-24","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Ovarian Cancer Recurrent"],"interventions":["IN10018","Placebo of IN10018","Pegylated Liposomal Doxorubicin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).","sourceUrl":"https://clinicaltrials.gov/study/NCT06014528"},{"nctId":"NCT05768932","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"SillaJen, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2022-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-24","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-24","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced Solid Tumor","TNBC - Triple-Negative Breast Cancer","Gastric Cancer","Leukemia Acute Myeloid Leukemia (AML)"],"interventions":["BAL0891","Tislelizumab","Paclitaxel"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and tolerability of increasing doses of BAL0891 in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia. An adaptive model-based design will be used to guide the dose escalation. Subject assignment to Substudy 1, 2, 3 and 4 will be finalized following approval from the investigator and sponsor. The dose-expansion stage will be conducted with the RP2D to further evaluate the preliminary anti-tumor activity, safety, and tolerability","sourceUrl":"https://clinicaltrials.gov/study/NCT05768932"},{"nctId":"NCT06525350","title":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":256,"enrollmentType":"ESTIMATED","startDate":"2024-07","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-25","completionType":"ESTIMATED","lastUpdated":"2024-07-29","conditions":["Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression"],"interventions":["Glumetinib tablets","HB1801 (docetaxel, albumin-bound）","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of glumetinib Tablets and Docetaxel for Injection（Albumin Bound）(HB1801) in the treatment of MET-overexpressed non-small cell lung cancer (NSCLC); The main purpose of Stage 2 is to evaluate the efficacy of the combination of glumetinib tablets and HB1801 compared to glumetinib tablets monotherapy or docetaxel in the treatment of MET-expressed NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06525350"},{"nctId":"NCT05653453","title":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","sponsor":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":512,"enrollmentType":"ESTIMATED","startDate":"2022-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-28","completionType":"ESTIMATED","lastUpdated":"2025-03-24","conditions":["Locally Advanced Pancreatic Cancer"],"interventions":["Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel","Gemcitabine hydrochloride and albumin binding paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05653453"},{"nctId":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","sponsor":"CanariaBio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":615,"enrollmentType":"ACTUAL","startDate":"2020-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-26","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Carcinoma, Ovarian Epithelial","Ovarian Neoplasms","Ovarian Cancer","Ovarian Serous Adenocarcinoma","Fallopian Tube Neoplasms","Fallopian Tube Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Peritoneal Cancer","Peritoneal Carcinoma","Peritoneal Neoplasms"],"interventions":["Oregovomab","Paclitaxel","Carboplatin","Placebo"],"countries":["United States","Argentina","Belgium","Brazil","Canada","Chile","Czechia","Hungary","India","Italy","Mexico","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":148,"serviceSignals":["Broad CGP"],"summary":"Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.","sourceUrl":"https://clinicaltrials.gov/study/NCT04498117"},{"nctId":"NCT05563220","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":435,"enrollmentType":"ESTIMATED","startDate":"2023-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-27","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-28","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Breast Cancer","Metastatic Breast Cancer"],"interventions":["Elacestrant","Alpelisib","Everolimus","Ribociclib","Palbociclib","Capivasertib","Abemaciclib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","France","Israel","Italy","Luxembourg","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":83,"serviceSignals":["HER2 profiling"],"summary":"This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the recommended Phase 2 dose (RP2D) of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, capivasertib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05563220"},{"nctId":"NCT07572396","title":"Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities","sponsor":"Amplexd Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-27","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["High-risk HPV (Any Strain)","LSIL, Low Grade Squamous Intraepithelial Lesion","ASC-US","HPV Infection","Cervical Abnormalities","Uterine Cervical Dysplasia"],"interventions":["EGCG and Quinine Sulfate Vaginal Suppository","Placebo"],"countries":["Hong Kong"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if an investigational vaginal suppository therapy works to treat low-grade cervical lesions (ASC-US and LSIL) associated with high-risk human papillomavirus (hr-HPV) infection in women. It will also learn about the safety and tolerability of this investigational therapy. The main questions it aims to answer are: * Does the investigational therapy lead to regression of cervical lesions? * Does the investigational therapy help clear hr-HPV infection? * Do any adverse effects occur from using this medical product? Researchers will compare the investigational therapy to a placebo (a look-alike substance that contains no active drug) to see if the inves","sourceUrl":"https://clinicaltrials.gov/study/NCT07572396"},{"nctId":"NCT05555862","title":"Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL","sponsor":"Frantz Viral Therapeutics, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2023-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Anal High Grade Squamous Intraepithelial Lesion","Anal Precancerous Condition","AIN 2/3","HPV Infection","Anal Dysplasia","HPV Disease"],"interventions":["Artesunate","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)","sourceUrl":"https://clinicaltrials.gov/study/NCT05555862"},{"nctId":"NCT04641247","title":"A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2021-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-28","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-28","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Ovarian Neoplasms","Breast Neoplasms"],"interventions":["Niraparib"],"countries":["United States","Austria","Canada","Denmark","France","Israel","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592, NCT03308942, NCT02657889) that has fulfilled the requirements for the primary objective.","sourceUrl":"https://clinicaltrials.gov/study/NCT04641247"},{"nctId":"NCT06533059","title":"A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors","sponsor":"Alterome Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2024-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-29","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Cancer","Breast Cancer","Endometrial Cancer","Metastatic Cancer","Advanced Solid Tumor"],"interventions":["ALTA2618"],"countries":["United States","Australia","France","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06533059"},{"nctId":"NCT06658353","title":"Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2025-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Locally Advanced Solid Tumor"],"interventions":["VC004 Capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Study is a single arm, open label, multicenter phase III clinical trial to evaluate the safety and efficacy of VC004 in patients with locally advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06658353"},{"nctId":"NCT05573555","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ACTUAL","startDate":"2023-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Breast Cancer"],"interventions":["ARV-471","Ribociclib"],"countries":["United States","Canada","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer. This study is seeking participants who have breast cancer that: * is advanced, may have spread to other organs (metastatic) and cannot be fully treated by surgery or radiation therapy * is sensitive to hormonal therapy (it is called estrogen receptor positive); and * is no longer responding to previous treatments This study is divided into separate sub-studies. For Sub-Study B: All participants will receive ARV-471 and a medicine called ribociclib. ARV-471 and ribociclib","sourceUrl":"https://clinicaltrials.gov/study/NCT05573555"},{"nctId":"NCT05909397","title":"Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":59,"enrollmentType":"ACTUAL","startDate":"2023-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Breast Cancer"],"interventions":["Vepdegestrant (ARV-471/PF-07850327)","Palbociclib","Letrozole"],"countries":["United States","Australia","Brazil","China","Hungary","Italy","Japan","Slovakia","Spain","Switzerland"],"northAmerica":true,"chinaSites":true,"siteCount":29,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer. In particular, the study will compare the combination of vepdegestrant plus palbociclib to standard of care therapy (letrozole plus palbociclib). Both letrozole and palbociclib are medicines already used for treatment of breast cancer. Vepdegestrant is a new medicine under study. This study is seeking participants who have breast cancer that: * Have a locally advanced or metastatic disease and cannot be fully cured by surgery or radiation therapy. A metastatic disease is when disease has spread to other parts of","sourceUrl":"https://clinicaltrials.gov/study/NCT05909397"},{"nctId":"NCT06751485","title":"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2025-01-15","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2024-12-31","conditions":["Ovarian Cancer","Primary Peritoneal","Fallopian Tube Cancers"],"interventions":["JSKN003","Doxorubicin","Paclitaxel","Topotecan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06751485"},{"nctId":"NCT07181473","title":"A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Phrontline Biopharma","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-15","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Lung Cancer (NSCLC)","Prostate Cancer","Esophageal Cancer","Solid Tumor Malignancies"],"interventions":["TJ101"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors. The main objectives of this study are : * To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ101 * to show preliminary antitumor activity in patients with advanced solid tumors Participants will: * Receive intravenous (IV) infusions of TJ101 at escalating dose levels (during dose escalation) or at the selected expansion dose. * Undergo regular tumor imaging to assess response. * Provide blood samples for pharmacokinetics (PK) and biomarker analysis. * Be monitored for side","sourceUrl":"https://clinicaltrials.gov/study/NCT07181473"},{"nctId":"NCT04886804","title":"Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":554,"enrollmentType":"ESTIMATED","startDate":"2021-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Neoplasm Metastasis","Non-Small Cell Lung Cancer"],"interventions":["zongertinib"],"countries":["United States","Australia","Austria","Belgium","China","France","Germany","Hong Kong","Israel","Italy","Japan","Netherlands","Portugal","Singapore","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":85,"serviceSignals":["HER2 profiling"],"summary":"The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are","sourceUrl":"https://clinicaltrials.gov/study/NCT04886804"},{"nctId":"NCT06225856","title":"An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies","sponsor":"Shanghai Yuyao Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2024-01-31","conditions":["Advanced Solid Tumor","Hematological Malignancy"],"interventions":["YY201"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06225856"},{"nctId":"NCT04658862","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":518,"enrollmentType":"ACTUAL","startDate":"2020-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Urinary Bladder Neoplasms"],"interventions":["Cetrelimab","TAR-200","Cisplatin","Gemcitabine","Conventional radiation therapy","Hypo-fractioned radiation therapy"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","India","Italy","Japan","Mexico","Poland","Portugal","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":290,"serviceSignals":["Broad CGP"],"summary":"The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04658862"},{"nctId":"NCT03667170","title":"KN035 for dMMR/MSI-H Advanced Solid Tumors","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2018-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Solid Tumor"],"interventions":["KN035"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy. For colorectal cancer participants, who are required to have been previously treated with standard therapies , other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03667170"},{"nctId":"NCT05363800","title":"Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":74,"enrollmentType":"ACTUAL","startDate":"2022-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma"],"interventions":["HRS-3738"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05363800"},{"nctId":"NCT05451602","title":"HEC169096 in Participants With Advanced Solid Tumors","sponsor":"Sunshine Lake Pharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":456,"enrollmentType":"ESTIMATED","startDate":"2022-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Advanced Solid Tumor"],"interventions":["HEC169096"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05451602"},{"nctId":"NCT05335993","title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","sponsor":"CanariaBio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ACTUAL","startDate":"2022-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Recurrent Ovarian Cancer","Recurrent Epithelial Cancer of Ovary","Recurrent Epithelial Ovarian Cancer","Recurrent Fallopian Tube Cancer","Peritoneal Cancer","Recurrent Carcinoma of Ovary","Adenocarcinoma of Ovary"],"interventions":["Oregovomab","Niraparib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Study to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05335993"},{"nctId":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","sponsor":"TScan Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":840,"enrollmentType":"ESTIMATED","startDate":"2024-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Head and Neck Cancer","Cervical Cancer","Non-small Cell Carcinoma","Melanoma","Ovarian Cancer","Anogenital Cancers","HPV - Anogenital Human Papilloma Virus Infection","HPV-Related Cervical Carcinoma","HPV-Related Carcinoma","HPV-Related Squamous Cell Carcinoma","HPV-Related Malignancy","HPV-Related Adenocarcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma","HPV-Related Adenosquamous Carcinoma","HPV-Associated Vaginal Adenocarcinoma","HPV-Related Endocervical Adenocarcinoma","HPV-Related Anal Squamous Cell Carcinoma","HPV-Related Verrucous Carcinoma","HPV-Related Penile Squamous Cell Carcinoma","HPV-Related Vulvar Squamous Cell Carcinoma","HPV Positive Rectal Squamous Cell Carcinoma"],"interventions":["TSC-204-A0201","TSC-204-C0702","TSC-200-A0201","TSC-204-A0201 + TSC-204-C0702","TSC-204-A0201 + TSC-200-A0201","TSC-204-C0702 + TSC-200-A0201","TSC-204-A0201 + TSC-203-A0201","TSC-204-C0702 + TSC-203-A0201","TSC-200-A0201 + TSC-203-A0201","TSC-203-A0201","TSC-204-A0101","TSC-201-B0702","TSC-204-A0201 + TSC-204-A0101","TSC-204-A0201 + TSC-201-B0702","TSC-204-C0702 + TSC-204-A0101","TSC-204-C0702 + TSC-201-B0702","TSC-200-A0201 + TSC-204-A0101","TSC-200-A0201 + TSC-201-B0702","TSC-203-A0201 + TSC-204-A0101","TSC-203-A0201 + TSC-201-B0702","TSC-202-A0201","TSC-204-A0201 + TSC-202-A0201","TSC-204-C0702 + TSC-202-A0201","TSC-200-A0201 + TSC-202-A0201","TSC-203-A0201 + TSC-202-A0201","TSC-204-A0101 + TSC-202-A0201","TSC-201-B0702 + TSC-202-A0201"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["HLA / TCR"],"summary":"TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after lymphodepleting chemotherapy in participants with locally advanced, metastatic solid tumors disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT05973487"},{"nctId":"NCT05023018","title":"NEO100 and High-Grade Meningioma","sponsor":"Neonc Technologies, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2022-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Residual, Progressive or Recurrent Grade II or III Meningioma"],"interventions":["NEO100"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT05023018"},{"nctId":"NCT06813365","title":"Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2024-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-30","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Nonsmall-cell Lung Cancer"],"interventions":["DZD6008"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate safety and antitumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations. This is the first time the drug is tested in human.","sourceUrl":"https://clinicaltrials.gov/study/NCT06813365"},{"nctId":"NCT06194734","title":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":490,"enrollmentType":"ESTIMATED","startDate":"2024-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2024-03-07","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["KC1036","Irinotecan","Docetaxel","S-1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06194734"},{"nctId":"NCT06088004","title":"Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":218,"enrollmentType":"ESTIMATED","startDate":"2023-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Solid Tumor, Adult"],"interventions":["ABO2011 Injection","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06088004"},{"nctId":"NCT07459738","title":"A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Hormone Receptor Positive HER-2 Negative Breast Cancer"],"interventions":["HLX43"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a Phase II Study of HLX43 in Hormone Receptor Positive，HER-2 negative Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first)","sourceUrl":"https://clinicaltrials.gov/study/NCT07459738"},{"nctId":"NCT06465563","title":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":93,"enrollmentType":"ACTUAL","startDate":"2024-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Biliary Tract Cancer"],"interventions":["SHR-8068","Adebrelimab","Cisplatin","Gemcitabine","Bevacizumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Cohort A and B: This cohort aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab in combination with Cisplatin plus Gemcitabine (CisGem), compared with Adebrelimab in combination with CisGem, as first-line treatment in patients with Advanced Biliary Tract cancer. Cohort C: This cohort aims to evaluate the efficacy and safety of SHR-8068 and Adebrelimab and Bevacizumab in combination with Cisplatin Plus Gemcitabine (CisGem) as first-line treatment in patients with Advanced Biliary Tract cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06465563"},{"nctId":"NCT07106892","title":"Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Colorectal Cancer (CRC)"],"interventions":["HLX43 Dose 1;","HLX43 Dose 2;","HLX43 Dose 3;"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Colorectal Cancer (CRC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07106892"},{"nctId":"NCT05841563","title":"Clinical Trial of PM54 in Advanced Solid Tumors Patients.","sponsor":"PharmaMar","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2023-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Advanced Solid Tumor"],"interventions":["PM54"],"countries":["United States","Belgium","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The first part of the study (phase Ia - dose escalation) will evaluate the safety and tolerability and identify the dose-limiting toxicities (DLTs) of PM54. The second part of the study (phase Ib - safety run-in and expansion) will be to reassess the maximum tolerated dose (MTD) defined in the Phase Ia stage in a framework of more extensive premedication, and to evaluate the antitumor activity of PM54 according to the RECIST v.1.1 (or mRECIST v.1.1 in case of MPM) and/or serum markers as appropriate, in patients with selected advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05841563"},{"nctId":"NCT04993430","title":"A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2021-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["ER-Positive, HER2-Negative Breast Cancer"],"interventions":["HRS8807","HRS8807、SHR6390"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The study is to assess safety and tolerability of HRS8807 monotherapy and in combination with SHR6390 in subjects with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT04993430"},{"nctId":"NCT05725291","title":"AMT-116 in Patients With Advanced Solid Tumors","sponsor":"Multitude Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2023-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Advanced Solid Tumor"],"interventions":["AMT-116"],"countries":["United States","American Samoa","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05725291"},{"nctId":"NCT06830850","title":"A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer","sponsor":"Atridia Pty Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2025-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-15","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Metastatic Castration Resistant Prostate Cancer"],"interventions":["HRS-5041 Single dose of HRS-5041 orally administered"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06830850"},{"nctId":"NCT07072728","title":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","sponsor":"Psyence Australia Pty Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Adjustment Disorder","Adjustment Disorder With Anxious Mood","Cancer","Cancer Cachexia","Cancer of Endometrium","Cancer of Kidney","Cancer of Prostate","Cancer of the Breast","Cancer of Stomach","Cancer Melanoma Skin","Cancer Pancreas"],"interventions":["Psilocybin therapy"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustment disorder. Study details Participants in this study will be randomly allocated by chance (similar to flipping a coin) to one of three groups: a 25mg NPX-5 dose group, a 10 mg NPX-5 dose group or a 1mg NPX-5 dose group. Participants will be allocated a dose that will be administered during their psilocybin-assisted psychotherapy (PAP) d","sourceUrl":"https://clinicaltrials.gov/study/NCT07072728"},{"nctId":"NCT06468358","title":"A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"L & L Bio Co., Ltd., Ningbo, China","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":194,"enrollmentType":"ESTIMATED","startDate":"2024-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Solid Tumor"],"interventions":["LB1410","LB4330"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody，LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06468358"},{"nctId":"NCT06459869","title":"NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","sponsor":"Akamis Bio","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Locally Advanced Rectal Cancer (LARC)"],"interventions":["NG-350A IV administration","Capecitabine oral administration","Radiotherapy"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.","sourceUrl":"https://clinicaltrials.gov/study/NCT06459869"},{"nctId":"NCT06782373","title":"A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","sponsor":"Swedish Orphan Biovitrum","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2025-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-22","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["VEXAS","VEXAS Syndrome"],"interventions":["Pacritinib","Placebo"],"countries":["United States","Canada","France","Germany","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. 78 participants will be enrolled, randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.","sourceUrl":"https://clinicaltrials.gov/study/NCT06782373"},{"nctId":"NCT07381829","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","sponsor":"HC Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":328,"enrollmentType":"ESTIMATED","startDate":"2025-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Advanced Solid Tumor Cancer"],"interventions":["HC010","Paclitaxel (Chemotherapy)","Pemetrexed","Etoposide","Carboplatin/Cisplatin","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for subsequent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07381829"},{"nctId":"NCT06646055","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"interventions":["AK112, Cadonilimab, nab-paclitaxel, gemcitabine","AK112, nab-paclitaxel, gemcitabine","nab-paclitaxel, gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase Ib/II study. All patients are stage IV pancreatic cancer (PDAC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. The purpose of this study is to evaluate the safety and efficacy of AK112 and Cadonilimab combined with chemotherapy as first-line treatment for patients with metastatic pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06646055"},{"nctId":"NCT04221204","title":"A Monotherapy in Subjects With Advanced Solid Tumors","sponsor":"3D Medicines (Beijing) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2019-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Solid Tumor, Adult"],"interventions":["Highly selective FGFR1-3 inhibitor"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT04221204"},{"nctId":"NCT05227664","title":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2022-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Metastatic Triple-negative Breast Cancer","Locally Advanced Triple-negative Breast Cancer"],"interventions":["AK117","AK112","Nab paclitaxel","paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of AK117/AK112 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05227664"},{"nctId":"NCT03259867","title":"Combination of TATE and PD-1 Inhibitor in Liver Cancer","sponsor":"Teclison Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2017-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Hepatocellular Carcinoma","Gastric Cancer"],"interventions":["Nivolumab Injectable Product","Trans-arterial tirapazamine embolization"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT03259867"},{"nctId":"NCT05781048","title":"A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":56,"enrollmentType":"ACTUAL","startDate":"2023-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Advanced Solid Tumors"],"interventions":["HRS-6209"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, andsafety of HRS-6209in subjects with advanced solid tumors.To explore the reasonable dosage of HRS-6209.This study also preliminarily evaluated the efficacy of HRS-6209 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05781048"},{"nctId":"NCT06699576","title":"ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":448,"enrollmentType":"ESTIMATED","startDate":"2024-12-20","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2024-11-21","conditions":["Osteosarcoma","Soft Tissue Sarcoma (STS)"],"interventions":["HS-20093","Anlotinib","Epirubicin","Adebrelimab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on bone and soft tissue sarcoma. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced bone and soft tissue sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06699576"},{"nctId":"NCT03592472","title":"A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)","sponsor":"Xynomic Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":413,"enrollmentType":"ESTIMATED","startDate":"2018-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Renal Cell Carcinoma"],"interventions":["Pazopanib","Abexinostat","Placebo"],"countries":["United States","China","Italy","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03592472"},{"nctId":"NCT05563844","title":"Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":74,"enrollmentType":"ACTUAL","startDate":"2022-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Diffuse Large B Cell Lymphoma，DLBCL"],"interventions":["PM 8.4 mg/m^2","PM 11.2 mg/m^2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"Purinostat mesylate for injection (PM) was the novel and highly potent Class Ia and IIb HDAC selective inhibitor. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic mice showed that the treatment of PM in each group reduced the proportion of peripheral blood tumor cells in mice. Therefore, PM has the potential to treat diffuse large B cell lymphoma. Compared with the blank control group, the body weight of the tumor-bearing animals in each dose of PM group did not decrease significantly during the treatment process, and the animals were in good condition during the whole experiment, indicating that the PM is efficacious and safe. Ma","sourceUrl":"https://clinicaltrials.gov/study/NCT05563844"},{"nctId":"NCT07362264","title":"A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Liver Cancer"],"interventions":["SH006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07362264"},{"nctId":"NCT07390838","title":"A Study of SH009 Injection in Patients With Advanced Solid Tumors.","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Liver Cancer (Locally Advanced or Metastatic)","Lung Cancer (NSCLC)","Head and Neck Cancer Squamous Cell Carcinoma","Breast Cancer (Locally Advanced or Metastatic)","Esophageal Cancer","Gastric Cancer (GC)","Solid Tumor Malignancies"],"interventions":["SH009"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07390838"},{"nctId":"NCT06998173","title":"Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor","sponsor":"Danatlas Pharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-30","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["Advanced Solid Tumors"],"interventions":["DAT-1604 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objective of the study is to evaluate the safety, tolerability, PK, and preliminary efficacy of a Polθ Inhibitor DAT-1604 in patients with advanced/metastatic solid tumors, which is refractory to standard therapies, or for which no standard therapies exist.","sourceUrl":"https://clinicaltrials.gov/study/NCT06998173"},{"nctId":"NCT05357651","title":"A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）","sponsor":"L & L Bio Co., Ltd., Ningbo, China","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Solid Tumor","Lymphoma"],"interventions":["LB1410"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05357651"},{"nctId":"NCT07169552","title":"HC010 in First-line PD-L1 Positive Advanced NSCLC Patients","sponsor":"HC Biopharma Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-12-09","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["NSCLC"],"interventions":["HC010"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)","sourceUrl":"https://clinicaltrials.gov/study/NCT07169552"},{"nctId":"NCT05283226","title":"Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy","sponsor":"NATCO Pharma Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2022-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Carcinoma","Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma"],"interventions":["NRC-2694-A","Paclitaxel"],"countries":["United States","India"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.","sourceUrl":"https://clinicaltrials.gov/study/NCT05283226"},{"nctId":"NCT05870579","title":"[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":28,"enrollmentType":"ACTUAL","startDate":"2023-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-27","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Breast Cancer"],"interventions":["[68Ga]Ga-NeoB","[177Lu]Lu-NeoB","Ribociclib","Fulvestrant","Goserelin"],"countries":["United States","China","France","Germany","Poland","Portugal","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this trial is to estimate the recommended dose (RD) of \\[177Lu\\]Lu-NeoB in combination with ribociclib and fulvestrant in participants with estrogen receptor (ER) positive (ER+), human epidermal growth factor receptor-2 (HER2) negative (HER2-) and gastrin releasing peptide receptor (GRPR) positive (GRPR+) advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or who have progressed on endocrine therapy in combination with a CDK4/6 inhibitor for advanced disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT05870579"},{"nctId":"NCT05631262","title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":321,"enrollmentType":"ACTUAL","startDate":"2022-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Selected Subjects With Advanced Solid Tumors"],"interventions":["SKB264","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and efficacy of SKB264 monotherapy in subjects with selected advanced solid tumors.The study is divided into two parts: the Part Ⅰ consists of 5 cohorts, and the Part Ⅱ for expansion. Eligible subjects will receive SKB264 monotherapy, until there is no longer clinical benefit, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT05631262"},{"nctId":"NCT05048368","title":"Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function","sponsor":"Sunshine Lake Pharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2026-10-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Esophageal Cancer","Advanced Solid Tumor"],"interventions":["Larotinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration","sourceUrl":"https://clinicaltrials.gov/study/NCT05048368"},{"nctId":"NCT04588922","title":"Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML","sponsor":"Sellas Life Sciences Group","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2021-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Hematologic Malignancies"],"interventions":["SLS009","venetoclax","azacitidine"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009 are assessed in two dose escalation groups (Group 1 in patients with relapsed/refractory AML, Group 2 in patients with relapse/refractory lymphoma/CLL/SLL). The safety, tolerability, and antitumor activity of SLS009 in combination with venetoclax and azacitidine in patient with relapsed/refractory AML who have relapsed on or are refractory to venetoclax-based regimens are being assessed in five cohorts of the expansion Group 3. Groups 4 and 5 have been added to evaluate efficacy, safety, and tolerability of GFH009 in combination with ","sourceUrl":"https://clinicaltrials.gov/study/NCT04588922"},{"nctId":"NCT05114759","title":"A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":176,"enrollmentType":"ACTUAL","startDate":"2022-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Advanced Solid Tumors"],"interventions":["SHR-A2009"],"countries":["China","Japan","South Korea"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05114759"},{"nctId":"NCT06514794","title":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","sponsor":"Allotera Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2025-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["T-cell Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma"],"interventions":["WU-CART-007"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response","sourceUrl":"https://clinicaltrials.gov/study/NCT06514794"},{"nctId":"NCT06415487","title":"ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)","sponsor":"Acepodia Biotech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-27","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["Cyclophosphamide","Fludarabine","ACE2016","Pembrolizumab"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR). The ACE2016-001 study is an open-label, Phase I, first-in-human (FIH) study that aims to evaluate the safety and tolerability, persistency, pharmacodynamics and efficacy of ACE2016 in patients with Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR).","sourceUrl":"https://clinicaltrials.gov/study/NCT06415487"},{"nctId":"NCT02912949","title":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","sponsor":"Partner Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2015-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-29","conditions":["Solid Tumours Harboring NRG1 Fusion","NSCLC Harboring NRG1 Fusion","Pancreatic Cancer Harboring NRG1 Fusion","NRG1 Fusion"],"interventions":["zenocutuzumab (MCLA-128)"],"countries":["United States","Austria","Belgium","Canada","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","Norway","Singapore","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["RNA fusion","HER2 profiling"],"summary":"This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)","sourceUrl":"https://clinicaltrials.gov/study/NCT02912949"},{"nctId":"NCT05867420","title":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","sponsor":"AskGene Pharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":594,"enrollmentType":"ESTIMATED","startDate":"2023-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Advanced Solid Tumors"],"interventions":["ASKG915","Paclitaxel + Bevacizumab","Fruquintinib","Docetaxel"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05867420"},{"nctId":"NCT07146672","title":"Exploratory Study of Super DC Cell Injection in Preventing Recurrence After Radical Surgery for Tumors","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-28","conditions":["Solid Tumor Cancer"],"interventions":["Super DC Vaccine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is a controlled, open-label exploratory clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07146672"},{"nctId":"NCT06532344","title":"An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":32,"enrollmentType":"ACTUAL","startDate":"2021-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-11-14","conditions":["Metastatic Pancreatic Cancer"],"interventions":["ONO-7913","ONO-4538","Oxaliplatin","Levofolinate","Irinotecan","Fluorouracil"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06532344"},{"nctId":"NCT07274085","title":"A Phase 1 Study of HDM2017 in Advanced Solid Tumors","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["Solid Tumors"],"interventions":["HDM2017"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I clinical study. All subjects are patients with advanced solid tumors. The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary antitumor efficacy of HDM2017 in patients with advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07274085"},{"nctId":"NCT05269316","title":"Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors","sponsor":"Impact Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":61,"enrollmentType":"ESTIMATED","startDate":"2022-02-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-01","conditions":["Solid Tumor","Advanced Solid Tumor"],"interventions":["IMP9064"],"countries":["United States","Australia","China","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05269316"},{"nctId":"NCT06950034","title":"A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)","sponsor":"Solu Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Chronic Myelomonocytic Leukemia","Chronic Myelomonocytic Leukemia (CMML)","Chronic Myelomonocytic Leukemia-1","Chronic Myelomonocytic Leukemia-2","Refractory Chronic Myelomonocytic Leukemia","CMML","Acute Myeloid Leukemia","Acute Myeloid Leukemia (AML)","Acute Myeloid Leukemia Post Cytotoxic Therapy","Acute Myeloid Leukemias","Refractory Acute Myeloid Leukemia (AML)","Acute Monocytic Leukemia"],"interventions":["STX-0712"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.","sourceUrl":"https://clinicaltrials.gov/study/NCT06950034"},{"nctId":"NCT04271644","title":"BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2019-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2025-02-25","conditions":["Multiple Myeloma","Neoplasm, Plasma Cell","Multiple Myeloma in Relapse"],"interventions":["BCMA CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04271644"},{"nctId":"NCT05944224","title":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2023-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumors"],"interventions":["SPH4336","Cadonilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05944224"},{"nctId":"NCT05226871","title":"Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":35,"enrollmentType":"ACTUAL","startDate":"2022-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Breast Cancer","Head and Neck Cancer"],"interventions":["Palbociclib","Cetuximab","Fulvestrant","Letrozole"],"countries":["United States","China","Mexico","South Korea","Taiwan","Thailand","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences o","sourceUrl":"https://clinicaltrials.gov/study/NCT05226871"},{"nctId":"NCT04776330","title":"a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2021-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2025-02-25","conditions":["Multiple Myeloma","Neoplasm, Plasma Cell","Multiple Myeloma in Relapse"],"interventions":["BCMA targeted prime CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04776330"},{"nctId":"NCT06081959","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":376,"enrollmentType":"ESTIMATED","startDate":"2023-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Metastatic Breast Cancer"],"interventions":["SKB264","Eribulin","Capecitabine","Gemcitabine","Vinorelbine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06081959"},{"nctId":"NCT06239467","title":"First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer","sponsor":"OnKure, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2024-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced Cancer","Breast Cancer","Advanced Solid Tumors","PI3K Gene Mutation"],"interventions":["OKI-219","Fulvestrant","Trastuzumab","Tucatinib","Atirmociclib","Ribociclib"],"countries":["United States","Belgium","France","Italy","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"OKI-219-101 is a Phase 1a/1b, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and efficacy of OKI-219 as monotherapy and in combination with other anti-cancer drugs. Phase 1a (Part A) will investigate escalating doses of OKI-219 monotherapy, and Phase 1b will investigate OKI-219 (at a tolerated dose determined in Part A) in combination with fulvestrant (Part B), trastuzumab and tucatinib (Part C), atirmociclib (Part D), and ribociclib and fulvestrant (Part E). Participants will continue to receive study treatment until disease progression, intolerable toxicity, or other study treatment withdrawal cri","sourceUrl":"https://clinicaltrials.gov/study/NCT06239467"},{"nctId":"NCT06730581","title":"Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-12","conditions":["Gastric Cancer Adenocarcinoma Metastatic","Ovarian Cancer","Bile Duct Cancer"],"interventions":["Utidelone Capsule 60mg/m2/d","Utidelone capsule 75mg/m2","Utidelone Capsule"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This trial is an open, multicenter, phase II clinical trial to evaluate the efficacy and safety of Utidelone capsules in patients with advanced solid tumors. The target population of the study is patients with advanced solid tumors (gastric cancer, ovarian cancer, cholangiocarcinoma and other tumors (esophageal cancer, hepatocellular carcinoma, colorectal cancer, cervical cancer). The number of evaluable cases for tumor enrollment in gastric, ovarian, and bile duct cancers will be 20 cases each, and the total number of other tumors (including esophageal, liver, colorectal, and cervical cancers) will be no more than 40 cases. Patients who met the enrollment criteria received Utidelone capsule","sourceUrl":"https://clinicaltrials.gov/study/NCT06730581"},{"nctId":"NCT03006172","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ACTUAL","startDate":"2016-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Breast Cancer","Solid Tumor"],"interventions":["Inavolisib","Fulvestrant","Letrozole","Palbociclib","Metformin","Trastuzumab","Pertuzumab"],"countries":["United States","Canada","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in patients with locally advanced or metastatic PIK3CA-mutant solid tumors, including breast cancer, and in combination with standard-of-care endocrine and/or targeted therapies for the treatment of locally advanced or metastatic PIK3CA-mutant breast cancer. Participants will be enrolled in two stages: a dose-escalation stage (Stage I) and an expansion stage (Stage II). Participants will be assigned to one of seven regimens: inavolisib as a single agent (Arm A), inavolisib in combination with palbociclib and letrozole (Arm B","sourceUrl":"https://clinicaltrials.gov/study/NCT03006172"},{"nctId":"NCT06770881","title":"JSKN033 in Chinese Subjects with Advanced Malignant Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2025-01-15","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-13","conditions":["Advanced Malignant Tumors"],"interventions":["JSKN033"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II multicenter study to evaluate the safety and efficacy of JSKN033 in Chinese subjects with unresectable locally advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06770881"},{"nctId":"NCT07128914","title":"A Clinical Study of GO306 in Patients With Advanced Solid Tumors","sponsor":"GeneSail Biotech (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Solid Tumor Malignancies"],"interventions":["GO306"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study employs a single-arm, open-label, non-randomized, dose-escalation design to investigate the safety, tolerability, and efficacy of GO306 Recombinant Oncolytic Vaccinia Virus Injection. * Part 1: Utilizes the 3+3 design principle to evaluate the safety and tolerability of a single administration of GO306 at different dose levels. The primary goal is to determine the Maximum Tolerated Dose (MTD), providing the basis for selecting the Recommended Phase 2 Dose (RP2D). * Part 2: Evaluates the safety and tolerability of repeated intratumoral (IT) or intracavitary administrations of GO306 in patients with specific tumor types.","sourceUrl":"https://clinicaltrials.gov/study/NCT07128914"},{"nctId":"NCT05302284","title":"A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma","sponsor":"RemeGen Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":452,"enrollmentType":"ESTIMATED","startDate":"2022-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2023-12-18","conditions":["Urothelial Carcinoma","HER2-expressing"],"interventions":["RC48-ADC","Toripalimab","Gemcitabine","Cisplatin","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05302284"},{"nctId":"NCT07162883","title":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2025-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["QL2107","Keytruda®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to demonstrate Pharmacokinetic similarity in exposure after the initial dose and at steady state of QL2107 compared with Keytruda.","sourceUrl":"https://clinicaltrials.gov/study/NCT07162883"},{"nctId":"NCT07733674","title":"Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"Radiomedix, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Glioblastoma Multiforme (GBM)","Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["203Pb-RMX-VHPIB injection","SPECT/CT Imaging"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: How does 203Pb-RMX-VH-PIB spread in the body (biodistribution)? What is the radiation dose delivered to organs (dosimetry)? Participants will: Receive a single intravenous (IV) injection of 203Pb-RMX-VH-PIB. Undergo multiple single-photon emission computed tomography/computed tomography (SPECT/CT) imaging scans. Have blood, urine, vital signs, and electrocardiogram (ECG) monitored for safety. Be fo","sourceUrl":"https://clinicaltrials.gov/study/NCT07733674"},{"nctId":"NCT05872347","title":"Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2023-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Breast Cancer Brain Metastases"],"interventions":["SPH4336 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["HER2 profiling"],"summary":"This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT05872347"},{"nctId":"NCT05304481","title":"Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma","sponsor":"Lukas Biomedical Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2022-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-03-06","conditions":["Hepatocellular Carcinoma"],"interventions":["ATL administration"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).","sourceUrl":"https://clinicaltrials.gov/study/NCT05304481"},{"nctId":"NCT06214143","title":"A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Advanced Solid Tumors"],"interventions":["T3011 high dose","T3011 middle dose","T3011 low dose"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06214143"},{"nctId":"NCT04184050","title":"Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)","sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ACTUAL","startDate":"2020-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Multiple Myeloma in Relapse","Multiple Myeloma","Multiple Myeloma of Bone","Multiple Myeloma With Failed Remission"],"interventions":["MK-4002"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.","sourceUrl":"https://clinicaltrials.gov/study/NCT04184050"},{"nctId":"NCT02320435","title":"A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2015-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Solid Tumors"],"interventions":["Pertuzumab","Trastuzumab","Other Combination Anti-Cancer Therapies"],"countries":["Brazil","China","Costa Rica","France","Germany","Italy","Japan","Mexico","Peru","Poland","Portugal","Russia","South Korea","Spain","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":61,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, multi-center, open-label extension study designed to provide continued pertuzumab therapy to patients receiving pertuzumab as an investigational medicinal product (IMP) in a Roche-sponsored global study and who continue to receive pertuzumab at the end of the Parent study, as well as to collect long-term safety and efficacy data of pertuzumab therapy. Patients with solid tumors who have not experienced progressive disease in the Parent study and, in the investigator's opinion, may potentially benefit from continued pertuzumab treatment, will continue to receive pertuzumab until disease progression, unacceptable toxicity, investigator/patient decision, patient non-compli","sourceUrl":"https://clinicaltrials.gov/study/NCT02320435"},{"nctId":"NCT07514065","title":"TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy","sponsor":"Tasly Pharmaceutical Group Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2026-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Metastatic Castration-Resistant Prostate Cancer Patients"],"interventions":["Treatment arm: TSL2109 capsules。Oral administration。"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"TSL2109 is a novel CDK4/6-DYRK2 dual-target inhibitor developed by Jiangsu Tasly Diyee Pharmaceutical Co., Ltd. for solid tumor treatment. Preclinical studies confirm its selective targeting of CDK4/6 and DYRK2, a eukaryotic CMGC family kinase. In palbociclib-resistant cell lines, TSL2109 downregulates cell cycle-related proteins and DYRK2 pathway ribosomal synthesis regulators (RRS1, CDK2), and upregulates p53, thus exerting synergistic antitumor effects and overcoming resistance to enzalutamide and palbociclib. As a small-molecule inhibitor with novel targets, structure and mechanism, TSL2109 blocks tumor cell cycle progression independently of hormonal signaling. Preclinical studies show ","sourceUrl":"https://clinicaltrials.gov/study/NCT07514065"},{"nctId":"NCT06011109","title":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","sponsor":"Aveta Biomics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Glioma","Glioblastoma Multiforme"],"interventions":["APG-157"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this interventional study is to evaluate the efficacy of APG-157 in combination with Bevacizumab in subjects with recurrent high-grade glioma. The main questions the study aims to answer are: * Progression-free and overall survival of patients receiving this combination; * Quality of Life (QOL); and * Tumor response on imaging The participants will take APG-157 daily by dissolving two pastilles in their mouth at around breakfast, lunch and dinner time (total of six pastilles per day). The pastilles dissolve in the mouth. The participants will continue to receive Bevacizumab as standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT06011109"},{"nctId":"NCT06343311","title":"T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)","sponsor":"Estrella Biopharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2024-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["B-Cell Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkins","Lymphomas Non-Hodgkin's B-Cell","Non-Hodgkin Lymphoma","Non-Hodgkin's Lymphoma","Large B-Cell Lymphoma","Lymphoma, Non-Hodgkin's, Adult","Lymphoma","Refractory Non-Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Lymphoma, Non-Hodgkin","HIV Associated Lymphoma","CNS Lymphoma","High-grade B-cell Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma"],"interventions":["EB103"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT06343311"},{"nctId":"NCT05983432","title":"Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","sponsor":"SystImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":470,"enrollmentType":"ESTIMATED","startDate":"2023-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-21","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Non Small Cell Lung Cancer","Lung Cancer","Breast Cancer","Esophageal Cancer","Small Cell Lung Cancer","Nasopharyngeal Cancer","Head and Neck Squamous Cell Carcinoma","Prostate Adenocarcinoma","Ovarian Cancer","Endometrial Cancer","Cervical Cancer","Triple Negative Breast Cancer"],"interventions":["BL-B01D1"],"countries":["United States","France","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05983432"},{"nctId":"NCT06625593","title":"A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2024-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Solid Tumor"],"interventions":["BG-C137","Anticancer Agents"],"countries":["United States","Australia","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with advanced solid tumors. The study will be conducted in two phases: Phase 1a (Monotherapy Dose Escalation, and Safety Expansion; Combination Dose Confirmation and Safety Expansion) and Phase 1b (Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT06625593"},{"nctId":"NCT05894239","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2023-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-28","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Metastatic Breast Cancer"],"interventions":["Inavolisib","Phesgo","Placebo","Taxane-based Chemotherapy","Optional Endocrine Therapy of Investigator's Choice"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Colombia","Finland","France","Germany","Hong Kong","India","Italy","Japan","Jordan","Kenya","Mexico","Oman","Poland","Singapore","South Africa","South Korea","Spain","Taiwan","Tunisia","Turkey (Türkiye)","Uganda","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":192,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05894239"},{"nctId":"NCT04041050","title":"A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":85,"enrollmentType":"ACTUAL","startDate":"2019-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-14","conditions":["Myeloproliferative Neoplasm"],"interventions":["Navitoclax","Ruxolitinib","Celecoxib"],"countries":["United States","Belgium","Bulgaria","Croatia","France","Germany","Italy","Japan","Serbia","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Hematology NGS"],"summary":"There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable dose of ruxolitinib therapy for at least 12 weeks prior to study enrollment. In Part 3, all eligible participants will receive navitoclax, with the primary objective being to evaluate potential navitoclax effect on QTc prolongation. In Part 4, effect of navitoclax is evaluated on the PK, safety, and tolerability of a single dose of celecoxib. In Part 5, all eligible participants will receive ruxoliti","sourceUrl":"https://clinicaltrials.gov/study/NCT04041050"},{"nctId":"NCT06970496","title":"A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.","sponsor":"Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Relapsed or Refractory B Cell Non Hodgkin Lymphoma"],"interventions":["B019"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06970496"},{"nctId":"NCT06434610","title":"A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.","sponsor":"Shanghai Jiaolian Drug Research and Development Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Platinum-resistant Recurrent Ovarian Cancer"],"interventions":["B013","Paclitaxel","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06434610"},{"nctId":"NCT05163028","title":"A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations","sponsor":"HUYABIO International, LLC.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2021-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Non Small Cell Lung Cancer","Colorectal Cancer","Pancreatic Cancer","Solid Tumor","Cancer","Cancer of Pancreas","Cancer of Colon"],"interventions":["HBI-2376"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["RAS genotyping"],"summary":"A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.","sourceUrl":"https://clinicaltrials.gov/study/NCT05163028"},{"nctId":"NCT06043466","title":"A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2023-09-21","conditions":["Colorectal Cancer","Esophagus Cancer","Gastric Cancer","Pancreas Cancer","Non-small Cell Lung Cancer","Breast Cancer","Bile Duct Cancer"],"interventions":["CEA-targeted CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA positive late malignant solid tumors, and explore the applicable dose regimen for phase II clinical trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT06043466"},{"nctId":"NCT06514508","title":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Multiple Myeloma"],"interventions":["Motixafortide+G-CSF","Placebo+G-CSF"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06514508"},{"nctId":"NCT06580301","title":"Study of YK012 in B-cell Acute Lymphoblastic Leukemia","sponsor":"Excyte Biopharma Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2024-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["B-cell Acute Lymphoblastic Leukemia"],"interventions":["YK012"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06580301"},{"nctId":"NCT06125522","title":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":11,"enrollmentType":"ACTUAL","startDate":"2024-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Breast Cancer"],"interventions":["vepdegestrant","Samuraciclib"],"countries":["United States","Belgium","France","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn about the safety and effects of the study medicine called vepdegestrant. The safety and effects of vepdegestrant will be see when given with other medicines. Vepdegestrant is studied to see if it can be a possible treatment for advanced metastatic breast cancer. This type of cancer would have spread from where it started (breast) to other parts of the body and would be tough to treat. The study is seeking for participants who have breast cancer that: * is hard to treat (advanced) and may have spread to other organs (metastatic). is sensitive to hormonal therapy (it is called estrogen receptor positive). * is no longer responding to treatments taken befor","sourceUrl":"https://clinicaltrials.gov/study/NCT06125522"},{"nctId":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":604,"enrollmentType":"ESTIMATED","startDate":"2023-09-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"interventions":["RMC-9805","RMC-6236"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["RAS genotyping"],"summary":"This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06040541"},{"nctId":"NCT04792489","title":"DALY II USA/ MB-CART2019.1 for DLBCL","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":315,"enrollmentType":"ESTIMATED","startDate":"2021-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Refractory Diffuse Large B Cell Lymphoma (DLBCL)","Relapsed Diffuse Large B Cell Lymphoma","High Grade B-cell Lymphoma (HGBCL)","Primary Mediastinal B-cell Lymphoma (PMBCL)","Transformed Lymphoma","Central Nervous System Lymphoma","Mantle Cell Lymphoma (MCL)","Richter Transformation","Transplant-ineligible 2nd Line DLBCL"],"interventions":["zamtocabtagene autoleucel (MB-CART2019.1)","Cyclophosphamide","Fludarabine","Bendamustine"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymphoma (DLBCL) after receiving at least 2 lines of therapy, primary or secondary central nervous system (CNS) lymphoma (PCNSL) and (SCNSL) after receiving at least one line of therapy, mantle cell lymphoma (MCL) and Richter's transformation (RT) after receiving at least one line of therapy, and DLBCL transplant-ineligible after receiving at least one line of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04792489"},{"nctId":"NCT05326243","title":"Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma","sponsor":"Pell Bio-Med Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2022-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2025-05-13","conditions":["Diffuse Large B Cell Lymphoma","Primary Mediastinal Large B Cell Lymphoma","Large B-cell Lymphoma","Follicular Lymphoma Grade 3A","Follicular Lymphoma Grade 3B"],"interventions":["CD19-targeted chimeric antigen receptor T-cell"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a multiple center, non-randomized, open-label, phase 1/2 study. The primary objective of Phase 1 is to evaluate the safety of PL001 and find the recommended Phase 2 dose (RP2D). The objective of Phase 2 is to evaluate the safety and efficacy of CD19 CAR-T(known as PL001).","sourceUrl":"https://clinicaltrials.gov/study/NCT05326243"},{"nctId":"NCT06079112","title":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced Urothelial Carcinoma"],"interventions":["9MW2821","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or metastatic urothelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06079112"},{"nctId":"NCT07203898","title":"A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.","sponsor":"Beijing Immupeutics Medicine Technology Limited","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["IPM514"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter study to assess the safety, tolerability, and preliminary efficacy of IPM514 in patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma. IPM514 will be administered by intramuscular injection. Six ascending dose cohorts of IPM514 will be evaluated, with each cohort planned to enroll 3-6 qualified participants after a screening period of up to 28 days, following 3 + 3 study design format, the dose levels are as follows: 50 µg, 100 µg, 200 µg, 300 µg, 450 µg, and 600 µg. It may be adjusted during the dose escalation study based on the emerging data of safety, efficacy, and biological responses upon Safety Monito","sourceUrl":"https://clinicaltrials.gov/study/NCT07203898"},{"nctId":"NCT06768151","title":"A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-10","conditions":["Advanced Lung Cancer"],"interventions":["Targeted CEA CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months. CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expressed in lung cancer, esophageal cancer, bile duct cancer, colorectal cancer, gastric cancer and other tumor types. In previous CAR-T-related clinical trials ","sourceUrl":"https://clinicaltrials.gov/study/NCT06768151"},{"nctId":"NCT05659732","title":"A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer","sponsor":"PharmaEngine","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2023-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["Acute Myeloid Leukemia","Lymphoma, Mantle-Cell"],"interventions":["PEP07"],"countries":["Australia","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is * To assess the safety and tolerability of PEP07 administered orally as a single dose and at escalating dose levels, and, to determine the dose-limiting toxicity (DLT) of study treatment in patients with Acute Myeloid Leukemia (AML) and Mantle Cell Lymphoma (MCL). * To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of PEP07 monotherapy. Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity, confirmed pregnancy, death, consent withdrawal, HSCT or other anti-cancer treatment is required, or the Sponsor ","sourceUrl":"https://clinicaltrials.gov/study/NCT05659732"},{"nctId":"NCT06108492","title":"A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2023-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2024-12-03","conditions":["Intermediate and High-risk Non-muscle Invasive Bladder Cancer"],"interventions":["SHR-2005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate and high-risk non-muscle invasive bladder cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06108492"},{"nctId":"NCT06496971","title":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","sponsor":"NaviFUS Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2024-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Glioblastoma Multiforme","Glioblastoma","Glioblastoma Multiforme, Adult","Glioma","Brain Tumor","Brain Tumor, Recurrent","Neoplasms","Neoplasms, Nerve Tissue"],"interventions":["Bevacizumab","Microbubble","Low-Intensity Focused Ultrasound"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT06496971"},{"nctId":"NCT03491683","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","sponsor":"Inovio Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":52,"enrollmentType":"ACTUAL","startDate":"2018-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Glioblastoma"],"interventions":["INO-5401","INO-9012","Cemiplimab","Radiation Therapy","Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).","sourceUrl":"https://clinicaltrials.gov/study/NCT03491683"},{"nctId":"NCT06375733","title":"A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2024-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Large B-cell Lymphoma"],"interventions":["GFH009","Zanubrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","sourceUrl":"https://clinicaltrials.gov/study/NCT06375733"},{"nctId":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":13,"enrollmentType":"ACTUAL","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Solid Tumor","Metastatic Colorectal Carcinoma","Head and Neck Squamous Cell Carcinoma","Non-small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Gastric Cancer","Renal Cell Carcinoma"],"interventions":["FPI-2053","[111In]-FPI-2107","[225Ac]-FPI-2068"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \\[225Ac\\]-FPI-2068, \\[111In\\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC, GC, RCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06147037"},{"nctId":"NCT04662580","title":"ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":183,"enrollmentType":"ACTUAL","startDate":"2021-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Metastatic Prostate Cancer"],"interventions":["ARX517","Apalutamide","Abiraterone acetate","Prednisone"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04662580"},{"nctId":"NCT05229497","title":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2022-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Advanced Malignant Tumors"],"interventions":["AK112","AK117","Carboplatin","Cisplatin","5-Fluorouracil","Gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK112 (anti-PD-1 and VEGF bispecific antibody) combined with AK117#AntiCD47 Antibody# in advanced malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05229497"},{"nctId":"NCT04977024","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","sponsor":"GeoVax, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":63,"enrollmentType":"ACTUAL","startDate":"2021-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["COVID-19 Infection","Hematopoietic and Lymphoid System Neoplasm","Leukemia","Lymphoma","Plasma Cell Myeloma"],"interventions":["COVID-19 Vaccine","Diagnostic Laboratory Biomarker Analysis","Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or cellular therapy. GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines, created from a new version of MVA, called synthetic MVA. GEO-CM04S1 works by inducing immunity (the ability to recognize and fight against an infection) to SARS-CoV-2. The immune system is stimulated to produce antibodies against SARS-CoV-2 that would block the virus from entering healthy cells. The immune system also grows new disease fighting T cells that can recognize ","sourceUrl":"https://clinicaltrials.gov/study/NCT04977024"},{"nctId":"NCT04752826","title":"BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)","sponsor":"BioInvent International AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":176,"enrollmentType":"ESTIMATED","startDate":"2021-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-15","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Advanced Malignancies","Ovarian Cancer","T-cell Lymphoma","Melanoma"],"interventions":["BI-1808","Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection"],"countries":["United States","Denmark","Hungary","Russia","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Hematology NGS"],"summary":"The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1808 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials. Participants will receive infusions of BI-1808 alone or combination with pembrolizumab every 3 weeks. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors and subjects with T-cell lymphoma (TCL),","sourceUrl":"https://clinicaltrials.gov/study/NCT04752826"},{"nctId":"NCT03319940","title":"Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":269,"enrollmentType":"ACTUAL","startDate":"2017-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Small Cell Lung Carcinoma"],"interventions":["Tarlatamab","Pembrolizumab","CRS Mitigation Strategies"],"countries":["United States","Australia","Austria","France","Germany","Hong Kong","Japan","Netherlands","Poland","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["ADC biomarker"],"summary":"A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT03319940"},{"nctId":"NCT04064359","title":"Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors","sponsor":"Oxford BioTherapeutics Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2019-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-16","conditions":["Solid Tumor"],"interventions":["OBT076, a CD205-directed antibody-drug conjugate"],"countries":["United States","Belgium","France","Greece","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an \"Investigational Drug\", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory a","sourceUrl":"https://clinicaltrials.gov/study/NCT04064359"},{"nctId":"NCT07114367","title":"NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma","sponsor":"NOBO Medicine","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2025-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Non Hodgkin Lymphoma (NHL)"],"interventions":["NB02 (Poseltinib)"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients with relapsed/refractory NHL including FL, MCL and MZL","sourceUrl":"https://clinicaltrials.gov/study/NCT07114367"},{"nctId":"NCT06695845","title":"A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors","sponsor":"Jazz Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Breast Cancer","Gastric Cancer","Esophageal Cancer","Gastroesophageal Cancer","Colorectal Cancer","Endometrial Cancer","Non-small Cell Lung Cancer","Ovarian Cancer","Urothelial Carcinoma","Salivary Gland Cancer","Pancreatic Cancer","HER-2 Protein Overexpression"],"interventions":["Zanidatamab"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.","sourceUrl":"https://clinicaltrials.gov/study/NCT06695845"},{"nctId":"NCT06834282","title":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","sponsor":"CERo Therapeutics Holdings, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["AML","Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"interventions":["CER-1236","Cyclophosphamide","Fludarabine","Mesna"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This is a first in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT06834282"},{"nctId":"NCT06574568","title":"A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Excyte Biopharma Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2024-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["YKST02"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT06574568"},{"nctId":"NCT06349408","title":"IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Locally Advanced Solid Tumor"],"interventions":["IBI3001"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.","sourceUrl":"https://clinicaltrials.gov/study/NCT06349408"},{"nctId":"NCT04446351","title":"Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":107,"enrollmentType":"ACTUAL","startDate":"2020-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-27","conditions":["Neoplasms"],"interventions":["GSK6097608","Dostarlimab","Cobolimab","Belrestotug"],"countries":["United States","Canada","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants. The study may assess the PK/PD cohorts for Arm E and/or Arm F in participants outside of China and Japan. Additionally, dostarlimab will be given in combination with cobolimab in Japanese participants. Drug name mention","sourceUrl":"https://clinicaltrials.gov/study/NCT04446351"},{"nctId":"NCT07249632","title":"A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)","sponsor":"RemeGen Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Myasthenia Gravis, Ocular"],"interventions":["Telitacicept","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular Myasthenia Gravis (OMG).Approximately 120 eligible subjects aged 12 to 80 years with a diagnosis of OMG (Myasthenia Gravis Foundation of America \\[MGFA\\] Clinical Classification Type I) will be randomized in a 1:1 ratio to receive either Telitacicept or a matching placebo. Subjects must be on a stable standard-of-care therapy and have an MG Impairment Index (PRO) ocular score of ≥6 at screening and baseline.The dose is age and weight based.The primary objective is to evaluate the efficacy of Telitacicept compared to plac","sourceUrl":"https://clinicaltrials.gov/study/NCT07249632"},{"nctId":"NCT06769152","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-05","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Cervical Cancer","Ovarian Cancer"],"interventions":["HLX43"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or intolerance to standard first-line therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06769152"},{"nctId":"NCT05382364","title":"Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ACTUAL","startDate":"2022-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Metastatic HER2+ Advanced Breast Cancer","Breast Neoplasms","Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)","Colorectal Cancer"],"interventions":["Tucatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["HER2 profiling"],"summary":"The primary purpose of this study is to characterize the safety and tolerability of tucatinib (MK-7119) in Chinese participants with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, gastric or gastroesophageal junction adenocarcinoma (GEC), and colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05382364"},{"nctId":"NCT06826040","title":"SKB445 for Injection in Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2025-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumors"],"interventions":["SKB445 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB445 for injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06826040"},{"nctId":"NCT06413745","title":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":59,"enrollmentType":"ACTUAL","startDate":"2024-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["HER2 Expression / Amplification in Patients With Biliary Tract Cancer"],"interventions":["SHR-A1811"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06413745"},{"nctId":"NCT04443088","title":"An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2020-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Cancer","Solid Tumor, Adult","Cancer Metastatic","Solid Carcinoma","Solid Tumor, Unspecified, Adult","Tumor, Solid"],"interventions":["INV-1120","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04443088"},{"nctId":"NCT07022002","title":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-12","completionType":"ESTIMATED","lastUpdated":"2025-08-03","conditions":["Locally Advanced, Recurrent or Metastatic Malignancies"],"interventions":["SSGJ-705","PD-1/L1 inhibitor combined with chemotherapy","SSGJ-705 combined with chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07022002"},{"nctId":"NCT05645692","title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":204,"enrollmentType":"ACTUAL","startDate":"2023-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Urothelial Cancer"],"interventions":["Atezolizumab","Tobemstomig","Tiragolumab"],"countries":["United States","Australia","Brazil","China","Denmark","France","Germany","Greece","Italy","Mexico","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05645692"},{"nctId":"NCT05303532","title":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":214,"enrollmentType":"ESTIMATED","startDate":"2022-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Cancer"],"interventions":["Durvalumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Greece","Hungary","India","Italy","Japan","Malaysia","Mexico","Philippines","Poland","Romania","Russia","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":123,"serviceSignals":["Broad CGP"],"summary":"The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.","sourceUrl":"https://clinicaltrials.gov/study/NCT05303532"},{"nctId":"NCT06763159","title":"A Study of HS-20124 in Patients with Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-08","conditions":["Solid Cancer"],"interventions":["HS-20124 (Phase Ia：Dose escalation )","HS-20124 (Phase Ib: Dose expansion)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"HS-20124 is a novel DAR-8 antibody-drug conjugate （ADC） targeting CDH6. In preclinical studies, it inhibited tumor cell growth expressing CDH6 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20124 in Patients With Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06763159"},{"nctId":"NCT06714591","title":"Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1","sponsor":"SystImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Relapsed/Refractory Acute Myeloid Leukemia"],"interventions":["BL-M11D1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06714591"},{"nctId":"NCT04691804","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":496,"enrollmentType":"ACTUAL","startDate":"2021-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-12-31","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"interventions":["Fuzuloparib , Abiraterone acetate and Prednisone","Fuzuloparib Placebo， Abiraterone acetate and Prednisone"],"countries":["United States","Australia","Belgium","China","Czechia","France","Hungary","Poland","Russia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":147,"serviceSignals":["Broad CGP"],"summary":"To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects unselected for deoxyribonucleic acid (DNA) damage repair deficiencies (DRD) status (Cohort 1) to evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of rPFS in mCRPC subjects harboring DRD (Cohort 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT04691804"},{"nctId":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","sponsor":"Klus Pharma Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1410,"enrollmentType":"ACTUAL","startDate":"2020-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Epithelial Ovarian Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Urothelial Carcinoma","Non-Small Cell Lung Cancer","Small-Cell Lung Cancer","Endometrial Carcinoma","Head and Neck Squamous Cell Carcinoma","Breast Cancer","Cervical Cancer"],"interventions":["SKB264"],"countries":["United States","Canada","Chile","China","South Korea","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":109,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies. Patient must have historically documented, incurable, locally advanced or metastatic cancer that are refractory to standard therapies of one of the following types: 1. Triple negative breast cancer 2. Epithelial ovarian cancer 3. Non-small cell lung cancer 4. Gastric adenocarcinoma/Gastroesophageal junction adenocarcinoma 5. Small cell lung cancer 6. HR+/ HER2-breast cancer 7. Head and neck squamous cell carcinoma 8. Endometrial carcinoma 9. Urothelial carcinoma 10. Cervical cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04152499"},{"nctId":"NCT04835805","title":"A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2021-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Melanoma"],"interventions":["Belvarafenib","Cobimetinib","Nivolumab"],"countries":["United States","Australia","Canada","Germany","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["RAS genotyping"],"summary":"This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04835805"},{"nctId":"NCT07402070","title":"IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-02-04","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Resectable Stage II-III Non-small Cell Lung Cancer"],"interventions":["IBI363"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 study to evaluate the safety, and efficacy of IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07402070"},{"nctId":"NCT05911217","title":"A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer","sponsor":"CARsgen Therapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2024-05-28","conditions":["Pancreatic Cancer"],"interventions":["CT041 autologous CAR T-cell injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05911217"},{"nctId":"NCT05848739","title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","sponsor":"Sapience Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Colon Cancer","Metastatic Colon Cancer"],"interventions":["ST316","FOLFIRI regimen & bevacizumab","Fruquintinib","Lonsurf & bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin signaling pathway. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT05848739"},{"nctId":"NCT07275853","title":"Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors","sponsor":"TCRx Therapeutics Co.Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["Advanced Solid Tumors"],"interventions":["KXV01 TCR Lentinvivo Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07275853"},{"nctId":"NCT05055609","title":"Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors","sponsor":"Trethera","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2021-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2025-09-12","conditions":["Solid Tumor, Adult","Oncology"],"interventions":["TRE-515"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"TRE-515 is a first-in-class small molecule inhibitor of deoxycytidine kinase (dCK) that is being developed for oral administration in patients with solid tumors. In cancer cells, rapid and upregulated DNA replication creates high replication stress, as such, cancer cells are more susceptible than normal cells to perturbations in nucleotide metabolism by DNA-targeting treatments such as TRE-515. The Primary objective is to determine the safety and maximum tolerability of TRE-515 when administered orally once daily as a single agent. The secondary objectives are to establish a recommended phase 2 dose (RP2D), to characterize pharmacokinetics (PK) and pharmacodynamics (PD) of TRE-515, prelimina","sourceUrl":"https://clinicaltrials.gov/study/NCT05055609"},{"nctId":"NCT05902520","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","sponsor":"AgonOx, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2023-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["HNSCC","Melanoma","Gynecologic Cancer","Colorectal Cancer","Lung Cancer","Urogenital Cancer"],"interventions":["DP CD8 TIL","DP CD8 TIL KD","Low dose IL-2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies. The TIL selection process is based on evidence showing that CD8+ TIL which co-express both CD39 and CD103 harbor the bulk of tumor-reactivity and that the remaining CD8 TIL is mainly composed of non-tumor reactive bystander cells. All of the expanded TIL that are produced (1-40 billion are expected) will be delivered in the form of a cell suspension to the participants by intravenous infusion. It is proposed that these selected TIL will produce a more potent and efficacious treatment of late-stage cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05902520"},{"nctId":"NCT06799637","title":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2023-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Advanced Solid Tumors","Pancreatic Carcinoma","Ovarian Cancer","Cervical Cancers"],"interventions":["XNW28012"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.","sourceUrl":"https://clinicaltrials.gov/study/NCT06799637"},{"nctId":"NCT04771572","title":"Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.","sponsor":"Newave Pharmaceutical Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Non Hodgkin Lymphoma","Richter Transformation","Multiple Myeloma","T-cell-prolymphocytic Leukemia","Acute Myeloid Leukemia","Acute Lymphocytic Leukemia","Myeodysplastic Syndrome","Myelodysplastic/Myeloproliferative Neoplasm","Myelofibrosis","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Chronic Myelomonocytic Leukemia-2","Myelodysplastic Neoplasm in Blast Phase"],"interventions":["LP-118"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT04771572"},{"nctId":"NCT05257590","title":"CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma","sponsor":"TaiRx, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2022-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Hepatocellular Carcinoma","Advanced Cancer"],"interventions":["Nivolumab Injection [Opdivo]","CVM-1118"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05257590"},{"nctId":"NCT05265091","title":"A Study of KL590586 in Patients With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":414,"enrollmentType":"ESTIMATED","startDate":"2021-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumor"],"interventions":["KL590586 Capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes","sourceUrl":"https://clinicaltrials.gov/study/NCT05265091"},{"nctId":"NCT03148418","title":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":382,"enrollmentType":"ACTUAL","startDate":"2017-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Cancer"],"interventions":["Atezolizumab","Bevacizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Serbia","Slovenia","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":170,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient c","sourceUrl":"https://clinicaltrials.gov/study/NCT03148418"},{"nctId":"NCT02609776","title":"Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":751,"enrollmentType":"ACTUAL","startDate":"2016-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["Amivantamab","Lazertinib","Carboplatin","Pemetrexed"],"countries":["United States","Australia","Canada","China","France","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":69,"serviceSignals":["MET profiling"],"summary":"The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT02609776"},{"nctId":"NCT06487624","title":"An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors","sponsor":"FBD Biologics Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Solid Tumor","Refractory Hodgkin Lymphoma"],"interventions":["HCB301"],"countries":["United States","China","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":7,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.","sourceUrl":"https://clinicaltrials.gov/study/NCT06487624"},{"nctId":"NCT05485974","title":"A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation","sponsor":"HUYABIO International, LLC.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2022-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Lung Cancer","Non Small Cell Lung Cancer","Colorectal Cancer","Cancer of Pancreas","Colon Cancer","Solid Tumor","Cancer"],"interventions":["HBI-2438"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["RAS genotyping"],"summary":"A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.","sourceUrl":"https://clinicaltrials.gov/study/NCT05485974"},{"nctId":"NCT06461156","title":"A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Locally Advanced or Metastatic NSCLC"],"interventions":["HS-10504"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06461156"},{"nctId":"NCT07362888","title":"First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors","sponsor":"Adcendo ApS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-14","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Solid Tumors (Phase 1)"],"interventions":["ADCE-B05"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.","sourceUrl":"https://clinicaltrials.gov/study/NCT07362888"},{"nctId":"NCT04566380","title":"ONO-4538 Phase II Rollover Study (ONO-4538-98)","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":59,"enrollmentType":"ESTIMATED","startDate":"2020-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-06-03","conditions":["Pan-tumor"],"interventions":["ONO-4538","oxaliplatin","S-1","capecitabine","bevacizumab","temozolomide"],"countries":["Japan","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT04566380"},{"nctId":"NCT06143774","title":"Study of TRX-920 for Patients With Advanced Solid Tumors","sponsor":"TaiRx, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-15","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Solid Tumor"],"interventions":["TRX-920 Oral Gel (10 mg and 30 mg)"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The study drug TRX-920 Oral Gel contains SN38, an active metabolite of Irinotecan (CPT-11), which is a widely prescribed anti-cancer drug that has been approved in many countries for the treatment of colorectal and pancreatic cancer. TRX-920 is the oral gel formulation that directly contains SN38 instead of Irinotecan. A series of biology and animal studies have demonstrated that the TRX-920 Oral Gel could inhibit tumor growth with fewer side effects compared to Irinotecan.","sourceUrl":"https://clinicaltrials.gov/study/NCT06143774"},{"nctId":"NCT06215950","title":"A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2024-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-01-22","conditions":["Ovarian Cancer","Cervix Cancer","Metastatic Cancer","Advanced Cancer","Gynecologic Cancer"],"interventions":["CD70 CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain recommended doses and infusion patterns.","sourceUrl":"https://clinicaltrials.gov/study/NCT06215950"},{"nctId":"NCT07087158","title":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Renal Cell Carcinoma (RCC)"],"interventions":["IBR854","Pazopanib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, active-controlled Phase II clinical study evaluating the efficacy and safety of IBR854 combined with Pazopanib versus Pazopanib in Advanced Renal Cell Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07087158"},{"nctId":"NCT06944457","title":"Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor","sponsor":"Pharosgen Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-04-25","conditions":["Cancer","Solid Tumor Cancer","Biomarkers"],"interventions":["MPD-1"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor","sourceUrl":"https://clinicaltrials.gov/study/NCT06944457"},{"nctId":"NCT06970847","title":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","sponsor":"Clarity Pharmaceuticals Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Prostate Cancer","Prostate Cancer Patients With Detectable PSA Following Prostatectomy","Prostate Cancer Recurrent","Prostate Cancer Patients Who Have Brachytherapy Seed Implant","Prostate Cancer Patients Treated by Radiotherapy","Cryotherapy"],"interventions":["64Cu-SAR-bisPSMA"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06970847"},{"nctId":"NCT06959615","title":"A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":334,"enrollmentType":"ESTIMATED","startDate":"2024-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Advanced Solid Tumor"],"interventions":["JAB-23E73"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":32,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06959615"},{"nctId":"NCT07196579","title":"Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors","sponsor":"TCRx Therapeutics Co.Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Advanced Solid Cancer"],"interventions":["KXV01 TCR Lentinvivo Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07196579"},{"nctId":"NCT04993690","title":"A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2021-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["B-cell Lymphoma"],"interventions":["LP-168 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT04993690"},{"nctId":"NCT05565807","title":"Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma","sponsor":"Zhejiang ACEA Pharmaceutical Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2023-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-19","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["STI-6129"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a phase Ib/IIa, open-label, dose-escalation, and extension study to evaluate the safety and efficacy of an anti-CD38 antibody drug conjugate (STI-6129) in patients with relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05565807"},{"nctId":"NCT03505320","title":"A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":143,"enrollmentType":"ACTUAL","startDate":"2018-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Pharmacokinetics of Zolbetuximab","Gastric Cancer","Gastro-esophageal Junction (GEJ) Cancer","Pharmacokinetics of Oxaliplatin","Pharmacokinetics of Fluorouracil Bolus (5-FU)"],"interventions":["zolbetuximab","oxaliplatin","leucovorin","fluorouracil","Pembrolizumab","folinic acid","nivolumab","Docetaxel"],"countries":["United States","France","Italy","Japan","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["ADC biomarker"],"summary":"Zolbetuximab is being studied as a treatment for people with cancer in and around the stomach or cancer where the food pipe (esophagus) joins the stomach (gastroesophageal junction cancer). Most people with this type of cancer have a protein called Claudin 18.2 in their tumor. Zolbetuximab is thought to work by attaching to Claudin 18.2 in their tumor. This switches on the body's immune system to attack the tumor. There is an unmet medical need to treat people with advanced cancer in and around the stomach or gastroesophageal junction cancer. This study will provide more information on zolbetuximab given by itself and in combination with other treatments in adults with advanced stomach or ga","sourceUrl":"https://clinicaltrials.gov/study/NCT03505320"},{"nctId":"NCT01804686","title":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2013-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Mantle Cell Lymphoma","Follicular Lymphoma","Diffuse Large B-cell Lymphoma","Waldenstrom Macroglobulinemia","Chronic Graft Versus Host Disease"],"interventions":["Ibrutinib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Colombia","Czechia","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":175,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT01804686"},{"nctId":"NCT04553133","title":"PF-07104091 as a Single Agent and in Combination Therapy","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":157,"enrollmentType":"ACTUAL","startDate":"2020-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Small Cell Lung Cancer","Ovarian Cancer","Breast Cancer"],"interventions":["PF-07104091 monotherapy dose escalation","PF-07104091 + palbociclib + fulvestrant","PF-07104091 + palbociclib + letrozole","PF-07104091 monotherapy dose expansion (ovarian)","PF-07104091 monotherapy dose expansion (SCLC)","PF-07104091 + Fulvestrant (post CDK4/6)","PF-0704091 + Fulvestrant (post CDK4/6)"],"countries":["United States","Argentina","Bulgaria","China"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT04553133"},{"nctId":"NCT05059522","title":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":77,"enrollmentType":"ACTUAL","startDate":"2021-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Advanced Malignancies","NSCLC","Ovarian Cancer","Urothelial Cancer","Solid Tumors"],"interventions":["Avelumab","Lorlatanib","Talazoparib","Pemetrexed","Axitinib","CMP 001","Utomilumab","PF04518600"],"countries":["United States","Australia","Belgium","Canada","Denmark","France","Hungary","Israel","Italy","Japan","Mexico","New Zealand","Poland","Russia","Serbia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":71,"serviceSignals":["Broad CGP"],"summary":"This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05059522"},{"nctId":"NCT06008288","title":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2023-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["KRAS P.G12C","Pancreatic Cancer","Solid Tumor"],"interventions":["JAB-21822"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["RAS genotyping"],"summary":"Patients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06008288"},{"nctId":"NCT06961201","title":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2025-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-07","conditions":["Extensive-stage Small Cell Lung Cancer (ES-SCLC)","The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy"],"interventions":["Nano-crystalline Megestrol Acetate Oral Suspension","standard treatment"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) in both the pre-cachexia and cachexia phases. Participants enrolled in the study are those with ES-SCLC in the pre-cachexia or cachexia phase who have not received systemic treatment and are not eligible for curative therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06961201"},{"nctId":"NCT07036185","title":"A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors","sponsor":"Shanghai Bao Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-06-24","startDateType":"ESTIMATED","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2025-06-25","conditions":["Gastric/Gastroesophageal Junction Cancer","Breast Cancer","Colorectal Cancer","Non-small Cell Lung Cancer (NSCLC)","Bile Duct Cancer","Head and Neck Squamous Cell Carcinoma"],"interventions":["KJ015 Injection (Subcutaneous Injection)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07036185"},{"nctId":"NCT05424835","title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":381,"enrollmentType":"ACTUAL","startDate":"2022-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane"],"interventions":["SHR-A1811","Pyrotinib in combination with Capecitabine."],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The study is being conducted to evaluate whether the efficacy of SHR-A1811 is better than Pyrotinib in combination with Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane.","sourceUrl":"https://clinicaltrials.gov/study/NCT05424835"},{"nctId":"NCT06049212","title":"Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-29","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-small Cell Lung Cancer","Solid Tumors","Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)"],"interventions":["Sacituzumab tirumotecan","Pembrolizumab","Supportive care measures"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1 trial of the safety, tolerability, and pharmacokinetics (PK) of sacituzumab tirumotecan monotherapy, and of sacituzumab tirumotecan in combination with pembrolizumab (MK-3475) or pembrolizumab + carboplatin, in Japanese participants with advanced solid tumors or treatment-naïve advanced or metastatic non-small cell lung cancer (NSCLC). Per protocol amendment 04, Arm 3: Pembrolizumab/Carboplatin + sacituzumab tirumotecan Combination Therapy was discontinued, and subsequently all Arm 3 procedures, recruitment, and descriptions were removed.","sourceUrl":"https://clinicaltrials.gov/study/NCT06049212"},{"nctId":"NCT06434597","title":"A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Biliary Tract or Colorectal Cancer With Her2-positive/Mutated"],"interventions":["SPH5030"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":30,"serviceSignals":["HER2 profiling"],"summary":"To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06434597"},{"nctId":"NCT06343064","title":"Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2023-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-21","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["Vebreltinib","PLB1004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"Efficacy and Safety Evaluation of Vebreltinib Plus PLB1004 in EGFR TKI Relapsed MET Amplified or MET Expression in NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT06343064"},{"nctId":"NCT04429542","title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","sponsor":"Bicara Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":292,"enrollmentType":"ESTIMATED","startDate":"2020-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Head and Neck Squamous Cell Carcinoma","Squamous Cell Carcinoma of Anal Canal","Colorectal Cancer","Squamous Cell Carcinoma of the Lung","EGFR Amplification","Epithelial Ovarian Cancer","Pancreas Cancer","Cutaneous Squamous Cell Carcinoma","Head and Neck Neoplasms","Carcinoma, Squamous Cell","Squamous Cell Carcinoma of Head and Neck"],"interventions":["BCA101","Pembrolizumab"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["RNA fusion"],"summary":"The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04429542"},{"nctId":"NCT06281119","title":"Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years","sponsor":"Serum Institute of India Pvt. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Human Papillomavirus Infection"],"interventions":["Cervavac as three dose regimen","Cervavac as two dose regimen","Gardasil as three dose regimen"],"countries":["Kenya","Mozambique","South Africa"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Human papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly infected. The main burden of HPV-related disease is due to cervical cancer. Since cervical screening only detects precancerous and cancerous changes after they have occurred, HPV vaccination is primary prevention. People with HIV infection, even when effectively treated with antiretroviral therapy (ARV),are at higher risk of acquiring infection with multiple HPV types and are also known to be predisposed to a higher risk of HPV infection and subsequent CIN lesions. V","sourceUrl":"https://clinicaltrials.gov/study/NCT06281119"},{"nctId":"NCT06703255","title":"A Phase 2 Study of HX301 in Patients with High-grade Giloma","sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-15","conditions":["Glioma"],"interventions":["HX301+/Temozolomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study will include a dose-escalation and dose-expansion component to establish the recommended Phase 2 dose (RP2D) for HX301 in combination with Temozolomide and to evaluate the preliminary antitumor activity of HX301.HX301 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06703255"},{"nctId":"NCT06892379","title":"A Study of HS-20110 in Participants With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":475,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Solid Tumors"],"interventions":["HS-20110 (Phase Ia：Dose escalation )","HS-20110 (Phase Ib:Dose expansion )"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06892379"},{"nctId":"NCT05473624","title":"Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2022-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Advanced Solid Tumors"],"interventions":["HRS-1167"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05473624"},{"nctId":"NCT06378437","title":"A Study of GLB-001 in Patients With Myeloid Malignancies","sponsor":"Hangzhou GluBio Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2024-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Polycythemia Vera","Essential Thrombocythemia","Myelofibrosis","Myelodysplastic Syndromes","Acute Myeloid Leukemia","Myeloid Malignancy"],"interventions":["GLB-001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), lower-risk myelodysplastic syndrome (LR-MDS), higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML). This study consists of 3 parts, dose escalation (Phase 1a), dose exploration (Phase 1b) and dose expansion (Phase 1c). Dose escalation (Phase 1a) and dose exploration (Phase 1b) will evaluate the safety, tolerability, PK, PD ","sourceUrl":"https://clinicaltrials.gov/study/NCT06378437"},{"nctId":"NCT04192344","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":276,"enrollmentType":"ESTIMATED","startDate":"2020-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2026-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["Neoplasms","Tenosynovial Giant Cell Tumor"],"interventions":["ABSK021"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT04192344"},{"nctId":"NCT06189209","title":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","sponsor":"Rhizen Pharmaceuticals SA","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2026-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2025-12-02","conditions":["Triple Negative Breast Cancer (TNBC)"],"interventions":["Tenalisib"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06189209"},{"nctId":"NCT04704323","title":"CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia","sponsor":"Catapult Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2021-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-07-17","conditions":["Lymphocytic Leukemia, Chronic","SLL"],"interventions":["CAP-100"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-chemotherapy regimens (e.g., fludarabine, cyclophosphamide, and rituximab for patients aged \\<65 years without del17p/TP53 mutations or bendamustine and rituximab for patients ≥65 years who have additional comorbidities). Despite the gradual introduction of targeted therapies, new treatment strategies efficacious for patients ineligible for/unresponsive to these therapies are still required. These new strategies should ideally overcome disease rela","sourceUrl":"https://clinicaltrials.gov/study/NCT04704323"},{"nctId":"NCT07052214","title":"PSMA PET Combined With MRI for the Detection of PCa","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":338,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["PCA","Prostate Cancer","Prostatic Neoplasm","PSMA PET","Diagnostic Imaging","Elevated PSA","Positron Emission Tomography","Prostate Biopsy","Carcinoma of the Prostate"],"interventions":["68Ga-PSMA-11"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).","sourceUrl":"https://clinicaltrials.gov/study/NCT07052214"},{"nctId":"NCT06328738","title":"ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer","sponsor":"Enliven Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":275,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["HER2-positive Breast Cancer","HER2-positive Gastric Cancer","HER2 Positive Solid Tumors","HER2 Amplification","Colorectal Cancer"],"interventions":["ELVN-002","Trastuzumab","5-Fluorouracil","Oxaliplatin","Capecitabine","Eribulin","paclitaxel","Leucovorin"],"countries":["United States","Belgium","France","Italy","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06328738"},{"nctId":"NCT06994676","title":"A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias","sponsor":"Crossbow Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["High-risk Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia (CMML)","AML - Acute Myeloid Leukemia","Chronic Myeloid Leukemia"],"interventions":["CBX-250"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.","sourceUrl":"https://clinicaltrials.gov/study/NCT06994676"},{"nctId":"NCT05283330","title":"Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","sponsor":"Orano Med Theranostics, SAS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2022-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-05","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Cervical Cancer","Breast Cancer","Colon Cancer","NSCLC","mCRPC (Metastatic Castration-resistant Prostate Cancer)","Glioblastoma","Nonsmall Cell Lung Cancer"],"interventions":["²¹²Pb-DOTAM-GRPR1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05283330"},{"nctId":"NCT06860971","title":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2025-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Thyroid Cancer"],"interventions":["AL2846 Capsules","AL2846 Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"This study aims to demonstrate that, in subjects with locally advanced or metastatic iodine - refractory differentiated thyroid cancer who have failed previous VEGFR - targeted therapy, AL2846 can significantly prolong progression - free survival (PFS) compared with placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT06860971"},{"nctId":"NCT07368270","title":"Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Diffuse Large B Cell Lymphoma"],"interventions":["Anti-PD1 armored CD19 CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07368270"},{"nctId":"NCT06741644","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","sponsor":"CStone Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":660,"enrollmentType":"ESTIMATED","startDate":"2025-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Solid Tumors"],"interventions":["CS2009","Pemetrexed","Carboplatin","Paclitaxel","Etoposide","Nab-paclitaxel","Oxaliplatin","Capecitabine","Docetaxel","Leucovorin","5-FU","Cisplatin"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06741644"},{"nctId":"NCT06561607","title":"A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":542,"enrollmentType":"ESTIMATED","startDate":"2024-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2024-08-20","conditions":["Breast Cancer"],"interventions":["TQB2102 for Injection","Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":34,"serviceSignals":["HER2 profiling"],"summary":"The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1 randomized groups to receive TQB2102 or investigator's choice of single-agent chemotherapy (capecitabine, p","sourceUrl":"https://clinicaltrials.gov/study/NCT06561607"},{"nctId":"NCT07144852","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities","sponsor":"Sun Pharmaceutical Industries, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2025-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Actinic Keratosis"],"interventions":["Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%","Vehicle","Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E."],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the upper extremities. Approximately 260 adult patients with 4-8 mild to moderate AK lesions on one arm will be randomized to receive either active treatment or vehicle control, followed by exposure to blue light. During the study, up to 2 PDT sessions may be administered depending on the clearance of lesions. The primary endpoint is complete clearance rate (CCR) at Week 12. Secondary endpoints include AK clearance ra","sourceUrl":"https://clinicaltrials.gov/study/NCT07144852"},{"nctId":"NCT07258836","title":"A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":41,"enrollmentType":"ESTIMATED","startDate":"2025-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Neoplasms","Healthy"],"interventions":["LY4214835"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to check how safe and well-tolerated \\[18F\\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.","sourceUrl":"https://clinicaltrials.gov/study/NCT07258836"},{"nctId":"NCT05131022","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","sponsor":"Nurix Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":572,"enrollmentType":"ESTIMATED","startDate":"2022-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)","Diffuse Large B Cell Lymphoma (DLBCL)","Follicular Lymphoma (FL)","Mantle Cell Lymphoma (MCL)","Marginal Zone Lymphoma (MZL)","Waldenstrom Macroglobulinemia (WM)","Primary Central Nervous System Lymphoma (PCNSL)","Secondary Central Nervous System Lymphoma (SCNSL)"],"interventions":["NX-5948"],"countries":["United States","France","Italy","Netherlands","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":62,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05131022"},{"nctId":"NCT06867705","title":"Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only","sponsor":"Resilience","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1458,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Cancer"],"interventions":["Resilience PRO"],"countries":["France","Germany"],"northAmerica":false,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if Resilience PRO, a digital solution performing remote symptoms monitoring, can improve the quality of life of patients with a diagnosis of cancer receiving systemic anticancer treatment. The main question it aims to answer is: \\- Do patients with a diagnosis of cancer receiving systemic anticancer therapy and using Resilience PRO have an improved quality of life? Researchers will compare patients using Resilience PRO plus care as usual to patients receiving care as usual only. Participants in the intervention arm will use Resilience PRO, a mobile phone application regularly asking participants about their symptoms. For clinically important sympto","sourceUrl":"https://clinicaltrials.gov/study/NCT06867705"},{"nctId":"NCT02942290","title":"A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":129,"enrollmentType":"ESTIMATED","startDate":"2017-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Myelodysplastic Syndromes (MDS)"],"interventions":["Azacitidine","Venetoclax"],"countries":["United States","Australia","Canada","France","Germany","Italy","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.","sourceUrl":"https://clinicaltrials.gov/study/NCT02942290"},{"nctId":"NCT06384261","title":"A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy","sponsor":"OncoVerity, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Leukemia, Myeloid, Acute"],"interventions":["Cusatuzumab","Venetoclax","Azacitidine"],"countries":["United States","Canada","Germany","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?","sourceUrl":"https://clinicaltrials.gov/study/NCT06384261"},{"nctId":"NCT06702605","title":"To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-11","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2024-11-25","conditions":["Relapsed/Refractory Peripheral T Cell Lymphoma"],"interventions":["XNW5004 tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multi-center clinical study to evaluate the efficacy and safety of XNW5004 tablets in subjects with R/R PTCL. The study plans to enroll approximately 50 subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06702605"},{"nctId":"NCT07298772","title":"A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2026-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Advanced Solid Tumor"],"interventions":["SHR-4375 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07298772"},{"nctId":"NCT05828459","title":"First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors","sponsor":"Onward Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2023-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-03-20","conditions":["Hematological Malignancy","Solid Tumor"],"interventions":["OT-A201","IMids","Bevacizumab","Paclitaxel","TBD Compound"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This phase 1 study is aimed at establishing the safety basis of OT-A201 in the treatment of hematological malignancies and solid tumors. In the dose of escalation part it is to characterize the overall safety and tolerability profile and determine the recommended dose(s) of OT-A201 as monotherapy, and in various combination regimens. Preliminary information about anti-cancer activity will be further explored in the expansion part of the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05828459"},{"nctId":"NCT05143996","title":"CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","sponsor":"Cullinan Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2021-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Relapsed/Refractory Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)"],"interventions":["CLN-049"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","sourceUrl":"https://clinicaltrials.gov/study/NCT05143996"},{"nctId":"NCT06386146","title":"JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Solid Tumors"],"interventions":["JAB-30355"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06386146"},{"nctId":"NCT05865002","title":"A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)","sponsor":"Aurigene Discovery Technologies Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Relapsed Malignant Solid Neoplasm"],"interventions":["AUR107"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT05865002"},{"nctId":"NCT07208773","title":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2025-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Advanced Solid Tumors","Non Small Cell Lung Cancer","Small Cell Lung Cancer"],"interventions":["YL201","Ivonescimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07208773"},{"nctId":"NCT04454658","title":"Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ACTUAL","startDate":"2020-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2025-07-16","conditions":["Myelofibrosis (MF)"],"interventions":["ABBV-744","Navitoclax","Ruxolitinib"],"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Chile","Hungary","Israel","Italy","Japan","South Korea","Spain","Sweden","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Broad CGP"],"summary":"Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to see how safe and tolerable ABBV-744 is, when given alone, and in combination with ruxolitinib or navitoclax, for adult participants with MF. ABBV-744 is an investigational drug being developed for the treatment of MF. The study has 4 segments - A, B, C, and D. In Segment A, the safe dosing regimen of ABBV-744 is identified and then, given alone as monotherapy. In Segment B, C, and D, combination t","sourceUrl":"https://clinicaltrials.gov/study/NCT04454658"},{"nctId":"NCT04485949","title":"A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma","sponsor":"Imvax","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":99,"enrollmentType":"ACTUAL","startDate":"2023-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Glioblastoma"],"interventions":["IGV-001 Cell Immunotherapy","Placebo","Standard of Care (SOC): Radiation Therapy","SOC: Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT04485949"},{"nctId":"NCT06897228","title":"PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors","sponsor":"Shenzhen Celconta Life Science Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-03-26","conditions":["Solid Tumors, Adult"],"interventions":["PANK-003 cell injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A single-center, single-arm, dose-escalation exploratory clinical trial on the safety and efficacy of PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )combined with standard adjuvant chemotherapy after surgery in patients with solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06897228"},{"nctId":"NCT04662255","title":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","sponsor":"Loxo Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2021-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Lymphoma, Mantle-Cell"],"interventions":["Pirtobrutinib","Ibrutinib","Acalabrutinib","Zanubrutinib"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Russia","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":189,"serviceSignals":["Hematology NGS"],"summary":"This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.","sourceUrl":"https://clinicaltrials.gov/study/NCT04662255"},{"nctId":"NCT06186414","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2024-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-01-15","conditions":["Non-Muscle-Invasive Bladder Cancer (NMIBC)"],"interventions":["SIM0237","SIM0237 and BCG"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with Non-Muscle-Invasive Bladder Cancer (NMIBC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06186414"},{"nctId":"NCT06786533","title":"Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML","sponsor":"Hemogenyx Pharmaceuticals LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)"],"interventions":["Anti-FLT3 CAR-T cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety. Up to 18 evaluable adult and 18 evaluable pediatric subjects will be enrolled. Evaluable subjects are defined as those who have received an infusion of HG-CT-1. Primary clinical objectives: i. Determine the safety of HG-CT-1 based on the proportion of subjects infused with HG-CT-1 who experience a dose limiting toxicity (DLT). Secondary clinical objectives: i. Estimate the efficacy of HG-CT-1 according to standard clinical response criteria for AML. ii. Estimate overall survival of evaluable subjects. iii. Estimate progression-free survival o","sourceUrl":"https://clinicaltrials.gov/study/NCT06786533"},{"nctId":"NCT07300241","title":"Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma","sponsor":"Neomorph, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma","RCC","Clear Cell Renal Cell Carcinoma Metastatic","ccRCC","VHL-Associated Clear Cell Renal Cell Carcinoma","VHL-Associated Renal Cell Carcinoma","Kidney Cancer Metastatic","Kidney Cancers"],"interventions":["NEO-811"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07300241"},{"nctId":"NCT06674538","title":"Clinical Trial to Treat Stage IV Cancer Patients","sponsor":"Moonshot Antibodies","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Soft Tissue Cancer"],"interventions":["Moonshot antibodies"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this research is to study the safety and effectiveness of investigational antibodies attacking certain areas on the surface of cancer cells so that the body can kill the cancer cells. The antibodies will be made in a laboratory from cells taken from each subject's tumor so they will be made specifically per subject. The first step is to take blood and tumor samples so that the laboratory can produce antibodies specific to each subject's tumor. During this process, the study team will identify specific areas on the cancer cells that are not normally present in healthy cells so that the antibodies can find the cancer cells that should be destroyed. The second step is to deliver ","sourceUrl":"https://clinicaltrials.gov/study/NCT06674538"},{"nctId":"NCT06026410","title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","sponsor":"Kura Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Solid Tumors With HRAS Alterations","Non Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Renal Cell Carcinoma (Kidney Cancer)","Non Clear Cell Renal Cell Carcinoma (nccRCC)"],"interventions":["Darlifarnib","Cabozantinib","Adagrasib"],"countries":["United States","France","Germany","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["RAS genotyping"],"summary":"This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06026410"},{"nctId":"NCT05751928","title":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","sponsor":"Biocad","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":411,"enrollmentType":"ACTUAL","startDate":"2023-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Melanoma Stage III","Melanoma (Skin)"],"interventions":["BCD-217","anti-PD1","Excision of the primary lesion","Regional lymphadenectomy"],"countries":["Belarus","Russia"],"northAmerica":false,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, randomized, comparative phase III study, which will include subjects with resectable stage III skin melanoma (up to 3 resectable transient metastases are acceptable).","sourceUrl":"https://clinicaltrials.gov/study/NCT05751928"},{"nctId":"NCT06879717","title":"A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients","sponsor":"iOnctura","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2025-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","Advanced Non Squamous NSCLC"],"interventions":["roginolisib","Dostarlimab","Docetaxel"],"countries":["Belgium","Italy","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer. The main questions it aims to answer are: To compare across the treatment arms the proportion of patients with a reduction in Treg cells To evaluate the safety and tolerability of roginolisib plus dostarlimab, with or without docetaxel","sourceUrl":"https://clinicaltrials.gov/study/NCT06879717"},{"nctId":"NCT05755113","title":"A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma","sponsor":"QBiotics Group Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Soft Tissue Sarcoma"],"interventions":["Tigilanol Tiglate"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.","sourceUrl":"https://clinicaltrials.gov/study/NCT05755113"},{"nctId":"NCT06601335","title":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2024-11-14","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["AK117 in combination with AK112","Placebo in combination with Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3 study. All subjects arerecurrent or metastatic head and neck squamous Cell Carcinoma (R/M HNSCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 combined with AK117 versus pembrolizumab combined with placebo in patients with R/M HNSCC whose tumors have programmed cell death-ligand 1 (PD-L1) positive \\[Combined Positive Score (CPS) greater than or equal to 1\\].","sourceUrl":"https://clinicaltrials.gov/study/NCT06601335"},{"nctId":"NCT06223256","title":"A Study of NBL-028 in Patients With Advanced Solid Tumors","sponsor":"NovaRock Biotherapeutics, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2024-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01","completionType":"ESTIMATED","lastUpdated":"2024-03-18","conditions":["Advanced Solid Tumor"],"interventions":["NBL-028"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a multi-center, single agent study conducted in patients with advanced solid tumor types known to express Claudin 6 (CLDN6) for whom standard of care therapies are not available, are no longer effective, or not tolerated. This study consists two stages: dose-escalating and dose-expansion. Dose escalation will be guided by the Bayesian optimal interval (BOIN) design including accelerated titration to determine the maximum tolerated dose (MTD) of NBL-028. Dose expansion - Additional patients (no more than 200) will be enrolled at the recommended dose or multiple doses (if necessary) determined in the dose escalation stage. Sponsor may elect to enroll specific tumor types into four coho","sourceUrl":"https://clinicaltrials.gov/study/NCT06223256"},{"nctId":"NCT05329766","title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":332,"enrollmentType":"ACTUAL","startDate":"2022-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Gastrointestinal Tract Malignancies"],"interventions":["Domvanalimab","Quemliclustat","Zimberelimab","Fluorouracil","Leucovorin","Oxaliplatin"],"countries":["United States","Canada","Chile","France","Serbia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).","sourceUrl":"https://clinicaltrials.gov/study/NCT05329766"},{"nctId":"NCT07144345","title":"Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp","sponsor":"Sun Pharmaceutical Industries, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Actinic Keratosis"],"interventions":["Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%","Vehicle containing excipients only (VEH) without active ingredient","Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study evaluates the efficacy and safety of reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the face or bald scalp. Approximately 160 adult patients with 4-8 mild to moderate AK lesions will be randomized into four treatment arms based on two variables: type of treatment (active drug or vehicle) and incubation time. During the study, up to 2 PDT sessions may be administered depending on the clearance of lesions. The primary endpoint is complete clearance rate (CCR) at Week 12. Secondary endpoints include AK ","sourceUrl":"https://clinicaltrials.gov/study/NCT07144345"},{"nctId":"NCT05156203","title":"Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors","sponsor":"Taivex Therapeutics Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2021-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-11-12","conditions":["Advanced Solid Tumor","Lymphoma"],"interventions":["T-1301 Capsules"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"T-1301 is a novel small-molecule inhibitor of multiple kinases being developed as an oral drug for the treatment of advanced solid tumors. The nonclinical study results demonstrate the nonclinical efficacy and safety of T-1301 and support the design of this Phase 1, first-in-human (FIH) clinical trial in subjects with advanced cancer. This study is an open-label, multi-center, Phase I dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of T-1301 capsules in subjects with advanced solid tumors (including lymphoma), and to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D). Approximately 30 patients will be enrolled for the dose-escal","sourceUrl":"https://clinicaltrials.gov/study/NCT05156203"},{"nctId":"NCT06521554","title":"A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)","sponsor":"Nuvalent Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2024-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["NVL-330"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["HER2 profiling"],"summary":"Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-small lung cancer (NSCLC). Phase 1a dose escalation is designed to assess the safety and tolerability of NVL-330 and to select the candidate RP2D(s) and, if applicable, the MTD. Phase 1b expansion is designed to further evaluate the overall safety and tolerability of the candidate RP2D(s) of NVL-330 and to determine the RP2D of NVL-330 in participants with advanced or metastatic HER2 mutant NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06521554"},{"nctId":"NCT06827613","title":"A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors","sponsor":"Marengo Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Triple Negative Locally Advanced Non-resectable Breast Cancer","HR+, HER2-, Advanced Breast Cancer"],"interventions":["STAR0602","Sacituzumab Govitecan (SG)"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["RNA fusion","HER2 profiling","HLA / TCR"],"summary":"This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06827613"},{"nctId":"NCT06667687","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2025-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Non-Hodgkin's Lymphoma"],"interventions":["ABBV-291"],"countries":["United States","Australia","Israel","Japan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed. ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansi","sourceUrl":"https://clinicaltrials.gov/study/NCT06667687"},{"nctId":"NCT07369492","title":"Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["B-cell Lymphoma"],"interventions":["BAFF-R CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07369492"},{"nctId":"NCT05941507","title":"A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors","sponsor":"LigaChem Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-10-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Advanced Solid Tumors"],"interventions":["LCB84","Anti-PD-1 monoclonal antibody"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanced solid tumors refractory to standard of care, or for whom no standard of care exists. After the MTD and/or RP2D for single agent LCB84 is determined, dose escalation cohorts with select tumor types will be enrolled. Combination LCB84 and anti-PD-1 Ab will be evaluated in dose escalation after a minimum of 2 dose levels of single agent LCB84 have established DLT safety, to determine the MTD and/or","sourceUrl":"https://clinicaltrials.gov/study/NCT05941507"},{"nctId":"NCT06473961","title":"A Phase Ib Study of GC101 in NSCLC","sponsor":"Shanghai Juncell Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Non Small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer"],"interventions":["Autologous Tumor Infiltrating Lymphocytes"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT06473961"},{"nctId":"NCT07341737","title":"SL-28 for Advanced Solid Tumours","sponsor":"Second Life Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-07-13","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Head & Neck Cancer","Pancreas Carcinoma","Pancreas Cancer, Metastatic","Lung Adenocarcinoma","Lung Cancer (NSCLC)","Lung Cancer (Non-Small Cell)","Esophageal Cancer","Stomach (Gastric) Cancer","Liver Cancer","Intestinal Cancer","Bladder Cancer","Renal Cancer","Prostate Cancer","Melanoma (Skin Cancer)","Breast Cancer","Ovarian Cancer","Endometrial Cancer","Colorectal Cancer"],"interventions":["SL-28"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patie","sourceUrl":"https://clinicaltrials.gov/study/NCT07341737"},{"nctId":"NCT07081555","title":"A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer","sponsor":"Affibody","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2025-10-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-01","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Metastatic Breast Cancer","HER2 + Breast Cancer"],"interventions":["[177Lu]Lu-ABY-271"],"countries":["Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"This is a FiH phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of \\[177Lu\\]Lu-ABY-271 in subjects with HER2 positive metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07081555"},{"nctId":"NCT05879055","title":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","sponsor":"Biotheus Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2023-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Neuroendocrine Neoplasm"],"interventions":["PM8002","FOLFIRI"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).","sourceUrl":"https://clinicaltrials.gov/study/NCT05879055"},{"nctId":"NCT06838546","title":"A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-02-24","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2025-02-20","conditions":["Advanced Colorectal Cancer"],"interventions":["B1962"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, two-stage Phase IIb clinical study to evaluate the efficacy and safety of B1962 in the treatment of advanced colorectal cancer. The subjects were patients with distant metastasis or unresectable locally advanced colorectal cancer who had previously failed oxaliplatin, irinotecan, fluorouracil-based drugs therapy containing disease progression or intolerable toxic side effects. Two dose groups were investigated: Dose group 1: B1962 35 mg/kg, intravenous infusion, Q2W, Dose group 2: B1962 45 mg/kg, intravenous infusion, Q2W.","sourceUrl":"https://clinicaltrials.gov/study/NCT06838546"},{"nctId":"NCT06179160","title":"A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":710,"enrollmentType":"ESTIMATED","startDate":"2024-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Solid Tumors"],"interventions":["INCB161734","Cetuximab","Retifanlimab","GEMNabP","mFOLFIRINOX","FOLFOX","FOLFIRI","INCA33890"],"countries":["United States","Australia","Belgium","Canada","France","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["RAS genotyping"],"summary":"This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06179160"},{"nctId":"NCT04597411","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","sponsor":"Endocyte","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":101,"enrollmentType":"ACTUAL","startDate":"2021-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Prostatic Neoplasms, Castration-Resistant"],"interventions":["225^Ac-PSMA-617","68^Ga-PSMA-11"],"countries":["Australia","South Africa"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, international, dose escalation study to evaluate the safety of \\[225Ac\\]Ac-PSMA-617 (225Ac-PSMA-617) in men with PSMA-positive prostate cancer who have and have not had prior exposure to \\[177Lu\\]Lu-PSMA-617 (177Lu-PSMA-617) or \\[177Lu\\]Lu-PSMA I\\&T (177Lu-PSMA I\\&T).","sourceUrl":"https://clinicaltrials.gov/study/NCT04597411"},{"nctId":"NCT07260305","title":"A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients","sponsor":"Kangabio AUSTRALIA LTD PTY","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":57,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["KGX101 injection","Envafolimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, multi-center, dose escalation and expansion study in advanced or metastatic solid tumor patients. The're are two goals set in this study: one is to explore the safety and tolerability of KGX101 when mono and combo with envafolimab in Chinese patients, the other is to determine recommended phase 2 dose of KGX101 mono and combo with envafolimab. Participants will: 1. Take drug KGX101 mono or combo with envafolimab every 3 weeks; 2. Visit the clinic for checkups and tests. Schedule will be about 6-8 times in the first month and then about every 3 weeks afterwards.","sourceUrl":"https://clinicaltrials.gov/study/NCT07260305"},{"nctId":"NCT03401385","title":"First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)","sponsor":"Daiichi Sankyo Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":890,"enrollmentType":"ESTIMATED","startDate":"2018-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-01","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Hormone Receptor Positive Breast Cancer","Triple Negative Breast Cancer","Non-small Cell Lung Cancer"],"interventions":["Datopotamab Deruxtecan (Dato-DXd)","Steroid Containing Mouthwash","Non-Steroid Containing Mouthwash"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: * Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a * Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are l","sourceUrl":"https://clinicaltrials.gov/study/NCT03401385"},{"nctId":"NCT06715124","title":"QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations","sponsor":"Quanta Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":237,"enrollmentType":"ESTIMATED","startDate":"2025-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-02","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Advanced Solid Tumors"],"interventions":["QTX3544","Cetuximab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["RAS genotyping"],"summary":"Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06715124"},{"nctId":"NCT06356311","title":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2024-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-06","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Gastroesophageal Cancer"],"interventions":["Sacituzumab tirumotecan","Trifluridine-Tipiracil","Irinotecan","Paclitaxel","Docetaxel","Rescue medications","Supportive care measures"],"countries":["United States","Belgium","Brazil","Canada","Chile","China","Colombia","Denmark","France","Germany","Hong Kong","Israel","Italy","Japan","Malaysia","Mexico","Peru","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":168,"serviceSignals":["Broad CGP"],"summary":"This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumotecan is superior to TPC with respect to Overall Survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06356311"},{"nctId":"NCT05397496","title":"Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2022-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-04","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["B-cell Non-Hodgkin Lymphoma (B-NHL)","B-cell Acute Lymphoblastic Leukemia (B-ALL)"],"interventions":["PIT565"],"countries":["United States","Belgium","China","France","Israel","Italy","Japan","Singapore","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05397496"},{"nctId":"NCT05259709","title":"A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-06","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["89Zr˗DFO˗REGN5054","cemiplimab"],"countries":["Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer. The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the st","sourceUrl":"https://clinicaltrials.gov/study/NCT05259709"},{"nctId":"NCT05784441","title":"A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ACTUAL","startDate":"2023-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-06","primaryCompletionType":"ESTIMATED","completionDate":"2040-01-03","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"],"interventions":["JNJ-90009530"],"countries":["United States","Australia","Israel","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?","sourceUrl":"https://clinicaltrials.gov/study/NCT05784441"},{"nctId":"NCT04794699","title":"Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion","sponsor":"IDEAYA Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":169,"enrollmentType":"ACTUAL","startDate":"2021-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-04","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Solid Tumor"],"interventions":["IDE397","Sacituzumab govitecan"],"countries":["United States","Australia","France","Germany","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).","sourceUrl":"https://clinicaltrials.gov/study/NCT04794699"},{"nctId":"NCT04857372","title":"A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":137,"enrollmentType":"ACTUAL","startDate":"2021-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-08","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Mesothelioma"],"interventions":["IAG933"],"countries":["United States","Australia","Canada","France","Germany","Italy","Japan","Netherlands","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT04857372"},{"nctId":"NCT07319871","title":"A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["Pasritamig","JNJ-86974680"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07319871"},{"nctId":"NCT07673029","title":"A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2025-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-09","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["HER2-positive Breast Cancer"],"interventions":["GQ1005","T-DM1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":70,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to compare efficacy and safety of GQ1005 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.","sourceUrl":"https://clinicaltrials.gov/study/NCT07673029"},{"nctId":"NCT05519085","title":"A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":810,"enrollmentType":"ESTIMATED","startDate":"2022-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-10","primaryCompletionType":"ESTIMATED","completionDate":"2033-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["mezigdomide","Pomalidomide","Bortezomib","Dexamethasone"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Finland","France","Germany","Greece","India","Ireland","Israel","Italy","Japan","New Zealand","Poland","Portugal","Puerto Rico","Romania","South Africa","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":266,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.","sourceUrl":"https://clinicaltrials.gov/study/NCT05519085"},{"nctId":"NCT06659341","title":"A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2024-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Advanced Solid Tumors Harboring KRAS G12C Mutation"],"interventions":["BAY3498264"],"countries":["Australia","Denmark","Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["RAS genotyping"],"summary":"Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cells which contain mutated KRASG12C protein; it can stop the cancer cells from growing and can lead to their death. Sotorasib is already approved to be used by doctors. However, when sotorasib works, it normally only works for a period of time, after which the cancer starts to grow again, and the patient may need a different treatment. BAY3498264 is a drug that is currently under development. It is expected to prevent the activity of a protein called son of sevenless 1 (SOS1). The SOS1 protein works together with KRAS; by blocking the act","sourceUrl":"https://clinicaltrials.gov/study/NCT06659341"},{"nctId":"NCT06177041","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":486,"enrollmentType":"ESTIMATED","startDate":"2023-12-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-11","completionType":"ESTIMATED","lastUpdated":"2024-02-28","conditions":["Locally Advanced Unresectable or Metastatic Gastric Cancer","Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"interventions":["M108 monoclonal antibody","Placebo","Oxaliplatin","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"Gastric/GEJ adenocarcinoma, which is one of the major leading causes of cancer-related deaths worldwide, is a global challenge to human health. However, standard chemotherapy has limited efficacy in advanced gastric cancer, and there is an urgent need to explore and develop new therapeutic targets and combination therapy modalities. The main purpose of this study is to explore the efficacy of M108 monoclonal antibody plus capecitabine and oxaliplatin (CAPOX) versus placebo plus CAPOX as first-line treatment measured by progression free survival (PFS). This study will also evaluate safety, tolerability, pharmacokinetics and the immunogenicity profile of M108 monoclonal antibody, as well as it","sourceUrl":"https://clinicaltrials.gov/study/NCT06177041"},{"nctId":"NCT05615974","title":"A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":139,"enrollmentType":"ESTIMATED","startDate":"2023-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-11","completionType":"ESTIMATED","lastUpdated":"2024-12-19","conditions":["Malignant Tumors"],"interventions":["LM101","Toripalimab","Rituximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05615974"},{"nctId":"NCT05609968","title":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":614,"enrollmentType":"ESTIMATED","startDate":"2023-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-23","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Sacituzumab Govitecan","Pembrolizumab"],"countries":["United States","Australia","Brazil","Canada","Chile","China","Estonia","Germany","Greece","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Peru","Philippines","Poland","Romania","South Korea","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":180,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).","sourceUrl":"https://clinicaltrials.gov/study/NCT05609968"},{"nctId":"NCT06951503","title":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2025-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-07","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Colorectal Adenocarcinoma"],"interventions":["AK112","Oxaliplatin","Irinotecan","Leucovorin and 5-FU","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06951503"},{"nctId":"NCT05552469","title":"Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":62,"enrollmentType":"ACTUAL","startDate":"2023-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-13","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Myeloid Diseases"],"interventions":["DFV890"],"countries":["United States","France","Germany","Hong Kong","Italy","Singapore","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of three groups evaluating DFV890 in patients with myeloid diseases. The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy and recommended dose for single agent DFV890 in patients with lower risk (LR: very low, low or intermediate risk) myelodysplastic syndromes (LR MDS), lower risk chronic myelomonocytic leukemia (LR CMML) and High-Risk Clonal Cytopenia of Undetermined Significance (HR CCUS).","sourceUrl":"https://clinicaltrials.gov/study/NCT05552469"},{"nctId":"NCT05396833","title":"Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ACTUAL","startDate":"2022-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-14","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-14","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Metastatic or Locally Advanced Unresectable Solid Tumors"],"interventions":["Tuvusertib","Lartesertib","Avelumab"],"countries":["United States","Australia","Canada","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["ctDNA / MRD"],"summary":"This is an open-label, multicenter, clinical study conducted in multiple parts to establish the safety, tolerability, Pharmacokinetic/Pharmacodynamic (PK/PD) profile, maximum tolerated dose (MTD) combinations (if observed) and recommended dose for expansion (RDE) combination for tuvusertib in combination with lartesertib (in Part A1), food effect on the PK of lartesertib as monotherapy followed by treatment with tuvusertib in combination with lartesertib in participants with specific tumor types (in Part A1.1), relative bioavailability of a tuvusertib tablet formulation vs capsule formulation followed by treatment with tuvusertib (capsule) in combination with lartesertib in participants with","sourceUrl":"https://clinicaltrials.gov/study/NCT05396833"},{"nctId":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","sponsor":"Circle Pharma","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-14","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-14","completionType":"ESTIMATED","lastUpdated":"2025-09-15","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Refractory Solid Tumor","Cancer","Lung Cancer","Triple Negative Breast Cancer","Breast Neoplasms","Neuroendocrine Tumors","Neuroendocrine Carcinoma","RB1 Gene Mutation"],"interventions":["CID-078 Monotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06577987"},{"nctId":"NCT06764940","title":"A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases","sponsor":"Biostar Pharma, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-15","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["HER2-negative Breast Cancer Patients With Brain Metastases"],"interventions":["Utidelone","Utidelone in combination with capecitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receive treatment of utidelone alone or in combination with capecitabine. The objectives both in stage I and stage II are to evaluate the intracranial and systemic efficacy and safety of utdelone plus capecitabine for the treatment of HER2-negative breast cancer patients with brain metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764940"},{"nctId":"NCT05987332","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","sponsor":"IDEAYA Biosciences","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2023-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-15","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Metastatic Uveal Melanoma"],"interventions":["IDE196","Crizotinib","Pembrolizumab","Ipilimumab","Nivolumab","Dacarbazine"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["HLA / TCR"],"summary":"This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).","sourceUrl":"https://clinicaltrials.gov/study/NCT05987332"},{"nctId":"NCT06641089","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","sponsor":"MoonLake Immunotherapeutics AG","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2024-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-15","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Arthritis, Psoriatic"],"interventions":["Sonelokimab","Placebo","Risankizumab"],"countries":["United States","Bulgaria","Canada","Czechia","France","Georgia","Germany","Hungary","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":139,"serviceSignals":["Broad CGP"],"summary":"This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06641089"},{"nctId":"NCT07376629","title":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","sponsor":"Huabo Biopharm Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-15","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["TNBC"],"interventions":["HB0025 20 mg/kg plus nab-paclitaxel","HB0025 10 mg/kg plus nab-paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07376629"},{"nctId":"NCT06755450","title":"Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma","sponsor":"Aurigene Discovery Technologies Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-15","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Relapsed Advanced Lymphomas"],"interventions":["AUR112"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)","sourceUrl":"https://clinicaltrials.gov/study/NCT06755450"},{"nctId":"NCT06265727","title":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","sponsor":"Corbus Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":348,"enrollmentType":"ESTIMATED","startDate":"2024-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-27","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Solid Tumor, Adult"],"interventions":["CRB-701","Anti-PD-1"],"countries":["United States","France","Italy","Moldova","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06265727"},{"nctId":"NCT05374603","title":"Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":47,"enrollmentType":"ACTUAL","startDate":"2022-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-18","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-18","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Lung Cancer"],"interventions":["Savolitinib","Durvalumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, interventional, multiple-center, exploratory Phase II study sponsored by AstraZeneca Investment(China)Co., LTD. to evaluate the efficacy and safety of Savolitinib combine with Durvalumab in Chinese EGFR wild-type locally advanced or metastatic NSCLC patients with MET alteration.","sourceUrl":"https://clinicaltrials.gov/study/NCT05374603"},{"nctId":"NCT06251310","title":"SW-682 in Advanced Solid Tumors","sponsor":"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-18","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-18","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Solid Tumor","Mesothelioma, Malignant"],"interventions":["SW-682","Combination Therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose","sourceUrl":"https://clinicaltrials.gov/study/NCT06251310"},{"nctId":"NCT05584670","title":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","sponsor":"Sanofi","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":542,"enrollmentType":"ESTIMATED","startDate":"2022-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-28","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Solid Tumor"],"interventions":["SAR445877","Cetuximab","ADG126","Bevacizumab","Nivolumab","Ipilimumab"],"countries":["United States","Chile","Israel","Japan","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include 2 parts: A dose escalation Part 1: for finding the therapeutic dose(s) of SAR445877 in a monotherapy given every 2 weeks (Q2W) or weekly (QW) and in combination with other anticancer therapies when applicable. A multicohort dose expansion/dose optimization Part 2: for the assessment of safety and preliminary efficacy of SAR445877 in monotherapy and in combination with cetuximab or with next generat","sourceUrl":"https://clinicaltrials.gov/study/NCT05584670"},{"nctId":"NCT07077434","title":"A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-19","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-19","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Advanced Solid Tumors"],"interventions":["BMS-986504"],"countries":["China","Japan"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07077434"},{"nctId":"NCT06622486","title":"First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors","sponsor":"Egle Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-23","completionType":"ESTIMATED","lastUpdated":"2024-11-07","conditions":["Solid Tumor, Adult"],"interventions":["EGL-001"],"countries":["France","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06622486"},{"nctId":"NCT04699188","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":344,"enrollmentType":"ACTUAL","startDate":"2021-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-25","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["KRAS G12C Mutant Solid Tumors","Carcinoma, Non-Small-Cell Lung","Carcinoma, Colorectal","Cancer of Lung","Cancer of the Lung","Lung Cancer","Neoplasms, Lung","Neoplasms, Pulmonary","Pulmonary Cancer","Pulmonary Neoplasms"],"interventions":["JDQ443","TNO155","tislelizumab"],"countries":["United States","Australia","Belgium","Canada","China","Denmark","France","Germany","Hong Kong","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["RAS genotyping"],"summary":"This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor patients. After the determination of the maximum tolerated dose / recommended dose for a particular treatment arm, dose expansion will assess the anti-tumor activity and further assess the safety, tolerability, and PK/PD of each regimen at the maximum tolerated dose / recommended dose or lower dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT04699188"},{"nctId":"NCT06616532","title":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","sponsor":"Biotheus Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":404,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-25","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["SCLC"],"interventions":["PM8002","Paclitaxel","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with Paclitaxel as second-line treatment for SCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT06616532"},{"nctId":"NCT07069712","title":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-06","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Gastroesophageal Adenocarcinoma"],"interventions":["AZD0901","Rilvegostomig","Trastuzumab Deruxtecan (T-DXd)","Capecitabine","5-Fluorouracil (5-FU)","FLOT Chemotherapy"],"countries":["United States","Canada","China","Georgia","Italy","Japan","Poland","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT07069712"},{"nctId":"NCT05038735","title":"Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":210,"enrollmentType":"ACTUAL","startDate":"2021-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Breast Cancer"],"interventions":["Alpelisib","Fulvestrant","Alpelisib-matching placebo"],"countries":["Belgium","Bulgaria","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Ireland","Italy","Poland","Portugal","Romania","Slovakia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":69,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT05038735"},{"nctId":"NCT06136884","title":"A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases","sponsor":"A2A Pharmaceuticals Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":86,"enrollmentType":"ESTIMATED","startDate":"2023-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-27","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Solid Tumor Malignancies","Brain Metastases From Solid Tumors"],"interventions":["AO-252"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06136884"},{"nctId":"NCT07082920","title":"A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["JNJ-78278343","JNJ-95298177"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07082920"},{"nctId":"NCT04544189","title":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2021-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-29","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Breast Neoplasms"],"interventions":["Alpelisib","Fulvestrant","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["HER2 profiling"],"summary":"The primary objective is to evaluate whether treatment with alpelisib in combination with fulvestrant prolongs Progression Free Survival (PFS) compared to treatment with placebo in combination with fulvestrant. The primary scientific question of interest is: what is the treatment effect based on PFS for alpelisib in combination with fulvestrant versus placebo in combination with fulvestrant in Chinese men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who received prior treatment with an aromatase inhibitor (AI) either as (neo) adjuvant treatment or as treatment for advanced disease, regardless of study treatment discontinuation or sta","sourceUrl":"https://clinicaltrials.gov/study/NCT04544189"},{"nctId":"NCT07174063","title":"A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6,"enrollmentType":"ACTUAL","startDate":"2025-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Metastatic Prostate Cancer (mCRPC)"],"interventions":["JSB462"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This Phase I study aims to evaluate the safety, tolerability and PK of JSB462 in Japanese patients with metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07174063"},{"nctId":"NCT05911295","title":"Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":412,"enrollmentType":"ACTUAL","startDate":"2023-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Urothelial Carcinoma"],"interventions":["disitamab vedotin","pembrolizumab","gemcitabine","cisplatin","carboplatin"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Czechia","France","Greece","Hungary","Ireland","Israel","Italy","Japan","Netherlands","Peru","Portugal","Singapore","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":268,"serviceSignals":["HER2 profiling"],"summary":"This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Pa","sourceUrl":"https://clinicaltrials.gov/study/NCT05911295"},{"nctId":"NCT07000149","title":"A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":9,"enrollmentType":"ACTUAL","startDate":"2025-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-29","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Advanced Clear Cell Renal Cell Carcinoma"],"interventions":["Volrustomig","Casdatifan"],"countries":["Australia","South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC). The Phase III part of the study will no longer be conducted.","sourceUrl":"https://clinicaltrials.gov/study/NCT07000149"},{"nctId":"NCT03947385","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","sponsor":"IDEAYA Biosciences","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":336,"enrollmentType":"ESTIMATED","startDate":"2019-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-15","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Metastatic Uveal Melanoma","Cutaneous Melanoma","Colorectal Cancer","Other Solid Tumors"],"interventions":["IDE196","Binimetinib","Crizotinib"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmaco","sourceUrl":"https://clinicaltrials.gov/study/NCT03947385"},{"nctId":"NCT06549946","title":"Ixovex-1 Single Agent and Combination Therapy","sponsor":"Psivac Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-30","completionType":"ESTIMATED","lastUpdated":"2025-01-30","conditions":["Solid Tumor","Head and Neck Cancer"],"interventions":["Ixovex-1","Pembrolizumab"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection. This will be assessed in patients with palpable locally advanced, unresectable, or metastatic tumours, for whom all approved therapeutic options have been exhausted, are not available, are unlikely to have significant clinical benefit, or are declined by the patient.","sourceUrl":"https://clinicaltrials.gov/study/NCT06549946"},{"nctId":"NCT06035497","title":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2023-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-10","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Relapsed or Refractory T-cell Lymphomas"],"interventions":["BMS-986369"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":40,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory T-cell lymphomas in Japan (GOLSEEK-3).","sourceUrl":"https://clinicaltrials.gov/study/NCT06035497"},{"nctId":"NCT06132217","title":"A Study of Simmitinib Plus SG001 in Advanced Solid Tumors","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2024-01-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-30","completionType":"ESTIMATED","lastUpdated":"2023-11-15","conditions":["Advanced Solid Tumor"],"interventions":["Simmitinib","SG001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.","sourceUrl":"https://clinicaltrials.gov/study/NCT06132217"},{"nctId":"NCT06958679","title":"Evaluation of SYS6005 in Patients With Advanced Malignant Tumor","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2025-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-14","conditions":["B-cell Malignancies","Solid Tumors"],"interventions":["SYS6005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This Phase I, open-label, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of SYS6005 in advanced malignancies, comprising dose-escalation and expansion phases. The escalation phase employs a BOIN design with accelerated titration across seven dose levels, featuring a 21-day DLT observation period in Cycle 1, with dose adjustments guided by a Safety Monitoring Committee. In the expansion phase, one or more dosing regimens and tumor types will be selected, and participants will receive SYS6005 R2PD for further exploration and validation. Treatment continues until disease progression, unacceptable toxicity, or other discontinuation criteria. Safe","sourceUrl":"https://clinicaltrials.gov/study/NCT06958679"},{"nctId":"NCT06474806","title":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","sponsor":"Curasight","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2024-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-30","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Prostate Cancer"],"interventions":["64Cu-DOTA-AE105"],"countries":["Denmark","Germany","Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade). The aim is that the diagnostic PET imaging agent may be used as an alternative or supplement to biopsies in the monitoring of patients with low-risk prostate cancer in active surveillance. Patients diagnosed with untreated, low-grade, localized prostate cancer may participate in the trial. The experimental diagnostic agent 64Cu-DOTA-AE105 is a radiopharmaceutical which is injected into the veins and binds to uPAR expressing cells in the tumour which can then be visualized in a PET scanner. The main question the trial aims to answer is:","sourceUrl":"https://clinicaltrials.gov/study/NCT06474806"},{"nctId":"NCT05570422","title":"A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01","sponsor":"Kortuc, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-30","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Cervical Cancer"],"interventions":["KRC-01","External Beam Radiation Therapy","cisplatin","brachytherapy"],"countries":["India","Thailand","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01. Phase 2 component is a randomized, open label, controlled, multi-center study in 60 patients to evaluate the preliminary antitumor effect of KRC-01 in combination with CRT.","sourceUrl":"https://clinicaltrials.gov/study/NCT05570422"},{"nctId":"NCT04241185","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2020-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-11-01","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Urinary Bladder Neoplasms"],"interventions":["Pembrolizumab","Conventional Radiotherapy (Bladder only)","Conventional Radiotherapy (Bladder and pelvic nodes)","Hypofractionated Radiotherapy (Bladder only)","Cisplatin","Fluorouracil (5-FU)","Mitomycin C (MMC)","Gemcitabine","Placebo to Pembrolizumab"],"countries":["United States","Australia","Chile","Czechia","Denmark","Estonia","France","Guatemala","Hungary","Israel","Italy","Japan","Latvia","Malaysia","Netherlands","Poland","Portugal","Puerto Rico","Romania","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":134,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body. MIBC is treated by having surgery to remove the bladder (cystectomy). Not all people choose to have surgery and want to keep their bladder using other treatments. Chemoradiotherapy (CRT)- is a type of non-surgical treatment for MIBC which combines Chemotherapy (a treatment with medicine to destroy cancer cells or stop them growing) and Radiation therapy (a treatment that uses beams of intense energy \\[like X-rays\\] to shrink or get rid of tumors). Pembrolizumab is an immunotherapy, which is a treatment th","sourceUrl":"https://clinicaltrials.gov/study/NCT04241185"},{"nctId":"NCT07334119","title":"Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors","sponsor":"Myeloid Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-30","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["HER2-Expressing Solid Tumors"],"interventions":["MT-304","MT-304 + Nivolumab"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["HER2 profiling"],"summary":"This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors. The main questions it aims to answer are: * What is the safety profile of MT-304 when administered alone or with nivolumab? * What is the recommended Phase 2 dose (RP2D) of MT-304? Participants will: * Receive MT-304 alone (every 14 days) or with nivolumab (every 28 days). * Attend regular clinic visits for assessments and monitoring. * Continue treatment until disease progression, unacceptable toxicity, or study discontinuation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07334119"},{"nctId":"NCT07288879","title":"DALY II Japan/MB-CART2019.1 for DLBCL","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2025-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["DLBCL - Diffuse Large B Cell Lymphoma","CAR T Cell Therapy"],"interventions":["MB-CART2019.1"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07288879"},{"nctId":"NCT07638891","title":"A Study of HDM2020 in Patients With Advanced Sq-NSCLC","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-03","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Squamous Non-small Cell Lung Cancer(NSCLC)"],"interventions":["HDM2020 (FGFR2b-ADC)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if the study drug can treat in advanced squamous non-small cell lung cancer(NSCLC) patients. The main questions it aims to answer are: Is the drug safe and tolerable? Does the drug show antitumor activity? Participants will receive the study drug once(D1) or twice(D1.D8) every three weeks, and undergo imaging-based efficacy assessments every six weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07638891"},{"nctId":"NCT06910657","title":"IDOV-Immune for Advanced Solid Tumors","sponsor":"ViroMissile, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2025-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Colorectal Cancer","Pancreatic Cancer","Melanoma","Ovarian Cancer","Gastric Cancer","Esophageal Cancer","Hepatocellular Carcinoma","Renal Cell Carcinoma","Breast Cancer","Sarcoma","Bladder Cancer","Lung Cancer","Prostate Cancer","Cervical Cancers","Head and Neck Cancers","Adrenal Gland Tumors"],"interventions":["IDOV-Immune (oncolytic vaccinia virus)"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intra","sourceUrl":"https://clinicaltrials.gov/study/NCT06910657"},{"nctId":"NCT06241781","title":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","sponsor":"Grit Biotechnology","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":83,"enrollmentType":"ESTIMATED","startDate":"2024-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Adult"],"interventions":["GT101 injection","Gemcitabine injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants with recurrent or metastatic cervical cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06241781"},{"nctId":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":1394,"enrollmentType":"ESTIMATED","startDate":"2021-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-28","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Renal Cell Carcinoma (RCC)","Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Urothelial Carcinoma (UC)","Solid Tumor","Hepatocellular Carcinoma (HCC)","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","Drug-Drug Interaction (DDI)"],"interventions":["Zanzalintinib","Nivolumab","Ipilimumab","Nivolumab + Relatlimab","Prednisone","Docetaxel","DDI Probe Cocktail"],"countries":["United States","Australia","Austria","Belgium","France","Germany","Israel","Italy","New Zealand","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":122,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) and in combination with docetaxel and prednisone in participants with advanced solid tumors. In addition, the study will evaluate the effect of multiple dose administration of zanzalintinib on the single-dose pharmacokinetics of sensitive CYP3A4, CYP2C9, CYP2C19, or CYP1A2 substrates in participants with advanced solid tumors. In the Expansi","sourceUrl":"https://clinicaltrials.gov/study/NCT05176483"},{"nctId":"NCT05908734","title":"A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":71,"enrollmentType":"ACTUAL","startDate":"2023-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Cetrelimab","Amivantamab"],"countries":["United States","Brazil","Italy","Malaysia","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05908734"},{"nctId":"NCT07344311","title":"A Phase I Trial of A-CAR032 in Participants With mCRPC","sponsor":"Shanghai AbelZeta Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2026-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2042-01-31","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Prostate Cancer","Metastatic Castration-Resistant Prostate Cancer"],"interventions":["dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This FTiH, single-arm, open-label, investigator-initiated Phase I trial will evaluate the safety, antitumour activity, CK/pharmacodynamics (PD), biomarkers, immunogenicity, and feasibility of A-CAR032 in adult participants with mCRPC, who have previously progressed after ARPI treatment of prostate cancer (whether before or in the metastatic castration-resistant setting) and, in the judgment of the investigator, are ineligible for standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07344311"},{"nctId":"NCT03836261","title":"Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL","sponsor":"Acerta Pharma BV","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":984,"enrollmentType":"ACTUAL","startDate":"2019-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Acalabrutinib","Venetoclax","Chemoimmunotherapy","Obinutuzumab"],"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","China","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","Russia","Saudi Arabia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":170,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL","sourceUrl":"https://clinicaltrials.gov/study/NCT03836261"},{"nctId":"NCT04079166","title":"SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)","sponsor":"Scancell Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":173,"enrollmentType":"ESTIMATED","startDate":"2019-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-01-31","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Malignant Melanoma","Melanoma (Skin)","Melanoma Stage III","Melanoma Stage IV"],"interventions":["SCIB1 or iSCIB1+ DNA vaccine"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda). Pembrolizumab or nivolumab with ipilimumab are standard treatments approved for patients with advanced melanoma (skin cancer). The study will also look to see if SCIB1 or iSCIB1+ can increase the likelihood that melanoma patients will respond to the standard treatments, and also if SCIB1 and iSCIB1+ can help to make those responses last longer. SCIB1 and iSCIB1+ are considered experimental. SCIB1 has been given to melanoma patients in an earlier study. It was generally well-","sourceUrl":"https://clinicaltrials.gov/study/NCT04079166"},{"nctId":"NCT06806033","title":"A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["B-Cell Non-Hodgkins Lymphoma"],"interventions":["Obinutuzumab","Glofitamab","Gemcitabine","Oxaliplatin"],"countries":["United States","Australia","Canada","France","Germany","Italy","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Hematology NGS"],"summary":"This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06806033"},{"nctId":"NCT07093073","title":"Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["B Cell Lymphoma"],"interventions":["ssCART-19"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label clinical study evaluating the efficacy and safety of U01 (ssCART-19) in patients with relapsed or refractory B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07093073"},{"nctId":"NCT05382286","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":443,"enrollmentType":"ACTUAL","startDate":"2022-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Triple Negative Breast Cancer","PD-L1 Positive"],"interventions":["Sacituzumab Govitecan-hziy","Pembrolizumab","Paclitaxel","nab-Paclitaxel","Gemcitabine","Carboplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Puerto Rico","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":504,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).","sourceUrl":"https://clinicaltrials.gov/study/NCT05382286"},{"nctId":"NCT06792734","title":"Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas","sponsor":"Bantam Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Lymphoma, B-Cell"],"interventions":["BTM-3566"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are: What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)? Participants will: Take BTM-3566 in 14-day periods with 7 days of dosing followed by 7 days of no dosing Visit the clinic regularly for checkups and te","sourceUrl":"https://clinicaltrials.gov/study/NCT06792734"},{"nctId":"NCT06413706","title":"A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2024-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Glioma"],"interventions":["Abemaciclib","Temozolomide"],"countries":["United States","Australia","Belgium","Denmark","France","Italy","Japan","Netherlands","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.","sourceUrl":"https://clinicaltrials.gov/study/NCT06413706"},{"nctId":"NCT05076760","title":"MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors","sponsor":"Memgen, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2022-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Solid Tumor","Advanced Cancer","Metastatic Cancer","Non Small Cell Lung Cancer","Cutaneous Squamous Cell Carcinoma","Merkel Cell Carcinoma","Melanoma","Pancreatic Cancer","Triple Negative Breast Cancer","Head and Neck Cancer"],"interventions":["MEM-288 Intratumoral Injection","Nivolumab","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible subjects must have a tumor lesion(s) which is accessible for injection. The dose escalation phase (Part 1A - advanced solid tumors) has completed and is closed to enrollment. This phase evaluated multiple doses of MEM-288 dosed via intratumoral injection once every 3 weeks to assess safety, tolerability, preliminary efficacy, and to determine the MTD. The dose expansion phase has multiple parts for ad","sourceUrl":"https://clinicaltrials.gov/study/NCT05076760"},{"nctId":"NCT07036133","title":"Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment","sponsor":"Acrotech Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2022-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Advanced Solid Tumors","Hematologic Malignancies"],"interventions":["Pralatrexate Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of every 7-week treatment cycle in patients with hepatic impairment. Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT07036133"},{"nctId":"NCT06939595","title":"A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer","sponsor":"Celltrion","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":225,"enrollmentType":"ACTUAL","startDate":"2025-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Non Squamous Non Small Cell Lung Cancer"],"interventions":["CT-P51","EU-approved Keytruda"],"countries":["Georgia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06939595"},{"nctId":"NCT06907628","title":"A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-04-25","conditions":["Advanced Solid Tumors"],"interventions":["SHR-3792 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06907628"},{"nctId":"NCT06241846","title":"A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2025-08-27","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["YL201 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06241846"},{"nctId":"NCT07173556","title":"A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2025-09-15","conditions":["Advanced Breast Cancer"],"interventions":["QLC1401"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study is an open-label, multicenter, Phase Ib/II clinical trial designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of QLC1401 tablets in combination with CDK4/6 inhibitors or mTOR inhibitors in patients with ER+/HER2- locally advanced or metastatic breast cancer. The study consists of two stages: a Phase Ib dose-escalation stage and a Phase II dose-expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07173556"},{"nctId":"NCT05433142","title":"Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma","sponsor":"Xencor, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":307,"enrollmentType":"ESTIMATED","startDate":"2022-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Clear Cell Renal Cell Carcinoma"],"interventions":["XmAb819"],"countries":["United States","Belgium","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).","sourceUrl":"https://clinicaltrials.gov/study/NCT05433142"},{"nctId":"NCT06463665","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","sponsor":"Genelux Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":142,"enrollmentType":"ESTIMATED","startDate":"2024-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Advanced Non-squamous Non-small-cell Lung Cancer","Advanced Squamous Non-Small Cell Lung Carcinoma","Metastatic Non-squamous Non Small Cell Lung Cancer","Metastatic Squamous Non-Small Cell Lung Carcinoma","Non-small Cell Lung Cancer","Non-small Cell Lung Cancer Stage III","Non-small Cell Lung Cancer Stage IV","Non-small Cell Lung Cancer Recurrent"],"interventions":["Olvimulogene nanivacirepvec","Platinum chemotherapy: carboplatin or cisplatin","Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC","Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT06463665"},{"nctId":"NCT07136142","title":"A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Malignant Solid Tumor"],"interventions":["FH-006 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07136142"},{"nctId":"NCT06400472","title":"A Study of LY4170156 in Participants With Selected Advanced Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":495,"enrollmentType":"ESTIMATED","startDate":"2024-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Ovarian Neoplasms","Endometrial Neoplasms","Uterine Cervical Neoplasms","Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Neoplasms","Pancreatic Neoplasm","Colorectal Neoplasms"],"interventions":["LY4170156","bevacizumab","carboplatin","Itraconazole","pembrolizumab"],"countries":["United States","Australia","France","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06400472"},{"nctId":"NCT07172802","title":"A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors","sponsor":"GI Innovation, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-09-15","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Non-small Cell Lung Cancer (NSCLC)","Head and Neck (HNSCC)","Pancreatic Cancer","Renal Cell Carcinoma (RCC)"],"interventions":["GI-108"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07172802"},{"nctId":"NCT07068932","title":"A Clinical Study of SHR-4506 Injection in Patients With Malignant Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Malignant Tumors of Adults"],"interventions":["SHR-4506 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety and tolerability of SHR-4506 Injection in patients with malignant tumors and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD).","sourceUrl":"https://clinicaltrials.gov/study/NCT07068932"},{"nctId":"NCT06619236","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":530,"enrollmentType":"ESTIMATED","startDate":"2025-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-23","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Platinum-resistant Ovarian Cancer"],"interventions":["Rina-S","Paclitaxel","Topotecan","Pegylated liposomal doxorubicin (PLD)","Gemcitabine"],"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","Denmark","France","Germany","Greece","Italy","Japan","Netherlands","Norway","Poland","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":177,"serviceSignals":["ADC biomarker"],"summary":"This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT06619236"},{"nctId":"NCT07266285","title":"BTM-3566 in Advanced Solid Tumors","sponsor":"Bantam Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Advanced Solid Tumors"],"interventions":["BTM-3566"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn about what doses of BTM-356 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of BTM-3566 are in treating cancer. The main questions it aims to answer are: What adverse events and toxicities (harmful side effects) are associated with different doses of BTM-3566? What are the blood levels of BTM-3566 in your body at different timepoints? What effect does BTM-3566 have on reducing tumor size and/or preventing the worsening of cancer? All participants will receive BTM-3566 and none will receive placebo (a look-alike substance that contains no drug). Participants will: * Take BTM-356","sourceUrl":"https://clinicaltrials.gov/study/NCT07266285"},{"nctId":"NCT06484816","title":"TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-02-24","conditions":["Non Small Cell Lung Cancer","Advanced Solid Tumor","Hematologic Malignancy"],"interventions":["TGRX-1942"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06484816"},{"nctId":"NCT05527184","title":"First in Human Study of IMGN151 in Recurrent Gynaecological Cancers","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":256,"enrollmentType":"ACTUAL","startDate":"2023-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-02-20","conditions":["Endometrial Cancer","High Grade Serous Adenocarcinoma of Ovary","Primary Peritoneal Carcinoma","Fallopian Tube Cancer","Cervical Cancer"],"interventions":["IMGN151"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Ireland","Italy","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["ADC biomarker"],"summary":"IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05527184"},{"nctId":"NCT07165132","title":"Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.","sponsor":"RayzeBio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2033-04","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET","Solid Tumor","Somatostatin Receptor"],"interventions":["RYZ401"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.","sourceUrl":"https://clinicaltrials.gov/study/NCT07165132"},{"nctId":"NCT05512390","title":"A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2023-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Diffuse Large B-Cell Lymphoma","Chronic Lymphocytic Leukemia","Follicular Lymphoma"],"interventions":["ABBV-319"],"countries":["United States","Australia","Canada","Israel","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), R/R follicular lymphoma (FL), or R/R CLL. Adverse events will be assessed. ABBV-319 is an investigational drug being developed for the treatment of R/R DLBCL, R/R FL, or R/R CLL. This study will inc","sourceUrl":"https://clinicaltrials.gov/study/NCT05512390"},{"nctId":"NCT06226571","title":"A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias","sponsor":"Syndax Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":76,"enrollmentType":"ACTUAL","startDate":"2024-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Acute Myeloid Leukemias"],"interventions":["SNDX-5613","Chemotherapy Regimen","HiDAC"],"countries":["United States","Australia","Canada","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06226571"},{"nctId":"NCT06228326","title":"A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs","sponsor":"Krystal Biotech, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-10-24","conditions":["Lung Cancer, Non-small Cell","Lung Cancer Metastatic","Solid Tumor, Adult","Advanced Cancer","Lung Cancer (NSCLC)"],"interventions":["KB707","Pembrolizumab (KEYTRUDA®)","Chemotherapy","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local tumor microenvironment in the lungs. KB707 is administered via nebulization, delivering the therapy directly through the airways to the lungs of subjects with advanced solid tumor malignancies. This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study designed to evaluate the safety, tolerability, preliminary efficacy, and immunologic effect of KB707. Monotherapy KB707 dose escalation and expansion cohorts enrolled adults with advanced solid ","sourceUrl":"https://clinicaltrials.gov/study/NCT06228326"},{"nctId":"NCT04086264","title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","sponsor":"AbbVie","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":218,"enrollmentType":"ACTUAL","startDate":"2019-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Acute Myeloid Leukemia"],"interventions":["Azacitidine","IMGN632","Venetoclax"],"countries":["United States","France","Germany","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in participants with relapsed and frontline CD123-positive AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT04086264"},{"nctId":"NCT06223516","title":"Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2024-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Multiple Myeloma"],"interventions":["Subcutaneous (SC) Etentamig","Intravenous (IV) Etentamig"],"countries":["United States","Germany","Israel","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety and pharmacokinetics of Etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R MM. This study is broken into 3 Arms: Arm A with 2 parts and Arm B as an expansion. Participants will receive ABBV-3","sourceUrl":"https://clinicaltrials.gov/study/NCT06223516"},{"nctId":"NCT06985147","title":"A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)","sponsor":"Disc Medicine, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Polycythemia Vera (PV)"],"interventions":["DISC-3405"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This open-label, multicenter, within-participant dose escalation study examining up to 2 dose levels of DISC-3405 will assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of DISC-3405 in participants with polycythemia vera (PV).","sourceUrl":"https://clinicaltrials.gov/study/NCT06985147"},{"nctId":"NCT05377996","title":"A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors","sponsor":"Day One Biopharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2022-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Triple Negative Breast Cancer","Breast Cancer","Endometrial Cancer","Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cavity Cancer","Adenoid Cystic Carcinoma"],"interventions":["Emi-Le"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"A Study of Emi-Le in Participants with Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05377996"},{"nctId":"NCT06554795","title":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2024-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Solid Tumor, Adult"],"interventions":["DB-1419"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06554795"},{"nctId":"NCT05355298","title":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","sponsor":"Amplia Therapeutics Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2022-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Pancreatic Cancer","PDAC","Pancreatic Ductal Adenocarcinoma"],"interventions":["AMP945 ascending doses","AMP945 RP2D"],"countries":["Australia","South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a multicentre, open label, two-part study to determine whether the focal adhesion kinase (FAK) inhibitor AMP945, when given prior to dosing with gemcitabine and nab-paclitaxel, improves response to therapy in first-line patients with unresectable or metastatic pancreatic cancer. Part A is a phase 1b dose-escalation design that will enrol at least 3 participants in each of 4 dose-level cohorts, to determine the RP2D of AMP945 to be explored in Part B. Part B will determine the efficacy of the AMP945 regimen at the RP2D, and will be run as a Simon Two-stage design; Stage 1 will enrol 26 participants. If ≤5 of the 26 participants show an objective response, then recruitment will be paus","sourceUrl":"https://clinicaltrials.gov/study/NCT05355298"},{"nctId":"NCT05440708","title":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","sponsor":"Tvardi Therapeutics, Incorporated","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":193,"enrollmentType":"ESTIMATED","startDate":"2023-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-10","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Hepatocellular Carcinoma"],"interventions":["TTI-101","Pembrolizumab","Atezolizumab","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the RP2D to participants with locally advanced or metastatic, and unresectable HCC and to assess the preliminary efficacy of TTI-101 as a single agent in participants with locall","sourceUrl":"https://clinicaltrials.gov/study/NCT05440708"},{"nctId":"NCT06419634","title":"Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-16","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"interventions":["BMS-986497","Azacitidine","Venetoclax"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, in double combination with Azacitidine and in triple combination with Azacitidine and Venetoclax in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06419634"},{"nctId":"NCT02934568","title":"Ribociclib (LEE011) Rollover Study for Continued Access","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":22,"enrollmentType":"ACTUAL","startDate":"2016-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-01","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies"],"interventions":["LEE011"],"countries":["United States","France","Germany","Singapore","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-sponsored ribociclib (LEE011) study that has reached its primary objective(s) or has been halted for other reasons.","sourceUrl":"https://clinicaltrials.gov/study/NCT02934568"},{"nctId":"NCT07702162","title":"A Clinical Study of PA5 in Patients With Advanced Solid Tumors","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2025-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-04","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Advanced Solid Tumors","Cancer"],"interventions":["PA5"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5. The main questions it aims to answer are: * Is intravenous infusion of PA5 monotherapy safe and tolerable for patients with advanced/metastatic solid tumors? * What is the maximum tolerated dose (MTD) and recommended dose for Phase II clinical trials (RP2D) of PA5 monotherapy? In the escalation phase, participants will receive PA5 via intravenous infusion on Day 1 of Cycle 1 (28-day cycle). If no dose-limiting toxicity (DLT) occurs, treatment continues from Cycle 2 onward with adjusted frequency (every 2-4 weeks). I","sourceUrl":"https://clinicaltrials.gov/study/NCT07702162"},{"nctId":"NCT06636682","title":"FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","sponsor":"Cellvax Therapeutics Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-04","completionType":"ESTIMATED","lastUpdated":"2024-10-21","conditions":["Prostate Cancer (Adenocarcinoma)","Prostate CA","Prostate Cancers","Prostate Cancer (Post Prostatectomy)","Prostate Cancer","Prostate Cancer Patients Undergoing Radical Prostatectomy","High-risk Prostate Cancer"],"interventions":["FK-PC101","Standard of Care (SOC)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are: Does FK-PC101 delay or prevent the return of prostate cancer following surgery? What medical problems do participants (subjects) have when taking FK-PC101? Researchers will compare FK-PC101 to current treatment practice to see if FK-PC101 works to prevent or delay the return of prostate cancer following surgery to remove the prostate cancer tumor. Subjects will: Have a sample of the prostate cancer tissue collected at th","sourceUrl":"https://clinicaltrials.gov/study/NCT06636682"},{"nctId":"NCT04417621","title":"Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":134,"enrollmentType":"ACTUAL","startDate":"2020-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-02","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Melanoma"],"interventions":["LXH254","LTT462","Trametinib","Ribociclib"],"countries":["United States","Argentina","Australia","Belgium","France","Germany","Israel","Italy","Netherlands","Norway","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["RAS genotyping"],"summary":"The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT04417621"},{"nctId":"NCT06760819","title":"A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","sponsor":"Bayer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":111,"enrollmentType":"ESTIMATED","startDate":"2025-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-25","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Solid Tumors","HER2 Mutation"],"interventions":["BAY2927088"],"countries":["United States","Australia","Canada","China","Denmark","France","Italy","Japan","South Korea","Spain","Switzerland"],"northAmerica":true,"chinaSites":true,"siteCount":54,"serviceSignals":["HER2 profiling"],"summary":"Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the breast, the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCL","sourceUrl":"https://clinicaltrials.gov/study/NCT06760819"},{"nctId":"NCT07546760","title":"A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2026-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-04","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Hepatic Impairment"],"interventions":["AZD6234","AZD9550"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.","sourceUrl":"https://clinicaltrials.gov/study/NCT07546760"},{"nctId":"NCT06946797","title":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-25","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Nivolumab","Ipilimumab","Carboplatin","Paclitaxel","Pemetrexed","Cisplatin"],"countries":["United States","Brazil","Chile","France","Greece","Italy","Poland","Romania","South Africa"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate two dosing regimens of subcutaneous Nivolumab in combination with intravenous Ipilimumab and chemotherapy in participants with previously untreated metastatic or recurrent Non-Small Cell Lung Cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06946797"},{"nctId":"NCT05771584","title":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","sponsor":"Aston Sci. Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2023-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Gastric Cancer"],"interventions":["AST-301","rhuGM-CSF"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have completed the standard adjuvant treatment (including those who discontinued the standard adjuvant treatment due to intolerance). Participants will be randomized 1:1 to either Arm 1 (Q3W, 3 cycles), or Arm 2 (Q3W, 6 cycles) of the study. Safety Monitoring Committee (SMC) will oversee safety of study at 25% (6 participants), 50% (12 participants), and 75% (18 participants) of participants receive at least 1 dose of AST-301 and survival follow up will be performed to determine ","sourceUrl":"https://clinicaltrials.gov/study/NCT05771584"},{"nctId":"NCT06349980","title":"A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":117,"enrollmentType":"ESTIMATED","startDate":"2024-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-10","completionType":"ESTIMATED","lastUpdated":"2024-12-18","conditions":["Carcinoma, Hepatocellular"],"interventions":["HLX53 (1000mg)","HLX53 (2000mg)","HLX10","HLX04","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With or Without HLX53 (an Anti-TIGIT Fc Fusion Protein) in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06349980"},{"nctId":"NCT04077463","title":"A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":701,"enrollmentType":"ACTUAL","startDate":"2019-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-27","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Lazertinib","Amivantamab","Carboplatin","Pemetrexed"],"countries":["United States","China","France","Germany","Italy","Japan","Puerto Rico","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":78,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (JNJ-61186372) (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B, C, D and E), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC ","sourceUrl":"https://clinicaltrials.gov/study/NCT04077463"},{"nctId":"NCT04224493","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","sponsor":"Epizyme, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":599,"enrollmentType":"ACTUAL","startDate":"2020-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Relapsed/Refractory Follicular Lymphoma","Follicular Lymphoma","Refractory Follicular Lymphoma"],"interventions":["Tazemetostat","Placebo oral tablet","Lenalidomide","Rituximab"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Hungary","Italy","Poland","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":204,"serviceSignals":["Hematology NGS"],"summary":"The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when r","sourceUrl":"https://clinicaltrials.gov/study/NCT04224493"},{"nctId":"NCT07744256","title":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Small Cell Lung Cancer (SCLC)","Relapsed/Refractory SCLC","Extensive-stage SCLC"],"interventions":["EB-DART-NK01","Lymphodepleting chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3/CD56, DLL3/GD2, and CD56/GD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07744256"},{"nctId":"NCT07486089","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Breast Cancer (Locally Advanced or Metastatic)","HER2-positive Breast Cancer","Triple-Negative Breast Cancer (TNBC)"],"interventions":["Dual-target CAR-NK cells (EB-DT-CAR-NK)","Lymphodepleting chemotherapy","Supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07486089"},{"nctId":"NCT07589530","title":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced Solid Tumors","Metastatic Solid Tumors","TROP2-Expressing Solid Tumors"],"interventions":["EB-NK-301","Fludarabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy. The primary goals are to assess safety and tolerability, identify dose-limiting toxicities (DLTs), and determine a recommended Phase 2 dose (RP2D). Secondary goals include preliminary anti-tumor activity, persistence of infused CAR-NK cells, and exploratory immune biomarkers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07589530"},{"nctId":"NCT06987500","title":"A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-16","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Tumor, Solid"],"interventions":["XNW29016"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .","sourceUrl":"https://clinicaltrials.gov/study/NCT06987500"},{"nctId":"NCT07480928","title":"Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-26","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)","Unresectable Locally Advanced or Metastatic Disease"],"interventions":["EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)","EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)","Lymphodepleting chemotherapy (Flu/Cy)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assigned to one of two biomarker-defined cohorts based on tumor antigen expression: (A) Mesothelin (MSLN) and/or MUC1, or (B) Claudin 18.2 (CLDN18.2) and/or MUC1. The study uses a dose-escalation followed by dose-expansion design to define a recommended Phase 2 dose (RP2D) and to estimate response rates in each cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT07480928"},{"nctId":"NCT07480213","title":"Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Small Cell Lung Cancer (SCLC)","Relapsed/Refractory SCLC","SCLC, Extensive Stage"],"interventions":["EB-DART-NK01 (DLL3/CD56 CAR-NK cells)","Lymphodepleting chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3/CD56, DLL3/GD2, and CD56/GD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07480213"},{"nctId":"NCT07467863","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-17","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Non-Small Cell Lung Cancer","Advanced/Metastatic NSCLC"],"interventions":["Dual-target CAR-NK cells","Lymphodepleting chemotherapy","Supportive Care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens: Mesothelin (MSLN), EGFR, and HER2/ERBB2. Participants will receive lymphodepleting chemotherapy followed by infusion of the CAR-NK product matched to their tumor antigen profile. A data-driven interim assessment will be used to select the most suitable construct for expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07467863"},{"nctId":"NCT06801002","title":"Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies","sponsor":"Jabez Bioscience, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2025-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-15","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Solid Tumor"],"interventions":["JBZ-001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This will be a phase 1, open-label, dose-escalation and expansion, FIH trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of JBZ-001, a DHODH inhibitor, in patients with refractory solid and hematological malignancies. The study design includes two independent parts: dose escalation in solid tumors and NHL (Part 1), and up to four indication expansions in selected solid tumor types and NHL (Part 2). The dose escalation will enroll patients with solid tumors and NHL following a standard \"3+3\" design enrolling a minimum of 3 and up to 6 patients per dose level.","sourceUrl":"https://clinicaltrials.gov/study/NCT06801002"},{"nctId":"NCT02972840","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","sponsor":"Acerta Pharma BV","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":635,"enrollmentType":"ACTUAL","startDate":"2017-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-15","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Lymphoma, Mantle Cell"],"interventions":["Acalabrutinib","Bendamustine","Rituximab","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","New Zealand","Peru","Poland","Romania","Russia","South Korea","Spain","Taiwan","Ukraine","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":228,"serviceSignals":["Hematology NGS"],"summary":"This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT02972840"},{"nctId":"NCT07480954","title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-17","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Carcinoma","Recurrent or Refractory Disease After Standard Therapies"],"interventions":["Dual-target CAR-NK cell product","Lymphodepleting chemotherapy","Standard supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.","sourceUrl":"https://clinicaltrials.gov/study/NCT07480954"},{"nctId":"NCT06613100","title":"Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-17","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-04","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Prostate Cancer"],"interventions":["Xaluritamig","GnRH Antagonist"],"countries":["United States","Germany"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered as monotherapy or in combination with an oral Gonadotropin-releasing Hormone (GnRH) antagonist in the neoadjuvant setting followed by radical prostatectomy, and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered as monotherapy or in combination with an oral GnRH antagonist in the neoadjuvant setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06613100"},{"nctId":"NCT07480941","title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","sponsor":"Beijing Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Glioblastoma","High-grade Glioma","Malignant Glioma","Recurrent Glioblastoma","Recurrent High-grade Glioma"],"interventions":["Dual-target CAR-NK cells","Cyclophosphamide","Fludarabine","Intracranial catheter/reservoir for locoregional delivery"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-grade glioma (HGG). Participants will undergo tumor antigen profiling for IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276). Based on this assessment, each participant will receive the most suitable dual-target CAR construct to reduce antigen-escape risk.","sourceUrl":"https://clinicaltrials.gov/study/NCT07480941"},{"nctId":"NCT06065748","title":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1050,"enrollmentType":"ESTIMATED","startDate":"2023-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-19","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-12","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"],"interventions":["Giredestrant","Fulvestrant","Abemaciclib","Palbociclib","Ribociclib","LHRH Agonist","FoundationOne Liquid CDx Assay (F1LCDx)"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Costa Rica","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Israel","Italy","Kenya","Mexico","New Zealand","Peru","Poland","Portugal","Puerto Rico","Romania","Singapore","Slovenia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":352,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06065748"},{"nctId":"NCT07019675","title":"A Study of SKB518 in Patients With Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2025-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-20","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Lung Carcinoma"],"interventions":["SKB518","Tislelizumab","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer. Eligible subjects will receive SKB518 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT07019675"},{"nctId":"NCT04529772","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","sponsor":"Acerta Pharma BV","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":611,"enrollmentType":"ACTUAL","startDate":"2020-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-22","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["acalabrutinib","placebo","Prednisone","Rituximab","Cyclophosphamide","Vincristine","Doxorubicin"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","India","Israel","Italy","Japan","Mexico","Poland","Portugal","Russia","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":243,"serviceSignals":["Hematology NGS"],"summary":"Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04529772"},{"nctId":"NCT05629234","title":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2023-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-22","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Cancer"],"interventions":["Osimertinib"],"countries":["China","France","Japan","Malaysia","Poland","South Korea","Taiwan","United Kingdom"],"northAmerica":false,"chinaSites":true,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"The rationale of the ROSY-T study is to continue to provide study treatment for patients who have participated in a parent study with osimertinib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.","sourceUrl":"https://clinicaltrials.gov/study/NCT05629234"},{"nctId":"NCT06421935","title":"M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-22","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Advanced Solid Tumor"],"interventions":["M9466","Tuvusertib","Abiraterone acetate","Prednisone/Prednisolone"],"countries":["United States","Australia","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.","sourceUrl":"https://clinicaltrials.gov/study/NCT06421935"},{"nctId":"NCT05983523","title":"A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients with Advanced or Metastatic Solid Tumors","sponsor":"PharmaEngine","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2024-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2024-11-07","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["PEP07"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is To establish the safety profile and determine the dose-limited toxicity (DLT) of PEP07 monotherapy in patients with advanced or metastatic solid tumors. To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of PEP07 monotherapy. Participants will receive PEP07 administered orally once daily (QD) for 2 consecutive days and 5 days off, every week for 4 weeks until disease progression, intolerable toxicity, confirmed pregnancy, death, consent withdrawal, or other anti-cancer treatment is required, or the Sponsor ends the study, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT05983523"},{"nctId":"NCT01872260","title":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":255,"enrollmentType":"ACTUAL","startDate":"2013-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Breast Cancer"],"interventions":["LEE011","Letrozole","BYL719"],"countries":["United States","Australia","France","Italy","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this trial is to inform the future clinical development of the two investigational agents in ER+ breast cancer, LEE011 (CDK4/6 inhibitor) and BYL719 (PI3K-alpha inhibitor). This is a multi-center, open-label Phase Ib study. The Phase Ib dose escalation will estimate the MTD and/or RP2D for three regimens: two double combinations, LEE011 with letrozole and BYL719 with letrozole, followed by triple combinations of LEE011 + BYL719 with letrozole (Arms 3 and 4). The Phase Ib dose escalation part will be followed by Phase Ib dose expansions to further characterize the safety, tolerability, PK and preliminary clinical anti-tumor activity of the combinations. Optional crossover for p","sourceUrl":"https://clinicaltrials.gov/study/NCT01872260"},{"nctId":"NCT05535244","title":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2022-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Multiple Myeloma"],"interventions":["Cevostamab","Tocilizumab"],"countries":["United States","Australia","Belgium","France","Germany","Israel","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT05535244"},{"nctId":"NCT04133636","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":208,"enrollmentType":"ACTUAL","startDate":"2019-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-25","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["JNJ-68284528","Lenalidomide","Daratumumab","Bortezomib","Dexamethasone"],"countries":["United States","Belgium","France","Germany","Israel","Netherlands","Saudi Arabia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.","sourceUrl":"https://clinicaltrials.gov/study/NCT04133636"},{"nctId":"NCT03634540","title":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2018-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2024-12-20","conditions":["Renal Cell Carcinoma (RCC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Kidney Cancer","Renal Cancer","Renal Cell Carcinoma","Renal Cell Cancer Metastatic","Renal Cell Carcinoma Recurrent","Renal Cell Cancer, Recurrent","Kidney"],"interventions":["Belzutifan","Cabozantinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.","sourceUrl":"https://clinicaltrials.gov/study/NCT03634540"},{"nctId":"NCT04524000","title":"Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2021-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-27","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Breast Cancer"],"interventions":["Alpelisib","Fulvestrant"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2 (HER2)-negative, advanced breast cancer harboring a PIK3CA mutation in Japan, whose disease has progressed on or after aromatase inhibitor (AI) treatment regardless of prior CDK4/6 inhibitor use.","sourceUrl":"https://clinicaltrials.gov/study/NCT04524000"},{"nctId":"NCT06208410","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":306,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["Advanced Solid Tumors"],"interventions":["JS105","Fulvestrant injection","Dalpiciclib Isetionate Tablets","Toripalimab Injection","Paclitaxel for Injection (Albumin Bound)","Fluzoparib Capsules","Pyrotinib Maleate Tablets","Capecitabine Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT06208410"},{"nctId":"NCT04208178","title":"Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":19,"enrollmentType":"ACTUAL","startDate":"2020-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-26","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Advanced HER2+Breast Cancer"],"interventions":["Alpelisib","Alpelisib matching Placebo","Trastuzumab","Pertuzumab"],"countries":["United States","Belgium","China","France","Italy","Malaysia","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":11,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this two part multicenter, randomized, double-blind, placebo-controlled, Phase III study is to evaluate the efficacy and safety of alpelisib compared to alpelisib matching-placebo in combination with trastuzumab and pertuzumab as maintenance treatment of patients with HER2-positive advanced breast cancer whose tumor harbors a PIK3CA mutation following induction therapy with a taxane in combination with trastuzumab and pertuzumab. Part 1 is the open-label, safety run-in part of the study, designed to confirm the recommended phase 3 dose (RP3D) dose of alpelisib in combination with trastuzumab and pertuzumab. Following Part 1, Part 2 will be initiated, which is the randomized, P","sourceUrl":"https://clinicaltrials.gov/study/NCT04208178"},{"nctId":"NCT04587830","title":"ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme","sponsor":"Polaris Group","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ACTUAL","startDate":"2020-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2025-08-26","conditions":["Glioblastoma Multiforme (GBM)"],"interventions":["ADI-PEG 20","Temozolomide","Placebo"],"countries":["South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"A randomized, double-blind, placebo-controlled study. Weekly ADI-PEG 20 (36 mg/m2) or placebo will be combined with Stupp Protocol (Stupp 2005) radiotherapy and TMZ","sourceUrl":"https://clinicaltrials.gov/study/NCT04587830"},{"nctId":"NCT05120596","title":"First in Human Study of T3P-Y058-739 (T3P)","sponsor":"T3 Pharmaceuticals AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-15","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Solid Tumor"],"interventions":["Pembrolizumab+T3P-Y058-739","T3P-Y058-739 (IV)","T3P-Y058-739 (IT)"],"countries":["Spain","Switzerland","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05120596"},{"nctId":"NCT06970795","title":"A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2025-05-14","conditions":["Small Cell Lung Cancer","Other Advanced Solid Tumors"],"interventions":["SYS6040 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is the first-in-human Phase I study of SYS6040 for injection, comprising two phases: Dose escalation with backfill (Phase Ia) and cohort expansion (Phase Ib).The planned study population consists of subjects with advanced solid tumors.The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SYS6040 for injection as monotherapy in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06970795"},{"nctId":"NCT06245122","title":"A Study of CS23546 in Subjects With Advanced Tumors","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2024-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Advanced Tumors"],"interventions":["CS23546"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06245122"},{"nctId":"NCT07021066","title":"Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors","sponsor":"SystImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Gastric Adenocarcinoma","Advanced Pancreatic Ductal Adenocarcinoma","Esophageal Adenocarcinoma","Biliary Tract Cancer","Other Solid Tumors"],"interventions":["BL-M05D1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects with Advanced or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07021066"},{"nctId":"NCT06531486","title":"A Study of XS-02 Capsules in Patients With Advanced Solid Tumors","sponsor":"NovaOnco Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2024-07-29","startDateType":"ESTIMATED","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2024-08-01","conditions":["Solid Tumor","Ovarian Cancer","Breast Cancer","Endometrial Cancer"],"interventions":["XS-02 capsules"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate the safety, tolerability, Pharmacokinetics(pk), and efficacy of XS-02 capsules in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06531486"},{"nctId":"NCT07357220","title":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ESTIMATED","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Colorectal Cancer With Hepatic Metastases"],"interventions":["VG2025","AK112"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An open-label, multicenter, phase Ib/II study of AK112 in combination with VG2025 for advanced colorectal cancer with liver metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT07357220"},{"nctId":"NCT06623136","title":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","sponsor":"Elpiscience (Suzhou) Biopharma, Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-26","conditions":["Non-Small Cell Lung Cancer"],"interventions":["ES102","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06623136"},{"nctId":"NCT07180862","title":"A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants","sponsor":"Bio-Thera Solutions","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["BAT3306","US-Keytruda®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Comparing the PK similarity of BAT3306 and Keytruda; in NSCLC participants who were completely removed by surgery as an auxiliary treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT07180862"},{"nctId":"NCT05857332","title":"SG1906 for CLDN18.2-Positive Solid Tumors","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Locally Advanced Unresectable or Metastatic Solid Tumors"],"interventions":["SG1906"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG1906 in Patients with CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05857332"},{"nctId":"NCT07596381","title":"FAK Inhibitor in Patients With Advanced Solid Tumors","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2026-05-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Advanced Solid Tumors"],"interventions":["IN10028"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is A Phase I/Ib Study，aimed to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of Focal Adhesion Kinase Inhibitor IN10028 as Monotherapy and Combination Therapy in Patients with Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07596381"},{"nctId":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","sponsor":"Neonc Technologies, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Diffuse Astrocytoma, IDH-Mutant","Glioblastoma, IDH-wildtype","Brain Metastases, Adult","Cervical Cancer","Colorectal Cancer","Esophageal Cancer","Esophageal Squamous Cell Carcinoma","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Melanoma","Merkel Cell Carcinoma","Microsatellite Instability-High Solid Malignant Tumor","Mismatch Repair Deficient Solid Malignant Tumor","Microsatellite Instability-High Colorectal Cancer","Mismatch Repair Deficient Colorectal Cancer","Non-small Cell Lung Cancer","Renal Cell Carcinoma","Small Cell Lung Cancer","Squamous Cell Carcinoma","Urothelial Carcinoma"],"interventions":["NEO212 Oral Capsule","Ipilimumab","Pembrolizumab","Nivolumab","Regorafenib","Carboplatin","Paclitaxel","FOLFIRI Protocol","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["MSI / TMB"],"summary":"This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.","sourceUrl":"https://clinicaltrials.gov/study/NCT06047379"},{"nctId":"NCT05717348","title":"A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours","sponsor":"Elpiscience (Suzhou) Biopharma, Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Solid Tumor","Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["ES014"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human, open-label, multicenter, non-randomized study designed to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD), optimal biological dose (OBD), and recommended phase 2 dose (RP2D) of ES014 by evaluating the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of ES014 administered intravenously to subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05717348"},{"nctId":"NCT05267626","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","sponsor":"Aulos Bioscience, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":159,"enrollmentType":"ESTIMATED","startDate":"2022-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Solid Tumor","Metastatic Cancer","Cutaneous Melanoma","Non-Small Cell Lung Cancer"],"interventions":["AU-007","Aldesleukin","Avelumab","Nivolumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05267626"},{"nctId":"NCT06645886","title":"A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":13,"enrollmentType":"ACTUAL","startDate":"2024-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Hematologic Malignancies","Adult"],"interventions":["KQB198","Dasatinib"],"countries":["United States","France","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are: * What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs? * Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor? * What happens to KQB198 in the body? Participants will: * Take KQB198 daily, alone or in combination with another anti-cancer drug * Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that","sourceUrl":"https://clinicaltrials.gov/study/NCT06645886"},{"nctId":"NCT05957367","title":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2023-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["GIST"],"interventions":["Inlexisertib","Ripretinib"],"countries":["United States","Denmark","France","Germany","Italy","Netherlands","Portugal","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.","sourceUrl":"https://clinicaltrials.gov/study/NCT05957367"},{"nctId":"NCT05873686","title":"A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers","sponsor":"Nuvectis Pharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Solid Tumor","NSCLC (Non-small Cell Lung Cancer)","Renal Cancer","Mesothelioma","Non-Small Cell Squamous Lung Cancer","Non-small Cell Lung Adenocarcinoma"],"interventions":["NXP900"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.","sourceUrl":"https://clinicaltrials.gov/study/NCT05873686"},{"nctId":"NCT06774131","title":"A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer","sponsor":"UroGen Pharma Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Upper Urinary Tract Urothelial Carcinoma","Urothelial Carcinoma"],"interventions":["UGN-104"],"countries":["United States","Bulgaria","Georgia","Hungary","Israel","Latvia","Poland","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":62,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \\[mitomycin\\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06774131"},{"nctId":"NCT05141721","title":"A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer","sponsor":"Seattle Project Corporation","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2022-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-05-16","conditions":["Colorectal Neoplasms"],"interventions":["GRT-C901","GRT-R902","Atezolizumab","Ipilimumab","Fluoropyrimidine plus leucovorin","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["HLA / TCR"],"summary":"The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.","sourceUrl":"https://clinicaltrials.gov/study/NCT05141721"},{"nctId":"NCT06703892","title":"A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies","sponsor":"GenomeFrontier Therapeutics TW Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Diffuse Large B Cell Lymphoma Relapsed","Diffuse Large B Cell Lymphoma Refractory","Follicular Lymphoma ( FL)","Primary Mediastinal Large B-Cell Lymphoma-Refractory","Primary Mediastinal Large B-Cell Lymphoma-Recurrent","High-grade B-cell Lymphoma (HGBCL)"],"interventions":["GF-CART01"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I, prospective, dose-finding study to evaluate the safety, persistence, and clinical activity of GF-CART01 in subjects aged 18-70 with relapsed or refractory (R/R) B-cell hematological malignancies and failure of two-line or more standard chemotherapies or auto-hematopoietic stem cell transplantation (HSCT).This study is a traditional 3+3 dose-escalation design to observe dose-limiting toxicity (DLT), establish the maximum tolerated dose(MTD)/recommended phase 2 doses (RP2D), and preliminary efficacy of GF-CART01. RP2D may equal to or lower than MTD","sourceUrl":"https://clinicaltrials.gov/study/NCT06703892"},{"nctId":"NCT06520488","title":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2024-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Advanced Solid Tumors"],"interventions":["HRS-4642"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06520488"},{"nctId":"NCT07371104","title":"Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer","sponsor":"Daewoong Pharmaceutical Co. LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Cancer","Ovarian Cancer"],"interventions":["DWZ2501 (Olaparib 150mg)","DWC202510 (Olaparib 150mg)"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07371104"},{"nctId":"NCT06888921","title":"A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer","sponsor":"Compugen Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Ovarian Cancer","Ovarian Cancer Recurrent"],"interventions":["COM701","Normal Saline"],"countries":["United States","France","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general heal","sourceUrl":"https://clinicaltrials.gov/study/NCT06888921"},{"nctId":"NCT07061626","title":"Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma","sponsor":"Plus Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Ependymoma","High Grade Gliomas"],"interventions":["Rhenium-186 Nanoliposome"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and high-grade glioma (HGG) will be included in this study of treatment with Rhenium-186 Nanoliposome (186RNL). Phase 1 of the study will look to determine the maximum tolerated dose (MTD) of 186RNL in this patient population. Phase 2 of the study will use the recommended dose determined in Phase 1 to continue to look at overall response rate and progression-free survival following 186RNL treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07061626"},{"nctId":"NCT07623616","title":"A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia","sponsor":"Kyowa Kirin Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["ziftomenib"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia","sourceUrl":"https://clinicaltrials.gov/study/NCT07623616"},{"nctId":"NCT07241416","title":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":206,"enrollmentType":"ESTIMATED","startDate":"2025-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"],"interventions":["Rezvilutamide Tablets","Enzalutamide Soft Capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07241416"},{"nctId":"NCT06783829","title":"A Study of SHR-4394 Injection in Subjects With Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-02-27","conditions":["Prostate Cancer"],"interventions":["SHR4394"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06783829"},{"nctId":"NCT07044349","title":"Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-06-30","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["Utidelone capsule 75mg/m2/d QD","Utidelone capsule 40mg/m2/d BID","Utidelone capsule 50mg/m2/d BID","Utidelone capsule 35mg/m2/d BID"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules. Approximately 72 patients will be included in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07044349"},{"nctId":"NCT06400160","title":"Clinical Trial of TB511 in Advanced Solid Tumors","sponsor":"Twinpig Biolab, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["NSCLC","Prostate Cancer","Colorectal Cancer","Hepatocellular Carcinoma"],"interventions":["TB511","Keytruda"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"1. Study population \\[TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial\\] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC). \\[Immune checkpoint inhibitors (ICIs) Combination Therapy Cohort for Phase 2a Clinical Trial\\] Patients with advanced solid tumors who are refractory to immune checkpoint inhibitors (ICIs) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 inhibitors or who have no available standard of care. 2. Objectives of the Clinical Trial 2.1 Primary Objectives \\[Phase 1 Clinical Trial\\] * To evaluate the safety and tolerability of TB511 monotherapy in patients with advanced solid tumors and to determine the Maximum To","sourceUrl":"https://clinicaltrials.gov/study/NCT06400160"},{"nctId":"NCT07059221","title":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2025-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma"],"interventions":["SHR-A2102","Adebrelimab","Cetuximab","SHR-9839(sc)","Carboplatin / Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839（sc） for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07059221"},{"nctId":"NCT04890613","title":"Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation","sponsor":"Senhwa Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2021-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Advanced Solid Tumor"],"interventions":["CX-5461"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ctDNA / MRD","HRD / HRR"],"summary":"This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT04890613"},{"nctId":"NCT03155061","title":"Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":183,"enrollmentType":"ESTIMATED","startDate":"2017-04-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-06-05","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["ONO-4578","ONO-4538"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"The objective of the study is to evaluate the safety, tolerability, pharmacokinetics, efficacy and biomarker of ONO-4578 and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors and subjects with unresectable, advanced or recurrent gastric cancer, unresectable, advanced or recurrent colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03155061"},{"nctId":"NCT06334432","title":"Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors","sponsor":"Nuvation Bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":466,"enrollmentType":"ESTIMATED","startDate":"2024-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Advanced Solid Tumor","HER2-negative Breast Cancer","Metastatic Castration-resistant Prostate Cancer (mCRPC)","Pancreatic Cancer","Platinum-resistant Ovarian Cancer (PROC)"],"interventions":["NUV-1511"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06334432"},{"nctId":"NCT06484985","title":"Study of AXT-1003 in Subjects With Advanced Malignant Tumors.","sponsor":"Axter Therapeutics (Beijing) Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2024-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Non-Hodgkin Lymphoma","Advanced Solid Tumor"],"interventions":["AXT-1003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06484985"},{"nctId":"NCT04002297","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":510,"enrollmentType":"ACTUAL","startDate":"2019-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Mantle Cell Lymphoma; Non-Hodgkin Lymphoma"],"interventions":["zanubrutinib","bendamustine","rituximab"],"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","Ireland","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Romania","Russia","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":176,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04002297"},{"nctId":"NCT05428969","title":"A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies","sponsor":"Faron Pharmaceuticals Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":181,"enrollmentType":"ESTIMATED","startDate":"2022-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndromes","Relapsed/Refractory AML"],"interventions":["Bexmarilimab","Azacitidine","Venetoclax"],"countries":["United States","Finland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML); Phase 1 aims to identify the recommended phase 2 dose (RP2D) of bexmarilimab based on safety, tolerability and pharmacological activity; Phase 2 will investigate the preliminary efficacy of the combination treatment in selected indications from Phase 1.","sourceUrl":"https://clinicaltrials.gov/study/NCT05428969"},{"nctId":"NCT06225804","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":164,"enrollmentType":"ESTIMATED","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2024-03-18","conditions":["Non-Small Cell Lung Cancer"],"interventions":["ABSK112"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06225804"},{"nctId":"NCT07604285","title":"A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma","sponsor":"Myosin Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Glioblastoma"],"interventions":["MT-125"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2 days off for the 6 weeks of outpatient treatment of Radiotherapy (RT) plus TMZ. Participants with newly diagnosed histologically or molecularly confirmed IDH wild type and MGMT methylated GBM will be eligible to enroll. The dose-limiting toxicity (DLT) observation window will be 6 weeks, starting with the first dose of MT-125 administration and chemoradiation. A Bayesian Optimal Interval (BOIN) adaptive trial design will be used to efficiently evaluate up to four dose","sourceUrl":"https://clinicaltrials.gov/study/NCT07604285"},{"nctId":"NCT07504458","title":"Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia","sponsor":"Quetzal Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Acute Promyelocytic Leukemia (APL)","Acute Promyelocytic Leukaemia","Acute Promyelocytic Leukemia With PML-RARA","Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","Acute Promyelocytic Leukemia"],"interventions":["QTX-2101 + ATRA","IV arsenic trioxide (ATO) + ATRA"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.","sourceUrl":"https://clinicaltrials.gov/study/NCT07504458"},{"nctId":"NCT06777316","title":"A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors","sponsor":"Cogent Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Intrahepatic Cholangiocarcinoma (Icc)","Cholangiocarcinoma","Other Solid Tumors, Adult","FGFR2 Gene Fusion/Rearrangement","FGFR2 Gene Amplification","FGFR2 Gene Short Variants","FGFR3 Gene Fusion/Rearrangement","FGFR3 Gene Amplification","FGFR3 Gene Short Variants","FGFR2 Genetic Alterations","FGFR3 Genetic Alterations","Advanced Solid Tumors"],"interventions":["CGT4859"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["RNA fusion"],"summary":"This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06777316"},{"nctId":"NCT07215637","title":"Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors","sponsor":"Chong Kun Dang Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["CKD-512","Pembrolizumab"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors who have failed all standard available therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07215637"},{"nctId":"NCT05190471","title":"A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)","sponsor":"Bio-Path Holdings, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2022-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-03-10","conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"interventions":["BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide","Decitabine (in combination with BP1002)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This study evaluates the safety and tolerability of escalating doses of BP1002 (Liposomal Bcl-2 Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs, biologically effective doses, PK, PD and potential anti-leukemic effects of BP1002 as single agent (dose escalation phase) followed by assessing BP1002 in combination with decitabine (dose expansion phase).","sourceUrl":"https://clinicaltrials.gov/study/NCT05190471"},{"nctId":"NCT06934616","title":"A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors","sponsor":"Genor Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Solid Tumor Cancer"],"interventions":["GB268"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific PD-1/CTLA-4/VEGF Antibody GB268 in Participants with Advanced Solid Tumors. The study will consist of a dose-escalation stage and an dose-expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT06934616"},{"nctId":"NCT06632951","title":"Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2025-08-11","conditions":["Urothelial Carcinoma"],"interventions":["Livmoniplimab","Budigalimab","Docetaxel","Paclitaxel","Gemcitabine"],"countries":["United States","Canada","France","Israel","Japan","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for participants who have recurrent disease and disease that has progressed after frontline treatment. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of mUC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at one of 2 dif","sourceUrl":"https://clinicaltrials.gov/study/NCT06632951"},{"nctId":"NCT04855435","title":"Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours","sponsor":"MonTa Biosciences ApS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":106,"enrollmentType":"ESTIMATED","startDate":"2021-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Advanced Solid Tumor","Uveal Melanoma, Metastatic","Cutaneous Melanoma"],"interventions":["MBS8(1V270)","MBS8(1V270) and pembrolizumab combination"],"countries":["Denmark","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The Phase I trial is evaluating safety, tolerability, pharmacokinetics and preliminary efficacy of MBS8(1V270) in subjects with advanced solid tumours. The trial is designed to provide data for further clinical development of MBS8(1V270)","sourceUrl":"https://clinicaltrials.gov/study/NCT04855435"},{"nctId":"NCT06797986","title":"A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.","sponsor":"Cellid Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2026-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)","HPV (Human Papillomavirus)-Associated Carcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma"],"interventions":["BVAC-E6E7 (low level)","BVAC-E6E7 (high level)","BVAC-E6E7 (RP2D)"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"BVAC-E6E7 is an immunotherapeutic vaccine designed to treat unresectable recurrent or metastatic head and neck squamous cell carcinoma positive to HPV 16 or 18. This clinical trial for BVAC-E6E7 consists of two phases: PhaseⅠfocuses on safety and tolerance to determine the maximum tolerated dose (MTD), while Phase Ⅱ evaluates its efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06797986"},{"nctId":"NCT04833894","title":"Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis","sponsor":"argenx","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2021-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Generalized Myasthenia Gravis"],"interventions":["Efgartigimod IV"],"countries":["United States","Austria","Belgium","Canada","France","Georgia","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)","sourceUrl":"https://clinicaltrials.gov/study/NCT04833894"},{"nctId":"NCT05483868","title":"A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer","sponsor":"Aura Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2022-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-muscle-invasive Bladder Cancer","NMIBC","Non-Muscle Invasive Bladder Carcinoma","Non-Muscle Invasive Bladder Neoplasms","Non-Muscle Invasive Bladder Urothelial Carcinoma","Urothelial Carcinoma Bladder"],"interventions":["AU-011","AU-011 in Combination with Medical Laser Adminstration","AU-011 in Combination with Medical Laser Administration"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.","sourceUrl":"https://clinicaltrials.gov/study/NCT05483868"},{"nctId":"NCT06118788","title":"Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-04-17","conditions":["Leukemia, Myeloid, Acute"],"interventions":["BG1805"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, single-dose dose-escalation and dose-expansion study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06118788"},{"nctId":"NCT03878849","title":"Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer","sponsor":"Allarity Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2019-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-08-28","conditions":["Advanced Ovarian Cancer"],"interventions":["2X-121"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in recurrent, advanced ovarian cancer patients that have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. The optimal dose will be selected based on an integrated analysis of PK/PD, safety, and efficacy data.","sourceUrl":"https://clinicaltrials.gov/study/NCT03878849"},{"nctId":"NCT07538973","title":"A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Lung Cancer"],"interventions":["Anecatibin Fumarate Capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Evaluation of the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects with Impaired Liver Function versus Normal Liver Function","sourceUrl":"https://clinicaltrials.gov/study/NCT07538973"},{"nctId":"NCT05106127","title":"Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem","sponsor":"Evergreen Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-12-08","conditions":["Advanced Endometrial Cancer"],"interventions":["EG-007","Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection","Lenvatinib Capsules"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.","sourceUrl":"https://clinicaltrials.gov/study/NCT05106127"},{"nctId":"NCT06515990","title":"A Study of DM005 in Patients With Advanced Solid Tumors","sponsor":"Doma Biopharmaceutical（Suzhou）Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":208,"enrollmentType":"ESTIMATED","startDate":"2024-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Carcinoma, Non-Small-Cell Lung","Squamous Cell Carcinoma of Head and Neck","Solid Carcinoma"],"interventions":["DM005"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be a screening period of up to 28 days, a treatment period consisting of 21-day cycles, an end of treatment (EOT) Visit (+7 days), and a Follow-up Visit at 30 days (±7 days) after the EOT Visit. Participants with advanced solid malignant tumors will be treated with DM005 on Day 1 of each cycle (every 3 weeks, Q3W). An initial dose of DM005 will be infused intravenously (IV) into each participant for ","sourceUrl":"https://clinicaltrials.gov/study/NCT06515990"},{"nctId":"NCT06626919","title":"A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","sponsor":"Arcellx, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Muscular Diseases","Neuromuscular Manifestations","Autoimmune","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis","Muscle Weakness"],"interventions":["anito-cel","Standard Lymphodepletion regimen"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06626919"},{"nctId":"NCT07110363","title":"A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer","sponsor":"Biotroy Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Advanced Malignant Solid Tumor","Advanced Lung Cancer","Non-Small Cell Lung Cancer","Small Cell Lung Cancer"],"interventions":["BT02"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness. Participants of all genders, aged between 18 and 75(inclusive), are eligible to join. These patients will receive the investigational drug intravenously every two weeks. If their condition doesn't worsen and they don't experience unbearable side effects, they can continue the treatment for up to two years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07110363"},{"nctId":"NCT07372625","title":"A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.","sponsor":"PMV Pharmaceuticals, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":14,"enrollmentType":"ESTIMATED","startDate":"2026-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["TP53 Y220C Mutation","Advanced Solid Tumors"],"interventions":["metformin hydrochloride 500 mg tablet","rosuvastatin 10 mg tablet","repaglinide 0.5 mg tablet","midazolam hydrochloride syrup","rezatapopt"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07372625"},{"nctId":"NCT05451810","title":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma","sponsor":"Genmab","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":184,"enrollmentType":"ESTIMATED","startDate":"2022-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-01-24","conditions":["Diffuse Large B-Cell Lymphoma","Classic Follicular Lymphoma"],"interventions":["Epcoritamab"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":72,"serviceSignals":["Hematology NGS"],"summary":"B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy including at least 1 anti-CD20 monoclonal antibody-containing therapy or R/R classic follicular lymphoma (cFL). Adverse events will be assessed. Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R cFL. Study doctors wil","sourceUrl":"https://clinicaltrials.gov/study/NCT05451810"},{"nctId":"NCT06770764","title":"Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors","sponsor":"Trutino Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2025-01-13","conditions":["Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["ODC-IL2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single agent via intravenous infusion on Days 1 and 15 of a 28-day cycle. Up to approximately 50 patients will be enrolled in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06770764"},{"nctId":"NCT06122584","title":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","sponsor":"ABX advanced biochemical compounds GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2024-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Prostate Cancer"],"interventions":["[18F]PSMA-1007"],"countries":["France","Germany","Italy","Japan","Netherlands","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study assess the Diagnostic Performance of \\[18F\\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06122584"},{"nctId":"NCT05271318","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","sponsor":"TILT Biotherapeutics Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":29,"enrollmentType":"ESTIMATED","startDate":"2022-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Platinum-refractory Ovarian Carcinoma","Platinum-resistant Ovarian Cancer","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Platinum-Refractory Fallopian Tube Carcinoma","Platinum-Refractory Primary Peritoneal Carcinoma","Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin","Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin","Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin"],"interventions":["TILT-123","pembrolizumab","pegylated liposomal doxorubicin"],"countries":["United States","Finland"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, phase 1/1b, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab, or Pembrolizumab and Pegylated Liposomal Doxorubicin in patients with platinum resistant or refractory ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05271318"},{"nctId":"NCT06929624","title":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["SHR-A1912 Injection","Rituximab Injection","Gemcitabine Hydrochloride for Injection","Oxaliplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06929624"},{"nctId":"NCT07075185","title":"A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma","sponsor":"Kelonia Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2042-05","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Multiple Myeloma in Relapse","Myeloma Multiple","Multiple Myeloma Progression","Neoplasms by Histologic Type","Neoplasm","Hemostatic Disorders","Vascular Disorder","Paraproteinemias","Blood Protein Disorders","Hematologic Disease and Disorders","Lymphoproliferative Disorders","Immunoproliferative Disorders","Immune System Disease","Gene Therapy"],"interventions":["KLN-1010"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07075185"},{"nctId":"NCT06716814","title":"Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa","sponsor":"Swedish Orphan Biovitrum","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2025-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Haemophilia A (Moderate or Severe)"],"interventions":["Efanesoctocog alfa"],"countries":["Bulgaria","France","Greece","Italy","Norway","Spain","Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a multinational, prospective, open-label, roll-over study in patients with haemophilia A, ≥6 years of age, who have completed participation in any of the parental studies with efanesoctocog alfa; XTEND-ed study (LTS16294), FREEDOM study (Sobi.BIVV001-001), PK comparison study (Sobi.BIVV001-003) or SHINE study (Sobi.BIVV001-004). The aim of the study is to provide patients with continuous benefit from efanesoctocog alfa treatment and to further continue clinical monitoring for safety and efficacy until efanesoctocog alfa is commercially available in each patient's respective country (or until March 2027, whichever comes first). The study starts with the Baseline Visit, which will be d","sourceUrl":"https://clinicaltrials.gov/study/NCT06716814"},{"nctId":"NCT07473726","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["HLX48"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["MET profiling","ADC biomarker"],"summary":"This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX48 in patients with advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07473726"},{"nctId":"NCT06238479","title":"A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":490,"enrollmentType":"ESTIMATED","startDate":"2024-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Metastatic Solid Tumor","Recurrent Solid Tumor","Advanced Solid Tumor","Urinary Bladder Neoplasm","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Esophageal Cancer","Pancreatic Cancer","Ovarian Cancer","Cervical Cancer","Head and Neck Squamous Cell Carcinoma","Prostate Cancer","Renal Pelvis Cancer","Bladder Cancer"],"interventions":["LY4101174"],"countries":["United States","Australia","Belgium","China","France","Japan","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":28,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase 1a (dose-escalation, dose-optimization) and phase 1b (dose-expansion). The study will last up to approximately 4 years. Eligible patients will have the option to continue taking study drug after the study is complete.","sourceUrl":"https://clinicaltrials.gov/study/NCT06238479"},{"nctId":"NCT05443126","title":"A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies","sponsor":"Ellipses Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":265,"enrollmentType":"ESTIMATED","startDate":"2022-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["NSCLC"],"interventions":["EP0031","Platinum chemotherapy","Pemetrexed"],"countries":["United States","France","Germany","Italy","Poland","Spain","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05443126"},{"nctId":"NCT02817633","title":"A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)","sponsor":"Tesaro, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":463,"enrollmentType":"ACTUAL","startDate":"2016-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2025-10-28","conditions":["Neoplasms"],"interventions":["TSR-022","Nivolumab","TSR-042","TSR-033","Docetaxel","Pemetrexed","Cisplatin","Carboplatin"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":89,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT02817633"},{"nctId":"NCT06944444","title":"A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2025-04-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-29","conditions":["Malignant Tumors"],"interventions":["SSS59"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06944444"},{"nctId":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","sponsor":"NeoTX Therapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2019-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-01","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["ER+ Breast Cancer","Ovarian Cancer","Cervical Squamous Cell Carcinoma","Pancreatic Adenocarcinoma","Endometrial Cancer","Renal Cell Carcinoma","Urothelial Cancer","Head and Neck Squamous Cell Carcinoma","Mesothelioma","Melanoma","Hepatocellular Carcinoma","Prostate Cancer","NSCLC","HER2-negative Breast Cancer","Triple Negative Breast Cancer","Bladder Cancer","Colorectal Cancer Metastatic","GastroEsophageal Cancer","NSCL2 Gene Mutation","Esophageal Cancer"],"interventions":["Obinutuzumab, naptumomab estafenatox and durvalumab","Naptumomab estafenatox and durvalumab"],"countries":["India","Israel"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["HER2 profiling"],"summary":"This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03983954"},{"nctId":"NCT06372717","title":"A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS","sponsor":"Apollo Therapeutics Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Acute Myeloid Leukemia Refractory","Myelodysplastic Syndrome Acute Myeloid Leukemia","Myelodysplastic Syndrome With Excess Blasts","Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia (AML)"],"interventions":["APL-4098","Azacitidine and APL-4098","Azacitidine and Venetoclax and APL-4098"],"countries":["Australia","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).","sourceUrl":"https://clinicaltrials.gov/study/NCT06372717"},{"nctId":"NCT06031441","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2023-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-03","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Locally Advanced Solid Tumors","Recurrent Solid Tumors","Metastatic Solid Tumors"],"interventions":["RO7566802","Atezolizumab"],"countries":["United States","Australia","Canada","Singapore","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06031441"},{"nctId":"NCT06855069","title":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":468,"enrollmentType":"ESTIMATED","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-07","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Ovarian Cancer"],"interventions":["HS-20089","Paclitaxel","Doxorubicin","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06855069"},{"nctId":"NCT06326502","title":"A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma","sponsor":"Etnova Therapeutics Corp.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-07","completionType":"ESTIMATED","lastUpdated":"2024-03-27","conditions":["Hepatocellular Carcinoma","Advanced Hepatocellular Carcinoma","Liver Cancer"],"interventions":["ETN101"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta. Both in vitro and in vivo studies showed that ETN101 treatment/administration inhibited cancer cell survival and proliferation. In animal models, ETN101 had antitumor activity when administered to animals that did not respond to conventional targeted anticancer agents.","sourceUrl":"https://clinicaltrials.gov/study/NCT06326502"},{"nctId":"NCT05489237","title":"First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors","sponsor":"IDRX, Inc., a wholly owned subsidiary of GSK, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":276,"enrollmentType":"ACTUAL","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-26","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Gastrointestinal Neoplasms","Gastrointestinal Stromal Tumor (GIST)","Digestive System Disease","Gastrointestinal Diseases","Metastatic Cancer"],"interventions":["IDRX-42"],"countries":["United States","Belgium","China","France","Germany","Italy","Japan","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.","sourceUrl":"https://clinicaltrials.gov/study/NCT05489237"},{"nctId":"NCT03873402","title":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":437,"enrollmentType":"ACTUAL","startDate":"2019-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-11","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Renal Cell Carcinoma"],"interventions":["Nivolumab","Ipilimumab","Ipilimumab placebo"],"countries":["United States","Argentina","Austria","Chile","Czechia","France","Greece","Italy","Mexico","Poland","Portugal","Romania","Russia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":78,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.","sourceUrl":"https://clinicaltrials.gov/study/NCT03873402"},{"nctId":"NCT07617805","title":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-17","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","Biomarker-positive EGFR/HER2- Expressing HNSCC"],"interventions":["EGFR/HER2 Dual-Target CAR-NK Cells","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2. The study is designed as a biomarker-enriched, open-label, non-randomized trial with a dose-escalation safety lead-in followed by an expansion cohort at the recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07617805"},{"nctId":"NCT07641036","title":"Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-17","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Cholangiocarcinoma","Intrahepatic Cholangiocarcinoma","Extrahepatic Cholangiocarcinoma","Gallbladder Carcinoma","Biliary Tract Cancer"],"interventions":["EB-HC01 dual-target CARNK cells","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This example phase 1/2, open-label, biomarker-selected study evaluates EB-HC01, an allogeneic dual-target CARNK product composed of a 1:1 mixture of HER2-CAR-NK and CEACAM5-CAR-NK cells, in adults with unresectable or metastatic cholangiocarcinoma or other biliary tract cancers after standard therapy. Part A determines safety, dose-limiting toxicities (DLTs), and the recommended phase 2 dose (RP2D) after reduced-intensity lymphodepletion. Part B evaluates preliminary anti-tumor activity, CAR-NK persistence, and biomarker-response associations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07641036"},{"nctId":"NCT07589517","title":"Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Colorectal Cancer","Metastatic Colorectal Adenocarcinoma","Unresectable Colorectal Cancer"],"interventions":["EB-DUO-CAR-NK-CEA/GCC","Lymphodepletion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07589517"},{"nctId":"NCT07510828","title":"PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["EB-PT-CAR-NK-S","EB-PT-CAR-NK-D","Lymphodepleting chemotherapy","Cytokine support"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ctDNA / MRD"],"summary":"This Phase 1/2, open-label, biomarker-guided platform study evaluates the safety, tolerability, and preliminary anti-tumor activity of banked allogeneic donor-derived chimeric antigen receptor natural killer (CAR-NK) cells in adults with advanced solid tumors. During screening, tumor antigen profiling is performed using tissue biopsy and/or liquid biopsy (circulating tumor DNA and/or circulating tumor cells). Participants are assigned to receive either a single-target CAR-NK product (matched to the dominant tumor antigen) or a dual-target CAR-NK product (matched to two co-expressed antigens) to reduce the risk of antigen escape.","sourceUrl":"https://clinicaltrials.gov/study/NCT07510828"},{"nctId":"NCT07500220","title":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Advanced Hepatocellular Carcinoma (HCC)","Metastatic Liver Cancer"],"interventions":["EB-G3B7-NK dual-target CAR-NK cells","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma. The design intentionally uses GPC3 as the primary target anchor because GPC3 is the dominant HCC cell-therapy antigen in current clinical development, while adding B7-H3 to reduce antigen escape and to broaden coverage across tumor and tumor-microenvironment compartments. The study first evaluates safety and dose-limiting toxicities, then expands at the recommended phase 2 dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT07500220"},{"nctId":"NCT07510802","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Breast Cancer (Advanced/Metastatic)","HER2-positive Breast Cancer","Triple-negative Breast Cancer"],"interventions":["Dual-target CAR-NK cells","Lymphodepleting","Supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07510802"},{"nctId":"NCT07502287","title":"Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-17","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Relapsed Neuroblastoma","Refractory Neuroblastoma","High-Risk Neuroblastoma","Ganglioneuroblastoma"],"interventions":["EB-DTNB-NK","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates preliminary activity","sourceUrl":"https://clinicaltrials.gov/study/NCT07502287"},{"nctId":"NCT07589543","title":"Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Epithelial Ovarian Cancer","Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum"],"interventions":["EB-DUALNK","Cyclophosphamide","Fludarabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial ovarian cancer. Candidates for targeting include GD2, MUC1, PSMA, and mesothelin. After baseline biomarker assessment (tumor antigen expression), the program will select the most suitable dual-target pair for clinical testing. Participants will receive lymphodepleting chemotherapy followed by EB-DUALNK infusion and safety/response follow-up.","sourceUrl":"https://clinicaltrials.gov/study/NCT07589543"},{"nctId":"NCT07551362","title":"Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Advanced Gastric Adenocarcinoma","Advanced Gastroesophageal Junction Adenocarcinoma"],"interventions":["EB-DT-CAR-NK","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This example planning study proposes a phase 1/2 evaluation of an allogeneic, cord-blood-derived dual-target CAR-NK product directed against CLDN18.2 and HER2 (ERBB2) in adults with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma after prior standard systemic therapy. CLDN18.2 is selected as the anchor antigen because it has the more disease-specific gastric/GEJ cell-therapy development footprint, while HER2 is retained as the complementary second antigen to address co-expressing or heterogeneous disease. Phase 1 uses a 3+3 dose-escalation design after fludarabine/cyclophosphamide lymphodepletion followed by three intravenous CAR-NK infusions on Days 0, 3, and ","sourceUrl":"https://clinicaltrials.gov/study/NCT07551362"},{"nctId":"NCT07641049","title":"Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer","sponsor":"Beijing Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-17","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Metastatic Castration-resistant Prostate Cancer","Advanced Prostate Adenocarcinoma","PSCA-positive Prostate Cancer","PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer"],"interventions":["ETB-DualNK-01","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic castration-resistant prostate cancer (mCRPC). Part A uses dose escalation to determine the maximum tolerated dose and/or recommended Phase 2 dose. Part B expands at the selected dose in biomarkerconfirmed disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT07641049"},{"nctId":"NCT07510815","title":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Malignant Pleural Mesotheliomas"],"interventions":["EB-MF-CAR-NK-01","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma. Eligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT07510815"},{"nctId":"NCT07523555","title":"Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-17","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL","Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia","Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm","BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia","T-lymphoblastic Lymphoma","Peripheral T-cell Lymphoma"],"interventions":["Autologous CD19/CD22 dual-target CAR-T module","Autologous CD19/CD20 dual-target CAR-T module","Autologous BCMA/CD19 dual-target CAR-T module","Autologous BCMA/CD38 dual-target CAR-T module","Autologous BCMA/GPRC5D dual-target CAR-T","Autologous CD33/CD123 dual-target CAR-T module","Autologous CD33/CLL1 dual-target CAR-T module","Autologous CD5/CD7 dual-target CAR-T module"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, including overall response rate and MRD-negative response. Lymphodepletion with fludarabine/cyclophosphamide precedes infusion. The design is intended to reduce antigen escape by ma","sourceUrl":"https://clinicaltrials.gov/study/NCT07523555"},{"nctId":"NCT07641023","title":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-17","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Non-Small Cell Lung Cancer","Advanced/Metastatic"],"interventions":["Dual-target CAR-NK cells","Lymphodepleting chemotherapy","Supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors co-express at least two of the following antigens: Mesothelin (MSLN), EGFR, and HER2/ERBB2. Participants will receive lymphodepleting chemotherapy followed by infusion of the CAR-NK product matched to their tumor antigen profile. A data-driven interim assessment will be used to select the most suitable construct for expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07641023"},{"nctId":"NCT06178614","title":"A Study of JNJ-87890387 for Advanced Solid Tumors","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-07","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Neoplasms","Advanced Solid Tumors"],"interventions":["JNJ-87890387"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT06178614"},{"nctId":"NCT06246916","title":"A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2024-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-22","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-10","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Melanoma"],"interventions":["fianlimab","cemiplimab","relatlimab+nivolumab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":110,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called \"study drugs\". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the","sourceUrl":"https://clinicaltrials.gov/study/NCT06246916"},{"nctId":"NCT06624085","title":"A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-22","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Lymphoma"],"interventions":["Glofitamab","Tocilizumab","Obinutuzumab","Gemcitabine","Oxaliplatin"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06624085"},{"nctId":"NCT04976634","title":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":730,"enrollmentType":"ESTIMATED","startDate":"2021-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-22","completionType":"ESTIMATED","lastUpdated":"2025-04-06","conditions":["Neoplasm Malignant"],"interventions":["Pembrolizumab","Belzutifan","Lenvatinib"],"countries":["United States","Australia","Belgium","Chile","France","Israel","Netherlands","New Zealand","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":57,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04976634"},{"nctId":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":477,"enrollmentType":"ACTUAL","startDate":"2020-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-23","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer","Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer"],"interventions":["Trastuzumab deruxtecan"],"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","India","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":89,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastric cancer, and colorectal cancer), B) any tumor type that is HER2 IHC 2+/ISH+ (excluding breast, gastric cancer, and colorectal cancer), C) HER2 IHC 2+ or 1+ endometrial cancer, D) HER2 IHC 2+ or 1+ ov","sourceUrl":"https://clinicaltrials.gov/study/NCT04482309"},{"nctId":"NCT04590326","title":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":612,"enrollmentType":"ESTIMATED","startDate":"2020-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","Endometrial Cancer"],"interventions":["REGN5668","Cemiplimab","Ubamatamab","Sarilumab","Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]"],"countries":["United States","Belgium","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, saf","sourceUrl":"https://clinicaltrials.gov/study/NCT04590326"},{"nctId":"NCT06380348","title":"JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":398,"enrollmentType":"ESTIMATED","startDate":"2024-04-26","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-26","completionType":"ESTIMATED","lastUpdated":"2024-04-23","conditions":["Local Advanced or Metastatic NSCLC"],"interventions":["JMT101 Injection","Osimertinib tablet","Cisplatin injection","Pemetrexed injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in participants with local advanced or metastatic non-small-cell lung cancer harboured EGFR 20ins mutation without prior systemic therapy. Primary objective of this study is to assess the efficacy of JMT101 combined with Osimertinib versus Cisplatin combined with pemetrexed using by （Independent Review Center）IRC-assessed Progression Free Survival (PFS) per RECIST 1.1 as primary endpoint. Approximately 398 participants are estimated to be randomized into the study. Participant","sourceUrl":"https://clinicaltrials.gov/study/NCT06380348"},{"nctId":"NCT06818812","title":"A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-27","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Solid Tumors"],"interventions":["INCB186748","Cetuximab","GEMNabP","mFOLFIRINOX"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06818812"},{"nctId":"NCT07744763","title":"A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2025-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Solid Tumors"],"interventions":["SYS6041"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is the first-in-human study of SYS6041, a multicenter, open-label, dose-escalation, dose-reassignment and cohort-expansion Phase I/IIa clinical study, which aims to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary antitumor efficacy of SYS6041 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07744763"},{"nctId":"NCT06088888","title":"TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-02-21","conditions":["Chronic Myelogenous Leukemia"],"interventions":["TGRX-678"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT06088888"},{"nctId":"NCT06597721","title":"ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours","sponsor":"Adcendo ApS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2024-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Advanced Solid Tumor"],"interventions":["ADCE-T02"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.","sourceUrl":"https://clinicaltrials.gov/study/NCT06597721"},{"nctId":"NCT05388695","title":"To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2025-06-18","conditions":["19 and 22+ B Cell Hematologic Tumors","19 and 20+ B Cell Hematologic Tumors"],"interventions":["Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).","sourceUrl":"https://clinicaltrials.gov/study/NCT05388695"},{"nctId":"NCT07483970","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["High Risk Non-muscle Invasive Bladder Cancer"],"interventions":["JL19001 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ia, an open-label, sequential, dose escalation study to evaluate the tolerability and safety of JL19001 Injection alone in subjects with high risk NMIBC. The investigators plan to test 3 dose levels, 100, 200, and 400 μg in the Phase Ia study. A traditional 3 + 3 dose escalation design will be used. Eligible subjects will be sequentially enrolled and will be observed for DLT(s) during the DLT monitoring period (Day 1 \\~ 21).","sourceUrl":"https://clinicaltrials.gov/study/NCT07483970"},{"nctId":"NCT05990738","title":"DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2024-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Small Cell Lung Carcinoma (SCLC)"],"interventions":["BI 764532","Topotecan","Single agent chemotherapy"],"countries":["United States","France","Germany","Poland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that people can tolerate when taken together with a single agent chemotherapy. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants may continue to take BI 764532 as long as they benefit from treatment and can tolerate it. During this time, participants visit the study site regularly. The visits also depend on the response to the treatment. At ","sourceUrl":"https://clinicaltrials.gov/study/NCT05990738"},{"nctId":"NCT07462468","title":"A Phase 1 Clinical Study to Evaluate the Safety and Efficacy of WSK-IM02 in Patients With Platinum-resistant Recurrent Ovarian Cancer.","sponsor":"WestVac Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Platinum-resistant Recurrent Ovarian Cancer (PROC)"],"interventions":["WSK-IM02"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A Phase 1, single-arm, single-center, open-label, prospective, dose-escalation, and cohort expansion study to assess the safety, tolerability, pharmacokinetic (PK), and preliminary efficacy of WSK-IM02 administered as a single agent to patients with platinum-resistant recurrent ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07462468"},{"nctId":"NCT04068597","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","sponsor":"CellCentric Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2019-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Haematological Malignancy","Acute Myeloid Leukemia","Non Hodgkin Lymphoma","Multiple Myeloma","Higher-risk Myelodysplastic Syndrome","Peripheral T Cell Lymphoma"],"interventions":["CCS1477","Pomalidomide","Dexamethasone","Azacitidine","Venetoclax","Bortezomib","Ixazomib","Elranatamab","Teclistamab","Lenalidomide","Daratumumab"],"countries":["United States","France","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.","sourceUrl":"https://clinicaltrials.gov/study/NCT04068597"},{"nctId":"NCT04008797","title":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","sponsor":"Eisai Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":301,"enrollmentType":"ESTIMATED","startDate":"2019-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Endometrial Neoplasms","Neoplasms","Carcinoma, Hepatocellular","Liver Neoplasms","Colorectal Neoplasms"],"interventions":["E7386","Lenvatinib","Doxorubicin","Paclitaxel"],"countries":["United States","Canada","China","Denmark","France","Italy","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":106,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).","sourceUrl":"https://clinicaltrials.gov/study/NCT04008797"},{"nctId":"NCT06567743","title":"Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC","sponsor":"CG Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":325,"enrollmentType":"ESTIMATED","startDate":"2024-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["High-Risk Non-Muscle-Invasive Bladder Cancer"],"interventions":["Cretostimogene Grenadenorepvec"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06567743"},{"nctId":"NCT04078295","title":"A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor","sponsor":"Eisai Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":125,"enrollmentType":"ACTUAL","startDate":"2019-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Solid Neoplasms"],"interventions":["E7389-LF","Nivolumab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to evaluate safety and tolerability of E7389 liposomal formulation (E7389-LF) in combination with nivolumab and to determine the recommended Phase 2 dose (RP2D) in Phase 1b part and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in each tumor type in Phase 2 part.","sourceUrl":"https://clinicaltrials.gov/study/NCT04078295"},{"nctId":"NCT04543617","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":760,"enrollmentType":"ACTUAL","startDate":"2020-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["Tiragolumab","Atezolizumab","Tiragolumab Matching Placebo","Atezolizumab Matching Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","China","France","Germany","Greece","Hungary","Israel","Italy","Japan","Kenya","Morocco","New Zealand","Poland","Portugal","Russia","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":167,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).","sourceUrl":"https://clinicaltrials.gov/study/NCT04543617"},{"nctId":"NCT07398339","title":"Cosiporfin Sodium for Injection Photodynamic Therapy","sponsor":"Shanghai Guangsheng Biopharmaceutical Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Biliary Tract Cancers (BTC)"],"interventions":["Cosiporfin Sodium for injection, DVDMS","Gemcitabine Hydrochloride for Injection","Cisplatin for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Study Design: Multicenter, open-label, Single Group Study Population: Patients with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma who are inoperable or unwilling to undergo surgery. Primary Research Objective: To preliminarily evaluate the efficacy of photodynamic therapy (PDT) with sodium protoporphyrin combined with gemcitabine and cisplatin (GC regimen) chemotherapy in patients with advanced extrahepatic cholangiocarcinoma complicated by biliary obstruction. Secondary Study Objective: To preliminarily evaluate the safety and tolerability of photodynamic therapy (PDT) with heme porphyrin sodium combined with gemcitabine and cisplatin (GC regimen) chemotherapy in ","sourceUrl":"https://clinicaltrials.gov/study/NCT07398339"},{"nctId":"NCT06909474","title":"Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2025-04-03","conditions":["T-ALL/Lymphoma"],"interventions":["Anti-CD5 CAR NK cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06909474"},{"nctId":"NCT03833700","title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","sponsor":"Eisai Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2019-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Solid Neoplasms","Colorectal Neoplasms","Gastrointestinal Tumors"],"interventions":["E7386"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT03833700"},{"nctId":"NCT05270044","title":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","sponsor":"Pierre Fabre Medicament","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":815,"enrollmentType":"ESTIMATED","startDate":"2022-05-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2035-05-02","completionType":"ESTIMATED","lastUpdated":"2023-11-22","conditions":["Melanoma"],"interventions":["Encorafenib and Binimetinib","Placebo to match Encorafenib ; Placebo to match Binimetinib"],"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Greece","Hungary","Italy","Netherlands","Norway","Poland","Portugal","Romania","Serbia","South Africa","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":155,"serviceSignals":["Broad CGP"],"summary":"The purpose of the Columbus-AD study is to evaluate the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma versus the current standard of care (surveillance).","sourceUrl":"https://clinicaltrials.gov/study/NCT05270044"},{"nctId":"NCT06921928","title":"Study for AZD4360 in Participants With Advanced Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2025-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-16","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer","Biliary Tract Cancer","Pancreatic Ductal Adenocarcinoma"],"interventions":["AZD4360"],"countries":["United States","China","Germany","Japan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.","sourceUrl":"https://clinicaltrials.gov/study/NCT06921928"},{"nctId":"NCT04970901","title":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)","sponsor":"ADC Therapeutics S.A.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":154,"enrollmentType":"ACTUAL","startDate":"2022-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["B-Cell Non-Hodgkin Lymphoma","Relapsed B-Cell Non-Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma"],"interventions":["Loncastuximab Tesirine","Polatuzumab Vedotin","Glofitamab","Mosunetuzumab","Obinutuzumab"],"countries":["United States","Belgium","Czechia","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.","sourceUrl":"https://clinicaltrials.gov/study/NCT04970901"},{"nctId":"NCT05759923","title":"First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours","sponsor":"Molecure S.A.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced Ovarian Carcinoma","Advanced Renal Cell Carcinoma","Advanced Pancreatic Carcinoma","Advanced Colorectal Carcinoma","Metastatic Pancreatic Carcinoma","Metastatic Colorectal Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Ovarian Carcinoma"],"interventions":["OATD-02"],"countries":["Poland"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05759923"},{"nctId":"NCT06640361","title":"A Study of Olverembatinib in SDH-deficient GIST.","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["GIST"],"interventions":["Olverembatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously been treated with one-line therapy, and to evaluate the progression-free survival and clinical benefit rate of olverembatinib in patients with SDH-deficient GIST.","sourceUrl":"https://clinicaltrials.gov/study/NCT06640361"},{"nctId":"NCT07669519","title":"Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","sponsor":"Natureceuticals Sdn Bhd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Fatigue","Colon Cancer"],"interventions":["Nuvastatic™","Placebo"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population? Researchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \\~60 treatment days). Continue their standard first-line chemotherapy regimen. Provide blood","sourceUrl":"https://clinicaltrials.gov/study/NCT07669519"},{"nctId":"NCT06810544","title":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","sponsor":"Tango Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":191,"enrollmentType":"ESTIMATED","startDate":"2025-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Non Small Cell Lung Cancer","Glioma Glioblastoma Multiforme","Glioma, Malignant","Solid Tumor","Non-Small Cell Adenocarcinoma","Lung Cancer","Brain Tumor"],"interventions":["TNG456","abemaciclib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06810544"},{"nctId":"NCT03264664","title":"Study of E7386 in Participants With Selected Advanced Neoplasms","sponsor":"Eisai Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2017-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Advanced Neoplasms"],"interventions":["E7386"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.","sourceUrl":"https://clinicaltrials.gov/study/NCT03264664"},{"nctId":"NCT06947928","title":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma","sponsor":"TuHURA Biosciences, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2025-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Advanced Or Metastatic Merkel Cell Carcinoma"],"interventions":["IFx-Hu2.0","Placebo","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with advanced or metastatic Merkel Cell Carcinoma. A total of 118 participants will be randomized to receive either IFx-Hu2.0 or placebo via intralesional injection in a single lesion, followed by pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06947928"},{"nctId":"NCT04701476","title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","sponsor":"Teclison Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2021-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Colorectal Cancer; Lung Cancer"],"interventions":["TATE and pembrolizumab","TAS-102 pill","Regorafenib Pill"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT04701476"},{"nctId":"NCT05462717","title":"Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":222,"enrollmentType":"ESTIMATED","startDate":"2022-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma","Advanced Solid Tumor"],"interventions":["RMC-6291"],"countries":["United States","Australia","Czechia","France","Italy","Malaysia","Poland","Serbia","Singapore","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT05462717"},{"nctId":"NCT04094311","title":"Study of Out of Specification for Tisagenlecleucel","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2019-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["B-cell Acute Lymphoblastic Leukemia","Diffuse Large B-cell Lymphoma"],"interventions":["CTL019"],"countries":["Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety of tisagenlecleucel that is out of specification( OOS) for release as commercial product. Specifically, this study will evaluate the safety of CTL019 in the patients treated within the approved label by Japan Health Authority in Part 2. Only for Part 1, in addition to safety, key efficacy of CTL019 will also be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT04094311"},{"nctId":"NCT06915246","title":"A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma","sponsor":"VIVUS LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2025-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Lymphoma","Non-Hodgkin Lymphoma","Hodgkin Lymphoma"],"interventions":["VI-0609","BiCNU"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT06915246"},{"nctId":"NCT06620029","title":"BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer","sponsor":"BioMimetix JV, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2024-10-01","conditions":["Ovarian Neoplasms","Endometrial Cancer, Endometrial Neoplasm"],"interventions":["BMX-001","Paclitaxel (Taxol)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["ctDNA / MRD"],"summary":"This research project addresses the urgent need for novel therapeutic strategies to overcome chemotherapy resistance and mitigate chemotherapy-induced peripheral neuropathy (CIPN) in patients with recurrent ovarian and endometrial cancers, which are among the most lethal gynecologic malignancies worldwide. The study focuses on BMX-001, a redox-active manganese metalloporphyrin compound that uniquely combines the ability to enhance anti-tumor efficacy and protect normal tissues from the toxic effects of chemotherapy, specifically paclitaxel (PTX). PTX, despite being a cornerstone of treatment, is associated with significant dose-limiting neurotoxicity, which severely impacts patients quality ","sourceUrl":"https://clinicaltrials.gov/study/NCT06620029"},{"nctId":"NCT05496686","title":"Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma","sponsor":"Modulation Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2022-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-25","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Uveal Melanoma","Metastatic"],"interventions":["4.7 microCi 225Ac-MTI-201","9.5 microCi of 225Ac-MTI-201","19 microCi of 225Ac-MTI-201","38 microCi of 225Ac-MTI-201","76 microCi of 225Ac-MTI-201","152 microCi of 225Ac-MTI-201","254 microCi of 225Ac-MTI-201","424 microCi of 225Ac-MTI-201","564 microCi of 225Ac-MTI-201","750 microCi of 225Ac-MTI-201","998 microCi of 225Ac-MTI-201","1327 microCi of 225Ac-MTI-201"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary aim of the study is to establish the maximum-tolerated dose (MTD) of 225Ac-MTI-201 in participants with metastatic uveal melanoma. The secondary aims are to describe the pharmacokinetics of 225Ac-MTI-201 and the toxic effects of 225Ac-MTI-201 in participants with metastatic uveal melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05496686"},{"nctId":"NCT04077723","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":498,"enrollmentType":"ESTIMATED","startDate":"2019-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["Englumafusp alfa","Obinutuzumab","Glofitamab","Tocilizumab"],"countries":["United States","Australia","Belgium","Canada","China","Denmark","France","Italy","New Zealand","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":35,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).","sourceUrl":"https://clinicaltrials.gov/study/NCT04077723"},{"nctId":"NCT04898634","title":"A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ACTUAL","startDate":"2021-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["JNJ-78278343"],"countries":["United States","China","France","Japan","Netherlands","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the recommended phase 2 dose(s) (RP2Ds) of JNJ-78278343 in Part 1 (Dose Escalation) and the safety at the RP2Ds in Part 2 (Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT04898634"},{"nctId":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"],"interventions":["zolbetuximab","Pembrolizumab","Capecitabine","Oxaliplatin","Folinic acid (leucovorin or local equivalent)","5-fluorouracil (5-FU)","Placebo"],"countries":["United States","Australia","Belgium","Brazil","Chile","China","Czechia","France","Germany","Italy","Japan","Lithuania","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":249,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive). Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. Certain stomach and GEJ cancers may be treated with immunotherapy, which helps the body's immu","sourceUrl":"https://clinicaltrials.gov/study/NCT06901531"},{"nctId":"NCT06508983","title":"A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2024-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["SG301 Injection","SG301 placebo","pomalidomide","dexamethasone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06508983"},{"nctId":"NCT06704828","title":"A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2024-11-26","conditions":["Advanced Solid Tumors"],"interventions":["SHR-4602"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4602 as montherapy or in combination with other anti-tumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-4602 for advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06704828"},{"nctId":"NCT06665100","title":"PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)","sponsor":"Pulmotect, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Hematologic Malignancies","Hematopoietic Stem Cell Transplant (HSCT)"],"interventions":["PUL-042","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation with documented viral infections due to PIV, hMPV, or RSV. PUL-042 or a placebo will be administered 3 times over a 6-day period. The total duration of the study will be approximately 30 days.","sourceUrl":"https://clinicaltrials.gov/study/NCT06665100"},{"nctId":"NCT02343042","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","sponsor":"Karyopharm Therapeutics Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2015-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Multiple Myeloma"],"interventions":["Selinexor","Dexamethasone","Lenalidomide","Pomalidomide","Bortezomib","Daratumumab","Carfilzomib","Ixazomib","Elotuzumab","Clarithromycin","Belantamab Mafodotin","Mezigdomide"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Hematology NGS"],"summary":"This study will independently assess the efficacy and safety of 11 combination therapies in 12 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: * Arm 1: Selinexor + dexamethasone + pomalidomide (SPd); enrollment complete * Arm 2: Selinexor + dexamethasone + bortezomib (SVd); enrollment complete * Arm 3: Selinexor + dexamethasone + lenalidomide (SRd) in RRMM; enrollment complete * Arm 4: Selinexor + dexamethasone + pomalidomide + bortezomib (SPVd); enrollment complete * Arm 5: Selinexor + dexamethasone + daratumumab (SDd); ","sourceUrl":"https://clinicaltrials.gov/study/NCT02343042"},{"nctId":"NCT07453394","title":"QLS5132 Combination Therapy in Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":626,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Gastric Cancer (GC)","Non-small Cell Lung Cancer (NSCLC)","Endometrial Cancer","Advanced Solid Tumors","Ovarian Cancer"],"interventions":["QLS5132; Bevacizumab","QLS5132; Platinum; Bevacizumab","QLS5132; Olaparib; Bevacizumab","QLS5132; QL1706; QL2107","QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion. The main questions it aims to answer are: * In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5132 combination therapy, and what are the recommended dose(s) for expansion? * In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5132 combination therapy at","sourceUrl":"https://clinicaltrials.gov/study/NCT07453394"},{"nctId":"NCT06736704","title":"SNV4818 in Participants With Advanced Solid Tumors","sponsor":"Pikavation Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Advanced Solid Tumors"],"interventions":["SNV4818","Fulvestrant","Palbociclib"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.","sourceUrl":"https://clinicaltrials.gov/study/NCT06736704"},{"nctId":"NCT06307795","title":"A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2024-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["ANS014004"],"countries":["United States","Canada","China"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["RNA fusion"],"summary":"This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06307795"},{"nctId":"NCT05410145","title":"A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation","sponsor":"D3 Bio (Wuxi) Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":442,"enrollmentType":"ESTIMATED","startDate":"2022-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["KRAS P.G12C"],"interventions":["D3S-001","Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed","Cetuximab"],"countries":["United States","Australia","China","France","Germany","Hong Kong","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["RAS genotyping"],"summary":"This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001 or combination therapy in subjects with advanced KRAS p.G12C mutant solid tumors. D3S-001 will be taken daily by oral administration in 21-day treatment cycles.","sourceUrl":"https://clinicaltrials.gov/study/NCT05410145"},{"nctId":"NCT05142423","title":"A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2021-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Advanced Solid Tumor"],"interventions":["AK109+AK104"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .","sourceUrl":"https://clinicaltrials.gov/study/NCT05142423"},{"nctId":"NCT07255664","title":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","sponsor":"CuraCell TX AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Metastatic Colorectal Cancer","Prostate Cancer Metastatic","Prostate Cancer Locally Advanced"],"interventions":["CC-38","Pembrolizumab","Cyclophosphamid","Interleukin-2","Uromitexan"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07255664"},{"nctId":"NCT06171750","title":"Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors","sponsor":"Ankyra Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":97,"enrollmentType":"ESTIMATED","startDate":"2024-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Advanced Solid Tumor","Cutaneous Tumor","Subcutaneous Tumor","Malignant Solid Tumor","Solid Tumor","Metastatic Solid Tumor","Metastasis to Soft Tissue","Non Small Cell Lung Cancer","Cutaneous Squamous Cell Carcinoma"],"interventions":["tolododekin alfa","Cemiplimab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in three parts; in Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral lesions will receive ANK-101 as a single agent; and in Part 3, participants with cutaneous squamous cell carcinoma (CSCC) will receive ANK-101 in combination with cemiplimab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06171750"},{"nctId":"NCT05445778","title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":520,"enrollmentType":"ACTUAL","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2032-05","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer"],"interventions":["Mirvetuximab soravtansine plus Bevacizumab","Bevacizumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Germany","Greece","Ireland","Israel","Italy","Japan","Philippines","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":264,"serviceSignals":["ADC biomarker"],"summary":"GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT05445778"},{"nctId":"NCT06399757","title":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","sponsor":"Apollo Therapeutics Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Colorectal Cancer","Cholangiocarcinoma","Appendiceal Adenocarcinoma","Pancreatic Adenocarcinoma","Gastric Adenocarcinoma","Endometrial Adenocarcinoma","Triple Negative Breast Cancer","Ovarian Cancer","Prostate Cancer"],"interventions":["APL-5125"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06399757"},{"nctId":"NCT06162572","title":"Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Servier Bio-Innovation LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":102,"enrollmentType":"ACTUAL","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["S095018","S095024","S095029","S095018 Recommended Dose Expansion (RDE)","S095024 RDE","S095029 RDE","Cemiplimab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","France","Hong Kong","Hungary","Italy","Romania","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":63,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with previously untreated advanced/metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression. The study includes two parts: part A, the combination-therapy safety lead-in phase to determine the recommended dose for expansion (RDE) for S095018, S095024, and S095029 in combination with cemiplimab and part B, the randomized dose expansion phase to assess the efficacy of S095018, S095024, or S095029 in combination with cemiplimab. Study treatment will be administered fo","sourceUrl":"https://clinicaltrials.gov/study/NCT06162572"},{"nctId":"NCT06846606","title":"Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS","sponsor":"Auron Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2025-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Relapsed Acute Myeloid Leukemia (AML)","Refractory Acute Myeloid Leukemia (AML)","Relapsed/Refractory AML","Relapsed Myelodysplastic Syndromes","Refractory Myelodysplastic Syndromes","Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)"],"interventions":["AUTX-703"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06846606"},{"nctId":"NCT07229638","title":"A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Solid Tumor"],"interventions":["SHR-9839(sc) For Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multi-center Phase IB/II clinical trial of SHR-9839(sc) combined with anti-tumor therapy in patients with advanced solid tumors, aimed at evaluating the safety, tolerability, and efficacy of SHR-9839(sc) in combination with anti-tumor therapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229638"},{"nctId":"NCT07629726","title":"A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms","sponsor":"Kyowa Kirin Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Hematologic Neoplasms"],"interventions":["KK2430"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"KK2430 (\"Study Drug\") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.","sourceUrl":"https://clinicaltrials.gov/study/NCT07629726"},{"nctId":"NCT07226843","title":"A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2026-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-02","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Lymphoma, Non-Hodgkin's","Lymphoma, Diffuse Large B-Cell","Follicular Lymphoma"],"interventions":["LY4584180","Rituximab"],"countries":["United States","France","Germany","Italy","Japan","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":46,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.","sourceUrl":"https://clinicaltrials.gov/study/NCT07226843"},{"nctId":"NCT06903377","title":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Non-small Cell Lung Cancer"],"interventions":["ZG005 for Injection","Gecacitinib Hydrochloride Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT06903377"},{"nctId":"NCT05263960","title":"A Study of CM350 in Patients With Advanced Solid Tumors","sponsor":"Keymed Biosciences Co.Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":248,"enrollmentType":"ESTIMATED","startDate":"2022-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2025-05-04","conditions":["Advanced Solid Tumor"],"interventions":["CM350 group1","CM350 group2","CM350 group3"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open label, dose escalation and expansion Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of CM350 in patients with advanced solid tumors. The phase I study consists of a dose escalation phase and a dose expansion phase The safety and tolerability of CM350 and the maximum tolerated dose (MTD) (if applicable) will be evaluated in dose escalation phase. The recommended phase 2 dose (RP2D) of CM350 will be determined in dose expansion phase. The phase II study is to evaluate the efficacy of CM350 at the recommended phase 2 dose (RP2D) for advanced glypican-3 (GPC3)-positive solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05263960"},{"nctId":"NCT06872580","title":"A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":149,"enrollmentType":"ESTIMATED","startDate":"2025-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Advanced Solid Tumor"],"interventions":["QLS1209"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors，determine the maximum tolerated dose (MTD) or maximum drug dose（MAD）of QLS1209, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT06872580"},{"nctId":"NCT07033026","title":"An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.","sponsor":"NGM Biopharmaceuticals, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2025-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Colorectal Cancer","CRC (Colorectal Cancer)","Cancer Cachexia"],"interventions":["NGM120 Q4W","NGM120 Q8W","Placebo given"],"countries":["United States","Georgia","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.","sourceUrl":"https://clinicaltrials.gov/study/NCT07033026"},{"nctId":"NCT06368167","title":"A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2024-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2024-04-16","conditions":["Follicular Lymphoma"],"interventions":["SHR2554"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The study is being conducted to evaluate the efficacy and safety of SHR2554 in Patients with Relapsed or Refractory Follicular Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06368167"},{"nctId":"NCT06347458","title":"BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2024-04-04","conditions":["Leukemia","Acute Myeloid Leukemia"],"interventions":["BG1805"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, single-dose dose-escalation and dose-expansion study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06347458"},{"nctId":"NCT07101328","title":"A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":215,"enrollmentType":"ESTIMATED","startDate":"2026-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Lymphoma, Non-Hodgkin","B-cell Lymphoma","Lymphoma, Large B-Cell, Diffuse","Lymphoma, Follicular","Lymphoma, B-cell Marginal Zone","Waldenstrom Macroglobulinemia","Lymphoma, Mantle Cell"],"interventions":["LY4152199 - IV"],"countries":["United States","Australia","Canada","Denmark","France","Germany","Italy","Japan","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":50,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.","sourceUrl":"https://clinicaltrials.gov/study/NCT07101328"},{"nctId":"NCT06873659","title":"SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors","sponsor":"Qurgen Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Solid Tumor","Gastric Cancer","Liver Cancer"],"interventions":["SON-DP"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06873659"},{"nctId":"NCT06883526","title":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Lymphoma"],"interventions":["ZG005 for Injection","Gecacitinib Hydrochloride Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06883526"},{"nctId":"NCT07172126","title":"Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":291,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-09-15","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["TQB3201 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker. The phase I phase of this trial aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3201 tablets for the treatment of advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07172126"},{"nctId":"NCT07221734","title":"Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma","sponsor":"mAbxience Research S.L.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":632,"enrollmentType":"ESTIMATED","startDate":"2025-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Advanced (Unresectable or Metastatic) Melanoma"],"interventions":["MB11 (Proposed Nivolumab Biosimilar)","EU-Opdivo®","US- sourced Opdivo®"],"countries":["Portugal","Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07221734"},{"nctId":"NCT05696626","title":"Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation","sponsor":"LeonaBio","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2023-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Metastatic Breast Cancer"],"interventions":["Lasofoxifene in combination with abemaciclib","Fulvestrant in combination with abemaciclib"],"countries":["United States","Australia","Belgium","Canada","China","France","Germany","Israel","Italy","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":224,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of","sourceUrl":"https://clinicaltrials.gov/study/NCT05696626"},{"nctId":"NCT06506955","title":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","sponsor":"Taiho Oncology, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2024-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced/Metastatic Cancer"],"interventions":["futibatinib","futibatinib, fulvestrant"],"countries":["United States","France","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06506955"},{"nctId":"NCT05270213","title":"Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors","sponsor":"Riboscience, LLC.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":164,"enrollmentType":"ESTIMATED","startDate":"2022-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Advanced Cancer"],"interventions":["RBS2418","Pembrolizumab","Other approved anti-cancer therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selecti","sourceUrl":"https://clinicaltrials.gov/study/NCT05270213"},{"nctId":"NCT04956640","title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","sponsor":"Eli Lilly and Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2021-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-04","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Carcinoma, Non-Small-Cell Lung","Colorectal Neoplasms","Endometrial Neoplasms","Ovarian Neoplasms","Pancreatic Neoplasms","Biliary Tract Neoplasms"],"interventions":["LY3537982","Pembrolizumab","Cetuximab","Pemetrexed","Cisplatin","Carboplatin"],"countries":["United States","Australia","Canada","France","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT04956640"},{"nctId":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","sponsor":"Parabilis Medicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":619,"enrollmentType":"ESTIMATED","startDate":"2023-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Cancer","Colorectal Cancer","Solid Tumor","Locally Advanced Solid Tumor","Metastatic Cancer","WNT Pathway","HCC","Desmoid","Microsatellite Stable Colorectal Cancer","Metastatic Castration-resistant Prostate Cancer","Familial Adenomatous Polyposis (FAP)","Endometrial Carcinoma","Prostate Cancer","Microsatellite Instability-High Colorectal Cancer","Adamantinomatous Craniopharyngioma"],"interventions":["FOG-001","mFOLFOX-6","Nivolumab","Trifluridine/tipiracil","Bevacizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).","sourceUrl":"https://clinicaltrials.gov/study/NCT05919264"},{"nctId":"NCT06225310","title":"A Trial of Selinexor, Ruxolitinib and Methylprednisolone","sponsor":"Oncotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Multiple Myeloma in Relapse","Multiple Myeloma, Refractory"],"interventions":["Selinexor","Ruxolitinib","Methylprednisolone"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Selinexor, a first-in-class, oral selective exportin 1 (XPO1) inhibitor, has shown promise in pre-clinical and clinical studies. It functions by inhibiting the nuclear export protein XPO1, resulting in the accumulation of tumor suppressor proteins and inhibition of oncoprotein mRNAs, which is selectively lethal to myeloma cells. Selinexor has demonstrated activity in combination with various drugs, including glucocorticoids and proteasome inhibitors, leading to its FDA approval for the treatment of relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06225310"},{"nctId":"NCT07563829","title":"NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies","sponsor":"NextPoint Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Metastatic Malignant Neoplasm"],"interventions":["NPX372"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7. In this research study we are: * Evaluating the safety and possible effectiveness of NPX372. * Identifying a safe and tolerable dose or doses for further study. Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.","sourceUrl":"https://clinicaltrials.gov/study/NCT07563829"},{"nctId":"NCT05709249","title":"Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer","sponsor":"Jiangsu Famous Medical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":730,"enrollmentType":"ESTIMATED","startDate":"2022-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-01","completionType":"ESTIMATED","lastUpdated":"2024-12-30","conditions":["Colon Cancer"],"interventions":["XLJDOD compound granule","placebo (XLJDOD mimetic agent)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Subjects in the intervention group will be treated with XLJDOD compound granule. Subjects in the control group will be treated with placebo (XLJDOD mimetic agent).","sourceUrl":"https://clinicaltrials.gov/study/NCT05709249"},{"nctId":"NCT06227377","title":"QTX3034 in Patients With KRAS G12D Mutation","sponsor":"Quanta Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-01","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Solid Tumors"],"interventions":["QTX3034","Cetuximab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["RAS genotyping"],"summary":"Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06227377"},{"nctId":"NCT06564272","title":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-09-27","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-01","completionType":"ESTIMATED","lastUpdated":"2024-08-23","conditions":["Ewing Sarcoma"],"interventions":["KC1036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT06564272"},{"nctId":"NCT03319667","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","sponsor":"Sanofi","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":475,"enrollmentType":"ACTUAL","startDate":"2017-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Plasma Cell Myeloma"],"interventions":["Isatuximab SAR650984","Bortezomib","Lenalidomide","Dexamethasone"],"countries":["United States","Australia","Belgium","China","Czechia","Denmark","France","Germany","Greece","Italy","Japan","Lithuania","Mexico","New Zealand","Poland","Portugal","Russia","Spain","Sweden","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":104,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and dexamethasone, in participants with newly diagnosed multiple myeloma (NDMM) not eligible for transplant. Secondary Objectives: * To evaluate in both randomized (isatuximab, bortezomib, lenalidomide and dexamethasone combination (IVRd) and bortezomib, lenalidomide and dexamethasone combination (VRd)) arms: * Complete response (CR) rate, as defined by the International Myeloma Working Group (IMWG) criteria. * Minimal residual disease (MRD) negativity rate in participants w","sourceUrl":"https://clinicaltrials.gov/study/NCT03319667"},{"nctId":"NCT05434234","title":"A Study of YL201 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":312,"enrollmentType":"ESTIMATED","startDate":"2022-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-06","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Advanced Solid Tumor"],"interventions":["YL201","YL201 and atezolizumab"],"countries":["United States","Canada","China","France","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":45,"serviceSignals":["ADC biomarker"],"summary":"This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.","sourceUrl":"https://clinicaltrials.gov/study/NCT05434234"},{"nctId":"NCT04421963","title":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":185,"enrollmentType":"ACTUAL","startDate":"2020-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-06","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Ovarian Cancer","Breast Cancer"],"interventions":["Olaparib"],"countries":["United States","Belgium","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","Poland","Portugal","Russia","Slovenia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":107,"serviceSignals":["HER2 profiling"],"summary":"The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.","sourceUrl":"https://clinicaltrials.gov/study/NCT04421963"},{"nctId":"NCT04108195","title":"A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":290,"enrollmentType":"ACTUAL","startDate":"2020-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-07","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Daratumumab","Talquetamab","Teclistamab","Pomalidomide"],"countries":["United States","Canada","Germany","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.","sourceUrl":"https://clinicaltrials.gov/study/NCT04108195"},{"nctId":"NCT03930953","title":"A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)","sponsor":"Celgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":438,"enrollmentType":"ESTIMATED","startDate":"2019-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-09","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["CC-99282","Rituximab","Obinutuzumab","Tafasitamab","Valemetostat"],"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Chile","China","Denmark","France","Israel","Italy","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":66,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT03930953"},{"nctId":"NCT06847334","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":772,"enrollmentType":"ESTIMATED","startDate":"2025-04-27","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-24","completionType":"ESTIMATED","lastUpdated":"2025-02-26","conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"interventions":["HLX17","US-sourced Keytruda®","EU-sourced Keytruda®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicentre, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the similarity in efficacy, safety, PK profile, and immunogenicity of HLX17 vs. Keytruda®( US- and EU-sourced) in the first-line treatment of advanced non-squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06847334"},{"nctId":"NCT02393625","title":"Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":57,"enrollmentType":"ACTUAL","startDate":"2015-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-09","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["ALK-positive NSCLC"],"interventions":["Ceritinib (LDK378)","Nivolumab"],"countries":["United States","Australia","Belgium","Canada","Hong Kong","Italy","Singapore","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients","sourceUrl":"https://clinicaltrials.gov/study/NCT02393625"},{"nctId":"NCT07358377","title":"A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer","sponsor":"Atridia Pty Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-10","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Breast Cancer"],"interventions":["HRS-6209 Capsules and fulvestrant injection"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07358377"},{"nctId":"NCT06215118","title":"A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2024-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-09","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Iberdomide"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part ","sourceUrl":"https://clinicaltrials.gov/study/NCT06215118"},{"nctId":"NCT07559474","title":"A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2026-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-13","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Hepatic Insufficiency","Liver Diseases"],"interventions":["INCB123667"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07559474"},{"nctId":"NCT06116786","title":"A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2023-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-07","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-small-Cell Lung"],"interventions":["JNJ-86974680","Cetrelimab","Radiation Therapy"],"countries":["United States","Germany","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06116786"},{"nctId":"NCT07627711","title":"Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)","Unresectable Locally Advanced","Metastatic Disease"],"interventions":["EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)","EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1)","Lymphodepleting chemotherapy (Flu/Cy)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This example study evaluates the safety, tolerability, and preliminary anti-tumor activity of investigational, dual-targeting chimeric antigen receptor natural killer (CAR-NK) cell products for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants are assigned to one of two biomarker-defined cohorts based on tumor antigen expression: (A) Mesothelin (MSLN) and/or MUC1, or (B) Claudin 18.2 (CLDN18.2) and/or MUC1. The study uses a dose-escalation followed by dose-expansion design to define a recommended Phase 2 dose (RP2D) and to estimate response rates in each cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT07627711"},{"nctId":"NCT07551336","title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","sponsor":"Beijing Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Malignant Glioma","High-Grade Gliomas","Glioblastoma","Recurrent High-Grade Gliomas","Recurrent Glioblastoma"],"interventions":["Dual-target CAR-NK cells","Cyclophosphamide","Intracranial catheter/reservoir for locoregional delivery","Fludarabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a draft, ClinicalTrials.gov-style example record for a first-in-human Phase 1 study evaluating locoregional administration of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in adults with recurrent or progressive glioblastoma (GBM) or other high-grade glioma (HGG). Participants will undergo tumor antigen profiling for IL13Rα2, EGFR/EGFRvIII, and B7-H3 (CD276). Based on this assessment, each participant will receive the most suitable dual-target CAR construct to reduce antigen-escape risk.","sourceUrl":"https://clinicaltrials.gov/study/NCT07551336"},{"nctId":"NCT07523529","title":"Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Unresectable","Metastatic"],"interventions":["Autologous dual-target CAR-T cells selected from the predefined target library.","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target-pair library. The trial is designed to test whether biomarkerguided dual targeting can improve tumor control, reduce antigenescape risk, and preserve safety in solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07523529"},{"nctId":"NCT07551349","title":"Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Advanced or Metastatic Clear Cell Renal Cell Carcinoma"],"interventions":["EB-701/CA9-NK","Fludarabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2 study evaluates the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CD70/CAIX CAR-NK cells after fludarabine/cyclophosphamide lymphodepletion in adults with advanced or metastatic clear cell RCC that has progressed after standard therapy. The study is designed to determine a recommended dose and schedule, characterize hepatobiliary safety, and explore whether CD70-high, CAIX-high, or dual-high tumors derive the greatest benefit. Biomarker-defined activity signals will be used to guide whether later development should prioritize CD70, CAIX/CA9, or continued dual-targeting.","sourceUrl":"https://clinicaltrials.gov/study/NCT07551349"},{"nctId":"NCT07409103","title":"A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)","sponsor":"Elevara Medicines Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Active Rheumatoid Arthritis"],"interventions":["ELV001 25 mg","ELV001 75 mg","ELV001 125 mg","Placebo"],"countries":["United States","South Africa"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled. The number of participants can be extended to maximally 220 to account for dropouts during the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07409103"},{"nctId":"NCT07539285","title":"A Study of HDM2024 in Participants With Advanced Solid Tumors","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2026-04-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-28","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Advanced Solid Tumors"],"interventions":["HDM2024"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07539285"},{"nctId":"NCT06641908","title":"Anti-GD2 ADC M3554 in Advanced Solid Tumors","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2024-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-16","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Advanced Solid Tumor"],"interventions":["M3554"],"countries":["United States","Belgium","France","Japan","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months","sourceUrl":"https://clinicaltrials.gov/study/NCT06641908"},{"nctId":"NCT05652335","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2022-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-28","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Relapsed or Refractory Multiple Myeloma","Previously Treated Amyloid Light-chain (AL) Amyloidosis"],"interventions":["JNJ-79635322"],"countries":["United States","Belgium","France","Japan","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\\[s\\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at the RP2D(s) selected and in disease subgroups in Part 2 (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05652335"},{"nctId":"NCT07137598","title":"A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-19","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-08","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Rheumatoid Arthritis"],"interventions":["Afimkibart","Placebo"],"countries":["United States","Argentina","Belgium","Brazil","Denmark","France","Germany","Italy","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe rheumatoid arthritis (RA) who have an inadequate response or intolerance to TNF and/or JAK inhibitors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07137598"},{"nctId":"NCT06549465","title":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","sponsor":"Convergent Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":93,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-20","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["PSMA PET-Positive Castration-Resistant Prostate Cancer"],"interventions":["In-111 rosopatamab tetraxetan","45 kBq/kg Ac-225 rosopatamab tetraxetan","45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan","60 kBq/kg Ac-225 rosopatamab tetraxetan","Single dose 22 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan","Single dose 34 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan","Single dose 45 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan","55 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan","60 kBq/kg or equivalent fixed dose activity Ac-225 rosopatamab tetraxetan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a four-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to characterize the biodistribution of the radioantibody to target organs and prostate cancer lesions. Participants then will be enrolled into either Part 2 (Dose Optimization) or Part 3 (Dose Escalation and Expansion) depending on their prior treatment history. Part 4 will be an extended regimen in dose escalation and expansion. Participants qualifying for Part 2 will be randomized to receive Ac-225 rosopatamab tetraxetan in a single fractionated cycle (dose ad","sourceUrl":"https://clinicaltrials.gov/study/NCT06549465"},{"nctId":"NCT07648472","title":"A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.","sponsor":"Joint Biosciences Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-20","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced Solid Tumors"],"interventions":["OVV-01 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, single-arm, dose escalation clinical study to evaluate the safety and preliminary efficacy of OVV-01 Injection in patients with advanced solid tumors, following both intravenous (iv.) and intratumoral (it.) injections. This study consists of two parts: Part 1 is a dose escalation study of iv. administration; Part 2 is a dose escalation study of iv. and it. administration.","sourceUrl":"https://clinicaltrials.gov/study/NCT07648472"},{"nctId":"NCT05774951","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":4300,"enrollmentType":"ESTIMATED","startDate":"2023-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-20","primaryCompletionType":"ESTIMATED","completionDate":"2036-05-29","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Breast Cancer, Early Breast Cancer"],"interventions":["Camizestrant","Tamoxifen","Anastrozole","Letrozole","Exemestane"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","France","Georgia","Germany","Greece","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Peru","Philippines","Poland","Portugal","Romania","Serbia","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":709,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT05774951"},{"nctId":"NCT07601620","title":"A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2026-07-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-22","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["HER2 + Breast Cancer"],"interventions":["HLX319","EU-Phesgo®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .","sourceUrl":"https://clinicaltrials.gov/study/NCT07601620"},{"nctId":"NCT06305767","title":"A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2024-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-23","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-20","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Bladder Cancer"],"interventions":["Pembrolizumab","Intismeran autogene","Placebo","Enfortumab Vedotin","Surgery (RC plus PLND)"],"countries":["United States","Australia","Canada","Chile","Colombia","France","Germany","Italy","New Zealand","Peru","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":74,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surgery, some people receive more treatment to prevent cancer from returning. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Enfortumab vedotin (EV) is an","sourceUrl":"https://clinicaltrials.gov/study/NCT06305767"},{"nctId":"NCT04943536","title":"Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer","sponsor":"Alessa Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2021-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-24","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-15","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Prostate Adenocarcinoma"],"interventions":["bicalutamide","Stereotactic body radiation therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is indicated for the treatment of localized prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04943536"},{"nctId":"NCT06598306","title":"Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-24","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-24","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["Tarlatamab"],"countries":["United States","Australia","Belgium","China","Germany","Japan","Poland","Spain","Switzerland","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06598306"},{"nctId":"NCT05720117","title":"A Study of PYX-201 in Advanced Solid Tumors","sponsor":"Pyxis Oncology, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2023-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Solid Tumor","Advanced Solid Tumor"],"interventions":["PYX-201"],"countries":["United States","Belgium","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.","sourceUrl":"https://clinicaltrials.gov/study/NCT05720117"},{"nctId":"NCT06942143","title":"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-25","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Sarcoma","Lung Cancers","Melanoma"],"interventions":["Super1 TCR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06942143"},{"nctId":"NCT07197645","title":"Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2025-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-05","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Bone Pain","Metastatic Bone Tumor","Bone Metastases in Subjects With Advanced Cancer"],"interventions":["153Sm-DOTMP"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT07197645"},{"nctId":"NCT05379595","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2022-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced or Metastatic Colorectal Cancer"],"interventions":["Amivantamab IV","Fluorouracil","Leucovorin","Oxaliplatin","Irinotecan","Amivantamab"],"countries":["United States","Belgium","Canada","China","Germany","Italy","Malaysia","Puerto Rico","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) and to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts).","sourceUrl":"https://clinicaltrials.gov/study/NCT05379595"},{"nctId":"NCT07023627","title":"A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","sponsor":"Incyte Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-24","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Ovarian Cancer"],"interventions":["INCB123667"],"countries":["United States","Australia","Belgium","Japan","Puerto Rico","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":74,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07023627"},{"nctId":"NCT05488314","title":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":57,"enrollmentType":"ACTUAL","startDate":"2022-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-28","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Capmatinib","Amivantamab"],"countries":["United States","Brazil","Canada","China","France","Germany","Italy","Japan","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":78,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to identify the recommended Phase 2 combination dose (RP2CD\\[s\\]) of the amivantamab and capmatinib combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection), and to evaluate the antitumor effect of the amivantamab and capmatinib combination therapy in mesenchymal-epithelial transition (MET) exon 14 skipping mutation and MET amplified NSCLC, when administered at the selected RP2CD(s) in Phase 2 (expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05488314"},{"nctId":"NCT07345637","title":"Phase I Study of FXS887 in the Treatment of Solid Tumors","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":14,"enrollmentType":"ESTIMATED","startDate":"2026-01-05","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Solid Tumor Refractory to Conventional Treatment"],"interventions":["FXS887"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07345637"},{"nctId":"NCT06394414","title":"A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":187,"enrollmentType":"ACTUAL","startDate":"2024-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-29","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Advanced Solid Tumors"],"interventions":["YL201"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, multicenter, open-label stydy to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Serplulimab with or without Platinum-based Chemotherapy in Selected Subjects with Advanced Solid Tumors conducted in China. The study will include 2 parts: a dose escalation part (Part 1) followed by a cohort expansion part (Part 2). Part 1 will estimate the safety, tolerability and MTD/RED(s) of YL201 in combination with serplulimab with or without platinum-based chemotherapy in selected subjects with advanced solid tumors. Part 2 will estimate the efficacy of YL201 in combination with serplulimab with or without platinum-based chemotherapy in selected subject","sourceUrl":"https://clinicaltrials.gov/study/NCT06394414"},{"nctId":"NCT06634849","title":"An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).","sponsor":"Pathios Therapeutics Pty Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-30","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Advanced Solid Tumor"],"interventions":["PTT-4256"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This open label, dose escalation module will evaluate the safety, tolerability, PK, PD, and preliminary efficacy of PTT-4256 in participants with solid tumours using a combination of accelerated dose titration (ADT) and Bayesian Optimal Interval (BOIN) design.","sourceUrl":"https://clinicaltrials.gov/study/NCT06634849"},{"nctId":"NCT07222969","title":"A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors","sponsor":"Vibrant Sciences Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2026-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Advanced Solid Tumors"],"interventions":["VIB305 for Injection"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard treatments or refused the existing treatments. This study is divided into a dose-escalation phase (Phase I) and a dose-expansion phase (Phase II). Phase I (dose escalation) is designed to preliminarily evaluate the safety and tolerability of VIB305 in advanced solid tumors, to determine the nature and incidence of dose-limiting toxicities (DLTs), and thereby to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Based on the findings from th","sourceUrl":"https://clinicaltrials.gov/study/NCT07222969"},{"nctId":"NCT07160335","title":"A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2025-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-27","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Non-small Cell Lung Cancer","Melanoma","Renal Cell Carcinoma"],"interventions":["HLX17","US-sourced Keytruda®"],"countries":["United States","China","Georgia","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":69,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07160335"},{"nctId":"NCT05492682","title":"START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer","sponsor":"Valo Therapeutics Oy","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2023-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Melanoma (Skin)","Triple-Negative Breast Cancer","Non-Small Cell Lung Cancer","Synovial Sarcoma","Myxoid Liposarcoma","Colorectal Cancer","Osteosarcoma","Sarcoma"],"interventions":["PeptiCRAd-1","Cyclophosphamide","Pembrolizumab"],"countries":["Germany","Italy"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05492682"},{"nctId":"NCT04279847","title":"Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ACTUAL","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Myelofibrosis","Myelodysplastic Syndrome","Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome","Myeloproliferative Neoplasm","Relapsed or Refractory Primary Myelofibrosis","Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)","ET (Essential Thrombocythemia)"],"interventions":["INCB057643","Ruxolitinib"],"countries":["United States","Canada","China","Finland","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT04279847"},{"nctId":"NCT07414953","title":"A Phase Ib Study of HS-10504 Combined Therapy in NSCLC","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-03-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Lung Cancer"],"interventions":["HS-10504","SHR-A2009","HS-20122","HS-20117","SHR-1826","SHR-A2102"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07414953"},{"nctId":"NCT07554859","title":"GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-05-20","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["ArmA:GFH375","Arm B:GFH375","Arm C:GFH375"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["RAS genotyping"],"summary":"This study is a multicenter, open-label, randomized clinical trial aimed at exploring the efficacy and safety of three treatment regimens for treatment-naive advanced NSCLC patients with KRAS G12D mutation: GFH375 monotherapy (Cohort 1), GFH375 combined with cetuximab (Cohort 2), and GFH375 combined with pemetrexed (Cohort 3).Every cohort will recruit 30 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07554859"},{"nctId":"NCT06799065","title":"First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer","sponsor":"Accent Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Solid Tumors","Breast Cancer Recurrent","Ovarian Cancer","High-grade Serous Ovarian Carcinoma","Triple Negative Breast Cancer"],"interventions":["ATX-295"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06799065"},{"nctId":"NCT05537740","title":"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":129,"enrollmentType":"ACTUAL","startDate":"2022-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-04","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Solid Tumors"],"interventions":["BAY3375968","Pembrolizumab"],"countries":["United States","Belgium","Canada","China","France","Singapore","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are solid cancers that may have spread to nearby tissue, lymph nodes and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. A new therapy available for advanced solid cancers is immunotherapy with PD-1/PD-L1 inhibitors. This drug class stimulates immune cells to kill cancer cells by blocking a protein called PD-1. Although PD-1/PD-L1 inhibitors have shown benefits in treatment of cancer, only a subset of patients benefit from the initial therapy, while in others the cancer comes back. One reason could be that the abil","sourceUrl":"https://clinicaltrials.gov/study/NCT05537740"},{"nctId":"NCT03301805","title":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","sponsor":"Rgene Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Pancreatic Cancer"],"interventions":["BLEX 404"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy at the recommended dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT03301805"},{"nctId":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","sponsor":"Nanobiotix","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":145,"enrollmentType":"ESTIMATED","startDate":"2019-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-10-24","conditions":["Radiotherapy","Immunotherapy","Microsatellite Instability-High Solid Malignant Tumour","Metastasis From Malignant Tumor of Liver","Squamous Cell Carcinoma of Head and Neck","Metastasis From Malignant Tumor of Cervix","Metastatic Renal Cell Carcinoma","Metastasis From Malignant Melanoma of Skin (Disorder)","Metastatic Triple-Negative Breast Carcinoma","Metastatic NSCLC","Metastasis From Malignant Tumor of Bladder (Disorder)"],"interventions":["NBTXR3","SABR","Nivolumab","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["MSI / TMB"],"summary":"The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03589339"},{"nctId":"NCT04145622","title":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2019-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Advanced Solid Tumor","Malignant Solid Tumor"],"interventions":["Ifinatamab deruxtecan (I-DXd)"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is a single group study of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts. The primary purpose of the parts are: * Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of ifinatamab deruxtecan (I-DXd). * Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of I-DXd when administered as a single agent. This study is expected to last approximately 5 years from the time the first participant is enrolled to the time the last participant is off the study. ","sourceUrl":"https://clinicaltrials.gov/study/NCT04145622"},{"nctId":"NCT06548672","title":"A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer","sponsor":"Biocity Biopharmaceutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":148,"enrollmentType":"ESTIMATED","startDate":"2024-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2024-08-12","conditions":["Advanced Cancer","Metastatic Solid Tumor"],"interventions":["BC3195"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression or intolerance). This study will consist of two parts: Dose escalation (Part 1) and dose expansion (Part 2). Each part will include a screening period, a treatment period, and follow-up period.","sourceUrl":"https://clinicaltrials.gov/study/NCT06548672"},{"nctId":"NCT05216432","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","sponsor":"Relay Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":930,"enrollmentType":"ESTIMATED","startDate":"2021-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-04-30","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["PIK3CA Mutation","Solid Tumor, Adult","HER2-negative Breast Cancer","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer","Unresectable Solid Tumor"],"interventions":["RLY-2608","Fulvestrant","Palbociclib 125mg","Ribociclib 400mg","Ribociclib 600mg","PF-07220060 100mg","PF-07220060 300 mg"],"countries":["United States","Australia","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients w","sourceUrl":"https://clinicaltrials.gov/study/NCT05216432"},{"nctId":"NCT07444281","title":"An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer","sponsor":"Shanghai AbelZeta Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-12-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-30","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Squamous Cell Lung Cancer"],"interventions":["C-CAR031"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This single-arm, open-label, multicenter, Phase I study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK)/pharmacodynamics (PD), biomarker, and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/metastatic squamous cell lung cancer, who are not amenable to curative therapy and have progressed or are intolerant to no more than 3 lines of prior systemic treatment including immune checkpoint inhibitors (CPIs) and platinum-based doublet chemotherapy, concurrently or sequentially.","sourceUrl":"https://clinicaltrials.gov/study/NCT07444281"},{"nctId":"NCT05907954","title":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","sponsor":"IDEAYA Biosciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2023-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Uveal Melanoma"],"interventions":["Darovasertib"],"countries":["United States","Australia","Canada","France","Germany","Italy","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05907954"},{"nctId":"NCT06398418","title":"R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors","sponsor":"Rise Therapeutics LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-04","conditions":["Solid Tumor, Adult","Solid Tumor","Melanoma","Basal Cell Cancer","Squamous Cell Cancer","Adenoma"],"interventions":["R-5780"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06398418"},{"nctId":"NCT06947291","title":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2025-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-30","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors"],"interventions":["Glumetinib Tablets","Docetaxel for Injection (Albumin-bound)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The trial consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (proof-of-concept study). Among them, Stage 2 adopts a randomized, controlled, open-label, and multicenter design.","sourceUrl":"https://clinicaltrials.gov/study/NCT06947291"},{"nctId":"NCT06600022","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.","sponsor":"Sinocelltech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":441,"enrollmentType":"ESTIMATED","startDate":"2024-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2025-01-16","conditions":["Advanced Malignant Solid Tumours"],"interventions":["SCTB41"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT06600022"},{"nctId":"NCT06517758","title":"A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-27","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Generalized Myasthenia Gravis"],"interventions":["Iptacopan","Matching Placebo"],"countries":["United States","Argentina","Australia","Brazil","China","Denmark","France","Germany","Greece","Israel","Italy","Japan","Poland","Portugal","Serbia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":125,"serviceSignals":["Broad CGP"],"summary":"The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.","sourceUrl":"https://clinicaltrials.gov/study/NCT06517758"},{"nctId":"NCT07056777","title":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","sponsor":"Zhejiang Doer Biologics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Gastrointestinal Cancer"],"interventions":["DR30206","Oxaliplatin","Capecitabine","Calcium Folinate","5-FU","Irinotecan (CPT-11)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07056777"},{"nctId":"NCT05347225","title":"A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2022-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-29","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Hematological Malignancies"],"interventions":["Nemtabrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of oral nemtabrutinib in Chinese participants at least 18 years of age who have Relapsed/Refractory hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05347225"},{"nctId":"NCT06431490","title":"A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2024-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Biliary Tract Cancer"],"interventions":["TQB2102 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":43,"serviceSignals":["HER2 profiling"],"summary":"To evaluate the efficacy and safety TQB2102 for injection in the treatment of patients with Her2-positive biliary tract cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06431490"},{"nctId":"NCT06938321","title":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Biliary Tract Cancer"],"interventions":["AK112","AK130"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"There're 2 parts in this interventional study: 1. The goal of phase Ib trial is to evaluate the safety and tolerability of AK130 in combination with AK112 therapy for the purpose of observing the incidence of dose limit toxicity (DLT) as well as the confirmation of maximum tolerable dose (MTD) in the treatment of advanced biliary tract cancer (BTC), so as to determine the recommended phase 2 dose (RP2D) in the second part of the trial. 2. The goal of phase II trial is to evaluate the safety and efficacy of AK112 in combination with AK130 therapy or monotherapy in the treatment of advanced BTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06938321"},{"nctId":"NCT06954077","title":"A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["Gastrointestinal Tumor","Solid Tumor"],"interventions":["BL-M09D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, dose-escalation and expanded-enrollment, nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M09D1 for injection in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06954077"},{"nctId":"NCT06927687","title":"Study of ZG005 in Patients With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":50,"enrollmentType":"ACTUAL","startDate":"2025-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Advanced Solid Tumor"],"interventions":["ZG005 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06927687"},{"nctId":"NCT06993116","title":"A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":15,"enrollmentType":"ACTUAL","startDate":"2025-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Advanced Solid Tumor"],"interventions":["SHR-4712 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.","sourceUrl":"https://clinicaltrials.gov/study/NCT06993116"},{"nctId":"NCT06978114","title":"A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2025-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-07-02","conditions":["Advanced Biliary Tract Cancer"],"interventions":["BL-B01D1","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a clinical study to explore the efficacy and safety of BL-B01D1+PD-1/PD-L1 monoclonal antibody in patients with advanced biliary tract cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06978114"},{"nctId":"NCT06318273","title":"A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":152,"enrollmentType":"ACTUAL","startDate":"2024-03-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["ABBV-969"],"countries":["United States","Australia","Canada","France","Israel","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 230 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses will","sourceUrl":"https://clinicaltrials.gov/study/NCT06318273"},{"nctId":"NCT06691360","title":"AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2024-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["Advanced Malignant Tumors"],"interventions":["AK137"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of AK137 in patients with advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06691360"},{"nctId":"NCT05948865","title":"A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","sponsor":"Conjupro Biotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2023-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Cancer","Cancer, Lung"],"interventions":["CPO301"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) * To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B) * To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * ","sourceUrl":"https://clinicaltrials.gov/study/NCT05948865"},{"nctId":"NCT05949125","title":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","sponsor":"AvenCell Europe GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-01-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2025-05-14","conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"interventions":["Cyclophosphamide (Non-IMP, Lymphodepletion)","Fludarabine (Non-IMP, Lymphodepletion)","R-TM123","Allo-RevCAR01-T"],"countries":["Germany","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug. The cellular component Allo-RevCAR01-T consists of an allogeneic human T-cell genetically multi-edited and expressing a reversed, universal chimeric antigen receptor (RevCAR) presenting an extracellular peptide epitope (RevCAR epitope). R-TM123 functions as a bridging module between Allo-RevCAR01-T and a CD123-expressing target cancer cell by selectively binding the RevCAR epitope and CD123.","sourceUrl":"https://clinicaltrials.gov/study/NCT05949125"},{"nctId":"NCT06957886","title":"A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":566,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["HER2-low Breast Cancer"],"interventions":["BL-M07D1","Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06957886"},{"nctId":"NCT07262164","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors","sponsor":"Shanghai Virogin Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Advanced Malignant Solid Tumor"],"interventions":["Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2062, and recommended dose of VG2062 for Phase II trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07262164"},{"nctId":"NCT06932094","title":"Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":256,"enrollmentType":"ESTIMATED","startDate":"2025-05","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2025-04-23","conditions":["Advanced Solid Tumors"],"interventions":["QLS5132"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The Phase 1 trial includes Phase 1a (dose-escalation) and Phase 1b (dose-expansion): * Phase 1a: Assesses safety, tolerability, PK, and preliminary efficacy of QLS5132 in advanced solid tumors using ATD + BOIN, given IV every 3 weeks. Up to 12 subjects may be enrolled in promising dose levels. * Phase 1b: Evaluates QLS5132's anti-tumor efficacy in specific CLDN6-positive solid tumors, including ovarian cancer, NSCLC, gastric cancer, and others. Expansion studies at 1\\~3 selected dose levels follow successful Phase 1a results.","sourceUrl":"https://clinicaltrials.gov/study/NCT06932094"},{"nctId":"NCT05856981","title":"Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors","sponsor":"Sairopa B.V.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2023-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Solid Tumor, Adult","Metastatic Solid Tumor","Refractory Cancer","CRC, Colorectal Cancer","RCC, Clear Cell Adenocarcinoma","NSCLC (Advanced Non-small Cell Lung Cancer)","Endometrial Cancer"],"interventions":["ADU-1805","Pembrolizumab"],"countries":["United States","Belgium","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).","sourceUrl":"https://clinicaltrials.gov/study/NCT05856981"},{"nctId":"NCT06710288","title":"A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Platinum-resistant Ovarian Cancer"],"interventions":["Gemcitabine","N-803","M-CENK"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is phase 2 single arm study evaluating the safety and preliminary efficacy of M-CENK adoptive cell therapy and fixed dose of N-803 in combination with gemcitabine in participants with platinum-resistant high-grade ovarian cancer (HGOC).Up to 20 participants will receive M-CENK (IV) and N-803 (SC) in combination with gemcitabine (IV). Participants will undergo an apheresis procedure for the collection of mononuclear cells (MNCs) at least 1 day prior to Cycle 1 for manufacturing of M-CENK. Starting in Cycle 1, participants will receive gemcitabine and starting in Cycle 2 they will also receive M-CENK and N-803, until no additional M-CENK is available or confirmed PD per iRECIST, unless th","sourceUrl":"https://clinicaltrials.gov/study/NCT06710288"},{"nctId":"NCT07581314","title":"Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)","sponsor":"Telomir Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Triple-Negative Breast Cancer (TNBC)","Advanced Triple-Negative Breast Cancer","Metastatic Triple-negative Breast Cancer"],"interventions":["Zn-Telomir"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, open-label Phase I/II study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of oral Zn-Telomir monotherapy in adults with advanced or metastatic triple-negative breast cancer. Phase I uses a modified 3+3 dose-escalation design to determine safety, tolerability, maximum tolerated dose, and recommended Phase II dose. Phase II uses a Simon two-stage expansion design at the recommended Phase II dose to evaluate preliminary antitumor activity, including objective response rate per Response Evaluation Criteria in Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07581314"},{"nctId":"NCT05101096","title":"Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":135,"enrollmentType":"ACTUAL","startDate":"2021-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor","Metastatic Triple-Negative Breast Cancer","HR+/HER2- Metastatic Breast Cancer","Metastatic Urothelial Cancer"],"interventions":["Sacituzumab Govitecan-hziy"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":36,"serviceSignals":["HER2 profiling"],"summary":"The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose (RP2D) of SG in Japanese participants with advance solid tumors. Phase 2: Evaluate the safety and efficacy of SG in Japanese participants with metastatic triple-negative breast cancer (mTNBC), hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC), and metastatic urothelial cancer (mUC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05101096"},{"nctId":"NCT07133750","title":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","sponsor":"Biotheus Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["CRC (Colorectal Cancer)"],"interventions":["PM8002","Chemotherapy Regimen 1","Chemotherapy Regimen 2","Chemotherapy Regimen 3"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["MSI / TMB"],"summary":"PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07133750"},{"nctId":"NCT06921837","title":"A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer","sponsor":"Bolt Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2025-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Gastric Cancer Adenocarcinoma Metastatic","Gastroesophageal Adenocarcinoma"],"interventions":["BDC-4182"],"countries":["Australia","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"A first-in-human study using BDC-4182 as a single agent in gastric and gastroesophageal cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT06921837"},{"nctId":"NCT05429632","title":"Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","sponsor":"Priothera SAS","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":366,"enrollmentType":"ESTIMATED","startDate":"2022-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Adult Acute Myeloid Leukemia"],"interventions":["mocravimod"],"countries":["United States","Argentina","Brazil","France","Germany","Israel","Italy","Japan","Poland","Romania","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":111,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, randomized, double-blinded, placebo controlled trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT05429632"},{"nctId":"NCT07107178","title":"A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma","sponsor":"Biotroy Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2025-08-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["Advanced Melanoma","Advanced Solid Tumor"],"interventions":["BT02"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive). Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.","sourceUrl":"https://clinicaltrials.gov/study/NCT07107178"},{"nctId":"NCT06962787","title":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2025-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Renal Cancer"],"interventions":["BL-B01D1","Axitinib","Lenvatinib","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 in combination with tyrosine kinase inhibitor (TKI) with or without pembrolizumab (BL-B01D1+TKI±Pembrolizumab) in patients with locally advanced or metastatic renal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06962787"},{"nctId":"NCT06249048","title":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","sponsor":"Strand Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2024-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2025-10-29","conditions":["Advanced Solid Tumor"],"interventions":["STX-001","Keytruda®"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06249048"},{"nctId":"NCT05999994","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2020-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Neoplasms","Child","Adolescent"],"interventions":["Ramucirumab","Cyclophosphamide","Vinorelbine","Gemcitabine","Docetaxel","Abemaciclib","Irinotecan","Temozolomide"],"countries":["United States","Australia","Belgium","France","Germany","Italy","Japan","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":72,"serviceSignals":["Broad CGP"],"summary":"The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.","sourceUrl":"https://clinicaltrials.gov/study/NCT05999994"},{"nctId":"NCT04104672","title":"A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":196,"enrollmentType":"ACTUAL","startDate":"2019-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced Pancreatic Cancer"],"interventions":["AB680","Zimberelimab","Nab-paclitaxel","Gemcitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04104672"},{"nctId":"NCT07054567","title":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-08-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Cervical Cancer","Endometrial Cancer"],"interventions":["BL-B01D1","Pembrolizumab","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase II study is a clinical trial to evaluate the efficacy and safety of BL-B01D1 + pembrolizumab dual therapy with or without bevacizumab (BL-B01D1 + pembrolizumab ± bevacizumab) in patients with recurrent or metastatic cervical cancer and endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07054567"},{"nctId":"NCT06456580","title":"A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)","sponsor":"Vor Biopharma","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Generalized Myasthenia Gravis"],"interventions":["Telitacicept","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Georgia","Italy","Japan","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":111,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT06456580"},{"nctId":"NCT06928389","title":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":536,"enrollmentType":"ESTIMATED","startDate":"2025-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Ivonescimab, docetaxel","Placebo, docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06928389"},{"nctId":"NCT06908928","title":"A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2025-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-03-17","conditions":["Triple Negative Breast Cancer"],"interventions":["bulumtatug fuvedotin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.","sourceUrl":"https://clinicaltrials.gov/study/NCT06908928"},{"nctId":"NCT06764628","title":"A Study of SHR-4375 in Subjects With Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":208,"enrollmentType":"ESTIMATED","startDate":"2025-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Solid Tumors"],"interventions":["SHR-4375"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764628"},{"nctId":"NCT06465069","title":"A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2024-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Metastatic Solid Tumor","Recurrent Solid Tumor","Advanced Solid Tumor","Urinary Bladder Neoplasm","Triple Negative Breast Cancer","Non-small Cell Lung Cancer","Esophageal Cancer","Pancreatic Cancer","Ovarian Cancer","Cervical Cancer","Head and Neck Squamous Cell Carcinoma","Prostate Cancer","Renal Pelvis Cancer","Bladder Cancer"],"interventions":["LY4052031"],"countries":["United States","Australia","China","France","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06465069"},{"nctId":"NCT07108114","title":"SLV-324 Treatment of Metastatic Solid Tumors","sponsor":"Solve Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Metastatic Solid Tumors"],"interventions":["SLV-324 intravenous (IV infusion)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07108114"},{"nctId":"NCT06909825","title":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Fusion Pharmaceuticals Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["FPI-2265","Olaparib"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter study designed to investigate the efficacy, safety and tolerability of FPI-2265 (225Ac-PSMA-I\\&T) in combination with Olaparib in participants with mCRPC. The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 and Olaparib in participants with metastatic castration-resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06909825"},{"nctId":"NCT06954246","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2025-06-18","conditions":["Small Cell Lung Cancer Extensive Stage"],"interventions":["MHB088C for Injection","Topotecan","Irinotecan","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06954246"},{"nctId":"NCT06670196","title":"A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SKB264","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic non-squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06670196"},{"nctId":"NCT04736173","title":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":169,"enrollmentType":"ACTUAL","startDate":"2021-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-05","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non Small Cell Lung Cancer","Nonsquamous Non Small Cell Lung Cancer","Squamous Non Small Cell Lung Cancer","Lung Cancer"],"interventions":["Domvanalimab","Zimberelimab","Carboplatin","Paclitaxel","Pemetrexed","Pembrolizumab"],"countries":["United States","Hong Kong","Malaysia","Mexico","Philippines","Slovakia","South Africa","South Korea","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04736173"},{"nctId":"NCT05320198","title":"Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia","sponsor":"Disc Medicine, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2022-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Myelofibrosis; Anemia","Anemia","Myelofibrosis","Myelofibrosis Due to and Following Polycythemia Vera","Primary Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Myelodysplastic Syndromes"],"interventions":["DISC-0974"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Hematology NGS"],"summary":"This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT05320198"},{"nctId":"NCT06828354","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Ovarian Cancer"],"interventions":["SHR-A1811","Paclitaxel Injection","Doxorubicin Hydrochloride Liposome Injection","Gemcitabine Hydrochloride for Injection","Topotecan Hydrochloride for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06828354"},{"nctId":"NCT06687070","title":"APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Platinum-resistant Recurrent Ovarian Cancer","Advanced Solid Tumor"],"interventions":["APG -2449","PLD"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.","sourceUrl":"https://clinicaltrials.gov/study/NCT06687070"},{"nctId":"NCT06938880","title":"Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Advanced Solid Tumor"],"interventions":["ZGGS18 for Injection","ZG005 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06938880"},{"nctId":"NCT06926998","title":"9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2025-04-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Gynecological Malignancies"],"interventions":["9MW2821+other anticancer therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06926998"},{"nctId":"NCT07646106","title":"THE-0504 in Patients With Solid Tumors","sponsor":"Thena Biotech S.r.l.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Small Cell Lung Cancer (SCLC)","Colorectal Carcinoma (CRC)","Gastric Cancer (GC)","Triple -Negative Breast Cancer","Pancreas Adenocarcinoma"],"interventions":["THE-0504"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07646106"},{"nctId":"NCT06188702","title":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","sponsor":"Servier Bio-Innovation LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["MTAP-deleted Solid Tumors"],"interventions":["S095035","TNG462"],"countries":["United States","Australia","France","Germany","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \\[MAT2A\\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \\[PRMT5\\] inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06188702"},{"nctId":"NCT07431216","title":"A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression","sponsor":"Starlight Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2026-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Glioblastoma (GBM)"],"interventions":["STAR-001 (LP-184) will be administered via IV infusion over 30 (± 5) minutes on Day 1 and Day 8 of each 21-day cycle.","Spironolactone (drug)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Approximately 58-68 total subjects will be enrolled. In the first stage, 10 response evaluable subjects (either IDHwt or IDHm Grade 4 astrocytoma) will be enrolled. If 1 or more of the first 10 response evaluable subjects achieve an objective response, 19 further subjects may be accrued in the second stage (for a total of 29 response evaluable subjects). Subjects enrolling in the study will provide fresh (in subjects who undergo a planned tumor resection) or archival (all subjects) tumor tissue sample (at least 10 unstained slides of 5-micron thickness) at screening for retrospective exploratory biomarker analysis and determination of intertumoral PTGR1 levels. STAR-001 (LP-184) will be admi","sourceUrl":"https://clinicaltrials.gov/study/NCT07431216"},{"nctId":"NCT03793478","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2018-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-01","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Acute Myeloid Leukemia"],"interventions":["Quizartinib","Fludarabine","Cytarabine","Intrathecal (IT) triple chemotherapy prophylaxis","Etoposide"],"countries":["United States","Belgium","Canada","Denmark","France","Israel","Italy","Netherlands","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Hematology NGS"],"summary":"Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or is not responding to treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT03793478"},{"nctId":"NCT06922539","title":"Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer","sponsor":"SciTech Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2025-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Small Cell Lung Cancer"],"interventions":["Fenretinide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06922539"},{"nctId":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1609,"enrollmentType":"ESTIMATED","startDate":"2015-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-04","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Advanced Cancer","Anal Carcinoma","Anal Cancer","Biliary Cancer","Cholangiocarcinoma","Bile Duct Cancer","Neuroendocrine Tumor","Carcinoid Tumor","Endometrial Carcinoma","Endometrial Cancer","Cervical Carcinoma","Cervical Cancer","Vulvar Carcinoma","Vulvar Cancer","Small Cell Lung Carcinoma","Small Cell Lung Cancer (SCLC)","Mesothelioma","Thyroid Carcinoma","Thyroid Cancer","Salivary Gland Carcinoma","Salivary Gland Cancer","Salivary Cancer","Parotid Gland Cancer","Advanced Solid Tumors","Colorectal Carcinoma"],"interventions":["pembrolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MSI / TMB"],"summary":"In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).","sourceUrl":"https://clinicaltrials.gov/study/NCT02628067"},{"nctId":"NCT04380636","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":870,"enrollmentType":"ESTIMATED","startDate":"2020-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-06","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Lung Neoplasms","Carcinoma, Non-Small-Cell Lung"],"interventions":["Pembrolizumab","Olaparib","Placebo for olaparib","Etoposide","Carboplatin","Cisplatin","Paclitaxel","Pemetrexed","Thoracic Radiotherapy","Durvalumab"],"countries":["United States","Argentina","Canada","Chile","China","Czechia","Estonia","France","Germany","Hungary","Italy","Japan","Latvia","Lithuania","Mexico","Norway","Peru","Poland","Romania","Russia","South Korea","Spain","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":205,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are: 1. Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall su","sourceUrl":"https://clinicaltrials.gov/study/NCT04380636"},{"nctId":"NCT06428396","title":"Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-25","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Metastatic Breast Cancer"],"interventions":["Belzutifan","Fulvestrant","Everolimus","Exemestane"],"countries":["United States","Argentina","Canada","Chile","Colombia","South Korea","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06428396"},{"nctId":"NCT07660211","title":"Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）","sponsor":"VitsGen Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-06-16","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-06","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["177Lu-PSMA-VG01"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I clinical trial conducted in participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). After confirmation of PSMA positivity, participants receive intravenous administration of 177Lu-PSMA-VG01. The objectives are: to evaluate the biodistribution, radiation dosimetry, safety and tolerability of 177Lu-PSMA-VG01 in participants; and to assess the pharmacokinetics (PK), preliminary anti-tumor activity, and in vivo stability of 177Lu-PSMA-VG01 in participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07660211"},{"nctId":"NCT07052253","title":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["TT-00420 (tinengotinib)","AK104","AK112"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07052253"},{"nctId":"NCT06074588","title":"Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":556,"enrollmentType":"ESTIMATED","startDate":"2023-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-11","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Sacituzumab tirumotecan","Docetaxel","Pemetrexed"],"countries":["United States","Australia","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Malaysia","Mexico","Philippines","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":194,"serviceSignals":["RNA fusion","MET profiling","Hematology NGS","ADC biomarker"],"summary":"The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypothesis is that sacituzumab tirumotecan is superior to chemotherapy with respect to overall survival (OS) in NSCLC ","sourceUrl":"https://clinicaltrials.gov/study/NCT06074588"},{"nctId":"NCT03564340","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":890,"enrollmentType":"ESTIMATED","startDate":"2018-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-10","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Recurrent Ovarian Cancer","Recurrent Fallopian Tube Cancer","Recurrent Primary Peritoneal Cancer","Recurrent Endometrial Cancer","Endometrial Cancer","Low-grade Serous Ovarian Cancer"],"interventions":["Ubamatamab","Cemiplimab","Sarilumab","Tocilizumab"],"countries":["United States","Australia","Belgium","France","Israel","Italy","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (","sourceUrl":"https://clinicaltrials.gov/study/NCT03564340"},{"nctId":"NCT06537310","title":"A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ACTUAL","startDate":"2024-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-10","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Cancer-Neoplasms"],"interventions":["RO7567132 and Atezolizumab"],"countries":["Australia","Belgium","Canada","Denmark","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of RO7567132 as single agent and in combination with atezolizumab. The study will enroll adult participants with selected locally advanced and/or metastatic solid tumors for whom standard therapy does not exist, or has proven to be ineffective or intolerable.","sourceUrl":"https://clinicaltrials.gov/study/NCT06537310"},{"nctId":"NCT06566547","title":"GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2024-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-01","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Multiple Myeloma"],"interventions":["GR1803 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.","sourceUrl":"https://clinicaltrials.gov/study/NCT06566547"},{"nctId":"NCT07462143","title":"A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-05-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Colorectal (Colon or Rectal) Cancer"],"interventions":["RC148 (Dose 1) plus Capecitabine and Oxaliplatin","RC148 (Dose 2) plus Capecitabine and Oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07462143"},{"nctId":"NCT06953999","title":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":999,"enrollmentType":"ESTIMATED","startDate":"2025-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-14","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Pancreatic Cancer"],"interventions":["Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine","Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine","Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, randomized, double-blind clinical trial aimed at evaluating the efficacy and safety of Ivonescimab plus chemotherapy with or without AK117 versus placebo plus chemotherapy in patients with metastatic pancreatic cancer. The study seeks to determine whether the addition of Ivonescimab and/or AK117 improves clinical outcomes compared to standard chemotherapy alone. Participants will be randomly assigned to receive either Ivonescimab with/without AK117 or placebo, both in combination with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06953999"},{"nctId":"NCT06445062","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":1130,"enrollmentType":"ESTIMATED","startDate":"2024-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-15","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Colorectal Cancer","CRC","Pancreatic Ductal Adenocarcinoma","PDAC","Gastrointestinal Cancer","Metastatic Pancreatic Ductal Adenocarcinoma"],"interventions":["RMC-6236","mFOLFOX6 regimen","bevacizumab","mFOLFIRINOX regimen","cetuximab","gemcitabine","nab-paclitaxel","RMC-9805"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 + 5-fluorouracil-based regimens Subprotocol E: RMC-9805 with or without RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol F: RMC-9805 with or without RMC-6236 + gemcitabine + nab-paclitaxel","sourceUrl":"https://clinicaltrials.gov/study/NCT06445062"},{"nctId":"NCT07705334","title":"A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors","sponsor":"SHY Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-15","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced or Metastatic Solid Tumors","Triple Negative Breast Cancer (TNBC)","HR+ Breast Cancer","Colon Cancer","Gastric Cancer","Hepatecellular Carcinoma","NSCLC (Advanced Non-small Cell Lung Cancer)","Mesothelioma","Pancreatic Carcinoma Metastatic","Hormone Refractory Prostate Cancer","Soft Tissue Sarcomas"],"interventions":["SHY-ONC6"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors who have progressed on or are intolerant to standard therapies. The study will consist of 2 parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b).","sourceUrl":"https://clinicaltrials.gov/study/NCT07705334"},{"nctId":"NCT07487519","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-04-25","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-22","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Breast Cancer (Triple Negative Breast Cancer (TNBC))"],"interventions":["HLX43 DOSE 1 IN ≥2L TNBC","HLX43 DOSE 2 IN ≥2L TNBC","HLX43 DOSE 1 + HLX10","HLX43 DOSE1 IN 1L TNBC","HLX43 DOSE 2 IN 1L TNBC","HLX43 DOSE2 + HLX10"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07487519"},{"nctId":"NCT05315167","title":"A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors","sponsor":"Zhuhai Yufan Biotechnologies Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":267,"enrollmentType":"ESTIMATED","startDate":"2022-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2024-12-17","conditions":["Advanced Solid Tumor","Advanced Solid Malignancies"],"interventions":["PRJ1-3024"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.","sourceUrl":"https://clinicaltrials.gov/study/NCT05315167"},{"nctId":"NCT07478952","title":"A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age","sponsor":"ModernaTX, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-15","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Epstein-Barr Virus"],"interventions":["mRNA-1189"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The main objective of this trial is to evaluate the safety and immunogenicity of mRNA-1189 after intradermal and intramuscular delivery.","sourceUrl":"https://clinicaltrials.gov/study/NCT07478952"},{"nctId":"NCT04150887","title":"Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia","sponsor":"OncoVerity, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":61,"enrollmentType":"ACTUAL","startDate":"2019-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-15","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Leukemia, Myeloid, Acute"],"interventions":["Cusatuzumab","Azacitidine","Venetoclax"],"countries":["United States","Canada","Germany","Poland","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).","sourceUrl":"https://clinicaltrials.gov/study/NCT04150887"},{"nctId":"NCT05624554","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-19","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-17","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Nemtabrutinib","Fludarabine","Cyclophosphamide","Bendamustine","Rituximab","Truxima","Ruxience","Riabni"],"countries":["United States","Australia","Brazil","Bulgaria","Chile","China","Colombia","Denmark","Guatemala","Hong Kong","Hungary","Lithuania","Malaysia","Mexico","Poland","Romania","Singapore","South Africa","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":97,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).","sourceUrl":"https://clinicaltrials.gov/study/NCT05624554"},{"nctId":"NCT06465329","title":"A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-20","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-02","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Cemiplimab","Platinum-based chemotherapy","REGN7075"],"countries":["United States","Brazil","France","Germany","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":50,"serviceSignals":["Broad CGP"],"summary":"This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus chemotherapy without the additional drug. The study is also looking at several other research questions, including: * What are the side effects associated with the investigational treatments in comparison to the control treatment? * Do the investigational treatments or the control treatment have an effect on the type of surgery that is performed? * How much of the study drug(s) are in t","sourceUrl":"https://clinicaltrials.gov/study/NCT06465329"},{"nctId":"NCT07477587","title":"A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2026-05-27","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-22","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Multiple Myeloma (MM)"],"interventions":["HLX15-SC-Rd","US-DARZALEX FASPRO®-Rd"],"countries":["United States","Australia","China","Georgia","Serbia"],"northAmerica":true,"chinaSites":true,"siteCount":81,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in newly diagnosed MM patients ineligible for transplant. Participants who meet all inclusion criteria and none of the exclusion criteria will receive either the HLX15-SC-Rd regimen or the D-Rd regimen for 4 cycles (one cycle = 4 weeks). After 4 cycles of treatment, based on clinical benefit and participant preference, participants may continue to receive the locally marketed daratumumab subcutaneous formulation (Dara-SC) in combination with Rd according to clinical pra","sourceUrl":"https://clinicaltrials.gov/study/NCT07477587"},{"nctId":"NCT07125872","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-25","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Relapsed B-Cell Non Hodgkin Lymphoma"],"interventions":["CD19 t-haNK- IV Administration"],"countries":["South Africa"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07125872"},{"nctId":"NCT05067140","title":"A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":152,"enrollmentType":"ACTUAL","startDate":"2021-09-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-25","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Prostate Cancer Metastatic"],"interventions":["ARV-766 Part A&B","ARV-766 + Abiraterone Part C&D"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05067140"},{"nctId":"NCT06799286","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2025-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-26","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Small Cell Lung Carcinoma"],"interventions":["BMS-986489"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of BMS-986489 in Chinese participants with R/R SCLC (Relapsed/Refractory Small Cell Lung Cancer).","sourceUrl":"https://clinicaltrials.gov/study/NCT06799286"},{"nctId":"NCT05973773","title":"REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)","sponsor":"Taiho Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":285,"enrollmentType":"ACTUAL","startDate":"2023-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-27","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation"],"interventions":["TAS6417"],"countries":["United States","Belgium","Brazil","Bulgaria","Canada","Chile","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","Philippines","Poland","Romania","Singapore","South Korea","Spain","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":130,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05973773"},{"nctId":"NCT05173987","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2022-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-27","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Endometrial Neoplasms"],"interventions":["pembrolizumab","carboplatin","paclitaxel","docetaxel","cisplatin"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","Germany","Hungary","Ireland","Israel","Italy","Japan","Netherlands","New Zealand","Norway","Poland","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":194,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is superior to the combination of carboplatin and paclitaxel with respect to Progression Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and Overall Survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT05173987"},{"nctId":"NCT04644068","title":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":702,"enrollmentType":"ACTUAL","startDate":"2020-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-28","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Ovarian Cancer","Breast Cancer","Pancreatic Cancer","Prostate Cancer","Additional Indications Below for Module 4 and 5","Non-small Cell Lung Cancer","Colorectal Cancer","Bladder Cancer","Gastric Cancer","Biliary Cancer","Cervical Cancer","Endometrial Cancer","Small Cell Lung Cancer Only in Module 5"],"interventions":["AZD5305","Paclitaxel","Carboplatin","T- Dxd","Dato-DXd","Camizestrant"],"countries":["United States","Australia","Canada","China","Czechia","Hungary","Italy","Japan","Poland","Russia","South Korea","Spain","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":68,"serviceSignals":["Broad CGP"],"summary":"This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04644068"},{"nctId":"NCT07170644","title":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","sponsor":"SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ACTUAL","startDate":"2025-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-09","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Desmoid Tumor","Aggressive Fibromatosis"],"interventions":["Nirogacestat oral tablet"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07170644"},{"nctId":"NCT07545044","title":"A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-05-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-30","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["HER2-positive Recurrent or Metastatic Breast Cancer"],"interventions":["JSKN003","Trastuzumab","Pertuzumab","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study is a randomized, controlled, open-label, multicenter, phase II superiority clinical trial. The planned study population consists of participants with HER2-positive recurrent or metastatic breast cancer who have not previously received systemic therapy for advanced disease (participants who have undergone one prior endocrine treatment regimen are eligible for enrollment). The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab combined with pertuzumab and docetaxel as first-line treatment for participants with HER2-positive recurrent or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07545044"},{"nctId":"NCT05892718","title":"A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors","sponsor":"FBD Biologics Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2023-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-15","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Advanced Solid Tumor","Refractory Non-Hodgkin Lymphoma"],"interventions":["HCB101"],"countries":["United States","China","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":8,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.","sourceUrl":"https://clinicaltrials.gov/study/NCT05892718"},{"nctId":"NCT04910022","title":"Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma","sponsor":"Nerviano Medical Sciences","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2021-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-07","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Glioblastoma","Diffuse Glioma"],"interventions":["NMS-03305293","Temozolomide"],"countries":["United States","Italy","Netherlands","Puerto Rico","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.","sourceUrl":"https://clinicaltrials.gov/study/NCT04910022"},{"nctId":"NCT07590531","title":"AMT-116 in Combination With Ivosidan in Patients With Lung Cancer","sponsor":"Multitude Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2026-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Advanced Non-small Cell Lung Cancer (NSCLC)"],"interventions":["AMT-116","AK112"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07590531"},{"nctId":"NCT04480619","title":"Safety and Efficacy of Ga68-IAC PET/CT for Diagnosis and Clinical Management in Metastatic Breast Cancer Patients","sponsor":"Advanced Imaging Projects, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2025-10-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-07-16","conditions":["Angiogenic Breast Cancer"],"interventions":["Ga-68-IAC"],"countries":["India","South Africa"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/IIa, open label, multicenter interventional study of Gallium-68 radiolabeled Integrin Adhesion Complex antagonist conjugate (Ga-68-IAC) Positron Emission Tomography (PET/CT) imaging, intended for diagnosis, and clinical management of patients with Metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT04480619"},{"nctId":"NCT07182149","title":"A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","sponsor":"Normunity AccelCo, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["HNSCC","ESCC","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Ovarian Cancer","NSCLC","Cervical Cancer","Endometrial Cancer","Triple Negative Breast Cancer (TNBC)"],"interventions":["NRM-823"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07182149"},{"nctId":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","sponsor":"Olema Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-10-10","conditions":["Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)","Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Metastatic Breast Cancer","Fulvestrant","Palazestrant"],"interventions":["OP-3136","Fulvestrant","Palazestrant"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT06784193"},{"nctId":"NCT06234423","title":"A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors","sponsor":"OnCusp Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":263,"enrollmentType":"ESTIMATED","startDate":"2024-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Ovarian Cancer","Solid Tumor"],"interventions":["CUSP06"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06234423"},{"nctId":"NCT06179069","title":"A Study of ZL-1310 in Subjects With Small Cell Lung Cancer","sponsor":"Zai Lab (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":339,"enrollmentType":"ESTIMATED","startDate":"2024-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["SCLC"],"interventions":["ZL-1310","Atezolizumab","Carboplatin"],"countries":["United States","China","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06179069"},{"nctId":"NCT05548296","title":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","sponsor":"Acrivon Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2022-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Endometrial Adenocarcinoma"],"interventions":["ACR-368","Gemcitabine","OncoSignature"],"countries":["United States","France","Germany","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":91,"serviceSignals":["Broad CGP"],"summary":"This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05548296"},{"nctId":"NCT05918783","title":"Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer","sponsor":"Impact Biotech Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-05-28","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Peripheral Lung Tumor"],"interventions":["Padeliporfin Vascular Targeted Photodynamic (VTP) therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05918783"},{"nctId":"NCT06988488","title":"A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma","sponsor":"Celgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2025-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-03","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Mezigdomide","Dexamethasone"],"countries":["United States","Canada","China","Germany","Greece","Norway","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06988488"},{"nctId":"NCT07556120","title":"Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG)","sponsor":"Shenzhen MagicRNA Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2026-05-05","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Generalized Myasthenia Gravis"],"interventions":["HN2301 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, single arm study, to evaluate safety, tolerability and preliminary efficacy of HN2301 in patients with Generalized Myasthenia Gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07556120"},{"nctId":"NCT06004245","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors","sponsor":"Vividion Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2024-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumors","Colorectal Cancer"],"interventions":["VVD-133214","Pembrolizumab","Bevacizumab"],"countries":["United States","Australia","Belgium","Canada","Denmark","France","Malaysia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["MSI / TMB"],"summary":"This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. VVD-133214 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, VVD-133214 may be able to block the growth of these types of cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06004245"},{"nctId":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":754,"enrollmentType":"ESTIMATED","startDate":"2022-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-26","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"interventions":["RMC-6236"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["RAS genotyping"],"summary":"Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05379985"},{"nctId":"NCT04775485","title":"A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors","sponsor":"Day One Biopharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":141,"enrollmentType":"ESTIMATED","startDate":"2021-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Low-grade Glioma","Advanced Solid Tumor"],"interventions":["Tovorafenib"],"countries":["United States","Australia","Canada","Denmark","Germany","Israel","Netherlands","Singapore","South Korea","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.","sourceUrl":"https://clinicaltrials.gov/study/NCT04775485"},{"nctId":"NCT07103668","title":"A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients","sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-10-23","conditions":["Gastric Adenocarcinoma"],"interventions":["CAR T cells","Control"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"An open-label, randomized, comparative phase II study including patients with CLDN18.2-positive unresectable locally advanced gastric cancer. To evaluate the objective response rate (ORR) and progression-free survival (PFS) of IMC002 compared with investigator's choice of treatment (ICT) as third-line or later therapy in patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with positive CLDN18.2 expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07103668"},{"nctId":"NCT05620017","title":"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection","sponsor":"Bio-Thera Solutions","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2022-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Advanced Solid Tumors"],"interventions":["BAT8008 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT05620017"},{"nctId":"NCT05845814","title":"A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2023-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Metastatic Urothelial Carcinoma","Urothelial Neoplasms"],"interventions":["Coformulated favezelimab/pembrolizumab","Coformulated vibostolimab/pembrolizumab","EV","Pembrolizumab"],"countries":["United States","Australia","Canada","Chile","France","Israel","Italy","Netherlands","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the efficacy and safety of coformulated favezelimab/pembrolizumab plus EV and coformulated vibostolimab/pembrolizumab plus EV relative to pembrolizumab plus EV. There will be no comparison of coformulated favezelimab/pembrolizumab plus EV versus coformulated vibostolimab/pembrolizumab plus EV. If ORR and/or DRR are substantially better on coformulated favezelimab/pembrolizumab plus EV and/or coformulated vibostolimab/pembrolizumab plus EV compared with pembrolizumab plus EV, after evaluation of the totality of data, the sponsor might ","sourceUrl":"https://clinicaltrials.gov/study/NCT05845814"},{"nctId":"NCT06120140","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":305,"enrollmentType":"ACTUAL","startDate":"2024-02-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Amivantamab IV","Amivantamab SC","Lazertinib","Doxycycline","Minocycline","Clindamycin","Chlorhexidine","Noncomedogenic skin moisturizer","Ruxolitinib","Tacrolimus","Zinc gluconate","Propranolol","Timolol","Clobetasol"],"countries":["United States","Argentina","Brazil","China","France","Germany","Malaysia","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":93,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous ","sourceUrl":"https://clinicaltrials.gov/study/NCT06120140"},{"nctId":"NCT06930755","title":"Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer","sponsor":"Nerviano Medical Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-26","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Ovarian Cancer"],"interventions":["NMS-03305293","Topotecan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.","sourceUrl":"https://clinicaltrials.gov/study/NCT06930755"},{"nctId":"NCT06639347","title":"A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2024-11-18","conditions":["Advanced Urothelial Carcinoma"],"interventions":["SHR-A2102","Adebrelimab injection","SHR-8068 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06639347"},{"nctId":"NCT06952010","title":"A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":303,"enrollmentType":"ESTIMATED","startDate":"2025-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Solid Tumor","Advanced Solid Tumor","Metastatic Solid Tumor","Immune Sensitive Tumor"],"interventions":["XB628","Zanzalintinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\\[s\\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT06952010"},{"nctId":"NCT06545942","title":"Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","sponsor":"MOMA Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Prostate Cancer","Pancreas Cancer","Breast Cancer","Ovarian Cancer","Homologous Recombination Deficiency"],"interventions":["MOMA-313","Olaparib"],"countries":["United States","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HRD / HRR"],"summary":"This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06545942"},{"nctId":"NCT06221072","title":"A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":1360,"enrollmentType":"ESTIMATED","startDate":"2024-04-05","startDateType":"ESTIMATED","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2024-01-24","conditions":["Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors"],"interventions":["JMT103","zoledronic acid"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ⅲ, multicenter, randomized, double-blind, study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from malignant solid tumors. The purpose of this study is to determine if JMT103 is non-inferior to zoledronic acid.","sourceUrl":"https://clinicaltrials.gov/study/NCT06221072"},{"nctId":"NCT04277637","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":437,"enrollmentType":"ACTUAL","startDate":"2020-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-05-31","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Mature B-Cell Malignancies"],"interventions":["Sonrotoclax","Zanubrutinib","Obinutuzumab"],"countries":["United States","Australia","Germany","Italy","New Zealand","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the safety, tolerability; and to define the maximum tolerated dose (MTD) and Recommended Phase 2 Dose (RP2D); and to evaluate the safety and tolerability of the ramp-up dosing schedule and at the RP2D of BGB-11417 monotherapy, and when given in combination with zanubrutinib and obinutuzumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT04277637"},{"nctId":"NCT05706129","title":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","sponsor":"Lumara Bio Oncologics GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2023-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2025-10-20","conditions":["Clear Cell Renal Cell Cancer (ccRCC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Colorectal Cancer (CRC)","Urothelial Carcinoma (UC)","Indeterminate Renal Mass (IDRM)","Muscle Invasive Bladder Cancer (MIBC)","Head and Neck Cancer (H&N)","Triple Negative Breast Cancer (TNBC)","Squamous Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["[68Ga]Ga-DPI-4452","[177Lu]Lu-DPI-4452"],"countries":["Australia","France"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \\[68Ga\\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \\[maximum tolerated dose (MTD) or lower dose\\] for \\[177Lu\\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \\[177Lu\\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic conc","sourceUrl":"https://clinicaltrials.gov/study/NCT05706129"},{"nctId":"NCT07644559","title":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer","sponsor":"Verastem, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)","G12D Mutated KRAS"],"interventions":["VS-7375","cetuximab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07644559"},{"nctId":"NCT06260514","title":"Study of APR-1051 in Patients With Advanced Solid Tumors","sponsor":"Aprea Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Advanced Solid Tumor"],"interventions":["APR-1051"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06260514"},{"nctId":"NCT07070440","title":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-08-29","conditions":["Non Small Cell Lung Cancer"],"interventions":["DZD6008","Pemetrexed","Carboplatin","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07070440"},{"nctId":"NCT06732323","title":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":504,"enrollmentType":"ESTIMATED","startDate":"2025-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["Triple-Negative Breast Cancer (TNBC)"],"interventions":["ESG401","Investigator's Choice Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06732323"},{"nctId":"NCT06437522","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2024-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["BL-B01D1","PD-1 monoclonal antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (non-nasopharyngeal carcinoma) and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06437522"},{"nctId":"NCT06150183","title":"Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors","sponsor":"BioNTech SE","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":41,"enrollmentType":"ACTUAL","startDate":"2023-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Advanced Malignant Solid Tumor"],"interventions":["BNT314"],"countries":["United States","Belgium","Denmark","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.","sourceUrl":"https://clinicaltrials.gov/study/NCT06150183"},{"nctId":"NCT07462442","title":"Study of QLS5308 in Patients With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2026-03-28","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Metastatic Solid Tumors"],"interventions":["QLS5308 IV infusion"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS5308 monotherapy in participants with Advanced Solid Tumors. This study is divided into two phases: Phase Ia is the dose escalation phase, where dose escalation of QLS5308 conducted and RP2D is explored; In the Phase Ib tumor type expansion study stage, the primary objective is to evaluate the objective response rate (ORR) of QLS5308 with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07462442"},{"nctId":"NCT07137637","title":"HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia","sponsor":"Hangzhou Polymed Biopharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)"],"interventions":["HPB-092 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity. Its highly selective and potent inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) may provide additional therapeutic benefits that could enhance treatment efficacy and durability for patients with relapsed or refractory acute myeloid leukemia (RR-AML), further improving clinical outcomes in this population. HPB-092 also has a favorable safety profile, with no major risks identified in preclinical studies. Phas 1 Study Outline: 1. This is a multicenter, open-label, phase 1 stu","sourceUrl":"https://clinicaltrials.gov/study/NCT07137637"},{"nctId":"NCT03666000","title":"Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)","sponsor":"Imugene Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2019-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Non-Hodgkin Lymphoma","B-cell Acute Lymphoblastic Leukemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Azer-cel","Fludarabine","Cyclophosphamide","IL-2"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.","sourceUrl":"https://clinicaltrials.gov/study/NCT03666000"},{"nctId":"NCT07055724","title":"Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":17,"enrollmentType":"ESTIMATED","startDate":"2025-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["AL Amyloidosis"],"interventions":["Eque-cel CAR-T Therapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if Equecabtagene Autoleucel(Eque-cel), a Chimeric Antigen Receptor T-cell (CAR-T) therapy, works to treat severe Light Chain (AL) Amyloidosis in newly diagnosed adults with Mayo Stage IIIb. It will also learn about the safety and effects of Eque-cel. The main questions it aims to answer are: Does Eque-cel lead to hematologic remission (achieving a very good partial response or better) in AL amyloidosis? How safe is Eque-cel for these patients, and what side effects might occur? Participants will: Undergo blood cell collection to create personalized Eque-cel therapy. Receive pre-treatment to prepare their body for the therapy (lymphodepletion). Rece","sourceUrl":"https://clinicaltrials.gov/study/NCT07055724"},{"nctId":"NCT05926765","title":"A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia","sponsor":"MeiraGTx, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":290,"enrollmentType":"ACTUAL","startDate":"2023-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands"],"interventions":["AAV2-hAQP1 Concentration 1","AAV2-hAQP1 Concentration 2","Placebo","AAV2-hAQP1 Concentration 3","AAV2-hAQP1 Concentration 4"],"countries":["United States","Canada","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.","sourceUrl":"https://clinicaltrials.gov/study/NCT05926765"},{"nctId":"NCT05578976","title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2023-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2025-01-23","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["Epcoritamab","Cyclophosphamide","Rituximab","Vincristine","Doxorubicin","Prednisone"],"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Czechia","Denmark","France","Greece","Hungary","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":331,"serviceSignals":["Hematology NGS"],"summary":"B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed","sourceUrl":"https://clinicaltrials.gov/study/NCT05578976"},{"nctId":"NCT07296445","title":"A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)","sponsor":"SDK Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Acute Promyelocytic Leukemia (APL)","Acute Promyelocytic Leukaemia","Acute Promyelocytic Leukemia With PML-RARA","Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA","APL","Acute Promyelocytic Leukemia","Leukaemia","Leukemia Acute Promyelocytic Leukemia (APL)","Leukemia, Acute"],"interventions":["Oral ATO","IV Arsenic Trioxide","all-trans retinoic acid (ATRA)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation Therapy in Participants With Newly Diagnosed, Non-High Risk, Acute Promyelocytic Leukemia Rationale: SDK Therapeutics is developing an oral formulation of arsenic trioxide (ATO) for the treatment of acute promyelocytic leukemia (APL). Patients with APL are usually treated with arsenic trioxide (ATO) through an IV along with all-trans retinoic acid (ATRA) taken by mouth. Receiving ATO through an IV requires patients with APL to go to the hospital a lot and get long tre","sourceUrl":"https://clinicaltrials.gov/study/NCT07296445"},{"nctId":"NCT02899052","title":"Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2017-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-05","conditions":["Multiple Myeloma"],"interventions":["Carfilzomib","Venetoclax","Dexamethasone"],"countries":["United States","Australia","Hungary","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 of this study is currently enrolling.","sourceUrl":"https://clinicaltrials.gov/study/NCT02899052"},{"nctId":"NCT06994195","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["BL-B01D1","Liposomal doxorubicin, Paclitaxel or Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent epithelial ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06994195"},{"nctId":"NCT07356453","title":"A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.","sponsor":"FoRx Therapeutics AG","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Advanced Solid Tumors"],"interventions":["FORX-428"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HRD / HRR"],"summary":"The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD) and Recommended Cohort Expansion Dose (RCED) of FORX-428 as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07356453"},{"nctId":"NCT05833724","title":"Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)","sponsor":"Great Novel Therapeutics Biotech & Medicals Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2024-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Relapsed or Refractory Peripheral T-cell Lymphoma"],"interventions":["Chidamide"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT05833724"},{"nctId":"NCT07007988","title":"A Phase I Study of SIM0388 in Participants With Malignant Ascites.","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Malignant Ascites"],"interventions":["SIM0388"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles (SIM0388) for injection in patients with malignant ascites","sourceUrl":"https://clinicaltrials.gov/study/NCT07007988"},{"nctId":"NCT06656494","title":"ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":266,"enrollmentType":"ESTIMATED","startDate":"2024-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Acute Myelogenous Leukemia","Myelodysplastic Syndromes (MDS)"],"interventions":["ICP-248","Azacitidine"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06656494"},{"nctId":"NCT06718634","title":"A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2025-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Relapsed or Refractory Lymphoid Malignancies"],"interventions":["BL-M08D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and extended-enrollment, nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M08D1 for injection in relapsed or refractory lymphoid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06718634"},{"nctId":"NCT07532148","title":"Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","sponsor":"Chong Kun Dang Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Ovarian Cancer"],"interventions":["CKD-215","D215"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Clinical Trial to evaluate the pharmacokinetic Characteristics, safety and Tolerability among CKD-215 and D215","sourceUrl":"https://clinicaltrials.gov/study/NCT07532148"},{"nctId":"NCT06922591","title":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","sponsor":"Tango Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":183,"enrollmentType":"ESTIMATED","startDate":"2025-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC","RAS Mutation","MTAP Deletion","Lung Cancer","Pancreatic Cancer Metastatic","Thoracic Cancer"],"interventions":["TNG462","RMC-9805","RMC-6236","mFOLFIRINOX","gemcitabine/nab-paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["RAS genotyping"],"summary":"TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT06922591"},{"nctId":"NCT07484022","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","sponsor":"Generate Biomedicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":37,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Advanced Urothelial Cancer","Metastatic Urothelial Carcinoma"],"interventions":["GB-4362","enfortumab vedotin (EV)","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety and tolerability of an investigational drug called GB-4362 when it is given together with enfortumab vedotin and pembrolizumab in adults with advanced or metastatic urothelial cancer. GB-4362 is a monoclonal antibody designed to bind and neutralize free monomethyl auristatin E (MMAE), a chemotherapy payload released from enfortumab vedotin that is associated with side effects such as peripheral neuropathy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07484022"},{"nctId":"NCT07246590","title":"Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)","sponsor":"Verrica Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Common Warts","Common Warts (Verruca Vulgaris)","Human Papilloma Virus (HPV)","Warts"],"interventions":["VP-102","Vehicle"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \\[Cantharidin and Occlusion in Verruca Epithelium\\]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.","sourceUrl":"https://clinicaltrials.gov/study/NCT07246590"},{"nctId":"NCT06533579","title":"Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)","sponsor":"Vironexis Biotherapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-09","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["B-cell Acute Lymphoblastic Leukemia","Large B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Marginal Zone Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Burkitt Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Non Hodgkin Lymphoma","Mixed Phenotype Acute Leukemia"],"interventions":["Dose Level 1, VNX-101","Dose Level 2, VNX-101","Dose Level 3, VNX-101","Dose Level 4, VNX-101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06533579"},{"nctId":"NCT07138846","title":"A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer","sponsor":"Lepu Biopharma Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":231,"enrollmentType":"ESTIMATED","startDate":"2027-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced Pancreatic Cancer"],"interventions":["MRG004A plus best supportive care","Placebo plus best supportive care"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, multi-center, phase III study to evaluate the efficacy and safety, pharmacokinetic profile and immunogenicity of MRG004A in patients with advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07138846"},{"nctId":"NCT05063565","title":"TheraSphere With Durvalumab and Tremelimumab for HCC","sponsor":"Boston Scientific Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Hepatocellular Carcinoma"],"interventions":["TheraSphere Y-90 glass microsphere therapy","Durvalumab (Imfinzi) immunotherapy","Tremelimumab immunotherapy"],"countries":["United States","France","Italy","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05063565"},{"nctId":"NCT07272590","title":"Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2025-12-09","conditions":["Metastatic Solid Tumors"],"interventions":["QLC5513 IV infusion","QL1706, IV infusion","platinum, IV infusion"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase Ib/II interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant solid tumors. This study is divided into two phases: Phase Ib is the combined dose escalation phase, where dose escalation of QLC5513 combined with QL1706± platinum is conducted and RP2D is explored; In the Phase II tumor type expansion study stage, the primary objective is to evaluate the objective response rate (ORR) of QLC5513 combined with QL1706± platinum-based treatment in patients with advanced or metastatic malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07272590"},{"nctId":"NCT04919226","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","sponsor":"ITM Solucin GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":259,"enrollmentType":"ACTUAL","startDate":"2021-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Neuroendocrine Tumors"],"interventions":["177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT","CAPTEM (Capecitabine and Temozolomide)","Amino-Acid Solution","Everolimus","FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)"],"countries":["United States","Australia","China","France","Germany","India","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":42,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the efficacy, safety \\& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.","sourceUrl":"https://clinicaltrials.gov/study/NCT04919226"},{"nctId":"NCT07262567","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Metastatic Pancreatic Cancer"],"interventions":["GFH375","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This study plans to enroll participants with previously treated metastatic pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. These participants are required to experience disease progression on or after at least one prior standard systemic therapy containing fluorouracil or gemcitabine, and either progressed on or were intolerant to the last treatment. Eligible participants will be randomized 1:1 to the experimental group or the control group for treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07262567"},{"nctId":"NCT07069062","title":"A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":261,"enrollmentType":"ESTIMATED","startDate":"2025-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Solid Tumor"],"interventions":["Test product HY0001a for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase I/Ⅱ study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of HY0001a for injection in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07069062"},{"nctId":"NCT06480240","title":"A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors","sponsor":"OBI Pharma, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":117,"enrollmentType":"ESTIMATED","startDate":"2024-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-08","conditions":["Advanced Solid Tumor"],"interventions":["OBI-992"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) is intended to further characterize the safety and preliminary clinical activity profile of the RP2D of OBI-992 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06480240"},{"nctId":"NCT06475300","title":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2024-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Non-small Cell Lung Cancer","Nasopharyngeal Carcinoma","Solid Tumor"],"interventions":["BL-B01D1","PD-1 Monoclonal Antibody","Pemetrexed Disodium"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06475300"},{"nctId":"NCT06514027","title":"Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations","sponsor":"BeBetter Med Inc","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2024-07-23","conditions":["Non Small Cell Lung Cancer"],"interventions":["BEBT-109 Capsules","Pemetrexed Disodium for Injection","Carboplatin Injection","Cisplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic characteristics of BEBT-109 combined with injectable pemetrexed disodium and carboplatin or cisplatin injection as first-line treatment for locally advanced, recurrent, or metastatic non-small cell lung cancer carrying EGFR exon 20 insertion mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06514027"},{"nctId":"NCT06755242","title":"A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-01-01","conditions":["Gastrointestinal Tumors","Solid Tumor"],"interventions":["GNC-077"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06755242"},{"nctId":"NCT06787664","title":"A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":27,"enrollmentType":"ACTUAL","startDate":"2025-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Chordoma"],"interventions":["BL-B01D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter phase II study to evaluate the safety, efficacy and pharmacokinetic characteristics of BL-B01D1 for Injection in patients with locally advanced or metastatic chordoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06787664"},{"nctId":"NCT07659795","title":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","sponsor":"Verastem, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Colorectal Cancer"],"interventions":["VS-7375","cetuximab","panitumumab","Cetuximab + mFOLFOX6"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07659795"},{"nctId":"NCT06162221","title":"Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":616,"enrollmentType":"ESTIMATED","startDate":"2024-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Non-Small Cell Lung Cancer, NSCLC","KRAS, NRAS, HRAS-mutated NSCLC","KRAS G12C-mutated Solid Tumors, Lung Cancer","Lung Cancer Stage IV, Advanced Solid Tumor, Cancer","RAS G12D-mutated NSCLC"],"interventions":["RMC-6291","RMC-6236","Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed","RMC-9805"],"countries":["United States","Australia","Austria","Czechia","Denmark","France","Germany","Greece","Italy","Netherlands","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":93,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805","sourceUrl":"https://clinicaltrials.gov/study/NCT06162221"},{"nctId":"NCT06449209","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","sponsor":"BioNTech SE","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2024-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Extensive-stage Small-cell Lung Cancer","Small-cell Lung Cancer"],"interventions":["BNT327 Dose Level 1 (DL1)","BNT327 Dose Level 2 (DL2)","Etoposide","Carboplatin","Paclitaxel","Topotecan"],"countries":["United States","Australia","South Korea","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.","sourceUrl":"https://clinicaltrials.gov/study/NCT06449209"},{"nctId":"NCT06906731","title":"A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-04-02","conditions":["Advanced Solid Tumors"],"interventions":["SHR-9803"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, multiple doses Phase I/II study to evaluate the safety, tolerability ,pharmacokinetics and efficacy of SHR-9803 for injection in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06906731"},{"nctId":"NCT07032077","title":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Solid Tumors"],"interventions":["HRS-7058"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and tolerability of HRS-7058 combined with antitumor drugs in subjects with solid tumors, and to determine the recommended dosage for Phase II. Evaluate the objective response rate of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07032077"},{"nctId":"NCT05633654","title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1514,"enrollmentType":"ESTIMATED","startDate":"2022-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Triple Negative Breast Cancer"],"interventions":["Sacituzumab govitecan-hziy (SG)","Pembrolizumab","Capecitabine"],"countries":["United States","Australia","Belgium","Brazil","France","Germany","Ireland","Italy","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":356,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05633654"},{"nctId":"NCT06959082","title":"Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer","sponsor":"VSPharmTech Co.,Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Head and Neck Cancer Squamous Cell Carcinoma"],"interventions":["VS-101","Cisplatin","Radiation"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This will be a multi-center, randomized, open-label, parallel-group study in adult patients with head and neck cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06959082"},{"nctId":"NCT05566795","title":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","sponsor":"Day One Biopharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":418,"enrollmentType":"ACTUAL","startDate":"2023-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-06","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Low-grade Glioma","Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma","Pediatric Low-grade Glioma"],"interventions":["Tovorafenib","Chemotherapeutic Agent"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Egypt","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Jordan","Netherlands","New Zealand","Norway","Qatar","Singapore","Slovenia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":138,"serviceSignals":["Broad CGP"],"summary":"This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05566795"},{"nctId":"NCT07675876","title":"Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer","sponsor":"Carcinex Inc","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Locally Advanced Non-Small Cell Lung Cancer","Lung Adenocarcinoma"],"interventions":["Cromolyn Sodium"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Brief Summary This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer. Cromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory disease. Increasing evidence suggests that inflammatory signaling, mast cell activation, and stromal remodeling contribute to tumor progression, immune dysregulation, and resistance to therapy within the lung tumor microenvironment. Modulation of these pathways may represent a novel therapeutic strategy in lung cancer. Appro","sourceUrl":"https://clinicaltrials.gov/study/NCT07675876"},{"nctId":"NCT06541847","title":"A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1","sponsor":"Healx Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2025-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Neurofibromatosis Type 1"],"interventions":["HLX-1502"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The trial will be an open label, single arm, phase 2 study to assess the tolerability and efficacy of HLX-1502 in participants with NF1 that are 16 years or older in age with progressive and/or symptomatic PN. This study will also investigate the safety and efficacy of HLX-1502 in a small cohort of 12 to 15 year olds.","sourceUrl":"https://clinicaltrials.gov/study/NCT06541847"},{"nctId":"NCT04554914","title":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","sponsor":"Pierre Fabre Medicament","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2021-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Epstein-Barr Virus (EBV)-Associated Diseases","EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)","EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)","EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)","EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)","Solid Organ Transplant Complications","Lymphoproliferative Disorders","Allogeneic Hematopoietic Cell Transplant","Stem Cell Transplant Complications","EBV+ Sarcomas","Leiomyosarcoma"],"interventions":["Tabelecleucel"],"countries":["United States","Austria","Belgium","France","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.","sourceUrl":"https://clinicaltrials.gov/study/NCT04554914"},{"nctId":"NCT07252661","title":"Study of ACC-1898 in Adult Participants With Advanced Solid Tumors","sponsor":"AccSalus Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Hepatocellular Carcinoma","Renal Cell Carcinoma","Thyroid Carcinoma, Medullary","Thyroid Carcinoma Primary Differentiated","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Melanoma","Gall Bladder Cancer","Advanced Solid Tumor"],"interventions":["ACC-1898"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread. The purpose of this Phase 1 clinical trial is to find a safe dose of ACC-1898 and to understand how the body absorbs, distributes, and eliminates the drug (pharmacokinetics / PK). The study will also look for early signs that ACC-1898 may slow or shrink tumors and explore possible biological markers related to drug activity. Adults with advanced or metastatic solid tumors who have no remaining standard treatment options may take part. All participants will receive ACC-1898 tablets by mouth once ","sourceUrl":"https://clinicaltrials.gov/study/NCT07252661"},{"nctId":"NCT06452160","title":"A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors","sponsor":"BridGene Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":103,"enrollmentType":"ESTIMATED","startDate":"2024-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-08-09","conditions":["Mesothelioma","Epithelioid Hemangioendothelioma(EHE)","Solid Tumor"],"interventions":["BGC515"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06452160"},{"nctId":"NCT07473128","title":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","sponsor":"Pharmacosmos A/S","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Limited Stage Small Cell Lung Cancer"],"interventions":["Trilaciclib","Saline (0.9% NaCl)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT07473128"},{"nctId":"NCT05614739","title":"FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":535,"enrollmentType":"ESTIMATED","startDate":"2023-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Urinary Bladder Neoplasms","Neoplasm Metastasis","Ureteral Neoplasms"],"interventions":["LOXO-435","Pembrolizumab","enfortumab vedotin"],"countries":["United States","Australia","Canada","China","France","Germany","Israel","Italy","Japan","Netherlands","Norway","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":82,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.","sourceUrl":"https://clinicaltrials.gov/study/NCT05614739"},{"nctId":"NCT07239986","title":"A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma","sponsor":"Broadenbio Ltd., Co.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["BB102"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma. This study has two phase: dose escalation phase and expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07239986"},{"nctId":"NCT06857175","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":508,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Urothelial Carcinoma"],"interventions":["BL-B01D1","Docetaxel or Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic urothelial carcinoma after failure of PD-1/PD-L1 monoclonal antibody and platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06857175"},{"nctId":"NCT05864144","title":"A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","sponsor":"Sensei Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":98,"enrollmentType":"ACTUAL","startDate":"2023-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Solid Tumor, Adult","Advanced Solid Tumor","Head and Neck Cancer","Breast Cancer","Colon Cancer","Pancreatic Cancer","Gastric Cancer","Esophageal Cancer","Prostate Cancer","Uterine Cancer","Cervix Cancer","Ovarian Cancer","Kidney Cancer","Bladder Cancer","Thyroid Cancer","Melanoma","Sarcoma","Advanced Cancer","Metastatic Cancer","Refractory Cancer","Non Small Cell Lung Cancer","Merkel Cell Carcinoma"],"interventions":["SNS-101 (anti-VISTA)","Cemiplimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05864144"},{"nctId":"NCT06726265","title":"Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)","sponsor":"Immutep S.A.S.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":756,"enrollmentType":"ESTIMATED","startDate":"2025-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["eftilagimod alfa","carboplatin plus paclitaxel","cisplatin or carboplatin + pemetrexed","pembrolizumab (KEYTRUDA®)","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Croatia","Georgia","Germany","Greece","Hungary","India","Ireland","Italy","Latvia","Lithuania","Malaysia","Poland","Portugal","Romania","Spain","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":147,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC). Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06726265"},{"nctId":"NCT07653685","title":"A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Colorectal Cancer"],"interventions":["TQB2930 injection + Oxaliplatin injection + Capecitabine tablets + Bevacizumab injection","TQB2930 injection + Oxaliplatin injection + Capecitabine tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["HER2 profiling"],"summary":"To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in subjects with HER2-positive unresectable locally advanced or metastatic colorectal cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07653685"},{"nctId":"NCT07464925","title":"A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma","sponsor":"Tetragon Biosciences Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Glioblastoma Multiforme of Brain","Glioma","Glioblastoma"],"interventions":["GLIX1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter dose-escalation study to be followed by a dose expansion to define the optimal dose of GLIX1 as monotherapy by reviewing safety and tolerability, disease characteristics and pharmacokinetic profiles and preliminary clinical activity in participants with a high grade diffuse glioma that progressed during or recurred after prior standard of care therapies or investigational therapies as clinically indicated. Patients will be treated daily with GLIX1 capsules until disease progression or unacceptable safety.","sourceUrl":"https://clinicaltrials.gov/study/NCT07464925"},{"nctId":"NCT05552755","title":"Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)","sponsor":"Recursion Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2023-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Familial Adenomatous Polyposis"],"interventions":["REC-4881","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, two-part trial in participants with FAP.","sourceUrl":"https://clinicaltrials.gov/study/NCT05552755"},{"nctId":"NCT07085091","title":"A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors","sponsor":"ALX Oncology Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)","HNSCC","CRC (Colorectal Cancer)","ESCC","Colo-rectal Cancer","Head and Neck Cancer","Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":["ALX2004"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07085091"},{"nctId":"NCT06975410","title":"Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors","sponsor":"Yuhan Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["EGFR Overexpression","Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["YH32364"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.","sourceUrl":"https://clinicaltrials.gov/study/NCT06975410"},{"nctId":"NCT03821935","title":"Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":364,"enrollmentType":"ACTUAL","startDate":"2019-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2025-05-25","conditions":["Advanced Solid Tumors Cancer"],"interventions":["Livmoniplimab","Budigalimab"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Israel","Italy","Japan","Poland","Puerto Rico","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["Broad CGP"],"summary":"The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT03821935"},{"nctId":"NCT04999761","title":"AB122 Platform Study","sponsor":"Taiho Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":917,"enrollmentType":"ESTIMATED","startDate":"2021-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Advanced or Metastatic Solid Tumor","Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Non-small Cell Lung Cancer","Gastric Cancer","Alveolar Soft Part Sarcoma","Esophageal Cancer","Head and Neck Cancer","Biliary Tract Cancer"],"interventions":["AB122","TAS-116","TAS-120","TAS-115","TAS-102","Ramucirumab","Bevacizumab","Fluorouracil","Cisplatin","AB154","Carboplatin","nab-Paclitaxel","Gemcitabine"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT04999761"},{"nctId":"NCT07275242","title":"A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":107,"enrollmentType":"ESTIMATED","startDate":"2025-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Solid Tumor"],"interventions":["SHR-A1811 Subcutaneous Injection","SHR-A1811 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07275242"},{"nctId":"NCT05413421","title":"Study of ORIC-944 in Patients With Metastatic Prostate Cancer","sponsor":"ORIC Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":275,"enrollmentType":"ESTIMATED","startDate":"2022-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Metastatic Prostate Cancer"],"interventions":["ORIC-944","Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets","Apalutamide (Erleada™) 60 mg or 240 mg tablets","Darolutamide (Nubeqa®) 300 mg tablets","Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets"],"countries":["United States","Australia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05413421"},{"nctId":"NCT07659782","title":"A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer","sponsor":"Verastem, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Non-Small Cell Lung Cancer"],"interventions":["VS-7375"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07659782"},{"nctId":"NCT05742607","title":"IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)","sponsor":"Innate Pharma","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-06","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Non Small Cell Lung Cancer"],"interventions":["IPH5201 + durvalumab + standard chemotherapy"],"countries":["United States","France","Greece","Hungary","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC). Study Design was updated following the results of interim analysis # 2 (protocol amendment, adding cohort 2). Cohort 2 includes patients with resectable Stage II to IIIB NSCLC expressing PD-L1 ≥1%, receiving (only) neoadjuvant IPH5201+ durvalumab + chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT05742607"},{"nctId":"NCT06832202","title":"A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2025-06-15","conditions":["HER2-low Hormone Receptor Positive Breast Cancer"],"interventions":["HLX22","Trastuzumab Deruxtecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase II Study of HLX22 in Combination with Trastuzumab Deruxtecan (T-DXd) in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression or Intolerable Adverse Reaction on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).","sourceUrl":"https://clinicaltrials.gov/study/NCT06832202"},{"nctId":"NCT07134205","title":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-01","completionType":"ESTIMATED","lastUpdated":"2025-08-21","conditions":["Metastatic Colorectal Cancer (mCRC)"],"interventions":["JMT101","Irinotecan","Regorafenib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07134205"},{"nctId":"NCT07682337","title":"Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects","sponsor":"SCBIO Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":74,"enrollmentType":"ESTIMATED","startDate":"2026-06-29","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Solid Tumor","Obesity","Idiopathic Pulmonary Fibrosis"],"interventions":["SCB0020160","Placebo"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans. Healthy adult men aged 18 to 65 years who meet the study eligibility criteria. Study details Participants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160. Participants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse event","sourceUrl":"https://clinicaltrials.gov/study/NCT07682337"},{"nctId":"NCT07560111","title":"A Phase II Study of GC101 in NSCLC","sponsor":"Shanghai Juncell Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-01","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Non Small Cell Lung Cancer"],"interventions":["Autologous Tumor Infiltrating Lymphocytes"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"28 participants are expected to be enrolled for the Phase II clinical trial, this trial is expected to be finished in 36 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT07560111"},{"nctId":"NCT07408258","title":"Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors","sponsor":"OncoC4, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-01","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Advanced Solid Tumor"],"interventions":["ONC-783"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07408258"},{"nctId":"NCT04379596","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2020-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Gastric Cancer"],"interventions":["Fluorouracil (5-FU)","Capecitabine","Durvalumab","Oxaliplatin","Trastuzumab","Trastuzumab deruxtecan","Cisplatin","Pembrolizumab","Volrustomig","Rilvegostomig"],"countries":["United States","Brazil","Canada","China","Germany","Italy","Japan","Netherlands","Poland","Russia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":100,"serviceSignals":["HER2 profiling"],"summary":"DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing. T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor admini","sourceUrl":"https://clinicaltrials.gov/study/NCT04379596"},{"nctId":"NCT06398444","title":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","sponsor":"Sinotau Pharmaceutical Group","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2024-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-01","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Neuroendocrine Neoplasm"],"interventions":["Lutetium[177Lu] Oxodotreotide Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium \\[177Lu\\] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neoplasms (NEN) other than grade G1/G2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and Neuroendocrine Carcinoma（NEC）.","sourceUrl":"https://clinicaltrials.gov/study/NCT06398444"},{"nctId":"NCT04485013","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","sponsor":"Tizona Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2020-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-01","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Cancer"],"interventions":["TTX-080","pembrolizumab","cetuximab","FOLFIRI"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["HLA / TCR"],"summary":"TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizumab (PD-1 inhibitor), cetuximab (EGFR inhibitor) or FOLFIRI plus cetuximab (EGFR inhibitor) in patients with advanced refractory / resistant solid malignancies including metastatic colorectal cancer (mCRC) patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT04485013"},{"nctId":"NCT05458674","title":"Tucatinib+Trastuzumab+Eribulin in HER2+ MBC","sponsor":"Criterium, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2024-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Breast Cancer","Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer"],"interventions":["Tucatinib","Eribulin","Trastuzumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.","sourceUrl":"https://clinicaltrials.gov/study/NCT05458674"},{"nctId":"NCT05317858","title":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","sponsor":"InSightec","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2022-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Brain Tumor","Non Small Cell Lung Cancer"],"interventions":["Blood Brain Barrier Opening - Oncology","Pembrolizumab","Atezolizumab","Cemiplimab","Nivolumab","Iptilimumab"],"countries":["United States","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved, on-label systemic therapy utilizing immune checkpoint inhibitors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05317858"},{"nctId":"NCT06253130","title":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","sponsor":"Eikon Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2023-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced Solid Tumor"],"interventions":["IMP1734"],"countries":["United States","Australia","Canada","China","Denmark","France","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":57,"serviceSignals":["Broad CGP"],"summary":"This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06253130"},{"nctId":"NCT07488884","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","sponsor":"ImmunityBio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-01","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Pancreatic Cancer Resectable","Pancreatic Cancer"],"interventions":["Nogapendekin Alfa Inbakicept (N803)","Sotevtamab","Zabadinostat (CXD101)","Nab paclitaxel / gemcitabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, phase 1 clinical trial to evaluate the safety and preliminary efficacy of neoadjuvant chemoimmunotherapy (NAI, sotevtamab, and zabadinostat in combination with gemcitabine and nab-paclitaxel) followed by resection and adjuvant immunotherapy for participants with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). Eligible participants will undergo endoscopic ultrasound (EUS)-guided biopsies of the primary pancreatic tumor within 7 days of enrollment and prior to study day 1. EUS-guided biopsies will be used for histopathological examination to give clinical diagnostic information (as SoC) and will be stored in an ethically approved tissue","sourceUrl":"https://clinicaltrials.gov/study/NCT07488884"},{"nctId":"NCT06532006","title":"A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2024-11-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Gastroesophageal-junction Cancer","Monoclonal Antibody","Gastric Cancer","HER2-positive Gastric Cancer"],"interventions":["HLX22","Pembrolizumab","Trastuzumab","Oxaliplatin","Capecitabine"],"countries":["United States","Argentina","Australia","Brazil","Chile","China","Georgia","Germany","Greece","Italy","Japan","Peru","Poland","Romania","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":208,"serviceSignals":["HER2 profiling"],"summary":"This is a double-blind, randomized, multiregion, comparative phase Ⅲ clinical study designed to evaluate the efficacy and safety of HLX22 in combination with trastuzumab and chemotherapy as first-line treatment in patients with HER2-positive locally advanced/metastatic adenocarcinoma of the gastric and/or gastroesophageal junction (G/GEJ).Eligible subjects will be randomized to the two groups based on a 1:1 ratio. Enrolled subjects shall be treated with the study drug until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent, or other reasons specified by the protocol (whichever occurs first).","sourceUrl":"https://clinicaltrials.gov/study/NCT06532006"},{"nctId":"NCT06401356","title":"An Extension Study for Patients Previously Enrolled in Studies With Pelabresib","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2024-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Hematologic Malignancy","Solid Tumor","Advanced Malignancies"],"interventions":["Pelabresib"],"countries":["United States","Belgium","Italy","Netherlands","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).","sourceUrl":"https://clinicaltrials.gov/study/NCT06401356"},{"nctId":"NCT07670468","title":"Evaluation of the Safety and Efficacy of LB-DTK-MV in Patients Diagnosed With Antiviral-Resistant CMV, BKV, or EBV Infection or Associated Diseases Following Anticancer Therapy or Allogeneic Hematopoietic Stem Cell Transplantation.","sponsor":"LucasBio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-04","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["BKV Infection","EBV Infection","CMV Infection"],"interventions":["LB-DTK-MV"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the efficacy and safety of Multi-Virus Specific T cells (LB-DTK-MV) to treat patients diagnosed with antiviral-resistant CMV, BKV, or EBV infection or associated diseases after anticancer therapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). The main questions it aims to answer are: * What is the maximum tolerated dose of LB-DTK-MV based on dose-limiting toxicity? * Does the number of CMV, BKV, or EBV virus viral load decrease within 7 or 14 days after the second infusion of LB-DTK-MV? * Do treatment emergent adverse events occur after the second infusion? Participants will: * Receive a single intravenous infusion of LB-DTK-","sourceUrl":"https://clinicaltrials.gov/study/NCT07670468"},{"nctId":"NCT06841185","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma","sponsor":"Shanghai Henlius Biotech","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":656,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-05","completionType":"ESTIMATED","lastUpdated":"2025-02-24","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["HLX13","US-sourced YERVOY®","EU-sourced YERVOY®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the efficacy, safety, PK, and immunogenicity of HLX13 and YERVOY® in patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06841185"},{"nctId":"NCT05899049","title":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":249,"enrollmentType":"ESTIMATED","startDate":"2022-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-07","completionType":"ESTIMATED","lastUpdated":"2025-11-10","conditions":["Carcinoma, Renal Cell"],"interventions":["Pembrolizumab","Belzutifan","Pembrolizumab/Quavonlimab","Lenvatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The goal of this China extension study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in Chinese participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT05899049"},{"nctId":"NCT06052306","title":"A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2023-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-08","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-10","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["BAY3546828"],"countries":["United States","Canada","Finland","Italy","Netherlands","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat people who have advanced metastatic castration-resistant prostate cancer (mCRPC). In participants with metastatic castration-resistant prostate cancer (mCRPC), the cancer of the prostate has spread to other parts of the body (metastatic) and does not respond to the lowering of testosterone levels in the body (castration resistant). The cancer is 'advanced' and is unlikely to be cured or controlled with currently available treatments. Despite new treatment options for participant(s) with prostate cancer in recent years, the cancer often returns and worsens. The study treatment actinium-225-macropa-pelgifatamab (also called 225Ac-pelgi or BAY35","sourceUrl":"https://clinicaltrials.gov/study/NCT06052306"},{"nctId":"NCT05319730","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2023-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-10","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["Paclitaxel","Irinotecan","Pembrolizumab","MK-4830","Lenvatinib","Sacituzumab tirumotecan","Antihistamine","H2 Receptor Antagonist","Acetaminophen (or equivalent)","Dexamethasone (or equivalent)","Steroid Mouthwash (dexamethasone or equivalent)","Supportive care measures"],"countries":["United States","Brazil","Chile","China","Germany","Italy","Japan","Norway","Singapore","South Korea","Switzerland","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05319730"},{"nctId":"NCT07405151","title":"A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Oesophageal Squamous Cell Carcinoma"],"interventions":["I-DXd","Rescue Medication"],"countries":["United States","Brazil","China","Czechia","Japan","Norway","South Korea","Switzerland","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":23,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants who receive I-DXd have the cancer respond, which means the cancer gets smaller or goes away.","sourceUrl":"https://clinicaltrials.gov/study/NCT07405151"},{"nctId":"NCT07627698","title":"Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-17","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Unresectable Melanoma","Metastatic Cutaneous Melanoma","Metastatic Uveal Melanoma"],"interventions":["EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells","Fludarabine","Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells (EBDTKN-401) after lymphodepleting chemotherapy in adults with unresectable or metastatic cutaneous melanoma or metastatic uveal melanoma whose disease has progressed after standard therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07627698"},{"nctId":"NCT07598955","title":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["B2 Thymoma","Thymic Carcinoma"],"interventions":["Cyclophosphamide","Fludarabine","EB-CAR30-NK","EB-CAR5-NK","EB-CARMSLN-NK","Rimiducid (AP1903)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma. Participants undergo centralized tumor antigen assessment (CD30, CD5, and mesothelin). Based on the dominant and clinically actionable antigen expression profile, each participant is assigned to one of three parallel cohorts (CD30-CAR-NK, CD5-CAR-NK, or mesothelin-CAR-NK). All cohorts use the same lymphodepleting conditioning regimen followed by CAR-NK infusion(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT07598955"},{"nctId":"NCT07617753","title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-17","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Carcinoma","Recurrent or Refractory Disease After Standard Therapies"],"interventions":["Dual-target CAR-NK cell product","Cyclophosphamide","supportive"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells in participants with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. At screening, each participant's tumor is assessed for expression of Mesothelin (MSLN), Folate Receptor alpha (FRalpha/FOLR1), and MUC16 (CA 125). Participants are assigned to the dual-target CAR-NK product that best matches their tumor antigen profile to reduce the risk of antigen escape.","sourceUrl":"https://clinicaltrials.gov/study/NCT07617753"},{"nctId":"NCT07266441","title":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":157,"enrollmentType":"ESTIMATED","startDate":"2026-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["JNJ-79635322"],"countries":["United States","China","Israel","Italy","Japan","Poland","South Korea","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":71,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07266441"},{"nctId":"NCT07492628","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","sponsor":"Beijing Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-17","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Bladder Cancer","Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Upper Tract Urothelial Carcinoma"],"interventions":["EB-DT-NK-UC101","Cyclophosphamide","Fludarabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally advanced or metastatic urothelial carcinoma. Based on public urothelial-cancer evidence, Nectin-4 was selected as the lead antigen because it has the strongest disease-specific clinical validation; HER2/ERBB2 was chosen as the secondary co-target to broaden tumor coverage and reduce antigen-escape risk. EpCAM is not selected as a therapeutic co-target in this example because of broader normal epithelial expression and weaker tumor specificity in urothelial carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07492628"},{"nctId":"NCT06775236","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2025-03-20","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-15","completionType":"ESTIMATED","lastUpdated":"2025-03-19","conditions":["Advanced Solid Tumors","Breast Cancer"],"interventions":["SYS6010 jnjection","monotherapy chemotherapy","SYH2051 tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The study consists of two phases. Phase 1b and Phase 2. Phase 1b aims to evaluate the safety, tolerability, and preliminary efficacy of SYS6010 as a monotherapy and in combination with SYH2051, and to determine the recommended Phase 2 dose (RP2D) for subsequent Phase 2 studies. Phase 2 aims to assess the efficacy and safety of SYS6010 monotherapy or in combination with SYH2051 compared to investigator-selected chemotherapy in patients with EGFR-expressing, unresectable locally advanced or metastatic advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06775236"},{"nctId":"NCT06333509","title":"Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL","sponsor":"CARsgen Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":166,"enrollmentType":"ESTIMATED","startDate":"2024-04-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-03-27","conditions":["Multiple Myeloma","Primary Plasma Cell Leukemia"],"interventions":["CT071"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06333509"},{"nctId":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":1006,"enrollmentType":"ESTIMATED","startDate":"2020-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-22","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small Cell Lung","Squamous Cell Carcinoma of Head and Neck","HER2 Negative Breast Neoplasms","Esophageal Squamous Cell Carcinoma","Esophageal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Ovarian Neoplasms","Cutaneous Squamous Cell Cancer","Exocrine Pancreatic Adenocarcinoma","Urinary Bladder Neoplasms","Uterine Cervical Neoplasms","Stomach Neoplasms"],"interventions":["sigvotatug vedotin","pembrolizumab","cisplatin","carboplatin"],"countries":["United States","France","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":158,"serviceSignals":["HER2 profiling"],"summary":"This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how sa","sourceUrl":"https://clinicaltrials.gov/study/NCT04389632"},{"nctId":"NCT07253142","title":"A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-19","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Non Small Cell Lung Cancer","Small Cell Lung Cancer"],"interventions":["HLX43 dose 1","HLX43 dose 2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["ADC biomarker"],"summary":"The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07253142"},{"nctId":"NCT06598007","title":"A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors","sponsor":"Crossignal Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2024-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Solid Tumor, Adult","Colorectal Cancer","Pancreatic Ductal Adenocarcinoma"],"interventions":["CT3001","FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an FIH, multicenter, open-label, dose escalation and dose expansion/dose optimization study of CT3001, which will be conducted in 2 phases: Phase 1 and Phase 2b. Phase 1 will be a standard 3+3 dose escalation and dose finding study in patients with advanced solid tumors for whom there is no available therapy (or patients are not candidates for such therapy) for the assessment of DLTs at up to 7 dose levels of CT3001. Phase 2b is a dose finding/dose optimization study of CT3001 in combination with SOC chemotherapy (FOLFOX) to evaluate the safety and preliminary efficacy of CT3001 in patients with advanced CRC who are eligible for re-engaging FOLFOX-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06598007"},{"nctId":"NCT06796907","title":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":305,"enrollmentType":"ESTIMATED","startDate":"2025-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-10","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Tumours, Gynecological"],"interventions":["Mo-Rez","Dostarlimab","Bevacizumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Denmark","Finland","France","Germany","Greece","Italy","Japan","Mexico","Netherlands","Norway","Panama","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":81,"serviceSignals":["Broad CGP"],"summary":"Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns. Researchers are developing new treatments that combine different medicines for those who do not respond to single medicine. This study is looking at how safe and tolerable Mocertatug Rezetecan (Mo-Rez) is, how the body handles it, and how well it works when used with other cancer medicines. The study will include participants with advanced solid tumors who have either not responded to standard treatments or cannot tolerate them or have no available effective treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06796907"},{"nctId":"NCT06095089","title":"A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":355,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-28","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Prostatic Neoplasms"],"interventions":["JNJ-78278343","JNJ-87189401","Apalutamide","Lutetium Lu-177 Vipivotide Tetraxetan","JNJ-101556143"],"countries":["United States","Australia","China","France","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06095089"},{"nctId":"NCT03731260","title":"(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis","sponsor":"Blueprint Medicines Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":251,"enrollmentType":"ACTUAL","startDate":"2019-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-23","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["Indolent Systemic Mastocytosis"],"interventions":["Avapritinib","Placebo"],"countries":["United States","Belgium","Canada","Denmark","France","Germany","Italy","Netherlands","Norway","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.","sourceUrl":"https://clinicaltrials.gov/study/NCT03731260"},{"nctId":"NCT05861895","title":"HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors","sponsor":"HighField Biopharmaceuticals Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2023-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-23","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Solid Tumors, Adult"],"interventions":["HF158K1 / 1.4 g lipid dose","HF158K1 / 2.2 g lipid dose","HF158K1 / 2.9 g lipid dose"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.","sourceUrl":"https://clinicaltrials.gov/study/NCT05861895"},{"nctId":"NCT06351527","title":"Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies","sponsor":"InnoCare Pharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2024-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-25","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Mature B-cell Malignancies"],"interventions":["ICP-248","Obinutuzumab (G)","Rituximab (R)"],"countries":["United States","Puerto Rico","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06351527"},{"nctId":"NCT07649200","title":"Study of SNH-118110 in Advanced Solid Tumors","sponsor":"ScinnoHub Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-06-26","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-26","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Solid Tumors"],"interventions":["SNH-118110 Soft Capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally. The study consists of a dose-escalation phase and a dose-expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07649200"},{"nctId":"NCT07724756","title":"Phase II Study of QLC2519 in Pediatric Solid Tumor Participants","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-06-26","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-26","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Pediatric Malignant Solid Tumor","Febrile Neutropenia (FN)","Neutropenia"],"interventions":["Albipagrastim alf"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"QLC2519 (Mai Li Sheng®) is a new protein drug created by fusing the N-terminal of highly active modified G-CSF with the C-terminal of HSA. The modified G-CSF retained high activity while reducing affinity for the G-CSF receptor, which can significantly inhibit the the G-CSF receptor-mediated (RMC) pathway. The aim of this study is to evaluate the PK/PD characteristics of QLC2519 in preventing chemotherapy-induced neutropenia (CIN) in children with sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07724756"},{"nctId":"NCT07096882","title":"SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection","sponsor":"Cytocraft Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2025-07-26","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-26","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SDT-M001 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the recommended Phase II dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07096882"},{"nctId":"NCT07533708","title":"A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-05-25","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-24","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["mCRPC or Advanced/Metastatic Solid Tumors"],"interventions":["HLX3902"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT07533708"},{"nctId":"NCT07423117","title":"A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy","sponsor":"IntoCell, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2026-02-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-20","conditions":["Metastatic Castration-resistant Prostate Cancer","Non-small Cell Lung Cancer","Triple Negative Breast Cancer","Metastatic Solid Tumor"],"interventions":["ITC-6146RO"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The study consists of Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, sequential cohorts of subjects will receive escalating doses of ITC-6146RO to determine maximum tolerated dose (MTD) and/or optimal biological dose (OBD). In Phase 1b, the recommended phase 2 dose (RP2D) chosen from Phase 1a will be evaluated to further investigate safety, tolerability, pharmacokinetic (PK) and anti-tumor efficacy of ITC-6146RO.","sourceUrl":"https://clinicaltrials.gov/study/NCT07423117"},{"nctId":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":534,"enrollmentType":"ACTUAL","startDate":"2015-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Breast Cancer","Cholangiocarcinoma","Colorectal Cancer","Head and Neck Neoplasms","Lymphoma, Large-Cell, Anaplastic","Melanoma","Neuroendocrine Tumors","Non-Small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Papillary Thyroid Cancer","Primary Brain Tumors","Renal Cell Carcinoma","Sarcomas","Salivary Gland Cancers","Adult Solid Tumor"],"interventions":["Entrectinib"],"countries":["United States","Australia","Belgium","China","France","Germany","Hong Kong","Italy","Japan","Netherlands","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":130,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT02568267"},{"nctId":"NCT07557004","title":"A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["HR+ / HER2- Advanced Breast Cancer"],"interventions":["SH3765+Fulvestrant"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"Evaluate the efficacy and safety of the SH3765 tablet combined with fulvestrant in the treatment of patients with advanced HR-positive breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07557004"},{"nctId":"NCT06961188","title":"Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2025-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-07","conditions":["Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity","Untreated With Systemic Therapy"],"interventions":["Nano-crystalline Megestrol Acetate Oral Suspension","Standard Therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) and cachexia and pre-cachexia. The enrolled patients were those with advanced NSCLC who had not received therapy, negative for driver genes and ineligible for curative treatment, and were planned to receive PD-1 inhibitors in combination with platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06961188"},{"nctId":"NCT04634552","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2021-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Hematological Malignancies"],"interventions":["Talquetamab"],"countries":["United States","Belgium","China","France","Germany","Israel","Japan","Netherlands","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":78,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).","sourceUrl":"https://clinicaltrials.gov/study/NCT04634552"},{"nctId":"NCT03862430","title":"A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM","sponsor":"NuvOx LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2023-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Glioblastoma Multiforme"],"interventions":["NanO2TM","Placebo Saline Infusion"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03862430"},{"nctId":"NCT05800665","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2023-05-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Prostate Cancer","Metastatic Prostate Cancer"],"interventions":["RO7656594"],"countries":["United States","Australia","Canada","France","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05800665"},{"nctId":"NCT06094556","title":"An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2023-12-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Advanced Solid Tumors"],"interventions":["SHR-1826"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open, multi-center, dose-escalation/dose-expansion/efficacy expansion phase I clinical study to evaluate the tolerability, safety, PK, and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors, and to preliminatively observe its antitumor efficacy. The whole study was divided into three stages: dose increment, dose extension and therapeutic effect extension.","sourceUrl":"https://clinicaltrials.gov/study/NCT06094556"},{"nctId":"NCT06297226","title":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2024-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Multiple Myeloma"],"interventions":["Arlocabtagene Autoleucel"],"countries":["United States","Australia","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06297226"},{"nctId":"NCT06717750","title":"A Study of CSCJC3456 in Patients With Advanced Malignant Tumors","sponsor":"Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2025-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Advanced Malignant Solid Tumors"],"interventions":["CSCJC3456 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06717750"},{"nctId":"NCT07356037","title":"Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2026-01-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Cachexia","Hepatocellular Carcinoma"],"interventions":["Nanocrystalline Megestrol Acetate","Standard Antitumor Therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a prospective, randomized, parallel-controlled clinical trial. The primary objective is to evaluate the superiority and safety of nanocrystalline megestrol acetate in combination with standard therapy compared with standard therapy alone in improving appetite and body mass index (BMI) during treatment in patients with early-stage or locally advanced hepatocellular carcinoma at the cachexia stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07356037"},{"nctId":"NCT06123494","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2024-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2024-01-16","conditions":["HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma"],"interventions":["SHR-A1811","Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will assess the efficacy and safety of SHR-A1811 compared with treatment chosen by the investigator in participants with HER2-positive (defined as immunohistochemistry \\[IHC\\] 3+ or IHC 2+/in situ hybridization \\[ISH\\]+) gastric or GEJ adenocarcinoma (based on \\[American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines who have progressed on or after a first-line anti-HER2 therapy-containing regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT06123494"},{"nctId":"NCT05112965","title":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":49,"enrollmentType":"ACTUAL","startDate":"2021-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Neoplasms"],"interventions":["Atezolizumab","Bevacizumab","Pemetrexed","Paclitaxel","Enzalutamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05112965"},{"nctId":"NCT06885645","title":"First-In-Human Study in Participants With Advanced Solid Tumors","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-03","conditions":["Advanced Solid Tumors"],"interventions":["KH815 for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06885645"},{"nctId":"NCT05279300","title":"A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas","sponsor":"CStone Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2022-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-11","conditions":["Advanced Solid Tumor","Advanced Lymphoma"],"interventions":["CS5001","Rituximab","Gemcitabine","Oxaliplatin","Lenalidomide","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05279300"},{"nctId":"NCT06182072","title":"ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"ProDa BioTech, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2023-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["ProAgio Dose Levels (DL) 1,2,3,4","Gemcitabine, nab paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label Phase I/Ib dose-escalation, dose-expansion clinical trial of the safety, pharmacokinetics and clinical activity of ProAgio combined with gemcitabine, nab-paclitaxel (G-nP) or gemcitabine, nab-paclitaxel (G-nP) and atezolizumab in previously untreated subjects with metastatic pancreatic ductal adenocarcinoma (PDAC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06182072"},{"nctId":"NCT07589205","title":"Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":493,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Solid Tumor","Colorectal Cancer","Non-small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Head and Neck Squamous Cell Carcinoma"],"interventions":["Drug: IBI3028"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07589205"},{"nctId":"NCT07543471","title":"A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":387,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["mCRC"],"interventions":["Cetuximab","mFOLFOX6"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"This is a multicentre, randomized, double-blind, parallel-controlled Phase 1 clinical study designed to evaluate the pharmacokinetic (PK) similarity, efficacy, safety, and immunogenicity of HLX05-N compared with US-sourced ERBITUX® and EU-sourced ERBITUX® in participants with metastatic colorectal cancer (mCRC) with wild-type KRAS/NRAS and no BRAF V600E mutation. Approximately 387 participants will be randomized in a 1:1:1 ratio to receive HLX05-N, US-ERBITUX®, or EU-ERBITUX®. Randomization will be stratified by Eastern Cooperative Oncology Group (ECOG) performance status (0 vs. 1) and sex (male vs. female). During the treatment period, participants will receive study treatment in combinatio","sourceUrl":"https://clinicaltrials.gov/study/NCT07543471"},{"nctId":"NCT06564844","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ACTUAL","startDate":"2024-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Non-small Cell Lung Cancer"],"interventions":["Datopotamab Deruxtecan","Rilvegostomig","Carboplatin","Cisplatin","Etoposide","Pemetrexed","Vinorelbine","UFT"],"countries":["United States","Brazil","Canada","Hong Kong","Japan","Malaysia","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":90,"serviceSignals":["ctDNA / MRD"],"summary":"This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.","sourceUrl":"https://clinicaltrials.gov/study/NCT06564844"},{"nctId":"NCT06631989","title":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","sponsor":"Wayshine Biopharm, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-29","conditions":["EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer"],"interventions":["WSD0922-FU"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open label, single-arm phase I/II clinical trial of WSD0922-FU for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with thrid-generation EGFR-TKI .","sourceUrl":"https://clinicaltrials.gov/study/NCT06631989"},{"nctId":"NCT05265273","title":"A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2022-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-02","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Myasthenia Gravis"],"interventions":["Nipocalimab"],"countries":["United States","Japan","Netherlands","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (\\<) 18 years of age (globally) and 8 to \\<18 years of age (for Unites Stated (US) sites only), the safety and tolerability of treatment with nipocalimab in children and adolescents and to evaluate the pharmacokinetics (PK) of nipocalimab in children and adolescents with generalized myasthenia gravis (gMG) who have an insufficient clinical response to ongoing, stable standard-of-care therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05265273"},{"nctId":"NCT07327034","title":"ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":141,"enrollmentType":"ESTIMATED","startDate":"2025-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["ABSK-011+BSC","Placebo+BSC"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":51,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until disease progression, intolerable toxicity, start of new anti-tumor therapy, death, patient refuse to ","sourceUrl":"https://clinicaltrials.gov/study/NCT07327034"},{"nctId":"NCT06228053","title":"Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer","sponsor":"Syntrix Biosystems, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":53,"enrollmentType":"ESTIMATED","startDate":"2024-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["SX-682","Enzalutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed prior therapy with androgen receptor pathway inhibitors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06228053"},{"nctId":"NCT07498478","title":"Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment","sponsor":"TransThera Sciences (Nanjing), Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Breast Cancer"],"interventions":["Tinengotinib at the optimal dose combined with Fulvestrant","Tinengotinib","tinengotinib combined with fulvestrant"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if tinengotinib combined with fulvestrant works to treat patients with HR-Positive and HER-2-Negative or low-expressing advanced breast cancer. It will also learn about the safety of combination therapy. The main questions it aims to answer are: 1. Does tinengotinib combined with fulvestrant reduce the tumor burden in participants? 2. What medical problems do participants have when taking the combination therapy? Participants will: Take tinengotinib and fulvestrant to find the optimal dose of tinengotinib for the combination therapy in Part A. In Part B, will take tinengotinib at the optimal dose with fulvestrant or tinengotinib alone to see if the","sourceUrl":"https://clinicaltrials.gov/study/NCT07498478"},{"nctId":"NCT07027514","title":"A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer","sponsor":"Ankyra Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Non Small Cell Lung Cancer"],"interventions":["tolododekin alfa","Cetrelimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07027514"},{"nctId":"NCT07304128","title":"A Study of PLB-002 in Advanced Solid Tumors","sponsor":"Primelink BioTherapeitics(ShenZhen) Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Advanced Solid Tumor"],"interventions":["PLB-002"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"This study will test the safety, including side effects, and determine the characteristics of a drug called PLB-002 in participants with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07304128"},{"nctId":"NCT06150885","title":"A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors","sponsor":"Ever Supreme Bio Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2024-12-03","conditions":["Solid Tumor"],"interventions":["HLA-G-CAR.BiTE allogeneic γδ T cells"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This study is composed of phase I and IIa parts. The dose-escalation phase I part aims to find the maximum tolerated dose (MTD) and to identify the safety of CAR001 in subjects with relapsed/refractory solid tumor; the dose-expansion phase IIa part aims to evaluate the potential efficacy of CAR001 in subjects with relapsed/refractory non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), colorectal cancer (CRC) or Glioblastoma multiforme (GBM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06150885"},{"nctId":"NCT06224855","title":"A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies","sponsor":"Hangzhou DAC Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2024-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Advanced Solid Tumors","Hematological Malignancies"],"interventions":["DXC006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06224855"},{"nctId":"NCT06635785","title":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","sponsor":"OncoC4, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":387,"enrollmentType":"ESTIMATED","startDate":"2025-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Advanced Solid Tumor"],"interventions":["AI-081"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06635785"},{"nctId":"NCT07615101","title":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","sponsor":"Norroy Bioscience Co., LTD","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":365,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Prostate Cancer (Diagnosis)"],"interventions":["68-Ga-NYM032"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.","sourceUrl":"https://clinicaltrials.gov/study/NCT07615101"},{"nctId":"NCT06942234","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Inoperable Locally Advanced HER2-Negative Breast Cancer","Metastatic HER2-Negative Breast Cancer"],"interventions":["JSKN016","Capecitabine","Paclitaxel (albumin bound)","Eribulin","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study aims to evaluate the safety and effectiveness of JSKN016 in combination with different treatments for patients with HER2-negative breast cancer that cannot be removed by surgery or has spread to other parts of the body. The study includes four groups of patients based on treatment history and tumor characteristics. Each group will receive JSKN016 with chemotherapy or immunotherapy. The goal is to find out how well the treatment works and how safe it is.","sourceUrl":"https://clinicaltrials.gov/study/NCT06942234"},{"nctId":"NCT06686745","title":"Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-01-07","conditions":["Advanced Solid Tumors"],"interventions":["SIM0508 Tablets","SIM0508 in combination with olaparib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, first-in-human study to evaluate the safety,efficacy, and PK/PD characteristics of SIM0508 as a single agent and in combination with olaparib in participants with locally advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06686745"},{"nctId":"NCT07095478","title":"Safety and Efficacy of Oral Artesunate for Pre-cervical Cancer","sponsor":"Metanoic Health Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["CIN 2/3"],"interventions":["Artesunate"],"countries":["Malaysia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"NeoART-CIN is a Phase II clinical study evaluating the safety and effectiveness of oral artesunate in patients with pre-cancerous cervical intra-epithelial neoplasia (CIN2/3), to investigate if a course of treatment with oral artesunate can reverse pre-cancerous changes in the cervix and prevent the development and progression of invasive cancer. Findings from this study will increase our understanding of the effects of artesunate on CIN2/3 and if confirmatory inform future clinical studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07095478"},{"nctId":"NCT07066098","title":"A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":201,"enrollmentType":"ESTIMATED","startDate":"2025-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Pancreatic Cancer"],"interventions":["IBI343","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received at least 2 Prior Lines of Therapy. The primary objective of this study is to determine Overall Survival (OS) of IBI343 plus best supportive care (BSC) compared with placebo plus BSC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07066098"},{"nctId":"NCT06418061","title":"Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2025-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Unresectable","Locally Advanced or Metastatic Solid Tumors"],"interventions":["IBI3005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.","sourceUrl":"https://clinicaltrials.gov/study/NCT06418061"},{"nctId":"NCT06775483","title":"Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-01-17","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2025-01-15","conditions":["Advanced Non-small Cell Lung Cancer"],"interventions":["JSKN016","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.The study is divided into two parts. The main objective of part I is to assess the efficacy and safety of JSKN016 in selected subjects with advanced non-small cell lung cancer. The main objective of part II is to compare the efficacy of JSKN016 and docetaxel in subjects with advanced non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06775483"},{"nctId":"NCT07646626","title":"SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Locally Advanced (Unresectable) or Metastatic Solid Tumors"],"interventions":["SSGJ-705","SSGJ-612","SSGJ-705 combined with chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Plus SSGJ-612 ± Chemotherapy in patients with advanced HER2-Expressing Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07646626"},{"nctId":"NCT03967977","title":"Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma","sponsor":"BeiGene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":420,"enrollmentType":"ACTUAL","startDate":"2019-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-21","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Urothelial Carcinoma"],"interventions":["Tislelizumab","Placebo","Cisplatin","Gemcitabine Hydrochloride","Carboplatin"],"countries":["China","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":46,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab + either cisplatin or carboplatin + gemcitabine versus placebo+ either cisplatin or carboplatin + gemcitabine in approximately 420 participants with locally advanced or metastatic urothelial carcinoma who have not received prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT03967977"},{"nctId":"NCT06993844","title":"Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors","sponsor":"Ensem Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":233,"enrollmentType":"ESTIMATED","startDate":"2025-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Solid Tumors","Advanced Breast Cancer"],"interventions":["ETX-636 dose escalation","ETX-636 dose escalation in combination with fulvestrant","ETX-636 dose expansion in combination with fulvestrant"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06993844"},{"nctId":"NCT05458219","title":"A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":470,"enrollmentType":"ESTIMATED","startDate":"2022-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Locally Advanced Unresectable or Metastatic Solid Tumors"],"interventions":["IBI343","FOLFIRINOX/mFOLFIRINOX","mFOLFOX"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ia/Ib, multicenter, open-label, first-in-human study to evaluate the safety, tolerability, PK, and efficacy of IBI343 in participants with locally advanced unresectable or metastatic solid tumors. It is planned to be carried out in different countries or regions such as China, Australia and US. There are three parts in phase Ia. Part 1 includes dose escalation and expansion phase and part 2 is designed for dose optimization for IBI343 monotherapy. Part 3 1L G/GEJ AC and 1L PDAC cohorts will include an initial safety lead-in stage to confirm the tolerability of IBI343 in combination with chemotherapy in 1L PDAC and G/GEJ AC, followed by a randomized dose-optimization stage des","sourceUrl":"https://clinicaltrials.gov/study/NCT05458219"},{"nctId":"NCT06383767","title":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":378,"enrollmentType":"ESTIMATED","startDate":"2024-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2025-06-19","conditions":["Metastatic Breast Cancer"],"interventions":["ESG401","Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06383767"},{"nctId":"NCT04686305","title":"Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":304,"enrollmentType":"ESTIMATED","startDate":"2021-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer"],"interventions":["T-DXd","Durvalumab","Cisplatin","Carboplatin","Pemetrexed","Volrustomig","Rilvegostomig"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Israel","Italy","Malaysia","Netherlands","Philippines","Poland","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":91,"serviceSignals":["HER2 profiling"],"summary":"DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.","sourceUrl":"https://clinicaltrials.gov/study/NCT04686305"},{"nctId":"NCT05739981","title":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","sponsor":"Imunon","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["Paclitaxel","Carboplatin","Bevacizumab","IMNN-001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT05739981"},{"nctId":"NCT03960840","title":"Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":217,"enrollmentType":"ACTUAL","startDate":"2019-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Diffuse Large B-cell Lymphoma","Acute Lymphoblastic Leukemia","Large B-cell Lymphoma"],"interventions":["Rapcabtagene autoleucel single agent","Ibrutinib"],"countries":["United States","Australia","Austria","France","Germany","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and as single agent in diffuse large B-cell lymphoma (3L+ DLBCL), adult acute lymphoblastic leukemia (ALL) and 1st Line High Risk Large B-Cell Lymphoma (1L HR LBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT03960840"},{"nctId":"NCT04988555","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","sponsor":"Sumitomo Pharma America, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":606,"enrollmentType":"ESTIMATED","startDate":"2022-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Leukemia, Myeloid, Acute","Leukemia, Lymphocytic, Acute","Multiple Myeloma","Myelodysplastic Syndromes"],"interventions":["Enzomenib","azoles","Venetoclax","Gilteritinib","Azacitidine (AZA)","Intensive chemotherapy with 7 + 3"],"countries":["United States","Belgium","Canada","France","Italy","Japan","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":104,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT04988555"},{"nctId":"NCT04140500","title":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":170,"enrollmentType":"ACTUAL","startDate":"2019-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Solid Tumors","Metastatic Melanoma","Non-small Cell Lung Cancer","Esophageal Squamous Cell Carcinoma"],"interventions":["RO7247669"],"countries":["Denmark","Georgia","Israel","Mexico","Singapore","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluate preliminary anti-tumor activity in participants with solid tumors. An expansion part of the study is planned to enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RP2D o","sourceUrl":"https://clinicaltrials.gov/study/NCT04140500"},{"nctId":"NCT06365840","title":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","sponsor":"ImmuneOncia Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["TMB-H","Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors"],"interventions":["IMC-001"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06365840"},{"nctId":"NCT07308106","title":"A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Non-small Lung Cancer"],"interventions":["SKB571 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of the study to evaluate the safety and efficacy of SKB571 for injection as monotherapy in patients with locally advanced or metastatic Non-Small Cell Lung Cancer with MET abnormalities. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT07308106"},{"nctId":"NCT04550260","title":"Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":640,"enrollmentType":"ACTUAL","startDate":"2020-10-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["Durvalumab","Placebo","cisplatin + fluorouracil","cisplatin + capecitabine","Radiation"],"countries":["United States","Belgium","Brazil","Canada","China","France","Japan","Mexico","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":133,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study to assess the efficacy and safety of durvalumab administered concurrently with dCRT in patients with locally advanced, unresectable esophageal squamous cell carcinoma (ESCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04550260"},{"nctId":"NCT06155396","title":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer","sponsor":"RemeGen Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-02-28","conditions":["Cervical Cancer"],"interventions":["Disitamab Vedotin","Zimberelimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab Injection for the Treatment ,at least first-line platinum-containing standard therapy failed in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06155396"},{"nctId":"NCT05920356","title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2023-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-29","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["Sotorasib","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Latvia","Malaysia","Mexico","Netherlands","Peru","Poland","Portugal","Puerto Rico","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":407,"serviceSignals":["RAS genotyping"],"summary":"The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05920356"},{"nctId":"NCT05651022","title":"Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors","sponsor":"Indaptus Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Solid Tumor, Adult","HCC - Hepatocellular Carcinoma","CRC (Colorectal Cancer)","Pancreatic Adenocarcinoma","NSCLC Non-small Cell Lung Cancer","Squamous Cell Cancer of the Head and Neck","UC (Urothelial Cancer)","MSI-H Cancer"],"interventions":["Decoy20","Tislelizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["MSI / TMB"],"summary":"INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05651022"},{"nctId":"NCT07260058","title":"Immune Cell Therapy for Advanced Solid Tumors","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-02","conditions":["Lung Cancer (Locally Advanced or Metastatic)","Liver Cancer (Locally Advanced or Metastatic)","Colorectal Cancer (Locally Advanced or Metastatic)","Breast Cancer (Locally Advanced or Metastatic)","Advanced Solid Tumors"],"interventions":["Autologous immune Cells","Standard chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The autologous immune cell induction technology used in this project involves transforming peripheral blood mononuclear cells (PBMC) into autologous DC cells, NK cells, CIK cells and other immune cells through cytokine induction, and then re-administering them to the patients. This therapy utilizes biotechnology to culture the immune cells of cancer patients in vitro and then re-infuse them back into the body, stimulating and enhancing the body's own immune function, killing and inhibiting cancer cells, eliminating small and residual lesions, or achieving the goal of treating cancer by significantly inhibiting the proliferation of residual cancer cells.","sourceUrl":"https://clinicaltrials.gov/study/NCT07260058"},{"nctId":"NCT07150663","title":"Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2025-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Non-small Cell Lung Cancer"],"interventions":["Nano-crystalline Megestrol Acetate Oral Suspension","Standard Therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a prospective, randomized, parallel-controlled clinical trial, primarily aimed at evaluating the efficacy and safety of Nanocrystalline Megestrol Acetate combined with standard therapy, compared with placebo combined with standard therapy, in improving appetite and body weight during concurrent chemoradiotherapy for patients with locally advanced non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07150663"},{"nctId":"NCT05522868","title":"SB17170 Phase 1 Clinical Trial in Solid Tumors","sponsor":"SPARK Biopharma","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2022-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Solid Tumor"],"interventions":["SB17170"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"Phase 1 Open-label, multicenter, dose escalation, dose expansion study","sourceUrl":"https://clinicaltrials.gov/study/NCT05522868"},{"nctId":"NCT07612137","title":"Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":282,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Solid Tumor"],"interventions":["IBI3005","Sintilimab","Bevacizumab biosimilar","Limertinib","Osimertinib","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07612137"},{"nctId":"NCT06636435","title":"A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer","sponsor":"Chiome Bioscience Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2020-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Solid Tumors","Hepatocellular Carcinoma (HCC)","Malignant Melanoma","Pediatric Cancer"],"interventions":["CBA-1205 Part 1","CBA-1205 Part 2","CBA-1205 Part 3","CBA-1205 Part 4","CBA-1205 Part 5"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5). The purpose of this FIH study is to evaluate the safety and tolerability profile of CBA-1205.","sourceUrl":"https://clinicaltrials.gov/study/NCT06636435"},{"nctId":"NCT06792695","title":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-29","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Metastatic Colorectal Cancer"],"interventions":["Volrustomig","FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)","Bevacizumab"],"countries":["United States","Australia","Canada","China","France","Germany","Italy","Netherlands","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":76,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06792695"},{"nctId":"NCT05030506","title":"A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2021-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-06-30","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Renal Cell Carcinoma"],"interventions":["Belzutifan","Pembrolizumab","Lenvatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles, and preliminary efficacy of belzutifan as monotherapy followed by belzutifan+lenvatinib combination therapy, as well as belzutifan combined with lenvatinib and pembrolizumab in China participants with advanced renal cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05030506"},{"nctId":"NCT05862012","title":"Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)","sponsor":"Ichnos Sciences SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["ISB 2001"],"countries":["United States","Australia","France","India","Italy","Norway","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT05862012"},{"nctId":"NCT03887273","title":"Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis","sponsor":"Q Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2022-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Transverse Myelitis"],"interventions":["Q-Cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects with Transverse Myelitis. For each of the dose levels, transplantation of Q-Cells® unilaterally into spinal cord demyelinated lesions will be evaluated. Subjects will be blinded to side of treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT03887273"},{"nctId":"NCT06859762","title":"A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Advanced Solid Tumor"],"interventions":["YL217"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06859762"},{"nctId":"NCT07362459","title":"A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.","sponsor":"Sinocelltech Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":246,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Non-Small Cell Lung Carcinoma (NSCLC)"],"interventions":["SCTB14","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase III, randomized, double-blind study compares the efficacy and safety of SCTB14 versus pembrolizumab as first-line treatment in patients with driver gene-negative, TPS ≥10% locally advanced or metastatic non-small cell lung cancer (NSCLC). The primary objective is to assess superiority of SCTB14 over pembrolizumab in prolonging progression-free survival. Safety will be closely monitored.","sourceUrl":"https://clinicaltrials.gov/study/NCT07362459"},{"nctId":"NCT07061639","title":"A Study of QLS5133 Monotherapy in Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":212,"enrollmentType":"ESTIMATED","startDate":"2025-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Advanced Solid Tumors"],"interventions":["QLS5133"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The phase 1/2 clinical study includes three stages: Phase 1 dose escalation, phase 1 PK expansion and phase 2 cohort expansion： * Phase 1: Assesse safety, tolerability, PK, immunogenicity and preliminary efficacy of QLS5133 in advanced solid tumors. Phase 1 dose escalation will use ATD + BOIN, the maximum sample size for each dose group is 12. For Phase 1 PK expansion, 1 to 4 appropriate doses will be selected. After the DLT observation period in the selected dose group up to 12 subjects (including those subjects in the dose escalation stage) can be further enrolled for PK expansion. * Phase 2: Evaluates QLS5133's anti-tumor efficacy in subjects with advanced solid tumors. at least 2 dose gr","sourceUrl":"https://clinicaltrials.gov/study/NCT07061639"},{"nctId":"NCT06417554","title":"A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2024-12-31","conditions":["Advanced Solid Tumors"],"interventions":["SHR-A2102","SHR-A2102 ; Adebrelimab injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06417554"},{"nctId":"NCT06999187","title":"A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas","sponsor":"Dren Bio","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Triple Negative Breast Cancer","HER2-negative Breast Cancer","Non Small Cell Lung Cancer","Cervical Cancer","Castrate Resistant Prostate Cancer","Pancreatic Ductal Adenocarcinoma","Head-and-neck Squamous Cell Carcinoma","Endometrial Cancer","Ovarian Cancer","Gastric Cancer","Gastroesophageal-junction Cancer","Urothelial Carcinoma"],"interventions":["DR-0202"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["HER2 profiling"],"summary":"A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas","sourceUrl":"https://clinicaltrials.gov/study/NCT06999187"},{"nctId":"NCT05519449","title":"Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)","sponsor":"Janux Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":272,"enrollmentType":"ESTIMATED","startDate":"2022-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Castration Resistant Prostatic Cancer"],"interventions":["JANX007","Darolutamide"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05519449"},{"nctId":"NCT06419621","title":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","sponsor":"Biotheus Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2024-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Triple Negative Breast Cancer(TNBC)"],"interventions":["PM8002","Nab-Paclitaxel","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"This multicenter, randomized, double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally advanced/metastatic triple-negative breast cancer(TNBC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06419621"},{"nctId":"NCT07216560","title":"First-in-human Study of 7MW4911 in GI Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["GI Cancers"],"interventions":["7MW4911"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07216560"},{"nctId":"NCT07259590","title":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2025-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-12-02","conditions":["Advanced Solid Tumors Cancer","PDAC","CRC (Colorectal Cancer)"],"interventions":["GFH375"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase Ib/II clinical study aimed at exploring the safety and efficacy of Regimen A (GFH375 in combination with Cetuximab) and Regimen B (GFH375 in combination with AG) in participants with solid tumors.Phase Ib: To evaluate the safety/tolerability and pharmacokinetic (PK) characteristics of GFH375 in combination with cetuximab or AG in participants with solid tumors, and to explore the efficacy of the combination therapy. Phase II: To evaluate the efficacy, safety/tolerability and PK characteristics of the combination therapy, and to explore the correlation between bio-marker and clinical efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07259590"},{"nctId":"NCT05595460","title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","sponsor":"RayzeBio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ACTUAL","startDate":"2022-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["SCLC,Extensive Stage"],"interventions":["RYZ101 Dose Level 1","RYZ101 Dose Level 2","RYZ101 Dose Level 3","RYZ101 Dose Level -1","Atezolizumab","Carboplatin","Etoposide"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05595460"},{"nctId":"NCT06253663","title":"Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","sponsor":"Kite, A Gilead Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ACTUAL","startDate":"2024-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Relapsed/Refractory Mantle Cell Lymphoma","Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia"],"interventions":["KTE-X19","Cyclophosphamide","Fludarabine"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical study is to learn more about KTE-X19, and how safe and effective it is in adult Japanese participants with relapsed/refractory (r/r) Mantle Cell Lymphoma (MCL) or r/r B-precursor Acute Lymphoblastic Leukemia (B-ALL). The primary objectives of this study are to evaluate the efficacy of KTE-X19, as measured by: * Objective response rate (ORR) per investigator assessment, in adult Japanese participants with r/r MCL * Overall complete remission (OCR) defined as complete remission (CR) and complete remission with incomplete hematologic recovery (CRi) per investigator assessment, in adult Japanese participants with r/r ALL","sourceUrl":"https://clinicaltrials.gov/study/NCT06253663"},{"nctId":"NCT05735080","title":"Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer","sponsor":"Incyclix Bio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2023-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Breast Cancer","Breast Cancer Metastatic","Hormone Receptor Positive Tumor","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Ovarian Cancer","CCNE1 Amplification","Solid Tumor","Advanced Cancer","Metastatic Cancer"],"interventions":["INX-315","Fulvestrant","Abemaciclib"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HER2 profiling"],"summary":"Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 in patients with recurrent advanced/metastatic cancer, including hormone receptor positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) regimen, and CCNE1-amplified solid tumors who progressed on standard of care treatment. The study will be conducted in 3 parts: Part A (INX-315 monotherapy do","sourceUrl":"https://clinicaltrials.gov/study/NCT05735080"},{"nctId":"NCT05005403","title":"Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":694,"enrollmentType":"ESTIMATED","startDate":"2021-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Non-Small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Micro Satellite Stable Colorectal Cancer","Gastric/Esophageal Cancer","High-Grade Serous Ovarian Cancer","Pancreatic Cancer","Triple Negative Breast Cancer"],"interventions":["Azirkitug","Budigalimab","Bevacizumab","Telisotuzumab Adizutecan"],"countries":["United States","Canada","Israel","Japan","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC,","sourceUrl":"https://clinicaltrials.gov/study/NCT05005403"},{"nctId":"NCT07639047","title":"An Initial Evaluation of AN8025 in Solid Tumors","sponsor":"Adlai Nortye Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":91,"enrollmentType":"ESTIMATED","startDate":"2025-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Advanced Solid Tumor (Phase 1)"],"interventions":["AN8025 is a multifunctional antibody fusion protein"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"The goal of this clinical trial is to determine the appropriate dose of AN8025 for use in the treatment of advanced solid tumors. This study will be conducted in in adults \\>18 years of age. The main questions to answer: 1. Determine which dose level of AN8025 is safe and tolerability in participants with advanced solid tumors 2. To determine the maximum tolerated of AN8025 for future testing. Participants will visit their study site in 3 week cycles, during which they will be under go treatment with AN8025 and visit their clinical site during each cycle for check ups and testing.","sourceUrl":"https://clinicaltrials.gov/study/NCT07639047"},{"nctId":"NCT06281847","title":"An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia","sponsor":"Advesya SAS","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":143,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2041-08","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"interventions":["CCTx-001"],"countries":["France","Germany","Spain","Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this adaptive Phase 1/2 study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antileukemic activity of CCTx-001 in adult patients with r/r Acute Myeloid Leukemia (AML). CCTx-001 targets IL-1RAP, which is specifically expressed in leukemic cells. In preclinical studies, IL-1RAP-targeted Chimeric antigen receptors (CARs) have demonstrated encouraging activity in both in vitro and in vivo experiments in AML models. Based on these promising preclinical results, it is expected that CCTx-001 could potentially alter the natural course of r/r AML and provide a potential novel treatment option.","sourceUrl":"https://clinicaltrials.gov/study/NCT06281847"},{"nctId":"NCT06291220","title":"A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":4,"enrollmentType":"ACTUAL","startDate":"2025-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Obinutuzumab","ABBV-453"],"countries":["United States","Australia","Germany","Israel","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adverse events, pharmacokinetics, and change in disease activity will be assessed. ABBV-453 is an investigational drug for the treatment of CLL and SLL. Participants will be enrolled with a specific target dose and receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the appropriate target dose is achieved. Approximately 60 adult participants with previously R/R CLL/SLL will be enrolled in the study in approxi","sourceUrl":"https://clinicaltrials.gov/study/NCT06291220"},{"nctId":"NCT06956690","title":"A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors","sponsor":"Hummingbird Bioscience","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Melanoma (Skin)","Non Small Cell Lung Cancer","Breast Cancer"],"interventions":["ENV-501"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalat","sourceUrl":"https://clinicaltrials.gov/study/NCT06956690"},{"nctId":"NCT07071337","title":"A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2031-02","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Metastatic Breast Cancer"],"interventions":["SKB264","Nab-paclitaxel","Paclitaxel","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07071337"},{"nctId":"NCT07265622","title":"First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Solid Tumors"],"interventions":["7MW4911"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is the first-in-human study of 7MW4911 in Chinese patients, to investigate its prelimary safety and efficacy in patients with Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07265622"},{"nctId":"NCT04196257","title":"BP1001-A in Patients With Advanced or Recurrent Solid Tumors","sponsor":"Bio-Path Holdings, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2022-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-03-07","conditions":["Solid Tumor, Adult","Carcinoma, Ovarian Epithelial","Fallopian Tube Neoplasms","Endometrial Cancer","Peritoneal Cancer","Solid Tumor"],"interventions":["BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)","BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.","sourceUrl":"https://clinicaltrials.gov/study/NCT04196257"},{"nctId":"NCT07100730","title":"Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Neoplastic Disease","Glioblastoma","Glioblastoma (GBM)","Glioblastoma Multiform","Glioblastoma Multiforme, Adult","Glioblastoma Multiforme (GBM) WHO Grade IV"],"interventions":["TLX-101-Tx + Lomustine","TLX101-Tx"],"countries":["Australia","Austria","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.","sourceUrl":"https://clinicaltrials.gov/study/NCT07100730"},{"nctId":"NCT05880706","title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":198,"enrollmentType":"ACTUAL","startDate":"2023-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-09-19","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","Osimertinib Mesylate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase II clinical study to evaluate the efficacy and safety of BL-B01D1 for injection and BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05880706"},{"nctId":"NCT05970497","title":"A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors","sponsor":"Krystal Biotech, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2023-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-07","completionType":"ESTIMATED","lastUpdated":"2025-05-18","conditions":["Cancer","Melanoma Stage III","Melanoma Stage IV","Cutaneous Melanoma"],"interventions":["KB707","Opdualag","KEYTRUDA ®( Pembrolizumab)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"KB707-01 is a Phase 1/2, open-label, multicenter, dose escalation and expansion study. The study will evaluate the safety and tolerability of KB707 in adults with locally advanced or metastatic solid tumors who have progressed on standard of care therapy, cannot tolerate standard of care therapy, refused standard of care therapy, or for whom there is no standard of care therapy as well as the safety, tolerability, preliminary efficacy, and immunologic effect of KB707 administered in combination with Opdualag to subjects with unresectable or metastatic melanoma. Subjects in dose escalation (Cohorts 1 through 3) and dose expansion (Cohort 4) will receive intratumoral injections of KB707 approx","sourceUrl":"https://clinicaltrials.gov/study/NCT05970497"},{"nctId":"NCT06730347","title":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","sponsor":"MacroGenics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Platinum-resistant Ovarian Cancer","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Clear Cell Adenocarcinoma of Ovary","Clear Cell Adenocarcinoma of Vulva","Clear Cell Adenocarcinoma of Vagina","Clear Cell Adenocarcinoma of Cervix","Clear Cell Adenocarcinoma of Uterus","Clear Cell Adenocarcinoma of Fallopian Tube","Clear Cell Adenocarcinoma of Peritoneum","Endometrial Cancer"],"interventions":["Lorigerlimab"],"countries":["United States","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be ","sourceUrl":"https://clinicaltrials.gov/study/NCT06730347"},{"nctId":"NCT05579366","title":"Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":884,"enrollmentType":"ESTIMATED","startDate":"2022-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["High Grade Epithelial Ovarian Cancer","High Grade Serous Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer","Endometrial Cancer","Non-small Cell Lung Cancer","Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)","Mesothelioma","Breast Adenocarcinoma","Triple Negative Breast Cancer","Hormone Receptor-positive/Her2 Negative Breast Cancer","Platinum-resistant Ovarian Cancer (PROC)","Platinum Sensitive Ovarian Cancer (PSOC)","Primary Refractory Ovarian Cancer","Uterine Cancer"],"interventions":["Rina-S","Carboplatin","Bevacizumab","Pembrolizumab"],"countries":["United States","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":66,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).","sourceUrl":"https://clinicaltrials.gov/study/NCT05579366"},{"nctId":"NCT06752811","title":"Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2025-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Pancreatic Cancer Metastatic"],"interventions":["paclitaxel polymeric micelles for injection","Gemcitabine Hydrochloride for Injection","Paclitaxel for Injection (albumin bound )"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine.","sourceUrl":"https://clinicaltrials.gov/study/NCT06752811"},{"nctId":"NCT07640425","title":"Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture","sponsor":"CONNEXT","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-25","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Dupuytren Contracture","Dupuytren Disease of Finger"],"interventions":["[Step1] CNT201 First-dose","[Step1] CNT201 Low-dose","[Step1] CNT201 Intermediate-dose","[Step1] CNT201 High-dose","[Step2] CNT201","[Step2] Placebo"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a multicenter, Phase 1/2, study to assess the safety, tolerability, efficacy, PK, and immunogenicity of CNT201 in adult participants with DC (Dupuytren's Contracture).","sourceUrl":"https://clinicaltrials.gov/study/NCT07640425"},{"nctId":"NCT05966194","title":"RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer","sponsor":"EpicentRx, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2024-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Oral Mucositis"],"interventions":["RRx-001","Intensity Modulated Radiation Therapy (IMRT)","Cisplatin for injection 100 mg/m2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers. All patients in this study will receive 7 weeks of standard of care radiation therapy given with the chemotherapy agent, cisplatin. Patients will receive RRx-001 or placebo before start of standard of care treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05966194"},{"nctId":"NCT06234904","title":"Study of IBR733 Cell Injection in Acute Myeloid Leukemia","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2024-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Acute Myeloid Leukemia"],"interventions":["IBR733 Cell Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label clinical study: phase Ia is the dose-escalation part, and phase Ib is the dose-expansion part. The phase Ia study is to evaluate the safety, tolerability, recommended phase II dose, pharmacokinetics, immunogenicity and preliminary efficacy of IBR733 cell injection in relapsed/refractory acute myeloid leukemia (AML).","sourceUrl":"https://clinicaltrials.gov/study/NCT06234904"},{"nctId":"NCT06277804","title":"A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor","sponsor":"Letolab","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2024-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2024-02-26","conditions":["Adult Solid Tumor"],"interventions":["LTC004 in Combination With Cyclophosphamide and Fludarabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This was a multicenter, open PHASE I study of LTC004 in Combination With Cyclophosphamide and Fludarabine in Patients With Advanced/Metastatic Malignancies Tumor, the study design consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib expansion). The objective of this study was to evaluate combination safety, tolerability, pharmacokinetic,pharmacodynamics characteristics, and initial efficacy in advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06277804"},{"nctId":"NCT06428500","title":"QTX3046 in Patients With KRAS G12D Mutations","sponsor":"Quanta Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["Advanced Solid Tumor"],"interventions":["QTX3046","Cetuximab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["RAS genotyping"],"summary":"Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06428500"},{"nctId":"NCT07136779","title":"First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies","sponsor":"VelaVigo Bio Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Participants With Advanced Solid Tumor Malignancies"],"interventions":["VBC101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC101.","sourceUrl":"https://clinicaltrials.gov/study/NCT07136779"},{"nctId":"NCT04419532","title":"A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2020-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-01","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Solid Tumor","Advanced Cancer","Metastatic Solid Tumor"],"interventions":["DS-1055a"],"countries":["United States","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability of DS-1055a in participants with relapsed or refractory locally advanced or metastatic solid tumors for which no standard treatment is available.","sourceUrl":"https://clinicaltrials.gov/study/NCT04419532"},{"nctId":"NCT05954091","title":"OH2 Administered by Intratumoral Injection","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":29,"enrollmentType":"ESTIMATED","startDate":"2025-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-01","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Solid Tumor"],"interventions":["OH2 Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary efficacy of intratumoral injection of OH2 in patients with locally advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05954091"},{"nctId":"NCT07004296","title":"A Study of HDM2005 in Patients With Advanced Solid Tumor","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2025-06-08","conditions":["Advanced Solid Tumors"],"interventions":["HDM2005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a study evaluating the efficacy, safety, and pharmacokinetics ofHDM2005 in participants with metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07004296"},{"nctId":"NCT04227847","title":"A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2020-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-03","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Myelodysplastic Syndrome","Acute Myeloid Leukemia"],"interventions":["SEA-CD70","azacitidine","Venetoclax"],"countries":["United States","Japan","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Hematology NGS"],"summary":"This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or \"parts.\" * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat partici","sourceUrl":"https://clinicaltrials.gov/study/NCT04227847"},{"nctId":"NCT06211036","title":"Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":563,"enrollmentType":"ACTUAL","startDate":"2024-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Extensive-Stage Small-Cell Lung Cancer","Small-Cell Lung Cancer"],"interventions":["Tarlatamab","Durvalumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":219,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06211036"},{"nctId":"NCT07726342","title":"SMP-656 for HER2-Positive Advanced Breast Cancer","sponsor":"Chengdu SciMount Pharmatech Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-07-16","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-07","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-20","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["HER2-positive Breast Cancer","Metastatic Breast Cancer","Locally Advanced Breast Cancer (LABC)"],"interventions":["SMP-656 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also evaluate the safety of SMP-656 and identify the optimal dose for future trials. The main questions it aims to answer are: What is the objective tumor response rate (DOR, PFS, DCR, OS) of two different dose regimens of intravenous SMP-656? What are the side effects and safety risks of these two SMP-656 dose regimens? Which dose level achieves the best balance of anti-cancer activity and tolerability? This is a randomi","sourceUrl":"https://clinicaltrials.gov/study/NCT07726342"},{"nctId":"NCT06212076","title":"Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients","sponsor":"Nanjing Immunophage Biotech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-09","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Solid Tumor"],"interventions":["IPG1094"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).","sourceUrl":"https://clinicaltrials.gov/study/NCT06212076"},{"nctId":"NCT06312176","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1200,"enrollmentType":"ESTIMATED","startDate":"2024-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Breast Neoplasms"],"interventions":["Sacituzumab tirumotecan","Pembrolizumab","Paclitaxel","Nab-paclitaxel","Capecitabine","Liposomal doxorubicin"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Colombia","Costa Rica","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Peru","Philippines","Poland","Portugal","Puerto Rico","Romania","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":259,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06312176"},{"nctId":"NCT06460961","title":"A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2024-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-13","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Neoplasm Metastasis"],"interventions":["MK-6837","Pembrolizumab","Rescue Medications"],"countries":["United States","Australia","Canada","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06460961"},{"nctId":"NCT05370430","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","sponsor":"PeproMene Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2022-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-13","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-13","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma"],"interventions":["BAFFR-CAR T cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)","sourceUrl":"https://clinicaltrials.gov/study/NCT05370430"},{"nctId":"NCT06205706","title":"BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors","sponsor":"BioInvent International AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":35,"enrollmentType":"ACTUAL","startDate":"2023-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-07","completionType":"ESTIMATED","lastUpdated":"2025-09-19","conditions":["Solid Tumors","Non Small Cell Lung Cancer","Hepatocellular Carcinoma"],"interventions":["BI-1910","Pembrolizumab"],"countries":["Denmark","Germany","Spain","Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1910 * what is maximum tolerated or administrated dose * to determine recommended dose for further clinical trials Participants will receive infusions of BI-1910 alone or combination with pembrolizumab every 3 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT06205706"},{"nctId":"NCT05057494","title":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":607,"enrollmentType":"ACTUAL","startDate":"2022-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-10","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"],"interventions":["Acalabrutinib","Venetoclax","Obinutuzumab"],"countries":["United States","Australia","Czechia","France","Hungary","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05057494"},{"nctId":"NCT06618001","title":"A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":64,"enrollmentType":"ACTUAL","startDate":"2025-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Leukemia, Myeloid, Acute","Myelodysplastic Neoplasms"],"interventions":["JNJ-89853413"],"countries":["Canada","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The purpose of Part 1 (Dose Escalation) of the study is to assess the safety and tolerability, and to identify the recommended Phase 2 dose\\[s\\] (RP2D\\[s\\]) in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) (that is a type of blood cancer that has come back after treatment/or has stopped responding to treatment) or R/R higher-risk type of myelodysplastic neoplasms (MDS, type of blood cancer). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS.","sourceUrl":"https://clinicaltrials.gov/study/NCT06618001"},{"nctId":"NCT06220201","title":"A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-15","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Multiple Sclerosis","Myasthenia Gravis"],"interventions":["CC-97540","Fludarabine","Cyclophosphamide"],"countries":["United States","Belgium","France","Germany","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).","sourceUrl":"https://clinicaltrials.gov/study/NCT06220201"},{"nctId":"NCT06533761","title":"Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML","sponsor":"Stelexis BioSciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-15","completionType":"ESTIMATED","lastUpdated":"2025-10-22","conditions":["AML, Adult","MDS"],"interventions":["Eganelisib","Eganelisib in combination with cytarabine"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b open-label, multicenter, dose-escalation and dose-optimization study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor efficacy of eganelisib as monotherapy and in combination with cytarabine in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) or r/r higher-risk myelodysplastic syndromes (HR-MDS). The study consists of 2 parts: * Part 1: Dose Escalation (DE) in both monotherapy and in combination. * Part 2: Dose Optimization","sourceUrl":"https://clinicaltrials.gov/study/NCT06533761"},{"nctId":"NCT06005493","title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2023-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-16","completionType":"ESTIMATED","lastUpdated":"2026-02-24","conditions":["Gastric Cancer","Gastro-esophageal Junction Cancer","Pancreatic Ductal Adenocarcinoma","Esophageal Adenocarcinoma"],"interventions":["AZD5863"],"countries":["United States","China","France","Japan","Netherlands","South Korea","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":25,"serviceSignals":["ADC biomarker"],"summary":"This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06005493"},{"nctId":"NCT07070518","title":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","sponsor":"GV20 Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2025-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-16","completionType":"ESTIMATED","lastUpdated":"2025-12-03","conditions":["Solid Tumor Cancer","Adult Refractory Cancer","Endometrial Carcinoma (EC)","Squamous Head and Neck Carcinoma","pMMR/MSS Adenocarcinoma of the Colon or Rectum","Non-Small Cell Lung Cancer","Melanoma","HCC - Hepatocellular Carcinoma","Small Cell Lung Cancer"],"interventions":["GV20-0251"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT07070518"},{"nctId":"NCT07047118","title":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":138,"enrollmentType":"ACTUAL","startDate":"2025-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-14","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Prostatic Cancer, Castration-Resistant"],"interventions":["JSB462","AAA617"],"countries":["United States","Australia","Austria","Canada","China","Czechia","France","Germany","Israel","Italy","Netherlands","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"This Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT07047118"},{"nctId":"NCT07161414","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-19","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-24","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Solid Tumors"],"interventions":["IV Rilvegostomig","Recombinant Human Hyaluronidase (rHu)","SC Rilvegostomig","SC rilvegostomig + rHu"],"countries":["United States","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.","sourceUrl":"https://clinicaltrials.gov/study/NCT07161414"},{"nctId":"NCT06496568","title":"A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-21","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-21","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["PIK3CA-Mutated Cancers"],"interventions":["Inavolisib","Atezolizumab"],"countries":["United States","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the safety and efficacy of inavolisib as a single-agent and in combination with atezolizumab in participants with phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA)-mutated cancers, including previously treated head and neck squamous cell carcinoma (HNSCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06496568"},{"nctId":"NCT07062965","title":"A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-22","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-04","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Breast Cancer"],"interventions":["PF-07248144","Fulvestrant","Everolimus","Exemestane"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Finland","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":202,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spr","sourceUrl":"https://clinicaltrials.gov/study/NCT07062965"},{"nctId":"NCT05238922","title":"Study of INCB123667 in Subjects With Advanced Solid Tumors","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":291,"enrollmentType":"ACTUAL","startDate":"2022-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Solid Tumors"],"interventions":["INCB0123667","Palbociclib","Bevacizumab","Olaparib","Paclitaxel","Ribociclib","Fulvestrant"],"countries":["United States","France","Italy","Japan","Netherlands","Puerto Rico","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).","sourceUrl":"https://clinicaltrials.gov/study/NCT05238922"},{"nctId":"NCT06103864","title":"A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":625,"enrollmentType":"ESTIMATED","startDate":"2023-11-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Breast Cancer"],"interventions":["Dato-DXd","Durvalumab","Paclitaxel","Nab-paclitaxel","Gemcitabine","Carboplatin","Pembrolizumab"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","France","Germany","Hong Kong","India","Italy","Japan","Mexico","Philippines","Poland","Singapore","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":321,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06103864"},{"nctId":"NCT07358585","title":"A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2026-01-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-23","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Colon Cancer Adenocarcinoma"],"interventions":["HLX43 dose 1 + HLX07","HLX43 dose 2 + HLX07","HLX43 dose 3 + Serplulimab","HLX43 dose 4 + Serplulimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07358585"},{"nctId":"NCT06096779","title":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","sponsor":"Genentech, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":30,"enrollmentType":"ACTUAL","startDate":"2024-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Hepatocellular Carcinoma"],"interventions":["Atezolizumab","Bevacizumab"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT06096779"},{"nctId":"NCT06132828","title":"Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Zhejiang Doer Biologics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2023-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Solid Tumor"],"interventions":["DR30206"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to characterize the safety,tolerability, pharmacokinetics(PK),and preliminary anti-tumor activity of DR30206, in subjects with advanced or metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06132828"},{"nctId":"NCT06448754","title":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Non-small Cell Lung Cancer"],"interventions":["Volrustomig","Carboplatin","Pemetrexed","Ramucirumab","Paclitaxel"],"countries":["United States","Canada","China","France","Georgia","Greece","Italy","Malaysia","Portugal","Romania","Serbia","South Korea","Spain","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":77,"serviceSignals":["Broad CGP"],"summary":"Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06448754"},{"nctId":"NCT07232290","title":"Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Polycythemia Vera (PV)"],"interventions":["Flonoltinib 75mg","Flonoltinib 100mg","Flonoltinib 125mg","Extended Phase Dose Group"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial adopts an open, randomized, parallel controlled, multicenter clinical trial design planning to enroll patients with polycythemia vera who are resistant/intolerant to hydroxyurea or interferon。The study divided into two stages: dose exploration stage: three dose groups are tentatively set, with three subjects in each group, totaling nine subjects in each group; Dose extension stage: Based on the safety, efficacy, and pharmacokinetic results of the comprehensive dose exploration stage, 2-3 dose groups are planned to be selected for dose extension trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232290"},{"nctId":"NCT06465914","title":"A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":9000,"enrollmentType":"ACTUAL","startDate":"2024-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-30","completionType":"ESTIMATED","lastUpdated":"2024-12-12","conditions":["Genital Wart","Penile Cancer","Anal Cancer","PIN-1","PIN2","PIN3","AIN1","AIN2","AIN3","HPV-Related Carcinoma"],"interventions":["9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male subjects aged 18-45 years. The primary hypothesis in the study is the 9-valent HPV recombinant vaccine reduces the incidence of vaccine HPV types-related genital warts compared with placebo in Chinese men.","sourceUrl":"https://clinicaltrials.gov/study/NCT06465914"},{"nctId":"NCT07073833","title":"The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma","sponsor":"Imbioray (Hangzhou) Biomedicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Relapsed/Refractory B-cell Non-Hodgkin Lymphoma"],"interventions":["IBR900 cell injection","rituximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is an open label clinical study: Phase Ia is a dose escalation phase, evaluating the safety, tolerability, RP2D, PK characteristics, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory B-cell non Hodgkin lymphoma (NHL); Phase Ib is the dose expansion stage, which is divided into two parts: monotherapy expansion (queue 1) and combination expansion (queue 2). The monotherapy expansion part evaluates the safety, tolerability, and preliminary efficacy of IBR900 cell injection in the treatment of relapsed/refractory CD20 positive B-cell non Hodgkin lymphoma, while the combination expansion part evaluates the safety, tolerability, and preliminary efficacy","sourceUrl":"https://clinicaltrials.gov/study/NCT07073833"},{"nctId":"NCT07122063","title":"Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":266,"enrollmentType":"ESTIMATED","startDate":"2025-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Advanced Solid Tumors"],"interventions":["SYS6045"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is the first-in-human (Phase I/II) trial of SYS6045, a multicenter, open-label, dose-escalation and dose-expansion clinical study. It aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of SYS6045 in patients with HER2-positive, expressing, or mutated advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07122063"},{"nctId":"NCT07280377","title":"A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab","sponsor":"Oncolytics Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2021-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Anal Cancer Metastatic","Squamous Cell Carcinoma of the Anus Stage Unspecified","Pancreatic Cancer Metastatic","Unresectable Pancreatic Carcinoma"],"interventions":["Pelareorep","Atezolizumab","Gemcitabine and nab-paclitaxel","Trifluridine Tipiracil","mFOLFIRINOX Treatment Regimen"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate \\[ORR; Cohorts 1,2, 4,and 5\\] and disease control rate \\[DCR; Cohort 3\\]) in patients with advanced or metastatic gastrointestinal (GI) tumors. Cohorts 1-4 are not randomized; however, Cohort 5 is comprised of two treatment arms to which patients are randomized in a 1:1 ratio.","sourceUrl":"https://clinicaltrials.gov/study/NCT07280377"},{"nctId":"NCT04524871","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":518,"enrollmentType":"ESTIMATED","startDate":"2020-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Advanced Liver Cancers"],"interventions":["Atezolizumab","Bevacizumab 15 mg/kg","Tiragolumab","Tocilizumab","TPST-1120","Tobemstomig 2100 mg","Bevacizumab 10 mg/kg","Tobemstomig 600 mg","Tobemstomig 1200 mg","ADG126","IO-108 1800 mg","NKT2152","IO-108 1200 mg"],"countries":["United States","China","France","Israel","New Zealand","South Korea","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several t","sourceUrl":"https://clinicaltrials.gov/study/NCT04524871"},{"nctId":"NCT06756932","title":"BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Hormone-receptor-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer"],"interventions":["BGB-21447","Fulvestrant","BGB-43395"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["HER2 profiling","Hematology NGS"],"summary":"This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06756932"},{"nctId":"NCT05794906","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","sponsor":"Bayer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":985,"enrollmentType":"ACTUAL","startDate":"2023-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-29","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Biochemically Recurrent Prostate Cancer"],"interventions":["Darolutamide (BAY1841788, Nubeqa)","Placebo matching darolutamide","ADT"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Hungary","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":226,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker of prostate cancer cells activity. The PSA increase means that the cancer has come back even though conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bone scans does not show any lesion of prostate cancer. Recently a more sensitive imaging method called prostate-specific membrane antigen \\[PSMA\\] positron emission tomography \\[PET\\]) /computed tomogra","sourceUrl":"https://clinicaltrials.gov/study/NCT05794906"},{"nctId":"NCT05878691","title":"A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.","sponsor":"Glenmark Specialty S.A.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2022-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2024-07-22","conditions":["Advanced Solid Tumor","Lymphoma"],"interventions":["GRC 54276","GRC 54276 + Pembrolizumab","GRC 54276 + Atezolizumab"],"countries":["United States","India"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or atezolizumab in participants with advanced solid tumors and lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05878691"},{"nctId":"NCT06635824","title":"Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":191,"enrollmentType":"ACTUAL","startDate":"2024-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC"],"interventions":["Acasunlimab","Pembrolizumab","Docetaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Croatia","Estonia","France","Germany","Greece","Hungary","Ireland","Italy","Japan","Netherlands","Poland","Portugal","Puerto Rico","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":247,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06635824"},{"nctId":"NCT03040973","title":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":29,"enrollmentType":"ACTUAL","startDate":"2017-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Advanced Solid Tumors Which Are cMET-dependent"],"interventions":["Capmatinib","Nazartinib","Gefitinib","Osimertinib"],"countries":["United States","Belgium","Canada","China","Denmark","France","Germany","Italy","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study","sourceUrl":"https://clinicaltrials.gov/study/NCT03040973"},{"nctId":"NCT07249892","title":"A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases","sponsor":"Chengdu Syncor Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":195,"enrollmentType":"ESTIMATED","startDate":"2025-11-19","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-06","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Metastatic Solid Tumors"],"interventions":["BPR-6023021 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of BPR-6023021 in subjects with advanced solid tumors with bone metastases","sourceUrl":"https://clinicaltrials.gov/study/NCT07249892"},{"nctId":"NCT07503808","title":"A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types","sponsor":"IDEAYA Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Esophageal Squamous Cell Carcinoma","High Grade Serous Ovarian Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Cancer","Castration-resistant Prostate Cancer","Non Small Cell Lung Cancer","Endometrium Cancer","Triple Negative Breast Cancer"],"interventions":["IDE034"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.","sourceUrl":"https://clinicaltrials.gov/study/NCT07503808"},{"nctId":"NCT07080619","title":"SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers","sponsor":"Tianjin ConjuStar Biologics Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-09-20","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["TNBC - Triple-Negative Breast Cancer","HR+ Breast Cancer"],"interventions":["SC-101"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.","sourceUrl":"https://clinicaltrials.gov/study/NCT07080619"},{"nctId":"NCT05503888","title":"Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2022-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-30","completionType":"ESTIMATED","lastUpdated":"2022-08-17","conditions":["Relapsed or Advanced Non-small Cell Lung Cancer"],"interventions":["Almonertinib combined with SHR-1701","Almonertinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the first-line treatment of relapsed or advanced NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT05503888"},{"nctId":"NCT05455320","title":"A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":864,"enrollmentType":"ACTUAL","startDate":"2022-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-25","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Multiple Myeloma"],"interventions":["Talquetamab","Daratumumab","Pomalidomide","Dexamethasone"],"countries":["United States","Belgium","Brazil","China","Czechia","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":216,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).","sourceUrl":"https://clinicaltrials.gov/study/NCT05455320"},{"nctId":"NCT03332797","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":181,"enrollmentType":"ACTUAL","startDate":"2017-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Breast Cancer"],"interventions":["GDC-9545","Palbociclib","LHRH Agonist"],"countries":["United States","Australia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and/or luteinizing hormone-releasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 \\[HER2\\]-negative) breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03332797"},{"nctId":"NCT07054190","title":"A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-28","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Breast Cancer"],"interventions":["Inavolisib","Ribociclib","Letrozole"],"countries":["United States","Argentina","Brazil","Canada","Germany","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer (BC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07054190"},{"nctId":"NCT06459973","title":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2024-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-31","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Advanced Solid Tumors"],"interventions":["intravenous (IV) infusion"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":43,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06459973"},{"nctId":"NCT05207670","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","sponsor":"Genentech, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":320,"enrollmentType":"ACTUAL","startDate":"2022-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Non-Hodgkin Lymphoma"],"interventions":["Mosunetuzumab (Cohorts A-C)","Mosunetuzumab (Cohorts D-E)","Tocilizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-Hodgkin's lymphoma \\[NHL\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT05207670"},{"nctId":"NCT03854110","title":"A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine","sponsor":"Persevere Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2019-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Ovarian Cancer"],"interventions":["misetionamide (also known as GP-2250)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cancer (PROC) into Part 2 of the study. Part 1 of the study evaluating misetionamide in combination with gemcitabine in subjects with advanced pancreatic cancer previously treated with 5-fluorouracil-based chemotherapy completed enrolment.","sourceUrl":"https://clinicaltrials.gov/study/NCT03854110"},{"nctId":"NCT06484777","title":"A Clinical Study of SHR-9539 in Patients With Multiple Myeloma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Multiple Myeloma"],"interventions":["SHR-9539 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in patients with multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06484777"},{"nctId":"NCT03067051","title":"Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System","sponsor":"SpectraCure AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2017-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Recurrent Prostate Cancer"],"interventions":["Verteporfin","SpectraCure P18 System"],"countries":["United States","Canada","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT03067051"},{"nctId":"NCT07362940","title":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","sponsor":"Henan Genuine Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Non-Small Cell Lung Cancer"],"interventions":["GEN-725 tablets + Dositinib mesylate tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is an open-label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GEN-725 in combination with Dositinib in participants with locally advanced or metastatic EGFR-mutant non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07362940"},{"nctId":"NCT06908304","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","sponsor":"Maia Biotechnology","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Carcinoma, Non-Small -Cell Lung"],"interventions":["6-Thio-2'-Deoxyguanosine","Cemiplimab","Docetaxel","Vinorelbine","Gemcitabine alone"],"countries":["Poland","Romania","Taiwan","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or ","sourceUrl":"https://clinicaltrials.gov/study/NCT06908304"},{"nctId":"NCT05927571","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-08-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["Cevostamab","Elranatamab","Tocilizumab"],"countries":["Australia","Israel","South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT05927571"},{"nctId":"NCT06763965","title":"Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-07-31","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Recurrent High-grade Glioma"],"interventions":["BioTTT001 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, dose-escalation and dose-expanding Phase Ⅰb/Ⅱ clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in patients with recurrent/progressive high-grade glioma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06763965"},{"nctId":"NCT06815575","title":"A Safety and Pharmacokinetics Study of RC220 Combined With Doxorubicin in Adult Participants With Solid Tumours.","sponsor":"Racura Oncology Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":53,"enrollmentType":"ESTIMATED","startDate":"2025-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Solid Tumours","Advanced Solid Tumours"],"interventions":["RC220","Doxorubicin (Adriamycin)"],"countries":["Australia","Hong Kong","South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a multi-centre, two-part, open-label, phase 1, first in human study of multiple ascending doses of RC220 bisantrene formulation alone and in combination with fixed dose doxorubicin to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) in adult patients with locally advanced unresectable or metastatic solid tumours where doxorubicin may be considered as a treatment option / or is indicated. The study will consist of two parts: Part 1 - This part involves a fixed-dose doxorubicin (60 mg/m2) tolerability lead-in period, followed by dose-escalating doses of IV RC220 alone, and in combination, with fixed dose doxorubicin, to determine the maximum tolerated com","sourceUrl":"https://clinicaltrials.gov/study/NCT06815575"},{"nctId":"NCT07029399","title":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","sponsor":"NiKang Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":361,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["HR+ Breast Cancer","Triple Negative Breast Cancer (TNBC)","CCNE1 Amplified Advanced Solid Tumors","HR+ HER2- Breast Cancer"],"interventions":["NKT5097 CDK2/CDK4 dual degrader","Fulvestrant","Letrozole"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HER2 profiling"],"summary":"The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2, for both monotherapy and in combination with ET * What medical issues/symptoms do participants experience when taking NKT5097 as monotherapy as well as in combination with ET","sourceUrl":"https://clinicaltrials.gov/study/NCT07029399"},{"nctId":"NCT06736327","title":"A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumors"],"interventions":["SKB500"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, PK profile, immunogenicity, and antitumor activity of SKB500 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06736327"},{"nctId":"NCT07080216","title":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Cervical Cancer"],"interventions":["ZG005","Gecacitinib","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07080216"},{"nctId":"NCT06962267","title":"A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-05-08","conditions":["Pancreatic Cancer"],"interventions":["TQB2916 Injection","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial was a single-arm, open-label design to evaluate the efficacy and safety of \"TQB2916+ gemcitabine + albumin-paclitaxel\" as the first-line treatment for metastatic pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06962267"},{"nctId":"NCT06771219","title":"SLV-154 Treatment of Advanced Cancers","sponsor":"Solve Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Advanced Cancer","Advanced Solid Tumor","Metastatic Cancer"],"interventions":["SLV-154"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06771219"},{"nctId":"NCT06057038","title":"A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors","sponsor":"Genmab","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":8,"enrollmentType":"ACTUAL","startDate":"2023-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Malignant Solid Tumor"],"interventions":["GEN1042","Pembrolizumab","Cisplatin","Carboplatin","5-Fluorouracil"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants. The main purpose is to assess the safety and tolerability of GEN1042 monotherapy or GEN1042 in combination in Japanese study participants with cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06057038"},{"nctId":"NCT06240728","title":"A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2","sponsor":"NextPoint Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-06-27","conditions":["Metastatic Malignant Neoplasm"],"interventions":["NPX887"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"NPX887 is a human, antagonistic immunoglobulin G1 (IgG1) monoclonal antibody targeting B7-H7 (HHLA2) that may potentiate an anti-tumor immune response. The goal of this first-in-human study is to learn whether NPX887 is safe and tolerable and shows a preliminary efficacy in participants with B7-H7 (HHLA2) expressing tumors at selected dose(s). The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? * what is the preliminary anti-tumor activities? Participants who are treated will receive an intravenous (IV) infusion of NPX887 if their disease has not progressed, and be closely monitored by the treati","sourceUrl":"https://clinicaltrials.gov/study/NCT06240728"},{"nctId":"NCT07730190","title":"A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":151,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Malignancies"],"interventions":["TQB6426 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"TQB6426 is a glypican-3 (GPC3)-targeted antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Preclinical studies have demonstrated its potent anti-tumor activity coupled with a favorable therapeutic safety window, which provides sufficient pharmacological and toxicological evidence to support the initiation of human clinical trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07730190"},{"nctId":"NCT06885281","title":"A Study of ZL-1310 in Participants With Selected Solid Tumors","sponsor":"Zai Lab (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":166,"enrollmentType":"ESTIMATED","startDate":"2025-05-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Solid Tumors"],"interventions":["ZL-1310"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06885281"},{"nctId":"NCT07723482","title":"ML-016 in Advanced Cancer With Lung and/or Liver Involvement","sponsor":"BrYet US, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumor With Lung and/or Liver Involvement"],"interventions":["ML-016"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).","sourceUrl":"https://clinicaltrials.gov/study/NCT07723482"},{"nctId":"NCT07129252","title":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","sponsor":"Crinetics Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["SST2-positive Neuroendocrine Neoplasms","Neuroendocrine Tumors","Neuroendocrine Neoplasm"],"interventions":["CRN09682"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT07129252"},{"nctId":"NCT06116136","title":"A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.","sponsor":"Servier Bio-Innovation LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":48,"enrollmentType":"ACTUAL","startDate":"2024-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["MSI-H/dMMR Gastroesophageal-junction Cancer","MSI-H/dMMR Gastric Cancer"],"interventions":["S095029","pembrolizumab 200 mg (KEYTRUDA ®)"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Denmark","France","Hungary","Italy","Japan","Puerto Rico","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":49,"serviceSignals":["MSI / TMB"],"summary":"This study will investigate the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) in combination with pembrolizumab in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT06116136"},{"nctId":"NCT06064877","title":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","sponsor":"AVEO Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Metastatic Head-and-neck Squamous-cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma"],"interventions":["Ficlatuzumab","Cetuximab","Placebo"],"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","France","Germany","Hungary","Italy","Netherlands","Poland","Romania","Serbia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":112,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.","sourceUrl":"https://clinicaltrials.gov/study/NCT06064877"},{"nctId":"NCT07357519","title":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","sponsor":"Lantheus Medical Imaging","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2026-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2032-05","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Relapsed / Refractory Osteosarcoma"],"interventions":["LNTH2403 Phase 1 dose","Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D)."],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07357519"},{"nctId":"NCT07444541","title":"ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer","sponsor":"Anova Innovation Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Pancreatic Cancer"],"interventions":["ANO31905","Nanoparticle Albumin-Bound Paclitaxel","Gemcitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07444541"},{"nctId":"NCT07483684","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":142,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["HER2 IHC3+ Advanced Colorectal Cancer"],"interventions":["TQB2102 Injection","Trifluridine /Tipiracil (TAS-102) tablets / Fruquintinib / Regorafenib tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":48,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III, randomized, open-label, active-controlled, multicenter study designed to evaluate the efficacy and safety of Injection TQB2102 compared with investigator's choice of treatment in subjects with Human Epidermal Growth Factor Receptor 2 (HER2) ImmunoHistoChemistry score 3 (IHC3+) advanced colorectal cancer who have failed prior treatment with oxaliplatin, irinotecan, and fluoropyrimidine-based regimens. The primary endpoint of this study is progression-free survival (PFS) as assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). Other secondary endpoints include investigator-assessed PFS, objective response rate (ORR), durati","sourceUrl":"https://clinicaltrials.gov/study/NCT07483684"},{"nctId":"NCT06699771","title":"Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies","sponsor":"GC Cell Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":53,"enrollmentType":"ESTIMATED","startDate":"2025-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Lymphoma, T-Cell"],"interventions":["GCC2005","Cyclophosphamide","Fludarabine"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lines of therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06699771"},{"nctId":"NCT07552077","title":"A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)","sponsor":"Palvella Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Angiokeratomas"],"interventions":["PTX-022"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and effectiveness of the experimental drug PTX-022 in the treatment of angiokeratomas","sourceUrl":"https://clinicaltrials.gov/study/NCT07552077"},{"nctId":"NCT07637734","title":"Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3)","sponsor":"Verrica Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Common Warts","Common Warts (Verruca Vulgaris)","Human Papilloma Virus (HPV)","Warts"],"interventions":["VP-102 (US) / TO-208 (Japan)","Vehicle (US) / Vehicle (Japan)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-302; referred to as COVE-3 \\[Cantharidin and Occlusion in Verruca Epithelium\\]) to evaluate the efficacy and safety of YCANTH (VP-102/TO-208) treatment in subjects with common warts.","sourceUrl":"https://clinicaltrials.gov/study/NCT07637734"},{"nctId":"NCT07002203","title":"Personalized Neoantigen Peptide Vaccines for Solid Tumors","sponsor":"Seqker Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2024-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Solid Tumors","Advanced Cancer","Recurrent Cancer","Neoantigen-Specific Immunotherapy","Personalized Cancer Vaccine"],"interventions":["Personalized Neoantigen Peptide Vaccine"],"countries":["Thailand"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is to help the patient's immune system recognize and attack their cancer. The study will enroll adult patients (20 years or older) who have solid tumors that meet specific stage-related criteria. These include advanced cancers that are resistant to prior treatments and early-stage cancers at high risk of recurrence, where there are no standard adjuvant therapies available. Participants will receive: * A personalized ne","sourceUrl":"https://clinicaltrials.gov/study/NCT07002203"},{"nctId":"NCT06590961","title":"UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies","sponsor":"Ubix Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Relapsed/Refractory B-cell Malignancies"],"interventions":["UBX-303061"],"countries":["United States","Poland","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06590961"},{"nctId":"NCT07566585","title":"Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation","sponsor":"BlueSphere Bio, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":19,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["AML - Acute Myeloid Leukemia","AML With Mutated NPM1","AML, Adult Recurrent"],"interventions":["SOC+ BSB-2002","SOC+BSB-2002"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07566585"},{"nctId":"NCT06614192","title":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":74,"enrollmentType":"ACTUAL","startDate":"2024-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Metastatic Colorectal Cancer"],"interventions":["Telisotuzumab Adizutecan"],"countries":["United States","Australia","Israel","Japan","Puerto Rico","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["MET profiling"],"summary":"Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab adizutecan in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants are put into treatment arms and each treatment arm receives a different dose of telisotuzumab adizutecan. Up to approximately 60 adult participants with c-Met protein above cutoff level refractory mCRC, will be enrolled in the study at approximate","sourceUrl":"https://clinicaltrials.gov/study/NCT06614192"},{"nctId":"NCT06727812","title":"Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":206,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Solid Tumors"],"interventions":["HRS-6208"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06727812"},{"nctId":"NCT07114315","title":"A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Pancreatic Cancer"],"interventions":["AK112","AK130"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center phase II clinical study consisting of two parts: Part I: To evaluate the safety and efficacy of AK130 combined with AK112 in advanced pancreatic cancer. Part II: To evaluate the safety and efficacy of AK112, either as monotherapy or in combination with AK130, in advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07114315"},{"nctId":"NCT06234397","title":"Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors","sponsor":"Hanmi Pharmaceutical Company Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":245,"enrollmentType":"ESTIMATED","startDate":"2023-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["BH3120","pembrolizumab"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation part is planned to establish the MTD or RD for Dose-Expansion part, while Dose-Expansion part is designed to assess potential efficacy of BH3120, as a single agent and in combination with pembrolizumab, when administered at the RD to subjects in indication-specific expansion cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT06234397"},{"nctId":"NCT05607420","title":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","sponsor":"Cellectis S.A.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2022-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2025-08-24","conditions":["B-cell Non-Hodgkin Lymphoma (B-NHL)"],"interventions":["UCART20x22","CLLS52"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT05607420"},{"nctId":"NCT06917079","title":"BBO-11818 in Adult Subjects With KRAS Mutant Cancer","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":665,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Non-Small Cell Lung Cancer","NSCLC","PDAC - Pancreatic Ductal Adenocarcinoma","CRC (Colorectal Cancer)","Metastatic Non-Small Lung Cell Cancer","Metastatic Colorectal Cancer (CRC)","KRAS G12A","KRAS G12C","KRAS G12D","KRAS G12S","KRAS G12V","Metastatic Pancreatic Ductal Adenocarcinoma","Advanced Lung Carcinoma","Solid Tumor, Adult"],"interventions":["BBO-11818","Pembrolizumab","Platinum chemotherapy (cisplatin or carboplatin)","Pemetrexed","Cetuximab","mFOLFOX6","BBO-10203","mFOLFIRINOX","Gemcitabine","Nab-paclitaxel"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["RAS genotyping"],"summary":"A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06917079"},{"nctId":"NCT05901285","title":"Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors","sponsor":"Vaxiion Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Advanced Solid Tumor","Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab"],"interventions":["VAX014","Nivolumab or pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of this research study is to evaluate the safety, tolerability and activity of VAX014 for intratumoral injections (VAX014) as a single agent as well as in combination with Investigator's choice of nivolumab or pembrolizumab in patients with advanced solid tumors. VAX014 is a targeted oncolytic agent designed to kill tumor cells following intratumoral injection into advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05901285"},{"nctId":"NCT06464991","title":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-07-20","conditions":["Multiple Myeloma"],"interventions":["Equecabtagene Autoleucel Injection","Daratumumab","Pomalidomide","Bortezomib","Dexamethasone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, randomized, controlled, open-label, phase III clinical study to evaluate the efficacy of Equecabtagene Autoleucel Injection versus standard therapy in subjects with lenalidomid-refractory RRMM who have received 1-2 lines of prior therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06464991"},{"nctId":"NCT03844048","title":"An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":165,"enrollmentType":"ACTUAL","startDate":"2019-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-08","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Chronic Lymphocytic Leukemia","Acute Myeloid Leukemia","Multiple Myeloma","Non-Hodgkin's Lymphoma","Acute Lymphoblastic Leukemia","Cancer"],"interventions":["Venetoclax"],"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Greece","Hong Kong","Ireland","Japan","Mexico","New Zealand","Poland","Portugal","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT03844048"},{"nctId":"NCT07087054","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","sponsor":"Crinetics Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":141,"enrollmentType":"ESTIMATED","startDate":"2025-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Carcinoid Syndrome","Carcinoid","Carcinoid Tumor","Carcinoid Tumor of Ileum","Carcinoid Tumor of Cecum","Carcinoid Tumor of Liver","Carcinoid Tumor of Pancreas","Carcinoid Syndrome Diarrhea","Carcinoid Intestine Tumor"],"interventions":["Paltusotine","Placebo"],"countries":["United States","Argentina","Brazil","Chile","Colombia","France","Germany","Italy","Mexico","Poland","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome.","sourceUrl":"https://clinicaltrials.gov/study/NCT07087054"},{"nctId":"NCT05081609","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","sponsor":"Ascendis Pharma Oncology Division A/S","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":320,"enrollmentType":"ACTUAL","startDate":"2022-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-02-24","conditions":["Advanced Solid Tumor","Locally Advanced Solid Tumor","Metastatic Solid Tumor","Platinum-resistant Ovarian Cancer","Post Anti-PD-1 Melanoma","2L+ Cervical Cancer","Neoadjuvant Melanoma","Neoadjuvant Non-Small Cell Lung Cancer","Post Anti-PD-(L)1 Non-Small Cell Lung Cancer","Post Anti-PD-(L)1 Small Cell Lung Cancer","Third Line or Later (3L+) HER2+ Breast Cancer","Second or Third Line (2L/3L) Cervical Cancer","Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)"],"interventions":["TransCon IL-2 β/γ","Pembrolizumab","Chemotherapy drug","TransCon TLR7/8 Agonist","Surgery","Trastuzumab","Trastuzumab emtansine (T-DM1)"],"countries":["United States","Australia","Belgium","Canada","Italy","Poland","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["HER2 profiling"],"summary":"TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05081609"},{"nctId":"NCT07701486","title":"A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer","sponsor":"Theriva Biologics SL","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2026-08-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Pancreas Cancer, Metastatic","Pancreas Cancer, Stage IV","Ductal Adenocarcinoma of the Pancreas"],"interventions":["VCN-01 oncolytic adenovirus (zabilugene almadenorepvec)","Nab-paclitaxel + Gemcitabine"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer. Participants will receive three planned doses of VCN-01, given once every 56 days. Each dose of VCN-01 is followed one week later by two cycles of standard chem","sourceUrl":"https://clinicaltrials.gov/study/NCT07701486"},{"nctId":"NCT06804824","title":"A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors","sponsor":"Vividion Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-01","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Advanced Solid Tumors"],"interventions":["VVD-159642","Sotorasib","Trametinib"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping","HER2 profiling"],"summary":"A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06804824"},{"nctId":"NCT06868199","title":"A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-01","completionType":"ESTIMATED","lastUpdated":"2025-09-12","conditions":["Advanced Solid Tumours"],"interventions":["LM-168","Toripalimab"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours. For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT06868199"},{"nctId":"NCT07481383","title":"A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer","sponsor":"Continuity Biosciences, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Pancreatic Adenocarcinoma Non-resectable"],"interventions":["ACT Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is being done to find out if delivering gemcitabine using the ACT-IOP-003 device directly to the area where the tumor is in the pancreas is safe and tolerable. The main questions the study aims to answer are: * Is ACT-IOP-003 safe and tolerable when given to patients with nonmetastatic, locally advanced, nonresectable pancreatic cancer. * How much study drug (gemcitabine) is found in the blood before and after treatment. * If the tumor responds to treatment. * If the gemcitabine side effects are less than seen when delivered intravenously (IV). Study participants will: * Have the study device surgically placed on the pancreas at the beginning of the study. * Complete 8 weeks of tr","sourceUrl":"https://clinicaltrials.gov/study/NCT07481383"},{"nctId":"NCT07747506","title":"Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)","sponsor":"Verastem, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":2,"enrollmentType":"ESTIMATED","startDate":"2026-08-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Low Grade Ovarian Serous Adenocarcinoma","Ovarian Cancer"],"interventions":["avutometinib + defactininb combination"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["RAS genotyping"],"summary":"This Open-Label Extension (OLE) study provides participants with recurrent low-grade serous ovarian cancer (LGSOC) who have completed the VS-6766-201(RAMP-201) study continued, uninterrupted access to avutometinib in combination with defactinib. The study is designed to support patients in France with access to avutometinib and defactinib who maintain ongoing clinical benefit while collecting safety and tolerability data during extended treatment. Participation is restricted to patients transferring directly from VS-6766-201(RAMP-201), ensuring continuity of care without enrollment of new patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07747506"},{"nctId":"NCT05862324","title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","sponsor":"Triumvira Immunologics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":113,"enrollmentType":"ESTIMATED","startDate":"2023-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-01","completionType":"ESTIMATED","lastUpdated":"2025-02-14","conditions":["Metastatic Solid Tumor"],"interventions":["TAC01-CLDN18.2"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2. TAC directs T-cells to the targeted antigen (CLDN 18.2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase ½ study that aims to establish safety, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), pharmacokinetic profile and efficacy of TAC01-CLDN18.2.","sourceUrl":"https://clinicaltrials.gov/study/NCT05862324"},{"nctId":"NCT06505395","title":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2024-08-26","conditions":["Gastrointestinal Neuroendocrine Pancreatic Tumor"],"interventions":["SYHX2008 injection","Sandostatin LAR@"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the effectiveness, safety, pharmacokinetics (PK) of SYHX2008 vs Octreotide Microspheres (Sandostatin LAR@) in patients with advanced, well-differentiated GEP-NET.","sourceUrl":"https://clinicaltrials.gov/study/NCT06505395"},{"nctId":"NCT05120349","title":"A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":390,"enrollmentType":"ACTUAL","startDate":"2022-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-02","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Osimertinib","Placebo"],"countries":["United States","Argentina","Brazil","Canada","China","Germany","Italy","Japan","Malaysia","Poland","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":139,"serviceSignals":["Broad CGP"],"summary":"This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.","sourceUrl":"https://clinicaltrials.gov/study/NCT05120349"},{"nctId":"NCT05538130","title":"A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2022-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-18","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Melanoma","Glioma","Thyroid Cancer","Non-Small Cell Lung Cancer","Malignant Neoplasms","Brain Neoplasms","Advanced or Metastatic Solid Tumors","HGG","LGG","Low Grade Glioma","High Grade Glioma","Differentiated Thyroid Cancer","NSCLC (Non-small Cell Lung Cancer)"],"interventions":["PF-07799544","PF-07799933"],"countries":["United States","Australia","Brazil","Canada","China","Israel","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":83,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two parts: PF-07799544 as a single agent (Phase 1a) and PF-07799544 in combination with another study medicine called PF-07799933 (Phase 1b). Phase 1a is no longer open for enrollment. In Phase1b (noted as \"this study\"), we are seeking participants who have: * a solid tumor which is metastatic or recurrent (excluding colorectal cancer) * tumor with the mutation (abnormal gene) called \"BRAF V600\" * received required prior treatment for cancer per cohort assigned. A","sourceUrl":"https://clinicaltrials.gov/study/NCT05538130"},{"nctId":"NCT06880549","title":"A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors","sponsor":"ModernaTX, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-03","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Advanced Solid Tumors"],"interventions":["mRNA-4106","Pembrolizumab","mRNA-4200"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06880549"},{"nctId":"NCT06188520","title":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":564,"enrollmentType":"ESTIMATED","startDate":"2023-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-04","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["ER+ HER2- Advanced Breast Cancer","High-grade Serous Ovarian Cancer (HGSOC)"],"interventions":["AZD8421","Camizestrant","Ribociclib","Palbociclib","Abemaciclib"],"countries":["United States","Australia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to evaluate AZD8421 alone and in combination with selected targeted anti-cancer drugs in patients with ER+HER2- advanced breast cancer, and patients with metastatic high-grade serious ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06188520"},{"nctId":"NCT02962414","title":"Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":206,"enrollmentType":"ACTUAL","startDate":"2017-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-13","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Tuberous Sclerosis Complex"],"interventions":["everolimus"],"countries":["United States","Australia","Belgium","Canada","Colombia","France","Hungary","Italy","Japan","Mexico","Poland","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be benefiting from continued treatment as judged by the investigator at the completion of EXIST-3","sourceUrl":"https://clinicaltrials.gov/study/NCT02962414"},{"nctId":"NCT05317416","title":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":854,"enrollmentType":"ACTUAL","startDate":"2022-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-31","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Lenalidomide"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Finland","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Netherlands","Norway","Poland","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":209,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be approximately five years","sourceUrl":"https://clinicaltrials.gov/study/NCT05317416"},{"nctId":"NCT07742527","title":"A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2026-10-16","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-18","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Multiple Myeloma"],"interventions":["Belantamab SC","Belantamab IV","Recombinant Human Hyaluronidase PH20 (rHuPH20)","Standard of care"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable eventual development of SC formulation. It will assess how much belantamab is absorbed and how long it stays in the blood as well as assess whether it is safe and tolerated well by participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07742527"},{"nctId":"NCT06651229","title":"A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2025-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-21","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Leukemia, Myeloid, Acute","Myelodysplastic Neoplasms"],"interventions":["JNJ-90189892","Azacitadine (AZA)","Venetoclax (VEN)"],"countries":["Australia","France","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose\\[s\\] \\[RP2Ds\\]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS \\[type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment\\]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommen","sourceUrl":"https://clinicaltrials.gov/study/NCT06651229"},{"nctId":"NCT06356129","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":850,"enrollmentType":"ESTIMATED","startDate":"2024-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-26","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Large B-cell Lymphoma"],"interventions":["Golcadomide","Placebo","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone"],"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","India","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","Puerto Rico","Romania","Saudi Arabia","Singapore","Slovakia","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":325,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06356129"},{"nctId":"NCT05916313","title":"A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Glioma"],"interventions":["BI 764532"],"countries":["United States","Austria","Germany","Netherlands","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bispecific). This may help the immune system fight cancer. Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, ","sourceUrl":"https://clinicaltrials.gov/study/NCT05916313"},{"nctId":"NCT07697339","title":"HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell Lymphoma","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-07-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Mantle Cell Lymphoma"],"interventions":["Phase Ib Cohort 1: HDM2005 1.2 mg/kg + R-Len","Rituximab plus lenalidomide","Phase Ib Cohort 2: HDM2005 1.4 mg/kg + R-Len","HDM2005 plus rituximab and lenalidomide"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a Phase Ib/III, multicenter, open-label clinical study of HDM2005 in combination with rituximab and lenalidomide in adult patients with relapsed or refractory mantle cell lymphoma. Mantle cell lymphoma is a type of non-Hodgkin lymphoma. Some patients have disease that comes back after treatment or does not respond well to available treatments. This study is designed to evaluate whether adding HDM2005 to rituximab and lenalidomide may provide clinical benefit for patients with relapsed or refractory mantle cell lymphoma who have previously received an anti-CD20 antibody-containing regimen and at least one Bruton's tyrosine kinase inhibitor. The study includes two parts. In the Phase I","sourceUrl":"https://clinicaltrials.gov/study/NCT07697339"},{"nctId":"NCT07486817","title":"Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab","sponsor":"Boehringer Ingelheim","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-25","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Lung Cancer, Non-squamous, Non-small Cell"],"interventions":["Zongertinib","Cisplatin","Carboplatin","Pemetrexed","Pembrolizumab"],"countries":["Australia","China","France","Germany","Japan","South Korea","Spain"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread. People who have a tumor with a HER2 mutation and have not received previous treatment for their lung cancer can participate in the study. The purpose of this study is to find out how well a medicine called zongertinib is tolerated in people with this type of lung cancer, when combined with chemotherapy, with or without pembrolizumab. Zongertinib works by targeting and blocking HER2, a protein involved in cancer cell growth. Participants are put into two groups randomly, which means by chance. One group gets zongertinib tablets combined wit","sourceUrl":"https://clinicaltrials.gov/study/NCT07486817"},{"nctId":"NCT07518043","title":"A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-13","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Esophageal and/or Cardia Cancer","Melanoma","Urothelial Carcinoma (UC)"],"interventions":["HLX18","OPDIVO®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety and immunogenicity of HLX18 and OPDIVO® in patients with resected esophageal or gastroesophageal junction cancer (EC/GEJC), melanoma (MEL), or urothelial carcinoma (UC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07518043"},{"nctId":"NCT05438329","title":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1123,"enrollmentType":"ESTIMATED","startDate":"2022-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-10","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Advanced Solid Tumor"],"interventions":["DB-1305/BNT325","Pembrolizumab","BNT327"],"countries":["United States","China","Puerto Rico"],"northAmerica":true,"chinaSites":true,"siteCount":93,"serviceSignals":["Broad CGP"],"summary":"This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05438329"},{"nctId":"NCT06868849","title":"A Study of JMT203 in Patients With Cancer Cachexia","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":307,"enrollmentType":"ESTIMATED","startDate":"2024-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-15","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Non Small Cell Lung Cancer","Pancreatic Cancer","Cancer Cachexia","Colorectal Cancer Cachexia","Pancreatic Cancer Cachexia"],"interventions":["JMT203 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia","sourceUrl":"https://clinicaltrials.gov/study/NCT06868849"},{"nctId":"NCT07698886","title":"Treatment of Recurrent Genital Warts by Combination of CO2 Laser and Geniwa Gel","sponsor":"KTH Biopharma","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-15","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["HPV (Human Papillomavirus)-Associated","Genital Warts"],"interventions":["Geniwa gel","Placebo gel"],"countries":["Vietnam"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase II, a randomized, double-blind, placebo-controlled clinical trial to evaluate the effectiveness and recurrence of genital warts by combination of CO2 laser and Geniwa gel compared to laser CO2 combined with gel placebo. The clinical trial is conducted at National Dermatology Hospital, Hanoi, Vietnam.","sourceUrl":"https://clinicaltrials.gov/study/NCT07698886"},{"nctId":"NCT05356741","title":"To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","sponsor":"Vir Biotechnology, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":645,"enrollmentType":"ESTIMATED","startDate":"2022-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-16","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Locally Advanced or Metastatic HER2-Expressing Cancers"],"interventions":["VIR-5818","pembrolizumab"],"countries":["Australia","France","Portugal","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["HER2 profiling"],"summary":"This first-in-human (FIH) Phase 1 open-label multicenter dose-escalation and dose-expansion study is designed to evaluate the safety, pharmacokinetics, and preliminary activity of VIR-5818 (Formerly AMX-818) as a single agent and in combination with pembrolizumab in participants with HER2+ tumors across multiple tumor types. The study will be conducted in four parts: * Part 1 (dose escalation): Single-agent VIR-5818 * Part 2 (dose escalation): VIR-5818 plus pembrolizumab * Part 3 (dose expansion): Single-agent VIR-5818 * Part 4 (dose expansion): VIR-5818 plus pembrolizumab The total length of the study, from screening of the first participant to the end of the study, is expected to be approx","sourceUrl":"https://clinicaltrials.gov/study/NCT05356741"},{"nctId":"NCT06106945","title":"AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":226,"enrollmentType":"ESTIMATED","startDate":"2023-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-16","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-16","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Multiple Myeloma"],"interventions":["AZD0305","Elranatamab","Pomalidomide","Dexamethasone"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Japan","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":43,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.","sourceUrl":"https://clinicaltrials.gov/study/NCT06106945"},{"nctId":"NCT07476326","title":"Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma","sponsor":"Biocon Biologics UK PLC","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-16","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Melanoma"],"interventions":["Bmab1700","Opdivo"],"countries":["Georgia","Romania","Serbia","South Africa","Spain","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to investigate the pharmacokinetics (PK) similarity of Bmab1700 (an intended nivolumab biosimilar), compared with United States (US)-licensed Opdivo, in participants after complete surgical removal of melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07476326"},{"nctId":"NCT06540144","title":"An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 3","phases":["PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-17","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-17","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Generalized Myasthenia Gravis"],"interventions":["rozanolixizumab"],"countries":["Italy","Japan","Poland","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.","sourceUrl":"https://clinicaltrials.gov/study/NCT06540144"},{"nctId":"NCT05498428","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2022-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-18","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-small-Cell Lung"],"interventions":["Amivantamab","Lazertinib","Carboplatin","Pemetrexed","Direct Oral Anticoagulant (DOAC)","Low Molecular Weight Heparin (LMWH)"],"countries":["United States","Brazil","China","France","Germany","Israel","Italy","Japan","Malaysia","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":110,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \\[SC-CF\\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).","sourceUrl":"https://clinicaltrials.gov/study/NCT05498428"},{"nctId":"NCT06550895","title":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":11,"enrollmentType":"ACTUAL","startDate":"2024-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-26","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Cilta-cel","Talquetamab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06550895"},{"nctId":"NCT07596784","title":"Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-27","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-27","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Generalized Myasthenia Gravis","gMG"],"interventions":["Ravulizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT07596784"},{"nctId":"NCT04199689","title":"Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6033,"enrollmentType":"ACTUAL","startDate":"2020-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-27","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2025-03-25","conditions":["Papillomavirus Infections"],"interventions":["9vHPV Vaccine","Placebo (Saline for Injection)"],"countries":["United States","Belgium","Brazil","Colombia","Czechia","France","Germany","Israel","Italy","Japan","Mexico","Peru","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":false,"siteCount":103,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9vHPV vaccine in men 20 to 45 years of age. The primary hypothesis tested after the primary database lock is that administration of a 3-dose regimen of 9vHPV vaccine will reduce the incidence of human papillomavirus (HPV) 16/18/31/33/45/52/58-related oral persistent infection (6 months or longer) compared with placebo. There will also be an Extension Study to offer an opportunity to complete the 3 dose regimen of 9vHPV vaccine for participants who received placebo in the Base Study, or received less than 3 doses of 9vHPV vaccine in the Base Study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04199689"},{"nctId":"NCT06465433","title":"Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab","sponsor":"Incyte Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2022-11-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-29","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["Hematologic Malignancies"],"interventions":["Tafasitamab"],"countries":["Hungary","Italy","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..","sourceUrl":"https://clinicaltrials.gov/study/NCT06465433"},{"nctId":"NCT06218914","title":"Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2024-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2043-11-18","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Non-small Cell Lung Cancer","Colorectal Carcinoma","Pancreatic Ductal Adenocarcinoma","Endometrial Cancer","Solid Tumor, Adult","KRAS G12D"],"interventions":["NT-112: Autologous, engineered T Cells targeting KRAS G12D","AZD0240: Autologous, engineered T Cells targeting KRAS G12D"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["RAS genotyping","HLA / TCR"],"summary":"Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06218914"},{"nctId":"NCT07283198","title":"A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-12-15","conditions":["Non Small Cell Lung Cancer (NSCLC)"],"interventions":["JSKN033 Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase II clinical study designed to evaluate the safety and efficacy of JSKN033 in the treatment of patients with advanced NSCLC. The study is divided into two phases: Part 1 (Dose Selection) and Part 2 (Cohort Expansion). Enrolled subjects are patients with locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative treatment. Part 1 (Dose Selection): It consists of two dose groups, with a maximum of 20 subjects enrolled in each group. Part 2 (Cohort Expansion): It consists of two cohorts, with a maximum of 60 subjects enrolled in each cohort.","sourceUrl":"https://clinicaltrials.gov/study/NCT07283198"},{"nctId":"NCT05205109","title":"A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors","sponsor":"Antengene Therapeutics Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2022-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2025-06-09","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["ATG-037","KEYTRUDA ®( Pembrolizumab)"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05205109"},{"nctId":"NCT07446322","title":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","sponsor":"Oncolytics Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Ras-mutated Metastatic Colorectal Cancer","mCRC","MSS Metastatic Colorectal Cancer"],"interventions":["Bevacizumab","FOLFIRI","Pelareorep"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["MSI / TMB"],"summary":"This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07446322"},{"nctId":"NCT07669779","title":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":348,"enrollmentType":"ESTIMATED","startDate":"2026-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Advanced Non Small Cell Lung Cancer (NSCLC)"],"interventions":["AK146D1 for injection","AK112 Injection","Platinum chemotherapy","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07669779"},{"nctId":"NCT07391670","title":"A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Solid Tumours"],"interventions":["SC durvalumab + rHu","IV durvalumab","Tremelimumab"],"countries":["Australia","Georgia","Poland","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).","sourceUrl":"https://clinicaltrials.gov/study/NCT07391670"},{"nctId":"NCT06805825","title":"A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit","sponsor":"Novelty Nobility, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2025-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["Gastrointestinal Stromal Tumors","Small-cell Lung Cancer","Adenoid Cystic Carcinoma","Uveal Melanoma","Neuroendocrine Tumors","Chromophobe Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma"],"interventions":["NN3201"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.","sourceUrl":"https://clinicaltrials.gov/study/NCT06805825"},{"nctId":"NCT07217704","title":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","sponsor":"SOFIE","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Esophageal Cancer","Gastric Cancer (GC)","Gastroesophageal Junction"],"interventions":["[18F]FAPI-74 PET/CT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \\[¹⁸F\\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junction or esophageal cancer. Following screening, using a standardized administration protocol and dose, participants will undergo \\[¹⁸F\\]FAPI-74 PET/CT screening. SOC procedures and interventions will be captured during 3 months +/-14 days post injection. The primary objective is to evaluate the sensitivity and specificity of such \\[¹⁸F\\]FAPI-74 PET/CT using a composite SOT panel. The maximum expected duration of the trial is approximately 24 months from firs","sourceUrl":"https://clinicaltrials.gov/study/NCT07217704"},{"nctId":"NCT07272642","title":"A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.","sponsor":"Radiopharm Theranostics, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Imaging","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Non-Small Cell Lung Cancer","Triple Negative Breast Cancer (TNBC)"],"interventions":["LNTH-2403"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor (TGF) - β-driven biomarker expressed on the cell membrane of cancer cells and/or cancer-associated fibroblasts 9CAFs) in select tumor types. Upon binding, LNTH-2403 is rapidly internalized, such that it can serve as a dual-purpose agent for both non-invasive imaging and radiotheranostic treatment of LRRC15- positive tumors. This first-in-human (FIH) imaging study will evaluate the safety and imaging of LNTH-2403 in participants with locally advanced or metastatic solid ","sourceUrl":"https://clinicaltrials.gov/study/NCT07272642"},{"nctId":"NCT06613009","title":"Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Small Cell Lung Cancer"],"interventions":["IBI3009"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.","sourceUrl":"https://clinicaltrials.gov/study/NCT06613009"},{"nctId":"NCT05984147","title":"A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)","sponsor":"Aurigene Discovery Technologies Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2023-10-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-30","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Relapsed Advanced Lymphomas"],"interventions":["AUR108"],"countries":["India"],"northAmerica":false,"chinaSites":false,"siteCount":27,"serviceSignals":["Hematology NGS"],"summary":"An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT05984147"},{"nctId":"NCT04891198","title":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2021-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Solid Tumor"],"interventions":["Envafolimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"An open, single-arm, multi-center Phase II clinical study of ENVAFOLIMAB single-agent treatment in patients with advanced solid tumors,to compare the overall response rate of TMB-high and TMB-Low,to determine the cut off value between TMB-high and TMB-Low of diagnosis device.Then,observe the efficacy of ENVAFOLIMAB uesd comfirmed TMB-H Value","sourceUrl":"https://clinicaltrials.gov/study/NCT04891198"},{"nctId":"NCT07557602","title":"mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults","sponsor":"Vaccine Company, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-05-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["EBV"],"interventions":["VXCO-102","Placebo"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07557602"},{"nctId":"NCT05818683","title":"A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-23","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Metastatic Castration-resistant Prostate Neoplasms","Metastatic Hormone-sensitive Prostate Cancer"],"interventions":["Pasritamig","Cetrelimab","Cabazitaxel","Docetaxel","Apalutamide","Enzalutamide","Darolutamide","Abiraterone acetate plus prednisone (AAP)","Lutetium Lu-177 vipivotide tetraxetan","JNJ-101556143"],"countries":["United States","Australia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT05818683"},{"nctId":"NCT07564466","title":"A Study of SKB571 in Participants With Gastrointestinal Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Gastrointestinal Tumors"],"interventions":["SKB571 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07564466"},{"nctId":"NCT07662720","title":"A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer","sponsor":"Glycyx Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)"],"interventions":["axelopran","Pembolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Axelopran is a peripherally acting mu-opioid receptor antagonist being developed to address opioid-induced immunodeficiency, a condition that may impair anti-tumor immune responses and reduce the effectiveness of immune checkpoint inhibitors. Many patients with advanced HNSCC require opioid analgesics for cancer-related pain management. Emerging evidence suggests that opioid signaling may suppress immune function and diminish the therapeutic activi","sourceUrl":"https://clinicaltrials.gov/study/NCT07662720"},{"nctId":"NCT05593094","title":"A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2020-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Advanced Solid Tumors","HER2-positive Breast Cancer"],"interventions":["ZN-A-1041","ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b","ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b","ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b","ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c","ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c","ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c"],"countries":["United States","Australia","France","Italy","New Zealand","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["HER2 profiling"],"summary":"This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).","sourceUrl":"https://clinicaltrials.gov/study/NCT05593094"},{"nctId":"NCT05079282","title":"Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":217,"enrollmentType":"ESTIMATED","startDate":"2021-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Relapsed or Refractory T Cell Lymphoma"],"interventions":["ONO-4685"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05079282"},{"nctId":"NCT06245330","title":"A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors","sponsor":"Ascentawits Pharmaceuticals, Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2022-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2024-02-07","conditions":["Solid Tumor","Pancreatic Cancer"],"interventions":["AST-001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.","sourceUrl":"https://clinicaltrials.gov/study/NCT06245330"},{"nctId":"NCT05850234","title":"AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2023-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-14","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["AZD0120"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05850234"},{"nctId":"NCT06806852","title":"A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":91,"enrollmentType":"ACTUAL","startDate":"2025-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["BI 770371","Pembrolizumab","Cetuximab"],"countries":["United States","Australia","Brazil","Bulgaria","France","Georgia","Germany","Hungary","Italy","Japan","Mexico","Moldova","Poland","Romania","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer. The tested medicines in this study are antibodies that act in different ways against cancer. BI 770371 and pembrolizumab may help the immune system fight cancer. Cetuximab blocks growth signals and may prevent the tumor from growing. Participants are put into 3 groups randomly. Each group receives a different combination of study medicines. All study medicines are given as an infusion into a vein at the study site. Participants can stay in the study as long as they benefit from treatment. Doctors ","sourceUrl":"https://clinicaltrials.gov/study/NCT06806852"},{"nctId":"NCT05969041","title":"Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors","sponsor":"Myeloid Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2024-01-18","conditions":["Epithelial Tumors, Malignant"],"interventions":["MT-302 (A)"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05969041"},{"nctId":"NCT07329322","title":"Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Sacituzumab Tirumotecan","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07329322"},{"nctId":"NCT07306624","title":"Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer","sponsor":"STCube, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2026-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Non Small Cell Lung Cancer"],"interventions":["Nelmastobart and Docetaxel"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07306624"},{"nctId":"NCT06566079","title":"Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors","sponsor":"InSilico Medicine Hong Kong Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Malignant Mesothelioma","Metastatic Malignant Solid Tumor","Advanced Solid Tumor"],"interventions":["ISM6331"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT06566079"},{"nctId":"NCT07292402","title":"JSKN022 in Subjects With Advanced Malignant Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2025-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Advanced Malignant Solid Tumors"],"interventions":["JSKN022"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.","sourceUrl":"https://clinicaltrials.gov/study/NCT07292402"},{"nctId":"NCT05277051","title":"First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":152,"enrollmentType":"ACTUAL","startDate":"2022-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Neoplasms"],"interventions":["Remzistotug","Dostarlimab","Belrestotug","Nelistotug","GSK5764227"],"countries":["United States","Australia","Canada","China","France","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.","sourceUrl":"https://clinicaltrials.gov/study/NCT05277051"},{"nctId":"NCT07413328","title":"HWS116 Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Wuhan Humanwell Innovative Drug Research and Development Center Limited Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2026-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Advanced Solid Tumors"],"interventions":["HWS116 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I open-label study that will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HWS116 monotherapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07413328"},{"nctId":"NCT05487391","title":"A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":632,"enrollmentType":"ESTIMATED","startDate":"2022-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-22","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["QL1706 injection","Vinorelbine Tartrate","Paclitaxel","Cisplatin","Carboplatin","Pemetrexed","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.","sourceUrl":"https://clinicaltrials.gov/study/NCT05487391"},{"nctId":"NCT05838768","title":"Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":123,"enrollmentType":"ACTUAL","startDate":"2023-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-08-31","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers"],"interventions":["HRO761","pembrolizumab","irinotecan"],"countries":["United States","Belgium","China","France","Germany","Israel","Italy","Japan","Norway","Singapore","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":28,"serviceSignals":["MSI / TMB"],"summary":"The main purpose of the study is to evaluate the safety and tolerability of HRO761 and identify the recommended dose(s), i.e., the optimal safe and active dose of HRO761 alone or in combination with pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite Instability-high) or dMMR (Mismatch Repair Deficient) that might work best to treat these specific cancer types and to understand how well HRO761 is able to treat those cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05838768"},{"nctId":"NCT05671510","title":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","sponsor":"OncoC4, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2023-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Non Small Cell Lung Cancer"],"interventions":["Gotistobart","Docetaxel"],"countries":["United States","Australia","Belgium","Canada","China","Germany","Italy","Netherlands","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":152,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase 3 clinical trial is to study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once every 21 days, for up to 17 cycles in approximately one year.","sourceUrl":"https://clinicaltrials.gov/study/NCT05671510"},{"nctId":"NCT07197580","title":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["ccRCC","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Renal Cell Cancer Metastatic","Renal Cell Cancer, Recurrent","Clear Cell Renal Cell Cancer (ccRCC)"],"interventions":["177Lu-TLX250"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D). Part 2 will compare 177Lu-TLX250 with investigator's choice of monotherapy aligned with Australian standard-of-care.","sourceUrl":"https://clinicaltrials.gov/study/NCT07197580"},{"nctId":"NCT06147570","title":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2023-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2023-11-27","conditions":["Nonsmall Cell Lung Cancer"],"interventions":["HS-10365 capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients without any systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06147570"},{"nctId":"NCT06084936","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2023-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Lymphoma"],"interventions":["Obinutuzumab","Glofitamab","Rituximab","Bendamustine","Lenalidomide","Tocilizumab"],"countries":["United States","Australia","Brazil","Canada","China","France","Italy","Puerto Rico","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":82,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06084936"},{"nctId":"NCT06026501","title":"A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2023-09-07","conditions":["Advanced Solid Tumors"],"interventions":["PE0116,PE0105"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a one-arm, open, multicenter phase 1b/2 clinical trial of PE0116combined with PE0105 in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can be divided into two parts: dose escalation part and expansion part.PE0105 is administered as a fixed-dose intravenous injection(3mg/kg Q3w）.","sourceUrl":"https://clinicaltrials.gov/study/NCT06026501"},{"nctId":"NCT05607953","title":"Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma","sponsor":"TriSalus Life Sciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-07-04","conditions":["Locally Advanced Pancreatic Adenocarcinoma"],"interventions":["SD-101","anti-PD-1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, phase 1/1b study of the pressure-enabled intrapancreatic infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with locally advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05607953"},{"nctId":"NCT05365659","title":"IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas","sponsor":"Iksuda Therapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2023-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["B-cell Non-Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","B-cell Lymphoma"],"interventions":["IKS03"],"countries":["United States","Australia","Canada","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05365659"},{"nctId":"NCT07180771","title":"A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.","sponsor":"Boryung Pharmaceutical Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2026-02","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Peripheral T Cell Lymphoma"],"interventions":["BR101801"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07180771"},{"nctId":"NCT07057349","title":"CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer","sponsor":"Cytosite Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2025-07-09","conditions":["Metastatic Cancer","Unresectable Solid Tumor"],"interventions":["[18F]CSB-321"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Single-center with the option to expand to multi-center, international, open label, non-randomized, multiple-dose, multi-cohort study, in participants with metastatic or unresectable cancer. Eligible participants will receive an initial injection of \\[18F\\]CSB-321 followed by PET imaging prior to administration of the I-O therapy and a second and third injection post treatment each with PET imaging. The images will be analyzed for the distribution of radioactivity. Participants will be followed for adverse events up to 3-4 hours post injection. Available clinical, imaging, and histology data will be collected at follow-up to establish the disease progression for evaluation of \\[18F\\]CSB-321.","sourceUrl":"https://clinicaltrials.gov/study/NCT07057349"},{"nctId":"NCT07181239","title":"Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients","sponsor":"Keymed Biosciences Co.Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Multiple Myeloma (MM)"],"interventions":["CM336 Injection","Standard Of Care( SOC)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07181239"},{"nctId":"NCT07164313","title":"A Study of ZW251 in Participants With Advanced Solid Tumors","sponsor":"Zymeworks BC Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Hepatocellular Carcinoma","Squamous Cell Non-Small Cell Lung Cancer","Germ Cell Tumor"],"interventions":["ZW251"],"countries":["United States","Ireland","Japan","Portugal","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).","sourceUrl":"https://clinicaltrials.gov/study/NCT07164313"},{"nctId":"NCT06229366","title":"[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":142,"enrollmentType":"ESTIMATED","startDate":"2024-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Oligometastatic Prostate Carcinoma","Hormone Sensitive Prostate Cancer"],"interventions":["[Ac-225]-PSMA-62 (mCRPC)","[Ac-225]-PSMA-62 (OmHSPC)"],"countries":["Canada"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"ACCEL is a multicenter, open label phase Ia/Ib/II study of \\[Ac-225\\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06229366"},{"nctId":"NCT07337525","title":"A First in Human Study of PLT012 in Participants With Solid Tumor Cancers","sponsor":"Pilatus Biosciences Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Malignant Solid Tumor","Solid Tumor Cancer"],"interventions":["PLT012"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer. The main questions it aims to answer are: What adverse events and toxicities (harmful side effects) are associated with different doses of PLT012? What are the blood levels of PLT012 in your body at different timepoints? What effect does PLT012 have on reducing tumor size and/or preventing the worsening of cancer? All participants will receive PLT012 and none will receive placebo (a look-alike substance that contains no drug). Participants will receive PLT012 by intraven","sourceUrl":"https://clinicaltrials.gov/study/NCT07337525"},{"nctId":"NCT05958121","title":"IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors","sponsor":"Immatics Biotechnologies GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2023-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","Cancer"],"interventions":["IMA402","IMA402 and checkpoint inhibitor","IMA402 and chemotherapy","IMA402 and IMA401","IMA402 and monoclonal antibody","IMA402 and chemotherapy +/- monoclonal antibody"],"countries":["Germany","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: * To determine the maximum tolerated doses and/or recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia) * To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I/II) * To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) Secondary objectives: * To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I) * To evaluate anti-tumor activity of IMA402","sourceUrl":"https://clinicaltrials.gov/study/NCT05958121"},{"nctId":"NCT07043725","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":544,"enrollmentType":"ESTIMATED","startDate":"2025-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["HER2-positive Breast Cancer"],"interventions":["TQB2102 for injection","Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":78,"serviceSignals":["HER2 profiling"],"summary":"This is a randomized, open, positive drug control, multi center phase III study. Through the evaluation of tpCR, bpCR, ORR, EFS, IDFS, OS , AEs and other indicators, it proves the effectiveness and safety of TQB2102 for injection versus TCbHP in the neoadjuvant treatment of HER2 positive breast cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07043725"},{"nctId":"NCT07259317","title":"Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma","sponsor":"Corcept Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Adenocarcinoma","Carcinoma, Pancreatic Ductal"],"interventions":["Relacorilant","Nab-paclitaxel","Gemcitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07259317"},{"nctId":"NCT07359820","title":"A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement","sponsor":"Elevar Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["FGFR2 Gene Fusion/Rearrangement","Other Solid Tumors, Adult"],"interventions":["Lirafugratinib"],"countries":["United States","France","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["RNA fusion"],"summary":"The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.","sourceUrl":"https://clinicaltrials.gov/study/NCT07359820"},{"nctId":"NCT06592326","title":"9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2024-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Urothelial Carcinoma"],"interventions":["9MW2821","Toripalimab","Gemcitabine","Cisplatin/Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, controlled, open-label, multicenter phase 3 clinical study to evaluate the efficacy, safety and immunogenicity of 9MW2821 combined with Toripalimab versus standard chemotherapy in first-line locally advanced or metastatic urothelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06592326"},{"nctId":"NCT07457164","title":"A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer","sponsor":"Antev Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Advanced Prostate Cancer","GnRH Antagonist"],"interventions":["Teverelix DP 180 mg"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to \\< 0.5 ng/mL with the lower bound of the 95% confidence interval (CI) being \\> 90% to meet the evaluation criteria for efficacy. The main question it aims to answer is: •Is the dosing regimen of Teverelix DP in this study effective at achieving the required testosterone suppression to castrate levels. Participants will * Receive a single loading dose consisting of 3 injections of teverelix DP (180 mg IM + 2x 180 mg SC) on Day 1. * Receive a maintenance dose consisting of 2 injections (2X 180 mg SC) from week 4","sourceUrl":"https://clinicaltrials.gov/study/NCT07457164"},{"nctId":"NCT06819735","title":"Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors","sponsor":"Domain Therapeutics Australia Pty Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2025-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Advanced Solid Tumors"],"interventions":["DT-7012","Immune checkpoint inhibitor"],"countries":["United States","Australia","France"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06819735"},{"nctId":"NCT07003321","title":"A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Solid Tumor"],"interventions":["HRS-4508 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07003321"},{"nctId":"NCT06961565","title":"PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas","sponsor":"Pasithea Therapeutics Corp.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2025-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-04","conditions":["NF1 Mutation","Neurofibroma Plexiform","Neurofibroma, Plexiform","Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)","Neurofibromatosis Type 1 (NF1)"],"interventions":["PAS-004 Tablets"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1). The main questions it aims to answer are: * How well participants are able tolerate different doses of PAS-004, and * What side effects PAS-004 might have. This study will have two parts, Part A and Part B. The main goal of Part A of this study is to learn more about how participants tolerate different doses of PAS-004, and what side effects PAS-004 might have. What we learn from Part A of the study will help decide what doses of the study drug (PAS-004) should be used in Part B of the study, and if it is safe. In Part B, two differe","sourceUrl":"https://clinicaltrials.gov/study/NCT06961565"},{"nctId":"NCT05602363","title":"AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma","sponsor":"Carna Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["B-cell Malignancy","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Waldenstrom Macroglobulinemia","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Follicular Lymphoma","Non-Hodgkin Lymphoma"],"interventions":["Docirbrutinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05602363"},{"nctId":"NCT06679985","title":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma","sponsor":"Coherus Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2024-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Hepatocellular Carcinoma"],"interventions":["Casdozokitug","Toripalimab","Bevacizumab"],"countries":["United States","Australia","Canada","Hong Kong","Singapore","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06679985"},{"nctId":"NCT07683013","title":"Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer","sponsor":"Hyundai Bioscience Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Castration-Resistant Prostate Cancer (CRPC)"],"interventions":["CP-PCA07","Enzalutamide 40 mg capsule"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC). This is an open-label, dose-escalation, multicenter Phase 1 study. The primary objective is to assess the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) to determine the recommended Phase 2 dose (RP2D) of the combination therapy. The secondary objective is to assess changes in Prostate-Specific Antigen (PSA) levels and pharmacokinetic characteristics. Exploratory objectives include assessment of tumor response, disease control, progression-free survival, and biomarker analyses, inc","sourceUrl":"https://clinicaltrials.gov/study/NCT07683013"},{"nctId":"NCT02926690","title":"Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer","sponsor":"OncoTherapy Science, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2017-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer"],"interventions":["OTS167PO"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT02926690"},{"nctId":"NCT06539182","title":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"interventions":["DZD8586"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.","sourceUrl":"https://clinicaltrials.gov/study/NCT06539182"},{"nctId":"NCT06016920","title":"Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma","sponsor":"Nykode Therapeutics ASA","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2023-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2024-12-17","conditions":["HPV Positive Oropharyngeal Squamous Cell Carcinoma","HNSCC"],"interventions":["VB10.16","Pembrolizumab"],"countries":["Czechia","France","Germany","Hungary","Norway","Poland","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC). The trial is designed to investigate VB10.16, an investigational therapeutic DNA vaccine in combination with another medicine, pembrolizumab, which is the standard of care for patients with previously untreated metastatic or resectable recurrent PD-L1 positive HNSCC. The study is divided in 2 parts: a phase 1, dose escalation part, testing 3 different doses of VB10.16 in combination with a standard fixed dose of pembrolizumab. The goal of this part is to evaluate the safety and tolerability of the combined treatment and to decide on t","sourceUrl":"https://clinicaltrials.gov/study/NCT06016920"},{"nctId":"NCT07046559","title":"A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Healthy","Cancer"],"interventions":["LY4066708","Placebo"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant.","sourceUrl":"https://clinicaltrials.gov/study/NCT07046559"},{"nctId":"NCT05891171","title":"Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2023-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Cancer","Advanced Malignancies","Bladder Cancer","Cervical Cancer","Esophageal Cancer","Gastric Cancer","Gastroesophageal-junction Cancer (GEJ)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Non-Small Cell Lung Cancer (NSCLC)","Ovarian Cancer","Renal Cell Carcinoma (RCC)","Triple Negative Breast Cancer (TNBC)"],"interventions":["AB598","Zimberelimab","Fluorouracil","Leucovorin","Oxaliplatin"],"countries":["United States","Australia","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05891171"},{"nctId":"NCT07604766","title":"An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Platinum-resistant Ovarian Cancer"],"interventions":["Rina-S","Paclitaxel","Topotecan","Pegylated liposomal doxorubicin (PLD)","Gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this Chinese extension study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo. This study is an extension study of the protocol GCT1184-02 (NCT06619236).","sourceUrl":"https://clinicaltrials.gov/study/NCT07604766"},{"nctId":"NCT07138001","title":"Phase 2 Clinical Trial of KH617","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Recurrent Glioblastoma"],"interventions":["KH617+TMZ","KH617","TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of KH617 for injection in combination with temozolomide versus investigator's choice therapy or KH617 monotherapy for recurrent glioblastoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07138001"},{"nctId":"NCT05608044","title":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","sponsor":"Agenus Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":234,"enrollmentType":"ACTUAL","startDate":"2022-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2025-09-04","conditions":["Metastatic Colorectal Cancer"],"interventions":["Botensilimab","Balstilimab","Standard of Care"],"countries":["United States","Belgium","Brazil","France","Georgia","Italy","Russia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["MSI / TMB"],"summary":"This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05608044"},{"nctId":"NCT07040436","title":"Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1","sponsor":"Oncodesign Precision Medicine","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":41,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-06-27","conditions":["Advanced Melanoma"],"interventions":["OPM-101"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1b/2a study including a dose escalation part (Phase 1b) and an extension part (Phase 2a). Both parts will be open-label, multicenter study of OPM-101 combined with the anti-PD-1 pembrolizumab as per standard of care in patients with MM who have been receiving an anti-PD-1-based treatment and have shown resistance to it, as defined by the Society for Immunotherapy of Cancer (SITC) criteria (Kluger, 2020). The objective of the study is to assess whether the addition of OPM-101 will resensitisze the tumour to the anti-PD-1-based treatment. Potential patients will be screened for this study during the period between initial evidence of disease progression on anti-PD-1 treatment a","sourceUrl":"https://clinicaltrials.gov/study/NCT07040436"},{"nctId":"NCT06193889","title":"KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis","sponsor":"Kyverna Therapeutics","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2024-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Myasthenia Gravis","Generalized Myasthenia Gravis"],"interventions":["Standard of Care Treatment","Standard lymphodepletion regimen","KYV-101"],"countries":["United States","Australia","Brazil","Germany","Saudi Arabia","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Patients with Myasthenia Gravis","sourceUrl":"https://clinicaltrials.gov/study/NCT06193889"},{"nctId":"NCT04542824","title":"Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ACTUAL","startDate":"2020-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Primary Mediastinal Large B Cell Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Small Lymphocytic Lymphoma"],"interventions":["Epcoritamab (monotherapy)","Epcoritamab","Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone","Gemcitabine and oxaliplatin","Epcoritamab (maintenance)","Rituximab and lenalidomide"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2). The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase-2 dose (RP2D), as well as to establish the safety profile of epcoritamab in Japanese participants with relapsed, progressive or ","sourceUrl":"https://clinicaltrials.gov/study/NCT04542824"},{"nctId":"NCT06084481","title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":302,"enrollmentType":"ACTUAL","startDate":"2023-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Hepatocellular Carcinoma","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancers","Esophageal Squamous Cell Carcinoma","Triple Negative Breast Cancer","Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer","Head and Neck Squamous-Cell Carcinoma","Platinum Resistant High Grade Epithelial Ovarian Cancer"],"interventions":["ABBV-400","Itraconazole (ITZ)","Bevacizumab"],"countries":["United States","Australia","Israel","Japan","Puerto Rico","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["HER2 profiling"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab. All cohorts are followed by a safety follow-up period. Approximately 325 adult participants with hepatocellular carcinom","sourceUrl":"https://clinicaltrials.gov/study/NCT06084481"},{"nctId":"NCT07211659","title":"Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients","sponsor":"Theolytics Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Ovarian Cancer"],"interventions":["THEO-260"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered by the intraperitoneal route to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT07211659"},{"nctId":"NCT05445908","title":"SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":175,"enrollmentType":"ESTIMATED","startDate":"2022-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Triple-negative Breast Cancer and HR+/HER2- BC"],"interventions":["SKB264","KL-A167"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to assess the safety and tolerability and preliminary antitumor activity of SKB264 with/without KL-A167 in patients with unresectable locally advanced, recurrent or metastatic TNBC and HR+/HER2- BC .The study is divided into three parts.Part 1（TNBC）: exploratory phase of the efficacy and safety of the combination treatment. Part 2（TNBC）: The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 . Part 3（HR+/HER2- BC）: The subjects will be randomized to treatment group for SKB264 + KL-A167 or SKB264 .","sourceUrl":"https://clinicaltrials.gov/study/NCT05445908"},{"nctId":"NCT06525298","title":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","sponsor":"Eisbach Bio GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2024-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced Solid Tumor","Homologous Recombination Deficiency","HRR Deficiency"],"interventions":["EIS-12656","Olaparib","Trastuzumab deruxtecan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["HRD / HRR","ADC biomarker"],"summary":"This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT06525298"},{"nctId":"NCT05752552","title":"Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours","sponsor":"DeuterOncology","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2022-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Adult Solid Tumor","Advanced Solid Tumor","Refractory Tumor","Non-small Cell Lung Cancer","Non-small Cell Carcinoma","Lung Cancer","Hereditary Renal Papillary Cancer"],"interventions":["DO-2"],"countries":["Belgium","France","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative. The dose escalation is completed, Part 2 of the study is ongoing.","sourceUrl":"https://clinicaltrials.gov/study/NCT05752552"},{"nctId":"NCT07038096","title":"ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Small Cell Lung Cancer","Neuroendocrine Carcinoma"],"interventions":["ZG006","ZG005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07038096"},{"nctId":"NCT07103018","title":"A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)","sponsor":"K36 Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2025-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Metastatic Castration-resistant Prostate Cancer","Metastatic Castration-Resistant Prostate Cancer Patients","Metastatic Castration-resistant Prostate Cancer, mCRPC","mCRPC","mCRPC (Metastatic Castration-resistant Prostate Cancer)"],"interventions":["KTX-2001","KTX-2001 + Darolutamide (NUBEQA®)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective in treating metastatic castration-resistant prostate cancer, and measuring how the drug(s) behaves in the body.","sourceUrl":"https://clinicaltrials.gov/study/NCT07103018"},{"nctId":"NCT07127874","title":"A Study of PHN-012 in Patients With Advanced Solid Tumors","sponsor":"Pheon Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Colon Cancer","Pancreatic Cancer","Lung Cancer (NSCLC)","Advanced Cancer","Advanced Solid Tumors"],"interventions":["PHN-012"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["ADC biomarker"],"summary":"This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07127874"},{"nctId":"NCT06589440","title":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)","sponsor":"Stingray Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2024-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-09","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)"],"interventions":["SR-8541A"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["MSI / TMB"],"summary":"This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT06589440"},{"nctId":"NCT06905197","title":"A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Non Small Cell Lung Cancer"],"interventions":["DZD6008","Sunvozertinib"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06905197"},{"nctId":"NCT05361174","title":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":53,"enrollmentType":"ESTIMATED","startDate":"2022-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Unresectable Melanoma","Metastatic Melanoma","Stage III Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer"],"interventions":["IOV-4001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05361174"},{"nctId":"NCT07622342","title":"A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Generalized Myasthenia Gravis"],"interventions":["SHR-2173 injection","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of SHR-2173 compared to placebo as an add-on therapy to standard of care (SOC) for the treatment of generalized myasthenia gravis (gMG). The study consists of a 4-week screening period, a 24-week treatment period, and a 12-week safety follow-up period.","sourceUrl":"https://clinicaltrials.gov/study/NCT07622342"},{"nctId":"NCT07393542","title":"A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":462,"enrollmentType":"ESTIMATED","startDate":"2026-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Locally Advanced or Metastatic Urothelial Carcinoma"],"interventions":["SHR-A2102 and Adebrelimab","Gemcitabine and cisplatin / carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07393542"},{"nctId":"NCT07009457","title":"A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":24,"enrollmentType":"ACTUAL","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Widespread Small Cell Lung Cancer"],"interventions":["SHR-1316 (sc) Injection","SHR-1316 Injection","Carboplatin Injection","Etoposide Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open label phase I clinical trial aimed at evaluating the pharmacokinetics, tolerability, safety and immunogenicity of SHR-1316 (sc) subcutaneous administration combined with carboplatin and etoposide as first-line treatment for extensive stage small cell lung cancer, and to observe the initial anti-tumor efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07009457"},{"nctId":"NCT05544929","title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":126,"enrollmentType":"ACTUAL","startDate":"2022-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-01","completionType":"ESTIMATED","lastUpdated":"2026-01-06","conditions":["Carcinoma, Non-Small-Cell Lung","Cutaneous Melanoma","Carcinoma, Renal Cell","Carcinoma, Ovarian Epithelial","Nasopharyngeal Carcinoma","Carcinoma, Thymic","Anal Cancer","Mesothelioma","Esophagogastric Cancer","High Microsatellite Instability Colorectal Carcinoma","Squamous Cell Carcinoma of Head and Neck","Triple Negative Breast Neoplasms"],"interventions":["KFA115","pembrolizumab"],"countries":["United States","Canada","China","France","Germany","Hong Kong","Italy","Japan","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":19,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT05544929"},{"nctId":"NCT06617897","title":"Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery","sponsor":"CSL Behring","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-29","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Acquired Fibrinogen Deficiency"],"interventions":["CSL511 Fibrinogen concentrate (human)","Cryoprecipitate"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a phase 3, prospective, single center, randomized, open label, controlled, parallel arm, interventional study to investigate the efficacy and safety of CSL511, in participants undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP) with predicted intraoperative blood loss of greater than or equal to (\\>=) 2 liter (L). Eligible participants will be randomized in a 1:1 ratio to 1 of 2 treatment arms, to receive CSL511 or cryoprecipitate.","sourceUrl":"https://clinicaltrials.gov/study/NCT06617897"},{"nctId":"NCT07591090","title":"A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-04","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Breast Cancer"],"interventions":["AK146D1 for injection","AK112 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 combined with AK112 in advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07591090"},{"nctId":"NCT06459687","title":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","sponsor":"Lee's Pharmaceutical Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2024-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2025-05-14","conditions":["Cervical Cancer"],"interventions":["Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab","Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the efficacy and safety of Socazolimab combined with chemotherapy with or without bevacizumab as first-Line treatment in persistent, recurrent, or metastatic cervical cancer. The main question it aims to answer is: Does Socazolimab combined with chemotherapy with or without bevacizumab better benefit patients with persistent, recurrent, or metastatic cervical cancer as first-line treatment compared with placebo combined with chemotherapy with or without bevacizumab. Participants will be treated with Socazolimab/placebo + chemotherapy ± bevacizumab) for 6\\~8 cycles (Q3w), following maintenance treatment of Socazolimab/placebo (Q3w).","sourceUrl":"https://clinicaltrials.gov/study/NCT06459687"},{"nctId":"NCT06172478","title":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":740,"enrollmentType":"ESTIMATED","startDate":"2024-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-10","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced Solid Tumor","Melanoma","Head and Neck Cancer","Gastric Cancer","Ovarian Carcinoma","Cervical Cancer","Endometrial Cancer","Bladder Cancer","Esophageal Cancer","Pancreatic Carcinoma","Prostate Cancer","Non-small Cell Lung Cancer (NSCLC)","Lung Cancer","Breast Cancer"],"interventions":["HER3-DXd"],"countries":["United States","Australia","Belgium","Canada","China","France","Germany","Hungary","Italy","Japan","Netherlands","Norway","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":85,"serviceSignals":["HER2 profiling"],"summary":"This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \\[cutaneous/acral\\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06172478"},{"nctId":"NCT07680322","title":"A Phase 2 Study of the Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy","sponsor":"Aeovian Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-21","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Tuberous Sclerosis Complex","Epilepsy"],"interventions":["AV078","Placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC). Approximately 42 participants will be randomized in a 5:1 ratio to receive AV078 or placebo. The study will include a Screening Period collecting 4 weeks of pre-treatment Baseline data on seizure frequency, and progress to a 12-week Treatment Period, followed by an in person final follow-up visit approximately 2 weeks after the last dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT07680322"},{"nctId":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","sponsor":"SystImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2025-11-04","conditions":["Breast Cancer Stage III","HER2-positive Metastatic Breast Cancer","Unresectable Breast Carcinoma","Her2-Positive","HER2 Gene Mutation","Gastroesophageal-junction Cancer","Non Small Cell Lung Cancer","Endometrial Neoplasms","Peritoneal Cancer","Fallopian Tube Cancer","Ovarian Cancer","Urothelial Carcinoma Bladder","Solid Tumor, Adult","Gastric Cancer"],"interventions":["BL-M17D1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["HER2 profiling"],"summary":"The objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06714617"},{"nctId":"NCT07743112","title":"A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia","sponsor":"Maxinovel Pty., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":43,"enrollmentType":"ESTIMATED","startDate":"2025-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Acute Myeloid Leukemia"],"interventions":["MAX-40279","Azacitidine","Venetoclax"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT07743112"},{"nctId":"NCT07363967","title":"A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors","sponsor":"Beijing StoneWise Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-01","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Solid Tumor Malignancies"],"interventions":["SWA1211"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this phase I, first-in-human, open-label study is to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SWA1211 in subjects with advanced solid tumors. It includes a Phase Ia dose escalation study and a Phase Ib dose expansion study. The main questions it aims to answer are: 1. Assess the safety and tolerability of SWA1211 in subjects with advanced solid tumors. 2. Identify the dose-limiting toxicity (DLT) to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or the recommended Phase II dose (RP2D) of SWA1211. 3. Assess the PK characteristics of SWA1211. 4. Evaluate the preliminary anti-tumor activity of SWA1211.","sourceUrl":"https://clinicaltrials.gov/study/NCT07363967"},{"nctId":"NCT05976568","title":"A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":668,"enrollmentType":"ESTIMATED","startDate":"2023-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-01","completionType":"ESTIMATED","lastUpdated":"2023-08-04","conditions":["Hepatocellular Carcinoma"],"interventions":["QL1706","Bevacizumab","Oxaliplatin injection","Capecitabine","Sintilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05976568"},{"nctId":"NCT05976828","title":"IBRX-042 In Participants With HPV-Associated Tumors","sponsor":"ImmunityBio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-02","primaryCompletionType":"ESTIMATED","completionDate":"2033-08-14","completionType":"ESTIMATED","lastUpdated":"2025-10-20","conditions":["HPV-Related Carcinoma"],"interventions":["IBRX-042"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are: * What is the maximum tolerated dose of IBRX-042? * How well does the study drug treat cancer? * What effects the study drug may have on the human body and cancer? Participants will receive IBRX-042 at one of three dose levels every 3 weeks for a total of 3 injections. Participants will undergo tests, exams, and procedures that are part of standard of care and for study purposes. IBRX-042 will be administere","sourceUrl":"https://clinicaltrials.gov/study/NCT05976828"},{"nctId":"NCT06764485","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":960,"enrollmentType":"ESTIMATED","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-19","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["BMS-986365","Enzalutamide","Abiraterone","Docetaxel","Predinsone/Prednisolone"],"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","China","Czechia","Denmark","France","Germany","India","Ireland","Italy","Japan","Poland","Puerto Rico","Romania","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":281,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764485"},{"nctId":"NCT04422366","title":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":8000,"enrollmentType":"ESTIMATED","startDate":"2020-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-15","completionType":"ESTIMATED","lastUpdated":"2024-06-07","conditions":["Cervical Cancer","Vulvar Cancer","Vaginal Cancer","CIN1","CIN2","CIN3","VaIN1","VaIN2","VaIN3","Genital Wart","VIN 1","VIN 2","VIN 3","AIS"],"interventions":["9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)","GARDASIL®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .","sourceUrl":"https://clinicaltrials.gov/study/NCT04422366"},{"nctId":"NCT03162536","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2017-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-17","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-17","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Lymphoma, B-Cell","Small Lymphocytic Lymphoma","Chronic Lymphocytic Leukemia","Waldenstrom Macroglobulinemia","Mantle Cell Lymphoma","Diffuse Large B Cell Lymphoma","Richter's Transformation","Follicular Lymphoma","Marginal Zone Lymphoma"],"interventions":["Nemtabrutinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT03162536"},{"nctId":"NCT07299825","title":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Her 2 Positive Breast Cancer"],"interventions":["A166"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"Evaluation of the efficacy of A166 in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with TOP1 inhibitor Antibody-Drug Conjugates","sourceUrl":"https://clinicaltrials.gov/study/NCT07299825"},{"nctId":"NCT05629585","title":"A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1174,"enrollmentType":"ACTUAL","startDate":"2022-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-20","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-30","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Breast Cancer"],"interventions":["Dato-DXd","Durvalumab","Capecitabine","Pembrolizumab"],"countries":["United States","Belgium","Brazil","Canada","China","Denmark","France","Germany","Greece","Italy","Japan","Puerto Rico","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":276,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05629585"},{"nctId":"NCT07294872","title":"A Study of TIL in Advanced Solid Tumors (CZ)","sponsor":"Shanghai Juncell Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-12-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-20","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-20","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumor, Adult"],"interventions":["GC101TIL"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.","sourceUrl":"https://clinicaltrials.gov/study/NCT07294872"},{"nctId":"NCT04925479","title":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":34,"enrollmentType":"ESTIMATED","startDate":"2021-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-21","primaryCompletionType":"ESTIMATED","completionDate":"2031-11-01","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Myeloid Leukemia, Philadelphia Positive"],"interventions":["Asciminib Pediatric formulation group","Asciminib Adult formulation group"],"countries":["United States","China","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","Poland","Russia","South Korea","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"The aim of this study is to support development of asciminib in the pediatric population (1 to \\<18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML in the pediatric population has the same pathogenesis, similar clinical characteristics and progression pattern as in adults.","sourceUrl":"https://clinicaltrials.gov/study/NCT04925479"},{"nctId":"NCT06431594","title":"A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":675,"enrollmentType":"ESTIMATED","startDate":"2024-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Solid Tumors","Neoplasms"],"interventions":["Mocertatug rezetecan"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Finland","France","Italy","Japan","Netherlands","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to assess the safety and tolerability of Mocertatug Rezetecan . The study will also see how the levels of Mo-Rez change over time at different dose amount","sourceUrl":"https://clinicaltrials.gov/study/NCT06431594"},{"nctId":"NCT06008106","title":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","sponsor":"Shanghai Kechow Pharma, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2023-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-22","completionType":"ESTIMATED","lastUpdated":"2024-06-28","conditions":["Melanoma"],"interventions":["tunlametinib","paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in advanced melanoma patients with NRAS mutation who have received immunotherapy before. Subjects were stratified according to the baseline lactate dehydrogenase level and chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06008106"},{"nctId":"NCT07198321","title":"A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-09-22","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-30","conditions":["Cancer","PDAC","CRC (Colorectal Cancer)","NSCLC"],"interventions":["GFH276"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This study is an investigation to evaluate the safety/tolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations. The primary objectives of the Phase I study are to assess the safety/tolerability, PK, and preliminary efficacy of GFH276 in patients with advanced solid tumors harboring RAS mutations, and to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of GFH276. The primary objective of the Phase II study is to evaluate the efficacy of GFH276 in patients with RAS-mutant advanced pancreatic ductal adenocarcinoma (PDAC), advanced non-small cell lung cancer (NSCLC), advanced colore","sourceUrl":"https://clinicaltrials.gov/study/NCT07198321"},{"nctId":"NCT05139017","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2022-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-24","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-24","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["DLBCL","Diffuse Large B-Cell Lymphoma"],"interventions":["Zilovertamab vedotin","Rituximab","Gemcitabine","Oxaliplatin","Bendamustine","Granulocyte Colony-Stimulating Factor (G-CSF)"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Costa Rica","Denmark","France","Greece","Guatemala","Hong Kong","Israel","Italy","Japan","Mexico","New Zealand","Peru","Poland","South Korea","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":135,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with be","sourceUrl":"https://clinicaltrials.gov/study/NCT05139017"},{"nctId":"NCT07077252","title":"Phase I/II Study of SCTB39G in Advanced Solid Tumours","sponsor":"Sinocelltech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-07-28","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-17","completionType":"ESTIMATED","lastUpdated":"2025-07-22","conditions":["Advanced Malignant Solid Tumor"],"interventions":["SCTB39G"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07077252"},{"nctId":"NCT06233942","title":"Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":308,"enrollmentType":"ESTIMATED","startDate":"2024-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-15","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Advanced Solid Tumor"],"interventions":["BG-C9074","Tislelizumab","Bevacizumab"],"countries":["United States","Australia","Brazil","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":37,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06233942"},{"nctId":"NCT07217587","title":"Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2026-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Myasthenia Gravis"],"interventions":["Nipocalimab","Efgartigimod"],"countries":["United States","Israel","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).","sourceUrl":"https://clinicaltrials.gov/study/NCT07217587"},{"nctId":"NCT05785767","title":"A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":149,"enrollmentType":"ACTUAL","startDate":"2023-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-28","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced Non-Small Cell Lung Cancer"],"interventions":["fianlimab","cemiplimab","Placebo"],"countries":["United States","Australia","Canada","Georgia","Israel","Malaysia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a \"study drug\" or collectively called \"study drugs\". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in your blood at different times * Whether the body makes antibodies ","sourceUrl":"https://clinicaltrials.gov/study/NCT05785767"},{"nctId":"NCT05123482","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2021-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-29","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Breast Cancer","Biliary Tract Carcinoma","Ovarian Cancer","Endometrial Cancer","Squamous Non-Small Cell Lung Cancer"],"interventions":["AZD8205","AZD8205 and AZD2936 (Rilvegostomig)","AZD8205 and AZD5305 (saruparib)","AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig)","AZD8205 in combination with AZD9574","AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)"],"countries":["United States","Australia","Belgium","Canada","China","Hungary","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["ADC biomarker"],"summary":"This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents","sourceUrl":"https://clinicaltrials.gov/study/NCT05123482"},{"nctId":"NCT05997615","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer","sponsor":"Vir Biotechnology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":437,"enrollmentType":"ESTIMATED","startDate":"2023-08-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-29","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Hormone-refractory Prostate Cancer"],"interventions":["VIR-5500","ARSI"],"countries":["United States","Australia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The study will be conducted in 4 parts and will commence with dose escalation of VIR-5500 as a monotherapy (Part 1), followed by combination escalation (Part 3a), monotherapy dose expansion (Part 2) and combination dose expansion (Part 4a). * Part 1 (Monotherapy Dose Escalation): Single-agent VIR-5500 dose escalation * Part 2 (Monotherapy Dose Expansion): Single-agent VIR-5500 dose expansion * Part 3 (Combination Dose Escalation): VIR-5500 plus another therapeutic agent dose escalation Part 3a (Combination Dose Escalation): VIR-5500 in combination with an androgen receptor signaling inhibitor (ARSI) * Part 4 (Combination Dose Expansion): VIR-5500 plus another therapeutic agent dose expansion","sourceUrl":"https://clinicaltrials.gov/study/NCT05997615"},{"nctId":"NCT06800196","title":"A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","sponsor":"KinoTeck Therapeutics Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":151,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumors With FGFR2 Alterations, Adult"],"interventions":["KNT-0916"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase1, open-label, dose escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of KNT-0916 in patients with unresectable or metastatic solid tumors harboring FGFR2 alterations who have failed prior systemic therapy. This study is divided into 2 parts, dose escalation part(part A), dose expansion part(partB).","sourceUrl":"https://clinicaltrials.gov/study/NCT06800196"},{"nctId":"NCT06515470","title":"Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer","sponsor":"Biotheryx, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2024-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Breast Cancer"],"interventions":["BTX-9341","Fulvestrant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to test BTX-9341 alone or in combination with fulvestrant (a currently marketed medication for breast cancer) in participants with advanced and/or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer. The study includes a dose escalation part (Part A) where small groups of participants will receive increasing doses of BTX-9341 or BTX-9341 + fulvestrant followed by a dose expansion part (Part B) where participants will receive the dose of BTX-9341 selected in Part A + fulvestrant.","sourceUrl":"https://clinicaltrials.gov/study/NCT06515470"},{"nctId":"NCT07016490","title":"A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Advanced Malignant Tumors"],"interventions":["SSGJ-709"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07016490"},{"nctId":"NCT06120491","title":"Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1898,"enrollmentType":"ACTUAL","startDate":"2023-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Metastatic Castration-Sensitive Prostate Cancer"],"interventions":["Saruparib","Placebo","Abiraterone Acetate","Darolutamide","Enzalutamide"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Hungary","India","Italy","Japan","Malaysia","Netherlands","Peru","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":322,"serviceSignals":["Broad CGP"],"summary":"The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06120491"},{"nctId":"NCT05753722","title":"A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies","sponsor":"Incendia Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2023-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Advanced or Metastatic Solid Tumors","Non Small Cell Lung Cancer","NSCLC"],"interventions":["PRTH-101","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05753722"},{"nctId":"NCT07722767","title":"A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients","sponsor":"Cullinan Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-10-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["AML (Acute Myeloid Leukemia)"],"interventions":["CLN-049","Azacitidine","Venetoclax"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT07722767"},{"nctId":"NCT06662669","title":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-11-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-30","completionType":"ESTIMATED","lastUpdated":"2024-10-29","conditions":["Metastatic Pancreatic Cancer"],"interventions":["YL-13027","HY-0102","Gemcitabine","Nab-paclitaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"In Phase 1b study, six subjects will be enrolled in Arm A (YL-13027 + AG regimen) and Arm B (HY-0102 + AG regimen). The first 12 subjects will be evaluated for safety after one cycle. After safety assessment, subjects will start to enroll in Arm C (YL-13027 + HY-0102 + AG regimen). Each group is planned to include 12-20 subjects. According to the safety and efficacy results of 3 arms of subjects in phase Ib, 1-2 groups were selected for expansion, and a randomized controlled study will be conducted with the standard treatment AG （Arm 4）regimen chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06662669"},{"nctId":"NCT07519564","title":"A Phase I Clinical Study to Evaluate the Efficacy and Safety of GB18 Injection in Patients With Tumor Cachexia","sponsor":"Kexing Biopharm Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Cachexia; Cancer"],"interventions":["GB18"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"KXZY-GB18-101(1B) is an extension of KXZY-GB18-101, a first-in-human, dose-escalation trial in healthy adult participants to evaluate the safety, tolerability, PK, PD, and immunogenicity of GB18. As a humanized GDF15 monoclonal antibody, GB18 is expected to improve anorexia and weight loss caused by metabolic disorders driven by overactivation of the GDF15-GFRAL-RET signaling pathways. With favorable readouts of KXZY-GB18-101, this study aims to evaluate the effects of GB18 in patients with tumor cachexia. This open-label, multiple-ascending-dosing study will enroll 18-36 participants into 3 dosing-level cohorts (B1-B3, each with 6-12 participants).","sourceUrl":"https://clinicaltrials.gov/study/NCT07519564"},{"nctId":"NCT05208944","title":"THIO Sequenced With Cemiplimab in Advanced NSCLC","sponsor":"Maia Biotechnology","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":227,"enrollmentType":"ESTIMATED","startDate":"2022-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["6-Thio-2'-Deoxyguanosine","Cemiplimab"],"countries":["United States","Australia","Bulgaria","Hungary","Poland","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or ","sourceUrl":"https://clinicaltrials.gov/study/NCT05208944"},{"nctId":"NCT06660654","title":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","sponsor":"Daiichi Sankyo","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Advanced Solid Tumor","Metastatic Solid Tumors"],"interventions":["Raludotatug deruxtecan"],"countries":["United States","Belgium","China","Denmark","France","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \\[ccRCC\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT06660654"},{"nctId":"NCT03233139","title":"Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":146,"enrollmentType":"ACTUAL","startDate":"2017-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Advanced Malignancies"],"interventions":["Cemiplimab","Ipilimumab","Platinum-doublet chemotherapy","Gemcitabine","Pemetrexed","Paclitaxel","Fianlimab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor. Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT03233139"},{"nctId":"NCT02955940","title":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","sponsor":"Incyte Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":10,"enrollmentType":"ACTUAL","startDate":"2016-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Pancreatic Cancer","Colorectal Cancer (CRC)","Breast Cancer","Lung Cancer"],"interventions":["Ruxolitinib","Capecitabine","Regorafenib"],"countries":["United States","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.","sourceUrl":"https://clinicaltrials.gov/study/NCT02955940"},{"nctId":"NCT06589596","title":"An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":525,"enrollmentType":"ESTIMATED","startDate":"2025-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Solid Tumor"],"interventions":["BGB-58067","BG-89894","Standard of Care Therapy"],"countries":["United States","Australia","Brazil","China","Denmark","France","Malaysia","Moldova","South Korea","Spain","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":98,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), and in combination with standard of care therapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.","sourceUrl":"https://clinicaltrials.gov/study/NCT06589596"},{"nctId":"NCT07633873","title":"SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2026-06-02","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SYS6010 injection","Enlonstobart injection","Tislelizumab injection","Paclitaxel+Carboplatin or Pemetrexed + Cisplatin/Carboplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for patients with PD-L1-Positive locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07633873"},{"nctId":"NCT06600321","title":"A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma","sponsor":"Alnylam Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":158,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma"],"interventions":["ALN-BCAT","Pembrolizumab"],"countries":["United States","Italy","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06600321"},{"nctId":"NCT04663347","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":543,"enrollmentType":"ACTUAL","startDate":"2020-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"interventions":["rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone","rituximab and lenalidomide","rituximab and bendamustine","rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin","gemcitabine and oxaliplatin","Epcoritamab","rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone","Lenalidomide","rituximab, ifosfamide, carboplatin, and etoposide phosphate","Rituximab and Lenalidomide"],"countries":["United States","Australia","Belgium","Czechia","Denmark","Finland","France","Italy","Netherlands","Norway","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":57,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The treatment duration for each part","sourceUrl":"https://clinicaltrials.gov/study/NCT04663347"},{"nctId":"NCT06868485","title":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","sponsor":"Wayshine Biopharm, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Non Small Cell Lung Cancer"],"interventions":["WSD0922-FU Tablets, Dose level A","WSD0922-FU Tablets, Dose level B"],"countries":["United States","China","France"],"northAmerica":true,"chinaSites":true,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.","sourceUrl":"https://clinicaltrials.gov/study/NCT06868485"},{"nctId":"NCT05981703","title":"A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":217,"enrollmentType":"ESTIMATED","startDate":"2023-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Advanced Solid Tumor","Solid Tumor"],"interventions":["BGB-26808","Tislelizumab","Chemotherapy"],"countries":["United States","Australia","China","New Zealand"],"northAmerica":true,"chinaSites":true,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.","sourceUrl":"https://clinicaltrials.gov/study/NCT05981703"},{"nctId":"NCT06352359","title":"Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors","sponsor":"OncoC4, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2024-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Advanced Solid Tumor"],"interventions":["ONC-841"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose expansion in the last dose level. The Phase 2 part will test the combination of ONC-841 with SOC in GBM and in CRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06352359"},{"nctId":"NCT06444815","title":"A Study of VET3-TGI in Patients With Solid Tumors","sponsor":"KaliVir Immunotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Solid Tumor, Adult","Microsatellite Stable Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Cervical Cancer","Kidney Cancer","Renal Cell Carcinoma","Melanoma Stage IV","Merkel Cell Carcinoma of Skin","Mesothelioma","Non-small Cell Lung Cancer","Cutaneous Squamous Cell Carcinoma (CSCC)","Urothelial Carcinoma Bladder","Squamous Cell Carcinoma"],"interventions":["VET3-TGI","Atezolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["MSI / TMB"],"summary":"VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).","sourceUrl":"https://clinicaltrials.gov/study/NCT06444815"},{"nctId":"NCT07474727","title":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","sponsor":"Multitude Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Colorectal Cancer"],"interventions":["AMT-676","5-FU","Leucovorin","Bevacizumab","Cetuximab","Irinotecan","Oxaliplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multi-center, phase II study, aiming to evaluate the safety, tolerability and efficacy of AMT-676 combined with 5-fluorouracil, leucovorin, bevacizumab (or cetuximab) in participants with advanced colorectal cancer, and to assess the PK(Pharmacokinetic) characteristics and immunogenicity of AMT-676.","sourceUrl":"https://clinicaltrials.gov/study/NCT07474727"},{"nctId":"NCT06118086","title":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","sponsor":"Remix Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2023-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Adenoid Cystic Carcinoma","Metastatic Adenoid Cystic Carcinoma","Recurrent Adenoid Cystic Carcinoma"],"interventions":["REM-422"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with advanced Adenoid Cystic Carcinoma (ACC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06118086"},{"nctId":"NCT07454187","title":"To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["SG2918"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of this study was to evaluate the safety and tolerability of SG2918 in patients with relapsed/refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07454187"},{"nctId":"NCT07564102","title":"dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy","sponsor":"Mochida Medical USA, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Prostate Cancer"],"interventions":["dMD-002","Control"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to conduct a US Pilot study of dMD-002 as a peripheral nerve repair sheet in patients with cavernous nerve injury following radical prostatectomy. The study will determine which endpoints and timepoints will be used for the pivotal study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07564102"},{"nctId":"NCT07156136","title":"Study of IMC-P115C in Advanced PRAME-Positive Cancers","sponsor":"Immunocore Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["PRAME Positive","Cancer","HLA-A*02:01-positive"],"interventions":["IMC-P115C"],"countries":["Australia","France","Italy","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["HLA / TCR"],"summary":"Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.","sourceUrl":"https://clinicaltrials.gov/study/NCT07156136"},{"nctId":"NCT06532331","title":"A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":87,"enrollmentType":"ESTIMATED","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2025-04-18","conditions":["Metastatic Pancreatic Cancer"],"interventions":["ONO-7475","ONO-4538","Nab-paclitaxel","Gemcitabine"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study is PhaseⅠstudy to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06532331"},{"nctId":"NCT06487559","title":"A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2024-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-03-04","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["Livmoniplimab","Budigalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to assess adverse events and how livmoniplimab in combination with budigalimab moves through the body in adult Chinese participants with Locally Advanced or metastatic Child-Pugh A Hepatocellular Carcinoma (HCC). Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. Stage 1 is a safety run-in. There are 2 treatment arms in stage 1 and participants will receive escalating doses of Livmoniplimab i","sourceUrl":"https://clinicaltrials.gov/study/NCT06487559"},{"nctId":"NCT07436611","title":"Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains","sponsor":"AFT Pharmaceuticals, Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Port Wine Stains"],"interventions":["Rapamycin cream","Pulsed dyed laser"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the use of rapamycin cream can be used as a treatment together with pulsed dyed laser in treating port wine stain birthmarks. The main question it aims to answer is: Will rapamycin cream and laser treatment show a greater improvement in appearance of port wine birthmarks, compared to treatment with placebo cream and laser? Researchers will compare two concentrations of rapamycin cream (0.6% or 1.0%) with placebo treatment to see if appearance is improved following 12 weeks of treatment. Participants will receive laser treatment of their port wine birthmark and then apply the rapamycin or placebo cream daily for 12 weeks. Patients will visit the ","sourceUrl":"https://clinicaltrials.gov/study/NCT07436611"},{"nctId":"NCT05254743","title":"A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","sponsor":"Loxo Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":737,"enrollmentType":"ESTIMATED","startDate":"2022-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Chronic Lymphocytic Leukemia","Leukemia, Lymphocytic","Leukemia, B-cell","Small Lymphocytic Lymphoma"],"interventions":["Pirtobrutinib","Ibrutinib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Hungary","Israel","Italy","Japan","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":143,"serviceSignals":["Hematology NGS"],"summary":"The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT05254743"},{"nctId":"NCT06686030","title":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-04-16","conditions":["Platinum-sensitive Ovarian Cancer"],"interventions":["AK112 low dose","Chemotherapy","Olaparib","AK112 high dose"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer(PSOC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06686030"},{"nctId":"NCT07296341","title":"HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Locally Advanced or Metastatic Pancreatic Cancer With"],"interventions":["HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine","HRS-4642;nab-paclitaxel; gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, multicenter Phase II clinical trial designed to evaluate the Safety, Tolerability and Preliminary Efficacy of HRS-4642 Combination with Other Antitumor Therapies in Patients with Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07296341"},{"nctId":"NCT06561685","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2024-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor","Non-small Cell Lung Cancer","SMARCA4-Deficient Tumor"],"interventions":["LY4050784","Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed","Paclitaxel","Nab paclitaxel"],"countries":["United States","France","Germany","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two parts - phase Ia (dose-escalation) and phase Ib (dose-optimization, dose-expansion). The study will last up to approximately 4 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06561685"},{"nctId":"NCT06911489","title":"Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2025-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Solid Tumor Malignancy"],"interventions":["68Ga-NRT6020 Injection","177Lu-NRT6020 Injection (stage 2)","177Lu-NRT6020 Injection (stage 3)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Stage 1 (Safety study for 68Ga-NRT6020 Injection): The goal of this clinical trial stage is to evaluate the safety of 68Ga-NRT6020 Injection in participants with advanced solid tumors. The study will also assess the biodistribution, radiation dosimetry, imaging profile, and pharmacokinetics of the drug. Additionally, researchers aim to investigate how consistent the PET/CT imaging results of 68Ga-NRT6020 are with 18F-FDG PET/CT imaging and FAP immunohistochemistry (IHC) results. Stage 2 (Safety and tolerability study for 177Lu-NRT6020 Injection): This stage focuses on evaluating the safety and tolerability of 177Lu-NRT6020 Injection in FAP-positive participants with advanced solid tumors. Re","sourceUrl":"https://clinicaltrials.gov/study/NCT06911489"},{"nctId":"NCT06941142","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":382,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-04-23","conditions":["Advanced Breast Cancer"],"interventions":["Sirolimus (albumin - bound)","Palbociclib tablet","Fulvestrant injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study adopts multicenter/randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant in this patient population.","sourceUrl":"https://clinicaltrials.gov/study/NCT06941142"},{"nctId":"NCT07265674","title":"A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer","sponsor":"J-Pharma Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Advanced Biliary Tract Cancer","Biliary Tract Cancer (BTC)"],"interventions":["Nanvuranlat","Physician's Best Choice"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the trial will be randomly assigned to receive 1 of 3 nanvuranlat dose regimens or PBC. In Part B, participants will be randomly assigned to receive nanvuranlat or PBC. Participants will receive treatment every 2 weeks for as long as they do not experience safety issues, or their cancer gets worse, and the study doctor feels they should stop treatment. Health measurements including physical examinations, vital signs, ECGs, a","sourceUrl":"https://clinicaltrials.gov/study/NCT07265674"},{"nctId":"NCT07406633","title":"KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["GIST - Gastrointestinal Stromal Tumor","GIST","GIST Metastatic Cancer","Gastro Intestinal Stromal Tumour","Gastrointestinal Tumors"],"interventions":["KQB198","Imatinib (Gleevec)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study will test an experimental drug called KQB198 in combination with imatinib. The goal is to determine if this combination is safe and tolerable and assess how effective the combination is at treating GIST. Imatinib has been approved by the FDA for the treatment of different types of cancer including GIST.","sourceUrl":"https://clinicaltrials.gov/study/NCT07406633"},{"nctId":"NCT07475572","title":"A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma","sponsor":"Alvotech Swiss AG","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-06-19","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-14","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Melanoma"],"interventions":["AVT32-DRL_PB","Keytruda"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, parallel-group, 2 treatment group, repeated dose study to compare the PK, efficacy, safety, and immunogenicity of AVT32-DRL\\_PB (proposed Keytruda® biosimilar) versus Keytruda (pembrolizumab) when administered as monotherapy in participants with fully resected Stage IIB/C or Stage III melanoma requiring adjuvant treatment with pembrolizumab. Eligible participants will be randomized in a 1:1 ratio to the AVT32-DRL\\_PB or Keytruda treatment group and stratified by sex (female versus male) and body weight category (≤75 kg versus \\>75 kg). Study treatments will be administered every 3 weeks (Q3W) as an intravenous (IV) infusion over 30 minutes (1 ","sourceUrl":"https://clinicaltrials.gov/study/NCT07475572"},{"nctId":"NCT06782555","title":"A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab","sponsor":"ImmunoGenesis","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2025-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2025-01-21","conditions":["Metastatic Prostate Cancer","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Pancreatic Cancer"],"interventions":["Evofosfamide","Zalifrelimab","Balstilimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).","sourceUrl":"https://clinicaltrials.gov/study/NCT06782555"},{"nctId":"NCT07142837","title":"Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-08-27","conditions":["Advanced Solid Tumor"],"interventions":["ZG005","Gecacitinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07142837"},{"nctId":"NCT07179679","title":"A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Multiple Myeloma"],"interventions":["TQB2934 injection (subcutaneous injection)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07179679"},{"nctId":"NCT05528055","title":"A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2022-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2022-09-06","conditions":["Solid Tumor","Non Hodgkin Lymphoma"],"interventions":["SCR-6920 capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05528055"},{"nctId":"NCT07140393","title":"A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-10-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Solid Tumor"],"interventions":["HRS-4508+ Capecitabine","HRS-4508+ Trastuzumab","HRS-4508+ Trastuzumab+ Pertuzumab","HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel","HRS-4508+ Trastuzumab + Nab-paclitaxel","HRS-4508+ Trastuzumab+ Capecitabine","Trastuzumab+ Capecitabine","Trastuzumab+ Pertuzumab","HRS-4508+SHR-A1811"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.","sourceUrl":"https://clinicaltrials.gov/study/NCT07140393"},{"nctId":"NCT04570423","title":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","sponsor":"Spectrum Pharmaceuticals, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2021-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Solid Tumors","Lymphoma"],"interventions":["Eflapegrastim","Chemotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04570423"},{"nctId":"NCT06690775","title":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2024-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal","Fallopian Tube Cancer","Endometrioid Ovarian Cancer"],"interventions":["TORL-1-23","Pegfilgrastim (drug)"],"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Ireland","Italy","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["ADC biomarker"],"summary":"A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06690775"},{"nctId":"NCT06904235","title":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","sponsor":"Helsinn Healthcare SA","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2025-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Nausea and Vomiting Chemotherapy-Induced","Nausea Post Chemotherapy"],"interventions":["IV NEPA (fosnetupitant/palonosetron)","Reference Treatment: IV ondansetron infusion","Reference Treatment: IV fosaprepitant infusion"],"countries":["Greece","Poland","Romania","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed. The two substances are: palonosetron, an antagonist of 5 HT3 receptors, and fosnetupitant, an antagonist of NK1 receptors that transforms into netupitant in the body. The medication is administered through intravenous injection (IV- drip). This study is built from 2 parts: Part 1: phase 2, open label Part 2: phase 3 double blind The detailed description, study design, study milestones and eligibility criteria will reflect the Part 1 requirements","sourceUrl":"https://clinicaltrials.gov/study/NCT06904235"},{"nctId":"NCT04851717","title":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","sponsor":"Acacia Pharma Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2021-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["Pediatric ALL"],"interventions":["Remimazolam"],"countries":["United States","Denmark"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy of intravenous remimazolam in inducing and maintaining suitable sedation levels for paediatric patients undergoing diagnostic and/or therapeutic procedures","sourceUrl":"https://clinicaltrials.gov/study/NCT04851717"},{"nctId":"NCT07100249","title":"A Study of HDM2012 in Patients With Advanced Solid Tumor","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":129,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-08-08","conditions":["Advanced Solid Tumors"],"interventions":["HDM2012"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug HDM2012 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07100249"},{"nctId":"NCT07497074","title":"JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Cervical Cancer"],"interventions":["JSKN033","Platinum","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer. It will also learn about the antitumor activity and pharmacokinetic/ pharmacodynamic profiles of this therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07497074"},{"nctId":"NCT06057610","title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":868,"enrollmentType":"ACTUAL","startDate":"2023-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2032-10","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["HER2-PositiveRecurrent or Metastatic Breast Cancer"],"interventions":["SHR-A1811 Injection","SHR-A1811 Injection ； Pertuzumab Injection","Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06057610"},{"nctId":"NCT01481532","title":"Open Label Clinical Trial of Intravenous Crotoxin Part 3","sponsor":"Celtic Biotech Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Cancer"],"interventions":["Crotoxin"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objective of the study is to assess whether human subjects can be made tolerant to intravenously administered Crotoxin and achieve higher and more therapeutically effective doses levels without the previously reported adverse effects associated with bolus i.m. administration.","sourceUrl":"https://clinicaltrials.gov/study/NCT01481532"},{"nctId":"NCT07104110","title":"Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2025-08-05","conditions":["Prostatic Neoplasms"],"interventions":["QLH12016","abiraterone acetate","enzalutamide"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07104110"},{"nctId":"NCT07745361","title":"Study of Oral MRT-2359 With Apalutamide in Prostate Cancer","sponsor":"Monte Rosa Therapeutics, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Castration-Resistant Prostate Cancer (CRPC)","Castration-Resistant Prostate Cancer","Prostate Cancer","Prostate Cancer (Adenocarcinoma)"],"interventions":["Oral MRT-2359","Apalutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT07745361"},{"nctId":"NCT06634394","title":"APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML","sponsor":"Aptevo Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2024-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2025-05-11","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["APVO436","Venetoclax","Azacitidine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"A multi-center, open-label, dose-finding study of five dose levels of APVO436 in combination with venetoclax and azacitidine (ven/aza) in adult patients with newly diagnosed, CD123+ AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT06634394"},{"nctId":"NCT07673627","title":"ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis","sponsor":"argenx","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["AChR-Ab Seropositive Generalized Myasthenia Gravis","Myasthenia Gravis (MG)","MG - Myasthenia Gravis","gMG"],"interventions":["Empasiprubart IV","Placebo IV","Efgartigimod PH20 SC PFS"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA2 is to investigate the effects of empasiprubart in participants with AChR-Ab seropositive generalized myasthenia gravis (gMG). The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adaptforward2","sourceUrl":"https://clinicaltrials.gov/study/NCT07673627"},{"nctId":"NCT06244771","title":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","sponsor":"Frontier Medicines Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":403,"enrollmentType":"ESTIMATED","startDate":"2024-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Advanced Solid Tumors With KRAS G12C Mutations","Solid Tumor, Adult","Unresectable Solid Tumor","Metastatic Solid Tumor","Non Small Cell Lung Cancer","Colorectal Cancer","KRAS G12C","Pancreatic Cancer"],"interventions":["FMC-376"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["RAS genotyping"],"summary":"The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants with advanced solid tumors will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT06244771"},{"nctId":"NCT05514054","title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":8000,"enrollmentType":"ESTIMATED","startDate":"2022-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2032-03","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Breast Neoplasms"],"interventions":["Imlunestrant","Tamoxifen","Anastrozole","Letrozole","Exemestane"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","Singapore","Slovakia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":672,"serviceSignals":["HER2 profiling"],"summary":"The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT05514054"},{"nctId":"NCT06937177","title":"Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy","sponsor":"Endevica Bio","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Cancer Weight Loss"],"interventions":["TCMCB07","Placebo"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newly diagnosed, advanced, unresectable colorectal cancer (CRC) or 2) patients with newly diagnosed, advanced, unresectable pancreatic ductal adenocarcinoma (PDAC). Within each cohort, patients will be randomized 1:1:1:1 to receive placebo or one of three different doses of mifomelatide (12.5 mg, 25 mg, or 50 mg). This study is designed to evaluate the effects of different doses of mifomelatide on weight, body composition and BMI. The double-blind (DB) phase wi","sourceUrl":"https://clinicaltrials.gov/study/NCT06937177"},{"nctId":"NCT05801029","title":"A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ACTUAL","startDate":"2023-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["Osimertinib","Amivantamab"],"countries":["Hong Kong","Malaysia","Singapore","South Korea","Taiwan","Thailand"],"northAmerica":false,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05801029"},{"nctId":"NCT07049458","title":"Study of CHO-A04 in Advanced Solid Tumors","sponsor":"Cho Pharma Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-01","completionType":"ESTIMATED","lastUpdated":"2025-07-03","conditions":["Advanced Solid Tumors"],"interventions":["CHO-A04"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if the study drug, CHO-A04, works to treat solid cancers in adults. It will also aim to learn about the safety of CHO-A04 and find the best dose to use in future cancer treatment. The main questions it aims to answer are: * Which dose of CHO-A04 shows the best anti-cancer ability? * How will your body respond to CHO-A04 treatment? * How long will CHO-A04 remain in your body? There are two stages of investigation in this study: * Phase I: to find the best anti-cancer dose of CHO-A04 * Phase IIa: to find the CHO-A04 anti-cancer ability in specific cancer types In this study, each participant will be assigned to one of the CHO-A04 dose levels. Partici","sourceUrl":"https://clinicaltrials.gov/study/NCT07049458"},{"nctId":"NCT07310173","title":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["HCC - Hepatocellular Carcinoma"],"interventions":["AST-3424","Regorafenib Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if drug AST-3424 works to treat AKR1C3 high expressing advanced hepatocellular carcinoma after failure of systemic therapy with immune checkpoint inhibitors. The main question it aims to answer is: Does AST-3424 prolong survival in patients with AKR1C3-high Expressing advanced Hepatocellular Carcinoma who have progressed after immune checkpoint inhibitors based therapies? Researchers will compare AST-3424 to regorafenib (current optional therapy for target patients) to see if AST-3424 works. Participants will: Receive AST-3424 infusion on Day 1 and Day 8 of each 21-day treatment cycle or take regorafenib once a day on Day 1 -Day 21 of each 28-day t","sourceUrl":"https://clinicaltrials.gov/study/NCT07310173"},{"nctId":"NCT05950945","title":"Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2023-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Breast Cancer"],"interventions":["Trastuzumab Deruxtecan"],"countries":["United States","Australia","Belgium","Brazil","China","Ireland","Italy","Netherlands","Portugal","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":88,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \\[HR\\]-negative and HR-positive) unresectable and/or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05950945"},{"nctId":"NCT05489211","title":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":454,"enrollmentType":"ESTIMATED","startDate":"2022-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Endometrial Cancer","Gastric Cancer","Metastatic Castration-resistant Prostate Cancer","Ovarian Cancer","Colorectal Cancer","Urothelial Cancer","Biliary Tract Cancer"],"interventions":["Datopotamab deruxtecan (Dato-DXd)","Capecitabine","5-Fluorouracil","Volrustomig","Carboplatin","Bevacizumab","Rilvegostomig","Prednisone/ prednisolone","Cisplatin"],"countries":["United States","Canada","China","France","Germany","Italy","Japan","Poland","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":96,"serviceSignals":["ADC biomarker"],"summary":"TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT05489211"},{"nctId":"NCT07087197","title":"A Study of SKB107 in Advanced Solid Tumors With Bone Metastases","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Metastatic Solid Tumors"],"interventions":["SKB107 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A multicenter, open-label Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, dosimetry and efficacy of SKB107 in subjects with advanced solid tumors with bone metastases.","sourceUrl":"https://clinicaltrials.gov/study/NCT07087197"},{"nctId":"NCT05415072","title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":66,"enrollmentType":"ACTUAL","startDate":"2022-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Metastatic Uveal Melanoma"],"interventions":["DYP688"],"countries":["United States","Australia","France","Germany","Netherlands","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05415072"},{"nctId":"NCT07086105","title":"A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma","sponsor":"Adze Biotechnology Australia Pty Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Metastatic Melanoma"],"interventions":["Adze1.C"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is Phase I, open label, multi-center clinical trial evaluating an investigational treatment, Adze1.C. Adze1.C is a type of oncolytic virus therapy for adults with advanced Melanoma that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight tumors. The purpose of this study is to assess preliminary efficacy, determine the safety of Adze1.C, how well it is tolerated, and to identify the highest dose that can be safely given.","sourceUrl":"https://clinicaltrials.gov/study/NCT07086105"},{"nctId":"NCT06751329","title":"A Study of DM002 in Patients With Advanced Solid Tumors","sponsor":"Xadcera Biopharmaceutical (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2025-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-18","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Ovarian Neoplasms","Prostatic Neoplasms","Endometrial Neoplasms","Colorectal Neoplasms","Solid Carcinoma","Pancreatic Cancer"],"interventions":["DM002"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced s","sourceUrl":"https://clinicaltrials.gov/study/NCT06751329"},{"nctId":"NCT06387082","title":"A Clinical Study of HMPL-506 in Patients With Hematological Malignancies","sponsor":"Hutchmed","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2024-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-08","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-08","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Hematological Malignancies"],"interventions":["HMPL-506"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies. Only eligible patients who provide the signed informed consent form (ICF) can be enrolled in this study. The study consists of two phases, i.e., a dose escalation phase and a dose expansion phase. The study is expected to enroll approximately 60 to 132 patients, including approximately 30 to 38 patients in the dose escalation phase and approximately 30 to 72 patients in the dose expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT06387082"},{"nctId":"NCT06132113","title":"DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2024-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Neuroendocrine Neoplasms"],"interventions":["BI 764532","Carboplatin","Etoposide","Cisplatin"],"countries":["United States","Belgium","France","Germany","Japan","Netherlands","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["ADC biomarker"],"summary":"This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3. The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has Part A1, Part A2, and Part B. Part A1 of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. Part A2 of this study is to find out how well people tolerate a low dose of BI 764532 combined with the chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researcher","sourceUrl":"https://clinicaltrials.gov/study/NCT06132113"},{"nctId":"NCT06937957","title":"A Study of BR111 in Patients With Advanced Malignancies","sponsor":"BioRay Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":166,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-09","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Advanced Malignancies"],"interventions":["BR111 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR111-101 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR111-101 for injection in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06937957"},{"nctId":"NCT07052383","title":"Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas","sponsor":"Tcelltech Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-10","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Osteosarcoma","Soft Tissue Sarcoma"],"interventions":["DIT309 cell injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a open-Label, dose-escalation study to evaluate the safety, tolerability and antitumor activity of DIT309 in subjects with advanced bone and soft tissue sarcomas.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07052383"},{"nctId":"NCT04807881","title":"Phase Ib Clinical Study of Keynatinib","sponsor":"Medolution Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2020-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-10","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Lymphoma, B-Cell"],"interventions":["Keynatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R/R-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT04807881"},{"nctId":"NCT07122414","title":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-10","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Non-muscle Invasive Bladder Cancer (NMIBC)"],"interventions":["FL115","FL115+BCG"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG. To evaluate the preliminary efficacy of FL115 alone or in combination with BCG in the treatment of NMIBC. The study consists of three parts: FL115 monotherapy dose escalation (Phase Ia), FL115 combined with BCG dose escalation (Phase Ib), and FL115 combined with BCG cohort expansion (Phase II). Each subject will receive FL115 alone or in combination with intravesical BCG, administered over three treatment periods: induction, enhanced induction/maintenance 1, and maintenance 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT07122414"},{"nctId":"NCT06544655","title":"A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":213,"enrollmentType":"ESTIMATED","startDate":"2024-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-14","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-14","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Advanced Solid Tumors"],"interventions":["BMS-986484","Nivolumab","Oxaliplatin","Capecitabine","Fluorouracil","Calcium folinate"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).","sourceUrl":"https://clinicaltrials.gov/study/NCT06544655"},{"nctId":"NCT07402915","title":"Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-15","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Fallopian Tube Cancer","Ovarian Cancer","Primary Peritoneal"],"interventions":["AZD5335","Itraconazole"],"countries":["Georgia","Ireland","Portugal","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.","sourceUrl":"https://clinicaltrials.gov/study/NCT07402915"},{"nctId":"NCT05907057","title":"An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.","sponsor":"Servier Affaires Médicales","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":245,"enrollmentType":"ESTIMATED","startDate":"2023-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-15","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["Ivosidenib 500mg Oral Tablet","Azacitidine"],"countries":["Austria","France","Italy","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive \\[IDH1m\\]) and cannot receive treatment with intensive chemotherapy (IC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05907057"},{"nctId":"NCT06764771","title":"A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":437,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-15","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced Malignant Tumors"],"interventions":["BMS-986488","Adagrasib","Cetuximab","Nivolumab"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764771"},{"nctId":"NCT07044336","title":"Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":800,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-17","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Endometrial Cancer","Malignant Solid Tumour"],"interventions":["Puxitatug Samrotecan","Doxorubicin","Paclitaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hungary","Israel","Italy","Japan","Lithuania","Netherlands","Poland","Singapore","Slovenia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":320,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07044336"},{"nctId":"NCT07227012","title":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-17","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Carcinoma, Hepatocellular","Hepatocellular Cancer","Hepatocellular Carcinoma","Unresectable Hepatocellular Carcinoma","Liver Neoplasms","Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma"],"interventions":["PF-08634404","Ipilimumab"],"countries":["United States","Japan","Puerto Rico","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced or metastatic HCC. * Is not a candidate for complete surgical or loco-regional therapies. * Have not received any whole-body treatment for HCC. Participants will receive PF-08634404 either alone or in combination with ipilimumab. The medicine will be given t","sourceUrl":"https://clinicaltrials.gov/study/NCT07227012"},{"nctId":"NCT03876769","title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":121,"enrollmentType":"ACTUAL","startDate":"2019-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-19","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-19","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["B-Cell Acute Lymphoblastic Leukemia"],"interventions":["CTL019"],"countries":["United States","Belgium","Canada","Denmark","France","Italy","Netherlands","Norway","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment \\& follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months for the first year, every 6 months for the second year, then yearly until the end of the study. Efficacy and safety will be assessed at study visits and as clinically indicated throughout the study. T","sourceUrl":"https://clinicaltrials.gov/study/NCT03876769"},{"nctId":"NCT06656390","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":202,"enrollmentType":"ESTIMATED","startDate":"2024-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-22","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Advanced Cancer","Advanced Solid Tumors"],"interventions":["ALK201"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK201.","sourceUrl":"https://clinicaltrials.gov/study/NCT06656390"},{"nctId":"NCT02861573","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1200,"enrollmentType":"ESTIMATED","startDate":"2016-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-24","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["Pembrolizumab 200 mg","Olaparib 400 mg","Docetaxel 75 mg/m^2","Prednisone 5 mg","Enzalutamide 160 mg","Dexamethasone 8 mg","Olaparib 300 mg","Abiraterone acetate 1000 mg","Lenvatinib","Pembrolizumab/Vibostolimab coformulation","Carboplatin","Etoposide","Belzutifan 120mg"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I wi","sourceUrl":"https://clinicaltrials.gov/study/NCT02861573"},{"nctId":"NCT06640049","title":"A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":23,"enrollmentType":"ACTUAL","startDate":"2024-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-24","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-15","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Neoplasms, Rectal"],"interventions":["Dostarlimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["MSI / TMB"],"summary":"The main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient (dMMR)/ Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06640049"},{"nctId":"NCT06638307","title":"A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-24","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-23","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Advanced Breast Cancer"],"interventions":["MEN2312","Elacestrant"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06638307"},{"nctId":"NCT06705725","title":"Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma","sponsor":"Carbiogene Therapeutics Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2024-12-26","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-22","completionType":"ESTIMATED","lastUpdated":"2024-11-26","conditions":["Multiple Myeloma"],"interventions":["CBG002 CAR-T Cell Suspension"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06705725"},{"nctId":"NCT06672523","title":"A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2025-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-25","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Advanced Solid Tumors With Homozygous MTAP Deletion"],"interventions":["BMS-986504","[14C]-BMS-986504"],"countries":["Hungary","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \\[14C\\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06672523"},{"nctId":"NCT06966453","title":"A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-27","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Breast Cancer","Breast Neoplasms"],"interventions":["Disitamab vedotin"],"countries":["United States","Australia","Brazil","Canada","Germany","Italy","Japan","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":166,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or","sourceUrl":"https://clinicaltrials.gov/study/NCT06966453"},{"nctId":"NCT06926075","title":"Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","sponsor":"Filamon LTD","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-26","completionType":"ESTIMATED","lastUpdated":"2026-03-17","conditions":["Prostate Cancers","Breast Cancer","Lung Cancers","Ovarian Cancer","Glioblastoma Multiforme (GBM)","Pancreas Cancer","Skin Cancer"],"interventions":["A novel hGIIA-Vimentin Inhibitor","Dose expansion"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06926075"},{"nctId":"NCT07124936","title":"A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":97,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-25","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Diffuse Large B Cell Lymphoma (DLBCL)"],"interventions":["HDM2005","Rituximab or Rituximab biosimilar","Gemcitabine","Oxaliplatin","Cyclophosphamide","Doxorubicin","Prednisone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.","sourceUrl":"https://clinicaltrials.gov/study/NCT07124936"},{"nctId":"NCT06435312","title":"An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 3","phases":["PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2024-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-19","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Generalized Myasthenia Gravis"],"interventions":["Zilucoplan"],"countries":["Italy","Poland","South Korea","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the long-term safety and tolerability of an additional 52 weeks of Zilucoplan treatment administered by subcutaneous injection once daily in pediatric study participants","sourceUrl":"https://clinicaltrials.gov/study/NCT06435312"},{"nctId":"NCT06990880","title":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-09","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Neoplasms, Prostate"],"interventions":["GSK5458514"],"countries":["United States","Canada","France","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).","sourceUrl":"https://clinicaltrials.gov/study/NCT06990880"},{"nctId":"NCT06090539","title":"A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2023-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-28","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Relapsed/Refractory Non-Hodgkin Lymphoma"],"interventions":["BMS-986458","Rituximab","Glofitamab/Obinutuzumab","Mosunetuzumab","Epcoritamab","Golcadomide"],"countries":["United States","Chile","China","France","Germany","Greece","Hong Kong","Italy","Japan","Netherlands","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06090539"},{"nctId":"NCT04624204","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":672,"enrollmentType":"ESTIMATED","startDate":"2020-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-28","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-28","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Small Cell Lung Cancer"],"interventions":["Pembrolizumab 200 mg","Pembrolizumab 400 mg","Pembrolizumab placebo (saline)","Olaparib 300 mg BID","Olaparib matching placebo","Etoposide 100 mg/m^2","Platinum, investigator's choice","Standard Thoracic Radiotherapy","Prophylactic Cranial Irradiation (PCI)"],"countries":["United States","Australia","Belgium","Bulgaria","Canada","China","Estonia","France","Greece","Hungary","Israel","Italy","Japan","Lithuania","Mexico","Portugal","Romania","Russia","Serbia","South Africa","South Korea","Spain","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":187,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung to other parts of the body. The purpose of this study is to learn if pembrolizumab and olaparib, when given with chemotherapy and radiation treatment (CRT), can be effective in treating LS-SCLC. The researchers want to know if participants who receive CRT and pembrolizumab, with or without olaparib, have a longer overall survival compared to participants who only receive CRT.","sourceUrl":"https://clinicaltrials.gov/study/NCT04624204"},{"nctId":"NCT06452277","title":"A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)","sponsor":"Bayer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":444,"enrollmentType":"ESTIMATED","startDate":"2024-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-27","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced Non-small Cell Lung Cancer, HER2 Mutation"],"interventions":["Sevabertinib","Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Romania","Singapore","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":285,"serviceSignals":["HER2 profiling"],"summary":"Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building plans (genes) for this protein in cancer cells leads to a production of abnormal HER2 and therefore abnormal cell growth and division. The study treatment, sevabertinib, is expected to block the mutat","sourceUrl":"https://clinicaltrials.gov/study/NCT06452277"},{"nctId":"NCT07648030","title":"A Study of Rusfertide in Japanese Adults With Polycythemia Vera","sponsor":"Takeda","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2026-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-17","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Polycythemia Vera"],"interventions":["Rusfertide"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"Polycythemia vera (PV) is a rare blood cancer in which the body makes too many red blood cells. This can make the blood thicker and may increase the risk of serious health problems such as blood clots. Many people with PV need regular phlebotomy, which is a procedure to remove blood, to help keep their hematocrit level under control. Hematocrit is the proportion of red blood cells in the blood. The main aim of this study is to evaluate whether rusfertide helps Japanese participants with PV keep their hematocrit under control and avoid the need for phlebotomy. All participants in this study will receive rusfertide. This study is open-label, which means both the participants and the study team","sourceUrl":"https://clinicaltrials.gov/study/NCT07648030"},{"nctId":"NCT06470438","title":"A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":58,"enrollmentType":"ACTUAL","startDate":"2024-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-29","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Lymphoma, Non-Hodgkin","Refractory B-Cell NHL","Relapsed B-cell NHL"],"interventions":["JNJ-88998377"],"countries":["China","Italy","Japan","Poland","South Korea","Taiwan","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":true,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT06470438"},{"nctId":"NCT02843945","title":"Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source","sponsor":"CivaTech Oncology","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2017-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2025-06-17","conditions":["Pancreatic Cancer"],"interventions":["Directional Brachytherapy Source Implant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Initial study to evaluate local control and the preferred method of attachment of the CivaSheet in the setting of suspected close or positive margins at the time of surgical tumor removal.","sourceUrl":"https://clinicaltrials.gov/study/NCT02843945"},{"nctId":"NCT05929235","title":"A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma","sponsor":"Flare Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-08-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-30","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Advanced Urothelial Carcinoma","Oral Drug Administration","Open Label"],"interventions":["FX-909","Pembrolizumab (KEYTRUDA ®)","KEYTRUDA ®( Pembrolizumab)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question\\[s\\] it aims to answer are: * Is FX-909 safe and tolerable, as a monotherapy and in combination with Pembrolizumab * What is the right dose level for patients Participants will be asked to take FX-909 daily in tablet form, or FX-909 daily and Pembrolizumab every 3 weeks, and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor samples as well as have regular CT/MRI scans.","sourceUrl":"https://clinicaltrials.gov/study/NCT05929235"},{"nctId":"NCT04740424","title":"FS222 First in Human Study in Patients With Advanced Malignancies","sponsor":"invoX Pharma Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2020-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-30","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["Advanced Cancer","Metastatic Cancer"],"interventions":["FS222"],"countries":["Australia","Georgia","Germany","Netherlands","Poland","Romania","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT04740424"},{"nctId":"NCT05903833","title":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy","sponsor":"AGO Research GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-30","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Recurrent Vulvar Cancer","Persistent Vulvar Cancer","Metastatic Vulva Cancer","Locally Advanced Vulvar Cancer"],"interventions":["Pembrolizumab","Lenvatinib"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05903833"},{"nctId":"NCT07241936","title":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":444,"enrollmentType":"ESTIMATED","startDate":"2025-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Advanced Solid Tumors"],"interventions":["sirolimus (albumin-bound)","DP303c","SYS6043","SYS6002","SYS6010"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study adopts a multi-center, open-label, non-randomized trial design. It plans to enroll patients with Advanced solid tumor. Dose-escalation and PK-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with Different ADCs (DP303c/SYS6043/SYS6002/SYS6010) in this patient population, and to confirm the recommended phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07241936"},{"nctId":"NCT06690827","title":"Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2024-11-15","conditions":["AML (Acute Myeloid Leukemia)","BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)"],"interventions":["Anti-CD123 CAR NK cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06690827"},{"nctId":"NCT06095505","title":"A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer","sponsor":"Puma Biotechnology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-02-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Small Cell Lung Cancer"],"interventions":["Alisertib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.","sourceUrl":"https://clinicaltrials.gov/study/NCT06095505"},{"nctId":"NCT07530666","title":"Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia","sponsor":"Dartsbio Pharmaceuticals Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Cancer","Cachexia"],"interventions":["DS010 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia","sourceUrl":"https://clinicaltrials.gov/study/NCT07530666"},{"nctId":"NCT06378177","title":"A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)","sponsor":"Lyvgen Biopharma Holdings Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":64,"enrollmentType":"ESTIMATED","startDate":"2024-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["LVGN6051 Monoclonal Antibody Injection","toripalimab Injection","Paclitaxel injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and efficacy of LVGN6051 (4-1BB agonistic antibody) combined with toripalimab (anti-PD-1 antibody) and paclitaxel (anti-tubulin chemotherapy) in patients with recurrent/metastatic head and neck squamous cell carcinoma who rapidly progress from previous neoadjuvant, curative, or adjuvant platinum-containing therapy, or who are currently contraindicated for platinum-containing treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06378177"},{"nctId":"NCT05296798","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":922,"enrollmentType":"ESTIMATED","startDate":"2022-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["Phesgo","Giredestrant","Docetaxel","Paclitaxel","LHRH Agonist","Optional Endocrine Therapy of Investigator's Choice"],"countries":["United States","Argentina","Belgium","Brazil","China","Colombia","Egypt","France","Germany","Hungary","India","Italy","Jordan","Kenya","Lebanon","Mexico","Oman","Poland","Portugal","Saudi Arabia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Uganda","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":202,"serviceSignals":["HER2 profiling"],"summary":"This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT05296798"},{"nctId":"NCT06861088","title":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","sponsor":"Quercis Pharma AG","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-31","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Venous Thromboembolism","Metastatic Pancreatic Cancer","Locally Advanced Pancreatic Adenocarcinoma"],"interventions":["Kinisoquin™","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06861088"},{"nctId":"NCT06547385","title":"Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2021-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2024-08-09","conditions":["Colorectal Cancer"],"interventions":["ONO-4578","ONO-4538","Capecitabine","Oxaliplatin","Fluorouracil","Calcium Levofolinate Hydrateb","Bevacizumab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06547385"},{"nctId":"NCT05907980","title":"A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors","sponsor":"Chugai Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":209,"enrollmentType":"ESTIMATED","startDate":"2023-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-10-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Solid Tumor"],"interventions":["ROSE12","Atezolizumab","Pembrolizumab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.","sourceUrl":"https://clinicaltrials.gov/study/NCT05907980"},{"nctId":"NCT07658183","title":"A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer","sponsor":"Shanghai Best-Link Bioscience, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-20","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Breast Cancer (Locally Advanced or Metastatic)"],"interventions":["BL0175"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. The main questions it aims to answer are: 1. Which dose level of BL0175 demonstrates the optimal ORR? 2. What is the recommended phase 3 dose (RP3D) based on efficacy and safety data across the tested dose levels?","sourceUrl":"https://clinicaltrials.gov/study/NCT07658183"},{"nctId":"NCT07154368","title":"JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.","sponsor":"Guangzhou JOYO Pharma Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":207,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-19","conditions":["Non Small Cell Lung Cancer"],"interventions":["Pemetrexed injection","Cross-over to JYP0322","JYP0322 tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RNA fusion"],"summary":"The primary purpose of the study was to compare progression-free survival of JYP0322 vs. platinum-based doublet chemotherapy in patients previously treated with ROS1-TKIs. Patients in the chemotherapy arm are given the option to switch to JYP0322 after BICR confirmed progressive disease (PD), while also have the choice to pursue with other drugs after discussing with their physicians.","sourceUrl":"https://clinicaltrials.gov/study/NCT07154368"},{"nctId":"NCT07109531","title":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","sponsor":"Jiangsu Aosaikang Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":286,"enrollmentType":"ESTIMATED","startDate":"2025-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Locally Advanced or Metastatic NSCLC"],"interventions":["ASKC202+ Limertinib","Pemetrexed + Cisplatin /Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07109531"},{"nctId":"NCT04170283","title":"Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies","sponsor":"BeiGene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":955,"enrollmentType":"ACTUAL","startDate":"2020-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["B-cell Malignancies"],"interventions":["Zanubrutinib","Tislelizumab"],"countries":["United States","Australia","China","Czechia","France","Germany","Greece","Italy","Japan","Netherlands","New Zealand","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":152,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04170283"},{"nctId":"NCT07163325","title":"EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors","sponsor":"Epics Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Advanced Solid Tumor (Phase 1)"],"interventions":["EP102"],"countries":["Belgium","Czechia","Netherlands","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies. This study will inform on recommended doses for further studies, e.g. dose optimization studies and / or efficacy and safety studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07163325"},{"nctId":"NCT05544019","title":"Study of SGR-1505 in Mature B-Cell Neoplasms","sponsor":"Schrödinger, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2023-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Mature B-Cell Neoplasm","Non Hodgkin Lymphoma","DLBCL","Waldenstrom Macroglobulinemia","MALT Lymphoma","Follicular Lymphoma","Pediatric-Type Follicular Lymphoma","IRF4 Gene Rearrangement","EBV-Positive DLBCL, Nos","Burkitt Lymphoma","Plasmablastic Lymphoma","High-grade B-cell Lymphoma","Primary Cutaneous Follicle Center Lymphoma","Primary Effusion Lymphoma","Mantle Cell Lymphoma","DLBCL Germinal Center B-Cell Type","Primary Mediastinal Large B Cell Lymphoma","T-Cell/Histiocyte Rich Lymphoma","ALK-Positive Large B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma","Splenic Marginal Zone Lymphoma","Chronic Lymphocytic Leukemia","Nodal Marginal Zone Lymphoma","HHV8-Positive DLBCL, Nos","Lymphoplasmacytic Lymphoma","Duodenal-Type Follicular Lymphoma"],"interventions":["SGR-1505"],"countries":["United States","France","Italy","Moldova","Poland","Romania","Spain","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.","sourceUrl":"https://clinicaltrials.gov/study/NCT05544019"},{"nctId":"NCT06561048","title":"Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma","sponsor":"Corvus Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Peripheral T-Cell Lymphoma, Not Otherwise Specified","Angioimmunoblastic T-cell Lymphoma","Follicular T-Cell Lymphoma","Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","Systemic Anaplastic Large Cell Lymphoma","Lymphoma, T-Cell, Peripheral","Lymphoma, T-Cell"],"interventions":["Soquelitinib","Belinostat","Pralatrexate"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06561048"},{"nctId":"NCT06772623","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","sponsor":"AbbVie","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2025-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non Small Cell Lung Carcinoma"],"interventions":["Telisotuzumab Adizutecan","Budigalimab","Pembrolizumab","Carboplatin","Pemetrexed","Cisplatin"],"countries":["United States","Belgium","China","France","Germany","Italy","Japan","Poland","Puerto Rico","Romania","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":117,"serviceSignals":["Broad CGP"],"summary":"Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination w","sourceUrl":"https://clinicaltrials.gov/study/NCT06772623"},{"nctId":"NCT06119581","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1264,"enrollmentType":"ESTIMATED","startDate":"2023-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Carcinoma, Non-Small-Cell Lung","Neoplasm Metastasis"],"interventions":["LY3537982","Pembrolizumab","Placebo","Cisplatin","Carboplatin","Pemetrexed"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","India","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","Romania","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":419,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.","sourceUrl":"https://clinicaltrials.gov/study/NCT06119581"},{"nctId":"NCT07241767","title":"A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Lung Cancer"],"interventions":["FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin","FH-006 ; SHR-1316 ; BP102","FH-006; SHR-1316 ; SHR-8068"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07241767"},{"nctId":"NCT06173518","title":"A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)","sponsor":"Autolus Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia","Relapsed or Refractory B Cell Non-Hodgkin Lymphoma"],"interventions":["AUTO1"],"countries":["United States","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 in pediatric patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B ALL) and r/r B cell Non-Hodgkin lymphoma (B NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06173518"},{"nctId":"NCT07570823","title":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","sponsor":"Sinocelltech Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":101,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["DLBCL - Diffuse Large B Cell Lymphoma"],"interventions":["SCTB35 injection","Rituxumab","Gemcitabine","Oxaliplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07570823"},{"nctId":"NCT06973564","title":"JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":294,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Advanced Solid Tumors"],"interventions":["JAB-23E73"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["RAS genotyping"],"summary":"This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06973564"},{"nctId":"NCT06589609","title":"Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer","sponsor":"BlueSky Immunotherapies GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Oropharyngeal Squamous Cell Carcinoma (SCC)"],"interventions":["FluBHPVE6E7"],"countries":["Austria"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A clinical study of an immunotherapy in patients with head or neck cancers associated with the HPV16 virus","sourceUrl":"https://clinicaltrials.gov/study/NCT06589609"},{"nctId":"NCT07271667","title":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","sponsor":"Curis, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Chronic Lymphocytic Leukemia","B-cell Malignancies"],"interventions":["Emavusertib","Zanubrutinib"],"countries":["United States","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07271667"},{"nctId":"NCT07216443","title":"Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","sponsor":"Orca Biosystems, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Leukemia, Myeloid, Acute","Myelodysplastic Syndromes","Mixed Phenotype Acute Leukemia"],"interventions":["Orca-T"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).","sourceUrl":"https://clinicaltrials.gov/study/NCT07216443"},{"nctId":"NCT07407283","title":"A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Prostate Cancer"],"interventions":["SHR-4394","Rezvilutamide","HRS-5041 Tablets","Tazemetostat"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer based on Prostate-Specific Antigen (PSA) response rate.","sourceUrl":"https://clinicaltrials.gov/study/NCT07407283"},{"nctId":"NCT05029882","title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":520,"enrollmentType":"ACTUAL","startDate":"2021-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-10-29","conditions":["Non-Small Cell Lung Cancer","Advanced Solid Tumors","Gastroesophageal Adenocarcinoma","Colorectal Cancer"],"interventions":["ABBV-400","Trifluridine/Tipiracil","Bevacizumab"],"countries":["United States","Australia","France","Israel","Japan","Poland","Puerto Rico","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":82,"serviceSignals":["MET profiling"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm receives a different dose of ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with be","sourceUrl":"https://clinicaltrials.gov/study/NCT05029882"},{"nctId":"NCT05599984","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":288,"enrollmentType":"ACTUAL","startDate":"2022-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Advanced Solid Tumors"],"interventions":["ABBV-706","Cisplatin","Budigalimab","Carboplatin"],"countries":["United States","Australia","China","France","Germany","Israel","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":66,"serviceSignals":["Broad CGP"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy and in combination with budigalimab, carboplatin, or cisplatin. ABBV-706 is an investigational drug being developed for the treatment of small cell lung cancer (SCLC), high-grade central nervous system (CNS) tumors and high-grade neuroendocrine carcinomas (NECs). There are multiple treatment arms in this study. Participants will either receive ABBV-706 as a single agent or in combination with budigalimab (another investigational drug), carboplatin or cisplatin at diff","sourceUrl":"https://clinicaltrials.gov/study/NCT05599984"},{"nctId":"NCT06974110","title":"Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors","sponsor":"MOMA Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2025-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Endometrial Cancer","MSI-H Cancer","Colorectal Cancer","Gastric Cancer","dMMR Cancer"],"interventions":["MOMA-341","Irinotecan","Immunotherapy"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["MSI / TMB"],"summary":"This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients with microsatellite instability high (MSI-H) or DNA mismatch repair deficiency (dMMR) solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06974110"},{"nctId":"NCT07123103","title":"A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Solid Tumors"],"interventions":["XB371"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.","sourceUrl":"https://clinicaltrials.gov/study/NCT07123103"},{"nctId":"NCT04219254","title":"A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","sponsor":"BioInvent International AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":197,"enrollmentType":"ESTIMATED","startDate":"2020-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Solid Tumor, Adult"],"interventions":["BI1206"],"countries":["United States","Georgia","Germany","Poland","Romania","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT04219254"},{"nctId":"NCT07548177","title":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2026-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Alveolar Soft Part Sarcoma"],"interventions":["Benmelstobart injection combined with Anlotinib hydrochloride capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07548177"},{"nctId":"NCT07018050","title":"Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["QLS32015","Pomalidomide","Dexamethasone","QL2109 or Daratumumab","Bortezomib","Lenalidomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT07018050"},{"nctId":"NCT07346846","title":"A Study of BGM-2121 in Patients With Advanced Solid Tumors","sponsor":"BioGate Precision Medicine Corp.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2026-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Advanced Solid Tumors"],"interventions":["BGM-2121"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07346846"},{"nctId":"NCT06332755","title":"Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC","sponsor":"LG Chem","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2024-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Non-small Cell Lung Cancer(NSCLC)","Head and Neck Squamous Cell Carcinoma(HNSCC)","Renal Cell Carcinoma(RCC)","Urothelial Carcinoma","Malignant Melanoma"],"interventions":["Phase 1a: LB-LR1109","Phase 1b: LB-LR1109 and Atezolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and/or metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and/or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06332755"},{"nctId":"NCT07232524","title":"A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2027-11","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Head and Neck Squamous Cell Carcinoma","Solid Tumor"],"interventions":["BL-M24D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic head and neck squamous cell carcinoma and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232524"},{"nctId":"NCT07147348","title":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":375,"enrollmentType":"ESTIMATED","startDate":"2025-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced Solid Tumor"],"interventions":["BNT3212","Pumitamig"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["ADC biomarker"],"summary":"The aim of this first-in-human (FIH) open-label, multi-site study is to evaluate safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary clinical efficacy of BNT3212, including identification of the recommended dose of BNT3212 for use as monotherapy and with pumitamig (also known as BNT327 or PM8002) as combination therapy, in adults with advanced solid tumors who have exhausted other treatment options.","sourceUrl":"https://clinicaltrials.gov/study/NCT07147348"},{"nctId":"NCT07678593","title":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":222,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumors Cancer","Pancreatic Ductal Adenocarcinoma","RAS Mutation"],"interventions":["GFH276","Cetuximab","Nab paclitaxel","Gemcitabine","Fluorouracil","Leucovorin","Irinotecan","Oxaliplatin"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["RAS genotyping"],"summary":"A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT07678593"},{"nctId":"NCT07181681","title":"A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2025-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-01","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Solid Tumors","Advanced Solid Tumor"],"interventions":["BG-C0902"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT07181681"},{"nctId":"NCT05687266","title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1350,"enrollmentType":"ACTUAL","startDate":"2022-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-01","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["NSCLC"],"interventions":["Datopotamab deruxtecan","Durvalumab","Carboplatin","Pembrolizumab","Cisplatin","Pemetrexed","Paclitaxel"],"countries":["United States","Austria","Brazil","Bulgaria","Canada","China","France","Germany","Greece","Hungary","India","Italy","Japan","Mexico","Peru","Poland","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":254,"serviceSignals":["RNA fusion","ADC biomarker"],"summary":"This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).","sourceUrl":"https://clinicaltrials.gov/study/NCT05687266"},{"nctId":"NCT04256317","title":"A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)","sponsor":"Taiho Oncology, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":316,"enrollmentType":"ESTIMATED","startDate":"2020-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Myelodysplastic Syndromes","Acute Myeloid Leukemia","Myelodysplastic Syndrome/Neoplasm","Chronic Myelomonocytic Leukemia"],"interventions":["Azacitidine","ASTX030 (cedazuridine + azacitidine)","Cedazuridine","Venetoclax"],"countries":["United States","Canada","Czechia","France","Germany","Hungary","Italy","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":71,"serviceSignals":["Hematology NGS"],"summary":"Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 Monotherapy is a randomized open-label crossover study comparing the final fixed dose of oral ASTX030 to SC azacitidine. Phase 1 Combination Therapy is an open-label, multicent","sourceUrl":"https://clinicaltrials.gov/study/NCT04256317"},{"nctId":"NCT06820268","title":"A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies","sponsor":"NovaOnco Therapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2025-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-15","completionType":"ESTIMATED","lastUpdated":"2025-03-04","conditions":["B-cell Lymphoma","Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"interventions":["XS-04 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06820268"},{"nctId":"NCT04862663","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":895,"enrollmentType":"ESTIMATED","startDate":"2021-05-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-14","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"interventions":["Capivasertib","Fulvestrant","Palbociclib","Ribociclib","Abemaciclib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","India","Italy","Japan","Malaysia","Poland","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":284,"serviceSignals":["HER2 profiling"],"summary":"A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)","sourceUrl":"https://clinicaltrials.gov/study/NCT04862663"},{"nctId":"NCT07719348","title":"A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies","sponsor":"Servier","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":64,"enrollmentType":"ESTIMATED","startDate":"2026-09-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome Acute Myeloid Leukemia"],"interventions":["S241656","Posaconazole"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656. The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatm","sourceUrl":"https://clinicaltrials.gov/study/NCT07719348"},{"nctId":"NCT05417594","title":"Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":695,"enrollmentType":"ESTIMATED","startDate":"2022-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Solid Malignancies"],"interventions":["AZD9574","Temozolomide (TMZ)","[11C]AZ1419 3391","Trastuzumab Deruxtecan (T-DXd)","Datopotamab Deruxtecan (Dato-DXd)"],"countries":["United States","Australia","Germany","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.","sourceUrl":"https://clinicaltrials.gov/study/NCT05417594"},{"nctId":"NCT07621159","title":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Colorectal Cancer Metastatic"],"interventions":["HDM2017","Fruquintinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ib/II clinical study. All participants are patients with advanced colorectal cancer (CRC). The purpose of this study is to to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary anti-tumor efficacy of HDM2017 in combination with standard of care in patients with advanced CRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07621159"},{"nctId":"NCT06641024","title":"Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-11-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2039-11-01","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Acute Lymphoblastic Leukemia, in Relapse","Refractory Acute Lymphoblastic Leukemia"],"interventions":["MC-1-50"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B Cell Acute Lymphoblastic Leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06641024"},{"nctId":"NCT07227415","title":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2026-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Renal Cell","Advanced Renal Cell Carcinoma","Renal Cancer","Renal Neoplasm","Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Clear-cell Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell Metastasis","Advanced or Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell, Advanced","Metastatic Renal Cell Cancer","Metastatic Renal Cell Carcinoma ( mRCC)","Metastatic/Advanced Renal Cell Carcinoma"],"interventions":["PF-08634404","Ipilimumab","Axitinib"],"countries":["United States","Australia","China","Germany","Japan","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":128,"serviceSignals":["Broad CGP"],"summary":"This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the study medicine, when given alone or with other anticancer medicines, and how this type of cancer responds to them. To join the study, participants must be adults; with locally advanced or metastatic RCC; who have not received treatment for their advanced kidney cancer. Participants will receive study medicine either alone or with other anticancer medicines. The medicine will be given through intra","sourceUrl":"https://clinicaltrials.gov/study/NCT07227415"},{"nctId":"NCT06604715","title":"A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2024-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-03","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["JNJ-87562761"],"countries":["Canada","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\\[s\\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).","sourceUrl":"https://clinicaltrials.gov/study/NCT06604715"},{"nctId":"NCT07214961","title":"Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"ARTBIO Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-03","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Prostate Cancer (CRPC)","Metastatic Castrate Resistant Prostate Cancer (mCRPC)"],"interventions":["AB001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who are either 177Lu-PSMA naïve or experienced. The study includes dose escalation to identify a recommended dose and dose expansion to further assess safety and anti-tumour activity. Primary objectives are to characterize the safety profile and determine the optimal dose and schedule for future studies","sourceUrl":"https://clinicaltrials.gov/study/NCT07214961"},{"nctId":"NCT06979596","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-04","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-04","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Malignant Neoplasm"],"interventions":["Opevesostat","Fludrocortisone/ Fludrocortisone acetate","Dexamethasone/Dexamethasone acetate","Rescue Medications","Fulvestrant","Exemestane","Megestrol acetate/Medroxyprogesterone acetate","Tamoxifen","Letrozole"],"countries":["United States","Argentina","Brazil","Canada","Chile","Malaysia","Peru","Singapore","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["Broad CGP"],"summary":"Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in this study. The goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06979596"},{"nctId":"NCT07467629","title":"QLS5212 for Participants With Advanced Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-05","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Solid Tumor Cancer"],"interventions":["QLS5212"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered QLS5212 in participants with unresectable locally, advanced or metastatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07467629"},{"nctId":"NCT07099898","title":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2025-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-28","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Neoplasms, Lung"],"interventions":["Ris-Rez","Topotecan"],"countries":["Argentina","Australia","Brazil","Bulgaria","Canada","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Poland","Portugal","Romania","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":126,"serviceSignals":["ADC biomarker"],"summary":"In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided","sourceUrl":"https://clinicaltrials.gov/study/NCT07099898"},{"nctId":"NCT07667842","title":"Study of D3L-002 in Subjects With Advanced Solid Tumors","sponsor":"D3 Bio (Wuxi) Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-07-18","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-12","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Advanced Solid Tumor"],"interventions":["D3L-002"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, open-label, single-arm, dose-escalation Phase 1 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of D3L-002 monotherapy in subjects with advanced solid tumors. D3L-002 will be administered as an intravenous infusion every 3 weeks (Q3W) in 21-day cycles. Approximately 24 subjects will be enrolled. Dose escalation will follow a Bayesian Optimal Interval (BOIN) design to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07667842"},{"nctId":"NCT06928363","title":"A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.","sponsor":"Novatim Immune Therapeutics (Zhejiang) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":212,"enrollmentType":"ESTIMATED","startDate":"2025-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-15","completionType":"ESTIMATED","lastUpdated":"2025-04-15","conditions":["Solid Tumors"],"interventions":["KY-0301"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This trial is a first-in-human, multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of KY-0301 as monotherapy in patients with advanced solid tumors. This trial will be conducted at approximately multi-sites nationwide, and approximately110\\~212 participants with unresectable locally advanced or metastatic solid tumors will be invited to participate. The study consists of three parts: Phase I dose escalation \\& dose expansion phases of KY-0301 as monotherapy, Phase II cohort expansion phase of KY-0301 as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06928363"},{"nctId":"NCT03972657","title":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":345,"enrollmentType":"ESTIMATED","startDate":"2019-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-15","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Clear Cell Renal Cell Carcinoma (ccRCC)"],"interventions":["REGN5678","Cemiplimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\\[s\\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s) of REGN5678 when it is given alone or in combination with cemiplimab. The goal of Part 2 (dose expansion) is to use the REGN5678 drug dose(s) found in Part 1 to see how well REGN5678 alone or in combination with cemiplimab works to shrink tumors. This study is looking at several other research questions, including: 1. Side effects that may be experienced by taking REGN5678 alone o","sourceUrl":"https://clinicaltrials.gov/study/NCT03972657"},{"nctId":"NCT06952478","title":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma","sponsor":"Celltrion","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":486,"enrollmentType":"ESTIMATED","startDate":"2025-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-25","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Refractory or Relapsed Multiple Myeloma"],"interventions":["CT-P44(Daratumumab)","Darzalex Faspro(Daratumumab)"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a phase 1/3 study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination with Lenalidomide and Dexamethasone in Patients with Refractory or Relapsed Multiple Myeloma","sourceUrl":"https://clinicaltrials.gov/study/NCT06952478"},{"nctId":"NCT06007690","title":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","sponsor":"Aura Biosciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":108,"enrollmentType":"ACTUAL","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-15","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Choroidal Melanoma","Indeterminate Lesions","Uveal Melanoma","Ocular Melanoma"],"interventions":["Bel-sar","Suprachoroidal Microinjector","Infrared Laser","Sham Infrared Laser","Sham Microinjector"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Israel","Italy","Netherlands","New Zealand","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["Broad CGP"],"summary":"The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06007690"},{"nctId":"NCT04975997","title":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":939,"enrollmentType":"ACTUAL","startDate":"2022-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-16","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-25","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Multiple Myeloma"],"interventions":["Dexamethasone","Daratumumab","Bortezomib","Iberdomide"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","India","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Norway","Poland","Portugal","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":259,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT04975997"},{"nctId":"NCT06581380","title":"JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer","sponsor":"JenKem Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":394,"enrollmentType":"ESTIMATED","startDate":"2024-09-16","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-16","completionType":"ESTIMATED","lastUpdated":"2024-09-03","conditions":["Small Cell Lung Cancer"],"interventions":["JK-1201I","Topotecan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06581380"},{"nctId":"NCT07529717","title":"First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-17","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-17","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Metastatic Prostate Cancer"],"interventions":["AZD8359"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT07529717"},{"nctId":"NCT06468033","title":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","sponsor":"PharmaEssentia","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ACTUAL","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-11","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Primary Myelofibrosis","Myeloproliferative Neoplasm"],"interventions":["Ropeginterferon alfa-2b","Placebo"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk. Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06468033"},{"nctId":"NCT07602777","title":"A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":113,"enrollmentType":"ESTIMATED","startDate":"2026-06-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-23","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Sarcoma"],"interventions":["Ris-Rez","G-CSF"],"countries":["Canada","France","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The main goal of this study is to test a new medicine, Risvutatug Rezetecan also called Ris-Rez. We want to see if this medicine can help people with certain types of cancer, whether its safe to use, how well people tolerate it, and how their bodies handle the drug (how its absorbed and broken down). This research is for adolescents and adults who have either: Osteosarcoma, which is a type of bone cancer, or Soft Tissue Sarcoma, which is a type of cancer that starts in soft body tissues (like muscle, fat, or nerves). In both cancer types the cancer must have already been treated, but has come back or spread, and cant be removed by surgery","sourceUrl":"https://clinicaltrials.gov/study/NCT07602777"},{"nctId":"NCT07107230","title":"A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2025-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-24","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Colorectal Neoplasms"],"interventions":["JNJ-95437446"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT07107230"},{"nctId":"NCT07225946","title":"A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":800,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-19","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-20","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Prostatic Neoplasms, Castration-Resistant"],"interventions":["Pasritamig","Docetaxel","Prednisone/Prednisolone"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Italy","Japan","Malaysia","Puerto Rico","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":150,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).","sourceUrl":"https://clinicaltrials.gov/study/NCT07225946"},{"nctId":"NCT06567015","title":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","sponsor":"Pierre Fabre Medicament","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":171,"enrollmentType":"ESTIMATED","startDate":"2024-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-20","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["STX-241"],"countries":["United States","China","France","Germany","Netherlands","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to C797X double acquired (secondary) mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06567015"},{"nctId":"NCT03313778","title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","sponsor":"ModernaTX, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":161,"enrollmentType":"ACTUAL","startDate":"2017-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-21","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-21","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Solid Tumors"],"interventions":["mRNA-4157","Pembrolizumab","SoC Treatment"],"countries":["United States","Australia","Japan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03313778"},{"nctId":"NCT07288177","title":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer","sponsor":"Genmab","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-22","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Rina-S"],"countries":["United States","Australia","Belgium","China","France","Germany","Hungary","Italy","Japan","Netherlands","Poland","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":57,"serviceSignals":["Broad CGP"],"summary":"This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment fo","sourceUrl":"https://clinicaltrials.gov/study/NCT07288177"},{"nctId":"NCT06759649","title":"A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies","sponsor":"Compugen Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-22","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-22","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Neoplasm","Cancer, Malignant Tumors"],"interventions":["COM503","Zimberelimab"],"countries":["United States","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06759649"},{"nctId":"NCT06526793","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-24","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-21","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["B-cell Non-Hodgkin Lymphoma","Follicular Lymphoma (FL)","Large B-Cell Lymphoma (LBCL)"],"interventions":["Surovatamig"],"countries":["United States","Australia","Brazil","Canada","China","Denmark","France","Germany","Hong Kong","Italy","Japan","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":94,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT06526793"},{"nctId":"NCT04521231","title":"A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL","sponsor":"Amgen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":181,"enrollmentType":"ACTUAL","startDate":"2021-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-24","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-25","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["B Cell Precursor Acute Lymphoblastic Leukemia"],"interventions":["Blinatumomab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Romania","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":109,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to determine the maximum tolerated dose (MTD), and recommended phase 2 dose(s) (RP2D) of SC administered blinatumomab. The Phase II part of the study will evaluate the safety, efficacy, and tolerability of SC blinatumomab for treatment of R/R B-ALL and Minimum Residual Disease Positive (MRD+) B-ALL in participants 12 years old and greater. It will also conduct a clinical pharmacokinetic (PK) evaluation of SC1 and SC2 blinatumomab formulations.","sourceUrl":"https://clinicaltrials.gov/study/NCT04521231"},{"nctId":"NCT03331198","title":"Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2017-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-26","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Leukemia, Lymphocytic, Chronic, B-Cell","Lymphoma, Small Lymphocytic"],"interventions":["JCAR017 (lisocabtagene maraleucel)","JCAR017 (lisocabtagene maraleucel) + ibrutinib","JCAR017 (lisocabtagene maraleucel) + venetoclax"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":84,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the efficacy and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Another separate Phase 1 cohort will assess the combination of JCAR017 and concurrent venetoclax. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will","sourceUrl":"https://clinicaltrials.gov/study/NCT03331198"},{"nctId":"NCT06079671","title":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":800,"enrollmentType":"ESTIMATED","startDate":"2023-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-26","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Locally Advanced Cervical Cancer"],"interventions":["Volrustomig","Placebo"],"countries":["United States","Brazil","Canada","China","Denmark","Germany","India","Italy","Japan","Mexico","Norway","Peru","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":205,"serviceSignals":["Broad CGP"],"summary":"This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.","sourceUrl":"https://clinicaltrials.gov/study/NCT06079671"},{"nctId":"NCT07693751","title":"A Study Testing SOT109 for the First Time in Patients, to Assess How Safe SOT109 is, How Well it Works, and How the Body Handles it in Patients With Advanced Colorectal Cancer That Can Not be Removed by Surgery or is Metastatic","sponsor":"SOTIO Biotech a.s.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-06-29","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-04","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Colorectal Cancer (Locally Advanced or Metastatic)"],"interventions":["SOT109"],"countries":["United States","Moldova"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT109, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.","sourceUrl":"https://clinicaltrials.gov/study/NCT07693751"},{"nctId":"NCT07597629","title":"A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Advanced Breast Cancer"],"interventions":["SYS6023","KN026"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07597629"},{"nctId":"NCT06994806","title":"A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2025-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Solid Tumor Malignancies"],"interventions":["KQB168","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor? * What happens to KQB168 in the body? Participants will: * Take KQB168 daily, alone or in combination with pembrolizumab * Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that","sourceUrl":"https://clinicaltrials.gov/study/NCT06994806"},{"nctId":"NCT05642780","title":"SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors","sponsor":"Klus Pharma Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2023-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-14","conditions":["Solid Tumor"],"interventions":["SKB264","Pembrolizumab"],"countries":["United States","Australia","Belgium","Canada","China","Poland"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of combination of SKB264 and Pembrolizumab in patients with selected solid tumors including cervical cancer, urothelial cancer, ovarian cancer, prostate cancer,advanced endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05642780"},{"nctId":"NCT05586074","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","sponsor":"Sunshine Lake Pharma Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":324,"enrollmentType":"ESTIMATED","startDate":"2023-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Leukemia, Acute Myeloid (AML)"],"interventions":["Clifutinib","LoDAC","Azacitidine","Decitabine","Ara-C±IDA","FLAG-IDA"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT05586074"},{"nctId":"NCT06108050","title":"JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors","sponsor":"Jazz Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":177,"enrollmentType":"ESTIMATED","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["JZP898","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06108050"},{"nctId":"NCT07698457","title":"Clinical Benefit of 18F-FET in Glioma.","sponsor":"Primo Biotechnology Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Glioma","18F-Fluoroethyl-l-tyrosine"],"interventions":["18F-Fluoroethyl-l-tyrosine"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This Phase II clinical trial, sponsored by \\*\\*Primo Biotechnology Co., Ltd.\\*\\*, evaluates the clinical benefit of \\*\\*$\\^{18}$F-FET PET/CT\\*\\* in diagnosing glioma. The study aims to compare the diagnostic performance of $\\^{18}$F-FET PET imaging against traditional brain MRI, using surgical histopathology as the gold standard for verification. \\*\\*Study Design and Participants\\*\\* This is a single-center, open-label, non-randomized trial conducted in Taiwan. The study will enroll a total of \\*\\*36 participants\\*\\*, consisting of 6 healthy volunteers (to assess biodistribution and dosimetry) and 30 patients with suspected primary gliomas scheduled for surgery. \\*\\*Methodology\\*\\* The test ","sourceUrl":"https://clinicaltrials.gov/study/NCT07698457"},{"nctId":"NCT07684287","title":"A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Epithelioid Hemangioendothelioma"],"interventions":["Sirolimus for injection (Albumin-bound)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Single-Arm, Non-Randomized, Open-Label Phase 2 Study of Nab-Sirolimus in Patients with Progressive or Symptomatic Epithelioid Hemangioendothelioma. Detailed Description: Avoid duplicating information that will be entered or uploaded elsewhere in the record.","sourceUrl":"https://clinicaltrials.gov/study/NCT07684287"},{"nctId":"NCT07384377","title":"JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2026-02-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-15","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["HER2-positive Colorectal Cancer"],"interventions":["JSKN003","Physician choiced treatment, include: TAS-102, Regorafenib, Fruquintinib."],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT07384377"},{"nctId":"NCT03448042","title":"A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":123,"enrollmentType":"ACTUAL","startDate":"2018-06-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Solid Tumors"],"interventions":["Runimotamab","Trastuzumab","Tocilizumab"],"countries":["United States","Australia","Belgium","Canada","Denmark","France","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the safety, tolerability, and pharmacokinetics of Runimotamab administered intravenously as a single agent and in combination with Trastuzumab in participants with locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT03448042"},{"nctId":"NCT05702229","title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":163,"enrollmentType":"ESTIMATED","startDate":"2023-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-31","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Gastric Cancer"],"interventions":["Rilvegostomig","Volrustomig","FOLFOX","XELOX","AZD0901","5-Fluorouracil","Capecitabine"],"countries":["United States","China","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05702229"},{"nctId":"NCT05309668","title":"Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ACTUAL","startDate":"2022-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-28","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Neurofibromatosis Type 1"],"interventions":["Selumetinib granule formulation","Selumetinib capsule formulation"],"countries":["United States","Germany","Italy","Japan","Netherlands","Russia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to \\< 7 years with NF1 related symptomatic, inoperable PN.","sourceUrl":"https://clinicaltrials.gov/study/NCT05309668"},{"nctId":"NCT07567846","title":"A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer","sponsor":"Genentech, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Prostate Cancer","Metastatic Prostate Cancer"],"interventions":["GDC-1261"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07567846"},{"nctId":"NCT07475806","title":"A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Muscle-invasive Bladder Cancer"],"interventions":["Enfortumab Vedotin","Pembrolizumab"],"countries":["United States","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"People with a type of bladder cancer called muscle-invasive bladder cancer have cancer that has spread into the muscle wall of the bladder. The standard treatment is to have chemotherapy, followed by surgery to completely remove the bladder. This has a significant impact on people with long-term life-altering changes. There are also limited options for people who cannot have chemotherapy or who do not want their bladder removed. Studies show that enfortumab vedotin, when given with pembrolizumab, can help people with advanced bladder cancer. This treatment has also worked well for people with muscle-invasive bladder cancer who can't receive chemotherapy when it was given before and after bla","sourceUrl":"https://clinicaltrials.gov/study/NCT07475806"},{"nctId":"NCT07234162","title":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":218,"enrollmentType":"ESTIMATED","startDate":"2024-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Peripheral T-cell Lymphoma"],"interventions":["Golidocitinib","Chidamide","Gemcitabine"],"countries":["China","Taiwan","Thailand"],"northAmerica":false,"chinaSites":true,"siteCount":51,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT07234162"},{"nctId":"NCT07652073","title":"A Study of DAT-2645 in Patients With BRCA1/2 Mutations or HRD-Positive Ovarian Cancer","sponsor":"Danatlas Pharmaceuticals Co., Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-30","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Advanced or Metastatic Ovarian Cancer"],"interventions":["DAT-2645 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HRD / HRR"],"summary":"This is a Phase II, multicenter, single-arm dose expansion trial planned to enroll up to 30 subjects with advanced or metastatic ovarian cancer. The Objective is to conduct a preliminary evaluation of the efficacy, the safety, tolerability and PK profile of DAT-2645","sourceUrl":"https://clinicaltrials.gov/study/NCT07652073"},{"nctId":"NCT06526624","title":"A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":406,"enrollmentType":"ESTIMATED","startDate":"2024-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2024-07-30","conditions":["Limited-stage Small-cell Lung Cancer"],"interventions":["HS-20093"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06526624"},{"nctId":"NCT06265688","title":"First In Human Study of CX-2051 in Advanced Solid Tumors","sponsor":"CytomX Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2024-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Solid Tumor, Adult"],"interventions":["CX-2051","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06265688"},{"nctId":"NCT07023731","title":"A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation","sponsor":"Arvinas Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":159,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-02","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["KRAS G12D Mutation","Advanced Solid Cancer"],"interventions":["ARV-806"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["RAS genotyping"],"summary":"This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806. Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be the first time ARV-806 will be used in people. The investigational drug will be given through a vein. This is called intravenous (IV) infusion. This study w","sourceUrl":"https://clinicaltrials.gov/study/NCT07023731"},{"nctId":"NCT07210047","title":"Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients","sponsor":"HuniLife Biotechnology, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2025-10-07","conditions":["Multiple Myeloma Refractory"],"interventions":["HuL001-10 mg/kg","HuL001-15 mg/kg","Lenalidomide and Dexamethasone"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if the antibody drug HuL001, combined with Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients. It will also learn about the safety and tolerability of the therapeutic combination. The objectives of this study are: 1. To evaluate the safety and tolerability of HuL001 (in combination with Len/Dex). 2. To evaluate the efficacy of HuL001 (in combination with Len/Dex). Researchers will use the antibody drug HuL001, combined with Len/Dex, to see if this works for Multiple Myeloma therapy. Participants will: * Receive HuL001 antibody injections every 2 weeks * Take Lenalidomide for 21 consecutive days each month * Take Dexamethasone every","sourceUrl":"https://clinicaltrials.gov/study/NCT07210047"},{"nctId":"NCT04329728","title":"The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies","sponsor":"AVM Biotechnology Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2020-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Lymphoid Malignancies"],"interventions":["AVM0703"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04329728"},{"nctId":"NCT07672769","title":"Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes","sponsor":"Faron Pharmaceuticals Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Higher Risk Myelodysplastic Syndromes"],"interventions":["bexmarilimab (1mg/kg)","azacitidine","Placebo","bexmarilimab (3mg/kg)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with treatment-naïve higher-risk myelodysplastic syndromes (HR-MDS). Participants will be randomized to receive bexmarilimab at one of two dose levels (1 mg/kg or 3 mg/kg) plus azacitidine, or placebo plus azacitidine. The primary aim is to select the recommended dose of bexmarilimab for subsequent development based on a predefined integration of clinical response and safety/tolerability.","sourceUrl":"https://clinicaltrials.gov/study/NCT07672769"},{"nctId":"NCT07297329","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","sponsor":"Sinocelltech Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":292,"enrollmentType":"ESTIMATED","startDate":"2025-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Multiple Myeloma (MM)"],"interventions":["SCTC21C","Bortezomib","Lenalidomide","Dexamethasone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The purpose of this study is to evaluate if the addition of SCTC21C to bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma not eligible for transplant will prolong progression-free survival (PFS) and/or improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT07297329"},{"nctId":"NCT05363280","title":"Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment","sponsor":"Advenchen Pharmaceuticals, LLC.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2022-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Small Cell Lung Cancer","Renal Cell Carcinoma (RCC)","Non-Small Cell Lung"],"interventions":["AL8326 40 mg","AL8326 60 mg","AL8326 80 mg--stopped"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .","sourceUrl":"https://clinicaltrials.gov/study/NCT05363280"},{"nctId":"NCT07093970","title":"A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors","sponsor":"Lepu Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":343,"enrollmentType":"ESTIMATED","startDate":"2024-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Advanced Solid Tumors"],"interventions":["MRG006A"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG006A in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07093970"},{"nctId":"NCT06778863","title":"A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation","sponsor":"Clasp Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Advanced Solid Tumor","Unresectable Solid Tumor","Metastatic Solid Tumor","Colorectal Adenocarcinoma","Pancreatic Adenocarcinoma","Lung Cancer","Ovarian Cancer","Breast Cancer","Head and Neck Squamous Cell Carcinoma","Prostate Cancer","Bladder Cancer"],"interventions":["CLSP-1025"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["HLA / TCR"],"summary":"Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06778863"},{"nctId":"NCT05679895","title":"Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL","sponsor":"OneChain Immunotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2023-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["T-cell Acute Lymphoblastic Leukemia","Lymphoblastic T-Cell Lymphoma"],"interventions":["CD1a-CAR T"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"First in humans, exploratory, open-label, single-arm, multicentre, non-competitive, dose escalation study to assess the safety and efficacy of CD1a-CAR T therapy in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)","sourceUrl":"https://clinicaltrials.gov/study/NCT05679895"},{"nctId":"NCT06555068","title":"A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":528,"enrollmentType":"ESTIMATED","startDate":"2024-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Advanced Unresectable or Metastatic Breast Cancer"],"interventions":["HRS-6209 in Combination with Fulvestrant","HRS-6209 in Combination with HRS-1358","HRS-6209 in Combination with Letrozole","HRS-6209 in Combination with HRS-8080","HRS-6209 in Combination with HRS-9813 and Letrozole","HRS-6209 in Combination with HRS-9813 and HRS-8080"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06555068"},{"nctId":"NCT07102901","title":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":351,"enrollmentType":"ESTIMATED","startDate":"2025-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Advanced Gastric Cancer","Metastatic Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["SHR2554 Tablets","SHR-A1811 Injection","SHR-A1904 Injection","SHR-1701 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, phase 2, open label study to evaluate safety, tolerability and efficacy of SHR2554 combined with other anti-tumor treatments in patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07102901"},{"nctId":"NCT05952947","title":"HRYZ-T101 Injection for HPV18 Positive Solid Tumor","sponsor":"HRYZ Biotech Co.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2024-02-02","conditions":["Cervical Cancer","Head and Neck Squamous Cell Carcinoma","Carcinoma of Vagina","Carcinoma of Penis","Anal Cancer","Carcinoma of Vulva"],"interventions":["HRYZ-T101 Injection","Fludarabine + Cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor. The study will investigate RP2D of HRYZ-T101 TCR-T cell injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT05952947"},{"nctId":"NCT06010329","title":"A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC","sponsor":"Teligene US","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2023-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Non-small Cell Lung Cancer"],"interventions":["Sutetinib Maleate Capsule"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).","sourceUrl":"https://clinicaltrials.gov/study/NCT06010329"},{"nctId":"NCT07056556","title":"A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Non-small Cell Lung Cancer","Solid Tumor"],"interventions":["BL-M09D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and cohort-expansion, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M09D1 for injection in patients with locally advanced or metastatic non-small cell lung cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07056556"},{"nctId":"NCT05539430","title":"Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma","sponsor":"Legend Biotech USA Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2023-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-12","conditions":["Gastric Cancer","Gastroesophageal-junction Cancer","Esophageal Cancer","Pancreatic Cancer"],"interventions":["LB1908"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05539430"},{"nctId":"NCT06809114","title":"FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors","sponsor":"Axcynsis Therapeutics Pte Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":83,"enrollmentType":"ESTIMATED","startDate":"2026-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Solid Tumor"],"interventions":["AT03-65"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06809114"},{"nctId":"NCT07229586","title":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Solid Tumor"],"interventions":["SHR-7367 Injection","SHR-1316 Injection","Paclitaxel for Injection","Gemcitabine Hydrochloride for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07229586"},{"nctId":"NCT06303505","title":"FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC","sponsor":"Tubulis GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Ovarian Cancer","Non-small Cell Lung Cancer"],"interventions":["TUB-040"],"countries":["United States","Belgium","Germany","Romania","Spain","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for patients. TUB-04","sourceUrl":"https://clinicaltrials.gov/study/NCT06303505"},{"nctId":"NCT07322094","title":"CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["FIGO Stage III and IV Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer"],"interventions":["TORL-1-23 and paclitaxel","TORL-1-23 and carboplatin","TORL-1-23, paclitaxel, and carboplatin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07322094"},{"nctId":"NCT03556228","title":"VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","sponsor":"VM Oncology, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":242,"enrollmentType":"ESTIMATED","startDate":"2018-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Head and Neck Carcinoma","Adenoid Cystic Carcinoma","Lung Cancer","Non-Small Cell Lung Cancer","Pancreatic Cancer","Mesothelioma","Esophageal Cancer","Any Solid Tumors Progressed After a Prior Immunotherapy","Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma HNSCC","Salivary Gland Carcinomas","Head and Neck Cancers - Salivary Gland","Head and Neck Cancers - Nasopharyngeal","Head and Neck Cancers - Throat","Small Cell Lung Cancer ( SCLC )","Lung Cancer (Locally Advanced or Metastatic)","Head and Neck Cancers - Tonsils","Head and Neck Cancers Hypopharynx","Head and Neck Cancers Larynx","Head and Neck Cancers Lip","Head and Neck Cancers Nasopharynx","Head and Neck Cancers Oral Cavity","Head and Neck Cancers","Head and Neck Cancers Oropharynx","Head and Neck Cancers Trachea"],"interventions":["VMD-928 100 mg Tablet","VMD-928 Tablet and Pembrolizumab (200 mg)"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists","sourceUrl":"https://clinicaltrials.gov/study/NCT03556228"},{"nctId":"NCT06908434","title":"A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2025-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Solid Tumors Harboring a TP53 Y220C Mutation"],"interventions":["GenSci128 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GenSci128 Tablet in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT06908434"},{"nctId":"NCT05951777","title":"Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury","sponsor":"Hope Biosciences LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2024-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Traumatic Brain Injury"],"interventions":["Autologous HB-adMSCs","Normal Saline"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.","sourceUrl":"https://clinicaltrials.gov/study/NCT05951777"},{"nctId":"NCT07368478","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies","sponsor":"Biocity Biopharmaceutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Advanced Solid Malignancies"],"interventions":["BC2027 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ia/Ib, open-label, dose escalation and dose expansion study designed to evaluate the safety, tolerability, PK, and preliminary anticancer activity of BC2027 in patients with advanced solid Malignanciesr","sourceUrl":"https://clinicaltrials.gov/study/NCT07368478"},{"nctId":"NCT05680922","title":"DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer","sponsor":"Legend Biotech USA Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":41,"enrollmentType":"ESTIMATED","startDate":"2023-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Small Cell Lung Cancer Extensive Stage","Large Cell Neuroendocrine Carcinoma of the Lung"],"interventions":["LB2102"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05680922"},{"nctId":"NCT05568680","title":"SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma","sponsor":"Verismo Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2023-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Ovarian Cancer","Cholangiocarcinoma Recurrent","Mesothelioma, Malignant"],"interventions":["SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05568680"},{"nctId":"NCT06943677","title":"A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Advanced Malignant Cancer"],"interventions":["TQB3019 capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3019 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3019 capsules.","sourceUrl":"https://clinicaltrials.gov/study/NCT06943677"},{"nctId":"NCT05139602","title":"A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":210,"enrollmentType":"ACTUAL","startDate":"2021-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Hidradenitis Suppurativa"],"interventions":["Lutikizumab","Placebo"],"countries":["United States","Australia","Canada","Germany","Greece","Japan","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. Despite the clinical benefit anti-tumor necrosis factor (TNF) therapy offers to patients with HS, there remains a significant unmet medical need for patients who fail to achieve adequate benefit with anti-TNF therapy. This study will compare lutikizumab (ABT-981) versus placebo for the treatment of adult participants with moderate to severe HS who have failed anti-TNF therapy. Lutikizumab (ABT-981) is an investigational drug being developed for the treatm","sourceUrl":"https://clinicaltrials.gov/study/NCT05139602"},{"nctId":"NCT05683418","title":"A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer","sponsor":"Totus Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":241,"enrollmentType":"ESTIMATED","startDate":"2023-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["HR+/HER2-negative Breast Cancer"],"interventions":["TOS-358","Fulvestrant","Palbociclib","Ribociclib"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are: 1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2? 2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day? 3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)","sourceUrl":"https://clinicaltrials.gov/study/NCT05683418"},{"nctId":"NCT07751991","title":"A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML","sponsor":"Charm Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["AML (Acute Myeloid Leukemia)"],"interventions":["CHM-029"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The main questions the study aims to answer are: * What is an appropriate dose of CHM-029? * What side effects may occur with CHM-029? * How does the body process CHM-029? Researchers will evaluate increasing dose levels of CHM-029 to better understand its safety and how the body responds to treatment. Participants will visit the study clinic regularly for safety assessments, blood tests, electrocardiograms (ECGs), and bone marrow evaluations to monitor their health and response to treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07751991"},{"nctId":"NCT06014502","title":"Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors","sponsor":"ImmunoGenesis","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2023-09-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Solid Tumor"],"interventions":["IMGS-001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors that have come back or are not improving after receiving other drugs that are commonly used for their cancer. Phase 1a (Part 1) will test the safety of five different doses of IMGS-001 to use in further studies. Patients with cancer that have advanced or spread to other parts of the body following treatment with other available therapies will be treated in Part 1. Phase 1b (Part 2) will test two doses of IMGS-001 identified in Part 1 to further determine the safety and potential effectiveness in s","sourceUrl":"https://clinicaltrials.gov/study/NCT06014502"},{"nctId":"NCT03802695","title":"A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","sponsor":"Orca Biosystems, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2019-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Mixed Phenotype Acute Leukemia","Acute Lymphoblastic Leukemia"],"interventions":["OrcaGraft (Orca-Q)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts (\"OrcaGraft\"/\"Orca-Q\") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT03802695"},{"nctId":"NCT07024277","title":"Study of ZG006 in Participants With Neuroendocrine Prostate Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-06-17","conditions":["Neuroendocrine Prostate Cancer"],"interventions":["ZG006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07024277"},{"nctId":"NCT06253871","title":"A Phase 1/1b Study of IAM1363 in HER2 Cancers","sponsor":"Iambic Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":383,"enrollmentType":"ESTIMATED","startDate":"2024-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["HER2 Mutation-Related Tumors","HER2","HER2-positive Breast Cancer","HER2 + Breast Cancer","Brain Metastases From Solid Tumors","Brain Metastases From HER2 and Breast Cancer","CNS Metastases","HER2-Positive Solid Tumors","NSCLC (Non-small Cell Lung Cancer)","HER2-positive Bladder Cancer","HER2-positive Colorectal Cancer","HER2 + Gastric Cancer","HER2-positive Gastroesophageal Cancer"],"interventions":["IAM1363"],"countries":["United States","France","Ireland","Italy","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06253871"},{"nctId":"NCT06220864","title":"SNV1521 in Participants With Advanced Solid Tumors","sponsor":"Synnovation Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2024-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Advanced Solid Tumor"],"interventions":["SNV1521","DB-1310","Abiraterone","Darolutamide"],"countries":["United States","Australia","Belgium","Canada","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06220864"},{"nctId":"NCT07138209","title":"A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2025-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["QLS32015","Pomalidomide","Selinexor","Dexamethasone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07138209"},{"nctId":"NCT05671822","title":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2023-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma"],"interventions":["SHR-A1811 and SHR-1701","SHR-A1811 and capecitabine","SHR-A181, SHR-1701, and capecitabine","SHR-A1811, SHR-1316, and capecitabine","SHR-A1811, SHR-1316, capecitabine,and oxaliplatin","SHR-A1811, SHR-1316, and 5-FU","SHR-1316 and SHR-A1811","SHR-A1811and 5-FU"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is an open,multicentre phase Ib/II study. The purpose of phase Ib is to evaluated the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of SHR-A1811 in combination with chemotherapy and/or immunotherapy in HER2 expression advanced/metastatic gastric/gastroesophageal junction adenocarcinoma patients. The Phase II study was designed to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and/or immunotherapy for advanced/metastatic HER2 expression gastric/gastroesophageal conjunctional adenocarcinoma patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05671822"},{"nctId":"NCT05547321","title":"Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.","sponsor":"Oncomatryx Biopharma S.L.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2022-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Advanced Solid Tumor"],"interventions":["OMTX705","Pembrolizumab","Tislelizumab (BGB-A317)"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the treatment of patients with advanced or metastatic cancer in whom there is no available standard therapeutic option.","sourceUrl":"https://clinicaltrials.gov/study/NCT05547321"},{"nctId":"NCT07311538","title":"Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies","sponsor":"BioRay Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Advanced Gynecological Malignancies"],"interventions":["BRY812 for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, multicenter Phase IIa trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of BRY812 for Injection in patients with LIV-1-positive advanced gynecological malignancies. The study comprises two cohorts. For Cohort 1 (ovarian cancer), a Simon's two-stage design is adopted. In the first stage, 13 evaluable subjects will be enrolled. If fewer than 3 subjects achieve an objective response among these 13, enrollment in this cohort will be terminated. Otherwise, the cohort will proceed to the second stage, and additional 23 evaluable subjects will be enrolled, bringing the total to 36. If at least 10 out of the 36 evaluable subjects ach","sourceUrl":"https://clinicaltrials.gov/study/NCT07311538"},{"nctId":"NCT05077215","title":"Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer","sponsor":"Evergreen Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2026-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-08","conditions":["Advanced Endometrial Cancer"],"interventions":["EG-007","Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection","Lenvatinib Capsules"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol). Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors: * Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer) * ECOG score at baseline (0 vs 1) * Geographic region (Asia vs ROW)","sourceUrl":"https://clinicaltrials.gov/study/NCT05077215"},{"nctId":"NCT07730489","title":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Colorectal Cancer"],"interventions":["BL-M07D1","Regorafenib","Fruquintinib","TAS-102"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in patients with advanced colorectal cancer who have HER2 IHC3+ and have failed prior treatment with oxaliplatin, fluorouracil and irinotecan.","sourceUrl":"https://clinicaltrials.gov/study/NCT07730489"},{"nctId":"NCT07115446","title":"Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2025-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Advanced Prostate Cancer"],"interventions":["HS-20093","HRS-5041"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors. This is a phase Ib, open-label, multi-center study to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-20093 combination with HRS-5041 in patients with advanced prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07115446"},{"nctId":"NCT05168566","title":"Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Teligene US","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2022-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Non-small Cell Lung Cancer"],"interventions":["Sutetinib Maleate Capsule"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)","sourceUrl":"https://clinicaltrials.gov/study/NCT05168566"},{"nctId":"NCT07245446","title":"A Study of Ivonescimab in First-Line ES-SCLC","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Extensive-stage Small Cell Lung Cancer (ES-SCLC)"],"interventions":["Ivonescimab","Cadonilimab","AK117","Etoposide","Carboplatin (AUC 5)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). The main questions the study aims to answer are: * What side effects do participants experience from these combination treatments? * How well do the treatments work to shrink tumors? Researchers will compare three groups to see which combination works best. All participants will receive Ivonescimab and chemotherapy (etoposide and carboplatin). The differences are: * Group 1 will also receive an additional drug called AK117. *","sourceUrl":"https://clinicaltrials.gov/study/NCT07245446"},{"nctId":"NCT06973863","title":"A Study of PEP08 in Patients With MTAP-Del Advanced or Metastatic Solid Tumors","sponsor":"PharmaEngine","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Advanced Solid Tumor","Solid Tumors","MTAP-deleted Solid Tumors","MTAP Deletion"],"interventions":["PEP08"],"countries":["Australia","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human clinical study of PEP08, a novel cancer therapy being evaluated both as monotherapy and in combination with other treatments in patients with advanced or metastatic solid tumors harboring MTAP deletion. The study will be conducted in three parts, with Part 1 currently open for enrollment. The primary objectives of the study are to: * Evaluate the safety and tolerability of PEP08, PK and PD * Determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) * Assess preliminary signs of anti-tumor activity of PEP08 Key study questions include: * What is the recommended dose of PEP08 for further development? * Wht is the tolerable dose of PEP08 when adm","sourceUrl":"https://clinicaltrials.gov/study/NCT06973863"},{"nctId":"NCT07336771","title":"JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Metastatic Breast Cancer","Locally Advanced Breast Cancer (LABC)"],"interventions":["JSKN016 Q2W","JSKN016 Q3W","D-0502"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a multicenter, open-label, Phase Ib/II randomized study designed to evaluate the safety, tolerability, dose-limiting toxicities (DLTs), and preliminary antitumor activity of JSKN016 in combination with the oral selective estrogen receptor degrader (SERD) D-0502 in patients with locally advanced or metastatic hormone receptor-positive (HR+), HER2-negative breast cancer who have previously progressed on CDK4/6 inhibitor-based endocrine therapy. Approximately 60 patients will be randomized in a 1:1 ratio to receive JSKN016 administered intravenously every 2 weeks (Q2W) or every 3 weeks (Q3W), in combination with daily oral D-0502. Each dosing cohort will include a safety lead-in phase t","sourceUrl":"https://clinicaltrials.gov/study/NCT07336771"},{"nctId":"NCT07358806","title":"Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors","sponsor":"Oscotec Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2025-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Solid Tumor","Breast Cancer","Head and Neck Cancer","Non-Small Cell Lung Cancer","Prostate Cancer","Gastric/Gastroesophageal Junction Cancer"],"interventions":["OCT-598","Docetaxel"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study intended to determine the MTD of OCT-598 following multiple-dose therapy and to establish the RP2D for OCT-598 as a single agent, by assessing its safety and tolerability as monotherapy and in combination with standard-of-care treatments in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07358806"},{"nctId":"NCT07581184","title":"A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Aktis Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Castration Resistant Metastatic Prostate Cancer","Prostate Cancer","mCRPC (Metastatic Castration-resistant Prostate Cancer)","mCRPC","B7H3"],"interventions":["[225Ac]Ac-AKY-2519 (therapeutic)","[64Cu]Cu-AKY-2519 (imaging)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of \\[64Cu\\]Cu-AKY-2519 and/or \\[225Ac\\]Ac-AKY-2519, as well as the preliminary anti-tumor activity of \\[225Ac\\]Ac-AKY-2519 in participants with metastatic castration-resistant prostate cancer (mCRPC) with and without prior exposure to 177Lu-PSMA-617 (PLUVICTO™).","sourceUrl":"https://clinicaltrials.gov/study/NCT07581184"},{"nctId":"NCT03567889","title":"Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients","sponsor":"Philogen S.p.A.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2018-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Melanoma Stage IIIB","Melanoma Stage IIIC","Melanoma Stage IIID"],"interventions":["Daromun","Surgery","Adjuvant therapy"],"countries":["United States","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with respect to the standard of care (surgery and adjuvant therapy).","sourceUrl":"https://clinicaltrials.gov/study/NCT03567889"},{"nctId":"NCT06821503","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Advanced Pancreatic Cancer"],"interventions":["LM-108 injection","Penpulimab injection","Paclitaxel for injection (albumin bound)","Gemcitabine hydrochloride for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid tumors. The dose of LM-108 combined with penpulimab, albumin paclitaxel, and gemcitabine is recommended in Phase Ib.Explore the efficacy and safety of LM-108 combined with anti-tumor therapy in patients with advanced pancreatic cancer in Phase II.","sourceUrl":"https://clinicaltrials.gov/study/NCT06821503"},{"nctId":"NCT07196774","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":740,"enrollmentType":"ACTUAL","startDate":"2025-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Early-stage or Locally Advanced HER2-positive Breast Cancer"],"interventions":["SHR-A1811 for Injection","Docetaxel injection","Trastuzumab Injection","Carboplatin for Injection","Pertuzumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study is a multicenter, randomized, open-label, parallel Phase III clinical trial. 650 early-stage or locally advanced breast cancer participants will be enrolled and randomly assigned to SHR-A1811 monotherapy group (trial group) or TCbHP treatment group (control group) at a 1:1 ratio. Participants will receive neoadjuvant treatments of SHR-A1811 or TCbHP, while those who have completed neoadjuvant therapy and are suitable for surgery must undergo surgical treatment. The participants will be evaluated on tumor efficacy through postoperative pathological assessment by IRC and pathologists from the research center. The primary endpoint will be tpCR evaluated by IRC. Participants who compl","sourceUrl":"https://clinicaltrials.gov/study/NCT07196774"},{"nctId":"NCT07418749","title":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":398,"enrollmentType":"ESTIMATED","startDate":"2026-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Recurrent Cervical Cancer","Metastatic Cervical Cancer"],"interventions":["SHR-A2102 for Injection","Pemetrexed Disodium for Injection","Gemcitabine Hydrochloride for Injection","Topotecan Hydrochloride for Injection","Paclitaxel for Injection (Albumin bound)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07418749"},{"nctId":"NCT07623707","title":"A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":264,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Solid Tumor"],"interventions":["FG-B901","standard or investigator-determined chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"FG-B901 is a recombinant humanized IgG2 bispecific antibody targeting PD-L1 and CD40. It is designed to provide PD-L1-dependent CD40 agonism, thereby enhancing selectivity for the tumor microenvironment and reducing systemic toxicity compared with conventional CD40 agonists. Preclinically, FG-B901 promotes antigen-presenting cell activation and synergizes with PD-L1/PD-1 blockade to potentiate T-cell anti-tumor immunity. This is an open-label, multicenter phase I/II trial in subjects with unresectable locally advanced or metastatic solid tumors. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of FG-B901 as monotherapy and in combination with chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07623707"},{"nctId":"NCT07591155","title":"A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2026-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Solid Tumors"],"interventions":["BL-ARC002"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-ARC002 for injection in patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07591155"},{"nctId":"NCT07600554","title":"A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer","sponsor":"Philogen S.p.A.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Prostate Cancer"],"interventions":["[68Ga]Ga-OncoACP3"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to assess the safety and dosimetry of imaging with \\[68Ga\\]Ga-OncoACP3 in patients with prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07600554"},{"nctId":"NCT06075030","title":"A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy","sponsor":"Kind Pharmaceuticals LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2027-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Chemotherapy Induced Anemia"],"interventions":["AND017"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06075030"},{"nctId":"NCT06655246","title":"A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","sponsor":"Kura Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":157,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Gastrointestinal Stromal Tumor (GIST)","Gastrointestinal Stromal Cancer","Gastrointestinal Stromal Neoplasm","Gastrointestinal Stromal Tumor, Malignant","Gastrointestinal Stromal Cell Tumors"],"interventions":["ziftomenib","imatinib mesylate"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT06655246"},{"nctId":"NCT06644300","title":"Study of BM230 in Patients With Advanced Solid Tumors","sponsor":"Suzhou Biomissile Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Solid Tumor"],"interventions":["BM230"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"This study is a Phase I, multicenter, non-randomized, open-label, first-in-human study of BM230 conducted globally. The study will include two parts: a dose escalation part (Phase Ia) followed by a dose expansion part (Phase Ib). Phase Ia part will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors (HER2-related solid tumors). The Phase Ib part will enroll 5 distinct cohorts of patients with advanced solid tumors related to HER2 under MTD/RED doses, to better define the safety profile of BM230 and evaluate the efficacy of BM230.","sourceUrl":"https://clinicaltrials.gov/study/NCT06644300"},{"nctId":"NCT06359847","title":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","sponsor":"Beijing Scitech-Mq Pharmaceuticals Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-08-24","conditions":["Differentiated Thyroid Carcinoma"],"interventions":["ST-1898 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity.","sourceUrl":"https://clinicaltrials.gov/study/NCT06359847"},{"nctId":"NCT07279428","title":"A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2026-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Gastrointestinal Tumors","Solid Tumors"],"interventions":["BL-M24D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M24D1 for Injection in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07279428"},{"nctId":"NCT07654400","title":"A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":["BL-M14D1","Atezolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07654400"},{"nctId":"NCT03016819","title":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","sponsor":"Advenchen Laboratories, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":325,"enrollmentType":"ESTIMATED","startDate":"2017-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Alveolar Soft Part Sarcoma","Leiomyosarcoma","Synovial Sarcoma","Soft-Tissue Sarcoma"],"interventions":["AL3818","Dacarbazine","AL3818 or placebo","Midazolam 2 mg for CYP3A4 phenotyping","Digoxin (0.25mg)","Rosuvastatin 10 mg tablet."],"countries":["United States","China","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.","sourceUrl":"https://clinicaltrials.gov/study/NCT03016819"},{"nctId":"NCT06742138","title":"To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":284,"enrollmentType":"ESTIMATED","startDate":"2025-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2024-12-19","conditions":["Multiple Myeloma"],"interventions":["QL2109","Pomalidomide","Dexamethasone","DARZALEX FASPRO®"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, double-blind, multicenter trial，parallel control designed to evaluate treatment with pomalidomide + QL2109 + dexamethasone compared with pomalidomide + DARZALEX FASPRO® + dexamethasone in the participants with relapsed or refractory Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06742138"},{"nctId":"NCT07232420","title":"A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2025-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Non Small Cell Lung Cancer","Solid Tumor"],"interventions":["BL-M24D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M24D1 in patients with locally advanced or metastatic non-small cell lung cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232420"},{"nctId":"NCT07481058","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":["KC1036","Toripalimab","Paclitaxel","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07481058"},{"nctId":"NCT07255404","title":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer","sponsor":"BioNTech SE","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["Pumitamig","Nab-paclitaxel","Gemcitabine","mFOLFIRINOX"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (also known as BNT327, BMS-986545, or PM8002) in combination with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07255404"},{"nctId":"NCT04581512","title":"Study to Evaluate the Safety and Tolerability of EP0042","sponsor":"Ellipses Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2020-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndromes"],"interventions":["EP0042","Venetoclax","Azacitidine (AZA)"],"countries":["Australia","Netherlands","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).","sourceUrl":"https://clinicaltrials.gov/study/NCT04581512"},{"nctId":"NCT07232407","title":"A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2025-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Gastrointestinal Tumors","Solid Tumors"],"interventions":["Lutetium [177Lu] BL-ARC001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, non-randomized Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of Lutetium \\[177Lu\\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232407"},{"nctId":"NCT06735144","title":"Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2024-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Malignant Solid Tumor"],"interventions":["FH-006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in subjects with advanced malignant solid tumors, and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended dose for phase II clinical trials (RP2D), and preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06735144"},{"nctId":"NCT06956001","title":"Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2024-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["EGFR","NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["Firmonertinib Mesilate Tablets","Pemetrexed Disodium for Injection","Cisplatin for injection","Carboplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or metastatic NSCLC who have not been treated with systemic antitumor therapy and carry EGFR PaCC mutation or EGFR l861q mutation. Eligible patients were stratified by EGFR mutation type and CNS metastasis at the time of enrollment. Approximately 300 patients would be randomly assigned 1:1 to receive either firmonertinib mesylate (240mg, orally on an empty stomach daily) or platinum containing dual agent chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06956001"},{"nctId":"NCT07274852","title":"A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":22,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-06","conditions":["Lung Cancer","Breast Cancer","Head and Neck Squamous Cell Carcinoma","Solid Tumors"],"interventions":["Lutetium [177Lu] BL-ARC001"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \\[177Lu\\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07274852"},{"nctId":"NCT06824064","title":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","sponsor":"Riboscience, LLC.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Metastatic Colorectal Cancer","Advanced Colorectal Cancer"],"interventions":["RBS2418","Placebo"],"countries":["United States","Puerto Rico","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses in adult subjects for the treatment of advanced, metastatic, and progressive colorectal cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06824064"},{"nctId":"NCT07482592","title":"Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Advanced Malignant Cancer"],"interventions":["TQB3205 capsules"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The trial was divided into two phases: dose escalation and dose expansion. The dosing regimens were single-dose study and continuous dosing study. A single-center, open, non-randomized, single-arm clinical trial design was adopted. Subjects with advanced malignant tumors were selected to take TQB3205 capsules orally to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TQB3205 capsules.","sourceUrl":"https://clinicaltrials.gov/study/NCT07482592"},{"nctId":"NCT07358884","title":"First in Human Study of QLS5316 in Solid Tumors","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Solid Tumors","Colorectal Cancer","Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","Non-small Cell Lung Cancer"],"interventions":["QLS5316"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) Phase I, multi-center, open-label, study of QLS5316, in patients with advanced solid tumors. The study aim to evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of QLS5316 as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07358884"},{"nctId":"NCT05482893","title":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)","sponsor":"Phanes Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Gastric or Gastroesophageal Junction Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer (BTC)"],"interventions":["Spevatamig (PT886)","Paclitaxel","Gemcitabine","Abraxane","KEYTRUDA® (pembrolizumab)","FOLFOX","CAPOX","FOLFIRINOX"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for screening: unresectable or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, biliary tract carcinoma (BTC) and pancreatic ductal adenocarcinoma (PDAC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05482893"},{"nctId":"NCT06158841","title":"Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2024-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Multiple Myeloma"],"interventions":["Etentamig","Carfilzomib","Pomalidomide","Elotuzumab","Selinexor","Bortezomib","Dexamethasone"],"countries":["United States","Australia","Austria","Belgium","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Japan","Poland","Portugal","Puerto Rico","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":166,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/refractory (R/R) MM. Etentamig is an investigational drug being developed for the treatment of R/R MM. This study is broken into 2 Arms; Arm A and Arm B. In Arm A, participants will receive etentamig a","sourceUrl":"https://clinicaltrials.gov/study/NCT06158841"},{"nctId":"NCT02781883","title":"Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML","sponsor":"Bio-Path Holdings, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2016-05","startDateType":"","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-03-07","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["BP1001 in combination with Ventoclax plus decitabine","BP1001 plus decitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \\[CR\\], Complete Remission with incomplete hematologic recovery \\[CRi\\], Complete Remission with partial hematologic recovery \\[CRh\\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT02781883"},{"nctId":"NCT05294172","title":"KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":295,"enrollmentType":"ACTUAL","startDate":"2022-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Nasopharyngeal Carcinoma","Recurrent or Metastatic"],"interventions":["KL-A167","Gemcitabine","Cisplatin","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1","sourceUrl":"https://clinicaltrials.gov/study/NCT05294172"},{"nctId":"NCT06752681","title":"To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Day One Biopharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2024-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["DAY301"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of DAY301, a PTK7-directed antibody-drug conjugate (ADC) in participants with advanced or metastatic solid tumors. The study comprises of 2 phases: Phase 1a dose escalation where participants will be administered DAY301 at escalating dose levels to assess safety and tolerability, and to determine the maximum tolerated dose (MTD) and/or the recommended dose (RD); In Phase 1b dose expansion, DAY301 will be evaluated in dose expansion cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT06752681"},{"nctId":"NCT03594422","title":"A Study of HQP1351 in Patients With GIST or Other Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2018-07-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Gastrointestinal Stromal Tumor (GIST)","Solid Tumor, Adult"],"interventions":["HQP1351"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03594422"},{"nctId":"NCT05423262","title":"A Study of TRK-950 in Patients With Advanced Solid Tumors","sponsor":"Toray Industries, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2022-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Solid Tumor","Melanoma"],"interventions":["TRK-950","Nivolumab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists","sourceUrl":"https://clinicaltrials.gov/study/NCT05423262"},{"nctId":"NCT06475599","title":"Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2024-07","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2024-06-27","conditions":["Endometrial Cancer"],"interventions":["Anlotinib hydrochloride capsule + TQB2450 injection","Chemotherapy drug"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":61,"serviceSignals":["MSI / TMB"],"summary":"To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).","sourceUrl":"https://clinicaltrials.gov/study/NCT06475599"},{"nctId":"NCT07039916","title":"Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis","sponsor":"Immunovant Sciences GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":231,"enrollmentType":"ESTIMATED","startDate":"2025-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Generalized Myasthenia Gravis"],"interventions":["IMVT-1402","Placebo"],"countries":["United States","Argentina","Czechia","Denmark","Georgia","Germany","Greece","Hungary","Italy","Mexico","Poland","Romania","Serbia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":88,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07039916"},{"nctId":"NCT05676931","title":"Study With Various Immunotherapy Treatments in Participants With Lung Cancer","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2023-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Advanced Non-Small Cell Lung Cancer"],"interventions":["Domvanalimab","Quemliclustat","Zimberelimab","Docetaxel","Platinum-Based Doublet"],"countries":["United States","Australia","France","Georgia","Italy","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05676931"},{"nctId":"NCT07255898","title":"A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2026-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Multiple Myeloma","Hematologic Malignancies"],"interventions":["BL-M24D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is an open, multicenter, non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics characteristics and preliminary efficacy of BL-M24D1 in patients with relapsed or refractory multiple myeloma and other hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07255898"},{"nctId":"NCT07612488","title":"A Study of CS231295 in Patients With Advanced Solid Tumors","sponsor":"ThalassaX Therapeutics United States Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advance Solid Tumors","Advanced Malignant Solid Tumors"],"interventions":["a small molecular multi-target kinase inhibitor"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors. Eligible patients must be 18 years or older and have histologically or cytologically confirmed unresectable advanced, recurrent, or metastatic solid tumors, who have failed or are intolerant to previous standard treatments and currently have no other standard treatment options available. Patients should have at least one measurable target lesion (glioma, according to RANO 2.0; other solid tumors according to RECIST v1.1) and a Karnofsky Performance Status (KPS) score ≥ 60 (glioma) or an ECOG Performance Status score of 0 or 1 (other solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07612488"},{"nctId":"NCT06687941","title":"A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors","sponsor":"Aptamer Sciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Neoplasms","Carcinoma, Hepatocellular","Carcinoma, Non-Small-Cell Lung","Liver Neoplasms"],"interventions":["AST-201"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.","sourceUrl":"https://clinicaltrials.gov/study/NCT06687941"},{"nctId":"NCT07250750","title":"A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis","sponsor":"ImmunAbs Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2026-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Myasthenia Gravis"],"interventions":["IM-101 Part A","Placebo Part A","IM-101 Part B","Placebo Part B"],"countries":["United States","Bulgaria","Italy","Poland","Serbia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in participants with AChR antibody-negative gMG and participants with AChR antibody-positive or AChR antibody-negative oMG.","sourceUrl":"https://clinicaltrials.gov/study/NCT07250750"},{"nctId":"NCT06922357","title":"A Phase I/II of HRS-6719 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["HRS-6719"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06922357"},{"nctId":"NCT07556848","title":"A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":356,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Locally Advanced or Metastatic Triple-negative Breast Cancer"],"interventions":["9MW2821","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to compare the efficacy and safety of 9MW2821 versus investigator's choice of chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer who have previously received taxane-based chemotherapy with or without immunotherapy and an antibody-drug conjugate with a topoisomerase inhibitor payload","sourceUrl":"https://clinicaltrials.gov/study/NCT07556848"},{"nctId":"NCT07050459","title":"A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-07-03","conditions":["Locally Advanced Solid Tumors"],"interventions":["SIM0686"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0686 in Adult Participants with Locally Advanced/Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07050459"},{"nctId":"NCT03917043","title":"APG-2449 in Patients With Advanced Solid Tumors","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2019-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Cancer","Non Small Cell Lung Cancer","Esophageal Cancer","Ovarian Cancer","Malignant Pleural Mesothelioma"],"interventions":["APG-2449"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["RNA fusion"],"summary":"APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study","sourceUrl":"https://clinicaltrials.gov/study/NCT03917043"},{"nctId":"NCT07264816","title":"A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Non-squamous Non-small Cell Lung Cancer"],"interventions":["BL-M07D1","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This trial is a multicenter, open-label, Phase II clinical study to explore the efficacy and safety of BL-M07D1 in combination with pembrolizumab in patients with locally advanced or metastatic HER2-overexpressing non-squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07264816"},{"nctId":"NCT04855656","title":"Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors","sponsor":"Debiopharm International SA","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":464,"enrollmentType":"ESTIMATED","startDate":"2021-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Advanced Solid Tumor"],"interventions":["Lunresertib","RP-3500","Debio0123"],"countries":["United States","Canada","Denmark","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT04855656"},{"nctId":"NCT06072612","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","sponsor":"BriaCell Therapeutics Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":404,"enrollmentType":"ESTIMATED","startDate":"2023-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Breast Cancer","Metastatic Breast Cancer","Breast Neoplasm","Breast Cancer Metastatic","End Stage Cancer"],"interventions":["SV-BR-1-GM","Cyclophosphamide","Interferon infiltration of the inoculation site","Retifanlimab","Treatment of Physician's Choice"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":79,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \\[Retifanlimab\\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.","sourceUrl":"https://clinicaltrials.gov/study/NCT06072612"},{"nctId":"NCT07208136","title":"A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors","sponsor":"Jemincare","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2025-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-01","conditions":["Advanced Solid Tumors"],"interventions":["JMKX005425"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07208136"},{"nctId":"NCT05304377","title":"A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia","sponsor":"Enliven Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2022-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Chronic Myeloid Leukemia","Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","Cml"],"interventions":["ELVN-001"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Hungary","Israel","Italy","Netherlands","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in patients with chronic myeloid leukemia with and without T315I mutations in patients who are relapsed, refractory or intolerant to TKIs.","sourceUrl":"https://clinicaltrials.gov/study/NCT05304377"},{"nctId":"NCT07007559","title":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","sponsor":"ALX Oncology Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Breast Cancer, Metastatic"],"interventions":["Evorpacept (ALX148)","Trastuzumab","Paclitaxel","Capecitabine","Eribulin","Gemcitabine","Vinorelbine"],"countries":["United States","Canada","France","Italy","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["HER2 profiling"],"summary":"The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting. ASPEN-09-03 is a substudy under Master Protocol ASPEN-09, and additional substudies are as follows: * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not open. * Recurrent/metastatic head and neck cancer (HNSCC) - dose escalation phase to evaluate evorpacept in combination ","sourceUrl":"https://clinicaltrials.gov/study/NCT07007559"},{"nctId":"NCT06278454","title":"Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) and Advanced Pancreatic Cancer With Lymph Node Metastases","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2024-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Unresectable Pancreatic Cancer","Advanced Pancreatic Cancer","Lymph Node Metastases"],"interventions":["NRT6008 Injection + Systematic chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a single arm, open label, multi-center phase I study, including phase Ia dose escalation and phase Ib dose expansion. Safety review committee (SRC) will be formed to monitor safety and efficacy data through the study. And the independent review committee (IRC) will be formed to monitor efficacy data through the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06278454"},{"nctId":"NCT07575191","title":"Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer","sponsor":"Smartwise Sweden AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2026-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Pancreatic Cancer Non-resectable"],"interventions":["Gemcitabine","Extroducer Infusion Catheter System"],"countries":["Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is testing a new way to deliver the chemotherapy drug Gemcitabine in pancreatic tumors using the catheter Extroducer® Infusion Catheter System. The study will include patients with Locally Advanced Pancreatic Cancer that cannot be removed with surgery. Patients will receive four treatment sessions, given every two weeks, in which Gemcitabine is infused directly into or near the tumor. The study will test up to three increasing dose levels of Gemcitabine (200 mg, 400 mg, and 100 mg). The study will enroll three groups of three patients each. After each group completes treatment, an independent safety committee will review the results to decide whether it is safe to move to the next","sourceUrl":"https://clinicaltrials.gov/study/NCT07575191"},{"nctId":"NCT05759728","title":"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer","sponsor":"Carina Biotech Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2023-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Colorectal Cancer Metastatic"],"interventions":["CNA3103: 5 x 10^7 cells","CNA3103: 1.5 x 10^8 cells","CNA3103: 4.5 x 10^8 cells","CNA3103: 1.5 x 10^9 cells","CNA3103: 2.5 x 10^7 cells","CNA3103: 6.75 × 10^8 cells"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to determine the safety and best response of treatment with CNA3103 (Leucine-rich repeat-containing G protein-coupled receptor 5 \\[LGR5\\]-targeted, Autologous Chimeric Antigen Receptor (CAR) -T Cells), for participants with Metastatic Colorectal Cancer. Participants may undergo a pre-screening biopsy procedure to determine expression of LGR5. Participants will undergo screening procedures, including leukapheresis (collection of T cells) and lymphodepletion (chemotherapy), up to 47 days prior to CNA3103 dosing. Participants will receive a single Intravenous dose of CNA3103. Expansion cohorts will open after determination of the maximum tolerated dose and recommended phase 2 do","sourceUrl":"https://clinicaltrials.gov/study/NCT05759728"},{"nctId":"NCT06276491","title":"Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors","sponsor":"Xencor, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":282,"enrollmentType":"ESTIMATED","startDate":"2024-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Ovarian Cancer","Endometrial Cancer","Germ Cell Tumor","Testicular Germ Cell Tumor","Ovarian Germ Cell Tumor"],"interventions":["XmAb541"],"countries":["United States","Denmark"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06276491"},{"nctId":"NCT05652686","title":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","sponsor":"Phanes Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":203,"enrollmentType":"ESTIMATED","startDate":"2023-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Small Cell Lung Cancer (SCLC)","Large Cell Neuroendocrine Cancer (LCNEC)","Neuroendocrine Prostate Cancer (NEPC)","Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)","Neuroendocrine Carcinomas (NEC)","Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)"],"interventions":["Peluntamig (PT217)","Carboplatin + Etoposide","Paclitaxel.","Atezolizumab","Lurbinectedin","Irinotecan (drug)","Topotecan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05652686"},{"nctId":"NCT07225621","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","sponsor":"Alpheus Medical, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":103,"enrollmentType":"ESTIMATED","startDate":"2026-01-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Glioblastoma","GBM"],"interventions":["5-ALA HCl + LIDU SDT","Placebo + Sham SDT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study is evaluating an experimental treatment for glioblastoma that uses an investigational drug (5-ALA) combined with a non-invasive ultrasound device (LIDU) to target tumor cells. Patients meeting the entry requirements to be in the study, will be equally randomly assigned to receive the study device plus the active study drug plus active ultrasound, or to a \"sham\" procedure where the ultrasound is not being activated and the study drug is a placebo (looks the","sourceUrl":"https://clinicaltrials.gov/study/NCT07225621"},{"nctId":"NCT07232849","title":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-12","conditions":["Lung Cancer"],"interventions":["HRS-4508 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232849"},{"nctId":"NCT06717126","title":"A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma","sponsor":"iOnctura","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Uveal Melanoma","Ocular Melanoma"],"interventions":["roginolisib","Investigator choice of standard therapy"],"countries":["Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?","sourceUrl":"https://clinicaltrials.gov/study/NCT06717126"},{"nctId":"NCT07565285","title":"The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma","sponsor":"Primmune Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Melanoma Stage III"],"interventions":["PRTX007","Pembrolizumab"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This Phase 2, multi-center, single-arm study evaluates the safety, tolerability, and activity of neoadjuvant PRTX007 in combination with pembrolizumab in participants with resectable Stage III melanoma. Neoadjuvant immunotherapy has demonstrated improved clinical outcomes compared with adjuvant-only approaches, but there remains a need to enhance pathologic response rates without significant added toxicity. Participants will receive oral PRTX007, a Toll-like receptor 7 (TLR7) agonist prodrug, administered in combination with intravenous pembrolizumab prior to surgical resection. The primary objective is to determine the major pathologic response (MPR) rate following neoadjuvant therapy. Seco","sourceUrl":"https://clinicaltrials.gov/study/NCT07565285"},{"nctId":"NCT07178795","title":"A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2025-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Non-squamous Non-small Cell Lung Cancer"],"interventions":["BL-M07D1","Pembrolizumab","Pemetrexed","Carboplatin","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registrational phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with first-line treatment of HER2-mutant advanced or metastatic non-squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07178795"},{"nctId":"NCT06520345","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2024-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["177Lu-TLX591","Enzalutamide","Abiraterone","Docetaxel"],"countries":["United States","Australia","Canada","New Zealand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06520345"},{"nctId":"NCT07477366","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-17","conditions":["Relapsed B-Cell Non-Hodgkin Lymphoma"],"interventions":["CD19 t-haNK- IV Administration","N-803","rituximab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07477366"},{"nctId":"NCT07545356","title":"A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Kivu Bioscience Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Solid Tumors"],"interventions":["KIVU-305"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"This is a 2-part, first-in-human, open-label study to determine the safety, tolerability and preliminary efficacy of KIVU-305, a CEACAM5-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07545356"},{"nctId":"NCT07338838","title":"To Evaluate the Tolerability and Pharmacokinetics of TQB3142 for Injection in Patients With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Malignant Tumors"],"interventions":["TQB3142 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"To explore the safety, tolerability and pharmacokinetics of TQB3142 for injection in subjects with advanced malignant tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07338838"},{"nctId":"NCT07043751","title":"A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2025-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Advanced Malignant Tumors"],"interventions":["TQB6411 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":19,"serviceSignals":["MET profiling","ADC biomarker"],"summary":"TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation of EGFR and c-Met signaling pathways. The ADC is enzymatically transported to the lysosome. The linker releases toxins after enzyme cleavage, resulting in DNA damage and cell death. TQB6411 for injection is intended for the treatment of advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07043751"},{"nctId":"NCT05734105","title":"A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["GIST"],"interventions":["Ripretinib","Sunitinib"],"countries":["United States","Australia","Brazil","Canada","Chile","France","Germany","Italy","Netherlands","Norway","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations. Upon disease progression as determined by an independent radiologic review, participants randomized to sunitinib will be given the option to either crossover to receive ripretinib 150 mg QD or discontinue sunitinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05734105"},{"nctId":"NCT06500273","title":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","sponsor":"Allogene Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Large B-cell Lymphoma"],"interventions":["cemacabtagene ansegedleucel","Fludarabine","Cyclophosphamide","Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™"],"countries":["United States","Australia","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":82,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. In this study, participants with MRD are randomized 1:1 to treatment with cema-cel or an observation arm. Treatment includes cema-cel ","sourceUrl":"https://clinicaltrials.gov/study/NCT06500273"},{"nctId":"NCT07726212","title":"A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002","sponsor":"Hangzhou MacroLink Biopharmaceutical LLC","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":143,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Advanced Esophageal Cancer","Advanced Lung Cancer"],"interventions":["MC002（ADC）"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002. The main questions it aims to answer are: Does participants tolerate the drug MC002 ? What medical problems do participants have when treating with MC002? Does participants benefit from the MC002 . Participants will: Intravenous infusion MC002 every 3 weeks in clinical Visit the clinic once every 3 weeks for checkups and tests Keep a diary of their symptoms","sourceUrl":"https://clinicaltrials.gov/study/NCT07726212"},{"nctId":"NCT07509684","title":"A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors","sponsor":"Zhejiang Anglikang Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Solid Tumors"],"interventions":["ALK-N001 for Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, dose-escalation and cohort-expansion Phase Ib/II clinical trial conducted in patients with advanced solid tumors, aiming to evaluate the safety, pharmacokinetics and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07509684"},{"nctId":"NCT05908643","title":"A First-In-Human Trial of pTTL in Advanced Colorectal Cancer","sponsor":"Neogap Therapeutics AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2025-05-29","conditions":["Colorectal Cancer"],"interventions":["pTTL"],"countries":["Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["HLA / TCR"],"summary":"This is an open-label, non-randomised FIH trial investigating the safety and tolerability of a novel ATMP, pTTL, composed of autologous tumour-draining lymph node-derived T cells stimulated in vitro with personalised cancer neoantigens. The neoantigens are selected through a process starting with next generation sequencing (NGS) of tumour material from the patient followed by selection of neoantigenic mutations using an in-house software, PIOR®. Selected neoantigen epitopes are expressed as recombinant proteins, NAG, and used to stimulate T cells to promote neoantigen-specific T cell expansion in vitro in pTTL production. pTTL is thus based on autologous cells stimulated with patient-specifi","sourceUrl":"https://clinicaltrials.gov/study/NCT05908643"},{"nctId":"NCT06263231","title":"A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)","sponsor":"Intensity Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":333,"enrollmentType":"ESTIMATED","startDate":"2024-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-07-29","conditions":["Sarcoma,Soft Tissue"],"interventions":["INT230-6","Eribulin","Trabectedin","Pazopanib"],"countries":["United States","Canada","France","Germany","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT06263231"},{"nctId":"NCT05384626","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","sponsor":"Nuvalent Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":840,"enrollmentType":"ESTIMATED","startDate":"2022-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["Neladalkib (NVL-655)","Midazolam","Repaglinide","Itraconazole"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":74,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of neladalkib and will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of neladalkib in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of neladalkib at the RP2D. Secondary objectives will include the duration of response (DOR), ","sourceUrl":"https://clinicaltrials.gov/study/NCT05384626"},{"nctId":"NCT07586124","title":"Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma","sponsor":"Lepu Biopharma Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["Becotatug Vedotin for Injection","Placebo","Pucotenlimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"A multicenter, randomized, double-blind, phase II clinical study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of Becotatug Vedotin for Injection in combination with PD-1 in patients with locally advanced resectable head and neck squamous cell carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07586124"},{"nctId":"NCT05431270","title":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)","sponsor":"Phanes Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2022-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Non Small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma"],"interventions":["Mavrostobart (PT199)","Tislelizumab","Gemcitabine + nab-Paclitaxel","Docetaxel","Pemetrexed","Gemcitabine","Carboplatin + Pemetrexed","Pembrolizumab + Carboplatin + Pemetrexed"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05431270"},{"nctId":"NCT07082686","title":"A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2025-08-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Relapsed or Refractory Mantle Cell Lymphoma (MCL)"],"interventions":["ICP-248"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07082686"},{"nctId":"NCT06464692","title":"Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ACTUAL","startDate":"2024-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Colorectal Cancer"],"interventions":["Telisotuzumab Adizutecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and how telisotuzumab adizutecan moves through the body of adult participants with unresectable locally advanced/metastatic CRC. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Study doctors put the participants in cohorts called treatment arms. Each treatment arm receives a different dose of telisotuzumab adizutecan. This study will include a dose escalation phase followed by a dose expansion phase. Up to approximately 30 adult participants with unresectable locally advanced/metastatic CRC, will ","sourceUrl":"https://clinicaltrials.gov/study/NCT06464692"},{"nctId":"NCT07407803","title":"Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":177,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Plexiform Neurofibroma"],"interventions":["TQ-B3234 capsules","TQ-B3234 placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"This study aims to demonstrate that in subjects with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1, TQ-B3234 capsules significantly improve the objective response rate at Week 24 compared to placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT07407803"},{"nctId":"NCT05874414","title":"Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma","sponsor":"Genfit","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2023-08-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Cholangiocarcinoma"],"interventions":["GNS561 + Trametinib"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RAS genotyping"],"summary":"This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT05874414"},{"nctId":"NCT07348211","title":"First in Human Study of SIM0610 in Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Advanced Solid Tumours","Non-Small Cell Lung Cancer","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Hepatocellular Carcinoma"],"interventions":["SIM0610 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of SIM0610 in subjects with locally advanced/metastatic solid tumors. Accelerated titration (ATD) and Bayesian optimal interval design (BOIN) will be used to guide dose escalation in part1, the preliminary anti-tumor effect of SIM0610 will to be further evaluated in part 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT07348211"},{"nctId":"NCT05914116","title":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":862,"enrollmentType":"ESTIMATED","startDate":"2023-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Advanced Solid Tumors"],"interventions":["DB-1311","Lopinavir and Ritonavir Tablets","itraconazole","Enzalutamide","Abiraterone"],"countries":["United States","Australia","China","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":107,"serviceSignals":["ADC biomarker"],"summary":"This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05914116"},{"nctId":"NCT07311694","title":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":370,"enrollmentType":"ESTIMATED","startDate":"2026-02-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer"],"interventions":["HRS-4357 injection","Enzalutamide；Abiraterone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC). The efficacy of HRS-4357 versus novel androgen receptor pathway inhibitors (ARPI) in the treatment of PSMA-positive advanced metastatic castration-resistant prostate cancer (mCRPC) will be evaluated based on radiographic progression-free survival (rPFS) assessed by the BIRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07311694"},{"nctId":"NCT03838926","title":"Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies","sponsor":"Vanda Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2018-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Relapsed or Refractory Hematologic Malignancies"],"interventions":["Trichostatin A"],"countries":["United States","Poland"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT03838926"},{"nctId":"NCT06707610","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":234,"enrollmentType":"ESTIMATED","startDate":"2025-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-03-12","conditions":["Advanced Cancer","Advanced Solid Tumor"],"interventions":["ALK202"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.","sourceUrl":"https://clinicaltrials.gov/study/NCT06707610"},{"nctId":"NCT05722418","title":"CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Caribou Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["CB-011"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that has come back (relapsed) or that is no longer responding to other treatment (refractory).","sourceUrl":"https://clinicaltrials.gov/study/NCT05722418"},{"nctId":"NCT07073534","title":"Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":203,"enrollmentType":"ESTIMATED","startDate":"2025-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Patients With Advanced or Metastatic Malignant Tumors"],"interventions":["SHR-1501, Adebrelimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter phase I/II clinical study. The entire study is divided into three stages: dose escalation, dose expansion, and efficacy expansion. Objective: To evaluate the objective response rate (ORR), safety and tolerability of the combination of SHR-1501 and adibelizumab in the treatment of advanced malignant tumors, and to provide the recommended dose (RP2D) for subsequent clinical studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07073534"},{"nctId":"NCT07189871","title":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","sponsor":"Radiopharm Theranostics, Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":61,"enrollmentType":"ESTIMATED","startDate":"2026-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Castration-Resistant Prostate Cancer (CRPC)","Colorectal Cancer","NSCLC (Non-small Cell Lung Cancer)","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","TNBC, Triple Negative Breast Cancer","Small Cell Lung Cancer (SCLC )","Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)","Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":["177Lu-BetaBart"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07189871"},{"nctId":"NCT06911827","title":"A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":149,"enrollmentType":"ESTIMATED","startDate":"2025-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Advanced Solid Tumor"],"interventions":["QLP2117","QL2107"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and efficacy of QLP2117 in combination with QL2107 in Advanced Solid Tumor Patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06911827"},{"nctId":"NCT06754930","title":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-04-17","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["SHR-1826","SHR-1316","SHR-9839","SHR-8068","Ametinib mesylate","BP-102","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06754930"},{"nctId":"NCT07020117","title":"A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","sponsor":"Aktis Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Urothelial Carcinoma Bladder","Triple Negative Breast Cancer (TNBC)","Hormone Receptor Positive Breast Adenocarcinoma","Non Small Cell Lung Cancer","Cervical Adenocarcinoma","Colorectal Adenocarcinoma","Head and Neck Cancer"],"interventions":["[225Ac]Ac-AKY-1189 (therapeutic)","[64Cu]Cu-AKY-1189 (imaging)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\\[225Ac\\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT07020117"},{"nctId":"NCT07227168","title":"A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer","sponsor":"Sutro Biopharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Head and Neck Squamous Cell Carcinoma HNSCC","Non-Small Cell Lung Cancer NSCLC","Esophageal Cancer","Gastric Cancer","Colorectal Cancer","Pancreatic Ductal Adenocarcinoma (PDAC)","Cervical Cancer","Endometrial Cancer","Urothelial Cancer"],"interventions":["STRO-004","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.","sourceUrl":"https://clinicaltrials.gov/study/NCT07227168"},{"nctId":"NCT07215650","title":"Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)","sponsor":"Candid Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2025-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Generalized Myasthenia Gravis"],"interventions":["Cizutamig"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, PK, PD, immunogenicity, and preliminary clinical activity of Cizutamig in patients with Generalized Myasthenia Gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07215650"},{"nctId":"NCT07661537","title":"A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["B-cell Non-Hodgkin Lymphoma"],"interventions":["SHR-3079 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07661537"},{"nctId":"NCT06010342","title":"A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients","sponsor":"Teligene US","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Solid Tumor"],"interventions":["TL118 Capsule"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":19,"serviceSignals":["RNA fusion"],"summary":"The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions","sourceUrl":"https://clinicaltrials.gov/study/NCT06010342"},{"nctId":"NCT04623541","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":194,"enrollmentType":"ACTUAL","startDate":"2020-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Relapsed/Refractory Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","Richter's Syndrome","Treatment-naïve High Risk Chronic Lymphocytic Leukemia"],"interventions":["Epcoritamab","rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","Venetoclax","Lenalidomide","Pirtobrutinib"],"countries":["United States","Australia","Belgium","Czechia","Denmark","France","Germany","Israel","Italy","Netherlands","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":81,"serviceSignals":["Hematology NGS"],"summary":"The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Richter's Syndrome (RS): * epcoritamab + lenalidomide * epcoritamab + R-CHOP (i.e., rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine \\[Oncovin®\\] and prednisone). The study includes participant","sourceUrl":"https://clinicaltrials.gov/study/NCT04623541"},{"nctId":"NCT06794957","title":"A Study of AL8326 in Non-Small Cell Lung Cancer","sponsor":"Advenchen Laboratories, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":158,"enrollmentType":"ESTIMATED","startDate":"2022-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2025-01-27","conditions":["Non-small Cell Lung Cancer"],"interventions":["AL8326 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06794957"},{"nctId":"NCT07173595","title":"A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2025-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Relapsed or Refractory Hematologic Malignancies"],"interventions":["QLS2309"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, multicenter, dose-escalation, dose-expansion and efficacy-expansion phase I clinical study to evaluate the tolerability, safety, pharmacokinetics and preliminary antitumor activity of QLS2309 injection in patients with CD70+ relapsed/refractory hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07173595"},{"nctId":"NCT07255872","title":"A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Acute Myeloid Leukemia"],"interventions":["BL-M11D1","Cytarabine","Daunorubicin","Venetoclax","Azacitidine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is an open, multicenter, dose-escalation and expansion, non-randomized phase II/III clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M11D1 in combination with cytarabine + daunorubicin or venetoclax + azacitidine in patients with acute myeloid leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT07255872"},{"nctId":"NCT05039892","title":"Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma","sponsor":"3D Medicines (Beijing) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-12","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-05-20","conditions":["Cholangiocarcinoma,Adult"],"interventions":["3D185"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is evaluate the efficacy of 3D185 in subjects with advanced/metastatic cholangiocarcinoma with FGFR2 Gene Alterations who have failed at least 1 previous treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05039892"},{"nctId":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","sponsor":"Revolution Medicines, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":590,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["NSCLC (Non-small Cell Lung Cancer)","Non-Small Cell Lung Cancer","NSCLC","NSCLC (Non-small Cell Lung Carcinoma)","NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["daraxonrasib","docetaxel"],"countries":["United States","Australia","Belgium","France","Germany","Hong Kong","Ireland","Italy","Japan","Netherlands","New Zealand","Poland","Puerto Rico","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":152,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.","sourceUrl":"https://clinicaltrials.gov/study/NCT06881784"},{"nctId":"NCT05910827","title":"A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers","sponsor":"Hummingbird Bioscience","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":398,"enrollmentType":"ESTIMATED","startDate":"2024-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","Advanced Head and Neck Squamous Cell Carcinoma","Advanced Esophageal Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Advanced Cutaneous Squamous Cell Carcinoma","Nasopharyngeal Cancinoma (NPC)","Squamous Cell Carcinoma"],"interventions":["HMBD-001","Docetaxel","Cetuximab"],"countries":["Australia","Moldova","Singapore","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT05910827"},{"nctId":"NCT07541534","title":"A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":41,"enrollmentType":"ESTIMATED","startDate":"2026-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-01","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["HLX316"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["RNA fusion","ADC biomarker"],"summary":"This study is an open-label, first-in-human Phase I clinical study to evaluate the safety, tolerability, PK characteristics, and preliminary antitumor activity of HLX316 in participants with advanced/metastatic solid tumors. The study will consist of 2 parts: a Phase Ia dose-escalation part and a Phase Ib dose-expansion part. Phase Ia and Phase Ib will focus on exploring the preliminary antitumor activity of HLX316 in participants with platinum-resistant ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07541534"},{"nctId":"NCT07504263","title":"Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies","sponsor":"Recurv Pharma Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-01","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Advanced Malignancies","Oncology","Colorectal Cancer","Pancreatic Cancer","Cancer"],"interventions":["RP-001"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2a Study of RP-001 in participants with Advanced Malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT07504263"},{"nctId":"NCT06672068","title":"A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC","sponsor":"TYK Medicines, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2024-12-30","conditions":["NSCLC"],"interventions":["TY-9591 80mg QD+pemetrexed+Cisplatin/Carboplatin","TY-9591 160mg QD+pemetrexed+Cisplatin/Carboplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR sensitive mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06672068"},{"nctId":"NCT06629597","title":"A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2024-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2025-02-10","conditions":["Nasopharyngeal Carcinoma"],"interventions":["YL201","Docetaxel","Capecitabine","Gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06629597"},{"nctId":"NCT06612151","title":"A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":438,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Small Cell Lung Cancer"],"interventions":["YL201","topotecan hydrochloride for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06612151"},{"nctId":"NCT05876754","title":"An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma","sponsor":"Servier Affaires Médicales","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":299,"enrollmentType":"ACTUAL","startDate":"2023-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Cholangiocarcinoma"],"interventions":["Ivosidenib Oral Tablet"],"countries":["Armenia","Australia","Austria","Belgium","Canada","France","Germany","Ireland","Italy","Japan","Netherlands","Romania","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":84,"serviceSignals":["Broad CGP"],"summary":"A Phase 3b research study to consolidate the data that ivosidenib is safe and effective in adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma (CCA). All patients who meet inclusion criteria will be enrolled to receive ivosidenib tablets orally once daily for 28 day cycles, continuing as long as clinical benefit and consent for participation is maintained. There will be a minimum of 6 study visits from screening until the final follow-up, if one cycle of treatment is completed and consent is maintained through 18 months of follow-up. Each additional cycle completed will add one study visit, on the first day of each cycle.","sourceUrl":"https://clinicaltrials.gov/study/NCT05876754"},{"nctId":"NCT05733598","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","sponsor":"Replimune, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Hepatocellular Carcinoma","Biliary Tract Cancer"],"interventions":["RP2","Bevacizumab","Atezolizumab","Durvalumab","RP2 Monotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05733598"},{"nctId":"NCT06748872","title":"EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma","sponsor":"Medigene AG","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2025-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2042-08-01","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Epithelial Ovarian Cancer","Gastro-esophageal Junction Cancer","Soft Tissue Sarcoma (STS)","Myxoid Liposarcoma","Synovial Sarcoma"],"interventions":["Lymphodepletion","TCR-T cells (MDG1015)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The study purpose is to establish the safety, tolerability and preliminary efficacy of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma that expresses NY-ESO-1 and/or LAGE-1a. The main questions this clinical trial aims to answer are: Can this TCR-T therapy MDG1015 be given to patients safely? What is the optimal dose of the TCR-T therapy MDG1015? If and what side effects do participants experience after receiving the TCR-T therapy MDG1015? Do participants expe","sourceUrl":"https://clinicaltrials.gov/study/NCT06748872"},{"nctId":"NCT07299747","title":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","sponsor":"VelaVigo Bio Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":255,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Participants With Advanced Solid Tumor Malignancies"],"interventions":["VBC103"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study is a multicenter, open-label, multi-dose, first-in-human (FIH) Phase I/IIa study to determine the safety and tolerability of VBC103, as well as the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), PK and further evaluate its efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07299747"},{"nctId":"NCT07455045","title":"A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-01","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["High Grade Glioma (III or IV)","Diffuse Midline Glioma (DMG)","Glioblastoma (GBM)"],"interventions":["FZ-AD005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with HGG, especially in DMG and other Recurrent HGG.","sourceUrl":"https://clinicaltrials.gov/study/NCT07455045"},{"nctId":"NCT06961617","title":"Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma","sponsor":"Lion TCR Pte. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2024-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2025-05-08","conditions":["Hepatocellular Carcinoma"],"interventions":["LioCyx-M, HBV antigen-specific TCR-redirected T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06961617"},{"nctId":"NCT06854276","title":"Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-01","completionType":"ESTIMATED","lastUpdated":"2025-03-03","conditions":["Chemotherapy-induced Anemia","Non-myeloid Malignancies"],"interventions":["SSS06","rhEPO"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study employs a multicenter, randomized, open-label, positive drug-controlled, multiple ascending dose clinical trial design to comprehensively evaluate the safety, tolerability, immunogenicity, and pharmacokinetic characteristics of SSS06 injection in patients with chemotherapy-induced anemia from non-myeloid malignancies, while also exploring its potential efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06854276"},{"nctId":"NCT06184035","title":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","sponsor":"Spago Nanomedical AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Solid Tumor","Metastatic Cancer","Unresectable Solid Tumor","Recurrent Solid Tumor","Locally Advanced Solid Tumor","Refractory Cancer"],"interventions":["[177Lu]Lu-SN201"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of \\[177Lu\\]Lu-SN201 in adult participants with advanced solid tumors who have no standard of care treatment options. \\[177Lu\\]Lu-SN201 is a radiolabeled, nanomedical investigational medicinal product (IMP) whose mechanism of delivery is based on the Enhanced Permeability and Retention (EPR) effect.","sourceUrl":"https://clinicaltrials.gov/study/NCT06184035"},{"nctId":"NCT06680037","title":"A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders","sponsor":"TG Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["B-cell Mediated Autoimmune Disorders"],"interventions":["Azercabtagene zapreleucel (azer-cel)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).","sourceUrl":"https://clinicaltrials.gov/study/NCT06680037"},{"nctId":"NCT07158918","title":"ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors","sponsor":"ABL Bio, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-02","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-02","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Solid Tumors"],"interventions":["ABL103","KEYTRUDA® (pembrolizumab)","Taxane"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"This study is to assess the safety and antitumor activity of ABL103 plus pembrolizumab, with or without taxane, in advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07158918"},{"nctId":"NCT07226427","title":"A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-01-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-02","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Platinum-resistant Ovarian Cancer"],"interventions":["MEN2501"],"countries":["United States","Australia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07226427"},{"nctId":"NCT07421700","title":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2026-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-05","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Urothelial Cancer","Advanced/Metastatic Urothelial Cancer","Urothelial Carcinoma"],"interventions":["PF-08634404","Enfortumab Vedotin"],"countries":["United States","Australia","China","Japan","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":115,"serviceSignals":["Broad CGP"],"summary":"This study is being done to learn more about a new medicine called PF-08634404. It is for adults with a type of bladder cancer called locally advanced or metastatic urothelial cancer (LA/mUC), meaning the cancer has spread to nearby tissues or other parts of the body. The purpose of the study is to see if PF-08634404 is safe, how well it works, how it moves through the body, and how it affects the cancer. The study will also look at how the medicine may change certain markers in the body that are linked to cancer. To join the study, participants must: * Be adults (18 years or older) and * Have locally advanced or metastatic urothelial cancer, The study has two groups: * Cohort A: People who ","sourceUrl":"https://clinicaltrials.gov/study/NCT07421700"},{"nctId":"NCT06795412","title":"Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors","sponsor":"Pyxis Oncology, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-06","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-06","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Advanced Solid Tumors"],"interventions":["PYX-201","pembrolizumab"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06795412"},{"nctId":"NCT07631793","title":"Phase I Clinical Trial of YKYY031 for Injection in Patients With Advanced Solid Tumors","sponsor":"Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2026-05-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-07","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Malignant Neoplasms"],"interventions":["YKYY031 group (the first stage)","YKYY031 group (the second stage)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase I study of YKYY031 for injection in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07631793"},{"nctId":"NCT06692166","title":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2024-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2024-11-22","conditions":["Cervical Cancer"],"interventions":["9MW2821","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the efficacy and safety of 9MW2821 and chemotherapy in participants with recurrent or metastatic cervical cancer who progressed on or after platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06692166"},{"nctId":"NCT05245500","title":"Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":336,"enrollmentType":"ESTIMATED","startDate":"2022-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-10","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-10","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Mesothelioma","Non Small Cell Lung Cancer","Malignant Peripheral Nerve Sheath Tumors","Solid Tumor","Pancreatic Adenocarcinoma","Advanced Solid Tumor"],"interventions":["MRTX1719"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.","sourceUrl":"https://clinicaltrials.gov/study/NCT05245500"},{"nctId":"NCT06890884","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":594,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-13","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-16","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Lymphoma, Large B-Cell, Diffuse"],"interventions":["Zilovertamab vedotin","Rituximab","Cyclophosphamide","Doxorubicin","Rituximab Biosimilar","Prednisone","Prednisolone","Polatuzumab vedotin","Rescue Medication"],"countries":["United States","Belgium","Germany","Ireland","Israel","Italy","Japan","Poland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":140,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.","sourceUrl":"https://clinicaltrials.gov/study/NCT06890884"},{"nctId":"NCT07689201","title":"A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Gastrointestinal Neoplasms"],"interventions":["Velzatinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who progressed or were intolerant to standard therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07689201"},{"nctId":"NCT06084884","title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2023-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-13","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-13","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Hepatocellular Carcinoma"],"interventions":["AZD5851"],"countries":["United States","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06084884"},{"nctId":"NCT06472245","title":"Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor","sponsor":"OSE Immunotherapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":363,"enrollmentType":"ESTIMATED","startDate":"2024-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-15","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Patients With Non-Small Cell Lung Cancer"],"interventions":["OSE2101","Docetaxel","NGS HLAA2 assay"],"countries":["United States","Belgium","Canada","France","Germany","Greece","Hungary","Italy","Netherlands","Poland","Portugal","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":207,"serviceSignals":["HLA / TCR"],"summary":"Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).","sourceUrl":"https://clinicaltrials.gov/study/NCT06472245"},{"nctId":"NCT07581509","title":"Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma","sponsor":"Biocon Biologics UK PLC","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-21","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)"],"interventions":["Bmab1800","US-Licensed Keytruda"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the pharmacokinetic (PK) equivalence of Bmab1800 as compared with reference product Keytruda® in a randomized, double-blind, two-arm, parallel comparative, multi-center study in patients with resected melanoma (Stage IIB, or Stage IIC, or Stage III) as an adjuvant treatment. This study also compares the safety and immunogenicity of Bmab1800 and Keytruda.","sourceUrl":"https://clinicaltrials.gov/study/NCT07581509"},{"nctId":"NCT07243340","title":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","sponsor":"ImmVira Pharma Co. Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-12-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-15","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Glioma, Malignant"],"interventions":["Herpes Virus C5252 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.","sourceUrl":"https://clinicaltrials.gov/study/NCT07243340"},{"nctId":"NCT06750094","title":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-13","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Colorectal Neoplasms"],"interventions":["Amivantamab","Cetuximab","Bevacizumab","5-fluorouracil","Leucovorin calcium/Levoleucovorin","Irinotecan"],"countries":["United States","Australia","Belgium","Brazil","China","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Puerto Rico","Romania","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":250,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06750094"},{"nctId":"NCT07669415","title":"A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2026-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-15","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Solid Tumor"],"interventions":["LM-168","Tislelizumab","Docetaxel injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"For Safety introduction phase，this study is to evaluate the safety and tolerability of LM-168 in combination with other anti-tumor treatment regimens in participants of advanced solid tumor trials, determine the maximum tolerated dose (MTD), and explore the recommended phase II dose (RP2D). For Dose expansion phase，this study is to evaluate the preliminary antitumor activity of LM-168 in combination with other antitumor treatment regimens in participants of advanced solid tumor trials, measured by objective response rate (ORR)","sourceUrl":"https://clinicaltrials.gov/study/NCT07669415"},{"nctId":"NCT05963074","title":"A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":333,"enrollmentType":"ACTUAL","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-19","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Leukemia, Lymphocytic, Chronic, B-Cell","Small Lymphocytic Lymphoma"],"interventions":["Ibrutinib","Venetoclax"],"countries":["United States","Canada","Czechia","France","Hungary","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":74,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing of ibrutinib is either proactively reduced or reactively modified in response to adverse events (AEs).","sourceUrl":"https://clinicaltrials.gov/study/NCT05963074"},{"nctId":"NCT04065399","title":"A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation","sponsor":"Syndax Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":447,"enrollmentType":"ESTIMATED","startDate":"2019-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-15","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Mixed Lineage Acute Leukemia","Mixed Phenotype Acute Leukemia","Acute Leukemia of Ambiguous Lineage"],"interventions":["revumenib","cobicistat"],"countries":["United States","Australia","Canada","France","Germany","Israel","Italy","Lithuania","Netherlands","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":57,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.","sourceUrl":"https://clinicaltrials.gov/study/NCT04065399"},{"nctId":"NCT05882058","title":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","sponsor":"Boehringer Ingelheim","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":204,"enrollmentType":"ESTIMATED","startDate":"2023-10-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-08","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Small Cell Lung Carcinoma","Neuroendocrine Neoplasms","Extra-pulmonary Neuroendocrine Carcinoma"],"interventions":["BI 764532, dose 1","BI 764532, dose 2","Ventana DLL3 RxDx assay"],"countries":["United States","Belgium","Bulgaria","China","France","Germany","Japan","Portugal","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":59,"serviceSignals":["ADC biomarker"],"summary":"This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 (also called obrixtamig) that people with advanced cancer can tolerate. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. The study has 3 parts. In Part 1, participants are put into 2 groups randomly, which means by chance. Participan","sourceUrl":"https://clinicaltrials.gov/study/NCT05882058"},{"nctId":"NCT05276310","title":"A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy","sponsor":"ImmuneOncia Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":62,"enrollmentType":"ESTIMATED","startDate":"2022-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Advanced Cancer"],"interventions":["IMC-002"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT05276310"},{"nctId":"NCT07231081","title":"Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors","sponsor":"Tcelltech Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-20","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-20","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Solid Tumors"],"interventions":["Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a single-arm, open-label, Phase I study to evaluate the safety, tolerability, and antitumor activity of TX103 CAR-T cells in subjects with TX103-positive advanced solid tumors. The study also aims to explore the maximum tolerated dose (MTD) and determine the recommended Phase II dose (RP2D) of TX103 CAR-T cell therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07231081"},{"nctId":"NCT07462650","title":"Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer","sponsor":"Beijing Biotech","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-22","completionType":"ESTIMATED","lastUpdated":"2026-03-10","conditions":["Colorectal Cancer Metastatic","Adenocarcinoma of Colon"],"interventions":["EB-DUO-CAR-NK-CEA/GCC (IV)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic colorectal cancer (CRC). Participants are assigned to one of three dual-target arms based on tumor antigen co-expression: (1) CEA+GUCY2C, (2) CEA+HER2, or (3) GUCY2C+HER2. Following dose escalation, the most suitable target pair (based on safety, feasibility, and early efficacy/biomarker signals) will be selected for dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07462650"},{"nctId":"NCT07414927","title":"A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy","sponsor":"Shanghai Best-Link Bioscience, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-03-27","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-20","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Small Cell Carcinoma of Lung"],"interventions":["BL0020"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"The primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI). After a certain period of treatment with EGFR TKI, acquired resistance emerges most frequently with a secondary mutation, p.T790M, followed by MET amplification. Interestingly, up to 3-14% of patients experience histological transformation into small cell lung cancer (SCLC), which has an aggressive clinical course and a poor prognosis. The transformed SCLC retains the original EGFR mutation but significantly down regulates EGFR protein expression, eliminating its dependence on EGFR signaling while simultan","sourceUrl":"https://clinicaltrials.gov/study/NCT07414927"},{"nctId":"NCT06710132","title":"Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":184,"enrollmentType":"ACTUAL","startDate":"2025-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-23","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-23","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Solid Tumors","Gastric Cancer","Non-Small Cell Lung Cancer (NSCLC)","Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["M9140"],"countries":["United States","Australia","Austria","China","France","Germany","Italy","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":81,"serviceSignals":["ADC biomarker"],"summary":"The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC);","sourceUrl":"https://clinicaltrials.gov/study/NCT06710132"},{"nctId":"NCT05745623","title":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2022-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-25","completionType":"ESTIMATED","lastUpdated":"2025-09-11","conditions":["Advanced Solid Tumors Harboring NTRK Fusion","Primary Central Nervous System Tumors Harboring NTRK Fusion"],"interventions":["ICP-723"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05745623"},{"nctId":"NCT07042802","title":"A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-25","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Ovarian Cancer"],"interventions":["LBL-024 for Injection","Paclitaxel Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This trial is an open-label, multicenter phase Ib/II clinical study of LBL-024 combination therapy in patients with platinum-resistant ovarian cancer (OC),To evaluate the efficacy and safety of LBL-024 combination therapy in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC) patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07042802"},{"nctId":"NCT07111546","title":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-26","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-26","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Advanced Solid Tumour"],"interventions":["LBL-024 for Injection","Cisplatin Injection","Gemcitabine Hydrochloride for Injection","Bevacizumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"An open-label, multicenter, phase II clinical study to evaluate the efficacy and safety of LBL-024 in combination with other drugs for the treatment of patients with advanced solid tumour.","sourceUrl":"https://clinicaltrials.gov/study/NCT07111546"},{"nctId":"NCT07165067","title":"A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors","sponsor":"AP Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-01-21","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-27","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-30","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Solid Tumours"],"interventions":["AP601"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"A Phase 1, Open-Label Study of the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics and Clinical Activity of AP601 in Patients with Solid Tumours.The study is designed to find the highest dose of AP601 that can be given safely. Participants will be assigned to one of six cohorts. Each cohort will receive a different dose of the study medication, AP601, based on the body weight. Each cohort will initially enrol 1-3 participants. If no serious side effects are seen in the first participant(s), the next cohort will receive the next dose level.","sourceUrl":"https://clinicaltrials.gov/study/NCT07165067"},{"nctId":"NCT06834672","title":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-28","completionType":"ESTIMATED","lastUpdated":"2025-04-13","conditions":["Ovarian","Primary Peritoneal","Fallopian Tube Cancer"],"interventions":["IBI354","paclitaxel/Gemcitabine/Liposomal doxorubicin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a multiregional, multicenter, randomized, open-label, phase III study to compare the efficacy, safety, and tolerability of IBI354 monotherapy with investigator's choice of chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan) in patients with HER2-expressing, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants with advanced ovarian, primary peritoneal, fallopian tube cancer who have failed or are intolerant to first-line or more platinum-based chemotherapy will be randomly assigned in a 2:1 ratio to two treatment arms: Experimental Arm: IBI354 monotherapy arm, 12 mg/kg IBI354 on Day 1 of each 3-week cycle; Control Arm: Investig","sourceUrl":"https://clinicaltrials.gov/study/NCT06834672"},{"nctId":"NCT07427394","title":"Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-29","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Advanced Breast Cancer"],"interventions":["Camizestrant","Atirmociclib"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07427394"},{"nctId":"NCT06975293","title":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas","sponsor":"STORM Therapeutics LTD","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":107,"enrollmentType":"ESTIMATED","startDate":"2025-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-29","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Solid Tumor","Sarcoma","Leiomyosarcoma","Dedifferentiated Liposarcoma"],"interventions":["STC-15 in combination with toripalimab","STC-15 monotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \\[PD-1\\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).","sourceUrl":"https://clinicaltrials.gov/study/NCT06975293"},{"nctId":"NCT07164443","title":"A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1203,"enrollmentType":"ESTIMATED","startDate":"2025-09-02","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-18","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Metastatic Castration-resistant Prostate Neoplasms"],"interventions":["Pasritamig","Placebo","Best Supportive Care (BSC)"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Italy","Japan","Netherlands","Poland","Puerto Rico","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":172,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).","sourceUrl":"https://clinicaltrials.gov/study/NCT07164443"},{"nctId":"NCT06668103","title":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2024-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2024-12-12","conditions":["Non-Small Cell Lung Cancer With EGFR Mutation"],"interventions":["ABSK043 in combination with Firmonertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06668103"},{"nctId":"NCT06736379","title":"Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer","sponsor":"VLP Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":41,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Head and Neck Cancers- Squamous Cell","Head and Neck Cancer","Solid Tumors","HNSCC","SCC - Squamous Cell Carcinoma","SCCHN","Head Neck Cancer","Head and Neck Squamous Cell Cancer","Squamous Cell Carcinoma of the Head and Neck","Squamous Cell Carcinoma, Head And Neck","Squamous Cell Head and Neck Carcinoma","Oral Cavity","Oral Cavity Carcinoma"],"interventions":["VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection)","Pembrolizumab (KEYTRUDA®)","VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients. The main questions being addressed are: The safety and tolerability of intratumoral (IT) injections of VRP-encapsulated saRNA encoding IL-12 (VLPONC-01) The tumor response to IT injections of VLPONC-01 The tumor response due to the combination of IT injections of VLPONC-01 and system IV administration of neoadjuvant pembrolizumab (anti-PD-1) treatment Researchers will compare neoadjuvant pembrolizumab alone to the combination therapy to see if the combination enhances tumor responses.","sourceUrl":"https://clinicaltrials.gov/study/NCT06736379"},{"nctId":"NCT05438420","title":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","sponsor":"Qurient Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-30","completionType":"ESTIMATED","lastUpdated":"2026-02-24","conditions":["Esophageal Cancer","Gastric Cancer","Hepatocellular Cancer","Cervical Cancer"],"interventions":["Q702","Pembrolizumab"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study is a phase 1B/2 open-label, study to determine safety and preliminary efficacy of Q702 in combination with pembrolizumab in study subjects with advanced esophageal, gastric/GEJ, hepatocellular, and cervical cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05438420"},{"nctId":"NCT06989671","title":"SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2025-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-30","completionType":"ESTIMATED","lastUpdated":"2025-08-27","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["JMT101","SYS6002","SG001"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase II study of anti-nectin-4 ADC combined with the EGFR monoclonal antibody and the PD-1 monoclonal antibody in participants with advanced head and neck squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06989671"},{"nctId":"NCT05718895","title":"A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Antengene Biologics Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2023-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["ATG-022"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05718895"},{"nctId":"NCT06369285","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","sponsor":"Puma Biotechnology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2024-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer","Recurrent Breast Cancer"],"interventions":["Alisertib","Endocrine therapy"],"countries":["United States","Portugal","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":53,"serviceSignals":["HER2 profiling"],"summary":"PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alis","sourceUrl":"https://clinicaltrials.gov/study/NCT06369285"},{"nctId":"NCT06705686","title":"Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer","sponsor":"TechnoGenesys, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-30","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Metastatic Castration-resistant Prostate Cancer (CRPC)","Metastatic Castration-resistant Prostate Carcinoma"],"interventions":["(R)-9bMS"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"TITLE: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9bMS in Patients with Prostate Cancer (PHAROS) STUDY DESCRIPTION: Prostate cancer (PC) patients receive androgen deprivation therapy (ADT), but recalcitrant disease recurs typically within 2-3 years, referred to as the Castration Resistant Prostate Cancer (CRPC). Androgen receptor (AR) targeted therapies, such as Enzalutamide (Enz) or Abiraterone (Abi), are FDA-approved therapeutics for CRPC patients. However, virtually all patients develop resistance. A non-receptor tyrosine kinase, ACK1 act as a novel epigenetic modifier in prostate tumors, regulating AR and its splice variant, AR-V7 expre","sourceUrl":"https://clinicaltrials.gov/study/NCT06705686"},{"nctId":"NCT06304818","title":"Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.","sponsor":"Sinocelltech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":515,"enrollmentType":"ESTIMATED","startDate":"2024-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2024-03-15","conditions":["Advanced Malignant Solid Tumours"],"interventions":["SCTB14"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT06304818"},{"nctId":"NCT04668690","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":193,"enrollmentType":"ACTUAL","startDate":"2021-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["Peripheral T Cell Lymphoma"],"interventions":["Mitoxantrone Hydrochloride Liposome Injection","Chidamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, open-label, active controlled, multi-center, phase 3 clinical study to compare the efficacy and safety of Mitoxantrone Hydrochloride Liposome Injection with Chidamide in patients with relapsed/refractory Peripheral T Cell Lymphoma (PTCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT04668690"},{"nctId":"NCT06598735","title":"A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced Solid Tumors"],"interventions":["HRS-4508"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy and safety of HRS-4508 in subjects with advanced or metastatic solid tumors and explore the reasonable dosage of HRS-4508.","sourceUrl":"https://clinicaltrials.gov/study/NCT06598735"},{"nctId":"NCT06716138","title":"A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration"],"interventions":["ANS03"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":5,"serviceSignals":["RNA fusion"],"summary":"This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06716138"},{"nctId":"NCT04616209","title":"Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients","sponsor":"Precision Biotech Taiwan Corp.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2020-11-15","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-14","conditions":["Non-small Cell Lung Cancer"],"interventions":["donor-derived NK cell infusion"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04616209"},{"nctId":"NCT06123754","title":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2023-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Non-small Cell Lung Cancer"],"interventions":["Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection","placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects with resectable stage IIIA and IIIB (N2) NSCLC. Primary study endpoints are MPR rate assessed by BIPR and EFS assessed by BIRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06123754"},{"nctId":"NCT07567521","title":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","sponsor":"C Ray Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Prostate Cancer"],"interventions":["Radiopharmaceuticals"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate safety and tolerability, pharmacokinetics （PK）, efficacy of TRC003 injection in patients with progressive PSMA-positive mCRPC who have been treated with androgen receptor pathway inhibitor (ARPI) or taxane-based chemotherapy. We plan to recruit 90 participants who will be randomly assigned to 1 of 3 dose cohorts (30 cases per dose cohort) with up to 6 cycles of treatment in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07567521"},{"nctId":"NCT06350006","title":"SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":924,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["CLDN18.2-positive Advanced Solid Tumor"],"interventions":["SHR-A1904; Adebrelimab","SHR-A1904; CAPOX; Adebrelimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study consists of two research phases: Phase Ib (includes dose escalation stage and efficacy expansion stage): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive advanced solid tumors, and to determine the recommended dose and recommended population for the Phase III combination study. Phase III: A randomized, Open-Label, multicenter clinical study of SHR-A1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06350006"},{"nctId":"NCT04183166","title":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","sponsor":"Transgene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":80,"enrollmentType":"ACTUAL","startDate":"2019-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Squamous Cell Carcinoma of Head and Neck"],"interventions":["TG4050"],"countries":["United States","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).","sourceUrl":"https://clinicaltrials.gov/study/NCT04183166"},{"nctId":"NCT07442565","title":"SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":506,"enrollmentType":"ESTIMATED","startDate":"2026-03-10","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-30","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SYS6010","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of SYS6010 versus docetaxel in participants with Locally Advanced or Metastatic EGFR Wild-type Non-squamous Non-small Cell Lung Cancer who Have Failed Standard Therapy. The primary Objective is to evaluate the efficacy of SYS6010 versus docetaxel in participants with EGFR wild-type locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Secondary Objectives includes safety, quality of life, immunogenicity, biomarkers, and efficacy correlations of SYS6010 compared to docetaxel in the same patient population.","sourceUrl":"https://clinicaltrials.gov/study/NCT07442565"},{"nctId":"NCT07314294","title":"Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2025-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Metastatic Colorectal Cancer"],"interventions":["EMB-01 1600 mg administered once weekly throughout the study","EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07314294"},{"nctId":"NCT07603791","title":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["ALK202 for injection","Osimertinib Mesylate Tablets","Ivonescimab Injection","carboplatin injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MET profiling"],"summary":"This study is an open, multicenter, phase II clinical study for evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ALK202 for injection combined with different drugs in participants with locally advanced or metastatic NSCLC. The study consists of two phases: the Phase IIa (dose escalation) and the Phase IIb (efficacy extension). Phase IIa (dose escalation) :This stage consists of 3 cohorts, which will respectively recruit participants meeting the criteria for each cohort who have locally advanced or metastatic NSCLC, to complete the dose escalation for each combination regimen. The Escalation cohort 1: participants with locally advanced or metastatic EGFR mutati","sourceUrl":"https://clinicaltrials.gov/study/NCT07603791"},{"nctId":"NCT06643754","title":"A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2024-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-01-08","conditions":["Advanced Solid Tumors"],"interventions":["SHR-3276"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3276 for injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06643754"},{"nctId":"NCT06615479","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2025-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-22","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"interventions":["BMS-986393","Cyclophosphamide","Fludarabine","Daratumumab","Pomalidomide","Dexamethasone","Carfilzomib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","Norway","Poland","Portugal","Romania","Saudi Arabia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":141,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06615479"},{"nctId":"NCT05275374","title":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","sponsor":"Xynomic Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":221,"enrollmentType":"ESTIMATED","startDate":"2025-12-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Cancer","BRAF V600 Mutation","Melanoma","Colorectal Cancer","Thyroid Cancer","Nonsmall Cell Lung Cancer"],"interventions":["XP-102","Trametinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05275374"},{"nctId":"NCT07584226","title":"A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors","sponsor":"Relay Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2026-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced NRAS-Mutant Melanoma","Advanced NRAS-Mutant Solid Tumors","NRAS Mutation","NRAS G12D","NRAS G13R","NRAS G13D","NRAS G12V","NRAS Q61R","NRAS Q61K","NRAS Q61L","NRAS Q61H"],"interventions":["RLY-8161"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07584226"},{"nctId":"NCT05785741","title":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2023-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Advanced Solid Tumor"],"interventions":["DB-1310","Trastuzumab","Osimertinib","capecitabine"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05785741"},{"nctId":"NCT07415863","title":"Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":820,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["SYS6043"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"Phase I/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors This study is a first-in-human phase I/II, multicenter, open-label, dose-escalation trial with PK expansion and cohort expansion, designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile and preliminary anti-tumor efficacy of SYS6043 (a B7-H3-targeted antibody-drug conjugate) in patients with advanced/metastatic solid tumors. It consists of three parts: dose escalation, PK expansion and cohort expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07415863"},{"nctId":"NCT05060016","title":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)","sponsor":"Amgen","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":222,"enrollmentType":"ACTUAL","startDate":"2021-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Relapsed/Refractory Small Cell Lung Cancer"],"interventions":["Tarlatamab"],"countries":["United States","Austria","Belgium","Denmark","France","Germany","Greece","Italy","Japan","Netherlands","Poland","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":80,"serviceSignals":["Broad CGP"],"summary":"The main aim of this study is to: * evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \\[RECIST 1.1\\] by investigator) of 2 dose levels of tarlatamab for Part 1 only * evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2 * evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3","sourceUrl":"https://clinicaltrials.gov/study/NCT05060016"},{"nctId":"NCT07750041","title":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Unresectable Advanced or Metastatic Colorectal Cancer"],"interventions":["SYS6090 (Fixed Dose Level A) + bevacizumab","SYS6090 (Fixed Dose Level B ) + bevacizumab","SYS6090 RP2D + bevacizumab +mFOLFOX6","SYS6090 RP2D + bevacizumab","Regorafenib","SYS6090 PR2D+ bevacizumab + FOLFOXIRI","bevacizumab + FOLFOXIRI"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study constitutes an open-label, multi-cohort, multi-center Phase Ib/II clinical study, developed to assess the safety, tolerability, and therapeutic efficacy of SYS6090 injection when administered in combination with bevacizumab, or in triple combination with bevacizumab and chemotherapy, among patients diagnosed with advanced colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07750041"},{"nctId":"NCT04449874","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":498,"enrollmentType":"ESTIMATED","startDate":"2020-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Non-Small Cell Lung Cancer","Colorectal Cancer","Advanced Solid Tumors"],"interventions":["GDC-6036","Atezolizumab","Cetuximab","Bevacizumab","Erlotinib","GDC-1971","Inavolisib"],"countries":["United States","Australia","Belgium","Brazil","Canada","Hungary","Israel","Italy","Kenya","Netherlands","New Zealand","Norway","Poland","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":64,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04449874"},{"nctId":"NCT06478693","title":"A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC","sponsor":"Myeloid Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2024-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Hepatocellular Carcinoma"],"interventions":["MT-303","MT-303 +Atezolizumab + Bevacizumab"],"countries":["Australia","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.","sourceUrl":"https://clinicaltrials.gov/study/NCT06478693"},{"nctId":"NCT05503797","title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","sponsor":"Fore Biotherapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2023-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-28","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Cancer Harboring BRAF Alterations","HGG","LGG","Solid Tumors"],"interventions":["Plixorafenib"],"countries":["United States","Australia","Canada","France","Germany","Italy","Netherlands","Norway","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT05503797"},{"nctId":"NCT07105215","title":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":312,"enrollmentType":"ESTIMATED","startDate":"2025-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2025-11-26","conditions":["Solid Tumors"],"interventions":["RC278"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"The primary objective is to evaluate the safety and tolerability of RC278; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC278; and determine the recommended phase 2 dose (RP2D)， and assess the efficacy of RC278 at the RP2D dose;","sourceUrl":"https://clinicaltrials.gov/study/NCT07105215"},{"nctId":"NCT07231068","title":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","sponsor":"Henan Genuine Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2022-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Dositinib mesylate tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is an open label phase I/phase II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, preliminary efficacy of Dositinib in participants of locally advanced or metastatic non-small cell lung cancer with positive EGFR mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07231068"},{"nctId":"NCT06725758","title":"A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","sponsor":"Orion Corporation, Orion Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":315,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Solid Tumours"],"interventions":["ODM-212"],"countries":["United States","Finland","France","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours","sourceUrl":"https://clinicaltrials.gov/study/NCT06725758"},{"nctId":"NCT05422911","title":"Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.","sponsor":"Sun Pharmaceutical Industries Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Metastatic Cancer","Neoplasm, Prostate","Castrate-sensitive","Castrate-sensitive Prostate Cancer"],"interventions":["Abiraterone acetate","Apalutamide","Enzalutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings should now be explored. In the egalitarian system that is the VHA the treatment of prostate cancer is excellent and uniform across the US. The choices made are clearly personalized, given not all men received all therapies and that younger Veterans were treated more aggressively. But with survivals that rival those in registration trials that enroll optimally fit individuals usually not encumbered ","sourceUrl":"https://clinicaltrials.gov/study/NCT05422911"},{"nctId":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","sponsor":"7 Hills Pharma, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2024-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Cancer","Advanced Solid Tumor","Melanoma","Metastasis","Pleural Mesothelioma","Renal Cell Carcinoma","MSI-High","Mismatch Repair Deficiency","Colorectal Cancer","Hepatocellular Carcinoma","Hepatocellular Cancer","Renal Cell Cancer","Kidney Cancer","Skin Cancer","Non Small Cell Lung Cancer","NSCLC","Anaplastic Lymphoma Kinase Genomic Tumor Aberrations","ALK Genomic Tumor Aberrations"],"interventions":["Alintegimod","Ipilimumab","Nivolumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["MSI / TMB","Hematology NGS"],"summary":"This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b","sourceUrl":"https://clinicaltrials.gov/study/NCT06362369"},{"nctId":"NCT06358053","title":"CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers","sponsor":"Corregene Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-04-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2024-04-10","conditions":["Cervical Cancer","Anal Cancer","Head and Neck Cancers","Other Solid Tumors"],"interventions":["CRTE7A2-01 TCR-T cell therapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HLA / TCR"],"summary":"A single center, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cells in HLA-A\\*02:01+ Subjects HPV16 positive advanced cervical, anal, or head and neck cancers. The study will determine RP2D of CRTE7A2-01 TCR-T cell injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06358053"},{"nctId":"NCT06903117","title":"Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2025-04-03","conditions":["Advanced Lung Cancer"],"interventions":["Targeted CEA CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months. CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expressed in lung cancer, esophageal cancer, bile duct cancer, colorectal cancer, gastric cancer and other tumor types. In previous CAR-T-related clinical trials ","sourceUrl":"https://clinicaltrials.gov/study/NCT06903117"},{"nctId":"NCT07466160","title":"A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2026-02-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Solid Tumor"],"interventions":["7MW3711","JS207","Cisplatin","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07466160"},{"nctId":"NCT05764928","title":"Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy","sponsor":"Rgene Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2026-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Nonsquamous Nonsmall Cell Neoplasm of Lung"],"interventions":["BLEX 404"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Maitake is reported with immunomodulatory functions against tumor growth in terms of its unique molecular structure, β-glucan polysaccharides within 1, 6 main chain having 1, 3 branches and a 1, 3 main chain having 1, 6 branches configuration. The β-glucan is identified as a main component of BLEX 404. Not only with therapeutic potential on several types of cancer, BLEX 404 has also shown the potential to improve hematopoiesis, granulocyte colony stimulating factor (G-CSF) production, and the cytotoxicity activity of immune cells in recent animal studies. Its antitumor effect on tumor-bearing mice is exerted by enhancing the immune system through activation of macrophages, T cells, and natur","sourceUrl":"https://clinicaltrials.gov/study/NCT05764928"},{"nctId":"NCT07327294","title":"A Phase I/II Study to Evaluate XNW34017 in Patients With Advanced or Metastatic Solid Tumor","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-01-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Advanced Solid Tumors"],"interventions":["XNW34017"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, dose-escalation, multicenter Phase I/II study conducted in patients with advanced solid tumors. The target population for this study consists of patients with advanced solid tumors who have failed or are intolerant to standard treatments. The study is divided into two parts: the dose-escalation phase and the dose-expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07327294"},{"nctId":"NCT07283835","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","sponsor":"Lepu Biopharma Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Non Muscle Invasive Bladder Cancer","High-grade Ta/ T1 Papillary Disease Bladder Cancer"],"interventions":["Cretostimogene Grenadenorepvec","n-dodecyl-B-D-maltoside"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the efficacy and safety of Cretostimogene in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without Ta/T1 papillary tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07283835"},{"nctId":"NCT06694480","title":"Study of FID-022 in Participants With Advanced Solid Tumors","sponsor":"Fulgent Pharma LLC.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Advanced Solid Tumors"],"interventions":["FID-022"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this Phase I Clinical Trial is to evaluate the safety and tolerability of FID-022 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06694480"},{"nctId":"NCT06329570","title":"Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)","sponsor":"NaviFUS Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2024-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Glioblastoma Multiforme","Glioblastoma","Glioma","Brain Tumor","Neoplasms","Neoplasms, Nerve Tissue"],"interventions":["NaviFUS System","Lumason","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT06329570"},{"nctId":"NCT07416474","title":"RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)","sponsor":"RemeGen Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":574,"enrollmentType":"ESTIMATED","startDate":"2026-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Non-Small Cell Lung Cancer"],"interventions":["RC148 plus Carboplatin and Paclitaxel","Tislelizumab plus Carboplatin and Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":78,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.","sourceUrl":"https://clinicaltrials.gov/study/NCT07416474"},{"nctId":"NCT06883539","title":"A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.","sponsor":"LaunXP Biomedical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-03-19","conditions":["Solid Tumor Malignancies, Cancer","Solid Cancers","Solid Tumor Cancer","Solid Tumor, Unspecified, Adult","Solid Tumour","Solid Tumors Refractory to Standard Therapy","HCC - Hepatocellular Carcinoma","RCC, Renal Cell Cancer","Pancreas Cancer"],"interventions":["LXP1788 is administered intravenously via Port-A"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Phase I, open-label, first-in-human study to determine the MTD, recommended phase 2 dose (RP2D), assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of LXP1788 Injection in patients with advanced solid tumor. Patients with advanced solid tumors that are refractory to currently available therapies or for whom no effective treatment is available will be selected. The main questions it aims to answer are: 1. To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of LXP1788 Injection 2. To evaluate the pharmacokinetics (PK) of LXP1788 Injection","sourceUrl":"https://clinicaltrials.gov/study/NCT06883539"},{"nctId":"NCT07644403","title":"Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.","sponsor":"Suzhou Immunofoco Biotechnology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Epithelial Cancer Patients"],"interventions":["Autologous CAR-T cell injection targeting EpCAM"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open -label phase I /IIa study designed to evaluate the safety and efficacy of IMC001 in patients with advanced epithelial solid tumors. The study comprises two parts: a phase I dose-escalation phase and a phase IIa phase to further explore and validate efficacy .In the Phase I dose-escalation phase of this study, approximately 7-15 subjects with advanced epithelial solid tumors will be recruited to evaluate the safety and tolerability of autologous IMC001 treatment . In the expansion phase, at least two dose groups will be selected , each recruiting 5-10 subjects. Combined with the subjects from the escalation phase, each dose group will be expanded to approximately 10 subjects t","sourceUrl":"https://clinicaltrials.gov/study/NCT07644403"},{"nctId":"NCT06970782","title":"Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":278,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-21","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["Vebreltinib","PLB1004","Pemetrexed plus Carboplatin or Cisplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MET profiling"],"summary":"Efficacy and Safety of Vebreltinib in Combination With PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFR Mutations, MET Amplification and/or Overexpression, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Following EGFR-TKI Treatment Failure","sourceUrl":"https://clinicaltrials.gov/study/NCT06970782"},{"nctId":"NCT06540261","title":"The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":65,"enrollmentType":"ACTUAL","startDate":"2021-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Unresectable Colorectal Cancer"],"interventions":["ONO-7913","ONO-4538","Fluorouracil","Oxaliplatin","Levofolinate","Bevacizumab","Cetuximab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06540261"},{"nctId":"NCT07667868","title":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"BrightPath Biotherapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Relapsed/Refractory Multiple Myeloma (RRMM)"],"interventions":["BP2202"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07667868"},{"nctId":"NCT07314723","title":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Urothelial Carcinoma"],"interventions":["9MW2821","Toripalimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07314723"},{"nctId":"NCT06496048","title":"Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC","sponsor":"Luye Pharma Group Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2024-12-12","conditions":["Relapsed Small Cell Lung Cancer"],"interventions":["Lurbinectedin","Irinotecan","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined therapy versus Topotecan comparator in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.","sourceUrl":"https://clinicaltrials.gov/study/NCT06496048"},{"nctId":"NCT06631092","title":"Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer","sponsor":"NEC Bio B.V","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2024-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Triple Negative Breast Cancer"],"interventions":["Oral DNA Vaccine"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["HLA / TCR"],"summary":"Phase I/II, multicenter, open-label, single-arm trial in triple-negative breast cancer patients under first-line neoadjuvant therapy with approved standard of care anti-PD-1 monoclonal antibody (PD-1 inhibitor), epirubicin/cyclophosphamide chemotherapy, and nab-paclitaxel therapy (cohort 1) or SoC carboplatin/paclitaxel and epirubicin/cyclophosphamide or doxorubicin/cyclophosphamide chemotherapy (cohort 2). NECVAX-NEO1 treatment in addition to standard of care anti-PD1 monoclonal antibody therapy can be prolonged after breast cancer surgery for another 24 weeks, according to the investigator's decision taking into consideration the study patient's health status.","sourceUrl":"https://clinicaltrials.gov/study/NCT06631092"},{"nctId":"NCT04634357","title":"ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma","sponsor":"Eureka Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2022-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Hepatoblastoma","Hepatocellular Carcinoma (HCC)","Liver Neoplasms","Metastatic Liver Cancer","Liver Cancer","HEMNOS"],"interventions":["ET140203 T Cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT04634357"},{"nctId":"NCT07461454","title":"YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":376,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["YL202","Eribulin","Capecitabine","Gemcitabine","Vinorelbine","Sacituzumab govitecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The study will evaluate the safety and efficacy of YL202, when compared with treatment of physician's choice (eribulin, capecitabine, vinorelbine, gemcitabine or sacituzumab govitecan) in participants with unresectable locally advanced, recurrent or metastatic hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer who had failed at least one line of chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07461454"},{"nctId":"NCT07521852","title":"A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC","sponsor":"TaiRx, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["HCC - Hepatocellular Carcinoma"],"interventions":["CVM-1118 + Sintilimab + TACE"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label Phase IIa study designed to evaluate the efficacy, safety, and PK of CVM-1118 in combination with Sintilimab (Tyvyt ®) and TACE in participants with incurable/non-metastatic HCC. Approximately 40 participants will be enrolled, all receiving CVM-1118 (200 mg orally \\[PO\\], twice daily \\[BID\\]) in combination with Sintilimab (200 mg via intravenous \\[IV\\] infusion every 3 weeks \\[Q3W\\]) and TACE. All participants will initiate treatment with CVM-1118 and Sintilimab on Cycle 1 Day 1 (C1D1), with each cycle lasting 21 days, continuing until the occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, for 2 years (i.e., Cycle 34) or stu","sourceUrl":"https://clinicaltrials.gov/study/NCT07521852"},{"nctId":"NCT04906434","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2020-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Advanced Liver Cancer"],"interventions":["ABSK-011"],"countries":["United States","China","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"This is an open-label phase 1 study with an escalation part and an expansion part.","sourceUrl":"https://clinicaltrials.gov/study/NCT04906434"},{"nctId":"NCT04864054","title":"GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","sponsor":"Eureka Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2022-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Hepatocellular Carcinoma","Liver Cancer, Adult","Liver Neoplasm","Metastatic Liver Cancer"],"interventions":["ECT204 T cells"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT04864054"},{"nctId":"NCT07239323","title":"In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["B-Acute Lymphoblastic Leukemia","B Cell Non-Hodgkin's Lymphoma","Multiple Myeloma"],"interventions":["Invivo CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors. It is an early exploratory clinical study of the safety, tolerability and initial efficacy in the treatment of relapsed or refractory malignant hematological tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07239323"},{"nctId":"NCT07300943","title":"Study in Advanced Solid Tumor Patients","sponsor":"Callio Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":306,"enrollmentType":"ESTIMATED","startDate":"2026-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-17","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Advanced Solid Tumor"],"interventions":["CLIO-8221"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The study will be conducted in 2 phases: Phase 1: Dose-escalation and Dose Level Expansion, Phase 1 will determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE). Phase 2: Tumor-Specific Expansions with Dose Optimization, Phase 2 will further evaluate CLIO-8221 in tumor-specific expansion cohorts to optimize dosing and assess preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07300943"},{"nctId":"NCT05651932","title":"A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma","sponsor":"K36 Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2023-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Multiple Myeloma","Myeloma","Myeloma Multiple"],"interventions":["Cohort A1 & A2: KTX-1001","Cohort B1 & B2: KTX-1001+Mezigdomide","Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)","Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT05651932"},{"nctId":"NCT04093570","title":"A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)","sponsor":"Taiho Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":332,"enrollmentType":"ESTIMATED","startDate":"2019-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndromes"],"interventions":["ASTX727"],"countries":["United States","Armenia","Austria","Bulgaria","Canada","France","Germany","Hungary","Italy","Poland","Romania","Slovakia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["Hematology NGS"],"summary":"Extension study to provide ongoing long-term treatment with ASTX727 for participants who were benefitting from ASTX727 treatment in a previous Taiho (formerly Astex)-sponsored clinical study of ASTX727 (including, but not limited to ASTX727-01 \\[NCT02103478\\], ASTX727-02 \\[NCT03306264\\], ASTX727-04 \\[NCT03813186\\]), ASTX727-06 \\[NCT04093570\\] food effect substudy, ASTX727-17 \\[NCT04953897\\], and ASTX727-18 \\[NCT04953910\\] to obtain long-term safety information. The purpose of the Food Effect Substudy was to evaluate the pharmacokinetics (PK) and safety of decitabine and cedazuridine when ASTX727 was given under fed (high-calorie/high-fat meal or low-calorie/low-fat meal) versus fasted condit","sourceUrl":"https://clinicaltrials.gov/study/NCT04093570"},{"nctId":"NCT07567859","title":"A Study of HS-10587 in Patients With Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":362,"enrollmentType":"ESTIMATED","startDate":"2026-06-04","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["MTAP Deletion"],"interventions":["HS-10587"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicenter, open-label clinical trial with dose escalation/dose expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic (PK/PD) profiles, and antitumor efficacy characteristics of HS-10587 in patients with MTAP-deleted advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07567859"},{"nctId":"NCT05508906","title":"Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer","sponsor":"Olema Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2022-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2025-10-22","conditions":["Metastatic Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","Breast Cancer","Locally Advanced Breast Cancer"],"interventions":["Palazestrant","Ribociclib","Alpelisib","Everolimus","Atirmociclib"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05508906"},{"nctId":"NCT07589634","title":"A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-02","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["Ramantamig","Tocilizumab","Placebo"],"countries":["United States","Malaysia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.","sourceUrl":"https://clinicaltrials.gov/study/NCT07589634"},{"nctId":"NCT06582017","title":"Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma","sponsor":"Nammi Therapeutics Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2024-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Ovarian Cancer","Pancreas Cancer","Urothelial Carcinoma","Renal Cell Carcinoma","Hepatocellular Carcinoma","Gastrointestinal Cancer","Lung Cancer","Prostate Cancer","Breast Cancer"],"interventions":["QXL138AM Injection every 2 weeks by IV Infusion"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose. Dose escalation in solid tumors (Part A1) will be followed by dose finding in multiple myeloma (Part A2). Part B consists of dose expansion in solid tumors (Part B1) and multiple myeloma (Pa","sourceUrl":"https://clinicaltrials.gov/study/NCT06582017"},{"nctId":"NCT07469774","title":"BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Biocity Biopharmaceutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":111,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["BC3195","Pembrolizumab/KEYTRUDA®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, open-label, dose escalation and expansion study to assess the safety, pharmacokinetics, and preliminary efficacy of BC3195 in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07469774"},{"nctId":"NCT05655312","title":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","sponsor":"Perspective Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Recurrent Melanoma (Skin)","Metastatic Melanoma","Melanoma Stage IV","Melanoma Stage III"],"interventions":["[203Pb]VMT01","[212Pb]VMT01","Nivolumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"In this first-in human, phase I/IIa study, the safety and efficacy of \\[212Pb\\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05655312"},{"nctId":"NCT07382531","title":"OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors","sponsor":"Binhui Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2023-09-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Solid Tumor"],"interventions":["OH2+BS006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"BS008-001 is a multicenter, open-label phase Ib /II trial in heavily pre-treated patients with advanced solid tumors. Patients received biweekly sequential intratumoral injections of OH2 (fixed dose: 10⁷ CCID₅₀/mL) followed by BS006 (dose escalation: 10⁶-10⁷ CCID₅₀/mL), with identical volumes being injected at the same lesion. The primary endpoint is safety and tolerability; secondary endpoints included efficacy outcomes assessed by RECIST 1.1/iRECIST.","sourceUrl":"https://clinicaltrials.gov/study/NCT07382531"},{"nctId":"NCT06088472","title":"TIL Injection for the Treatment of Metastatic or Recurrent Solid Tumors","sponsor":"Grit Biotechnology","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2021-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["Solid Tumors, Adult"],"interventions":["TIL injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-center, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, NMA-LD chemotherapy , treatment and observation period, and follow-up period.","sourceUrl":"https://clinicaltrials.gov/study/NCT06088472"},{"nctId":"NCT06963281","title":"Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":285,"enrollmentType":"ESTIMATED","startDate":"2025-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2025-06-06","conditions":["Solid Tumors"],"interventions":["IBI3020"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.","sourceUrl":"https://clinicaltrials.gov/study/NCT06963281"},{"nctId":"NCT05287945","title":"Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma","sponsor":"Oncorena AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2023-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Carcinoma, Renal Cell"],"interventions":["Orellanine"],"countries":["United States","Portugal","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.","sourceUrl":"https://clinicaltrials.gov/study/NCT05287945"},{"nctId":"NCT07029737","title":"A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2025-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Mantle-cell Lymphoma"],"interventions":["Acalabrutinib + R-CHOP standard of care","Acalabrutinib combination with Rituximab","Acalabrutinib monotherapy"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, multicenter, non-indication seeking phase II trial to describe the efficacy and safety of patients with mantle cell lymphoma (MCL) receiving acalabrutinib in combination with R-CHOP for the front-line treatment of MCL in Spain. Acalabrutinib will be administered until disease progression if medically appropriate, along with R-CHOP based on institutional standards. After 6 cycles of acalabrutinib in combination with R-CHOP, subjects who tolerate treatment and not progressing, will then receive monotherapy acalabrutinib. In addition, subjects who achieve a response (PR or greater) will receive maintenance rituximab every other 28-day cycle for a maximum of 12 ","sourceUrl":"https://clinicaltrials.gov/study/NCT07029737"},{"nctId":"NCT07448922","title":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2026-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Advanced Gynecological Malignancies"],"interventions":["SKB518 for injection","Carboplatin (AUC 5)","Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase II clinical study to evaluate the efficacy and safety of SKB518 as monotherapy or combination therapy in patients with advanced gynecological malignancies. This study will include 5 cohorts: SKB518 as monotherapy in advanced ovarian cancer; SKB518 as monotherapy in advanced cervical cancer and endometrial cancer; SKB518 in combination with Carboplatin in advanced ovarian cancer; SKB518 in combination with Carboplatin and Bevacizumab in advanced ovarian cancer; and SKB518 in combination with Bevacizumab in advanced ovarian cancer. Study hypothesis: SKB518 will show meaningful clinical activity and a favorable risk benefit profile in gynecological mali","sourceUrl":"https://clinicaltrials.gov/study/NCT07448922"},{"nctId":"NCT05253651","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2022-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-03","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Colorectal Neoplasms"],"interventions":["tucatinib","trastuzumab","bevacizumab","cetuximab","oxaliplatin","leucovorin","levoleucovorin","fluorouracil"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Greece","Ireland","Italy","Japan","Netherlands","Norway","Poland","Portugal","Slovakia","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":366,"serviceSignals":["HER2 profiling"],"summary":"This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get ei","sourceUrl":"https://clinicaltrials.gov/study/NCT05253651"},{"nctId":"NCT07189065","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"interventions":["Rocbrutinib","Bendamustine","Rituximab","Lenalidomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":41,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with non-GCB DLBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07189065"},{"nctId":"NCT04567420","title":"DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)","sponsor":"Criterium, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2021-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Breast Cancer"],"interventions":["Palbociclib","Fulvestrant","Adjuvant Therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["ctDNA / MRD"],"summary":"A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)","sourceUrl":"https://clinicaltrials.gov/study/NCT04567420"},{"nctId":"NCT06487455","title":"A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Advanced Solid Tumor"],"interventions":["SPH7485"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06487455"},{"nctId":"NCT06166836","title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2022-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Solid Tumor"],"interventions":["D1553","IN10018（Ifebemtinib）"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["RAS genotyping"],"summary":"This is a phase 1b/II, open-label study to evaluate the safety, tolerability, pharmacokinetics and antitumor activities of D-1553 in combination with IN10018 in subjects with locally advanced or metastatic solid tumor with KRAS G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06166836"},{"nctId":"NCT07336472","title":"A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma","sponsor":"Fortvita Biologics (USA)Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Multiple Myeloma"],"interventions":["IBI3003"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma","sourceUrl":"https://clinicaltrials.gov/study/NCT07336472"},{"nctId":"NCT05379946","title":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","sponsor":"InventisBio Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2022-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Solid Tumor"],"interventions":["D-1553","IN10018"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, open label study of D-1553 in combination with IN10018 to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT05379946"},{"nctId":"NCT06051409","title":"A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2023-08-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Ph+ ALL","Leukemia, Lymphoblastic, Acute, Philadelphia-Positive"],"interventions":["Olverembatinib","Investigator's choice of TKI"],"countries":["United States","Australia","China","Czechia","France","Italy","Romania","Singapore","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":90,"serviceSignals":["Hematology NGS"],"summary":"A global multicenter, open-label, randomized and registrational Phase 3 study to evaluate efficacy and safety of olverembatinib combined with chemotherapy versus investigator's choice of tyrosine kinase inhibitor (TKI) combined with chemotherapy in subjects with newly-diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06051409"},{"nctId":"NCT06764186","title":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":101,"enrollmentType":"ACTUAL","startDate":"2025-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["Fulvestrant","Capivasertib"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the effectiveness and safety of capivasertib + fulvestrant treatment administration in patients with locally advanced (inoperable) or metastatic HR+ / HER2- breast cancer with PIK3CA/AKT1/PTEN-altered following recurrence or progression on or after endocrine therapy and CDK4/6 inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764186"},{"nctId":"NCT06596473","title":"A Study of BG-C477 in Participants With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2024-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Advanced Solid Tumors"],"interventions":["BG-C477","Tislelizumab","Chemotherapy"],"countries":["United States","Australia","China","Japan","Malaysia","New Zealand","South Korea","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":58,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06596473"},{"nctId":"NCT04775745","title":"Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.","sponsor":"Newave Pharmaceutical Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2021-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["CLL/SLL","Waldenstrom Macroglobulinemia","Follicular Lymphoma","Diffuse Large B Cell Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Hairy Cell Leukemia"],"interventions":["LP-168"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT04775745"},{"nctId":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","sponsor":"SystImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Small Cell Lung Cancer Metastatic or Locally Advanced","Neuroendocrine Cancer","Metastatic Neuroendocrine Prostate Cancer","Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma","Metastatic Advanced Merkel Cell Carcinoma","Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung","Locally Advanced Extrapulmonary Neuroendocrine Carcinoma","Locally Advanced Neuroendocrine Prostate Cancer","Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine","Locally Advanced Merkel Cell Carcinoma","Metastatic Large Cell Neuroendocrine Carcinoma of the Lung"],"interventions":["BL-M14D1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms","sourceUrl":"https://clinicaltrials.gov/study/NCT07080242"},{"nctId":"NCT07490262","title":"A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":680,"enrollmentType":"ESTIMATED","startDate":"2026-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["Bevacizumab","Capecitabine","Oxaliplatin","IBI310","Sintilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent surgical resection or local therapy, or have experienced disease progression following prior surgical resection or local therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07490262"},{"nctId":"NCT07310784","title":"A Phase II Trial of LM103 in Advanced Melanoma","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2025-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Advanced Melanoma"],"interventions":["LM103 TILs Injection","Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"A total of 92 subjects with advanced melanoma who met the inclusion criteria will be randomly assigned in a 1:1 ratio to the experimental group and the control group in this phase II trial. The study will be followed up until 24 months after treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07310784"},{"nctId":"NCT07406724","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-02-26","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Melanoma (Excluding Uveal Melanoma)"],"interventions":["Tumor Tissue Sampling","Lymphodepletion Conditioning","Infusion of HS-IT101 Injection","IL-2 Administration for Tumor-Infiltrating Lymphocyte (TIL) Therapy","Investigator's selection of appropriate chemotherapy regimen"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized controlled, open-label Phase II clinical study designed to evaluate the efficacy and safety of HS-IT101 Injection versus the investigator's choice of chemotherapy in participants with advanced melanoma. A total of 90 participants are planned to be enrolled, and eligible participants will be randomly assigned to the experimental group or control group at a 1:1 ratio. The experimental group will receive a single administration of autologous tumor-infiltrating lymphocyte therapy, while the control group will receive chemotherapy regimens selected by the research physicians. Efficacy and safety evaluations will be conducted for all enrolled participants througho","sourceUrl":"https://clinicaltrials.gov/study/NCT07406724"},{"nctId":"NCT07036250","title":"Clinical Study of U32 in Patients With Acute Myeloid Leukemia","sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-07-03","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-06-25","conditions":["Acute Myeloid Leukaemia"],"interventions":["U32 CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT07036250"},{"nctId":"NCT05118789","title":"A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)","sponsor":"Nuvalent Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":359,"enrollmentType":"ESTIMATED","startDate":"2022-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-24","conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["Zidesamtinib (NVL-520)"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":63,"serviceSignals":["RNA fusion"],"summary":"Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of zidesamtinib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progr","sourceUrl":"https://clinicaltrials.gov/study/NCT05118789"},{"nctId":"NCT03600441","title":"Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma","sponsor":"Xynomic Pharmaceuticals, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":139,"enrollmentType":"ESTIMATED","startDate":"2018-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-04-10","conditions":["Follicular Lymphoma"],"interventions":["Abexinostat"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a \"one week on, one week off\" schedule.","sourceUrl":"https://clinicaltrials.gov/study/NCT03600441"},{"nctId":"NCT07742956","title":"Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.","sponsor":"Shanghai Allink Biotherapeutics Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2026-08-20","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["ALK201 for injection","Ivonescimab Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of ALK201 for Injection combined with Ivonescimab Injection in adult patients with locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) who are FGFR2b-positive, EGFR mutation-negative, and ALK-negative. The study consists of two parts: Part A (dose escalation) and Part B (dose optimization). Part A Dose Escalation Stage: This stage includes three dose levels. Eligible patients with locally advanced or metastatic sqNSCLC who have failed standard therapy will be enrolled to complete DLT assessment. Part B Dose Optimization Stage: Th","sourceUrl":"https://clinicaltrials.gov/study/NCT07742956"},{"nctId":"NCT07477743","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors","sponsor":"HC Biopharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":331,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-03-17","conditions":["Advanced Solid Tumor Cancer"],"interventions":["HC010","Paclitaxel","Oxaliplatin","Capecitabine","HC006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced gastrointestinal cancer and determine the recommended dose for subsequent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07477743"},{"nctId":"NCT06992258","title":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","sponsor":"Criterium, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-17","conditions":["Colorectal Cancer"],"interventions":["Fruquintinib+ Lonsurf (trifluridine and tipiracil)","Fruquintinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["MSI / TMB"],"summary":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06992258"},{"nctId":"NCT06328439","title":"A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2024-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["ANS014004"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Brief Summary: This is a Phase I, first-in-human, open-label, multi-center study designed to explore the safety, tolerability, PK, and anti-tumor antitumor activity of ANS014004 monotherapy in subjects with locally advanced or metastatic solid tumors. * The study consists of two parts: a dose-escalation part (Part 1) and a dose-expansion part (Part 2). For each subject, the study will consist of a screening period (Day -28 to Day -1), a treatment period (until discontinuation of treatment) and a follow-up period (including safety follow-up and survival follow-up). * During the Treatment Period, subjects will receive ANS014004 single-agent oral administration until the subject meets any treat","sourceUrl":"https://clinicaltrials.gov/study/NCT06328439"},{"nctId":"NCT07296484","title":"Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)","sponsor":"Sparrow Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":1500,"enrollmentType":"ESTIMATED","startDate":"2025-11-29","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Type 2 Diabetes","Cortisol Excess"],"interventions":["clofutriben","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":60,"serviceSignals":["Broad CGP"],"summary":"CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).","sourceUrl":"https://clinicaltrials.gov/study/NCT07296484"},{"nctId":"NCT05133882","title":"A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML","sponsor":"Sunshine Lake Pharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":133,"enrollmentType":"ESTIMATED","startDate":"2022-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Acute Myeloid Leukemia, Adult"],"interventions":["Clifutinib Besylate"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML","sourceUrl":"https://clinicaltrials.gov/study/NCT05133882"},{"nctId":"NCT07281976","title":"A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2026-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Triple Negative Breast Cancer"],"interventions":["LBL-024 for Injection","albumin-bound Paclitaxel injection","Toripalimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07281976"},{"nctId":"NCT06945523","title":"Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2025-06-04","conditions":["Advanced Lung Cancer"],"interventions":["Targeted CEA CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months. CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expressed in lung cancer, esophageal cancer, bile duct cancer, colorectal cancer, gastric cancer and other tumor types. In previous CAR-T-related clinical trials ","sourceUrl":"https://clinicaltrials.gov/study/NCT06945523"},{"nctId":"NCT06708663","title":"HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours","sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2025-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Biliary Tract Cancer","Melanoma"],"interventions":["HX009+IN10018"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06708663"},{"nctId":"NCT04939610","title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":222,"enrollmentType":"ESTIMATED","startDate":"2021-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Solid Tumor"],"interventions":["68Ga-FAP-2286","177Lu-FAP-2286"],"countries":["United States","Australia","Canada","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["Broad CGP"],"summary":"Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesenchymal origin, notably sarcoma and mesothelioma, FAP expression has also been observed on the tumor cells themselves. Given the restricted expression profile, FAP is a promising target for peptide-targeted radionuclide imaging and therapeutic agents. Phase 1 of this study is designed to evaluate the safety and establish the recommended intravenous (IV) Phase 2 dose (RP2D) for \\[177Lu\\]Lu FAP 2286 mon","sourceUrl":"https://clinicaltrials.gov/study/NCT04939610"},{"nctId":"NCT07242274","title":"Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC","sponsor":"Jemincare","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":472,"enrollmentType":"ESTIMATED","startDate":"2025-12-31","startDateType":"ESTIMATED","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["NSCLC (Non-small Cell Lung Cancer)"],"interventions":["JMKX001899","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, randomized, open-label, phase 3 clinical trial designed to evaluate the efficacy and safety of JMKX001899 compared to docetaxel in patients with previously treated, KRAS G12C-mutant advanced or metastatic non-small cell lung cancer (NSCLC). KRAS G12C mutation is present in a subset of NSCLC patients. While docetaxel is a standard chemotherapy option, JMKX001899 is an investigational, targeted therapy designed to selectively inhibit the KRAS G12C mutation. This trial aims to determine whether JMKX001899 offers a superior clinical benefit compared to standard chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07242274"},{"nctId":"NCT07545603","title":"Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2026-02-14","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Follicular Lymphoma, Grade 1","Follicular Lymphoma, Grade 2","Follicular Lymphoma, Grade 3","Follicular Lymphoma Grade 3A"],"interventions":["XNW5004 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, multicenter Phase II clinical study designed to enroll 65 subjects with relapsed or refractory follicular lymphoma (EZH2 wild-type). The study procedures include a pre-screening phase, screening phase, treatment phase, and follow-up phase.Eligible subjects will enter the treatment phase and receive 1200 mg of XNW5004 tablets twice daily, with a 10-14-hour interval between doses. Each treatment cycle consists of 28 consecutive days of dosing, and pharmacokinetic (PK) blood samples will be collected at the designated time points.Safety assessments and quality-of-life (QoL) assessments will be performed in accordance with the study follow-up schedule.Tumor asse","sourceUrl":"https://clinicaltrials.gov/study/NCT07545603"},{"nctId":"NCT04390737","title":"Evaluate the Safety and Clinical Activity of HH2853","sponsor":"Haihe Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2020-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["FL Lymphoma","Epithelioid Sarcoma","Peripheral T Cell Lymphoma","Advanced Solid Tumor"],"interventions":["HH2853 Tablets"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":25,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicenter, first-in-human phase I/II study which is composed of 3 parts: phase I dose escalation, phase I dose extension and phase II. HH2853 will be administered orally on a continuous BID schedule on a continuous 28-day treatment cycle.","sourceUrl":"https://clinicaltrials.gov/study/NCT04390737"},{"nctId":"NCT04145375","title":"Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol","sponsor":"Zenith Epigenetics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2019-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2027-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["mCRPC"],"interventions":["ZEN003694","Enzalutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol","sourceUrl":"https://clinicaltrials.gov/study/NCT04145375"},{"nctId":"NCT07444437","title":"A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Non-Small Cell Lung Cancer"],"interventions":["LM103 TILs Injection","PD-1 / PD-L1 monoclonal antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"After receiving neoadjuvant treatment with PD-1 antibody and undergoing radical resection, a total 36 to 45 NSCLC patients who met the inclusion criteria, will be randomly assigned in a 1:1:1 ratio to the experimental group 1, experimental group 2 and the control group in this Phase IIa clinical trial. The study will be followed up until 24 to 36 months after treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07444437"},{"nctId":"NCT07596693","title":"KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)","sponsor":"TCRx Therapeutics Co.Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2027-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Advanced Solid Tumors"],"interventions":["KXV01 TCR Lentinvivo Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07596693"},{"nctId":"NCT07728942","title":"SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors","sponsor":"Solve Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Metastatic Solid Tumors"],"interventions":["SLR-108","SLX-1411"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study evaluating the feasibility of using SLR-108 for positron-emission tomography (PET) imaging of metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07728942"},{"nctId":"NCT04657068","title":"A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors","sponsor":"Artios Pharma Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":542,"enrollmentType":"ESTIMATED","startDate":"2021-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Cancer","Metastatic Cancer","Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer","Endometrial Cancer","Metastatic Colorectal Cancer","Pancreatic Ductal Adenocarcinoma","Acinar Cell Carcinoma"],"interventions":["ART0380","Gemcitabine","Irinotecan"],"countries":["United States","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":82,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan","sourceUrl":"https://clinicaltrials.gov/study/NCT04657068"},{"nctId":"NCT07024784","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":377,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Gynecologic Cancers","Platinum-Sensitive Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer (PSOC)"],"interventions":["IMGN151","Carboplatin","Bevacizumab","Olaparib"],"countries":["United States","Israel","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combina","sourceUrl":"https://clinicaltrials.gov/study/NCT07024784"},{"nctId":"NCT07341100","title":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Ovarian Epithelial Cancer"],"interventions":["SKB264","Clarithromycin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label study to evaluate the preliminary efficacy of SKB264 and the effect of clarithromycin on the PK of SKB264 in patients with ovarian epithelial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07341100"},{"nctId":"NCT07249905","title":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","sponsor":"ModeX Therapeutics, An OPKO Health Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Lymphoma","Waldenström Macroglobulinemia (WM)","DLBCL - Diffuse Large B Cell Lymphoma","PMBCL","HGBCL","FL Lymphoma","Lymphoplasmacytic Lymphoma","Follicular Lymphoma (FL)"],"interventions":["MDX2003"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07249905"},{"nctId":"NCT04414475","title":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","sponsor":"Karyopharm Therapeutics Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":127,"enrollmentType":"ESTIMATED","startDate":"2020-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Multiple Myeloma, Refractory"],"interventions":["Selinexor","Dexamethasone","Bortezomib"],"countries":["Greece","Israel"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04414475"},{"nctId":"NCT06525220","title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","sponsor":"Merus B.V.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2024-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["Petosemtamab","Pembrolizumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Croatia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Lithuania","Malaysia","Mexico","Netherlands","Poland","Portugal","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":205,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06525220"},{"nctId":"NCT07282873","title":"Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors","sponsor":"TYK Medicines, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":219,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Solid Tumor Malignancies","Malignant Mesothelioma (MM)"],"interventions":["TYK-01054"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07282873"},{"nctId":"NCT05985655","title":"Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2023-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)","Pancreatic Adenocarcinoma","Non-small Cell Lung Cancer (NSCLC)","Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)","Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma","Triple Negative Breast Cancer (TNBC)"],"interventions":["GTAEXS617","SoC"],"countries":["United States","Belgium","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05985655"},{"nctId":"NCT07354711","title":"A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","sponsor":"3H Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2026-01-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Lung Cancer","Stomach Cancer"],"interventions":["3H-10000"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .","sourceUrl":"https://clinicaltrials.gov/study/NCT07354711"},{"nctId":"NCT06699836","title":"The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)","sponsor":"CytoDyn, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":66,"enrollmentType":"ACTUAL","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Metastatic Colorectal Cancer (mCRC)"],"interventions":["350 mg leronlimab","700 mg leronlimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["MSI / TMB"],"summary":"This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and tipiracil + bevacizumab in patients with MSS, mCRC who have progressed on prior treatment before participating in the study. The main questions this study aims to answer are: 1. Can leronlimab, in combination with standard of care therapies trifluridine and tipiracil+ bevacizumab, increase the objective response rate in persons with MSS, mCRC who have progressed on prior treatment before participating in the study. 2. Is leronlimab safe and well tolerated in these subjects w","sourceUrl":"https://clinicaltrials.gov/study/NCT06699836"},{"nctId":"NCT06708897","title":"A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies","sponsor":"Lomond Therapeutics Holdings, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2025-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["CLL / SLL","CLL (Chronic Lymphocytic Leukemia)","SLL (Small Lymphocytic Lymphoma)","Marginal Zone Lymphoma(MZL)","Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia"],"interventions":["Lonitoclax (ZE50-0134)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and select low-grade B-cell lymphomas. The study has two sequential parts. Part 1 uses dose escalation to determine the biologically effective dose and/or maximum tolerated dose of lonitoclax. Participants receive a 3-day step-up regimen followed by continuous once-daily or twice-daily oral dosing in 28-day cycles. Part 2 is a randomized dose-expansion comparison of two selected lonitoclax dose levels in ven","sourceUrl":"https://clinicaltrials.gov/study/NCT06708897"},{"nctId":"NCT06915753","title":"Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations","sponsor":"Tyra Biosciences, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Metastatic Hepatocellular Carcinoma","Solid Tumors","Solid Tumor, Adult","FGFR Gene Amplification","FGFR Gene Alterations","FGFR3 Gene Alteration","FGFR3 Gene Mutation","Advanced Solid Tumors","FGFR4 Gene Mutation","FGFR4 Gene Fusions","FGF19 Gene Amplification","FGF19 Gene Overexpression","FGFR3 Gene Fusions","Locally Advanced Unresectable Hepatocellular Carcinoma"],"interventions":["TYRA-430"],"countries":["United States","Canada","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06915753"},{"nctId":"NCT07156565","title":"Actinium Therapy for Late-stage Aggressive Sarcomas","sponsor":"Ratio Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-01","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Advanced Soft Tissue Sarcoma"],"interventions":["[Ac 225]RTX-2358","[Cu64]LNTH-1363S"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn about the safety of drug \\[Ac225\\]RTX-2358 and the diagnostic imaging agent \\[Cu64\\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \\[Ac225\\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \\[Ac225\\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \\[Ac225\\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \\[Ac225\\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months * Visit the clinic three times fo","sourceUrl":"https://clinicaltrials.gov/study/NCT07156565"},{"nctId":"NCT07148128","title":"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.","sponsor":"Auricula Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma","Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer","Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer","Advanced Solid Tumors","Advanced or Metastatic KRAS-mutant Tumor"],"interventions":["WEF-001"],"countries":["United States","Canada","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["RAS genotyping"],"summary":"This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT07148128"},{"nctId":"NCT07076550","title":"A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma","sponsor":"Alpha-9 Oncology USA Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Melanoma Metastatic","Uveal Melanoma, Metastatic","Mucosal Melanoma"],"interventions":["[225Ac]Ac-A9-3408","[68Ga]Ga-A9T-3202"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this trial is to see if this investigational drug is safe for adult patients with melanoma that has spread to other parts of the body or cannot be removed by surgery. It will also see if this investigational drug can shrink melanoma tumors in the body. The main questions this study aims to answer are: * What are the side effects of this investigational drug? * What is the highest dose of this investigational drug that can be given safely? Participants will: * Take the investigational drug once every 6 weeks, for up to 6 times in total * Visit a doctor's office on a regular basis for checkups and tests","sourceUrl":"https://clinicaltrials.gov/study/NCT07076550"},{"nctId":"NCT06854653","title":"A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL","sponsor":"Prescient Therapeutics, Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2025-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["CTCL"],"interventions":["PTX-100"],"countries":["United States","Australia","France","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.","sourceUrl":"https://clinicaltrials.gov/study/NCT06854653"},{"nctId":"NCT06657144","title":"A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors","sponsor":"Coherus Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor"],"interventions":["CHS-114","Toripalimab","5 Fluorouracil","Cisplatin"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06657144"},{"nctId":"NCT06190899","title":"Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer","sponsor":"Celcuity Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2024-01-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["mCRPC (Metastatic Castration-resistant Prostate Cancer)","Genital Diseases, Male","Urogenital Diseases, Male","Prostatic Disease","Prostatic Neoplasms, Castration-Resistant","Prostate Cancer"],"interventions":["Gedatolisib","Darolutamide"],"countries":["United States","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06190899"},{"nctId":"NCT07107204","title":"A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies","sponsor":"Biotroy Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2025-10","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Relapsed or Refractory Hematologic Malignancies","Leukemia","Lymphoma","Multiple Myeloma (MM)"],"interventions":["BT02"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.","sourceUrl":"https://clinicaltrials.gov/study/NCT07107204"},{"nctId":"NCT07541430","title":"A Study in Adults With Desmoid Tumors","sponsor":"Elpiscience (Suzhou) Biopharma, Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Desmoid Tumor"],"interventions":["ES014"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07541430"},{"nctId":"NCT07221500","title":"A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)","sponsor":"Nurix Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)"],"interventions":["NX-5948"],"countries":["United States","France","Italy","Poland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Hematology NGS"],"summary":"This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.","sourceUrl":"https://clinicaltrials.gov/study/NCT07221500"},{"nctId":"NCT06787144","title":"ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants","sponsor":"Enliven Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2025-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["CML (Chronic Myelogenous Leukemia)","Chronic Phase CML"],"interventions":["ELVN-001"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability and determine the recommended dose for further clinical evaluation of ELVN-001 in Japanese patients with chronic phase chronic myeloid leukemia with and without T315I mutations in patients who has failed, or the patient is intolerant to, or not a candidate for, at least 2 prior TKIs.","sourceUrl":"https://clinicaltrials.gov/study/NCT06787144"},{"nctId":"NCT05474859","title":"Subjects With Advanced or Metastatic Solid Tumor Malignancies","sponsor":"Xenthera, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2024-07-31","conditions":["Metastatic Solid Tumor","Advanced Solid Tumor"],"interventions":["XT-0528"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, Phase 1, multicenter, continuous dose escalation study of XT-0528 in adult subjects with Advanced or Metastatic Solid Tumor Malignancies. The study will consist of 4 periods: Screening Period (up to 28 days prior to Cycle 1 Day 1) Safety Run-in Period (Cycle 1; continuous dosing on Days 1-21 of 28-day cycle) Continuous Dosing Period (Cycle 2 and beyond; continuous dosing on Days 1-28 of 28-day cycle) Safety Follow-up Period (30 days post-last dose).","sourceUrl":"https://clinicaltrials.gov/study/NCT05474859"},{"nctId":"NCT07297212","title":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","sponsor":"BioNTech SE","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2026-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Recurrent Glioblastoma"],"interventions":["Pumitamig","Bevacizumab","Temozolomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This multi-site Phase II study will enroll adults with histologically confirmed diagnosis of World Health Organization (WHO) Grade IV glioblastoma (GBM), isocitrate dehydrogenase (IDH)-wildtype consistent with WHO central nervous system (CNS) 2021 criteria who have received prior first-line treatment including with at least radiotherapy and temozolomide, with a Karnofsky performance status (KPS) ≥60, adequate organ function, and at least one measurable lesion according to the response assessment in neuro-oncology (RANO) 2.0 criteria.","sourceUrl":"https://clinicaltrials.gov/study/NCT07297212"},{"nctId":"NCT06776952","title":"A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Relapsed/Refractory Peripheral T Cell Lymphoma"],"interventions":["XNW5004 ; Chidamide placebo","XNW5004 placebo; Chidamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT06776952"},{"nctId":"NCT04644289","title":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","sponsor":"AGO Research GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2022-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-10-03","conditions":["Epithelial Ovarian Cancer"],"interventions":["olaparib","durvalumab"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic confirmation and evaluation of disease spread will be registered into the trial after providing a 1st written informed consent.","sourceUrl":"https://clinicaltrials.gov/study/NCT04644289"},{"nctId":"NCT07216105","title":"FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors","sponsor":"Fate Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":113,"enrollmentType":"ESTIMATED","startDate":"2025-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Non-Small Cell Lung Cancer","Colorectal Cancer","Breast Cancer","Ovarian Cancer","Endometrial Carcinoma","Head and Neck Squamous Cell Carcinoma"],"interventions":["FT836","Paclitaxel","Cetuximab","Trastuzumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07216105"},{"nctId":"NCT06807359","title":"Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System","sponsor":"SpectraCure AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":43,"enrollmentType":"ESTIMATED","startDate":"2025-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Prostate Cancer"],"interventions":["Photodynamic Therapy (PDT)","Verteporfin Injection"],"countries":["United States","Germany"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to obtain safety data, establish dose parameters, and effectiveness of treatment for the SpectraCure P18 System with IDOSE®, together with verteporfin for injection (VFI) as photosensitizer, for the treatment of primary localized prostate cancer. The study will be divided into two parts, with Phase I, dose-escalation, to study safety and establish an effective light dose, followed by Phase II, cohort expansion, to evaluate clinical efficacy and confirm safety/tolerability. The subjects will be followed for a period of 18 months to determine the primary outcome. The long-term follow-up is an additional 18 months, i.e. a total of 36 months. Interstitial Photodynamic T","sourceUrl":"https://clinicaltrials.gov/study/NCT06807359"},{"nctId":"NCT06782425","title":"Treating Claudin18.2-positive Advanced Solid Tumors with XKDCT225(Targeting Claudin18.2-CAR-T)","sponsor":"Shenzhen Celconta Life Science Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01","completionType":"ESTIMATED","lastUpdated":"2025-01-17","conditions":["Claudin18.2 Positive Advanced Solid Tumors"],"interventions":["XKDCT225"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A single-center, single-arm, dose-escalation exploratory clinical trial of the safety, efficacy, and pharmacokinetics of XKDCT225 cell injection in Claudin18.2-positive advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06782425"},{"nctId":"NCT05598151","title":"Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors","sponsor":"Hanmi Pharmaceutical Company Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2023-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-04-30","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["HM97662"],"countries":["Australia","South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a Phase1 study to assess the safety, PK, PD and efficacy of HM97662, EZH1/2 dual inhibitor, in solid tumors. The study is comprised of Dose-Escalation Part followed by randomized Dose-Ranging Part and Dose-Expansion Part. Dose-Escalation Part is planned with a 3+3 Dose-Escalation design and is to establish the MTD or RD for randomized Dose-Ranging Part. Dose-Ranging Part is designed mainly to further evaluate safety and preliminary efficacy of HM97662 monotherapy in subjects with specific genomic alterations to more precisely determine the potential RP2D that are to be tested in a Dose-Expansion Part. Dose-Expansion Part is designed to assess the potential efficacy of HM97662 monothe","sourceUrl":"https://clinicaltrials.gov/study/NCT05598151"},{"nctId":"NCT07524140","title":"A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors","sponsor":"Eilean Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced Solid Tumor Cancer","Metastatic Solid Tumor"],"interventions":["ZE94-0605"],"countries":["Australia","Uzbekistan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors. Phase 1a will use sequential dose escalation to determine the maximally tolerated dose and biologically effective dose. Phase 1b will randomize participants with CCNE1 amplification, or another prospectively specified molecular feature, between two dose levels to select the recommended Phase 2 dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT07524140"},{"nctId":"NCT07622524","title":"A Phase I Study of CS5007 in Participants With Advanced Solid Tumors","sponsor":"CStone Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Advanced Solid Tumors"],"interventions":["CS5007"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human (FIH), open-label, and multi-center Phase I study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5007 as monotherapy in participants with advanced solid tumors. The study is comprised of a Phase Ia dose escalation and Phase Ib dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07622524"},{"nctId":"NCT06743126","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","sponsor":"Immatics US, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2025-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-10","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Melanoma, Cutaneous Malignant"],"interventions":["IMA203","nivolumab plus relatlimab","lifileucel","nivolumab","pembrolizumab","ipilimumab","Dacarbazine","temozolomide","paclitaxel","paclitaxel plus carboplatin","Albumin-Bound Paclitaxel"],"countries":["United States","Canada","France","Germany","Netherlands","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommended phase 2 dose versus investigator's choice of treatment in patients with previously treated, unresectable or metastatic cutaneous melanoma. For patients interested in additional information on how to participate, please follow this link: https://mytomorrows.com/trials/suprame/en-us/","sourceUrl":"https://clinicaltrials.gov/study/NCT06743126"},{"nctId":"NCT04686682","title":"A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2021-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["NSCLC","SCLC","CRPC","ESCC","Ovarian Carcinoma","AML","MF","Malignant Tumor"],"interventions":["JAB-8263"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study. These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.","sourceUrl":"https://clinicaltrials.gov/study/NCT04686682"},{"nctId":"NCT07749976","title":"GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors","sponsor":"Vitruviae","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2027-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Acute Myeloid Leukemia","Diffuse Large B Cell Lymphoma (DLBCL)","High Risk Myelodysplastic Syndrome","Solid Tumor Malignancies","Pediatric Acute Myeloid Leukemia"],"interventions":["VTRU200"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"About this study This is the first study of VTRU200 in people. The main purpose of this study is to find a safe dose of VTRU200 and learn how the medicine behaves in the body. Researchers will also look for early signs that it may help treat cancer. VTRU200 is an experimental immunotherapy. It is designed to help the body's immune system find and destroy cancer cells while limiting effects on healthy cells. Unlike many cancer treatments that target a single protein, VTRU200 recognizes stress signals that are commonly found on cancer cells. These signals include certain sugars (called glycans) and fats (called phospholipids) that are present on many types of cancer cells but are uncommon on n","sourceUrl":"https://clinicaltrials.gov/study/NCT07749976"},{"nctId":"NCT06571461","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":408,"enrollmentType":"ESTIMATED","startDate":"2024-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2024-08-27","conditions":["Pancreatic Cancer"],"interventions":["Liposomal Irinotecan","Oxaliplatin","S-1","Gemcitabine","Capecitabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of adjuvant therapy with liposomal irinotecan in combination with oxaliplatin, and S-1 compared with capecitabine combined with capecitabine in participants with pancreatic ductal adenocarcinoma after radical surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT06571461"},{"nctId":"NCT07361003","title":"A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":464,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Refractory Metastatic Colorectal Cancer"],"interventions":["Suvemcitug injection, trifluridine/tipiracil tablets","Suvemcitug placebo injection, trifluridine/tipiracil tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine/tipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine/tipiracil tablets to see if Suvemcitug + trifluridine/tipiracil tablets works better in treating refractory metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07361003"},{"nctId":"NCT07071090","title":"A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors","sponsor":"Heronova Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2025-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-01","completionType":"ESTIMATED","lastUpdated":"2025-07-23","conditions":["Solid Tumor Malignancies"],"interventions":["DC50292A"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid tumors. The study consists of two parts: dose escalation and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07071090"},{"nctId":"NCT06719479","title":"A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-01","completionType":"ESTIMATED","lastUpdated":"2024-12-05","conditions":["NPC","HNSCC","Recurrence","Metastasis"],"interventions":["IAE0972+ Methotrexate","IAE0972+Docetaxel","IAE0972+Gemcitabine","IAE0972+Taxanes","IAE0972+Capecitabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R/M HNSCC/NPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy. Phase III: According to the RECIST 1.1, the effectiveness of IAE0972 combined with chemotherapy regimen chosen by doctors compared with placebo plus chemotherapy regimen chosen by doctors was evaluated through OS in patients with R/M NPC who failed or progressed after treatment with ≤2-line system.","sourceUrl":"https://clinicaltrials.gov/study/NCT06719479"},{"nctId":"NCT06771622","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","sponsor":"FBD Biologics Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-01","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Solid Cancer"],"interventions":["HCB101","Trastuzumab","Pertuzumab","Oxaliplatin","Capecitabine","Ramucirumab","Paclitaxel","Bevacizumab","Cetuximab","Irinotecan","Leucovorin","5-FU","Toripalimab","Albumin-bound paclitaxel","Pembrolizumab","Carboplatin (AUC 5)","Etoposide","Atezolizumab","Trastuzumab deruxtecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a non-randomized, open-label, dose-escalation, and dose-expansion Phase Ib/IIa study to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of HCB101 administered in combination with standard or approved anticancer therapies in subjects with advanced solid tumors. The trial includes a Part-I (Phase Ib) of the dose-escalation phase and a Part-II (Phase IIa) of the dose-expansion phase. Part-I: Dose-escalation phase (Phase Ib): Part I uses a standard 3+3 dose-escalation design to characterize safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of HCB101 when administered in combination regimens. The","sourceUrl":"https://clinicaltrials.gov/study/NCT06771622"},{"nctId":"NCT07230626","title":"SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":412,"enrollmentType":"ESTIMATED","startDate":"2025-11-20","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Cervical Cancer"],"interventions":["SYS6002","Investigator's Choice of Chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, multicenter phase Ⅲ clinical trial, which aims to evaluate the efficacy and safety of SYS6002 versus investigator's choice of chemotherapy in the treatment of participants with recurrent or metastatic cervical cancer who have failed platinum-containing chemotherapy and PD-1/L1 inhibitor therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07230626"},{"nctId":"NCT07102381","title":"A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer","sponsor":"Jazz Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2025-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["HER2-positive Breast Cancer","Breast Cancer"],"interventions":["Zanidatamab","Paclitaxel","Docetaxel","Carboplatin","Trastuzumab","Pertuzumab"],"countries":["United States","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07102381"},{"nctId":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":714,"enrollmentType":"ESTIMATED","startDate":"2022-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-04","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Carcinoma, Non-Small-Cell Lung","Squamous Cell Carcinoma of the Head and Neck","Esophageal Squamous Cell Carcinoma","Triple Negative Breast Neoplasms","Gastric Cancer","Endometrial Cancer","Pancreatic Adenocarcinoma","Hepatocellular Carcinoma"],"interventions":["PF-08046054","pembrolizumab"],"countries":["United States","Belgium","Canada","China","France","Germany","Italy","Japan","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":62,"serviceSignals":["Broad CGP"],"summary":"This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E,","sourceUrl":"https://clinicaltrials.gov/study/NCT05208762"},{"nctId":"NCT07636707","title":"QLF4113 in Participants With Metastatic Prostate Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-07-20","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-05","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Prostate Cancer"],"interventions":["QLF4113 for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose-escalation and expansion Phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profile, immunogenicity, and preliminary antitumor activity of QLF4113 monotherapy in participants with metastatic prostate cancer. The Phase I trial consists of two parts: Phase Ia and Phase Ib. Phase Ia is a dose-escalation study of QLF4113 monotherapy to determine the recommended phase two dose and assess safety and PK. Then the study will proceed to Phase Ib, a dose-expansion study to further evaluate the preliminary efficacy and safety of QLF4113 monotherapy under the selected doses.","sourceUrl":"https://clinicaltrials.gov/study/NCT07636707"},{"nctId":"NCT06307431","title":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":272,"enrollmentType":"ESTIMATED","startDate":"2024-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-08","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-08","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Renal Cell Carcinoma"],"interventions":["Intismeran autogene","Pembrolizumab","Placebo"],"countries":["United States","Argentina","Australia","Canada","Chile","France","Germany","Italy","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":63,"serviceSignals":["Broad CGP"],"summary":"The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.","sourceUrl":"https://clinicaltrials.gov/study/NCT06307431"},{"nctId":"NCT07446049","title":"A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression","sponsor":"Convalife (Shanghai) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-08","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Locally Advanced or Metastatic Solid Tumors","PTEN Loss or Low Expression"],"interventions":["CVL237 tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, multicenter, Phase Ib/II clinical trial of CVL237 tablets in combination with serplulimab injection for the treatment of advanced solid tumors with PTEN loss or low expression","sourceUrl":"https://clinicaltrials.gov/study/NCT07446049"},{"nctId":"NCT07015242","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2025-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-10","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Lymphoma"],"interventions":["Rituximab","Methotrexate","Procarbazine","Temozolomide","Liso-cel","Fludarabine","Cyclophosphamide","Calcium folinate"],"countries":["United States","France","Germany"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07015242"},{"nctId":"NCT06885034","title":"A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":451,"enrollmentType":"ESTIMATED","startDate":"2025-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-09","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Gastrointestinal Neoplasms"],"interventions":["Risvutatug Rezetecan","Drug 1","Drug 2","Drug 3","Drug 4"],"countries":["United States","Australia","Belgium","Brazil","Canada","Finland","France","Germany","Italy","Japan","Mexico","Netherlands","Norway","Panama","Poland","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":85,"serviceSignals":["Broad CGP"],"summary":"This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06885034"},{"nctId":"NCT06132958","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":710,"enrollmentType":"ESTIMATED","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-10","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Endometrial Cancer"],"interventions":["Sacituzumab tirumotecan","Doxorubicin","Paclitaxel","Nab-paclitaxel","Rescue medications"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Greece","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Poland","Puerto Rico","Singapore","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":241,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06132958"},{"nctId":"NCT06311721","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":315,"enrollmentType":"ACTUAL","startDate":"2024-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-24","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer"],"interventions":["ABP 234","Pembrolizumab (US)","Pembrolizumab (EU)"],"countries":["United States","Argentina","Austria","Brazil","Bulgaria","Chile","France","Georgia","Germany","Italy","Japan","Malaysia","Peru","Philippines","Poland","Serbia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":218,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this trial is to demonstrate pharmacokinetic (PK) similarity of ABP 234 compared with the pembrolizumab reference product (Keytruda®).","sourceUrl":"https://clinicaltrials.gov/study/NCT06311721"},{"nctId":"NCT07456046","title":"A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.","sponsor":"D3 Bio (Wuxi) Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-11","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["KRAS P.G12D"],"interventions":["D3S-003"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["RAS genotyping"],"summary":"This is a first-in-human (FIH) multicenter, open-label, dose-escalation Phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of D3S-003 in participants with advanced KRAS p.G12D mutant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07456046"},{"nctId":"NCT07525141","title":"A Study of JNJ-1761981 in Participants With Solid Tumors","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Neoplasms"],"interventions":["JNJ-1761981","Cetrelimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.","sourceUrl":"https://clinicaltrials.gov/study/NCT07525141"},{"nctId":"NCT07649369","title":"A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion","sponsor":"Shanghai Jeyou Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-08-17","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-14","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Malignant Pleural Effusions (Mpe)"],"interventions":["JMKX000197","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07649369"},{"nctId":"NCT07294508","title":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":706,"enrollmentType":"ESTIMATED","startDate":"2026-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["HER2 + Breast Cancer"],"interventions":["HLX87 + HLX22","HLX87 + Pertuzumab","T-Dxd + Pertuzumab","THP"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07294508"},{"nctId":"NCT07630961","title":"Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-16","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","Non-small Cell Lung Cancer (NSCLC)","HR+/HER2- Ductal Breast Cancer (BC)","HR+/HER2- Lobular Breast Cancer (BC)","Triple Negative Breast Cancer (TNBC)","Colorectal Cancer (CRC)","Soft Tissue Sarcoma (STS)"],"interventions":["68Ga-DFC413","68Ga-NNS309"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of \\[68Ga\\]Ga-DFC413, and in Part 2 compare to \\[68Ga\\]Ga-NNS309 in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC), colorectal cancer (CRC), and soft tissue sarcoma (STS). In Part 2 of this study (comparison of \\[68Ga\\]Ga-DFC413 and \\[68Ga\\]Ga-NNS309), not all indications might be explored.","sourceUrl":"https://clinicaltrials.gov/study/NCT07630961"},{"nctId":"NCT06989437","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","sponsor":"Pfizer","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":982,"enrollmentType":"ESTIMATED","startDate":"2025-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-10","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Cachexia","Metastatic Pancreatic Ductal Adenocarcinoma"],"interventions":["ponsegromab","placebo"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","China","France","Germany","India","Israel","Italy","Japan","Mexico","Poland","Puerto Rico","Slovakia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":214,"serviceSignals":["Broad CGP"],"summary":"Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06989437"},{"nctId":"NCT06609005","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2025-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-17","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Advanced Metastatic Castration Resistant Prostate Cancer"],"interventions":["INV-9956"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06609005"},{"nctId":"NCT07522476","title":"A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma","sponsor":"Virogin Biotech Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-13","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Intrahepatic Cholangiocarcinoma"],"interventions":["VG2025"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. Currently, one phase I dose escalation safety study has been completed in China and the United States respectively, both demonstrating excellent safety profiles with no dose-limiting toxicities (DLTs) observed and no maximum tolerated dose (MTD) identified. Moreover, it has shown preliminary efficacy in treating advanced tumors. Considering the actual clinical needs and the volume of intratumoral administration, a more appropriate recommended phase 2 dose (RP2D) level has been selected for the phase II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07522476"},{"nctId":"NCT06788509","title":"A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Leukemia, Myeloid, Acute","Leukemia, Lymphocytic, Chronic, B-Cell","Lymphoma, Non-Hodgkin","Myelodysplastic Syndromes","Neoplasms","Solid Tumor, Adult","Prostatic Neoplasms, Castration-Resistant"],"interventions":["JNJ-75348780","JNJ-67856633","JNJ-54179060","JNJ-64264681","JNJ-74856665","JNJ-70218902","JNJ-64619178","JNJ-80948543","JNJ-87801493"],"countries":["Australia","Belgium","France","Georgia","Greece","Israel","Japan","Moldova","Poland","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the blood and bone marrow in which the bone marrow makes a large number of abnormal blood cells) and advanced solid tumors and metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06788509"},{"nctId":"NCT07230405","title":"A Phase II Study of SKB571 in Patients With Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":295,"enrollmentType":"ESTIMATED","startDate":"2026-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-19","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Lung Cancer (Non-Small Cell)"],"interventions":["SKB571 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, phase II study. The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of SKB571 in patients with advanced non-small cell lung cancer. Eligible subjects will receive SKB571 monotherapy, until radiographic disease progression, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT07230405"},{"nctId":"NCT07333469","title":"A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma","sponsor":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-01-19","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-19","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-19","completionType":"ESTIMATED","lastUpdated":"2026-01-13","conditions":["Solid Tumor and Lymphoma"],"interventions":["HX111 for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The study will consist of a Phase I dose-escalation and Phase IIa dose-expansion component. Phase I dose-escalation phase will establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D),and evaluate the preliminary antitumor activity of HX111.","sourceUrl":"https://clinicaltrials.gov/study/NCT07333469"},{"nctId":"NCT07681882","title":"First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-08-03","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-21","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-21","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Unresectable Solid Tumor"],"interventions":["DS1025a"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy signals of DS1025a, given as a single agent to participants with advanced, metastatic, or unresectable solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07681882"},{"nctId":"NCT06392477","title":"A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma","sponsor":"Sanofi","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2024-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-11","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["B-cell Non Hodgkin Lymphoma"],"interventions":["SAR448501"],"countries":["Australia","Serbia","Singapore","South Korea","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL). The purpose of the study is to identify possible optimal biological dosage(s) by assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics, clinical activity and immunogenicity of SAR448501/DR-0201. The study duration per participant will be approximately 3 years, including a screening period of up to 28 days, a treatment period of 52 weeks, a safety follow-up period of approximately 28 days and a long-term follow-up period of every 3 months until withdrawal of consent, participant death or study closure, whichever is soone","sourceUrl":"https://clinicaltrials.gov/study/NCT06392477"},{"nctId":"NCT06054555","title":"A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":633,"enrollmentType":"ACTUAL","startDate":"2023-11-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-25","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Melanoma"],"interventions":["ABP 206","Nivolumab"],"countries":["United States","Argentina","Bosnia and Herzegovina","Canada","Chile","Croatia","Czechia","Estonia","France","Georgia","Germany","Italy","Jordan","Lebanon","Lithuania","Malaysia","Mexico","Moldova","Netherlands","Philippines","Portugal","Romania","Serbia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":180,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06054555"},{"nctId":"NCT06170788","title":"Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":614,"enrollmentType":"ESTIMATED","startDate":"2023-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-27","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Sacituzumab tirumotecan","Pembrolizumab","Supportive care measures"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Italy","Japan","Mexico","Netherlands","Peru","Poland","Portugal","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":220,"serviceSignals":["Broad CGP"],"summary":"The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central review (BICR)-verified progressive disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) after initial treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06170788"},{"nctId":"NCT04685226","title":"A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2020-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-25","completionType":"ESTIMATED","lastUpdated":"2025-09-02","conditions":["Solid Tumors"],"interventions":["ICP-723"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"A Multicenter, Nonrandomized, Open-Label Phase I/IIClinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients with Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT04685226"},{"nctId":"NCT05557591","title":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":51,"enrollmentType":"ACTUAL","startDate":"2023-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-16","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Advanced Non-Small Cell Lung Cancer"],"interventions":["BNT116","Cemiplimab"],"countries":["United States","Georgia","Germany","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"This study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a \"study drug\", and together be called \"study drugs\". The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of this study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treating cancer. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drugs * How much study drug is in the blood at different times * Whether the ","sourceUrl":"https://clinicaltrials.gov/study/NCT05557591"},{"nctId":"NCT06873854","title":"A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours","sponsor":"LaNova Medicines Limited","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2025-03-26","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-26","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-26","completionType":"ESTIMATED","lastUpdated":"2025-03-13","conditions":["Advanced Solid Tumor"],"interventions":["LM-108","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of LM-108 in combination with Toripalimab in patients with advanced malignant solid tumours with unresectable or metastatic MSI-H/dMMR who have failed previous anti-PD-1 /PD-L1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06873854"},{"nctId":"NCT04471727","title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","sponsor":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2020-12-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-28","completionType":"ESTIMATED","lastUpdated":"2026-02-24","conditions":["Small-Cell Lung Cancer","Neuroendocrine Carcinoma"],"interventions":["Gocatamig","Atezolizumab","Ifinatamab Deruxtecan (I-DXd)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).","sourceUrl":"https://clinicaltrials.gov/study/NCT04471727"},{"nctId":"NCT05734066","title":"Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma","sponsor":"Jazz Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2023-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-20","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Refractory Ewing Sarcoma","Relapsed Ewing Sarcoma","Ewing Sarcoma"],"interventions":["Lurbinectedin"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05734066"},{"nctId":"NCT05902169","title":"Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM","sponsor":"CarThera","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2024-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Glioblastoma","Recurrent Glioblastoma","GBM"],"interventions":["SonoCloud-9 (SC9)","Carboplatin","Lomustine","Temozolomide"],"countries":["United States","Austria","Belgium","Denmark","France","Germany","Italy","Netherlands","Spain","Sweden","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["Broad CGP"],"summary":"The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the tumour is seated. The SonoCloud-9 (SC9) is an investigational device using ultrasound technology and specially developed to open the BBB in the area of and surrounding the tumour. The transient openi","sourceUrl":"https://clinicaltrials.gov/study/NCT05902169"},{"nctId":"NCT07493512","title":"Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["Xaluritamig"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this trial is to determine the safety profile of xaluritamig at the proposed regimen in adult participants with metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07493512"},{"nctId":"NCT06203210","title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2024-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Small Cell Lung Cancer"],"interventions":["Ifinatamab deruxtecan","Topotecan","Amrubicin","Lurbinectedin"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","Italy","Japan","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":229,"serviceSignals":["ADC biomarker"],"summary":"This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06203210"},{"nctId":"NCT05393466","title":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Xcovery Holdings, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-31","completionType":"ESTIMATED","lastUpdated":"2025-10-07","conditions":["Non-small Cell Lung Carcinoma"],"interventions":["BPI-361175"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a three-stage study, consisting of Phase Ia dose-escalation, Phase Ib dose expansion, and a Phase II component.","sourceUrl":"https://clinicaltrials.gov/study/NCT05393466"},{"nctId":"NCT07615894","title":"WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)","sponsor":"WestVac Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Advanced Solid Tumors","Malignant Pleural Effusions","Malignant Ascites"],"interventions":["WSK-IM02"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in patients with advanced solid tumors complicated by malignant pleural or peritoneal effusions who have failed standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT07615894"},{"nctId":"NCT05867251","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","sponsor":"Avenzo Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2023-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Advanced Solid Tumor","HR+/HER2- Breast Cancer","HR+, HER2-, Advanced Breast Cancer","CCNE1 Amplification","Epithelial Ovarian Cancer","Primary Peritoneal Cancer","Fallopian Tube Cancer","Endometrial Cancer","TNBC - Triple-Negative Breast Cancer"],"interventions":["AVZO-021","Palbociclib","Fulvestrant","Letrozole","Ribociclib","Abemaciclib","Carboplatin","Sacituzumab Govitecan-hziy"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2 (CDK 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT05867251"},{"nctId":"NCT07244341","title":"A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["Valemetostat","Darolutamide"],"countries":["United States","China","Ireland","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07244341"},{"nctId":"NCT07012109","title":"Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)","sponsor":"BeBetter Med Inc","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-06-05","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2025-06-10","conditions":["Polycythemia Vera"],"interventions":["BEBT-507 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase I clinical trial of BEBT-507 in subjects with polycythemia vera(PV). Phase Ia is a single-agent dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), preliminary efficacy, and pharmacodynamics of BEBT-507 in subjects with PV . Based on the results of Phase Ia, two doses will be selected for further evaluation in Phase Ib to assess the efficacy, safety, and PK profile of BEBT-507 in subjects with PV , and to recommend a dose for Phase III clinical trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07012109"},{"nctId":"NCT06927570","title":"A Study of HS-20122 in Patients With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":1050,"enrollmentType":"ESTIMATED","startDate":"2025-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["Advanced Solid Tumors"],"interventions":["HS-20122"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) Phase I, multi-center, open-label, study of HS-20122, in patients with advanced solid tumors. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-20122 in advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06927570"},{"nctId":"NCT06710756","title":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","sponsor":"Perspective Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2025-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Pancreatic Ductal Adenocarcinoma","Gastric Cancer","Esophageal Cancer","Colorectal Cancer","Ovarian Cancer","Head and Neck Cancer","Sarcoma","Mesothelioma"],"interventions":["[203Pb]Pb-PSV359","[212Pb]Pb-PSV359"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"Phase I/IIa image-guided, alpha-particle therapy study of \\[203Pb\\]Pb-PSV359 and \\[212Pb\\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.","sourceUrl":"https://clinicaltrials.gov/study/NCT06710756"},{"nctId":"NCT07252479","title":"Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations","sponsor":"Adlai Nortye Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2026-01-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-01","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Solid Tumors (Phase 1)","RAS Mutation"],"interventions":["AN9025 oral capsule"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["RAS genotyping"],"summary":"The goal of this clinical trial is to learn determine if AN9025 is safe and tolerable to treat solid cancer tumors with specific genetic mutations. It will help identify doses for use in future testing and establish the safety profile of the drug. The main questions it aims to answer are: Which dose(s) of AN9025 are safe and tolerable for use in evaluating anti-tumor activity in participants with Rat Sarcoma oncogene (RAS) mutated solid tumors? What medical problems do participants have when taking AN9025? Participants will: Take AN9025 by mouth every day or once a week until their disease progresses, they experience severe ill side effects from taking the drug, or withdraw from the study du","sourceUrl":"https://clinicaltrials.gov/study/NCT07252479"},{"nctId":"NCT07676175","title":"A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)","sponsor":"BeBetter Med Inc","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Previously Untreated Peripheral T-Cell Lymphoma"],"interventions":["Ifupinostat Hydrochloride for Injection","Cyclophosphamide for Injection","Doxorubicin Hydrochloride for Injection","Vincristine Sulfate for Injection","Prednisone Acetate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical study is to find the best way to combine the study drug BEBT-908 (ifupinostat hydrochloride for injection) with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for treating previously untreated peripheral T-cell lymphoma, and to find out whether this best combination is better than standard CHOP treatment alone. The main questions this study will try to answer are: What percentage of participants will respond well to treatment with BEBT-908 plus CHOP? Is BEBT-908 plus CHOP better than standard CHOP treatment? What medical problems will participants have while receiving this combination treatment? This study includes an Exploration Phase and an Expa","sourceUrl":"https://clinicaltrials.gov/study/NCT07676175"},{"nctId":"NCT07024615","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2025-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Pancreatic Ductal Adenocarcinoma"],"interventions":["ASP2138","Oxaliplatin","Leucovorin","5-FU","Irinotecan","Gemcitabine","Nab-paclitaxel","Capecitabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell \"tells\" the immune system to attack the tumor. This study is for people with resectable PDAC. Resectable means that the tumor can be removed by surgery. In this study, adults with resectable PDAC will receive an ASP2138 injection just below the skin (subcutaneous) 2 weeks before surgery. After surgery, they will be given standard chemotherapy treatments chosen by their study doctor. These include mFOLFIRINOX, gemcitabine with nab-paclitaxel, or gemcitabine with capeci","sourceUrl":"https://clinicaltrials.gov/study/NCT07024615"},{"nctId":"NCT07432633","title":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","sponsor":"Blue Earth Diagnostics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2026-02-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-01-31","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Colorectal Cancer","Epithelial Ovarian Cancer","Gastric Cancer","Invasive Lobular Breast Carcinoma","Pancreatic Ductal Adenocarcinoma"],"interventions":["[18F]FPyQCP"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \\[18F\\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07432633"},{"nctId":"NCT07459634","title":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","sponsor":"Jazz Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":["Lurbinectedin","Durvalumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07459634"},{"nctId":"NCT06384807","title":"A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors","sponsor":"Biohaven Therapeutics Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2024-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Solid Tumor"],"interventions":["BHV-1510","Cemiplimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06384807"},{"nctId":"NCT07359066","title":"An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors","sponsor":"Shanghai SciBrunch Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2026-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Advanced Solid Tumors","PARP Inhibitor"],"interventions":["SRP1020"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HRD / HRR"],"summary":"This study is a multicenter, open-label study designed to evaluate SPR1020 in adult patients with advanced solid tumors. The study aims to characterize the safety, tolerability, pharmacokinetic (PK) profile, and preliminary antitumor activity of SPR1020 monotherapy in this population. The study consists of two parts: Phase I component (dose escalation and backfill) and Phase II component (dose expansion). The primary objectives of the Phase I part are to investigate the safety, tolerability, and PK profile of SPR1020 and to determine the Recommended Phase II Dose (RP2D) and/or the Maximum Tolerated Dose (MTD), if attainable. The Phase II part will be initiated once the RP2D and/or MTD is est","sourceUrl":"https://clinicaltrials.gov/study/NCT07359066"},{"nctId":"NCT07055594","title":"A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors","sponsor":"Shine-On Biomedical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-11-06","conditions":["Solid Tumors"],"interventions":["SOA101"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"The investigational drug, SOA101, is a nanobody-based trispecific antibody T cell engager targeting PD-L1/HLA-G/CD3. This is a Phase I/IIa study including dose-escalation, dose optimization and dose expansion parts to exam safety, tolerability, pharmacokinetics, immunogenecity and efficacy of SOA101 on advanced or metastatic solid tumor treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07055594"},{"nctId":"NCT07652242","title":"Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer","sponsor":"Immunomic Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Triple Negative Breast Cancer (TNBC)"],"interventions":["ITI-5000 mRNA Vaccine","Pembrolizumab","Olaparib","Capecitabine","ITI-5000 MTD (Maximum Tolerated Dose)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study tests an investigational cancer vaccine called ITI-5000 in people who have completed standard treatment for early-stage triple-negative breast cancer (TNBC). ITI-5000 is a self-amplifying RNA (saRNA) vaccine that instructs the immune system to recognize and attack cancer cells expressing two proteins found on TNBC cells-HERV-K and CT83-fused with a molecule called LAMP-1 that helps the immune system respond more strongly. The vaccine is delivered inside lipid nanoparticles (LNPs), similar to other approved mRNA vaccines. The study has two parts: * Part A: Participants receive ITI-5000 alone at one of two dose levels (1 µg or 10 µg), given as an injection into the upper arm muscle ","sourceUrl":"https://clinicaltrials.gov/study/NCT07652242"},{"nctId":"NCT07702292","title":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","sponsor":"Blue Earth Diagnostics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Colorectal Cancer","Epithelial Ovarian Cancer","Gastric Cancer (GC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Invasive Lobular Breast Carcinoma"],"interventions":["[68Ga]BED003"],"countries":["Italy","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-centre, open-label, single-arm, Phase 2 study designed to evaluate the diagnostic performance of \\[68Ga\\]BED003 in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07702292"},{"nctId":"NCT06800963","title":"ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG","sponsor":"ImmunityBio, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["NMIBC"],"interventions":["Intravesical Recombinant Mycobacterium (rMBCG)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder cancer (NMIBC) who have not received Bacillus Calmette-Guérin and have histologically confirmed presence of Carcinoma in situ (CIS) or have primary or recurrent stage Ta and/or T1 papillary tumors following Transurethral resection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06800963"},{"nctId":"NCT07470853","title":"A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.","sponsor":"Whitehawk Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":265,"enrollmentType":"ESTIMATED","startDate":"2026-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["PROC","Platinum Resistant Ovarian Cancer","Endometrial Cancer"],"interventions":["HWK-016, MUCIN-16-targeted ADC","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors. The study employs a dose escalation and dose expansion design without a control group. The study consists of 2 parts (Part A: monotherapy and Part B: combination therapy with bevacizumab); each part has 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). Enrollment to Part A (Phase 1a and Phase 1b) will include ovarian and endometrial cancers. Enrollment to Part B (Phase 1a and Phase 1b) will include ovarian cancer only. A subsequent protocol amendment may evaluate additional t","sourceUrl":"https://clinicaltrials.gov/study/NCT07470853"},{"nctId":"NCT07532018","title":"DXP-106 in Solid Tumor Patients.","sponsor":"Singlomics Biopharmaceuticals Zhuhai Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2026-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Solid Tumor","Cancer"],"interventions":["DXP-106"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of DXP-106 in Chinese patients with advanced solid tumors. The main questions it aims to answer are: For Part I: 1. The safety and tolerability of DXP-106 monotherapy in patients with advanced solid tumors; 2. The dose-limiting toxicities (DLTs) and determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D); 3. The pharmacokinetics (PK) profile, the immunogenicity of DXP-106 following administration in patients with advanced solid tumors; 4. The preliminary efficacy of DXP-106 in patients with advanced solid tumors; 5. The pharmacodynamic (PD) profiles of DXP-106 following administration in","sourceUrl":"https://clinicaltrials.gov/study/NCT07532018"},{"nctId":"NCT06792552","title":"A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors","sponsor":"NextCure, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":738,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Solid Tumors","Platinum Resistant Ovarian Cancer","Fallopian Tube Cancer","Renal Cell Carcinoma (RCC)","Papillary Renal Cell Carcinoma (Prcc)","Uterine Serous Carcinoma (USC)","NSCLC (Non-small Cell Lung Cancer)","Primary Peritoneal Cancer"],"interventions":["SIM0505 for injection"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06792552"},{"nctId":"NCT07481357","title":"A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma","sponsor":"Dong-A ST Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2026-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Gastric (Stomach) Cancer","GastroEsophageal Cancer","Pancreatic Ductal Adenocarcinoma (mPDAC)"],"interventions":["DA-3501"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC. Participants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.","sourceUrl":"https://clinicaltrials.gov/study/NCT07481357"},{"nctId":"NCT07618377","title":"Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Gastrointestinal Stromal Tumors"],"interventions":["DCC-2618"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies","sourceUrl":"https://clinicaltrials.gov/study/NCT07618377"},{"nctId":"NCT06995677","title":"Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer","sponsor":"Tyra Biosciences, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Low-grade NMIBC","FGFR Gene Amplification","FGFR Gene Alterations","FGFR3 Gene Alteration","FGFR3 Gene Mutation","FGFR3 Gene Fusions"],"interventions":["TYRA-300 60mg","TYRA-300 50mg","TYRA-300 Dose TBD"],"countries":["United States","Australia","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC","sourceUrl":"https://clinicaltrials.gov/study/NCT06995677"},{"nctId":"NCT06522737","title":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","sponsor":"SecuraBio","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2025-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Lymphoma"],"interventions":["Duvelisib","Gemcitabine","Bendamustine"],"countries":["Belgium","Czechia","Denmark","France","Germany","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":44,"serviceSignals":["Hematology NGS"],"summary":"The study will evaluate the progression-free survival benefit of duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma with TFH phenotype.","sourceUrl":"https://clinicaltrials.gov/study/NCT06522737"},{"nctId":"NCT06568939","title":"A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Telisotuzumab Vedotin"],"countries":["United States","Brazil","China","Israel","Japan","Serbia","Singapore"],"northAmerica":true,"chinaSites":true,"siteCount":80,"serviceSignals":["MET profiling"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adu","sourceUrl":"https://clinicaltrials.gov/study/NCT06568939"},{"nctId":"NCT07326488","title":"A Study of MHB009C in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Advanced Malignant Solid Tumor"],"interventions":["MHB009C for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I/II study of MHB009C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB009C monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07326488"},{"nctId":"NCT05573126","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","sponsor":"Ellipses Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2023-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Hormone Receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer"],"interventions":["EP0062","Elacestrant","Everolimus","Abemaciclib","Fulvestrant","Exemestane"],"countries":["United States","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05573126"},{"nctId":"NCT07121946","title":"This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma","sponsor":"LTZ Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Non-Hodgkin Lymphoma Refractory/ Relapsed","DLBCL - Diffuse Large B Cell Lymphoma","Mantle Cell Lymphoma (MCL)","Follicular Lymphoma ( FL)","Marginal Zone Lymphoma (MZL)"],"interventions":["LTZ-301"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07121946"},{"nctId":"NCT06534060","title":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","sponsor":"March Biosciences Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2025-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2025-10-03","conditions":["Lymphoma, T-Cell"],"interventions":["Genetic: MB-105"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.","sourceUrl":"https://clinicaltrials.gov/study/NCT06534060"},{"nctId":"NCT07311993","title":"Phase 1 Study of CLR 125 in Triple Negative Breast Cancer","sponsor":"Cellectar Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Breast Cancer"],"interventions":["Iopofosine I 131","CLR 125"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: * What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. * What side effects do participants have when taking CLR 125. Participants will: * Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications. Some participants may also receive one dose of CLR 131 to evaluate the amount of radi","sourceUrl":"https://clinicaltrials.gov/study/NCT07311993"},{"nctId":"NCT06496178","title":"A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)","sponsor":"Merus B.V.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2024-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["Petosemtamab","Investigator's Choice"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Lithuania","Netherlands","Poland","Portugal","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":218,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT06496178"},{"nctId":"NCT07258979","title":"A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":202,"enrollmentType":"ESTIMATED","startDate":"2025-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2025-12-02","conditions":["Recurrent or Metastatic Nasopharyngeal Carcinoma"],"interventions":["YL201","Toripalimab","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase Ib/II study conducted in China to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of YL201 combined with Toripalimab (doublet regimen) or YL201 combined with Toripalimab and Cisplatin (triplet regimen) in subjects with recurrent or metastatic nasopharyngeal carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07258979"},{"nctId":"NCT07294300","title":"A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Relapsed/Refractory Hematological Malignancies"],"interventions":["QLS2313"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07294300"},{"nctId":"NCT07421856","title":"Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-02-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-01","completionType":"ESTIMATED","lastUpdated":"2026-02-19","conditions":["Multiple Myeloma in Relapse","Multiple Myeloma Refractory"],"interventions":["Autologous BCMA-targeting CAR T cells"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma","sourceUrl":"https://clinicaltrials.gov/study/NCT07421856"},{"nctId":"NCT06080776","title":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":242,"enrollmentType":"ESTIMATED","startDate":"2023-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-01","completionType":"ESTIMATED","lastUpdated":"2023-10-12","conditions":["Non-small Cell Lung Cancer"],"interventions":["SH-1028 tablets","Placebo SH-1028 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06080776"},{"nctId":"NCT06314373","title":"A Study for HSK39775 in Participants With Solid Tumors","sponsor":"Xizang Haisco Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":243,"enrollmentType":"ESTIMATED","startDate":"2024-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2024-03-18","conditions":["Advanced Solid Tumors"],"interventions":["HSK39775 Monotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This research is designed to determine if HSK39775 is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06314373"},{"nctId":"NCT03934372","title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","sponsor":"Incyte Biosciences International Sàrl","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2020-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Acute Myeloid Leukemia","Accelerated Phase Chronic Myeloid Leukemia","Blast Phase Chronic Myeloid Leukemia","Chronic Phase Chronic Myeloid Leukemia","Acute Lymphoblastic Leukemia","Acute Lymphocytic Leukemia","Leukemia","Lymphoma","Solid Tumors"],"interventions":["Ponatinib"],"countries":["Belgium","France","Italy","Netherlands","Spain","Sweden","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \\< 18 years with advanced leukemias, lymphomas, and solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT03934372"},{"nctId":"NCT06127407","title":"Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen","sponsor":"Servier Bio-Innovation LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2024-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-26","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen"],"interventions":["Ivosidenib 500mg","Placebo"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Italy","Japan","Netherlands","Puerto Rico","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":114,"serviceSignals":["Broad CGP"],"summary":"Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib. Participants are required to have a histopathological diagnosis consistent with isocitrate dehydrogenase-1 (IDH1) gene-mutated, locally advanced or metastatic conventional chondrosarcoma Grades 1, 2, or 3 and not eligible for curative resection. IDH1 mutant status will be determined during pre-screening/screening phase. Participant must have radiographic progression/recurrence of disease according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and have received 0 to 1 prior systemic treatment regimen in the advanced/meta","sourceUrl":"https://clinicaltrials.gov/study/NCT06127407"},{"nctId":"NCT07205822","title":"A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-02","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Breast Cancer"],"interventions":["Dato-DXd"],"countries":["United States","China","France","Italy","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":40,"serviceSignals":["HER2 profiling"],"summary":"A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07205822"},{"nctId":"NCT02332668","title":"A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":370,"enrollmentType":"ESTIMATED","startDate":"2015-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-02","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Melanoma","Lymphoma","Solid Tumor","Classical Hodgkin Lymphoma","Microsatellite-instability-high Solid Tumor"],"interventions":["Pembrolizumab"],"countries":["United States","Brazil","France","Germany","Israel","Italy","Portugal","South Korea","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["MSI / TMB","Hematology NGS"],"summary":"Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smalle","sourceUrl":"https://clinicaltrials.gov/study/NCT02332668"},{"nctId":"NCT07663630","title":"A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Weight Loss","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-07-22","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-29","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Non-small Cell Lung Cancer (NSCLC)","Cachexia"],"interventions":["ponsegromab","placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.","sourceUrl":"https://clinicaltrials.gov/study/NCT07663630"},{"nctId":"NCT07612891","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":201,"enrollmentType":"ESTIMATED","startDate":"2025-07-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-04","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Breast Cancer (Locally Advanced or Metastatic)","Advanced Solid Cancers","Metastatic (Stage IV) Breast Cancer","Ovarian Cancer","Endometrial Cancer"],"interventions":["INV-6452"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT07612891"},{"nctId":"NCT06091254","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":822,"enrollmentType":"ESTIMATED","startDate":"2023-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-03","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Follicular Lymphoma (FL)"],"interventions":["Odronextamab","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone/prednisolone","Bendamustine"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Israel","Italy","Poland","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":190,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the \"comparator drug\") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition","sourceUrl":"https://clinicaltrials.gov/study/NCT06091254"},{"nctId":"NCT04771130","title":"A Study of BGB-11417 in Participants With Myeloid Malignancies","sponsor":"BeOne Medicines","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2021-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-08","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasm"],"interventions":["BGB-11417","Azacitidine","Posaconazole"],"countries":["United States","Australia","China","France","Germany","Italy","New Zealand","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":46,"serviceSignals":["Hematology NGS"],"summary":"The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .","sourceUrl":"https://clinicaltrials.gov/study/NCT04771130"},{"nctId":"NCT06456463","title":"A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":85,"enrollmentType":"ACTUAL","startDate":"2025-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-11","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Acute Myeloid Leukemia"],"interventions":["Tagraxofusp","Venetoclax","Azacitidine"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \\[μg/kg/day\\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06456463"},{"nctId":"NCT06046495","title":"A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2024-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-09","completionType":"ESTIMATED","lastUpdated":"2025-04-23","conditions":["Non-Small Cell Lung Cancer"],"interventions":["PLB1004"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound, given alone in NSCLC patients with EGFR exon 20 insertion mutations，uncommon mutations, classical mutations (Ex19del and L858R), and drug-resistant mutation (T790M). Patients will be enrolled and dosed according to the most current protocol. This study is made of two Parts. Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a total of 21 - 42 patients. The patient population of the dos","sourceUrl":"https://clinicaltrials.gov/study/NCT06046495"},{"nctId":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","sponsor":"TICAROS Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":98,"enrollmentType":"ESTIMATED","startDate":"2023-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-10","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Relapsed Large B-cell Lymphoma","Refractory Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma (DLBCL)","High-grade B-cell Lymphoma (HGBL)","Transformed Follicular Lymphoma (TFL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)"],"interventions":["TC011"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, phase I/II study to determine the safety and efficacy of TC011(CD19 Targeted CAR-T) in adult patients with relapsed or refractory large B-cell non -hodgkin lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07473167"},{"nctId":"NCT05201066","title":"Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":33,"enrollmentType":"ACTUAL","startDate":"2023-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-14","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Myelodysplastic Syndromes","Leukemia, Myelomonocytic, Chronic"],"interventions":["decitabine","spartalizumab","sabatolimab","azacitidine","venetoclax","INQOVI (oral decitabine)"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","Italy","Japan","Malaysia","Spain","Switzerland","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.","sourceUrl":"https://clinicaltrials.gov/study/NCT05201066"},{"nctId":"NCT06829459","title":"A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2025-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-15","completionType":"ESTIMATED","lastUpdated":"2025-04-08","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Glumetinib","Osimertinib mesylate","Pemetrexed","Cisplatin or carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"The is a randomized, controlled, open-label Phase III clinical study to evaluate the efficacy and safety of glumetinib combined with osimertinib mesylate versus platinum-based doublet chemotherapy in non-small cell lung cancer( NSCLC) patients with MET amplification and/or overexpression after resistance to EGFR-TKIs.. Approximately 350 NSCLC patients with MET amplification and/or overexpression after previous treatment with EGFR-TKIs are planned to be enrolled. After patients sign the informed consent form (ICF), those who are eligible for enrollment after screening examinations will be randomized to the investigational group or the control group in a 1:1 ratio by the central randomization ","sourceUrl":"https://clinicaltrials.gov/study/NCT06829459"},{"nctId":"NCT06948448","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2025-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Colorectal Cancer"],"interventions":["ONO-4578","Opdivo®","Oxaliplatin","5-Fluorouracil","Bevacizumab","Leucovorin"],"countries":["United States","Canada","France","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo® when added to mFOLFOX6 and bevacizumab versus SOC as first-line treatment for advanced CRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06948448"},{"nctId":"NCT07719361","title":"A Study in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Flare Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-15","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Metastatic Castration Resistant Prostate Cancer","mCRPC","mCRPC (Metastatic Castration-resistant Prostate Cancer)","Prostatic Neoplasms","Prostatic Neoplasms, Castration-Resistant","mCRPC or Advanced/Metastatic Solid Tumors","mCRPC, Metastatic Castration Resistant Prostate Cancer","Neoplasms Prostate","Neoplasms of Prostate"],"interventions":["FX-111"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will have regular physical and laboratory examinations to check health and tumor status.","sourceUrl":"https://clinicaltrials.gov/study/NCT07719361"},{"nctId":"NCT06747585","title":"A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors","sponsor":"Alentis Therapeutics AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-15","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Squamous Non-small-cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Esophageal Squamous Cell Carcinoma"],"interventions":["ALE.P02"],"countries":["United States","France","Hong Kong","Italy","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06747585"},{"nctId":"NCT07415031","title":"A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2026-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-16","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Solid Tumors"],"interventions":["Adagrasib","Pembrolizumab","Cetuximab","Pemetrexed","Docetaxel","Irinotecan","Leucovorin","Oxaliplatin","Fluorouracil"],"countries":["United States","Australia","Belgium","Canada","China","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","Poland","Portugal","Romania","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":101,"serviceSignals":["RAS genotyping"],"summary":"This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07415031"},{"nctId":"NCT06832982","title":"Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002","sponsor":"Shanghai Pushi Medical Science Co. Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-19","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Solid Tumors"],"interventions":["FS-8002 injection","Toripalimab Injection","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"this is a single-arm, open phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics, and preliminary efficacy of FS-8002 and combination therapy in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06832982"},{"nctId":"NCT07301229","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-12-29","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-23","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["HLX43 DOSE 1 (2.5 mg/kg)","HLX43 DOSE 2 (3.0 mg/kg)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07301229"},{"nctId":"NCT06913218","title":"A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-23","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-06","completionType":"ESTIMATED","lastUpdated":"2025-04-06","conditions":["Pancreas Cancer","Pancreas Cancer, Duct Cell Adenocarcinoma"],"interventions":["AK154","Cadonilimab","Ivonescimab (SMT112 or AK112) Injection","mFOLFORINOX"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC","sourceUrl":"https://clinicaltrials.gov/study/NCT06913218"},{"nctId":"NCT06744920","title":"A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-25","primaryCompletionType":"ESTIMATED","completionDate":"2033-02-26","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Generalized Myasthenia Gravis"],"interventions":["Remibrutinib (Blinded)","Placebo","Remibrutinib (Open Label)"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Georgia","Germany","India","Italy","Japan","Poland","Romania","Serbia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":130,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06744920"},{"nctId":"NCT06663319","title":"A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2024-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-19","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Colorectal Neoplasms","Gastrointestinal Neoplasms"],"interventions":["JNJ-89402638","Bevacizumab","FOLFOX","FOLFIRI"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06663319"},{"nctId":"NCT06795022","title":"First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":304,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-25","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Hepatocellular Carcinoma"],"interventions":["AZD9793 Intravenous (IV) monotherapy","AZD9793 Subcutaneous (SC) monotherapy"],"countries":["United States","China","Hong Kong","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.","sourceUrl":"https://clinicaltrials.gov/study/NCT06795022"},{"nctId":"NCT06730386","title":"A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-30","completionType":"ESTIMATED","lastUpdated":"2025-03-06","conditions":["Solid Cancer"],"interventions":["AK138D1"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06730386"},{"nctId":"NCT03833206","title":"A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients","sponsor":"BioLite, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2027-01-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Major Depressive Disorder"],"interventions":["PDC-1421 Capsule"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.","sourceUrl":"https://clinicaltrials.gov/study/NCT03833206"},{"nctId":"NCT04931342","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":176,"enrollmentType":"ACTUAL","startDate":"2021-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Ovarian Cancer"],"interventions":["Ipatasertib","Cobimetinib","Trastuzumab Emtansine","Atezolizumab","Bevacizumab","Paclitaxel","Giredestrant","Abemaciclib","Inavolisib","Palbociclib","Letrozole","Olaparib","Luteinizing Hormone-Releasing Hormone (LHRH) Agonists","Cyclophosphamide"],"countries":["United States","Australia","Canada","Czechia","France","Germany","Italy","Russia","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT04931342"},{"nctId":"NCT07075328","title":"A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma","sponsor":"Otsuka Medical Devices Co., Ltd. Japan","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2024-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Adult T-Cell Leukemia/Lymphoma (ATLL)"],"interventions":["Drug:5-ALA, Device:Photodynamic system"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This study aims to evaluate the tolerability of OJP-001, a therapeutic system combining photodynamic therapy (PDT) using OMD-001 and extracorporeal circulation therapy using OJE-001 and OJC-001, in patients with adult T-cell leukemia/lymphoma (ATL). The study will also investigate the recommended dose and pharmacokinetics of OMD-001, as well as the efficacy and safety of OJP-001.","sourceUrl":"https://clinicaltrials.gov/study/NCT07075328"},{"nctId":"NCT06462794","title":"First In Human Study of CX-801 in Advanced Solid Tumors","sponsor":"CytomX Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2024-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Solid Tumor, Adult"],"interventions":["CX-801","pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human study, CTMX-801-101, is to characterize the safety, tolerability, and antitumor activity of CX-801 as monotherapy and in combination with pembrolizumab in adult participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06462794"},{"nctId":"NCT07287917","title":"Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors","sponsor":"Aminex Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2026-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-29","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Melanoma (Skin Cancer)","HER2-low Hormone Receptor Positive Breast Cancer"],"interventions":["AMXT 1501 Dicaprate","DFMO","Fulvestrant","Capivasertib","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- breast cancer receiving fulvestrant and capivasertib * Cohort 2: Patients with unresectable or metastatic cutaneous melanoma receiving pembrolizumab The Phase 1b portion will find the recommended Phase 2 dose (RP2D). The Phase 2 portion will further evaluate clinical activity at the RP2D using response criteria for solid tumors (RECIST 1.1). The study will also evaluate pharmacokinetics, pharmacodynamics, disease control, and overall safety.","sourceUrl":"https://clinicaltrials.gov/study/NCT07287917"},{"nctId":"NCT05798897","title":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma","sponsor":"Marker Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":79,"enrollmentType":"ESTIMATED","startDate":"2023-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2025-08-20","conditions":["Non-Hodgkin Lymphoma, Adult","Non-Hodgkin Lymphoma, Refractory","Non-Hodgkin Lymphoma, Relapsed","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Hodgkin Lymphoma, Adult","Hodgkin's Lymphoma, Relapsed, Adult"],"interventions":["MT-601"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\\^6 cells (flat dosing).","sourceUrl":"https://clinicaltrials.gov/study/NCT05798897"},{"nctId":"NCT07733180","title":"A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC","sponsor":"BeOne Medicines","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced Esophageal Squamous Cell Carcinoma","Metastatic Esophageal Squamous Cell Carcinoma"],"interventions":["Tislelizumab","Oxaliplatin","Leucovorin","5-fluorouracil (5-FU)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line treatment in Japanese participants with previously untreated, unresectable locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07733180"},{"nctId":"NCT03093116","title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","sponsor":"Turning Point Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2017-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-29","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Locally Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["Oral repotrectinib (TPX-0005)"],"countries":["United States","Australia","Belgium","Canada","China","Denmark","France","Germany","Hong Kong","Hungary","Italy","Japan","Netherlands","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":165,"serviceSignals":["RNA fusion"],"summary":"Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary o","sourceUrl":"https://clinicaltrials.gov/study/NCT03093116"},{"nctId":"NCT07428616","title":"A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","sponsor":"Exelixis","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Meningioma"],"interventions":["Zanzalintinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07428616"},{"nctId":"NCT07355231","title":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","sponsor":"Xemed LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-29","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Hyperpolarized xenon MRI"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of functional compromised tissue to deliver sufficient dose to the tumor while preserving as much functioning lung as possible. Hyperpolarized xenon-129 MRI can provide maps of ventilatory function and gas exchange to the bloodstream. Improving treatment plans based on this novel imaging modality could reduce risk or severity of radiation pneumonitis and improve post-treatment quality of life.","sourceUrl":"https://clinicaltrials.gov/study/NCT07355231"},{"nctId":"NCT06548217","title":"A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2024-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-29","completionType":"ESTIMATED","lastUpdated":"2025-07-03","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["ONO-4538HSC"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, uncontrolled, phase I study to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ONO-4538HSC administered subcutaneously in participants with advanced or metastatic solid tumors. This study consists of the tolerability confirmation part to determine the recommended dose for Japanese participants by evaluating the DLTs and the expansion part to evaluate the safety and pharmacokinetics and to explore the efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06548217"},{"nctId":"NCT05936359","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2023-09-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-02-29","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Myeloproliferative Neoplasms"],"interventions":["INCA033989","Ruxolitinib"],"countries":["Australia","Canada","Denmark","France","Germany","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT05936359"},{"nctId":"NCT07559019","title":"Safety and Preliminary Activity of BI115 in Advanced SCLC","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-30","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Small Cell Lung Cancer (SCLC)"],"interventions":["IBI115"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07559019"},{"nctId":"NCT06992583","title":"Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2025-05-28","conditions":["Advanced Lung Cancer"],"interventions":["Targeted CEA CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Lung cancer is the leading cause of morbidity and mortality in the world, of which 80%-85% are non-small cell lung cancer (NSCLC). Most patients with NSCLC are at the advanced stage of diagnosis and have a poor prognosis. The 5-year survival rate of stage III patients is about 15%, the 5-year survival rate of stage IV patients is less than 5%, and the median survival time is only 7 months. CEACAM5 (CEA), also known as CD66e, is a classic tumor marker that has been used as a marker for many types of tumors for 50 years. It is mainly expressed in lung cancer, esophageal cancer, bile duct cancer, colorectal cancer, gastric cancer and other tumor types. In previous CAR-T-related clinical trials ","sourceUrl":"https://clinicaltrials.gov/study/NCT06992583"},{"nctId":"NCT07286331","title":"A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Neoplasms, Endometrial"],"interventions":["Mocertatug rezetecan","Paclitaxel","Doxorubicin"],"countries":["Argentina","Australia","Canada","Japan","Panama"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["ADC biomarker"],"summary":"This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.","sourceUrl":"https://clinicaltrials.gov/study/NCT07286331"},{"nctId":"NCT06504147","title":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","sponsor":"Oncoinvent Solutions AS","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2024-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-28","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Peritoneal Carcinomatosis","Ovarian Cancer"],"interventions":["Radspherin"],"countries":["United States","Belgium","Italy","Norway","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["HRD / HRR"],"summary":"This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are HR proficient and scheduled to undergo NACT and IDS. The study will be conducted in 2 parts; first, a Safety Lead-in Cohort will be recruited followed by the randomised part of the study. For both parts of the study, patients must be scheduled to undergo NACT and IDS and complete resection to no residual tumour (R0) should be deeme","sourceUrl":"https://clinicaltrials.gov/study/NCT06504147"},{"nctId":"NCT06161025","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":860,"enrollmentType":"ESTIMATED","startDate":"2024-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-02-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Solid Cancer"],"interventions":["R-DXd","Paclitaxel","Topotecan","PLD"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","Finland","France","Germany","Greece","Italy","Japan","Poland","Portugal","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":164,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06161025"},{"nctId":"NCT04879043","title":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","sponsor":"Heidelberg Pharma AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2022-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Multiple Myeloma","Plasma Cell Disorder"],"interventions":["HDP-101"],"countries":["United States","Germany","Hungary","Poland","Romania"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT04879043"},{"nctId":"NCT07070232","title":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":1438,"enrollmentType":"ESTIMATED","startDate":"2025-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Solid Tumor"],"interventions":["BNT326","Pumitamig","Itraconazole","Paroxetine"],"countries":["United States","Australia","Belgium","Germany","Italy","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":67,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either metastatic or recurrent tumors with no further definitive treatment possible) and/or have relapsed/progressed after prior therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07070232"},{"nctId":"NCT05549297","title":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","sponsor":"Immunocore Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2022-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Advanced Melanoma"],"interventions":["Tebentafusp","Tebentafusp with Pembrolizumab","Investigators Choice"],"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Italy","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":82,"serviceSignals":["RNA fusion","Hematology NGS","HLA / TCR"],"summary":"The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \\[SoC\\], best supportive care \\[BSC\\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05549297"},{"nctId":"NCT04901741","title":"Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer","sponsor":"TME Pharma AG","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2025-06-27","conditions":["Metastatic Pancreatic Cancer"],"interventions":["Olaptesed pegol","Pembrolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to provide a go/no-go decision for a randomized expansion study by assessing the disease control rate (DCR) at 6 weeks for the combination of olaptesed pegol on top of pembrolizumab and (Arm 1) nanoliposomal irinotecan, 5-FU and leucovorin or (Arm 2) gemcitabine and nab-paclitaxel, to assess safety and tolerability and time-to-event endpoints.","sourceUrl":"https://clinicaltrials.gov/study/NCT04901741"},{"nctId":"NCT07736937","title":"Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer","sponsor":"Tubulis GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Ovarian Cancer"],"interventions":["TUB-040 + Carbo + BEV"],"countries":["Belgium","Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the safety, tolerability, and preliminary effectiveness of TUB-040 when given in combination with standard ovarian cancer treatments in participants with high-grade epithelial serous or endometrioid ovarian cancer. This study will also evaluate the appropriate dose of TUB-040 when used with carboplatin (Carbo) and bevacizumab (BEV), including determining the maximum tolerated dose (MTD) in participants with platinum-sensitive ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07736937"},{"nctId":"NCT06287918","title":"A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","sponsor":"3H (Suzhou) Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Solid Tumors With FGFR2 Alterations, Adult"],"interventions":["3HP-2827"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations. Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II).","sourceUrl":"https://clinicaltrials.gov/study/NCT06287918"},{"nctId":"NCT07258407","title":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","sponsor":"T.O.A.D. Oncology SA","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Metastatic Castration-Resistant Prostatic Cancer"],"interventions":["TD001"],"countries":["United States","Australia","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07258407"},{"nctId":"NCT07251166","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Advanced Solid Tumors"],"interventions":["GenSci140 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, multi-center, open-label, dose-escalation (Part 1) and dose-expansion (Part 2) first-in-human study in China to evaluate the safety, tolerability, PK profile and efficacy of GenSci140 in participants with advanced solid tumors, and to determine the MTD (if any) and RDE. The dose-expansion study aims to evaluate the efficacy, safety and PK profile of GenSci140 in the treatment of ovarian cancer or other FRα-positive advanced solid tumors at different dose levels, and to select an appropriate RP2D (if applicable).","sourceUrl":"https://clinicaltrials.gov/study/NCT07251166"},{"nctId":"NCT07480681","title":"Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["HLX97","Fulvestrant"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07480681"},{"nctId":"NCT04486833","title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","sponsor":"Genprex, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":158,"enrollmentType":"ESTIMATED","startDate":"2021-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Carcinoma, Non-Small Cell Lung"],"interventions":["quaratusugene ozeplasmid","osimertinib","Platinum-Based Chemotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this randomized study is to determine the safety and efficacy of quaratusugene ozeplasmid (Reqorsa) added to osimertinib in NSCLC patients with activating EGFR mutations who have progressed while on treatment with osimertinib. Quaratusugene ozeplasmid consists of non-viral lipid nanoparticles that encapsulate a DNA plasmid with the TUSC2 tumor suppressor gene and is the first systemic gene therapy for cancer. The study is comprised of a Phase 1 dose escalation portion and two Phase 2 portions evaluating safety and efficacy. Enrollment in the Phase 1 dose escalation portion is complete and the recommended Phase 2 dose (RP2D) was determined. Phase 2a has initiated and enrolled p","sourceUrl":"https://clinicaltrials.gov/study/NCT04486833"},{"nctId":"NCT07111832","title":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer"],"interventions":["SHR-A1811 for Injection","SHR-1316 Injection","Toripalimab Injection","Paclitaxel for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT07111832"},{"nctId":"NCT06393738","title":"A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.","sponsor":"Arvinas Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":255,"enrollmentType":"ESTIMATED","startDate":"2024-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)","Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)"],"interventions":["ARV-393","Glofitamab"],"countries":["United States","Canada","Denmark","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.","sourceUrl":"https://clinicaltrials.gov/study/NCT06393738"},{"nctId":"NCT06508658","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":379,"enrollmentType":"ACTUAL","startDate":"2024-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["Epcoritamab","Rituximab","Lenalidomide","Oxaliplatin","Gemcitabine"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Croatia","Czechia","France","Greece","Hungary","Japan","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Serbia","Singapore","South Africa","South Korea","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":176,"serviceSignals":["Hematology NGS"],"summary":"B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Around 360 adult participants with R/R DLBC","sourceUrl":"https://clinicaltrials.gov/study/NCT06508658"},{"nctId":"NCT07512583","title":"Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2026-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Advanced Solid Tumor"],"interventions":["TQB2930 injection+TQB2102 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07512583"},{"nctId":"NCT07066657","title":"A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors","sponsor":"ArriVent BioPharma, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":572,"enrollmentType":"ESTIMATED","startDate":"2025-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Locally Advanced or Metastatic Solid Tumors","Colorectal Cancer","Gastric Cancer","Pancreatic Cancer"],"interventions":["MRG007","MRG007 and Bevacizumab"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07066657"},{"nctId":"NCT06340568","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","sponsor":"BioNTech SE","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2025-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Endometrial Cancer"],"interventions":["BNT323/DB-1303","Doxorubicin","Paclitaxel","Docetaxel"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Greece","Hungary","Israel","Italy","Netherlands","Norway","Poland","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":171,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how well BNT323 (also known as DB-1303) or chemotherapy (doxorubicin or paclitaxel \\[or docetaxel, if participants cannot take paclitaxel\\]) works by determining the progression-free survival (PFS) of participants who have been previously treated with immune checkpoint inhibitors (ICIs). In Cohort 2, the main goal is to assess how well BNT323 works by determining the objective response rate (ORR), that is, the percentage of participants whose tumor shrinks (pa","sourceUrl":"https://clinicaltrials.gov/study/NCT06340568"},{"nctId":"NCT06428019","title":"A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2024-08-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Venetoclax","Acalabrutinib","Obinutuzumab"],"countries":["United States","Australia","France","Greece","Puerto Rico","Serbia","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":70,"serviceSignals":["Hematology NGS"],"summary":"Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in disease activity will be assessed. Venetoclax in combination with obinutuzumab or acalabrutinib is being investigated in the treatment of CLL. Study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 170 adult participants with CLL wh","sourceUrl":"https://clinicaltrials.gov/study/NCT06428019"},{"nctId":"NCT07008976","title":"Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":246,"enrollmentType":"ESTIMATED","startDate":"2025-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Metastatic Breast Cancer"],"interventions":["TQB2102 Injection","Trastuzumab Emtansine for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["HER2 profiling"],"summary":"This study adopted a randomized, open-label, positive drug-controlled, multi-center trial design. The primary endpoint was PFS evaluated by the Independent Review Committee (IRC). Eligible subjects were randomly assigned in a 1:1 ratio to receive either TQB2102 for injection or trastuzumab emtansine for injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT07008976"},{"nctId":"NCT06789796","title":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":636,"enrollmentType":"ESTIMATED","startDate":"2025-02","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2025-02-11","conditions":["Small-cell Lung Cancer"],"interventions":["Iparomlimab and Tuvonralimab (QL1706)","placebo for QL1604","QL1604","placebo for Iparomlimab and Tuvonralimab (QL1706)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after concurrent or sequential chemoradiotherapy. QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06789796"},{"nctId":"NCT07030478","title":"A Study to Evaluate the Safety and Tolerability of EP0089","sponsor":"Ellipses Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2025-06-22","conditions":["Solid Cancers","Solid Tumours"],"interventions":["EP0089-101"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), first-in-class, Phase I/IIa, open-label study designed to evaluate the safety and tolerability of EP0089 (study drug). Study drug will initially be given via intravenous (IV) infusion once every 2 weeks (Q2W), with one treatment cycle defined as 14 days. The study will enroll patients with advanced solid tumours for whom no standard therapy exists or for whom standard therapy has failed. An independent Safety Monitoring Committee (SMC) will review safety data at regular intervals to ensure participant safety and support dose escalation decisions.","sourceUrl":"https://clinicaltrials.gov/study/NCT07030478"},{"nctId":"NCT06225596","title":"Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)","sponsor":"BicycleTx Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":375,"enrollmentType":"ESTIMATED","startDate":"2024-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-03","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Metastatic Urothelial Cancer"],"interventions":["Zelenectide pevedotin","Pembrolizumab","Gemcitabine + cisplatin Or carboplatin","Avelumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","France","Georgia","Germany","Hungary","Israel","Italy","Poland","Serbia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":102,"serviceSignals":["Broad CGP"],"summary":"This is a global, multicenter, randomized, open-label study. The main objective of the study is to measure the clinical activity and safety of zelenectide pevedotin formally BT8009, in combination with pembrolizumab versus chemotherapy, and as monotherapy in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection for zelenectide pevedotin and is comprised of 2 cohorts. Cohort 1 will include participants who have not received any prior systemic therapy for locally advanced or metastatic UC and are eligible to receive platinum-based chemotherapy, whereas Cohort 2 will include participants who have received ≥ 1 prior systemic therapy for loca","sourceUrl":"https://clinicaltrials.gov/study/NCT06225596"},{"nctId":"NCT06820463","title":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Metastatic Colorectal Cancer"],"interventions":["Telisotuzumab Adizutecan","Fluorouracil","Oxaliplatin","Leucovorin","Bevacizumab","Panitumumab"],"countries":["United States","Australia","Austria","Brazil","Canada","Czechia","France","Greece","Israel","Japan","Puerto Rico","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab","sourceUrl":"https://clinicaltrials.gov/study/NCT06820463"},{"nctId":"NCT07723248","title":"A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)","sponsor":"ORIC Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Metastatic Castration Resistant Prostate Cancer"],"interventions":["Rinzimetostat","Darolutamide","Enzalutamide","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castration resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate. The primary objective of this study is to demonstrate superiority in radiographic progression free survival (rPFS) of the investigational arm of rinzimetostat + darolutamide combination versus physician's choice of control: ARPI (darolutamide or enzalutamide) or docetaxel.","sourceUrl":"https://clinicaltrials.gov/study/NCT07723248"},{"nctId":"NCT07488923","title":"A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)","sponsor":"Moonlight Bio, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Small Cell Lung Cancer (SCLC )","Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","Gastroenteropancreatic NEC (GEP NEC)","Neuroendocrine Prostate Cancer (NEPC)"],"interventions":["ML261"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["RNA fusion","ADC biomarker"],"summary":"This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants with R/R SCLC or select NECs","sourceUrl":"https://clinicaltrials.gov/study/NCT07488923"},{"nctId":"NCT07368127","title":"A Study of TPD3310 in Patients With Advanced Malignant Tumors","sponsor":"TAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2026-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Advanced Malignant Solid Tumors"],"interventions":["TPD3310 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open phase I clinical study of dose escalation,cohort expansion study to evaluate the safety,tolerability,pharmacokinetics,pharmacodynamics, and preliminary efficacy of TPD3310 in patients withadvanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07368127"},{"nctId":"NCT07123454","title":"A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":91,"enrollmentType":"ESTIMATED","startDate":"2025-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-01","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["B-cell Non-Hodgkin Lymphoma"],"interventions":["AZD4512"],"countries":["United States","Australia","China","Italy","Japan","South Korea","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07123454"},{"nctId":"NCT07684456","title":"Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":308,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced Breast Cancer"],"interventions":["Utidelone Capsule","Utidelone Injection","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized controlled study.The primary objective is to evaluate the Progression-Free Survival(PFS) of Utidelone Capsule combined with Capecitabine compared with Utidelone Injection combined with Capecitabine in patients with HER-2 negative advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07684456"},{"nctId":"NCT05460507","title":"Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment","sponsor":"Plus Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-01","completionType":"ESTIMATED","lastUpdated":"2025-03-30","conditions":["Glioma"],"interventions":["Retreatment Rhenium Liposome"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase 1 study to establish the safety and efficacy/tolerability of a single dose of 186RNL by the intraventricular route (via intraventricular catheter) for recurrence glioma in patients who received a prior treatment of 186RNL.","sourceUrl":"https://clinicaltrials.gov/study/NCT05460507"},{"nctId":"NCT07189403","title":"A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-01","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Advanced or Metastatic Adrenocortical Carcinoma","Metastatic Castration-resistant Prostate Cancer"],"interventions":["DS9051b"],"countries":["United States","France","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07189403"},{"nctId":"NCT05727904","title":"Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":670,"enrollmentType":"ESTIMATED","startDate":"2023-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-01","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Metastatic Melanoma","Unresectable Melanoma","Melanoma"],"interventions":["Lifileucel plus Pembrolizumab","Pembrolizumab with Optional Crossover Period"],"countries":["United States","Australia","Belgium","Canada","Finland","France","Germany","Israel","Italy","Netherlands","Singapore","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":81,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.","sourceUrl":"https://clinicaltrials.gov/study/NCT05727904"},{"nctId":"NCT07586202","title":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2026-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-03","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Amivantamab","Lazertinib","Carboplatin","Pemetrexed"],"countries":["Canada","China","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.","sourceUrl":"https://clinicaltrials.gov/study/NCT07586202"},{"nctId":"NCT07284420","title":"ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","sponsor":"argenx","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-07","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["AChR-Ab Seropositive Generalized Myasthenia Gravis","Myasthenia Gravis","MG","gMG","Generalized Myasthenia Gravis","Generalized Myasthenia Gravis (gMG)"],"interventions":["Efgartigimod IV","Empasiprubart IV"],"countries":["United States","Belgium","Germany","Greece","Italy","Japan","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170 More information can be found here: https://clinicaltrials.argenx.com/adap","sourceUrl":"https://clinicaltrials.gov/study/NCT07284420"},{"nctId":"NCT05142696","title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":55,"enrollmentType":"ACTUAL","startDate":"2022-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-07","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["[177Lu]Lu-DOTA-TATE","Atezolizumab","[68Ga]Ga-DOTA-TATE","Carboplatin","Etoposide"],"countries":["United States","Austria","Canada","China","Czechia","France","Germany","Israel","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"This study aims to establish a safe and well tolerated dose of \\[177Lu\\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.","sourceUrl":"https://clinicaltrials.gov/study/NCT05142696"},{"nctId":"NCT07063329","title":"Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive","sponsor":"Avistone Pharmaceutical（Ningbo）Co., LTD.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2025-08-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-08","completionType":"ESTIMATED","lastUpdated":"2025-07-25","conditions":["NSCLC (Non-small Cell Lung Cancer)"],"interventions":["PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy","RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Tyrosine Kinase Inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with EGFR-TKI, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining PLB1004 with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer. In recent years, clinical studies on the combination of EGFR-TKI and chemotherapy have made important progress, suggesting that the combination of EGFR-TKI and che","sourceUrl":"https://clinicaltrials.gov/study/NCT07063329"},{"nctId":"NCT07340190","title":"A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-07","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Malignancies"],"interventions":["pelabresib","repaglinide","midazolam","drospirenone","ethinyl estradiol"],"countries":["Italy","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B) a single dose of combined drospirenone and ethinyl estradiol. The study will be conducted in adult participants with advanced malignancies for whom no standard or curative treatment options are available.","sourceUrl":"https://clinicaltrials.gov/study/NCT07340190"},{"nctId":"NCT07144280","title":"A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":680,"enrollmentType":"ESTIMATED","startDate":"2025-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-10","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-10","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Non-small Cell Carcinoma","Non-Small Cell Lung Cancer Metastatic","Non-Small Cell Lung Carcinoma"],"interventions":["PF-08046054","Docetaxel monotherapy"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Puerto Rico","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":402,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cancer progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted treatment regimen(s) for participants with known actionable genomic alterations (AGAs). Participants in this study must have cancer that has spread through their body or can't be removed with surgery or treated with definitive radiation. Participants will randomly (like a flip of the coin) be assigned to either the PF-08046054 treatment group or ","sourceUrl":"https://clinicaltrials.gov/study/NCT07144280"},{"nctId":"NCT06943833","title":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":37,"enrollmentType":"ACTUAL","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-13","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Locally Advanced Cervical Cancer"],"interventions":["Volrustomig"],"countries":["Russia"],"northAmerica":false,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT).","sourceUrl":"https://clinicaltrials.gov/study/NCT06943833"},{"nctId":"NCT06926868","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-09-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-13","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-15","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Breast Neoplasms"],"interventions":["Iza-bren","Nab-paclitaxel","Paclitaxel","Capecitabine","Carboplatin","Gemcitabine"],"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","China","Colombia","France","Germany","Greece","India","Israel","Italy","Japan","Mexico","Poland","Portugal","Romania","South Africa","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":295,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06926868"},{"nctId":"NCT07008118","title":"A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-14","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Myeloproliferative Neoplasms"],"interventions":["INCA035784"],"countries":["United States","Australia","Belgium","Germany","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT07008118"},{"nctId":"NCT06616766","title":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","sponsor":"Yuhan Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":161,"enrollmentType":"ESTIMATED","startDate":"2024-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-29","completionType":"ESTIMATED","lastUpdated":"2025-11-04","conditions":["NSCLC (Non-small Cell Lung Cancer)","Solid Tumor"],"interventions":["YH42946"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.","sourceUrl":"https://clinicaltrials.gov/study/NCT06616766"},{"nctId":"NCT07037758","title":"A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2025-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-18","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-18","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["Tarlatamab","AB248"],"countries":["United States","South Korea","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07037758"},{"nctId":"NCT07476287","title":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-19","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-19","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Small Cell Lung Cancer","Small Cell Lung Cancer ( SCLC )","Transformed Small Cell Lung Cancer","Lung Neoplasms","Carcinoma, Small Cell Lung","Small Cell Cancer Of The Lung"],"interventions":["PF-08634404","Chemotherapy"],"countries":["United States","Brazil","China","France","Israel","Japan","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The study is for adults with Transformed Small Cell Lung Cancer (T-SCLC ). T SCLC is a rare lung cancer that happens when one type of lung cancer changes into a more aggressive type after treatment stops working. To join the study, participants must meet the following conditions: * Are aged 18 years or older * Diagnosed with T-SCLC and have not received treatment for this type of lung cancer (a single","sourceUrl":"https://clinicaltrials.gov/study/NCT07476287"},{"nctId":"NCT06305247","title":"A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours","sponsor":"Ipsen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ACTUAL","startDate":"2024-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-20","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-20","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Melanoma","Head and Neck Squamous Cell Carcinoma","Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Solid Tumor"],"interventions":["IPN01194"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).","sourceUrl":"https://clinicaltrials.gov/study/NCT06305247"},{"nctId":"NCT06350097","title":"Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":582,"enrollmentType":"ESTIMATED","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-21","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-29","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Non-small Cell Lung Cancer"],"interventions":["Osimertinib","Datopotamab Deruxtecan"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Hong Kong","India","Italy","Japan","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":166,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study details include: 1. The study duration will be event-driven, with an estimated duration of approximately 8 years. 2. Participants may receive study treatment until disease progression, unacceptable toxicity, or other specific discontinuation criteria are met. 3. The visit frequency will be every 3 weeks during the treatment period. Note: Participants on osimertinib treatment(osimertinib only arm or who ","sourceUrl":"https://clinicaltrials.gov/study/NCT06350097"},{"nctId":"NCT07332455","title":"First-Time-in-Human Study of GSK5471713 in Adults With mCRPC","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2026-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-24","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-26","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Neoplasms, Prostate"],"interventions":["GSK5471713"],"countries":["United States","Australia","Canada","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07332455"},{"nctId":"NCT05137054","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":317,"enrollmentType":"ESTIMATED","startDate":"2022-08-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-25","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-24","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Multiple Myeloma"],"interventions":["Linvoseltamab","Daratumumab","Carfilzomib","Lenalidomide","Bortezomib","Pomalidomide","Isatuximab","Fianlimab","Cemiplimab","Nirogacestat","Cevostamab"],"countries":["United States","France","Greece","Israel","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evidence of myeloma in their bodies). This study is the first time linvoseltamab will be combined with other cancer therapies. The main goal is to understand if linvoseltamab can be given safely with other","sourceUrl":"https://clinicaltrials.gov/study/NCT05137054"},{"nctId":"NCT07140900","title":"Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Metastatic Hormone-sensitive Prostate Cancer (mHSPC)"],"interventions":["Xaluritamig","Darolutamide","Abiraterone"],"countries":["United States","Australia","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.","sourceUrl":"https://clinicaltrials.gov/study/NCT07140900"},{"nctId":"NCT07136181","title":"Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","sponsor":"Novelwise Pharmaceutical Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Metastatic Uveal Melanoma","Uveal Melanoma, Metastatic","Uveal Melanoma, Recurrent","Eye Cancer, Intraocular Melanoma","Eye Cancer"],"interventions":["NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers."],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body. The study will help doctors learn about the side effects of NBM-BMX, how the drug is processed in the body, and whether it may slow down or shrink tumors. Participants will take NBM-BMX as a capsule by mouth twice daily on an empty stomach with at least six ounces (180 mL) of water. No food or drink (other than water) should be consumed for at least two hours after each dose. Participants will visit the clinic about once every week or two for exams and blood tests while taking NBM-BMX. After stoppi","sourceUrl":"https://clinicaltrials.gov/study/NCT07136181"},{"nctId":"NCT07369895","title":"Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma","sponsor":"O&D BioTech Group CO., Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-10-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-28","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a single-center, open and dose-escalation clinical study to evaluate the safety, tolerability, PK/PD characteristics and preliminary efficacy of the investigational drug O\\&D-001 injection in the treatment of relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07369895"},{"nctId":"NCT06091865","title":"A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":904,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Diffuse Large B-cell Lymphoma (DLBCL)"],"interventions":["Odronextamab","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone/Prednisolone"],"countries":["United States","Australia","Austria","Belgium","Chile","Czechia","France","Germany","Ireland","Israel","Italy","Malaysia","Poland","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":172,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called \"previously untreated\"). Patients with DLBCL that have come back after treatment (called \"relapsed\"), or have not responded to treatment (called \"refractory\"), can also participate in this study. This study will be made up of Part 1A, Part 1B, and Part 2.The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to ","sourceUrl":"https://clinicaltrials.gov/study/NCT06091865"},{"nctId":"NCT06781125","title":"One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","sponsor":"Immorna Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Malignant Solid Tumors"],"interventions":["JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06781125"},{"nctId":"NCT06877650","title":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":436,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Advanced Malignant Tumors"],"interventions":["JMT108","Pembrolizumab","Ivonescimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06877650"},{"nctId":"NCT05316155","title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":235,"enrollmentType":"ACTUAL","startDate":"2022-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-24","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"interventions":["Erdafitinib Intravesical Delivery System"],"countries":["United States","Canada","Germany","Israel","Japan","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\\[s\\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion; MoonRISe-2) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).","sourceUrl":"https://clinicaltrials.gov/study/NCT05316155"},{"nctId":"NCT06644768","title":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":137,"enrollmentType":"ESTIMATED","startDate":"2024-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Non-small Cell Lung Cancer","Lung Cancer"],"interventions":["valemetostat tosylate","pembrolizumab"],"countries":["United States","Argentina","Brazil","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations","sourceUrl":"https://clinicaltrials.gov/study/NCT06644768"},{"nctId":"NCT07718737","title":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy","sponsor":"Multitude Therapeutics Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":512,"enrollmentType":"ESTIMATED","startDate":"2026-08-28","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["AMT-116","Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This clinical trial consists of two parts: phase 2 and phase 3. The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype non-small cell lung cancer (NSCLC) in adults. It will also learn about the safety of AMT-116. The main questions it aims to answer are: * Which level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC? * What medical problems do participants have when taking AMT-116? The goal of phase 3 of this clinical trial is to compare AMT-116 to study doctor's choice (a kind of retainable treatment for you in the opinion of the study doctor) to see ","sourceUrl":"https://clinicaltrials.gov/study/NCT07718737"},{"nctId":"NCT07609823","title":"A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2026-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"interventions":["Lacutoclax"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Lacutoclax is a potent and selective BCL-2 inhibitor with relatively weaker inhibitory activity against BCL-XL and BCL-W. Preliminary clinical data have demonstrated promising efficacy and an acceptable safety profile in patients with CLL/SLL and other B-cell non-Hodgkin lymphomas (B-NHLs). This is an open-label, single-arm, multicenter Phase II study evaluating the efficacy and safety of oral Lacutoclax tablets in patients with relapsed or refractory CLL/SLL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07609823"},{"nctId":"NCT02174549","title":"Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer","sponsor":"Teclison Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2014-09","startDateType":"","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Hepatocellular Carcinoma","Gastrointestinal Cancer Metastatic","Neuroendocrine Tumors"],"interventions":["Tirapazamine","Conventional Transarterial Embolization (TAE)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapazamine will be given by intra-arterial injection before embolization. Treatment effect is evaluated by MRI based on mRECIST criteria. Repeat treatment is necessary only if disease progression. Dose escalation cohort has been completed. Expansion cohort is open for metastatic liver dominant neuroendocrine tumor.","sourceUrl":"https://clinicaltrials.gov/study/NCT02174549"},{"nctId":"NCT07083323","title":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":262,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Advanced Solid Tumor"],"interventions":["HY05350 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07083323"},{"nctId":"NCT03998254","title":"Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":6000,"enrollmentType":"ESTIMATED","startDate":"2019-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Papillomavirus Infections"],"interventions":["V503","Gardasil"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age. The primary hypotheses are: 9vHPV vaccine reduces the incidence of HPV 31-, 33-, 45-, 52-, and 58-related 12-month persistent infection at least 1 month post Dose 3, compared with quadrivalent HPV (qHPV) vaccine in women 20 to 45 years of age who are seronegative at Day 1 and polymerase chain reaction (PCR) negative Day 1 through Month 7 to the relevant HPV type; and 9vHPV vaccine induces non-inferior competitive luminex immunoassay (cLIA) geometric mean titers (GMTs) for each of HPV 6, 11, 16, and 18 one month post Dose 3, compared w","sourceUrl":"https://clinicaltrials.gov/study/NCT03998254"},{"nctId":"NCT07378098","title":"to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia","sponsor":"JW Pharmaceutical","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2026-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-03","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Menorrhagia","Uterine Fibroids"],"interventions":["KLH-2109+ Leurprorelin acetate Placebo","KLH-2109 Placebo + Leurprorelin acetate"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial was to determine whether the investigational drug KLH-2109 is effective for treating excessive menstrual bleeding in patients with uterine fibroids. Uterine fibroids are benign tumors that grown in the uterus. The primary objectives of this trial were to answer the following questions: * Does KLH-2109 lower the amount of menstrual bleeding? * Does KLH-2109 reduce menstrual bleeding? * Is KLH-2109 safe for participants to use? Investigators will compare KLH-2109 with a standard of care treatment (control) to determine which treatment is more effective. Participants will be required to follow: * Take either KLH-2109 or the common treatment as a pill * Visit the ","sourceUrl":"https://clinicaltrials.gov/study/NCT07378098"},{"nctId":"NCT07287150","title":"A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["Inavolisib","Enzalutamide","Abiraterone","Docetaxel"],"countries":["United States","Australia","Brazil","Canada","France","Germany","Italy","Mexico","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.","sourceUrl":"https://clinicaltrials.gov/study/NCT07287150"},{"nctId":"NCT05523947","title":"Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor","sponsor":"Yuhan Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":147,"enrollmentType":"ESTIMATED","startDate":"2022-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["HER2-Positive Solid Tumor"],"interventions":["YH32367"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["HER2 profiling"],"summary":"This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05523947"},{"nctId":"NCT06041802","title":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":19,"enrollmentType":"ESTIMATED","startDate":"2023-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Squamous Cell Carcinoma"],"interventions":["Pembrolizumab (+) Berahyaluronidase alfa"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of subcutaneous (SC) pembrolizumab (+) berahyaluronidase alfa in Japanese participants with recurrent or metastatic cutaneous squamous cell carcinoma or locally advanced unresectable cSCC. The primary hypothesis is that pembrolizumab (+) berahyaluronidase alfa will result in greater than 10% objective response rate (ORR) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT06041802"},{"nctId":"NCT07179692","title":"CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2025-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Lung Cancer","Gastric Cancer","Colon Cancer","Rectal Cancer","Esophageal Cancer","Pancreas Cancer"],"interventions":["CEA-targeted CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.","sourceUrl":"https://clinicaltrials.gov/study/NCT07179692"},{"nctId":"NCT04111458","title":"A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":71,"enrollmentType":"ACTUAL","startDate":"2019-11-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumors, KRAS Mutation; SOS1"],"interventions":["BI 1701963","Trametinib"],"countries":["United States","Germany","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["RAS genotyping"],"summary":"This is a study in adults with advanced cancer (solid tumours) in whom previous chemotherapy was not successful. Only people who have a tumour with a KRAS mutation can participate in the study. A KRAS mutation makes cancer grow faster. The study tests 2 medicines called BI 1701963 and trametinib. BI 1701963 prevents reactivation of KRAS. In this study, BI 1701963 is given to humans for the first time. Trametinib is an approved medicine (MEK inhibitor). The purpose of this study is to find out the highest dose of BI 1701963 alone and in combination with trametinib the participants can tolerate. Another purpose is to check whether BI 1701963 in combination with trametinib is able to make tumou","sourceUrl":"https://clinicaltrials.gov/study/NCT04111458"},{"nctId":"NCT06483334","title":"A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2024-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Metastatic Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma"],"interventions":["Sacituzumab tirumotecan","Enfortumab Vedotin","Pembrolizumab","Supportive care measures"],"countries":["United States","Canada","France","Israel","Italy","Netherlands","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"This study is a substudy being conducted under one pembrolizumab umbrella master study KEYMAKER-U04. The substudy will consist of 2 parts. Part 1 will evaluate the safety and preliminary efficacy of sacituzumab tirumotecan plus enfortumab vedotin (EV). Part 2 will be based on Part 1 results and will evaluate the efficacy, pharmacokinetics, and safety of sacituzumab tirumotecan plus EV in combination with pembrolizumab in participants with advanced urothelial carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06483334"},{"nctId":"NCT06414460","title":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","sponsor":"InSilico Medicine Hong Kong Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2025-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Locally Advanced/Metastatic Solid Tumors"],"interventions":["ISM3412"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.","sourceUrl":"https://clinicaltrials.gov/study/NCT06414460"},{"nctId":"NCT07649655","title":"EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Unresectable/Metastatic Colorectal Cancer"],"interventions":["EMB-01","Irinotecan","TAS-102","mFOLFOX6","FOLFIRI"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase Ib trial designed to evaluate the safety, tolerability, and preliminary efficacy of EMB-01 in combination with chemotherapy in patients with unresectable or metastatic colorectal cancer (CRC), and to determine the recommended Phase II combination dose (RP2CD). The study consists of a dose escalation phase followed by a dose expansion phase. Approximately 30 patients are planned to be enrolled in each combination treatment group across both phases, with a maximum total enrollment of approximately 120 patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07649655"},{"nctId":"NCT07229313","title":"A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Kivu Bioscience Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-31","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Advance Solid Tumors"],"interventions":["KIVU-107"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229313"},{"nctId":"NCT04408638","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2021-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Diffuse Large B-cell Lymphoma"],"interventions":["Obinutuzumab","Glofitamab","Rituxumab","Tocilizumab","Gemcitabine","Oxaliplatin"],"countries":["United States","Australia","Belgium","China","Denmark","France","Germany","Poland","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":63,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT04408638"},{"nctId":"NCT07465757","title":"A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)","sponsor":"Puma Biotechnology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Small Cell Lung Cancer ( SCLC )"],"interventions":["Alisertib","Paclitaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to determine how well people tolerate treatment with alisertib at different doses when it is used together with paclitaxel to treat people with SCLC. The main question it aims to answer is: * What percentage of side effects, both mild and serious, do participants experience when being treated with alisertib and paclitaxel based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v.5.0)? The study will consist of different groups, called cohorts, in which alisertib will be studied at increasing doses. Participants in the first group, Cohort 1, will take 30 mg of alisertib by mouth 2 times a day. The dose wil","sourceUrl":"https://clinicaltrials.gov/study/NCT07465757"},{"nctId":"NCT06842498","title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Kyntra Bio","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2026-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["FG-3246"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06842498"},{"nctId":"NCT07181720","title":"CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Renal Cell Carcinoma (RCC)","Lung Cancer","Anaplastic Thyroid Carcinomas","Ovarian Cancer","Cervical Cancer","Thymic Carcinoma"],"interventions":["CD70-targeted CAR-T cells"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CD70-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CD70-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CD70-positive advanced malignancies were obtained and the recommended dose and infusion schedule.","sourceUrl":"https://clinicaltrials.gov/study/NCT07181720"},{"nctId":"NCT07483554","title":"IBI343 in Combination Therapy for Advanced Malignant Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":389,"enrollmentType":"ESTIMATED","startDate":"2026-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["CLDN18.2 Positive","Gastric/Gastroesophageal Junction Adenocarcinoma","Pancreatic Ductal Adenocarcinoma"],"interventions":["IBI343,Gemcitabine, Albumin-bound Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination therapy for patients with advanced malignant solid tumors.Enrollment of subjects with advanced gastric/gastroesophageal junction adenocarcinoma positive for CLDN18.2, and subjects with pancreatic ductal adenocarcinoma positive for CLDN18.2.","sourceUrl":"https://clinicaltrials.gov/study/NCT07483554"},{"nctId":"NCT07652281","title":"A Clinical Study of SHR-5421 in Patients With Multiple Myeloma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":97,"enrollmentType":"ESTIMATED","startDate":"2026-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Multiple Myeloma"],"interventions":["SHR-5421 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-5421 in patients with multiple myeloma (MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT07652281"},{"nctId":"NCT06979674","title":"Study of ESG406 in Adults With Solid Tumors","sponsor":"Shanghai Escugen Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":556,"enrollmentType":"ESTIMATED","startDate":"2025-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2025-09-12","conditions":["Locally Advanced/Metastatic Solid Tumors"],"interventions":["ESG406"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.","sourceUrl":"https://clinicaltrials.gov/study/NCT06979674"},{"nctId":"NCT07168200","title":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":720,"enrollmentType":"ESTIMATED","startDate":"2025-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Advanced Cervical Cancer"],"interventions":["SHR-1316 Injection","Cisplatin Injection","Carboplatin Injection","Paclitaxel Injection","SHR-1316 Placebo Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT07168200"},{"nctId":"NCT06885840","title":"Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2025-03-20","conditions":["Non-Small Cell Lung Cancer"],"interventions":["MCLA-129"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["MET profiling"],"summary":"This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy, safety, pharmacokinetic characteristics of MCLA-129.","sourceUrl":"https://clinicaltrials.gov/study/NCT06885840"},{"nctId":"NCT07324629","title":"Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Thymic Carcinoma"],"interventions":["Sacituzumab tirumotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are: * How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT? Participants will: * Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07324629"},{"nctId":"NCT07469891","title":"A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms","sponsor":"Prelude Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Polycythemia Vera (PV)","Myelofibrosis (MF)","Myeloproliferative Neoplasms (MPNs)","Post-Polycythemia Vera Myelofibrosis","Post-Essential Thrombocythemia Myelofibrosis","Primary Myelofibrosis (PMF)"],"interventions":["PRT12396"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\\[s\\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT07469891"},{"nctId":"NCT07524322","title":"Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors","sponsor":"Regor Pharmaceuticals Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Breast Cancer","Ovarian Cancer","Endometrial Cancer","PIK3CA Mutation","HER2- Negative Breast Cancer","Advanced Breast Cancer","Unresectable Solid Tumor","Hormone Receptor Positive Tumor","Cervical Cancer"],"interventions":["RGT-490"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["HER2 profiling"],"summary":"This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.","sourceUrl":"https://clinicaltrials.gov/study/NCT07524322"},{"nctId":"NCT06781983","title":"Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors","sponsor":"Innate Pharma","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":145,"enrollmentType":"ESTIMATED","startDate":"2025-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["IPH4502"],"countries":["United States","France"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4","sourceUrl":"https://clinicaltrials.gov/study/NCT06781983"},{"nctId":"NCT06800313","title":"Study of HLD-0915 in Patients With Metastatic Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Metastatic Prostate Cancer"],"interventions":["HLD-0915 Hard Capsule","HLD-0915 Tablet","HLD-0915 Soft Capsule"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"Assessment of the safety and efficacy of HLD-0915 in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06800313"},{"nctId":"NCT06835400","title":"Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer","sponsor":"Health Hope Pharma","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Metastatic Breast Cancer"],"interventions":["Paclitaxel Capsule","IV Paclitaxel","Encequidar tablet"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT06835400"},{"nctId":"NCT07349537","title":"Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":574,"enrollmentType":"ESTIMATED","startDate":"2026-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","PDAC","CRC","NSCLC","Pancreatic Cancer","Lung Cancer (NSCLC)","Advanced Solid Tumors"],"interventions":["RMC-5127","daraxonrasib","cetuximab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07349537"},{"nctId":"NCT07514975","title":"First-In-Human Study of KHN922 for Injection","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":276,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Advanced Solid Tumors Cancer"],"interventions":["KHN922 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07514975"},{"nctId":"NCT07479485","title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","sponsor":"Lepu Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Hepatocellular Carcinoma"],"interventions":["MRG006A","Pucotenlimab","Bevacizumab","PD1/VEGF antibody","TKI"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of MRG006A in combination with immune checkpoint inhibitors and targeted therapy in patients with advanced hepatocellular carcinoma (HCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07479485"},{"nctId":"NCT06788990","title":"FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC","sponsor":"Bicara Therapeutics","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":650,"enrollmentType":"ESTIMATED","startDate":"2025-01-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Metastatic Head and Neck Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma"],"interventions":["Ficerafusp alfa","Pembrolizumab (KEYTRUDA®)","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Greece","India","Ireland","Israel","Italy","Malaysia","New Zealand","Poland","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":203,"serviceSignals":["Broad CGP"],"summary":"Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06788990"},{"nctId":"NCT05840211","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":654,"enrollmentType":"ESTIMATED","startDate":"2023-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-04","completionType":"ESTIMATED","lastUpdated":"2025-10-03","conditions":["Locally Advanced or Unresectable Metastatic Breast Cancer","Stage IV Breast Cancer"],"interventions":["Sacituzumab Govitecan-hziy","Paclitaxel","Nab-paclitaxel","Capecitabine"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Poland","Portugal","Singapore","South Africa","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":288,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT05840211"},{"nctId":"NCT07244705","title":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","sponsor":"Anbogen Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-11","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Colorectal Cancer (Diagnosis)","Colorectal Cancer Metastatic","Colorectal Cancer (CRC)","Immunotherapy"],"interventions":["ABT-301","Tislelizumab","Bevacizumab (Avastin)"],"countries":["Australia","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of ABT-301 in combination with fixed doses of tislelizumab 200 mg IV infusion and bevacizumab 7.5 mg/kg IV infusion Q3W, in participants with pMMR/non-MSI-H colorectal cancer (CRC). It will also determine the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) of ABT-301. Participants will receive ABT-301 administered once daily (QD ±3 hours) or twice daily (Q12H ±3 hours, at least 9 hours apart) with water in 21-day treatment cycles. Tislelizumab 200 mg IV and bevacizumab 7.5 mg/kg IV Q3W will be given in both parts of the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07244705"},{"nctId":"NCT07624214","title":"Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors","sponsor":"Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"interventions":["LT-010391"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07624214"},{"nctId":"NCT07490613","title":"A Phase I Study of SHR-3836 in Patients With Multiple Myeloma","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2026-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Multiple Myeloma"],"interventions":["SHR-3836 administered as multiple doses."],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT07490613"},{"nctId":"NCT07011719","title":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":720,"enrollmentType":"ESTIMATED","startDate":"2025-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Metastatic Clear Cell Renal Cell Carcinoma","Advanced Clear Cell Renal Cell Carcinoma"],"interventions":["Casdatifan","Cabozantinib","Placebo"],"countries":["United States","Argentina","Australia","Canada","Czechia","France","Germany","Italy","Japan","Netherlands","New Zealand","Poland","Romania","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":159,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07011719"},{"nctId":"NCT07551778","title":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","sponsor":"BOE Technology Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)","Colorectal Cancer","Advanced Solid Tumors"],"interventions":["NK Cells","NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy","NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of allogeneic natural killer (NK) cell injection combined with standard maintenance therapy in patients with locally advanced or metastatic solid tumors. The study consists of three cohorts: Cohort 1 (advanced non-squamous NSCLC with NK cells + PD-(L)1 inhibitor + pemetrexed), Cohort 2 (advanced colorectal adenocarcinoma with NK cells + cetuximab/bevacizumab + capecitabine), and Cohort 3 (lymphodepletion exploration cohort with fludarabine + cyclophosph preconditioning followed by NK cells + PD-(L)1 inhibitor + pemetrexed).","sourceUrl":"https://clinicaltrials.gov/study/NCT07551778"},{"nctId":"NCT06767514","title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","sponsor":"Summit Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":780,"enrollmentType":"ESTIMATED","startDate":"2025-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Ivonescimab Injection","Pembrolizumab Injection"],"countries":["United States","Belgium","Canada","China","France","Germany","Greece","Hungary","Italy","Japan","Mexico","Poland","Portugal","Romania","Serbia","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":270,"serviceSignals":["Broad CGP"],"summary":"Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.","sourceUrl":"https://clinicaltrials.gov/study/NCT06767514"},{"nctId":"NCT06346067","title":"A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)","sponsor":"Erasca, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ACTUAL","startDate":"2024-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced or Metastatic NRAS-mutant Melanoma"],"interventions":["Naporafenib","Dacarbazine","Temozolomide","Trametinib"],"countries":["United States","Australia","Canada","Czechia","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["RAS genotyping"],"summary":"Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).","sourceUrl":"https://clinicaltrials.gov/study/NCT06346067"},{"nctId":"NCT07480356","title":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","sponsor":"Protara Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":284,"enrollmentType":"ESTIMATED","startDate":"2026-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2032-11","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Bladder (Urothelial, Transitional Cell) Cancer","Non-Muscle Invasive Bladder Carcinoma","Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"],"interventions":["TARA-002","Investigator's Choice of Intravesical Chemotherapy"],"countries":["United States","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe? * What are the side effects of the study drug? Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07480356"},{"nctId":"NCT07306832","title":"A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Acute Myeloid Leukemia"],"interventions":["Pivekimab Sunirine"],"countries":["United States","Australia","France","Italy","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse events and how pivekimab sunirine moves through the body in pediatric participants with relapsed or refractory (R/R) AML. Pivekimab sunirine is a drug being evaluated in the treatment of AML. This is an open label, single arm study, participants will be enrolled in 1 of the 3 cohorts based on their age and will receive pivekimab sunirine at a dose based on their weight. Around 18 pediatric participants with a diagnosis of AML will be enrolled in the study at approximately 30 sites around the world. ","sourceUrl":"https://clinicaltrials.gov/study/NCT07306832"},{"nctId":"NCT06345482","title":"A Study of MHB039A for Advanced Solid Tumor","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":196,"enrollmentType":"ESTIMATED","startDate":"2024-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-01","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["Advanced Solid Tumor"],"interventions":["MHB039A"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06345482"},{"nctId":"NCT07419841","title":"A Phase 1 Study of the Safety and Tolerability of CTX-10726","sponsor":"Compass Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Gastroesophageal Cancer (GC)","Hepatocellular Carcinoma (HCC)","Endometrial Cancer","Renal Cell Carcinoma (RCC)"],"interventions":["CTX-10726"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07419841"},{"nctId":"NCT07066397","title":"A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL","sponsor":"TriArm Therapeutics (Taiwan) Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2041-04-01","completionType":"ESTIMATED","lastUpdated":"2025-07-23","conditions":["Acute Lymphoblastic Leukemia"],"interventions":["ARM011","Fludarabine","Cyclophosphamide"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07066397"},{"nctId":"NCT06667960","title":"Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer","sponsor":"Salubris Biotherapeutics Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":255,"enrollmentType":"ESTIMATED","startDate":"2024-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Solid Tumor"],"interventions":["JK06"],"countries":["Belgium","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06667960"},{"nctId":"NCT07747935","title":"Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma","sponsor":"ReBio Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-01","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Uveal Melanoma"],"interventions":["RBP-01"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Neoadjuvant RBP-01 in patients with primary uveal melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07747935"},{"nctId":"NCT05557045","title":"A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815","sponsor":"Jazz Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":332,"enrollmentType":"ESTIMATED","startDate":"2022-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-01","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Advanced Cancer","Metastatic Cancer","Solid Tumor"],"interventions":["JZP815"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.","sourceUrl":"https://clinicaltrials.gov/study/NCT05557045"},{"nctId":"NCT06919965","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-16","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"interventions":["TAR-210","Mitomycin C","Gemcitabine"],"countries":["United States","Argentina","Belgium","Brazil","China","France","Germany","Greece","Israel","Italy","Japan","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":112,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06919965"},{"nctId":"NCT06646276","title":"A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":530,"enrollmentType":"ESTIMATED","startDate":"2025-02-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-05","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Extensive-Stage Small Cell Lung Cancer"],"interventions":["BMS-986489 (BMS-986012+Nivolumab)","Atezolizumab","Carboplatin","Etoposide"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","India","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Romania","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":183,"serviceSignals":["Broad CGP"],"summary":"The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06646276"},{"nctId":"NCT06756451","title":"This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.","sponsor":"Nanjing RegeneCore Biotech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-14","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Hematologic Malignancies"],"interventions":["RJK-RT2831 dose-escalation phase Ia","RJK-RT2831 Dose Expansion Phase Ib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"This study is a first-in-human (FIH) study which is required to understand the safety, tolerability, pharmacokinetics and preliminary efficacy of RJK-RT2831 injection in patients with hematologic malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06756451"},{"nctId":"NCT06712680","title":"A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-10","completionType":"ESTIMATED","lastUpdated":"2025-12-23","conditions":["Solid Tumor"],"interventions":["Test Product HYP-6589"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center , open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of HYP-6589 in monotherapy in advanced solid tumors and combination with tyrosine kinase inhibitors in patients with advanced NSCLC with target-driven gene positivity.","sourceUrl":"https://clinicaltrials.gov/study/NCT06712680"},{"nctId":"NCT07360132","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2026-01-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-10","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Squamous Non-small Cell Lung Cancer"],"interventions":["Carboplatin Injection","Paclitaxel Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, controlled, double-blind, multi-center phase III registration clinical trial, aiming to observe, compare and evaluate the efficacy and safety of HB0025 combined with paclitaxel + carboplatin compared with pembrolizumab combined with paclitaxel + carboplatin as the first-line treatment for locally advanced or metastatic squamous NSCLC. The study subjects are patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) who have not received systemic anti-tumor treatment before. The study will use the PFS evaluated by BICR as the primary endpoint, and plan to enroll approximately 480 subjects, with the proportion of locally advanced subjec","sourceUrl":"https://clinicaltrials.gov/study/NCT07360132"},{"nctId":"NCT07383116","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2026-01-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-10","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Non Squamous Non-small Cell Lung Cancer"],"interventions":["Pemetrexed injection","Carboplatin Injection","Cisplatin injection","HB0025 Injection","Tislelizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, controlled, double-blind, multicenter Phase III registration clinical trial, aiming to evaluate the efficacy and safety of HB0025 combined with chemotherapy (pemetrexed plus carboplatin/cisplatin) versus tislelizumab combined with chemotherapy (pemetrexed plus carboplatin/cisplatin) as a first-line treatment for unresectable locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) nonsquamous non-small cell lung cancer (NSCLC). The study will take progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) as the primary endpoint, and plans to enroll approximately 500 subjects. After being eligible for screening, patients will be rando","sourceUrl":"https://clinicaltrials.gov/study/NCT07383116"},{"nctId":"NCT07149857","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-10-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-06","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Cilta-cel","Cyclophosphamide","Induction therapy","Fludarabine"],"countries":["United States","Australia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT07149857"},{"nctId":"NCT07643870","title":"Human ADME Study of [14C]-AZD1390","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-12","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Advanced Solid Malignancies"],"interventions":["AZD1390"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of \\[14C\\]-AZD1390.","sourceUrl":"https://clinicaltrials.gov/study/NCT07643870"},{"nctId":"NCT06533644","title":"A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Syncromune, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":91,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-14","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["Partial Oncolysis","SV-102"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06533644"},{"nctId":"NCT05890742","title":"A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":453,"enrollmentType":"ACTUAL","startDate":"2023-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-15","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["MSI-H"],"interventions":["Sintilimab","IBI310&Sintilimab","Radical surgery"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"Evaluate efficacy and safety of IBI310 (CTLA-4 antibody) in combination with Sintilimab, for neoadjuvant treatment of MSI-H/dMMR resectable colon cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05890742"},{"nctId":"NCT06948981","title":"GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies","sponsor":"Grit Biotechnology","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2025-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2025-09-16","conditions":["Hematological Malignancy (Leukemia- Lymphoma)"],"interventions":["GT719 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a prospective single-arm open-labled phase I/II clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 46 subjects (anticipated) will be enrolled in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06948981"},{"nctId":"NCT06973187","title":"A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-09-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-17","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["BGB-16673","Pirtobrutinib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","China","France","Germany","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Puerto Rico","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":204,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).","sourceUrl":"https://clinicaltrials.gov/study/NCT06973187"},{"nctId":"NCT07094113","title":"AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":434,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-18","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-20","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["KRAS Altered Advanced or Metastatic Solid Tumors"],"interventions":["AMG 410","Pembrolizumab","Panitumumab"],"countries":["United States","Australia","Belgium","Canada","China","Denmark","France","Germany","Italy","Japan","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in participants with advanced or metastatic solid tumors harboring KRAS alterations. This is a dose-escalation study in which participants will be assigned to multiple dose levels (DLs) of AMG 410, either as monotherapy or in combination with other agents, followed by expansion cohorts. The goal is to determine the Maximum Tolerated Dose (MTD)-the highest dose with acceptable safety and manageable side effects-or the Recommended Phase 2 Dose (RP2D) of AMG 410 in adult par","sourceUrl":"https://clinicaltrials.gov/study/NCT07094113"},{"nctId":"NCT03460977","title":"A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":453,"enrollmentType":"ESTIMATED","startDate":"2018-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-20","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-07","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)","Small Cell Lung Cancer (SCLC)","Follicular Lymphoma (FL)"],"interventions":["Mervometostat (PF-06821497)","Enzalutamide","Itraconazole"],"countries":["United States","Bulgaria","China","Japan","Poland","Russia","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":82,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consi","sourceUrl":"https://clinicaltrials.gov/study/NCT03460977"},{"nctId":"NCT06907615","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":243,"enrollmentType":"ESTIMATED","startDate":"2025-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-20","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-04","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Non Small Cell Lung Cancer"],"interventions":["HLX43 DOSE 1 (2.0 mg/kg)","HLX43 DOSE 2 (2.5 mg/kg)"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06907615"},{"nctId":"NCT07361705","title":"Zorifertinib With Osimertinib for NSCLC With Meningeal Progression","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-23","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-15","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment"],"interventions":["Zorifertinib and Osimertinib Combination Therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal metastases) after being treated with Osimertinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT07361705"},{"nctId":"NCT05355701","title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":267,"enrollmentType":"ESTIMATED","startDate":"2022-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-25","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Melanoma","Non-Small-Cell Lung Cancer","Thyroid Cancer","Glioma","Advanced Colorectal Cancer (Part 1)"],"interventions":["PF-07799933","binimetinib","cetuximab","midazolam","fluorouracil","leucovorin","oxaliplatin"],"countries":["United States","Canada","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called \"BRAF\" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine: * People with melanoma or other solid tumors may also receive binime","sourceUrl":"https://clinicaltrials.gov/study/NCT05355701"},{"nctId":"NCT06911502","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-24","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-31","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Follicular Lymphoma"],"interventions":["Golcadomide","Rituximab","Lenalidomide","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone/Prednisolone","Bendamustine"],"countries":["United States","Australia","Brazil","Canada","Chile","China","Finland","France","Germany","Greece","India","Italy","Japan","Netherlands","Poland","Saudi Arabia","South Korea","Spain","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":160,"serviceSignals":["Hematology NGS"],"summary":"The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06911502"},{"nctId":"NCT05939414","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2024-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-25","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-03","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Oligometastatic Prostate Cancer (OMPC)"],"interventions":["AAA617"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Colombia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Puerto Rico","Singapore","Slovakia","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":144,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will provide evidence for the treatment of AAA617 in early-stage prostate cancer patients to control recurrent tumor from progressing to fatal metastatic disease while preserving quality of life by delaying treatment with androgen deprivation therapy (ADT).","sourceUrl":"https://clinicaltrials.gov/study/NCT05939414"},{"nctId":"NCT06246643","title":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","sponsor":"Bayer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":13,"enrollmentType":"ESTIMATED","startDate":"2024-01-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-27","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Solid Malignant Tumors"],"interventions":["Regorafenib (Stivarga, BAY73-4506)"],"countries":["France","Japan","South Korea","Spain","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Regorafenib is an anti-cancer drug that blocks several proteins which are involved in the growth of cancer. It has been approved for different types of cancers of the digestive system and is being tested for use in some other solid tumors. Cancers that start in an organ, a muscle, or a bone form a solid tumor. This study is for participants with solid tumors who have been taking regorafenib in other Bayer studies. They can continue taking regorafenib if it is working when treatment with regorafenib in their previous study ends. The main purpose of this study is to find: * How safe is the continued treatment with regorafenib in participants with solid tumors? * How well is the continued treat","sourceUrl":"https://clinicaltrials.gov/study/NCT06246643"},{"nctId":"NCT07550842","title":"A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer","sponsor":"Shanghai Best-Link Bioscience, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2026-06-16","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-18","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Small Cell Carcinoma of Lung"],"interventions":["BL0020","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally. Globally, lung cancer is the leading cause of cancer-related deaths in men and the second leading cause in women after breast cancer. Among them, small cell lung cancer (SCLC) accounts for approximately 14% of all newly diagnosed lung cancers. Small cell lung cancer (SCLC) is a highly heterogeneous and aggressive disease with poor survival outcomes. A 2-stage system dividing patients into limited and extensive disease was developed in 1973 by the United States (US) Veteran's Administration Lung Cancer Study Group (VALG), ","sourceUrl":"https://clinicaltrials.gov/study/NCT07550842"},{"nctId":"NCT07377643","title":"IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer","sponsor":"Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2026-02-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["HER2-positive Breast Cancer"],"interventions":["Trastuzumab","IBI354","Docetaxel","Pertuzumab","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a randomized, multicenter, open-label, phase 3 study evaluating the efficacy, safety, and tolerability of IBI354 combined with or without pertuzumab vs. THP as first-line treatment for HER2-positive unresectable, locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07377643"},{"nctId":"NCT06435429","title":"A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer","sponsor":"Jazz Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2024-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-18","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Metastatic HER2-positive Breast Cancer"],"interventions":["Zanidatamab","Trastuzumab","Eribulin","Vinorelbine","Gemcitabine","Capecitabine"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","France","Germany","Greece","Italy","Japan","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":166,"serviceSignals":["HER2 profiling"],"summary":"The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06435429"},{"nctId":"NCT07109219","title":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":83,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-03","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["B-cell Acute Lymphoblastic Leukemia (B-ALL)"],"interventions":["AZD4512 monotherapy"],"countries":["United States","Australia","Canada","China","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07109219"},{"nctId":"NCT06803680","title":"A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-29","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["BGB-B455","Chemotherapy"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":13,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims to answer are: * What is the recommended dosing for BGB-B455? * What medical problems do participants have when taking BGB-B455? The study has two parts: * Phase 1a: dose escalation and safety expansion * Phase 1b: dose expansion","sourceUrl":"https://clinicaltrials.gov/study/NCT06803680"},{"nctId":"NCT07472790","title":"A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma","sponsor":"Beijing Bio-Targeting Therapeutics Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["High-grade Glioma"],"interventions":["Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A single-arm clinical study on the efficacy and safety of the novel oncolytic virus Ad-TD-nsIL12 combined with PD-1 inhibitors in the treatment of recurrent high-grade glioma","sourceUrl":"https://clinicaltrials.gov/study/NCT07472790"},{"nctId":"NCT07624864","title":"A Study to Evaluate the Safety, Tolerability, PK and Efficacy of Hemay5087 in Patients With Advanced Solid Tumors","sponsor":"Ganzhou Hemay Pharmaceutical Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Solid Tumors"],"interventions":["Hemay5087"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"An open-label phase I clinical study,which enrolled subjects with advanced solid tumors who have failed to respond to adequate standard therapies or have no available effective standard therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07624864"},{"nctId":"NCT06747455","title":"BCG for Therapeutic Use Phase Ⅲ Clinical Trial","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":439,"enrollmentType":"ACTUAL","startDate":"2025-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["BCG"],"interventions":["BCG for Therapeutic Use","BCG for Therapeutic Use ( BI SAI JI )"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Research topic: A randomized, double-blind, active-controlled, multicenter phase III clinical trial evaluating the efficacy and safety of therapeutic BCG for the prevention of postoperative recurrence of non-muscle-invasive bladder cancer in people aged 18 years and older. The name of the drug: Bacillus Calmette-Guérin for treatment(BCG). Clinical indications: It is used for the treatment of bladder carcinoma in situ and the prevention of recurrence, and for the prevention of recurrence of bladder papilloma after transurethral resection in Ta or T1 stage. This product is not used for papillomas beyond the T1 stage. Study population: Patients aged 18 years and above with intermediate- and hig","sourceUrl":"https://clinicaltrials.gov/study/NCT06747455"},{"nctId":"NCT02802423","title":"Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.","sponsor":"BioLite, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2027-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-28","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Triple Negative Breast Cancer"],"interventions":["BLEX 404 Oral Liquid"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to determine the safety and recommended dose level (RDL) of BLEX 404 Oral Liquid combined with Docetaxel monotherapy in a 21-day schedule. The secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with Docetaxel monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT02802423"},{"nctId":"NCT06041776","title":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2023-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2023-09-22","conditions":["Non-Small Cell Lung Cancer","EGFR Sensitive Mutation","Adjuvant Therapy"],"interventions":["Befotertinib + Icotinib placebo","Icotinib + Befotertinib placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This multicenter, randomized, controlled, double-blind, double-simulated, Phase III study is designed to evaluate the efficacy and safety of Befotertinib compared with Icotinib as adjuvant treatment in EGFR-sensitive mutation-positive stage IB-IIIB (T3N2M0) non-small cell lung cancer after surgical resection.","sourceUrl":"https://clinicaltrials.gov/study/NCT06041776"},{"nctId":"NCT07715630","title":"In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma","sponsor":"Chongqing Precision Biotech Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"interventions":["Invivo CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is an investigator-initiated, single-center, single-arm clinical study with a target population of patients with relapsed or refractory multiple myeloma. It is an early exploratory clinical study evaluating the safety, tolerability, and preliminary efficacy of PICX Injection, an in vivo prepared CAR-T cell therapy, in the treatment of relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07715630"},{"nctId":"NCT07409428","title":"A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","sponsor":"Hutchmed","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Relapsed/Refractory Diffuse Large B-Cell Lymphoma"],"interventions":["HMPL-760","HMPL-760 Placebo","R-GemOx"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":50,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07409428"},{"nctId":"NCT07493044","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","sponsor":"Guangzhou FineImmune Biotechnology Co., LTD.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-30","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Advanced Hepatocellular Carcinoma (HCC)","GPC3 Positive Hepatocellular Carcinoma"],"interventions":["Super CAR-T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07493044"},{"nctId":"NCT07457918","title":"Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)","sponsor":"Verrica Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-22","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Common Warts (Verruca Vulgaris)","Common Warts","Human Papilloma Virus (HPV)","Warts"],"interventions":["Cantharidin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are: * To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs). * To evaluate the efficacy of continued skin application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments. Participants with eligible common warts present will receive YCANTH (VP-102/TO-208) with an interval o","sourceUrl":"https://clinicaltrials.gov/study/NCT07457918"},{"nctId":"NCT06982521","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","sponsor":"Relay Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2025-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["PIK3CA Mutation","HER2- Negative Breast Cancer","Hormone Receptor Positive Tumor","Breast Cancer","Metastatic Breast Cancer","Advanced Breast Cancer"],"interventions":["Zovegalisib","Capivasertib","Fulvestrant"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Denmark","France","Germany","Greece","Hong Kong","Italy","Netherlands","Poland","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":222,"serviceSignals":["HER2 profiling"],"summary":"This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06982521"},{"nctId":"NCT07277413","title":"A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors","sponsor":"IDEAYA Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["NSCLC Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastric Adenocarcinoma","Adenocarcinoma of Esophagus","Squamous Cell Car. - Esophagus","Urothelial Carcinoma (UC)","Bladder Cancer","Mesothelioma","Pleural Mesothelioma","Peritoneal Mesothelioma","Non-Small Cell Lung Cancer NSCLC","Pancreatic Cancer","Biliary Tract Carcinoma"],"interventions":["IDE892","IDE397"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["ctDNA / MRD"],"summary":"This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.","sourceUrl":"https://clinicaltrials.gov/study/NCT07277413"},{"nctId":"NCT07524855","title":"A Study of HLD-0117 in Patients With Metastatic Breast Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2026-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Metastatic Breast Cancer"],"interventions":["HLD-0117"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Assessment of the safety and efficacy of HLD-0117 as monotherapy in patients with estrogen receptor positive (ER+) metastatic breast cancer (MBC) or locally advanced breast cancer that have progressed on prior systemic therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07524855"},{"nctId":"NCT07714668","title":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":171,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Ovarian Cancer","Recurrent Ovarian Cancer"],"interventions":["SYS6041, bevacizumab","SYS6041, carboplatin, bevacizumab","paclitaxel, carboplatin, bevacizumab","SYS6041, enlonstobart, bevacizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase II clinical study conducted in subjects with recurrent ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07714668"},{"nctId":"NCT07468851","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-06-10","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["High-risk Non-muscle-invasive Bladder Cancer"],"interventions":["HS-10566"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase I/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10566 in patients with high-risk non-muscle-invasive bladder cancer who are ineligible for or refuse radical cystectomy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07468851"},{"nctId":"NCT04930432","title":"Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2021-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Solid Tumor","Non-Small Cell Lung Cancer","Head and Neck Cancer","Colorectal Cancer"],"interventions":["MCLA-129"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":87,"serviceSignals":["MET profiling"],"summary":"This is a multi-center, open-label, Phase I/II clinical study of MCLA-129 as monotherapy in patients with advanced solid tumors to evaluate the safety, pharmacokinetic characteristics and antitumor activity of MCLA-129.","sourceUrl":"https://clinicaltrials.gov/study/NCT04930432"},{"nctId":"NCT04725474","title":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","sponsor":"CatalYm GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":263,"enrollmentType":"ACTUAL","startDate":"2020-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Solid Tumor, Adult"],"interventions":["visugromab (CTL-002)"],"countries":["Germany","Spain","Switzerland"],"northAmerica":false,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors. Enrolment into the Ph 1 part is completed. The Phase 2 parts (Part B) are cohort expansions with visugromab (CTL-002) in combination with a defined CPI at a fixed dose into seven different solid tumor indications.","sourceUrl":"https://clinicaltrials.gov/study/NCT04725474"},{"nctId":"NCT07707674","title":"Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Metastatic Pancreatic Cancer"],"interventions":["XNW28012"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"A Phase I, Open-Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of XNW28012 Monotherapy in the Treatment of Subjects with Metastatic Pancreatic Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07707674"},{"nctId":"NCT07168226","title":"Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101","sponsor":"MetaFines","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2026-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Cachexia; Cancer"],"interventions":["Active Comparator","ASCA101 24.32mg/kg","ASCA101 32.43mg/kg","Placebo"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the efficacy and safety of ASCA101 for the treatment of Cachexia in solid tumor patients. The main questions it aims to answer are: Can the efficacy of ASCA101 in improving cachexia be evaluated based on changes in body weight measured by InBody after 12 weeks (3 cycles) of weekly administration, compared to baseline, for each dose group? Do participants experience adverse events during administration of ASCA101 and/or within 4 weeks after the end of administration? This clinical trial comprises two parts. \\[Study 1. Active-Controlled, Open-Label Study\\] Participants who provide written informed consent will undergo screening procedures. Those w","sourceUrl":"https://clinicaltrials.gov/study/NCT07168226"},{"nctId":"NCT06936527","title":"XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation","sponsor":"NovaOnco Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2025-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-30","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Colorectal Cancer","Metastatic Colorectal Cancer With RAS Mutation"],"interventions":["Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI","Drug: XS-03","Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT06936527"},{"nctId":"NCT04752722","title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","sponsor":"enGene, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2021-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Superficial Bladder Cancer","Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","Non-muscle Invasive Bladder Cancer"],"interventions":["EG-70 (phase 1)","EG-70 (phase 2) Master Protocol","Surfactant Bladder Pre-Rinse and EG-70 (Substudy)"],"countries":["United States","Australia","Canada","France","Germany","Italy","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":102,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with: NMIBC with CIS for whom BCG therapy is unresponsive, and other high risk patients with NMIBC. A Substudy will include a surfactant bladder rinse prior to the instillation of detalimogene in patients with NMIBC with CIS for whom BCG therapy is unresponsive.","sourceUrl":"https://clinicaltrials.gov/study/NCT04752722"},{"nctId":"NCT06630234","title":"A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Gastrointestinal Stromal Tumor (GIST)"],"interventions":["DCC-3009"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase 1/2 master protocol study is to evaluate if DCC-3009 is safe, tolerable and works effectively in the treatment of GIST. The study will use a modular approach with each module being defined according to therapy: DCC-3009 alone or DCC-3009 in combination with other anticancer therapies. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). Participants will be treated in 28-day treatment cycles with an estimated duration of up to 2 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06630234"},{"nctId":"NCT07361562","title":"A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors","sponsor":"Cogent Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced Solid Tumor, Adult","ERBB2 Altered Breast Cancer","ERBB2 Gene Amplification","HER2 Overexpression","Non-Small Cell Lung Cancer","HER2"],"interventions":["CGT4255"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["RNA fusion","HER2 profiling"],"summary":"This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07361562"},{"nctId":"NCT07586618","title":"First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.","sponsor":"Allterum Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Lymphoblastic Lymphoma","Acute Lymphoblastic Leukemia ALL"],"interventions":["4A10"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"ALT-101 is a first-in-human Phase 1 clinical trial testing a new antibody drug called 4A10 in patients with relapsed or hard-to-treat acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma. 4A10 is a targeted therapy designed to recognize and attach to a specific protein (CD127) found on leukemia cells. Once it binds, it works in two ways: it blocks growth signals that help cancer cells survive, and it helps the immune system find and destroy those cancer cells. In this study, patients receive 4A10 through an intravenous (IV) infusion once a week. The main goal of the trial is to find out if the drug is safe, what dose can be given, and how the body processes it. Researchers will also ","sourceUrl":"https://clinicaltrials.gov/study/NCT07586618"},{"nctId":"NCT07401381","title":"A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer","sponsor":"Rovi Pharmaceuticals Laboratories","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Hormone Receptor Positive Early Breast Cancer"],"interventions":["US-sourced oral Femara® + Letrozole SIE","EU sourced oral Femara® + Letrozole SIE"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.","sourceUrl":"https://clinicaltrials.gov/study/NCT07401381"},{"nctId":"NCT06242470","title":"A Study of MGC026 in Participants With Advanced Solid Tumors","sponsor":"MacroGenics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Advanced Solid Tumor","Advanced Cancer","Metastatic Cancer","Squamous Cell Carcinoma of Head and Neck","Non Small Cell Lung Cancer","Small-cell Lung Cancer","Bladder Cancer","Sarcoma","Endometrial Cancer","Melanoma","Castration Resistant Prostatic Cancer","Cervical Cancer","Colorectal Cancer","Gastric Cancer","Gastro-esophageal Cancer","Pancreas Cancer","Clear Cell Renal Cell Carcinoma","Hepatocellular Carcinoma","Platinum-resistant Ovarian Cancer","Breast Cancer","Ovarian Cancer","Esophageal Squamous Cell Cancer (SCC)"],"interventions":["MGC026 Dose Escalation","MGC026 Dose for Expansion"],"countries":["United States","Australia","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing l","sourceUrl":"https://clinicaltrials.gov/study/NCT06242470"},{"nctId":"NCT07134998","title":"Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2025-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Advanced KRAS G12D Mutant Solid Tumors"],"interventions":["HRS-6093"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["RAS genotyping"],"summary":"This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors. The study consists of dose escalation, dose expansion and efficacy expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07134998"},{"nctId":"NCT06075043","title":"A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy","sponsor":"Kind Pharmaceuticals LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2027-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Cancer-Related Anemia"],"interventions":["AND017"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety and efficacy of various doses of AND017 after 6 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06075043"},{"nctId":"NCT07601048","title":"A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment"],"interventions":["HRS-7058","Fulzerasib Tablets","Garsorasib Tablets","Glecirasib Citrate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"The study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT07601048"},{"nctId":"NCT03526835","title":"A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors","sponsor":"Merus B.V.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2018-05-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced/Metastatic Solid Tumors","Colorectal Cancer","Gastric Cancer","Gastroesophageal-junction Cancer","NSCLC","HNSCC","Head and Neck Squamous Cell Carcinoma","Esophageal Cancer"],"interventions":["MCLA-158","MCLA-158 + Pembrolizumab","MCLA-158 + FOLFIRI","MCLA-158 + FOLFOX"],"countries":["United States","Belgium","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with ","sourceUrl":"https://clinicaltrials.gov/study/NCT03526835"},{"nctId":"NCT06481592","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2024-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2025-10-30","conditions":["Endometrial Cancer"],"interventions":["Lifileucel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06481592"},{"nctId":"NCT06990698","title":"A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors","sponsor":"Zhuhai Fapon Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2025-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["Advanced Solid Tumors"],"interventions":["FP008 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06990698"},{"nctId":"NCT07545811","title":"Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Janux Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":43,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Castration-resistant Prostate Cancer"],"interventions":["JANX014"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07545811"},{"nctId":"NCT07128303","title":"Study of GS-5319 in Adults With Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2025-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-05","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Advanced Solid Tumor"],"interventions":["GS-5319"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors and to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose for expansion (RDE).","sourceUrl":"https://clinicaltrials.gov/study/NCT07128303"},{"nctId":"NCT06823167","title":"A Phase 1 Study of IM-1021 in Participants With Advanced Cancer","sponsor":"Immunome, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":117,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Solid Malignancies","Hematologic Malignancies"],"interventions":["IM-1021"],"countries":["United States","Denmark","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06823167"},{"nctId":"NCT07562022","title":"A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma","sponsor":"Sinocelltech Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":93,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Follicular Lymphoma (FL)"],"interventions":["SCTB35 injection","Rituximab","Lenalidomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07562022"},{"nctId":"NCT06983743","title":"A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Erasca, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Metastatic Solid Tumors"],"interventions":["ERAS-0015","ERAS-0015 in combination"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT06983743"},{"nctId":"NCT06499285","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","sponsor":"Takeda","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-01","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Myelodysplastic Syndromes"],"interventions":["Elritercept","Placebo"],"countries":["United States","Australia","Brazil","Bulgaria","Canada","Chile","Czechia","France","Germany","Hungary","India","Ireland","Israel","Italy","Lithuania","Peru","Poland","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":179,"serviceSignals":["Hematology NGS"],"summary":"The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.","sourceUrl":"https://clinicaltrials.gov/study/NCT06499285"},{"nctId":"NCT06672185","title":"ARC101 in Advanced Solid Tumors","sponsor":"Third Arc Bio","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Advanced Solid Tumor"],"interventions":["ARC101"],"countries":["United States","Australia","Canada","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06672185"},{"nctId":"NCT07500805","title":"UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma","sponsor":"UTC Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2026-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-01","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["CD70-positive Advanced Renal Clear Cell Carcinoma"],"interventions":["UCL70805F"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of UCL70805F in patients with CD70-positive advanced renal clear cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07500805"},{"nctId":"NCT07002177","title":"A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC","sponsor":"Forward Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":196,"enrollmentType":"ESTIMATED","startDate":"2025-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Metastatic Breast Cancer","Breast Cancer Stage I","Breast Cancer Stage II","Locally Advanced Breast Cancer (LABC)","ER+ Breast Cancer"],"interventions":["FWD1802","Palbociclib 125mg","Ribociclib 200Mg Oral Tablet","Abemaciclib 150 MG","Everolimus 10 mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07002177"},{"nctId":"NCT06445972","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-08","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer"],"interventions":["Ramucirumab","Paclitaxel","Sacituzumab Tirumotecan","Rescue Medications","HER3-DXd"],"countries":["United States","Brazil","Chile","China","France","Germany","Italy","Norway","South Korea","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.","sourceUrl":"https://clinicaltrials.gov/study/NCT06445972"},{"nctId":"NCT06136650","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1314,"enrollmentType":"ESTIMATED","startDate":"2023-12-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-02","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Prostatic Neoplasms"],"interventions":["Opevesostat","Dexamethasone","Fludrocortisone acetate","Hydrocortisone","Abiraterone acetate","Prednisone acetate","Enzalutamide"],"countries":["United States","Australia","Brazil","Canada","Chile","China","Colombia","Costa Rica","Czechia","Estonia","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","New Zealand","Peru","Portugal","Puerto Rico","Romania","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":329,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as assessed by Blinded Independent Central Review (BICR), in androgen receptor ligand binding domain (AR LBD)","sourceUrl":"https://clinicaltrials.gov/study/NCT06136650"},{"nctId":"NCT04064060","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","sponsor":"Celgene","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":665,"enrollmentType":"ESTIMATED","startDate":"2019-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Myelodysplastic Syndromes (MDS)","Beta-thalassemia","Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis"],"interventions":["Luspatercept"],"countries":["United States","Australia","Belgium","Bulgaria","Canada","China","France","Germany","Greece","Israel","Italy","Japan","Lebanon","Malaysia","Netherlands","Spain","Sweden","Taiwan","Thailand","Tunisia","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":143,"serviceSignals":["Hematology NGS"],"summary":"A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants: * Participants receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit from continuing treatment with luspatercept * Participants in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met * The study design is divided into the Transition P","sourceUrl":"https://clinicaltrials.gov/study/NCT04064060"},{"nctId":"NCT07030907","title":"A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer","sponsor":"Outpace Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-15","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Ovarian Cancer Recurrent","Ovarian Cancer","Platinum Resistant Ovarian Cancer"],"interventions":["OPB-101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.","sourceUrl":"https://clinicaltrials.gov/study/NCT07030907"},{"nctId":"NCT06846671","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-14","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["CLL","Chronic Lymphocytic Leukemia"],"interventions":["BGB-16673","Bendamustine","Idelalisib","Rituximab","Venetoclax"],"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","Germany","Italy","Japan","Netherlands","Poland","South Korea","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":127,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \\[for CLL only\\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).","sourceUrl":"https://clinicaltrials.gov/study/NCT06846671"},{"nctId":"NCT06985368","title":"A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients","sponsor":"Shanghai Institute Of Biological Products","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-15","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Solid Tumor Malignancy"],"interventions":["SIBP-A18"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The main purpose To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A18 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D). A secondary purpose To preliminarily evaluate the anti-tumor efficacy of SIBP-A18. Evaluate the effect of SIBP-A18 injection on Q to T interval/Corrected QT interval (QT/QTc interval) in participants with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06985368"},{"nctId":"NCT06944496","title":"A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","sponsor":"RemeGen Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":616,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-15","completionType":"ESTIMATED","lastUpdated":"2025-04-25","conditions":["Gastric Carcinoma"],"interventions":["Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","Tislelizumab+Oxaliplatin+Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of \\*\\*Disitamab Vedotin combined with Tislelizumab and CAPOX versus Tislelizumab combined with CAPOX\\*\\* as first-line treatment for patients with HER2-low advanced gastric or gastroesophageal junction adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06944496"},{"nctId":"NCT06621615","title":"Clinical Study of CVL006 Injection in Advanced Solid Tumors","sponsor":"Convalife (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-11-20","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-20","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-20","completionType":"ESTIMATED","lastUpdated":"2024-10-01","conditions":["Advanced Solid Tumor"],"interventions":["CVL006 Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Evaluate the safety and tolerability of CVL006 monotherapy in patients with advanced solid tumors; Observe the dose limiting toxicity (DLT) of CVL006 monotherapy in patients with advanced solid tumors, evaluate the maximum tolerated dose (MTD), and recommend the dosage for phase II clinical trials (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06621615"},{"nctId":"NCT07312188","title":"A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-20","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-20","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["F182112+P","F182112+CD38"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single - arm, multi - cohort, open - label, multi - center Phase II clinical study. It aims to evaluate the efficacy and safety of F182112 combined with different administration regimens in patients with relapsed or refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07312188"},{"nctId":"NCT07387081","title":"Phase II Study of LM-24C5","sponsor":"LaNova Medicines Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2025-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-25","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Advanced Solid Tumor Cancer"],"interventions":["LM-24C5"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor","sourceUrl":"https://clinicaltrials.gov/study/NCT07387081"},{"nctId":"NCT07531095","title":"Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-21","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-21","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Small Cell Lung Cancer"],"interventions":["ZL-1310","Tarlatamab","Durvalumab"],"countries":["United States","Belgium","France","Germany","Poland","Spain","Switzerland","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07531095"},{"nctId":"NCT06743503","title":"UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-21","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-31","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Large B-cell Lymphoma"],"interventions":["UB-VV400","Rapamycin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is an exploratory, open-label, investigator-initiated trial (IIT) of the safety, efficacy, and PK/Pd of UB-VV400 alone and in combination with rapamycin in adult subjects with R/R LBCL. LBCL will include subjects with aggressive lymphoma, defined as diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), including high-grade lymphoma (HGL) with double/triple hit DLBCL; transformed DLBCL (tDLBCL), including Richter's transformation; follicular lymphoma Grade 3B (FL3B); and primary mediastinal B-cell lymphoma (PMBCL). The study will include subjects who have had prior CD19-directed CAR T-cell exposure and subjects who are CAR T cell-naive. Clinical unmet need exists in both p","sourceUrl":"https://clinicaltrials.gov/study/NCT06743503"},{"nctId":"NCT06464055","title":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2024-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-23","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-02-10","conditions":["Advanced Malignant Solid Tumors"],"interventions":["Dose Escalation","Dose Expansion1","Dose Expansion2","Dose Expansion3","phase II"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1010 and preliminary anti-tumor efficacy in advanced malignant solid tumor subjects","sourceUrl":"https://clinicaltrials.gov/study/NCT06464055"},{"nctId":"NCT06389292","title":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":486,"enrollmentType":"ESTIMATED","startDate":"2024-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-26","completionType":"ESTIMATED","lastUpdated":"2025-11-25","conditions":["Acute Myeloid Leukemia"],"interventions":["APG-2575(Lisaftoclax )","Placebo","Azacitidine Injection"],"countries":["China","Russia"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"A global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with azacitidine in newly diagnosed acute myeloid leukemia who are not eligible for standard induction chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06389292"},{"nctId":"NCT07073547","title":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-26","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Multiple Myeloma"],"interventions":["AZD0120"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT07073547"},{"nctId":"NCT06230224","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ACTUAL","startDate":"2024-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-29","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["B-Cell Non-Hodgkin Lymphoma (B-NHL)"],"interventions":["Odronextamab","Ifosfamide","Carboplatin","Etoposide","Rituximab","Dexamethasone","Cisplatin","Cytarabine","Gemcitabine"],"countries":["Argentina","Australia","Brazil","Chile","Colombia","Hungary","Malaysia","Romania","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":81,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug versus Standard of Care (SOC) * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could ","sourceUrl":"https://clinicaltrials.gov/study/NCT06230224"},{"nctId":"NCT06427941","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2024-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Metastatic Hepatocellular Carcinoma","Local Advanced Hepatocellular Carcinoma","Alpha-fetoprotein (AFP)-Producing Gastric Cancer","Extragonadal Yolk Sac Tumors","Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer"],"interventions":["BGB-B2033","Tislelizumab","Bevacizumab"],"countries":["United States","Brazil","China","France","Italy","Japan","New Zealand","Puerto Rico","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06427941"},{"nctId":"NCT05009836","title":"Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC","sponsor":"Hutchison Medipharma Limited","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":412,"enrollmentType":"ESTIMATED","startDate":"2021-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Non-small Cell Lung Cancer"],"interventions":["Savolitinib","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05009836"},{"nctId":"NCT07390383","title":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2026-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Advanced Solid Tumour"],"interventions":["LBL-024 for Injection","Capecitabine tablets","Tislelizumab Injection","Oxaliplatin injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.","sourceUrl":"https://clinicaltrials.gov/study/NCT07390383"},{"nctId":"NCT06389526","title":"A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors","sponsor":"Coherus Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-02-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-30","completionType":"ESTIMATED","lastUpdated":"2024-09-19","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["CHS-1000","Toripalimab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06389526"},{"nctId":"NCT07218926","title":"A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-29","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Gastrointestinal Neoplasms"],"interventions":["IDRX-42","Sunitinib"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Hungary","Italy","Japan","Netherlands","Norway","Poland","Romania","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":124,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.","sourceUrl":"https://clinicaltrials.gov/study/NCT07218926"},{"nctId":"NCT07416695","title":"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC","sponsor":"Shanghai Henlius Biotech","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["SCLC","NEC"],"interventions":["HLX3901"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3901 in patients with Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07416695"},{"nctId":"NCT06012695","title":"NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","sponsor":"Novelwise Pharmaceutical Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":79,"enrollmentType":"ESTIMATED","startDate":"2023-08-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Malignant Neoplasm","Malignant Neoplasm of Brain"],"interventions":["NBM-BMX Capsule","Temozolomide","Standard radiotherapy"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06012695"},{"nctId":"NCT07228832","title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","sponsor":"Summit Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Metastatic Colorectal Cancer (CRC)"],"interventions":["Drug: Ivonescimab Injection","Drug: Bevacizumab Injection"],"countries":["United States","Belgium","Canada","Czechia","France","Germany","Italy","Japan","Poland","Puerto Rico","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":166,"serviceSignals":["Broad CGP"],"summary":"A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)","sourceUrl":"https://clinicaltrials.gov/study/NCT07228832"},{"nctId":"NCT05948943","title":"Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2023-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2033-05-02","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Lymphatic Malformations"],"interventions":["Alpelisib","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Czechia","France","Germany","Italy","Netherlands","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":60,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT05948943"},{"nctId":"NCT06497985","title":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2024-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["Colorectal Cancer"],"interventions":["Tucidinostat","Sintilimab","Bevacizumab","Fruquintinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A randomised, open-label, multicenter phase III study to evaluate the efficacy and safety of tucidinostat in combination with sintilimab and bevacizumab versus fruquintinib monotherapy in MSS/pMMR colorectal cancer patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06497985"},{"nctId":"NCT06515613","title":"A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","sponsor":"Context Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2024-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Platinum-resistant Ovarian Cancer","Testicular Cancer","Endometrial Cancer"],"interventions":["CTIM-76"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).","sourceUrl":"https://clinicaltrials.gov/study/NCT06515613"},{"nctId":"NCT07312903","title":"DPTX3186 in Wnt Pathway Activated Solid Tumors","sponsor":"Dewpoint Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Solid Tumors"],"interventions":["DPTX3186"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a first-in human clinical study of DPTX3186 in subjects with Wnt-pathway activated solid tumors where no other treatments exist. The study will evaluate safety, pharmacokinetics, and initial activity of DPTX3186, as well as explore pharmacodynamic parameters to identify potential biomarkers of efficacy","sourceUrl":"https://clinicaltrials.gov/study/NCT07312903"},{"nctId":"NCT07591285","title":"A Study of SYS6051 in Subjects With Advanced Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2026-05-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced Solid Tumors"],"interventions":["SYS6051"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, dose-escalation and backfill, and cohort-expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy of SYS6051 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07591285"},{"nctId":"NCT05365581","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":398,"enrollmentType":"ESTIMATED","startDate":"2022-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma","Pancreatic Adenocarcinoma"],"interventions":["ASP2138","Pembrolizumab","Oxaliplatin","Leucovorin","Fluorouracil","Ramucirumab","Paclitaxel","Irinotecan","Capecitabine"],"countries":["United States","China","France","Italy","Japan","Puerto Rico","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":46,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This \"tells\" the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. GEJ is where the tube that carries food (esophagus) joins the stomach. Before ASP2138 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. In this study, ASP2138 will ","sourceUrl":"https://clinicaltrials.gov/study/NCT05365581"},{"nctId":"NCT06361888","title":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","sponsor":"Hutchmed","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":502,"enrollmentType":"ESTIMATED","startDate":"2024-05-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Metastatic Pancreatic Cancer"],"interventions":["Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine","Nab-paclitaxel Plus Gemcitabine","Surufatinib with Nab-paclitaxel, and Gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06361888"},{"nctId":"NCT07237425","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","sponsor":"Glonova Pharma Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2025-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Lipoma","Submental Fullness"],"interventions":["Ronkyla Plus","Placebo","Kybella"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, efficacy, and pharmacokinetics of Ronkyla Plus, a combinational drug that forms a hydrogel at the injection site, promising a better experience of lipolysis injection for the treatment of superficial lipoma. The study consists of a Part I dose-escalation study to investigate the drug's maximum tolerated dose (MTD) for this indication and a Part II study for evaluating its relative bioavailability in comparison to an FDA-approved lipolysis injection, Kybella.","sourceUrl":"https://clinicaltrials.gov/study/NCT07237425"},{"nctId":"NCT06640413","title":"A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors","sponsor":"Philogen S.p.A.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2025-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["FAP"],"interventions":["[177Lu]Lu-OncoFAP-23","L19IL2"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to assess the safety of \\[177Lu\\]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic Fibroblast Activation Protein (FAP)-positive solid tumors and to establish a Recommended Dose (RD).","sourceUrl":"https://clinicaltrials.gov/study/NCT06640413"},{"nctId":"NCT05101070","title":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","sponsor":"Shionogi","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":282,"enrollmentType":"ESTIMATED","startDate":"2022-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Solid Tumors"],"interventions":["S-531011","Pembrolizumab","Bevacizumab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D with or without pembrolizumab. The primary objective of Parts D and E is to evaluate the antitumor activity of S-531011 at the RP2D in combination with bevacizumab with our without pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05101070"},{"nctId":"NCT07360288","title":"Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma","sponsor":"TICAROS Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-28","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["Follicular Lymphoma (FL)"],"interventions":["TC011 single-arm"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a). The primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.","sourceUrl":"https://clinicaltrials.gov/study/NCT07360288"},{"nctId":"NCT07546500","title":"A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2026-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Ovarian Cancer"],"interventions":["Investigator's choice of Chemotherapy","Azenosertib"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Ireland","Italy","Poland","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07546500"},{"nctId":"NCT06619587","title":"A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2024-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Solid Tumor"],"interventions":["Phase I Arm A","Phase I Arm B"],"countries":["United States","Australia","Canada","France","Israel","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["RAS genotyping"],"summary":"This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic solid tumors that harbor the KRAS G12D mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06619587"},{"nctId":"NCT05732103","title":"A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","sponsor":"Chordia Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":225,"enrollmentType":"ESTIMATED","startDate":"2023-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"interventions":["CTX-712"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS), or MDS/MPN (including CMML). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by initial expansion cohorts in AML and/or HR-MDS where patients will be treated with CTX-712 at the RP2D to gain ","sourceUrl":"https://clinicaltrials.gov/study/NCT05732103"},{"nctId":"NCT06980116","title":"Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Relapsed or Refractory B-cell Malignancies","Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","Follicular Lymphoma (FL)","Marginal Zone Lymphoma (MZL)","Mantle Cell Lymphoma (MCL)","Diffuse-large B-cell Lymphoma (DLBCL)","Waldenstrom's Macroglobulinemia (WM)"],"interventions":["EXS73565"],"countries":["Georgia","Moldova","Spain","Ukraine","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06980116"},{"nctId":"NCT06618235","title":"Trial of THEO-260 in Ovarian Cancer Patients","sponsor":"Theolytics Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":44,"enrollmentType":"ESTIMATED","startDate":"2024-09-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Ovarian Cancer"],"interventions":["THEO-260"],"countries":["Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT06618235"},{"nctId":"NCT07618260","title":"SIM0613 in Participants With Advanced Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":294,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Advanced Solid Cancer"],"interventions":["SIM0613"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, first-in-human (FIH) study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic characteristics of SIM0613 in participants with locally advanced/ metastatic solid tumors. The study starts with a dose escalation part (Part 1) followed by a dose expansion part (Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT07618260"},{"nctId":"NCT07141706","title":"A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":253,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Advanced/Metastatic Solid Tumors"],"interventions":["DB-1317"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.","sourceUrl":"https://clinicaltrials.gov/study/NCT07141706"},{"nctId":"NCT06750185","title":"Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors","sponsor":"BioNTech SE","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2025-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Advanced Solid Tumor"],"interventions":["BNT317 DL1","BNT317 DL2","BNT317 DL3","BNT317 DL4","BNT317 DL5 (intermediate)","BNT317 DL6 (intermediate)","BNT317 DL7 (additional)"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06750185"},{"nctId":"NCT07661797","title":"Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":294,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Patients With Advanced Solid Tumors"],"interventions":["LNF2105(Antibody-Drug Conjugate (ADC) targeting Nectin-4)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07661797"},{"nctId":"NCT07602842","title":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","sponsor":"InduPro, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Head and Neck Squamous Cell Carcinoma","Cutaneous Squamous Cell Carcinoma","Squamous Cell Carcinoma of the Cervix","Non Squamous Non Small Cell Lung Cancer","Squamous Cell Carcinoma of the Esophagus","Squamous Cell Carcinoma of the Anus","Squamous Cell Carcinoma"],"interventions":["IDP-001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).","sourceUrl":"https://clinicaltrials.gov/study/NCT07602842"},{"nctId":"NCT05262010","title":"A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years","sponsor":"National Vaccine and Serum Institute, China","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":13500,"enrollmentType":"ESTIMATED","startDate":"2022-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-16","conditions":["HPV InfectioN","HPV-Related Carcinoma"],"interventions":["11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)","placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"A total of 13500 Chinese women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 35-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1. All subjects enrolled in the upper arm deltoid muscle were injected with 3 doses of test vaccine or placebo according to the 0, 2, and 6 months immunization program.","sourceUrl":"https://clinicaltrials.gov/study/NCT05262010"},{"nctId":"NCT07595913","title":"A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Neuroendocrine Carcinoma"],"interventions":["ZG006","5-fluorouracil, Calcium folinate and Irinotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This Phase III, multicenter, randomized, open-label, controlled study is designed to assess the efficacy and safety of ZG006 versus investigator-selected chemotherapy in participants with DLL3-positive advanced neuroendocrine carcinoma who have received prior systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07595913"},{"nctId":"NCT07573111","title":"Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation","sponsor":"Laguna Biotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Acute Leukemia","Myelodysplastic Syndrome"],"interventions":["QUAIL-100"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"Study of QUAIL-100 in Patients With High Risk Acute Leukemia and Myelodysplastic Syndrome Who Have Received Hematopoietic Stem Cell Transplant","sourceUrl":"https://clinicaltrials.gov/study/NCT07573111"},{"nctId":"NCT06441331","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","sponsor":"ITM Solucin GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2034-04","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Somatostatin Receptor Positive","NETs","Lymphoma","Solid Tumor","CNS Tumors","Rhabdomyosarcoma","Peripheral Primitive Neuroectodermal Tumor","GIST"],"interventions":["Lutetium Lu 177-Edotreotide","Amino Acid Solution"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \\<18 years of age with somatostatin receptor (SSTR)-positive tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06441331"},{"nctId":"NCT07465835","title":"A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)","sponsor":"Electra Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2026-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["T Cell Malignancies"],"interventions":["ELA026"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07465835"},{"nctId":"NCT07497386","title":"A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Unresectable Locally Recurrent Breast Cancer","Unresectable Locally Metastatic Breast Cancer"],"interventions":["Trastuzumab Rezetecan for Injection","Trastuzumab Deruxtecan for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.","sourceUrl":"https://clinicaltrials.gov/study/NCT07497386"},{"nctId":"NCT07079475","title":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Non-Small Cell Lung Cancer"],"interventions":["DZD6008","Sunvozertinib","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT07079475"},{"nctId":"NCT06424340","title":"MB-dNPM1-TCR.1 in Relapsed/Refractory AML","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":29,"enrollmentType":"ESTIMATED","startDate":"2024-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Leukemia, Myeloid, Acute"],"interventions":["MB-dNPM1-TCR.1"],"countries":["Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this Phase I/II, single arm, prospective, open label, dose escalation trial is to assess safety, feasibility and efficacy of ex vivo expanded autologous T cells genetically modified to express a T cell receptor (TCR) specific for dNPM1 peptides restricted to human leukocyte antigen (HLA) A\\*02:01 in patients with relapsed or refractory AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT06424340"},{"nctId":"NCT07047365","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2025-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["HER2-positive Advanced Breast Cancer"],"interventions":["TQB2930+ chemotherapy","Trastuzumab+ chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":75,"serviceSignals":["HER2 profiling"],"summary":"TQB2930 is a HER2 bispecific antibody drug. This study aims to evaluate the efficacy and safety of TQB2930 combined with investigator's choice of chemotherapy versus trastuzumab combined with investigator's choice of chemotherapy in subjects with HER2-positive advanced breast cancer who have received at least two prior lines of anti-HER2 therapy in the advanced station.","sourceUrl":"https://clinicaltrials.gov/study/NCT07047365"},{"nctId":"NCT07491445","title":"Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","sponsor":"Revolution Medicines, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2026-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma"],"interventions":["daraxonrasib","gemcitabine","nab-paclitaxel"],"countries":["United States","Australia","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT07491445"},{"nctId":"NCT06926920","title":"A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer","sponsor":"Gilead Sciences","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Triple Negative Breast Cancer"],"interventions":["Sacituzumab Govitecan-hziy (SG)"],"countries":["United States","Australia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06926920"},{"nctId":"NCT07552376","title":"This Study Aims to Evaluate the Efficacy and Safety of QLS1317 in Patients With MSI-H/dMMR Advanced Solid Tumors.","sponsor":"Shanghai Qilu Pharmaceutical Research and Development Center LTD","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["MSI-H or dMMR Advanced Solid Tumors"],"interventions":["QLS1317"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MSI / TMB"],"summary":"The goal of this study aims to evaluate the efficacy and safety of QLS1317 in patients with MSI-H/dMMR advanced solid tumors who failed standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07552376"},{"nctId":"NCT05502237","title":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1021,"enrollmentType":"ACTUAL","startDate":"2022-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Non-small Cell Lung Cancer"],"interventions":["Zimberelimab","Domvanalimab","Pembrolizumab","Carboplatin","Cisplatin","Paclitaxel","Nab-paclitaxel","Pemetrexed"],"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Portugal","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":186,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of this study is to compare the effect of zimberelimab (ZIM) and domvanalimab (DOM) in combination with chemotherapy relative to pembrolizumab (PEMBRO) in combination with chemotherapy on overall survival (OS) in patients with untreated metastatic non-small cell lung cancer with no actionable genomic alteration.","sourceUrl":"https://clinicaltrials.gov/study/NCT05502237"},{"nctId":"NCT06934538","title":"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer","sponsor":"Brenus Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Unresectable Metastatic Colorectal Cancer","Unresectable Locally Advanced Colorectal Cancer"],"interventions":["STC-1010 + IS regimen + SOC therapy"],"countries":["United States","Belgium","France"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/IIA, first-in-human (FIH), two-part, open-label, multicenter study to characterize the safety, tolerability profile, and clinical efficacy of STC-1010 associated with GM-CSF and cyclophosphamide immunostimulant (IS) regimen administered with standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab) to participants with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) colorectal cancer (CRC). The trial will be conducted in two parts: * A Phase I consisting of a dose escalation part and small expansion part to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D) and safety profile of the STC-1010 + IS re","sourceUrl":"https://clinicaltrials.gov/study/NCT06934538"},{"nctId":"NCT05645536","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","sponsor":"Tolmar Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2022-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Breast Cancer"],"interventions":["TOL2506","Tamoxifen","Letrozole tablets","Anastrozole Tablets","Exemestane Tablets"],"countries":["United States","Argentina","Brazil","India","Mexico","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["HER2 profiling"],"summary":"TOL2506A (OVELIA) is a Phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 in suppressing ovarian function in premenopausal women with HR+, HER2-negative breast cancer and men with HR+ breast cancer. The TOL2506A-EXT study described here is a safety extension study to assess and collect long-term data on the ongoing safety and tolerability of TOL2506 in combination with tamoxifen or an AI for up to 4 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT05645536"},{"nctId":"NCT05319314","title":"LYL273 for Patients With Relapsed or Refractory mCRC","sponsor":"Lyell Immunopharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2022-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Colorectal Cancer"],"interventions":["LYL273"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05319314"},{"nctId":"NCT06051695","title":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","sponsor":"A2 Biotherapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":474,"enrollmentType":"ESTIMATED","startDate":"2024-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Solid Tumor, Adult","Colorectal Cancer","NSCLC","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreas Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Colon Cancer","Rectal Cancer","Cancer","Ovarian Cancer","Ovarian Neoplasms","Mesothelioma","Mesothelioma, Malignant","Ovary Cancer","Lung Cancer","MESOM"],"interventions":["A2B694","A2B543","xT CDx with HLA-LOH Assay"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and ","sourceUrl":"https://clinicaltrials.gov/study/NCT06051695"},{"nctId":"NCT03767348","title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","sponsor":"Replimune, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2017-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-02-13","conditions":["Non-Small Cell Lung Cancer (NSCLC)","Microsatellite Instability-High (MSI-H)","Non-melanoma Skin Cancer (NMSC)","Cutaneous Melanoma"],"interventions":["RP1","nivolumab"],"countries":["United States","France","Germany","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["MSI / TMB"],"summary":"The Phase 2 study is a multicenter, open-label study of RP1 to further investigate safety and to estimate the efficacy of RP1 at the RP2D in combination with nivolumab in patients with Stage IIIb-IV unresectable melanoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, non-melanoma skin cancer (NMSC), and non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03767348"},{"nctId":"NCT07562152","title":"Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma","sponsor":"Immuneering Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2026-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Adenocarcinoma Metastatic","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma"],"interventions":["Atebimetinib","GnP","mGnP"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT07562152"},{"nctId":"NCT07690189","title":"Study of NTB-928 in R/R OC","sponsor":"TeneoSeven, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Relapsed/Refractory Ovarian Carcinoma"],"interventions":["NTB-928"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are: * What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given s","sourceUrl":"https://clinicaltrials.gov/study/NCT07690189"},{"nctId":"NCT06778031","title":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2025-03-06","conditions":["HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer"],"interventions":["SHR-A1811","SHR-1316","SHR-8068"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study is an open, multicenter Phase II clinical trial to evaluate the efficacy and safety of the SHR-A1811 combination in HER2 positive patients with locally advanced or metastatic biliary tract cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06778031"},{"nctId":"NCT07711184","title":"A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Prostate Cancer"],"interventions":["HRS-7525 tablets"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.","sourceUrl":"https://clinicaltrials.gov/study/NCT07711184"},{"nctId":"NCT07560449","title":"QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Malignant Plasma Cell Neoplasms"],"interventions":["QLS4131","QL2109","Pomalidomide","Lenalidomide","Dexamethasone"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to compare the efficacy of QLS4131(SC) in combination with QL2109, with or without pomalidomide or lenalidomide, and QLS4131 (SC) in combination with QL2109, and QLS4131 (SC) in combination with Pomalidomide, and QLS4131(SC) in combination with QL2109 and Lenalidomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT07560449"},{"nctId":"NCT05813665","title":"A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2023-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2023-04-19","conditions":["Giant Cell Tumor of Bone"],"interventions":["Narlumosbart","Denosumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase Ⅲ, multi-center, randomized, double-blind, active-controlled study to evaluate the efficacy and safety of narlumosbart (JMT103) in patients with unresectable or surgically difficult giant cell tumor of bone (GCTB). This clinical trial study hypothesizes narlumosbart administration groups are not inferior to active control administration groups.","sourceUrl":"https://clinicaltrials.gov/study/NCT05813665"},{"nctId":"NCT06128837","title":"Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer","sponsor":"Luye Pharma Group Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":686,"enrollmentType":"ESTIMATED","startDate":"2024-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2024-03-15","conditions":["Relapsed Small Cell Lung Cancer"],"interventions":["Irinotecan hydrochloride liposome Injection","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter，randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06128837"},{"nctId":"NCT07704645","title":"The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Resectable Non-small Cell Lung Cancer"],"interventions":["Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection","Adebrelimab Injection combined with HRS-7058 Capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )","sourceUrl":"https://clinicaltrials.gov/study/NCT07704645"},{"nctId":"NCT06588478","title":"A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"Loxo Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":249,"enrollmentType":"ESTIMATED","startDate":"2025-01-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Pirtobrutinib"],"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Poland","Romania","Slovakia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":131,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06588478"},{"nctId":"NCT06532565","title":"Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":154,"enrollmentType":"ESTIMATED","startDate":"2024-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Advanced Solid Tumors"],"interventions":["GS-2121","Zimberelimab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06532565"},{"nctId":"NCT05580562","title":"ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)","sponsor":"Jazz Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2023-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-06","primaryCompletionType":"ESTIMATED","completionDate":"2028-06","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["H3 K27M","Glioma"],"interventions":["Dordaviprone (ONC201)","Dordaviprone (ONC201) + Placebo","Placebo"],"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Denmark","Germany","Hong Kong","Israel","Italy","Japan","Netherlands","Singapore","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":162,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05580562"},{"nctId":"NCT07559929","title":"A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.","sponsor":"Hangzhou DAC Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Small Cell Lung Cancer"],"interventions":["DXC006","Toripalimab","Carboplatin","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor (ICI) or platinum-based chemotherapy in patients with small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07559929"},{"nctId":"NCT06731478","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":726,"enrollmentType":"ESTIMATED","startDate":"2025-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-01","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Gastric Cancer","Gastroesophageal Junction Cancer"],"interventions":["Trastuzumab Deruxtecan","pembrolizumab","Trastuzumab","Chemotherapy"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Italy","Japan","Netherlands","Norway","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":250,"serviceSignals":["HER2 profiling"],"summary":"This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus standard of care (SoC) chemotherapy plus trastuzumab plus pembrolizumab as first-line therapy in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS ≥1 gastric or GEJ cancer in the Main Cohort. An Exploratory Cohort will also be evaluated to assess the efficacy and safety of T-DXd plus a fluoropyrimidine versus SoC chemotherapy plus trastuzumab in participants with unresectable, locally advanced or metastatic HER2-positive tumor PD-L1 CPS \\<1 gastric or GEJ c","sourceUrl":"https://clinicaltrials.gov/study/NCT06731478"},{"nctId":"NCT05381103","title":"PSMA-PET to Guide Prostatectomy","sponsor":"Five Eleven Pharma, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":288,"enrollmentType":"ESTIMATED","startDate":"2021-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2025-01-31","conditions":["Prostate Cancer"],"interventions":["PSMA-PET and SOC MRI","SOC MRI"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"In this study, 196 patients will be randomized 1:1 to either having only the standard of care MRI prior to surgery versus having the standard of care MRI and the PSMA PET scan. PET (and MRI) findings will be validated against whole mount pathology. Pre-surgical imaging findings will also be evaluated in the context of affecting subsequent surgical plans and impacting actual patient outcomes.","sourceUrl":"https://clinicaltrials.gov/study/NCT05381103"},{"nctId":"NCT06644781","title":"A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["Ifinatamab deruxtecan","Docetaxel","Paclitaxel","Irinotecan hydrochloride (HCl)"],"countries":["United States","Belgium","China","Denmark","France","Germany","Italy","Japan","Netherlands","Norway","Poland","Romania","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":132,"serviceSignals":["Broad CGP"],"summary":"This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06644781"},{"nctId":"NCT07494435","title":"Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Hepato Cellular Carcinoma (HCC)","Renal Cell Cancer"],"interventions":["WGI-0301","Nivolumab (240 mg)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer or advanced kidney cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07494435"},{"nctId":"NCT06769698","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-28","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)"],"interventions":["FDC fianlimab+cemiplimab","Cemiplimab","Placebo"],"countries":["United States","Australia","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called \"study drugs\" in this form. The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The study is looking at several other research questions, including: * What side effects may happen from taking the stu","sourceUrl":"https://clinicaltrials.gov/study/NCT06769698"},{"nctId":"NCT07607678","title":"A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-15","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Solid Cancer","Metastatic Solid Cancer"],"interventions":["BI 3819026","Ezabenlimab (BI 754091)"],"countries":["United States","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced cancer. The purpose of this study is to find the highest dose of BI 3819026 that people with advanced cancer can tolerate when taken alone and together with ezabenlimab. BI 3819026 and ezabenlimab are study medicines that may fight cancer. Participants first receive one treatment of BI 3819026 alone, followed by treatment with a combination of BI 3819026 and ezabenlimab. Different doses of BI3819026 are given to small groups of participants, starting with the lowest dose. Treatment with the next higher dose of BI 3819026 starts only if the previous dose was tolerated. Each participant remains on the same dose of BI 3819026 throughout the study. Part","sourceUrl":"https://clinicaltrials.gov/study/NCT07607678"},{"nctId":"NCT07463573","title":"QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":466,"enrollmentType":"ESTIMATED","startDate":"2026-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-05","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":["QLC5508","Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07463573"},{"nctId":"NCT07560124","title":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":286,"enrollmentType":"ESTIMATED","startDate":"2026-06-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-14","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Breast Cancer"],"interventions":["AK138D1","Ivonescimab","treatment of physician's choice"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced breast cancer. Participants will receive study treatment with AK138D1 alone or in combination with ivonescimab, undergo safety assessments and tumor evaluations, and be followed for treatment tolerability, antitumor activity, and clinical outcomes.","sourceUrl":"https://clinicaltrials.gov/study/NCT07560124"},{"nctId":"NCT06824168","title":"Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission","sponsor":"Daiichi Sankyo","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-07-14","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Acute Myeloid Leukemia","Leukemia"],"interventions":["Quizartinib High Dose","Quizartinib Low Dose"],"countries":["United States","Australia","Brazil","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":58,"serviceSignals":["Hematology NGS"],"summary":"This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).","sourceUrl":"https://clinicaltrials.gov/study/NCT06824168"},{"nctId":"NCT06478719","title":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","sponsor":"Febico Biomedical Corp.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-06","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Hepatocellular Carcinoma"],"interventions":["Placebo","FB-1603"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess the efficacy of FB-1603 on improving liver function impairment in hepatocellular carcinoma patients receiving transarterial chemoembolization. The main question it aims to answer is: Changes in the level of liver function parameters, including AST, ALT, or total bilirubin, from baseline to Visit 3, Visit 4, Visit 5, and Visit 6 There is a comparison group: Researchers will compare arm 1 placebo to see if FB-1603 is work to treat the liver function. Participants will 1. Take drug FB-1603 990mg/day, FB-1603 1980mg/day or a placebo every day for 10 weeks. 2. Visit the clinic on day 4, 7, 10, 14, 28, 56 and 84 (follow-up)","sourceUrl":"https://clinicaltrials.gov/study/NCT06478719"},{"nctId":"NCT06467357","title":"Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":620,"enrollmentType":"ESTIMATED","startDate":"2024-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-16","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Biliary Tract Cancer"],"interventions":["Gemcitabine","Cisplatin","Durvalumab","Trastuzumab deruxtecan","Rilvegostomig"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Hong Kong","India","Italy","Japan","Malaysia","Netherlands","Philippines","Poland","Saudi Arabia","Slovakia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":270,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06467357"},{"nctId":"NCT07391657","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":508,"enrollmentType":"ESTIMATED","startDate":"2026-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-29","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Relapsed Refractory Multiple Myeloma"],"interventions":["AZD0120","Daratumumab","Carfilzomib","Dexamethasone","Bortezomib","Pomalidomide"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Italy","Japan","Norway","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":142,"serviceSignals":["Hematology NGS"],"summary":"This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \\[daratumumab, carfilzomib, and dexamethasone\\], DPd \\[daratumumab, pomalidomide, and dexamethasone\\], PVd \\[pomalidomide, bortezomib and dexamethasone\\], or Kd \\[carfilzomib and dexamethasone\\]) in participants with RRMM.","sourceUrl":"https://clinicaltrials.gov/study/NCT07391657"},{"nctId":"NCT07612280","title":"Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis","sponsor":"Jubilant Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-15","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Essential Thrombocythemia (ET)","Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)","Myeloproliferative Neoplasms (MPN)"],"interventions":["JBI-802"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"This study aims to assess the safety and efficacy of orally administered JBI-802 in subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/ Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis. Who is it for? You may be eligible to join this study if you are aged 18 years and over have been diagnosed with Essential Thrombocythemia and either a Morphologically confirmed diagnosis of Myeloproliferative Neoplasms (MPN) or Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Study details: Participants in this study will receive JBI-802 administered orally daily for a 28 day treatment cycle for up to 2-years as long as the participant experiences clinical benefit in the op","sourceUrl":"https://clinicaltrials.gov/study/NCT07612280"},{"nctId":"NCT07450599","title":"A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.","sponsor":"Bayer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2026-04-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-15","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["High-Risk Localized Prostate Cancer"],"interventions":["Darolutamide","ADT"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["ctDNA / MRD"],"summary":"Researchers are looking for a better way to treat men who have high-risk localized prostate cancer, which refers to a type of prostate cancer that is still confined to the prostate gland but has certain characteristics that make it more likely to grow and spread. The study treatment darolutamide plus androgen deprivation therapy (ADT) is under development as treatment before surgery for men who have high-risk localized prostate cancer. Darolutamide works by blocking the attachment of androgen hormones to androgen receptors in cancer cells, thereby blocking cancer progression and growth. ADT is an established treatment that is used to lower the amount of androgen hormones (e.g., testosterone)","sourceUrl":"https://clinicaltrials.gov/study/NCT07450599"},{"nctId":"NCT06459180","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":686,"enrollmentType":"ESTIMATED","startDate":"2024-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-15","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Cervical Cancer"],"interventions":["Sacituzumab Tirumotecan","Pemetrexed","Tisotumab Vedotin","Topotecan","Vinorelbine","Gemcitabine","Irinotecan"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Denmark","Finland","France","Germany","Greece","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Poland","Puerto Rico","Singapore","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":240,"serviceSignals":["ADC biomarker"],"summary":"This study will have two phases: a sacituzumab tirumotecan safety run-in and a Phase 3 portion. The safety run-in phase will be used to evaluate the efficacy and safety of sacituzumab tirumotecan at the dose for evaluation in the Phase 3 portion. The purpose of this study is to compare the efficacy and safety of sacituzumab tirumotecan versus treatment of physician's choice as second-line treatment for participants with recurrent or metastatic cervical cancer in the Phase 3 portion. The primary study hypotheses are that, in the Phase 3 portion, sacituzumab tirumotecan results in a superior overall survival compared to TPC in participants with high trophoblast cell surface antigen 2 (TROP2) e","sourceUrl":"https://clinicaltrials.gov/study/NCT06459180"},{"nctId":"NCT07259889","title":"Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors","sponsor":"Guangzhou Xiling Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":13,"enrollmentType":"ESTIMATED","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-15","completionType":"ESTIMATED","lastUpdated":"2025-12-02","conditions":["Advanced Solid Tumors (Phase 1)"],"interventions":["NK cell preparation"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and immunogenicity of CEL001 injection in the treatment of advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07259889"},{"nctId":"NCT07623642","title":"A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.","sponsor":"GV20 Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":227,"enrollmentType":"ESTIMATED","startDate":"2026-06-02","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-15","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Uterine Cervical Neoplasms","Triple Negative Breast Neoplasms","Prostatic Neoplasms","Squamous Cell Carcinoma of Head and Neck","Esophageal Squamous Cell Carcinoma","Cholangiocarcinoma","Gallbladder Neoplasms","Colorectal Neoplasms","Pancreatic Ductal Adenocarcinoma","Carcinoma, Non-Small-Cell Lung","Small Cell Lung Carcinoma"],"interventions":["GV20-0251","anti-PD-1 monoclonal antibodies"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors who are refractory to, intolerant of, or ineligible for standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT07623642"},{"nctId":"NCT06378593","title":"A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations","sponsor":"3H (Suzhou) Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-16","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Solid Tumors With FGFR2 Alterations, Adult"],"interventions":["3HP-2827"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06378593"},{"nctId":"NCT07623356","title":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","sponsor":"Akeso","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":265,"enrollmentType":"ESTIMATED","startDate":"2026-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-03","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non-Small Cell Lung Cancer"],"interventions":["AK138D1","Ivonescimab","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of AK138D1 as monotherapy or in combination with ivonescimab in patients with advanced non-small cell lung cancer. Participants will receive study treatment with AK138D1 alone or in combination with ivonescimab, undergo safety assessments and tumor evaluations, and be followed for treatment tolerability, antitumor activity, and clinical outcomes.","sourceUrl":"https://clinicaltrials.gov/study/NCT07623356"},{"nctId":"NCT04594642","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":226,"enrollmentType":"ACTUAL","startDate":"2021-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-19","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["B-cell Non Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","Follicular Lymphoma"],"interventions":["AZD0486 IV"],"countries":["United States","Australia","Japan","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Hematology NGS"],"summary":"This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma (B-NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT04594642"},{"nctId":"NCT07632690","title":"QLC5508 in Participants With Metastatic Prostate Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2026-06-20","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-20","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-20","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Prostate Cancer"],"interventions":["QLC5508","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, active-controlled, multicenter Phase III trial evaluating QLC5508 versus docetaxel in participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after prior treatment with novel hormonal agents (NHAs). Participants are randomized to receive either QLC5508 monotherapy (experimental arm) or docetaxel (control arm). The primary objective is to compare the efficacy of QLC5508 versus docetaxel, as measured by radiographic progression-free survival (rPFS) assessed by an Independent Radiological Review Committee (IRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07632690"},{"nctId":"NCT05853367","title":"Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":95,"enrollmentType":"ACTUAL","startDate":"2023-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-24","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-24","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Metastatic Solid Tumors","Advanced Solid Tumors"],"interventions":["MK-0472","Pembrolizumab","MK-1084"],"countries":["United States","Canada","Chile","Israel","Poland","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05853367"},{"nctId":"NCT05665062","title":"Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies","sponsor":"Synthekine","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2023-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-24","primaryCompletionType":"ESTIMATED","completionDate":"2041-11","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["CLL/SLL","NHL","Mantle Cell Lymphoma","Follicular Lymphoma","Large B-cell Lymphoma","Indolent B-Cell Non-Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma"],"interventions":["SYNCAR-001","STK-009","Cyclophosphamide","Fludarabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05665062"},{"nctId":"NCT04464226","title":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","sponsor":"Bayer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":402,"enrollmentType":"ESTIMATED","startDate":"2020-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-26","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Cancer"],"interventions":["Darolutamide (Nubeqa, BAY1841788)"],"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Brazil","Bulgaria","Canada","China","Colombia","Czechia","Estonia","Finland","France","Germany","Hungary","Israel","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Peru","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":335,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.","sourceUrl":"https://clinicaltrials.gov/study/NCT04464226"},{"nctId":"NCT07718581","title":"HMPL-A830 in Solid Tumors","sponsor":"Hutchmed","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":147,"enrollmentType":"ESTIMATED","startDate":"2026-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-26","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Solid Tumor, Adult"],"interventions":["HMPL-A830"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A830 in participants with histologically or cytologically confirmed, unresectable, advanced, or metastatic solid tumors\\*, who are refractory or progressed on/after available standard treatment. The study will be conducted in 2 parts: Dose Escalation (Part A, Phase I), approximately 57 participants will be enrolled. Dose Optimization (Part B, Phase IIa), approximately 90 participants will be enrolled.","sourceUrl":"https://clinicaltrials.gov/study/NCT07718581"},{"nctId":"NCT06925737","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1440,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-06","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Prostate Cancer","Prostatic Neoplasms"],"interventions":["Ifinatamab deruxtecan","Docetaxel","Prednisone","Rescue Medication"],"countries":["United States","Argentina","Australia","Austria","Brazil","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Guatemala","Hong Kong","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Peru","Poland","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":290,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06925737"},{"nctId":"NCT04603807","title":"A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2021-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-26","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Entrectinib","Crizotinib"],"countries":["Brazil","China","Croatia","France","Germany","Greece","India","Italy","Jordan","Lebanon","Mexico","Netherlands","Romania","Slovakia","Spain","Sweden","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":61,"serviceSignals":["RNA fusion"],"summary":"The study will compare the efficacy and safety of entrectinib with crizotinib in participants with advanced or metastatic ROS1 non-small cell lung cancer (NSCLC). The participants will self-administer oral entrectinib or crizotinib as described in the protocol and local prescribing information. Treatments will continue until progressive disease, unacceptable toxicity, death, or withdrawal from the study, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT04603807"},{"nctId":"NCT07282509","title":"Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2025-12-23","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-03","completionType":"ESTIMATED","lastUpdated":"2025-12-15","conditions":["Advanced Hepatocellular Carcinoma (HCC)"],"interventions":["HA131","Enlonstobart Injection","Pembrolizumab Injection","Lenvatinib Mesilate Capsules"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This trial is an open-label, dose-escalation, and randomized controlled Phase Ib/II clinical study for second-line treatment in participants with advanced hepatocellular carcinoma (HCC). Its primary objective is to evaluate the safety, tolerability, pharmacokinetic profiles, and efficacy of transcatheter arterial infusion of HA131 combined with systemic therapy in the second-line treatment of participants with advanced HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07282509"},{"nctId":"NCT06780670","title":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":443,"enrollmentType":"ESTIMATED","startDate":"2025-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-27","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-19","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Prostate Cancer"],"interventions":["Investigators choice of SoC","AAA817"],"countries":["United States","Australia","Brazil","China","Hong Kong","Israel","Japan","Malaysia","Singapore","South Korea","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":81,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \\[177Lu\\]Lu-PSMA targeted therapy. Treatment of interest: the investigational treatment is AAA817 regardless of subsequent anti-neoplastic treatment. The control treatment is investigator's choice of Standard of Care, regardless of subsequent anti-neoplastic treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06780670"},{"nctId":"NCT06319820","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":641,"enrollmentType":"ESTIMATED","startDate":"2024-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-28","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"interventions":["TAR-210","Gemcitabine","MMC"],"countries":["United States","Argentina","Austria","Belgium","Brazil","China","Czechia","Denmark","France","Germany","Hong Kong","Ireland","Israel","Italy","Japan","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":193,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06319820"},{"nctId":"NCT07422610","title":"Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-02","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Advanced Malignancies and Hepatic Impairment"],"interventions":["pelabresib"],"countries":["France","Italy","Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to evaluate the impact of hepatic function on the pharmacokinetic (PK) profile of pelabresib in participants with advanced malignancies who have either hepatic impairment (HI) or normal liver function. To reduce participant burden and maximize benefit, the PK of pelabresib will be assessed at steady-state rather than after a single dose, avoiding treatment-free washout periods.","sourceUrl":"https://clinicaltrials.gov/study/NCT07422610"},{"nctId":"NCT05394714","title":"A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study","sponsor":"Medigen Biotechnology Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2022-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Colon Cancer Stage I"],"interventions":["Magicell-NK contains NK cells suspended in 100 mL normal saline"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label study to explore the safety profile and to find the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of Magicell-NK in subjects diagnosed with stage I or stage IIa colon cancer post resection from a single site in Taiwan. During this study, 3 dose levels of Magicell-NK will be tested with a 3+3 design to determine the MTD/MFD: Cohort 1, low dose (2×10\\^8 cells), Cohort 2, middle dose (6×10\\^8 cells), and Cohort 3, high dose (12\\~18 ×10\\^8 cells).","sourceUrl":"https://clinicaltrials.gov/study/NCT05394714"},{"nctId":"NCT04353375","title":"HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma","sponsor":"Hutchmed","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":235,"enrollmentType":"ESTIMATED","startDate":"2020-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-28","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Advanced Intrahepatic Cholangiocarcinoma","Solid Tumor, Adult"],"interventions":["HMPL-453"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"The goal of this clinical trial is to evaluate in patients with advanced intrahepatic cholangiocarcinoma harboring FGFR2 fusion/rearrangement. The main questions it aims to answer are: To evaluate the objective response rate (ORR) of HMPL-453 tartrate in the treatment of patients with advanced intrahepatic cholangiocarcinoma (ICC) habouring fibroblast growth factor receptor (FGFR) 2 fusions/rearrangements after at least one line of systemic treatment failure or intolerance Participants will receive HMPL-453 tartrate 300 mg QD orally (for 14 consecutive days \\[Days 1 to 14\\] followed by 7 days off \\[Day 15 to 21\\], 21 days as a treatment cycle.\\]","sourceUrl":"https://clinicaltrials.gov/study/NCT04353375"},{"nctId":"NCT07218146","title":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","sponsor":"Zai Lab (Shanghai) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2025-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Small-cell Lung Cancer"],"interventions":["ZL-1310","Investigator's Choice of Therapy"],"countries":["United States","Austria","China","Japan","Netherlands","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":76,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07218146"},{"nctId":"NCT07584954","title":"Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors","sponsor":"Jun Zhou","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Solid Tumor Cancer","Solid Tumor Cancer Treatment With Immunotherapy"],"interventions":["IUAb190708, a cytotoxic antibody"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor","sourceUrl":"https://clinicaltrials.gov/study/NCT07584954"},{"nctId":"NCT07112222","title":"A Study of LM-350 in Subjects With Advanced Solid Tumours","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Malignant Tumors"],"interventions":["LM-350 for injection"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07112222"},{"nctId":"NCT07649122","title":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","sponsor":"Norroy Bioscience Co., LTD","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Prostate Cancer"],"interventions":["68-Ga-NYM032"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study evaluates the diagnostic performance and safety of 68Ga-NYM032 PET/CT imaging in patients with suspected recurrence of prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07649122"},{"nctId":"NCT06785636","title":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","sponsor":"Pathos AI, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-02-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["mCRPC (Metastatic Castration-resistant Prostate Cancer)","Prostate Cancer"],"interventions":["Pocenbrodib","Pocenbrodib and Darolutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06785636"},{"nctId":"NCT06998771","title":"JSKN003 Combined Treatment of HER2-positive Gastric Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2025-06-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["HER2-positive Gastric Cancer"],"interventions":["JSKN003","KN026","Capecitabine","Enlonstobart","Oxaliplatin","Trastuzumab","Pembolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06998771"},{"nctId":"NCT06257693","title":"Enzalutamide Implants (Enolen) in Patients With Prostate Cancer","sponsor":"Alessa Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2024-06-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-30","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Prostate Adenocarcinoma"],"interventions":["enzalutamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06257693"},{"nctId":"NCT07644650","title":"Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors","sponsor":"Mabsoft Therapeutics (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Neoplams"],"interventions":["MST-168"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors. The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07644650"},{"nctId":"NCT05427487","title":"Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours","sponsor":"ImmVirx Pty Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Colorectal Cancer","Gastric Cancer","Ovarian Cancer"],"interventions":["IVX037","Sintilimab"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS) colorectal cancer, or gastric or ovarian cancer. The study is run in 2 parts. Phase 1a is dose escalation IVX037 monotherapy and Phase 1b is IVX037 with checkpoint inhibitor, sintilimab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05427487"},{"nctId":"NCT07092748","title":"A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-07-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-30","conditions":["Advanced Solid Cancers"],"interventions":["HS387"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)","sourceUrl":"https://clinicaltrials.gov/study/NCT07092748"},{"nctId":"NCT07339748","title":"A Clinical Study of ZL-85FA Tablets","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-15","conditions":["Advanced Solid Tumor"],"interventions":["ZL-85FA tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An open-label, multicenter phase I/IIa clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZL-85FA tablets in treating advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07339748"},{"nctId":"NCT04977453","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","sponsor":"GI Innovation, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":317,"enrollmentType":"ESTIMATED","startDate":"2021-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Cervical Cancer","Urothelial Carcinoma","Clear Cell Renal Cell Cancer (ccRCC)","Squamous Cell Non Small Cell Lung Cancer"],"interventions":["GI-101","Pembrolizumab (KEYTRUDA®)","Lenvatinib","GI-101A"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04977453"},{"nctId":"NCT04516447","title":"A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer","sponsor":"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":172,"enrollmentType":"ESTIMATED","startDate":"2020-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Solid Tumor","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer"],"interventions":["Azenosertib","Carboplatin","Pegylated liposomal doxorubicin","Paclitaxel","Gemcitabine","Bevacizumab"],"countries":["United States","Australia","Bosnia and Herzegovina","Bulgaria","Georgia","Serbia","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.","sourceUrl":"https://clinicaltrials.gov/study/NCT04516447"},{"nctId":"NCT06840483","title":"Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer","sponsor":"BicycleTx Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Breast Cancer"],"interventions":["Zelenectide pevedotin (BT8009)"],"countries":["United States","Australia","Belgium","France","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \\[HR+/HER2-\\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06840483"},{"nctId":"NCT07715747","title":"A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors","sponsor":"TJ Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2026-08-21","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Solid Tumor","Metastatic Ovary Cancer","Metastatic Gastric Cancer","Metastatic Endometrial Carcinoma"],"interventions":["TJ037130"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of TJ037130 in participants with advanced or metastatic solid tumors, and to determine the Potential Optimal Biological Dose (POBD) of TJ037130 for subsequent investigations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07715747"},{"nctId":"NCT07310355","title":"68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","sponsor":"Chengdu StarRay Therapeutics Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["68Ga-PSMA-0057","177Lu-PSMA-0057"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, dosimetry, pharmacodynamics, and preliminary efficacy of Gallium \\[68Ga\\] PSMA-0057 Injection and Lutetium \\[177Lu\\] PSMA-0057 Injection as an integrated theranostic regimen in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The study consists of a Phase I dose-escalation phase to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of 177Lu-PSMA-0057, followed by a Phase II dose-expansion phase to further evaluate preliminary antitumor efficacy and confirm safety and pharmacologic profiles. Eligible pa","sourceUrl":"https://clinicaltrials.gov/study/NCT07310355"},{"nctId":"NCT06256588","title":"A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":864,"enrollmentType":"ESTIMATED","startDate":"2024-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-26","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Neoplasms, Head and Neck"],"interventions":["Dostarlimab","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Mexico","Norway","Poland","Portugal","Romania","Saudi Arabia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":277,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06256588"},{"nctId":"NCT06510374","title":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","sponsor":"Ferring Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":454,"enrollmentType":"ESTIMATED","startDate":"2024-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Intermediate Risk Non-Muscle Invasive Bladder Cancer"],"interventions":["Nadofaragene Firadenovec"],"countries":["United States","Canada","Czechia","Denmark","France","Japan","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["Broad CGP"],"summary":"A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06510374"},{"nctId":"NCT07601334","title":"Safety and Activity of HF50 in Patients With Advanced Solid Tumors","sponsor":"HighField Biopharmaceuticals Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Advanced Solid Tumors"],"interventions":["HF50"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07601334"},{"nctId":"NCT05898399","title":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","sponsor":"Artios Pharma Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":181,"enrollmentType":"ESTIMATED","startDate":"2023-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["ART6043","Olaparib"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["HER2 profiling"],"summary":"This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.","sourceUrl":"https://clinicaltrials.gov/study/NCT05898399"},{"nctId":"NCT06868732","title":"Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":288,"enrollmentType":"ESTIMATED","startDate":"2025-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Advanced Non-small Cell Lung Cancer"],"interventions":["JSKN016","Carboplatin","Furmonertinib Mesylate","Ivonescimab","Docetaxel","Tislelizumab","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06868732"},{"nctId":"NCT07050641","title":"Phase I/II Study of SCTB39-1 in Advanced Solid Tumours","sponsor":"Sinocelltech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2025-07-04","conditions":["Advanced Malignant Solid Tumor"],"interventions":["SCTB39-1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07050641"},{"nctId":"NCT04892173","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2021-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Squamous Cell"],"interventions":["JNJ-90301900 (NBTXR3)","Cetuximab","Radiation Therapy"],"countries":["United States","Austria","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Czechia","Finland","France","Georgia","Germany","Greece","Hungary","India","Israel","Japan","Philippines","Portugal","Romania","Serbia","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":193,"serviceSignals":["Broad CGP"],"summary":"This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participants with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT04892173"},{"nctId":"NCT04576156","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","sponsor":"Geron Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":327,"enrollmentType":"ACTUAL","startDate":"2021-04-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Myelofibrosis"],"interventions":["Imetelstat","Best Available Therapy (BAT)"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Colombia","Denmark","France","Georgia","Germany","Hungary","India","Israel","Italy","Malaysia","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":144,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04576156"},{"nctId":"NCT07749703","title":"A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":346,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Histologically or Cytologically Confirmed Advanced Solid Tumors"],"interventions":["SIM0532 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of SIM0532 in participants with advanced solid tumors. The study commences with a dose-escalation part (Part 1), followed by a dose-expansion part (Part 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT07749703"},{"nctId":"NCT05579132","title":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","sponsor":"MSD R&D (China) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":203,"enrollmentType":"ESTIMATED","startDate":"2022-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Acute Lymphoblastic Leukemia"],"interventions":["MK-1045"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.","sourceUrl":"https://clinicaltrials.gov/study/NCT05579132"},{"nctId":"NCT06281964","title":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":327,"enrollmentType":"ESTIMATED","startDate":"2023-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Non-Small-Cell Lung Cancer"],"interventions":["PLB1004","Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Efficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.","sourceUrl":"https://clinicaltrials.gov/study/NCT06281964"},{"nctId":"NCT07589257","title":"A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine Glioma","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-05-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Intrinsic Pontine Glioma"],"interventions":["VRT106 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG","sourceUrl":"https://clinicaltrials.gov/study/NCT07589257"},{"nctId":"NCT06545955","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","sponsor":"Ferring Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"],"interventions":["Nadofaragene Firadenovec","Gemcitabine","Docetaxel","Pembrolizumab"],"countries":["United States","Canada","Czechia","France","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":76,"serviceSignals":["Broad CGP"],"summary":"The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta/T1).","sourceUrl":"https://clinicaltrials.gov/study/NCT06545955"},{"nctId":"NCT06845241","title":"Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2025-02","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-02-25","conditions":["Relapsed or Refractory Non-Hodgkin Lymphoma"],"interventions":["ICP-490"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed or refractory non-hodgkin lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06845241"},{"nctId":"NCT06247605","title":"A Phase IIII Study of AL8326 in Small Cell Lung Cancer","sponsor":"Advenchen Laboratories Nanjing Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":243,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2024-02-08","conditions":["Small Cell Lung Carcinoma"],"interventions":["AL8326 tablets","placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of AL8326 tablets in small cell lung cancer (SCLC) patients with disease progression or recurrence after receiving at least second-line treatment regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT06247605"},{"nctId":"NCT06413498","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","sponsor":"Kite, A Gilead Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":452,"enrollmentType":"ACTUAL","startDate":"2024-08-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2031-07","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Multiple Myeloma"],"interventions":["Anitocabtagene Autoleucel","Cyclophosphamide","Fludarabine","Pomalidomide","Bortezomib","Dexamethasone","Daratumumab","Carfilzomib"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Italy","Japan","Netherlands","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":117,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.","sourceUrl":"https://clinicaltrials.gov/study/NCT06413498"},{"nctId":"NCT07614646","title":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 in Combination With Ivonescimab in Sq-NSCLC Patients","sponsor":"Everest Medicines (Beijing) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":13,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Squamous Non-Small Cell Lung Cancer sqNSCLC"],"interventions":["EVM14","Ivonescimab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) combination with Ivonescimab in patients with sq-NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07614646"},{"nctId":"NCT06789172","title":"A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors","sponsor":"Epkin","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2025-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Solid Tumours","Sarcoma","HNSCC","Non Small Cell Lung Cancer","NSCLC","Colorectal Cancer (CRC)","Myxofibrosarcoma (MFS)","Solitary Fibrous Tumors","Dedifferentiated Liposarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Leiomyosarcoma","Leiomyosarcoma (LMS)","Gastric Cancer (GC)","Gastric Cancer Adenocarcinoma Metastatic","Gastric / Gastroesophageal Junction Adenocarcinoma"],"interventions":["OKN4395","Pembrolizumab","Fasting","Fed","H2 Receptor Antagonist"],"countries":["United States","Australia","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. This study will be split into 2 parts. Part 1a will look at multiple doses of OKN4395 either alone (monotherapy) or with pembrolizumab (combination therapy) administered on day 1 of each 21-day cycle in patients with ","sourceUrl":"https://clinicaltrials.gov/study/NCT06789172"},{"nctId":"NCT07033598","title":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","sponsor":"Theradex","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Leukemia, Myelomonocytic, Chronic"],"interventions":["Pacritinib","Hydroxyurea"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults. The main questions it aims to answer are: * Does pacritinib improve disease control compared to hydroxyurea? * What medical problems do participants have when taking pacritinib or hydroxyurea? Researchers will compare pacritinib to hydroxyurea to see if pacritinib is more effective and better tolerated in people with advanced proliferative chronic myelomonocytic leukemia. Participants will be randomly assigned to receive either pacritinib twice a day or hydroxyurea for up to 48 weeks. After treatment ends, participants will be foll","sourceUrl":"https://clinicaltrials.gov/study/NCT07033598"},{"nctId":"NCT05100862","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":799,"enrollmentType":"ACTUAL","startDate":"2022-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Relapsed/Refractory Follicular Lymphoma","Marginal Zone Lymphoma"],"interventions":["Zanubrutinib","Rituximab","Lenalidomide","Obinutuzumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Czechia","France","Georgia","Germany","Greece","Ireland","Israel","Italy","Japan","Poland","Portugal","Puerto Rico","Romania","South Africa","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":268,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R\\^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lug","sourceUrl":"https://clinicaltrials.gov/study/NCT05100862"},{"nctId":"NCT07213791","title":"A Study of LY4337713 in Participants With FAP-Positive Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":241,"enrollmentType":"ESTIMATED","startDate":"2025-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2033-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Ovarian Neoplasms","Breast Neoplasms","Pancreatic Intraductal Neoplasms","Colorectal Neoplasms","Esophageal Neoplasms","Stomach Neoplasms","Cholangiocarcinoma"],"interventions":["LY4337713"],"countries":["United States","China","Germany","Japan","Netherlands"],"northAmerica":true,"chinaSites":true,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07213791"},{"nctId":"NCT06284590","title":"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients","sponsor":"Philogen S.p.A.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2024-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2024-10-26","conditions":["Melanoma Stage III","Melanoma Stage IV"],"interventions":["L19IL2","L19TNF","L19IL2/L19TNF","KEYTRUDA®"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06284590"},{"nctId":"NCT07387471","title":"Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma"],"interventions":["Venetoclax"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"Lymphoplasmacytic Lymphoma (LPL) is a rare type of low-grade B-cell lymphoma. The purpose of this study is to assess the change in disease activity of adult participants with relapsed or refractory Waldenström macroglobulinemia(WM)/LPL receiving venetoclax. Venetoclax is being investigated in the treatment of WM/LPL. Participants will receive oral venetoclax at doses ramping up to the target dose, as part of treatment. Approximately 14 adult participants with WM/LPL will be enrolled in the study at approximately 20 sites in Japan. Participants will receive oral venetoclax at doses ramping up to the target dose. The total study duration is approximately 28 months. There may be higher treatmen","sourceUrl":"https://clinicaltrials.gov/study/NCT07387471"},{"nctId":"NCT07339176","title":"Intratumoral N17350 in Advanced Solid Tumors","sponsor":"Onchilles Pharma Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":275,"enrollmentType":"ESTIMATED","startDate":"2026-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Neoplasms, Solid Tumor","Breast Neoplasms, Triple-Negative","Squamous Cell Carcinoma of Skin","Melanoma","Head and Neck Neoplasms","Carcinoma, Squamous Cell","Carcinoma, Non-Small-Cell Lung"],"interventions":["N17350"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: 1. Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? 2. Are there any side effects for participants when taking N17350? 3. What is the safest dose of N17350 and the dose that should be used for further study? 4. Researchers will give N17350 directly into tumor lesions using a needle (intratumoral injection). This is an open-label study, meaning all participants will receive N17350 and there is no p","sourceUrl":"https://clinicaltrials.gov/study/NCT07339176"},{"nctId":"NCT07689539","title":"Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Pancreatic Cancer"],"interventions":["DN022150","Chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07689539"},{"nctId":"NCT07131722","title":"Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II","sponsor":"PRG Science & Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":25,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Neurofibromatosis Type II","NF2"],"interventions":["Trineumin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if Trineumin(Code name:PRG-N-01) works to treat Neurofibromatosis Type II(NF2) in adults. It will also learn about the safety and tolerability and toxicity of PRG-N-01. The main questions it aims to answer are: * What dose was determined as the Maximum Tolerated Dose (MTD) of Trineumin? * What dose was explored as the optimal effective dose of Trineumin based on radiographic response? * Does Trineumin reduce tumor size or improve participants' quality of life, including hearing function? * What medical problems do participants have when taking Trineumin? Participants will: * Take Trineumin every day for 96 weeks * Visit the clinic once 1, 4, 8, 12,","sourceUrl":"https://clinicaltrials.gov/study/NCT07131722"},{"nctId":"NCT06504732","title":"To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":574,"enrollmentType":"ESTIMATED","startDate":"2024-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Stomach Neoplasms","Solid Tumor"],"interventions":["IAH0968","Trastuzumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"The safety, tolerability, and determination of the maximum tolerated dose (MTD) of the combination therapy were first evaluated for IAH0968 in combination with or without the CAPEOX regimen in unsystematically treated subjects with HER2-expressing advanced/metastatic colorectal or gastric cancers (including adenocarcinomas of the gastro-esophageal junction) or HER2-hypo-expressing advanced/metastatic solid tumors. The efficacy of IAH0968 in combination with the CAPEOX regimen versus trastuzumab in combination with the CAPEOX regimen in subjects with HER2-positive advanced/metastatic gastric cancer, including gastro-esophageal junction adenocarcinoma, was then assessed by progression-free sur","sourceUrl":"https://clinicaltrials.gov/study/NCT06504732"},{"nctId":"NCT05382299","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":623,"enrollmentType":"ACTUAL","startDate":"2022-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-07","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Triple Negative Breast Cancer","PD-L1 Negative"],"interventions":["Sacituzumab Govitecan-hziy","Paclitaxel","nab-Paclitaxel","Gemcitabine","Carboplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Romania","Slovakia","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":363,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.","sourceUrl":"https://clinicaltrials.gov/study/NCT05382299"},{"nctId":"NCT07025239","title":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":430,"enrollmentType":"ESTIMATED","startDate":"2025-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2025-06-17","conditions":["Metastatic Colorectal Cancer"],"interventions":["QL1706","Bevacizumab","Oxaliplatin","Capecitabine","Placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of QL1706 Injection in combination with bevacizumab and XELOX compared with placebo in combination with bevacizumab and XELOX for first-line treatment in patients with unresectable mCRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07025239"},{"nctId":"NCT07742215","title":"A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)","sponsor":"Biocad","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-07","primaryCompletionType":"ESTIMATED","completionDate":"2032-10","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Myeloma Multiple"],"interventions":["BCD-248 + daratumumab","Daratumumab + pomalidomide + dexamethasone"],"countries":["Belarus","Russia"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma. The study will be conducted in a population of male and female subjects aged 18 years and older, with confirmed symptomatic multiple myeloma with measurable disease, who have received one prior line of therapy that included a proteasome inhibitor and lenalidomide and were refractory to lenalidomide, or who have received two or three prior lines of therapy that included a proteasome inhibitor and lenalidomide, with disease progression during or after the last ","sourceUrl":"https://clinicaltrials.gov/study/NCT07742215"},{"nctId":"NCT07475559","title":"JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Advanced Solid Tumor Malignancies"],"interventions":["JSKN016HC"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07475559"},{"nctId":"NCT07673744","title":"A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)","sponsor":"TG Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Myasthenia Gravis"],"interventions":["Ublituximab","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.","sourceUrl":"https://clinicaltrials.gov/study/NCT07673744"},{"nctId":"NCT07172919","title":"A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation","sponsor":"Amgen","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":14,"enrollmentType":"ESTIMATED","startDate":"2026-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumors"],"interventions":["Sotorasib","Panitumumab"],"countries":["United States","Australia","France","Germany","Greece","Italy","Japan","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RAS genotyping"],"summary":"The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.","sourceUrl":"https://clinicaltrials.gov/study/NCT07172919"},{"nctId":"NCT07668557","title":"Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"iCell Gene Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-04","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07668557"},{"nctId":"NCT03768063","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2019-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-05","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Cancer"],"interventions":["Atezolizumab","Bevacizumab","Alectinib","Cobimetinib","Vemurafenib","FAP IL2V","Venetoclax","Enzalutamide","Pembrolizumab","Sunitinib","Niraparib","Cabozantinib","Pemetrexed","Paclitaxel","Emactuzumab","Rucaparib"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Chile","Czechia","Denmark","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Italy","Japan","Mexico","Poland","Romania","Russia","South Korea","Spain","Thailand","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":80,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.","sourceUrl":"https://clinicaltrials.gov/study/NCT03768063"},{"nctId":"NCT07230977","title":"GenSci139 in Patients With Advanced Solid Tumors","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2025-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-08","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Advanced Solid Tumors"],"interventions":["GenSci139"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, two-part, multicenter, first-in-human study. The Part 1 study will assess the safety, tolerability, preliminary anti-tumor activities, PK profile, immunogenicity and biomarker of GenSci139 in participants with locally advanced or metastatic solid tumors, as well as identity MTD (if any) and RDE. The Part 2 study is to further evaluate the preliminary anti-tumor activities, safety, PK profile, immunogenicity and biomarker of GenSci139 at RDE dose levels with selected advanced cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07230977"},{"nctId":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2025-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-08","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced/Metastatic Solid Tumors","Bladder Cancer","Urothelial Carcinoma","Advanced Non-Small Cell Lung Cancer","Carcinoma, Non Small Cell Lung","Carcinoma, Squamous Cell of Head and Neck","Head and Neck Cancer","Esophageal Cancer","Gastroesophageal Junction Adenocarcinoma","Esophageal Squamous Cell Carcinoma","Esophageal Adenocarcinoma","Pancreatic Adenocarcinoma","Pancreatic Cancer"],"interventions":["PF-08046876"],"countries":["United States","Canada","Puerto Rico","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["ADC biomarker"],"summary":"The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.","sourceUrl":"https://clinicaltrials.gov/study/NCT07090499"},{"nctId":"NCT07043907","title":"PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC","sponsor":"Shenzhen Celconta Life Science Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2025-07-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-18","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["Stage IIIA Non-small Cell Lung Cancer"],"interventions":["PANK-003 cell injection combined with standard postoperative adjuvant chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07043907"},{"nctId":"NCT07226986","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2025-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-13","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy"],"interventions":["AMO959","AAA617","Enzalutamide","Abiraterone"],"countries":["United States","Australia","France","Germany","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \\[177Lu\\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane tre","sourceUrl":"https://clinicaltrials.gov/study/NCT07226986"},{"nctId":"NCT05211895","title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":860,"enrollmentType":"ESTIMATED","startDate":"2022-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-01","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Durvalumab","Domvanalimab","Placebo"],"countries":["United States","Belgium","Brazil","Canada","Chile","France","Germany","Greece","Hong Kong","Hungary","India","Italy","Japan","Malaysia","Mexico","Norway","Philippines","Poland","Romania","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":false,"siteCount":264,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.","sourceUrl":"https://clinicaltrials.gov/study/NCT05211895"},{"nctId":"NCT07519655","title":"Phase 1 Study of PF-08046033 in Advanced Solid Tumors","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2026-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-14","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Non-Small-Cell Lung","Esophageal Cancer","Cutaneous Melanoma"],"interventions":["PF-08046033"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma. The study has two parts: In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable ","sourceUrl":"https://clinicaltrials.gov/study/NCT07519655"},{"nctId":"NCT07219212","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-01-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-14","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Squamous Cell Carcinoma of Head and Neck"],"interventions":["JNJ-90301900","Cisplatin","Intensity Modulated Radiation Therapy (IMRT)","Carboplatin","Paclitaxel"],"countries":["United States","France","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \\& throat).","sourceUrl":"https://clinicaltrials.gov/study/NCT07219212"},{"nctId":"NCT06549751","title":"MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","sponsor":"Marker Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2026-07-16","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-16","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Pancreas Cancer","Pancreatic Cancer Metastatic","Pancreatic Cancer (Unresectable)"],"interventions":["MT-601 dose 200 million cells","MT-601 dose 400 million cells","MT-601 dose 800 million cells","MT-601 dose 1200 million cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\\[s\\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.","sourceUrl":"https://clinicaltrials.gov/study/NCT06549751"},{"nctId":"NCT06961006","title":"A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-22","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-05","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Malignant Melanoma"],"interventions":["Intismeran autogene","Pembrolizumab","Placebo"],"countries":["United States","Australia","Canada","France","Germany","Greece","Israel","Italy","New Zealand","Poland","Portugal","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"Researchers want to learn if intismeran autogene with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. A standard (or usual) treatment for advanced melanoma is immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Intismeran autogene is a study treatment designed to help a person's immune system attack their specific cancer. Pembrolizumab is an immunotherapy. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab live longer without the cancer growing or spreading tha","sourceUrl":"https://clinicaltrials.gov/study/NCT06961006"},{"nctId":"NCT06330064","title":"A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":680,"enrollmentType":"ESTIMATED","startDate":"2024-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-25","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Recurrent or Metastatic Solid Tumors"],"interventions":["Ifinatamab deruxtecan"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Chile","France","Germany","Ireland","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":120,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; cutaneous melanoma; and neuroendocrine carcinoma (NEC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06330064"},{"nctId":"NCT05888493","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":109,"enrollmentType":"ACTUAL","startDate":"2023-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-25","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-20","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Follicular Lymphoma (FL)"],"interventions":["Tisagenlecleucel","Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.","Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles","Lymphodepleting chemotherapy","Corticosteroids and/or Radiation (Bridging therapy)"],"countries":["Australia","Austria","Canada","Czechia","Hungary","Poland","Singapore","Slovakia","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05888493"},{"nctId":"NCT07403721","title":"AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":464,"enrollmentType":"ESTIMATED","startDate":"2026-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-28","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)"],"interventions":["AMG 436"],"countries":["United States","Australia","Belgium","Canada","China","France","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["MSI / TMB"],"summary":"The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07403721"},{"nctId":"NCT07489066","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Carcinoma","Non-Small-Cell Lung","Lung Cancer (NSCLC)","Lung Neoplasms","Carcinoma, Non-Small-Cell Lung (NSCLC)","Lung Disease","Non-Small Cell Lung Cancer","Non-small Cell Lung Cancer, Non-squamous","Non-small Cell Lung Cancer, Squamous"],"interventions":["PF-08634404","Chemotherapy Regimen 1","Chemotherapy Regimen 2"],"countries":["United States","China","Puerto Rico","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or may not be removable with surgery. The study is seeking participants who: * Are aged 18 years or older * Have either: * Early-stage or locally advanced (Stage II or IIIA/B) NSCLC and are a candidate for neoadjuvant therapy, followed by surgical removal of the tumor. Neoadjuvant therapy is a treatment given as a first step to shrink the tumor before surgery. * Early-stage or locally advanced (Stage II or IIIA/B) NSCLC","sourceUrl":"https://clinicaltrials.gov/study/NCT07489066"},{"nctId":"NCT06940401","title":"JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations","sponsor":"Suzhou Junjing BioSciences Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":44,"enrollmentType":"ACTUAL","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["NSCLC"],"interventions":["JS111 capsules (AP-L1898)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety, tolerability, and preliminary efficacy of JS111 capsules in patients with locally advanced, metastatic, or recurrent NSCLC harboring EGFR mutations;to determine the recommended Phase II dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06940401"},{"nctId":"NCT05520567","title":"A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Acute Myeloid Leukemia (AML)","FLT3-mutated Acute Myeloid Leukemia"],"interventions":["Gilteritinib","Venetoclax","Azacitidine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene. Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with AML with the changed FLT3 gene. They cannot have chemotherapy due to old age or other conditions. Before these combined 3 medicines are available as a treatment, the researchers need to understand how they are processed by and act upon the body when given together. In this study, they do this to find a suitable dose for venetoclax and to ","sourceUrl":"https://clinicaltrials.gov/study/NCT05520567"},{"nctId":"NCT07088588","title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2025-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2025-07-28","conditions":["Advanced Solid Cancer","Metastatic Solid Tumor","Ovarian Cancer","Breast Cancer","BRCA Mutation","HRR Deficiency"],"interventions":["SYN608"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN608 as monotherapy in adult patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07088588"},{"nctId":"NCT07374419","title":"Atamparib in Patients With Advanced Solid Tumors","sponsor":"Nerviano Medical Sciences (Shanghai) Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["NSCLC Adenocarcinoma","Solid Tumor"],"interventions":["atamparib escalation levels","atamparib RP2D"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multi-part, open-label, non-randomized phase Ib/II clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of atamparib, an investigational agent, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) adenocarcinoma. The study comprises dose escalation (phase Ib) and expansion (phase II).","sourceUrl":"https://clinicaltrials.gov/study/NCT07374419"},{"nctId":"NCT07287748","title":"A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer","sponsor":"Alpha Fusion Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["DTC - Differentiated Thyroid Cancer"],"interventions":["[211At]NaAt"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial consists of 2 parts, i.e., Part Ia and Ib. The Part Ia is to evaluate the safety and tolerability of a single intravenous dose of af-001 in patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma) refractory to or intolerant of standard-of-care therapy, who have received total thyroidectomy, and to determine the MTD (Maximum tolerated dose). Part Ib is to evaluate the efficacy and safety of af-001 mutiple doses to patients with radically unresectable, recurrent, metastatic differentiated thyroid cancer (papillary carcinoma, follicular carcinoma), who have received total thyroidectomy and are RAI naïve, ra","sourceUrl":"https://clinicaltrials.gov/study/NCT07287748"},{"nctId":"NCT07656038","title":"Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer","sponsor":"STCube, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Colonrectal Cancer (CRC)"],"interventions":["Nelmastobart in combination with TAS-102 and Bevacizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Nelmastobart（hSTC810） is a novel humanized monoclonal antibody that fuses on IgG4 and targets a novel immune checkpoint protein, BTN1A1+.This is an phase Ib bridging trial conducted in China to assess the safety, tolerability, and pharmacokinetic characteristics of Nelmastobart in combined with TAS-102 and Bevacizumab in Chinese participants with mCRC, and to verify that the safety results align with those from the Korean STCUBE-003 phase Ib trial. The phase Ib trial will also provide supportive data for conducting a randomized, double-blind, controlled Phase II study in China.","sourceUrl":"https://clinicaltrials.gov/study/NCT07656038"},{"nctId":"NCT07006688","title":"A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment","sponsor":"Servier Bio-Innovation LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["IDH1-Mutated Malignancies"],"interventions":["Ivosidenib Oral Tablet"],"countries":["United States","Australia","Brazil","Czechia","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to investigate the PK, PD, safety, and tolerability of ivosidenib in adult participants with IDH1-mutated malignancies and hepatic impairment (HI)/ renal impairment (RI). Participants will be enrolled into one of 5 groups based on their hepatic or renal function. During the treatment period participants will have study visits on days 1, 4, 8, 15, 22, and 28 of Cycle 1, on days 1 and 15 of Cycle 2 and 3, and on day 1 of each additional cycle. Each cycle is 28 consecutive days of treatment and cycles will be continuous until the end of the study. Approximately 30 days after treatment has ended, a safety follow-up visit will occur. Study visits may include blood t","sourceUrl":"https://clinicaltrials.gov/study/NCT07006688"},{"nctId":"NCT07160725","title":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2025-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Solid Tumours"],"interventions":["BMS-986517","Pumitamig"],"countries":["United States","Denmark","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07160725"},{"nctId":"NCT07609472","title":"FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma","sponsor":"FluoGuide A/S","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["High-Grade Glioma (WHO III-IV)"],"interventions":["FG001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This clinical trial aims to determine if FG001 can assist surgeons in identifying the difference between tumor and healthy tissue during surgery in participants with newly diagnosed high-grade glioma. The scheduled neurosurgical tumor resection will occur under NIR fluorescence guidance and support the surgeons in achieving complete removal of the cancer. FG001 is a 'fluorescent imaging agent,' which is a dye that glows under a special light to help doctors see certain tissues. The main questions it aims to answer are: 1. To see how well a special light (called NIR fluorescence imaging) can show the difference between the tumor and the nearby healthy tissue during surgery. This difference is","sourceUrl":"https://clinicaltrials.gov/study/NCT07609472"},{"nctId":"NCT05583617","title":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Multiple Myeloma"],"interventions":["Cevostamab","Lenalidomide","Tocilizumab","Iberdomide","Dexamethasone"],"countries":["Australia","France","Germany","Poland","South Korea","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"CO43923 is a platform study that will evaluate the safety, efficacy, and pharmacokinetics (PK) of multiple treatment combinations, as monotherapy or in combination, in participants with multiple myeloma (MM). The study is designed with the flexibility to open new treatment substudies as new treatments become available. Information regarding the opened substudies are found below.","sourceUrl":"https://clinicaltrials.gov/study/NCT05583617"},{"nctId":"NCT06500676","title":"A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":407,"enrollmentType":"ESTIMATED","startDate":"2024-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2025-11-20","conditions":["KRAS G12D Mutations","Advanced Solid Tumors"],"interventions":["GFH375"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06500676"},{"nctId":"NCT05581004","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":165,"enrollmentType":"ACTUAL","startDate":"2022-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-07-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Locally Advanced or Metastatic Solid Tumors","NSCLC","HNSCC","Melanoma","TNBC","Esophageal Cancer","Gastric Cancer","Cervical Cancer","Colorectal Cancer","Urothelial Carcinoma","Clear Cell RCC","HCC"],"interventions":["Enzelkitug","Atezolizumab","Pembrolizumab"],"countries":["United States","Australia","Belgium","Canada","Greece","Netherlands","South Korea","Spain","Sweden","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of enzelkitug when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT05581004"},{"nctId":"NCT05658562","title":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","sponsor":"Tanabe Pharma Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":46,"enrollmentType":"ACTUAL","startDate":"2023-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["MT-2111"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"\\[Phase I part\\] To investigate the safety, tolerability, and pharmacokinetics of MT-2111 monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In addition, the dose to be used in the Phase II part will be confirmed. \\[Phase II part\\] To evaluate the efficacy of MT-2111 monotherapy in patients with relapsed/refractory DLBCL. In addition, the safety and pharmacokinetics will be investigated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05658562"},{"nctId":"NCT07042100","title":"A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.","sponsor":"Sun Pharma Advanced Research Company Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":177,"enrollmentType":"ESTIMATED","startDate":"2025-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Solid Tumors"],"interventions":["Dose level (DL)1","DL2","DL3","DL4","DL5"],"countries":["United States","Australia","India"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07042100"},{"nctId":"NCT07021898","title":"A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.","sponsor":"Erasca, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-03","conditions":["Metastatic Solid Tumors"],"interventions":["ERAS-4001","ERAS-4001 in combination"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07021898"},{"nctId":"NCT06449222","title":"Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy","sponsor":"BioNTech SE","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":83,"enrollmentType":"ACTUAL","startDate":"2024-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Locally Advanced Breast Cancer","Triple Negative Breast Cancer","Metastatic Triple Negative Breast Cancers"],"interventions":["BNT327 Dose Level 1 (DL1)","BNT327 Dose Level 1 (DL2)","Nab-placlitaxel","Carboplatin","Gemcitabine","Paclitaxel","Eribulin","BNT327 Optimized Dose","BNT327 Equivalent Q3W Dose"],"countries":["United States","Australia","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06449222"},{"nctId":"NCT07489716","title":"A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-04-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SHR-1826"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, multicenter phase II clinical trial aimed at evaluating the efficacy, safety, and pharmacokinetics of SHR-1826 in treating locally advanced or metastatic non-small cell lung cancer . The recommended dose of SHR-1826 was administered via intravenous infusion once every 3 weeks (Q3W), with each treatment cycle lasting 21 days until meeting protocol-defined treatment discontinuation criteria.","sourceUrl":"https://clinicaltrials.gov/study/NCT07489716"},{"nctId":"NCT07374848","title":"Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors","sponsor":"Zai Lab (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Solid Tumors","Sarcomas"],"interventions":["ZL-6201"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07374848"},{"nctId":"NCT06082167","title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Exelixis","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2024-06-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2025-08-17","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["Zanzalintinib","Zanzalintinib-matched Placebo","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Chile","Colombia","Czechia","France","Germany","Greece","Hungary","Israel","Italy","Malaysia","Mexico","Poland","Romania","Slovakia","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":168,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT06082167"},{"nctId":"NCT07697586","title":"SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":206,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["NSCLC"],"interventions":["SKB264+SKB118"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with NSCLC. The study includes a dose escalation phase and an expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07697586"},{"nctId":"NCT06943521","title":"A Study of MT-4561 in Patients With Various Advanced Solid Tumors","sponsor":"Tanabe Pharma America, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-04-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2025-12-11","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)","Non-small Cell Lung Cancer (NSCLC)","Esophageal Cancer","Gastric Cancer","Biliary Tract Cancer","Pancreatic Ductal Adenocarcinoma (PDAC)","Breast Cancer","Ovarian Cancer","Cervical Cancer","Endometrial Cancer","Prostate Cancer","Urothelial Carcinoma","Neuroendocrine Tumor (NET)","Neuroendocrine Carcinoma (NEC)","Soft Tissue Sarcoma","Nuclear Protein in Testis (NUT) Carcinoma"],"interventions":["MT-4561"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.","sourceUrl":"https://clinicaltrials.gov/study/NCT06943521"},{"nctId":"NCT06998407","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","sponsor":"Avenzo Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2025-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["HR+/HER2- Breast Cancer","HR+, HER2-, Advanced Breast Cancer"],"interventions":["AVZO-021","Fulvestrant","Letrozole","AVZO-023"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"This study, the first clinical trial of AVZO-023, aims to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-023 in patients with advanced solid tumors. AVZO-023 is an oral medication that inhibits cyclin-dependent kinase 4 (CDK4).","sourceUrl":"https://clinicaltrials.gov/study/NCT06998407"},{"nctId":"NCT06239194","title":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","sponsor":"ModeX Therapeutics, An OPKO Health Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":285,"enrollmentType":"ESTIMATED","startDate":"2024-06-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Biliary Tract Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gastric Cancer","GastroEsophageal Cancer","Head and Neck Cancer","Hepatocellular Cancer","Non-small Cell Lung Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Renal Cancer","Thyroid Cancer"],"interventions":["MDX2001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06239194"},{"nctId":"NCT05886920","title":"A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations","sponsor":"D3 Bio (Wuxi) Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2023-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumors With MAPK Pathway Mutations"],"interventions":["D3S-002","D3S-001"],"countries":["United States","Australia","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05886920"},{"nctId":"NCT06458712","title":"Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies","sponsor":"Duke Street Bio Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)"],"interventions":["DSB2455"],"countries":["United States","France","Hungary","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HRD / HRR"],"summary":"Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT06458712"},{"nctId":"NCT03069469","title":"Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2017-02-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Advanced Malignant Neoplasm","Pigmented Villonodular Synovitis","Giant Cell Tumor of Tendon Sheath","Tenosynovial Giant Cell Tumor","Tenosynovial Giant Cell Tumor, Diffuse"],"interventions":["Vimseltinib"],"countries":["United States","Australia","Canada","France","Italy","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT03069469"},{"nctId":"NCT06038058","title":"A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies","sponsor":"BioRay Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":164,"enrollmentType":"ESTIMATED","startDate":"2023-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Advanced Malignancies"],"interventions":["BRY812 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BRY812 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BRY812 for injection in patients with advanced malignancies. Patients will receive treatment every 3 weeks until intolerable toxicity, disease progression, pregnancy, withdrawal of informed consent, death, study discontinuation, or withdrawal from the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06038058"},{"nctId":"NCT04503278","title":"A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors","sponsor":"BioNTech Cell & Gene Therapies GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":214,"enrollmentType":"ESTIMATED","startDate":"2020-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2041-08","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Solid Tumor"],"interventions":["CLDN6 CAR-T","CLDN6 uRNA-LPX/CLDN6 modRNA-LPX"],"countries":["Australia","Germany","Netherlands","Sweden"],"northAmerica":false,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6 ribonucleic acid lipoplexes (RNA-LPX) in patients with CLDN6-positive relapsed or refractory advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04503278"},{"nctId":"NCT06939283","title":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","sponsor":"Werewolf Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-02-10","conditions":["Advanced or Metastatic Solid Tumors","Non-Hodgkin Lymphoma"],"interventions":["WTX-330"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of the study drug WTX-330 when administered using a fixed dose regimen or a step-up dose regimen in adult patients with selected advanced or metastatic solid tumors or lymphoma. In addition to safety and tolerability, the study aims to: * determine the maximum initial dose of WTX-330 that may be used in the step-up dose regimen * determine whether the step-up dose regimen can increase WTX-330 exposure in patients due to improved tolerability * determine the maximum tolerated dose (MTD) of WTX-330 and/or recommended dose for expansion (RDE) for each regimen * evaluate the antitumor activity of WTX-330 * characterize th","sourceUrl":"https://clinicaltrials.gov/study/NCT06939283"},{"nctId":"NCT07623369","title":"A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors","sponsor":"Huahui Health","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":56,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-08","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Solid Tumor","Non-small Cell Lung Cancer","Hepatocellular Carcinoma","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Renal Cell Carcinoma","Endometrial Cancer","Cervical Cancer","Small-cell Lung Cancer","Triple Negative Breast Cancer","Urothelial Carcinoma","Gastroesophageal Adenocarcinoma"],"interventions":["HH160"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.","sourceUrl":"https://clinicaltrials.gov/study/NCT07623369"},{"nctId":"NCT07118709","title":"A Study of KC1086 in Patients With Advanced Solid Tumors","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-08-12","conditions":["Advanced Solid Tumors Cancer"],"interventions":["KC1086"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1086 in participants with advanced recurrent or metastatic solid tumors. The trial will be divided into two parts: dose-escalation phase and dose-expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07118709"},{"nctId":"NCT07750132","title":"Phase I Study of SM2275 Injection in Patients With Advanced Solid Tumors","sponsor":"Beijing StarMab Biomed Technology Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-02","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["SM2275"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, open-label Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of SM2275 in patients with advanced or metastatic solid tumors who have progressed after standard therapy or for whom no standard treatment is available. Phase Ia includes dose escalation to evaluate safety, identify dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D). Phase Ib will further evaluate safety, PK, PD, and preliminary antitumor activity in expansion cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT07750132"},{"nctId":"NCT07076095","title":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-01","completionType":"ESTIMATED","lastUpdated":"2025-07-21","conditions":["Small Cell Lung Cancer"],"interventions":["IBB0979","topotecan hydrochloride for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07076095"},{"nctId":"NCT06121843","title":"A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":187,"enrollmentType":"ESTIMATED","startDate":"2024-02-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Multiple Myeloma"],"interventions":["BMS-986393","Alnuctamab","Mezigdomide","Iberdomide","Elranatamab","Dexamethasone"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06121843"},{"nctId":"NCT07379047","title":"Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)","sponsor":"Ningbo Newbay Technology Development Co., Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":255,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["GIST - Gastrointestinal Stromal Tumor","Advanced"],"interventions":["NB003","regorafenib"],"countries":["China","South Korea"],"northAmerica":false,"chinaSites":true,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"NB003-04 is a phase II/III, multicenter, open-label clinical study designed to evaluate the efficacy, safety, and pharmacokinetic (PK) profile of NB003 in patients with gastrointestinal stromal tumors aged 18 years and above (or the legal adult age of consent per local regulations, whichever is older). Participants who are eligible for this study are those who have experienced disease progression or documented intolerance following treatment with either imatinib and sunitinib or following treatment with imatinib. This study consists of two parts. Part 1 (hereinafter referred to as Part 1) compares the efficacy of NB003 versus regorafenib in patients who need a third-line therapy for GIST who","sourceUrl":"https://clinicaltrials.gov/study/NCT07379047"},{"nctId":"NCT06136624","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1310,"enrollmentType":"ESTIMATED","startDate":"2023-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-15","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Prostate Cancer Metastatic"],"interventions":["Opevesostat","Abiraterone acetate","Enzalutamide","Hydrocortisone","Fludrocortisone acetate","Prednisone","Dexamethasone"],"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Poland","Puerto Rico","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":282,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -positive participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06136624"},{"nctId":"NCT07692204","title":"A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer","sponsor":"Sanofi","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-02","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Gastric Cancer","Oesophageal Carcinoma"],"interventions":["SAR445877"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling","MSI / TMB"],"summary":"This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric Cancer(GC)/Gastroesophageal Junction cancer (GEJ). Participants with advanced GC/GEJ who relapsed to at least 1 prior regimen which may or may not include an anti-PD1/PD-L1-based treatment depending on local standard of care, regardless combined positivity score (CPS) will be randomized in this study. In this study, SAR445877 will be assessed as a monotherapy in approximately 30 participants with advanced unresectable or metastatic GC or Siewert Type 2 and 3 GEJ, and for whom receivin","sourceUrl":"https://clinicaltrials.gov/study/NCT07692204"},{"nctId":"NCT05647122","title":"First in Human Study of AZD9592 in Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":167,"enrollmentType":"ACTUAL","startDate":"2022-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-03","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Advanced Solid Tumours","Carcinoma Non-small Cell Lung","Head and Neck Neoplasms","Colorectal Neoplasms"],"interventions":["AZD9592","Osimertinib","5-Fluorouracil (5-FU)","Leucovorin","Bevacizumab"],"countries":["United States","Australia","Canada","China","France","Italy","Japan","Malaysia","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":46,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.","sourceUrl":"https://clinicaltrials.gov/study/NCT05647122"},{"nctId":"NCT05714839","title":"A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":123,"enrollmentType":"ESTIMATED","startDate":"2023-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-03","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Multiple Myeloma"],"interventions":["Unconjugated belantamab antibody","Belantamab mafodotin","Unconjugated belantamab antibody and belantamab mafodotin","Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone"],"countries":["United States","Argentina","Australia","Brazil","Israel","Japan","Poland","South Korea","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"The study consists of three parts: Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of unconjugated belantamab antibody in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). Part 3: The Primary purpose of this part will evaluate the c","sourceUrl":"https://clinicaltrials.gov/study/NCT05714839"},{"nctId":"NCT05797168","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":602,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-04","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Ovarian Cancer","Lung Adenocarcinoma","Endometrial Cancer","Lung Squamous Cell Carcinoma"],"interventions":["Torvutatug samrotecan","Saruparib","Bevacizumab","Carboplatin","Palacaparib","Pembrolizumab"],"countries":["United States","Australia","Canada","China","Germany","Israel","Japan","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":60,"serviceSignals":["ADC biomarker"],"summary":"This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05797168"},{"nctId":"NCT06984588","title":"A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer","sponsor":"TJ Biopharma Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2024-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-05","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Non Small Cell Lung Cancer"],"interventions":["Uliledlimab","Toripalimab","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":64,"serviceSignals":["RNA fusion"],"summary":"This is a Phase II/III, randomized, open-label, active-controlled, multicenter study to compare intravenous uliledlimab combined with toripalimab, toripalimab monotherapy, and pembrolizumab monotherapy in patients with previously untreated locally advanced unresectable or metastatic PD-L1-positive (tumor proportion score \\[TPS\\] ≥ 1%) and CD73-positive (TC/IC \\> 30%; TC/IC defined as the higher of either the proportion of CD73-positive tumor cells or the proportion of CD73-positive immune cells at any intensity \\[IHC1+ or above\\]) NSCLC who are not suitable for targeted therapies such as EGFR, ALK, etc. The number of enrolled subjects with PD-L1 TPS ≥ 50% will be limited to approximately 60%","sourceUrl":"https://clinicaltrials.gov/study/NCT06984588"},{"nctId":"NCT06405230","title":"Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-10","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Lung Cancer, Non-Small Cell"],"interventions":["Pembrolizumab","Dostarlimab","Pemetrexed+ (carboplatin or cisplatin)"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to investigate the utility of biomarker tools Extracellular Vesicles (EVs), Patient-derived organoid (PDOs), and PDL1 PET imaging for predicting how participants with recurrent NSCLC respond to standard of care treatment in the advanced/metastatic stages.","sourceUrl":"https://clinicaltrials.gov/study/NCT06405230"},{"nctId":"NCT07616089","title":"Phase I Study of FXS0683 in the Treatment of Blood Tumors","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-08","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["B-Cell Lymphoma","Acute Myeloid Leukemia","Myelodysplastic Syndromes","Acute Lymphoblastic Leukemia"],"interventions":["FXS0683"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a first-in-human, multicenter, open-label, single-arm Phase I study of FXS0683 in participants with relapsed or refractory hematologic malignancies to evaluate safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity, and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07616089"},{"nctId":"NCT07157956","title":"CVL006 Combination Therapy in Advanced Solid Tumors","sponsor":"Convalife (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":318,"enrollmentType":"ESTIMATED","startDate":"2025-09-10","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2025-09-05","conditions":["Advanced Solid Tumor"],"interventions":["CVL006 combined with pemetrexed and carboplatin","CVL006 in combination with SKB264","CVL006 in combination with DS-8201","CVL006 in combination with Enfortumab Vedotin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with pemetrexed + carboplatin/SKB264/ DS-8201a/ Enfortumab Vedotin in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07157956"},{"nctId":"NCT07492680","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-07-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-20","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Solid Tumors"],"interventions":["BMS-986504","Daraxonrasib","Nivolumab + Relatlimab FDC","Temozolomide","Pumitamig","Pemetrexed","Carboplatin","Nab-paclitaxel","Gemcitabine","Paclitaxel"],"countries":["United States","Belgium","Canada","China","France","Germany","Hong Kong","Ireland","Italy","Japan","Norway","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":57,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT07492680"},{"nctId":"NCT07030257","title":"Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Tasca Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Solid Tumor Malignancies","Colorectal Carcinoma","Small Cell Lung Cancer ( SCLC )","Head and Neck (HNSCC)","Bladder Cancer","Non-Small Cell Lung Cancer","Pancreatic Cancer, Advanced or Metastatic"],"interventions":["CP-383"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383 Participants will: * Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer ","sourceUrl":"https://clinicaltrials.gov/study/NCT07030257"},{"nctId":"NCT06305754","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":551,"enrollmentType":"ESTIMATED","startDate":"2024-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-17","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-14","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Sacituzumab tirumotecan","Pemetrexed","Carboplatin","H1 Receptor Antagonist","H2 Receptor Antagonist","Acetaminophen (or equivalent)","Dexamethasone (or equivalent)","Steroid Mouthwash (dexamethasone or equivalent)"],"countries":["United States","Argentina","Canada","China","Colombia","France","India","Italy","Japan","Malaysia","Mexico","Poland","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":156,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06305754"},{"nctId":"NCT07362186","title":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","sponsor":"LaNova Medicines Limited","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-17","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-28","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Locally Advanced or Metastatic GC and GCJ Adenocarcinoma"],"interventions":["LM-108 in combination with Toripalimab","Paclitaxel injection intravenous infusion"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase III， Multicenter, Randomized study， evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07362186"},{"nctId":"NCT07195916","title":"A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2026-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-18","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Solid Tumors","Hematologic Malignancies"],"interventions":["INCA036873"],"countries":["United States","Australia","Belgium","Denmark","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07195916"},{"nctId":"NCT06292780","title":"A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-20","primaryCompletionType":"ESTIMATED","completionDate":"2035-02-20","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Relapsed/Refractory Systemic Light Chain Amyloidosis"],"interventions":["Linvoseltamab"],"countries":["United States","Greece","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called linvoseltamab (\"study drug\"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): * In Phase 1, linvoseltamab will be given to a small number of participants to study the side effects of the study drug and to determine the recommended doses of the study drug to be given to participants in Phase 2. * In Phase 2, linvoseltamab will be given to more participants to continue to assess the side effects of the study drug and to evaluate the ability of linvoseltamab to treat AL amyloidosis. The study is looki","sourceUrl":"https://clinicaltrials.gov/study/NCT06292780"},{"nctId":"NCT06463587","title":"Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":264,"enrollmentType":"ESTIMATED","startDate":"2024-06-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-23","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Generalized Myasthenia Gravis"],"interventions":["Placebo","Cladribine Low Dose","Cladribine High Dose"],"countries":["United States","Argentina","Australia","Belgium","Bulgaria","Canada","China","France","Georgia","Germany","Greece","Hungary","India","Italy","Japan","Poland","Romania","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":145,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in comparison to placebo. It will also investigate the sustained efficacy, the need for retreatment, and the long-term safety of oral cladribine in gMG. An additional component is included to characterize the Pharmacokinetics (PK) of the new cladribine formulation in gMG participants. This study is divided into 3 periods: the double-blind placebo control (DBPC) pivotal period, and 2 extensions, the blinded extension (BE) and the retreatment (RT) period. Furthermore, in trial interviews will be conducted as a sub-study to MyCl","sourceUrl":"https://clinicaltrials.gov/study/NCT06463587"},{"nctId":"NCT07636772","title":"A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":132,"enrollmentType":"ESTIMATED","startDate":"2026-06-22","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-24","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-24","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Urothelial Carcinoma (UC)"],"interventions":["AK146D1 for injection","AK112 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07636772"},{"nctId":"NCT07156253","title":"Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors","sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-08-26","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-25","completionType":"ESTIMATED","lastUpdated":"2025-09-05","conditions":["Metastatic Solid Tumor","Ovarian Cancer","Breast Cancer","BRCA 1 /2 and / or HRD","Advanced Solid Tumors"],"interventions":["SYN818 and Olaparib will be administered"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HRD / HRR"],"summary":"This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07156253"},{"nctId":"NCT05361395","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":184,"enrollmentType":"ACTUAL","startDate":"2022-08-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-28","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["Tarlatamab","Carboplatin","Etoposide","Atezolizumab","Durvalumab"],"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Israel","Italy","Japan","Netherlands","South Korea","Spain","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05361395"},{"nctId":"NCT07165886","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":298,"enrollmentType":"ESTIMATED","startDate":"2025-08-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-29","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Gastroenteropancreatic Neuroendocrine Tumors"],"interventions":["Sirolimus for injection (albumin bound)","Octreotide long-acting injection","Everolimus"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with poor prognostic factors. This trial is conducted to evaluate sirolimus for injection (albumin bound) combined with octreotide long-acting injection in patients with unresectable or recurrent GEP-NETs.","sourceUrl":"https://clinicaltrials.gov/study/NCT07165886"},{"nctId":"NCT07126990","title":"Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma","sponsor":"Xiaorong Wu","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-30","completionType":"ESTIMATED","lastUpdated":"2026-03-23","conditions":["Glioma"],"interventions":["Novel oncolytic virus Ad-TD-nsIL12"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Clinical study of a novel oncolytic virus Ad-TD-nsIL12 in the treatment of primary high-grade glioma","sourceUrl":"https://clinicaltrials.gov/study/NCT07126990"},{"nctId":"NCT06420089","title":"CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)","sponsor":"Vittoria Biotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2024-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2025-11-10","conditions":["T Cell Non-Hodgkin Lymphoma"],"interventions":["Senza5 CART5"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.","sourceUrl":"https://clinicaltrials.gov/study/NCT06420089"},{"nctId":"NCT07416994","title":"Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Non-Small Cell Lung Cancer"],"interventions":["YL202","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to evaluate YL202 monotherapy versus Docetaxel in participants with locally advanced or metastatic non-squamous NSCLC with EGFR mutation who have failed to EGFR-TKI therapy and platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07416994"},{"nctId":"NCT07393321","title":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2026-02-10","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-31","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer"],"interventions":["Placebo + fulvestrant","NTQ1062+Fulvestrant"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"NTQ1062-301 is a randomized, double-blind, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of the small-molecule AKT inhibitor NTQ1062 combined with fulvestrant versus placebo combined with fulvestrant in patients with HR positive, HER2 negative, locally advanced (unresectable) or metastatic breast cancer that has recurred or progressed during or after endocrine therapy and harbors PIK3CA/AKT1/PTEN alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07393321"},{"nctId":"NCT07582432","title":"A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma","sponsor":"Grifols Biologicals, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma"],"interventions":["Gamunex-C, 10% Injectable Solution"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"The main goal of this study is to show that people with certain immune problems (from Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma) get fewer serious infections when they receive Gamunex C through an IV once every 4 weeks, along with their usual medical care, for one year. All participants will receive Gamunex-C 500 mg/kg once every 4 weeks (total 13 doses) starting Day 1 (Week 1) through Week 48 (end of Treatment Phase).","sourceUrl":"https://clinicaltrials.gov/study/NCT07582432"},{"nctId":"NCT05967689","title":"A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.","sponsor":"Taiho Oncology, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2023-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations"],"interventions":["TAS6417","CYP Cocktail","Transporter Cocktail"],"countries":["United States","Australia","Canada","France","Germany","Hong Kong","Italy","Japan","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":80,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05967689"},{"nctId":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","sponsor":"Atavistik Bio, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2025-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Advanced Solid Tumors","Breast Cancer","Breast Carcinoma","Breast Neoplasms","ER Positive Breast Cancer","Cervical Cancers","Cervical Neoplasms","Cervical Carcinoma","Triple Negative Breast Cancer","Gynecologic Cancers","Gynecologic Neoplasm","Endometrial Cancer","Endometrial Neoplasm","Endometrial Carcinoma (EC)","Fallopian Cancer","Ovarian Carcinoma","Ovarian Cancer","Ovarian Neoplasms","Prostate Cancers","Prostate Carcinoma","Solid Tumors","Neoplasms","Neoplasms by Site","Breast Diseases","Uterine Neoplasms","Genital Neoplasms, Female","Urogenital Neoplasms"],"interventions":["ATV-1601","ATV-1601 + Fulvestrant"],"countries":["United States","France","Singapore","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with or without fulvestrant.","sourceUrl":"https://clinicaltrials.gov/study/NCT07038369"},{"nctId":"NCT04873362","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1188,"enrollmentType":"ACTUAL","startDate":"2021-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-10-02","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Breast Cancer"],"interventions":["Atezolizumab","Trastuzumab Emtansine","Placebo","Trastuzumab"],"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","China","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Italy","Kenya","Mexico","New Zealand","Poland","Portugal","Romania","Russia","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","Uganda","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":238,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT04873362"},{"nctId":"NCT06936735","title":"A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":502,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Advanced Solid Tumor"],"interventions":["HS-20108 Monotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06936735"},{"nctId":"NCT06680921","title":"A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2024-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2025-09-22","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["SIM0270","Everolimus (Afinitor®)","Exemestane tablets","Fulvestrant injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":60,"serviceSignals":["HER2 profiling"],"summary":"This Phase III, randomized, open label, multicenter study will evaluate the efficacy and safety of SIM0270 combined with everolimus compared to physician's choice of treatment in subjects with ER+/HER2- locally advanced or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitor.","sourceUrl":"https://clinicaltrials.gov/study/NCT06680921"},{"nctId":"NCT06082102","title":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":324,"enrollmentType":"ESTIMATED","startDate":"2023-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-25","completionType":"ESTIMATED","lastUpdated":"2025-09-15","conditions":["Relapsed/Refractory Marginal Zone Lymphoma"],"interventions":["Orelabrutinib","Rituximab","Lenalidomide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06082102"},{"nctId":"NCT06933329","title":"Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"BicycleTx Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":73,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-04-15","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Zelenectide pevedotin"],"countries":["France","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior line of systemic therapy in the advanced/metastatic setting (see inclusion criteria below). The study will comprise of 2 cohorts: Cohort A (non-squamous NSCLC) and Cohort B (squamous NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06933329"},{"nctId":"NCT07704866","title":"A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Claudin 18.2","Solid Tumor Malignancies"],"interventions":["FG-B901","FG-M108"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on, are intolerant to, or lack standard therapy. The Phase I dose-escalation part (using a BF-BOIN design) assesses safety, tolerability, and pharmacokinetics, and determines the recommended Phase II dose (RP2D) of FG-B901 when given with fixed-dose FG-M108. The Phase IIa expansion cohorts, grouped by tumor type, further evaluate safety and preliminary efficacy, with antitumor activity measured by RECIST 1.1 and iRECIST, while also exploring biomarker correlates. Key elig","sourceUrl":"https://clinicaltrials.gov/study/NCT07704866"},{"nctId":"NCT07308132","title":"A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2026-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["JNJ-95566692","JNJ-87801493"],"countries":["Australia","Belgium","France","Spain","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT07308132"},{"nctId":"NCT07100106","title":"A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer","sponsor":"Genentech, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":285,"enrollmentType":"ESTIMATED","startDate":"2025-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Breast Cancer"],"interventions":["GDC-4198","Giredestrant","Abemaciclib"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Italy","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: Phase Ib and Phase II. Phase Ib will evaluate the safety and pharmacokinetics (PK) of GDC-4198 alone and in combination with giredestrant. Phase II stage will compare the activity and safety of GDC-4198 and giredestrant with abemaciclib and giredestrant.","sourceUrl":"https://clinicaltrials.gov/study/NCT07100106"},{"nctId":"NCT04817007","title":"A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":216,"enrollmentType":"ESTIMATED","startDate":"2021-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-08-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Myelofibrosis"],"interventions":["BMS-986158","Ruxolitinib","Fedratinib"],"countries":["United States","Australia","France","Germany","Greece","Israel","Italy","Poland","Romania","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT04817007"},{"nctId":"NCT06742996","title":"A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Mantle Cell Lymphoma","B Cell Lymphoma"],"interventions":["Sonrotoclax","Zanubrutinib","Placebo"],"countries":["United States","Argentina","Australia","Austria","Brazil","China","France","Germany","Italy","Japan","New Zealand","Poland","Puerto Rico","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":155,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT06742996"},{"nctId":"NCT07639450","title":"N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors","sponsor":"Hefei Xinzhu Biological Technology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Advanced Malignant Solid Tumors"],"interventions":["N-3C01(Q2W)","N-3C01(Q3W)","N-3C01","Pembrolizumab"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This Phase I/II study evaluates the safety, tolerability, and efficacy of N-3C01 administered subcutaneously, both as monotherapy and in combination with a PD-(L)1 monoclonal antibody, in patients with advanced solid tumors. Phase I involves dose escalation for both monotherapy and combination therapy, while Phase II includes cohort expansion for the combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07639450"},{"nctId":"NCT06884618","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":405,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-25","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Neoplasms"],"interventions":["RO7673396"],"countries":["United States","Australia","Canada","China","Denmark","Hong Kong","New Zealand","Singapore","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["RAS genotyping"],"summary":"This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of RO7673396. Stage 2 will evaluate preliminary anti-tumor activity of the RDE(s) defined in Stage 1 and of other doses of interest for future development in selected solid tumor indications.","sourceUrl":"https://clinicaltrials.gov/study/NCT06884618"},{"nctId":"NCT07539311","title":"Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers","sponsor":"Genmab","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Gastrointestinal Cancers"],"interventions":["Rina-S"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective. The duration of the study will be different for every participant, but","sourceUrl":"https://clinicaltrials.gov/study/NCT07539311"},{"nctId":"NCT06167317","title":"Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":278,"enrollmentType":"ESTIMATED","startDate":"2024-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advanced Solid Tumors"],"interventions":["GS-0201","Sacituzumab Govitecan"],"countries":["United States","Israel"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors * To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06167317"},{"nctId":"NCT06979076","title":"A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL","sponsor":"MingSight Pharmaceuticals, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-09-29","conditions":["CLL (Chronic Lymphocytic Leukemia)","SLL (Small Lymphocytic Lymphoma)"],"interventions":["MS-553, DS1","MS-553, DS2"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06979076"},{"nctId":"NCT06699212","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","sponsor":"Rakuten Medical, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":412,"enrollmentType":"ESTIMATED","startDate":"2024-12-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2025-10-15","conditions":["Recurrent Head and Neck Squamous Cell Carcinoma"],"interventions":["ASP-1929 Photoimmunotherapy","Pembrolizumab","Carboplatin","Cisplatin","5-fluorouracil","Paclitaxel","Docetaxel"],"countries":["United States","Japan","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or docetaxel) according to physician's choice (control arm). The overall primary study hypothesis being tested is whether ASP-1929 PIT plus pembrolizumab combination treatment improves the overall surviva","sourceUrl":"https://clinicaltrials.gov/study/NCT06699212"},{"nctId":"NCT06538857","title":"CEB-01 in Locally Resectable Pancreatic Cancer","sponsor":"CEBIOTEX","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2024-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2025-05-23","conditions":["Pancreatic Carcinoma"],"interventions":["Standard surgery","CEB-01"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06538857"},{"nctId":"NCT07174908","title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-09-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Non-Small Cell Lung Cancer"],"interventions":["IN10018 in combination with D-1553","anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07174908"},{"nctId":"NCT06745908","title":"Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In","sponsor":"ImmunityBio, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":507,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["NSCLC Stage IV"],"interventions":["N-803","Tislelizumab","Docetaxel","Prior failed checkpoint inhibitor"],"countries":["United States","Canada","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) CPI and docetaxel (cohort B) versus docetaxel monotherapy (cohorts A and B). For each cohort, enrolled participants will be randomized 2:1 to treatment in the experimental arm or the control arm. For cohort A, the randomization will be stratified by geographical region (North America vs Europe vs Asia vs Other), NSCLC histology (squamous vs nonsquamous), and actionable genomic alteration (AGA) (epidermal growth factor recepto","sourceUrl":"https://clinicaltrials.gov/study/NCT06745908"},{"nctId":"NCT07278479","title":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","sponsor":"Molecular Partners AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2032-09","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Large Cell Neuroendocrine Carcinoma","Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)","Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","Small Cell Lung Cancer (SCLC)","Gastroenteropancreatic NEC (GEP NEC)","NEC of the Bladder","Other DLL3 Expressing epNEC"],"interventions":["[212Pb]Pb-MP0712","[203Pb]Pb-MP0712"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[212Pb\\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07278479"},{"nctId":"NCT06544265","title":"SynKIR-310 for Relapsed/Refractory B-NHL","sponsor":"Verismo Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2024-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["B Cell Lymphoma","NHL, Adult","Mantle Cell Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Aggressive B-Cell Non-Hodgkin Lymphoma","Indolent B-Cell Non-Hodgkin Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","DLBCL - Diffuse Large B Cell Lymphoma","HGBL With MYC and BCL2 and/or BCL6 Rearrangements","High-grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma","Large B-cell Lymphoma","T-Cell/Histiocyte Rich Lymphoma","Non-hodgkin Lymphoma,B Cell","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Epstein-Barr Virus Positive DLBCL, Nos","Follicular Lymphoma Grade 3B","DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation","High Grade B-Cell Lymphoma, Not Otherwise Specified","Follicular Lymphoma Grade 3","Marginal Zone Splenic Lymphoma","DLBCL","Waldenstrom Macroglobulinemia","Waldenstrom Macroglobulinaemia"],"interventions":["SynKIR-310"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.","sourceUrl":"https://clinicaltrials.gov/study/NCT06544265"},{"nctId":"NCT05684965","title":"XTX301 in Patients With Advanced Solid Tumors","sponsor":"Xilio Development, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":358,"enrollmentType":"ESTIMATED","startDate":"2023-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Solid Tumor"],"interventions":["XTX301"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05684965"},{"nctId":"NCT04389281","title":"X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma","sponsor":"Immunolight, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2021-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Advanced Solid Tumor Cancer"],"interventions":["X-PACT"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"In this Phase I trial for subjects with advanced head \\& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to establish the safety of X-PACT when dosed with 5 intra-tumoral injections of the combination product (the phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) over a period of 6 weeks (on day D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6). After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligi","sourceUrl":"https://clinicaltrials.gov/study/NCT04389281"},{"nctId":"NCT05765812","title":"A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma","sponsor":"Debiopharm International SA","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2023-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Astrocytoma, Grade III"],"interventions":["Debio 0123","Temozolomide","Radiotherapy"],"countries":["United States","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and to characterize the safety and tolerability of these combinations in adult participants with glioblastoma (GBM). Arm B which was previously added to the protocol, has been permanently halted per the safety monitoring committees' decision on the safety findings of this arm. The primary purpose of Phase 1 (Dose expansion) of the study is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development. The P","sourceUrl":"https://clinicaltrials.gov/study/NCT05765812"},{"nctId":"NCT04501120","title":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":682,"enrollmentType":"ESTIMATED","startDate":"2020-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Relapsed/Refractory Acute Myeloid Leukaemia","Myeloid Malignancy"],"interventions":["Lisaftoclax (APG-2575)","Reduced-dose HHT","standard-dose HHT","Azacitidine","olverembatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT04501120"},{"nctId":"NCT07702955","title":"Phase I Study of Single-Agent KGX105 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Kangabio AUSTRALIA LTD PTY","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["KGX105 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter, Phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), and preliminary antitumor activity of single-agent KGX105 in participants with locally advanced or metastatic solid tumors. The study consists of two parts: Phase 1a dose escalation and Phase 1b dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07702955"},{"nctId":"NCT07197827","title":"A Study of YL242 in Subjects With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":424,"enrollmentType":"ESTIMATED","startDate":"2025-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Advanced Solid Tumor"],"interventions":["YL242","YL242; Pembrolizumab","YL242; 5-FU; LV","YL242; Pembrolizumab; 5-FU"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07197827"},{"nctId":"NCT07049055","title":"A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer","sponsor":"Engeneic Pty Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2026-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Pancreatic Cancer, Metastatic","PDAC - Pancreatic Ductal Adenocarcinoma"],"interventions":["E-EDV-D682","EDV-GC","Gemcitabine","Nab paclitaxel."],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07049055"},{"nctId":"NCT07158840","title":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment","sponsor":"Akeso","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-09-05","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Non-Small Cell Lung Cancer"],"interventions":["AK112"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT07158840"},{"nctId":"NCT07429266","title":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2026-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Polycythemia Vera"],"interventions":["Sapablursen","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy. The study will be conducted in three sequential parts (Part 1a blinded treatment, Part 1b open-label treatment, \\& Part 2 long-term extension). Participants may receive treatment for up to 156 weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT07429266"},{"nctId":"NCT05804370","title":"Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)","sponsor":"NX Development Corp","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2024-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Ovarian Cancer"],"interventions":["Gleolan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.","sourceUrl":"https://clinicaltrials.gov/study/NCT05804370"},{"nctId":"NCT06755515","title":"A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":510,"enrollmentType":"ESTIMATED","startDate":"2024-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-09","completionType":"ESTIMATED","lastUpdated":"2025-01-01","conditions":["Cervical Cancer"],"interventions":["Rulonilimab","Placebo","cisplatin/carboplatin + paclitaxel ± bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was an randomized, double-Blind, placebo-controlled, multicenter Phase II/III study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06755515"},{"nctId":"NCT06892548","title":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":594,"enrollmentType":"ESTIMATED","startDate":"2025-05-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2032-05","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Advanced Lung Cancer"],"interventions":["BNT324","BNT327"],"countries":["United States","Australia","China","France","Italy","Poland","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":88,"serviceSignals":["ADC biomarker"],"summary":"This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06892548"},{"nctId":"NCT07684170","title":"Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms","sponsor":"Compass Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":58,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Neuroendocrine Neoplasm","Neuroendocrine Carcinomas","Neuroendocrine Tumors"],"interventions":["CTX-471"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will enroll patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment. CTX-471 to be administered as an intravenous (IV) infusion at either 0.3 mg/kg or 0.6 mg/kg every 2 weeks until disease progression or unacceptable toxicity. The study will be conducted in two stages. In Stage 1, 18 patients will be accrued for each dose level. If there are less than 2 objective responses in these 18 patients at either dose level, the dose level will be stopped. Otherwise, an additional 22 patients will be accrued in Stage 2 with 11 patients for each dose level.","sourceUrl":"https://clinicaltrials.gov/study/NCT07684170"},{"nctId":"NCT06463028","title":"Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer","sponsor":"Faeth Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Endometrial Cancer"],"interventions":["Sapanisertib","Serabelisib","Paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06463028"},{"nctId":"NCT05317819","title":"Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma","sponsor":"Polaris Group","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2022-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Hepatocellular Carcinoma","Advanced Hepatocellular Carcinoma"],"interventions":["ADI-PEG20","Placebo"],"countries":["Taiwan","Vietnam"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC","sourceUrl":"https://clinicaltrials.gov/study/NCT05317819"},{"nctId":"NCT07208149","title":"A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-01","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Triple-Negative Breast Cancer (TNBC)"],"interventions":["MR001 Bispecific Antibody for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07208149"},{"nctId":"NCT07159126","title":"A Study of DS3610a in Participants With Advanced Solid Tumor","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2025-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-01","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["Solid Tumors","Metastatic Solid Tumors"],"interventions":["DS3610a"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is designed to assess the safety, tolerability, and efficacy of DS3610a, given as a single agent to participants with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07159126"},{"nctId":"NCT06758401","title":"This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":714,"enrollmentType":"ESTIMATED","startDate":"2025-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung (NSCLC)"],"interventions":["Sigvotatug Vedotin","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Romania","Saudi Arabia","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":372,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of \"brake\" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatu","sourceUrl":"https://clinicaltrials.gov/study/NCT06758401"},{"nctId":"NCT07472517","title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","sponsor":"Boehringer Ingelheim","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":670,"enrollmentType":"ESTIMATED","startDate":"2026-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Small Cell Lung Cancer (SCLC)","Extensive-stage Small Cell Lung Cancer (ES-SCLC)"],"interventions":["obrixtamig","atezolizumab","carboplatin","etoposide"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Czechia","Estonia","Finland","France","Georgia","Germany","Greece","Hong Kong","Hungary","Ireland","Italy","Japan","Latvia","Malaysia","Mexico","Moldova","Netherlands","New Zealand","Norway","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":242,"serviceSignals":["ADC biomarker"],"summary":"This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as i","sourceUrl":"https://clinicaltrials.gov/study/NCT07472517"},{"nctId":"NCT06980480","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","sponsor":"Takeda","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":183,"enrollmentType":"ESTIMATED","startDate":"2026-01-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-11","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Multiple Myeloma","Secondary Immunodeficiency"],"interventions":["IGI, 10%"],"countries":["United States","Australia","Austria","Brazil","Canada","Czechia","Denmark","Greece","Hungary","Italy","Netherlands","Poland","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x cluster of differentiation 3 (CD3) directed bispecific antibody therapy. Participants will be randomly assigned to one of two groups: 1. Primary infection prevention group: They will receive IGI, 10% for 12 months. 2. Secondary infection prevention group: They will only receive IGI, 10% if they develop a serious infection during the 12 months study period. During the study, participants will visit thei","sourceUrl":"https://clinicaltrials.gov/study/NCT06980480"},{"nctId":"NCT07028853","title":"This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2025-09-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-12","primaryCompletionType":"ESTIMATED","completionDate":"2034-12-08","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Metastatic Castration Sensitive Prostate Cancer (mCSPC)","Hormone Sensitive Prostate Cancer","Prostate Cancer","Cancer of the Prostate"],"interventions":["Mevrometostat","Placebo","Enzalutamide"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Finland","France","Germany","Greece","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Slovakia","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":341,"serviceSignals":["Broad CGP"],"summary":"This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT07028853"},{"nctId":"NCT05471856","title":"A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2023-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-02","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumors"],"interventions":["BI 1703880","Ezabenlimab"],"countries":["United States","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with different types of advanced cancer. People can take part if previous treatment was not successful, or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1703880 that people with advanced cancer can tolerate when taken together with ezabenlimab. BI 1703880 and ezabenlimab are medicines that may help the immune system fight cancer. In this study, BI 1703880 is given to people for the first time. Participants get BI 1703880 and ezabenlimab as infusions into a vein. During the first 6 weeks, they get BI 1703880 once a week. Later, they get BI 1703880 every 3 weeks. After the first 3 weeks, they get ezabenlimab in a","sourceUrl":"https://clinicaltrials.gov/study/NCT05471856"},{"nctId":"NCT05808634","title":"Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.","sponsor":"BioAtla, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2023-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-15","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Advanced Adenocarcinoma"],"interventions":["BA3182"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05808634"},{"nctId":"NCT07522073","title":"A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma","sponsor":"Incyte Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":588,"enrollmentType":"ESTIMATED","startDate":"2026-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-19","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Solid Tumors"],"interventions":["INCB161734","Placebo","Investigator's choice of chemotherapy"],"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","Finland","France","Germany","Italy","Japan","Netherlands","Norway","Poland","Puerto Rico","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":219,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07522073"},{"nctId":"NCT07680764","title":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-15","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Locally Advanced Non-Small Cell Lung Cancer (NSCLC)","Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["Pumitamig","Imzokitug"],"countries":["United States","Argentina","Australia","Brazil","Chile","China","France","Germany","Italy","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":71,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07680764"},{"nctId":"NCT05239741","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2022-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-19","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Colorectal Neoplasms"],"interventions":["Pembrolizumab","Oxaliplatin","Leucovorin","5-fluorouracil","Irinotecan","Bevacizumab","Cetuximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":32,"serviceSignals":["MSI / TMB"],"summary":"In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT05239741"},{"nctId":"NCT07360314","title":"Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-20","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-28","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Solid Tumors"],"interventions":["M7437"],"countries":["United States","Canada","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07360314"},{"nctId":"NCT07114861","title":"The KN510713 Study in Combination With mFOLFIRINOX","sponsor":"New Cancer Cure-Bio Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-22","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-22","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOX","Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOX"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT07114861"},{"nctId":"NCT06252649","title":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2024-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-25","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-25","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Metastatic Colorectal Cancer"],"interventions":["FOLFIRI Regimen","Sotorasib","Panitumumab","Bevacizumab-awwb"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Czechia","Denmark","Estonia","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Romania","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":291,"serviceSignals":["RAS genotyping"],"summary":"The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.","sourceUrl":"https://clinicaltrials.gov/study/NCT06252649"},{"nctId":"NCT06726148","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2025-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-25","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-25","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Advanced HR+/HER2- Breast Cancer","Advanced CCNE1-amplified Solid Tumors","Extensive-stage Small Cell Lung Cancer"],"interventions":["ECI830","ribociclib","fulvestrant"],"countries":["United States","Australia","Canada","China","Czechia","Denmark","France","Germany","Israel","Italy","Japan","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["HER2 profiling"],"summary":"Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06726148"},{"nctId":"NCT07213609","title":"A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":47,"enrollmentType":"ESTIMATED","startDate":"2025-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-27","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Neoplasms, Colorectal","Neoplasms"],"interventions":["GSK5460025"],"countries":["United States","Canada","Denmark","Japan","Netherlands","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["MSI / TMB"],"summary":"Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.","sourceUrl":"https://clinicaltrials.gov/study/NCT07213609"},{"nctId":"NCT06855277","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":940,"enrollmentType":"ESTIMATED","startDate":"2025-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-29","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-04","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Prostate Cancer"],"interventions":["AAA817","ARPI","Standard of Care"],"countries":["United States","Australia","Brazil","China","Hong Kong","India","Japan","Singapore","South Korea","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":88,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine whether \\[225Ac\\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \\[177Lu\\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06855277"},{"nctId":"NCT07371663","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":266,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Solid Cancers","NSCLC (Advanced Non-small Cell Lung Cancer)","Gastric (Stomach) Cancer","Endometrial Cancer","Malignant Melanoma"],"interventions":["TCC1727 tablet 90mg","TCC1727 tablet 120mg","TCC1727 tablet 160mg","benmelstobart Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with advanced solid tumors. The Phase II expansion study will assess the efficacy and safety of TCC1727 combined with benmelstobart /olaparib/topotecanin selected advanced solid tumor indications. The study pre-specifies three treatment combinations, with Combination 1 (TCC1727 + benmelstobart) being prioritized for initial evaluation. The decision to proceed with Combination 2 and Combination 3will be based on clinical data from Combination 1.","sourceUrl":"https://clinicaltrials.gov/study/NCT07371663"},{"nctId":"NCT07294534","title":"A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":817,"enrollmentType":"ESTIMATED","startDate":"2026-01-27","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-01","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["HER2 + Breast Cancer"],"interventions":["HLX87+HX22","HLX87 + Pertuzumab","TCbHP"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The study is being conducted to evaluate the clinical efficacy of HLX87 in combination with HLX22 or pertuzumab vs. TCbHP in the neoadjuvant therapy of HER2-positive early or locally advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07294534"},{"nctId":"NCT07715097","title":"Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma","sponsor":"Beijing Tricision Biotherapeutics Inc","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Glioblastoma"],"interventions":["Survivin-targeted DC Cell Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The overall objective of this study is to preliminarily evaluate the efficacy and safety of Survivin-targeted DC Cell Injection in the postoperative treatment of newly diagnosed glioblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07715097"},{"nctId":"NCT06189391","title":"A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)","sponsor":"MSD R&D (China) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2021-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma"],"interventions":["MK-1045"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat people with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). B-cells are a type of white blood cells that make antibodies and help fight infections. Non-Hodgkin Lymphoma is a type of cancer in the lymphatic system causing enlarged lymph nodes and/or organs in belly or chest. Relapsed means a disease or condition comes back after treatment Refractory means a disease does not respond to treatment or stops responding to a treatment. MK-1045, the study medicine, is designed to treat relapsed or refractory B-NHL. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This is the first study in which MK-","sourceUrl":"https://clinicaltrials.gov/study/NCT06189391"},{"nctId":"NCT07730515","title":"Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":176,"enrollmentType":"ESTIMATED","startDate":"2025-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non-hodgkin Lymphoma","Peripheral T-cell Lymphoma"],"interventions":["XNW5004 combined with CHOP (incremental)","XNW5004 combined with CHOEP (incremental)","XNW5004 combined with CHOP (extended)","XNW5004 combined with CHOEP (extended)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT07730515"},{"nctId":"NCT07619287","title":"An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2026-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Myeloid Malignancy"],"interventions":["BG-75202","Hypomethylation Agent (HMA)"],"countries":["Australia","China","New Zealand"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07619287"},{"nctId":"NCT06598800","title":"Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":153,"enrollmentType":"ESTIMATED","startDate":"2024-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Advanced Solid Tumor"],"interventions":["Drug: BG-T187","Other Therapeutic Agents"],"countries":["United States","Australia","China","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":30,"serviceSignals":["MET profiling"],"summary":"This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06598800"},{"nctId":"NCT07070219","title":"A Study of CTD402 in T-ALL/LBL Patients","sponsor":"Imviva Bio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2025-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-05","conditions":["Acute Lymphocytic Leukemia Refractory","Lymphoma, Lymphoblastic"],"interventions":["CTD402 CAR T Cell Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07070219"},{"nctId":"NCT07611149","title":"Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma","sponsor":"Kure Cells, INC","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Multiple Myeloma in Relapse","Multiple Myeloma, Refractory"],"interventions":["Administration of CAR T-cells at 3 different dose levels"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to evaluate the safety of a new type of CAR T-cell, UF-KURE-BCMA, for the treatment of patients with advanced multiple myeloma that has not responded to other therapies. The main question is whether the use of these new CAR T-cells is safe for patients with this condition. Secondarily, the study will also look at the response of myeloma to this therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07611149"},{"nctId":"NCT07668154","title":"A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["HNSCC"],"interventions":["SKB571"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase II clinical study to assess the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with recurrent or metastatic HNSCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07668154"},{"nctId":"NCT07746141","title":"A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-09-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["RAS Mutation","Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["BG-85738","Tislelizumab","Cetuximab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT07746141"},{"nctId":"NCT07704515","title":"GKL-006Allo Injection in Patients With Advanced Solid Tumors","sponsor":"Beijing Gene Key Life Technology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2026-08-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Solid Tumor Malignancies"],"interventions":["GKL-006Allo Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of GKL-006Allo Injection in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07704515"},{"nctId":"NCT07529951","title":"Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers","sponsor":"Eilean Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Polycythemia Vera (PV)","Myelofibrosis (MF)"],"interventions":["ZE74-0282"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study will test an experimental drug called ZE74-0282 in people with certain blood disorders caused by a specific mutation called JAK2 V617F. The main goals are to find the right dose level, to see how safe and tolerable different doses are, how the drug moves through the body, and whether it shows early signs of anti-tumor activity. Participants will receive ZE74-0282 in one of several dose groups. The study is open-label, meaning both the doctor and the participant know which treatment is given. It will take place at multiple centers across different countries. Blood tests and regular check-ups will be done to monitor side effects and measure the effect on the disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT07529951"},{"nctId":"NCT07107490","title":"A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER","sponsor":"Chugai Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":122,"enrollmentType":"ESTIMATED","startDate":"2025-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-09-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Extensive Stage Small Cell Lung Cancer"],"interventions":["ALPS12","obinutuzumab"],"countries":["Hong Kong","Japan","Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study is a phase I, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ALPS12 in patients with extensive-stage small cell lung cancer. The study consists of two parts: a dose-escalation part and an expansion part.","sourceUrl":"https://clinicaltrials.gov/study/NCT07107490"},{"nctId":"NCT07385703","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":752,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Adenocarcinoma"],"interventions":["LM-302 Injection","Tislelizumab","Oxaliplatin Injection","Capecitabine Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":106,"serviceSignals":["ADC biomarker"],"summary":"This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients with CLDN18.2 positivity.","sourceUrl":"https://clinicaltrials.gov/study/NCT07385703"},{"nctId":"NCT07609251","title":"A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）","sponsor":"Sinocelltech Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["SCTB41","docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07609251"},{"nctId":"NCT07556822","title":"Phase I Study of HRS-3005 in B-cell Malignancies","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2026-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["B-cell Malignancy"],"interventions":["HRS-3005"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07556822"},{"nctId":"NCT07175220","title":"Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-10-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Locally Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["SHR2554; SHR-A2102","SHR2554; Adabelimumab","SHR2554; SHR-1701"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07175220"},{"nctId":"NCT06335355","title":"A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":401,"enrollmentType":"ESTIMATED","startDate":"2024-03","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2024-03-28","conditions":["Non-squamous Non-small Cell Lung Cancer"],"interventions":["Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin","Camrelizumab + Pemetrexed + Carboplatin","Adebrelimab + Pemetrexed + Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations","sourceUrl":"https://clinicaltrials.gov/study/NCT06335355"},{"nctId":"NCT07187960","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2025-11","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["Follicular Lymphoma"],"interventions":["TQB2825 Injection","Rituximab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":28,"serviceSignals":["Hematology NGS"],"summary":"Evaluation of the efficacy and safety of TQB2825 injection compared to immunotherapy in the treatment of recurrent/refractory follicular lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07187960"},{"nctId":"NCT07238283","title":"Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":662,"enrollmentType":"ESTIMATED","startDate":"2025-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-09","conditions":["First-line Treatment of Metastatic Pancreatic Cancer"],"interventions":["Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate","nab-paclitaxel; gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus nab-paclitaxel combined with gemcitabine as first-line treatment for advanced pancreatic cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07238283"},{"nctId":"NCT07444814","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","sponsor":"Whitehawk Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":226,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Metastatic","Ovarian Cancer Metastatic Recurrent","Non-squamous EGFR Wt NSCLC","Platinum Resistant Ovarian Cancer","PROC"],"interventions":["HWK-007"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.","sourceUrl":"https://clinicaltrials.gov/study/NCT07444814"},{"nctId":"NCT06841055","title":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment","sponsor":"BioNTech SE","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Non-small Cell Lung Cancer"],"interventions":["Pumitamig","Docetaxel"],"countries":["United States","Australia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the combination of pumitamig (also known as BNT327, BMS-986545 or PM8002) with standard of care. Part 1 is a safety run-in with pumitamig (Dose 1 or Dose 2) plus docetaxel and will include up to 12 participants in total to be treated in Part 1A and 1B sequentially. Part 2 is a dose expansion at the deemed safe dose of pumitamig plus docetaxel and will include up to 54 participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06841055"},{"nctId":"NCT07714187","title":"A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides","sponsor":"SecuraBio","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2027-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Mycosis Fungoides","Cutaneous T-cell Lymphoma"],"interventions":["Duvelisib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.","sourceUrl":"https://clinicaltrials.gov/study/NCT07714187"},{"nctId":"NCT07189455","title":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2025-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Small-cell Lung Cancer"],"interventions":["ZG006","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT07189455"},{"nctId":"NCT06216301","title":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","sponsor":"NovoCure GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":734,"enrollmentType":"ESTIMATED","startDate":"2024-07-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Metastatic Non-small Cell Lung Cancer"],"interventions":["NovoTTF-200T","Pembrolizumab","Platinum based chemotherapy"],"countries":["United States","Austria","Belgium","Czechia","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Poland","Singapore","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":98,"serviceSignals":["Broad CGP"],"summary":"This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06216301"},{"nctId":"NCT07680439","title":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","sponsor":"BrainChild Bio, Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":75,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Diffuse Intrinsic Pontine Glioma","DIPG","Brain Tumor","CNS Tumor","Central Nervous System Tumor","Pediatric Cancer","Adult Cancer Patients","CNS Tumor, Childhood","CNS Tumor, Adult","Brainstem Glioma","Diffuse Midline Glioma","DMG"],"interventions":["BCB-276"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with limited treatment options. CAR T cell therapy uses a patient's own immune cells that are changed in a laboratory to recognize and attack cancer cells. The purpose of this study is to determine whether BCB-276, when given after completion of standard radiation therapy, is safe and can improve survival for patients with DIPG. To participate, individuals must be between 1 and 26 years of age when they join the study, have a diagnosis of DIPG, and enroll for tre","sourceUrl":"https://clinicaltrials.gov/study/NCT07680439"},{"nctId":"NCT07676903","title":"A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-10","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Solid Tumor"],"interventions":["SHR-4685"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of SHR-4685 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07676903"},{"nctId":"NCT07225270","title":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":544,"enrollmentType":"ESTIMATED","startDate":"2026-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Ovarian Cancer","Platinum-sensitive Ovarian Cancer","PSOC"],"interventions":["Rina-S","Bevacizumab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer. Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets bette","sourceUrl":"https://clinicaltrials.gov/study/NCT07225270"},{"nctId":"NCT06680752","title":"Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS","sponsor":"ARCE Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2025-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-10","conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory","MDS (Myelodysplastic Syndrome)"],"interventions":["ARD103","Cyclophosphamide","Fludarabine"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.","sourceUrl":"https://clinicaltrials.gov/study/NCT06680752"},{"nctId":"NCT07123415","title":"A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors","sponsor":"Aptabio Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Advanced Solid Cancer","Advanced Solid Tumor (Phase 1)"],"interventions":["APX-343A","Pembrolizumab"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07123415"},{"nctId":"NCT07583212","title":"Phase I Study of HRS-1635 in B-cell Malignancies","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["B-cell Malignancy"],"interventions":["HRS-1635"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The study is being conducted to evaluate the safety and tolerability of HRS-1635. To observe the Dose-Limiting Toxicity (DLT) , explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-1635 in participants with B-cell malignancy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07583212"},{"nctId":"NCT06590857","title":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","sponsor":"RayzeBio, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":16,"enrollmentType":"ACTUAL","startDate":"2024-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-10","primaryCompletionType":"ESTIMATED","completionDate":"2033-01","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Metastatic Breast Cancer","HER2-negative Breast Cancer","ER+ Breast Cancer","Advanced Breast Cancer"],"interventions":["RYZ101"],"countries":["United States","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["HER2 profiling"],"summary":"Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.","sourceUrl":"https://clinicaltrials.gov/study/NCT06590857"},{"nctId":"NCT06833008","title":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","sponsor":"Ipsen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":85,"enrollmentType":"ESTIMATED","startDate":"2025-03-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-03","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-03","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Solid Tumor"],"interventions":["IPN01195"],"countries":["United States","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.","sourceUrl":"https://clinicaltrials.gov/study/NCT06833008"},{"nctId":"NCT06313593","title":"A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2024-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-09","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-09","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Myeloproliferative Neoplasms"],"interventions":["INCB160058","Standard disease-directed therapy"],"countries":["United States","Canada","France","Germany","Italy","Norway","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT06313593"},{"nctId":"NCT07735637","title":"A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2026-08-25","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10-11","primaryCompletionType":"ESTIMATED","completionDate":"2039-11-09","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Newly Diagnosed Multiple Myeloma (NDMM)"],"interventions":["AZD0120","Cyclophosphamide","Fludarabine","Melphalan (part of ASCT)","Lenalidomide"],"countries":["United States","Australia","Brazil","Canada","Denmark","France","Germany","Italy","Norway","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete response (CR) rate at 9 months as assessed by Blinded Independent Central Review (BICR), in participants with TE NDMM. Study details include: * The study duration is estimated to be up to 13 years from the date the first participant is randomised. * For participants in Arm A (AZD0120), the total duration of participant follow-up will be 15 years (including a Long Term Follow-up study) after the last participant has received the AZD0120 infusion. * The treatment durati","sourceUrl":"https://clinicaltrials.gov/study/NCT07735637"},{"nctId":"NCT07223047","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2025-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-13","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-13","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Advanced Solid Malignancies","Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["BMS-986523","Gemcitabine","Nab-Paclitaxel","Cetuximab","Pembrolizumab"],"countries":["United States","Canada","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT07223047"},{"nctId":"NCT07206498","title":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","sponsor":"Wayshine Biopharm, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-10-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-14","completionType":"ESTIMATED","lastUpdated":"2025-11-28","conditions":["Non Small Cell Lung Cancer (NSCLC)"],"interventions":["Osimertinib (Tagrisso®)","WSD0922-FU"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with C797S mutation or is newly diagnosed with CNS metastasis with EGFR Del19 or L858R mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT07206498"},{"nctId":"NCT06072781","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","sponsor":"Verastem, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2024-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-09","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Low Grade Serous Ovarian Cancer"],"interventions":["avutometinib","Defactinib","Pegylated liposomal doxorubicin","Paclitaxel","Letrozole","Anastrozole"],"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Ireland","Italy","Japan","Netherlands","New Zealand","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06072781"},{"nctId":"NCT07485504","title":"Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies","sponsor":"Tcelltech Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-15","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Relapsed or Refractory Hematologic Malignancies"],"interventions":["In Vivo CAR-T Therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects. DIT101 is an investigational in vivo CAR-T cell therapy administered by intravenous infusion. After administration, it is intended to generate CAR-T cells within the patient's body that can recognize and attack tumor cells. Unlike approved autologous CAR-T therapies, DIT101 does not require collection and ex vivo genetic modification of the participant's own cells. The study includes a screening period, DIT101 infusion treatment, a post-treatment intensive follow-up peri","sourceUrl":"https://clinicaltrials.gov/study/NCT07485504"},{"nctId":"NCT04067336","title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","sponsor":"Kura Oncology, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":263,"enrollmentType":"ESTIMATED","startDate":"2019-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-16","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Advanced Malignant Neoplasm","Acute Myeloid Leukemia","Mixed Lineage Leukemia","Mixed Lineage Acute Leukemia","Acute Leukemia of Ambiguous Lineage","Mixed Phenotype Acute Leukemia","Acute Lymphoblastic Leukemia"],"interventions":["Ziftomenib","Midazolam","Itraconazole"],"countries":["United States","Belgium","Canada","France","Germany","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":43,"serviceSignals":["Hematology NGS"],"summary":"In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Phase 1b, and Phase 2 portions), ziftomenib will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment. In Sub-studies 1 and 2, the effects of taking ziftomenib and other common drugs at the same time will be investigated in AML patients. In Sub-study 3, ziftomenib will be evaluated in patients with R/R acute lymphoblastic leukemia (ALL). In Sub-study 4, ziftomenib will be evaluated in patients with R/R AML with certain gene","sourceUrl":"https://clinicaltrials.gov/study/NCT04067336"},{"nctId":"NCT06551142","title":"A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":845,"enrollmentType":"ESTIMATED","startDate":"2024-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-08","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Neoplasms"],"interventions":["Ris-Rez","Cisplatin","Carboplatin","Atezolizumab","Pembrolizumab","Durvalumab","Cetuximab","Bevacizumab","Tarlatamab","Dostarlimab"],"countries":["United States","Argentina","Canada","France","Hong Kong","Israel","Italy","Japan","Panama","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab, tarlatamab, dostarlimab","sourceUrl":"https://clinicaltrials.gov/study/NCT06551142"},{"nctId":"NCT07300150","title":"A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors","sponsor":"PAQ Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2025-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-18","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-18","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Colorectal Cancer","Pancreatic Cancer","Non-Small Cell Lung Cancer","Solid Tumor"],"interventions":["PT0511","Cetuximab"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07300150"},{"nctId":"NCT06081920","title":"A Study of IBI363 in Subjects With Advanced Melanoma","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2023-10-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-19","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Melanoma"],"interventions":["IBI363"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients","sourceUrl":"https://clinicaltrials.gov/study/NCT06081920"},{"nctId":"NCT07064122","title":"A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-20","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-20","completionType":"ESTIMATED","lastUpdated":"2026-03-02","conditions":["Haematologic Neoplasms"],"interventions":["AZD2962"],"countries":["United States","Australia","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT07064122"},{"nctId":"NCT07533942","title":"A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma","sponsor":"Jazz Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-16","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Meningioma"],"interventions":["JZP3507"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT07533942"},{"nctId":"NCT07109414","title":"Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)","sponsor":"Novita Pharmaceuticals, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2025-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-24","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Platinum-resistant Ovarian Cancer"],"interventions":["NP-G2-044","PLD"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07109414"},{"nctId":"NCT06818643","title":"A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2025-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-25","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-25","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Advanced Solid Tumors","Malignant Neoplasm"],"interventions":["MK-3120"],"countries":["United States","Chile","China","France","Israel","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.","sourceUrl":"https://clinicaltrials.gov/study/NCT06818643"},{"nctId":"NCT06034002","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2023-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-29","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-29","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Myeloproliferative Neoplasms"],"interventions":["INCA033989","Ruxolitinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This study is being conducted to evaluate the safety, tolerability, dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a Monotherapy or in Combination With Ruxolitinib in participants with myeloproliferative neoplasms.","sourceUrl":"https://clinicaltrials.gov/study/NCT06034002"},{"nctId":"NCT07252414","title":"GenSci143 in Participants With Advanced Solid Tumors","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Advanced Solid Tumors"],"interventions":["GenSci143 for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07252414"},{"nctId":"NCT06787612","title":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["Ubamatamab","Bevacizumab","Cemiplimab","Fianlimab","PLD","Sarilumab"],"countries":["United States","Canada","South Korea","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called ubamatamab, also referred to as \"study drug\". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin \\[PLD\\]), referred to as \"combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether ","sourceUrl":"https://clinicaltrials.gov/study/NCT06787612"},{"nctId":"NCT07547553","title":"A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC","sponsor":"Huahui Health","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Advanced or Unresectable Hepatocellular Carcinoma (HCC)"],"interventions":["Will receive HH-009 injection 20 mg/kg, Q3W","Will receive HH-009 injection 30 mg/kg, Q3W"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC). The study will also assess pharmacokinetics, pharmacodynamics, immunogenicity, and exploratory biomarkers. Approximately 30 patients with FGF19-positive advanced HCC will be enrolled. Eligible participants will be randomized 1:1 to receive HH-009 at either 20 mg/kg or 30 mg/kg Q3W as monotherapy. Treatment will continue until disease progression, unacceptable toxicity, initiation of new anticancer therapy, study withdrawal, completion of two years of treatment, loss to follow-up, death, or other pro","sourceUrl":"https://clinicaltrials.gov/study/NCT07547553"},{"nctId":"NCT06678659","title":"A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer","sponsor":"Recursion Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2024-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Unresectable","Locally Advanced","Metastatic Cancers","Relapsed/Refractory Lymphomas"],"interventions":["REC-1245"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06678659"},{"nctId":"NCT07213817","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours","sponsor":"Ipsen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2025-12-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["IPN60300"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the body from their original location. All participants will receive the drug by injection. Study Phases: * Phase Ia: Participants with certain types of tumours will be treated in cohorts of increasingly higher doses of the drug to determine the safe and effective dose range (a high and a low dose). * Phase Ib: Participants with a specific tumour type will receive one of the two doses identified in phase Ia. The dose level will be assigned randomly (by chance). Study Periods: Screening: Up to 28 day","sourceUrl":"https://clinicaltrials.gov/study/NCT07213817"},{"nctId":"NCT07735104","title":"Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Cancer Cachexia Syndrome","Cancer Cachexia"],"interventions":["QLS2319","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Study To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia","sourceUrl":"https://clinicaltrials.gov/study/NCT07735104"},{"nctId":"NCT07555938","title":"Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2026-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2033-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Multiple Myeloma"],"interventions":["Cevostamab","Pomalidomide","Dexamethasone","Daratumumab","Elotuzumab","Carfilzomib"],"countries":["United States","Japan","Puerto Rico","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.","sourceUrl":"https://clinicaltrials.gov/study/NCT07555938"},{"nctId":"NCT07645222","title":"PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":396,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Lung Cancer"],"interventions":["HS-20122+Aumolertinib","HS-20122+Adbrelimab","HS-20122+Adbrelimab+Platinum-based Chemo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07645222"},{"nctId":"NCT04613596","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":626,"enrollmentType":"ESTIMATED","startDate":"2020-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Advanced Non-Small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer"],"interventions":["Adagrasib","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","Finland","France","Georgia","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Romania","Serbia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":770,"serviceSignals":["RAS genotyping"],"summary":"The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \\>=50% and who are candidates for first line treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04613596"},{"nctId":"NCT05951959","title":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":108,"enrollmentType":"ACTUAL","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Mantle Cell Lymphoma (MCL)"],"interventions":["Acalabrutinib","Venetoclax","Rituximab"],"countries":["United States","Australia","Brazil","Canada","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"TrAVeRse is a multicentre, open-label, Phase II study of AVR in treatment naïve MCL participants. The primary objective will be to assess the rate of MRD-negative CR at end of induction after completing 13 cycles of AVR. Participants achieving an MRD-negative CR at the end of AVR induction will be randomised to continued acalabrutinib or observation. Participants who progress during observation may receive retreatment with acalabrutinib","sourceUrl":"https://clinicaltrials.gov/study/NCT05951959"},{"nctId":"NCT03833154","title":"Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":724,"enrollmentType":"ACTUAL","startDate":"2019-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Durvalumab","Placebo","(Osimertinib cohort, single-arm, open-label separate cohort)"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Poland","Puerto Rico","Russia","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":209,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC. An additional cohort will assess Osimertinib following SBRT in patients with early stage unresected T1 to T3N0M0 NSCLC harbouring an EGFR mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT03833154"},{"nctId":"NCT07617727","title":"A Phase I Study of JSKN021 in Advanced Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":199,"enrollmentType":"ESTIMATED","startDate":"2026-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Malignant Solid Tumors"],"interventions":["JSKN021"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07617727"},{"nctId":"NCT07722494","title":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2026-07-20","startDateType":"ESTIMATED","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Colorectal Cancer"],"interventions":["IBI363 + bevacizumab","Investigator's choice of therapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase 3 study to evaluate the safety and tolerability of IBI363 plus bevacizumab in patients with advanced colorectal cancer refractory or intolerant to standard-of-care therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07722494"},{"nctId":"NCT06960577","title":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Urinary Bladder Neoplasms","Immune Checkpoint Inhibitors","Methotrexate","Vinblastine","Doxorubicin","Cisplatin","Gemcitabine"],"interventions":["Durvalumab","Methotrexate","Vinblastine","Doxorubicin","Cisplatin","Gemcitabine"],"countries":["Australia","Brazil","Canada","France","Italy","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Broad CGP"],"summary":"The Phase IIIb NIAGARA-2 study aims to expand on the data from the Phase III NIAGARA study by investigating perioperative durvalumab in combination with investigator-selected cisplatin-based neoadjuvant chemotherapy (either ddMVAC or gemcitabine/cisplatin) in a clinical practice setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06960577"},{"nctId":"NCT07368998","title":"To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Cancer"],"interventions":["Inavolisib","Fulvestrant"],"countries":["United States","Argentina","Australia","Belgium","Mexico","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT07368998"},{"nctId":"NCT06603987","title":"Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA","sponsor":"Stella Pharma Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-10-31","completionType":"ESTIMATED","lastUpdated":"2025-11-19","conditions":["Thoracic Solid Malignant Tumor"],"interventions":["BNCT","［18F］FBPA"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable. With \"lung,\" \"heart,\" \"liver,\" \"spinal cord,\" and \"esophagus\" as common risk organs in the treatment plan for BNCT using therapeutic CT to evaluate the safety and efficacy of BNCT in patients with unresectable and recurrent thoracic solid tumors which are difficult to treat with standard radiation and drug therapy. To evaluate the safety of ［18F］FBPA synthesized with MPS200FBPA. In addition, the usefulness of ［18F］FBPA-PET testing to determine the appropriateness of perfor","sourceUrl":"https://clinicaltrials.gov/study/NCT06603987"},{"nctId":"NCT07407933","title":"A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma"],"interventions":["YL201","Atezolizumab"],"countries":["United States","Belgium","Italy","Poland","Romania","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["ADC biomarker"],"summary":"This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage","sourceUrl":"https://clinicaltrials.gov/study/NCT07407933"},{"nctId":"NCT07326566","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","sponsor":"Black Diamond Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2026-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Glioblastoma (GBM)","Newly Diagnosed Glioblastoma","GBM","Glioblastoma Multiforme (GBM)","Glioma","Central Nervous System Diseases","Brain Cancer"],"interventions":["silevertinib in combination with temozolomide","temozolomide (TMZ)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozol","sourceUrl":"https://clinicaltrials.gov/study/NCT07326566"},{"nctId":"NCT06120283","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":399,"enrollmentType":"ESTIMATED","startDate":"2023-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumor","Advanced Breast Cancer","Metastatic Breast Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Malignant Neoplasm of Breast","HER2-negative Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Non-small Cell Lung Cancer"],"interventions":["BGB-43395","Fulvestrant","Letrozole","Elacestrant","Anti-Diarrheal Agent"],"countries":["United States","Australia","Brazil","China","France","Japan","Malaysia","Moldova","New Zealand","South Korea","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":63,"serviceSignals":["HER2 profiling"],"summary":"This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.","sourceUrl":"https://clinicaltrials.gov/study/NCT06120283"},{"nctId":"NCT06326411","title":"A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors","sponsor":"Nested Therapeutics, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2024-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Oncology","MEK Mutation","RAF Gene Mutation","Ras (KRAS or NRAS) Gene Mutation","Melanoma","NSCLC","Glioma","Solid Tumor, Adult","MAPK Pathway Gene Mutation"],"interventions":["NST-628"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["RAS genotyping"],"summary":"This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.","sourceUrl":"https://clinicaltrials.gov/study/NCT06326411"},{"nctId":"NCT07181499","title":"Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":28,"enrollmentType":"ESTIMATED","startDate":"2025-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-09-30","conditions":["NSCLC","Adjuvant Drug Therapy","EGFR"],"interventions":["Befotertinib","Pemetrexed + Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers. Approximately 30-40% of East Asian adenocarcinoma patients harbor EGFR mutations. Third-generation EGFR-TKIs achieve a median PFS of about 20 months as first-line therapy, but resistance eventually develops. Studies like MARIPOSA-2 confirm that amivantamab combined with chemotherapy ± lazertinib or immunotherapy regimens (ivucitinib/sintilimab + bevacizumab + chemotherapy) can extend median PFS post-resistance from approximately 4 months to 6-8 months. As a third-generation TKI, befitinib has demonstrated PFS of 16-22 months in both first-line and post-T790M mutation settings. This study aims to further evaluate the fe","sourceUrl":"https://clinicaltrials.gov/study/NCT07181499"},{"nctId":"NCT07111520","title":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":880,"enrollmentType":"ESTIMATED","startDate":"2025-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Non-small Cell Lung Cancer"],"interventions":["BNT326","Pumitamig"],"countries":["United States","Australia","China","Germany","Italy","Moldova","Poland","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":85,"serviceSignals":["ADC biomarker"],"summary":"This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available). The main goals of this study are: 1. To find the best dose levels (DLs) for the combination of BNT326 and pumitamig. 2. To look at how well participants with advanced NSCLC tolerate the combinat","sourceUrl":"https://clinicaltrials.gov/study/NCT07111520"},{"nctId":"NCT07213804","title":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1630,"enrollmentType":"ESTIMATED","startDate":"2025-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Ovarian Neoplasms","Fallopian Tube Neoplasms","Peritoneal Neoplasms","Neoplasm Metastasis"],"interventions":["Sofetabart Mipitecan","Paclitaxel","Topotecan","Gemcitabine","Pegylated liposomal doxorubicin (PLD)","MIRV","Bevacizumab","Carboplatin"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","Ireland","Italy","Japan","Mexico","Netherlands","Norway","Poland","Romania","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":265,"serviceSignals":["ADC biomarker"],"summary":"This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed during or within six months of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive cancer, whose disease responded and remained controlled for at least six months after completing platinum treatment. The researchers want to find out if Sofe-M works better than the standard treatments that doctors use now and to better understand how safe it is. Each participant's t","sourceUrl":"https://clinicaltrials.gov/study/NCT07213804"},{"nctId":"NCT06625775","title":"Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2024-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Solid Tumor, Adult","Metastatic Breast Cancer","Advanced Breast Cancer","HER2 Mutation-Related Tumors","HER2-positive Metastatic Breast Cancer","KRAS Mutant Metastatic Colorectal Cancer","Metastatic Lung Cancer","Metastatic Colorectal Cancer","Advanced Lung Cancer","HR-positive, HER2-negative Advanced Breast Cancer","HER2-positive Advanced Breast Cancer"],"interventions":["BBO-10203","Trastuzumab","Fulvestrant","Ribociclib","FOLFOX","Bevacizumab"],"countries":["United States","Australia","Brazil","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["RAS genotyping","HER2 profiling"],"summary":"First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06625775"},{"nctId":"NCT05206357","title":"Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab","sponsor":"Genmab","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":17,"enrollmentType":"ACTUAL","startDate":"2022-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2025-04-08","conditions":["Non-hodgkin Lymphoma"],"interventions":["Epcoritamab"],"countries":["United States","Australia","Belgium","Canada","Czechia","France","Germany","Israel","Italy","Japan","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["Hematology NGS"],"summary":"The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). Initial treatment cures 90% - 95% of children with these malignancies, leaving a very small population of relapsed/refractory disease with a poor prognosis. The purpose of this study is to assess the safety and tolerability of epcoritamab in pediatric participants with relapsed/refractory aggressive mature B-cell neoplasms and young adult participants with Burkitt's or Burkitt-like lymphoma/leukemia. Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of relapsed/refractory","sourceUrl":"https://clinicaltrials.gov/study/NCT05206357"},{"nctId":"NCT07229612","title":"A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-11","startDateType":"ESTIMATED","primaryCompletionDate":"2028-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-11","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Malignant Solid Tumors"],"interventions":["SHR-4298 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229612"},{"nctId":"NCT07217301","title":"A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer","sponsor":"Takeda","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["IO-resistant sqNSCLC"],"interventions":["TAK-928","Control Arm"],"countries":["United States","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":46,"serviceSignals":["Broad CGP"],"summary":"Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally. This study focuses on NSCLC in later stages (advanced). This means that the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery (unresectable). People with unresectable, advanced or metastatic NSCLC often get treatment with immunotherapy and/or platinum-based chemotherapy (such as cisplatin or carboplatin). Immunotherapy helps the body's germ-fighting (immune) system fight cancer. Chemotherapy kills cancer cells or slows their growth. Ov","sourceUrl":"https://clinicaltrials.gov/study/NCT07217301"},{"nctId":"NCT06244485","title":"A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":98,"enrollmentType":"ACTUAL","startDate":"2024-02-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Advanced Solid Tumor"],"interventions":["Valemetostat tosylate","T-DXd","Dato-DXd"],"countries":["United States","China","Italy","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":35,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd ADC in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06244485"},{"nctId":"NCT07226349","title":"A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2025-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor"],"interventions":["BG-75098","BGB-43395","Fulvestrant"],"countries":["United States","Australia","China","Denmark"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07226349"},{"nctId":"NCT06819007","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":582,"enrollmentType":"ESTIMATED","startDate":"2025-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-01-31","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Ovarian Cancer"],"interventions":["Trastuzumab Deruxtecan","Bevacizumab"],"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","China","Czechia","Denmark","France","Greece","Hungary","India","Israel","Italy","Japan","Malaysia","Poland","Romania","Singapore","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":208,"serviceSignals":["HER2 profiling"],"summary":"This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \\[IHC\\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06819007"},{"nctId":"NCT07235176","title":"Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Advanced ER+/HER2- Breast Cancer"],"interventions":["QLS1304 tablet+Fulvestrant or QLC1401","QLS1304 tablet+Fulvestrant，AI or QLC1401+CDK4/6i"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07235176"},{"nctId":"NCT06015568","title":"Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":172,"enrollmentType":"ESTIMATED","startDate":"2023-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-11-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-04","completionType":"ESTIMATED","lastUpdated":"2023-08-29","conditions":["Non-Small Cell Lung Cancer、EGFR Sensitive Mutation"],"interventions":["MCLA-129: 1500mg or 2000mg IV Q2W","Befotertinib: 75 mg or 100 mg Po QD"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["MET profiling"],"summary":"To evaluate the safety and tolerance of MCLA-129 combined with Befotertinib in patients with advanced non-small cell lung cancer with EGFR-sensitive mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06015568"},{"nctId":"NCT07407504","title":"GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-21","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated"],"interventions":["GenSci145 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An international, multicenter, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of GenSci145, as monotherapy or in combination therapy, in participants with PIK3CA-mutated, locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07407504"},{"nctId":"NCT06311578","title":"A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2024-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-08","primaryCompletionType":"ESTIMATED","completionDate":"2033-02-14","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Neoplasms"],"interventions":["JNJ-87704916","Cetrelimab","Standard of Care PD(L)-1"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06311578"},{"nctId":"NCT05739942","title":"Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":42,"enrollmentType":"ACTUAL","startDate":"2024-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-08","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-08","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Newly Diagnosed and Recurrent Glioblastoma"],"interventions":["[177Lu]Lu-NeoB","[68Ga]Ga-NeoB","Temozolomide"],"countries":["United States","France","Germany","Italy","Portugal","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study will investigate different doses of \\[177Lu\\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \\[177Lu\\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \\[68Ga\\]Ga-NeoB and characterize its uptake in the tumor area.","sourceUrl":"https://clinicaltrials.gov/study/NCT05739942"},{"nctId":"NCT06934044","title":"A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-15","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Multiple Myeloma"],"interventions":["Cevostamab","Tocilizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06934044"},{"nctId":"NCT07214779","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","sponsor":"Incyte Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":466,"enrollmentType":"ESTIMATED","startDate":"2025-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-14","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Ovarian Cancer"],"interventions":["INCB123667","Investigator's choice of chemotherapy"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Ireland","Italy","Japan","Netherlands","Poland","Puerto Rico","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":181,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07214779"},{"nctId":"NCT06097728","title":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":863,"enrollmentType":"ACTUAL","startDate":"2023-11-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-16","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-16","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Unresectable Pleural Mesothelioma"],"interventions":["Volrustomig","Pemetrexed","Carboplatin","Cisplatin","Nivolumab","Ipilimumab"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Italy","Japan","Netherlands","Norway","Poland","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":151,"serviceSignals":["Broad CGP"],"summary":"This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06097728"},{"nctId":"NCT07218809","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1100,"enrollmentType":"ESTIMATED","startDate":"2025-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-27","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Epithelial Ovarian Cancer"],"interventions":["AZD5335","Mirvetuximab Soravtansine (MIRV)","Paclitaxel","Pegylated liposomal Doxorubicin (PLD)","Topotecan"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","France","Germany","Greece","India","Ireland","Israel","Italy","Japan","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":299,"serviceSignals":["Broad CGP"],"summary":"The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.","sourceUrl":"https://clinicaltrials.gov/study/NCT07218809"},{"nctId":"NCT06112379","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1902,"enrollmentType":"ACTUAL","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-20","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-23","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Breast Cancer"],"interventions":["Dato-DXd","Durvalumab","Pembrolizumab","Doxorubicin","Epirubicin","Cyclophosphamide","Paclitaxel","Carboplatin","Capecitabine","Olaparib"],"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","France","Germany","Hong Kong","Hungary","India","Italy","Japan","Malaysia","Poland","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":283,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06112379"},{"nctId":"NCT07445308","title":"The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-03-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-11-21","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-21","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["NMIBC"],"interventions":["SPGL008"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of clinical trial is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With on-Muscle-Invasive Bladder Cancer. The main questions it aims to answer are: 1. Determine the recommend Phase II dose of SPGL008 Alone or in Combination With BCG.To 2. Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.","sourceUrl":"https://clinicaltrials.gov/study/NCT07445308"},{"nctId":"NCT06531499","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":106,"enrollmentType":"ESTIMATED","startDate":"2024-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-24","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-24","completionType":"ESTIMATED","lastUpdated":"2025-12-31","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["AAA617","Gonadotropin-releasing hormone (GnRH) analogues","Gonadotropin-releasing hormone (GnRH) antagonists"],"countries":["United States","Germany","Netherlands","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as \\[177Lu\\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).","sourceUrl":"https://clinicaltrials.gov/study/NCT06531499"},{"nctId":"NCT07250269","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2025-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-24","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-24","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Relapsed/Refractory AL Amyloidosis"],"interventions":["GC012F Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b open-label, multicenter, non-randomized study of GC012F, a CD19/BCMA dual CAR T cell therapy, in adult participants with relapsed/refractory AL amyloidosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07250269"},{"nctId":"NCT06217822","title":"First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2024-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-26","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Advanced Metastatic Castration-resistant Prostate Cancer","Prostate Specific Membrane Antigen (PSMA) Expression"],"interventions":["225Ac-PSMA-Trillium (BAY3563254)"],"countries":["United States","Belgium","Canada","Finland","Italy","Japan","Netherlands","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prostate (male reproductive gland found below the bladder) that has spread to other parts of the body. This type of prostate cancer does not respond to hormone treatment used to lower the level of testosterone, a male sex hormone, to prevent cancer from growing. The study treatment 225Ac-PSMA-Trillium, also called BAY3563254, is under development to treat advanced metastatic castration-resistant prostate cancer. It works by binding to PSMA and giving off radiation that can damage cancer cells and stop them from growing. The main purpose of ","sourceUrl":"https://clinicaltrials.gov/study/NCT06217822"},{"nctId":"NCT07321574","title":"A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors","sponsor":"Shanghai AB PharmaTech Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-28","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["SCLC, Extensive Stage","Advanced Solid Tumors"],"interventions":["ABP1011T"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open-label, multi-cohort investigation exploring the efficacy and safety of ABP1011T tablets in participants with specific target solid tumors, providing a foundation for subsequent clinical research. Based on safety and efficacy data from the prior Phase I/IIa clinical trial (Protocol Number: ABP1011T-I/II-01), priority enrollment is given to participants with advanced solid tumors including small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma (excluding osteosarcoma). Cohort A (Cohort A1, Cohort A2, Cohort A3) comprises the small cell lung cancer cohort: Participants must have failed at least two prior systemic th","sourceUrl":"https://clinicaltrials.gov/study/NCT07321574"},{"nctId":"NCT06922383","title":"A Clinical Study of Arfolitixorin in Patients With mCRC","sponsor":"Isofol Medical AB","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Metastatic Colorectal Cancer (mCRC)"],"interventions":["Arfolitixorin","Leucovorin"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a clinical research study taking place in Germany. Patients with colorectal cancer at a stage of the disease where metastases occur may take part in the study. A maximum of 90 people will participate in the study. There is already a standard therapy for treatment of colorectal cancer. This therapy contains a combination of the medicines leucovorin, fluorouracil, oxaliplatin/irinotecan and bevacizumab/cetuximab/panitumumab. The sponsoring company is developing the new therapy called arfolitixorin. In this study, patients with colorectal cancer will be given arfolitixorin instead of the standard treatment leucovorin. Different patients will receive treatment with different strengths (d","sourceUrl":"https://clinicaltrials.gov/study/NCT06922383"},{"nctId":"NCT06793215","title":"A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-Small Cell Lung Cancer","KRAS G12C Lung Cancer"],"interventions":["Divarasib","Pembrolizumab","Pemetrexed","Carboplatin","Cisplatin"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Greece","Hong Kong","Hungary","Ireland","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Portugal","Singapore","South Africa","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":268,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06793215"},{"nctId":"NCT07253116","title":"A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors","sponsor":"Nanjing Jingao biomidical technology Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Advanced Solid Tumors"],"interventions":["WJ22096"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/II, open-label, preliminary study of safety, tolerability, pharmacokinetics, and efficacy. The study comprises three parts: a Dose Escalation cohort, a Dose Expansion cohort, and an Efficacy Expansion cohort. Dose Escalation cohort aims to evaluate the safety, tolerability, pharmacokinetic (PK) characteristics, and preliminary efficacy of WJ22096 Tablets in patients with advanced solid tumors for whom standard therapies have failed, are not tolerated, or for whom no standard therapy exists. Dose Expansion cohort Based on an evaluation of preliminary data, the Sponsor and the Safety Monitoring Committee (SMC) will select 1-2 dose levels to further evaluate preliminary effica","sourceUrl":"https://clinicaltrials.gov/study/NCT07253116"},{"nctId":"NCT07259213","title":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","sponsor":"Radiopharm Theranostics, Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":73,"enrollmentType":"ESTIMATED","startDate":"2026-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Castration-resistant Prostate Cancer"],"interventions":["161Tb RAD402"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/2a Study to Evaluate the Safety, Tolerability, Whole-Body Distribution, and Preliminary Clinical Activity of 161Tb-RAD402, a Radiolabeled Anti-KLK3 Monoclonal Antibody Targeting Free Prostate-Specific Antigen, in Participants with Castration-Resistant Prostate Cancer (CRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07259213"},{"nctId":"NCT06535607","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":257,"enrollmentType":"ESTIMATED","startDate":"2024-08-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)","Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)","Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)","Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)"],"interventions":["Volrustomig","Cisplatin","Carboplatin","Paclitaxel","5-FU"],"countries":["United States","Australia","Brazil","Canada","China","Germany","Italy","Japan","South Korea","Taiwan","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":97,"serviceSignals":["Broad CGP"],"summary":"eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06535607"},{"nctId":"NCT07227025","title":"A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Amivantamab","Olomorasib"],"countries":["United States","Canada","China","South Korea","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":13,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of this study is to find out the most suitable dose (recommended phase 2 combination dose \\[RP2CD\\]) of amivantamab and olomorasib combination therapy and to assess how well the combination slows down or prevents the growth of tumors in participants with KRAS G12C mutant metastatic non-small cell lung cancer (NSCLC: the most common type of lung cancer; metastatic: has spread to other parts of the body; KRAS G12C mutant: mutation \\[change\\] in the kirsten rat sarcoma viral oncogene homolog \\[KRAS\\] gene in tumor cells in which glycine \\[G\\] at position 12 is replaced with cystine \\[C\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT07227025"},{"nctId":"NCT07094204","title":"A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors","sponsor":"Astellas Pharma Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":364,"enrollmentType":"ESTIMATED","startDate":"2025-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Solid Tumor","Non-Small-Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma","Colorectal Cancer"],"interventions":["ASP5834","panitumumab"],"countries":["United States","France","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["RAS genotyping"],"summary":"Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with solid tumors who have certain KRAS gene mutations. Some people with solid tumors of the colon or rectum (colorectal cancer), will be given ASP5834 with panitumumab. Panitumumab is a treatment for colorectal cancer. In this study, the researchers will learn how ASP5834 is processed by and acts upon the body. This information will help find a suitable dose of ASP5834 and check for any potential medic","sourceUrl":"https://clinicaltrials.gov/study/NCT07094204"},{"nctId":"NCT06644755","title":"First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2025-07-24","conditions":["Solid Tumors","Sarcoma"],"interventions":["DS-2243a"],"countries":["United States","Belgium","France","Netherlands","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["HLA / TCR"],"summary":"This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06644755"},{"nctId":"NCT06746116","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":45,"enrollmentType":"ACTUAL","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced or Recurrent Endometrial Cancer"],"interventions":["Durvalumab + Chemotherapy phase","Durvalumab + Olaparib phase"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC as the primary endpoint. The study will include approximately 85 patients distributed in approximately 20 sites in Spain. The planned duration of patient recruitment is approximately 12 months. Each patient will be followed up from screening for 36 months, until end of study period, death, withdrawal from study or loss to follow-up; whichever occurs first. Enrolment will be opened to all eligible patients treated with durvalumab in combinati","sourceUrl":"https://clinicaltrials.gov/study/NCT06746116"},{"nctId":"NCT04913285","title":"A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors","sponsor":"Pierre Fabre Medicament","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2021-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Solid Tumor, Adult","Non-small Cell Lung Cancer","Melanoma"],"interventions":["KIN-2787","KIN-2787 and binimetinib"],"countries":["United States","Australia","China","France","Italy","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":50,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04913285"},{"nctId":"NCT05669989","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","sponsor":"Sanofi","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2023-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Plasma Cell Myeloma"],"interventions":["Isatuximab intravenous (IV)","Cemiplimab (SAR439684)","Dexamethasone","Lenalidomide","Pomalidomide","Isatuximab subcutaneous (SC)","Carfilzomib"],"countries":["United States","Australia","Brazil","Chile","China","Czechia","Finland","France","Greece","Italy","Japan","New Zealand","Russia","South Korea","Spain","Sweden","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"* This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study. * This Treatment Extension study has the purpose to provide continued access to isatuximab. Adult participants with multiple myeloma who have enrolled on an isatuximab parental study for which study objectives are completed will be eligible to be enrolled in this Treatment Extension study. * The primary objective of the study is to assess long-term safety of isatuximab as study treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT05669989"},{"nctId":"NCT06767046","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","sponsor":"Corregene Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":8,"enrollmentType":"ACTUAL","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Colorectal","Pancreatic","Non-small Cell Lung Cancer (NSCLC)"],"interventions":["KRAS-specific Autologous TCR-T cell injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping","HLA / TCR"],"summary":"This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06767046"},{"nctId":"NCT06581432","title":"Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations","sponsor":"Boehringer Ingelheim","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":588,"enrollmentType":"ESTIMATED","startDate":"2024-10-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-29","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumours"],"interventions":["Zongertinib"],"countries":["United States","Australia","Belgium","Canada","China","France","Germany","Italy","Japan","Netherlands","Norway","Puerto Rico","Singapore","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":89,"serviceSignals":["HER2 profiling"],"summary":"This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into groups based on the type of advanced cancer they have, the type of HER2 alterations they have, and the dose of zongertinib they receive. Depending on the group they are in, participants take 1 of 2 different doses of zongertinib each day. Participants can continue the treatment as long as th","sourceUrl":"https://clinicaltrials.gov/study/NCT06581432"},{"nctId":"NCT07228247","title":"A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors","sponsor":"Hutchmed","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":147,"enrollmentType":"ESTIMATED","startDate":"2025-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Solid Tumors, Adult"],"interventions":["HMPL-A251"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07228247"},{"nctId":"NCT06132503","title":"Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors","sponsor":"Lantern Pharma Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2023-01-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-11-30","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Relapsed or Refractory Lymphomas","Advanced Solid Tumor"],"interventions":["LP-284"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.","sourceUrl":"https://clinicaltrials.gov/study/NCT06132503"},{"nctId":"NCT07142980","title":"A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Solid Tumors Harboring RAS Mutations or Amplifications"],"interventions":["HRS-7172 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.","sourceUrl":"https://clinicaltrials.gov/study/NCT07142980"},{"nctId":"NCT07648914","title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":446,"enrollmentType":"ESTIMATED","startDate":"2026-07-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Breast Cancer"],"interventions":["BL-B01D1","Albumin-Bound Paclitaxel","Paclitaxel","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer after failure of prior endocrine therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07648914"},{"nctId":"NCT04150042","title":"SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells","sponsor":"General Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2021-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-29","conditions":["Pancreatic Adenocarcinoma Metastatic","BRCA1 Mutation","BRCA2 Mutation","Pancreatic Acinar Cell Carcinoma","Pancreatic Ductal Adenocarcinoma","Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Ductal Adenocarcinoma","Breast Cancer Metastatic","Breast Cancer Stage IV","Pancreatic Cancer Stage IV","HER2-negative Breast Cancer","HER2 Negative Breast Carcinoma","Adenocarcinoma of the Breast","PALB2 Gene Mutation","Pancreas Cancer, Metastatic","Pancreas Cancer, Recurrent","Pancreas Cancer","Stage IV Pancreatic Cancer","Stage 4 Pancreatic Cancer"],"interventions":["Melphalan","BCNU","Vitamin B12B","Vitamin C","Autologous Hematopoietic Stem Cells"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["HRD / HRR","HER2 profiling"],"summary":"The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, vitamin B12b, and vitamin C with autologous hematopoietic stem cell infusion. A dose-escalation schedule is being employed for the vitamin C.","sourceUrl":"https://clinicaltrials.gov/study/NCT04150042"},{"nctId":"NCT06770569","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Advanced Solid Tumors"],"interventions":["HRS-3802"],"countries":["Australia","China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06770569"},{"nctId":"NCT04928846","title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":768,"enrollmentType":"ESTIMATED","startDate":"2022-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Non Small Cell Lung Cancer"],"interventions":["Telisotuzumab Vedotin","Docetaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":317,"serviceSignals":["MET profiling"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group re","sourceUrl":"https://clinicaltrials.gov/study/NCT04928846"},{"nctId":"NCT06772415","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":163,"enrollmentType":"ESTIMATED","startDate":"2025-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-03","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Advanced Solid Tumor"],"interventions":["GenSci122 tablet 50mg","GenSci122 tablet 250mg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, open-label, phase I study to evaluate the safety, tolerability, PK and preliminary efficacy of GenSci122 in participants with advanced solid tumors. The study consists of 2 parts: Part 1- dose-escalation and Part 2- dose expansion. The primary endpoint of Dose escalation is To assess the safety and tolerability of GenSci122. The primary endpoint of Dose expansion is to evaluate the preliminary anti-tumor activity of GenSci122 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06772415"},{"nctId":"NCT06891833","title":"A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-10-02","conditions":["HER2-positive Breast Cancer"],"interventions":["BL-M07D1","Pertuzumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":30,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registered phase III, randomized, open and multicenter study to evaluate the efficacy and safety of BL-M07D1 with or without Pertuzumab in the neoadjuvant treatment of HER2-positive breast cancer. The study is divided into a single-arm study phase (Phase II) and a randomized controlled study phase (Phase III).","sourceUrl":"https://clinicaltrials.gov/study/NCT06891833"},{"nctId":"NCT06907043","title":"A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","sponsor":"Eikon Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2025-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-08-19","conditions":["Advanced Solid Tumors"],"interventions":["EIK1004-001 (IMP1707-001)"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":10,"serviceSignals":["HRD / HRR","HER2 profiling"],"summary":"This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2","sourceUrl":"https://clinicaltrials.gov/study/NCT06907043"},{"nctId":"NCT06526819","title":"SMP-3124LP in Adults With Advanced Solid Tumors","sponsor":"Sumitomo Pharma America, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Solid Tumor"],"interventions":["SMP3124LP"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06526819"},{"nctId":"NCT07328217","title":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":203,"enrollmentType":"ESTIMATED","startDate":"2026-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Advanced Solid Tumors"],"interventions":["GW5282"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.","sourceUrl":"https://clinicaltrials.gov/study/NCT07328217"},{"nctId":"NCT07391813","title":"SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer","sponsor":"SN BioScience","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-09","conditions":["Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)"],"interventions":["SNB-101"],"countries":["Serbia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of the Phase 1 research is to test the safety, tolerability, maximum tolerated dose, and pharmacokinetics (PK- the study of how a medicine moves through subject body. It looks at how the drug is absorbed, travels in your blood, reaches different parts of subject body, and is eventually broken down and removed) of the SNB-101.The Phase 2 is to determine the optimal dose (amount of medicine that works best to treat a condition while causing the fewest side effects) of SNB-101 for further research and to collect a further information on PK, safety and tolerability. Once subject has completed assessments during screening and if subject is found eligible to participate in the study, s","sourceUrl":"https://clinicaltrials.gov/study/NCT07391813"},{"nctId":"NCT06128551","title":"Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":534,"enrollmentType":"ESTIMATED","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Non-Small Cell Lung Cancer (NSCLC)","Colorectal Cancer","Pancreatic Ductal Adenocarcinoma"],"interventions":["Elironrasib","Daraxonrasib"],"countries":["United States","France","Germany","Italy","Netherlands","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":55,"serviceSignals":["RAS genotyping"],"summary":"This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06128551"},{"nctId":"NCT07380334","title":"A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Advanced Solid Tumor"],"interventions":["SHR-1049 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a multicenter, open label, dose exploration/efficacy extension Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics and efficacy of SHR-1049 injection in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07380334"},{"nctId":"NCT07647510","title":"A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)","sponsor":"Dianthus Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":195,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-09","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Myasthenia Gravis, Generalized"],"interventions":["Claseprubart","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT07647510"},{"nctId":"NCT07189949","title":"A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Advanced Solid Tumors Harboring RAS Mutations or Amplifications"],"interventions":["HRS-2329 Tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.","sourceUrl":"https://clinicaltrials.gov/study/NCT07189949"},{"nctId":"NCT06895928","title":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-03-28","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-04-22","conditions":["Advanced Solid Tumors"],"interventions":["SHR-A2102","Bevacizumab Injection","Adebelimab Injection","Ametinib Mesylate Tablets","Osimertinib Mesylate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06895928"},{"nctId":"NCT07231445","title":"Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Small Cell Lung Cancer"],"interventions":["ZG006","Serplulimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, multicenter, phase Ib study to evaluate the safety and efficacy of ZG006 combined with PD-1/PD-L1 immune checkpoint inhibitors (±chemotherapy) as first-line therapy in Participants with extensive stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07231445"},{"nctId":"NCT07744243","title":"A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Urological Cancer","Solid Cancer"],"interventions":["SI-B036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and dose-expansion, non-randomized phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic urological tumors and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07744243"},{"nctId":"NCT07266298","title":"TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors","sponsor":"Neowise Biotechnology","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-12-12","conditions":["Solid Metastatic Tumor"],"interventions":["NW-101C"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HLA / TCR"],"summary":"This clinical trial is a prospective, dose-escalation, multicenter, single- arm, Phase 1 clinical trial to evaluate the safety, tolerability, PK and preliminary clinical activity of PRAME Antigen-targeted TCR-T Cells (NW-101C) infusion in patients with previously heavily treated, metastatic solid malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07266298"},{"nctId":"NCT07354022","title":"A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":912,"enrollmentType":"ESTIMATED","startDate":"2026-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Locally Advanced or Metastatic Breast Cancer"],"interventions":["HRS-8080 Tablet ; Dalpiciclib Isethionate","Fulvestrant injection ;Dalpiciclib Isethionate"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced/metastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07354022"},{"nctId":"NCT07367529","title":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":465,"enrollmentType":"ESTIMATED","startDate":"2026-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Advanced Lung Cancer"],"interventions":["TQB6411 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of TQB6411 for Injection in subjects with advanced lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07367529"},{"nctId":"NCT07266428","title":"A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors","sponsor":"Ottimo Pharma Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2025-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Solid Tumors"],"interventions":["OTP-01"],"countries":["United States","Australia","Ireland","New Zealand","Portugal","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety ","sourceUrl":"https://clinicaltrials.gov/study/NCT07266428"},{"nctId":"NCT05425576","title":"OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition","sponsor":"Oncotelic Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2025-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2024-03-15","conditions":["Malignant Pleural Mesothelioma"],"interventions":["OT-101"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a study of OT-101, a TGF-b2 inhibitor in combination of pembrolizumab in patients with malignant pleural mesothelioma. Both efficacy assessment, and safety and tolerability of various dose of OT-101 in combination of pembrolizumab are evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT05425576"},{"nctId":"NCT07230106","title":"A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":218,"enrollmentType":"ESTIMATED","startDate":"2025-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Prostate Cancer"],"interventions":["HS-20093 for Injection","SHR3680 Tablet","Abiraterone Tablet","SHR2554 Tablet","Enzalutamide Tablet","Darotamine Capsule"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT07230106"},{"nctId":"NCT07569757","title":"Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Multiple Myeloma"],"interventions":["TQB2934 injection","Pomalidomide Capsule","Selinexor tablets","Dexamethasone tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"This study is a randomized, open-label, multicenter Phase III clinical trial involving patients with relapsed/refractory multiple myeloma. The estimated total sample size is 260 cases, who will be randomly assigned in a 1:1 ratio to the test group and the control group. The primary objective of the study is to demonstrate the efficacy of TQB2934 for injection compared to the investigator-selected regimen in subjects with relapsed or refractory multiple myeloma (RRMM) by evaluating progression-free survival (PFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT07569757"},{"nctId":"NCT07753226","title":"A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Breast Cancer","Solid Tumor"],"interventions":["SI-B036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic breast cancer and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07753226"},{"nctId":"NCT07389733","title":"A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Advanced Unresectable or Metastatic Breast Cancer of Adults"],"interventions":["HRS-6208 Capsule","HRS-6209 Capsule","HRS-8080 Tablet","Fulvestrant injection","Letrozole tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07389733"},{"nctId":"NCT07613723","title":"A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies","sponsor":"Zelluna Immunotherapy AS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":9,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Ovarian Cancer","Squamous Non-Small Cell Lung Cancer (NSCLC)","Synovial Sarcomas","Head and Neck Cancer"],"interventions":["ZI-MA4-1 (TCR-NK cells)","Cyclophosphamide","Fludarabine"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["HLA / TCR"],"summary":"This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours. Currently, these patients have a poor prognosis and a relatively short overall survival. There is a lack of meaningful, effective therapies available that improve the outcome for these patients. The treatment being investigated in this study is ZIMA4-1, an allogeneic cell therapy product. This is the first time ZI-MA4-1 will be administered to humans. The study is planned to consist of two parts (A and B). Part A includes up to four dose escalation cohorts and aims ","sourceUrl":"https://clinicaltrials.gov/study/NCT07613723"},{"nctId":"NCT07661641","title":"A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors","sponsor":"Alpha-9 Oncology USA Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Breast Cancer","Prostate Cancer","Colorectal Cancer","GRPR-positive Solid Tumors"],"interventions":["[68Ga]Ga-A9-6217","Low dose [177Lu]Lu-A9-0631","[177Lu]Lu-A9-0631","[225Ac]Ac-A9-0642"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1-1b multicenter clinical study to evaluate the safety, efficacy, and dosimetry of \\[177Lu\\]Lu-A9-0631 and \\[225Ac\\]Ac-0642 in participants with Gastrin-Releasing Peptide Receptor (GRPR) expressing locally advanced, unresectable or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07661641"},{"nctId":"NCT07177716","title":"Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer","sponsor":"L & L Bio Co., Ltd., Ningbo, China","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-10","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-09-17","conditions":["Cervical Cancer"],"interventions":["LB1410","LB4330","Lenvatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330）versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07177716"},{"nctId":"NCT07258121","title":"Study of ZGGS34 in Participants With Advanced Solid Tumors","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Solid Tumor"],"interventions":["ZG006"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion phase to assess the efficacy and safety of ZGGS34 (± chemotherapy) in selected MUC17-positive advanced solid tumor participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07258121"},{"nctId":"NCT07738679","title":"Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":127,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced Solid Tumors"],"interventions":["TQB3454 tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter phase II study designed to evaluate the efficacy and safety of TQB3454 as monotherapy in patients with advanced solid tumors, divided into three cohorts.Cohort 1: Enrolled patients with diffuse glioma harbouring IDH1 R132 mutations. Cohort 2: Enrolled patients with advanced solid tumours (excluding glioma) harbouring IDH1 R132 mutations who failed standard therapy. Cohort 3: Enrolled patients with locally advanced, recurrent and/or metastatic biliary tract cancer without IDH1 mutations who progressed after gemcitabine or fluoropyrimidine-based treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07738679"},{"nctId":"NCT03715933","title":"Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas","sponsor":"Inhibrx Biosciences, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":411,"enrollmentType":"ESTIMATED","startDate":"2018-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Ewing Sarcoma","Colorectal Adenocarcinoma"],"interventions":["INBRX-109","Irinotecan","Temozolomide","carboplatin","pemetrexed","Leucovorin","Fluorouracil","Bevacizumab","Trifluridine + Tipiracil"],"countries":["United States","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).","sourceUrl":"https://clinicaltrials.gov/study/NCT03715933"},{"nctId":"NCT06712355","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","sponsor":"BioNTech SE","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":621,"enrollmentType":"ESTIMATED","startDate":"2025-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":["Pumitamig","Atezolizumab","Etoposide","Carboplatin (or cisplatin if carboplatin is not tolerated)"],"countries":["United States","Australia","China","France","Germany","Italy","Japan","Netherlands","Poland","Romania","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":221,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06712355"},{"nctId":"NCT07170592","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","sponsor":"Bionoxx Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2027-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Treatment-Refractory Solid Tumors"],"interventions":["OTS-412","Hydroxyurea (HU)","Atezolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07170592"},{"nctId":"NCT06657222","title":"First in Human Study of TUB-030 in Patients With Advanced Solid Tumors","sponsor":"Tubulis GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2024-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Advanced Solid Tumors","HNSCC","SCLC","NSCLC","TNBC - Triple-Negative Breast Cancer","CRC"],"interventions":["TUB-030"],"countries":["United States","Canada","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose. Participants will: Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for","sourceUrl":"https://clinicaltrials.gov/study/NCT06657222"},{"nctId":"NCT07678970","title":"A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Gastrointestinal Tumor","Solid Tumor"],"interventions":["SI-B036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, non-randomized Phase I clinical study with dose-escalation and expansion cohorts, designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic gastrointestinal tumors and other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07678970"},{"nctId":"NCT07554456","title":"A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["BL-B01D1","Tislelizumab","5-Fluorouracil","Cisplatin","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07554456"},{"nctId":"NCT05007782","title":"Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2021-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-12-29","conditions":["Advanced Solid Tumor"],"interventions":["Denikitug","Zimberelimab"],"countries":["United States","Australia","Canada","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05007782"},{"nctId":"NCT07606599","title":"A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":398,"enrollmentType":"ESTIMATED","startDate":"2026-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Biliary Tract Cancer"],"interventions":["BL-M07D1","Oxaliplatin","Calcium levofolinate","Fluorouracil","Irinotecan Hydrochloride Liposome","Irinotecan Hydrochloride","Capecitabine Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing locally advanced or metastatic biliary tract cancer after platinum-containing chemotherapy failure.","sourceUrl":"https://clinicaltrials.gov/study/NCT07606599"},{"nctId":"NCT07738939","title":"IKS04 Regimen in Advanced Solid Tumors That Express CA242","sponsor":"Iksuda Therapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-11","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Colorectal Cancer","Gastro Esophageal Junctional Cancer","Gastric Cancer (GC)","GEJ Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer (BTC)","Gall Bladder Cancer","Cholangiocarcinoma"],"interventions":["IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further evaluation in expansion (RDE). The regimen includes Isumab04 (unconjugated antibody) followed by the IKS04 antibody-drug conjugate, both directed against the CA242 (CanAg) tumor-associated antigen and administered intravenously (IV) in patients with advanced solid cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07738939"},{"nctId":"NCT07737600","title":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","sponsor":"Lepu Biopharma Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":316,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Colorectal Cancer"],"interventions":["MRG007","5-Fluorouracil / Leucovorin Calcium","Bevacizumab","Oxaliplatin","PD-1/VEGF antibody","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07737600"},{"nctId":"NCT07265921","title":"A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2025-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2025-12-05","conditions":["Advanced Solid Cancer"],"interventions":["SIM0609 for injection","dose expansion of SIM0609 in CRC","dose expansion of SIM0609 in GC/GEJC cohort","dose expansion of SIM0609 in PDAC cohort","dose expansion of SIM0609 in positive other solid tumors"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is an open-label,multicenter phase I study to evaluate the safety,Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants with Locally Advanced/Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07265921"},{"nctId":"NCT07446153","title":"A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":282,"enrollmentType":"ESTIMATED","startDate":"2026-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Solid Tumor"],"interventions":["HRS-8364 Tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is an open, multicenter, Phase I/II clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07446153"},{"nctId":"NCT07556757","title":"A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia","sponsor":"ImmunityBio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":10,"enrollmentType":"ESTIMATED","startDate":"2025-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["B-ALL","Leukemia"],"interventions":["CD19 t-haNK"],"countries":["South Africa"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1, open-label study to evaluate the safety and efficacy of CD19 t-haNK in patients with B-cell acute lymphoblastic leukemia. Up to 10 patients will receive at least 1 dose of study drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT07556757"},{"nctId":"NCT07263594","title":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","sponsor":"DualityBio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":127,"enrollmentType":"ESTIMATED","startDate":"2026-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Gastrointestinal Cancer"],"interventions":["DB-1324"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.","sourceUrl":"https://clinicaltrials.gov/study/NCT07263594"},{"nctId":"NCT07190833","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","sponsor":"Bionoxx Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2026-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Treatment-Refractory Solid Tumors"],"interventions":["OTS-412","Hydroxyurea (HU)","Atezolizumab"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This clinical trial aims to determine whether the administration of the investigational drug OTS-412, OTS-412 in combination with hydroxyurea or hydroxyurea/atezolizumab is safe and effective for patients with various types of cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07190833"},{"nctId":"NCT07660432","title":"A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":472,"enrollmentType":"ESTIMATED","startDate":"2027-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Neoplasms, Malignant"],"interventions":["SIM0689 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety, of SIM0689 and how the body processes it, how it affects the body, and its early signs of activity against tumors when given alone to Adult Participants with Locally Advanced or Metastatic Solid Tumors. The study has a dose escalation part to find the highest dose that can be given safely, or recommended dose (RD) for SIM0689 when given alone, and a dose expansion part in subjects with specific tumor types treated with SIM0689 as a single agent at RD.","sourceUrl":"https://clinicaltrials.gov/study/NCT07660432"},{"nctId":"NCT07190469","title":"PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer","sponsor":"ProteinQure Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2025-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Triple Negative Breast Cancer (TNBC)","Advanced Solid Tumors Cancer"],"interventions":["PQ203"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07190469"},{"nctId":"NCT04121455","title":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","sponsor":"TME Pharma AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":117,"enrollmentType":"ESTIMATED","startDate":"2019-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-06-25","conditions":["Glioblastoma"],"interventions":["Olaptesed pegol","Radiotherapy","Bevacizumab","Pembrolizumab","Temozolomide (TMZ)"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to obtain first, exploratory information on the safety and efficacy of (i) olaptesed pegol in combination with radiation therapy in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete tumor resection, and (ii) olaptesed pegol in combination with radiation therapy and bevacizumab in patients with newly diagnosed glioblastoma of unmethylated MGMT promoter status either not amenable to resection (biopsy only) or after incomplete or complete tumor resection. Further arms are included (i) to establish safety for the combination of olaptesed pegol at three different doses in ","sourceUrl":"https://clinicaltrials.gov/study/NCT04121455"},{"nctId":"NCT07606612","title":"A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2026-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Solid Tumor"],"interventions":["SI-B036"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, non-randomized Phase I clinical study of dose-escalation and expansion to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07606612"},{"nctId":"NCT07028281","title":"A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-07-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Malignant Solid Tumors"],"interventions":["SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07028281"},{"nctId":"NCT07268040","title":"A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Malignant Solid Tumors"],"interventions":["SHR-7787 Injection","SHR-1316 Injection","SHR-4849 Injection","Etoposide injection","Carboplatin injection","Cisplatin injection","BP102 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07268040"},{"nctId":"NCT07020221","title":"A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors","sponsor":"Verastem, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":295,"enrollmentType":"ESTIMATED","startDate":"2025-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Pancreatic Ductal Adenocarcinoma","Non Small Cell Lung Cancer","Colorectal Cancer","Solid Tumor, Adult","G12D Mutated KRAS"],"interventions":["VS-7375","Cetuximab","Carboplatin + Pemetrexed + Pembrolizumab","Gemcitabine","Gemcitabine + Nab-paclitaxel"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["RAS genotyping"],"summary":"This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07020221"},{"nctId":"NCT07593092","title":"Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors","sponsor":"Xencor, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Ovarian Cancer"],"interventions":["XmAb541","XmAb808"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to determine whether the investigational drug XmAb541 in combination with XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 in combination with XmAb808 on tumor outcomes.","sourceUrl":"https://clinicaltrials.gov/study/NCT07593092"},{"nctId":"NCT07085767","title":"Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer","sponsor":"Olema Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2025-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-01","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Breast Cancer","Locally Advanced Breast Cancer","Metastatic Breast Cancer","ER Positive Breast Cancer","HER2 Negative Breast Carcinoma"],"interventions":["Palazestrant","Letrozole-matching placebo","Ribociclib","Letrozole","Palazestrant matching-placebo"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Greece","Hong Kong","Hungary","Italy","Malaysia","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":167,"serviceSignals":["HER2 profiling"],"summary":"This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07085767"},{"nctId":"NCT06099990","title":"Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":660,"enrollmentType":"ESTIMATED","startDate":"2023-10","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2023-10-25","conditions":["High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)"],"interventions":["dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets","placebo; abiraterone acetate tablets; prednisone tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study was to evaluate the safety and efficacy of dalcilide tablets in combination with AA-P in the treatment of subjects with high tumor burden mHSPC and to determine the second stage starting dose and progression-free survival（rPFS） based on BICR assessment","sourceUrl":"https://clinicaltrials.gov/study/NCT06099990"},{"nctId":"NCT07582315","title":"A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":538,"enrollmentType":"ESTIMATED","startDate":"2026-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Biliary Tract Cancer"],"interventions":["BL-B01D1","Oxaliplatin","Calcium levofolinate","Fluorouracil","Irinotecan Hydrochloride Liposome","Irinotecan Hydrochloride","Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 compared with the investigator's choice of protocol in patients with locally advanced or metastatic biliary tract cancer who have failed prior platinum-based chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07582315"},{"nctId":"NCT06565689","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012","sponsor":"Excyte Biopharma Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2023-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma"],"interventions":["YK012"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study aims to provide a basis for further clinical development of YK012.","sourceUrl":"https://clinicaltrials.gov/study/NCT06565689"},{"nctId":"NCT07678957","title":"A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Breast Cancer"],"interventions":["BL-M07D1","DS-8201"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This trial is a randomized, open-label, multicenter Phase II study designed to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable locally recurrent or metastatic HR-positive, HER2-low expressing breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07678957"},{"nctId":"NCT06680258","title":"A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy","sponsor":"Tempest Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":740,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["TPST-1120","Atezolizumab","Bevacizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to determine if TPST-1120 in combination with atezolizumab and bevacizumab helps patients to live longer compared to atezolizumab and bevacizumab alone (the standard of care treatment) in adult patients with hepatocellular carcinoma that cannot be removed by surgery or has spread outside of the liver (called metastatic). The trial also will study the safety and side effects of the drug combination compared to the standard of care treatment. Other questions the trial aims to answer include: 1. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the time that patients are alive and cancer is not growing (progression free survival) compared","sourceUrl":"https://clinicaltrials.gov/study/NCT06680258"},{"nctId":"NCT07260708","title":"Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Advanced Cancers"],"interventions":["TQB2922 injection (subcutaneous injection)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07260708"},{"nctId":"NCT07527858","title":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2026-05-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Microsatellite Stable Colorectal Cancer"],"interventions":["Denikitug","Nivolumab","Bevacizumab","Trifluridine-Tipiracil"],"countries":["United States","Australia","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC). The primary objective of this study is to assess the effect of DEN as monotherapy and in combination with nivolumab (NIVO) or trifluridine-tipiracil (FTD-TPI) and bevacizumab (BVZ) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1).","sourceUrl":"https://clinicaltrials.gov/study/NCT07527858"},{"nctId":"NCT07280013","title":"A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects","sponsor":"C4 Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Multiple Myeloma (MM)"],"interventions":["Cemsidomide","Elranatamab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for","sourceUrl":"https://clinicaltrials.gov/study/NCT07280013"},{"nctId":"NCT07589569","title":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2026-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Pancreatic Cancer"],"interventions":["HRS-7058"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07589569"},{"nctId":"NCT07619898","title":"PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure","sponsor":"Therakos LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Colitis","Hepatitis","Melanoma (Skin Cancer)"],"interventions":["methoxsalen","Extracorporeal photopheresis (ECP)","Vedolizumab","Infliximab","Mycophenolate Mofetil (MMF)","Azathioprine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light. Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately. The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to cortic","sourceUrl":"https://clinicaltrials.gov/study/NCT07619898"},{"nctId":"NCT07600476","title":"A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors","sponsor":"Kupando GmbH","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Cutaneous Melanoma","Mucosal Melanoma","Cutaneous Squamous Cell Carcinoma (CSCC)","Merkel Cell Carcinoma of Skin","Basal Cell Carcinoma of Skin"],"interventions":["KUP-101A"],"countries":["Germany"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.","sourceUrl":"https://clinicaltrials.gov/study/NCT07600476"},{"nctId":"NCT07545460","title":"A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":404,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["BL-M07D1","Liposomal Doxorubicin","Paclitaxel","Topotecan"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07545460"},{"nctId":"NCT03686124","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","sponsor":"Immatics US, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":375,"enrollmentType":"ESTIMATED","startDate":"2019-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Refractory Cancer","Recurrent Cancer","Solid Tumor, Adult","Cancer"],"interventions":["IMA203 Product","IMA203 product- flat dose","IMA203CD8 Product","Nivolumab","IMADetect®"],"countries":["United States","Germany"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).","sourceUrl":"https://clinicaltrials.gov/study/NCT03686124"},{"nctId":"NCT07641855","title":"A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Castration-resistant Prostate Cancer"],"interventions":["BL-B01D1","Abiraterone","Olaparib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.","sourceUrl":"https://clinicaltrials.gov/study/NCT07641855"},{"nctId":"NCT07244835","title":"A Study of DEG6498 in Participants With Solid Tumors","sponsor":"Degron Therapeutics Co.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Malignant Neoplasms"],"interventions":["DEG6498"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors. It will also learn about DEG6498 pharmacokinetics (PK) profile and potential antitumor activity. The main questions it aims to answer are: * what is an appropriate dose to be given to participants? * are the side effects of treatment manageable? Participants who are treated in this study will receive DEG6498 orally once a day and be closely monitored by the treating physicians.","sourceUrl":"https://clinicaltrials.gov/study/NCT07244835"},{"nctId":"NCT07529808","title":"Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","sponsor":"BigHat Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":164,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Gastric Cancer","Gastric Adenocarcinoma","Gastric (Stomach) Cancer","Gastroesophageal Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastroesophageal Junction (GEJ) Adenocarcinoma","Gastroesophageal Junction (GEJ) Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Adenocarcinoma","Gastrointestinal Cancers","Colorectal (Colon or Rectal) Cancer","Pancreatic Cancer","CDH17-positive Advanced Solid Tumors","Advanced Gastric Cancer"],"interventions":["BHB810"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07529808"},{"nctId":"NCT07060989","title":"A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation","sponsor":"Nutshell Therapeutics (Shanghai) Co., LTD.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Advanced Solid Tumors"],"interventions":["NTS071"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07060989"},{"nctId":"NCT06838273","title":"A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":720,"enrollmentType":"ESTIMATED","startDate":"2025-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06838273"},{"nctId":"NCT07079228","title":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":602,"enrollmentType":"ESTIMATED","startDate":"2025-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2025-09-23","conditions":["Pancreatic Cancer"],"interventions":["QLS31905","Nab-paclitaxel.","Gemcitabine","Placebo for QLS31905"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"The goal of this study is to evaluate the efficacy of QLS31905 in combination with chemotherapy (nab-paclitaxel plus gemcitabine \\[AG\\]) versus placebo in combination with chemotherapy (AG) in the treatment of CLDN18.2-positive advanced pancreatic cancer in adult participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07079228"},{"nctId":"NCT02346747","title":"A Trial of Vigil for Participants With Ovarian Cancer","sponsor":"Gradalis, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":92,"enrollmentType":"ACTUAL","startDate":"2015-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-12","primaryCompletionType":"ESTIMATED","completionDate":"2028-12","completionType":"ESTIMATED","lastUpdated":"2025-10-29","conditions":["Ovarian Cancer","Ovarian Neoplasms"],"interventions":["Vigil","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is \"Will participants who receive treatment with Vigil have a longer time to disease recurrence versus the participants that were not given Vigil?\"","sourceUrl":"https://clinicaltrials.gov/study/NCT02346747"},{"nctId":"NCT07463521","title":"A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-22","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Ocular Myasthenia Gravis"],"interventions":["Rozanolixizumab","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07463521"},{"nctId":"NCT07107126","title":"Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes","sponsor":"Remedy Plan, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-02-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"interventions":["RPT1G"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).","sourceUrl":"https://clinicaltrials.gov/study/NCT07107126"},{"nctId":"NCT06282575","title":"Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer","sponsor":"Jazz Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":286,"enrollmentType":"ESTIMATED","startDate":"2024-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Biliary Tract Cancer"],"interventions":["Zanidatamab","Cisplatin","Gemcitabine","Pembrolizumab","Durvalumab"],"countries":["United States","Argentina","Belgium","Brazil","Canada","Chile","China","Czechia","Finland","France","Germany","India","Israel","Italy","Japan","Portugal","Puerto Rico","Romania","Serbia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":185,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local regulations) as first line of treatment for participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06282575"},{"nctId":"NCT06688435","title":"A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2033-05-01","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["Myasthenia Gravis"],"interventions":["SYS6020 injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open, 2-stage (dose-escalation phase and dose-expansion phase), multi-center, phase I clinical trial to evaluate the safety and tolerance of SYS6020 injection in the participants with refractory systemic myasthenia gravis, and determine the recommended dose (RD) for subsequent studies of the product, and to preliminarily evaluate the clinical efficacy of the product, as well as to explore the pharmacokinetics and immunogenicity of the product in vivo. The dose-escalation phase and dose-expansion phase include 7 periods, and they are respectively in sequence as follows: the screening period, apheresis period, pre-dosing assessment, SYS6020 injection infusion, DLT o","sourceUrl":"https://clinicaltrials.gov/study/NCT06688435"},{"nctId":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","sponsor":"Nuvation Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":365,"enrollmentType":"ESTIMATED","startDate":"2023-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Glioma","Astrocytoma, Grade IV","IDH1-mutant Glioma","Astrocytoma, IDH-Mutant, Grade 3","Astrocytoma, IDH-Mutant, Grade 4","Astrocytoma, IDH-Mutant, Grade 2","Oligodendroglioma","Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted"],"interventions":["safusidenib","Placebo"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":57,"serviceSignals":["Broad CGP"],"summary":"This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled. The purpose of Part 3 will be to evaluate the efficacy of safusidenib in p","sourceUrl":"https://clinicaltrials.gov/study/NCT05303519"},{"nctId":"NCT07686068","title":"First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors","sponsor":"VelaVigo Bio Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2026-08-18","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Participants With Advanced Solid Tumor Malignancies"],"interventions":["VBC106"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.","sourceUrl":"https://clinicaltrials.gov/study/NCT07686068"},{"nctId":"NCT06933524","title":"Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors","sponsor":"Autotelicbio","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2025-10-01","conditions":["Solid Tumors"],"interventions":["ATB-320"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and tolerability of ATB-320 in patients with progressive or metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06933524"},{"nctId":"NCT04884035","title":"Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma","sponsor":"Celgene","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2021-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Lymphoma, B-Cell"],"interventions":["CC-220","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone","CC-99282","Polatuzumab vedotin"],"countries":["United States","Australia","Greece","Poland","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1) will consist of 2 parallel arms in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP-21); CC-220 and R-CHOP-21 or CC-99282 and R-CHOP-21. Part 1 will be followed by a randomized dose expansion (Part 2) with CC-220 and/or CC-99282 at the Recommended Phase 2 Dose (RP2D) in combination with R-CHOP-21. A polatuzumab-R-CHP regimen in combination with CC-220 or CC-99282 will be explored with the addition of a new cohort only after the RP2D for the CC-220 a","sourceUrl":"https://clinicaltrials.gov/study/NCT04884035"},{"nctId":"NCT07349693","title":"Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma","sponsor":"Everfront Biotech Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":175,"enrollmentType":"ESTIMATED","startDate":"2026-11-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Recurrent Glioblastoma, IDH-Wildtype"],"interventions":["Cerebraca wafer","Temozolomide (for relapsed malignant glioma)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition","sourceUrl":"https://clinicaltrials.gov/study/NCT07349693"},{"nctId":"NCT06634589","title":"A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies","sponsor":"BeOne Medicines","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-02","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["B-cell Malignancy","Relapsed Cancer","Refractory Cancer","B-cell Lymphoma"],"interventions":["BGB-16673","Sonrotoclax","Zanubrutinib","Mosunetuzumab","Glofitamab","Obinutuzumab"],"countries":["United States","Australia","Brazil","China","Germany","Italy","New Zealand","Poland"],"northAmerica":true,"chinaSites":true,"siteCount":50,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.","sourceUrl":"https://clinicaltrials.gov/study/NCT06634589"},{"nctId":"NCT07561554","title":"Phase I Study of HSK42360-Na in Solid Tumors With BRAF V600 Mutation","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":159,"enrollmentType":"ESTIMATED","startDate":"2026-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-02","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-02","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Solid Tumors (Phase 1)"],"interventions":["HSK42360-Na"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and PD of HSK42360-Na when given orally in patients with active BRAF V600 mutation locally advanced or metastatic Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07561554"},{"nctId":"NCT07682870","title":"A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors","sponsor":"Virogin Biotech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2026-09-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-03","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced Malignant Solid Tumor"],"interventions":["Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. This Phase I study will be conducted in herpes simplex virus (HSV) -seropositive subjects with advanced malignant solid tumors that are refractory to conventional therapies. This is an open label study to determine the safety and tolerability of VG2025, and recommended dose of VG2025 for Phase II trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07682870"},{"nctId":"NCT06130553","title":"A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":334,"enrollmentType":"ESTIMATED","startDate":"2024-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-04","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-04","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Advanced Solid Tumors That Are MTAP Deficient"],"interventions":["AZD3470","Datopotamab deruxtecan"],"countries":["United States","Australia","China","France","Japan","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.","sourceUrl":"https://clinicaltrials.gov/study/NCT06130553"},{"nctId":"NCT07723703","title":"Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML","sponsor":"Amphista Therapeutics Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Acute Myeloid Leukaemia","High Risk Myelodysplastic Syndrome"],"interventions":["AMX-883","Posaconazole"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The purpose of the study is to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) and in combination with anticancer agents in participants with AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT07723703"},{"nctId":"NCT07134088","title":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","sponsor":"Amgen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2025-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-18","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia"],"interventions":["Blinatumomab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.","sourceUrl":"https://clinicaltrials.gov/study/NCT07134088"},{"nctId":"NCT06596694","title":"Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-11-03","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-07","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-07","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Gastrointestinal Cancer"],"interventions":["Patritumab deruxtecan"],"countries":["United States","Australia","Canada","Chile","China","France","Israel","Italy","New Zealand","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":62,"serviceSignals":["Broad CGP"],"summary":"Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06596694"},{"nctId":"NCT06784752","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-08","primaryCompletionType":"ESTIMATED","completionDate":"2034-01-23","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Somatostatin Receptor Positive (SSTR+)","Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"],"interventions":["[177Lu]Lu-DOTA-TATE","Octreotide LAR"],"countries":["United States","Canada","China","France","Germany","Hungary","Italy","Netherlands","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":65,"serviceSignals":["Broad CGP"],"summary":"The purpose of the current study is to evaluate the efficacy and safety of \\[177Lu\\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \\<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden","sourceUrl":"https://clinicaltrials.gov/study/NCT06784752"},{"nctId":"NCT07117214","title":"A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-11","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-11","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Breast Neoplasms","Carcinoma, Non-Small-Cell Lung"],"interventions":["[68Ga]Ga-DWJ155"],"countries":["Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a phase I, open label first in human study to evaluate the imaging performance, safety, biodistribution and pharmacokinetics of \\[68Ga\\]Ga-DWJ155 in patients ≥ 18 years of age with hormone receptor positive/HER2 negative (HR+/HER2-) and HER2 positive (HER2+) advanced breast cancer (aBC) and advanced Non-Small Cell Lung Cancer (aNSCLC) adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07117214"},{"nctId":"NCT07258511","title":"A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["JNJ-79635322","Teclistamab"],"countries":["United States","Australia","Canada","China","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Norway","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":124,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.","sourceUrl":"https://clinicaltrials.gov/study/NCT07258511"},{"nctId":"NCT06997029","title":"A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":234,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-14","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-14","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor","Advanced Breast Cancer","Advanced Ovarian Cancer"],"interventions":["BMS-986500","Palbociclib","Fulvestrant"],"countries":["United States","Denmark","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06997029"},{"nctId":"NCT07293754","title":"An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors","sponsor":"Repertoire Immune Medicines","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-15","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Advanced Malignant Solid Tumor"],"interventions":["RPTR-1-201","PD-1 / PD-L1 monoclonal antibody"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.","sourceUrl":"https://clinicaltrials.gov/study/NCT07293754"},{"nctId":"NCT06990464","title":"A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients","sponsor":"Shanghai Institute Of Biological Products","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2025-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-15","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Advanced Solid Tumors"],"interventions":["SIBP-A19"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A19 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06990464"},{"nctId":"NCT06293898","title":"Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors","sponsor":"SystImmune Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2024-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-15","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Endometrial Cancer","Cervical Cancer","Ovarian Cancer","Urothelial Carcinoma","Biliary Tract Cancer","Breast Cancer","Lung Cancer","Gastric Cancer","Gastroesophageal-junction Cancer","Esophageal Cancer"],"interventions":["BL-M07D1"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06293898"},{"nctId":"NCT06662786","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2024-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2032-01-20","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Colorectal Neoplasms"],"interventions":["Amivantamab","Cetuximab","5-fluorouracil","Leucovorin calcium/Levoleucovorin","Oxaliplatin","Irinotecan Hydrochloride"],"countries":["United States","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Netherlands","Poland","Puerto Rico","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":238,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06662786"},{"nctId":"NCT07100080","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-11-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-15","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Iza-bren","Carboplatin","Cisplatin","Pemetrexed"],"countries":["United States","Argentina","Belgium","Canada","Chile","China","Colombia","France","Germany","Greece","India","Italy","Japan","Mexico","Netherlands","Norway","Poland","Romania","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":186,"serviceSignals":["Broad CGP"],"summary":"A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07100080"},{"nctId":"NCT07282587","title":"Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma","sponsor":"Jazz Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-15","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Advanced Pheochromocytoma and Paraganglioma","PCPG"],"interventions":["ONC206","ONC206: Dose 1","ONC206: Dose 2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).","sourceUrl":"https://clinicaltrials.gov/study/NCT07282587"},{"nctId":"NCT06476808","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-19","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["High-grade Serous Ovarian Carcinoma (HGSOC)","Uterine Serous Carcinoma (USC)","Non-small Cell Lung Cancer (NSCLC)"],"interventions":["BMS-986463"],"countries":["United States","Canada","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06476808"},{"nctId":"NCT05957536","title":"A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors","sponsor":"D3 Bio (Wuxi) Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2023-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-19","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-19","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["HER-2 Positive Advanced Solid Tumors"],"interventions":["D3L-001"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":9,"serviceSignals":["HER2 profiling"],"summary":"This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05957536"},{"nctId":"NCT07405801","title":"A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-19","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-26","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Breast Cancer"],"interventions":["Inavolisib","Ribociclib","Fulvestrant","Placebo"],"countries":["United States","Argentina","Brazil","Canada","France","Germany","Italy","Mexico","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["HER2 profiling"],"summary":"A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07405801"},{"nctId":"NCT06380660","title":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","sponsor":"Acerand Therapeutics (Shanghai) Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":298,"enrollmentType":"ESTIMATED","startDate":"2024-03-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-21","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-21","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumor, Adult","BRCA1 Mutation","BRCA2 Mutation","Ovarian Cancer","Breast Cancer","Prostate Cancer"],"interventions":["ACE-86225106 tablet"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["HRD / HRR"],"summary":"The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06380660"},{"nctId":"NCT04910568","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":126,"enrollmentType":"ACTUAL","startDate":"2021-07-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-21","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-21","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Cevostamab","Tocilizumab","Pomalidomide","Daratumumab","Dexamethasone"],"countries":["United States","Australia","Canada","Czechia","Denmark","France","Israel","Italy","Japan","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT04910568"},{"nctId":"NCT07365280","title":"Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma","sponsor":"ZSky Biotech Inc","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2026-01-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-24","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-24","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Glioblastoma"],"interventions":["Personalized Dendritic Cell Vaccine ZSNeo-DC1.1","Temozolomide (TMZ)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This is a multicenter, open-label, randomized Phase II clinical study designed to evaluate the efficacy and safety of a personalized dendritic cell (DC) vaccine, ZSNeo-DC1.1, in combination with temozolomide (TMZ) as adjuvant therapy in patients with newly diagnosed glioblastoma (GBM). Eligible patients with histologically confirmed, IDH1/IDH2 wild-type newly diagnosed glioblastoma who have undergone tumor debulking surgery followed by standard concurrent chemoradiotherapy will be enrolled. After confirmation of tumor neoantigens and eligibility, patients will be randomized in a 1:1 ratio to receive either ZSNeo-DC1.1 in combination with TMZ or TMZ alone. The primary objective is to evaluate","sourceUrl":"https://clinicaltrials.gov/study/NCT07365280"},{"nctId":"NCT06682780","title":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2025-09-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2025-09-25","conditions":["Advanced Solid Tumor"],"interventions":["LM-2417","Docetaxel","Toripalimab/Tirelizumab","Carboplatin","Niraparib","Lenvatinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with advanced solid tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT06682780"},{"nctId":"NCT07205718","title":"A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors","sponsor":"Takeda","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":223,"enrollmentType":"ESTIMATED","startDate":"2025-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-21","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["TAK-188"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants to","sourceUrl":"https://clinicaltrials.gov/study/NCT07205718"},{"nctId":"NCT07331155","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","sponsor":"Nanjing Leads Biolabs Co.,Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2026-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-26","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-26","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Advanced Solid Tumour"],"interventions":["LBL-024 for Injection","Cisplatin Injection","Paclitaxel Injection","Tislelizumab Injection","5-Fluorouracil injection","Capecitabine tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.","sourceUrl":"https://clinicaltrials.gov/study/NCT07331155"},{"nctId":"NCT07435038","title":"Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-02-12","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-28","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Non-small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Advanced Solid Tumors"],"interventions":["BPI-572270"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07435038"},{"nctId":"NCT07284849","title":"A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer","sponsor":"Incyte Corporation","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2026-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-28","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["CRC (Colorectal Cancer)"],"interventions":["INCA33890","Placebo","Bevacizumab","FOLFOX"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Denmark","France","Georgia","Germany","Italy","Japan","Netherlands","Norway","Poland","Puerto Rico","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":254,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07284849"},{"nctId":"NCT05421663","title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":166,"enrollmentType":"ACTUAL","startDate":"2022-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2041-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Lymphoma, Non-Hodgkin","Lymphoma, B-Cell","Lymphoma, Large B-Cell, Diffuse"],"interventions":["JNJ-90014496"],"countries":["United States","Australia","Canada","Denmark","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05421663"},{"nctId":"NCT06855771","title":"A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2025-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-30","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["BMS-986504"],"countries":["United States","Australia","China","France","Germany","Italy","Japan","Poland","Romania","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06855771"},{"nctId":"NCT07109726","title":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","sponsor":"Terremoto Biosciences Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":205,"enrollmentType":"ESTIMATED","startDate":"2025-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Breast Cancer","Endometrial Cancer","Ovarian Cancer","Lung Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma","Esophageal Squamous Cell Carcinoma","Solid Tumor","Cervical Cancer"],"interventions":["TER-2013","Fulvestrant injection"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07109726"},{"nctId":"NCT07288957","title":"A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":266,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Solid Tumors (Phase 1)"],"interventions":["ABSK131"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK131 in patients with MTAP-Deficient Advanced/Metastatic Solid Tumors to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07288957"},{"nctId":"NCT07391644","title":"A Study of JSKN027 in Patients With Advanced Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2026-03-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Advanced Malignant Solid Tumor"],"interventions":["JSKN027"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase 1 (Ia/Ib) clinical study conducted in China to evaluate the safety and tolerability of JSKN027 in patients with advanced malignant solid tumors. The study will also assess the pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of JSKN027, and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D). The study includes two parts. Part Ia is a dose-escalation phase designed to evaluate the safety and tolerability of increasing dose levels of JSKN027. Part Ib is a dose-expansion phase in which additional patients will be enrolled at selected dose levels to further evaluate safety a","sourceUrl":"https://clinicaltrials.gov/study/NCT07391644"},{"nctId":"NCT07417189","title":"A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":401,"enrollmentType":"ESTIMATED","startDate":"2026-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Solid Tumors, Adult"],"interventions":["ABSK141-400mg","ABSK141-Recommended Dose for Expansion (RDE)","ABSK141-800mg","ABSK141-1200mg","ABSK141-Recommended Phase 2 dose (RP2D)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a first-in-human (FIH), exploratory, multicenter, open-label, phase I/II study of ABSK141 in patients with advanced solid tumors to to evaluate safety, tolerability, PK and optimize the dosage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07417189"},{"nctId":"NCT07508761","title":"IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","sponsor":"Nanjing Immunophage Biotech Co., Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2026-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Advanced Solid Tumor"],"interventions":["IPG7236","Toripalimab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07508761"},{"nctId":"NCT07164170","title":"A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":86,"enrollmentType":"ESTIMATED","startDate":"2025-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Non-Small Cell Lung Cancer"],"interventions":["ABSK043 in combination with Glecirasib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.","sourceUrl":"https://clinicaltrials.gov/study/NCT07164170"},{"nctId":"NCT07640737","title":"AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)","sponsor":"Aurigene Discovery Technologies Limited","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Neuroendocrine (NE) Tumors","Advanced NET of GI Origin"],"interventions":["AUR103 Calcium"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"A phase 2 Study Evaluating the Efficacy and Safety of Single Agent AUR103 Calcium in Patients with Advanced, Well or Moderately differentiated Neuroendocrine Tumours. This is a Proof of Concept (PoC) Phase 2 study of AUR103 calcium in patients with advanced, well or moderately differentiated neuroendocrine tumours. The main objective is to evaluate the efficacy of AUR103 calcium in patients with well or moderately differentiated neuroendocrine tumors. Patients with relapsed/refractory well or moderately differentiated neuroendocrine tumors. AUR103 calcium will be administered twice daily. Patients will receive AUR103 calcium until disease progression or intolerable toxicity.","sourceUrl":"https://clinicaltrials.gov/study/NCT07640737"},{"nctId":"NCT07695142","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":275,"enrollmentType":"ESTIMATED","startDate":"2026-07-09","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor (Phase 1)"],"interventions":["HSK46256"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HSK46256 tablets, a selective PARP1 inhibitor, in patients with advanced solid tumors. The study consists of a dose escalation phase and a dose expansion phase. In the dose escalation phase, a 3+3 dose escalation design will be used to evaluate multiple dose levels. The dose expansion phase will enroll patients into expansion cohorts at selected dose levels to further evaluate safety and preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07695142"},{"nctId":"NCT07621718","title":"Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )","sponsor":"Revolution Medicines, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":670,"enrollmentType":"ESTIMATED","startDate":"2026-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-22","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Pancreatic Cancer","Pancreatic Cancer Metastatic","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Pancreatic Adenosquamous Carcinoma"],"interventions":["Zoldonrasib","Placebo","Oxaliplatin","Leucovorin (Calcium Folinate)","5-Fluorouracil","Irinotecan","Gemcitabine (GEM)","Nab-paclitaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07621718"},{"nctId":"NCT07205198","title":"A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.","sponsor":"Shanghai Institute Of Biological Products","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-30","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Advanced Tumors"],"interventions":["SIBP-A10"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety, tolerability of SIBP-A10 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07205198"},{"nctId":"NCT07664150","title":"CW-301 FIH Study of CAN016","sponsor":"Canwell Biotech Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-06-18","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Patients With Advanced Solid Tumors"],"interventions":["CAN016"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase I/II, Open-Label, Non-Randomized, Multi-Centre First-in-Human Study of CAN016 in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07664150"},{"nctId":"NCT07622186","title":"A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Non-Small Cell Lung Cancer"],"interventions":["SKB571 for injection","Osimertinib","Furmonertinib","carboplatin","Cisplatin","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":27,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07622186"},{"nctId":"NCT07678684","title":"A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma","sponsor":"HighField Biopharmaceuticals Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Glioma","Adult"],"interventions":["HF1K16"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07678684"},{"nctId":"NCT07729371","title":"A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP).","sponsor":"Sapience Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2027-01-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Familial Adenomatous Polyposis (FAP)"],"interventions":["ST316 IV"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1b, open- label, dose-optimization study evaluating ST316 in adult participants with familial adenomatous polyposis (FAP) who have undergone colectomy and have recurrent polyps. This study uses a three-cohorts, sequential adaptive design to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ST316, as well as its preliminary efficacy in reducing polyp recurrence.","sourceUrl":"https://clinicaltrials.gov/study/NCT07729371"},{"nctId":"NCT07093814","title":"A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma","sponsor":"Guangzhou Virotech Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-09-02","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Glioblastoma"],"interventions":["VRT106"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, single-arm Phase I/II clinical trial with the primary objective of evaluating the safety, tolerability, and efficacy of VRT106 in patients with recurrent/progressive glioblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07093814"},{"nctId":"NCT06667908","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2024-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["JNJ-90301900","Durvalumab","Concurrent Chemo/Radiation Therapy (cCRT)","Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin","Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel"],"countries":["United States","Australia","Brazil","China","France","Hong Kong","Netherlands","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":43,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06667908"},{"nctId":"NCT07686445","title":"A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression","sponsor":"Adlai Nortye Biopharma Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2026-09-23","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Solid Tumor (Phase I)","RAS Mutation","CEACAM5"],"interventions":["Intravenous AN4035","Intravenous AN4035 followed by intravenous EGFR Inhibitor."],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["RAS genotyping"],"summary":"The goal of this clinical trial is to determine whether AN4035 is safe and tolerable in people with advanced or metastatic solid tumors that have Rat Sarcoma oncogene (RAS) mutated solid tumors and high levels of the CEACAM5 protein. RAS genes help control how cells grow and divide. Mutations in RAS can cause cells to grow uncontrollably and contribute to cancer. CEACAM5 is a protein found on the surface of some cancer cells and may serve as a target for AN4035. This is the first time AN4035 is being tested in humans. The study will help identify the best dose(s) for future studies, understand how the body processes the drug, and evaluate whether AN4035 shows signs of fighting cancer. The ma","sourceUrl":"https://clinicaltrials.gov/study/NCT07686445"},{"nctId":"NCT07019779","title":"Study of CM518D1 in Patients With Advanced Solid Tumors","sponsor":"Keymed Biosciences Co.Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":434,"enrollmentType":"ESTIMATED","startDate":"2025-06-27","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Advanced Solid Tumors"],"interventions":["CM518D1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an interventional study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of CM518D1 in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07019779"},{"nctId":"NCT07006077","title":"Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer","sponsor":"Hangzhou Converd Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-05","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Advanced Pancreatic Cancer"],"interventions":["Recombinant human IL-21-expressing oncolytic vaccinia virus injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The main goal of this clinical trial is to preliminary evaluate the efficacy of recombinant human IL-21-expressing oncolytic vaccinia virus injection (hV01) in patients with advanced pancreatic cancer.And the secondary purpose is to evaluate the safety of hV01.","sourceUrl":"https://clinicaltrials.gov/study/NCT07006077"},{"nctId":"NCT07748117","title":"A Clinical Study of GO321 in Patients With Advanced Solid Tumors","sponsor":"GeneSail Biotech (Shanghai) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2026-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumor Malignancies"],"interventions":["GO321"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn about the safety and tolerability of GO321 recombinant oncolytic virus injection, and if GO321 recombinant oncolytic virus injection works to treat advanced solid tumors in adults whose cancers have progressed after standard-of-care therapy. It will also learn about the pharmacokinetic features, viral shedding, immunogenicity of GO321, immune markers, and genomic and proteomic changes in patients. The main questions it aims to answer are: What safety issues and tolerability limitations do participants experience when receiving GO321 via intratumoral or intracavitary injection? Does GO321 have preliminary anti-tumor efficacy against advanced solid t","sourceUrl":"https://clinicaltrials.gov/study/NCT07748117"},{"nctId":"NCT07391566","title":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","sponsor":"Luye Pharma Group Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Metastatic Colorectal Cancer (mCRC)"],"interventions":["LPM6690176","Bevacizumab","FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07391566"},{"nctId":"NCT07339267","title":"A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2026-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Prostate Cancer","Metastatic Castration-Resistant Prostate Cancer","Metastatic Hormone Sensitive Prostate Cancer"],"interventions":["ASP5541","Prednisone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a steroid, and ADT is already given to the men as their standard of care for prostate cancer. The main aims of the study are to check the safety of ASP5541, when given with prednisone and ADT, and to check how ASP5541 moves through the bodies of Chinese men. The men will receive ASP5541 as an injection into a muscle (intramuscular injection) at the side of the hip. They will all receive the same dose of ASP5541. The men will be given prednisone and ADT according to their label. The men will continue to receive ASP5541 with p","sourceUrl":"https://clinicaltrials.gov/study/NCT07339267"},{"nctId":"NCT05382559","title":"A Study of ASP3082 in Adults With Advanced Solid Tumors","sponsor":"Astellas Pharma Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":681,"enrollmentType":"ESTIMATED","startDate":"2022-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Solid Tumor"],"interventions":["Setidegrasib","Cetuximab","Leucovorin","Oxaliplatin","Fluorouracil","Irinotecan","Nanoparticle albumin-bound-paclitaxel","Gemcitabine","Docetaxel","Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed","Liposomal Irinotecan"],"countries":["United States","China","France","Japan","Puerto Rico","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":66,"serviceSignals":["RAS genotyping"],"summary":"This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP3082. The study aims to check how safe and well-tolerated ASP3082 is for people with advanced solid tumors that have a specific mutation called KRAS G12D. This study will be in 2 parts. In Part 1, different small groups of people will receive lower to higher doses of ASP3082 by itself, or together with cetuximab. Any medical problems will be recorded at each dose. This is done to find suitable doses of ASP3082, by itself or together with cetuximab, to use in Part 2 of the study. The first group will receive the lowest dose of ASP3082. A medical expert panel will check the ","sourceUrl":"https://clinicaltrials.gov/study/NCT05382559"},{"nctId":"NCT06622057","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","sponsor":"InnoPharmax Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Biliary Tract Cancer (BTC)"],"interventions":["D07001-Softgel Capsules","Placebo","Capecitabine"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT06622057"},{"nctId":"NCT06792253","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","sponsor":"BeBetter Med Inc","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2025-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2025-01-24","conditions":["Relapsed/Refractory Diffuse Large B-Cell Lymphoma"],"interventions":["Ifupinostat Hydrochloride for Injection","Rituximab Injection","Gemcitabine Hydrochloride for Injection","Oxaliplatin Injection","Etoposide Injection","Ifosfamide for Injection","Carboplatin Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, randomized, controlled, open-label Phase III clinical trial, aimed at evaluating the efficacy and safety of BEBT-908 combined with rituximab (R) compared to investigator-selected standard chemotherapy regimens \\[Standard of Care (SOC)\\] \\[i.e., rituximab-gemcitabine-oxaliplatin (R-GemOx) or rituximab-ifosfamide-carboplatin-etoposide (R-ICE)\\] for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06792253"},{"nctId":"NCT06441084","title":"A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation","sponsor":"Nuwacell Biotechnologies Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2024-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-31","completionType":"ESTIMATED","lastUpdated":"2024-06-04","conditions":["Acute Myeloid Leukemia"],"interventions":["NCR300 injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06441084"},{"nctId":"NCT05826535","title":"Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma","sponsor":"Lyell Immunopharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2023-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Large B-cell Lymphoma"],"interventions":["Rondecabtagene autoleucel (ronde-cel)","Fludarabine","Cyclophosphamide"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT05826535"},{"nctId":"NCT07260812","title":"KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","sponsor":"TCRx Therapeutics Co.Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2025-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Non-Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)"],"interventions":["KSV01 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07260812"},{"nctId":"NCT07622225","title":"SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":264,"enrollmentType":"ESTIMATED","startDate":"2026-05-29","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Advanced Solid Tumors"],"interventions":["SYS6006","Enlonstobart"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase Ib/II clinical study. It includes two stages: Phase Ib and Phase II. In the Phase Ib stage, the primary objective is to evaluate the safety and tolerability of SYS6006 in combination with Enlonstobart Injection in participants with advanced solid tumors, and to provide a basis for dose selection in later clinical studies. The primary objective of the Phase II stage is to assess efficacy and safety of SYS6006 in combination with Enlonstobart Injection in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07622225"},{"nctId":"NCT07010263","title":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2025-06-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-31","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Small Cell Lung Cancer"],"interventions":["AK112","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, phase III clinical study to compare the efficacy and safety of AK112 to placebo as consolidation treatment for patients with limited stage small cell lung cancer who have not progressed following concurrent chemoradiation therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07010263"},{"nctId":"NCT07694765","title":"A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors","sponsor":"LaNova Medicines Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Malignant Tumors"],"interventions":["LM-364 for injection","Tislelizumab"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors. For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07694765"},{"nctId":"NCT06506643","title":"Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms","sponsor":"Vector Vitale LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2024-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["CLL","Solid Tumor, Adult"],"interventions":["Zinc-64 Aspartate"],"countries":["Ukraine"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to test the safety and preliminary efficacy of a new drug, KLS-1, in adults with different types of solid tumors and chronic lymphocytic leukemia (CLL). The main questions it aims to answer are: * To define Dose Limiting Toxicities (DLT) and maximum tolerated dose (MTD) of KLS-1 * To select the recommended Phase II Dose (P2D) of KLS-1 * To determine the single dose and multiple dose PK profile following IV administration of KLS-1 * What is the safest and most effective dose of KLS-1? * Does KLS-1 show anti-tumor activity in patients? * To evaluate preliminary efficacy of KLS-1 in up to 4 cohorts of locally advanced or metastatic solid tumor (malignant melan","sourceUrl":"https://clinicaltrials.gov/study/NCT06506643"},{"nctId":"NCT07324304","title":"NWRD06 DNA Plasmid for HCC After Curative Resection.","sponsor":"Newish Technology (Beijing) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12-08","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["NWRD06 administered by electroporation"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.","sourceUrl":"https://clinicaltrials.gov/study/NCT07324304"},{"nctId":"NCT07464327","title":"A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Non-Small Cell Lung Cancer"],"interventions":["HS-20093","Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07464327"},{"nctId":"NCT06971523","title":"A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies","sponsor":"CytosinLab Therapeutics Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2024-12-25","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2025-05-14","conditions":["Solid Tumor","Lymphoma"],"interventions":["CTS3497"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT06971523"},{"nctId":"NCT07296809","title":"SKB500 Combinations in Patients With Small Cell Lung Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Small Cell Lung Cancer"],"interventions":["SKB500 Powder for Injection","KL-A167 Injection","Carboplatin Injection","Etoposide Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07296809"},{"nctId":"NCT07700667","title":"SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["SKB500","Tislelizumab","Cisplatin","5 - FU"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into three parts: the safety run-in phase, randomized enrollment phase and cohort expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07700667"},{"nctId":"NCT07053904","title":"Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors","sponsor":"PharmaEssentia","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":54,"enrollmentType":"ESTIMATED","startDate":"2025-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2025-07-08","conditions":["Advanced Solid Tumors"],"interventions":["Sequential use of P1101 and P1801"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn the safety of sequential treatment with P1101 and P1801 in advanced solid tumors. It will also learn the maximum tolerated dose (MTD) of P1801. The main questions it aims to answer are: To evaluate the safety and tolerability of sequential treatment with P1101 and P1801 in patients with advanced solid tumors. To determine the maximum tolerated dose (MTD) of P1801. Participants will: Ttreated by 6 doses of P1101 once per 2 weeks (Q2W) at 450 mcg and then followed by the treatment with P1801 Q2W at the pre-determined dose level by cohort during each 28-day treatment cycle in the Dose Escalation Phase (Cohort 1-5). Once the MTD have been declared and ","sourceUrl":"https://clinicaltrials.gov/study/NCT07053904"},{"nctId":"NCT06908772","title":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2025-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2025-04-03","conditions":["Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression"],"interventions":["Glumetinib Tablets","Osimertinib Mesylate Tablets","Glumetinib Tablets Placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MET profiling"],"summary":"To evaluate the efficacy and safety of glumetinib combined with osimertinib as the first-line treatment for locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06908772"},{"nctId":"NCT07015697","title":"A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":76,"enrollmentType":"ESTIMATED","startDate":"2025-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Recurrent or Metastatic Solid Tumors"],"interventions":["Trastuzumab Deruxtecan"],"countries":["United States","Brazil","France","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07015697"},{"nctId":"NCT07730580","title":"Study of XNW5004 Tablets in Advanced Prostate Cancer","sponsor":"Evopoint Biosciences Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":242,"enrollmentType":"ESTIMATED","startDate":"2026-07-13","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Prostate Cancer"],"interventions":["XNW5004 1200 mg BID in Combination with Abiraterone plus Prednisone","XNW5004 1200 mg BID in Combination with Docetaxel plus Prednisone","XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO BID","XNW5004 800 mg or 1200 mg (1:1 randomization), PO, BID; Abiraterone 1000 mg PO, taken on an empty stomach at least 1 hour before and at least 2 hours after a meal, QD; plus Prednisone 5 mg PO, QDD","XNW5004 800/1200 mg BID in Combination with Docetaxel plus Prednisone","XNW5004 1200 mg, PO, BID (10-14 hours interval between two doses, taken with warm water); Enzalutamide 160 mg, PO, QD. Each treatment cycle consists of 4 weeks.","Subsequent development plans will be determined based on preliminary study results."],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Phase Ib A preliminary design of 2 cohorts is planned for this phase, with 3-6 participants to be enrolled in each cohort. A total of 6-12 participants with advanced prostate cancer are planned to be enrolled in this phase. The study will be conducted at multiple investigational sites. Phase II A preliminary design of 5 cohorts is planned for this phase. Cohorts 1, 2, and 3 are preset with 2 dose groups each, and each dose group plans to enroll 20-30 participants. Cohort 4 plans to enroll 20-50 participants. Cohort 5 will be adjusted based on results from prior study phases. A total of 140-230 participants with advanced prostate cancer are planned to be enrolled in this phase. The study will","sourceUrl":"https://clinicaltrials.gov/study/NCT07730580"},{"nctId":"NCT06963502","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":762,"enrollmentType":"ESTIMATED","startDate":"2025-05-30","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2025-05-09","conditions":["Advanced Solid Tumors","Colorectal Cancer","Non-Small Cell Lung Cancer"],"interventions":["HS-10370","HS-20117","Adebrelimab","Capecitabine","Oxaliplatin","Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan","HS-20093","platinum (cisplatin or carboplatin)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics, Activity and Immunogenicity of HS-10370 in Combination With Other Anti-cancer Therapies in Chinese patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in and Colorectal cancer(CRC) and non-Small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06963502"},{"nctId":"NCT07396584","title":"HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor","sponsor":"Hutchmed","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2026-03-04","startDateType":"ESTIMATED","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-30","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Solid Tumors, Adult"],"interventions":["HMPL-A580"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07396584"},{"nctId":"NCT07479667","title":"An Antibody-armored Dendritic Cell in Patients With Solid Tumors","sponsor":"Shanghai Cell Therapy Group Co.,Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":8,"enrollmentType":"ESTIMATED","startDate":"2026-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Solid Cancers","Adjuvant Therapy"],"interventions":["Armored Dendritic Cell Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a single-arm, open-label, single-administration dose-escalation study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07479667"},{"nctId":"NCT06387069","title":"A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia","sponsor":"Hutchmed","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":316,"enrollmentType":"ESTIMATED","startDate":"2024-04-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Acute Myeloid Leukemia"],"interventions":["HMPL-306 Regimen","Salvage Chemotherapy Regimen"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":53,"serviceSignals":["Hematology NGS"],"summary":"This study is a multicenter, randomized, open-label, phase III clinical study (RAPHAEL) to evaluate the efficacy, safety, and PK of HMPL-306 versus salvage chemotherapy in patients with R/R AML harboring IDH1 and IDH2 mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06387069"},{"nctId":"NCT06971614","title":"A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC","sponsor":"ImmVira Pharma Co. Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-31","completionType":"ESTIMATED","lastUpdated":"2025-07-23","conditions":["Nonmuscle-invasive Bladder Cancer"],"interventions":["T3011"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive intermediate/high-risk NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06971614"},{"nctId":"NCT05899608","title":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients","sponsor":"Summit Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1600,"enrollmentType":"ESTIMATED","startDate":"2023-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Ivonescimab Injection","Pembrolizumab Injection"],"countries":["United States","Belgium","Canada","China","France","Germany","Greece","Ireland","Italy","Japan","Mexico","Poland","Serbia","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":253,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.","sourceUrl":"https://clinicaltrials.gov/study/NCT05899608"},{"nctId":"NCT05441475","title":"A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":118,"enrollmentType":"ESTIMATED","startDate":"2021-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Hepatocellular Carcinoma"],"interventions":["ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w","ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg","ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd characteristics, and determine the treatment plan of Part B. Part B will evaluate absk-011 combined with atilizumab Anti FGF19 overexpression in advanced stage or non resectable patients who have not received systemic therapy or only received first-line systemic therapy before In addition to the safety and tolerability of HCC subjects, the antitumor activity of the combination will be further evaluated. Part C comprises two parts: Part C1 and Part C2. A maximum of 54","sourceUrl":"https://clinicaltrials.gov/study/NCT05441475"},{"nctId":"NCT06801236","title":"Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Acerand Therapeutics (Hong Kong) Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":88,"enrollmentType":"ESTIMATED","startDate":"2025-05-12","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2028-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Prostate Cancer (Adenocarcinoma)","mCRPC (Metastatic Castration-resistant Prostate Cancer)"],"interventions":["ACE-232 tablets"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06801236"},{"nctId":"NCT06781567","title":"Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma","sponsor":"HitGen Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2028-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2025-03-14","conditions":["Adenoid Cystic Carcinoma","Head and Neck Cancer"],"interventions":["HG146"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.","sourceUrl":"https://clinicaltrials.gov/study/NCT06781567"},{"nctId":"NCT07454642","title":"AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors","sponsor":"Avacta Life Sciences Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Vulvar Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Small Cell Carcinoma of Lung","Colorectal Cancer","Hormone Receptor Positive Breast Carcinoma"],"interventions":["AVA6103"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07454642"},{"nctId":"NCT07629258","title":"A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors","sponsor":"Groovy Medicine (Hangzhou) Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Advanced Tumors"],"interventions":["GW01-200"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07629258"},{"nctId":"NCT07139873","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-09-08","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"interventions":["DZD8586","Bendamustine","Idelalisib","Rituximab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07139873"},{"nctId":"NCT07278336","title":"A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":219,"enrollmentType":"ESTIMATED","startDate":"2025-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Ovarian Cancer"],"interventions":["ABBV-901","Bevacizumab"],"countries":["United States","China","Israel","Japan","New Zealand","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with bevacizumab, in participants with ovarian cancer. ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 4 Parts (Arms) where participants will receive ABBV-901, alone or in combination with the standard available therapy, bevacizumab. Around 219 participants will be enrolled in the study at approximately 75 sites around the world. In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901, alone to determ","sourceUrl":"https://clinicaltrials.gov/study/NCT07278336"},{"nctId":"NCT07612176","title":"A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors","sponsor":"NEOK Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Locally Advanced (Unresectable) or Metastatic Solid Tumors"],"interventions":["NEOK001","NEOK001 RDE"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).","sourceUrl":"https://clinicaltrials.gov/study/NCT07612176"},{"nctId":"NCT03625037","title":"First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma","sponsor":"Genmab","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":666,"enrollmentType":"ACTUAL","startDate":"2018-06-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["DLBCL","High-grade B-cell Lymphoma (HGBCL)","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","FL","MCL","Small Lymphocytic Lymphoma (SLL)","Marginal Zone Lymphoma (MZL)","Indolent B-cell Non-Hodgkin Lymphoma (iNHL)","Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)"],"interventions":["Epcoritamab"],"countries":["United States","Australia","Canada","Denmark","Finland","France","Germany","Italy","Netherlands","Poland","Singapore","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":85,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20): * The dose schedule for epcoritamab * The side effects seen with epcoritamab * What the body does with epcoritamab once it is administered * What epcoritamab does to the body once it is administered * How well epcoritamab works against relapsed and/or refractory B-cell lymphoma The trial consists of 3 parts: * a dose-escalation part (Phase 1, first-in-human \\[FIH\\]) * an expansion part (Phase 2a) * a dose-optimization part (OPT) (Phase 2a) The trial time for each participant depends o","sourceUrl":"https://clinicaltrials.gov/study/NCT03625037"},{"nctId":"NCT06586957","title":"A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors","sponsor":"NiKang Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2024-09-19","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Solid Tumor","Advanced Solid Tumor","Solid Tumor, Adult","Metastatic Tumor","Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Metastatic Ovarian Carcinoma","Endometrial Neoplasms","Endometrial Diseases","Metastatic Endometrial Cancer","Triple Negative Breast Cancer","Metastatic Endometrial Carcinoma","Advanced Endometrial Carcinoma","Advanced Ovarian Carcinoma","Gastric Cancer","Advanced Gastric Carcinoma","Metastatic Gastric Cancer","Metastatic Gastric Carcinoma","Small Cell Lung Cancer","Small Cell Lung Carcinoma","Triple Negative Breast Neoplasms","Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Carcinoma","CCNE1 Amplification","Hormone Receptor Negative Breast Carcinoma","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Progesterone-receptor-positive Breast Cancer"],"interventions":["NKT3964"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT06586957"},{"nctId":"NCT07578571","title":"A Phase 1 Study of IM-1617 in Participants With Advanced Cancer","sponsor":"Immunome, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":175,"enrollmentType":"ESTIMATED","startDate":"2026-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Colorectal Cancer","Non-Small Cell Lung Cancer","Breast Cancer","Esophageal Cancer","Stomach Cancer","Cancer"],"interventions":["IM-1617"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have two parts. Part A will test increasing doses of IM-1617 to find out the safe dose and schedule of IM-1617 for participants. Part B will use the dose and schedule found in Part A to further study the safety of IM-1617 and if it works to treat solid tumor cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07578571"},{"nctId":"NCT07691606","title":"A Study of ARC-02 in B-cell NHL","sponsor":"Taiho Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-06-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["B-cell Non Hodgkin Lymphoma"],"interventions":["ARC-02","Rituximab"],"countries":["United States","Australia","France","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.","sourceUrl":"https://clinicaltrials.gov/study/NCT07691606"},{"nctId":"NCT07059845","title":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Ovarian Cancer"],"interventions":["Mirvetuximab Soravtansine","Bevacizumab","Carboplatin"],"countries":["United States","Australia","Belgium","Czechia","Denmark","France","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":82,"serviceSignals":["Broad CGP"],"summary":"Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 3 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2","sourceUrl":"https://clinicaltrials.gov/study/NCT07059845"},{"nctId":"NCT07287098","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Neoplasms"],"interventions":["Imlunestrant","Goserelin","Tamoxifen 20 mg"],"countries":["United States","Belgium","France","Germany","Ireland","Italy","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":86,"serviceSignals":["HER2 profiling"],"summary":"This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days. Cohort 2: will help researchers understand how ","sourceUrl":"https://clinicaltrials.gov/study/NCT07287098"},{"nctId":"NCT07601243","title":"Study of GS-2426 in Participants With Advanced Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2026-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Advanced Solid Tumors"],"interventions":["GS-2426"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07601243"},{"nctId":"NCT05098132","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","sponsor":"Synthekine","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":364,"enrollmentType":"ESTIMATED","startDate":"2022-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Advanced Solid Tumor","Non Small Cell Lung Cancer","Untreated Advanced NSCLC","1st Line NSCLC"],"interventions":["STK-012","pembrolizumab KEYTRUDA®","pemetrexed","carboplatin"],"countries":["United States","Georgia","Ireland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative or STK11 mutated, non-squamous, non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05098132"},{"nctId":"NCT06564324","title":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","sponsor":"Nuvation Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":194,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Non Small Cell Lung Cancer"],"interventions":["Taletrectinib","Crizotinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":29,"serviceSignals":["RNA fusion"],"summary":"This is a Phase 3, randomized, open-label, comparative, multicenter, international study for NSCLC patients whose tumor tissue exhibits ROS1 fusion positivity (i.e., ROS1+) and who have not previously received an ROS1-targeted TKI (i.e., ROS1-TKI-naïve). Approximately 194 ROS-1 TKI- naïve ROS1+NSCLC patients will be randomized in a 1:1 ration to one of 2 study arms: * Arm A: Taletrectinib monotherapy at 600 mg once daily (QD); * Arm B: Crizotinib monotherapy at 250 mg twice daily (BID). Each cycle duration will be 28 days. Participants will be stratified by the presence of intracranial metastases at baseline (Yes versus No) and prior chemotherapy use for locally advanced or metastatic diseas","sourceUrl":"https://clinicaltrials.gov/study/NCT06564324"},{"nctId":"NCT07699328","title":"A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer","sponsor":"Voronoi, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":315,"enrollmentType":"ESTIMATED","startDate":"2024-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["EGFR-Mutant Non-Small Cell Lung Cancer"],"interventions":["VRN110755"],"countries":["Australia","Canada","France","Hong Kong","Malaysia","Singapore","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following","sourceUrl":"https://clinicaltrials.gov/study/NCT07699328"},{"nctId":"NCT06760637","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1035,"enrollmentType":"ACTUAL","startDate":"2025-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-02","primaryCompletionType":"ESTIMATED","completionDate":"2037-12-29","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Breast Cancer"],"interventions":["PF-07220060","letrozole","abemaciclib","palbociclib","ribociclib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","India","Ireland","Israel","Italy","Japan","Netherlands","Poland","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":463,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants wi","sourceUrl":"https://clinicaltrials.gov/study/NCT06760637"},{"nctId":"NCT06768489","title":"A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["JNJ-79635322","Daratumumab","Pomalidomide","Lenalidomide"],"countries":["United States","Australia","Israel","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \\[RP2Ds\\]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or without lenalidomide or with pomalidomide; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of JNJ-79635322 combination treatment regimens at selected RP2D(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT06768489"},{"nctId":"NCT06109779","title":"Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":760,"enrollmentType":"ACTUAL","startDate":"2023-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-03","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Biliary Tract Cancer"],"interventions":["Rilvegostomig","Placebo","Capecitabine","Gemcitabine/Cisplatin","S-1 [Tegafur/Oteracil/gimeracil]"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Hong Kong","India","Italy","Japan","Norway","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":177,"serviceSignals":["Broad CGP"],"summary":"A global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy in participants with BTC after surgical resection with curative intent.","sourceUrl":"https://clinicaltrials.gov/study/NCT06109779"},{"nctId":"NCT06691984","title":"Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":707,"enrollmentType":"ACTUAL","startDate":"2024-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-30","completionType":"ESTIMATED","lastUpdated":"2026-05-15","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["Xaluritamig","Abiraterone","Enzalutamide","Cabazitaxel"],"countries":["United States","Australia","Austria","Belgium","Canada","Denmark","France","Germany","Greece","Hong Kong","Italy","Japan","Netherlands","Poland","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":164,"serviceSignals":["Broad CGP"],"summary":"The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \\[ARDT\\]).","sourceUrl":"https://clinicaltrials.gov/study/NCT06691984"},{"nctId":"NCT05932862","title":"A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors","sponsor":"Exelixis","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":429,"enrollmentType":"ESTIMATED","startDate":"2024-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-03","completionType":"ESTIMATED","lastUpdated":"2025-09-05","conditions":["Advanced Solid Tumor"],"interventions":["XL309","Olaparib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05932862"},{"nctId":"NCT07005128","title":"A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":330,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-15","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Small-cell Lung Cancer","Extensive Stage Small-cell Lung Cancer"],"interventions":["Tarlatamab","Durvalumab","Carboplatin","Etoposide"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","China","Denmark","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":164,"serviceSignals":["Broad CGP"],"summary":"The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT07005128"},{"nctId":"NCT06697197","title":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":413,"enrollmentType":"ESTIMATED","startDate":"2025-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-05","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Advanced Solid Tumors"],"interventions":["BMS-986482","Nivolumab and rHuPH20","Nivolumab/relatlimab/rHuPH20","Bevacizumab"],"countries":["United States","Belgium","Denmark","France","Greece","Italy","Netherlands","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06697197"},{"nctId":"NCT04728893","title":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":490,"enrollmentType":"ESTIMATED","startDate":"2021-04-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-04","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Hematologic Malignancies","Waldenstroms Macroglobulinaemia","Non-Hodgkins Lymphoma","Chronic Lymphocytic Leukaemia"],"interventions":["Nemtabrutinib"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Czechia","Denmark","France","Germany","Hungary","Ireland","Israel","Italy","Poland","Romania","South Korea","Spain","Switzerland","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":120,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).","sourceUrl":"https://clinicaltrials.gov/study/NCT04728893"},{"nctId":"NCT06324357","title":"Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread","sponsor":"Boehringer Ingelheim","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":768,"enrollmentType":"ESTIMATED","startDate":"2024-06-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-08","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Metastatic Breast Cancer","Metastatic Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Colorectal Cancer"],"interventions":["Zongertinib","Trastuzumab deruxtecan","Trastuzumab emtansine","Trastuzumab","Capecitabine","mFOLFOX6","zanidatamab"],"countries":["United States","Belgium","China","France","Germany","Italy","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":105,"serviceSignals":["HER2 profiling"],"summary":"This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1), with trastuzumab and capecitabine, with zanidatamab, or with mFOLFOX6 (with or without trastuzumab). Another purpose is to check whether zongertinib alone and in combination with other treatments can","sourceUrl":"https://clinicaltrials.gov/study/NCT06324357"},{"nctId":"NCT06584032","title":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","sponsor":"Hutchmed","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":412,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-09","completionType":"ESTIMATED","lastUpdated":"2025-01-07","conditions":["Advanced Endometrial Cancer"],"interventions":["fruquintinib","sintilimab","paclitaxel","doxorubicin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to evaluate whether fruquintinib(HMPL-013) plus sintilimab(IBI308) is safe and effective in the treatment of advanced endometrial cancer(EMC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06584032"},{"nctId":"NCT06422143","title":"Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":851,"enrollmentType":"ESTIMATED","startDate":"2024-06-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Non-small Cell Lung Cancer","NSCLC"],"interventions":["Pembrolizumab","sac-TMT","Carboplatin","Paclitaxel","Nab-paclitaxel"],"countries":["United States","Argentina","Austria","Brazil","Canada","Chile","China","Colombia","Czechia","France","Germany","Hungary","Ireland","Israel","Italy","Japan","Peru","Poland","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":215,"serviceSignals":["Broad CGP"],"summary":"This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06422143"},{"nctId":"NCT07593144","title":"A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)","sponsor":"Foresight Therapeutics (Hefei) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-15","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Advanced Solid Tumors"],"interventions":["FS-207"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":17,"serviceSignals":["MSI / TMB"],"summary":"This is a Phase Ia/Ib clinical study of FS-207, an investigational oral tablet, in patients with advanced solid tumors that are microsatellite instability-high, also called MSI-H. MSI-H tumors have specific changes in DNA repair pathways and may depend on the WRN protein to survive. FS-207 is designed to inhibit WRN. The main purpose of this study is to evaluate the safety and tolerability of FS-207 and to understand how the drug moves through the body. The study will also look for early signs of anti-tumor activity. This study has two parts. In the first part, called dose escalation, small groups of patients will receive increasing dose levels of FS-207 to help identify a safe and appropria","sourceUrl":"https://clinicaltrials.gov/study/NCT07593144"},{"nctId":"NCT06353386","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-15","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Prostatic Neoplasms, Castration-Resistant"],"interventions":["Opevesostat","Olaparib","Docetaxel","Cabazitaxel","Fludrocortisone acetate","Dexamethasone","Prednisone"],"countries":["United States","Australia","Canada","Chile","Colombia","Denmark","Finland","France","Germany","Ireland","Israel","Italy","Japan","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":77,"serviceSignals":["Broad CGP"],"summary":"Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for the opevesostat-based treatment combinations. There will be no hypothesis testing in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06353386"},{"nctId":"NCT07181161","title":"Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":177,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-18","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Metastatic Prostate Cancer"],"interventions":["AZD0516","AZD9574"],"countries":["United States","Brazil","China","France","Italy","Japan","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["ADC biomarker"],"summary":"The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07181161"},{"nctId":"NCT06989112","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-19","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-19","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Endometrial Cancer"],"interventions":["Trastuzumab deruxtecan","Rilvegostomig","Pembrolizumab","Carboplatin","Paclitaxel","Docetaxel"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Denmark","Finland","France","Germany","Hungary","Italy","Japan","Netherlands","Norway","Poland","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":250,"serviceSignals":["HER2 profiling","MSI / TMB","ADC biomarker"],"summary":"DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participants with HER2-expressing (IHC 3+/2+), pMMR, primary advanced (Stage III/IV) or recurrent EC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06989112"},{"nctId":"NCT06149286","title":"A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":470,"enrollmentType":"ESTIMATED","startDate":"2023-12-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-23","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Relapsed/Refractory Follicular Lymphoma","Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)"],"interventions":["Odronextamab","Lenalidomide","Rituximab"],"countries":["United States","Australia","Austria","Belgium","Brazil","Czechia","France","Germany","Israel","Italy","Malaysia","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":169,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called \"relapsed\"), or did not respond to treatment (called \"refractory\"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determin","sourceUrl":"https://clinicaltrials.gov/study/NCT06149286"},{"nctId":"NCT07579234","title":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Shandong New Time Pharmaceutical Co., LTD","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":261,"enrollmentType":"ESTIMATED","startDate":"2026-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-25","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"interventions":["F182112 single-agent","Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma","sourceUrl":"https://clinicaltrials.gov/study/NCT07579234"},{"nctId":"NCT07106762","title":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":470,"enrollmentType":"ESTIMATED","startDate":"2025-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-26","primaryCompletionType":"ESTIMATED","completionDate":"2033-11-18","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Urothelial Cancer"],"interventions":["Iza-bren","Cisplatin","Gemcitabine","Carboplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Ireland","Israel","Italy","Japan","Netherlands","Norway","Romania","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":163,"serviceSignals":["Broad CGP"],"summary":"A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07106762"},{"nctId":"NCT07336446","title":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-26","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Prostate Cancer"],"interventions":["AZD9750","AZD5305"],"countries":["United States","Australia","Canada","China","Japan","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.","sourceUrl":"https://clinicaltrials.gov/study/NCT07336446"},{"nctId":"NCT07291037","title":"Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2025-10-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Datopotamab deruxtecan (Dato-DXd)","Docetaxel"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Italy","Japan","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":205,"serviceSignals":["ADC biomarker"],"summary":"TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).","sourceUrl":"https://clinicaltrials.gov/study/NCT07291037"},{"nctId":"NCT07217171","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas","sponsor":"EvolveImmune United, Inc","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2025-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-29","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Bladder Cancer","Squamous Cell Carcinoma of the Lung","Esophageal Squamous Cell Carcinoma","Tongue Squamous Cell Carcinoma","Cutaneous Squamous Cell Cancer","Penile Squamous Cell Carcinoma","Anal Squamous Cell Carcinoma","Vulvar Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Vaginal Squamous Cell Carcinoma","Urethral Squamous Cell Carcinoma"],"interventions":["EVOLVE104"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07217171"},{"nctId":"NCT07120984","title":"A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma","sponsor":"Philogen S.p.A.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-01-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-30","completionType":"ESTIMATED","lastUpdated":"2025-08-13","conditions":["Glioma"],"interventions":["L19TNF","L19TNF and TMZ","L19TNF and CCNU","L19TNF monotherapy","L19TNF and TMZ in recurrent astrocytoma","L19TNF and CCNU in recurrent astrocytoma","L19TNF monothery in recurrent oligodendroglioma"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RNA fusion"],"summary":"The purpose of this study is to explore the safety and efficacy of the antibody-cytokine fusion protein L19TNF alone or in combination with alkylating chemotherapy in patients with recurrent IDH mutant glioma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07120984"},{"nctId":"NCT05438043","title":"A Study of Daratumumab","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":213,"enrollmentType":"ACTUAL","startDate":"2022-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["Daratumumab","Carfilzomib","Dexamethasone","Lenalidomide","Pomalidomide"],"countries":["United States","Belgium","Brazil","China","Czechia","Denmark","France","Germany","Greece","Italy","Poland","Russia","South Korea","Spain","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":92,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT05438043"},{"nctId":"NCT06706076","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","sponsor":"BlossomHill Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":675,"enrollmentType":"ESTIMATED","startDate":"2025-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["BH-30643","BH-30643 combo therapy with Carboplatin/Pemetrexed"],"countries":["United States","Australia","Canada","Hong Kong","Japan","Malaysia","Singapore","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["HER2 profiling"],"summary":"This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations. Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643, both as a monotherapy and in combination with chemotherapy. Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.","sourceUrl":"https://clinicaltrials.gov/study/NCT06706076"},{"nctId":"NCT05294731","title":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","sponsor":"BeiGene","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2022-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-01-31","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["B-cell Malignancy","Non-Hodgkin Lymphoma","Mantle Cell Lymphoma","Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","Waldenström Macroglobulinemia","Marginal Zone Lymphoma","Follicular Lymphoma","DLBCL Unclassifiable","Richter's Transformation"],"interventions":["BGB-16673"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts","sourceUrl":"https://clinicaltrials.gov/study/NCT05294731"},{"nctId":"NCT06547528","title":"A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2023-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2025-06-03","conditions":["Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"interventions":["ONO-4685"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL","sourceUrl":"https://clinicaltrials.gov/study/NCT06547528"},{"nctId":"NCT05720130","title":"Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).","sponsor":"AdvanCell Pty Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-01","completionType":"ESTIMATED","lastUpdated":"2026-02-20","conditions":["Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Metastatic Hormone Sensitive Prostate Cancer"],"interventions":["[²¹²Pb]Pb-ADVC001 (Phase 1b)","[²¹²Pb]Pb-ADVC001 (Phase 2a)"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of \\[212Pb\\]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establish the recommended phase 2 doses (RP2D). The Phase 2a expansion aims to assess the efficacy and safety of \\[212Pb\\]Pb-ADVC001 at the RP2 doses in 3 participant groups.","sourceUrl":"https://clinicaltrials.gov/study/NCT05720130"},{"nctId":"NCT06622941","title":"Study to ONO-4538 in Patients With Rhabdoid Tumor","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":23,"enrollmentType":"ESTIMATED","startDate":"2024-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Rhabdoid Tumor"],"interventions":["ONO-4538"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06622941"},{"nctId":"NCT06730009","title":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","sponsor":"Medigen Biotechnology Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2024-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-31","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Pancreatic Carcinoma Stage II","Cholangiocarcinoma Resectable"],"interventions":["SLOG + Allogeneic NK cell","SLOG chemotherapy"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II study which intends to characterize the safety, tolerability, and preliminary efficacy of Allogeneic Magicell-NK infusion in PDA or cholangiocarcinoma patients after surgery. Subjects will receive a total of 6 intravenous (IV) infusions of the IP on the 11th day of each chemotherapy cycle. A total of 6 cycles of IP infusions are planned. The phase I part of the study is a first-in-human phase I trial of Allogeneic Magicell-NK and is therefore designed in an open-label, dose-escalation manner. A standard 3+3 design will be employed to assess the safety profile of Allogeneic Magicell-NK and to determine the MTD/MFD. Two dose cohorts are planned: the starting dose is 10 × 1","sourceUrl":"https://clinicaltrials.gov/study/NCT06730009"},{"nctId":"NCT07601204","title":"Treatment of Recurrent/Metastatic Head and Neck Cancer","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":128,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Recurrent/Metastatic Head and Neck Cancer"],"interventions":["TQB2922 Subcutaneous Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase Ib/II study of TQB2922 injection (subcutaneous). In the Phase Ib stage, a 3+3 dose-escalation design was used to determine the RP2D and pharmacokinetic characteristics of TQB2922 injection (subcutaneous) administered once every 3 weeks in subjects with R/M HNC. The Phase II stage explored the efficacy and safety of TQB2922 (subcutaneous) as monotherapy or in combination therapy in subjects with R/M HNC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07601204"},{"nctId":"NCT07157514","title":"Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML","sponsor":"Actinium Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":306,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2034-02","completionType":"ESTIMATED","lastUpdated":"2025-09-10","conditions":["Acute Leukemia","Myeloid Leukemia","Acute Myelogenous Leukemia","Acute Myeloid Leukemia","Acute Myeloid Leukemia, in Relapse","Myelogenous Leukemia","Myelogenous Leukemia, Acute","Myelogenous Leukemia in Relapse","Transplant-Related Disorder","Allogeneic Disease","Refractory AML"],"interventions":["131I-apamistamab","Fludarabine","Cyclophosphamide","Total Body Irradiation (TBI)","Allogeneic Hematopoietic Stem Cell Transplant (HSCT)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts. In Phase 2, we are testing three radiation dose levels of 131I-apamistamab combined with fludarabine and low-dose whole-body radiation before stem cell transplant to find the safest and most effective dose. In Phase 3, patients will be randomly assigned to receive either this treatment combination or a standard of care regimen before transplant. The main goal is to see if the new approach helps people live longer. Phase 2 will enroll about 60 people, and Phase 3 will enroll about 246 people.","sourceUrl":"https://clinicaltrials.gov/study/NCT07157514"},{"nctId":"NCT06790966","title":"Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"PDS Biotechnology Corp.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":252,"enrollmentType":"ESTIMATED","startDate":"2025-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Recurrent Head and Neck Cancer","Metastatic Head and Neck Cancer","HPV Positive Oropharyngeal Squamous Cell Carcinoma","Neoplasms, Head and Neck","Unresectable Head and Neck Squamous Cell Carcinoma"],"interventions":["Combination Treatment of PDS0101 and Pembrolizumab","Pembrolizumab Monotherapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This is a global, multi-center, Phase 3 study that is randomized 1:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06790966"},{"nctId":"NCT07335497","title":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Crescent Biopharma, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2026-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Locally Advanced / Metastatic Solid Tumors"],"interventions":["CR-001"],"countries":["United States","Australia","Ireland","Italy","Romania","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07335497"},{"nctId":"NCT07688148","title":"A First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of TAX2 in Patients With Relapsed/Refractory Advanced/Metastatic Solid Tumours","sponsor":"Apmonia Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Solid Tumor Cancers"],"interventions":["TAX2"],"countries":["Belgium","France"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to investigate the treatment for adult patients suffering from advanced or metastatic solid tumours and has 2 parts to the study: the Phase 1 where ascending doses of the experimental study drug, TAX2, will be tested and the Phase 2a where all the participants will receive the study drug at the same dose considered as the recommended Phase 2 dose from Phase 1 part. The participation in the Phase 1 or in the Phase 2a part depends on when the participant is proposed to join the study. The study purpose is to assess: * How safe and tolerable TAX2 is. This assessment will be based on the adverse effects collected during the study. * How well TAX2 enters the ","sourceUrl":"https://clinicaltrials.gov/study/NCT07688148"},{"nctId":"NCT06624644","title":"A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma","sponsor":"Linnaeus Therapeutics, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-02","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Melanoma (Skin Cancer)","Melanoma Stage IIIB-IV","Cutaneous Melanoma","Unresectable Melanoma"],"interventions":["LNS8801","Pembrolizumab","Chemotherapy (dacarbazine or temozolomide)","Immunotherapy (Pembrolizumab)","Immunotherapy (nivolumab and relatlimab)","Immunotherapy (ipilimumab and nivolumab)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years. In the second group (LNS8801 + pembrolizumab)","sourceUrl":"https://clinicaltrials.gov/study/NCT06624644"},{"nctId":"NCT07340658","title":"A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer","sponsor":"Rovi Pharmaceuticals Laboratories","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2033-12","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Advanced, Metastatic Breast Cancer"],"interventions":["Letrozole SIE + Ribociclib + Oral placebo","Oral Femara® + Ribociclib + Injectable placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07340658"},{"nctId":"NCT06712316","title":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","sponsor":"BioNTech SE","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":1260,"enrollmentType":"ESTIMATED","startDate":"2025-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Non-small Cell Lung Cancer"],"interventions":["Pumitamig","Pembrolizumab","Carboplatin","Pemetrexed","Paclitaxel"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","China","France","Georgia","Germany","Hungary","Italy","Japan","Poland","Romania","South Korea","Spain","Switzerland","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":261,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06712316"},{"nctId":"NCT06966024","title":"Study of DCC-2812 in Participants With Advanced Genitourinary Cancers","sponsor":"Deciphera Pharmaceuticals, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-08-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Renal Cell Carcinoma","Urothelial Carcinoma","Castration-resistant Prostate Cancer"],"interventions":["DCC-2812"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter clinical trial to evaluate the safety and preliminary activity of the selective general control nonderepressible 2 (GCN2) activator DCC-2812 as monotherapy in advanced/metastatic renal cell carcinoma (RCC), urothelial carcinoma, and castration-resistant prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06966024"},{"nctId":"NCT05541822","title":"To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation","sponsor":"Abion Inc","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2023-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2025-05-22","conditions":["Advanced Solid Tumors"],"interventions":["Vabametkib","Lazertinib"],"countries":["United States","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["MET profiling"],"summary":"ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05541822"},{"nctId":"NCT06930794","title":"A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-02","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Vebreltinib combined with platinum-based doublet chemotherapy.","platinum-based doublet chemotherapy."],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["MET profiling"],"summary":"This study is an open-label, randomized, controlled, multicenter Phase IIIb clinical study, aiming to evaluate the efficacy, safety, and tolerability of Vebreltinib Enteric Capsule combined with platinum-based doublet chemotherapy compared with platinum-based doublet chemotherapy in treating subjects with locally advanced or metastatic non-squamous NSCLC who have not received previous systemic treatment and MET-positive. The target population of this study is subjects with histologically confirmed locally advanced or metastatic non-squamous NSCLC who have not received previous systemic anti-tumor treatment and MET-positive( MET Amplification or Overexpression). This study adopts an enrichmen","sourceUrl":"https://clinicaltrials.gov/study/NCT06930794"},{"nctId":"NCT07612189","title":"A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors","sponsor":"NEOK Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2026-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Locally Advanced (Unresectable) or Metastatic Solid Tumors"],"interventions":["NEOK002","NEOK002 RDE"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).","sourceUrl":"https://clinicaltrials.gov/study/NCT07612189"},{"nctId":"NCT07185997","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","sponsor":"ArriVent BioPharma, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2025-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Non-Small-Cell Lung Cancer","Metastatic Non-Small-Cell Lung Cancer","Advanced Non-Small-Cell Lung Cancer","EGFR P-Loop and Alpha C-Helix Compressing","EGFR PACC","EGFR Uncommon Mutations"],"interventions":["Firmonertinib","EGFR-TKI inhibitor based on investigator's choice"],"countries":["United States","Australia","Canada","France","Greece","Hong Kong","Italy","Japan","Malaysia","Singapore","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":88,"serviceSignals":["Broad CGP"],"summary":"Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.","sourceUrl":"https://clinicaltrials.gov/study/NCT07185997"},{"nctId":"NCT06704152","title":"BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS","sponsor":"BlueSphere Bio, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":38,"enrollmentType":"ESTIMATED","startDate":"2025-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["AML, Adult Recurrent","ALL, Recurrent, Adult","MDS"],"interventions":["SOC + BSB-1001 Dose Escalation Cohort","SOC+BSB-1001 Expansion Dose"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06704152"},{"nctId":"NCT04416984","title":"Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)","sponsor":"Allogene Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2020-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma"],"interventions":["ALLO-501A","ALLO-647","Fludarabine","Cyclophosphamide"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open label, multicenter Phase 1/2 study evaluating ALLO-501A in adult subjects with R/R LBCL and CLL/SLL. The purpose of the ALPHA2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.","sourceUrl":"https://clinicaltrials.gov/study/NCT04416984"},{"nctId":"NCT05037279","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","sponsor":"Verity Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":540,"enrollmentType":"ESTIMATED","startDate":"2024-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-02","completionType":"ESTIMATED","lastUpdated":"2026-03-20","conditions":["Bladder Cancer","Bladder Cancer Recurrent","Neoplasm Recurrence","Urothelial Carcinoma Bladder","Urothelial Carcinoma Recurrent","Non-Invasive Bladder Urothelial Carcinoma"],"interventions":["Bacillus Calmette-Guerin: Strain Russian BCG-I","Bacillus Calmette-Guerin: Strain TICE"],"countries":["Canada"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.","sourceUrl":"https://clinicaltrials.gov/study/NCT05037279"},{"nctId":"NCT04712643","title":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":342,"enrollmentType":"ACTUAL","startDate":"2021-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-01","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Hepatocellular Carcinoma"],"interventions":["Atezolizumab","Becavizumab","Transarterial chemoembolization (TACE)"],"countries":["China","Japan"],"northAmerica":false,"chinaSites":true,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT04712643"},{"nctId":"NCT07448116","title":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","sponsor":"Betta Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":164,"enrollmentType":"ESTIMATED","startDate":"2026-01-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-01","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Solid Advanced Tumor"],"interventions":["MCLA-129","Ensartinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MET profiling"],"summary":"This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of the anti-EGFR/c-Met bispecific antibody MCLA-129 in combination with Ensartinib hydrochloride in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07448116"},{"nctId":"NCT07438782","title":"First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":97,"enrollmentType":"ESTIMATED","startDate":"2026-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-06","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Neoplasms"],"interventions":["GSK5533524"],"countries":["United States","Canada","Finland","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07438782"},{"nctId":"NCT07656376","title":"Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation","sponsor":"Jiangxi Kvvit Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":465,"enrollmentType":"ESTIMATED","startDate":"2027-06-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-08","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Pancreatic Cancer","Pancreatic Carcinoma"],"interventions":["DN022150+AG( Stage I ）","DN022150+AG（Stage II）","placebo+AG（Stage II）"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I ：explores the combination dose and the second phase; Stage II ：patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT07656376"},{"nctId":"NCT07124117","title":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","sponsor":"OBI Pharma, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":147,"enrollmentType":"ESTIMATED","startDate":"2025-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-08","completionType":"ESTIMATED","lastUpdated":"2026-01-05","conditions":["Advanced Solid Tumor"],"interventions":["OBI-902"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a 3-part study. Phase 1a (dose escalation) is designed to assess the safety and tolerability and to determine the maximum tolerated dose (MTD) and putative recommended phase 2 dose (RP2D) of study drug as monotherapy. Phase 1b (Cohort Expansion) is intended to further characterize the safety and preliminary antitumor activity of the putative RP2D of OBI-902 in selected tumor types. Phase 2 (Randomized Dose Optimization Cohorts) is intended to determine the optimal RP2D of OBI-902 in selected tumor types, before advancing to larger Phase 3 trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07124117"},{"nctId":"NCT06745323","title":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","sponsor":"Amgen","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":252,"enrollmentType":"ACTUAL","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-09","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Small Cell Lung Cancer (SCLC)"],"interventions":["Tarlatamab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","China","France","Germany","Greece","Italy","Japan","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":78,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06745323"},{"nctId":"NCT07611110","title":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":670,"enrollmentType":"ESTIMATED","startDate":"2026-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-20","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["AZD2265","Cabazitaxel","Abiraterone","Enzalutamide","Apalutamide","Darolutamide","Rezvilutamide","Radium-223"],"countries":["United States","Australia","Austria","Brazil","Canada","China","France","Germany","India","Japan","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":104,"serviceSignals":["Broad CGP"],"summary":"The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07611110"},{"nctId":"NCT04923893","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":743,"enrollmentType":"ACTUAL","startDate":"2021-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-14","primaryCompletionType":"ESTIMATED","completionDate":"2036-09-22","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Bortezomib","Dexamethasone","Lenalidomide","Cilta-cel","Cyclophosphamide","Fludarabine"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Japan","Netherlands","Norway","Poland","Portugal","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":136,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).","sourceUrl":"https://clinicaltrials.gov/study/NCT04923893"},{"nctId":"NCT07155226","title":"Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2026-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-15","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Acute Lymphoblastic Leukaemia","Acute Myeloid Leukaemia","Higher-risk Myelodysplastic Syndromes"],"interventions":["AZD3632","Posaconazole"],"countries":["United States","Australia","Canada","Denmark","Germany","Italy","Japan","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07155226"},{"nctId":"NCT07648264","title":"Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies","sponsor":"CSL Behring","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":63,"enrollmentType":"ESTIMATED","startDate":"2026-07-24","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-16","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Secondary Immune Deficiency"],"interventions":["IgPro20"],"countries":["United States","Belgium","Canada","Czechia","Denmark","France","Germany","Italy","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":60,"serviceSignals":["Hematology NGS"],"summary":"This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor T-cell (CAR T-cell) and T-cell redirecting therapies (such as T-cell engager bispecific antibody \\[TCE BsAb\\] therapy). The primary objective is to demonstrate that true annualized rate of serious bacterial infection (SBIs) is less than (\\<) 1.0. This study includes two cohorts: 1. Loading Cohort: Participants with serum immunoglobulin G (IgG) \\< 500 milligrams per deciliter (mg/dL) at Screening, with or without ongoing immunoglobulin replacement therapy (IgRT) duri","sourceUrl":"https://clinicaltrials.gov/study/NCT07648264"},{"nctId":"NCT06514534","title":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2025-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-18","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Chronic Myeloid Leukemia (CML)"],"interventions":["ABL001/Asciminib"],"countries":["France"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation. The presence of this mutation introduces treatment difficulties due to the limited available options. The study seeks to collect additional data on the effectiveness and safety of asciminib for these patients. By determining the drug's capacity to manage the disease and enhance patients outcomes, the study is designed to fill the unmet medical need and potentially offer a new therapeutic path for patients at a treatment deadlock.","sourceUrl":"https://clinicaltrials.gov/study/NCT06514534"},{"nctId":"NCT05314023","title":"Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1590,"enrollmentType":"ESTIMATED","startDate":"2022-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-19","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-19","completionType":"ESTIMATED","lastUpdated":"2023-01-19","conditions":["Genital Warts"],"interventions":["9vHPV vaccine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is designed to demonstrate non-inferior immunogenicity of 3 doses of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) in Chinese males 9 through 19 years of age, and 2 doses of the 9vHPV vaccine in Chinese males 9 through 14 years of age, compared to the 3 dose regimen in Chinese males 20 through 26 years of age (from Merck Protocol V503-052). The primary hypothesis is that each of the 3-dose regimen in Chinese males aged 9 through 19 years and 2-dose regimens in Chinese males aged 9 through 14 years induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) at one month post last dose compared to the 3-dose regimen in Chinese adul","sourceUrl":"https://clinicaltrials.gov/study/NCT05314023"},{"nctId":"NCT06345729","title":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2024-05-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-19","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-18","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Non-small Cell Lung Cancer"],"interventions":["Calderasib","Placebo","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Chile","China","France","Georgia","Germany","Greece","India","Italy","Japan","Mexico","Netherlands","New Zealand","Philippines","Poland","Romania","South Korea","Spain","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":225,"serviceSignals":["RAS genotyping"],"summary":"This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calde","sourceUrl":"https://clinicaltrials.gov/study/NCT06345729"},{"nctId":"NCT07566247","title":"A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor","sponsor":"Akeso","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02-21","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-07","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Advanced Malignant Solid Tumors"],"interventions":["AK150"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter, dose-escalation and dose-expansion Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of AK150 in patients with advanced malignant solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07566247"},{"nctId":"NCT07166601","title":"M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":77,"enrollmentType":"ESTIMATED","startDate":"2025-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-23","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Solid Tumor"],"interventions":["M0324","Pembrolizumab","mFOLFIRINOX"],"countries":["United States","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary signs of efficacy, pharmacokinetics (PK), and pharmacodynamics (PD). Three different treatments with M0324 will be studied, M0324 as a monotherapy(Part 1), M0324 in combination with pembrolizumab (Part 2), and in combination with mFOLFIRINOX (a chemotherapy treatment)(Part 3).","sourceUrl":"https://clinicaltrials.gov/study/NCT07166601"},{"nctId":"NCT06996782","title":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2025-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-23","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["Rilvegostomig","Cisplatin","Carboplatin","Pemetrexed","Paclitaxel","Nab-paclitaxel","Ramucirumab"],"countries":["United States","Belgium","Brazil","China","France","Georgia","Germany","Italy","Japan","Malaysia","Moldova","Netherlands","Peru","Poland","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":103,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06996782"},{"nctId":"NCT05562830","title":"A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2022-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-26","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Urothelial Carcinoma"],"interventions":["Zilovertamab vedotin","Pembrolizumab","MK-3120"],"countries":["United States","Australia","Canada","Chile","Denmark","Israel","Italy","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Broad CGP"],"summary":"This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT05562830"},{"nctId":"NCT06797999","title":"First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","sponsor":"Adcendo ApS","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2025-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-27","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-27","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Metastatic Soft Tissue Sarcoma","Unresectable Soft Tissue Sarcoma"],"interventions":["Antibody-drug conjugate (ADC)"],"countries":["United States","Belgium","France","Germany","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.","sourceUrl":"https://clinicaltrials.gov/study/NCT06797999"},{"nctId":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1410,"enrollmentType":"ESTIMATED","startDate":"2026-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-27","primaryCompletionType":"ESTIMATED","completionDate":"2032-08-26","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","Carcinoma, Non-Small-Cell Lung (NSCLC)","Metastatic Non Small Cell Lung Cancer","Lung Cancer"],"interventions":["PF-08634404","Pembrolizumab","Chemotherapy Regimen 1","Chemotherapy Regimen 2"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Poland","Puerto Rico","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":413,"serviceSignals":["Broad CGP"],"summary":"This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC. * Is not a candidate for complete surgical resection or curative chemoradiotherapy. * Do not have known actionable genomic alterations * Be ","sourceUrl":"https://clinicaltrials.gov/study/NCT07222566"},{"nctId":"NCT07578337","title":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","sponsor":"Nelum Corp","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Untreated","Advanced Pancreatic Cancer"],"interventions":["Gemcitabine (1000 mg/m2)","Nab-paclitaxel (Abraxane)","NLM-001","Botensilimab","Balstililmab"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Phase II, open label, randomized multicenter study to evaluate efficacy and safety of study treatment in previously untreated patients with advanced pancreatic cancer. Patients will receive study treatment for a maximum of 24 months or until progression disease or until unacceptable toxicity. In the experimental arm, patients who discontinue chemotherapy for reasons other than disease progression may continue receiving the remaining study drugs (NLM-001, botensilimab and balstilimab) up to a maximum of 24 months, according to schedule.","sourceUrl":"https://clinicaltrials.gov/study/NCT07578337"},{"nctId":"NCT07222488","title":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2025-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Bladder Cancer","Urinary Bladder Neoplasms"],"interventions":["MK-3120"],"countries":["United States","Austria","Belgium","Canada","France","Greece","Israel","Italy","Netherlands","Norway","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.","sourceUrl":"https://clinicaltrials.gov/study/NCT07222488"},{"nctId":"NCT07614360","title":"Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-08-03","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-11","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Dexamethasone","Bortezomib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The aim of this study is to assess safety, efficacy and pharmacokinetic (PK) parameters with alternative dosing schedules of belantamab mafodotin in combination with bortezomib and dexamethasone compared to the approved dosing regimen in participants with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy. The study will further characterize the risk of ocular toxicity and impact on efficacy measures and PK evaluations using alternative and approved dosing regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT07614360"},{"nctId":"NCT07472647","title":"SYS6090 Combination Therapy in Advanced Lung Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":596,"enrollmentType":"ESTIMATED","startDate":"2026-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-28","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Non-Small Cell Lung Cancer","Small Cell Lung Cancer"],"interventions":["SYS6090 + pemetrexed + platinum-based chemotherapy","SYS6090 + paclitaxel + platinum-based chemotherapy","SYS6090 + docetaxel","SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy","SYS6090 + SYS6010","SYS6090 + etoposide + platinum-based chemotherapy","SYS6090 + chemotherapy or other anticancer therapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or SYS6010 (an EGFR ADC) in participants with advanced lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07472647"},{"nctId":"NCT05984277","title":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":895,"enrollmentType":"ACTUAL","startDate":"2023-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Metastatic Non-small Cell Lung Cancer"],"interventions":["Volrustomig","Pembrolizumab","Carboplatin","Paclitaxel","Pemetrexed"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Hungary","India","Italy","Japan","Netherlands","Poland","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":247,"serviceSignals":["Broad CGP"],"summary":"The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 \\< 50%.","sourceUrl":"https://clinicaltrials.gov/study/NCT05984277"},{"nctId":"NCT07218003","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","sponsor":"Rondo Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ENROLLING_BY_INVITATION","enrollment":149,"enrollmentType":"ESTIMATED","startDate":"2025-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Non Small Cell Lung Cancer","Cervical Cancer","Head and Neck Squamous Cell Cancer","Triple Negative Breast Cancer (TNBC)","Urothelial Carcinoma Bladder","Gastroesophageal Junction (GEJ) Adenocarcinoma","Esophageal Squamous Cell Cancer","Gastric Cancer","Cancer","Solid Tumors (Phase 1)"],"interventions":["RNDO-564","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab. The study is focused on participants with certain solid tumors that are in an advanced stage and have certain tumor makers. This will be done by measuring the side effects that participants experience and how severe they are. Additionally, the study will evaluate how RNDO-564 moves into, through, and out of the body and how the treatment affects the body. The second goal of this study is to evaluate how well RNDO-564 works by itself or in combination with pembrolizumab at treating participants' cancer. This will be do","sourceUrl":"https://clinicaltrials.gov/study/NCT07218003"},{"nctId":"NCT07647328","title":"A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["ER-Positive HER2-Negative Breast Cancer"],"interventions":["Camizestrant","Ribociclib"],"countries":["United States","France","Germany","Italy","Poland","South Korea","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":84,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.","sourceUrl":"https://clinicaltrials.gov/study/NCT07647328"},{"nctId":"NCT06014762","title":"P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies","sponsor":"Poseida Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2024-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2041-03","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High-grade B-cell Lymphoma","Primary Mediastinal Large B-cell Lymphoma (PMBCL)","Transformed Follicular Lymphoma (tFL)","Follicular Lymphoma Grade 3B","DLBCL","DLBCL - Diffuse Large B Cell Lymphoma","DLBCL Arising From Follicular Lymphoma","DLBCL, Diffused Large B Cell Lymphoma","DLBCL NOS"],"interventions":["P-CD19CD20-ALLO1","Rimiducid"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06014762"},{"nctId":"NCT04960579","title":"P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma","sponsor":"Poseida Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":275,"enrollmentType":"ESTIMATED","startDate":"2022-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2042-03","completionType":"ESTIMATED","lastUpdated":"2026-04-24","conditions":["Multiple Myeloma"],"interventions":["P-BCMA-ALLO1 CAR-T cells","Rimiducid","Methotrexate"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Hematology NGS"],"summary":"Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT04960579"},{"nctId":"NCT06266299","title":"A Study of KK2269 in Adult Participants With Solid Tumors","sponsor":"Kyowa Kirin Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":101,"enrollmentType":"ESTIMATED","startDate":"2024-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma","Non Small Cell Lung Cancer"],"interventions":["KK2269","Docetaxel"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269. In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and d","sourceUrl":"https://clinicaltrials.gov/study/NCT06266299"},{"nctId":"NCT06970639","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","sponsor":"Allist Pharmaceuticals, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2024-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["NSCLC Patients With Brain Metastasis"],"interventions":["Furmonertinib Mesilate Tablets","Carboplatin Injection","Cisplatin for injection","Pemetrexed Disodium for Injection","Osimertinib Mesylate Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase III, international, multicenter, randomized, controlled, open-label clinical trial. The primary objective is to evaluate the efficacy and safety of furmonertinib plus platinum-based doublet chemotherapy (Arm A) versus osimertinib monotherapy (Arm B) in patients with EGFR sensitizing mutation-positive non-squamous non-small cell lung cancer (NSCLC) and brain metastases. Additionally, a proportion of subjects will receive furmonertinib monotherapy (Arm C) to further explore its efficacy and safety profile. Stage 1 is the safety run-in phase, planned to enroll approximately 30 subjects who will be randomized at a 1:1 ratio to receive either furmonertinib 80 mg QD plus plat","sourceUrl":"https://clinicaltrials.gov/study/NCT06970639"},{"nctId":"NCT07517198","title":"Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors","sponsor":"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Solid Tumor","Small Cell Lung Cancer (SCLC)","High Grade Neuroendocrine Cancer","Small Cell Carcinomas of Non-lung Origin","Non-small Cell Lung Cancer (NSCLC)","Prostate Cancer","Ovarian Cancer","Renal Carcinoma (Clear and Non-clear Cell)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatic Cancer","Gastric Cancer","Triple-negative Breast Cancer (TNBC)"],"interventions":["EXS74539"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07517198"},{"nctId":"NCT07192471","title":"A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma","sponsor":"Kyowa Kirin, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["T-cell NHL (PTCL or CTCL)"],"interventions":["KK2223"],"countries":["United States","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07192471"},{"nctId":"NCT07665515","title":"Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","sponsor":"Epitopea Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Ovarian Cancer","HGSOC","HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer"],"interventions":["CryptiVax-1001"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine. Following surgery and platin","sourceUrl":"https://clinicaltrials.gov/study/NCT07665515"},{"nctId":"NCT06528301","title":"A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies","sponsor":"Umoja Biopharma","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":106,"enrollmentType":"ESTIMATED","startDate":"2025-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-05-28","conditions":["Lymphoma, B-Cell","Lymphoma, Non-Hodgkin (NHL)","Lymphoma, Large B-Cell, Diffuse (DLBCL)","Chronic Lymphocytic Leukemia (CLL)"],"interventions":["UB-VV111","rapamycin"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).","sourceUrl":"https://clinicaltrials.gov/study/NCT06528301"},{"nctId":"NCT07545265","title":"SKB565 for Injection in Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced Solid Tumors"],"interventions":["SKB565"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II clinical study to evaluate the safety and efficacy of SKB565 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07545265"},{"nctId":"NCT06586515","title":"MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2024-09-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","Colorectal Cancer"],"interventions":["LY3962673","Cetuximab","Gemcitabine","nab-paclitaxel","Oxaliplatin","leucovorin","Irinotecan","5-fluorouracil"],"countries":["United States","Canada","China","France","Germany","Ireland","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of this study is to assess safety \\& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06586515"},{"nctId":"NCT07450859","title":"A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"BicycleTx Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":39,"enrollmentType":"ESTIMATED","startDate":"2026-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["nuzefatide pevedotin (BT5528)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2 study for nuzefatide pevedotin (BT5528) in adults with a specific type of pancreatic cancer called metastatic pancreatic ductal adenocarcinoma (PDAC) that has spread and worsened after one previous treatment. The drug, nuzefatide pevedotin (nuzefatide), is designed to find a specific protein called EphA2. The main aims of the study are to see how well the drug works against the tumor (efficacy), what side effects it may have (safety), and how the body processes it (pharmacokinetics). All participants in this study will receive nuzefatide, and both they and their doctors will know what is being administered (single-arm, open-label). The trial will take place at several diffe","sourceUrl":"https://clinicaltrials.gov/study/NCT07450859"},{"nctId":"NCT07045454","title":"A Study of MHB118C Injection in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-03","completionType":"ESTIMATED","lastUpdated":"2025-07-01","conditions":["Advanced Malignant Solid Tumor"],"interventions":["MHB118C for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB118C monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07045454"},{"nctId":"NCT05536141","title":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":362,"enrollmentType":"ESTIMATED","startDate":"2022-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Clear Cell Renal Cell Carcinoma","Solid Tumors"],"interventions":["casdatifan","Cabozantinib","Zimberelimab","Ipilimumab"],"countries":["United States","Australia","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT05536141"},{"nctId":"NCT06874335","title":"A Phase 1 Study of BHV-1530 in Advanced Solid Tumors","sponsor":"Biohaven Therapeutics Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Solid Tumor"],"interventions":["BHV-1530","Cemiplimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06874335"},{"nctId":"NCT07452198","title":"A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":358,"enrollmentType":"ESTIMATED","startDate":"2026-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Multiple Myeloma"],"interventions":["GR1803 injection","Daratumumab","Pomalidomide","Dexamethasone"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).","sourceUrl":"https://clinicaltrials.gov/study/NCT07452198"},{"nctId":"NCT07262619","title":"EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors","sponsor":"Eikon Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-01-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-03","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Advanced Solid Tumors","MSI-H or dMMR Advanced Solid Tumors","MSI-H/dMMR Gastric Cancer","MSI-H/dMMR Colorectal Cancer","MSI-H/dMMR Gastroesophageal-junction Cancer","Endometrial Cancer","Mismatch Repair Deficient or MSI-High Solid Tumors"],"interventions":["EIK1005","pembrolizumab (KEYTRUDA® )"],"countries":["United States","Australia","New Zealand"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07262619"},{"nctId":"NCT06708455","title":"Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma","sponsor":"Rapa Therapeutics LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2027-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-03-19","conditions":["Malignant Melanoma With Metastasis","Malignant Melanoma","Malignant Melanoma Stage IIIc","Malignant Melanoma Stage IV"],"interventions":["RAPA-201 Rapamycin Resistant T Cells","Chemotherapy Prior to RAPA-201 Therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06708455"},{"nctId":"NCT07596901","title":"Study of Aritinercept in Patients With Generalized Myasthenia Gravis","sponsor":"Aurinia Pharmaceuticals Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2026-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-02","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Myasthenia Gravis, Generalized"],"interventions":["Aritinercept","Placebo"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.","sourceUrl":"https://clinicaltrials.gov/study/NCT07596901"},{"nctId":"NCT07501702","title":"A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis","sponsor":"Vertex Pharmaceuticals Incorporated","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-02","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Myasthenia Gravis, Generalized"],"interventions":["Povetacicept","Placebo"],"countries":["United States","Australia","Poland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).","sourceUrl":"https://clinicaltrials.gov/study/NCT07501702"},{"nctId":"NCT07227298","title":"Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers","sponsor":"Pfizer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-08","primaryCompletionType":"ESTIMATED","completionDate":"2033-08-23","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer","Carcinoma, Non-Small Cell Lung","Non-Small Cell Lung Cancer"],"interventions":["PF-08634404","Sigvotatug Vedotin","Combination Agent 1"],"countries":["United States","China","France","Germany","Italy","Japan","Puerto Rico","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":73,"serviceSignals":["Broad CGP"],"summary":"This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of t","sourceUrl":"https://clinicaltrials.gov/study/NCT07227298"},{"nctId":"NCT05629689","title":"A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies","sponsor":"GE Healthcare","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2023-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-10","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Malignant Solid Tumor","Oncology"],"interventions":["GEH200520 Injection / GEH200521 (18F) Injection - Part A","Dynamic and Static - PET/CT scan","GEH200520 Injection / GEH200521 (18F) Injection - Part B","Static - PET/CT scan"],"countries":["Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Part A: The purpose of this part is to assess the safety of GEH200520 and GEH200521 (18F) when administered to patients with solid cancer. Subjects will be requested to complete 3 study visits: 1 screening visit, 1 imaging visit (over 24 hours) and 1 follow-up visit (7 days later). The estimated duration of Part A is 21 days. Part B: The purpose of this part of the study is to assess the imaging quality and findings as well as the safety and tolerability of GEH200520 and GEH200521 (18F) when administered to patients with cancer before and after immunotherapy treatment. Subjects will be requested to complete 7 study visits: 1 screening visit, the first imaging visit, followed by 2 immunothera","sourceUrl":"https://clinicaltrials.gov/study/NCT05629689"},{"nctId":"NCT06637423","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2024-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-14","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Non-Muscle Invasive Bladder Cancer"],"interventions":["Sacituzumab tirumotecan","Rescue medication","Supportive care measures"],"countries":["United States","Canada","France","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn how well the drug works.","sourceUrl":"https://clinicaltrials.gov/study/NCT06637423"},{"nctId":"NCT07623850","title":"A Phase I Study of JLM019 Injection","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2026-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-14","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-01","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Advanced Solid Tumor (Phase 1)","Hodgkin Lymphoma","Non-Hodgkin Lymphoma"],"interventions":["JLM019 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a multicenter, single-arm, open-label, dose escalation phase (Part A) and dose expansion (Part B) study to evaluate the safety and tolerability of JLM019 Injection in patients with advanced malignancies. The study subjects are adults with advanced malignancies including advanced solid tumors or relapsed/refractory lymphoma. During the dose escalation phase, the dose escalation scheme is the accelerated titration in 0.001 - 0.2 mg/kg cohorts plus a traditional '3 + 3' design in 0.6 - 10 mg/kg cohorts, jointly in nine dose cohorts 0.001, 0.01, 0.05, 0.2, 0.6, 1.5, 3, 6 and 10 mg/kg. JLM019 Injection is intended to be administered once a week (QW). However, the dose and interval of admi","sourceUrl":"https://clinicaltrials.gov/study/NCT07623850"},{"nctId":"NCT06378242","title":"To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2024-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2024-07-11","conditions":["High-risk Non-muscle Invasive Bladder Cancer"],"interventions":["Disitamab Vedotin for injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of intravesical instiliations of Disitamab Vedotin in patients with high-risk non-muscular invasive bladder cancer (NMIBC) that express HER2","sourceUrl":"https://clinicaltrials.gov/study/NCT06378242"},{"nctId":"NCT05827016","title":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1230,"enrollmentType":"ACTUAL","startDate":"2023-06-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2036-01-01","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Multiple Myeloma"],"interventions":["Iberdomide","Lenalidomide"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":271,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple myeloma (NDMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT05827016"},{"nctId":"NCT06921785","title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1220,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-16","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-15","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Hepatocellular Carcinoma"],"interventions":["Tremelimumab","Rilvegostomig","Bevacizumab","Atezolizumab"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Hong Kong","India","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":220,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy","sourceUrl":"https://clinicaltrials.gov/study/NCT06921785"},{"nctId":"NCT07746713","title":"A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-08-17","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-16","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Prostatic Neoplasms"],"interventions":["JNJ-98768111"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"The purpose of Part 1 of this study is to find out how safe JNJ-98768111 is and the most suitable dose (recommended phase 2 dose \\[RP2D\\]) regimen(s) of JNJ-98768111. The purpose of Part 2 of this study is to find out how safe JNJ-98768111 is at the RP2D regimen(s) in participants with advanced prostate cancer (cancer of the prostate, a male reproductive gland found below the bladder, which has spread extensively to other parts of the body).","sourceUrl":"https://clinicaltrials.gov/study/NCT07746713"},{"nctId":"NCT07533123","title":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":364,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03-17","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-17","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Triple Negative Breast Cancer"],"interventions":["JSKN016 Injection","Eribulin Mcsilate Injection","Vinorelbine Tartrate Injection","Capecitabine Tablets","Gemcitabine Hydrochloride for Injection","Sacituzumab Govitecan for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Primary Endpoint of this Study: To compare Progression-Free Survival (PFS) (as assessed by a Blinded Independent Review Committee \\[BIRC\\] based on Response Evaluation Criteria in Solid Tumors \\[RECIST v1.1\\]) between JSKN016 and Treatment of Physician's Choice (TPC) in participants with unresectable locally advanced, recurrent, or metastatic triple-negative breast cancer (TNBC). To compare Overall Survival (OS) between JSKN016 and TPC in the treatment of unresectable locally advanced, recurrent, or metastatic TNBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07533123"},{"nctId":"NCT05855200","title":"Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":892,"enrollmentType":"ESTIMATED","startDate":"2023-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-19","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-27","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Colonic Neoplasms","Neoplasms, Colon"],"interventions":["Dostarlimab","CAPEOX","FOLFOX"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","Estonia","Finland","France","Germany","Greece","India","Italy","Japan","Mexico","Netherlands","Norway","Panama","Poland","Portugal","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":266,"serviceSignals":["MSI / TMB"],"summary":"The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05855200"},{"nctId":"NCT06787950","title":"Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors","sponsor":"Jiangsu Yahong Meditech Co., Ltd aka Asieris","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-02-20","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03-20","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-20","completionType":"ESTIMATED","lastUpdated":"2025-01-22","conditions":["Advanced Solid Tumors"],"interventions":["ASN-3186"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I/IIa, open-label, multi-center, dose-escalation, and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of ASN-3186 when given orally in subjects with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06787950"},{"nctId":"NCT06843447","title":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2025-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-27","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-27","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Ovarian Cancer Recurrent"],"interventions":["Raludotatug Deruxtecan","Carboplatin","Paclitaxel","Bevacizumab","Rescue Medication","Pembrolizumab","Gemcitabine","Pegylated liposomal doxorubicin"],"countries":["United States","Canada","Israel","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatm","sourceUrl":"https://clinicaltrials.gov/study/NCT06843447"},{"nctId":"NCT06997497","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":477,"enrollmentType":"ESTIMATED","startDate":"2025-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-27","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Colon Adenocarcinoma","Rectal Adenocarcinoma"],"interventions":["Calderasib","Oxaliplatin","Leucovorin/levofolinate calcium","5-Fluorouracil","Cetuximab","Bevacizumab","Bevacizumab biosimilar"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Finland","France","Germany","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Philippines","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":223,"serviceSignals":["RAS genotyping"],"summary":"Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies. The goals of this study are to learn: * About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments * If people who receive calderasib with cetuximab and mFOLFOX6 live longe","sourceUrl":"https://clinicaltrials.gov/study/NCT06997497"},{"nctId":"NCT07192614","title":"A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2025-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-29","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Prostate Cancer"],"interventions":["AZD6621"],"countries":["United States","Belgium","Canada","China","Japan","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels of AZD6621 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD6621 doses in a larger group of participants (dose expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT07192614"},{"nctId":"NCT03075696","title":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":940,"enrollmentType":"ESTIMATED","startDate":"2017-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-30","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Non-Hodgkin's Lymphoma"],"interventions":["Glofitamab","Obinutuzumab","Tocilizumab"],"countries":["United States","Australia","Belgium","Canada","Czechia","Denmark","Finland","France","Italy","New Zealand","Poland","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-into-human (EIH) study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-participant dose-escalation cohorts will be used in Part I, followed by conversion to multiple participant dose-escalation cohorts (Part II), in order to define a tentative maximum tolerated dose (MTD) or o","sourceUrl":"https://clinicaltrials.gov/study/NCT03075696"},{"nctId":"NCT07302347","title":"A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Malignant Neoplasm","Carcinoma, Merkel Cell","Lymphoma"],"interventions":["Pembrolizumab"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT07302347"},{"nctId":"NCT07439653","title":"A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma","sponsor":"TORL Biotherapeutics, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma"],"interventions":["TORL-5-700","TORL-5-700 at MTD/RP2D","TORL-5-700 at MTD/RP2D in combination with another agent"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL","sourceUrl":"https://clinicaltrials.gov/study/NCT07439653"},{"nctId":"NCT07098988","title":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","sponsor":"CatalYm GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":107,"enrollmentType":"ESTIMATED","startDate":"2025-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Metastatic Non-Squamous Non-Small Cell Lung Cancer","Adult Solid Tumor"],"interventions":["Visugromab","Matching placebo for visugromab","Pembrolizumab 200 mg Q3W","Pemetrexed 500 mg/m^2","Carboplatin AUC 5"],"countries":["United States","Germany","Italy","Poland","Romania","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participan","sourceUrl":"https://clinicaltrials.gov/study/NCT07098988"},{"nctId":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","sponsor":"A2 Biotherapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-31","completionType":"ESTIMATED","lastUpdated":"2025-09-09","conditions":["Solid Tumor, Adult","Colorectal Cancer","Non-Small Cell Lung","NSCLC (Non-small Cell Lung Cancer)","Cancer","Colon Cancer","Rectal Cancer","Lung Cancer","CRC","Head and Neck Squamous Cell Cancer","HNSCC","Renal Cell Carcinoma","RCC","Kidney Cancer","Triple Negative Breast Cancer","TNBC","Colorectal Adenocarcinoma"],"interventions":["A2B395","xT CDx with HLA-LOH assay"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, an","sourceUrl":"https://clinicaltrials.gov/study/NCT06682793"},{"nctId":"NCT06395103","title":"Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-08-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["B-cell Acute Lymphoblastic Leukemia","Diffuse Large B-cell Lymphoma","Burkitt Lymphoma","Neuroblastoma","Ewing Sarcoma"],"interventions":["Zilovertamab vedotin"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":71,"serviceSignals":["Hematology NGS"],"summary":"Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06395103"},{"nctId":"NCT07657806","title":"DEC003M in Prostate Cancer","sponsor":"Hangzhou DAC Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-01","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Advanced Prostate Cancer"],"interventions":["DEC003M"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, multicenter Phase 1 study of DEC003M, in patients with advanced stage prostate cancer. The study consists of a dose-escalation phase to determine the dose for expansion, followed by a dose-expansion phase to evaluate preliminary antitumor activity, safety, and pharmacokinetics.","sourceUrl":"https://clinicaltrials.gov/study/NCT07657806"},{"nctId":"NCT06757634","title":"Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)","sponsor":"Celcuity Inc","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1180,"enrollmentType":"ESTIMATED","startDate":"2025-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-30","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Breast Cancer"],"interventions":["Arm A: Gedatolisib + Palbociclib + Fulvestrant","Arm B: Ribociclib + Fulvestrant","Arm C: Gedatolisib + Palbociclib + Letrozole","Arm D: Ribociclib + Letrozole"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Czechia","France","Germany","Greece","Hungary","Italy","Malaysia","Mexico","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":203,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06757634"},{"nctId":"NCT07321106","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer","sponsor":"Cartography Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Colorectal Cancer","Colorectal Cancer (CRC)","Colorectal (Colon or Rectal) Cancer","CRC","Metastatic Colon Cancer","Colon Cancer","Advanced Colorectal Cancer"],"interventions":["CBI-1214"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["MSI / TMB","Hematology NGS"],"summary":"This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07321106"},{"nctId":"NCT07492641","title":"BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1056,"enrollmentType":"ESTIMATED","startDate":"2026-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2037-08-07","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["HR+/HER2- Breast Cancer"],"interventions":["BGB-43395","Letrozole","Abemaciclib","Palbociclib","Ribociclib"],"countries":["United States","Australia","China","Japan","Malaysia","Puerto Rico","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":90,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT07492641"},{"nctId":"NCT07155174","title":"A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2031-09","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Small Cell Lung Cancer"],"interventions":["ABBV-706","Atezolizumab","Etoposide","Carboplatin","Lurbinectedin"],"countries":["United States","Belgium","China","Germany","Israel","Italy","Japan","Poland","Serbia","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":62,"serviceSignals":["Broad CGP"],"summary":"Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants wil","sourceUrl":"https://clinicaltrials.gov/study/NCT07155174"},{"nctId":"NCT07232875","title":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":588,"enrollmentType":"ESTIMATED","startDate":"2025-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting"],"interventions":["HRS-4642 + AG","HRS-4642 placebo + AG"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation. Patients were randomized 1:1 to receive either the experimental regimen HRS-4642 plus AG or the control regimen AG alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232875"},{"nctId":"NCT06840886","title":"A Study of PHST001 in Advanced Solid Tumors","sponsor":"Pheast Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":272,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2031-04","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Solid Tumors","Ovarian Cancer","Endometrial Cancer","Cholangiocarcinoma","CNS Tumor"],"interventions":["PHST001","Chemotherapy per Standard of Care"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). In Phase 1b cohort expansions, the study will focus on participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma. The study's primary objective is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of","sourceUrl":"https://clinicaltrials.gov/study/NCT06840886"},{"nctId":"NCT07241039","title":"A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2025-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Advanced Squamous Tumors"],"interventions":["ABBV-711","Budigalimab"],"countries":["United States","Canada","Israel","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors. ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide. In part ","sourceUrl":"https://clinicaltrials.gov/study/NCT07241039"},{"nctId":"NCT04534205","title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","sponsor":"BioNTech SE","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2021-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Unresectable Head and Neck Squamous Cell Carcinoma","Metastatic Head and Neck Cancer","Recurrent Head and Neck Cancer"],"interventions":["BNT113","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","France","Germany","Hungary","Israel","Italy","Mexico","Poland","Portugal","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":195,"serviceSignals":["Broad CGP"],"summary":"An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1. This trial has two parts. Part A, is an initial non-randomized Safety Run-In Phase to confirm the safety and tolerability at the selected dose range level of BNT113 in combination with pembrolizumab. Part B, is a randomized part to generate pivotal efficacy and safety data of BNT113 in combination with pembrolizumab versus pembrolizumab monotherapy in the first li","sourceUrl":"https://clinicaltrials.gov/study/NCT04534205"},{"nctId":"NCT07244393","title":"Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer","sponsor":"Cellbion Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-12","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2025-11-24","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["Lutetium (177Lu) DGUL","Pembrolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Participants will: Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals","sourceUrl":"https://clinicaltrials.gov/study/NCT07244393"},{"nctId":"NCT07699757","title":"HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Non-Small Cell Lung Cancer","Pancreatic Ductal Adenocarcinoma (mPDAC)","Advanced Solid Tumors"],"interventions":["HSK41959","Sintilimab","Pemetrexed + Cisplatin /Carboplatin","Paclitaxel + Carboplatin","Nab-paclitaxel + Carboplatin","Nab-paclitaxel + Gemcitabine","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors. The study consists of dose-escalation and dose-expansion parts and is intended to evaluate the safety, tolerability, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HSK41959 tablets when used together with standard therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07699757"},{"nctId":"NCT06902350","title":"Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2025-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2025-05-25","conditions":["Neoplasms","Glioblastoma, Adult","Small Cell Lung Carcinoma (SCLC)"],"interventions":["CS231295"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a single-arm, open-label, first-in-human study of CS231295, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion. The Dose-Limiting Toxicity (DLT) observation period includes 6 days for single-dose and the first cycle (28 days) for multiple-dose. The overall study consists of screening period, treatment period, and follow-up period. The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of CS231295 in patients with advanced solid tumors, and to recommended Phase 2 dose(s) (RP2D) of CS231295 in appropriate tumor(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT06902350"},{"nctId":"NCT06556563","title":"EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma","sponsor":"NovoCure GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":741,"enrollmentType":"ESTIMATED","startDate":"2025-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Glioblastoma"],"interventions":["Optune® device","Temozolomide","Pembrolizumab","Placebo"],"countries":["United States","Canada","Czechia","France","Germany","Israel","Italy","Japan","Poland","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":102,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06556563"},{"nctId":"NCT07679919","title":"BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies","sponsor":"Luminary Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-04","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia","Hairy Cell Leukemia","Multiple Myeloma"],"interventions":["LMY-922"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Therapy with chimeric antigen receptor T (CAR-T) cells has demonstrated activity against refractory hematologic malignancies, however not all tumors respond or remain in response to CD19 targeted CAR-T cells. We posit that CAR-T cells expressing BAFF (BAFF CAR-T cells) can become another strategy to treat refractory hematologic malignancies, even after relapse following cluster of differentiation antigen 19 (CD19) targeting CAR-T treatment. This phase 1 study will evaluate safe dose and provide initial signal of the activity of BAFF CAR-T cells against refractory hematologic malignancies using a single lymphodepletion regimen and using a BAFF CAR-T cell manufacturing process.","sourceUrl":"https://clinicaltrials.gov/study/NCT07679919"},{"nctId":"NCT07406542","title":"A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-01","completionType":"ESTIMATED","lastUpdated":"2026-02-12","conditions":["Recurrent or Metastatic Breast Cancer"],"interventions":["SYS6010","Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study is a multicenter, randomized, open-label, parallel-control Phase III clinical trial enrolling patients with unresectable HER2-negative, EGFR-positive recurrent/metastatic breast cancer who have previously failed first- or second-line chemotherapy. It aims to compare the efficacy and safety of SYS6010 monotherapy versus investigator-selected chemotherapy.The study plans to enroll approximately 400 subjects, randomly assigned in a 1:1 ratio to the treatment arm and control arm(Investigator's choice of standard chemotherapy regimen, including eribulin, capecitabine, gemcitabine, or vinorelbine).","sourceUrl":"https://clinicaltrials.gov/study/NCT07406542"},{"nctId":"NCT06844357","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-01","completionType":"ESTIMATED","lastUpdated":"2025-04-06","conditions":["HCC"],"interventions":["tirapazamine","Transarterial Embolization (TAE)","TACE"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC. The results will provide valuable insights into the potential benefits of TATE as a novel treatment option for HCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT06844357"},{"nctId":"NCT07644039","title":"Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies","sponsor":"PharmaMar","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":119,"enrollmentType":"ESTIMATED","startDate":"2026-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-02","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Malignancies"],"interventions":["Pembrolizumab","PM54"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT07644039"},{"nctId":"NCT07416123","title":"A Study of GEN1106 in Participants With Solid Tumors","sponsor":"Genmab","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":103,"enrollmentType":"ESTIMATED","startDate":"2026-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-25","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Solid Tumors","Urothelial Carcinoma"],"interventions":["GEN1106"],"countries":["United States","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what are the best doses to use. The second and third parts continues to test the safety of and how well GEN1106 works in additional participants with a specific cancer type and at doses chosen based on results from the first part of the trial. For each participant, the trial will last approximately 17 months but will vary for each person. This includes up to 21 days for screening prior to receiving tri","sourceUrl":"https://clinicaltrials.gov/study/NCT07416123"},{"nctId":"NCT07169734","title":"A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors","sponsor":"Alentis Therapeutics AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-04","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Cervical Squamous Cell Carcinoma","Squamous Non-small-cell Lung Cancer","Colorectal Cancer","Intrahepatic Cholangiocarcinoma","Urothelial Carcinoma"],"interventions":["ALE.P03"],"countries":["United States","France","Hong Kong","Italy","Netherlands","Singapore","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with selected squamous solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07169734"},{"nctId":"NCT07098338","title":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":278,"enrollmentType":"ESTIMATED","startDate":"2025-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-06","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Rilvegostomig","Ramucirumab","Dato-DXd"],"countries":["United States","Australia","Canada","China","France","Italy","Japan","Singapore","South Korea","Spain","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":83,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.","sourceUrl":"https://clinicaltrials.gov/study/NCT07098338"},{"nctId":"NCT07318805","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2025-12-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-14","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-14","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Breast Cancer","Metastatic Breast Cancer (HR+/ HER2-)","Colorectal Cancer","Metastatic Colorectal Adenocarcinoma","Triple Negative Breast Cancer"],"interventions":["PF-08032562","Fulvestrant","Cetuximab","Fluorouracil","Oxaliplatin","Leucovorin","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants that have advanced or metastatic breast cancer (BC), or advanced or metastatic colorectal cancer (CRC). All participants in this study will take the study medication (PF-08032562) as pill by mouth. This will be repeated for 28-day cycles. Depending on which part of the study participants are enrolled into, they will receive the study medication PF-08032562 alone or in com","sourceUrl":"https://clinicaltrials.gov/study/NCT07318805"},{"nctId":"NCT06994572","title":"Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma","sponsor":"Captor Therapeutics S.A.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":141,"enrollmentType":"ESTIMATED","startDate":"2025-05-26","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04-16","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-01","completionType":"ESTIMATED","lastUpdated":"2025-05-29","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["CT-01","EVEROLIMUS"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, open-label, multicenter, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CT-01, administered either as monotherapy or in combination with everolimus. The study population includes subjects with intermediate or advanced hepatocellular carcinoma (HCC) who have progressed on, or are intolerant to, at least one prior line of systemic treatment. All available standard-of-care therapies should have been received, if deemed appropriate by the investigator (unless contraindicated or considered inappropriate by the treating physician). Eligible subjects are classified as Barcelona Clinic Liv","sourceUrl":"https://clinicaltrials.gov/study/NCT06994572"},{"nctId":"NCT06879041","title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2025-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-16","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"interventions":["AZD2287","AZD2275","AZD2284"],"countries":["United States","Australia","South Africa"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.","sourceUrl":"https://clinicaltrials.gov/study/NCT06879041"},{"nctId":"NCT05952024","title":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2024-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-22","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-22","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["Acalabrutinib","Rituximab"],"countries":["United States","Brazil","Puerto Rico","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":57,"serviceSignals":["Hematology NGS"],"summary":"The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT05952024"},{"nctId":"NCT07325136","title":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2026-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-24","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Relapsed/Refractory Small Cell Lung Cancer"],"interventions":["BMS-986525","Pumitamig"],"countries":["United States","China","Italy","Japan","Romania","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07325136"},{"nctId":"NCT05406401","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2022-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-26","completionType":"ESTIMATED","lastUpdated":"2024-10-15","conditions":["Lymphoma, Large B-Cell, Diffuse (DLBCL)"],"interventions":["Zilovertamab Vedotin","Cyclophosphamide","Doxorubicin","Rituximab","Rituximab Biosimilar","Prednisone","Prednisolone"],"countries":["Canada","Israel","Italy","Poland","South Korea","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["Hematology NGS"],"summary":"This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease. The efficacy expansion phase is to determine the efficacy of the RP2D of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT05406401"},{"nctId":"NCT06764875","title":"A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":840,"enrollmentType":"ESTIMATED","startDate":"2025-03-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-09","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["HER2-positive Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["Rilvegostomig","Trastuzumab deruxtecan","Trastuzumab","Pembrolizumab","5-fluorouracil","Capecitabine","Cisplatin","Oxaliplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Hong Kong","Hungary","India","Italy","Japan","Malaysia","Netherlands","Peru","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":293,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764875"},{"nctId":"NCT06780137","title":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":327,"enrollmentType":"ESTIMATED","startDate":"2025-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-27","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Small Cell Lung Cancer"],"interventions":["Gocatamig","Ifinatamab Deruxtecan (I-DXd)","Durvalumab"],"countries":["United States","Argentina","Australia","Chile","China","Israel","Japan","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If goca","sourceUrl":"https://clinicaltrials.gov/study/NCT06780137"},{"nctId":"NCT07284433","title":"Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies","sponsor":"AvenCell Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2026-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-02","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Lymphoma Diffuse Large B-cell","Leukemia and Lymphoma","Leukemia Relapse","Lymphoma Receiving CAR-T Therapy"],"interventions":["Cyclophosphamide (Non-IMP, Lymphodepletion)","Fludarabine (Non-IMP, Lymphodepletion)","Allo-QuadCAR01-T"],"countries":["United States","Germany"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, which can save time and reduce costs. It targets two proteins, CD19 and CD20, to lower the chance of relapse and uses gene editing to make it safer. The trial has three parts: first to find a safe dose, then to confirm it, and finally to test how well it works in patients with diffuse large B-cell lymphoma (DLBCL). Patients will get one infusion after chemotherapy to prepare their body. The main goal is to check safety and see how many patients have a complet","sourceUrl":"https://clinicaltrials.gov/study/NCT07284433"},{"nctId":"NCT06824467","title":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":770,"enrollmentType":"ESTIMATED","startDate":"2025-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-27","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-09","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer"],"interventions":["Sacituzumab tirumotecan","Bevacizumab","H1 receptor antagonist","H2 receptor antagonist","Acetaminophen (or equivalent)","Dexamethasone (or equivalent)","Steroid mouthwash (dexamethasone or equivalent)"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","Finland","France","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Peru","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":187,"serviceSignals":["Broad CGP"],"summary":"The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06824467"},{"nctId":"NCT07518186","title":"A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2026-05-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-29","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-08","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["JNJ-79635322","Teclistamab"],"countries":["United States","Australia","China","France","Germany","Greece","India","Israel","Italy","Japan","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":88,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07518186"},{"nctId":"NCT06963398","title":"A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2025-05-09","conditions":["Advanced Solid Tumors"],"interventions":["HS-10529"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"HS-10529 is an oral, highly selective, small molecular inhibitor of KRAS G12D. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10529 in KRAS G12D patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06963398"},{"nctId":"NCT07414836","title":"A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":84,"enrollmentType":"ESTIMATED","startDate":"2026-04-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumor"],"interventions":["BG-C0979","Tislelizumab"],"countries":["United States","Australia","China","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":17,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).","sourceUrl":"https://clinicaltrials.gov/study/NCT07414836"},{"nctId":"NCT07615660","title":"Clinical Study of CVL006 Combination With 9MW2821","sponsor":"Convalife (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-04-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Advanced Solid Tumor"],"interventions":["CVL006 in combination with 9MW2821"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with 9MW821 patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07615660"},{"nctId":"NCT07397338","title":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","sponsor":"Revolution Medicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":370,"enrollmentType":"ESTIMATED","startDate":"2026-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Advanced Solid Tumors","Metastatic Solid Tumors","Non-small Cell Lung Cancer (NSCLC)","NSCLC","Colorectal Cancer (CRC)","CRC"],"interventions":["Daraxonrasib","Elironrasib","Zoldonrasib","Ivonescimab","Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)","cetuximab (Cohort C2 Only)","Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)","Daraxonrasib (Cohort B1 only)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07397338"},{"nctId":"NCT06890598","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2025-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2032-02","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Olomorasib","Pembrolizumab","Durvalumab","Placebo"],"countries":["United States","Australia","Austria","Belgium","Brazil","Chile","China","Czechia","France","Germany","Greece","Hungary","India","Israel","Italy","Japan","Netherlands","Norway","Poland","Portugal","Romania","Slovakia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":370,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.","sourceUrl":"https://clinicaltrials.gov/study/NCT06890598"},{"nctId":"NCT07610798","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations","sponsor":"Shenzhen Ionova Life Sciences Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":178,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Advance Solid Tumors","Colon and Rectal Cancer","Non - Small Cell Lung Cancer NSCLC","Pancreatic Adenocarcinoma Advanced or Metastatic","Ovarian Cancer","Endometrial Cancer","Biliary Cancers"],"interventions":["INV-8989"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07610798"},{"nctId":"NCT07229599","title":"A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2025-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2025-11-17","conditions":["Advanced Lung Cancer"],"interventions":["MHB036C for Injection","MHB039A for Injection","Furmonertinib","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229599"},{"nctId":"NCT07525206","title":"A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2026-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Colorectal Cancer"],"interventions":["Telisotuzumab adizutecan","Bevacizumab","Trifluridine/Tipiracil"],"countries":["United States","Belgium","Greece","Japan","Portugal","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["MET profiling"],"summary":"Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with c-Met over-expressed refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of c","sourceUrl":"https://clinicaltrials.gov/study/NCT07525206"},{"nctId":"NCT06193902","title":"LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.","sponsor":"Leucid Bio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":17,"enrollmentType":"ESTIMATED","startDate":"2023-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2025-09-03","conditions":["Tumor, Solid"],"interventions":["LEU011"],"countries":["United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.","sourceUrl":"https://clinicaltrials.gov/study/NCT06193902"},{"nctId":"NCT07650357","title":"A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)","sponsor":"Clasp Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["Advanced Solid Tumor","Non Small Cell Lung Cancer","Pancreatic Carcinoma","Colorectal Cancer"],"interventions":["CLSP-5282"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["RAS genotyping","Hematology NGS","HLA / TCR"],"summary":"Phase 1, open-label, multicenter study to evaluate the safety, tolerability, PK, PD, and preliminary clinical activity of CLSP 5282 when administered to HLA A\\*03:01-positive adult patients with advanced solid tumors that harbor the KRas G12V mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07650357"},{"nctId":"NCT06976190","title":"A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma","sponsor":"Shanghai Miracogen Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":446,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-01-20","conditions":["Recurrent or Metastatic Nasopharyngeal Carcinoma"],"interventions":["MRG003 + Pucotenlimab","Gemcitabine, Docetaxel, or Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06976190"},{"nctId":"NCT05318573","title":"A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2022-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2025-09-04","conditions":["Advanced Urothelial Carcinoma","Advanced Non Small Cell Lung Cancer"],"interventions":["Pembrolizumab","FF-10832"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["Broad CGP"],"summary":"To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05318573"},{"nctId":"NCT07688187","title":"A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma","sponsor":"PeptiDream Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Clear Cell Renal Cell Carcinoma"],"interventions":["PD-32766D (a Copper-64 [64Cu] labeled peptide)","PD-32766T (an Actinium-225 [225Ac] labeled peptide)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase IX (CA9)-expressing clear cell renal cell carcinoma (ccRCC). The primary objective is to evaluate the safety and tolerability of PD-32766T, and to characterize its pharmacokinetics and preliminary antitumor activity. Participants will first undergo imaging with PD-32766D to assess CA9 expression. Subjects with positive tumor uptake will be eligible to receive PD-32766T. In Phase 1a, PD-32766T will be administered in an escalating dose levels and schedule determined ac","sourceUrl":"https://clinicaltrials.gov/study/NCT07688187"},{"nctId":"NCT07558733","title":"Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer","sponsor":"Faeth Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":32,"enrollmentType":"ESTIMATED","startDate":"2026-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2033-05","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["HR+ HER2- Breast Cancer"],"interventions":["Serabelisib","Sapanisertib","Fulvestrant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["HER2 profiling"],"summary":"The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07558733"},{"nctId":"NCT06986811","title":"CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours","sponsor":"CEBIOTEX","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2025-05-31","conditions":["Locally Resectable Paediatric Tumours"],"interventions":["Standard surgery","CEB-01"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the abdominal cancer tumor, CEB-01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of abdominal tumors after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in pediatric patients with locally resectable abdominal tumors including Soft Tissue Sarcoma (STS), high-risk Neuroblastoma (NB), Wilms tumour (WT), germ cell tumors (GCT), extracranial mali","sourceUrl":"https://clinicaltrials.gov/study/NCT06986811"},{"nctId":"NCT02966756","title":"A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2017-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)"],"interventions":["Venetoclax"],"countries":["Australia","China","New Zealand","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":31,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 2, open-label, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status (Cohort 2).","sourceUrl":"https://clinicaltrials.gov/study/NCT02966756"},{"nctId":"NCT06295731","title":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","sponsor":"Inhibrx Biosciences, Inc","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2024-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-05","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Head and Neck Squamous Cell Carcinoma (HNSCC)"],"interventions":["INBRX-106","Pembrolizumab"],"countries":["United States","Australia","Belgium","Bulgaria","France","Italy","Malaysia","Poland","Romania","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":87,"serviceSignals":["Broad CGP"],"summary":"This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.","sourceUrl":"https://clinicaltrials.gov/study/NCT06295731"},{"nctId":"NCT07285694","title":"AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)","sponsor":"Arsenal Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2026-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2031-05","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Metastatic Castration Resistant Prostate Cancer (mCRPC)"],"interventions":["AB-3028"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07285694"},{"nctId":"NCT06835569","title":"A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations","sponsor":"Alterome Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":448,"enrollmentType":"ESTIMATED","startDate":"2025-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Cancer","PDAC - Pancreatic Ductal Adenocarcinoma","NSCLC (Non-small Cell Lung Cancer)","CRC (Colorectal Cancer)","Advanced Solid Tumors"],"interventions":["ALTA3263","cetuximab","mFOLFOX6","Pembrolizumab","Pemetrexed + Cisplatin /Carboplatin","mFOLFIRINOX","GnP","Midazolam"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06835569"},{"nctId":"NCT07174336","title":"A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":800,"enrollmentType":"ESTIMATED","startDate":"2025-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2033-05","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Neoplasms","Neoplasm Metastasis"],"interventions":["LY4064809","Placebo","Ribociclib","Palbociclib","Abemaciclib","Anastrozole","Letrozole","Exemestane","Fulvestrant"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Greece","Ireland","Italy","Japan","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":353,"serviceSignals":["HER2 profiling"],"summary":"The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.","sourceUrl":"https://clinicaltrials.gov/study/NCT07174336"},{"nctId":"NCT07356973","title":"Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma","sponsor":"CRISM Therapeutics LTD","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":147,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-01-26","conditions":["Glioblastoma"],"interventions":["irinotecan-ChemoSeed implementation into the resection cavity after surgical resection of GBM"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Part 1 (dose escalation, safety, and preliminary efficacy) Part 1 is a non-randomised, single-arm design in 12 participants with recurrent GBM suitable for maximal safe surgical resection. Part 1 will evaluate safety, determine the MTD of irinotecan-ChemoSeed and the RP2D (corresponding to coverage of as much of the resection cavity as possible, up to the MTD) and evaluate efficacy. All Part 1 participants will be administered irinotecan- ChemoSeed concurrent to Standard of Care (SoC) treatment. Part 1 dose- escalation will start at 72 mg of IRN Part 2, in 135 participants with newly diagnosed GBM suitable for maximal safe surgical resection, will assess the efficacy of irinotecan-ChemoSeed.","sourceUrl":"https://clinicaltrials.gov/study/NCT07356973"},{"nctId":"NCT06875128","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","sponsor":"Delcath Systems Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Metastatic Breast Cancer in the Liver"],"interventions":["Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)","Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)"],"countries":["United States","Italy"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["HER2 profiling"],"summary":"The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the liver-directed therapy with high dose chemotherapy works on the disease in the liver. Investigators will compare the use of the liver-directed therapy with high dose chemotherapy followed by approved cancer treatment or approved cancer treatment alone. Participants will: * Undergo up to two cycles of liver-directed therapy with high dose chemotherapy procedures followed by approved cancer treatment or take approved cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06875128"},{"nctId":"NCT07712757","title":"Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma","sponsor":"Nuvation Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2027-03","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2032-03","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation","Astrocytoma IDH Mutant Grade 2","Oligodendroglioma","Oligodendroglioma IDH-mutant and 1p/19q-codeleted","IDH-mutant Gliomas"],"interventions":["Safusidenib","Placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study comparing the efficacy and safety of safusidenib versus placebo in participants with residual or recurrent Grade 2 glioma (oligodendroglioma or astrocytoma) with an IDH1 mutation who have undergone surgery as their only treatment and are not in need of immediate chemotherapy or radiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07712757"},{"nctId":"NCT06985355","title":"A Study of MHB046C Injection in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-05","primaryCompletionType":"ESTIMATED","completionDate":"2031-05","completionType":"ESTIMATED","lastUpdated":"2025-09-18","conditions":["Advanced Solid Cancer"],"interventions":["MHB046C"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I/II study of MHB046C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB046C monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06985355"},{"nctId":"NCT07024706","title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2033-03-23","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)"],"interventions":["Acalabrutinib","Venetoclax"],"countries":["United States","Austria","Brazil","Czechia","Ireland","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi + BCL2i therapy (± obinutuzumab) and maintained a response for at least two years post-treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07024706"},{"nctId":"NCT06241456","title":"FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors","sponsor":"Fate Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":351,"enrollmentType":"ESTIMATED","startDate":"2024-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2044-05-01","completionType":"ESTIMATED","lastUpdated":"2025-12-09","conditions":["Advanced Solid Tumor"],"interventions":["FT825","Fludarabine","Cyclophosphamide","Bendamustine","Docetaxel","Cisplatin","Cetuximab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["HER2 profiling","Hematology NGS"],"summary":"This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.","sourceUrl":"https://clinicaltrials.gov/study/NCT06241456"},{"nctId":"NCT07413939","title":"RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive","sponsor":"Hoffmann-La Roche","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":650,"enrollmentType":"ESTIMATED","startDate":"2026-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-29","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["HER2-positive Breast Cancer"],"interventions":["RO7771950","Tucatinib","Trastuzumab","Capecitabine"],"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","China","Czechia","Germany","Hungary","Israel","Italy","New Zealand","Poland","Portugal","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":152,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.","sourceUrl":"https://clinicaltrials.gov/study/NCT07413939"},{"nctId":"NCT06137144","title":"AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":161,"enrollmentType":"ESTIMATED","startDate":"2024-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-03","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Lymphoma","Non-Hodgkin Lymphoma","Hodgkin Lymphoma","Peripheral T-cell Lymphoma (PTCL)","PTCL-NOS","ALCL","AITL"],"interventions":["AZD3470","Pembrolizumab"],"countries":["United States","Australia","China","France","Germany","Italy","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":37,"serviceSignals":["Hematology NGS"],"summary":"This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06137144"},{"nctId":"NCT05836324","title":"A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2023-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-03","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Solid Tumors","Advanced Solid Tumors","Metastatic Solid Tumors"],"interventions":["INCA33890","bevacizumab","FOLFIRI","FOLFOX","Cetuximab","ADG126"],"countries":["United States","China","Denmark","France","Italy","Japan","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05836324"},{"nctId":"NCT07076121","title":"A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":470,"enrollmentType":"ESTIMATED","startDate":"2025-10-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-03","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Pancreatic Ductal Adenocarcinoma"],"interventions":["Navlimetostat","Gemcitabine","Nab-paclitaxel","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hong Kong","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Romania","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":269,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.","sourceUrl":"https://clinicaltrials.gov/study/NCT07076121"},{"nctId":"NCT07261631","title":"Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-11-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-09","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Pancreatic Ductal Adenocarcinoma","Non-Small Cell Lung Cancer","HR+/HER2- Ductal and Lobular Breast Cancer","Triple Negative Breast Cancer","Colorectal Cancer","Soft Tissue Sarcoma"],"interventions":["68Ga-NNS309","177Lu-DFC413"],"countries":["Canada","Denmark","France","Germany","Israel","Singapore"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[177Lu\\]Lu-DFC413 and safety and imaging properties of \\[68Ga\\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07261631"},{"nctId":"NCT07252232","title":"Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"Revolution Medicines, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-12-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-10","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Pancreatic Cancer","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma (PDAC)","Resected Pancreatic Adenocarcinoma"],"interventions":["daraxonrasib"],"countries":["United States","France","Germany","Italy","Japan","Puerto Rico","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":60,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.","sourceUrl":"https://clinicaltrials.gov/study/NCT07252232"},{"nctId":"NCT05555732","title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1170,"enrollmentType":"ESTIMATED","startDate":"2023-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-11","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Metastatic Non Small Cell Lung Cancer"],"interventions":["Datopotamab Deruxtecan","Pembrolizumab","Pemetrexed","Carboplatin","Cisplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":260,"serviceSignals":["Broad CGP"],"summary":"This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05555732"},{"nctId":"NCT05458297","title":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":189,"enrollmentType":"ESTIMATED","startDate":"2022-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-17","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Chronic Lymphocytic Leukemia","Mantle Cell Lymphoma","Follicular Lymphoma","Richter Transformation Lymphoma"],"interventions":["Zilovertamab vedotin","Nemtabrutinib"],"countries":["United States","Brazil","Canada","Chile","China","Czechia","Estonia","Germany","Ireland","Israel","Italy","Japan","Peru","Poland","Portugal","Singapore","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":108,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL relapsed or refractory disease after at least 2 prior systemic therapies including a Bruton's tyrosine kinase inhibition/inhibitor (BTKi), and post therapy chimeric antigen receptor T (CAR-T) cell thera","sourceUrl":"https://clinicaltrials.gov/study/NCT05458297"},{"nctId":"NCT07572006","title":"A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2026-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-18","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-24","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Hematologic Neoplasms"],"interventions":["JNJ-95804306","AML SoC","CLL/SLL SoC"],"countries":["United States","Australia","Belgium","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended phase 2 dose \\[RP2D\\]) of JNJ-95804306. The purpose of Part 2 (Dose Expansion) is to further assess the safety of JNJ-95804306 and determine the anti-tumor activity alone and/or when administered in addition to standard of care (SoC) therapy at the putative RP2D(s) regimens in participants with hematological malignancies (cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system). For US sites: The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-9580","sourceUrl":"https://clinicaltrials.gov/study/NCT07572006"},{"nctId":"NCT03591510","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":22,"enrollmentType":"ACTUAL","startDate":"2019-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-18","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["FLT3-mutated Acute Myeloid Leukemia"],"interventions":["Midostaurin","Fludarabine","Cytarabine","Daunorubicin or idarubicin","Mitoxantrone","Etoposide"],"countries":["Czechia","Germany","Italy","Japan","Jordan","Poland","Russia","Slovenia","South Korea","Turkey (Türkiye)"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, efficacy and pharmacokinetics of midostaurin in combination with standard chemotherapy in pediatrics patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia. The study has two parts: Part 1 to define the Recommended Phase 2 Dose, and Part 2 to evaluate safety and tolerability and efficacy of midostaurin. Both parts will consist of 2 induction blocks, 3 consolidation blocks, 12 cycles of post-consolidation consisting of continuous therapy with midostaurin, and a follow-up phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT03591510"},{"nctId":"NCT07158710","title":"Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":159,"enrollmentType":"ESTIMATED","startDate":"2025-08-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-03","completionType":"ESTIMATED","lastUpdated":"2025-09-08","conditions":["Malignant Brain Tumors"],"interventions":["HSK42360"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07158710"},{"nctId":"NCT06667076","title":"A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-23","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-26","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Amivantamab","Lazertinib","Chemotherapy: Pemetrexed","Chemotherapy: Carboplatin"],"countries":["United States","Belgium","Finland","France","Germany","Greece","Israel","Italy","Poland","Portugal","Puerto Rico","Saudi Arabia","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":203,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).","sourceUrl":"https://clinicaltrials.gov/study/NCT06667076"},{"nctId":"NCT05285826","title":"Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":8100,"enrollmentType":"ESTIMATED","startDate":"2022-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-25","completionType":"ESTIMATED","lastUpdated":"2024-12-16","conditions":["Papillomavirus Infections"],"interventions":["9vHPV Vaccine","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":34,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy, immunogenicity, and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese men 20 to 45 years of age. It will enroll heterosexual men (HM) and men who have sex with men (MSM), will be stratified by age and sexual orientation, and will have two stages. The primary hypothesis of Stage I is: 9vHPV vaccine reduces the combined incidence of HPV 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52-, and 58-related external genital and intra-anal 12-month persistent infection (PI) compared with placebo in males 20 to 45 years of age who are seronegative at Day 1 and polymerase chain reaction (PCR) negative from Day 1 through one month post-Dose 3 to the rele","sourceUrl":"https://clinicaltrials.gov/study/NCT05285826"},{"nctId":"NCT06480552","title":"An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-26","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-25","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Advanced Solid Tumors"],"interventions":["TEV-56278","Pembrolizumab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Determine a RP2D of TEV-56278 in combination with pembrolizumab The secondary objectives of this trial are to: * Characterize the serum pharmacokinetics of TEV-56278 * Evaluate the antitumor activity of TEV-56278 * Determine the safety and tolerability of TEV-56278 * Evaluate other measures of antitumor activity of TEV-56278 * Evaluate anti-tumor activity Participants will be treated up to 12 months wi","sourceUrl":"https://clinicaltrials.gov/study/NCT06480552"},{"nctId":"NCT07594028","title":"Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours","sponsor":"Sinocelltech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2026-05-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Advanced Malignant Solid Tumor"],"interventions":["SCTB41+SCTB39-1"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39-1with or without standard therapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07594028"},{"nctId":"NCT04669171","title":"A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma","sponsor":"Enterome","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2021-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2034-05-30","completionType":"ESTIMATED","lastUpdated":"2026-01-30","conditions":["Follicular Lymphoma","Marginal Zone Lymphoma"],"interventions":["EO2463","lenalidomide","rituximab"],"countries":["United States","France","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL","sourceUrl":"https://clinicaltrials.gov/study/NCT04669171"},{"nctId":"NCT04802759","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":316,"enrollmentType":"ESTIMATED","startDate":"2021-06-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"],"interventions":["Giredestrant","Abemaciclib","Ipatasertib","Inavolisib","Ribociclib","Everolimus","Samuraciclib","PH FDC SC","Palbociclib","Atezolizumab"],"countries":["United States","Australia","Israel","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the patient population. Cohort 1 will focus on participants with inoperable, locally advanced or metastatic, estrogen receptor-positive (ER+), HER2-negative breast cancer who had disease progression during or following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i; e.g., palbociclib, ribociclib, abemaciclib) in the first- or second-line setting. Cohort 2 ","sourceUrl":"https://clinicaltrials.gov/study/NCT04802759"},{"nctId":"NCT07295821","title":"Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-30","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Lung Cancer"],"interventions":["Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).","sourceUrl":"https://clinicaltrials.gov/study/NCT07295821"},{"nctId":"NCT07623798","title":"A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":255,"enrollmentType":"ESTIMATED","startDate":"2026-06-05","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["Pomalidomide Capsules","Bortezomib for Injection","Daratumumab Injection (Subcutaneous Injection)","IBI3003"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd)","sourceUrl":"https://clinicaltrials.gov/study/NCT07623798"},{"nctId":"NCT07491497","title":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","sponsor":"TRIANA Biomedicines, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-01-30","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["ALK-positive NSCLC","ALK-Positive Lung Cancer","ALK-positive Non-small Cell Lung Cancer"],"interventions":["TRI-611"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["RNA fusion"],"summary":"The goal of this clinical trial is to learn about the safety and recommended dose of TRI-611 when administered to adults with ALK-positive non-small cell lung cancer (NSCLC). The trial will also evaluate the antitumor activity of TRI-611 in adults with ALK-positive NSCLC. The study will be conducted in two parts. The first part will examine different doses of TRI-611. The second part will look at how well TRI-611 works on ALK-positive NSCLC when administered to three groups of participants that differ based on what type of prior therapy they have received. In this study participants will: * Take TRI-611 on a continued basis, provided it is well-tolerated, for as long as their disease is not ","sourceUrl":"https://clinicaltrials.gov/study/NCT07491497"},{"nctId":"NCT07207070","title":"A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":312,"enrollmentType":"ESTIMATED","startDate":"2025-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Breast Cancer"],"interventions":["JS105","Dalpiciclib","Fulvestrant 50 Mg/mL Intramuscular Solution"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study is a randomised, open-label, multicentre phase III clinical study evaluating the efficacy and safety of JS105 combined with Dalpiciclib and Fulvestrant compared with Dalpiciclib and Fulvestrant in patients with PIK3CA-mutated, HR-positive, HER2-negative recurrent or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07207070"},{"nctId":"NCT07471789","title":"Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).","sponsor":"Gyala Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":33,"enrollmentType":"ESTIMATED","startDate":"2026-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-04","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Acute Myeloblastic Leukaemia","Leukemia, T-Cell"],"interventions":["CART84"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This Phase I/IIa clinical study is testing an experimental treatment called GYA01 (CART84) for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) whose disease has come back after treatment (relapsed) or did not respond to treatment (refractory). GYA01 (CART84) is a type of CAR T-cell therapy. In this approach, a participant's own T cells (a type of immune cell) are collected and changed in a laboratory to help them better recognize and attack leukemia cells. The modified cells GYA01 (CART84) are then given back to the participant through an infusion into a vein. The study is being done to: Find a dose that can be given safely (Phase I) by treating small ","sourceUrl":"https://clinicaltrials.gov/study/NCT07471789"},{"nctId":"NCT07607054","title":"A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-05-26","startDateType":"ESTIMATED","primaryCompletionDate":"2029-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-30","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["EMB-15"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to evaluate safety and tolerability profile of EMB-15, identify the recommended Phase 2 dose(s) (RP2Ds) for EMB-15. Pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and the anti-tumor activity of EMB-15 will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT07607054"},{"nctId":"NCT04729114","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2021-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-05-31","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Prostate Cancer","Metastatic Castration Resistant Prostate Cancer","Metastatic Castration-sensitive Prostate Cancer"],"interventions":["PRL-02 injection","prednisone","dexamethasone","enzalutamide"],"countries":["United States","Puerto Rico"],"northAmerica":true,"chinaSites":false,"siteCount":25,"serviceSignals":["Broad CGP"],"summary":"Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their cancer has come back after previous cancer treatment, or the previous cancer treatment they had didn't work. The main aims of the study are: * to check the safety of PRL-02 depot given with and without another medicine called enzalutamide. * to check if the men can tolerate PRL-02 depot given with or without enzalutamide. * to find a suitable dose of PRL-02 depot. This study will be in 2 parts. In the","sourceUrl":"https://clinicaltrials.gov/study/NCT04729114"},{"nctId":"NCT07647744","title":"To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer","sponsor":"Hrain Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":18,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2034-06","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Renal Cell Carcinoma (RCC)"],"interventions":["Anti-Human CD70 T-Cell Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, open-label, dose-escalating Phase 1 clinical study. It aims to evaluate the safety, tolerability and pharmacokinetic(PK) profiles of the investigational agent, and preliminarily assess its efficacy in subjects with advanced/metastatic renal cell carcinoma, and determine the recommended dose and infusion regimen for Phase 2 trials.","sourceUrl":"https://clinicaltrials.gov/study/NCT07647744"},{"nctId":"NCT04910386","title":"Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers","sponsor":"3D Medicines (Sichuan) Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":126,"enrollmentType":"ESTIMATED","startDate":"2027-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Biliary Tract Neoplasms"],"interventions":["Envafolimab plus Gemcitabine&Cisplatin","Gemcitabine&Cisplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Randomized, Open-Label, Multicenter Phase 2 Study to access the efficacy and safety of Envafolimab in Combination with Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients with Locally Advanced or Metastatic Biliary Tract Cancers","sourceUrl":"https://clinicaltrials.gov/study/NCT04910386"},{"nctId":"NCT07136558","title":"Evaluation of ICP-B794 in Patients With Advanced Solid Tumors","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2025-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-08-22","conditions":["Advanced Solid Tumors"],"interventions":["ICP-B794"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07136558"},{"nctId":"NCT07304154","title":"A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases","sponsor":"Kite, A Gilead Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2026-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Chronic Inflammatory Demyelinating Polyneuropathy","Myasthenia Gravis","Multiple Sclerosis"],"interventions":["KITE-363","Fludarabine","Cyclophosphamide"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.","sourceUrl":"https://clinicaltrials.gov/study/NCT07304154"},{"nctId":"NCT07452224","title":"ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer","sponsor":"iLeukon Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-06-29","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["ILKN421H","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, phase II study to evaluate the safety, tolerability, clinical activity, and pharmacokinetics of ILKN421H in combination with pembrolizumab in participants with locally advanced or metastatic NSCLC. The study consists of 4 cohorts in participants with locally advanced or metastatic NSCLC ( squamous \\[sq\\] or non-squamous \\[non-sq\\]) without functional genomic alterations including EGFR, ALK and Ros-1, who failed systemic PD-1/L1 inhibitor treatment either alone or in combination with standard chemotherapy (post-IO) (Cohort 1 and 2), or without any prior systemic anti-cancer therapy (1L) with PDL-1 TPS ≥1% (Cohort 3 and 4). Participants will be dosed either w","sourceUrl":"https://clinicaltrials.gov/study/NCT07452224"},{"nctId":"NCT07695831","title":"A Phase 1 Trial of GEN1119 in Participants With Solid Tumors","sponsor":"Genmab","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumours"],"interventions":["GEN1119"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to learn about the safety and efficacy of GEN1119 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial will test different doses of GEN1119 to find out if it is safe and to determine what are the best doses to use. The second part will further refine this optimal dose. The third part continues to test the safety and how well GEN1119 works in additional participants with specific cancer types and at doses chosen based on the results of the first 2 parts of the trial. For each participant, the trial will last approximately 18 months but this may vary for each individual. This inclu","sourceUrl":"https://clinicaltrials.gov/study/NCT07695831"},{"nctId":"NCT07219238","title":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)","sponsor":"GE Healthcare","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":175,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Colorectal Cancer","Gastric Cancers","Ovarian Cancers","Pancreatic Ductal Adenocarcinoma"],"interventions":["GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)"],"countries":["United States","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET/CT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the","sourceUrl":"https://clinicaltrials.gov/study/NCT07219238"},{"nctId":"NCT06474455","title":"A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2024-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-05-11","conditions":["Advanced Solid Tumors"],"interventions":["SHR-9839 for Injection","SHR-A1921 for Injection","SHR-A2009 for Injection","Almonertinib Mesilate Tablets","Pemetrexed Disodium for Injection","Carboplatin for injection","Paclitaxel injection","SHR-1316 Injection","SHR-9839 for Injection (sc)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06474455"},{"nctId":"NCT07211958","title":"Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation","sponsor":"Syndax Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":468,"enrollmentType":"ESTIMATED","startDate":"2025-11-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Acute Myeloid Leukemias"],"interventions":["Revumenib","Placebo","Intensive Chemotherapy Regimen"],"countries":["Australia","Austria","Belgium","Brazil","Canada","France","Georgia","Germany","Hungary","Israel","Italy","Malaysia","Romania","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":83,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess if adding revumenib to standard chemotherapy improves outcomes in participants with AML with certain genetic mutations compared to chemotherapy alone. The study will also assess the safety of adding revumenib to chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07211958"},{"nctId":"NCT06486441","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":640,"enrollmentType":"ESTIMATED","startDate":"2024-08-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Endometrial Cancer"],"interventions":["Sacituzumab govitecan-hziy","Doxorubicin","Paclitaxel"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":189,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06486441"},{"nctId":"NCT07562581","title":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Non-small Cell Lung Caner","KRAS-mutated","Metastasis","Previous Treamted"],"interventions":["luvometinib + anlotinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner","sourceUrl":"https://clinicaltrials.gov/study/NCT07562581"},{"nctId":"NCT06161974","title":"Study of Olutasidenib and Temozolomide in HGG","sponsor":"Rigel Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-02-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2035-06","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["High Grade Glioma","Astrocytoma","Astrocytoma, Grade III","Astrocytoma, Grade IV","Diffuse Intrinsic Pontine Glioma","WHO Grade III Glioma","WHO Grade IV Glioma","Metastatic Brain Tumor","Diffuse Midline Glioma, H3 K27M-Mutant","Thalamus Tumor","Spinal Tumor","IDH1 Mutation","IDH1 R132","IDH1 R132C","IDH1 R132H","IDH1 R132S","IDH1 R132G","IDH1 R132L","Oligodendroglioma"],"interventions":["Olutasidenib + TMZ"],"countries":["United States","Australia","Canada","Germany","Netherlands","New Zealand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.","sourceUrl":"https://clinicaltrials.gov/study/NCT06161974"},{"nctId":"NCT07498725","title":"A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of LRK-4189 Alone and in Combination in Patients With Solid Tumors","sponsor":"LARKSPUR BIOSCIENCES, INC.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-06","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Neoplasms"],"interventions":["LRK-4189 escalation","LRK-4189 expansion","LRK-4189 optimization","Chemo"],"countries":["France","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if investigational agent LRK-4189 works to treat solid tumors in adults, with a focus on colorectal cancer. It will also learn about the safety of drug LRK-4189. The main questions it aims to answer are: Is LRK-4189, administered alone or in combination with standard chemotherapy regimens, safe and tolerable in patients with solid tumors? Participants will: * Take investigational agent LRK-4189 alone or in combination with standard chemotherapy regimens every day for up to 3 years. * Visit the clinic once every week for checkups and tests.","sourceUrl":"https://clinicaltrials.gov/study/NCT07498725"},{"nctId":"NCT07730125","title":"Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies","sponsor":"CoRegen, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2026-11","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["HR-positive, HER2-negative Breast Cancer","TNBC - Triple-Negative Breast Cancer","Prostate Cancer"],"interventions":["CRG-150"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"The goal of this Phase 1/2a interventional study is to evaluate the safety and tolerability of CRG-150 in relapsed/refractory HR+HER2- breast cancer, Triple Negative Breast Cancer (TNBC) and prostate cancer. The main questions it aims to answer are: Phase 1 * Incidence of DLTs * Incidence of CRG-150 related AEs and SAEs * Select the Recommended Phase 2 Dose (RP2D), as determined through the dose escalation process for the specified indications Phase 2a * HR+HER2- Breast Cancer and TNBC: Overall Response Rate (ORR) (CR+PR) using FDG PET/CT and RECIST 1.1 by Investigator assessment * Prostate Cancer: ORR per PCWG3-modified RECIST 1.1 by Investigator assessment Participants will be required to ","sourceUrl":"https://clinicaltrials.gov/study/NCT07730125"},{"nctId":"NCT05690945","title":"A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":606,"enrollmentType":"ACTUAL","startDate":"2023-02-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Lung Cancer"],"interventions":["QL1706","Tilesizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy in PD-L1 negative, locally advanced or metastatic Non-small Cell Lung Cancer Patients. The subjects were randomly divided into two groups according to 1:1, with about 304 subjects in the experimental group and the control group.","sourceUrl":"https://clinicaltrials.gov/study/NCT05690945"},{"nctId":"NCT07455617","title":"Study of ABO2102 in KRAS-Mutated Solid Tumors","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":101,"enrollmentType":"ESTIMATED","startDate":"2026-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-02","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Advanced / Metastatic Solid Tumor"],"interventions":["ABO2102 Injection","Sintilimab injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07455617"},{"nctId":"NCT07739758","title":"A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":442,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["SCLC, Extensive Stage"],"interventions":["YL201","Serplulimab","Carboplatin","Etoposide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of YL201 in combination with serplulimab versus standard-of-care carboplatin and etoposide in combination with serplulimab as first-line treatment in patients with extensive-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07739758"},{"nctId":"NCT07361484","title":"Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)","sponsor":"BeyondSpring Pharmaceuticals Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":442,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Non-Small Cell Lung Cancer","Non-squamous Non-Small Cell Lung Cance"],"interventions":["Plinabulin","Docetaxel","Placebo (matching plinabulin placebo)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RNA fusion"],"summary":"This is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study evaluating docetaxel plus plinabulin versus docetaxel plus placebo in participants with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without EGFR, ALK, ROS1, or RET alterations who have experienced disease progression after prior anti-PD-1/PD-L1 immunotherapy and platinum-based chemotherapy. Approximately 442 participants will be randomized 1:1 to receive docetaxel (75 mg/m² IV on Day 1 of each 21-day cycle) in combination with plinabulin (30 mg/m² IV on Days 1 and 8) or matching placebo. Treatment will continue until disease progression, unacceptable toxicity, death, withdrawa","sourceUrl":"https://clinicaltrials.gov/study/NCT07361484"},{"nctId":"NCT07578649","title":"Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-10-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Endometrial Neoplasms","Endometrial Cancer"],"interventions":["PF-08634404","Pembrolizumab","Standard of Care Chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MSI / TMB"],"summary":"This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy. Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. Our bodies have a built-in DNA \"spell-checker,\" called the mismatch repair (MMR) system, that fixes genetic mistakes. In most endometrial cancers, this system works normally, and these cancers are called MMR-proficient (pMMR). However, pMMR tumors are harder for the immune system to recognize and attack. When endometrial cancer has spread beyond the uterus or comes back afte","sourceUrl":"https://clinicaltrials.gov/study/NCT07578649"},{"nctId":"NCT07129993","title":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","sponsor":"Daiichi Sankyo","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2025-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-22","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Urothelial Cancer","Bladder Cancer"],"interventions":["Dato-DXd","Carboplatin","Cisplatin","Gemcitabine"],"countries":["United States","Austria","China","France","Germany","Italy","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":100,"serviceSignals":["Broad CGP"],"summary":"This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A, Phase 2. During part A, Phase 2, preliminary efficacy and safety will be assessed, and the recommended Phase 3 dose (RP3D) will be identified when the data allow sufficient assessment of activity, safety, and tolerability. The Phase 3 part will start contingent upon the assessment in the Phase 2 part, taking into consideration the totality of information.","sourceUrl":"https://clinicaltrials.gov/study/NCT07129993"},{"nctId":"NCT07526792","title":"SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":406,"enrollmentType":"ESTIMATED","startDate":"2026-06-20","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Urothelial Carcinoma"],"interventions":["SYS6002","Investigator's Choice of Chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, controlled, open-label, multicenter phase III clinical trial, which aims to evaluate the efficacy,safety PK characteristics, and immunogenicity of SYS6002 compared with chemotherapy in participants with locally advanced or metastatic urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will commence only after formal approval is obtained from the relevant Ethics Committee).","sourceUrl":"https://clinicaltrials.gov/study/NCT07526792"},{"nctId":"NCT06564038","title":"A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":408,"enrollmentType":"ESTIMATED","startDate":"2025-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-11","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Chronic Lymphocytic Leukaemia","Small Lymphocytic Lymphoma","Mantle-cell Lymphoma","Large B-cell Lymphoma","B-cell Non-Hodgkin Lymphoma"],"interventions":["Surovatamig","Prednisone (or equivalent)","Rituximab","Cyclophosphamide","Vincristine","Doxorubicin","Acalabrutinib"],"countries":["United States","Australia","China","Czechia","Denmark","France","Germany","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":64,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT06564038"},{"nctId":"NCT07468071","title":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-06-08","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-17","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer","Advanced Solid Tumors Harboring the KRAS G12C Mutation"],"interventions":["Opnurasib","TNO155","trametinib","cetuximab","tislelizumab"],"countries":["Belgium","Canada","China","Japan","Malaysia","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":7,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07468071"},{"nctId":"NCT07748208","title":"A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Breast Cancer","Diabetes Type II"],"interventions":["Inavolisib","Fulvestrant","Palbociclib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.","sourceUrl":"https://clinicaltrials.gov/study/NCT07748208"},{"nctId":"NCT06914128","title":"A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors","sponsor":"Bayer","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-17","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["MTAP-deleted Solid Tumors"],"interventions":["BAY 3713372"],"countries":["United States","Australia","Belgium","China","Czechia","Denmark","Italy","Japan","Netherlands","Singapore","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":60,"serviceSignals":["Broad CGP"],"summary":"The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors. For this, the researchers will study and analyze: * the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity. * the number of participants who experience dose-limitin","sourceUrl":"https://clinicaltrials.gov/study/NCT06914128"},{"nctId":"NCT07276399","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-12-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-18","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Squamous Cell Carcinoma of Head and Neck"],"interventions":["Amivantamab","Pembrolizumab","Carboplatin","5-Flurouracil","Cisplatin"],"countries":["United States","Australia","Austria","Belgium","Brazil","China","Czechia","France","Germany","Hungary","India","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":198,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT07276399"},{"nctId":"NCT06852222","title":"A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2025-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-22","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-15","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Leukemia, Myeloid, Acute"],"interventions":["Bleximenib","Venetoclax (VEN)","Azacitidine (AZA)","Placebo"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","Poland","Portugal","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":257,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.","sourceUrl":"https://clinicaltrials.gov/study/NCT06852222"},{"nctId":"NCT07658352","title":"A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","sponsor":"Shanghai Helioson Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":114,"enrollmentType":"ESTIMATED","startDate":"2026-06-26","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-26","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["B-Cell Non-Hodgkin Lymphoma"],"interventions":["HP-002"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma This study consists of two phases: a dose-exploration phase and a dose-expansion phase. The safety and tolerability of HP-002 will be evaluated in Phase 1 study, as well as the maximum tolerated dose (MTD) and the recommended dose level for Phase 2 study will be determined. The efficacy of HP-002 will be evaluated in Phase 2 study.","sourceUrl":"https://clinicaltrials.gov/study/NCT07658352"},{"nctId":"NCT06992609","title":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":68,"enrollmentType":"ACTUAL","startDate":"2025-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Small Cell Lung Carcinoma"],"interventions":["Durvalumab"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"Lung cancer is a highly prevalent disease worldwide in women and men. In 2022, lung cancer stood as the most frequently diagnosed cancer with approximately 2.48 million new cases on a global scale, followed by cancers of the female breast (11.6%), colorectum (9.6%), prostate (7.3%), and stomach (4.9%). Lung cancer is the leading cause of cancer death worldwide according to data provided by the International Agency for Research on Cancer. In 2022 they estimated a 1.8 million deaths across the world. Specifically in Spain, from 1980 to 2022, lung cancer led to 745,182 deaths. Histologically, lung cancer (LC) can be classified into two major subtypes: non-small cell lung cancer (NSCLC) and smal","sourceUrl":"https://clinicaltrials.gov/study/NCT06992609"},{"nctId":"NCT07538804","title":"A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer","sponsor":"Avistone Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":294,"enrollmentType":"ESTIMATED","startDate":"2026-07-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Non-Small Cell Lung Cancer"],"interventions":["ANS02"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07538804"},{"nctId":"NCT06943755","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","sponsor":"Exelixis","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2025-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Pancreatic Neuroendocrine Tumor (pNET)","Extra-Pancreatic Neuroendocrine Tumor (epNET)"],"interventions":["Zanzalintinib","Everolimus"],"countries":["United States","Australia","Austria","Belgium","Canada","China","France","Germany","Italy","Netherlands","Poland","Puerto Rico","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":120,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06943755"},{"nctId":"NCT06911333","title":"AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors","sponsor":"Avelos Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2025-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-20","completionType":"ESTIMATED","lastUpdated":"2025-04-04","conditions":["Solid Tumor, Adult","Tumor, Solid","Solid Tumor","Solid Tumor, Unspecified, Adult","Solid Tumor Cancer","Solid Tumors Refractory to Standard Therapy","Solid Tumor in Advanced Stage"],"interventions":["AD1208"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or metastatic solid tumors. The main questions it aims to answer are: * Which dosage of AD1208 is safe and tolerable for participants? * What medical problems do participants have when taking AD1208? Participants will: * Take drug AD1208 every day up to 1 cycle at the least. * Visit the site once every 1 weeks for checkups and tests during cycle 1 and every 3 weeks from cycle 2 onwards. * Keep a diary of any adverse events and administrated drug","sourceUrl":"https://clinicaltrials.gov/study/NCT06911333"},{"nctId":"NCT07615413","title":"Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":636,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["KRAS G12C Mutation Advanced Solid Tumor"],"interventions":["HS-10541"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in participants with KRAS G12C mutation advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07615413"},{"nctId":"NCT06060613","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","sponsor":"Obsidian Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":208,"enrollmentType":"ESTIMATED","startDate":"2023-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Tumor Skin","Metastatic Melanoma","Melanoma","Lung Cancer","Metastatic Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer"],"interventions":["OBX-115"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06060613"},{"nctId":"NCT06720987","title":"A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["KRAS G12C Mutation","KRAS G12S Mutation","Solid Tumor Malignancies","CRC (Colorectal Cancer)"],"interventions":["KQB365","Cetuximab","KQB198"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RAS genotyping"],"summary":"The goal of this clinical trial is to learn if KQB365 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB365. The main questions it aims to answer are: * What is the safe dose of KQB365 by itself, in combination with cetuximab, or in combination with KQB198? * Does KQB365 alone, in combination with cetuximab, or in combination with KQB198 decrease the size of the tumor? * What happens to KQB365 in the body? Participants will: * Receive KQB365 infusion weekly alone, in combination with cetuximab, or in combination with oral KQB198. * Visit the clinic about 9 times in the first 6 weeks, and then once every week after that.","sourceUrl":"https://clinicaltrials.gov/study/NCT06720987"},{"nctId":"NCT06953323","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":86,"enrollmentType":"ESTIMATED","startDate":"2025-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-03-27","conditions":["Advanced Solid Tumor"],"interventions":["WJB001 Capsules+Paclitaxel/Paclitaxel-albumin","WJB001 Capsules+carboplatin/Nedaplatin","WJB001 Capsules+Paclitaxel+carboplatin","WJB001 Capsules+Niraparib","WJB001 Capsules+Bevacizumab","WJB001 Capsules+JS207/JS001","WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and efficacy extension (Phase II). The preliminary plan includes seven combination therapy regimens, namely Arm A: WJB001+taxanes (A1: WJB001+paclitaxel, A2: WJB001+albumin paclitaxel); Arm B: WJB001+platinum (B1: WJB001+carboplatin, B2: WJB001+nedaplatin); Arm C: WJB001+paclitaxel+carboplatin; Arm D: WJB001+PARP inhibitor; Arm E: WJB001+VEGF inhibitor; Arm F:WJB001+JS207/JS001（F1：WJB001+JS207，F2：WJB001+JS001）；Arm G：WJB001+JS207/JS001+paclitaxel+carboplatin（G1: WJB001+J","sourceUrl":"https://clinicaltrials.gov/study/NCT06953323"},{"nctId":"NCT07315750","title":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","sponsor":"RemeGen Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":555,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Gastric Carcinoma"],"interventions":["Disitamab Vedotin","Tislelizumab","CAPOX (oxaliplatin/capecitabine)","Trastuzumab","Pembrolizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07315750"},{"nctId":"NCT07287995","title":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":428,"enrollmentType":"ESTIMATED","startDate":"2026-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Locally Advanced or Metastatic Malignant Solid Tumors"],"interventions":["ASP2998","Pembrolizumab","Enfortumab Vedotin","Carboplatin"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being developed to attach to TROP2 and then attack the tumor cells in people with solid tumors. ASP2998 will either be given by itself, or given together with one or more of standard cancer treatments pembrolizumab, carboplatin, and enfortumab vedotin. This is an early development study to collect information about ASP2998 in people with solid tumors. In this study ASP2998 will be given to humans for the first time. Early development studies are mostly about safety, but also to find the most suitable dose. Other aims are to check if ASP2998 ","sourceUrl":"https://clinicaltrials.gov/study/NCT07287995"},{"nctId":"NCT07011056","title":"A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2025-09-19","conditions":["Recurrent and Refractory Diffuse Large B-cell Lymphoma"],"interventions":["Purinostat Mesylate for Injection","Selinexor Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The main objective of this study is to evaluate the differences in objective response rate and overall survival between the Purinostat mesylate for injection and selinexor, as assessed by blinded independent central review (BICR), in patients with relapsed or refractory diffuse large B-cell lymphoma. .The participants in the experimental group will receive treatment with Purinostat mesylate for injection. The dosage is 11.2 mg/m2. Each administration cycle consists of intravenous administration on days 1, 4, 8, and 11. A 21-day period constitutes one treatment cycle, and the total treatment cycle lasts for 6 cycles. .Participants in the control group will receive selinexor treatment. The rec","sourceUrl":"https://clinicaltrials.gov/study/NCT07011056"},{"nctId":"NCT07719920","title":"A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors","sponsor":"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":99,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Solid Tumors"],"interventions":["HW221043 Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HW221043 tablets in participants with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib).","sourceUrl":"https://clinicaltrials.gov/study/NCT07719920"},{"nctId":"NCT04404660","title":"A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)","sponsor":"Autolus Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":153,"enrollmentType":"ACTUAL","startDate":"2020-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia"],"interventions":["AUTO1"],"countries":["United States","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 1b/2 study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (ALL).","sourceUrl":"https://clinicaltrials.gov/study/NCT04404660"},{"nctId":"NCT07605728","title":"Probiotics for Abemaciclib-Induced Abdominal Discomfort.","sponsor":"Leeuwenhoek Laboratories Co. Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Breast Cancer","Chemotherapy-induced Diarrhea"],"interventions":["Synbiotic supplement followed by Placebo","Placebo followed by Probiotics"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate whether the addition of probiotics can help reduce abdominal discomfort (such as diarrhea) in breast cancer patients receiving Abemaciclib treatment. Abemaciclib is an effective targeted therapy but often causes gastrointestinal side effects. While Loperamide is the standard treatment for diarrhea, this study explores if probiotics can provide additional relief and improve metabolic health.Participants will be randomly assigned to receive either probiotics or a placebo alongside their standard care. The study will monitor the frequency of abdominal symptoms and analyze blood samples to observe changes in metabolic factors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07605728"},{"nctId":"NCT07665970","title":"SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors","sponsor":"Sinocelltech Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":112,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Advanced Malignant Solid Tumors"],"interventions":["SCTB41+SCTB39G"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced malignant solid tumors. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.","sourceUrl":"https://clinicaltrials.gov/study/NCT07665970"},{"nctId":"NCT05546866","title":"Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":51,"enrollmentType":"ACTUAL","startDate":"2023-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-small Cell Lung Cancer"],"interventions":["Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05546866"},{"nctId":"NCT07609862","title":"A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2026-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Mantle Cell Lymphoma (MCL)","Diffuse Large B-Cell Lymphoma (DLBCL)","Follicular Lymphoma ( FL)","Waldenström Macroglobulinemia (WM)","Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)"],"interventions":["Lacutoclax+Rocbrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit. This is a multi-center, open-label, single-arm Phase Ib/II clinical study. The purpose of this clinical trial is to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of Rocbrutinib, a fourth-generation Bruton tyrosine kinase inhibitor (BTKi), in combination with the BCL-2 inhibitor Lacutoclax in patients with mature B-cell malignancies. The Phase Ib will use a classic 3+3 dose-escalation design to evaluate dose-limiting toxicities (DLTs), determine the maximum tolerated dose (MTD), and ","sourceUrl":"https://clinicaltrials.gov/study/NCT07609862"},{"nctId":"NCT07174583","title":"A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer","sponsor":"IDEAYA Biosciences","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":262,"enrollmentType":"ESTIMATED","startDate":"2025-10-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Small-cell Lung Cancer","Neuroendocrine Carcinomas","Solid Tumor Show to Express DLL3"],"interventions":["IDE849","durvalumab","IDE161","Carboplatin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["ADC biomarker"],"summary":"This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07174583"},{"nctId":"NCT07003074","title":"A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":642,"enrollmentType":"ESTIMATED","startDate":"2025-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2025-06-25","conditions":["Breast Cancer"],"interventions":["TQB2102 for Injection","Docetaxel combined + Trastuzumab +Pertuzumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":25,"serviceSignals":["HER2 profiling"],"summary":"This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.","sourceUrl":"https://clinicaltrials.gov/study/NCT07003074"},{"nctId":"NCT07317505","title":"A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors","sponsor":"Conjupro Biotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2025-12-02","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-01-21","conditions":["Cancer","Cancer (Solid Tumors)"],"interventions":["JMT108"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of JMT108 at increasing doses and determine the dose and schedule to be used in the second part of the study (Phase 1a) * To assess effectiveness of JMT108 in participants with locally advanced or metastatic tumors (Phase 1b) * To evaluate how quickly JMT108 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To explore the pharmacod","sourceUrl":"https://clinicaltrials.gov/study/NCT07317505"},{"nctId":"NCT07702032","title":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":960,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2031-09","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Left-sided Colorectal Cancer"],"interventions":["Petosemtamab","Cetuximab","FOLFIRI","mFOLFOX6"],"countries":["Puerto Rico"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as t","sourceUrl":"https://clinicaltrials.gov/study/NCT07702032"},{"nctId":"NCT04933422","title":"CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)","sponsor":"Crimson Biopharm Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2027-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2024-08-21","conditions":["Glioblastoma"],"interventions":["CM93"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human study of CM93, an oral investigational drug, in adults with Epidermal Growth Factor Receptor-modified glioblastoma. The study is designed in three parts consisting of a dose-escalation phase, a dose-expansion phase and a window-of-opportunity surgical trial. The trial objectives are to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical effects of CM93 in this patient population.","sourceUrl":"https://clinicaltrials.gov/study/NCT04933422"},{"nctId":"NCT07026279","title":"A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer","sponsor":"Amplia Therapeutics Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Pancreatic Cancer Metastatic"],"interventions":["narmafotinib ascending doses","narmafotinib dose comparison"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study is testing narmafotinib, a type of drug called a focal adhesion kinase (FAK) inhibitor, when it is given in combination with 4 chemotherapy drugs in a regimen called FOLFIRINOX, to patients who have pancreatic cancer which has metastasised (spread). The study is being run in 2 parts. Part A will test increasing dose levels of narmafotinib in at least 3 people per dose at up to 4 dose levels to assess safety. Part B will test 2 of the dose levels from Part A in 20 people per dose, to select the best dose to take forward into future studies. Participants will take narmafotinib as oral capsules every day. They will also receive mFOLFIRINOX chemotherapy on Day 1 and and Day 15 of 28-d","sourceUrl":"https://clinicaltrials.gov/study/NCT07026279"},{"nctId":"NCT04349436","title":"Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies","sponsor":"Replimune, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":69,"enrollmentType":"ACTUAL","startDate":"2020-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Merkel Cell Carcinoma","Basal Cell Carcinoma","Locally Advanced Cutaneous Squamous Cell Carcinoma","Cancer"],"interventions":["RP1, intra-tumoral injection, oncolytic virus"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety and efficacy of RP1 (administered into the tumor) in 90 patients who have received an organ transplant in the past and currently have skin cancer. The skin cancer is either locally advanced (large tumors in the skin, muscles or nerves) or metastatic (spread to other parts of the body). This study will consist of a 28-day Screening Period, a Treatment Period, and a Follow-up Period. During the Treatment Period, patients will be dosed with RP1 every two weeks for up to 2 years (104 weeks). Tumor measurements will be done approximately every 8 weeks (and additionally if needed) until progressive disease, start of subsequent anticancer therapy, o","sourceUrl":"https://clinicaltrials.gov/study/NCT04349436"},{"nctId":"NCT07383506","title":"A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors","sponsor":"Cogent Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["PIK3CA Mutations","Advanced Solid Tumors, Adult","Endometrial Cancer","HR Positive/HER-2 Negative Breast Cancer","HER2-low Breast Cancer"],"interventions":["CGT6297"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations","sourceUrl":"https://clinicaltrials.gov/study/NCT07383506"},{"nctId":"NCT07714395","title":"Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors","sponsor":"Actuate Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Advanced Malignant Solid Tumor"],"interventions":["Elraglusib Oral Tablets"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is being done to test the safety of elraglusib when taken once a day and to assess: * How the body processes the drug (pharmacokinetics) * Assess potential effects of the drug on heart rhythm * Find the highest daily dose that can be given without causing side effects","sourceUrl":"https://clinicaltrials.gov/study/NCT07714395"},{"nctId":"NCT07462377","title":"A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC","sponsor":"EpiBiologics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2026-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Epidermal Growth Factor","Epidermal Growth Factor Receptor","Epidermal Growth Factor Receptor Gene Mutation","Non Small Cell","Non Small Cell Lung","Non Small Cell Lung Cancer","Head and Neck","Head and Neck Cancer","Head and Neck Cancers","Head and Neck Squamous Cell Cancer","Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma HNSCC","NSCLC (Non-small Cell Lung Cancer)","HNSCC","EGFR"],"interventions":["EPI-326"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"A phase 1 study to determine the safety, tolerability, PK, PD, and preliminary anti-tumor activity of ascending doses of EPI-326 administered to patients with locally advanced or metastatic HNSCC and to patients with any documented EGFR-mutant locally advanced or metastatic NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07462377"},{"nctId":"NCT06816108","title":"A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":35,"enrollmentType":"ACTUAL","startDate":"2025-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumor","NSCLC"],"interventions":["ONO-7428"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06816108"},{"nctId":"NCT05862272","title":"A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis","sponsor":"Sumitomo Pharma Switzerland GmbH","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2023-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2025-08-06","conditions":["Uterine Fibroids","Endometriosis"],"interventions":["Relugolix Combination Tablet"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":120,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT05862272"},{"nctId":"NCT05618028","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ACTUAL","startDate":"2023-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-07","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Diffuse Large B-Cell Lymphoma","Chronic Lymphocytic Leukemia","B Cell Malignancies","Non-Hodgkin's Lymphoma"],"interventions":["ABBV-525"],"countries":["United States","Australia","Belgium","France","Germany","Israel","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult participants will be enrolled in the study across sites worldwide. In part 1 (dose escalation), participants will receive escalating oral doses of ABBV-525. In part 2 (dose optimization), participants ","sourceUrl":"https://clinicaltrials.gov/study/NCT05618028"},{"nctId":"NCT07023315","title":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":760,"enrollmentType":"ESTIMATED","startDate":"2025-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-07","primaryCompletionType":"ESTIMATED","completionDate":"2031-07","completionType":"ESTIMATED","lastUpdated":"2026-02-11","conditions":["Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma"],"interventions":["Cadonilimab","SOX chemotherapy","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07023315"},{"nctId":"NCT07030712","title":"A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2025-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-01","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Metastatic Neoplasm"],"interventions":["MK-8294","CD8 PET Tracer"],"countries":["United States","Israel","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"MK-8294, the study medicine, is a type of targeted therapy designed to treat certain solid tumors. The main goals of this study are to learn about the safety of MK-8294 and if people can tolerate it and find the highest dose level of MK-8294 that people can tolerate.","sourceUrl":"https://clinicaltrials.gov/study/NCT07030712"},{"nctId":"NCT06717347","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1046,"enrollmentType":"ESTIMATED","startDate":"2025-01-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-02","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-29","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["Zilovertamab vedotin","Rituximab","Cyclophosphamide","Doxorubicin","Rituximab Biosimilar","Prednisone","Prednisolone","Vincristine","Rescue medication","Methylprednisolone"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Denmark","France","Greece","Guatemala","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Peru","Poland","Portugal","Puerto Rico","Romania","Singapore","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":268,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT06717347"},{"nctId":"NCT07221474","title":"A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-06","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Squamous Non-small Cell Lung Cancer"],"interventions":["Intismeran Autogene","Pembrolizumab","Carboplatin","Paclitaxel","Nab-paclitaxel","Placebo"],"countries":["United States","Argentina","Australia","Chile","France","Italy","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Broad CGP"],"summary":"Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatm","sourceUrl":"https://clinicaltrials.gov/study/NCT07221474"},{"nctId":"NCT07602855","title":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":184,"enrollmentType":"ESTIMATED","startDate":"2026-09-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-04","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Solid Tumors"],"interventions":["Ris-Rez","Ivonescimab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?","sourceUrl":"https://clinicaltrials.gov/study/NCT07602855"},{"nctId":"NCT07700160","title":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","sponsor":"VelaVigo Bio Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2026-07-13","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-17","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Advanced Solid Tumors"],"interventions":["VBC108"],"countries":["United States","Australia","China"],"northAmerica":true,"chinaSites":true,"siteCount":12,"serviceSignals":["ADC biomarker"],"summary":"This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC108.","sourceUrl":"https://clinicaltrials.gov/study/NCT07700160"},{"nctId":"NCT07426757","title":"An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-10","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Malignancies","Advanced Cancer"],"interventions":["PF-07994525","Midazolam"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.","sourceUrl":"https://clinicaltrials.gov/study/NCT07426757"},{"nctId":"NCT04606446","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2020-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-13","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-10","completionType":"ESTIMATED","lastUpdated":"2026-04-16","conditions":["Locally Advanced or Metastatic ER+ HER2- Breast Cancer","Locally Advanced or Metastatic Castration-resistant Prostate Cancer","Locally Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["PF-07248144","Fulvestrant","Letrozole","Palbociclib","PF-07220060","PF-07850327, ARV-471, vepdegestrant"],"countries":["United States","Australia","China","Japan","South Korea"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["HER2 profiling"],"summary":"This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents","sourceUrl":"https://clinicaltrials.gov/study/NCT04606446"},{"nctId":"NCT07670312","title":"Evaluation of XYA02 in Patients With Advanced Solid Tumors","sponsor":"XYone Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-15","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors","Non-Small Cell Lung Cancer","Ovarian Cancer","GEJ Adenocarcinoma","Colorectal Cancer","Pancreatic Adenocarcinoma"],"interventions":["XYA02"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07670312"},{"nctId":"NCT07684599","title":"A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":610,"enrollmentType":"ESTIMATED","startDate":"2026-09-03","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07-23","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-18","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Neoplasms, Endometrial"],"interventions":["GSK5733584","Dostarlimab","Pembrolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MSI / TMB","ADC biomarker"],"summary":"The purpose of this study is to see how well GSK5733584 in combination with standard treatment of choice works as maintenance therapy in participants with advanced or recurrent endometrial cancer (EC) compared to current standard of care. The study will also assess whether drug combination is safe and tolerated well by participants compared to the usual care and will help us better understand its impact on Health-Related Quality of Life of participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07684599"},{"nctId":"NCT07419295","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":590,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-23","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Bladder Cancer"],"interventions":["Sacituzumab tirumotecan","Vinflunine","Docetaxel","Paclitaxel","Rescue medications for sacituzumab tirumotecan","Rescue medications for chemotherapy"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Greece","Israel","Italy","Japan","Netherlands","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":79,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07419295"},{"nctId":"NCT07535112","title":"A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2026-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-09","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Advanced/Metastatic Colorectal Adenocarcinoma"],"interventions":["BAY 3771249","Cetuximab"],"countries":["United States","Australia","Belgium","Denmark","Finland","Italy","Netherlands","Singapore","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["RAS genotyping"],"summary":"Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS. Colorectal cancer (CRC) is a common type of cancer that affects the large bowel (colon) or the rectum (the section at the end of the bowel). When CRC spreads to other parts of the body, it is called advanced or metastatic CRC. Some people with CRC have the G12D mutation in the KRAS protein. This mutation is linked to a poorer outlook and fewer treatment options. Currently, there are no approved treatments that specifically target this mutation. KRAS is a protein that helps control how cells grow and divide. Whe","sourceUrl":"https://clinicaltrials.gov/study/NCT07535112"},{"nctId":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":54,"enrollmentType":"ACTUAL","startDate":"2024-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-28","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Breast Neoplasms","Gastroesophageal Junction Adenocarcinoma","HER2 Low Breast Neoplasms","HER2 Positive Breast Neoplasms","Stomach Neoplasms","Triple Negative Breast Neoplasms","Metastatic Breast Cancer","Metastatic Gastric Cancer","Advanced Breast Cancer","Advanced Gastric Cancer"],"interventions":["disitamab vedotin","tucatinib"],"countries":["United States","Australia","Canada","Germany","Italy","Japan","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":135,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are few treatment options for patients with advanced or metastatic solid tumors that express HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). Disitamab vedotin is a type of","sourceUrl":"https://clinicaltrials.gov/study/NCT06157892"},{"nctId":"NCT06097364","title":"A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":733,"enrollmentType":"ESTIMATED","startDate":"2023-11-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-29","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-29","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Follicular Lymphoma (FL)"],"interventions":["Odronextamab","Rituximab","Cyclophosphamide","Doxorubicin","Vincristine","Prednisone/Prenisolone"],"countries":["United States","Australia","Austria","Belgium","Brazil","Chile","Czechia","France","Germany","Israel","Italy","Poland","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":145,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL. Participants with follicular lymphoma that has come back after treatment (called \"relapsed\") or did not respond to treatment (called \"refractory\") are eligible to take part only in Part 1A of the study. This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled). The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the d","sourceUrl":"https://clinicaltrials.gov/study/NCT06097364"},{"nctId":"NCT07639879","title":"TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma","sponsor":"Tarapeutics Science Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-30","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["PTCL","NK T-Cell Lymphoma"],"interventions":["TR115","Investigator's Choice"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a randomized, open-label, multicenter Phase III study evaluating the efficacy and safety of TR115, an EZH2 inhibitor, versus investigator's choice (chidamide, golidocitinib, mitoxantrone liposome, or gemcitabine) in patients with relapsed and/or refractory peripheral T/NK-cell lymphoma. Approximately 180 patients will be randomized in a 1:1 ratio. The primary endpoint is progression-free survival (PFS) assessed by an Independent Review Committee (IRC). The key secondary endpoint is overall survival (OS). The study is being conducted at approximately 40 to 60 centers across China.","sourceUrl":"https://clinicaltrials.gov/study/NCT07639879"},{"nctId":"NCT06764316","title":"A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer","sponsor":"Bayer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":148,"enrollmentType":"ESTIMATED","startDate":"2025-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Hepatocellular Carcinoma"],"interventions":["BAY 3547926","BAY 3547922","BAY 3713391","BAY 3713389"],"countries":["United States","Belgium","Canada","China","Finland","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug. The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the firs","sourceUrl":"https://clinicaltrials.gov/study/NCT06764316"},{"nctId":"NCT02960022","title":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2016-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Prostate Cancer"],"interventions":["enzalutamide","abiraterone acetate","prednisone","Leuprolide acetate"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Georgia","Germany","Hong Kong","Israel","Italy","Japan","Malaysia","Moldova","Netherlands","New Zealand","Norway","Poland","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":241,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.","sourceUrl":"https://clinicaltrials.gov/study/NCT02960022"},{"nctId":"NCT05877599","title":"A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","sponsor":"AstraZeneca","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2023-07-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non-small Cell Lung Cancer","Head and Neck Squamous Cell Carcinoma","Colorectal Carcinoma","Pancreatic Adenocarcinoma","Breast Cancer","Other Solid Tumors","Ovarian Cancer","Myeloid Neoplasms (AML/MDS)"],"interventions":["NT-175"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HLA / TCR"],"summary":"Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT05877599"},{"nctId":"NCT07157033","title":"A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.","sponsor":"Xerient Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-01-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-07-31","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["Locally Advanced Pancreatic Adenocarcinoma","Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Ductal Adenocarcinoma"],"interventions":["XER-001"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07157033"},{"nctId":"NCT07221253","title":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1100,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Biliary Tract Cancer"],"interventions":["Rilvegostomig","Durvalumab","Gemcitabine/Cisplatin"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","France","Germany","India","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":174,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07221253"},{"nctId":"NCT07238075","title":"ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers","sponsor":"Adcytherix SAS","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2026-02-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Advanced Malignancy","Advanced Solid Cancers","Metastatic Solid Tumors"],"interventions":["ADCX-020"],"countries":["Australia","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this first-in-human study is to explore the safety, pharmacokinetics and effects of the study drug ADCX-020 in patients with advanced and metastatic solid tumors. ADCX-020 is an investigational anticancer therapy called antibody drug conjugate. This study is set up in multiple parts. In the first part of the study, participants receive increasing doses of ADCX-020. Then 2 or more doses will be assessed to identify the optimal dose. This optimal dose is subsequently evaluated for effect on different cancer types.","sourceUrl":"https://clinicaltrials.gov/study/NCT07238075"},{"nctId":"NCT07488676","title":"A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma","Pancreatic Adenocarcinoma"],"interventions":["ASP546C"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["ADC biomarker"],"summary":"This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP546C will be given once in 3-week cycles. It will be given slowly through a tube into a vein. This is called an infusion. In Part 1, people with gastric cancer or GEJ cancer can take part. They will receive an infusion of either a higher dose or a lower dose of ASP546C. In Part 2, people with pancreatic cancer or who have one of the other solid tumors can take part. Part 2 doesn't include people wit","sourceUrl":"https://clinicaltrials.gov/study/NCT07488676"},{"nctId":"NCT07130383","title":"A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2025-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Advanced Breast Cancer","Advanced Malignant Solid Tumor"],"interventions":["MHB036C for Injection","MHB039A for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter Phase II study of MHB036C combined with MHB039A in patients with advanced Breast Cancer or other advanced malignant solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MHB036C and MHB039A combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07130383"},{"nctId":"NCT07126665","title":"A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2025-09-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Advanced Malignant Solid Tumor"],"interventions":["MHB088C for Injection","MHB039A for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I/II study of MHB088C combined with MHB039A in patients with advanced malignant solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB088C and MHB039A combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07126665"},{"nctId":"NCT06788756","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","sponsor":"Moleculin Biotech, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":312,"enrollmentType":"ESTIMATED","startDate":"2025-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Acute Myeloid Leukaemia (AML)"],"interventions":["Placebo in combination with Cytarabine Injection","Liposomal Annamycin Injection in combination with Cytarabine Injection","Liposomal Annamycin for Injection in combination with Cytarabine Injection."],"countries":["United States","Czechia","Georgia","Italy","Lithuania","Poland","Romania","Spain","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":28,"serviceSignals":["Hematology NGS"],"summary":"This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.","sourceUrl":"https://clinicaltrials.gov/study/NCT06788756"},{"nctId":"NCT07697443","title":"Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":306,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Breast Cancer"],"interventions":["TQB3126"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The trial comprises Phase I dose escalation/expansion and Phase II combination therapy. Using a multicenter, open-label, non-randomized design, breast cancer patients will receive TQB3126 to assess its safety, tolerability, pharmacokinetics and preliminary efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07697443"},{"nctId":"NCT06946225","title":"ACTengine® IMA203 Combined With mRNA-4203","sponsor":"Immatics US, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-07-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-01-08","conditions":["Cutaneous Melanoma","Synovial Sarcoma"],"interventions":["IMA203","mRNA-4203"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06946225"},{"nctId":"NCT05645107","title":"A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma","sponsor":"Grifols Therapeutics LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":386,"enrollmentType":"ESTIMATED","startDate":"2022-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Hypogammaglobulinemia","Bacterial Infections","B-cell Chronic Lymphocytic Leukemia","Multiple Myleoma","Non-Hodgkin Lymphoma"],"interventions":["Xembify","Placebo"],"countries":["United States","Bosnia and Herzegovina","Bulgaria","Croatia","Hungary","Poland","Romania","Serbia"],"northAmerica":true,"chinaSites":false,"siteCount":62,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in B-cell CLL, MM, and NHL participants with hypogammaglobulinemia (HGG) in comparison to the Placebo plus SMT group.","sourceUrl":"https://clinicaltrials.gov/study/NCT05645107"},{"nctId":"NCT07166094","title":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":660,"enrollmentType":"ESTIMATED","startDate":"2025-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Endometrial Cancer","Recurrent or Progressive Endometrial Cancer"],"interventions":["Rina-S","IC"],"countries":["United States","Australia","Belgium","Canada","Denmark","Finland","France","Germany","Greece","Israel","Italy","Japan","Lithuania","Norway","Poland","Puerto Rico","Singapore","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":147,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal (50:50) chance of getting either Rina-S or a chemotherapy agent as treatment in this study. The study duration will be approximately 3 years. The treatment duration will be different for every participant, but an average of 4 to 6 months is expected. All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT07166094"},{"nctId":"NCT06960395","title":"Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Vir Biotechnology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Solid Tumor Malignancies","EGFR Positive Solid Tumors","EGFR"],"interventions":["VIR-5525","Pembrolizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR. The study will be conducted in the following 4 parts: * Part 1: VIR-5525 monotherapy dose escalation * Part 2: VIR-5525 monotherapy dose expansion * Part 3: VIR-5525 plus pembrolizumab dose escalation * Part 4: VIR-5525 plus pembrolizumab dose expansion","sourceUrl":"https://clinicaltrials.gov/study/NCT06960395"},{"nctId":"NCT07583771","title":"A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Pancreatic Adenocarcinoma","Non Small Cell Lung Cancer","Advanced Solid Tumors","Lymphoma","Diffuse Large B-Cell Lymphoma (DLBCL)"],"interventions":["CS08399"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion. The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of CS08399 in participants with MTAP-deleted solid tumors and Lymphoma, and to recommended Phase 2 dose(s) (RP2D) of CS08399 in appropriate tumor(s).","sourceUrl":"https://clinicaltrials.gov/study/NCT07583771"},{"nctId":"NCT06827236","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2025-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Locally Advanced Breast Cancer","Unresectable Breast Carcinoma","Metastatic Breast Cancer"],"interventions":["BNT323","BNT327"],"countries":["United States","Australia","Canada","China","France","Georgia","Italy","Moldova","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":68,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \\[IHC\\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06827236"},{"nctId":"NCT06517888","title":"Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma","sponsor":"Akouos, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-01-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-04-06","conditions":["Vestibular Schwannoma"],"interventions":["AAVAnc80-antiVEGF via Akouos Delivery Device"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.","sourceUrl":"https://clinicaltrials.gov/study/NCT06517888"},{"nctId":"NCT06492616","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","sponsor":"Stemline Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":4220,"enrollmentType":"ESTIMATED","startDate":"2024-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2032-10","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Breast Cancer"],"interventions":["Elacestrant","Anastrozole","Letrozole","Exemestane","Tamoxifen"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Finland","France","Georgia","Germany","Hong Kong","Hungary","Italy","Malaysia","Netherlands","Poland","Portugal","Romania","Singapore","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":555,"serviceSignals":["HER2 profiling"],"summary":"The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.","sourceUrl":"https://clinicaltrials.gov/study/NCT06492616"},{"nctId":"NCT05650632","title":"A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2023-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-08","primaryCompletionType":"ESTIMATED","completionDate":"2029-08","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Multiple Myeloma"],"interventions":["Etentamig (ABBV-383)"],"countries":["United States","Canada","Denmark","France","Israel","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":46,"serviceSignals":["Hematology NGS"],"summary":"Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of etentamig (ABBV-383) in adult participants with relapsed/refractory (R/R) MM. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study is broken into 4 Arms; Arm A (Parts 1 and 2), Arm B an","sourceUrl":"https://clinicaltrials.gov/study/NCT05650632"},{"nctId":"NCT06581419","title":"A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2024-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-01","completionType":"ESTIMATED","lastUpdated":"2025-01-15","conditions":["Advanced Malignant Neoplasm","Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["IAP0971"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Phase I: To evaluate the safety, tolerance and effectiveness of IAP0971 for the treatment of advanced malignant tumors. Phase II: Evaluation of IAP0971 therapy driver negative and PD-L1 positive (TPS≥50%) The initial treatment is effective in subjects with advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06581419"},{"nctId":"NCT07738341","title":"GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)","sponsor":"Eddingpharm (Zhuhai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Breast Cancer (Locally Advanced or Metastatic)"],"interventions":["GB268","Nab-Paclitaxel","Datopotamab Deruxtecan (Dato-DXd)","Sacituzumab Tirumotecan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase Ib/II, open-label, multi-cohort, multi-center study to evaluate the safety, tolerability, and preliminary anti-tumor activity of GB268, a biological product, as monotherapy or in combination with other therapies in patients with locally advanced unresectable or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07738341"},{"nctId":"NCT07725796","title":"A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC","sponsor":"UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-02","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Bladder (Urothelial, Transitional Cell) Cancer","NMIBC","Urothelial Carcinoma Bladder","Urothelial Carcinoma in Situ","Urothelial Carcinoma Recurrent","Urothelial Carcinoma of the Urinary Bladder","Non-Muscle Invasive Bladder Carcinoma","Non-muscle Invasive Bladder Cancer (NMIBC)"],"interventions":["UGN-501"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).","sourceUrl":"https://clinicaltrials.gov/study/NCT07725796"},{"nctId":"NCT05450705","title":"V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1500,"enrollmentType":"ESTIMATED","startDate":"2022-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-03","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-03","completionType":"ESTIMATED","lastUpdated":"2022-09-02","conditions":["Papillomavirus Infections"],"interventions":["9vHPV vaccine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This study aims to demonstrate that a 2-dose regimen of the 9-Valent Human Papillomavirus (9vHPV) vaccine (GARDASIL™9, V503) induces non-inferior competitive Luminex immunoassay (cLIA) geometric mean titers (GMTs) to each of the 9vHPV vaccine types in Chinese girls 9 through 14 years of age compared to a 3-dose regimen in Chinese women 20 through 26 years of age. The primary hypothesis is that a 2-dose regimen has a non-inferiority margin of 0.67 in the GMT ratio (girls vs. women) for each HPV type.","sourceUrl":"https://clinicaltrials.gov/study/NCT05450705"},{"nctId":"NCT07722312","title":"S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation","sponsor":"Servier","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-09-20","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08-11","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-25","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Relapsed or Refractory Acute Leukemia","Relapsed or Refractory Acute Myeloid Leukemia"],"interventions":["S243249 600mg","S243249 400mg","S243249 450mg","S243249 300mg"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization will determine the RP2D to be used in Phase 2 dose expansion. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. Participants may undergo blood tests, electrocardiogram (ECG), bone marrow aspirations, vital sign checks, questionnaires, and physical exams.","sourceUrl":"https://clinicaltrials.gov/study/NCT07722312"},{"nctId":"NCT07081646","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","sponsor":"Alexion Pharmaceuticals, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":91,"enrollmentType":"ESTIMATED","startDate":"2025-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-14","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Relapsed AL Amyloidosis","Refractory AL Amyloidosis","Light Chain Amyloidosis","Amyloidosis"],"interventions":["AZD0120"],"countries":["United States","Canada","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07081646"},{"nctId":"NCT07431281","title":"Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":2130,"enrollmentType":"ESTIMATED","startDate":"2026-02-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-16","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-27","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","Esophageal Cancer"],"interventions":["Sonesitatug vedotin","Rilvegostomig","Nivolumab","Capecitabine","5-Fluorouracil","Oxaliplatin","Zolbetuximab","Leucovorin"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Italy","Japan","Netherlands","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":286,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07431281"},{"nctId":"NCT07286149","title":"A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-17","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-13","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Lung Neoplasm Malignant"],"interventions":["MK-1084","Patritumab deruxtecan","Sacituzumab tirumotecan","Cetuximab","Rescue Medications"],"countries":["United States","Brazil","Chile","China","Germany","Greece","Hong Kong","Israel","Italy","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":27,"serviceSignals":["RAS genotyping"],"summary":"Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments","sourceUrl":"https://clinicaltrials.gov/study/NCT07286149"},{"nctId":"NCT07700979","title":"Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2026-08-20","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-18","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Gastric / Gastroesophageal Junction Adenocarcinoma"],"interventions":["Cadonilimab","CAPOX regimen","Nivolumab","Placebo"],"countries":["United States","China","Germany","Poland"],"northAmerica":true,"chinaSites":true,"siteCount":25,"serviceSignals":["HER2 profiling"],"summary":"The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatment of participants with HER2-negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma trial is to compare OS between cadonilimab combined with chemotherapy and chemotherapy in combination with or without nivolumab in the ITT population.","sourceUrl":"https://clinicaltrials.gov/study/NCT07700979"},{"nctId":"NCT06067841","title":"A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2023-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-24","primaryCompletionType":"ESTIMATED","completionDate":"2031-07-27","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["BMS-986460"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06067841"},{"nctId":"NCT03899155","title":"Pan Tumor Rollover Study","sponsor":"Bristol-Myers Squibb","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":1500,"enrollmentType":"ESTIMATED","startDate":"2019-08-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-25","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Cancer"],"interventions":["Nivolumab","Ipilimumab","Cabozantinib","Trametinib","Relatlimab","Nivolumab + Relatlimab","Capecitabine","Bevacizumab","Temozolomide","Rucaparib","Daratumumab","Regorafinib","Leucovorin","Fluorouracil","Oxaliplatin","Enzalutamide","Sunitinib","Pemetrexed","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Peru","Poland","Portugal","Puerto Rico","Romania","Russia","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":399,"serviceSignals":["Broad CGP"],"summary":"Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.","sourceUrl":"https://clinicaltrials.gov/study/NCT03899155"},{"nctId":"NCT04557059","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","sponsor":"Janssen Pharmaceutica N.V., Belgium","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":692,"enrollmentType":"ACTUAL","startDate":"2020-11-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-27","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-15","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Prostatic Neoplasms"],"interventions":["Radiotherapy","LHRHa","Apalutamide"],"countries":["United States","Australia","Austria","Belgium","Brazil","Czechia","Denmark","Finland","Germany","Hungary","Italy","Jordan","Lebanon","Mexico","Poland","Portugal","Russia","Slovakia","Spain","Sweden","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":141,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT04557059"},{"nctId":"NCT04365374","title":"Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)","sponsor":"GT Medical Technologies, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":230,"enrollmentType":"ESTIMATED","startDate":"2021-04-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2025-10-07","conditions":["Brain Metastases"],"interventions":["Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)","Stereotactic Radiation Therapy"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care.","sourceUrl":"https://clinicaltrials.gov/study/NCT04365374"},{"nctId":"NCT06088290","title":"Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)","sponsor":"PharmaMar","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":469,"enrollmentType":"ACTUAL","startDate":"2023-09-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-30","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Leiomyosarcoma"],"interventions":["Lurbinectedin","Doxorubicin"],"countries":["United States","Austria","Belgium","France","Germany","Italy","Netherlands","Poland","Portugal","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":97,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this phase III trial is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.","sourceUrl":"https://clinicaltrials.gov/study/NCT06088290"},{"nctId":"NCT07713459","title":"A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","sponsor":"Kure Cells, INC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":105,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Lymphoma Nonhodgkin","Marginal Zone B Cell Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)","Follicular B-cell Non-Hodgkin's Lymphoma","CAR T Cell Therapy"],"interventions":["CART Infusion"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured t…The goal of this Phase II single-arm, open-label clinical trial is to evaluate whether UF-KURE19, an autologous CD19-directed CAR-T cell therapy manufactured through an ultra-fast (less than 1 day) process, can treat adult patients (18 years and older, male or female) with relapsed or refractory B-cell Non-Hodgkin Lymphoma (NHL), including Large B-Cell Lymphoma (LBCL), Follicular Lymphoma (FL), and Marginal Zone Lymphoma (MZL). The participants will be divided in two cohorts: 81 participants in Cohort 1: Large B-Cell Lymphoma (LBCL) 2","sourceUrl":"https://clinicaltrials.gov/study/NCT07713459"},{"nctId":"NCT07510100","title":"Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":17,"enrollmentType":"ESTIMATED","startDate":"2026-05-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2026-04-03","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07510100"},{"nctId":"NCT03228667","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2018-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-14","conditions":["Non-Small Cell Lung Cancer","Small Cell Lung Cancer","Urothelial Carcinoma","Head and Neck Squamous Cell Carcinoma","Merkel Cell Carcinoma","Melanoma","Renal Cell Carcinoma","Gastric Cancer","Cervical Cancer","Hepatocellular Carcinoma","Microsatellite Instability","Mismatch Repair Deficiency","Colorectal Cancer"],"interventions":["N-803 + Pembrolizumab","N-803 + Nivolumab","N-803 + Atezolizumab","N-803 + Avelumab","N-803 + Durvalumab","N-803 + Pembrolizumab + PD-L1 t-haNK","N-803 + Nivolumab + PD-L1 t-haNK","N-803 + Atezolizumab + PD-L1 t-haNK","N-803 + Avelumab + PD-L1 t-haNK","N-803 + Durvalumab + PD-L1 t-haNK","N-803 + Docetaxel + Pembrolizumab","N-803 + Docetaxel + Nivolumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["MSI / TMB"],"summary":"QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.","sourceUrl":"https://clinicaltrials.gov/study/NCT03228667"},{"nctId":"NCT07409272","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":614,"enrollmentType":"ESTIMATED","startDate":"2026-02-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma"],"interventions":["Setidegrasib","Oxaliplatin","Leucovorin","Irinotecan","fluorouracil","liposomal irinotecan","Placebo"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["RAS genotyping"],"summary":"Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic). The standard treatment is chemotherapy, but other treatments are needed to improve outcomes in people with pancreatic cancer. The first treatment that people usually receive is chemotherapy. At the time this study started, some of the main standard chemotherapies for pancreatic cancer were mFOLFIRINOX or NALIRIFOX. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with pancreatic","sourceUrl":"https://clinicaltrials.gov/study/NCT07409272"},{"nctId":"NCT05374590","title":"Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis","sponsor":"argenx","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ENROLLING_BY_INVITATION","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2022-08-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-04-23","conditions":["Generalized Myasthenia Gravis","gMG"],"interventions":["Efgartigimod IV or Efgartigimod PH20 SC"],"countries":["United States","Belgium","Canada","France","Germany","Israel","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to evaluate the long-term safety of efgartigimod IV and efgartigimod PH20 SC administered to participants with gMG in the antecedent studies, ARGX-113-2006 and ARGX-113-2207, respectively. Participants will receive efgartigimod IV or efgartigimod PH20 SC, using the dose administered in the antecedent studies. Participants who have not reached the age of 18 can remain in the study until efgartigimod becomes commercially available in the respective country or available through another continued access program for gMG. Participants who have reached the age of 18 can remain in the study for a maximum of 2 years, until efgartigimod becomes commercially available in th","sourceUrl":"https://clinicaltrials.gov/study/NCT05374590"},{"nctId":"NCT06359041","title":"RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis","sponsor":"Cabaletta Bio","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":12,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Generalized Myasthenia Gravis (gMG)"],"interventions":["CABA-201"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Broad CGP"],"summary":"RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis","sourceUrl":"https://clinicaltrials.gov/study/NCT06359041"},{"nctId":"NCT06493552","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","sponsor":"Vasgene Therapeutics, Inc","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2025-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2034-08","completionType":"ESTIMATED","lastUpdated":"2025-04-03","conditions":["Muscle-Invasive Bladder Carcinoma","Metastatic Urothelial Carcinoma"],"interventions":["SEphB4-HSA","Pembrolizumab","Gemcitabine","Cisplatin","Enfortumab vedotin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.","sourceUrl":"https://clinicaltrials.gov/study/NCT06493552"},{"nctId":"NCT07703878","title":"A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors","sponsor":"Gilead Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":302,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Solid Tumor"],"interventions":["GS-1206"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug GS-1206, including its safety, tolerability, and antitumor activity in adult participants with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07703878"},{"nctId":"NCT07695740","title":"Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma","sponsor":"Excyte Biopharma Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":64,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Relapsed or Refractory Multiple Myeloma (RRMM)"],"interventions":["YKST02"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"The goal of this Phase 2 clinical trial is to learn whether YKST02 is effective and safe in adults with relapsed or refractory multiple myeloma. The study will also evaluate how YKST02 is processed by the body (pharmacokinetics), how it affects the body (pharmacodynamics), and whether it causes the body to produce anti-drug antibodies. The main questions it aims to answer are: Does YKST02 demonstrate clinical efficacy in adults with relapsed or refractory multiple myeloma? What side effects occur during treatment with YKST02? What are the pharmacokinetic, pharmacodynamic, and immunogenicity characteristics of YKST02? Participants will: Complete screening assessments to determine whether they","sourceUrl":"https://clinicaltrials.gov/study/NCT07695740"},{"nctId":"NCT07449754","title":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","sponsor":"Hanmi Pharmaceutical Company Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2026-02-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Advanced or Metastatic Melanoma"],"interventions":["Belvarafenib","Cobimetinib"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":10,"serviceSignals":["RAS genotyping"],"summary":"This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects. Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.","sourceUrl":"https://clinicaltrials.gov/study/NCT07449754"},{"nctId":"NCT07496229","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["T-cell Lymphomas"],"interventions":["GW5282 combined with Golidocitinib","Conventional CHOP regimen"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 1/2 open-label study to evaluate GW5282 in combination with golidocitinib (G2 regimen) for the treatment of T-cell lymphoma. In the first phase of the study, the maximum tolerated dose will be determined through dose escalation; in the second phase, the potential therapeutic advantages of the novel combination therapy over the conventional CHOP regimen will be preliminarily assessed through a randomized controlled design.","sourceUrl":"https://clinicaltrials.gov/study/NCT07496229"},{"nctId":"NCT07569965","title":"Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Mantle Cell Lymphoma (MCL)"],"interventions":["zamtocabtagene autoleucel (MB-CART2019.1)","Cyclophosphamide","Fludarabine"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"FRONTIER is a prospective, single arm, open label, multi-center, Phase II study of MB-CART2019.1 (Zamtocabtagene Autoleucel) therapy as frontline consolidation for high-risk Mantle Cell Lymphoma (MCL) participants","sourceUrl":"https://clinicaltrials.gov/study/NCT07569965"},{"nctId":"NCT07182682","title":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2025-12-15","conditions":["Non-Small Cell Lung Cancer"],"interventions":["sunvozertinib","Matching Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":49,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of sunvozertinib versus placebo as adjuvant therapy in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) or P-loop and αC-helix compression (PACC) mutations, who have had radical surgery, regardless of adjuvant chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07182682"},{"nctId":"NCT07464145","title":"A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer","sponsor":"Relmada Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":393,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2032-09","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Bladder (Urothelial, Transitional Cell) Cancer","Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)","Urothelial Carcinoma Bladder","Urothelial Carcinoma Recurrent","Urologic Cancer"],"interventions":["NDV-01 (sustained-release gemcitabine-docetaxel)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Study REL-NDV01-303 is a Phase 3, open-label, multi-center study to determine the safety and efficacy of NDV-01 in adult participants with NMIBC. The study will include two cohorts: * Cohort 1: a randomized, open-label, parallel group, multi-center, Phase 3 study evaluating the efficacy and safety of the NDV-01 versus observation in participants with histologically confirmed IR-NMIBC. * Cohort 2: an open-label, multi-center, single-arm Phase 3 study evaluating the efficacy and safety of the NDV-01 in two populations of high-risk NMIBC: * Cohort 2a: will include participants with HR-NMIBC who have a biopsy-proven recurrence with CIS ± papillary disease after receiving one or 2 lines of therap","sourceUrl":"https://clinicaltrials.gov/study/NCT07464145"},{"nctId":"NCT07563738","title":"A 2-part Phase 1/2 Open-label Trial on ODM-212","sponsor":"Orion Corporation, Orion Pharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":229,"enrollmentType":"ESTIMATED","startDate":"2026-03-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-05-04","conditions":["Mesothelioma","Pancreatic Cancer","NSCLC (Advanced Non-small Cell Lung Cancer)"],"interventions":["ODM-212","Ipilimumab and nivolumab","Gemcitabine and nab-paclitaxel","sotorasib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)","sourceUrl":"https://clinicaltrials.gov/study/NCT07563738"},{"nctId":"NCT07219459","title":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure","sponsor":"CatalYm GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":104,"enrollmentType":"ESTIMATED","startDate":"2026-03-19","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-09","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Unresectable or Metastatic Hepatocellular Carcinoma","Child-Pugh A Hepatocellular Carcinoma","Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound"],"interventions":["Visugromab RDE (recommended dose for expansion)","Nivolumab","Lenvatinib","Placebo Saline Infusion"],"countries":["United States","Germany","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2b, randomized, blinded clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and Lenvatinib compared to double placebo and Lenvatinib in participants with unresectable or metastatic HCC and compensated liver function (Child-Pugh A) after failure of 1L treatment that included an anti-PD-(L)1 compound. The trial consists of 2 Parts: a non-randomized Safety-run-in part (Part 1) and the subsequent randomized part (Part 2) with 2 treatment arms (A and B). Randomization of participants into Treatment Arm A and B will continue until 40 efficacy-evaluable participants are enrolled into each Treatment Arm.","sourceUrl":"https://clinicaltrials.gov/study/NCT07219459"},{"nctId":"NCT05633667","title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":192,"enrollmentType":"ACTUAL","startDate":"2023-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Lung Cancer","Advanced or Metastatic Non-Small-Cell Lung Cancer","Resectable Non-Small-Cell Lung Cancer"],"interventions":["Zimberelimab (ZIM)","Domvanalimab (DOM)","Sacituzumab govitecan-hziy (SG)","Etrumadenant (ETRUMA)","Carboplatin","Cisplatin","Pemetrexed","Paclitaxel","Nab-paclitaxel","Docetaxel","Nivolumab"],"countries":["United States","Brazil","Hong Kong","Israel","South Korea","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":89,"serviceSignals":["Broad CGP"],"summary":"The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: S","sourceUrl":"https://clinicaltrials.gov/study/NCT05633667"},{"nctId":"NCT07629960","title":"A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations","sponsor":"Blueprint Medicines Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":265,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-07","completionType":"ESTIMATED","lastUpdated":"2026-06-05","conditions":["Advanced Solid Tumor","Non-Small Cell Lung Cancer","Colorectal Neoplasms","Pancreatic Ductal Adenocarcinoma"],"interventions":["BLU-924"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07629960"},{"nctId":"NCT06552416","title":"Safety of MT-401-OTS in Patients With Relapsed AML or MDS","sponsor":"Marker Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Acute Myeloid Leukemia, in Relapse","MDS"],"interventions":["MT-401-OTS"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \\</= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \\</= 10% blasts following treatment with an HMA-based therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06552416"},{"nctId":"NCT07676162","title":"A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Advanced Colorectal Cancer"],"interventions":["SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab","Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study adopts a randomized, open-label, positive-controlled, multicenter design, aiming to evaluate the efficacy and safety of SHR-A1811 in combination with chemotherapy and bevacizumab versus standard therapy as first-line treatment for advanced colorectal cancer, and to explore the drug's immunogenicity and pharmacokinetic characteristics.","sourceUrl":"https://clinicaltrials.gov/study/NCT07676162"},{"nctId":"NCT07743541","title":"Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy","sponsor":"Tubulis GmbH","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09","primaryCompletionType":"ESTIMATED","completionDate":"2029-09","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Uterine Endometrial Cancer"],"interventions":["TUB-040 - Dose escalation","TUB-040 - RP2D"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with recurrent or progressive uterine endometrial cancer after platinum-based chemotherapy and immune checkpoint inhibitor therapy. The primary objectives of Phase 1 of this study are to determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). The primary objective of Phase 2 of this study is to evaluate the efficacy of TUB-040 monotherapy at the RP2D in endometrial cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07743541"},{"nctId":"NCT07651878","title":"Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment","sponsor":"Mendus","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-01","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["CML (Chronic Myelogenous Leukemia)"],"interventions":["vididencel"],"countries":["Norway"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The main purpose of the trial is to evaluate the safety and potential side effects of cell therapy vididencel in Chronic Myeloid Leukemia (CML) participants with measurable residual disease (MRD) unable to stop treatment with tyrosine kinase inhibitor (TKI). Patients may not receive any direct medical benefit from participating. Participants in the study should have been treated with TKI for at least 24 months prior to enrolment. This TKI must be of the same type throughout the 24 months. Participation in the active period of the study will take about 5 months after which patients will be followed with regular checks for a total of 3 years from the study start. The cell therapy is administer","sourceUrl":"https://clinicaltrials.gov/study/NCT07651878"},{"nctId":"NCT07694427","title":"Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":720,"enrollmentType":"ESTIMATED","startDate":"2026-10-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-08","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Ovarian Neoplasms"],"interventions":["Mocertatug rezetecan","Bevacizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HRD / HRR"],"summary":"This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) alone or in combination with bevacizumab works in treating ovarian cancer compared to bevacizumab alone or active observation (AO). The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to bevacizumab alone OR AO and will help provide a better understanding of the main side effects of the drugs.","sourceUrl":"https://clinicaltrials.gov/study/NCT07694427"},{"nctId":"NCT05827081","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1400,"enrollmentType":"ESTIMATED","startDate":"2024-02-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-20","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Early Breast Cancer"],"interventions":["Ribociclib","Letrozole","Ansastrozole","Goserelin","Leuprolide","Exemestane"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","Germany","Hong Kong","India","Israel","Mexico","Portugal","Puerto Rico","South Korea","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":229,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05827081"},{"nctId":"NCT07306559","title":"A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":187,"enrollmentType":"ESTIMATED","startDate":"2026-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Advanced Relapsed or Refractory Germ Cell Tumours","Advanced Relapsed or Refractory Endometrial Cancer","Advanced Relapsed or Refractory Ovarian Cancer"],"interventions":["BI 3820768"],"countries":["United States","Belgium","France","Germany","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can join the study if they have no remaining treatment options or if standard therapy is not suitable. The purpose of this study is to test increasing doses of BI 3820768 to find a dose that people with these types of cancer can tolerate and that may make tumours shrink. BI 3820768 is a type of treatment that may help the immune system fight cancer. This is the first time BI 3820768 is being tested in humans. The study has 2 parts based on the way BI 3820768 is given. Depending on when participants join the study, they will receive BI 38207","sourceUrl":"https://clinicaltrials.gov/study/NCT07306559"},{"nctId":"NCT06875310","title":"A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)","sponsor":"Mirati Therapeutics Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2025-04-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-07","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Adagrasib","Pembrolizumab","Carboplatin","Pemetrexed","Placebo","Cisplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","Saudi Arabia","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":351,"serviceSignals":["RAS genotyping"],"summary":"This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT06875310"},{"nctId":"NCT06131840","title":"A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":914,"enrollmentType":"ESTIMATED","startDate":"2023-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-12","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Colorectal Neoplasms","Carcinoma, Non-Small-Cell Lung","Stomach Neoplasms","Pancreatic Ductal Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Small Cell Lung Carcinoma"],"interventions":["PF-08046050","bevacizumab","5-Fluorouracil (5-FU)","Oxaliplatin","Leucovorin (LV)"],"countries":["United States","Canada","China","France","Israel","Japan","Netherlands","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["ADC biomarker"],"summary":"This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care dru","sourceUrl":"https://clinicaltrials.gov/study/NCT06131840"},{"nctId":"NCT06469944","title":"Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2024-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Neoplasms","Esophageal Cancer"],"interventions":["Pembrolizumab","Sacituzumab Tirumotecan (sac-TMT)","Capecitabine","Leucovorin","Levoleucovorin","5-Fluorouracil (5-FU)","Oxaliplatin","Patritumab Deruxtecan"],"countries":["United States","Brazil","Chile","China","France","Germany","Italy","Norway","South Korea","Switzerland","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":51,"serviceSignals":["HER2 profiling"],"summary":"This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunot","sourceUrl":"https://clinicaltrials.gov/study/NCT06469944"},{"nctId":"NCT06549790","title":"Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia","sponsor":"Nerviano Medical Sciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2024-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-15","completionType":"ESTIMATED","lastUpdated":"2025-10-31","conditions":["Relapsed/Refractory Acute Myeloid Leukemia"],"interventions":["NMS-03597812"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.","sourceUrl":"https://clinicaltrials.gov/study/NCT06549790"},{"nctId":"NCT05169515","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2022-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-15","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-15","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Non-Hodgkin Lymphoma"],"interventions":["SC Mosunetuzumab","IV Glofitamab","Iberdomide","Golcadomide","Obinutuzumab","Tocilizumab"],"countries":["United States","Israel","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.","sourceUrl":"https://clinicaltrials.gov/study/NCT05169515"},{"nctId":"NCT05714202","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1135,"enrollmentType":"ACTUAL","startDate":"2023-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-18","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Bladder Cancer"],"interventions":["TAR-200","Cetrelimab","BCG Vesiculture"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","India","Italy","Japan","Mexico","Netherlands","Poland","Portugal","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":240,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).","sourceUrl":"https://clinicaltrials.gov/study/NCT05714202"},{"nctId":"NCT07024394","title":"Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2025-06-12","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-23","completionType":"ESTIMATED","lastUpdated":"2025-06-17","conditions":["Neurofibromatosis 1","Plexiform Neurofibroma","NF1"],"interventions":["Luvometinib Tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"FCN-159 (Luvometinib Tablets), an orally available and highly potent selective inhibitor of MEK1/2,demonstrated good tolerability and exhibited notable anti-tumor activity in pediatric pts with NF1-related PN in study NCT04954001.This study is a 5-year long-term follow-up of the FCN-159-002 study, involving all enrolled patients to further assess safety, growth and development effects, and treatment efficacy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07024394"},{"nctId":"NCT07607925","title":"A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL","sponsor":"GlaxoSmithKline","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":49,"enrollmentType":"ESTIMATED","startDate":"2026-06-12","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09-24","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-24","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["GSK5926371"],"countries":["United States","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.","sourceUrl":"https://clinicaltrials.gov/study/NCT07607925"},{"nctId":"NCT07590934","title":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":152,"enrollmentType":"ESTIMATED","startDate":"2026-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-25","primaryCompletionType":"ESTIMATED","completionDate":"2029-09-25","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Metastatic Prostate Cancer"],"interventions":["AZD2265 (FPI-2265)","AZD9574","Docetaxel","AZD2287 (Imaging agent)"],"countries":["United States","Australia","Germany","Italy","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07590934"},{"nctId":"NCT07145255","title":"Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors","sponsor":"MBrace Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-09-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-02-17","conditions":["Prostate Cancer Castration-resistant Prostate Cancer","Breast Cancer","Colo-rectal Cancer","Lung Cancer (Non-Small Cell)","Pancreas Cancer, Duct Cell Adenocarcinoma"],"interventions":["ADC"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07145255"},{"nctId":"NCT07222267","title":"An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors","sponsor":"BeOne Medicines","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":86,"enrollmentType":"ESTIMATED","startDate":"2025-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2037-01-13","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Cancer","Advanced Solid Tumor"],"interventions":["BG-75202","CDK4 Inhibitor","Estrogen Receptor Antagonist","Aromatase Inhibitor"],"countries":["United States","Australia","China","Italy","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07222267"},{"nctId":"NCT06943872","title":"A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2025-06-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Sonrotoclax","Obinutuzumab","Rituximab","Venetoclax"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Ireland","Italy","Netherlands","New Zealand","Poland","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":192,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.","sourceUrl":"https://clinicaltrials.gov/study/NCT06943872"},{"nctId":"NCT00781612","title":"A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies","sponsor":"Genentech, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":720,"enrollmentType":"ESTIMATED","startDate":"2008-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2025-12-24","conditions":["Neoplasm Metastasis"],"interventions":["Docetaxel","Paclitaxel","Pertuzumab","Trastuzumab","Trastuzumab Emtansine","Atezolizumab"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Czechia","Denmark","France","Germany","Guatemala","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","New Zealand","North Macedonia","Norway","Panama","Peru","Philippines","Poland","Portugal","Russia","Slovenia","South Korea","Spain","Switzerland","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":178,"serviceSignals":["Broad CGP"],"summary":"This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT00781612"},{"nctId":"NCT07672223","title":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2026-06-25","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Non-small Cell Lung Cancer"],"interventions":["SYS6010","Enlonstobart","Tislelizumab","Toripalimab ±+platinum-based doublet chemotherapy","Durvalumab","Pembrolizumab","Nivolumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with. with completely resected stage II-IIIB, actionable genomic alterations (AGAs) negative non-small cell lung cancer (NSCLC) who did not achieve a major pathological response (MPR).","sourceUrl":"https://clinicaltrials.gov/study/NCT07672223"},{"nctId":"NCT07569042","title":"A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma","sponsor":"Novelwise Pharmaceutical Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-04-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Malignant Neoplasm of Brain"],"interventions":["NBM-BMX Capsule","Temozolomide"],"countries":["Taiwan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This clinical trial is a rollover study designed to provide continued access to NBM-BMX and temozolomide (TMZ) for eligible participants with newly diagnosed glioblastoma who have completed the designated treatment in Study NBM-BMX-003 (the parent study), and to evaluate the long-term safety and efficacy of NBM-BMX administered in combination with TMZ.","sourceUrl":"https://clinicaltrials.gov/study/NCT07569042"},{"nctId":"NCT07392060","title":"A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":440,"enrollmentType":"ESTIMATED","startDate":"2026-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2029-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Cervical Cancer Metastatic"],"interventions":["WX390 1.1mg + Toripalimab 240mg","Investigator's Choice of Chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior platinum-based systemic therapy, as assessed by overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT07392060"},{"nctId":"NCT07218380","title":"A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract","sponsor":"Eli Lilly and Company","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2033-05","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Carcinoma, Transitional Cell","Urinary Bladder Neoplasms","Neoplasm Metastasis"],"interventions":["Vepugratinib","Placebo","EV","Pembrolizumab"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","Denmark","France","Germany","Hungary","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":286,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07218380"},{"nctId":"NCT07663487","title":"A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to Bridge or Downstage Patients With Hepatocellular Carcinoma (HCC) to Liver Transplant or Resection and Elicit Pathologic Necrosis.","sponsor":"Sirtex Medical","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["SIR-Spheres Selectively Delivered to Liver Tumor"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This clinical investigation involves the use of an approved medical device (SIR-Spheres®) for a new purpose in patients with certain types of liver cancer. The goal is to determine whether this treatment can help patients qualify for or maintain eligibility for a liver transplant. Participation is completely voluntary and will not affect your standard medical care. The main risks involve possible side effects related to the use of radiation in the liver, such as fatigue, abdominal pain, nausea, or changes in liver function. You may or may not benefit personally from participating in this study, but the results may help improve future treatment for others. Your doctor is inviting you to take ","sourceUrl":"https://clinicaltrials.gov/study/NCT07663487"},{"nctId":"NCT07744126","title":"A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Head and Neck Squamous Cell Carcinoma"],"interventions":["Telisotuzumab Adizutecan","Pembrolizumab","Carboplatin","Cisplatin","Fluorouracil"],"countries":["United States","China","Japan","Portugal","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":20,"serviceSignals":["MET profiling"],"summary":"Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases. This study aims to evaluate the change in disease activity and optimal dose, and optimal dose of telisotuzumab adizutecan in combination with pembrolizumab as first-line treatment in participants with recurrent or metastatic head and neck squamous cell carcinoma. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of recurrent or metastatic HNSCC. Participants are placed into 3 treatment groups called treatment arms. Each group receives a different treatment. Adult participants diagnosed with recurrent or metastat","sourceUrl":"https://clinicaltrials.gov/study/NCT07744126"},{"nctId":"NCT07516093","title":"Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL","sponsor":"Nurix Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":620,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["NX-5948","Pirtobrutinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07516093"},{"nctId":"NCT07192120","title":"A Study of MHB048C in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["mCRPC (Metastatic Castration-resistant Prostate Cancer)","Advanced Malignant Solid Tumor"],"interventions":["MHB048C for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB048C monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07192120"},{"nctId":"NCT06801834","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","sponsor":"Gilead Sciences","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":695,"enrollmentType":"ESTIMATED","startDate":"2025-04-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Extensive Stage Small Cell Lung Cancer (ES-SCLC)"],"interventions":["Sacituzumab Govitecan (SG)","Topotecan","Amrubicin (Japan only)","Lurbinectedin (regions/countries where approved and available)"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Greece","Hungary","Israel","Italy","Japan","Malaysia","Netherlands","Norway","Poland","Romania","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":218,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06801834"},{"nctId":"NCT07192107","title":"A Study of MHB042C in Patients With Advanced Solid Tumors","sponsor":"Minghui Pharmaceutical (Hangzhou) Ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10","completionType":"ESTIMATED","lastUpdated":"2026-04-09","conditions":["Advanced Malignant Solid Tumor"],"interventions":["MHB042C for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, open-label, multicenter Phase I/II study of MHB042C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB042C monotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07192107"},{"nctId":"NCT07708753","title":"A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Platinum-resistant Ovarian Cancer","Platinum-resistant Primary Peritoneal Cancer","Platinum-resistant Fallopian Tube Cancer"],"interventions":["SYS6043","Liposomal doxorubicin, paclitaxel, or topotecan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07708753"},{"nctId":"NCT07595276","title":"Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.","sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":608,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-01","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Colorectal Cancer"],"interventions":["Enlituo®","Erbitux®"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, phase III clinical trial. The study aims to demonstrate that the treatment regimen of Enlituo® plus FOLFOX is equivalent to that of Erbitux® plus FOLFOX in participants with RAS/BRAF wild-type and MSS/pMMR locally advanced/metastatic colorectal cancer. Enrolled participants will be stratified according to ECOG performance status (0 vs. 1) and primary tumor location (left-sided or right-sided colon) and randomly assigned in a 1:1 ratio to either the experimental group (Enlituo® + FOLFOX) or the control group (Erbitux® + FOLFOX). Participants will: * Receive Enlituo®/Erbitux®: 500 mg/m², administered via intravenous infusion over a minimum of 120 minutes, on","sourceUrl":"https://clinicaltrials.gov/study/NCT07595276"},{"nctId":"NCT07128199","title":"A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection","sponsor":"Taiho Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2025-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-01","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["NSCLC, Stage IB-IIIA","Lung Cancer","Adjuvant","Post-surgical","EGFR","Exon 20","Early Stage Lung Cancer","Uncommon EGFR Mutations"],"interventions":["Cisplatin","Carboplatin","Pemetrexed","TAS6417","Zipalertinib Matching-placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","France","Germany","Greece","Hong Kong","Italy","Japan","Malaysia","Mexico","Netherlands","Peru","Poland","Romania","Singapore","South Korea","Spain","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":252,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the efficacy of zipalertinib combined with adjuvant chemotherapy versus placebo combined with adjuvant chemotherapy in participants with early stage (stage IB-IIIA) resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).","sourceUrl":"https://clinicaltrials.gov/study/NCT07128199"},{"nctId":"NCT07246863","title":"Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC","sponsor":"CatalYm GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":131,"enrollmentType":"ESTIMATED","startDate":"2025-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Metastatic Non-Squamous Non-Small Cell Lung Cancer","Adult Solid Tumor"],"interventions":["Visugromab RDE (recommended dose for expansion)","Visugromab 6mg/kg","Nivolumab","Placebo Saline Infusion","Docetaxel"],"countries":["United States","Germany","Italy","Poland","Romania","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose","sourceUrl":"https://clinicaltrials.gov/study/NCT07246863"},{"nctId":"NCT06093425","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":820,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-31","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Gastric Cancer","Gastroesophageal-junction Cancer","Advanced Cancer"],"interventions":["Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). In addition, the FDA has approved nivolumab, a PD-1 checkpoint inhibitor, in combination with chemotherapy as first line treatment for advanced or metastatic gastric/GEJ cancer. TST001 is a recombinant humanized monoclonal antibody against Claudin 18.2 (a tumor marker found in gastric/GEJ cancer. In this study, the combination therapy of chemotherapy or chemotherapy and pembrolizumab with and without TST001 could pro","sourceUrl":"https://clinicaltrials.gov/study/NCT06093425"},{"nctId":"NCT07115043","title":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-02","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-02","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Melanoma","Non-small Cell Lung Cancer","Squamous Cell Carcinoma (Skin)","Renal Cell Carcinoma","Merkel Cell Carcinoma","Triple Negative Breast Cancer","Head and Neck Squamous Cell Carcinoma","Gastric Cancer/Gastroesophageal Junction Cancer","High Grade Serous Ovarian Carcinoma"],"interventions":["AZD6750","rilvegostomig"],"countries":["United States","Australia","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07115043"},{"nctId":"NCT07600749","title":"Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-04","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-04","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Malignant Neoplasm"],"interventions":["MK-4884"],"countries":["United States","Israel","Japan","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat certain types of advanced and/or metastatic solid tumors. The main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.","sourceUrl":"https://clinicaltrials.gov/study/NCT07600749"},{"nctId":"NCT07224425","title":"A Study of BI 3810944 in Patients With Advanced Cancer","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":69,"enrollmentType":"ESTIMATED","startDate":"2026-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-05","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-05","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Solid Tumours","Melanoma"],"interventions":["BI 3810944"],"countries":["United States","Belgium","Netherlands"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced cancer (solid tumours) for whom previous treatment was not successful, or no treatment exists. The study tests different doses of BI 3810944 to find out which doses they can tolerate. Another purpose is to identify the most suitable dose of BI 3810944 and to find out whether it helps people with advanced cancer. BI 3810944 may help fight cancer. Participants get BI 3810944 usually once every 3 weeks. At treatment start, it is given once a week for a short time. Participants may continue to get BI 3810944 as long as they benefit from treatment but no longer than 2 years. During this time, they regularly visit the study site. The first study visits in","sourceUrl":"https://clinicaltrials.gov/study/NCT07224425"},{"nctId":"NCT06848088","title":"A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-10","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Melanoma"],"interventions":["Fianlimab+cemiplimab"],"countries":["United States","Ireland"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated with fianlimab and cemiplimab in the study called R3767-ONC-1613 (NCT03005782). The aim of the current study is to see how safe and effective the study drugs are in a long-term follow-up. No study drug will be given during this study. Cancer status will be monitored, in addition to routine care. The study is also collecting information about general health status, and other treatments that may have been received since participation in study R3767-ONC-1613 (NCT030057","sourceUrl":"https://clinicaltrials.gov/study/NCT06848088"},{"nctId":"NCT07291076","title":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":198,"enrollmentType":"ESTIMATED","startDate":"2026-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-15","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-14","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["Pumitamig","Ipilimumab"],"countries":["United States","Australia","Chile","China","France","Germany","Italy","Japan","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":64,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07291076"},{"nctId":"NCT07549412","title":"A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)","sponsor":"EMD Serono Research & Development Institute, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1020,"enrollmentType":"ESTIMATED","startDate":"2026-05-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-16","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Metastatic Colorectal Cancer"],"interventions":["Precemtabart tocentecan","Bevacizumab","Trifluridine/Tipiracil (FTD-TPI)"],"countries":["United States","Australia","Canada","Japan","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["ADC biomarker"],"summary":"This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocentecan (Precem-TcT) as single agent or Precem-TcT in combination with bevacizumab compared to trifluoride/tipiracil (FTD-TPI) plus bevacizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07549412"},{"nctId":"NCT06428409","title":"A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2024-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-16","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-16","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Colorectal Cancer","Pancreatic Ductal Adenocarcinoma","Biliary Tract Cancer"],"interventions":["Sacituzumab tirumotecan","Fluorouracil (5-FU)","Leucovorin (LV) or levoleucovorin","Rescue medication","Supportive care measures","Cisplatin","Pembrolizumab"],"countries":["United States","Australia","Canada","Chile","China","Italy","Japan","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":55,"serviceSignals":["Broad CGP"],"summary":"Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06428409"},{"nctId":"NCT07384715","title":"First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)","sponsor":"Genmab","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2026-02-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-20","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["R/R AML","R/R HR-MDS","Acute Myeloid Leukemia","Higher-Risk Myelodysplastic Syndrome"],"interventions":["GEN3018"],"countries":["Denmark","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"The drug that will be investigated in the trial is an antibody, GEN3018. Since this is the first trial of GEN3018 in humans, the main purpose is to evaluate safety. In addition to safety, the trial will determine the recommended GEN3018 dose(s) to be tested in a larger group of participants and assess preliminary anti-tumor activity of GEN3018. GEN3018 will be studied in refractory (resistant to treatment) or relapsed (disease has returned) acute myeloid leukemia (also known as R/R AML) and refractory or relapsed higher-risk myelodysplastic syndrome (also known as R/R HR-MDS). The trial consists of 2 parts: 1. Part 1 Dose Escalation will test increasing doses of GEN3018 to identify a safe do","sourceUrl":"https://clinicaltrials.gov/study/NCT07384715"},{"nctId":"NCT04708041","title":"Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2021-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-23","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-23","completionType":"ESTIMATED","lastUpdated":"2025-04-20","conditions":["Papillomavirus Infections"],"interventions":["9vHPV vaccine"],"countries":["United States","Colombia","Mexico","Poland","South Africa","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"This is a 96-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal is to establish that the investigational extended 2-dose regimens (0, 12 months; 0, 24 months; 0, 36 months; and 0, 60 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who receive the standard 3-dose regimen of 9-valent human papillomavirus (9vHPV) vaccine at 0, 2, and 6 months (i.e., the population and dose regimen used to establish 9vHPV vaccine efficacy).","sourceUrl":"https://clinicaltrials.gov/study/NCT04708041"},{"nctId":"NCT06704269","title":"Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2025-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-26","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Generalized Myasthenia Gravis"],"interventions":["YTB323"],"countries":["United States","France","Japan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"This is a phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis. YTB323 is a Biological CAR-T cell therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06704269"},{"nctId":"NCT05933577","title":"A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1089,"enrollmentType":"ESTIMATED","startDate":"2023-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-26","completionType":"ESTIMATED","lastUpdated":"2025-09-24","conditions":["Melanoma"],"interventions":["Intismeran autogene","Pembrolizumab","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Colombia","Denmark","France","Germany","Greece","Israel","Italy","Japan","New Zealand","Poland","Portugal","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":165,"serviceSignals":["HLA / TCR"],"summary":"The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \\[mRNA\\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.","sourceUrl":"https://clinicaltrials.gov/study/NCT05933577"},{"nctId":"NCT07681596","title":"A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":101,"enrollmentType":"ESTIMATED","startDate":"2026-07-09","startDateType":"ESTIMATED","primaryCompletionDate":"2029-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-10-30","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["AZD4045","Daratumumab","Aldesleukin"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.","sourceUrl":"https://clinicaltrials.gov/study/NCT07681596"},{"nctId":"NCT07342478","title":"ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL","sponsor":"Newave Pharmaceutical Inc","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":306,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["CLL / SLL","CLL (Chronic Lymphocytic Leukemia)","CLL, Refractory","CLL, Relapsed","SLL (Small Lymphocytic Lymphoma)","SLL","CLL","CLL Progression"],"interventions":["Rocbrutinib","Pirtobrutinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received a covalent Bruton's tyrosine kinase inhibitor (cBTKi). Approximately 306 participants will be randomized 1:1 to receive rocbrutinib 200 mg orally once daily or pirtobrutinib 200 mg orally once daily, administered continuously in 28-day cycles until disease progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria are met. Randomization will be stratified by presence of del(17p)/TP53 mutation (yes/no","sourceUrl":"https://clinicaltrials.gov/study/NCT07342478"},{"nctId":"NCT05957081","title":"Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309","sponsor":"PharmAbcine","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":67,"enrollmentType":"ESTIMATED","startDate":"2024-01-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2025-12-30","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["PMC-309 monotherapy","PMC-309 Dose Escalation in Combination with Pembrolizumab(KEYTRUDA®)","PMC-309 Dose Expansion"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1a/1b, first-in-human (FIH), open label study to evaluate the safety, tolerability, and pharmacokinetics (PK) of PMC-309, a mAb against the human VISTA ligand, in participants with advanced or metastatic solid tumors administered as a monotherapy and in combination with pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05957081"},{"nctId":"NCT07594964","title":"To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors","sponsor":"Shenzhen Xinhe Biomedical","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2025-08-25","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)","Pancreatic Ductal Adenocarcinoma (PDAC)","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)"],"interventions":["XH001 Injection","mFOLFIRINOX Treatment Regimen"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with high-risk recurrent solid tumors after radical surgery. The main questions it aims to answer are: What medical problems do participants have when using the combined treatment? Does XH001 injection combined with standard adjuvant treatment induce a specific T-cell response, and can it prolong the patient's relapse-free survival?","sourceUrl":"https://clinicaltrials.gov/study/NCT07594964"},{"nctId":"NCT06248411","title":"A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Kyowa Kirin Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":189,"enrollmentType":"ESTIMATED","startDate":"2023-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["KK2260"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is the first in human study of KK2260. In Part 1a, the maximum tolerated dose (MTD) will be determined while evaluating the safety and tolerability of KK2260 in patients with advanced or metastatic solid tumors (any cancer type). In Part 1b and Part 2, at least two dosing regimens and two dosing regimens by cancer type, respectively, will be selected, and the safety, tolerability, and efficacy of each regimen will be evaluated.","sourceUrl":"https://clinicaltrials.gov/study/NCT06248411"},{"nctId":"NCT07023289","title":"A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-09-02","startDateType":"ACTUAL","primaryCompletionDate":"2029-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Colorectal Cancer"],"interventions":["Telisotuzumab Adizutecan","Standard of Care"],"countries":["United States","Belgium","Denmark","Italy","Japan","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["ctDNA / MRD"],"summary":"Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given alone. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. This study will be divided into two groups called treatment arms. In arm 1 participants will receive telisotuzumab adizutecan alone. In arm 2 participants will receive SOC alone. Approximately 140 adult participants with CRC will be enrolled in the study in 45 sites worldwide. In arm 1, participants will receive intravenous (IV) doses of telisotuzumab adizutec","sourceUrl":"https://clinicaltrials.gov/study/NCT07023289"},{"nctId":"NCT07688577","title":"XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors","sponsor":"Xilio Development, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-11","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Metastatic NSCLC - Non-Small Cell Lung Cancer","Advanced Solid Tumor"],"interventions":["XTX501"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07688577"},{"nctId":"NCT07095868","title":"Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors","sponsor":"Everest Medicines (Beijing) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":94,"enrollmentType":"ESTIMATED","startDate":"2025-11-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Selected Types of Solid Tumor"],"interventions":["EVM14","Pembrolizumab"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07095868"},{"nctId":"NCT06679634","title":"Retinoblastoma Phase II Expanded Access Clinical Trial","sponsor":"Targeted Therapy Technologies, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-02-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-11","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Retinoblastoma"],"interventions":["Chemoplaque also referred to as Episcleral Topotecan"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with retinoblastoma. The goal of the study is to further determine/assess the safety and efficacy and optimal chemotherapy dose for retinoblastoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06679634"},{"nctId":"NCT04665206","title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors","sponsor":"Vivace Therapeutics, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":434,"enrollmentType":"ESTIMATED","startDate":"2021-03-24","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-02","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Solid Tumor, Adult","Mesothelioma","NSCLC"],"interventions":["VT3989","Nivolumab & Ipilimumab","Osimertinib","Pemetrexed/Carboplatin"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.","sourceUrl":"https://clinicaltrials.gov/study/NCT04665206"},{"nctId":"NCT07392736","title":"A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.","sponsor":"Advenchen Laboratories, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2021-10-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-07","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-07","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Solid Tumor"],"interventions":["AL8326 tablets","Toripalimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"This trial is an open, non-randomized, phase I/IIa clinical trial, which will evaluate the preliminary effectiveness and safety of AL8326 tablets in patients with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07392736"},{"nctId":"NCT07206056","title":"An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":188,"enrollmentType":"ESTIMATED","startDate":"2025-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Progressive Metastatic Castrate Resistant Prostate Cancer"],"interventions":["Tulmimetostat DL1 QD","Tulmimetostat DL2 QD","Tulmimetostat DL3 QD","Tulmimetostat Doses 1 or 2 QD","Tulmimetostat RP2D QD","JSB462 Dose 1 QD","JSB462 Dose 2 QD","JSB462 QD","Standard of Care (SoC)"],"countries":["United States","Australia","Canada","China","Denmark","France","Germany","Italy","Malaysia","Mexico","Poland","Singapore","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07206056"},{"nctId":"NCT07499362","title":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-22","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-22","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Tenosynovial Giant Cell Tumor"],"interventions":["Pimicotinib"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT","sourceUrl":"https://clinicaltrials.gov/study/NCT07499362"},{"nctId":"NCT05526755","title":"A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":188,"enrollmentType":"ACTUAL","startDate":"2023-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-22","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-22","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Stage II-IIIB Non-small Cell Lung Carcinoma"],"interventions":["Osimertinib 80 mg/40 mg"],"countries":["United States","Hong Kong","Italy","Malaysia","Philippines","Singapore","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"To assess the efficacy and safety of osimertinib in participants with EGFRm positive stage II-IIIB NSCLC, following complete tumour resection with or without adjuvant chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT05526755"},{"nctId":"NCT05636618","title":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","sponsor":"Perspective Therapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2023-09-27","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-26","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-26","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Neuroendocrine Tumors Unresectable","Neuroendocrine Tumor Metastatic","Gastroenteropancreatic Neuroendocrine Tumor","Bronchial Neuroendocrine Tumor","Paraganglioma","Pheochromocytoma","Meningioma"],"interventions":["[203Pb]VMT-α-NET","[212Pb]VMT-α-NET"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"This study is Phase I/IIa First-in-Human Study of \\[212Pb\\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT05636618"},{"nctId":"NCT07293351","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":254,"enrollmentType":"ESTIMATED","startDate":"2026-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-28","primaryCompletionType":"ESTIMATED","completionDate":"2031-11-26","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Renal Cell Carcinoma (RCC)"],"interventions":["Pumitamig","Ipilimumab","Cabozantinib"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","Czechia","Finland","France","Germany","Ireland","Italy","Japan","Mexico","Romania","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":91,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07293351"},{"nctId":"NCT05704244","title":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","sponsor":"Ferring Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":25,"enrollmentType":"ACTUAL","startDate":"2022-12-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2025-08-28","conditions":["Bladder Cancer"],"interventions":["FE 999326"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.","sourceUrl":"https://clinicaltrials.gov/study/NCT05704244"},{"nctId":"NCT07734116","title":"A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.","sponsor":"Ono Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-29","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Pediatric Malignant Solid Tumor and Epithelioid Sarcoma"],"interventions":["ONO-4538HSC"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07734116"},{"nctId":"NCT06632262","title":"A Phase 2 Clinical Study of ABSK061 and ABSK043","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":202,"enrollmentType":"ESTIMATED","startDate":"2024-11-13","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2024-11-19","conditions":["HER2-Gastric/Gastroesophageal Junction Cancer","Urothelial Carcinoma","Non-Small Cell Lung Cancer","Solid Tumors"],"interventions":["ABSK061 + ABSK043","ABSK061+ABSK043 in combination with CAPOX"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":21,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations","sourceUrl":"https://clinicaltrials.gov/study/NCT06632262"},{"nctId":"NCT05533775","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2022-11-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Mature B-Cell Non-Hodgkin Lymphoma"],"interventions":["Obinutuzumab","Glofitamab","Rituximab","Ifosfamide","Carboplatin","Etoposide","Tocilizumab"],"countries":["United States","Australia","Brazil","China","Czechia","Denmark","France","Germany","Hungary","Italy","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).","sourceUrl":"https://clinicaltrials.gov/study/NCT05533775"},{"nctId":"NCT06163430","title":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)","sponsor":"Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2024-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["Chronic Myeloid Leukemia, Chronic Phase","Chronic Myeloid Leukemia"],"interventions":["TERN-701"],"countries":["United States","Australia","France","Germany","Italy","New Zealand","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Hematology NGS"],"summary":"The goal of the study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of TERN-701, a highly selective allosteric inhibitor of BCR-ABL1, in participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML). The study has two parts: Part 1 of the trial (Dose Escalation) will evaluate sequential dose escalation cohorts of TERN-701 administered once daily. Part 2 (Dose Expansion) consists of randomized, parallel dose expansion cohorts of TERN-701 that will further evaluate the efficacy and safety of 2 recommended dose levels for expansion selected from Part 1. Part 2m (mutation cohort) will further evaluate the efficacy and safety of ","sourceUrl":"https://clinicaltrials.gov/study/NCT06163430"},{"nctId":"NCT06970743","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":153,"enrollmentType":"ACTUAL","startDate":"2025-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["BGB-16673","Bendamustine","Rituximab","Methylprednisolone","Chlorambucil","Obinutuzumab"],"countries":["China","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":62,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab or chlorambucil plus obinutuzumab) in participants with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to covalent Bruton tyrosine kinase inhibitor(s) (cBTKi).","sourceUrl":"https://clinicaltrials.gov/study/NCT06970743"},{"nctId":"NCT06697184","title":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","sponsor":"BeOne Medicines","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2025-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-30","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Chronic Lymphocytic Leukemia","CLL","Mantle Cell Lymphoma","MCL"],"interventions":["Sonrotoclax","Zanubrutinib"],"countries":["United States","Australia","France","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06697184"},{"nctId":"NCT05700448","title":"Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma","sponsor":"CStone Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2027-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Extranodal NK/T-cell Lymphoma"],"interventions":["Sugemalimab","Placebo","Pegaspargase","Gemcitabine","Oxaliplatin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the efficacy and safety of sugemalimab (CS1001) in combination with PGemOx regimen (pegaspargase, gemcitabine, oxaliplatin) in treatment of adult patients with Extranodal NK/T-Cell Lymphoma (ENKTL) who have relapsed or become refractory to asparaginase-based regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT05700448"},{"nctId":"NCT05751798","title":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","sponsor":"OSE Immunotherapeutics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":41,"enrollmentType":"ESTIMATED","startDate":"2022-12-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Solid Advanced Tumor","Lymphoma","NSCLC (Non-small Cell Lung Cancer)"],"interventions":["Part A: OSE-279 100mg","Part A: OSE-279 300mg","Part A: OSE-279 600mg","Part B: OSE-279 600 mg and OSE2101","Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive","Part C: OSE-279 600 mg - HLA-A2 positif","Part C: OSE-279 600 mg - HLA-A2 negative"],"countries":["Belgium","France","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT05751798"},{"nctId":"NCT07284186","title":"First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors","sponsor":"Plexium, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":155,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Esophageal Squamous Cell Carcinoma","Gastric Adenocarcinoma","Gastric Squamous Cell Carcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma","Metastatic Solid Tumor","Non-Small Cell Lung Carcinoma","Esophageal Adenocarcinoma","SMARCA4 Mutation","Gastroesophageal Junction Squamous Cell Carcinoma","Advanced Solid Tumor"],"interventions":["PLX-61639"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory, SMARCA4-deficient solid tumors who are intolerant of or have failed available, approved therapies. The study will be conducted in 3 parts: dose escalation (Part 1), dose optimization (Part 2), and cohort expansion (Part 3). Each part of the study will consist of a Screening Phase lasting up to 28 days during which participants will be assessed for eligibility, a Treatment Phase beginning on Cycle 1 Day 1 and consisting of consecutive 28-day cycles, an End of Treatment Visit, and a","sourceUrl":"https://clinicaltrials.gov/study/NCT07284186"},{"nctId":"NCT07112196","title":"Visugromab in Cachexia International Trial","sponsor":"CatalYm GmbH","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":518,"enrollmentType":"ESTIMATED","startDate":"2026-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Cancer-associated Cachexia"],"interventions":["Visugromab (CTL-002)","Placebo"],"countries":["United States","Bulgaria","Czechia","France","Germany","Italy","Norway","Poland","Romania","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.","sourceUrl":"https://clinicaltrials.gov/study/NCT07112196"},{"nctId":"NCT07564141","title":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":688,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Platinum-Sensitive Ovarian Cancer","Ovarian Cancer"],"interventions":["Rina-S","Bevacizumab","Carboplatin","Gemcitabine","Paclitaxel","PLD"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This Phase 3 study will be conducted in different countries around the world with up to about 688 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with or without bevacizumab and how it compares to an investigator's choice of platinum-based chemotherapy with or without bevacizumab. Participants will receive either: * Rina-S monotherapy (by itself), * Rina-S plus bevacizumab, * investigator's choice chemotherapy (by itself) (standard of care), or * investigator's choice chemotherapy plus bevacizumab (standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration wi","sourceUrl":"https://clinicaltrials.gov/study/NCT07564141"},{"nctId":"NCT07586943","title":"SKB118 Injection in Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":332,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Advanced Solid Tumors"],"interventions":["SKB118 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB118 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07586943"},{"nctId":"NCT07739199","title":"A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Squamous Non-small-cell Lung Cancer"],"interventions":["BL-B01D1","PD-1/VEGF bispecific antibody","Paclitaxel","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase II/III randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in combination with PD-1/VEGF bispecific antibody in first-line patients with locally advanced or metastatic squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07739199"},{"nctId":"NCT06765109","title":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","sponsor":"Nuvalent Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-07-17","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Non-small Cell Lung Cancer","Anaplastic Lymphoma Kinase-positive"],"interventions":["Neladalkib (NVL-655)","Alectinib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Malaysia","Mexico","Netherlands","Poland","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":157,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06765109"},{"nctId":"NCT07739186","title":"A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non-squamous Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","PD-1/VEGF Bispecific Antibody","Tislelizumab","Pemetrexed","Carboplatin","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational randomized, open-label, multicenter Phase II/III study designed to evaluate the efficacy and safety of BL-B01D1 in combination with a PD-1/VEGF bispecific antibody in patients with locally advanced or metastatic non-squamous non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07739186"},{"nctId":"NCT07542704","title":"A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies","sponsor":"Kumquat Biosciences Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-21","conditions":["Advanced Solid Tumors","Colorectal Cancer (CRC)","Non-Small Cell Lung Cancer","Uterine Cancer","KRAS G12C Mutations","KRAS G12S Mutations"],"interventions":["KQB368"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor? * What happens to KQB368 in the body? Participants will: * Take KQB368 orally daily in 21-day cycles * Return to the study site about 7 times in the first 5 weeks, and then once at the beginning of every 21-day cycle after that","sourceUrl":"https://clinicaltrials.gov/study/NCT07542704"},{"nctId":"NCT07424833","title":"A Study of APG-3288 in Relapsed/Refractory Blood Cancers","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Relapsed/Refractory Hematological Malignancies","Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL","Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)","Relapsed/Refractory Mantle Cell Lymphoma (MCL)","Relapsed/Refractory Waldenström Macroglobulinemia (WM)","Relapsed/Refractory Marginal Zone Lymphoma (MZL)","Relapsed/Refractory Follicular Lymphoma (FL)"],"interventions":["APG-3288"],"countries":["United States","China"],"northAmerica":true,"chinaSites":true,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07424833"},{"nctId":"NCT07229625","title":"A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":604,"enrollmentType":"ESTIMATED","startDate":"2026-01-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-01-28","conditions":["Advanced Biliary Tract Cancer"],"interventions":["SHR-8068 Injection","Adebrelimab Injection","Gemcitabine Hydrochloride for Injection","Cisplatin Injection","Durvalumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, multicenter phase III clinical trial, aiming to evaluate the efficacy and safety of SHR-8068 combined with adbelimab and platinum-based chemotherapy in contrast to varicumab combined with platinum-based chemotherapy in the first-line treatment of patients with advanced BTC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07229625"},{"nctId":"NCT07729956","title":"A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":436,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Triple-Negative Breast Cancer (TNBC)"],"interventions":["BL-B01D1","PD-1 monoclonal antibody","Nab-paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with a PD-1 monoclonal antibody in patients with PD-L1-positive, previously untreated, inoperable locally advanced or recurrent metastatic triple-negative breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07729956"},{"nctId":"NCT07518173","title":"A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":596,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["HER2-positive Breast Cancer"],"interventions":["BL-M07D1","Pertuzumab","Trastuzumab","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07518173"},{"nctId":"NCT07726992","title":"A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Papillary-Only Non-muscle-invasive Bladder Cancer"],"interventions":["SHR-1501+BCG","Placebo +BCG"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, Double-blind phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus Placebo Combined with BCG in patients with high-risk BCG-naive Papillary-Only non-muscle-invasive bladder cancer (NMIBC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07726992"},{"nctId":"NCT05409066","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":549,"enrollmentType":"ACTUAL","startDate":"2022-09-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Follicular Lymphoma (FL)"],"interventions":["Epcoritamab","Rituximab","Lenalidomide"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Puerto Rico","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":273,"serviceSignals":["Hematology NGS"],"summary":"Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of t","sourceUrl":"https://clinicaltrials.gov/study/NCT05409066"},{"nctId":"NCT05174637","title":"A Study of FDA018-ADC in Patients With Advanced Solid Tumors","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":78,"enrollmentType":"ESTIMATED","startDate":"2021-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Advanced/ Metastatic Solid Tumors"],"interventions":["FDA018-ADC"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05174637"},{"nctId":"NCT07285148","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":253,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2025-12-16","conditions":["Non-Small Cell Lung Cancer","EGFR Mutation","Metastatic Lung Cancer","MET Alteration"],"interventions":["ANS014004 + PLB1004","ANS014004 + Osimertinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Protocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe and tolerable dose of two investigational drugs, ANS014004 and PLB1004, when used together. Learn how effective this drug combination is at treating a type of lung cancer called \"EGFR mutation-positive non-small cell lung cancer (NSCLC)\" that has spread to other parts of the body (locally advanced or metastatic). This study is trying to answer the following questions: Safety \\& Dosing: What are the side effects of combining ANS014004 and PLB1004? What is the best do","sourceUrl":"https://clinicaltrials.gov/study/NCT07285148"},{"nctId":"NCT07522151","title":"Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer","sponsor":"Shanghai Shengdi Pharmaceutical Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":874,"enrollmentType":"ESTIMATED","startDate":"2026-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2034-02","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Locally Advanced Gastric or Gastroesophageal Junction Cancer"],"interventions":["Adebrelimab plus S-1 and oxaliplatin","Adebrelimab blank preparation plus S-1 and oxaliplatin."],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT07522151"},{"nctId":"NCT07502300","title":"A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":562,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Extensive-stage Small-cell Lung Cancer"],"interventions":["BL-B01D1","Tislelizumab","Carboplatin","Etoposide"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07502300"},{"nctId":"NCT07698587","title":"A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors","sponsor":"Suzhou Biomissile Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Solid Tumor"],"interventions":["BM230 & PD-1 inhibitor"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This study is a multicenter, non-randomized, open-label, Phase Ib/II combination therapy trial. The trial consists of two parts: Part 1 (Phase Ib), dose-escalation of combination therapy, followed by Part 2 (Phase II), tumor-type exploration of combination therapy. This study will evaluate the RP2D, safety, tolerability, and preliminary efficacy of BM230 in combination with PD-1 inhibitor in patients with HER2-related solid tumors (including but not limited to colorectal cancer, esophageal squamous cell carcinoma, urothelial carcinoma, cholangiocarcinoma, endometrial cancer, cervical cancer, ovarian cancer, etc.).","sourceUrl":"https://clinicaltrials.gov/study/NCT07698587"},{"nctId":"NCT07424547","title":"Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors","sponsor":"Conjupro Biotherapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":386,"enrollmentType":"ESTIMATED","startDate":"2026-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-04-07","conditions":["Cancer","Solid Tumor Cancer","Advanced Metastatic Cancer","Prostate","Small Cell Lung Cancer","Ovarian Cancer","Breast Cancer"],"interventions":["SYS6043"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent *","sourceUrl":"https://clinicaltrials.gov/study/NCT07424547"},{"nctId":"NCT07566897","title":"A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors","sponsor":"Philogen S.p.A.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2026-05-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Renal Carcinoma Metastatic","Pancreatic Adenocarcinoma Metastatic","Pancreatic Adenocarcinoma","Metastatic Colorectal Carcinoma (mCRC)"],"interventions":["L19IL2","Ruxolitinib"],"countries":["Italy"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07566897"},{"nctId":"NCT07439094","title":"A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer","sponsor":"Chong Kun Dang Pharmaceutical","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-04-16","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-04-27","conditions":["Advanced Solid Tumors","Non-Small Cell Lung Cancer"],"interventions":["CKD-703"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["MET profiling","ADC biomarker"],"summary":"This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung Cancer. CKD-703 is composed of a c-Met-targeting monoclonal antibody (mAb) coupled to a cytotoxic payload consisting of the anti-microtubule drug monomethyl auristatin E (MMAE); thus, CKD-703 is a novel ADC offering a highly targeted approach with potential improvement of efficacy while reducing off-target effects for patients with NSCLC and other cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07439094"},{"nctId":"NCT07154264","title":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2025-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"interventions":["DZD8586","Venetoclax"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":15,"serviceSignals":["Hematology NGS"],"summary":"This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.","sourceUrl":"https://clinicaltrials.gov/study/NCT07154264"},{"nctId":"NCT07173751","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","sponsor":"BioNTech SE","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":558,"enrollmentType":"ESTIMATED","startDate":"2025-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Breast Neoplasms"],"interventions":["Pumitamig","Nab-paclitaxel/Paclitaxel","Gemcitabine","Carboplatin","Eribulin","Matching placebo"],"countries":["United States","Australia","Belgium","Brazil","China","Czechia","Georgia","Germany","Italy","Japan","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":161,"serviceSignals":["Broad CGP"],"summary":"This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatments the participants actually receive. Participants will receive either the trial drug with chemotherapy or placebo (which looks like the trial drug but does not have any drug in it) with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07173751"},{"nctId":"NCT07188558","title":"A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy","sponsor":"Lyell Immunopharma, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-01-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Large B-cell Lymphoma","Lymphoma, B-Cell","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma Refractory/ Relapsed","Diffuse Large B Cell Lymphoma (DLBCL)","Diffuse Large B Cell Lymphoma Refractory","Diffuse Large B Cell Lymphoma Relapsed"],"interventions":["rondecabtagene autoleucel","axicabtagene ciloleucel","lisocabtagene maraleucel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":36,"serviceSignals":["Hematology NGS"],"summary":"This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT07188558"},{"nctId":"NCT07518147","title":"A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":438,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2029-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Gastric Cancer","Gastroesophageal Junction Adenocarcinoma"],"interventions":["BL-M05D1","Paclitaxel","Docetaxel","Irinotecan hydrochloride"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M05D1 in patients with Claudin (CLDN) 18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received prior first-line treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07518147"},{"nctId":"NCT06043817","title":"First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations","sponsor":"Pierre Fabre Medicament","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":345,"enrollmentType":"ESTIMATED","startDate":"2023-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-01","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Non-Small Cell Lung Cancer","NSCLC","EGFR/HER2 Exon 20 Insertion Mutation"],"interventions":["STX-721/PFL-721 (Escalated)","STX-721/PFL-721 (3 dose levels)","STX-721/PFL-721 (RP2D)"],"countries":["United States","France","Germany","Netherlands","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["HER2 profiling"],"summary":"Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06043817"},{"nctId":"NCT07434609","title":"Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors","sponsor":"Nanolattix Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2027-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-02-25","conditions":["Advanced Solid Tumor (Phase 1)"],"interventions":["T320 for Injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This is a first-in-human, non-randomized, open-label, multi-center, phase I study in patients with advanced solid tumor to evaluate the safety and tolerability, PK, immunogenicity, and preliminary anti-tumour activity of T320. This study consists of a dose escalation module and a backfill module. The trial process for each subject in both escalation and backfill module includes a screening period (28 days before the first T320 administration), a treatment period (from the first T320 administration to the end of reatment), a safety follow-up period (28 days after EOT/early withdrawal) and a progression follow-up period (every 12 weeks from safety follow-up visit). Patients will receive T320 a","sourceUrl":"https://clinicaltrials.gov/study/NCT07434609"},{"nctId":"NCT07190248","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":675,"enrollmentType":"ESTIMATED","startDate":"2025-10-08","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-07","primaryCompletionType":"ESTIMATED","completionDate":"2032-08-06","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["Calderasib","Pembrolizumab (+) Berahyaluronidase alfa","Pemetrexed","Cisplatin","Carboplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","France","Greece","Guatemala","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Peru","Poland","Romania","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":198,"serviceSignals":["RAS genotyping"],"summary":"Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07190248"},{"nctId":"NCT04938817","title":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2021-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-10","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-10","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Small Cell Lung Carcinoma"],"interventions":["coformulation pembrolizumab/quavonlimab","lenvatinib","MK-4830","coformulation favezelimab/pembrolizumab","R-DXd"],"countries":["United States","Australia","Austria","Canada","Hungary","Israel","Italy","Poland","Russia","South Korea","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation. Investigational agents will initiate directly in or be added to the efficacy evaluation after an initial evaluation of safety and tolerability of the investigational agent has been completed in a se","sourceUrl":"https://clinicaltrials.gov/study/NCT04938817"},{"nctId":"NCT07740720","title":"A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-09-17","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-12","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Neoplasms, Rectal"],"interventions":["Dostarlimab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["MSI / TMB"],"summary":"This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to treatment and avoid standard treatments like chemotherapy, radiation treatment, or surgery. Scans and endoscopy tests will be conducted to see if the tumor disappears and how long the cancer stays under control. The study will also collect information on side effects and health outcomes after dostarlimab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07740720"},{"nctId":"NCT07544654","title":"DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy","sponsor":"Boehringer Ingelheim","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2026-07-10","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-13","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-11","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Extrapulmonary Neuroendocrine Cancer (epNEC)"],"interventions":["Obrixtamig","Carboplatin","Etoposide","Ventana DLL3 RxDx assay"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","Denmark","Finland","France","Germany","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Poland","Portugal","South Korea","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":164,"serviceSignals":["ADC biomarker"],"summary":"This study is open to adults with advanced extrapulmonary neuroendocrine cancer. The purpose of this study is to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker delta-like ligand 3 (DLL3). Participants are put into 2 groups randomly, which means by chance. One group (treatment arm) receives obrixtamig and standard chemotherapy followed by obrixtamig alon","sourceUrl":"https://clinicaltrials.gov/study/NCT07544654"},{"nctId":"NCT07286266","title":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2026-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-17","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-17","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Ovarian Neoplasms"],"interventions":["Mocertatug rezetecan","Paclitaxel","Pegylated liposomal doxorubicin (PLD)","Topotecan","Gemcitabine","Pembrolizumab","Bevacizumab"],"countries":["Australia","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["ADC biomarker"],"summary":"This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.","sourceUrl":"https://clinicaltrials.gov/study/NCT07286266"},{"nctId":"NCT06380751","title":"Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":788,"enrollmentType":"ESTIMATED","startDate":"2024-08-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-18","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Breast Cancer"],"interventions":["Saruparib (AZD5305)","Camizestrant","Abemaciclib","Ribociclib","Palbociclib","Fulvestrant","Letrozole","Anastrozole","Exemestane"],"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","Canada","Chile","China","Czechia","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","Peru","Poland","Portugal","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":302,"serviceSignals":["HRD / HRR","HER2 profiling"],"summary":"The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06380751"},{"nctId":"NCT06542250","title":"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":174,"enrollmentType":"ESTIMATED","startDate":"2024-09-18","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-18","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-18","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["B-cell Malignancies"],"interventions":["AZD5492"],"countries":["United States","Australia","Canada","China","Denmark","France","Germany","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":31,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT06542250"},{"nctId":"NCT04924075","title":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":355,"enrollmentType":"ESTIMATED","startDate":"2021-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-27","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-27","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Pheochromocytoma/Paraganglioma","Pancreatic Neuroendocrine Tumor","Von Hippel-Lindau Disease","Advanced Gastrointestinal Stromal Tumor","HIF-2α Mutated Cancers"],"interventions":["Belzutifan"],"countries":["United States","Australia","Canada","Chile","China","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Netherlands","Norway","Portugal","Russia","Singapore","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":84,"serviceSignals":["Broad CGP"],"summary":"This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutifan per response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT04924075"},{"nctId":"NCT04260022","title":"Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL","sponsor":"Ascentage Pharma Group Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":242,"enrollmentType":"ESTIMATED","startDate":"2020-01-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-31","completionType":"ESTIMATED","lastUpdated":"2025-11-05","conditions":["Leukemia, Myeloid, Chronic","Myeloid Leukemia","Chronic Myeloid Leukemia","Philadelphia Positive Acute Lymphoblastic Leukemia","B Cell Precursor Type Acute Leukemia"],"interventions":["Ascentage Pharma HQP1351 bioavailable inhibitor","Blinatumomab"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolerance to at least one second or later generation TKI.","sourceUrl":"https://clinicaltrials.gov/study/NCT04260022"},{"nctId":"NCT06357533","title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":675,"enrollmentType":"ESTIMATED","startDate":"2024-04-11","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-28","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-28","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Datopotamab Deruxtecan","Rilvegostomig","Pembrolizumab"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Germany","Hungary","India","Italy","Japan","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":286,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT06357533"},{"nctId":"NCT07718165","title":"A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":247,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Solid Tumor (Phase I)"],"interventions":["ABSK211"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07718165"},{"nctId":"NCT07668960","title":"Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)","sponsor":"Shanghai Mianyi Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06-17","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-30","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection"],"interventions":["BBM-C101"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix. This study include two phases: Phase I and Phase IIa .","sourceUrl":"https://clinicaltrials.gov/study/NCT07668960"},{"nctId":"NCT06724042","title":"Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors","sponsor":"InSilico Medicine Hong Kong Limited","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":159,"enrollmentType":"ESTIMATED","startDate":"2026-12-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor","Advanced and/or Metastatic Solid Tumors"],"interventions":["ISM5939","Cisplatin","Docetaxel","Pembrolizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human Phase 1a/b, open-label, multicenter, dose escalation, optimization and expansion study of ISM5939 to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of ISM5939 in patients with advanced or metastatic solid tumors. The study will be conducted in 3 parts sequentially: Part 1 dose escalation ISM5939 monotherapy, Part 2 dose optimization to determine RP2D of ISM5939 monotherapy, and Part 3 dose expansion in 3 cohorts after initial safety run-in of ISM5939 combination therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06724042"},{"nctId":"NCT07251062","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":737,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2025-11-26","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)","Investigator's choice of SOC","SYS6010+SG001"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07251062"},{"nctId":"NCT07537881","title":"A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors","sponsor":"RemeGen Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":326,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Solid Tumors"],"interventions":["RC288 For Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The primary objective is to evaluate the safety and tolerability of RC288; determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of RC288; and determine the recommended phase 2 dose (RP2D), and assess the efficacy of RC288 at the RP2D dose;","sourceUrl":"https://clinicaltrials.gov/study/NCT07537881"},{"nctId":"NCT06797635","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":372,"enrollmentType":"ESTIMATED","startDate":"2025-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Breast Neoplasms","Breast Cancer"],"interventions":["Patritumab deruxtecan","Pembrolizumab","Paclitaxel","Carboplatin","Doxorubicin hydrochloride","Epirubicin hydrochloride","Cyclophosphamide","Capecitabine","Olaparib"],"countries":["United States","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":17,"serviceSignals":["HER2 profiling"],"summary":"Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people tolerate them * If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06797635"},{"nctId":"NCT07735546","title":"A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma","sponsor":"Umoja Biopharma","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Multiple Myeloma in Relapse","Multiple Myeloma (MM)"],"interventions":["UB-VV500","Rapamycin (sirolimus)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study is a Phase 1 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV500. The study will enroll patients with relapsed/refractory multiple myeloma.","sourceUrl":"https://clinicaltrials.gov/study/NCT07735546"},{"nctId":"NCT07328919","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","sponsor":"TransThera Sciences (Nanjing), Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-01","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-09","conditions":["Intrahepatic Cholangiocarcinoma (Icc)","Advanced Cholangiocarcinoma"],"interventions":["TT-00420 (tinengotinib)","Oxaliplatin, fluorouracil, calcium folinate, irinotecan, capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, randomized, controlled, multicenter, phase III clinical study designed to evaluate the efficacy and safety of TT-00420 tablets as monotherapy versus chemotherapy in subjects with unresectable advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions/rearrangements or mutations, who have experienced recurrence or progression after prior first-line systemic chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07328919"},{"nctId":"NCT07030959","title":"Study of AUBE00 in Patients With Solid Tumors","sponsor":"Chugai Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":130,"enrollmentType":"ESTIMATED","startDate":"2025-06-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Solid Tumors"],"interventions":["AUBE00","Cetuximab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.","sourceUrl":"https://clinicaltrials.gov/study/NCT07030959"},{"nctId":"NCT06977737","title":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","sponsor":"Accession Therapeutics Limited","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2025-03-21","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2034-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Solid Tumor, Adult"],"interventions":["ATTR-01"],"countries":["Spain","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.","sourceUrl":"https://clinicaltrials.gov/study/NCT06977737"},{"nctId":"NCT07370818","title":"To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer","sponsor":"Onconic Therapeutics Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2026-02-27","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-27","conditions":["Ovarian Cancer"],"interventions":["JPI-547","Bevacizumab"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study aims to to evaluate the efficacy, safety, and pharmacokinetics of JPI- 547 with bevacizumab maintenance therapy in relapsed ovarian cancer patients","sourceUrl":"https://clinicaltrials.gov/study/NCT07370818"},{"nctId":"NCT07610941","title":"Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies","sponsor":"Mestag Therapeutics Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":157,"enrollmentType":"ESTIMATED","startDate":"2026-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Cancer-Neoplasms"],"interventions":["MST-0312","Pembrolizumab"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The STARLYS trial is an adaptive, modular, Phase 1, open-label, multi-part, clinical trial evaluating MST-0312 in selected solid tumors. MST-0312 is a targeted bispecific antibody that is designed to locally stimulate the lymphotoxin beta receptor (LTBR) in order to boost the body's immune response to cancer. The LTBR pathway is important in forming tertiary lymphoid structures and high endothelial venules in tumors, which have been associated with improved patient outcomes. The purpose of this study is to determine the safety and tolerability, pharmacodynamics, pharmacokinetics and anti-tumor activity of MST-0312 in subjects with solid malignancies (initially non-small cell lung cancer (NSC","sourceUrl":"https://clinicaltrials.gov/study/NCT07610941"},{"nctId":"NCT07710612","title":"A Phase 2 Study of ABSK043 Combined With Osimertinib","sponsor":"Abbisko Therapeutics Co, Ltd","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":72,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive"],"interventions":["ABSK043 in combination with Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07710612"},{"nctId":"NCT06061809","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":34,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Glioblastoma"],"interventions":["Bevacizumab","PD-L1 t-haNK","N-803","Tumor Treating Fields (TTFields, 200 kHz)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. The phase 2B portion is an open-label, randomized study to evaluate the efficacy and safety for the following 2 experimental arms in participants with recurrent or progressive GBM: NAI, bevacizumab, and TTFields combination therapy (Arm A) or NAI, PD-L1 t-haNK, bevacizumab, and TTFields combination therapy (Arm B). Phase 2 Treatment for all enrolled participants will consist of repeated cycles of 28 days for a maximum treatment period of 76 weeks (19 cycles) as","sourceUrl":"https://clinicaltrials.gov/study/NCT06061809"},{"nctId":"NCT07140016","title":"A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2025-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Non-small Cell Lung Cancer (NSCLC)","Anaplastic Lymphoma Kinase (ALK) Positive"],"interventions":["gilteritinib"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase. People with NSCLC who have the faulty ALK gene are called ALK-positive. ALK inhibitors are an approved treatment for people with ALK positive NSCLC. Some people stop responding to treatment with ALK inhibitors over time due to more changes happening in their faulty ALK gene, so there is an unmet medical need. Gilteritinib is an approved treatment for people with acute myeloid leukemi","sourceUrl":"https://clinicaltrials.gov/study/NCT07140016"},{"nctId":"NCT06508931","title":"Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms","sponsor":"Miltenyi Biomedicine GmbH","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":31,"enrollmentType":"ESTIMATED","startDate":"2025-08-04","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["B-Cell Neoplasm"],"interventions":["zamtocabtagene autoleucel (MB-CART2019.1)"],"countries":["France","Germany","Italy","Netherlands"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \\<18 years, ≥6 kg body weight \\[BW\\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.","sourceUrl":"https://clinicaltrials.gov/study/NCT06508931"},{"nctId":"NCT07197554","title":"A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","sponsor":"SEED Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":171,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Advanced Solid Tumors","Ewing Sarcoma","Hepatocellular Carcinoma (HCC)","Biliary Tract Cancer (BTC)"],"interventions":["ST-01156"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies","sourceUrl":"https://clinicaltrials.gov/study/NCT07197554"},{"nctId":"NCT06726369","title":"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-07","conditions":["Advanced Solid Tumors"],"interventions":["MK-6204 (SKB535) for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"This is an open-label, nonrandomized, multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of MK-6204 as monotherapy in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06726369"},{"nctId":"NCT07380386","title":"SKB105 for Injection in Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":256,"enrollmentType":"ESTIMATED","startDate":"2026-03-05","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumors"],"interventions":["SKB105 for injection Monotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2 clinical study to evaluate the safety and efficacy of SKB105 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07380386"},{"nctId":"NCT07640295","title":"Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-06-22","startDateType":"ESTIMATED","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"interventions":["JAB-23E73 tablet，nab-paclitaxel，gemcitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.","sourceUrl":"https://clinicaltrials.gov/study/NCT07640295"},{"nctId":"NCT07459998","title":"SKB103 for Injection in Advanced Solid Tumors","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":277,"enrollmentType":"ESTIMATED","startDate":"2026-04-23","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-18","conditions":["Advanced Solid Tumors"],"interventions":["SKB103 for injection monotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07459998"},{"nctId":"NCT07283367","title":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":502,"enrollmentType":"ESTIMATED","startDate":"2025-12-22","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2029-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-01","conditions":["CRC"],"interventions":["Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin","Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin","Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label Phase Ib/II clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of the HS-20110 combination therapies in Patients with Advanced Colorectal Cancer. \"Rolling 6\" design would be used to conduct dose escalation part of this study. This study consists of phase Ib and phase II. After RP2D was determined in phase Ib, then a phase II study will be conducted to further evaluate the efficacy, safety, tolerability, and PK of the HS-20110 combination therapies in Patients with mCRC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07283367"},{"nctId":"NCT06292208","title":"A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":48,"enrollmentType":"ESTIMATED","startDate":"2024-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2029-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2025-01-17","conditions":["MTD"],"interventions":["IBD0333"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Primary Objectives Dose escalation phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the maximum tolerated dose (MTD), extended recommended dose (DRDE), and/or dose limiting toxicity (DLT). Dose expansion phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the recommended Phase 2 dose (RP2D). Clinical exploration phase To evaluate the preliminary efficacy of IBD0333 in patients with specific tumor. Secondary objectives Dose escalation phase \\& Dose expansion phase To evaluate the pharmac","sourceUrl":"https://clinicaltrials.gov/study/NCT06292208"},{"nctId":"NCT07625644","title":"BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)","sponsor":"SystImmune Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-06","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Small Cell Lung Cancer Extensive Stage","Small-cell Lung Cancer","Small Cell Carcinoma","Sclc","SCLC,Extensive Stage","Lung Cancer","Lung Cancer Metastatic","Lung Cancer Stage IV"],"interventions":["BL-M14D1 and Atezolizumab","Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07625644"},{"nctId":"NCT07662278","title":"rSIFN-co in Combination With Total Neo-adjuvant Therapy in Subjects With Mid-low Locally Advanced Rectal Cancer","sponsor":"Sichuan Huiyang Life Science and Technology Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2027-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Mid-low Locally Advanced Rectal Cancer"],"interventions":["Recombinant Super-Compound Interferon (rSIFN-co)","Total Neo-adjuvant therapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multi-center, randomized, phase II study, aimed to evaluate the efficacy of investigational product at a dose of 1800 µg/day when given in combination with TNT. There will be two arms included in this study: Arm A (TNT regimen \\+ 1800 µg/day of rSIFN-co treatment) and Arm B (TNT regimen only). Subjects will be randomly assigned to any of the two arms in a 2:1 ratio to receive TNT regimen concurrently with rSIFN-co treatment twice a week or TNT regimen only. The efficacy of rSIFN-co when given in combination with Total Neo-adjuvant Therapy (TNT) will be measured by complete response. Where, complete response is defined as subjects with pathological complete response (pCR) or clinica","sourceUrl":"https://clinicaltrials.gov/study/NCT07662278"},{"nctId":"NCT04696731","title":"Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma","sponsor":"Allogene Therapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2021-02-24","startDateType":"ACTUAL","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced/Metastatic Clear Cell Renal Cell Carcinoma"],"interventions":["ALLO-316","ALLO-647","Fludarabine","Cyclophosphamide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1 dose escalation study using a 3+3 study design, followed by a phase 1b expansion study. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, with or without ALLO-647 to define a Phase 2 dose.","sourceUrl":"https://clinicaltrials.gov/study/NCT04696731"},{"nctId":"NCT06607185","title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2024-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","Colorectal Cancer","Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["LY4066434.","Cetuximab","Nab paclitaxel","Gemcitabine","Oxaliplatin","Leucovorin","Irinotecan","5Fluorouracil","Carboplatin","Cisplatin","Pemetrexed","Pembrolizumab"],"countries":["United States","Belgium","France","Germany","Italy","Japan","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT06607185"},{"nctId":"NCT05643742","title":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","sponsor":"CRISPR Therapeutics AG","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2023-03-10","startDateType":"ACTUAL","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-02","completionType":"ESTIMATED","lastUpdated":"2025-11-14","conditions":["B-cell Lymphoma","Non-Hodgkin Lymphoma","B-cell Malignancy","Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Large B-cell Lymphoma"],"interventions":["CTX112"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT05643742"},{"nctId":"NCT07545122","title":"A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers","sponsor":"Context Therapeutics Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-01","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Triple Negative Breast Cancer (TNBC)","Colorectal Cancer","Urothelial Cancer"],"interventions":["CT-202"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.","sourceUrl":"https://clinicaltrials.gov/study/NCT07545122"},{"nctId":"NCT06581406","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","sponsor":"Replimune, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2024-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-10","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Metastatic Uveal Melanoma"],"interventions":["RP2","Ipilimumab","Nivolumab"],"countries":["United States","Australia","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":33,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06581406"},{"nctId":"NCT07587879","title":"Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors","sponsor":"IntraAb, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2027-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-01","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Advanced Solid Tumor"],"interventions":["mRNA-LNP"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"PMC2129G12 is an investigational intratumorally administered messenger RNA-lipid nanoparticle (mRNA-LNP) immunotherapy designed to enable localized, transient expression of a humanized EpCAM-targeted CD3-engaging bispecific antibody together with the immunostimulatory cytokines to kill tumors by recruited immune T cells.","sourceUrl":"https://clinicaltrials.gov/study/NCT07587879"},{"nctId":"NCT07213674","title":"A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2025-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-07","primaryCompletionType":"ESTIMATED","completionDate":"2032-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["Xaluritamig","Abiraterone acetate","Docetaxel","Cabazitaxel"],"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Greece","Italy","Japan","Netherlands","Portugal","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":144,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).","sourceUrl":"https://clinicaltrials.gov/study/NCT07213674"},{"nctId":"NCT07744152","title":"A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)","sponsor":"Boehringer Ingelheim","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":137,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2030-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-15","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumours"],"interventions":["BI 3822971"],"countries":["Belgium","Germany","Netherlands","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced or metastatic solid cancer, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer. People can join the study if they have no remaining standard treatment options and have a measurable lesion outside the central nervous system. The purpose of this study is to find out how well a medicine called BI 3822971 is tolerated in people with these cancers. Researchers also want to find a dose and dosing schedule of BI 3822971 that is safe and is well tolerated. In this study, BI 3822971 is given to humans for the first tim","sourceUrl":"https://clinicaltrials.gov/study/NCT07744152"},{"nctId":"NCT07459751","title":"A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":706,"enrollmentType":"ESTIMATED","startDate":"2026-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-15","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Advanced or Metastatic Squamous Non-Small Cell Lung Cancer"],"interventions":["HLX43","HLX43+HLX07","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["ADC biomarker"],"summary":"This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs. docetaxel in the treatment of advanced squamous NSCLC after failure of first-line treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07459751"},{"nctId":"NCT05800015","title":"A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":160,"enrollmentType":"ACTUAL","startDate":"2023-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-16","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-23","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Non-small Cell Lung Cancer"],"interventions":["fianlimab","cemiplimab","Pemetrexed","Paclitaxel","Carboplatin","Cisplatin","Placebo"],"countries":["United States","Australia","Canada","Georgia","Israel","Malaysia","South Korea","Taiwan","Thailand","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":76,"serviceSignals":["Broad CGP"],"summary":"This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a \"study drug\" or collectively called \"study drugs\". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who have advanced non-small cell lung cancer (NSCLC). The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is for treating advanced NSCLC, in comparison ","sourceUrl":"https://clinicaltrials.gov/study/NCT05800015"},{"nctId":"NCT06868277","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":830,"enrollmentType":"ESTIMATED","startDate":"2025-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-17","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-02","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Carcinoma, Non-Small Cell Lung"],"interventions":["Rilvegostomig","Pembrolizumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Costa Rica","France","Georgia","Germany","Greece","Ireland","Israel","Italy","Japan","Malaysia","Portugal","Romania","South Korea","Spain","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":304,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06868277"},{"nctId":"NCT07410117","title":"REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1120,"enrollmentType":"ESTIMATED","startDate":"2026-03-09","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-23","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-06","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Cancer-Associated Thrombosis (CAT)"],"interventions":["REGN7508","Placebo"],"countries":["United States","Georgia","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called REGN7508 (called \"study drug\"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at dif","sourceUrl":"https://clinicaltrials.gov/study/NCT07410117"},{"nctId":"NCT07662395","title":"SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","sponsor":"Sinocelltech Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2026-05-09","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-24","primaryCompletionType":"ESTIMATED","completionDate":"2030-01-24","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Double Blind"],"interventions":["SCTB41","Tislelizumab","Paclitaxel","Nab-paclitaxel","Carboplatin","Cisplatin","Pemetrexed"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter Phase II/III study evaluating the efficacy and safety of SCTB41 combined with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment in patients with driver-negative locally advanced or metastatic non-small cell lung cancer (NSCLC). The Phase II portion is an open-label safety run-in study enrolling approximately 30-60 patients to evaluate the safety and tolerability of SCTB41 plus chemotherapy. Following confirmation of acceptable safety and preliminary efficacy, the study will proceed to the Phase III portion. The Phase III portion is a randomized, double-blind, active-controlled study enrolling approximately 350 patients. Eligible partici","sourceUrl":"https://clinicaltrials.gov/study/NCT07662395"},{"nctId":"NCT07206225","title":"A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer","sponsor":"Pfizer","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":294,"enrollmentType":"ESTIMATED","startDate":"2025-11-06","startDateType":"ACTUAL","primaryCompletionDate":"2030-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2033-01-28","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Non-muscle Invasive Bladder Cancer"],"interventions":["PF-08052667","Sasanlimab","BCG","PF-02921367"],"countries":["United States","France","Israel","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":68,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will te","sourceUrl":"https://clinicaltrials.gov/study/NCT07206225"},{"nctId":"NCT07460375","title":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","sponsor":"LigaChem Biosciences, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":191,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2030-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Advanced Solid Tumors"],"interventions":["LCB02A"],"countries":["United States","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.","sourceUrl":"https://clinicaltrials.gov/study/NCT07460375"},{"nctId":"NCT07753590","title":"A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors","sponsor":"BioRay Pharmaceutical Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":258,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2030-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Advanced Solid Tumors"],"interventions":["BR113 for injection"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR113 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR113 for injection in patients with advanced malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07753590"},{"nctId":"NCT05142189","title":"Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer","sponsor":"BioNTech SE","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2022-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Non-Small Cell Lung Cancer"],"interventions":["BNT116","Cemiplimab","Docetaxel","Carboplatin","Paclitaxel","BNT316","anti-B7-H3 antibody conjugated to topoisomerase I inhibitor","anti-HER3 antibody conjugated to topoisomerase I inhibitor","Bispecific antibody for PD-L1 and VEGF-A","Osimertinib","ALK-inhibitor or RET-inhibitor"],"countries":["United States","Australia","Germany","Hungary","Poland","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, osimertinib, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), rearranged during transfection (RET) TKIs, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \\[CTLA-4\\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomer","sourceUrl":"https://clinicaltrials.gov/study/NCT05142189"},{"nctId":"NCT07584057","title":"An Phase I/IIa Clinical Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of INB301 Injection in Patients With Cancer Cachexia","sponsor":"Yunnan Baiyao Group Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":146,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2030-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Cancer Cachexia"],"interventions":["INB301 Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is an open-label, multicenter, multiple-dose Phase I/IIa clinical study to assess the safety/tolerability, PK characteristics,immunogenicity, and preliminary efficacy of INB301 Injection in patients with cancer cachexia. The indication to be explored for Phase I is malignant solid tumor with cachexia; Phase IIa will determine the specific study cohort after discussion between the investigator and the sponsor based on the previously obtained clinical trial data and the benefit/risk ratio of the subjects, and preliminarily consider 3 cohorts of tentative 20-30 patients each, including non-small cell lung cancer, pancreatic cancer and colorectal cancer with cachexia.","sourceUrl":"https://clinicaltrials.gov/study/NCT07584057"},{"nctId":"NCT06890338","title":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2030-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-02","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer","Neoadjuvant"],"interventions":["Carboplatin","Mirvetuximab Soravtansine","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":67,"serviceSignals":["ADC biomarker"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants wit","sourceUrl":"https://clinicaltrials.gov/study/NCT06890338"},{"nctId":"NCT07221357","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":990,"enrollmentType":"ESTIMATED","startDate":"2025-12-31","startDateType":"ACTUAL","primaryCompletionDate":"2030-02-02","primaryCompletionType":"ESTIMATED","completionDate":"2034-03-11","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Untreated, Unresectable, or Metastatic Colorectal Cancer"],"interventions":["Pumitamig","FOLFOX","FOLFIRI","Bevacizumab","CAPOX"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Hungary","India","Italy","Japan","Mexico","Netherlands","Poland","Romania","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":281,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07221357"},{"nctId":"NCT06413680","title":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2024-09-23","startDateType":"ACTUAL","primaryCompletionDate":"2030-02-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-03","completionType":"ESTIMATED","lastUpdated":"2026-04-28","conditions":["Melanoma","Clear-Cell Renal-Cell Carcinoma (ccRCC)","Advanced Solid Tumors"],"interventions":["REGN10597","Cemiplimab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RNA fusion"],"summary":"This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called \"study drug(s)\"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)","sourceUrl":"https://clinicaltrials.gov/study/NCT06413680"},{"nctId":"NCT07543055","title":"A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":36,"enrollmentType":"ESTIMATED","startDate":"2026-07-07","startDateType":"ESTIMATED","primaryCompletionDate":"2030-02-05","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-25","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Prostate Cancer"],"interventions":["BPX-601"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What is the best dose of BPX-601 * How well BPX-601 may work to destroy prostate cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07543055"},{"nctId":"NCT05067283","title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":830,"enrollmentType":"ESTIMATED","startDate":"2021-12-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-02-25","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-25","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Advanced Solid Tumors"],"interventions":["Calderasib","Pembrolizumab","carboplatin","pemetrexed","cetuximab","oxaliplatin","leucovorin","5-fluorouracil"],"countries":["United States","Argentina","Australia","Canada","Chile","China","Denmark","Israel","Italy","Japan","Lithuania","Malaysia","New Zealand","Panama","Poland","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":75,"serviceSignals":["RAS genotyping"],"summary":"This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT05067283"},{"nctId":"NCT04104776","title":"A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2019-09-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-02-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-02-27","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Solid Tumor","Diffuse Large B Cell Lymphoma","Lymphoma, T-Cell","Mesothelioma, Malignant","Prostatic Neoplasms, Castration-Resistant","Endometrial Cancer","Ovarian Clear Cell Carcinoma","Metastatic Castration-resistant Prostate Cancer"],"interventions":["Tulmimetostat","Enzalutamide"],"countries":["United States","France","Italy","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":81,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.","sourceUrl":"https://clinicaltrials.gov/study/NCT04104776"},{"nctId":"NCT07730021","title":"A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":392,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2030-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Locally Advanced or Metastatic Solid Tumors"],"interventions":["ASP388B","Pembrolizumab","Carboplatin","Oxaliplatin","5-fluorouracil"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies. The main aims of the study are to check the safety of ASP388B and find the most suitable dose. This study will be in 2 parts. In Part 1, different small groups of people with solid tumors will receive lower to higher doses of ASP388B. Some groups will receive ASP388B by itself, and other groups will receive ASP388B with standard cancer therapies. Any medical problems will be recorded for each dose. This is to find suitable doses of ASP388B to use in Part 2 of the study, and to inclu","sourceUrl":"https://clinicaltrials.gov/study/NCT07730021"},{"nctId":"NCT07284758","title":"A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"C4 Therapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-02-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Multiple Myeloma","Relapsed/Refractory Multiple Myeloma"],"interventions":["Cemsidomide","Dexamethasone"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).","sourceUrl":"https://clinicaltrials.gov/study/NCT07284758"},{"nctId":"NCT07193511","title":"BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)","sponsor":"Avenzo Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":355,"enrollmentType":"ESTIMATED","startDate":"2025-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumor Cancer","Locally Advanced","Metastatic Solid Tumors","Urothelial Cancer"],"interventions":["AVZO-103","Combination Agent"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["ADC biomarker"],"summary":"This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07193511"},{"nctId":"NCT06805305","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","sponsor":"Diakonos Oncology Corporation","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2032-03","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Glioblastoma (GBM)"],"interventions":["DOC1021","Tumor resection","Temodar (Temozolomide)","SOC cranial radiation"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both","sourceUrl":"https://clinicaltrials.gov/study/NCT06805305"},{"nctId":"NCT04683250","title":"Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities","sponsor":"Taiho Pharmaceutical Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":244,"enrollmentType":"ESTIMATED","startDate":"2020-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-03","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["RET-altered Non Small Cell Lung Cancer","RET-altered Solid Tumors"],"interventions":["TAS0953/HM06"],"countries":["United States","Japan","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.","sourceUrl":"https://clinicaltrials.gov/study/NCT04683250"},{"nctId":"NCT05491525","title":"Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC","sponsor":"Urovant Sciences GmbH","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2022-10-12","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Neurogenic Detrusor Overactivity"],"interventions":["Vibegron"],"countries":["United States","Belgium","Canada","Croatia","Denmark","Georgia","Jordan","Latvia","Lithuania","Malaysia","Philippines","Poland","Romania","Serbia","Slovakia","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC","sourceUrl":"https://clinicaltrials.gov/study/NCT05491525"},{"nctId":"NCT07432295","title":"Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)","sponsor":"I-Mab Biopharma US Limited","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-02-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Solid Tumor","Advanced Cancer","Metastatic Cancer","Gastric Cancer","Gastroesophageal Junction Carcinoma","Esophageal Adenocarcinoma"],"interventions":["Givastomig","Nivolumab","5Fluorouracil","Leucovorin","Oxaliplatin","Capecitabine"],"countries":["United States","China","Japan"],"northAmerica":true,"chinaSites":true,"siteCount":6,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer are: * Does the addition of givastomig to standard therapy increase the amount of time that participants survive without progression of their cancer? * What toxicities do participants experience when taking givastomig? Participants may be able to take part in the study if they have unresectable or metastatic GEA and if their cancer cells express certain proteins called Claudin 18.2 (CLDN18.2) and ","sourceUrl":"https://clinicaltrials.gov/study/NCT07432295"},{"nctId":"NCT07346144","title":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","sponsor":"Trogenix ltd","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2026-04-21","startDateType":"ACTUAL","primaryCompletionDate":"2030-03","primaryCompletionType":"ESTIMATED","completionDate":"2033-09","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Glioblastoma (GBM)","High Grade Gliomas","Recurrent Glioblastoma","Newly Diagnosed Glioblastoma"],"interventions":["TGX-007","Valaciclovir"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma. TGX-007 is a gene therapy drug delivered by a harmless adeno-associated virus (AAV) vector which delivers two combined therapeutic payloads to enable killing of proliferative cells and activation of an anti-tumour immune response. One is herpes simplex virus thymidine kinase (HSV-tk), which converts the pro-drug valaciclovir into an active drug that can kill tumour cells and the other is interleukin 12 (IL-12), which activates the body's immune system to recogni","sourceUrl":"https://clinicaltrials.gov/study/NCT07346144"},{"nctId":"NCT07392866","title":"A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-03-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-01","completionType":"ESTIMATED","lastUpdated":"2026-02-09","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["SH006","Bevacizumab","Oxaliplatin injection","Capecitabine","Regorafenib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07392866"},{"nctId":"NCT05952557","title":"An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":5500,"enrollmentType":"ESTIMATED","startDate":"2023-10-05","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-04","primaryCompletionType":"ESTIMATED","completionDate":"2037-05-06","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["Breast Cancer, Early Breast Cancer"],"interventions":["Camizestrant","Tamoxifen","Anastrozole","Letrozole","Exemestane","Abemaciclib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Estonia","France","Georgia","Germany","Greece","Hungary","India","Ireland","Israel","Italy","Japan","Malaysia","Mexico","New Zealand","Peru","Philippines","Poland","Portugal","Puerto Rico","Romania","Saudi Arabia","Serbia","South Africa","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Arab Emirates","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":798,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT05952557"},{"nctId":"NCT05215340","title":"Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":740,"enrollmentType":"ACTUAL","startDate":"2022-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-04","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-04","completionType":"ESTIMATED","lastUpdated":"2026-06-12","conditions":["Metastatic Non Small Cell Lung Cancer"],"interventions":["Datopotamab Deruxtecan","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":234,"serviceSignals":["Broad CGP"],"summary":"This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC) of non-squamous histology.","sourceUrl":"https://clinicaltrials.gov/study/NCT05215340"},{"nctId":"NCT06987539","title":"A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)","sponsor":"Amgen","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2030-03-13","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-13","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Generalized Myasthenia Gravis"],"interventions":["Inebilizumab"],"countries":["United States","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of inebilizumab administered in pediatric participants with gMG.","sourceUrl":"https://clinicaltrials.gov/study/NCT06987539"},{"nctId":"NCT05338931","title":"Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","sponsor":"AbClon","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":82,"enrollmentType":"ESTIMATED","startDate":"2022-03-15","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-15","completionType":"ESTIMATED","lastUpdated":"2022-05-26","conditions":["B-cell Non Hodgkin Lymphoma"],"interventions":["AT101(Anti-CD19 Chimeric Antigen Receptor T cell)"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.","sourceUrl":"https://clinicaltrials.gov/study/NCT05338931"},{"nctId":"NCT07182591","title":"A Study of DS5361b in Participants With Advanced Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2025-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-03","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Advanced Solid Tumor"],"interventions":["DS5361b","Pembrolizumab"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07182591"},{"nctId":"NCT04221542","title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":479,"enrollmentType":"ESTIMATED","startDate":"2020-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-22","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-21","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Prostate Cancer"],"interventions":["AMG 509","Abiraterone","Enzalutamide"],"countries":["United States","Australia","China","Germany","Japan","Portugal","South Korea","Spain","Switzerland","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":57,"serviceSignals":["Hematology NGS"],"summary":"The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.","sourceUrl":"https://clinicaltrials.gov/study/NCT04221542"},{"nctId":"NCT05125016","title":"A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":228,"enrollmentType":"ESTIMATED","startDate":"2021-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-28","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["REGN4336","REGN5678"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This study is researching an investigational drug called REGN4336 both alone or together with another investigational drug called REGN5678. The study is focused on participants with previously treated metastatic prostate cancer. The main purpose of the study is to look at the safety, tolerability (how the body reacts to the drug) and effectiveness (how well the drug works to shrink tumors) of REGN4336 when given in combination with REGN5678. The study has 2 parts. The purpose of Part 1 is to determine a safe dose(s) of REGN4336 to be given alone or in combination with REGN5678. Part 1 is known as the \"dose escalation\" phase. The purpose of Part 2, (known as the \"dose expansion\" phase), is to","sourceUrl":"https://clinicaltrials.gov/study/NCT05125016"},{"nctId":"NCT07222800","title":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":800,"enrollmentType":"ESTIMATED","startDate":"2025-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-01","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Intestinal Neoplasms","Gastrointestinal Neoplasms","Digestive System Neoplasms","Neoplasms by Site","Digestive System Diseases","Gastrointestinal Diseases","Colonic Diseases","Intestinal Diseases","Rectal Diseases","Colorectal Neoplasms"],"interventions":["PF-08634404","Bevacizumab","Chemotherapy"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Israel","Italy","Japan","Poland","Puerto Rico","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":285,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have colorectal cancer that has spread to other parts of your body. * Be in good enough health to receive study treatment. * Should not be pregnant before starting treatment. Participants will be randomized (like flipping a coin) to one of 2 di","sourceUrl":"https://clinicaltrials.gov/study/NCT07222800"},{"nctId":"NCT07446855","title":"Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-29","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Solid Tumours"],"interventions":["AZD4956","Saruparib"],"countries":["United States","Australia","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["HRD / HRR"],"summary":"The purpose of this modular, first trial in human study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of ascending dose levels (DLs) of AZD4956 monotherapy and in combination with other anti-cancer agents in participants with advanced/metastatic solid tumours with homologous recombination repair (HRR) deficiencies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07446855"},{"nctId":"NCT07540572","title":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors","sponsor":"IDEAYA Biosciences","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-03-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-16","conditions":["ER+, HER 2- Breast Cancer","Non-small Cell Lung Cancer (NSCLC)","Castration-resistant Prostate Cancer (CRPC)","Microsatellite Stable (MSS) Colorectal Carcinoma"],"interventions":["IDE574","Fulvestrant injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["HER2 profiling","MSI / TMB"],"summary":"IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic ER+, HER2- breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07540572"},{"nctId":"NCT07583316","title":"A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors","sponsor":"Corregene Biotechnology Co., Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":192,"enrollmentType":"ESTIMATED","startDate":"2026-05-29","startDateType":"ESTIMATED","primaryCompletionDate":"2030-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Lung Cancer (Locally Advanced or Metastatic)","Esophagus Cancer","Head and Neck Cancer","Hepatocellular Carcinoma (HCC)"],"interventions":["CRPA1A2"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS","HLA / TCR"],"summary":"This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A\\*02:01-positive and MAGE-A1-positive advanced solid tumors. The study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of CRPA1A2, and to identify recommended dose(s) for further evaluation. The study consists of 2 parts: a dose escalation part (Part A) and a dose optimization part (Part B). In Part A, participants will receive escalating doses of CRPA1A2 to determine the recommended dose(s) for optimization, with additional backfill cohorts permitted. In Part B, 2 to 3 selected recommended dose(s) wil","sourceUrl":"https://clinicaltrials.gov/study/NCT07583316"},{"nctId":"NCT07108270","title":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2025-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-31","completionType":"ESTIMATED","lastUpdated":"2025-12-22","conditions":["Neoplasms, Endometrial"],"interventions":["Dostarlimab","Carboplatin","Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.","sourceUrl":"https://clinicaltrials.gov/study/NCT07108270"},{"nctId":"NCT07751744","title":"Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma","sponsor":"Jubilant Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":113,"enrollmentType":"ESTIMATED","startDate":"2028-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Brain Metastases From Solid Tumors","Leptomeningeal Disease","High Grade Glioma (HGG)","Glioblastoma (GBM)"],"interventions":["JBI-778"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, multicenter, open-label, dose-escalation and dose-expansion study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), cerebrospinal fluid penetration, and preliminary antitumor activity of orally administered JBI-778, a selective PRMT5 inhibitor, in patients with brain metastases, leptomeningeal disease, or recurrent high-grade glioma. The study consists of a dose-escalation phase to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), followed by expansion cohorts to evaluate preliminary efficacy at the RP2D.","sourceUrl":"https://clinicaltrials.gov/study/NCT07751744"},{"nctId":"NCT07566156","title":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":390,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-29","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Urothelial Cancer","Urinary Bladder Neoplasms"],"interventions":["Enfortumab vedotin","Conventional Radiotherapy","Hypofractionated Radiotherapy","Cisplatin","Fluorouracil","Mitomycin C","Gemcitabine","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.","sourceUrl":"https://clinicaltrials.gov/study/NCT07566156"},{"nctId":"NCT07711067","title":"A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer","sponsor":"ElmediX","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":95,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Pancreatic Ductal Adenocarcinoma (mPDAC)","Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)"],"interventions":["Whole-body hyperthermia","Standard-of-Care Systemic therapy"],"countries":["Belgium","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis and limited treatment options following failure of first-line therapy. Whole-body hyperthermia (WBHT) is a non-invasive treatment approach that raises the body's core temperature under controlled conditions and may enhance the effects of anticancer therapies through multiple biological mechanisms, including improved drug delivery, modulation of the immune response, and increased sensitivity to treatment. The MATTERS-2 study is a multicentre, randomized clinical trial designed to evaluate the efficacy and safety of WBHT in combination with standard systemic anticancer therapy in patients with metastatic PDAC after failu","sourceUrl":"https://clinicaltrials.gov/study/NCT07711067"},{"nctId":"NCT07518329","title":"Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.","sponsor":"Arovella Therapeutics Ltd","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":46,"enrollmentType":"ESTIMATED","startDate":"2026-08-20","startDateType":"ESTIMATED","primaryCompletionDate":"2030-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-30","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non Hodgkin Lymphoma (NHL)","Leukaemia"],"interventions":["ALA-101"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101","sourceUrl":"https://clinicaltrials.gov/study/NCT07518329"},{"nctId":"NCT07605962","title":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","sponsor":"United Immunity, co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2026-05-20","startDateType":"ACTUAL","primaryCompletionDate":"2030-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Advanced Cancer"],"interventions":["UI-102"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.","sourceUrl":"https://clinicaltrials.gov/study/NCT07605962"},{"nctId":"NCT07114601","title":"A Study of LY4257496 in Participants With Cancer (OMNIRAY)","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":421,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2035-04","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Neoplasms","Colorectal Neoplasms","Prostate Neoplasm","Endometrial Neoplasms","Neoplasm Metastasis","Stomach Neoplasms","Esophageal Neoplasms"],"interventions":["LY4257496","Standard of Care Anticancer Therapies","LY4257529"],"countries":["United States","Canada","China","France","Germany","Japan","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":32,"serviceSignals":["Broad CGP"],"summary":"The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.","sourceUrl":"https://clinicaltrials.gov/study/NCT07114601"},{"nctId":"NCT05735184","title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML","sponsor":"Kura Oncology, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2023-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-03-13","conditions":["Acute Myeloid Leukemia","Mixed Lineage Leukemia Gene Mutation","Refractory AML","AML With Mutated NPM1","Acute Myeloid Leukemia Recurrent","Acute Myeloid Leukemia, in Relapse","NPM1 Mutation","KMT2Ar","Myeloid Sarcoma","Nucleophosmin 1-mutated Acute Myeloid Leukemia"],"interventions":["Ziftomenib","Venetoclax","Azacitidine","Daunorubicin","Cytarabine","Quizartinib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":44,"serviceSignals":["Hematology NGS"],"summary":"Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.","sourceUrl":"https://clinicaltrials.gov/study/NCT05735184"},{"nctId":"NCT05257993","title":"Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer","sponsor":"Onconic Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":71,"enrollmentType":"ESTIMATED","startDate":"2022-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Pancreatic Ductal Adenocarcinoma"],"interventions":["JPI-547","modified FOLFIRINOX","Gemcitabine-nab-paclitaxel"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and metastatic pancreatic cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT05257993"},{"nctId":"NCT03547973","title":"Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread","sponsor":"Gilead Sciences","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":827,"enrollmentType":"ESTIMATED","startDate":"2018-08-13","startDateType":"ACTUAL","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Metastatic Urothelial Cancer"],"interventions":["Sacituzumab Govitecan-hziy","Pembrolizumab","Cisplatin","Avelumab","Zimberelimab","Carboplatin","Gemcitabine","Domvanalimab","Enfortumab Vedotin"],"countries":["United States","France","Germany","Greece","Italy","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":135,"serviceSignals":["Broad CGP"],"summary":"The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03547973"},{"nctId":"NCT07501559","title":"A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Recurrent Glioblastoma Multiforme(GBM)"],"interventions":["JL15003Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to evaluate the safety and efficacy of JL15003 Injection in subjects with recurrent glioblastoma (rGMB).","sourceUrl":"https://clinicaltrials.gov/study/NCT07501559"},{"nctId":"NCT06926283","title":"A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors","sponsor":"Hangzhou DAC Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":110,"enrollmentType":"ESTIMATED","startDate":"2025-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-04","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Prostate Cancer","Other Solid Tumors","Ewing Sarcoma"],"interventions":["DXC008"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.","sourceUrl":"https://clinicaltrials.gov/study/NCT06926283"},{"nctId":"NCT06126640","title":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1615,"enrollmentType":"ACTUAL","startDate":"2023-11-20","startDateType":"ACTUAL","primaryCompletionDate":"2030-04","primaryCompletionType":"ESTIMATED","completionDate":"2032-04","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy"],"interventions":["SHR-A1811","Trastuzumab Emtansine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This study aims to Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants with Residual Invasive Disease Following Neoadjuvant Therapy，This study will examine SHR-A1811versus trastuzumab emtansine (T-DM1) in patients with HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes after neoadjuvant therapy.The primary objective is to compare invasive disease-free survival (IDFS) between SHR-A1811 and T-DM1 treatment arms in this population. The key secondary objective of the study is to evaluate disease-free survival (DFS), overall survival (OS) and distant recurrence-free inte","sourceUrl":"https://clinicaltrials.gov/study/NCT06126640"},{"nctId":"NCT07705035","title":"DBC-664 in Adult Patients With Solid Tumors","sponsor":"Duboce Biopharmaceuticals, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2026-06-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-01","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Malignant Germ Cell Tumor","Lung Adenocarcinoma","Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma","Urothelial Carcinoma","Endometrial Adenocarcinoma","Ovarian Adenocarcinoma"],"interventions":["DBC-664"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.","sourceUrl":"https://clinicaltrials.gov/study/NCT07705035"},{"nctId":"NCT07750158","title":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":600,"enrollmentType":"ESTIMATED","startDate":"2026-08-06","startDateType":"ESTIMATED","primaryCompletionDate":"2030-04-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-05","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Colorectal Cancer"],"interventions":["Zanzalintinib","MK-34574","Placebo"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ctDNA / MRD","MSI / TMB"],"summary":"The primary objective of this study is to evaluate the effectiveness of zanzalintinib + MK-3475A and zanzalintinib alone compared with placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT07750158"},{"nctId":"NCT06686394","title":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":81,"enrollmentType":"ESTIMATED","startDate":"2025-02-26","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-18","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Breast Neoplasms","Breast Cancer"],"interventions":["Patritumab deruxtecan","Trastuzumab","Trastuzumab Biosimilar","Pertuzumab","Tucatinib"],"countries":["United States","Canada","Israel","Japan","South Korea","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["HER2 profiling"],"summary":"Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT06686394"},{"nctId":"NCT06117774","title":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":404,"enrollmentType":"ACTUAL","startDate":"2024-02-20","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-20","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-20","completionType":"ESTIMATED","lastUpdated":"2026-04-29","conditions":["Limited Stage Small Cell Lung Cancer","Small Cell Lung Cancer"],"interventions":["Tarlatamab","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","China","Colombia","France","Germany","Greece","Hong Kong","Italy","Japan","Mexico","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":204,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS) based on blinded independent central review (BCIR) per response evaluation criteria in solid tumors v1.1 (RECIST 1.1) and on prolonging overall survival (OS).","sourceUrl":"https://clinicaltrials.gov/study/NCT06117774"},{"nctId":"NCT07558200","title":"Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors","sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":138,"enrollmentType":"ESTIMATED","startDate":"2026-05-15","startDateType":"ESTIMATED","primaryCompletionDate":"2030-04-23","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-18","completionType":"ESTIMATED","lastUpdated":"2026-04-30","conditions":["Solid Tumors","Non-Small Cell Lung Cancer","Hepatocellular Carcinoma"],"interventions":["Intervention1：FXB0871","Intervention2：FXB0871","Intervention3：FXB0871","Intervention4：FXB0871"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with selected locally advanced or metastatic solid tumors. In Part Ia, participants with selected solid tumors that have progressed after, are intolerant to, or are not suitable for standard therapy will receive FXB0871 in dose-escalation cohorts to determine the maximum tolerated dose and/or recommended phase 2 dose. In Part Ib, participants with PD-(L)1-resistant non-small cell lung cancer or hepatocellular carcinoma will receive FXB0871 in dose-expansion cohorts to further e","sourceUrl":"https://clinicaltrials.gov/study/NCT07558200"},{"nctId":"NCT06899126","title":"Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":686,"enrollmentType":"ESTIMATED","startDate":"2025-10-24","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-24","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-24","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Non-small Cell Lung Cancer"],"interventions":["Trastuzumab Deruxtecan","pembrolizumab","Pemetrexed","Platinum Chemotherapy"],"countries":["United States","Argentina","Belgium","Brazil","Chile","China","France","Germany","Greece","Hong Kong","India","Italy","Japan","Malaysia","Poland","Portugal","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":237,"serviceSignals":["HER2 profiling"],"summary":"This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \\<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.","sourceUrl":"https://clinicaltrials.gov/study/NCT06899126"},{"nctId":"NCT07707895","title":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","sponsor":"Boehringer Ingelheim","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-08-26","startDateType":"ESTIMATED","primaryCompletionDate":"2030-04-26","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-26","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Small Cell Lung Cancer","Large Cell Neuroendocrine Lung Carcinoma","Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology","Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology"],"interventions":["Obrixtamig","ZL-1310","Atezolizumab"],"countries":["United States","Australia","Belgium","China","France","Germany","Japan","Netherlands","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and ZL-1310 is tolerated when given with another medicine called a checkpoint inhibitor. Another purpose is to check whether the study treatment can stop the cancer from growing and keep it stable. Obrixtamig and ZL-1310 are being developed to help the immune system fight cancer. In Part 1, participants get obrixtamig and ZL-1310. In Part 2, participants get obrixtamig and ZL-1310 with a checkpoint inhibitor. Part 2 is ","sourceUrl":"https://clinicaltrials.gov/study/NCT07707895"},{"nctId":"NCT07710690","title":"A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma","sponsor":"Neuregen Therapeutics Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":24,"enrollmentType":"ESTIMATED","startDate":"2026-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["HGG","High Grade Glioma (III or IV)","High Grade Glioma"],"interventions":["NRG-103"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to determine the safe dose range of NRG-103 in patients and to recommend the dosage for subsequent treatment, while also evaluating the preliminary efficacy and tolerability of the product.","sourceUrl":"https://clinicaltrials.gov/study/NCT07710690"},{"nctId":"NCT05719558","title":"A Study of ASP1002 in Adults for Treatment of Solid Tumors","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":798,"enrollmentType":"ESTIMATED","startDate":"2023-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Solid Tumors"],"interventions":["ASP1002","Bevacizumab","Oxaliplatin","Leucovorin","Fluorouracil","Irinotecan","Trifluridine-Tipiracil","Pembrolizumab","Pemetrexed","Carboplatin","Ramucirumab","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["MSI / TMB","ADC biomarker"],"summary":"ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of the body. ASP1002 is thought to work by attaching to the CLDN4 protein in the tumor. This switches on the body's immune system to attack the tumor. Before ASP1002 can be used, researchers need to collect information about the safety of ASP1002 and how people with tumors tolerate it. In this study, ASP1002 will be given to humans for the first time. It will either be given by itself or together with o","sourceUrl":"https://clinicaltrials.gov/study/NCT05719558"},{"nctId":"NCT04058756","title":"Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":120,"enrollmentType":"ACTUAL","startDate":"2019-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Solid Tumors"],"interventions":["PDR001"],"countries":["United States","Belgium","Canada","China","Czechia","France","Germany","Hong Kong","Hungary","Italy","Netherlands","Poland","South Korea","Spain","Switzerland","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT04058756"},{"nctId":"NCT06590246","title":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","sponsor":"Shanghai AbelZeta Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2024-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2043-04-30","completionType":"ESTIMATED","lastUpdated":"2026-01-02","conditions":["Hepatocellular Carcinoma"],"interventions":["Armored and GPC3-targeted autologous CAR T-cell"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT06590246"},{"nctId":"NCT07710885","title":"Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer","sponsor":"Taiho Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":784,"enrollmentType":"ESTIMATED","startDate":"2026-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2030-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Biliary Tract Cancer"],"interventions":["Futibatinib","Zimberelimab","Durvalumab","Pembrolizumab","Gemcitabine","Cisplatin"],"countries":["Australia","Japan","South Korea","Thailand"],"northAmerica":false,"chinaSites":false,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07710885"},{"nctId":"NCT07162181","title":"Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers","sponsor":"Eli Lilly and Company","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":13,"enrollmentType":"ESTIMATED","startDate":"2025-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2030-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-04-17","conditions":["Lymphoma, Non-Hodgkin","Leukemia, Lymphocytic, Chronic, B-Cell","B-cell Lymphoma"],"interventions":["Pirtobrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07162181"},{"nctId":"NCT07186842","title":"A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":245,"enrollmentType":"ESTIMATED","startDate":"2025-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Advanced Solid Cancers"],"interventions":["BNT329","CA19-9-targeting monoclonal antibody"],"countries":["United States","Australia","Germany","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["ADC biomarker"],"summary":"The main goal of this study is to evaluate the safety of BNT329 and to identify the best dose of BNT329. This will be done by measuring the number of side effects that participants experience and how severe they are. The second goal of this study is to evaluate how well BNT329 works. This will be done by measuring the number of participants who respond to the treatment. The length of time where the tumor does not grow or spread will also be measured. The study will also evaluate how BNT329 moves into, through, and out of the body and how the treatment affects the body.","sourceUrl":"https://clinicaltrials.gov/study/NCT07186842"},{"nctId":"NCT07603479","title":"A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":14,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2030-05","primaryCompletionType":"ESTIMATED","completionDate":"2030-05","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Malignancies","Solid Malignant Tumor","NHL (Non-Hodgkin Lymphoma)","Solid Tumor Cancer"],"interventions":["JL19001, subcutaneous injection, 1 μg/kg","JL19001, subcutaneous injection, 5 μg/kg","JL19001, subcutaneous injection,10 μg/kg","JL19001, subcutaneous injection,15 μg/kg","JL19001, subcutaneous injection,20 μg/kg","JL19001, subcutaneous injection,25 μg/kg"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients with AST and r/r B-NHL. Only the Phase Ia protocol design is registered at this time. A total of 6 dose cohorts are planned for Phase Ia, i.e., 1, 5, 10, 15, 20, and 25 μg/kg, with the administration route being subcutaneous injection. A traditional 3 + 3 dose escalation design will be used. The MTD and Recommended Maximum Add-on Dose (RMAD) for JL19001 Injection will be determined.","sourceUrl":"https://clinicaltrials.gov/study/NCT07603479"},{"nctId":"NCT07489755","title":"TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients","sponsor":"Shenzhen TargetRx Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-04-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-05-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-01","completionType":"ESTIMATED","lastUpdated":"2026-03-24","conditions":["Chronic Myelogenous Leukemia","Chronic Myelogenous Leukemia - Chronic Phase"],"interventions":["TGRX-678","TKI"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs","sourceUrl":"https://clinicaltrials.gov/study/NCT07489755"},{"nctId":"NCT06153251","title":"A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":187,"enrollmentType":"ESTIMATED","startDate":"2024-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-02","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Relapsed and/or Refractory Multiple Myeloma"],"interventions":["BMS-986453","Fludarabine","Cyclophosphamide"],"countries":["United States","France","Germany","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT06153251"},{"nctId":"NCT07195682","title":"A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)","sponsor":"Bristol-Myers Squibb","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":125,"enrollmentType":"ESTIMATED","startDate":"2026-01-15","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-03","completionType":"ESTIMATED","lastUpdated":"2026-06-09","conditions":["Renal Cell Carcinoma"],"interventions":["BMS-986506"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07195682"},{"nctId":"NCT06585410","title":"Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":369,"enrollmentType":"ESTIMATED","startDate":"2025-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-03","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Cutaneous Squamous Cell Carcinoma (CSCC)"],"interventions":["Cemiplimab","Standard of care"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called Programmed cell Death-1 (PD-1) on the surface of certain immune cells. The main purpose of this study is to compare how well cemiplimab works compared to surgery, when injected into the lesion. The study is looking at: * The side effects cemiplimab might cause * How well cemiplimab works compared to surgery","sourceUrl":"https://clinicaltrials.gov/study/NCT06585410"},{"nctId":"NCT07223190","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","sponsor":"Amgen","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":560,"enrollmentType":"ESTIMATED","startDate":"2026-06-11","startDateType":"ESTIMATED","primaryCompletionDate":"2030-05-10","primaryCompletionType":"ESTIMATED","completionDate":"2033-08-09","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia"],"interventions":["Blinatumomab","HyperCVAD"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The main objective of this trial is to demonstrate that subcutaneous (SC) blinatumomab in conjunction with chemotherapy (Arm B) is non-inferior to continuous intravenous infusion (cIV) blinatumomab in conjunction with chemotherapy (Arm A) in overall survival (OS) in newly diagnosed participants with Philadelphia chromosome (Ph) negative B-cell precursor acute lymphoblastic leukemia (B-ALL) who are in complete remission (CR) or CR with incomplete peripheral count recovery (CRi) after induction.","sourceUrl":"https://clinicaltrials.gov/study/NCT07223190"},{"nctId":"NCT05765851","title":"A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":108,"enrollmentType":"ESTIMATED","startDate":"2023-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-15","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Solid Tumor"],"interventions":["DS-1103a","T-DXd"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT05765851"},{"nctId":"NCT06841354","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2025-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-18","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Triple Negative Breast Neoplasms"],"interventions":["Sacituzumab tirumotecan","Pembrolizumab","Rescue Medication","Paclitaxel","Nab-paclitaxel","Gemcitabine","Carboplatin"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Peru","Philippines","Poland","Romania","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":268,"serviceSignals":["ADC biomarker"],"summary":"Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06841354"},{"nctId":"NCT07684612","title":"A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":690,"enrollmentType":"ESTIMATED","startDate":"2026-09-22","startDateType":"ESTIMATED","primaryCompletionDate":"2030-05-21","primaryCompletionType":"ESTIMATED","completionDate":"2033-04-22","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Ovarian Neoplasms"],"interventions":["Mocertatug rezetecan (Mo-Rez)","Carboplatin","Paclitaxel","Gemcitabine","Pegylated liposomal doxorubicin (PLD)","Bevacizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes cancers smaller or disappear completely and if it helps participants live longer. The study also assesses whether Mo-Rez in combination with bevacizumab is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of Mo-Rez.","sourceUrl":"https://clinicaltrials.gov/study/NCT07684612"},{"nctId":"NCT07441694","title":"Study of INCA036978 in Participants With Myeloproliferative Neoplasms","sponsor":"Incyte Corporation","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":218,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-24","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-24","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Myeloproliferative Neoplasms"],"interventions":["INCA036978","Standard disease-directed therapy"],"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":54,"serviceSignals":["Hematology NGS"],"summary":"This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07441694"},{"nctId":"NCT07297979","title":"Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-04-08","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-26","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-26","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Ewing Sarcoma"],"interventions":["Xaluritamig"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.","sourceUrl":"https://clinicaltrials.gov/study/NCT07297979"},{"nctId":"NCT06469281","title":"A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2024-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-27","completionType":"ESTIMATED","lastUpdated":"2026-02-03","conditions":["Epithelial Ovarian Cancer","Primary Peritoneal Carcinoma","Fallopian Tube Cancer"],"interventions":["27T51","Cemiplimab","Bevacizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may inc","sourceUrl":"https://clinicaltrials.gov/study/NCT06469281"},{"nctId":"NCT05061550","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","sponsor":"AstraZeneca","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":630,"enrollmentType":"ESTIMATED","startDate":"2022-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-28","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-28","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Non-small Cell Lung Cancer"],"interventions":["Durvalumab","Oleclumab","Monalizumab","Dato-DXd","AZD0171","Carboplatin","Cisplatin","Pemetrexed/Cisplatin","Pemetrexed/Carboplatin","Carboplatin/Paclitaxel","Volrustomig","Rilvegostomig"],"countries":["United States","Belgium","Canada","France","Hungary","Ireland","Italy","Portugal","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":97,"serviceSignals":["Broad CGP"],"summary":"The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05061550"},{"nctId":"NCT03701334","title":"A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":5101,"enrollmentType":"ACTUAL","startDate":"2018-12-07","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-29","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Early Breast Cancer"],"interventions":["Ribociclib","Endocrine Therapy (ET)"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Hungary","Ireland","Italy","Poland","Romania","Russia","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":387,"serviceSignals":["HER2 profiling"],"summary":"A phase III, multicenter, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with Endocrine Therapy (ET) as an adjuvant treatment in women and men with Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 negative (HER2-) Early Breast Cancer (EBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT03701334"},{"nctId":"NCT06500884","title":"A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":210,"enrollmentType":"ESTIMATED","startDate":"2024-08-26","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Multiple Myeloma"],"interventions":["Talquetamab","Prophylaxis A","Prophylaxis B","Prophylaxis C","Prophylaxis D","Ramantamig"],"countries":["United States","Brazil","Netherlands","Puerto Rico","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.","sourceUrl":"https://clinicaltrials.gov/study/NCT06500884"},{"nctId":"NCT07681674","title":"Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product","sponsor":"BicycleTx Limited","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":16,"enrollmentType":"ESTIMATED","startDate":"2026-08-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Advanced Solid Tumors"],"interventions":["Zelenectide pevedotin","BT7480","Nuzefatide pevedotin"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07681674"},{"nctId":"NCT03394365","title":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy","sponsor":"Pierre Fabre Medicament","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":115,"enrollmentType":"ESTIMATED","startDate":"2017-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2030-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-08","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)","Solid Organ Transplant Complications","Lymphoproliferative Disorders","Allogeneic Hematopoietic Cell Transplant","Stem Cell Transplant Complications"],"interventions":["tabelecleucel"],"countries":["United States","Australia","Austria","Belgium","Canada","France","Italy","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":71,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.","sourceUrl":"https://clinicaltrials.gov/study/NCT03394365"},{"nctId":"NCT07620574","title":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","sponsor":"Exelixis","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":5000,"enrollmentType":"ESTIMATED","startDate":"2026-05-31","startDateType":"ESTIMATED","primaryCompletionDate":"2030-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-05-31","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Cancer","Renal Cell Carcinoma (RCC)","Pancreatic Neuroendocrine Tumors (pNET)","Extra-Pancreatic NET (epNET)","Hepatocellular Carcinoma (HCC)","Differentiated Thyroid Cancer (DTC)","Non-Clear Cell Renal Cell Carcinoma (nccRCC)","Colorectal Cancer","Prostate Cancer"],"interventions":["Cabozantinib","Zanzalintinib","Atezolizumab","Nivolumab","Abiraterone","Prednisone","Enzalutamide"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.","sourceUrl":"https://clinicaltrials.gov/study/NCT07620574"},{"nctId":"NCT07544056","title":"A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer","sponsor":"BeBetter Med Inc","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":446,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2030-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Locally Advanced Triple-negative Breast Cancer","Metastatic Triple-negative Breast Cancer"],"interventions":["BEBT-209 capsules","Carboplatin Injection","Gemcitabine Hydrochloride for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Title: A Study to See if BEBT-209 Combined With Chemotherapy Works to Treat People With Triple-Negative Breast Cancer Researchers want to learn if a new drug called BEBT-209 works to treat people with a specific type of breast cancer. This cancer is called locally advanced or metastatic triple-negative breast cancer (TNBC). The study has two parts. In the first part, researchers want to see if the new drug combination can shrink tumors. In the second part, researchers want to see if this treatment helps people live longer. Researchers will put participants into two groups by chance. This is like flipping a coin. Group 1: Participants get BEBT-209 plus two chemotherapy drugs. These drugs are ","sourceUrl":"https://clinicaltrials.gov/study/NCT07544056"},{"nctId":"NCT06270706","title":"A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors","sponsor":"Pliant Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":124,"enrollmentType":"ESTIMATED","startDate":"2023-08-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Advanced or Metastatic Solid Tumor"],"interventions":["PLN-101095","Pembrolizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["MSI / TMB"],"summary":"This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \\[primary resistance\\]) or relapsed \\[secondary resistance\\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design with a","sourceUrl":"https://clinicaltrials.gov/study/NCT06270706"},{"nctId":"NCT07038343","title":"AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)","sponsor":"Avenzo Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":480,"enrollmentType":"ESTIMATED","startDate":"2025-06-04","startDateType":"ACTUAL","primaryCompletionDate":"2030-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Solid Tumor Cancer","Locally Advanced","Metastatic Solid Tumors","Lung Cancers","Epithelial Tumor","Biliary Tract Cancer (BTC)","Urothelial Cancer","Nasopharyngeal Cancers"],"interventions":["AVZO-1418","Combination Agent 1","Combination Agent 2"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07038343"},{"nctId":"NCT07424287","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":236,"enrollmentType":"ESTIMATED","startDate":"2026-07-13","startDateType":"ACTUAL","primaryCompletionDate":"2030-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-06","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["NMIBC"],"interventions":["SHR-1501 for Injection","BCG for Injection","Epirubicin Hydrochloride for Injection","Pirarubicin Hydrochloride for Injection","Gemcitabine Hydrochloride for Injection","Hydroxycamptothecin for Injection","Mitomycin for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label phase III study to determine the efficacy and safety of intravesical SHR-1501 combined with Bacillus Calmette Guerin (BCG) versus investigator-selected chemotherapy in patients with BCG-unresponsive papillary-only non-muscle-invasive bladder cancer (NMIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07424287"},{"nctId":"NCT06726161","title":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","sponsor":"RayzeBio, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":590,"enrollmentType":"ESTIMATED","startDate":"2025-09-05","startDateType":"ACTUAL","primaryCompletionDate":"2030-06","primaryCompletionType":"ESTIMATED","completionDate":"2031-06","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Hepatocellular Carcinoma (HCC)"],"interventions":["RYZ811","RYZ801"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)","sourceUrl":"https://clinicaltrials.gov/study/NCT06726161"},{"nctId":"NCT07664735","title":"A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.","sponsor":"Outpace Bio, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ESTIMATED","primaryCompletionDate":"2030-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-06-24","conditions":["Endometrial Cancer Recurrent","Endometrial Cancer","Advanced Endometrial Cancer","Ovarian Cancer","Ovarian Cancer Recurrent","Platinum Resistant Ovarian Cancer","Endometrial Cancers"],"interventions":["OPB-201"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HLA / TCR"],"summary":"The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.","sourceUrl":"https://clinicaltrials.gov/study/NCT07664735"},{"nctId":"NCT07214662","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":136,"enrollmentType":"ESTIMATED","startDate":"2026-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-01","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Breast Cancer"],"interventions":["GDC-0587","Giredestrant","Omeprazole"],"countries":["United States","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["HER2 profiling"],"summary":"This is a first-in-human, Phase Ia/Ib, dose-escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-0587 (cyclin-dependent kinase-4 \\[CDK4\\] inhibitor) as a monotherapy and in combination with giredestrant in participants with locally advanced or metastatic estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer who have previously progressed during or after CDK 4/6 inhibitor therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07214662"},{"nctId":"NCT07570979","title":"A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":208,"enrollmentType":"ESTIMATED","startDate":"2026-05-25","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-03","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-03","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"interventions":["INR731","Enzalutamide","Abiraterone","Androgen deprivation therapy (ADT)"],"countries":["United States","Australia","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the safety, tolerability, pharmacokinetics/pharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07570979"},{"nctId":"NCT07215585","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2025-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-10","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-28","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Large B-cell Lymphoma"],"interventions":["AZD0486","R-mini-CHOP"],"countries":["Australia","Belgium","Brazil","Canada","China","Hong Kong","Japan","Poland","South Korea","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":68,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07215585"},{"nctId":"NCT07226999","title":"Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","sponsor":"Pfizer","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2025-12-09","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-14","primaryCompletionType":"ESTIMATED","completionDate":"2034-03-11","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Small Cell Lung Cancer (SCLC)"],"interventions":["PF-08634404","Atezolizumab","Chemotherapy"],"countries":["United States","Australia","China","France","Germany","Italy","Japan","Puerto Rico","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":73,"serviceSignals":["Broad CGP"],"summary":"This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have extensive-stage small cell lung cancer confirmed by lab tests. * Have not received chemotherapy or radiation for this type of lung cancer. * Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine is and how well peo","sourceUrl":"https://clinicaltrials.gov/study/NCT07226999"},{"nctId":"NCT07412613","title":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","sponsor":"Akeso","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":386,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-15","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-15","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Resectable Colon Cancer","MSI-H/dMMR Colorectal Cancer"],"interventions":["Cadonilimab (AK104)","Oxaliplatin","Capecitabine","5- Fluorouracil","Calcium Folinate"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer. The purpose of this study is to evaluate the efficacy and safety of neoadjuvant/adjuvant treatment of AK104 (Cadonilimab) versus adjuvant chemotherapy in patients with resectable MSI-H/dMMR colon cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07412613"},{"nctId":"NCT04452591","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","sponsor":"CG Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":190,"enrollmentType":"ESTIMATED","startDate":"2020-10-27","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-16","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-24","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Non Muscle Invasive Bladder Cancer","High-grade Ta/ T1 Papillary Disease Bladder Cancer"],"interventions":["Cretostimogene Grenadenorepvec","n-dodecyl-B-D-maltoside"],"countries":["United States","Australia","Canada","Japan","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":86,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, open-label, single arm trial designed to evaluate Cretostimogene patients with NMIBC who have failed prior BCG therapy. Up to approximately 115 CIS bladder cancer patients with or without HG Ta or HG T1 papillary disease will be enrolled under the original protocol through Amendment 4, which will comprise Cohort C. Cohort C is closed to enrollment. Under Amendment 5-1, Cohort P was added to enroll up to 70 patients with HG Ta/T1 papillary bladder cancer. Under Amendment 6, the target number of patients enrolled in Cohort P was increased to 75. Cohort P is open to enrollment Cohort C and Cohort P will be analyzed and reported separately. Patients will have had to fail prior","sourceUrl":"https://clinicaltrials.gov/study/NCT04452591"},{"nctId":"NCT05170204","title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":68,"enrollmentType":"ACTUAL","startDate":"2022-11-01","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-16","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-16","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Alectinib","Entrectinib","Durvalumab"],"countries":["United States","Australia","Belgium","Brazil","Chile","China","Colombia","France","Germany","Italy","Japan","Mexico","Poland","Singapore","South Korea","Sweden","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) NSCLC staging system.","sourceUrl":"https://clinicaltrials.gov/study/NCT05170204"},{"nctId":"NCT07116616","title":"A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"ModernaTX, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":166,"enrollmentType":"ESTIMATED","startDate":"2025-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-17","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-17","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["mRNA-2808"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).","sourceUrl":"https://clinicaltrials.gov/study/NCT07116616"},{"nctId":"NCT07154290","title":"A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-24","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-24","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced/Metastatic Non-Small Cell Lung Cancer"],"interventions":["Ubamatamab","REGN7075","Sarilumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate two study drugs called ubamatamab and REGN7075, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and REGN7075 works * The side effects that ubamatamab and REGN7075 might cause * How much ubamatamab and REGN7075 is in the blood at different times * If the body makes antibodies to ubamatamab and/or REGN7075, this may cause the ubamatamab to not work as well","sourceUrl":"https://clinicaltrials.gov/study/NCT07154290"},{"nctId":"NCT06077760","title":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":868,"enrollmentType":"ESTIMATED","startDate":"2023-12-06","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-25","primaryCompletionType":"ESTIMATED","completionDate":"2035-12-21","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non-small Cell Lung Cancer"],"interventions":["Intismeran autogene","Pembrolizumab","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Costa Rica","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Hungary","Ireland","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","New Zealand","Norway","Philippines","Poland","Portugal","Slovakia","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":229,"serviceSignals":["Broad CGP"],"summary":"The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \\[N2\\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.","sourceUrl":"https://clinicaltrials.gov/study/NCT06077760"},{"nctId":"NCT06578247","title":"Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2024-11-19","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-26","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-26","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Leukemia"],"interventions":["Quizartinib","Placebo","Chemotherapy"],"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Czechia","France","Germany","Hong Kong","Hungary","Italy","Japan","Norway","Poland","Portugal","Romania","Serbia","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":284,"serviceSignals":["Hematology NGS"],"summary":"This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).","sourceUrl":"https://clinicaltrials.gov/study/NCT06578247"},{"nctId":"NCT07383922","title":"A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer","sponsor":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":524,"enrollmentType":"ESTIMATED","startDate":"2026-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2030-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-02-04","conditions":["Pancreatic Cancer"],"interventions":["FG-M108","nab paclitaxel","Gemcitabine (GEM)","Placebo for FG-M108"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Pancreatic cancer, which stands as one of the most lethal malignancies and a leading cause of cancer-related deaths globally, poses a significant challenge to human health worldwide. However, standard chemotherapeutic regimens show limited effectiveness in advanced pancreatic cancer, creating an urgent demand to investigate and develop novel therapeutic targets and combination treatment strategies. The primary objective of this study is to evaluate the efficacy of FG-M108 combined with gemcitabine and nab-paclitaxel (Nab-P+GEM) versus placebo combined with Nab-P+GEM as first-line treatment, as measured by overall survival (OS). This study will also assess safety, tolerability, pharmacokineti","sourceUrl":"https://clinicaltrials.gov/study/NCT07383922"},{"nctId":"NCT07566052","title":"A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":356,"enrollmentType":"ESTIMATED","startDate":"2026-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Setidegrasib","Docetaxel"],"countries":["United States","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["RAS genotyping"],"summary":"Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells. If the cancer gets worse, the next main treatment is usually a medicine called docetaxel. This treatment doesn't stop most people's cancer from getting worse for very long. Other treatments are needed to improve outcomes in people with NSCLC. Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Many people with NSCLC have a faulty KRAS gene in their tumor. On","sourceUrl":"https://clinicaltrials.gov/study/NCT07566052"},{"nctId":"NCT06953089","title":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-06-30","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Solid Tumors"],"interventions":["DB-1311/BNT324","BNT327","DB-1305/BNT325"],"countries":["United States","Australia","China","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":37,"serviceSignals":["ADC biomarker"],"summary":"A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT06953089"},{"nctId":"NCT07668752","title":"A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-07-15","startDateType":"ESTIMATED","primaryCompletionDate":"2030-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-30","completionType":"ESTIMATED","lastUpdated":"2026-06-25","conditions":["KRAS G12D Mutation","NSCLC (Non-small Cell Lung Cancer)"],"interventions":["GFH375","Docetaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to compare the effectiveness, safety and tolerability of GFH375 versus docetaxel in participants with KRAS G12D-mutant non-small cell lung cancer (NSCLC). GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation. Preclinical studies showed GFH375 strongly blocks KRAS-driven signaling and cancer cell growth, and demonstrated anti-tumor activity in NSCLC animal models. Docetaxel is a chemotherapy drug for locally advanced or metastatic NSCLC. This is an open-label, randomized controlled trial. Both participant and study doctor will know which study medication each participant receives. After enrollment, participant","sourceUrl":"https://clinicaltrials.gov/study/NCT07668752"},{"nctId":"NCT07524348","title":"A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors","sponsor":"Samsung Bioepis Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":149,"enrollmentType":"ESTIMATED","startDate":"2026-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2030-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Advanced Solid Tumors"],"interventions":["E303"],"countries":["United States","Australia","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07524348"},{"nctId":"NCT06950385","title":"Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis","sponsor":"Rapamycin Holdings Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":168,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-07","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Familial Adenomatous Polyposis (FAP)"],"interventions":["eRapa (encapsulated rapamycin)","Placebo"],"countries":["United States","Denmark","Germany","Italy","Netherlands","Puerto Rico","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["Broad CGP"],"summary":"The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to be answered by this trial are: * Does taking eRapa help to slow down the progression of the disease in patients with FAP? * Is eRapa a safe treatment for patients diagnosed with FAP? * What is the effect of eRapa on the number of polyps found in GI tract of patients diagnosed with FAP? * How does treatment with eRapa affect a patient's quality of life? Participants will: * Take eRapa or placebo once per day every other week until disease progresses (gets wor","sourceUrl":"https://clinicaltrials.gov/study/NCT06950385"},{"nctId":"NCT06072131","title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","sponsor":"Acrotech Biopharma Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":504,"enrollmentType":"ESTIMATED","startDate":"2023-10-04","startDateType":"ACTUAL","primaryCompletionDate":"2030-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-11","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Peripheral T Cell Lymphoma"],"interventions":["Belinostat Injection","Pralatrexate Injection","CHOP","COP"],"countries":["United States","Canada","Germany","Hungary","Italy","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":69,"serviceSignals":["Hematology NGS"],"summary":"Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHO","sourceUrl":"https://clinicaltrials.gov/study/NCT06072131"},{"nctId":"NCT05768139","title":"First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors","sponsor":"Eli Lilly and Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":880,"enrollmentType":"ESTIMATED","startDate":"2023-04-17","startDateType":"ACTUAL","primaryCompletionDate":"2030-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Breast Cancer","Solid Tumors, Adult"],"interventions":["STX-478","Fulvestrant","Ribociclib","Palbociclib","Letrozole","Anastrozole","Exemestane","Tamoxifen","Abemaciclib","Imlunestrant","Metformin"],"countries":["United States","Belgium","France","Germany","Ireland","Italy","Japan","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":65,"serviceSignals":["HER2 profiling"],"summary":"Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant, tamoxifen, or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) ","sourceUrl":"https://clinicaltrials.gov/study/NCT05768139"},{"nctId":"NCT07046923","title":"A Study of LY4175408 in Participants With Advanced Cancer","sponsor":"Eli Lilly and Company","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":240,"enrollmentType":"ESTIMATED","startDate":"2025-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2030-07","primaryCompletionType":"ESTIMATED","completionDate":"2030-07","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Carcinoma, Non-Small-Cell Lung","Small Cell Lung Carcinoma","Endometrial Neoplasms","Neoplasm Metastasis","Triple Negative Breast Cancer"],"interventions":["LY4175408","Pembrolizumab","Carboplatin","Cisplatin"],"countries":["United States","China","France","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":27,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07046923"},{"nctId":"NCT06692738","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1160,"enrollmentType":"ESTIMATED","startDate":"2024-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Non-small Cell Lung Cancer"],"interventions":["Rilvegostomig","Pembrolizumab","Carboplatin","Paclitaxel","Nab-paclitaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Italy","Japan","Malaysia","Netherlands","Peru","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":312,"serviceSignals":["Hematology NGS"],"summary":"The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).","sourceUrl":"https://clinicaltrials.gov/study/NCT06692738"},{"nctId":"NCT07558915","title":"A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","sponsor":"Genentech, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":160,"enrollmentType":"ESTIMATED","startDate":"2026-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2030-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["RO7851624"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \\[PIs\\], immunomodulators \\[IMiDs\\], and anti-cluster of differentiation 38 \\[anti-CD38\\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07558915"},{"nctId":"NCT07519772","title":"A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":280,"enrollmentType":"ESTIMATED","startDate":"2026-05-03","startDateType":"ACTUAL","primaryCompletionDate":"2030-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-01","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Lymphoma, Non-Hodgkin","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse"],"interventions":["MK-1045"],"countries":["United States","Argentina","Australia","China","Israel","Italy","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes a","sourceUrl":"https://clinicaltrials.gov/study/NCT07519772"},{"nctId":"NCT07683754","title":"T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-09-04","startDateType":"ESTIMATED","primaryCompletionDate":"2030-07-04","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-28","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Advanced Breast Cancer","Metastatic Breast Cancer","HER2 Positive","HR Positive"],"interventions":["Trastuzumab deruxtecan","Trastuzumab","Pertuzumab","Endocrine Therapy","Palbociclib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate a structured sequential treatment strategy starting with T-DXd + pertuzumab upfront therapy, followed by an optimized maintenance therapy with dual HER2+blockade + CDK4/6i + ET and the opportunity to retreat with T-DXd once patients progress under maintenance aimed to maximizing disease control, optimizing tolerability, and preserving T-DXd as a future therapeutic option, while ensuring participant safety and regulatory compliance in participants with HER2+/HR+ advanced/metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07683754"},{"nctId":"NCT07751042","title":"Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","sponsor":"Strand Therapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-07-17","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-15","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumor"],"interventions":["STX-003","KEYTRUDA®"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07751042"},{"nctId":"NCT04373785","title":"NG101m Adjuvant Therapy in Glioblastoma Patients","sponsor":"NeuGATE Theranostics","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2027-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2025-10-21","conditions":["Glioblastoma Multiforme"],"interventions":["Intensity-modulated radiation therapy","Temozolomide","NG101m"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.","sourceUrl":"https://clinicaltrials.gov/study/NCT04373785"},{"nctId":"NCT06561386","title":"A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2024-10-07","startDateType":"ACTUAL","primaryCompletionDate":"2030-07-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-08-04","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Non-small Cell Lung Cancer"],"interventions":["Nivolumab","Relatlimab","Pembrolizumab","Carboplatin","Pemetrexed","Cisplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Denmark","France","Germany","India","Ireland","Italy","Japan","Mexico","Netherlands","New Zealand","Poland","Portugal","Romania","Saudi Arabia","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":320,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%","sourceUrl":"https://clinicaltrials.gov/study/NCT06561386"},{"nctId":"NCT07441707","title":"A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours","sponsor":"Ipsen","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":6,"enrollmentType":"ESTIMATED","startDate":"2026-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2030-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-07-31","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Low-grade Glioma"],"interventions":["Tovorafenib"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate safety and the way the body absorbs, distributes and gets rid of the study drug tovorafenib in the body in Japanese children, adolescents and young adults with specific brain tumours. This includes how the drug is absorbed, distributed and eliminated from the body (called pharmacokinetics). The study will also test how well the drug works to shrink brain tumours. In this study, all participants will receive tovorafenib orally once weekly. There will be four periods in this study: 1. Screening period (up to 4 weeks): Participants will be evaluated to determine if they can take part in the study, requiring at least one visit to the study centre. 2. Trea","sourceUrl":"https://clinicaltrials.gov/study/NCT07441707"},{"nctId":"NCT07739966","title":"A Study of DS-3939a in Participants With Solid Tumors","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2030-07-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Solid Tumor","Locally Advanced Non-Small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer"],"interventions":["DS-3939a","Pembrolizumab","Carboplatin","Pemetrexed","DS-1103a"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07739966"},{"nctId":"NCT04300556","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","sponsor":"Eisai Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":182,"enrollmentType":"ESTIMATED","startDate":"2020-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-08","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["Solid Tumor"],"interventions":["Farletuzumab ecteribulin","Prednisone","Prednisolone","Dexamethasone","Lenvatinib"],"countries":["United States","France","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":58,"serviceSignals":["ADC biomarker"],"summary":"The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \\[OC\\], endometrial cancer \\[EC\\], non-small cell lung carcinoma \\[NSCLC\\], triple-negative breast cancer \\[TNBC\\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzumab ecteribulin (MORAb-202) in participants with OC and EC at selected doses and to further evaluate the safety and tolerability of farletuzumab ecteribulin (MORAb-202) and (3) dose-optimization part.","sourceUrl":"https://clinicaltrials.gov/study/NCT04300556"},{"nctId":"NCT04836507","title":"Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients","sponsor":"Curocell Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":91,"enrollmentType":"ESTIMATED","startDate":"2021-03-02","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-15","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-26","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Relapsed Large B-cell Lymphoma","Refractory Large B-cell Lymphoma","Diffuse Large B-cell Lymphoma (DLBCL)","Primary Mediastinal Large B-Cell Lymphoma (PMBCL)","High-grade B-cell Lymphoma","Transformed Follicular Lymphoma (TFL)","ALL (Acute B-Lymphoblastic Leukemia)"],"interventions":["CRC01","Fludarabine","Cyclophosphamide"],"countries":["South Korea"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT04836507"},{"nctId":"NCT07436728","title":"A Study of TAK-505 in Adults With Solid Tumors","sponsor":"Takeda","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":151,"enrollmentType":"ESTIMATED","startDate":"2026-05-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-18","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Malignant Solid Tumors"],"interventions":["TAK-505"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["Broad CGP"],"summary":"Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in the general area where they started (called locally advanced) or may spread to other parts of the body (called metastatic), and doctors may not always be able to completely remove them with surgery (called unresectable). This study is a first in human (or FIH) study, which means that this is the first time that the medicine, TAK-505, is given to a smaller group of adults with solid tumors of certain cancer types, such as stomach cancer (gastric adenocarcinoma), cancer of the large bowel (colorec","sourceUrl":"https://clinicaltrials.gov/study/NCT07436728"},{"nctId":"NCT07713732","title":"TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors","sponsor":"Treeline Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-07-25","startDateType":"ESTIMATED","primaryCompletionDate":"2030-08-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-29","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Small Cell Lung Cancer ( SCLC )","Neuroendocrine Cancer","Malignant Pleural Mesotheliomas (Mpm)","Synovial Sarcomas"],"interventions":["TLN-499","Venetoclax"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07713732"},{"nctId":"NCT07227311","title":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2026-04-15","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-30","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Dexamethasone","Pomalidomide","Bortezomib","Carfilzomib"],"countries":["United States","France","Germany","Greece","Japan","Netherlands","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["Hematology NGS"],"summary":"This study is for adults with multiple myeloma (a type of blood cancer) that has come back after being treated earlier or isn't responding to the current treatment. The main goal is to find out if the study drug, belantamab mafodotin, given less often (on an extended schedule) with other cancer medicines, can still treat the cancer effectively while causing fewer side effects, especially those affecting the eyes. The study will also look at how well the treatment works overall and how safe it is when administered to the participants.","sourceUrl":"https://clinicaltrials.gov/study/NCT07227311"},{"nctId":"NCT07154706","title":"Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)","sponsor":"Nuvation Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-08-21","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-08-30","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Taletrectinib","Placebo"],"countries":["United States","Canada","China"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["RNA fusion"],"summary":"The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.","sourceUrl":"https://clinicaltrials.gov/study/NCT07154706"},{"nctId":"NCT04929223","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":542,"enrollmentType":"ESTIMATED","startDate":"2021-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Metastatic Colorectal Cancer"],"interventions":["Inavolisib","Bevacizumab","Cetuximab","Atezolizumab","Tiragolumab","SY-5609","Divarasib","FOLFOX","FOLFIRI","FoundationOne®Liquid CDx"],"countries":["United States","Australia","Canada","Denmark","Germany","Italy","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":84,"serviceSignals":["RAS genotyping"],"summary":"This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.","sourceUrl":"https://clinicaltrials.gov/study/NCT04929223"},{"nctId":"NCT05954312","title":"A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors","sponsor":"Vividion Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":290,"enrollmentType":"ESTIMATED","startDate":"2023-07-28","startDateType":"ACTUAL","primaryCompletionDate":"2030-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-28","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Solid Tumors"],"interventions":["VVD-130037","Docetaxel","Paclitaxel","Pembrolizumab"],"countries":["United States","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":26,"serviceSignals":["Broad CGP"],"summary":"A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05954312"},{"nctId":"NCT07617337","title":"AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer","sponsor":"Chugai Pharmaceutical","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2030-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-08-31","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["ALK Positive Non-small Cell Lung Cancer"],"interventions":["AQUA07","Lorlatinib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07617337"},{"nctId":"NCT06109272","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","sponsor":"AbbVie","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":660,"enrollmentType":"ESTIMATED","startDate":"2024-01-11","startDateType":"ACTUAL","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2025-08-15","conditions":["Hepatocellular Carcinoma"],"interventions":["Livmoniplimab","Budigalimab","Durvalumab","Atezolizumab","Bevacizumab","Tremelimumab"],"countries":["United States","France","Italy","Puerto Rico","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["Broad CGP"],"summary":"Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of HCC. There are 2 stages to this study. In Stage 1, there are 3 treatment arms and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug), atezoliz","sourceUrl":"https://clinicaltrials.gov/study/NCT06109272"},{"nctId":"NCT07703436","title":"Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease","sponsor":"Nuvation Bio Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":40,"enrollmentType":"ESTIMATED","startDate":"2027-03","startDateType":"ESTIMATED","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2032-03","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Grade 2 IDH1-mutant Glioma","Grade 3 IDH1-mutant Glioma","Glioma","IDH1-mutant Glioma","Oligodendroglioma","Oligodendroglioma IDH-1 Mutant and 1/p19q-codeleted","Astrocytoma IDH Mutant Grade 3","Astrocytoma IDH Mutant Grade 2"],"interventions":["Safusidenib"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review \\[BICR\\] per modified Response Assessment in Neuro-Oncology \\[RANO\\] 2.0), and are not in need of immediate chemotherapy or radiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07703436"},{"nctId":"NCT07155187","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","sponsor":"AbbVie","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":490,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Telisotuzumab Adizutecan","Standard of Care","Osimertinib"],"countries":["United States","Australia","Austria","Belgium","China","France","Germany","Israel","Italy","Japan","Netherlands","Poland","Portugal","Serbia","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":110,"serviceSignals":["Broad CGP"],"summary":"Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan as a monotherapy or in combination with osimertinib. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP","sourceUrl":"https://clinicaltrials.gov/study/NCT07155187"},{"nctId":"NCT07082803","title":"TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas","sponsor":"Treeline Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2025-06-23","startDateType":"ACTUAL","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-11","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Lymphoma","Lymphoma, Non Hodgkin"],"interventions":["TLN-121","TLN-254"],"countries":["United States","Australia","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas","sourceUrl":"https://clinicaltrials.gov/study/NCT07082803"},{"nctId":"NCT05667194","title":"Phase 1 Trial of KH617","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":45,"enrollmentType":"ESTIMATED","startDate":"2022-12-26","startDateType":"ACTUAL","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2024-11-27","conditions":["Advanced Solid Tumors"],"interventions":["KH617"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.","sourceUrl":"https://clinicaltrials.gov/study/NCT05667194"},{"nctId":"NCT07365241","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":531,"enrollmentType":"ESTIMATED","startDate":"2026-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Small Cell Lung Cancer"],"interventions":["ABBV-706","Topotecan","Lurbinectedin","Amrubicin"],"countries":["United States","Belgium","France","Greece","Japan","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":45,"serviceSignals":["Broad CGP"],"summary":"Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activity of ABBV-706 compared to standard of care (SOC) treatment (topotecan, lurbinectedin, or amrubicin). ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are two treatment arms in this study. Participants will either receive ABBV-706 or SOC. Approximately 531 adult participants will be enrolled in the study across 175 sites worldwide. Participants with SCLC will rec","sourceUrl":"https://clinicaltrials.gov/study/NCT07365241"},{"nctId":"NCT06858813","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":232,"enrollmentType":"ESTIMATED","startDate":"2025-04-14","startDateType":"ACTUAL","primaryCompletionDate":"2030-09","primaryCompletionType":"ESTIMATED","completionDate":"2030-09","completionType":"ESTIMATED","lastUpdated":"2026-03-25","conditions":["Hepatocellular Cancer","Squamous-Cell Non-Small Cell Lung Cancer"],"interventions":["Lenvatinib","ABBV-324"],"countries":["United States","China","Israel","Japan","Puerto Rico","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":22,"serviceSignals":["Broad CGP"],"summary":"HCC is a common cancer worldwide and a leading cause of cancer-related death. Lung cancer is the most frequently diagnosed cancer in the world, and the leading cause of cancer deaths. The purpose of this study is to assess adverse events and change in disease activity when ABBV-324 is given to adult participants to treat hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). ABBV-324 is an investigational drug being developed for the treatment of HCC and LUSC. Study doctors put the participants in groups called arms. Each arm receives ABBV-324 alone (monotherapy) or a comparator drug, lenvatinib followed by a safety follow-up period. Approximately 232 HCC or LUSC wil","sourceUrl":"https://clinicaltrials.gov/study/NCT06858813"},{"nctId":"NCT06577025","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":43,"enrollmentType":"ACTUAL","startDate":"2024-08-20","startDateType":"ACTUAL","primaryCompletionDate":"2030-09-02","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Cilta-cel","Talquetamab","Daratumumab","Teclistamab","Bortezomib","Lenalidomide","Dexamethasone","Cyclophosphamide","Fludarabine"],"countries":["United States","Australia","Brazil","Germany","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS","sourceUrl":"https://clinicaltrials.gov/study/NCT06577025"},{"nctId":"NCT07665450","title":"A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2026-09-14","startDateType":"ESTIMATED","primaryCompletionDate":"2030-09-04","primaryCompletionType":"ESTIMATED","completionDate":"2035-02-02","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Ramantamig","Daratumumab","Lenalidomide","Bortezomib","Dexamethasone"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and 12-month minimal residue disease (MRD)-negative complete response (CR) rate (percentage of participants in whom cancer cells are not detected) in participants with newly diagnosed multiple myeloma (NDMM; an initial stage of blood cancer that forms in a type of white blood cells \\[WBCs\\] called plasma cells) for whom stem cell transplant is not planned as initial therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07665450"},{"nctId":"NCT04246086","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":237,"enrollmentType":"ESTIMATED","startDate":"2020-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2030-09-06","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-06","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["Follicular Lymphoma"],"interventions":["Mosunetuzumab (IV)","Tocilizumab","Lenalidomide","Mosunetuzumab (SC)"],"countries":["United States","China","France","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":26,"serviceSignals":["Hematology NGS"],"summary":"This study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.","sourceUrl":"https://clinicaltrials.gov/study/NCT04246086"},{"nctId":"NCT07720284","title":"An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":915,"enrollmentType":"ESTIMATED","startDate":"2026-07-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-09-11","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-23","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["High-risk Muscle Invasive Urothelial Carcinoma"],"interventions":["Dato-DXd","Rilvegostomig","Durvalumab","Nivolumab","Pembrolizumab","Enfortumab vedotin"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","India","Italy","Japan","Poland","South Korea","Spain","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":160,"serviceSignals":["ADC biomarker"],"summary":"Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection. Study details: Duration: \\~78 months (6.5 years) from FSI to last subject visit Treatment length: up to \\~12 months, depending on randomized arm Visit frequency: every 3 weeks in Arms 1 and 2; every 2-4 weeks per SoC in Arm 3","sourceUrl":"https://clinicaltrials.gov/study/NCT07720284"},{"nctId":"NCT07361497","title":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":850,"enrollmentType":"ESTIMATED","startDate":"2026-03-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-09-18","primaryCompletionType":"ESTIMATED","completionDate":"2033-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Non-small Cell Lung Cancer (NSCLC)"],"interventions":["Pumitamig","Durvalumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Italy","Japan","Mexico","Netherlands","Poland","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":256,"serviceSignals":["Broad CGP"],"summary":"A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)","sourceUrl":"https://clinicaltrials.gov/study/NCT07361497"},{"nctId":"NCT03424005","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":1132,"enrollmentType":"ESTIMATED","startDate":"2018-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-09-30","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Metastatic Breast Cancer"],"interventions":["Capecitabine","Atezolizumab","Ipatasertib","SGN-LIV1A","Bevacizumab","Chemotherapy (Gemcitabine + Carboplatin or Eribulin)","Selicrelumab","Tocilizumab","Nab-Paclitaxel","Sacituzumab Govitecan","Abemaciclib","Fulvestrant","Ribociclib (Dose #1)","Inavolisib (Dose #1)","Trastuzumab Deruxtecan","Ribociclib (Dose #2)","Letrozole","Inavolisib (Dose #2)","Empagliflozin","Palbociclib","Metformin","Atirmociclib","Giredestrant"],"countries":["United States","Australia","France","Germany","Israel","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["HER2 profiling"],"summary":"This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \\[1L\\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNB","sourceUrl":"https://clinicaltrials.gov/study/NCT03424005"},{"nctId":"NCT07059650","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-08-19","startDateType":"ACTUAL","primaryCompletionDate":"2030-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2026-04-01","conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":["DZD8586+R-CHOP","DZD8586+R-GemOx","DZD8586+BR"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.","sourceUrl":"https://clinicaltrials.gov/study/NCT07059650"},{"nctId":"NCT05371093","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","sponsor":"Kite, A Gilead Company","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":231,"enrollmentType":"ACTUAL","startDate":"2022-09-22","startDateType":"ACTUAL","primaryCompletionDate":"2030-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2025-10-15","conditions":["Relapsed/Refractory Follicular Lymphoma"],"interventions":["Axicabtagene Ciloleucel","Cyclophosphamide","Fludarabine","Lenalidomide","Rituximab","Doxorubicin","Vincristine","Prednisone","Bendamustine"],"countries":["United States","France","Germany","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":52,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT05371093"},{"nctId":"NCT07455734","title":"Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":533,"enrollmentType":"ESTIMATED","startDate":"2026-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-10","primaryCompletionType":"ESTIMATED","completionDate":"2030-10","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Advanced Solid Tumor Cancer"],"interventions":["BNT3214"],"countries":["Australia","China","South Korea","Taiwan"],"northAmerica":false,"chinaSites":true,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07455734"},{"nctId":"NCT07015190","title":"Neoadjuvant Darovasertib in Primary Uveal Melanoma","sponsor":"IDEAYA Biosciences","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2026-01-25","startDateType":"ACTUAL","primaryCompletionDate":"2030-10","primaryCompletionType":"ESTIMATED","completionDate":"2031-03","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Uveal Melanoma"],"interventions":["Darovasertib","Primary Local Therapy"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Estonia","France","Germany","Greece","Israel","Italy","Netherlands","New Zealand","Poland","Slovakia","Slovenia","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":94,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)","sourceUrl":"https://clinicaltrials.gov/study/NCT07015190"},{"nctId":"NCT07732413","title":"Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer","sponsor":"Lumos Pharma","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-10-08","startDateType":"ESTIMATED","primaryCompletionDate":"2030-10-08","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-08","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Progressive Pediatric Brain Cancer"],"interventions":["NLG802 (indoximod Prodrug)","Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a open label Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme, in combination with temozolomide chemotherapy in children with primary brain tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07732413"},{"nctId":"NCT04270409","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","sponsor":"Sanofi","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":337,"enrollmentType":"ACTUAL","startDate":"2020-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-10-14","primaryCompletionType":"ESTIMATED","completionDate":"2033-10-21","completionType":"ESTIMATED","lastUpdated":"2025-12-12","conditions":["Plasma Cell Myeloma"],"interventions":["Isatuximab SAR650984","Lenalidomide","Dexamethasone","Montelukast or equivalent","Acetaminophen","Diphenhydramine or equivalent","Methylprednisolone or equivalent"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Lithuania","New Zealand","Norway","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":105,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"Primary Objectives: * Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) * Randomized Phase 3 Part: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to lenalidomide and dexamethasone in subjects with high-risk SMM Secondary Objectives: Safety run-in Part: * To assess overall response rate (ORR) * To assess duration of response (DOR) * To assess minimal residual disease (MRD) negativity in participants achieving very good partial response (VGPR) or com","sourceUrl":"https://clinicaltrials.gov/study/NCT04270409"},{"nctId":"NCT05623020","title":"A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant","sponsor":"Pfizer","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1116,"enrollmentType":"ESTIMATED","startDate":"2022-11-10","startDateType":"ACTUAL","primaryCompletionDate":"2030-10-18","primaryCompletionType":"ESTIMATED","completionDate":"2033-10-03","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Multiple Myeloma"],"interventions":["Elranatamab","Daratumumab","Lenalidomide","Dexamethasone","Bortezomib"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Finland","France","Germany","Greece","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Puerto Rico","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":127,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in people with newly diagnosed multiple myeloma. There are 2 parts to this study. Part 1 will characterize the safety and tolerability of elranatamab in combination with daratumumab and lenalidomide or in combination with lenalidomide and will identify the optimal dose(s) of the combination r","sourceUrl":"https://clinicaltrials.gov/study/NCT05623020"},{"nctId":"NCT07177937","title":"A Study of DXC014 in Patients With Advanced Solid Tumors.","sponsor":"Hangzhou DAC Biotechnology Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-03-03","startDateType":"ACTUAL","primaryCompletionDate":"2030-10-20","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-20","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Small Cell Lung Cancer","Melanoma","Prostate Cancer","Other Advanced Solid Tumors"],"interventions":["DXC014"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07177937"},{"nctId":"NCT06669117","title":"FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations","sponsor":"Pierre Fabre Medicament","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2024-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2030-10-21","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-01","completionType":"ESTIMATED","lastUpdated":"2025-07-02","conditions":["Solid Tumor","MET Alteration"],"interventions":["VERT-002"],"countries":["United States","Belgium","France","Germany","Italy","Netherlands","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT06669117"},{"nctId":"NCT07594106","title":"REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":265,"enrollmentType":"ESTIMATED","startDate":"2026-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2030-10-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-10-27","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)","Clear Cell Renal Cell Carcinoma (ccRCC)"],"interventions":["REGN15505","REGN15505+Cemiplimab","REGN15505+REGN4336"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Broad CGP"],"summary":"This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for: * Any side effects of study drugs * How well the study drugs work * How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times * If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected * ","sourceUrl":"https://clinicaltrials.gov/study/NCT07594106"},{"nctId":"NCT07221149","title":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":690,"enrollmentType":"ESTIMATED","startDate":"2026-03-13","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-08","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-11","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma"],"interventions":["Pumitamig","Folfox","Capox","Nivolumab"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","France","Germany","India","Italy","Japan","Mexico","Poland","Romania","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":161,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07221149"},{"nctId":"NCT06627647","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1160,"enrollmentType":"ESTIMATED","startDate":"2024-11-27","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-18","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-18","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Non-squamous Non-small Cell Lung Cancer"],"interventions":["Rilvegostomig","Pembrolizumab","Carboplatin","Cisplatin","Pemetrexed"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","France","Germany","Hungary","India","Italy","Japan","Malaysia","Netherlands","Peru","Poland","Puerto Rico","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":287,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06627647"},{"nctId":"NCT06378138","title":"ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":226,"enrollmentType":"ESTIMATED","startDate":"2024-05-15","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-25","primaryCompletionType":"ESTIMATED","completionDate":"2031-07-25","completionType":"ESTIMATED","lastUpdated":"2025-11-21","conditions":["Hematologic Malignancies"],"interventions":["ICP-248","Orelabrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":53,"serviceSignals":["Hematology NGS"],"summary":"Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","sourceUrl":"https://clinicaltrials.gov/study/NCT06378138"},{"nctId":"NCT07489495","title":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":758,"enrollmentType":"ESTIMATED","startDate":"2026-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-27","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-27","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Carcinoma, Renal Cell"],"interventions":["Belzutifan","Zanzalintinib","Placebo"],"countries":["United States","Argentina","Australia","Brazil","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Netherlands","Poland","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone. The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.","sourceUrl":"https://clinicaltrials.gov/study/NCT07489495"},{"nctId":"NCT06211764","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":272,"enrollmentType":"ACTUAL","startDate":"2024-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-27","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-14","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Non-Muscle Invasive Bladder Neoplasms"],"interventions":["TAR-200","Mitomycin C","Gemcitabine"],"countries":["United States","Argentina","Belgium","Brazil","China","France","Germany","Italy","Japan","Poland","Romania","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":123,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06211764"},{"nctId":"NCT07227597","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2026-01-29","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-29","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Small Cell Lung Cancer Extensive Stage"],"interventions":["Gocatamig","I-DXd","Atezolizumab","Carboplatin","Etoposide","Rescue Medications"],"countries":["United States","Argentina","Chile","China","Germany","Greece","Israel","Italy","South Korea","Spain","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":45,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"Researchers are looking for new ways to treat extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC is a type of lung cancer that has spread throughout the lung, to the other lung, or to other parts of the body. A standard (usual) treatment for ES-SCLC uses both chemotherapy and immunotherapy. * Chemotherapy is a treatment that works to destroy cancer cells or stop them from growing. * Immunotherapy is a treatment that helps the immune system fight cancer. Gocatamig and I-DXd (short for ifinatamab deruxtecan) are study medicines. Researchers want to know if giving gocatamig and I-DXd together can treat ES-SCLC. Researchers will also look at giving the study medicines with standard treatm","sourceUrl":"https://clinicaltrials.gov/study/NCT07227597"},{"nctId":"NCT06608927","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","sponsor":"Arcus Biosciences, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":610,"enrollmentType":"ESTIMATED","startDate":"2024-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma"],"interventions":["Quemliclustat","Placebo","Nab-paclitaxel","Gemcitabine"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","France","Germany","Italy","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":111,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT06608927"},{"nctId":"NCT07220616","title":"A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Hematological Malignancies","B-cell Non-Hodgkin Lymphoma"],"interventions":["DS3790a","Combination drug"],"countries":["United States","France","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS","ADC biomarker"],"summary":"This clinical trial is designed to assess the safety, preliminary efficacy, and pharmacokinetics (PK) of DS3790a monotherapy and combination regimens in participants with hematological malignancies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07220616"},{"nctId":"NCT07450976","title":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":151,"enrollmentType":"ESTIMATED","startDate":"2026-03-25","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-03-31","conditions":["Biliary Tract Cancer"],"interventions":["SHR-A1904 for Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["ADC biomarker"],"summary":"This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC). Patients will treat with SHR-A1904 until unacceptable toxicity or disease progression.","sourceUrl":"https://clinicaltrials.gov/study/NCT07450976"},{"nctId":"NCT07196644","title":"A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-12-01","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Solid Tumors Harboring MET Amplification"],"interventions":["Telisotuzumab Adizutecan"],"countries":["United States","Israel","Japan","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":37,"serviceSignals":["MET profiling"],"summary":"Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of locally advanced or metastatic solid tumors that harbor MET amplification. This study will have 1 arm where participants will receive telisotuzumab adizutecan. Approximately 100 participants 12 years of age or older. with solid tumors harboring MET amplification will be enrolled in the study in up to 50 sites around the world. Participants will receive intravenous (IV) telisotuzumab adizutecan, as ","sourceUrl":"https://clinicaltrials.gov/study/NCT07196644"},{"nctId":"NCT07239596","title":"Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":139,"enrollmentType":"ESTIMATED","startDate":"2026-01-06","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-03-16","conditions":["Advanced Renal Cell Carcinoma"],"interventions":["SHR-8068；Adebrelimab ；Bevacizumab","SHR-8068；Adebrelimab ；HS-10516","SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07239596"},{"nctId":"NCT07349069","title":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","sponsor":"Shandong Suncadia Medicine Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":5500,"enrollmentType":"ESTIMATED","startDate":"2026-03-04","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2034-01","completionType":"ESTIMATED","lastUpdated":"2026-05-22","conditions":["Breast Cancer"],"interventions":["HRS-8080 Tablets","Letrozole tablets","Tamoxifen Citrate Tablets","Anastrozole Tablets","Exemestane tablets"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07349069"},{"nctId":"NCT07679360","title":"A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Triple Negative Breast Cancer"],"interventions":["Trastuzumab Rezetecan for Injection","Adebrelimab Injection","Capecitabine tablets","Pembrolizumab injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers in the adjuvant treatment of triple negative breast cancer with invasive residual cancer after neoadjuvant treatment, and to explore the PK characteristics and immunogenicity of SHR-A1811 and Adebrelimab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07679360"},{"nctId":"NCT04614103","title":"Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":170,"enrollmentType":"ESTIMATED","startDate":"2021-05-07","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Metastatic Non Small Cell Lung Cancer"],"interventions":["LN-145"],"countries":["United States","Australia","Canada","France","Germany","Italy","Netherlands","Singapore","South Korea","Spain","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":71,"serviceSignals":["Broad CGP"],"summary":"This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT04614103"},{"nctId":"NCT07640789","title":"A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":418,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Non-small Cell Lung Cancer Stage III"],"interventions":["BL-B01D1","Osimertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in patients with unresectable EGFR-mutated Stage III non-small cell lung cancer who have not progressed following platinum-based chemoradiotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07640789"},{"nctId":"NCT07170995","title":"Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":460,"enrollmentType":"ESTIMATED","startDate":"2025-10-22","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-11-18","conditions":["Advanced or Metastatic Non-small Cell Lung Cancer"],"interventions":["SHR-8068，adebelizumab and platinum-based chemotherapy","tislelizumab, and platinum-based chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07170995"},{"nctId":"NCT07079631","title":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer","sponsor":"BioNTech SE","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":482,"enrollmentType":"ESTIMATED","startDate":"2025-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Metastatic Colorectal Cancer"],"interventions":["BNT314","Pumitamig","SoC chemotherapy treatment 1","SoC chemotherapy treatment 2","Bevacizumab"],"countries":["United States","Germany","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["MSI / TMB"],"summary":"This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07079631"},{"nctId":"NCT07617493","title":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":539,"enrollmentType":"ESTIMATED","startDate":"2026-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-06","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Advanced Solid Tumor"],"interventions":["ICP-B208"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07617493"},{"nctId":"NCT06953960","title":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)","sponsor":"AbbVie","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":199,"enrollmentType":"ESTIMATED","startDate":"2025-07-23","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Multiple Myeloma"],"interventions":["ABBV-453","Daratumumab","Dexamethasone","Pomalidomide"],"countries":["United States","Australia","Belgium","France","Germany","Israel","Italy","Japan","Poland","Portugal","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. Surzetoclax is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be a dose escalation phase where participants will receive various doses of surzetoclax in combination with daratumumab + dexamethasone, to determine the best dose of surzetoclax. This will be followed by a dose expansion and selection phase where particip","sourceUrl":"https://clinicaltrials.gov/study/NCT06953960"},{"nctId":"NCT06686576","title":"A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer","sponsor":"Qilu Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":363,"enrollmentType":"ESTIMATED","startDate":"2024-12-12","startDateType":"ACTUAL","primaryCompletionDate":"2030-12","primaryCompletionType":"ESTIMATED","completionDate":"2030-12","completionType":"ESTIMATED","lastUpdated":"2025-12-18","conditions":["Colon Cancer"],"interventions":["QL1706","CAPEOX/Capecitabine"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT06686576"},{"nctId":"NCT07247110","title":"A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2025-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2030-12-01","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-01","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Malignant Neoplasm"],"interventions":["MK-4716","Pembrolizumab","Cetuximab"],"countries":["United States","Australia","Canada","Chile","Israel","South Korea","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":19,"serviceSignals":["RAS genotyping"],"summary":"Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07247110"},{"nctId":"NCT06393374","title":"Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1530,"enrollmentType":"ESTIMATED","startDate":"2024-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2030-12-16","primaryCompletionType":"ESTIMATED","completionDate":"2037-12-14","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Triple-Negative Breast Cancer"],"interventions":["Pembrolizumab","Sacituzumab tirumotecan","Capecitabine"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Ireland","Israel","Italy","Japan","Malaysia","Mexico","Norway","Poland","Portugal","Singapore","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":308,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per inve","sourceUrl":"https://clinicaltrials.gov/study/NCT06393374"},{"nctId":"NCT07529405","title":"A Study of VG712 in Patients With Mycosis Fungoides","sponsor":"Virogen Biotechnology Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":386,"enrollmentType":"ESTIMATED","startDate":"2026-07-30","startDateType":"ESTIMATED","primaryCompletionDate":"2030-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-30","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Mycosis Fungoides"],"interventions":["VG712","Mogamulizumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["RNA fusion"],"summary":"VG712 (A-dmDT390-bisFv(UCHT1) fusion protein) is a recombinant anti-CD3 immunotoxin that selectively depletes CD3-positive T cells through irreversible inhibition of protein synthesis. This Phase II study (CurbMF-001) evaluates the safety and efficacy of VG712 compared with mogamulizumab in subjects with relapsed or refractory mycosis fungoides (MF) who have failed 2 or more prior systemic therapies. The study has two parts: a lead-in dosing part (BOIN design, up to 24 subjects) to determine RP2D, followed by a randomized part (approximately 322 subjects, 1:1 VG712 vs. mogamulizumab). Sponsor: Virogen Biotechnology Inc.","sourceUrl":"https://clinicaltrials.gov/study/NCT07529405"},{"nctId":"NCT06941272","title":"A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2025-05-26","startDateType":"ACTUAL","primaryCompletionDate":"2030-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Malignant Neoplasm"],"interventions":["Patritumab Deruxtecan"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","Slovakia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":63,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory: * Hepatoblastoma is a common liver cancer in babies and very young children * RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment The study treatment HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: ","sourceUrl":"https://clinicaltrials.gov/study/NCT06941272"},{"nctId":"NCT06619509","title":"A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine","sponsor":"Boehringer Ingelheim","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":90,"enrollmentType":"ACTUAL","startDate":"2024-12-30","startDateType":"ACTUAL","primaryCompletionDate":"2030-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Solid Tumours"],"interventions":["Brigimadlin"],"countries":["United States","Argentina","Australia","Belgium","Canada","China","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Japan","Norway","Poland","Spain","Sweden","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":50,"serviceSignals":["Broad CGP"],"summary":"This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study. The goal of this study is to find out how well people with solid tumours tolerate long-term treatment with brigimadlin. Brigimadlin is a so-called MDM2 inhibitor that was being developed to treat cancer. All participants take brigimadlin as tablets once every 3 weeks at the study site. At study visits, doctors check participants' health and take note of any unwanted effects. At some study visits, doctors also check the size of the tumour and whether it has spread to other parts of the body. Participants are in the study as long as they benefit from treatment and c","sourceUrl":"https://clinicaltrials.gov/study/NCT06619509"},{"nctId":"NCT04589234","title":"Saltikva for Metastatic Pancreatic Cancer","sponsor":"Salspera LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2020-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2030-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2030-12-31","completionType":"ESTIMATED","lastUpdated":"2026-05-14","conditions":["Metastatic Pancreatic Cancer"],"interventions":["Salmonella-IL2","FOLFIRINOX Alone (Historical Controls)","Gemcitabine/Abraxane Alone (Historical Controls)"],"countries":["Canada"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"Objectives: Assess the efficacy of multiple dose oral administration of Saltikva, an attenuated strain of Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX or Gemcitabine/Abraxane and Saltikva). Study Rationale: The addition of Saltikva to the standard of care regimen for Stage IV metastatic pancreatic cancer will significantly prolong the overall survival and prolong the time to disease progression. Patient Population: unresectable, metastatic pancreatic cancer patients 18 years of age or older","sourceUrl":"https://clinicaltrials.gov/study/NCT04589234"},{"nctId":"NCT07628062","title":"Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation","sponsor":"ImmunityBio, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":70,"enrollmentType":"ESTIMATED","startDate":"2026-07-22","startDateType":"ESTIMATED","primaryCompletionDate":"2030-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-27","completionType":"ESTIMATED","lastUpdated":"2026-06-04","conditions":["HPV-Positive Oropharyngeal Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma","Head and Neck Cancer"],"interventions":["Nogapendekin Alfa Inbakicept (NAI)","hAd5-HPV Vaccine (IBRX-042)","Nab-Paclitaxel","Cisplatin","De-Intensified IMRT","Standard of Care IMRT"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a safety lead-in followed by a randomized Phase 2 comparison of a de-intensified experimental chemoradiation approach versus standard-of-care chemoradiation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07628062"},{"nctId":"NCT07621601","title":"A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)","sponsor":"Hansoh BioMedical R&D Company","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":494,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2030-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-31","completionType":"ESTIMATED","lastUpdated":"2026-06-02","conditions":["Esophageal Squamous Cell Carcinoma (ESCC)"],"interventions":["HS-20093 for Injection","Irinotecan; Paclitaxel; Docetaxel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093- injection versus investigator's choice of chemotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma after progress of first-line standard therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07621601"},{"nctId":"NCT07387068","title":"Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors","sponsor":"Genmab","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":121,"enrollmentType":"ESTIMATED","startDate":"2026-04-07","startDateType":"ACTUAL","primaryCompletionDate":"2031-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Advanced Solid Tumors"],"interventions":["GEN1079"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":12,"serviceSignals":["Broad CGP"],"summary":"The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1079 to find out if it is safe and determine what are the best doses to use. The second and third parts continue to test the safety of and whether GEN1079 works in additional participants with specific cancer types and at doses chosen based on results from the previous parts of the trial. For each participant, the trial will last approximately 33 to 67 weeks but this may vary for each person. This includes up to 21 days for screening prior to receiving trial treatmen","sourceUrl":"https://clinicaltrials.gov/study/NCT07387068"},{"nctId":"NCT07288112","title":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","sponsor":"Diakonos Oncology Corporation","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":35,"enrollmentType":"ESTIMATED","startDate":"2026-04-06","startDateType":"ACTUAL","primaryCompletionDate":"2031-01","primaryCompletionType":"ESTIMATED","completionDate":"2033-01","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Refractory Melanoma"],"interventions":["DOC1021","Tumor resection","pIFN (peginterferon alfa-2a)"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"The goal of this clinical trial is to learn if DOC1021 + pIFN will be safe and will lead to tumor responses in patients with refractory melanoma. DOC1021 is a dendritic cell immunotherapy derived from a patient's own blood cells and loaded with antigens from the patient's tumor in the form of tumor lysate and mRNA. The goal is to stimulate a T cell immune response that eliminates tumor cells. The study consists of two components: an initial phase I safety study to confirm safety/tolerability of the treatment regimen, and, subsequently, a single-arm phase II cohort to assess efficacy of the treatment regimen. All participants will: * Take filgrastim subcutaneously x 5 doses and subsequently u","sourceUrl":"https://clinicaltrials.gov/study/NCT07288112"},{"nctId":"NCT07712588","title":"Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)","sponsor":"Dizal Pharmaceuticals","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":880,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2031-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-02","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"interventions":["Birelentinib","Rituximab","Cyclophosphamid","Doxorubicin","Vincristine","Prednisone","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":5,"serviceSignals":["Hematology NGS"],"summary":"This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP.","sourceUrl":"https://clinicaltrials.gov/study/NCT07712588"},{"nctId":"NCT07318883","title":"A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer","sponsor":"Shanghai Henlius Biotech","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":720,"enrollmentType":"ESTIMATED","startDate":"2026-03","startDateType":"ESTIMATED","primaryCompletionDate":"2031-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-01","completionType":"ESTIMATED","lastUpdated":"2026-01-06","conditions":["Squamous NSCLC"],"interventions":["HLX07","HLX07 placebo","Serplulimab","Pembrolizumab","Carboplatin","Paclitaxel or Nab-Paclitaxel"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study consists of two parts: Part I is a randomized, double-blind, multicenter, parallel-controlled phase II clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with serplulimab and chemotherapy as first-line treatment in patients with sqNSCLC. Part II is a randomized, double-blind, multicenter, parallel-controlled phase III clinical study to evaluate the efficacy and safety of HLX07 in combination with serplulimab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy as first-line treatment in patients with sqNSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07318883"},{"nctId":"NCT07701941","title":"A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":220,"enrollmentType":"ESTIMATED","startDate":"2026-08-03","startDateType":"ESTIMATED","primaryCompletionDate":"2031-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-01","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Hormone Receptor Positive","HER2-low or HER2-ultralow","Unresectable or Metastatic Breast Cancer"],"interventions":["Patritumab deruxtecan","Trastuzumab deruxtecan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07701941"},{"nctId":"NCT05968326","title":"A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC","sponsor":"Genentech, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":260,"enrollmentType":"ESTIMATED","startDate":"2023-10-18","startDateType":"ACTUAL","primaryCompletionDate":"2031-01-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-01","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Adenocarcinoma, Pancreatic Ductal"],"interventions":["Autogene cevumeran","Atezolizumab","mFOLFIRINOX"],"countries":["United States","Belgium","Canada","France","Germany","Netherlands","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":89,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer treatment for PDAC and have no evidence of disease after surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT05968326"},{"nctId":"NCT06562192","title":"Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":162,"enrollmentType":"ESTIMATED","startDate":"2024-10-15","startDateType":"ACTUAL","primaryCompletionDate":"2031-01-15","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-16","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Pancreatic Ductal Adenocarcinoma","Non-small Cell Lung Cancer","HR+/HER2- Ductal and Lobular Breast Cancer","Triple Negative Breast Cancer","Colorectal Cancer"],"interventions":["[68Ga]Ga-NNS309","[177Lu]Lu-NNS309"],"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Spain","Switzerland"],"northAmerica":true,"chinaSites":false,"siteCount":29,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[177Lu\\]Lu-NNS309 and the safety, dosimetry and imaging properties of \\[68Ga\\]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06562192"},{"nctId":"NCT07465289","title":"A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis","sponsor":"UCB Biopharma SRL","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2026-07-27","startDateType":"ESTIMATED","primaryCompletionDate":"2031-01-23","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-23","completionType":"ESTIMATED","lastUpdated":"2026-03-11","conditions":["Ocular Myasthenia Gravis"],"interventions":["Rozanolixizumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to assess the long-term safety and efficacy of rozanolixizumab in adult study participants with ocular myasthenia gravis.","sourceUrl":"https://clinicaltrials.gov/study/NCT07465289"},{"nctId":"NCT03725059","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1240,"enrollmentType":"ESTIMATED","startDate":"2018-12-27","startDateType":"ACTUAL","primaryCompletionDate":"2031-01-24","primaryCompletionType":"ESTIMATED","completionDate":"2031-01-24","completionType":"ESTIMATED","lastUpdated":"2025-07-11","conditions":["Breast Cancer"],"interventions":["Pembrolizumab (K)","Placebo (P)","Paclitaxel (X)","Doxorubicin (A)","Epirubicin (E)","Cyclophosphamide (C)","Endocrine therapy","Radiation therapy","Surgery"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Colombia","Costa Rica","France","Germany","Hungary","Ireland","Israel","Japan","New Zealand","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":244,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by pathological Complete Response (pCR) rate defined by the local pathologist, and 2) pembrolizumab is superior to placebo (both in combination with the protoco","sourceUrl":"https://clinicaltrials.gov/study/NCT03725059"},{"nctId":"NCT07365995","title":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","sponsor":"BioNTech SE","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":736,"enrollmentType":"ESTIMATED","startDate":"2026-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2031-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-02","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":["BNT324","Docetaxel","Prednisone/prednisolone"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["ADC biomarker"],"summary":"This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include participants with mCRPC that have been previously treated with androgen receptor pathway inhibitor, but with no previous taxane-based systematic chemotherapy for mCRPC. The main goals of this study are: * To find out if BNT324 helps participants live longer without their cancer getting worse (radiographic progression-free survival \\[rPFS\\]). * To find out if BNT324 helps participants live longer overall ","sourceUrl":"https://clinicaltrials.gov/study/NCT07365995"},{"nctId":"NCT07277231","title":"A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2026-01-22","startDateType":"ACTUAL","primaryCompletionDate":"2031-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Chronic Lymphocytic Leukemia"],"interventions":["Sonrotoclax","Zanubrutinib","Acalabrutinib","Venetoclax"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","France","Germany","Italy","Netherlands","New Zealand","Poland","Romania","South Korea","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":96,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07277231"},{"nctId":"NCT07227350","title":"L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)","sponsor":"Philogen S.p.A.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2031-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-02","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Locally Advanced Basal Cell Carcinoma"],"interventions":["L19IL2","L19TNF","L19IL2/L19TNF"],"countries":["United States","Germany","Greece","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Open label, randomized study in patients with LaBCC not eligible or refusing surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board. The primary objective of the study is to evaluate the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF, the secondary objectives of this study are to evaluate efficacy, safety and pharmacokinetics of immunocytokines. A minimum of 60 patients and a maximum of 180 evaluable patients will be randomized in a 1:1:1 ratio to one of the three different treatment arms of the study and will receive intralesional injections of: (i) Monotherapy 13 Mio IU (\\~2.17 mg) L19IL2; or (ii) Monotherapy 0.4 mg L19TNF; or (iii) Combination of ","sourceUrl":"https://clinicaltrials.gov/study/NCT07227350"},{"nctId":"NCT07227870","title":"L19IL2/TNF in Patients With Basal Cell Carcinoma","sponsor":"Philogen S.p.A.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2026-09","startDateType":"ESTIMATED","primaryCompletionDate":"2031-02","primaryCompletionType":"ESTIMATED","completionDate":"2031-02","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Locally Advanced Basal Cell Carcinoma"],"interventions":["L19IL2/L19TNF"],"countries":["United States","Germany","Greece","Italy","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["Broad CGP"],"summary":"Open-label, single-arm, multicentre study in patients with locally advanced BCC amenable to intratumoral injection, who have progressed on or are intolerant to systemic therapy as determined by a local multidisciplinary tumor board. The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four we","sourceUrl":"https://clinicaltrials.gov/study/NCT07227870"},{"nctId":"NCT05091424","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":332,"enrollmentType":"ESTIMATED","startDate":"2022-03-07","startDateType":"ACTUAL","primaryCompletionDate":"2031-02-10","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-10","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"],"interventions":["Mosunetuzumab","Tocilizumab","Venetoclax","Rituximab"],"countries":["United States","Australia","China","France","Germany","Italy","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":31,"serviceSignals":["Hematology NGS"],"summary":"This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This study will also allow participants who are currently progressing on a Bruton tyrosine kinase inhibitor (BTKi) and requiring salvage therapy as assessed by the treating physician to continue their BTKi throughout the screening period and for the first three cycles of mosunetuzumab. An additional arm (open to non-US participants only) has been added to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mosunetuzu","sourceUrl":"https://clinicaltrials.gov/study/NCT05091424"},{"nctId":"NCT06618287","title":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":416,"enrollmentType":"ESTIMATED","startDate":"2025-02-04","startDateType":"ACTUAL","primaryCompletionDate":"2031-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-26","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Lung Cancer","Breast Cancer"],"interventions":["BMS-986507","Osimertinib","Pembrolizumab","Nivolumab","Pumitamig"],"countries":["United States","Australia","Canada","Chile","France","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":61,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT06618287"},{"nctId":"NCT07673887","title":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":570,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2031-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-28","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Gastric Adenocarcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma"],"interventions":["ASP2138","Pembrolizumab","Oxaliplatin","Capecitabine","Folinic acid","5-FU","Placebo for ASP2138","Placebo for Pembrolizumab"],"countries":["Puerto Rico"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling","ADC biomarker"],"summary":"Claudin 18.2 or CLDN18.2 is a protein found on cells in the digestive system. It is also found in some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a type of immune cell called a T cell. This \"tells\" the immune system to attack the tumor. ASP2138 is a potential treatment for people with gastric cancer (also known as stomach cancer) or gastroesophageal junction cancer (GEJ cancer). GEJ is where the tube that carries food (esophagus) joins the stomach. This study is for people with gastric or GEJ cancer that has spread nearby (locally advanced) and is not removable by surgery (unresectable), or has spread to other","sourceUrl":"https://clinicaltrials.gov/study/NCT07673887"},{"nctId":"NCT07441174","title":"IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors","sponsor":"InxMed (Shanghai) Co., Ltd.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":92,"enrollmentType":"ESTIMATED","startDate":"2026-02-28","startDateType":"ESTIMATED","primaryCompletionDate":"2031-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2031-02-28","completionType":"ESTIMATED","lastUpdated":"2026-02-27","conditions":["Solid Tumor Cancer","PDAC"],"interventions":["IN10018 in combination with RNK08954"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase Ib/II clinical study. The study includes Phase Ib-Dose Exploration Stage and Phase II - Efficacy Exploration and Determination Stage.","sourceUrl":"https://clinicaltrials.gov/study/NCT07441174"},{"nctId":"NCT05753501","title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":135,"enrollmentType":"ACTUAL","startDate":"2023-06-09","startDateType":"ACTUAL","primaryCompletionDate":"2031-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Hematologic Cancer"],"interventions":["ABBV-101","Venetoclax"],"countries":["United States","Canada","France","Germany","Israel","Italy","Japan","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":51,"serviceSignals":["Hematology NGS"],"summary":"Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed. ABBV-101 is an investigational drug being developed for ","sourceUrl":"https://clinicaltrials.gov/study/NCT05753501"},{"nctId":"NCT05919537","title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","sponsor":"Hummingbird Bioscience","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":68,"enrollmentType":"ESTIMATED","startDate":"2023-09-06","startDateType":"ACTUAL","primaryCompletionDate":"2031-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-01","completionType":"ESTIMATED","lastUpdated":"2025-04-18","conditions":["Non-Small Cell Lung Cancer","Pancreatic Cancer","Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["HMBD-001","Docetaxel","Nab-paclitaxel","Gemcitabine"],"countries":["Australia"],"northAmerica":false,"chinaSites":false,"siteCount":5,"serviceSignals":["RNA fusion"],"summary":"This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.","sourceUrl":"https://clinicaltrials.gov/study/NCT05919537"},{"nctId":"NCT07564401","title":"A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2031-03-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-03","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Extensive-stage Small Cell Lung Cancer (ES-SCLC)"],"interventions":["DJI136"],"countries":["United States","Singapore"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["ADC biomarker"],"summary":"This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.","sourceUrl":"https://clinicaltrials.gov/study/NCT07564401"},{"nctId":"NCT05983198","title":"Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":33,"enrollmentType":"ACTUAL","startDate":"2023-11-07","startDateType":"ACTUAL","primaryCompletionDate":"2031-03-04","primaryCompletionType":"ESTIMATED","completionDate":"2031-03-04","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Prostate Cancer"],"interventions":["225Ac-PSMA-R2","68Ga-PSMA-R2","68Ga-PSMA-11"],"countries":["United States","Australia","Canada","France"],"northAmerica":true,"chinaSites":false,"siteCount":10,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to learn if the study drug, \\[225Ac\\]Ac-PSMA-R2, is safe and tolerable, and has anti-tumor activity in treated patients.","sourceUrl":"https://clinicaltrials.gov/study/NCT05983198"},{"nctId":"NCT07749586","title":"A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors","sponsor":"Arvinas Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":499,"enrollmentType":"ESTIMATED","startDate":"2026-07-29","startDateType":"ACTUAL","primaryCompletionDate":"2031-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumor"],"interventions":["ARV-6723","Pembrolizumab","SOC"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-6723. The investigational drug ARV-6723 will be given as an oral tablet on its own and also in combination with other drugs. Researchers think that ARV-6723 can help the body's immune system to better recognize, attack, and destroy cancer cells in adults with advanced solid tumors. ARV-6723 is an investigational drug, and this is the first time ARV-6723 will be used in humans. Depending on the treatment assignmen","sourceUrl":"https://clinicaltrials.gov/study/NCT07749586"},{"nctId":"NCT06343402","title":"Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer","sponsor":"TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":350,"enrollmentType":"ESTIMATED","startDate":"2024-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2031-04","primaryCompletionType":"ESTIMATED","completionDate":"2031-09","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Non-small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer","NSCLC","KRAS G12C","Metastatic Lung Cancer","Advanced Lung Carcinoma"],"interventions":["BBO-8520","Pembrolizumab","BBO-10203"],"countries":["United States","Australia","Canada","Denmark","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":35,"serviceSignals":["RAS genotyping"],"summary":"A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT06343402"},{"nctId":"NCT07691762","title":"A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":690,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2031-04","primaryCompletionType":"ESTIMATED","completionDate":"2031-04","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Hepatocellular Carcinoma"],"interventions":["SHR-8068+ Adebrelimab+ Bevacizumab","SHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab Placebo","SHR-8068 Placebo +Adebrelimab+ Bevacizumab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma. Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.","sourceUrl":"https://clinicaltrials.gov/study/NCT07691762"},{"nctId":"NCT06863272","title":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":360,"enrollmentType":"ESTIMATED","startDate":"2025-07-03","startDateType":"ACTUAL","primaryCompletionDate":"2031-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-01","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Castration-Resistant Prostatic Cancer","Metastasis"],"interventions":["Docetaxel","Ifinatamab Deruxtecan","Opevesostat","Abiraterone","Enzalutamide","Rescue Medication"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","France","Germany","Ireland","Israel","Italy","Netherlands","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":81,"serviceSignals":["Broad CGP"],"summary":"The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about: * The safety of the study treatment and if people tolerate it. * A safe dose level of I-DXd that can be used with other treatments. * Participant levels of prostate specific antigen (PSA) during treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT06863272"},{"nctId":"NCT05367440","title":"Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer","sponsor":"AstraZeneca","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":174,"enrollmentType":"ACTUAL","startDate":"2022-06-02","startDateType":"ACTUAL","primaryCompletionDate":"2031-04-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-11","completionType":"ESTIMATED","lastUpdated":"2026-06-01","conditions":["Metastatic Prostate Cancer"],"interventions":["AZD5305","Enzalutamide","Abiraterone Acetate","Darolutamide","Apalutamide"],"countries":["United States","Australia","Italy","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":20,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT05367440"},{"nctId":"NCT06679101","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2024-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2031-04-28","primaryCompletionType":"ESTIMATED","completionDate":"2031-04-28","completionType":"ESTIMATED","lastUpdated":"2026-04-22","conditions":["Multiple Myeloma","Newly Diagnosed Multiple Myeloma"],"interventions":["Belantamab mafodotin","Lenalidomide","Dexamethasone","Daratumumab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Czechia","France","Germany","Greece","India","Ireland","Israel","Italy","Japan","Norway","Poland","South Africa","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":181,"serviceSignals":["ctDNA / MRD","Hematology NGS"],"summary":"The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.","sourceUrl":"https://clinicaltrials.gov/study/NCT06679101"},{"nctId":"NCT05552222","title":"A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma","sponsor":"Janssen Research & Development, LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1590,"enrollmentType":"ESTIMATED","startDate":"2022-10-25","startDateType":"ACTUAL","primaryCompletionDate":"2031-04-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-10-28","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Multiple Myeloma"],"interventions":["Teclistamab","Daratumumab","Lenalidomide","Dexamethasone","Talquetamab"],"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","France","Germany","Greece","Israel","Italy","Japan","Netherlands","Norway","Poland","Portugal","South Korea","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":270,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).","sourceUrl":"https://clinicaltrials.gov/study/NCT05552222"},{"nctId":"NCT07636785","title":"A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors","sponsor":"VM Discovery, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":111,"enrollmentType":"ESTIMATED","startDate":"2026-06","startDateType":"ESTIMATED","primaryCompletionDate":"2031-05","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-06-18","conditions":["Hepatocellular Carcinoma (HCC)","Metastatic Uveal Melanoma","Renal Cell Carcinoma (RCC)","Nonsmall Cell Lung Cancer","Colorectal Cancer (CRC)"],"interventions":["VMD-102"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed. VMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver/HCC tumor models and preclinical toxicology and pharmacology studies ","sourceUrl":"https://clinicaltrials.gov/study/NCT07636785"},{"nctId":"NCT03314181","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":156,"enrollmentType":"ACTUAL","startDate":"2018-04-02","startDateType":"ACTUAL","primaryCompletionDate":"2031-05","primaryCompletionType":"ESTIMATED","completionDate":"2031-05","completionType":"ESTIMATED","lastUpdated":"2025-08-14","conditions":["Multiple Myeloma"],"interventions":["Dexamethasone","Daratumumab","Venetoclax","Bortezomib"],"countries":["United States","Australia","Canada","Denmark","France","Germany","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Part 1 includes participants with t(11;14) positive relapsed/refractory (R/R) multiple myeloma who will receive venetoclax in combination with daratumumab and dexamethasone (VenDd); Part 2 includes participants with R/R multiple myeloma who will receive venetoclax in combination with daratumumab, bortezomib, and dexamethasone (VenDVd); Part 3 includes participants with t(11;14) positive R/R multiple myeloma who ","sourceUrl":"https://clinicaltrials.gov/study/NCT03314181"},{"nctId":"NCT07753148","title":"Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":52,"enrollmentType":"ESTIMATED","startDate":"2026-09-17","startDateType":"ESTIMATED","primaryCompletionDate":"2031-05-05","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-05","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Clonal Cytopenia of Undetermined Significance (CCUS)","Low-Risk Myelodysplastic Syndrome (LR-MDS)"],"interventions":["REGN17235"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study will test a study drug called REGN17235 (the \"study drug\") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic mutation (SF3B1 Mutation). The study is looking at: * What side effects the study drug might cause * How well the study drug works * How much of the study drug is in the blood at different times * If the body makes antibodies (proteins that attach to substances your body does not recognize) against the study drug; this may cause the study drug to not work as well. * What is the best dose of the study drug to treat CCUS and LR-MDS","sourceUrl":"https://clinicaltrials.gov/study/NCT07753148"},{"nctId":"NCT07288359","title":"Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":205,"enrollmentType":"ESTIMATED","startDate":"2025-12-29","startDateType":"ACTUAL","primaryCompletionDate":"2031-05-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-05-09","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced HR+/HER2- Breast Cancer","Advanced CCNE1-amplified Solid Tumors","Metastatic Castration-resistant Prostate Cancer"],"interventions":["GVV858","Fulvestrant","Letrozole"],"countries":["United States","Czechia","Denmark","France","Germany","Italy","Japan","Singapore","Spain","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":15,"serviceSignals":["HER2 profiling"],"summary":"Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07288359"},{"nctId":"NCT07377578","title":"A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":394,"enrollmentType":"ESTIMATED","startDate":"2026-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2031-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-01-30","completionType":"ESTIMATED","lastUpdated":"2026-02-06","conditions":["Mantle Cell Lymphoma"],"interventions":["Rocbrutinib","Ibrutinib","Acalabrutinib","Zanubrutinib","Orelabrutinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Hematology NGS"],"summary":"Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-cell non-Hodgkin lymphoma (NHL). Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor that exhibits both covalent (irreversible) and non-covalent (reversible) binding. This unique dual mechanism of action has shown promising efficacy and a favorable safety profile across various B-cell NHL subtypes in prior Phase 1 and 2 studies. This is a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator's choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line ","sourceUrl":"https://clinicaltrials.gov/study/NCT07377578"},{"nctId":"NCT07623187","title":"A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy","sponsor":"Ipsen","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2026-11-01","startDateType":"ESTIMATED","primaryCompletionDate":"2031-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-31","completionType":"ESTIMATED","lastUpdated":"2026-06-03","conditions":["Acute Myeloid Leukaemia (AML)","Acute Myeloid Leukaemia"],"interventions":["IPN60340 + azacitidine + venetoclax","Placebo + azacitidine + venetoclax"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study's main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines). In this study all participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneou","sourceUrl":"https://clinicaltrials.gov/study/NCT07623187"},{"nctId":"NCT07711002","title":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":1330,"enrollmentType":"ESTIMATED","startDate":"2026-10-01","startDateType":"ESTIMATED","primaryCompletionDate":"2031-06-17","primaryCompletionType":"ESTIMATED","completionDate":"2033-06-14","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"interventions":["Saruparib","Placebo","Enzalutamide","Darolutamide","Abiraterone"],"countries":["Canada"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.","sourceUrl":"https://clinicaltrials.gov/study/NCT07711002"},{"nctId":"NCT06898957","title":"Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)","sponsor":"Amgen","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":29,"enrollmentType":"ACTUAL","startDate":"2025-05-16","startDateType":"ACTUAL","primaryCompletionDate":"2031-06-23","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-23","completionType":"ESTIMATED","lastUpdated":"2026-05-20","conditions":["Small Cell Lung Cancer"],"interventions":["YL201","Tarlatamab","Durvalumab"],"countries":["United States","Canada","China","France","Germany","Greece","Hungary","Italy","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":36,"serviceSignals":["Broad CGP"],"summary":"The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.","sourceUrl":"https://clinicaltrials.gov/study/NCT06898957"},{"nctId":"NCT06363994","title":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","sponsor":"InnoCare Pharma Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":476,"enrollmentType":"ESTIMATED","startDate":"2024-05-29","startDateType":"ACTUAL","primaryCompletionDate":"2031-06-25","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-25","completionType":"ESTIMATED","lastUpdated":"2024-12-27","conditions":["Mantle Cell Lymphoma"],"interventions":["Orelabrutinib","Bendamustine Injection","Rituximab","Orelabrutinib Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)","sourceUrl":"https://clinicaltrials.gov/study/NCT06363994"},{"nctId":"NCT07679269","title":"Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":51,"enrollmentType":"ESTIMATED","startDate":"2027-01-01","startDateType":"ESTIMATED","primaryCompletionDate":"2031-06-27","primaryCompletionType":"ESTIMATED","completionDate":"2031-07-25","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["PIK3CA-Related Overgrowth Spectrum (PROS)","Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)"],"interventions":["Alpelisib","Fulvestrant","Trastuzumab","Pertuzumab","Letrozole"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs. This study is intended for participants who are currently receiving alpelisib in a Novartis-sponsored clinical trial (parent study) and, in the Investigator's judgment, would benefit from continued treatment with alpelisib.","sourceUrl":"https://clinicaltrials.gov/study/NCT07679269"},{"nctId":"NCT06384352","title":"Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2024-05-01","startDateType":"ACTUAL","primaryCompletionDate":"2031-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-30","completionType":"ESTIMATED","lastUpdated":"2026-06-29","conditions":["Advanced Solid Tumors"],"interventions":["YL211","YL211+Pembrolizumab","YL211 + Pembro or Pembro+ Pemetrexed + (Carboplatin or Cisplatin)"],"countries":["United States","Australia","Canada","China"],"northAmerica":true,"chinaSites":true,"siteCount":21,"serviceSignals":["Broad CGP"],"summary":"This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tumors (Part 1) and in combination with pembrolizumab in patients with second or third line locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) (Part 4) To determine the maximum tolerated dose (MTD) and select the recommended expansion dose(s) (RED(s)) of YL211 as monotherapy in patients with advanced solid tumors (Part 1) and in combination with pembrolizumab ","sourceUrl":"https://clinicaltrials.gov/study/NCT06384352"},{"nctId":"NCT07110584","title":"Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors","sponsor":"ModeX Therapeutics, An OPKO Health Company","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":235,"enrollmentType":"ESTIMATED","startDate":"2025-10-01","startDateType":"ACTUAL","primaryCompletionDate":"2031-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-06-30","completionType":"ESTIMATED","lastUpdated":"2026-03-05","conditions":["Advanced Tumors"],"interventions":["MDX2004"],"countries":["Australia","Israel"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07110584"},{"nctId":"NCT06724016","title":"Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors","sponsor":"Hanmi Pharmaceutical Company Limited","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":292,"enrollmentType":"ESTIMATED","startDate":"2024-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2031-07","primaryCompletionType":"ESTIMATED","completionDate":"2031-07","completionType":"ESTIMATED","lastUpdated":"2025-12-17","conditions":["Advanced or Metastatic Solid Tumors"],"interventions":["HM16390","pembrolizumab"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Broad CGP"],"summary":"This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into each dose level. After a comprehensive review of available data from both Dose-Escalation Part and Dose-Ranging Part, the RDEs to be tested in the Dose-Expansion Part are determined. Dose-Expansion Part is designed to assess the potentia","sourceUrl":"https://clinicaltrials.gov/study/NCT06724016"},{"nctId":"NCT07493304","title":"Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1600,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2031-07-08","primaryCompletionType":"ESTIMATED","completionDate":"2031-07-08","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Venous Thromboembolism (VTE)"],"interventions":["REGN7508","Apixaban"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called REGN7508 (called \"study drug\") and will consist of 2 parts: Part 1 and Part 2. The study is focused on participants with or without cancer who develop blood clots in certain veins (called Deep Vein Thrombosis \\[DVT\\]) that block blood flow (Part 1) or focused on participants with cancer who develop blood clots in certain veins (DVT) or the lungs (also called Pulmonary Embolism \\[PE\\]) (Part 2). The aim of the study is to see how safe and effective the study drug is at treating and preventing further blood clots in participants with or without cancer (Part 1) or in participants with cancer (Part 2) compared with another treatment (apixaban","sourceUrl":"https://clinicaltrials.gov/study/NCT07493304"},{"nctId":"NCT07232602","title":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":55,"enrollmentType":"ESTIMATED","startDate":"2026-02-09","startDateType":"ACTUAL","primaryCompletionDate":"2031-07-08","primaryCompletionType":"ESTIMATED","completionDate":"2031-07-08","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Bladder Cancer"],"interventions":["MK-3120","EV","Pembrolizumab","Rescue Medication"],"countries":["United States","Chile","France","Israel","Netherlands","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: * The safety of the study treatment when given with standard treatment and if people tolerate it * The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07232602"},{"nctId":"NCT07392892","title":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","sponsor":"Pfizer","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":840,"enrollmentType":"ESTIMATED","startDate":"2026-05-14","startDateType":"ACTUAL","primaryCompletionDate":"2031-07-22","primaryCompletionType":"ESTIMATED","completionDate":"2032-07-21","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma","Metastatic Gastric Cancer","Gastroesophageal Junction Cancer","Esophageal Adenocarcinoma"],"interventions":["PF-08634404","Chemotherapy","Nivolumab"],"countries":["United States","China","Israel","Italy","Japan","Puerto Rico","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":70,"serviceSignals":["Broad CGP"],"summary":"This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine in combination wit","sourceUrl":"https://clinicaltrials.gov/study/NCT07392892"},{"nctId":"NCT07735533","title":"A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies","sponsor":"Umoja Biopharma","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":274,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2031-08","primaryCompletionType":"ESTIMATED","completionDate":"2031-08","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Lymphoma, B Cell","Lymphoma Non-Hodgkin","High Grade B Cell Lymphoma","Richter Transformation Lymphoma","Grade 3b Follicular Lymphoma","Primary Mediastinal B Cell Lymphoma","Diffuse Large B Cell Lymphoma (DLBCL)"],"interventions":["UB-VV400","Rapamycin (sirolimus)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07735533"},{"nctId":"NCT02448173","title":"A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer","sponsor":"Vaccinogen Inc","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":550,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2031-08","primaryCompletionType":"ESTIMATED","completionDate":"2033-08","completionType":"ESTIMATED","lastUpdated":"2026-02-02","conditions":["Stage II Colon Cancer"],"interventions":["OncoVAX and Surgery","Surgery"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"OncoVAX® is the first cancer therapy that both prevents cancer recurrence and addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's own cancer cells to mobilize the body's immune system to prevent the return of colon cancer following surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT02448173"},{"nctId":"NCT07063745","title":"A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","sponsor":"Bristol-Myers Squibb","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":590,"enrollmentType":"ESTIMATED","startDate":"2026-01-02","startDateType":"ACTUAL","primaryCompletionDate":"2031-08-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-12","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Metastatic Non-small Cell Lung Cancer With MTAP Deletion"],"interventions":["BMS-986504","Pembrolizumab","Placebo","Cisplatin","Carboplatin","Pemetrexed","Paclitaxel","Nab-paclitaxel"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Chile","China","Colombia","Czechia","Denmark","France","Germany","Greece","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Poland","Romania","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":318,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion","sourceUrl":"https://clinicaltrials.gov/study/NCT07063745"},{"nctId":"NCT07630974","title":"A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2026-07-02","startDateType":"ACTUAL","primaryCompletionDate":"2031-08-17","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-17","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Malignant Neoplasm"],"interventions":["Ifinatamab Deruxtecan"],"countries":["United States","Belgium","Denmark","France","Israel","South Korea","Spain","Sweden"],"northAmerica":true,"chinaSites":false,"siteCount":18,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat children with relapsed or refractory solid tumors: * Relapsed means the cancer came back after treatment * Refractory means the cancer did not respond (get smaller or go away) to treatment * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids The study treatment I-DXd (also known as MK-2400 or ifinatamab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of I-DXd and if children younger than 12 years old tolerate it * How many children who receive I-DXd ha","sourceUrl":"https://clinicaltrials.gov/study/NCT07630974"},{"nctId":"NCT07609706","title":"A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment","sponsor":"GlaxoSmithKline","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-10-23","startDateType":"ESTIMATED","primaryCompletionDate":"2031-08-22","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-22","completionType":"ESTIMATED","lastUpdated":"2026-05-27","conditions":["Multiple Myeloma"],"interventions":["Belantamab mafodotin","Bortezomib","Dexamethasone"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal liver function. It also compares how liver problems affect the body's handling of belantamab mafodotin and uses the results to help set safe and appropriate dosing guidance for MM participants with moderate liver problems.","sourceUrl":"https://clinicaltrials.gov/study/NCT07609706"},{"nctId":"NCT07509151","title":"Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":420,"enrollmentType":"ESTIMATED","startDate":"2026-05-05","startDateType":"ACTUAL","primaryCompletionDate":"2031-08-29","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-05","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV"],"interventions":["Surovatamig"],"countries":["Australia","Canada","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).","sourceUrl":"https://clinicaltrials.gov/study/NCT07509151"},{"nctId":"NCT07006727","title":"Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2025-10-16","startDateType":"ACTUAL","primaryCompletionDate":"2031-08-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-29","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Small Cell Lung Carcinoma","Large Cell Neuroendocrine Carcinoma of the Lung","Neuroendocrine Prostate Cancer","Gastroenteropancreatic Neuroendocrine Carcinoma"],"interventions":["225Ac-ETN029","111In-ETN029"],"countries":["United States","Canada","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[225Ac\\]Ac-ETN029 and the safety and imaging properties of \\[111In\\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07006727"},{"nctId":"NCT07743164","title":"A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":646,"enrollmentType":"ESTIMATED","startDate":"2026-07-17","startDateType":"ESTIMATED","primaryCompletionDate":"2031-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-31","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Ovarian Cancer","Peritoneal Cancer","Fallopian Tube Cancer"],"interventions":["R-DXd","Bevacizumab","Carboplatin","Paclitaxel","Gemcitabine","Pegylated liposomal doxorubicin (PLD)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that started in cells that cover the ovaries, in the lining of the belly, or in the fallopian tubes. The usual treatment for high-grade OC may include one or both of these: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing. * Bevacizumab, which is a targeted therapy that works to control how specific types of cancer cells grow and spread and targets","sourceUrl":"https://clinicaltrials.gov/study/NCT07743164"},{"nctId":"NCT04895709","title":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","sponsor":"Bristol-Myers Squibb","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":1109,"enrollmentType":"ESTIMATED","startDate":"2021-05-27","startDateType":"ACTUAL","primaryCompletionDate":"2031-08-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-08-31","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Cervical Cancer","Gastric/Gastroesophageal Junction Adenocarcinoma","Microsatellite Stable Colorectal Cancer","Non-Small-Cell Lung Cancer","Squamous Cell Carcinoma of Head and Neck","Carcinoma, Renal Cell","Urothelial Carcinoma","Pancreatic Adenocarcinoma","Melanoma","Ovarian Neoplasms","Triple Negative Breast Neoplasms"],"interventions":["BMS-986340","BMS-936558-01","Docetaxel","Pumitamig"],"countries":["United States","Australia","Canada","Germany","Israel","Italy","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":47,"serviceSignals":["MSI / TMB"],"summary":"The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT04895709"},{"nctId":"NCT06833073","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":308,"enrollmentType":"ESTIMATED","startDate":"2025-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2031-09-03","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-03","completionType":"ESTIMATED","lastUpdated":"2026-07-02","conditions":["Urinary Bladder Neoplasms","Non-Muscle Invasive Bladder Neoplasms","Carcinoma in Situ"],"interventions":["Intismeran autogene","BCG"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","Colombia","Denmark","France","Germany","Greece","Hungary","Italy","Netherlands","Peru","Poland","Spain","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":89,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat people with high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may have a high chance of getting worse or coming back after treatment. HR NMIBC can also include carcinoma in situ (CIS). CIS is bladder cancer that appears flat and is only in the inner layer (surface) of the bladder. CIS is not raised and is not growing toward the center of the bladder. The standard treatment for HR NMIBC is a procedure to remove the tumor called transurethral resection of the bladder tumor (TURBT) follow","sourceUrl":"https://clinicaltrials.gov/study/NCT06833073"},{"nctId":"NCT06247995","title":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":20,"enrollmentType":"ACTUAL","startDate":"2024-08-14","startDateType":"ACTUAL","primaryCompletionDate":"2031-09-09","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-09","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Breast Cancer"],"interventions":["[68Ga]Ga-NeoB","[177Lu]Lu-NeoB","Capecitabine"],"countries":["United States","Australia","Canada","China","France","Germany","Netherlands","Portugal","Singapore","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":23,"serviceSignals":["HER2 profiling"],"summary":"In the phase I part, to determine the recommended doses (RD) and dosing regimens of \\[177Lu\\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor. In the phase II part, to evaluate the preliminary anti-tumor activity of two different doses/regimens of \\[177Lu\\]Lu-NeoB in combination with capecitabine (dose optimization).","sourceUrl":"https://clinicaltrials.gov/study/NCT06247995"},{"nctId":"NCT04245839","title":"A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)","sponsor":"Celgene","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":276,"enrollmentType":"ESTIMATED","startDate":"2020-07-14","startDateType":"ACTUAL","primaryCompletionDate":"2031-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-09-30","completionType":"ESTIMATED","lastUpdated":"2025-11-05","conditions":["Lymphoma, Non-Hodgkin"],"interventions":["Fludarabine","Cyclophosphamide","JCAR017"],"countries":["United States","Austria","Canada","France","Germany","Italy","Japan","Spain","Sweden","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This study is divided into three periods: * Pretreatment, which consists of screening assessments, leukapheresis and the Pretreatment evaluation; * Treatment, which starts with the administration of lymphodepleting (LD) chemotherapy and continues through JCAR017 administration at Day 1 with follo","sourceUrl":"https://clinicaltrials.gov/study/NCT04245839"},{"nctId":"NCT05951179","title":"Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer","sponsor":"Protara Therapeutics","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":131,"enrollmentType":"ESTIMATED","startDate":"2023-09-15","startDateType":"ACTUAL","primaryCompletionDate":"2031-10","primaryCompletionType":"ESTIMATED","completionDate":"2032-03","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Non-muscle Invasive Bladder Cancer"],"interventions":["TARA-002"],"countries":["United States","Argentina","Brazil","Canada","Japan","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":71,"serviceSignals":["Broad CGP"],"summary":"TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101-Ph2) is to further assess the safety and efficacy of TARA-002 at the RP2D which has been established in the Phase 1a dose finding study (TARA-002-101-Ph1a). This Phase 2 study includes participants with CIS NMIBC (± Ta/T1) with active disease, defined as disease present at last tumor evaluation (within 3 months) prior to signing the ICF. Participants will be enrolled into one of 2 cohorts: Cohort A: * Participants with CIS (± Ta/T1) who are BCG naive, or *","sourceUrl":"https://clinicaltrials.gov/study/NCT05951179"},{"nctId":"NCT06898450","title":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","sponsor":"Nimbus Wadjet, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2025-03-31","startDateType":"ACTUAL","primaryCompletionDate":"2031-10","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-05-06","conditions":["Advanced Solid Tumors Cancer","MSI-H Cancer"],"interventions":["NDI-219216"],"countries":["United States","Australia","Canada","France","Ireland","Portugal","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":22,"serviceSignals":["MSI / TMB"],"summary":"The goal of this clinical trial is to learn if NDI-219216 is safe for patients, and if NDI-219216 might be a possible treatment for advanced solid tumors in the later phases of the study. The main questions it aims to answer are: Is NDI-219216 safe and what kinds of side effects might it cause? What kind of effects does NDI-219216 have on the body? Does NDI-219216 have any impact on tumor size? Participants will: Take NDI-219216 every day by mouth. Visit the clinic 6 times during Cycle 1, 2 times during Cycle 2, once a month thereafter for checkups and tests while on the study, then one time for an end of treatment visit. After the End of Study, a follow up will occur but can be done on the ","sourceUrl":"https://clinicaltrials.gov/study/NCT06898450"},{"nctId":"NCT06830889","title":"A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1450,"enrollmentType":"ESTIMATED","startDate":"2025-06-03","startDateType":"ACTUAL","primaryCompletionDate":"2031-10","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-01-22","conditions":["HER2-positive Breast Cancer"],"interventions":["BL-M07D1","T-DM1"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["HER2 profiling"],"summary":"This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT06830889"},{"nctId":"NCT07071714","title":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":200,"enrollmentType":"ESTIMATED","startDate":"2025-07-22","startDateType":"ACTUAL","primaryCompletionDate":"2031-10","primaryCompletionType":"ESTIMATED","completionDate":"2031-10","completionType":"ESTIMATED","lastUpdated":"2026-03-18","conditions":["Colorectal Cancer"],"interventions":["SHR-8068 Injection","Adebrelimab Injection","Bevacizumab Injection"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-8068 injection in combination with anti-tumor therapies in subjects with colorectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07071714"},{"nctId":"NCT06236438","title":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","sponsor":"AbbVie","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":840,"enrollmentType":"ESTIMATED","startDate":"2024-04-10","startDateType":"ACTUAL","primaryCompletionDate":"2031-10","primaryCompletionType":"ESTIMATED","completionDate":"2031-10","completionType":"ESTIMATED","lastUpdated":"2026-02-23","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Livmoniplimab","Budigalimab","Pembrolizumab","Pemetrexed","Cisplatin","Carboplatin"],"countries":["United States","Australia","Belgium","Chile","France","Israel","Japan","Netherlands","Puerto Rico","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":61,"serviceSignals":["Broad CGP"],"summary":"Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (anoth","sourceUrl":"https://clinicaltrials.gov/study/NCT06236438"},{"nctId":"NCT07361510","title":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2026-03-12","startDateType":"ACTUAL","primaryCompletionDate":"2031-10-14","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-14","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Non-Small Cell Lung Cancer (NSCLC)"],"interventions":["Pumitamig","Pembrolizumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Czechia","Finland","France","Germany","Hungary","India","Italy","Japan","Malaysia","Mexico","Netherlands","Norway","Peru","Poland","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":274,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.","sourceUrl":"https://clinicaltrials.gov/study/NCT07361510"},{"nctId":"NCT07660094","title":"Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)","sponsor":"Candel Therapeutics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ESTIMATED","primaryCompletionDate":"2031-10-22","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-22","completionType":"ESTIMATED","lastUpdated":"2026-06-22","conditions":["Non-squamous, Non-Small Cell Lung Cancer"],"interventions":["Aglatimagene Besadenovec","Valacyclovir","Pembrolizumab","Docetaxel"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient adenoviral vector encoding the herpes simplex virus thymidine kinase (HSV-tk) gene. When combined with an oral prodrug (valacyclovir), injection of aglatimagene induces targeted tumor cell death and stimulates a systemic immune response. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and sprea","sourceUrl":"https://clinicaltrials.gov/study/NCT07660094"},{"nctId":"NCT07049926","title":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-07-20","startDateType":"ACTUAL","primaryCompletionDate":"2031-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-26","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Renal Cell Carcinoma"],"interventions":["Belzutifan","Zanzalintinib"],"countries":["United States","Chile","France","Israel","Poland","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":30,"serviceSignals":["Broad CGP"],"summary":"Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\\[L\\]1) adjuvant therapy. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will b","sourceUrl":"https://clinicaltrials.gov/study/NCT07049926"},{"nctId":"NCT07216703","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1023,"enrollmentType":"ESTIMATED","startDate":"2026-01-19","startDateType":"ACTUAL","primaryCompletionDate":"2031-10-29","primaryCompletionType":"ESTIMATED","completionDate":"2031-10-29","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Cervical Cancer"],"interventions":["Pembrolizumab","Sacituzumab Tirumotecan","Bevacizumab","Paclitaxel","Cisplatin","Carboplatin","Rescue Medications"],"countries":["United States","Argentina","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","France","Germany","Greece","Hungary","India","Ireland","Israel","Italy","Japan","Mexico","Poland","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":159,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to learn about giving the study medicine sacituzumab tirumotecan (also called sac-TMT or MK-2870) along with pembrolizumab and bevacizumab treatments. Sac-TMT is an antibody drug conjugate, which is a type of medicine that attaches to specific targets on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn: * About the safety of sac-TMT with pembrolizumab and bevacizumab, and if people tolerate them when given togeth","sourceUrl":"https://clinicaltrials.gov/study/NCT07216703"},{"nctId":"NCT07468396","title":"A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer","sponsor":"Gan & Lee Pharmaceuticals.","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":65,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ESTIMATED","primaryCompletionDate":"2031-10-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-04-30","completionType":"ESTIMATED","lastUpdated":"2026-03-12","conditions":["Prostate Cancer"],"interventions":["GLR2037"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT07468396"},{"nctId":"NCT07007312","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","sponsor":"Kura Oncology, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1300,"enrollmentType":"ESTIMATED","startDate":"2025-09-26","startDateType":"ACTUAL","primaryCompletionDate":"2031-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Acute Myeloid Leukemia (AML)"],"interventions":["Ziftomenib","Placebo","Venetoclax","Azacitidine (AZA)","Daunorubicin","Cytarabine (Ara-C)"],"countries":["United States","Australia","Belgium","Canada","Czechia","France","Germany","Greece","Italy","Philippines","Poland","Portugal","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":106,"serviceSignals":["Hematology NGS"],"summary":"Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second","sourceUrl":"https://clinicaltrials.gov/study/NCT07007312"},{"nctId":"NCT07409246","title":"A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":127,"enrollmentType":"ESTIMATED","startDate":"2026-02-27","startDateType":"ACTUAL","primaryCompletionDate":"2031-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-05-19","conditions":["Multiple Myeloma"],"interventions":["ABBV-438"],"countries":["United States","Israel","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events, tolerability, how ABBV-438 moves through the body will be assessed. ABBV-438 is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms broken into 2 parts. ABBV-438 will be given alone and multiple doses will be explored. This study will include a dose escalation phase (Part 1) to determine the best dose of ABBV-438, fol","sourceUrl":"https://clinicaltrials.gov/study/NCT07409246"},{"nctId":"NCT06969430","title":"A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)","sponsor":"Debiopharm International SA","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":134,"enrollmentType":"ESTIMATED","startDate":"2025-05-30","startDateType":"ACTUAL","primaryCompletionDate":"2031-11","primaryCompletionType":"ESTIMATED","completionDate":"2031-11","completionType":"ESTIMATED","lastUpdated":"2026-03-30","conditions":["Acute Myeloid Leukemia"],"interventions":["Debio 1562M"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":7,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary objective of Phase 2 is to evaluate the antileukemic activity of Debio 1562M.","sourceUrl":"https://clinicaltrials.gov/study/NCT06969430"},{"nctId":"NCT06549595","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1018,"enrollmentType":"ESTIMATED","startDate":"2024-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2031-11-26","primaryCompletionType":"ESTIMATED","completionDate":"2031-11-26","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Untreated Follicular Lymphoma"],"interventions":["Surovatamig","R-CHOP","R-CVP","BR"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","Germany","Hong Kong","Hungary","India","Japan","Poland","Puerto Rico","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":224,"serviceSignals":["Hematology NGS"],"summary":"This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.","sourceUrl":"https://clinicaltrials.gov/study/NCT06549595"},{"nctId":"NCT06812104","title":"Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.","sponsor":"Kyowa Kirin Co., Ltd.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2024-10-10","startDateType":"ACTUAL","primaryCompletionDate":"2031-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Relapsed or Refractory AML and Other Hematologic Malignancies"],"interventions":["KK2845_1","KK2845_2","KK2845_3","KK2845_4","KK2845_5","KK2845_6","KK2845_7","KK2845_8","KK2845_alternative_1","KK2845_alternative_2"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"This is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies, in Part 1, the tolerability of KK2845 will be evaluated to determine the maximum tolerated dose (MTD). In Part 2, additional data will be collected by administering KK2845 at dose levels for which tolerability has been confirmed.","sourceUrl":"https://clinicaltrials.gov/study/NCT06812104"},{"nctId":"NCT07667296","title":"APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma","sponsor":"Aveta Biomics, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":826,"enrollmentType":"ESTIMATED","startDate":"2026-07","startDateType":"ESTIMATED","primaryCompletionDate":"2031-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-07-01","conditions":["Head and Neck Cancer","Head and Neck (HNSCC)","Oropharyngeal","Oral Cavity","Oral Cavity Carcinoma","Oropharynx Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma"],"interventions":["APG-157","Surgery","Radiation/Chemotherapy"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 administered as neoadjuvant therapy before curative-intent surgery in participants with resectable oral cavity or oropharyngeal cancer who are medically ineligible for perioperative pembrolizumab. Cohort B evaluates APG-157 administered as induction therapy before definitive chemoradiotherapy and as maintenance therapy after chemoradiotherapy in participants with unresectable or medically inoperable disease. Participants a","sourceUrl":"https://clinicaltrials.gov/study/NCT07667296"},{"nctId":"NCT06879145","title":"Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":840,"enrollmentType":"ESTIMATED","startDate":"2025-04-25","startDateType":"ACTUAL","primaryCompletionDate":"2031-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Muscular Invasive Bladder Cancer (MIBC)"],"interventions":["SHR-A2102；Adebrelimab"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06879145"},{"nctId":"NCT07005102","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","sponsor":"AbbVie","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":854,"enrollmentType":"ESTIMATED","startDate":"2025-08-03","startDateType":"ACTUAL","primaryCompletionDate":"2031-12","primaryCompletionType":"ESTIMATED","completionDate":"2036-11","completionType":"ESTIMATED","lastUpdated":"2026-06-08","conditions":["Non-Squamous Non-Small Cell Lung Cancer"],"interventions":["Standard of Care","Telisotuzumab Adizutecan","Osimertinib (Osi)","Cisplatin","Carboplatin","Pemetrexed"],"countries":["United States","Australia","Belgium","Canada","China","Israel","Italy","Japan","Portugal","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":53,"serviceSignals":["Broad CGP"],"summary":"Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity \"when telisotuzumab adizutecan is given in combination with a fixed dose of osimertinib (Osi)or standard of care (Osi plus platinum/pemetrexed chemotherapy). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. Osi is a drug approved for the treatment of NSCLC. This study will be divided into two stages, in the first stage participants will receive increasing doses of telisotuzumab adizutecan with Osi. Participants will then be randomized into 4 ","sourceUrl":"https://clinicaltrials.gov/study/NCT07005102"},{"nctId":"NCT07195591","title":"Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care","sponsor":"GT Medical Technologies, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":766,"enrollmentType":"ESTIMATED","startDate":"2025-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2031-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["Glioblastoma"],"interventions":["GammaTile®","External Beam Radiation Therapy","Temozolomide"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation of Arm A:Arm B. * A Perioperative/Operative Phase where patients will undergo tumor resection (Arm A) or tumor resection plus GammaTile implantation (Arm B). * An EBRT Prior to Start Period. This occurs within 10 business days prior to EBRT and Concurrent TMZ Phase. * An EBRT and Concurrent TMZ Phase, which will begin 30 ±10 days post-surgery. EBRT (30 fractions) and TMZ will be administered up to 5 days a week for 6 weeks in Arm A, and EBRT (20 fractions) a","sourceUrl":"https://clinicaltrials.gov/study/NCT07195591"},{"nctId":"NCT05232916","title":"Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects","sponsor":"Greenwich LifeSciences, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":2250,"enrollmentType":"ESTIMATED","startDate":"2022-12-16","startDateType":"ACTUAL","primaryCompletionDate":"2031-12","primaryCompletionType":"ESTIMATED","completionDate":"2031-12","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Breast Cancer"],"interventions":["Placebo","GLSI-100"],"countries":["United States","Belgium","France","Germany","Ireland","Italy","Poland","Portugal","Romania","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":179,"serviceSignals":["HER2 profiling","HLA / TCR"],"summary":"This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of care therapy. Treatment consists of 6 intradermal injections, Primary Immunization Series (PIS), over the first 6 months of treatment and 5 booster intradermal injections spaced 6 months apart. A third open-label arm will explore GLSI-100 immunotherapy in non-HLA-A\\*02 positive and HER2/neu positive subjects.","sourceUrl":"https://clinicaltrials.gov/study/NCT05232916"},{"nctId":"NCT07204340","title":"TLN-372 in Advanced KRAS Mutant Solid Tumors","sponsor":"Treeline Biosciences, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2025-09-29","startDateType":"ACTUAL","primaryCompletionDate":"2031-12-03","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-01","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["KRAS Mutant Solid Tumors"],"interventions":["TLN-372","TLN-372 in combination with cetuximab","TLN-372 in combination with pembrolizumab"],"countries":["United States","Australia","Canada","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["RAS genotyping"],"summary":"The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07204340"},{"nctId":"NCT07680790","title":"Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)","sponsor":"Bristol-Myers Squibb","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":850,"enrollmentType":"ESTIMATED","startDate":"2026-09-30","startDateType":"ESTIMATED","primaryCompletionDate":"2031-12-30","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-30","completionType":"ESTIMATED","lastUpdated":"2026-07-15","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Iza-bren","Osimertinib","Pemetrexed","Carboplatin","Cisplatin"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","France","Germany","India","Italy","Japan","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":200,"serviceSignals":["ADC biomarker"],"summary":"The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy","sourceUrl":"https://clinicaltrials.gov/study/NCT07680790"},{"nctId":"NCT06134232","title":"Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","sponsor":"Dendreon","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2023-10-02","startDateType":"ACTUAL","primaryCompletionDate":"2031-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-30","completionType":"ESTIMATED","lastUpdated":"2025-08-27","conditions":["Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"interventions":["Sipuleucel-T Injection"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06134232"},{"nctId":"NCT07554521","title":"A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States","sponsor":"BeOne Medicines","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":30,"enrollmentType":"ESTIMATED","startDate":"2026-04-30","startDateType":"ACTUAL","primaryCompletionDate":"2031-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2031-12-31","completionType":"ESTIMATED","lastUpdated":"2026-07-22","conditions":["Advanced Unresectable Gastric Adenocarcinoma","Esophageal Squamous Cell Carcinoma","Advanced Gastroesophageal Adenocarcinoma"],"interventions":["Tislelizumab","Capecitabine","5-fluorouracil (5-FU)","Oxaliplatin","Leucovorin"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":6,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (HER2)-negative, programmed death-ligand 1(PD-L1)-positive, unresectable or metastatic gastric or gastroesophageal cancer (GAC/GEA) or esophageal squamous cell carcinoma (ESCC). The study duration will be up to approximately 6 years.","sourceUrl":"https://clinicaltrials.gov/study/NCT07554521"},{"nctId":"NCT06780111","title":"Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":298,"enrollmentType":"ESTIMATED","startDate":"2025-07-30","startDateType":"ACTUAL","primaryCompletionDate":"2032-01-04","primaryCompletionType":"ESTIMATED","completionDate":"2032-01-04","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Esophageal Squamous Cell Carcinoma"],"interventions":["Pembrolizumab","I-DXd","Leucovorin","Levoleucovorin","5-Fluorouracil (5-FU)","Oxaliplatin","Sacituzumab tirumotecan","Rescue Medication"],"countries":["United States","Brazil","Chile","China","Czechia","France","Germany","Italy","Japan","Norway","Singapore","South Korea","Switzerland","Taiwan","Thailand"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This study will look at ESCC that is either locally advanced unresectable, which means it has spread into tissue near where it started and cannot be completely removed by surgery, or metastatic, which means it has spread to other body parts. Available treatments for these types of ESCC include pembrolizumab and chemotherapy. Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys ","sourceUrl":"https://clinicaltrials.gov/study/NCT06780111"},{"nctId":"NCT05789082","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":320,"enrollmentType":"ESTIMATED","startDate":"2023-06-20","startDateType":"ACTUAL","primaryCompletionDate":"2032-01-29","primaryCompletionType":"ESTIMATED","completionDate":"2032-01-29","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Non-Small Cell Lung Cancer"],"interventions":["Divarasib","Pembrolizumab","Carboplatin","Cisplatin","Pemetrexed"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","China","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":71,"serviceSignals":["RAS genotyping"],"summary":"The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).","sourceUrl":"https://clinicaltrials.gov/study/NCT05789082"},{"nctId":"NCT07541170","title":"A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2032-01-31","primaryCompletionType":"ESTIMATED","completionDate":"2035-03-31","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Non-small Cell Lung Cancer"],"interventions":["Divarasib","Pembrolizumab","Nivolumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["RAS genotyping"],"summary":"The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07541170"},{"nctId":"NCT06544798","title":"Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia","sponsor":"MeiraGTx, LLC","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":276,"enrollmentType":"ESTIMATED","startDate":"2024-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2032-02","primaryCompletionType":"ESTIMATED","completionDate":"2032-02","completionType":"ESTIMATED","lastUpdated":"2025-10-16","conditions":["Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands"],"interventions":["AAV2-hAQP1"],"countries":["United States","Canada"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This study will assess the long-term safety and efficacy of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.","sourceUrl":"https://clinicaltrials.gov/study/NCT06544798"},{"nctId":"NCT06073821","title":"Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)","sponsor":"BeOne Medicines","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":652,"enrollmentType":"ESTIMATED","startDate":"2023-11-11","startDateType":"ACTUAL","primaryCompletionDate":"2032-02","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["CLL"],"interventions":["Sonrotoclax","Zanubrutinib","Venetoclax","Obinutuzumab"],"countries":["United States","Australia","Austria","Brazil","Canada","China","Czechia","France","Germany","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Puerto Rico","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":201,"serviceSignals":["Hematology NGS"],"summary":"The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)","sourceUrl":"https://clinicaltrials.gov/study/NCT06073821"},{"nctId":"NCT06788912","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2025-03-20","startDateType":"ACTUAL","primaryCompletionDate":"2032-02-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-06","completionType":"ESTIMATED","lastUpdated":"2026-06-26","conditions":["Lung Neoplasm Malignant"],"interventions":["Pembrolizumab (neoadjuvant)","Cisplatin","Gemcitabine","Pemetrexed","Sacituzumab tirumotecan","H1 receptor antagonist","H2 receptor antagonist","Acetaminophen (or equivalent)","Dexamethasone (or equivalent)","Carboplatin","Pembrolizumab (adjuvant)","Paclitaxel","Steroid mouthwash (dexamethasone or equivalent)"],"countries":["United States","Chile","Greece","Hungary","Italy","Poland","Spain","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":38,"serviceSignals":["Broad CGP"],"summary":"The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.","sourceUrl":"https://clinicaltrials.gov/study/NCT06788912"},{"nctId":"NCT04165070","title":"KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2019-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2032-02-13","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-13","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Pembrolizumab","Carboplatin","Paclitaxel","Pemetrexed","Vibostolimab","Boserolimab","MK-4830","MK-0482","Ifinatamab Deruxtecan (I-DXd)","HER3-DXd"],"countries":["United States","Hungary","Israel","Italy","Poland","South Korea","Spain","Taiwan","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":46,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).","sourceUrl":"https://clinicaltrials.gov/study/NCT04165070"},{"nctId":"NCT05533697","title":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","sponsor":"ModernaTX, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":361,"enrollmentType":"ESTIMATED","startDate":"2022-09-01","startDateType":"ACTUAL","primaryCompletionDate":"2032-02-18","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-18","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Advanced Solid Tumors"],"interventions":["mRNA-4359","Pembrolizumab","Ipilimumab","Nivolumab"],"countries":["United States","Australia","Germany","Italy","Poland","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Broad CGP"],"summary":"The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT05533697"},{"nctId":"NCT07195695","title":"Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations","sponsor":"Boehringer Ingelheim","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-01-16","startDateType":"ACTUAL","primaryCompletionDate":"2032-02-26","primaryCompletionType":"ESTIMATED","completionDate":"2036-09-02","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Non-small Cell Lung Cancer"],"interventions":["Zongertinib","Pembrolizumab","Atezolizumab","Durvalumab","Nivolumab"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Denmark","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","Portugal","Romania","Singapore","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":199,"serviceSignals":["HER2 profiling"],"summary":"Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active sur","sourceUrl":"https://clinicaltrials.gov/study/NCT07195695"},{"nctId":"NCT07227402","title":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":904,"enrollmentType":"ESTIMATED","startDate":"2025-11-26","startDateType":"ACTUAL","primaryCompletionDate":"2032-02-27","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-27","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Renal Cell Carcinoma"],"interventions":["Belzutifan","Zanzalintinib","Cabozantinib"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Chile","Croatia","Czechia","Denmark","France","Germany","Greece","Hong Kong","Ireland","Italy","Mexico","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":127,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib. The goal of this study is to learn if: People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.","sourceUrl":"https://clinicaltrials.gov/study/NCT07227402"},{"nctId":"NCT04774718","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","sponsor":"Hoffmann-La Roche","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2021-09-14","startDateType":"ACTUAL","primaryCompletionDate":"2032-02-28","primaryCompletionType":"ESTIMATED","completionDate":"2032-02-28","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["ALK Fusion-positive Solid or CNS Tumors"],"interventions":["Alectinib"],"countries":["United States","Australia","Brazil","Canada","China","Denmark","France","Germany","Italy","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":33,"serviceSignals":["RNA fusion"],"summary":"This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.","sourceUrl":"https://clinicaltrials.gov/study/NCT04774718"},{"nctId":"NCT07174427","title":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma","sponsor":"Takara Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":5,"enrollmentType":"ESTIMATED","startDate":"2026-01-05","startDateType":"ACTUAL","primaryCompletionDate":"2032-03","primaryCompletionType":"ESTIMATED","completionDate":"2032-03","completionType":"ESTIMATED","lastUpdated":"2026-02-18","conditions":["Synovial Sarcomas"],"interventions":["TBI-1301","Cyclophosphamide","Fludarabine"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07174427"},{"nctId":"NCT06780098","title":"Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":144,"enrollmentType":"ESTIMATED","startDate":"2025-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2032-03-02","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-02","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Lung Neoplasm"],"interventions":["R-DXD","I-DXD","Docetaxel","Rescue Medications","Rescue Medication"],"countries":["United States","Chile","China","Germany","Greece","Hungary","Israel","Italy","Poland","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":true,"siteCount":44,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC. Researchers want to learn if study trea","sourceUrl":"https://clinicaltrials.gov/study/NCT06780098"},{"nctId":"NCT06731907","title":"A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2025-03-30","startDateType":"ACTUAL","primaryCompletionDate":"2032-03-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-12","completionType":"ESTIMATED","lastUpdated":"2026-05-26","conditions":["Non-small Cell Lung Cancer"],"interventions":["Pembrolizumab","Carboplatin","Paclitaxel","Nab-paclitaxel","Pemetrexed","HER3-DXd"],"countries":["United States","Chile","Greece","Hungary","Israel","Italy","Poland","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":false,"siteCount":41,"serviceSignals":["ADC biomarker"],"summary":"Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT06731907"},{"nctId":"NCT06780085","title":"A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":96,"enrollmentType":"ESTIMATED","startDate":"2025-05-13","startDateType":"ACTUAL","primaryCompletionDate":"2032-03-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-12","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Raludotatug Deruxtecan","Ifinatamab Deruxtecan","Docetetaxel","5-hydroxytryptamine subtype 3 receptor antagonist","Neurokinin-1 receptor antagonist","Corticosteroid"],"countries":["United States","Chile","Germany","Greece","Hungary","Israel","Italy","Poland","Spain","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["ADC biomarker"],"summary":"Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not start in squamous cells, which are flat cells that line the inside of the lungs. Standard treatment (usual treatment) for NSCLC is surgery, then immunotherapy with or without chemotherapy after surgery. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is a medicine that works to destroy cancer cells or stop them from growing. However, standard treatment may not work or may stop working for some people. Researchers want to ","sourceUrl":"https://clinicaltrials.gov/study/NCT06780085"},{"nctId":"NCT07022483","title":"Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer","sponsor":"Daiichi Sankyo","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":710,"enrollmentType":"ESTIMATED","startDate":"2025-09-30","startDateType":"ACTUAL","primaryCompletionDate":"2032-03-23","primaryCompletionType":"ESTIMATED","completionDate":"2032-03-23","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Endometrial Cancer"],"interventions":["Trastuzumab Deruxtecan","Chemotherapy"],"countries":["United States","Argentina","Chile","China","France","Germany","Italy","Japan","Poland","Portugal","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":75,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.","sourceUrl":"https://clinicaltrials.gov/study/NCT07022483"},{"nctId":"NCT06991556","title":"An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-07-07","startDateType":"ACTUAL","primaryCompletionDate":"2032-03-29","primaryCompletionType":"ESTIMATED","completionDate":"2035-10-19","completionType":"ESTIMATED","lastUpdated":"2026-06-10","conditions":["Metastatic Hormone-sensitive Prostate Cancer"],"interventions":["JSB462","Abiraterone","Enzalutamide"],"countries":["United States","Australia","Brazil","Canada","China","Czechia","France","Germany","Italy","Netherlands","Poland","Singapore","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated","sourceUrl":"https://clinicaltrials.gov/study/NCT06991556"},{"nctId":"NCT03391778","title":"Adoptive Cell Therapy Long-term Follow-up (LTFU) Study","sponsor":"USWM CT, LLC","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2018-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2032-04-01","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-01","completionType":"ESTIMATED","lastUpdated":"2026-03-03","conditions":["Neoplasms"],"interventions":["ADP adoptive cell therapy"],"countries":["United States","Australia","Canada","Germany","Italy","Netherlands","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":24,"serviceSignals":["Broad CGP"],"summary":"This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT03391778"},{"nctId":"NCT07209111","title":"A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2025-12-04","startDateType":"ACTUAL","primaryCompletionDate":"2032-04-09","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-09","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Neoplasm Malignant"],"interventions":["Calderasib","Cetuximab"],"countries":["United States","Australia","Canada","Chile","China","Denmark","France","Germany","Greece","Israel","Italy","Japan","Norway","Poland","South Korea","Spain","Sweden","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":70,"serviceSignals":["RAS genotyping"],"summary":"Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation. The goals of this study are to learn: * How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare * About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.","sourceUrl":"https://clinicaltrials.gov/study/NCT07209111"},{"nctId":"NCT04077099","title":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":231,"enrollmentType":"ESTIMATED","startDate":"2020-01-07","startDateType":"ACTUAL","primaryCompletionDate":"2032-04-22","primaryCompletionType":"ESTIMATED","completionDate":"2032-04-22","completionType":"ESTIMATED","lastUpdated":"2026-06-17","conditions":["NSCLC"],"interventions":["REGN5093"],"countries":["United States","France","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Broad CGP"],"summary":"This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or","sourceUrl":"https://clinicaltrials.gov/study/NCT04077099"},{"nctId":"NCT07581002","title":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","sponsor":"AbbVie","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":660,"enrollmentType":"ESTIMATED","startDate":"2026-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2032-05","primaryCompletionType":"ESTIMATED","completionDate":"2032-06","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Acute Myeloid Leukemia"],"interventions":["Pivekimab Sunirine","Venetoclax","Azacitidine","Matching Placebo for PVEK"],"countries":["United States","Israel","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow (the spongy tissue inside the bones) that affects white blood cells that helps to fight infections and also prevents normal blood cell production. This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA) in adult participants with AML ineligible to receive intensive chemotherapy. Pivekimab sunirine is a drug being evaluated in the treatment of AML.This is a Phase 2/Phase 3, study of PVEK. Phase 2 is open-la","sourceUrl":"https://clinicaltrials.gov/study/NCT07581002"},{"nctId":"NCT06140524","title":"A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":116,"enrollmentType":"ESTIMATED","startDate":"2024-09-16","startDateType":"ACTUAL","primaryCompletionDate":"2032-05-18","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-18","completionType":"ESTIMATED","lastUpdated":"2026-07-08","conditions":["Monoclonal Gammopathy of Undetermined Significance (MGUS)","Smoldering Multiple Myeloma (SMM)"],"interventions":["Linvoseltamab"],"countries":["United States","Belgium","France","Ireland","Italy","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":39,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an investigational drug called linvoseltamab (\"study drug\") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that consists of patients with precancerous conditions called High-Risk Monoclonal Gammopathy of Undetermined Significance (HR-MGUS) and Non-High-Risk Smoldering Multiple Myeloma (NHR-SMM). The primary purpose of the study is to understand how well the study drug can eliminate abnormal plasma cells and laboratory signs of HR-MGUS and NHR-SMM. The study is looking at several other research questions, including: * How many participants treated with linvoseltamab have improvement of their HR-MGUS or NH","sourceUrl":"https://clinicaltrials.gov/study/NCT06140524"},{"nctId":"NCT06952504","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1123,"enrollmentType":"ESTIMATED","startDate":"2025-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2032-05-24","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-24","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Endometrial Cancer"],"interventions":["Pembrolizumab","Carboplatin","Paclitaxel","Docetaxel","Sacituzumab Tirumotecan","Cisplatin"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Norway","Peru","Poland","Puerto Rico","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":260,"serviceSignals":["MSI / TMB","ADC biomarker"],"summary":"Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cells * Advanced means the cancer has spread locally or to other parts of the body (metastatic) and cannot be removed with surgery * Recurrent means the cancer came back after surgery Sacituzumab tirumotecan (also known as sac-TMT) and pembrolizumab are the study medicines. Sac-TMT is an antibody drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destro","sourceUrl":"https://clinicaltrials.gov/study/NCT06952504"},{"nctId":"NCT07660055","title":"Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":156,"enrollmentType":"ESTIMATED","startDate":"2026-06-16","startDateType":"ACTUAL","primaryCompletionDate":"2032-05-24","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-24","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["Breast Cancer","Non-small Cell Lung Cancer (NSCLC)","Gastric/Gastroesophageal Junction (GEJ) Cancer","Bladder Cancer"],"interventions":["[68Ga]Ga-DWJ155","[177Lu]Lu-DWJ155"],"countries":["United States","Australia","Canada","Japan"],"northAmerica":true,"chinaSites":false,"siteCount":4,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of \\[177Lu\\]Lu-DWJ155 and the safety and imaging properties of \\[68Ga\\]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction (GEJ) cancer, and bladder cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07660055"},{"nctId":"NCT06790693","title":"A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2025-04-09","startDateType":"ACTUAL","primaryCompletionDate":"2032-05-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Breast Cancer"],"interventions":["Inavolisib","Placebo","CDK4/6i","Letrozole"],"countries":["United States","Argentina","Australia","Brazil","Canada","China","France","Germany","Italy","Japan","Mexico","Poland","Puerto Rico","South Africa","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":239,"serviceSignals":["HER2 profiling"],"summary":"This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), advanced breast cancer (ABC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06790693"},{"nctId":"NCT07005154","title":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","sponsor":"Astellas Pharma Global Development, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":218,"enrollmentType":"ESTIMATED","startDate":"2025-06-19","startDateType":"ACTUAL","primaryCompletionDate":"2032-05-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-05-31","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Prostate Cancer","Metastatic Castration-Resistant Prostate Cancer","Metastatic Hormone Sensitive Prostate Cancer"],"interventions":["ASP5541","Prednisone","Prednisolone","abiraterone acetate","Adrenocorticotropic hormone"],"countries":["United States","China","France","Germany","Italy","Japan","Poland","Puerto Rico","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":52,"serviceSignals":["Broad CGP"],"summary":"Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much testosterone is made or block testosterone from reaching the prostate cancer cells. Abiraterone acetate (AA) is an ARPI that is used to treat advanced prostate cancer. This type of treatment is usually given as a tablet with a steroid called prednisone/prednisolone to manage any medical problems from the hormone therapy. ASP5541 is a different form of abiraterone acetate. It is given as an injecti","sourceUrl":"https://clinicaltrials.gov/study/NCT07005154"},{"nctId":"NCT06940739","title":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":42,"enrollmentType":"ESTIMATED","startDate":"2025-03-11","startDateType":"ACTUAL","primaryCompletionDate":"2032-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-07","completionType":"ESTIMATED","lastUpdated":"2026-06-15","conditions":["Unresectable Melanoma","Metastatic Melanoma","Ocular Melanoma"],"interventions":["IOV-3001"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["RNA fusion"],"summary":"A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.","sourceUrl":"https://clinicaltrials.gov/study/NCT06940739"},{"nctId":"NCT05947851","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":735,"enrollmentType":"ESTIMATED","startDate":"2023-08-08","startDateType":"ACTUAL","primaryCompletionDate":"2032-06-01","primaryCompletionType":"ESTIMATED","completionDate":"2035-07-01","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Leukemia, Lymphocytic, Chronic, B-Cell","Leukemia, Chronic Lymphocytic","Small-Cell Lymphoma","Lymphoma, Small Lymphocytic","CLL","SLL"],"interventions":["Nemtabrutinib","Venetoclax","Rituximab"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Colombia","France","Germany","Israel","Italy","Mexico","Puerto Rico","South Africa","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":59,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to assess the safety and tolerability and to confirm the dose of nemtabrutinib in combination with venetoclax in participants with R/R CLL/SLL. The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT05947851"},{"nctId":"NCT07604571","title":"Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":194,"enrollmentType":"ESTIMATED","startDate":"2026-05-28","startDateType":"ACTUAL","primaryCompletionDate":"2032-06-08","primaryCompletionType":"ESTIMATED","completionDate":"2032-06-08","completionType":"ESTIMATED","lastUpdated":"2026-06-30","conditions":["Advanced HR+/HER2- Breast Cancer"],"interventions":["IEV407","Fulvestrant","Letrozole"],"countries":["United States","Japan","Singapore"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07604571"},{"nctId":"NCT07722611","title":"A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":380,"enrollmentType":"ESTIMATED","startDate":"2026-09-21","startDateType":"ESTIMATED","primaryCompletionDate":"2032-06-25","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["Polycythemia Vera"],"interventions":["Bomedemstat","Ruxolitinib","Ropeginterferon alfa-2b"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat polycythemia vera (PV). People with PV may receive treatment to lower the number of red blood cells in the blood, but the usual treatments may not work for everyone. Researchers want to learn if a trial medicine called bomedemstat, also called MK-3543, can treat PV. In this study, researchers will compare bomedemstat to 2 usual treatments for PV. The goal of this study is to learn if more participants who take bomedemstat reach healthy blood cell counts and avoid major health problems from PV, compared to those who receive a usual treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07722611"},{"nctId":"NCT07541079","title":"A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)","sponsor":"Genentech, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":300,"enrollmentType":"ESTIMATED","startDate":"2026-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2032-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2034-06-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Early Breast Cancer"],"interventions":["Giredestrant"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI) intolerance. Giredestrant will be administered as adjuvant endocrine therapy for participants with low-, medium-, and high-risk, Stage I-III, histologically confirmed, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (eBC), as defined by the investigator. Participants will enroll if considered to be intolerant to a prior adjuvant AI therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07541079"},{"nctId":"NCT07332533","title":"A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":490,"enrollmentType":"ESTIMATED","startDate":"2025-12-30","startDateType":"ESTIMATED","primaryCompletionDate":"2032-06-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-31","completionType":"ESTIMATED","lastUpdated":"2026-01-12","conditions":["HER2-positive Gastric Cancer"],"interventions":["KN026","Capecitabine","Enlonstobart","Oxaliplatin","Trastuzumab","Pembolizumab","Cisplatin","Fluorouracil"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["HER2 profiling"],"summary":"This study is designed to compare the efficacy and safety of KN026 combined chemotherapy with or without Enlonstobart versus Trastuzumab combined chemotherapy with or without Pembrolizumab as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07332533"},{"nctId":"NCT06632912","title":"Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging","sponsor":"National Vaccine and Serum Institute, China","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1800,"enrollmentType":"ACTUAL","startDate":"2025-11-21","startDateType":"ACTUAL","primaryCompletionDate":"2032-07","primaryCompletionType":"ESTIMATED","completionDate":"2032-07","completionType":"ESTIMATED","lastUpdated":"2026-01-23","conditions":["Human Papillomavirus (HPV) Infection","HPV (Human Papillomavirus)-Associated Carcinoma"],"interventions":["2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)","3 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This vaccine was jointly developed by Chengdu Institute of Biological Products Co., Ltd. and National Vaccine and Serum Institute, China, is co-sponsoring this clinical trial. This trial plans to enroll 1,800 female subjects aged 9-35 years, 450 in each of the 18-25 years old 3-dose group, 26-35 years old 3-dose group, 9-17 years old 3-dose group and 9-14 years old 2-dose group. All subjects in the 9-14 years old 2-dose group will be injected with 2 doses of the experimental vaccine in the deltoid muscle of the upper arm according to the 0-6 month immunization schedule. Subjects in the non-immune persistence subgroup will need to complete 6 on-site visits and subjects in the immune persisten","sourceUrl":"https://clinicaltrials.gov/study/NCT06632912"},{"nctId":"NCT07213830","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies","sponsor":"Ipsen","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":102,"enrollmentType":"ESTIMATED","startDate":"2026-02-06","startDateType":"ACTUAL","primaryCompletionDate":"2032-07-14","primaryCompletionType":"ESTIMATED","completionDate":"2032-07-14","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Advanced Solid Tumor","Metastatic Solid Tumor"],"interventions":["IPN01203"],"countries":["United States","Canada","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours. Advanced solid tumours are cancers that can occur in various organs or tissues and have spread from their original site to nearby tissues or other parts of the body. There will be two parts to this study: * Phase Ia: This part (called dose escalation) will find the dose range that shows activity against the tumour and can be tolerated by participants by testing different increasing doses of IPN01203. * Phase Ib: This part (called dose optimisation) will assess the ability of the drug to prevent, slow down, or stop the growth of tumours and","sourceUrl":"https://clinicaltrials.gov/study/NCT07213830"},{"nctId":"NCT07634471","title":"A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":960,"enrollmentType":"ESTIMATED","startDate":"2026-06-22","startDateType":"ACTUAL","primaryCompletionDate":"2032-07-23","primaryCompletionType":"ESTIMATED","completionDate":"2035-07-23","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Follicular Lymphoma"],"interventions":["MK-1045","Rituximab","Rituximab biosimilar","Bendamustine","Cyclophosphamide","Vincristine","Prednisone","Prednisolone","Doxorubicin Hydrochloride"],"countries":["United States","Argentina","Israel","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":16,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemoth","sourceUrl":"https://clinicaltrials.gov/study/NCT07634471"},{"nctId":"NCT03741127","title":"Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101","sponsor":"Poseida Therapeutics, Inc.","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2018-10-29","startDateType":"ACTUAL","primaryCompletionDate":"2032-08","primaryCompletionType":"ESTIMATED","completionDate":"2032-11","completionType":"ESTIMATED","lastUpdated":"2026-03-04","conditions":["Multiple Myeloma"],"interventions":["Rimiducid may be administered as indicated"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":13,"serviceSignals":["Hematology NGS"],"summary":"Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.","sourceUrl":"https://clinicaltrials.gov/study/NCT03741127"},{"nctId":"NCT07190300","title":"TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":181,"enrollmentType":"ESTIMATED","startDate":"2026-01-13","startDateType":"ACTUAL","primaryCompletionDate":"2032-08-02","primaryCompletionType":"ESTIMATED","completionDate":"2032-08-02","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"interventions":["Tulmimetostat","Darolutamide","Abiraterone"],"countries":["United States","Australia","Brazil","Canada","China","France","Germany","Hong Kong","Hungary","Italy","South Korea","Spain","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":31,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).","sourceUrl":"https://clinicaltrials.gov/study/NCT07190300"},{"nctId":"NCT07567469","title":"A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2026-08-31","startDateType":"ESTIMATED","primaryCompletionDate":"2032-08-27","primaryCompletionType":"ESTIMATED","completionDate":"2034-08-17","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["High-Grade Glioma (HGG)","Posterior Fossa-A Ependymoma"],"interventions":["Cemiplimab","Cemiplimab+Fianlimab Fixed Dose Combination (FDC)"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This study is researching an experimental drug called cemiplimab (called \"study drug\") and the combination of experimental drugs of fianlimab and cemiplimab (called \"study drugs\"). The study is focused on children and young adults with recurrent or progressive High-Grade Glioma (HGG) or ependymoma. \"Recurrent\" means that the cancer came back after treatment. \"Progressive\" means that the tumor has grown or spread. The aim of the study is to see how safe, tolerable, and effective cemiplimab and the combination of fianlimab and cemiplimab are. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug(s) * Do the study drug(","sourceUrl":"https://clinicaltrials.gov/study/NCT07567469"},{"nctId":"NCT07095309","title":"Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer","sponsor":"Metanoic Health Ltd.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":120,"enrollmentType":"ESTIMATED","startDate":"2025-08-15","startDateType":"ESTIMATED","primaryCompletionDate":"2032-08-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-31","completionType":"ESTIMATED","lastUpdated":"2025-07-31","conditions":["Stage II/III Colon Cancer","Bowel Cancer"],"interventions":["Artesunate","Artesunate matching Placebo"],"countries":["Malaysia"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Broad CGP"],"summary":"TThis study evaluates the safety and effectiveness of pre-operative artesunate, given orally once a day for 14 days prior to surgery, in patients with Stage II/III colorectal cancer. Artesunate is an established antimalarial drug with an excellent safety profile. It is well tolerated, affordable, and widely available. Several laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells. One hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200 mg daily or a matching placebo for 14 days prior to surgery. Pati","sourceUrl":"https://clinicaltrials.gov/study/NCT07095309"},{"nctId":"NCT07585266","title":"A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)","sponsor":"GlaxoSmithKline","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":800,"enrollmentType":"ESTIMATED","startDate":"2026-07-10","startDateType":"ESTIMATED","primaryCompletionDate":"2032-09-06","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-05","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Gastrointestinal Stromal Neoplasms"],"interventions":["Velzatinib","Imatinib"],"countries":["United States","South Korea"],"northAmerica":true,"chinaSites":false,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.","sourceUrl":"https://clinicaltrials.gov/study/NCT07585266"},{"nctId":"NCT06136559","title":"A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1200,"enrollmentType":"ESTIMATED","startDate":"2023-12-13","startDateType":"ACTUAL","primaryCompletionDate":"2032-09-07","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-07","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["Nemtabrutinib","Ibrutinib","Acalabrutinib"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Germany","Greece","Hong Kong","Israel","Japan","Malaysia","Mexico","New Zealand","Norway","Peru","Poland","Portugal","South Africa","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":201,"serviceSignals":["Hematology NGS"],"summary":"The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent central review (BICR) and (2) nemtabrutinib is superior to ibrutinib or acalabrutinib with respect to progression free survival (PFS) per iwCLL Criteria 2018 by BICR.","sourceUrl":"https://clinicaltrials.gov/study/NCT06136559"},{"nctId":"NCT04589845","title":"Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study","sponsor":"Hoffmann-La Roche","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":920,"enrollmentType":"ESTIMATED","startDate":"2021-01-18","startDateType":"ACTUAL","primaryCompletionDate":"2032-09-25","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-25","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Solid Tumors"],"interventions":["Entrectinib","Alectinib","Atezolizumab","Ipatasertib","Trastuzumab emtansine","Inavolisib","Belvarafenib","Pralsetinib","Divarasib","Camonsertib"],"countries":["United States","Australia","Belgium","Brazil","Canada","China","Denmark","France","Germany","Hong Kong","Israel","Italy","Japan","New Zealand","Poland","Portugal","Puerto Rico","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":112,"serviceSignals":["MSI / TMB"],"summary":"TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment w","sourceUrl":"https://clinicaltrials.gov/study/NCT04589845"},{"nctId":"NCT04910685","title":"(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis","sponsor":"Blueprint Medicines Corporation","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":534,"enrollmentType":"ESTIMATED","startDate":"2021-11-30","startDateType":"ACTUAL","primaryCompletionDate":"2032-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Indolent Systemic Mastocytosis","Smoldering Systemic Mastocytosis"],"interventions":["Elenestinib","Placebo"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Colombia","Czechia","France","Germany","Greece","Ireland","Italy","Netherlands","Norway","Poland","Portugal","Spain","Sweden","Switzerland","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":75,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with","sourceUrl":"https://clinicaltrials.gov/study/NCT04910685"},{"nctId":"NCT06915025","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","sponsor":"Imunon","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2025-07-09","startDateType":"ACTUAL","primaryCompletionDate":"2032-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2032-10-31","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Epithelial Ovarian Cancer","Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma"],"interventions":["IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)","Paclitaxel","Carboplatin","Olaparib","Niraparib"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Broad CGP"],"summary":"This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.","sourceUrl":"https://clinicaltrials.gov/study/NCT06915025"},{"nctId":"NCT07752875","title":"A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","sponsor":"LG Chem","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":250,"enrollmentType":"ESTIMATED","startDate":"2026-12-01","startDateType":"ESTIMATED","primaryCompletionDate":"2032-10-31","primaryCompletionType":"ESTIMATED","completionDate":"2033-04-30","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Ovarian Cancer","Small Cell Lung Cancer","Non Small Cell Lung Cancer","Colorectal Cancer","Esophageal Cancer","Breast Cancer","Endometrial Cancer","Head and Neck Cancer","Pancreatic Cancer","Locally Advanced Unresectable or Metastatic Solid Tumor"],"interventions":["LG00313112"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation","sourceUrl":"https://clinicaltrials.gov/study/NCT07752875"},{"nctId":"NCT05283720","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","sponsor":"Genmab","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":264,"enrollmentType":"ACTUAL","startDate":"2022-06-14","startDateType":"ACTUAL","primaryCompletionDate":"2032-11","primaryCompletionType":"ESTIMATED","completionDate":"2032-11","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Non-Hodgkin Lymphoma"],"interventions":["Epcoritamab","Lenalidomide","Ibrutinib","Rituximab","Cyclophosphamide","Doxorubicin Hydrochloride [HCl]","Prednisone","Polatuzumab Vedotin","CC-99282"],"countries":["United States","China","Czechia","Denmark","France","Germany","Hungary","Israel","Japan","Netherlands","South Korea","Spain","Taiwan"],"northAmerica":true,"chinaSites":true,"siteCount":76,"serviceSignals":["Hematology NGS"],"summary":"B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximat","sourceUrl":"https://clinicaltrials.gov/study/NCT05283720"},{"nctId":"NCT07454720","title":"A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":165,"enrollmentType":"ESTIMATED","startDate":"2026-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2032-11","primaryCompletionType":"ESTIMATED","completionDate":"2035-11","completionType":"ESTIMATED","lastUpdated":"2026-05-05","conditions":["Locally Advanced Resectable Rectal Cancer"],"interventions":["Adebrelimab in combination with SHR-8068 and chemotherapy","Adebrelimab combined with chemotherapy","Chemotherapy"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07454720"},{"nctId":"NCT07183189","title":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":576,"enrollmentType":"ESTIMATED","startDate":"2025-10-30","startDateType":"ACTUAL","primaryCompletionDate":"2032-11","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-04-14","conditions":["Non-small Cell Lung Cancer"],"interventions":["SHR-A2009 ; Aumolertinib","Aumolertinib"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Broad CGP"],"summary":"This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve subjects with EGFR-mutated, locally advanced or metastatic non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07183189"},{"nctId":"NCT03897881","title":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)","sponsor":"ModernaTX, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":267,"enrollmentType":"ACTUAL","startDate":"2019-07-18","startDateType":"ACTUAL","primaryCompletionDate":"2032-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2032-11-30","completionType":"ESTIMATED","lastUpdated":"2025-12-03","conditions":["Melanoma"],"interventions":["mRNA-4157","Pembrolizumab"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":23,"serviceSignals":["HLA / TCR"],"summary":"The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.","sourceUrl":"https://clinicaltrials.gov/study/NCT03897881"},{"nctId":"NCT07642024","title":"A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":90,"enrollmentType":"ESTIMATED","startDate":"2026-07-24","startDateType":"ACTUAL","primaryCompletionDate":"2032-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Non-small Cell Lung Cancer"],"interventions":["BL-B01D1","Osimertinib","Carboplatin","Pemetrexed","Cisplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":2,"serviceSignals":["Broad CGP"],"summary":"This trial is a registrational Phase II/III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib in resectable EGFR-mutant non-small cell lung cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07642024"},{"nctId":"NCT06947967","title":"Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype","sponsor":"Chipscreen Biosciences, Ltd.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":224,"enrollmentType":"ESTIMATED","startDate":"2025-08-12","startDateType":"ACTUAL","primaryCompletionDate":"2032-12","primaryCompletionType":"ESTIMATED","completionDate":"2032-12","completionType":"ESTIMATED","lastUpdated":"2025-09-15","conditions":["Lymphoma, T-Cell, Peripheral"],"interventions":["CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)","Tucidinostat","Placebo"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["Hematology NGS"],"summary":"A Randomised, Double-blind, Multicenter Phase Ⅲ Study to Evaluate the Efficacy and Safety of Tucidinostat versus Placebo in Combination with CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma with Follicular Helper of T Cell Phenotype","sourceUrl":"https://clinicaltrials.gov/study/NCT06947967"},{"nctId":"NCT07288203","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2025-11-28","startDateType":"ACTUAL","primaryCompletionDate":"2032-12","primaryCompletionType":"ESTIMATED","completionDate":"2033-12","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Melanoma (Skin Cancer)","Unresectable Melanoma","Metastatic Melanoma"],"interventions":["Lifileucel"],"countries":["United States","Australia","Canada","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \\[TIL\\]) in participants with previously treated advanced melanoma","sourceUrl":"https://clinicaltrials.gov/study/NCT07288203"},{"nctId":"NCT07554339","title":"A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":310,"enrollmentType":"ESTIMATED","startDate":"2026-06-18","startDateType":"ACTUAL","primaryCompletionDate":"2032-12-15","primaryCompletionType":"ESTIMATED","completionDate":"2037-08-17","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["Calderasib","Durvalumab","Placebo to MK-1084"],"countries":["United States","Argentina","China","Germany","Greece","Italy","Netherlands","South Korea","Spain","Taiwan","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":53,"serviceSignals":["RAS genotyping"],"summary":"Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after chemotherapy and radiation therapy. The goal of this trial is to learn if participants who receive calderasib and durvalumab live longer without the cancer growing or spreading compared to participants who receive placebo and durvalumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07554339"},{"nctId":"NCT06385080","title":"A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer","sponsor":"Janssen Research & Development, LLC","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":287,"enrollmentType":"ESTIMATED","startDate":"2024-04-22","startDateType":"ACTUAL","primaryCompletionDate":"2032-12-27","primaryCompletionType":"ESTIMATED","completionDate":"2032-12-27","completionType":"ESTIMATED","lastUpdated":"2026-07-06","conditions":["Squamous Cell Carcinoma of Head and Neck"],"interventions":["Amivantamab","Pembrolizumab","Paclitaxel","Carboplatin"],"countries":["United States","China","France","Germany","Japan","Malaysia","Poland","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":56,"serviceSignals":["Broad CGP"],"summary":"The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel. The safety and preliminary efficacy of amivantamab in addition to pembrolizumab will also be determined in perioperative (before and after surgery) setting in participants with resectable locally advanced head and neck squamous cell carcinoma (HNSCC).","sourceUrl":"https://clinicaltrials.gov/study/NCT06385080"},{"nctId":"NCT07224672","title":"A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis","sponsor":"GlaxoSmithKline","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-06-24","startDateType":"ACTUAL","primaryCompletionDate":"2033-01-12","primaryCompletionType":"ESTIMATED","completionDate":"2033-01-12","completionType":"ESTIMATED","lastUpdated":"2026-07-17","conditions":["Amyloidosis"],"interventions":["Belantamab mafodotin","Cyclophosphamide","Bortezomib","Dexamethasone"],"countries":["United States","Australia"],"northAmerica":true,"chinaSites":false,"siteCount":5,"serviceSignals":["Broad CGP"],"summary":"The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .","sourceUrl":"https://clinicaltrials.gov/study/NCT07224672"},{"nctId":"NCT07252739","title":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":140,"enrollmentType":"ESTIMATED","startDate":"2025-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2033-01-14","primaryCompletionType":"ESTIMATED","completionDate":"2033-01-14","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Malignant Neoplasm"],"interventions":["MK-1084","Pembrolizumab","Cetuximab","Sacituzumab tirumotecan (sac-TMT)","Rescue medication"],"countries":["United States","Chile","China","Finland","Greece","Hong Kong","Italy","Netherlands","South Korea","Spain","Thailand","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":38,"serviceSignals":["RAS genotyping"],"summary":"Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.","sourceUrl":"https://clinicaltrials.gov/study/NCT07252739"},{"nctId":"NCT05955508","title":"A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":40,"enrollmentType":"ACTUAL","startDate":"2024-01-30","startDateType":"ACTUAL","primaryCompletionDate":"2033-01-25","primaryCompletionType":"ESTIMATED","completionDate":"2033-01-25","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["Smoldering Multiple Myeloma (SMM)"],"interventions":["Linvoseltamab"],"countries":["Spain"],"northAmerica":false,"chinaSites":false,"siteCount":17,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an investigational drug called linvoseltamab (\"study drug\") in participants at high risk of developing Multiple Myeloma (MM), a group commonly labeled as High-Risk Smoldering Multiple Myeloma (HR-SMM). The aim of the study is to understand the safety and tolerability (how the body reacts to linvoseltamab) as well as the effectiveness (how well linvoseltamab eliminates plasma cells and prevents the development of MM) of the study drug. There are 2 parts to the study. * In Part 1, linvoseltamab will be given to a small number of participants to study the early side effects (safety) of the study drug and make sure the treatment is acceptable. * In Part 2, linvoseltamab","sourceUrl":"https://clinicaltrials.gov/study/NCT05955508"},{"nctId":"NCT07728188","title":"A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":520,"enrollmentType":"ESTIMATED","startDate":"2026-11-30","startDateType":"ESTIMATED","primaryCompletionDate":"2033-02","primaryCompletionType":"ESTIMATED","completionDate":"2033-02","completionType":"ESTIMATED","lastUpdated":"2026-07-27","conditions":["Relapsed or Refractory Multiple Myeloma"],"interventions":["Etentamig","Pomalidomide","Daratumumab","Dexamethasone","Carfilzomib","Teclistamab"],"countries":["United States","Australia","Canada","France","Germany","Hungary","Italy","Netherlands","Norway","Portugal","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":66,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide. Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is ","sourceUrl":"https://clinicaltrials.gov/study/NCT07728188"},{"nctId":"NCT07354074","title":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","sponsor":"Novartis Pharmaceuticals","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-04-28","startDateType":"ACTUAL","primaryCompletionDate":"2033-02-23","primaryCompletionType":"ESTIMATED","completionDate":"2033-02-23","completionType":"ESTIMATED","lastUpdated":"2026-07-24","conditions":["Chronic Myelogenous Leukemia","Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive"],"interventions":["Asciminib single agent"],"countries":["United States","Australia","Canada","China","France","Italy","Japan","Netherlands","Poland","South Korea","Spain"],"northAmerica":true,"chinaSites":true,"siteCount":24,"serviceSignals":["Hematology NGS"],"summary":"The aim of this study is to support development of asciminib in the pediatric population (1 to \\< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.","sourceUrl":"https://clinicaltrials.gov/study/NCT07354074"},{"nctId":"NCT07318558","title":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":900,"enrollmentType":"ESTIMATED","startDate":"2026-02-16","startDateType":"ACTUAL","primaryCompletionDate":"2033-02-25","primaryCompletionType":"ESTIMATED","completionDate":"2033-02-25","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Ovarian Neoplasms","Ovarian Cancer"],"interventions":["Sacituzumab tirumotecan","Bevacizumab","Rescue Medications"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Colombia","Czechia","Denmark","Finland","France","Greece","Hungary","Ireland","Israel","Italy","Japan","Norway","Poland","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":144,"serviceSignals":["HRD / HRR"],"summary":"Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy.","sourceUrl":"https://clinicaltrials.gov/study/NCT07318558"},{"nctId":"NCT05862285","title":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","sponsor":"Hoffmann-La Roche","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2033-03-01","primaryCompletionType":"ESTIMATED","completionDate":"2033-03-01","completionType":"ESTIMATED","lastUpdated":"2026-07-10","conditions":["Cancer"],"interventions":["Ipatasertib","Tiragolumab","Atezolizumab","Tiragolumab and Atezolizumab","Bevacizumab","Entrectinib","Inavolisib","Divarasib"],"countries":["Belgium","Canada","China","Costa Rica","France","Greece","Japan","Mexico","Poland","Russia","South Korea","Taiwan","Thailand","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":67,"serviceSignals":["Broad CGP"],"summary":"The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\\[s\\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.","sourceUrl":"https://clinicaltrials.gov/study/NCT05862285"},{"nctId":"NCT06966700","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":2400,"enrollmentType":"ESTIMATED","startDate":"2025-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2033-03-23","primaryCompletionType":"ESTIMATED","completionDate":"2034-12-29","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"interventions":["Sacituzumab tirumotecan","Pembrolizumab","Rescue Medication","Carboplatin","Paclitaxel","Doxorubicin","Epirubicin","Cyclophosphamide","Capecitabine","Olaparib"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Israel","Italy","Japan","Malaysia","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Romania","Singapore","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":319,"serviceSignals":["HER2 profiling"],"summary":"Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of breast cancer in this study are triple-negative breast cancer (TNBC) and hormone receptor (HR)-low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. These cancers have zero or a low amount of a protein called HER2 and other proteins that attach to the hormones estrogen or progesterone. Sacituzumab tirumotecan (also known as sac-TMT or MK-2870), the study medicine, is","sourceUrl":"https://clinicaltrials.gov/study/NCT06966700"},{"nctId":"NCT03761108","title":"Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":387,"enrollmentType":"ESTIMATED","startDate":"2019-01-23","startDateType":"ACTUAL","primaryCompletionDate":"2033-03-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-06-16","completionType":"ESTIMATED","lastUpdated":"2026-04-20","conditions":["Multiple Myeloma"],"interventions":["Linvoseltamab"],"countries":["United States","Belgium","Germany","Japan","South Korea","Spain","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":40,"serviceSignals":["Hematology NGS"],"summary":"The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer","sourceUrl":"https://clinicaltrials.gov/study/NCT03761108"},{"nctId":"NCT06952803","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","sponsor":"AstraZeneca","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":700,"enrollmentType":"ESTIMATED","startDate":"2025-08-06","startDateType":"ACTUAL","primaryCompletionDate":"2033-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2036-04-30","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Prostate Cancer"],"interventions":["Saruparib","Placebo","Abiraterone + Prednisolone/Prednisone","Androgen Deprivation Therapy (ADT)"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Finland","France","Germany","Hungary","India","Israel","Italy","Japan","Malaysia","Netherlands","Peru","Poland","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":342,"serviceSignals":["Broad CGP"],"summary":"The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).","sourceUrl":"https://clinicaltrials.gov/study/NCT06952803"},{"nctId":"NCT05730036","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":410,"enrollmentType":"ESTIMATED","startDate":"2023-09-18","startDateType":"ACTUAL","primaryCompletionDate":"2033-04-19","primaryCompletionType":"ESTIMATED","completionDate":"2033-04-19","completionType":"ESTIMATED","lastUpdated":"2026-03-06","conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"interventions":["Linvoseltamab","Elotuzumab","Pomalidomide","Dexamethasone"],"countries":["United States","Australia","Belgium","Brazil","Canada","Chile","France","Germany","Israel","Italy","Japan","Netherlands","Poland","Singapore","South Korea","Spain","Taiwan","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":159,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These participants were no longer benefiting from standard medications and had no good treatment options. In that study, some participants who were treated with linvoseltamab had improvement of their myeloma (shrinkage of their tumors), including some participants who had complete responses (that is, the treatment got rid of all evidence of myeloma in their bodies). This study is focused on ","sourceUrl":"https://clinicaltrials.gov/study/NCT05730036"},{"nctId":"NCT07520006","title":"Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies","sponsor":"Nurix Therapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2033-05","primaryCompletionType":"ESTIMATED","completionDate":"2033-05","completionType":"ESTIMATED","lastUpdated":"2026-04-13","conditions":["B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"interventions":["NX-5948","venetoclax","rituximab","obinutuzumab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).","sourceUrl":"https://clinicaltrials.gov/study/NCT07520006"},{"nctId":"NCT06623422","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":680,"enrollmentType":"ESTIMATED","startDate":"2024-10-21","startDateType":"ACTUAL","primaryCompletionDate":"2033-05-16","primaryCompletionType":"ESTIMATED","completionDate":"2038-01-26","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":["Pembrolizumab","Cisplatin","Carboplatin","Pemetrexed","Gemcitabine","Paclitaxel","Intismeran autogene","Placebo"],"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Finland","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Netherlands","New Zealand","Peru","Poland","Romania","Singapore","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":239,"serviceSignals":["HLA / TCR"],"summary":"The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).","sourceUrl":"https://clinicaltrials.gov/study/NCT06623422"},{"nctId":"NCT05748171","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","sponsor":"Pfizer","phase":"Phase 2","phases":["PHASE2"],"status":"RECRUITING","enrollment":100,"enrollmentType":"ESTIMATED","startDate":"2023-05-17","startDateType":"ACTUAL","primaryCompletionDate":"2033-05-21","primaryCompletionType":"ESTIMATED","completionDate":"2036-05-25","completionType":"ESTIMATED","lastUpdated":"2026-07-09","conditions":["ACUTE LYMPHOBLASTIC LEUKEMIA"],"interventions":["Inotuzumab ozogamicin","ALLR3"],"countries":["Austria","Belgium","Czechia","Denmark","Finland","France","Germany","Israel","Italy","Netherlands","Norway","Poland","Slovakia","Spain","Sweden","Switzerland"],"northAmerica":false,"chinaSites":false,"siteCount":68,"serviceSignals":["Hematology NGS"],"summary":"This prospective, randomized, multicenter, open-label Phase 2 study is designed to evaluate the superiority of InO monotherapy vs ALLR3 after 1 cycle of induction treatment in paediatric participants (between 1 and \\<18 years) with High Risk (HR) or very high risk (VHR) first bone marrow relapse CD22-positive BCP ALL, and to evaluate the safety and tolerability, PK and long-term efficacy. Treatment with study intervention will end after induction therapy; follow-up will continue for up to 5 years from randomization.","sourceUrl":"https://clinicaltrials.gov/study/NCT05748171"},{"nctId":"NCT04198766","title":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)","sponsor":"Inhibrx Biosciences, Inc","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2019-12-10","startDateType":"ACTUAL","primaryCompletionDate":"2033-07","primaryCompletionType":"ESTIMATED","completionDate":"2033-07","completionType":"ESTIMATED","lastUpdated":"2026-07-29","conditions":["Solid Tumor","Non-Small Cell Lung Cancer","Head and Neck Cancer","Melanoma","Gastric Cancer","Renal Cell Carcinoma","Urothelial Carcinoma","Resectable Non-Small-Cell Lung Cancer"],"interventions":["INBRX-106 - Hexavalent OX40 agonist antibody","pembrolizumab 200 mg","pembrolizumab 400 mg","Carboplatin AUC-5","Carboplatin AUC-6","Pemetrexed 500 mg/m2","Cisplatin 75mg/m2","Paclitaxel 200mg/m2","Nab paclitaxel 100mg/m2","Gemcitabine (1000 mg/m2)"],"countries":["United States","Singapore","South Korea","Taiwan"],"northAmerica":true,"chinaSites":false,"siteCount":42,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \\& Dohme LLC, a subsidiary of Merck \\& Co., Inc., Rahway, NJ, USA.","sourceUrl":"https://clinicaltrials.gov/study/NCT04198766"},{"nctId":"NCT07060807","title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1000,"enrollmentType":"ESTIMATED","startDate":"2025-07-21","startDateType":"ACTUAL","primaryCompletionDate":"2033-07-14","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-14","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Breast Neoplasms"],"interventions":["Patritumab deruxtecan","Paclitaxel","Nab-paclitaxel","Capecitabine","Liposomal doxorubicin","Trastuzumab deruxtecan"],"countries":["United States","Argentina","Australia","Brazil","Canada","Chile","China","Colombia","France","Germany","Greece","Hong Kong","Hungary","Israel","Italy","Japan","Mexico","Peru","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":197,"serviceSignals":["HER2 profiling"],"summary":"Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estrogen or progesterone (hormones) which help the cancer to grow and spread * HER2 negative (HER2-) means the cancer cells have a low amount of a protein called HER2 * Unresectable locally advanced means the cancer cannot be completely removed by surgery and has spread into nearby tissue or muscles * Metastatic means the cancer has spread to other parts of the body Treatment for this type of breast ca","sourceUrl":"https://clinicaltrials.gov/study/NCT07060807"},{"nctId":"NCT07393282","title":"A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":270,"enrollmentType":"ESTIMATED","startDate":"2026-05-21","startDateType":"ACTUAL","primaryCompletionDate":"2033-07-27","primaryCompletionType":"ESTIMATED","completionDate":"2033-07-27","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["High Risk Smoldering Multiple Myeloma (HR-SMM)"],"interventions":["Linvoseltamab","Daratumumab"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called linvoseltamab (also called \"study drug\") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developing active multiple myeloma. The aim of this study is to find out whether linvoseltamab is better than daratumumab in delaying the development of MM. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)","sourceUrl":"https://clinicaltrials.gov/study/NCT07393282"},{"nctId":"NCT07192432","title":"Gene Therapy for HER-Positive Cancer (SENTRY-HER2)","sponsor":"Vironexis Biotherapeutics Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":27,"enrollmentType":"ESTIMATED","startDate":"2025-11-18","startDateType":"ACTUAL","primaryCompletionDate":"2033-09","primaryCompletionType":"ESTIMATED","completionDate":"2033-10","completionType":"ESTIMATED","lastUpdated":"2026-07-28","conditions":["HER2 Expressing Solid Tumors"],"interventions":["Dose Level 1, VNX-202","Dose Level 2, VNX-202","Dose Level 3, VNX-202","Dose Level 4, VNX-202"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["HER2 profiling"],"summary":"This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.","sourceUrl":"https://clinicaltrials.gov/study/NCT07192432"},{"nctId":"NCT05259839","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"ACTIVE_NOT_RECRUITING","enrollment":283,"enrollmentType":"ACTUAL","startDate":"2022-10-20","startDateType":"ACTUAL","primaryCompletionDate":"2033-09","primaryCompletionType":"ESTIMATED","completionDate":"2033-09","completionType":"ESTIMATED","lastUpdated":"2025-12-19","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["Etentamig","Dexamethasone","Lenalidomide","Pomalidomide","Daratumumab"],"countries":["United States","Australia","Germany","Italy","Japan","Poland","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), or daratumumab-dexamethasone (Dd), in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease activity will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Etentamig co-administered with Pd, Rd, or Dd, will be explored. Each treatment","sourceUrl":"https://clinicaltrials.gov/study/NCT05259839"},{"nctId":"NCT07741877","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":80,"enrollmentType":"ESTIMATED","startDate":"2026-09-01","startDateType":"ESTIMATED","primaryCompletionDate":"2033-09-01","primaryCompletionType":"ESTIMATED","completionDate":"2034-09-01","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Sarcoma","Soft Tissue Sarcoma (STS)","Advanced Soft Tissue Sarcoma","Undifferentiated Pleomorphic Sarcoma (UPS)","Dedifferentiated Liposarcoma (DDLPS)"],"interventions":["Lifileucel"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')","sourceUrl":"https://clinicaltrials.gov/study/NCT07741877"},{"nctId":"NCT07387926","title":"Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)","sponsor":"Novartis Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":50,"enrollmentType":"ESTIMATED","startDate":"2026-07-05","startDateType":"ACTUAL","primaryCompletionDate":"2033-09-19","primaryCompletionType":"ESTIMATED","completionDate":"2036-05-30","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Acute Lymphoblastic Leukemia","Leukemia, Lymphoblastic, Acute, Philadelphia-Positive","Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia"],"interventions":["Asciminib Adult formulation","Asciminib Pediatric formulation","Dexamethasone","Vincristine","Blinatumomab","Methotrexate (intrathecal)","Cytarabine (intrathecal)","Hydrocortisone (intrathecal)","Prednisolone (intrathecal)"],"countries":["Israel"],"northAmerica":false,"chinaSites":false,"siteCount":1,"serviceSignals":["RNA fusion","Hematology NGS"],"summary":"Multi-center, open-label, single arm study of asciminib in participants aged ≥1 year to ≤30 years old with r/r Ph+ or ABL-class Ph-like ALL. This study will have 2 parts: Part 1 dose escalation and Part 2 dose expansion. Part 1 dose escalation will enroll participants aged ≥1 year to ≤30 years to determine the recommended phase 2 dose (RP2D) of asciminib when administered with low intensity chemotherapy. Part 2 dose expansion will enroll participants aged ≥1 year to ≤30 years to evaluate safety, tolerability, and efficacy of asciminib at the RP2D with the treatment regimen.","sourceUrl":"https://clinicaltrials.gov/study/NCT07387926"},{"nctId":"NCT07455851","title":"A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":150,"enrollmentType":"ESTIMATED","startDate":"2026-03-26","startDateType":"ACTUAL","primaryCompletionDate":"2033-09-30","primaryCompletionType":"ESTIMATED","completionDate":"2033-09-30","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Relapsed Refractory Multiple Myeloma (RRMM)"],"interventions":["Linvoseltamab","REGN17372+Linvoseltamab"],"countries":["Australia","Greece"],"northAmerica":false,"chinaSites":false,"siteCount":6,"serviceSignals":["Hematology NGS"],"summary":"This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called \"study drug\" or \"study drugs\" when combined) in participants with relapsed (when a tumor comes back) or refractory (when a tumor does not respond to treatment) multiple myeloma. This study is the first time REGN17372 will be given to humans. The aim of the study is to understand if REGN17372 can be given safely with linvoseltamab, and if so, what dosing regimen should be used for this treatment combination, in comparison with linvoseltamab alone. The study is looking at: * What side effects may happen from taking REGN17372 with linvoseltamab * How well REGN17372 and linvose","sourceUrl":"https://clinicaltrials.gov/study/NCT07455851"},{"nctId":"NCT07570173","title":"A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":340,"enrollmentType":"ESTIMATED","startDate":"2026-05-18","startDateType":"ACTUAL","primaryCompletionDate":"2033-10-18","primaryCompletionType":"ESTIMATED","completionDate":"2033-10-18","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["B-cell Acute Lymphoblastic Leukemia"],"interventions":["MK-1045","Blinatumomab","Acetaminophen","Diphenhydramine","Dexamethasone","Tocilizumab","Siltuximab","Avtozma","Tyenne"],"countries":["Denmark","Greece","Israel","Italy","Japan","Netherlands","Spain"],"northAmerica":false,"chinaSites":false,"siteCount":18,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.","sourceUrl":"https://clinicaltrials.gov/study/NCT07570173"},{"nctId":"NCT06669247","title":"A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":186,"enrollmentType":"ESTIMATED","startDate":"2024-12-11","startDateType":"ACTUAL","primaryCompletionDate":"2033-11-11","primaryCompletionType":"ESTIMATED","completionDate":"2035-11-01","completionType":"ESTIMATED","lastUpdated":"2026-08-05","conditions":["Relapsed/Refractory Multiple Myeloma"],"interventions":["Linvoseltamab","REGN7945+Linvoseltamab"],"countries":["Australia","United Kingdom"],"northAmerica":false,"chinaSites":false,"siteCount":9,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a \"study drug\" or \"study drugs\" when combined). This study is the first time REGN7945 will be tested in humans. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after several other therapies had failed. The aim of the study is to see how safe, tolerable, and effective REGN7945 is when given in combination with linvoseltamab, compared with linvoseltamab alone. The study is looking at sever","sourceUrl":"https://clinicaltrials.gov/study/NCT06669247"},{"nctId":"NCT07709000","title":"A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":60,"enrollmentType":"ESTIMATED","startDate":"2026-08-21","startDateType":"ESTIMATED","primaryCompletionDate":"2033-11-16","primaryCompletionType":"ESTIMATED","completionDate":"2033-11-16","completionType":"ESTIMATED","lastUpdated":"2026-07-16","conditions":["Chronic Lymphocytic Leukaemia","Small Lymphocytic Lymphoma","Hematologic Malignancies"],"interventions":["MK-1045","Acetaminophen (or similar antipyretic)","Diphenhydramine (or similar antihistamine)","Dexamethasone","Tocilizumab","Tocilizumab biosimilar","Siltuximab"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.","sourceUrl":"https://clinicaltrials.gov/study/NCT07709000"},{"nctId":"NCT07321847","title":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","sponsor":"Immunophotonics, Inc.","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":717,"enrollmentType":"ESTIMATED","startDate":"2026-05","startDateType":"ESTIMATED","primaryCompletionDate":"2033-12","primaryCompletionType":"ESTIMATED","completionDate":"2033-12","completionType":"ESTIMATED","lastUpdated":"2026-01-07","conditions":["Colorectal Cancer (CRC)","Colon Cancer Liver Metastases","Rectal Cancer","Rectal Cancer With Liver Metastases","Colorectal Liver Metastasis (CRLM)"],"interventions":["1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water","1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water.","Microwave (thermal) tumor ablation"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Hematology NGS"],"summary":"The goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal cancer that has spread only to the liver. The study will determine if injecting IP-001 into a liver tumor(s) after ablation will reduce the risk of cancer coming back in the liver and from spreading elsewhere in the body, will stimulate the immune system, will have any side effects, and will help improve a patient's response to other cancer therapies. Researchers will compare a standard of care liver ablation alone (microwave ablation \\[MWA\\], a technique that destroys t","sourceUrl":"https://clinicaltrials.gov/study/NCT07321847"},{"nctId":"NCT07700758","title":"A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 2","phases":["PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":15,"enrollmentType":"ESTIMATED","startDate":"2026-11-23","startDateType":"ESTIMATED","primaryCompletionDate":"2034-01-02","primaryCompletionType":"ESTIMATED","completionDate":"2034-01-02","completionType":"ESTIMATED","lastUpdated":"2026-07-14","conditions":["Malignant Neoplasm"],"interventions":["Belzutifan"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumors. Participants were enrolled into pheochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumor (wtGIST), and Von Hippel-Lindau (VHL) disease-associated localized tumors cohorts: * PPGL are rare cancers that start in cells that make hormones in the adrenal glands * wtGIST is a less common type of cancer that starts in the digestive tract. Wild type means it does not have certain gene mutations (changes) * VHL disease-associated localized tumors are rare tumors caused by a certain gene mutation that may be passed down from parents to children * Locally adv","sourceUrl":"https://clinicaltrials.gov/study/NCT07700758"},{"nctId":"NCT07405164","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":450,"enrollmentType":"ESTIMATED","startDate":"2026-03-23","startDateType":"ACTUAL","primaryCompletionDate":"2034-01-14","primaryCompletionType":"ESTIMATED","completionDate":"2034-01-14","completionType":"ESTIMATED","lastUpdated":"2026-08-03","conditions":["Von Hippel-Lindau Disease","Malignant Neoplasms"],"interventions":["Belzutifan","Nivolumab","Lenvatinib","Cabozantinib"],"countries":["United States","Australia","Belgium","Brazil","Chile","Czechia","Denmark","Finland","France","Hungary","Israel","Japan","Netherlands","New Zealand","Poland","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":48,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called belzutifan. Belzutifan, also called MK-6482, is designed to block a protein that helps tumors grow and","sourceUrl":"https://clinicaltrials.gov/study/NCT07405164"},{"nctId":"NCT07416552","title":"A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)","sponsor":"Hoffmann-La Roche","phase":"Phase 1","phases":["PHASE1"],"status":"NOT_YET_RECRUITING","enrollment":180,"enrollmentType":"ESTIMATED","startDate":"2026-07-31","startDateType":"ESTIMATED","primaryCompletionDate":"2034-02-12","primaryCompletionType":"ESTIMATED","completionDate":"2034-02-12","completionType":"ESTIMATED","lastUpdated":"2026-07-07","conditions":["Metastatic Colorectal Cancer"],"interventions":["SPLIT Abs","203Pb-DOTAM","212Pb-DOTAM"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":1,"serviceSignals":["MSI / TMB"],"summary":"This study will evaluate the dosimetry, safety, efficacy, pharmacokinetics (PK), pharmacodynamics and immunogenicity of CEA-PRIT 2.0 in participants with metastatic microsatellite-stable (MSS) mCRC who are intolerant to or have progressed after having received available standard-of-care (SOC) therapies.","sourceUrl":"https://clinicaltrials.gov/study/NCT07416552"},{"nctId":"NCT06312137","title":"A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":780,"enrollmentType":"ESTIMATED","startDate":"2024-04-03","startDateType":"ACTUAL","primaryCompletionDate":"2034-02-21","primaryCompletionType":"ESTIMATED","completionDate":"2034-10-23","completionType":"ESTIMATED","lastUpdated":"2026-07-20","conditions":["Non Small Cell Lung Cancer"],"interventions":["Sacituzumab tirumotecan","Pembrolizumab","Cisplatin","Pemetrexed","Gemcitabine","Carboplatin","Paclitaxel","Rescue medication"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Czechia","France","Germany","Greece","Hong Kong","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Norway","Peru","Poland","Portugal","Romania","South Korea","Spain","Switzerland","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":267,"serviceSignals":["Broad CGP"],"summary":"This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).","sourceUrl":"https://clinicaltrials.gov/study/NCT06312137"},{"nctId":"NCT07743723","title":"A Study of IOV-5001 in Adults With Advanced Solid Tumors","sponsor":"Iovance Biotherapeutics, Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"NOT_YET_RECRUITING","enrollment":106,"enrollmentType":"ESTIMATED","startDate":"2026-08","startDateType":"ESTIMATED","primaryCompletionDate":"2034-03","primaryCompletionType":"ESTIMATED","completionDate":"2044-03","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Advanced Solid Tumors","Non-Small Cell Lung Cancer","Triple Negative Breast Cancer (TNBC)","Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Metastatic Solid Tumors","Unresectable Solid Tumor"],"interventions":["IOV-5001"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors","sourceUrl":"https://clinicaltrials.gov/study/NCT07743723"},{"nctId":"NCT07441460","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","sponsor":"Shanghai JMT-Bio Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":1800,"enrollmentType":"ESTIMATED","startDate":"2026-03-06","startDateType":"ACTUAL","primaryCompletionDate":"2034-08-07","primaryCompletionType":"ESTIMATED","completionDate":"2035-08-07","completionType":"ESTIMATED","lastUpdated":"2026-04-08","conditions":["Resectable HER2-positive Breast Cancer"],"interventions":["KN026","HB1801","Trastuzumab","Pertuzumab","Docetaxel","Epirubicin","Doxorubicin","Cyclophosphamide","Carboplatin"],"countries":["China"],"northAmerica":false,"chinaSites":true,"siteCount":1,"serviceSignals":["HER2 profiling"],"summary":"This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.","sourceUrl":"https://clinicaltrials.gov/study/NCT07441460"},{"nctId":"NCT07513376","title":"A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":876,"enrollmentType":"ESTIMATED","startDate":"2026-05-04","startDateType":"ACTUAL","primaryCompletionDate":"2034-08-22","primaryCompletionType":"ESTIMATED","completionDate":"2038-05-11","completionType":"ESTIMATED","lastUpdated":"2026-07-31","conditions":["Non-small Cell Lung Cancer"],"interventions":["Intismeran","Pembrolizumab coformulated with berahyaluronidase alfa","Placebo"],"countries":["United States","Australia","Canada","Germany","Greece","Hungary","Israel","Italy","Netherlands","Poland","Spain","Taiwan","Turkey (Türkiye)"],"northAmerica":true,"chinaSites":false,"siteCount":46,"serviceSignals":["Broad CGP"],"summary":"Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study ","sourceUrl":"https://clinicaltrials.gov/study/NCT07513376"},{"nctId":"NCT07723469","title":"Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery","sponsor":"SURGE Therapeutics","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-10","startDateType":"ESTIMATED","primaryCompletionDate":"2034-10","primaryCompletionType":"ESTIMATED","completionDate":"2034-10","completionType":"ESTIMATED","lastUpdated":"2026-07-23","conditions":["TNBC - Triple-Negative Breast Cancer"],"interventions":["BCS + SRG-514","BCS"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \\[API\\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.","sourceUrl":"https://clinicaltrials.gov/study/NCT07723469"},{"nctId":"NCT06351631","title":"A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2024-05-23","startDateType":"ACTUAL","primaryCompletionDate":"2034-12-04","primaryCompletionType":"ESTIMATED","completionDate":"2034-12-04","completionType":"ESTIMATED","lastUpdated":"2026-04-02","conditions":["Thrombocythemia, Essential","Primary Myelofibrosis","Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Polycythemia Vera"],"interventions":["Bomedemstat"],"countries":["United States","Australia","Hong Kong","Italy","New Zealand","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":21,"serviceSignals":["Hematology NGS"],"summary":"The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.","sourceUrl":"https://clinicaltrials.gov/study/NCT06351631"},{"nctId":"NCT03155191","title":"Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia","sponsor":"Takara Bio Inc.","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"ACTIVE_NOT_RECRUITING","enrollment":21,"enrollmentType":"ESTIMATED","startDate":"2017-06-01","startDateType":"ACTUAL","primaryCompletionDate":"2035-03-31","primaryCompletionType":"ESTIMATED","completionDate":"2035-03-31","completionType":"ESTIMATED","lastUpdated":"2024-11-20","conditions":["Lymphoblastic Leukemia, Acute Adult"],"interventions":["TBI-1501"],"countries":["Japan"],"northAmerica":false,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.","sourceUrl":"https://clinicaltrials.gov/study/NCT03155191"},{"nctId":"NCT05828511","title":"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment","sponsor":"Regeneron Pharmaceuticals","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":149,"enrollmentType":"ESTIMATED","startDate":"2023-12-19","startDateType":"ACTUAL","primaryCompletionDate":"2035-11-02","primaryCompletionType":"ESTIMATED","completionDate":"2035-11-02","completionType":"ESTIMATED","lastUpdated":"2026-05-13","conditions":["Multiple Myeloma"],"interventions":["Linvoseltamab"],"countries":["United States","France","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":32,"serviceSignals":["Hematology NGS"],"summary":"This study is researching an experimental drug called linvoseltamab (called \"study drug\"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible). The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM. This study consists of 2 phases: * In Phase 1 Parts A and B, the ","sourceUrl":"https://clinicaltrials.gov/study/NCT05828511"},{"nctId":"NCT06697301","title":"Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.","sponsor":"Eikon Therapeutics","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":740,"enrollmentType":"ESTIMATED","startDate":"2025-05-22","startDateType":"ACTUAL","primaryCompletionDate":"2035-12","primaryCompletionType":"ESTIMATED","completionDate":"2040-12","completionType":"ESTIMATED","lastUpdated":"2026-05-08","conditions":["Advanced Melanoma"],"interventions":["EIK1001","Pembrolizumab (KEYTRUDA® )"],"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Hungary","Israel","Italy","New Zealand","Norway","Poland","Portugal","Serbia","South Africa","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":107,"serviceSignals":["Broad CGP"],"summary":"The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.","sourceUrl":"https://clinicaltrials.gov/study/NCT06697301"},{"nctId":"NCT06892522","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations","sponsor":"AbbVie","phase":"Phase 1/Phase 2","phases":["PHASE1","PHASE2"],"status":"RECRUITING","enrollment":602,"enrollmentType":"ESTIMATED","startDate":"2025-06-30","startDateType":"ACTUAL","primaryCompletionDate":"2035-12","primaryCompletionType":"ESTIMATED","completionDate":"2035-12","completionType":"ESTIMATED","lastUpdated":"2026-07-21","conditions":["Multiple Myeloma"],"interventions":["Etentamig","Lenalidomide","Dexamethasone","Daratumumab","Carfilzomib","Mezigdomide","Iberdomide","ABBV-2001"],"countries":["United States","Australia","Israel","Japan","Norway","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":34,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM. Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 6 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Partici","sourceUrl":"https://clinicaltrials.gov/study/NCT06892522"},{"nctId":"NCT07365319","title":"A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","sponsor":"Eikon Therapeutics","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":750,"enrollmentType":"ESTIMATED","startDate":"2026-06-15","startDateType":"ACTUAL","primaryCompletionDate":"2035-12-31","primaryCompletionType":"ESTIMATED","completionDate":"2040-12-31","completionType":"ESTIMATED","lastUpdated":"2026-08-06","conditions":["Non Small Cell Lung Cancer (Squamous or Non Squamous)","Stage 4 NSCLC"],"interventions":["EIK1001","Pembrolizumab (KEYTRUDA®)","Placebo","Paclitaxel + Carboplatin","Nab-paclitaxel + Carboplatin","Pemetrexed + Cisplatin /Carboplatin"],"countries":["United States","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":14,"serviceSignals":["Broad CGP"],"summary":"This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.","sourceUrl":"https://clinicaltrials.gov/study/NCT07365319"},{"nctId":"NCT06896916","title":"Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":135,"enrollmentType":"ESTIMATED","startDate":"2025-08-07","startDateType":"ACTUAL","primaryCompletionDate":"2036-03","primaryCompletionType":"ESTIMATED","completionDate":"2036-03","completionType":"ESTIMATED","lastUpdated":"2026-05-12","conditions":["Multiple Myeloma"],"interventions":["Etentamig","Iberdomide"],"countries":["United States","Australia","Canada","France","Japan","Netherlands","Norway"],"northAmerica":true,"chinaSites":false,"siteCount":27,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose","sourceUrl":"https://clinicaltrials.gov/study/NCT06896916"},{"nctId":"NCT07659379","title":"Gotistobart Long Term Extension (LTE) Study","sponsor":"OncoC4, Inc.","phase":"Phase 3","phases":["PHASE3"],"status":"NOT_YET_RECRUITING","enrollment":20,"enrollmentType":"ESTIMATED","startDate":"2026-07-01","startDateType":"ESTIMATED","primaryCompletionDate":"2036-07-01","primaryCompletionType":"ESTIMATED","completionDate":"2037-01-01","completionType":"ESTIMATED","lastUpdated":"2026-06-23","conditions":["Advanced Solid Tumor"],"interventions":["Gotistobart"],"countries":[],"northAmerica":false,"chinaSites":false,"siteCount":0,"serviceSignals":["Broad CGP"],"summary":"This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.","sourceUrl":"https://clinicaltrials.gov/study/NCT07659379"},{"nctId":"NCT03435796","title":"Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells","sponsor":"Celgene","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":1541,"enrollmentType":"ESTIMATED","startDate":"2018-07-19","startDateType":"ACTUAL","primaryCompletionDate":"2036-11-30","primaryCompletionType":"ESTIMATED","completionDate":"2036-11-30","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Neoplasms"],"interventions":["Gene-modified (GM) T cell therapy"],"countries":["United States","Australia","Austria","Belgium","Canada","Finland","France","Germany","Israel","Italy","Japan","Netherlands","Norway","Poland","Romania","South Korea","Spain","Sweden","Switzerland","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":209,"serviceSignals":["Hematology NGS"],"summary":"This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.","sourceUrl":"https://clinicaltrials.gov/study/NCT03435796"},{"nctId":"NCT06191744","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","sponsor":"Genmab","phase":"Phase 3","phases":["PHASE3"],"status":"ACTIVE_NOT_RECRUITING","enrollment":1095,"enrollmentType":"ACTUAL","startDate":"2024-02-05","startDateType":"ACTUAL","primaryCompletionDate":"2037-11","primaryCompletionType":"ESTIMATED","completionDate":"2037-11","completionType":"ESTIMATED","lastUpdated":"2026-08-04","conditions":["Follicular Lymphoma (FL)"],"interventions":["Epcoritamab","Prednisone","Rituximab","Lenalidomide","Doxorubicin","Vincristine","Cyclophosphamide","Obinutuzumab","Bendamustine"],"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","China","Croatia","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Japan","Netherlands","New Zealand","Poland","Portugal","Puerto Rico","Romania","Serbia","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"],"northAmerica":true,"chinaSites":true,"siteCount":266,"serviceSignals":["Hematology NGS"],"summary":"Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Around 1095 adult participants","sourceUrl":"https://clinicaltrials.gov/study/NCT06191744"},{"nctId":"NCT06652633","title":"Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies","sponsor":"Lakefront Biotherapeutics NV","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":546,"enrollmentType":"ESTIMATED","startDate":"2024-09-09","startDateType":"ACTUAL","primaryCompletionDate":"2039-07","primaryCompletionType":"ESTIMATED","completionDate":"2039-07","completionType":"ESTIMATED","lastUpdated":"2026-07-13","conditions":["Hematological Malignancies"],"interventions":["GLPG CAR T-cell therapy"],"countries":["United States","Belgium","Finland","Netherlands","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":11,"serviceSignals":["Hematology NGS"],"summary":"This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion. Per Health Authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. The purpose of this study is to monitor all participants exposed to GLPG CAR T-cell therapies for 15 years following their last CAR T-cell infusion to assess the risk of delayed adverse events (AEs) and the long-term benefit/risk profile and to monitor for replication-competent lentivirus (","sourceUrl":"https://clinicaltrials.gov/study/NCT06652633"},{"nctId":"NCT07431827","title":"MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":400,"enrollmentType":"ESTIMATED","startDate":"2026-03-18","startDateType":"ACTUAL","primaryCompletionDate":"2039-10-26","primaryCompletionType":"ESTIMATED","completionDate":"2039-10-26","completionType":"ESTIMATED","lastUpdated":"2026-08-07","conditions":["Non-small Cell Lung Cancer"],"interventions":["Calderasib","MK-3475A","Placebo"],"countries":["Argentina","Australia","Brazil","Canada","China","France","Greece","Hong Kong","Italy","South Korea","Spain","Taiwan","Turkey (Türkiye)","Ukraine"],"northAmerica":true,"chinaSites":true,"siteCount":82,"serviceSignals":["RAS genotyping"],"summary":"This is a phase 3, randomized, double-blind study of adjuvant calderasib plus subcutaneous pembrolizumab and berahyaluronidase alfa (MK-3475A) versus adjuvant placebo plus MK-3475a in participants with completely resected stage IIA-IIIB (N2), KRAS G12C-mutant non-small cell lung cancer following receipt of either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The primary goal of the study is to compare adjuvant calderasib plus MK-3475A to adjuvant placebo plus MK-3475A with respect to disease-free survival (DFS) as assessed by the investigator.","sourceUrl":"https://clinicaltrials.gov/study/NCT07431827"},{"nctId":"NCT07095452","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","sponsor":"AbbVie","phase":"Phase 2/Phase 3","phases":["PHASE2","PHASE3"],"status":"RECRUITING","enrollment":660,"enrollmentType":"ESTIMATED","startDate":"2026-01-08","startDateType":"ACTUAL","primaryCompletionDate":"2042-01","primaryCompletionType":"ESTIMATED","completionDate":"2042-01","completionType":"ESTIMATED","lastUpdated":"2026-06-11","conditions":["Multiple Myeloma"],"interventions":["Etentamig","Lenalidomide","Daratumumab","Dexamethasone"],"countries":["United States","France","Japan","Spain"],"northAmerica":true,"chinaSites":false,"siteCount":49,"serviceSignals":["Hematology NGS"],"summary":"Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM. Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 2 phases; phase 2 with 3 study arms and phase 3 with 2 study arms. Participants in phase 2 will receive 1 of 3 doses of etentamig in combination with daratumumab. Participants in phase 3 will receive etentamig ","sourceUrl":"https://clinicaltrials.gov/study/NCT07095452"},{"nctId":"NCT03628612","title":"Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells","sponsor":"Autolus Limited","phase":"Phase 2","phases":["PHASE2"],"status":"ENROLLING_BY_INVITATION","enrollment":500,"enrollmentType":"ESTIMATED","startDate":"2018-08-02","startDateType":"ACTUAL","primaryCompletionDate":"2043-07","primaryCompletionType":"ESTIMATED","completionDate":"2043-12","completionType":"ESTIMATED","lastUpdated":"2025-08-07","conditions":["Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy","Multiple Myeloma","DLBCL","ALL, Adult and Pediatric","T Cell Lymphoma"],"interventions":["AUTO CAR T cell therapy"],"countries":["United States","United Kingdom"],"northAmerica":true,"chinaSites":false,"siteCount":8,"serviceSignals":["Hematology NGS"],"summary":"Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.","sourceUrl":"https://clinicaltrials.gov/study/NCT03628612"},{"nctId":"NCT03486873","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","sponsor":"Merck Sharp & Dohme LLC","phase":"Phase 3","phases":["PHASE3"],"status":"RECRUITING","enrollment":3500,"enrollmentType":"ESTIMATED","startDate":"2018-08-21","startDateType":"ACTUAL","primaryCompletionDate":"2043-08-04","primaryCompletionType":"ESTIMATED","completionDate":"2043-08-04","completionType":"ESTIMATED","lastUpdated":"2026-07-30","conditions":["Solid Tumors","Hematologic Malignancies"],"interventions":["Pembrolizumab","Standard of Care (SOC)","Lenvatinib","Olaparib","MK-4280","MK-4280A","Pembrolizumab (+) Berahyaluronidase alfa"],"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Costa Rica","Czechia","Denmark","Estonia","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Latvia","Lithuania","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Puerto Rico","Romania","Russia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","Vietnam"],"northAmerica":true,"chinaSites":true,"siteCount":780,"serviceSignals":["Hematology NGS"],"summary":"The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 3","sourceUrl":"https://clinicaltrials.gov/study/NCT03486873"},{"nctId":"NCT07544589","title":"A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers","sponsor":"Dispatch Biotherapeutics","phase":"Phase 1","phases":["PHASE1"],"status":"RECRUITING","enrollment":66,"enrollmentType":"ESTIMATED","startDate":"2026-04","startDateType":"ESTIMATED","primaryCompletionDate":"2046-04","primaryCompletionType":"ESTIMATED","completionDate":"2046-04","completionType":"ESTIMATED","lastUpdated":"2026-05-29","conditions":["Colorectal Cancer","Gastric Adenocarcinoma","Esophageal Adenocarcinoma","Gastroesophageal Adenocarcinoma"],"interventions":["DISP-10"],"countries":["United States"],"northAmerica":true,"chinaSites":false,"siteCount":3,"serviceSignals":["Broad CGP"],"summary":"This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \\[CAR\\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.","sourceUrl":"https://clinicaltrials.gov/study/NCT07544589"}]}